PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lo, PHY; Leung, ACC; Kwok, CYC; Cheung, WSY; Ko, JMY; Yang, LC; Law, S; Wang, LD; Li, J; Stanbridge, EJ; Srivastava, G; Tang, JCO; Tsao, SW; Lung, ML				Lo, P. H. Y.; Leung, A. C. C.; Kwok, C. Y. C.; Cheung, W. S. Y.; Ko, J. M. Y.; Yang, L. C.; Law, S.; Wang, L. D.; Li, J.; Stanbridge, E. J.; Srivastava, G.; Tang, J. C. O.; Tsao, S. W.; Lung, M. L.			Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9	ONCOGENE			English	Article						esophageal carcinoma; tumor suppressor gene; chromosome 3; microcell-mediated chromosome transfer; ADAMTS9	NASOPHARYNGEAL CARCINOMA; EPIGENETIC INACTIVATION; FUNCTIONAL EVIDENCE; CHROMOSOME 3P21.3; CANCER; LINES; EXPRESSION; HUMAN-CHROMOSOME-3; TUMORIGENICITY; ESTABLISHMENT	A gene critical to esophageal cancer has been identified. Functional studies using microcell-mediated chromosome transfer of intact and truncated donor chromosomes 3 into an esophageal cancer cell line and nude mouse tumorigenicity assays were used to identify a 1.61Mb tumor suppressive critical region (CR) mapping to chromosome 3p14.2. This CR is bounded by D3S1600 and D3S1285 microsatellite markers. One candidate tumor suppressor gene, ADAMTS9, maps to this CR. Further studies showed normal expression levels of this gene in tumor-suppressed microcell hybrids, levels that were much higher than observed in the recipient cells. Complete loss or downregulation of ADAMTS9 gene expression was found in 15 out of 16 esophageal carcinoma cell lines. Promoter hypermethylation was detected in the cell lines that do not express this gene. Re-expression of ADAMTS9 was observed after demethylation drug treatment, confirming that hypermethylation is involved in gene downregulation. Downregulation of ADAMTS9 was also found in 43.5 and 47.6% of primary esophageal tumor tissues from Hong Kong and from the high-risk region of Henan, respectively. Thus, this study identifies and provides functional evidence for a CR associated with tumor suppression on 3p14.2 and provides the first evidence that ADAMTS9, mapping to this region, may contribute to esophageal cancer development.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Ctr Canc Res, Kowloon, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Zhengzhou Univ, Ctr Med Expt, Canc Res Lab, Henan Key Lab Esophageal Canc, Zhengzhou 450052, Henan, Peoples R China; Yaocun Esophageal Canc Hosp, Dept Pathol, Linzhou, Henan, Peoples R China; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; University of Hong Kong; Zhengzhou University; University of California System; University of California Irvine; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bomaria@ust.hk	Tang, Johnny C. O./M-9639-2014; Ko, Josephine/U-2972-2019; Law, Simon/C-4324-2009; Tang, Johnny Cheuk-on/W-7214-2019; Lung, Maria Li/C-4495-2009	Tang, Johnny C. O./0000-0002-4261-3206; Ko, Josephine/0000-0002-7997-331X; Law, Simon/0000-0002-6518-5806; Tang, Johnny Cheuk-on/0000-0002-4261-3206; Lung, Maria Li/0000-0003-2559-3626				Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CHEUNG AL, 2005, IN PRESS CANC LETT; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Horiguchi K, 2003, ONCOGENE, V22, P7862, DOI 10.1038/sj.onc.1207082; HU CP, 1984, J NATL CANCER I, V72, P577; Hu YC, 2002, CANCER GENET CYTOGEN, V135, P120, DOI 10.1016/S0165-4608(01)00580-5; Ko JMY, 2005, GENE CHROMOSOME CANC, V43, P284, DOI 10.1002/gcc.20190; Ko JMY, 2001, CANCER LETT, V170, P131, DOI 10.1016/S0304-3835(01)00577-8; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2004, INT J CANCER, V112, P628, DOI 10.1002/ijc.20454; MOK CH, 1987, ANTICANCER RES, V7, P409; PAN Q, 1989, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V4, P52; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Qin Yan-Ru, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P80; RIMESSI P, 1994, ONCOGENE, V9, P3467; Rooney D E, 1986, HUMAN CYTOGENETICS P, VFirst; Sambrook J, 1989, MOL CLONING; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; Sekine I, 2005, ONCOGENE, V24, P2735, DOI 10.1038/sj.onc.1207694; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shiomi H, 2003, CANCER GENET CYTOGEN, V147, P50, DOI 10.1016/S0165-4608(03)00159-6; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; Wang L, 1996, ONCOGENE, V12, P699; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Yang LC, 2005, ONCOGENE, V24, P697, DOI 10.1038/sj.onc.1208179; Yang Y, 2001, P NATL ACAD SCI USA, V98, P1136, DOI 10.1073/pnas.98.3.1136	37	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					148	157		10.1038/sj.onc.1209767	http://dx.doi.org/10.1038/sj.onc.1209767			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799631				2022-12-25	WOS:000243236500015
J	Salto-Tellez, M; Peh, BK; Ito, K; Tan, SH; Chong, PY; Han, HC; Tada, K; Ong, WY; Soong, R; Voon, DC; Ito, Y				Salto-Tellez, M.; Peh, B. K.; Ito, K.; Tan, S. H.; Chong, P. Y.; Han, H. C.; Tada, K.; Ong, W. Y.; Soong, R.; Voon, D. C.; Ito, Y.			RUNX3 protein is overexpressed in human basal cell carcinomas	ONCOGENE			English	Article						basal cell carcinoma; RUNX3; beta-catenin; Sonic Hedgehog	TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; NUCLEAR BETA-CATENIN; SONIC HEDGEHOG; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; GASTRIC-CANCER; LINES; INACTIVATION	Basal cell carcinomas (BCC), which are the most common form of skin malignancy, are invariably associated with the deregulation of the Sonic Hedgehog (Shh) signalling pathway. As such, BCC represent a unique model for the study of interactions of the Shh pathway with other genes and pathways. We constructed a tissue microarray (TMA) of 75 paired BCC and normal skin and analysed the expression of beta-catenin and RUNX3, nuclear effectors of the wingless-Int (Wnt) and bone morphogenetic protein/transforming growth factor-beta pathways, respectively. In line with previous reports, we observed varying subcellular expression pattern of beta-catenin in BCC, with 31 cases (41%) showing nuclear accumulation. In contrast, all the BCC cases tested by the TMA showed RUNX3 protein uniformly overexpressed in the nuclei of the cancer cells. Analysis by Western blotting and DNA sequencing indicates that the overexpressed protein is normal and full-length, containing no mutation in the coding region, implicating RUNX3 as an oncogene in certain human cancers. Our results indicate that although the deregulation of Wnt signalling could contribute to the pathogenesis of a subset of BCC, RUNX3 appears to be a universal downstream mediator of a constitutively active Shh pathway in BCC.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore Hosp, Yong Loo Lin Med Sch, Dept Pathol, Singapore 117548, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Natl Skin Ctr, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National Skin Centre	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr Proteos, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg		Voon, Dominic Chih-Cheng/0000-0002-2963-9305; Soong, Richie/0000-0002-0152-1225; Salto-Tellez, Manuel/0000-0001-8586-282X				Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Boonchai W, 2000, ARCH DERMATOL, V136, P937, DOI 10.1001/archderm.136.7.937; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen YG, 2004, CELL RES, V14, P441, DOI 10.1038/sj.cr.7290246; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Daya-Grosjean L, 2005, CANCER LETT, V225, P181, DOI 10.1016/j.canlet.2004.10.003; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Gianakopoulos PJ, 2005, J BIOL CHEM, V280, P21022, DOI 10.1074/jbc.M502977200; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; Rubin AI, 2005, NEW ENGL J MED, V353, P2262, DOI 10.1056/NEJMra044151; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Salto-Tellez M, 2004, CLIN CHEM, V50, P1082, DOI 10.1373/clinchem.2003.030700; Unden AB, 1997, CANCER RES, V57, P2336; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yamazaki F, 2001, BRIT J DERMATOL, V145, P771, DOI 10.1046/j.1365-2133.2001.04468.x; Yanada M, 2005, ONCOL REP, V14, P817; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	36	67	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7646	7649		10.1038/sj.onc.1209739	http://dx.doi.org/10.1038/sj.onc.1209739			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767156				2022-12-25	WOS:000242655500009
J	Cerone, MA; Londono-Vallejo, JA; Autexier, C				Cerone, M. A.; Londono-Vallejo, J. A.; Autexier, C.			Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance	ONCOGENE			English	Article						telomeres; telomerase; anticancer drugs; telomere uncapping; mutant template hTR	IMMORTAL HUMAN-CELLS; CANCER-CELLS; REVERSE-TRANSCRIPTASE; MUTANT TELOMERASE; CHROMOSOME SEPARATION; HUMAN FIBROBLASTS; MELANOMA-CELLS; DNA-REPAIR; INHIBITION; RNA	Telomerase is a ribonucleoprotein complex that maintains the stability of chromosome ends and regulates replicative potential. Telomerase is upregulated in over 85% of human tumors, but not in adjacent normal tissues and represents a promising target for anticancer therapy. Most telomerase-based therapies rely on the inhibition of telomerase activity and require extensive telomere shortening before inducing any antiproliferative effect. Disturbances of telomere structure rather than length may be more effective in inducing cell death. Telomerase RNA subunits (hTRs) with mutations in the template region reconstitute active holoenzymes that incorporate mutated telomeric sequences. Here, we analysed the feasibility of an anticancer approach based on the combination of telomere destabilization and conventional chemotherapeutic drugs. We show that a mutant template hTR dictates the synthesis of mutated telomeric repeats in telomerase-positive cancer cells, without significantly affecting their viability and proliferative ability. Nevertheless, the mutant hTR increased sensitivity to anticancer drugs in cells with different initial telomere lengths and mechanisms of telomere maintenance and without requiring overall telomere shortening. This report is the first to show that interfering with telomere structure maintenance in a telomerase-dependent manner may be used to increase the susceptibility of tumor cells to anticancer drugs and may lead to the development of a general therapy for the treatment of human cancers.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Anat & Cell Biol,Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3T 1E2, Canada; Inst Curie, UPMC, IC,CNRS, Telomeres & Canc Lab, F-75231 Paris, France	Lady Davis Institute; McGill University; McGill University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Autexier, C (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Anat & Cell Biol,Bloomfield Ctr Res Aging, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	chantal.autexier@mcgill.ca	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Chen Z, 2003, CANCER RES, V63, P5917; Christodoulopoulos G, 1999, CLIN CANCER RES, V5, P2178; Chung HK, 2005, CURR MOL MED, V5, P233, DOI 10.2174/1566524053586635; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Folini M, 2000, EUR J CANCER, V36, P2137, DOI 10.1016/S0959-8049(00)00295-1; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lin J, 2004, MOL BIOL CELL, V15, P1623, DOI 10.1091/mbc.E03-10-0740; Ludwig A, 2001, CANCER RES, V61, P3053; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Misawa M, 2002, INT J ONCOL, V21, P1087; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; Park KH, 1998, INT J ONCOL, V13, P489; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tentori L, 2003, MOL PHARMACOL, V63, P192, DOI 10.1124/mol.63.1.192; Ward RJ, 2005, MOL PHARMACOL, V68, P779, DOI 10.1124/mol.105.011494; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	46	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7411	7420		10.1038/sj.onc.1209727	http://dx.doi.org/10.1038/sj.onc.1209727			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767163				2022-12-25	WOS:000242419100010
J	Hogg, T; Nagarajan, K; Herzberg, S; Chen, LL; Shen, X; Jiang, HL; Wecke, M; Blohmke, C; Hilgenfeld, R; Schmidt, CL				Hogg, Tanis; Nagarajan, Krishna; Herzberg, Saskia; Chen, Lili; Shen, Xu; Jiang, Hualiang; Wecke, Maria; Blohmke, Christoph; Hilgenfeld, Rolf; Schmidt, Christian L.			Structural and functional characterization of falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE FALCIPAIN-2; CRYSTAL-STRUCTURE; INHIBITORS; PEPTIDE; PAPAIN; BIOSYNTHESIS; DETERMINANTS; SPECIFICITY; PLASMEPSINS; DISRUPTION	Malaria is caused by protozoan erythrocytic parasites of the Plasmodium genus, with Plasmodium falciparum being the most dangerous and widespread disease-causing species. Falcipain-2 (FP-2) of P. falciparum is a papain-family (C1A) cysteine protease that plays an important role in the parasite life cycle by degrading erythrocyte proteins, most notably hemoglobin. Inhibition of FP-2 and its paralogues prevents parasite maturation, suggesting these proteins may be valuable targets for the design of novel antimalarial drugs, but lack of structural knowledge has impeded progress toward the rational discovery of potent, selective, and efficacious inhibitors. As a first step toward this goal, we present here the crystal structure of mature FP-2 at 3.1 angstrom resolution, revealing novel structural features of the FP-2 subfamily proteases including a dynamic beta-hairpin hemoglobin binding motif, a flexible N-terminal alpha-helical extension, and a unique active-site cleft. We also demonstrate by biochemical methods that mature FP-2 can proteolytically process its own precursor in trans at neutral to weakly alkaline pH, that the binding of hemoglobin to FP-2 is strictly pH-dependent, and that FP-2 preferentially binds methemoglobin over hemoglobin. Because the specificity and proteolytic activity of FP-2 toward its multiple targets appears to be pH-dependent, we suggest that environmental pH may play an important role in orchestrating FP-2 function over the different life stages of the parasite. Moreover, it appears that selectivity of FP-2 for methemoglobin may represent an evolutionary adaptation to oxidative stress conditions within the host cell.	Med Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, D-23538 Lubeck, Germany; Chinese Acad Sci, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai Inst Mat Med,Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 201203, Peoples R China	University of Lubeck; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Hilgenfeld, R (corresponding author), Med Univ Lubeck, Inst Biochem, Ctr Struct & Cell Biol Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	hilgenfeld@biochem.uni-luebeck.de	Hilgenfeld, Rolf/C-9675-2011					Akompong T, 2000, ANTIMICROB AGENTS CH, V44, P88, DOI [10.1128/AAC.44.11.3107-3111.2000, 10.1128/AAC.44.1.88-96.2000]; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207; Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; Baird JK, 2002, AM J TROP MED HYG, V66, P659, DOI 10.4269/ajtmh.2002.66.659; Banerjee R, 2003, MOL BIOCHEM PARASIT, V129, P157, DOI 10.1016/S0166-6851(03)00119-1; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; BODE W, 2000, BIOCHIM BIOPHYS ACTA, V1343, P160; Brinen LS, 2000, STRUCT FOLD DES, V8, P831, DOI 10.1016/S0969-2126(00)00173-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe Y, 2005, BIOORGAN MED CHEM, V13, P2141, DOI 10.1016/j.bmc.2004.12.053; Dahl EL, 2005, MOL BIOCHEM PARASIT, V139, P205, DOI 10.1016/j.molbiopara.2004.11.009; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dhawan S, 2003, J BIOL CHEM, V278, P30180, DOI 10.1074/jbc.M305132200; Eksi S, 2004, MOL MICROBIOL, V53, P243, DOI 10.1111/j.1365-2958.2004.04108.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fasan R, 2006, CHEMBIOCHEM, V7, P515, DOI 10.1002/cbic.200500452; Francis SE, 1997, J BIOL CHEM, V272, P14961, DOI 10.1074/jbc.272.23.14961; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gelhaus C, 2004, BIOL CHEM, V385, P435, DOI 10.1515/BC.2004.050; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; Goh LL, 2005, BIOCHEM BIOPH RES CO, V335, P762, DOI 10.1016/j.bbrc.2005.07.147; Goh LL, 2004, BIOCHEM BIOPH RES CO, V323, P565, DOI 10.1016/j.bbrc.2004.08.130; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; Guncar G, 2000, STRUCTURE, V8, P305, DOI 10.1016/S0969-2126(00)00108-8; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; Huang L, 2003, BIOORGAN MED CHEM, V11, P21, DOI 10.1016/S0968-0896(02)00427-3; Jambou R, 2005, LANCET, V366, P1960, DOI 10.1016/S0140-6736(05)67787-2; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kesavulu MM, 2005, J PEPT RES, V66, P211, DOI 10.1111/j.1399-3011.2005.00288.x; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Leung-Toung R, 2006, CURR MED CHEM, V13, P547, DOI 10.2174/092986706776055733; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Muller S, 2004, MOL MICROBIOL, V53, P1291, DOI 10.1111/j.1365-2958.2004.04257.x; Murata CE, 2003, MOL BIOCHEM PARASIT, V129, P123, DOI 10.1016/S0166-6851(03)00098-7; Murata CE, 2003, J BIOL CHEM, V278, P38022, DOI 10.1074/jbc.M306842200; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; Pandey KC, 2005, P NATL ACAD SCI USA, V102, P9138, DOI 10.1073/pnas.0502368102; Pandey KC, 2004, J BIOL CHEM, V279, P3484, DOI 10.1074/jbc.M310536200; PICKERSGILL RW, 1992, ACTA CRYSTALLOGR B, V48, P59, DOI 10.1107/S0108768191006572; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robert A, 2001, PURE APPL CHEM, V73, P1173, DOI 10.1351/pac200173071173; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1987, J EXP MED, V166, P816, DOI 10.1084/jem.166.3.816; Sabnis Y, 2002, J BIOMOL STRUCT DYN, V19, P765, DOI 10.1080/07391102.2002.10506783; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Semenov A, 1998, ANTIMICROB AGENTS CH, V42, P2254, DOI 10.1128/AAC.42.9.2254; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2002, J BIOL CHEM, V277, P14910, DOI 10.1074/jbc.M109680200; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Sijwali PS, 2001, PROTEIN EXPRES PURIF, V22, P128, DOI 10.1006/prep.2001.1416; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Singh A, 2001, ANTIMICROB AGENTS CH, V45, P949, DOI 10.1128/AAC.45.3.949-951.2001; Singh N, 2006, EXP PARASITOL, V112, P187, DOI 10.1016/j.exppara.2005.10.007; Sobolewski P, 2005, INFECT IMMUN, V73, P6704, DOI 10.1128/IAI.73.10.6704-6710.2005; Steller I, 1997, J APPL CRYSTALLOGR, V30, P1036, DOI 10.1107/S0021889897008777; STOCKER R, 1985, P NATL ACAD SCI USA, V82, P548, DOI 10.1073/pnas.82.2.548; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 2004, ACTA CRYSTALLOGR D, V60, P2144, DOI 10.1107/S0907444904019535; Than ME, 2004, J MOL BIOL, V336, P1103, DOI 10.1016/j.jmb.2003.12.075; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; *WHO, 2005, WORLD MAL REP	71	100	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25425	25437		10.1074/jbc.M603776200	http://dx.doi.org/10.1074/jbc.M603776200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16777845	hybrid			2022-12-25	WOS:000240031300045
J	Nitto, T; Dyer, KD; Czapiga, M; Rosenberg, HF				Nitto, Takeaki; Dyer, Kimberly D.; Czapiga, Meggan; Rosenberg, Helene F.			Evolution and function of leukocyte RNase A ribonucleases of the avian species, Gallus gallus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; AMINO-ACID-SEQUENCE; ANTIMICROBIAL PROTEIN; MOLECULAR RECOGNITION; CHICKEN HETEROPHILS; CATIONIC PROTEIN; RAPID EVOLUTION; GENE; SUPERFAMILY; EXPRESSION	In this study, we explore the evolution and function of two closely related RNase A ribonucleases from the chicken, Gallus gallus. Separated by similar to 10 kb on chromosome 6, the coding sequences of RNases A-1 and A-2 are diverging under positive selection pressure (d(N) > d(S)) but remain similar to one another ( 81% amino acid identity) and to the mammalian angiogenins. Immunoreactive RNases A-1 and A-2 ( both similar to 16 kDa) were detected in peripheral blood granulocytes and bone marrow. Recombinant proteins are ribonucleolytically active (k(cat) = 2.6 and 0.056 s(-1), respectively), and surprisingly, both interact with human placental ribonuclease inhibitor. RNase A-2, the more cationic (pI 11.0), is both angiogenic and bactericidal; RNase A-1 ( pI 10.2) has neither activity. We demonstrated via point mutation of the catalytic His(110) that ablation of ribonuclease activity has no impact on the bactericidal activity of RNase A-2. We determined that the divergent domains II ( amino acids 71 - 76) and III ( amino acids 89 - 104) of RNase A-2 are both important for bactericidal activity. Furthermore, we demonstrated that these cationic domains can function as independent bactericidal peptides without the tertiary structure imposed by the RNase A backbone. These results suggest that ribonucleolytic activity may not be a crucial constraint limiting the ongoing evolution of this gene family and that the ribonuclease backbone may be merely serving as a scaffold to support the evolution of novel, non-ribonucleolytic proteins.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIAID, Res Technol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rosenberg, HF (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C215,9000 Rockville Pike, Bethesda, MD 20892 USA.	hrosenberg@niaid.nih.gov			NIAID NIH HHS [AI000942] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000942, Z01AI000942] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beintema JJ, 1998, CELL MOL LIFE SCI, V54, P825, DOI 10.1007/s000180050211; BEINTEMA JJ, 1985, EUR J BIOCHEM, V153, P305, DOI 10.1111/j.1432-1033.1985.tb09301.x; Bojesen AM, 2004, AVIAN DIS, V48, P463, DOI 10.1637/7151; Caldwell RB, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2004-6-1-r6; Castella S, 2004, BIOL REPROD, V71, P1677, DOI 10.1095/biolreprod.104.031666; Castella S, 2004, BIOL REPROD, V70, P319, DOI 10.1095/biolreprod.103.022459; Cho S, 2005, GENOMICS, V85, P208, DOI 10.1016/j.ygeno.2004.10.008; Cho SC, 2006, GENE, V373, P116, DOI 10.1016/j.gene.2006.01.018; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Costanzi J, 2005, CANCER INVEST, V23, P643, DOI 10.1080/07357900500283143; Devor EJ, 2004, HUM BIOL, V76, P921, DOI 10.1353/hub.2005.0016; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; DIJKSTRA J, 1978, BIOCHIM BIOPHYS ACTA, V521, P363, DOI 10.1016/0005-2787(78)90278-2; Dyer KD, 2004, J MOL EVOL, V59, P657, DOI 10.1007/s00239-004-2657-0; DYER KD, 2006, IN PRESS MOL DIVERS; EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661, DOI 10.1002/jlb.56.5.661; Farnell MB, 2003, INT IMMUNOPHARMACOL, V3, P1677, DOI 10.1016/S1567-5769(03)00205-4; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; HAYANO K, 1993, J BIOCHEM, V114, P156, DOI 10.1093/oxfordjournals.jbchem.a124132; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Iyer S, 2005, J MOL BIOL, V347, P637, DOI 10.1016/j.jmb.2005.01.035; KLENOVA EM, 1992, BIOCHEM BIOPH RES CO, V185, P231, DOI 10.1016/S0006-291X(05)80980-5; Kogut MH, 2003, J INTERF CYTOK RES, V23, P319, DOI 10.1089/107999003766628160; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Liao YD, 2000, NUCLEIC ACIDS RES, V28, P4097, DOI 10.1093/nar/28.21.4097; Lou YC, 2006, J MOL BIOL, V355, P409, DOI 10.1016/j.jmb.2005.10.069; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; Mellata M, 2003, INFECT IMMUN, V71, P494, DOI 10.1128/IAI.71.1.494-503.2003; NAKANO T, 1992, ONCOGENE, V7, P527; Nitto T, 2005, GENE, V352, P36, DOI 10.1016/j.gene.2005.03.002; Nitto T, 2004, GENES IMMUN, V5, P668, DOI 10.1038/sj.gene.6364143; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; Penttinen J, 2003, MOL ENDOCRINOL, V17, P2138, DOI 10.1210/me.2003-0008; Rath NC, 1998, VET IMMUNOL IMMUNOP, V64, P83, DOI 10.1016/S0165-2427(98)00122-6; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; Rosenberg HF, 1997, NUCLEIC ACIDS RES, V25, P3532, DOI 10.1093/nar/25.17.3532; ROSENBERG HF, 1995, J BIOL CHEM, V270, P21539, DOI 10.1074/jbc.270.37.21539; Rosenberg HF, 2001, J MOL EVOL, V53, P31, DOI 10.1007/s002390010188; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; SCHERMER S, 1967, BLOOD MORPHOLOGY LAB, P127; Seo SH, 2000, VIROLOGY, V269, P183, DOI 10.1006/viro.2000.0211; Singhania NA, 1999, J MOL EVOL, V49, P721, DOI 10.1007/PL00006594; Spalletti-Cernia D, 2003, J CLIN ENDOCR METAB, V88, P2900, DOI 10.1210/jc.2002-020373; Strydom DJ, 1998, CELL MOL LIFE SCI, V54, P811, DOI 10.1007/s000180050210; Swaggerty CL, 2005, FEMS IMMUNOL MED MIC, V43, P149, DOI 10.1016/j.femsim.2004.07.013; Swaggerty CL, 2004, IMMUNOLOGY, V113, P139, DOI 10.1111/j.1365-2567.2004.01939.x; WU YN, 1993, J BIOL CHEM, V268, P10686; Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151; Zhang JZ, 2000, P NATL ACAD SCI USA, V97, P4701, DOI 10.1073/pnas.080071397; Zhang JZ, 2003, NUCLEIC ACIDS RES, V31, P602, DOI 10.1093/nar/gkg157; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708; ZHAO W, 1994, EUR J BIOCHEM, V219, P641, DOI 10.1111/j.1432-1033.1994.tb19979.x; Zijlstra A, 2006, BLOOD, V107, P317, DOI 10.1182/blood-2005-04-1458	56	55	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25622	25634		10.1074/jbc.M604313200	http://dx.doi.org/10.1074/jbc.M604313200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803891	hybrid			2022-12-25	WOS:000240031300065
J	Gao, Y; El-Mashtoly, SF; Pal, B; Hayashi, T; Harada, K; Kitagawa, T				Gao, Ying; El-Mashtoly, Samir F.; Pal, Biswajit; Hayashi, Takashi; Harada, Katsuyoshi; Kitagawa, Teizo			Pathway of information transmission from heme to protein upon ligand binding/dissociation in myoglobin revealed by UV resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-WHALE; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; OXYGEN SENSOR; HEMOGLOBIN; BINDING; MECHANISM; MUTANTS; DOMAIN	Gas sensory heme proteins respond to their environment by binding a specific gas molecule to heme and transmitting this primary binding signal to the protein. How the binding signal is transmitted from the heme to the protein remains to be clarified. Using UV resonance Raman (UVRR) spectroscopy, we investigated this pathway in sperm whale myoglobin as a model gas sensory heme protein. Based on the UVRR data and the effects of deleting one of three important pathways (His-93, 6-propionate, or 7-propionate), we determined the changes in the conformation of globin that occur upon binding of CO, nitric oxide (NO), or O-2 to heme and how they are transmitted from heme to globin. The UVRR results show that heme discriminates different ligands, resulting in different conformations in the globin protein. Specifically, NO induces changes in the spectrum of Trp residues in the A-helix that are significantly different from those induced by O-2 or CO binding. On the other hand, binding of O2 to heme produces changes in the Tyr residues of the H-helix that are different from those induced by CO or NO binding. Furthermore, we found that cleavage of the Fe-His-93 covalent bond eliminates communication to the terminal region of the H-helix and that the 7-propionate hydrogen-bonding network is essential for transmitting the CO or NO binding signal to the N and C termini. Finally, the 6-propionate is important only for NO binding. Thus, the hydrogen-bonding network in the protein appears to be critical for intramolecular signal transduction in gas sensory heme proteins.	Grad Univ Adv Studies, Sch Adv Studies, Kanagawa 2400193, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Osaka University	Kitagawa, T (corresponding author), Grad Univ Adv Studies, Sch Adv Studies, Kanagawa 2400193, Japan.	teizo@ims.ac.jp	El-Mashtoly, Samir/C-8761-2014	El-Mashtoly, Samir/0000-0001-6087-8817; Hayashi, Takashi/0000-0002-2215-935X				Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; AUSTIN JC, 1993, BIOMOLECULAR SPECT A, V20, P55; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Brucker EA, 1998, PROTEINS, V30, P352, DOI 10.1002/(SICI)1097-0134(19980301)30:4<352::AID-PROT2>3.0.CO;2-L; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; Chan MK, 2000, NAT STRUCT BIOL, V7, P822, DOI 10.1038/79559; Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Haruta N, 2001, BIOCHEMISTRY-US, V40, P6956, DOI 10.1021/bi002640k; HAUKSSON JB, 1990, J AM CHEM SOC, V112, P6198, DOI 10.1021/ja00173a006; Hayashi T, 2004, CHEM LETT, V33, P1512, DOI 10.1246/cl.2004.1512; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; KILMARTIN JV, 1978, BIOCHIM BIOPHYS ACTA, V534, P15, DOI 10.1016/0005-2795(78)90471-3; Mizutani Y, 2001, CHEM REC, V1, P258, DOI 10.1002/tcr.1012; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Sato A, 2002, J BIOL CHEM, V277, P32650, DOI 10.1074/jbc.M204559200; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P14986, DOI 10.1021/bi00254a006; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAKANO T, 1977, J MOL BIOL, V110, P569, DOI 10.1016/S0022-2836(77)80112-5; Takeuchi H, 2003, BIOPOLYMERS, V72, P305, DOI 10.1002/bip.10440; Takeuchi H., 1986, ADV SPECTROSCOPY SPE, V13, P113; Tuckerman JR, 2002, BIOCHEMISTRY-US, V41, P6170, DOI 10.1021/bi025628w; Uchida T, 2005, ACCOUNTS CHEM RES, V38, P662, DOI 10.1021/ar030267d; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6	36	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24637	24646		10.1074/jbc.M603198200	http://dx.doi.org/10.1074/jbc.M603198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16774917	hybrid			2022-12-25	WOS:000239847800058
J	Hua, QX; Nakagawa, S; Hu, SQ; Jia, WH; Wang, SH; Weiss, MA				Hua, Qing-xin; Nakagawa, Satoe; Hu, Shi-Quan; Jia, Wenhua; Wang, Shuhua; Weiss, Michael A.			Toward the active conformation of insulin - Stereospecific modulation of a structural switch in the B chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SURFACE; DIABETES-ASSOCIATED MUTATIONS; A-CHAIN; ALPHA-HELIX; CIRCULAR-DICHROISM; CHIRAL MUTAGENESIS; CRYSTAL-STRUCTURE; PROTEIN; ANALOG; RECOGNITION	How insulin binds to the insulin receptor has long been a subject of speculation. Although the structure of the free hormone has been extensively characterized, a variety of evidence suggests that a conformational change occurs upon receptor binding. Here, we employ chiral mutagenesis, comparison of corresponding D and L amino acid substitutions, to investigate a possible switch in the B-chain. To investigate the interrelation of structure, function, and stability, isomeric analogs have been synthesized in which an invariant glycine in a beta-turn (Gly(B8)) is replaced by D- or L- Ser. The D substitution enhances stability (Delta Delta G(u) 0.9 kcal/mol) but impairs receptor binding by 100-fold; by contrast, the L substitution markedly impairs stability (Delta Delta G(u) - 3.0 kcal/mol) with only 2-fold reduction in receptor binding. Although the isomeric structures each retain a native-like overall fold, the L-Ser(B8) analog exhibits fewer helix-related and long range nuclear Overhauser effects than does the D-Ser(B8) analog or native monomer. Evidence for enhanced conformational fluctuations in the unstable analog is provided by its attenuated CD spectrum. The inverse relationship between stereospecific stabilization and receptor binding strongly suggests that the B7-B10 beta-turn changes conformation on receptor binding.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Case Western Reserve University; University of Chicago	Weiss, MA (corresponding author), Case Western Reserve Univ, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	maw21@case.edu			NIDDK NIH HHS [DK0697674, DK4094K] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anil B, 2004, J AM CHEM SOC, V126, P13194, DOI 10.1021/ja047119i; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BENTLEY G, 1976, NATURE, V261, P166, DOI 10.1038/261166a0; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; BRANGE J, 1988, NATURE, V333, P679, DOI 10.1038/333679a0; Brunger A. T, 1993, XPLOR MANUAL VERSION; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; CHU YC, 1994, BIOCHEMISTRY-US, V33, P11278, DOI 10.1021/bi00203a025; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Dong J, 2003, J MOL BIOL, V330, P431, DOI 10.1016/S0022-2836(03)00536-9; Guo ZY, 2005, ACTA BIOCH BIOPH SIN, V37, P673, DOI 10.1111/j.1745-7270.2005.00093.x; HU SQ, 1993, BIOCHEMISTRY-US, V32, P2631, DOI 10.1021/bi00061a022; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; HUA QX, 1991, BIOCHEMISTRY-US, V30, P5505, DOI 10.1021/bi00236a025; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUA QX, 1993, J MOL BIOL, V230, P387, DOI 10.1006/jmbi.1993.1156; Huang K, 2004, J MOL BIOL, V341, P529, DOI 10.1016/j.jmb.2004.05.023; KARATAS Y, 1991, BIOL CHEM H-S, V372, P1035, DOI 10.1515/bchm3.1991.372.2.1035; KOBAYASHI M, 1982, BIOCHEM BIOPH RES CO, V107, P329, DOI 10.1016/0006-291X(82)91708-9; Ludvigsen S, 1998, J MOL BIOL, V279, P1, DOI 10.1006/jmbi.1998.1801; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; Nakagawa SH, 2005, BIOCHEMISTRY-US, V44, P4984, DOI 10.1021/bi048025o; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; Nymeyer H, 1998, P NATL ACAD SCI USA, V95, P5921, DOI 10.1073/pnas.95.11.5921; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; SCHWARTZ G, 1978, BIOCHEMISTRY-US, V17, P4550, DOI 10.1021/bi00614a029; SCHWARTZ GP, 1987, P NATL ACAD SCI USA, V84, P6408, DOI 10.1073/pnas.84.18.6408; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; Sosnick TR, 2000, METHOD ENZYMOL, V317, P393; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Wan ZL, 2005, BIOCHEMISTRY-US, V44, P5000, DOI 10.1021/bi047585k; Wan ZL, 2003, BIOCHEMISTRY-US, V42, P12770, DOI 10.1021/bi034430o; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; Weiss MA, 2001, J BIOL CHEM, V276, P40018, DOI 10.1074/jbc.M104634200; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xu B, 2004, BIOCHEMISTRY-US, V43, P8356, DOI 10.1021/bi0497796; Xu B, 2002, J MOL BIOL, V316, P435, DOI 10.1006/jmbi.2001.5377; Xu B, 2002, PROTEIN SCI, V11, P104, DOI 10.1110/ps.ps.32102; Xu J, 2001, PROTEIN SCI, V10, P1067, DOI 10.1110/ps.02101; ZHAO M, 1998, P AM PEPT S, P369	48	43	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24900	24909		10.1074/jbc.M602691200	http://dx.doi.org/10.1074/jbc.M602691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16762918	hybrid			2022-12-25	WOS:000239847800083
J	Lin, KI; Kao, YY; Kuo, HK; Yang, WB; Chou, A; Lin, HH; Yu, AL; Wong, CH				Lin, Kuo-I; Kao, Yeong-Yi; Kuo, Hui-Kai; Yang, Wen-Bin; Chou, Alice; Lin, Hsin-Hung; Yu, Alice L.; Wong, Chi-Huey			Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; B-CELL DIFFERENTIATION; SECRETING PLASMA-CELLS; TOLL-LIKE RECEPTORS; NF-KAPPA-B; GANODERMA-LUCIDUM; ANTITUMOR ACTIVITIES; REPRESSOR BLIMP-1; DENDRITIC CELLS; EXPRESSION	The polysaccharides of Ganoderma lucidum ( Reishi) possess immunomodulation activities; however, their mode of molecular action in regulating each cellular subset in the immune system is still not clear. Here, we investigate the function of the main polysaccharide fraction of Reishi (Reishi-F3) in B lymphocyte activation/differentiation. We find that Reishi-F3 causes mouse splenic B cell activation and differentiation to IgM-secreting plasma cells, and the process depends on Reishi-F3-mediated induction of Blimp-1, a master regulator capable of triggering the changes of a cascade of gene expression during plasmacytic differentiation. In human peripheral B lymphocytes, although Reishi-F3 fails to induce their activation, it is able to enhance antibody secretion, which is associated with Blimp-1 mRNA induction. The function of Reishi-F3 depends on the Toll-like receptors TLR4/TLR2 as neutralizing antibodies against TLR4/TLR2 block Reishi-F3-mediated induction of Blimp- 1 mRNA and Ig secretion. We have shown that interaction of Reishi-F3 with TLR4/TLR2 followed by signaling through p38 MAPK is involved in the induction of Blimp- 1 mRNA, whereas signaling through ERK, p38 MAPK, JNK, and IKK complex is involved in Reishi- F3-mediated Ig secretion. Furthermore, the differential mechanism of Reishi-F3 in mouse and human B cell activation is probably due to the presence of Blimp- 1 regulatory site in human CD86 promoter. These results establish the signaling and molecular mechanisms of Reishi- F3 on promoting antibody secretion.	Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	Academia Sinica - Taiwan	Lin, KI (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sec 2,Nankang Dist, Taipei 115, Taiwan.	kuoilin@gate.sinica.edu.tw	Lin, KUO-I/C-6928-2009; Lin, Hsin-Hung/J-5254-2013	Lin, Hsin-Hung/0000-0001-8327-6835; yu, alice/0000-0003-2444-0505				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bonner S, 2001, INFECT IMMUN, V69, P3143, DOI 10.1128/IAI.69.5.3143-3149.2001; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Cao LZ, 2002, IMMUNOL LETT, V83, P163, DOI 10.1016/S0165-2478(02)00087-1; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; Chang DH, 2002, MECH DEVELOP, V117, P305, DOI 10.1016/S0925-4773(02)00189-2; Chen HS, 2004, BIOORGAN MED CHEM, V12, P5595, DOI 10.1016/j.bmc.2004.08.003; CHENBETTECKEN U, 1985, P NATL ACAD SCI USA, V82, P7384, DOI 10.1073/pnas.82.21.7384; Chien CA, 2004, BIOORGAN MED CHEM, V12, P5603, DOI 10.1016/j.bmc.2004.08.004; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dirsch VM, 2001, CANCER RES, V61, P5817; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Gao YH, 2005, IMMUNOL INVEST, V34, P171, DOI 10.1081/IMM-200055813; Gao YH, 2003, IMMUNOL INVEST, V32, P201, DOI 10.1081/IMM-120022979; Hayashi EA, 2005, J IMMUNOL, V174, P6639, DOI 10.4049/jimmunol.174.11.6639; Hsu HY, 2004, J IMMUNOL, V173, P5989, DOI 10.4049/jimmunol.173.10.5989; Johnson K, 2005, MOL IMMUNOL, V42, P749, DOI 10.1016/j.molimm.2004.06.039; Kallies A, 2006, NAT IMMUNOL, V7, P466, DOI 10.1038/ni1321; Li JF, 2000, HUM IMMUNOL, V61, P486, DOI 10.1016/S0198-8859(00)00099-9; LIEU CW, 1992, ANTICANCER RES, V12, P1211; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lin YL, 2005, J LEUKOCYTE BIOL, V78, P533, DOI 10.1189/jlb.0804481; Lin ZB, 2004, ACTA PHARMACOL SIN, V25, P1387; Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; MIYAZAKI T, 1981, CHEM PHARM BULL, V29, P3611; Nick JA, 1996, J IMMUNOL, V156, P4867; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shao BM, 2004, BIOCHEM BIOPH RES CO, V323, P133, DOI 10.1016/j.bbrc.2004.08.069; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; SIECKMANN DG, 1978, J EXP MED, V147, P814, DOI 10.1084/jem.147.3.814; Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Wang SY, 1997, INT J CANCER, V70, P699, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5; Wang YY, 2002, BIOORGAN MED CHEM, V10, P1057, DOI 10.1016/S0968-0896(01)00377-7; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Wetzler LM, 2003, VACCINE, V21, pS55, DOI 10.1016/S0264-410X(03)00201-9; Zhang JS, 2002, LIFE SCI, V71, P623, DOI 10.1016/S0024-3205(02)01690-9	47	114	132	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24111	24123		10.1074/jbc.M601106200	http://dx.doi.org/10.1074/jbc.M601106200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798741	Green Submitted, hybrid			2022-12-25	WOS:000239847800006
J	Dowal, L; Provitera, P; Scarlata, S				Dowal, Louisa; Provitera, Paxton; Scarlata, Suzanne			Stable association between G alpha(q) and phospholipase C beta(1) in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; RECEPTOR-MEDIATED ACTIVATION; BETA-GAMMA-SUBUNITS; MUTATIONAL ACTIVATION; MEMBRANE; C-BETA(2); ALPHA; LOCALIZATION; BINDING; DOMAIN	Signal transduction through G alpha(q) involves stimulation of phospholipase C beta (PLC beta) that results in increased intracellular Ca2+ and activation of protein kinase C. We have measured complex formation between G alpha(q) and PLC beta(1) in vitro and in living PC12 and HEK293 cells by fluorescence resonance energy transfer. In vitro measurements show that PLC beta(1) will bind to G alpha(q)(guanosine 5 '-3-O-(thio) triphosphate) and also to G alpha(q) (GDP), and the latter association has a different protein- protein orientation. In cells, image analysis of fluorescent-tagged proteins shows that G alpha(q) is localized almost entirely to the plasma membrane, whereas PLC beta(1) has a significant cytosolic population. By using fluorescence resonance energy transfer, we found that these proteins are pre-associated in the unstimulated state in PC12 and HEK293 cells. By determining the cellular levels of the two proteins in transfected versus non-transfected cells, we found that under our conditions overexpression should not significantly promote complex formation. G alpha(q)-PLC beta(1) complexes are observed in both single cell measurements and measurements of a large (i. e. 10(6)) cell suspension. The high level (similar to 40% maximum) of FRET is surprising considering that G alpha(q) is more highly expressed than PLC beta(1) and that not all PLC beta(1) is plasma membrane-localized. Our measurements suggest a model in which G proteins and effectors can exist in stable complexes prior to activation and that activation is achieved through changes in intermolecular interactions rather than diffusion and association. These pre-formed complexes in turn give rise to rapid, localized signals.	SUNY Stony Brook, Dept Phys & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Dept Phys & Biophys, Stony Brook, NY 11794 USA.	Suzanne.Scarlata@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V1, P37; Ballou LM, 2006, BIOCHEM J, V394, P557, DOI 10.1042/BJ20051493; Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Bortul R, 2002, J CELL BIOCHEM, V84, P56, DOI 10.1002/jcb.1266; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dowal L, 2001, BIOCHEMISTRY-US, V40, P414, DOI 10.1021/bi001923+; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Evanko DS, 2005, CELL SIGNAL, V17, P1218, DOI 10.1016/j.cellsig.2004.12.008; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; Lo W, 1998, BIOTECHNIQUES, V25, P94, DOI 10.2144/98251st05; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Philip F, 2004, BIOCHEMISTRY-US, V43, P11691, DOI 10.1021/bi049381+; Phillips GN, 1997, CURR OPIN STRUC BIOL, V7, P821, DOI 10.1016/S0959-440X(97)80153-4; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Scarlata S, 2005, BIOPHYS J, V88, P2867, DOI 10.1529/biophysj.104.055715; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VANDERMEER W, 1994, RESONANCE ENERGY TRA, P10; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	38	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23999	24014		10.1074/jbc.M512330200	http://dx.doi.org/10.1074/jbc.M512330200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16754659	hybrid			2022-12-25	WOS:000239702900074
J	Goto, Y; Hattori, A; Ishii, Y; Mizutani, S; Tsujimoto, M				Goto, Yoshikuni; Hattori, Akira; Ishii, Yasuhiro; Mizutani, Shigehiko; Tsujimoto, Masafumi			Enzymatic properties of human aminopeptidase A - Regulation of its enzymatic activity by calcium and angiotensin IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUROMYCIN-SENSITIVE AMINOPEPTIDASE; PLACENTAL LEUCINE AMINOPEPTIDASE/OXYTOCINASE; SITE-DIRECTED MUTAGENESIS; RECOMBINANT SOLUBLE FORM; HAMSTER OVARY CELLS; C-TERMINAL DOMAIN; EXOPEPTIDASE SPECIFICITY; MOLECULAR-CLONING; OXYTOCINASE SUBFAMILY; AT(4) RECEPTOR	Aminopeptidase A (APA) is a type II membrane-bound protein implicated in the regulation of blood pressure in the brain renin-angiotensin system. In this study, a recombinant soluble form of APA was expressed in a baculovirus system, purified to homogeneity, and characterized. By using synthetic substrates, it was shown that although the enzyme has a rather broad substrate specificity in the absence of Ca2+, the preferential release of acidic amino acid residues was observed in the presence of Ca2+. Moreover, Ca2+ up-or down-regulated the enzymatic activity depending on the substrate. By searching for natural substrates of APA, we found that peptides having acidic amino acids at their N terminus (angiotensin II, neurokinin B, cholecystokinin-8, and chromogranin A) were cleaved by the enzyme efficiently in the presence but not in the absence of Ca2+. Moreover kallidin (Lys-bradykinin) was converted to bradykinin effectively only in the absence of Ca2+. These results suggest that Ca2+ increases the preference of the enzyme for the peptide substrates having N-terminal acidic amino acids. In addition, we found that angiotensin IV could bind to APA both in the presence and absence of Ca2+ and inhibited the enzymatic activity of APA competitively, suggesting that angiotensin IV acts as a negative regulator of the enzyme once generated from angiotensin II by the serial actions of aminopeptidases. Taken together, these results suggest that there exists a complex regulation of the enzymatic activity of APA, which may contribute to homeostasis such as regulation of blood pressure, maintenance of memory, and normal pregnancy by controlling the concentrations of peptide substrates.	RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Tokyo Univ Agr & Technol, Lab Appl Prot Chem, Fuchu, Tokyo 1830054, Japan; Nagoya Univ, Sch Med, Dept Med Sci Proteases, Showa Ku, Nagoya, Aichi 4668550, Japan	RIKEN; Tokyo University of Agriculture & Technology; Nagoya University	Tsujimoto, M (corresponding author), RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan.	tsujimot@riken.jp						Albiston AL, 2003, TRENDS ENDOCRIN MET, V14, P72, DOI 10.1016/S1043-2760(02)00037-1; Albiston AL, 2001, J BIOL CHEM, V276, P48623, DOI 10.1074/jbc.C100512200; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; DANIELSEN EM, 1980, BIOCHEM J, V189, P591, DOI 10.1042/bj1890591; FERACCI H, 1981, BIOCHIM BIOPHYS ACTA, V658, P148, DOI 10.1016/0005-2744(81)90258-8; Fruitier-Arnaudin I, 2002, PEPTIDES, V23, P1465, DOI 10.1016/S0196-9781(02)00083-9; Goto Y, 2006, FEBS LETT, V580, P1833, DOI 10.1016/j.febslet.2006.02.041; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; Hesp JR, 1997, BIOCHEMISTRY-US, V36, P3000, DOI 10.1021/bi962401q; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; ITOH S, 1990, DRUG DEVELOP RES, V21, P257, DOI 10.1002/ddr.430210402; Iturrioz X, 2000, BIOCHEMISTRY-US, V39, P3061, DOI 10.1021/bi9925726; Iturrioz X, 2001, BIOCHEMISTRY-US, V40, P14440, DOI 10.1021/bi011409j; LALU K, 1986, BIOCHIM BIOPHYS ACTA, V873, P190, DOI 10.1016/0167-4838(86)90045-2; Lew RA, 2003, J NEUROCHEM, V86, P344, DOI 10.1046/j.1471-4159.2003.01852.x; Matsumoto H, 2000, EUR J BIOCHEM, V267, P46, DOI 10.1046/j.1432-1327.2000.00949.x; Migaud M, 1996, PEPTIDES, V17, P601, DOI 10.1016/0196-9781(96)00036-8; Mitsui T, 2003, MOL MED, V9, P57, DOI 10.1007/BF03402108; MIZUTANI S, 1987, ARCH GYNECOL OBSTET, V240, P27, DOI 10.1007/BF02134061; Nakanishi Y, 2000, PLACENTA, V21, P628, DOI 10.1053/plac.2000.0564; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Nomura M, 2005, AM J HYPERTENS, V18, P538, DOI 10.1016/j.amjhyper.2004.11.010; Nomura S, 2005, BBA-PROTEINS PROTEOM, V1751, P19, DOI 10.1016/j.bbapap.2005.04.006; Ofner LD, 2002, BIOCHEM J, V362, P191, DOI 10.1042/0264-6021:3620191; OKUYAMA T, 1991, CLIN CHIM ACTA, V196, P207, DOI 10.1016/0009-8981(91)90074-M; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Reaux A, 1999, P NATL ACAD SCI USA, V96, P13415, DOI 10.1073/pnas.96.23.13415; Rozenfeld R, 2004, J BIOL CHEM, V279, P43285, DOI 10.1074/jbc.M404369200; Rozenfeld R, 2003, BIOCHEMISTRY-US, V42, P14785, DOI 10.1021/bi034358u; Rozenfeld R, 2002, J BIOL CHEM, V277, P29242, DOI 10.1074/jbc.M204406200; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Tobler AR, 1997, J NEUROCHEM, V68, P889; Tsujimoto M, 2005, BBA-PROTEINS PROTEOM, V1751, P9, DOI 10.1016/j.bbapap.2004.09.011; TSUJIMOTO M, 1992, ARCH BIOCHEM BIOPHYS, V292, P388, DOI 10.1016/0003-9861(92)90007-J; Vazeux G, 1998, EUR J BIOCHEM, V254, P671, DOI 10.1046/j.1432-1327.1998.2540671.x; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; WANG J, 1998, HDB PROTEOLYTIC ENZY, P1002; WANG JY, 1993, P NATL ACAD SCI USA, V90, P1222, DOI 10.1073/pnas.90.4.1222; Wright JW, 2004, PROG NEUROBIOL, V72, P263, DOI 10.1016/j.pneurobio.2004.03.003; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YAMADA R, 1988, ENZYME, V40, P223, DOI 10.1159/000469167; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	48	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23503	23513		10.1074/jbc.M603191200	http://dx.doi.org/10.1074/jbc.M603191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790432	hybrid			2022-12-25	WOS:000239702900025
J	Liu, H; Nakazawa, T; Tezuka, T; Yamamoto, T				Liu, Hui; Nakazawa, Takanobu; Tezuka, Tohru; Yamamoto, Tadashi			Physical and functional interaction of Fyn tyrosine kinase with a brain-enriched Rho GTPase-activating protein TCGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; D-ASPARTATE RECEPTOR; ACTIN STRESS FIBERS; SRC FAMILY KINASES; NEURITE OUTGROWTH; CELL-ADHESION; C-SRC; NEURONAL MORPHOGENESIS; BINDING-PROTEIN; AXON OUTGROWTH	Fyn, a member of the Src family of tyrosine kinases, is implicated in both brain development and adult brain function. In the present study, we identified a Rho GTPase-activating protein (GAP), TCGAP (Tc10Cdc42 GTPase-activating protein), as a novel Fyn substrate. TCGAP interacted with Fyn and was phosphorylated by Fyn, with Tyr-406 in the GAP domain as a major Fyn-mediated phosphorylation site. Fyn suppressed the GAP activity of wild-type TCGAP but not the Y406F mutant of TCGAP in a phosphorylation-dependent manner, suggesting that Fyn-mediated Tyr-406 phosphorylation negatively regulated the TCGAP activity. In situ hybridization analyses showed that TCGAP mRNA was expressed prominently in both immature and adult mouse brain, with high levels in cortex, corpus striatum, hippocampus, and olfactory bulb. Overexpression of wild-type TCGAP in PC12 cells suppressed nerve growth factor-induced neurite outgrowth, whereas a GAP-defective mutant of TCGAP enhanced the neurite outgrowth. Nerve growth factor enhanced tyrosine phosphorylation of TCGAP through activation of Src family kinases. These results suggest that TCGAP is involved in Fyn-mediated regulation of axon and dendrite outgrowth.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Nakazawa, Takanobu/E-1012-2014	Nakazawa, Takanobu/0000-0002-5049-9140; NAKAZAWA, Takanobu/0000-0003-4863-1277				Aoki K, 2004, J BIOL CHEM, V279, P713, DOI 10.1074/jbc.M306382200; Baron W, 1999, J NEUROBIOL, V41, P385, DOI 10.1002/(SICI)1097-4695(19991115)41:3<385::AID-NEU7>3.0.CO;2-E; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BIXBY JL, 1993, J NEUROSCI, V13, P3421; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chiang SH, 2003, EMBO J, V22, P2679, DOI 10.1093/emboj/cdg262; Dent EW, 1998, J NEUROBIOL, V35, P287, DOI 10.1002/(SICI)1097-4695(19980605)35:3<287::AID-NEU6>3.0.CO;2-V; Derrien A, 2003, J BIOL CHEM, V278, P16107, DOI 10.1074/jbc.M210371200; Dey N, 2005, EXP CELL RES, V307, P1, DOI 10.1016/j.yexcr.2005.02.029; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Fukazawa' Y, 2003, NEURON, V38, P447, DOI 10.1016/S0896-6273(03)00206-X; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kawa S, 2004, GENES CELLS, V9, P219, DOI 10.1111/j.1356-9597.2004.00714.x; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Knoll B, 2004, J NEUROSCI, V24, P6248, DOI 10.1523/JNEUROSCI.0985-04.2004; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Morse WR, 1998, J NEUROBIOL, V36, P53, DOI 10.1002/(SICI)1097-4695(199807)36:1<53::AID-NEU5>3.0.CO;2-9; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oh JS, 2004, J BIOL CHEM, V279, P17980, DOI 10.1074/jbc.M314109200; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Taniguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P151, DOI 10.1016/S0006-291X(03)00923-9; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wolf RM, 2001, J NEUROBIOL, V49, P62, DOI 10.1002/neu.1066; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; YAGI T, 1993, ONCOGENE, V8, P3343; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	67	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23611	23619		10.1074/jbc.M511205200	http://dx.doi.org/10.1074/jbc.M511205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777849	hybrid			2022-12-25	WOS:000239702900036
J	Garcia-Pedrero, JM; Kiskinis, E; Parker, MG; Belandia, B				Garcia-Pedrero, Juana M.; Kiskinis, Evangelos; Parker, Malcolm G.; Belandia, Borja			The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-DEPENDENT PHOSPHORYLATION; P160 COACTIVATOR PROTEINS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; TUMOR-SUPPRESSOR; EXPRESSION; BETA; PROLIFERATION; ALPHA; COMPLEX	Estrogen receptors (ERs) play critical roles in both normal mammary gland development and in the formation and progression of breast tumors, constituting a major therapeutic target for breast cancer treatment. We have previously described that ER transcriptional activity is potentiated by BAF57, a core subunit of the mammalian SWI/SNF chromatin remodeling complex. Here we provide evidence demonstrating an important role for BAF57 as regulator of ER functions in breast cancer cells. Different experimental manipulations leading to the abrogation of BAF57 expression and/or function severely reduced the expression of various endogenous ER target genes and blocked estrogen-stimulated proliferation in ZR-75-1 breast cancer cells. Moreover, using a structure-function analysis, we have defined the protein domains required for the functional interaction between ER alpha and BAF57, including a key region within the hinge of ER alpha that is essential for BAF57 recruitment and its function on ER-mediated transcription. Interestingly, we found that BAF57 is an ER subtype-selective modulator that specifically regulates ER alpha-mediated transcription. Taken together, our results suggest that targeting BAF57 could represent a new way to effectively inhibit the action of ER alpha.	Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Madrid 28029, Spain; Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Imperial College London	Belandia, B (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Arturo Duperier 4, Madrid 28029, Spain.	bbelandia@iib.uam.es	Belandia, Borja/H-1509-2015; Pedrero, Juana María García/AAP-4251-2021	Belandia, Borja/0000-0003-2448-206X; Pedrero, Juana María García/0000-0002-5891-9488	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arteaga CL, 1996, CANCER RES, V56, P1098; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; del Rio B, 2004, J BIOL CHEM, V279, P38294, DOI 10.1074/jbc.M403140200; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Lu CH, 2005, ONCOGENE, V24, P6516, DOI 10.1038/sj.onc.1208905; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mohrmann L, 2005, BBA-GENE STRUCT EXPR, V1681, P59, DOI 10.1016/j.bbaexp.2004.10.005; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	43	76	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22656	22664		10.1074/jbc.M602561200	http://dx.doi.org/10.1074/jbc.M602561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769725	hybrid			2022-12-25	WOS:000239542600026
J	Singh, AK; Mullick, J; Bernet, J; Sahu, A				Singh, Akhilesh K.; Mullick, Jayati; Bernet, John; Sahu, Arvind			Functional characterization of the complement control protein homolog of herpesvirus saimiri - Arg-118 is critical for factor I cofactor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE PATHWAY; FACTOR-H; MOLECULAR-MECHANISMS; SWISS-MODEL; AMINO-ACIDS; VACCINIA; IDENTIFICATION; INHIBITOR; COMPONENTS; REGULATOR	Herpesvirus saimiri (HVS) is a lymphotropic virus that causes T-cell lymphomas in New World primates. It encodes a structural homolog of complement control proteins named complement control protein homolog (CCPH). Previously, CCPH has been shown to inhibit C3d deposition on target cells exposed to complement. Here we have studied the mechanism by which it inactivates complement. We have expressed the soluble form of CCPH in Escherichia coli, purified to homogeneity and compared its activity to vaccinia virus complement control protein (VCP) and human complement regulators factor H and soluble complement receptor 1. The expressed soluble form of CCPH bound to C3b (K-D = 19.2 mu M) as well as to C4b (K-D = 0.8 mu M) and accelerated the decay of the classical/lectin as well as alternative pathway C3-convertases. In addition, it also served as factor I cofactor and supported factor I-mediated inactivation of both C3b and C4b. Time course analysis indicated that although its rate of inactivation of C4b is comparable with VCP, it is 14-fold more potent than VCP in inactivating C3b. Site-directed mutagenesis revealed that Arg-118, which corresponds to Lys-120 of variola virus complement regulator SPICE (a residue critical for its enhanced C3b cofactor activity), contributes significantly in enhancing this activity. Thus, our data indicate that HVS encodes a potent complement inhibitor that allows HVS to evade the host complement attack.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Sahu, A (corresponding author), Natl Ctr Cell Sci, Pune Univ Campus, Pune 411007, Maharashtra, India.	arvindsahu@nccs.res.in	Sahu, Arvind/C-2178-2012	Johnson, John/0000-0003-4287-4489; Sahu, Arvind/0000-0003-1664-2422				ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Bernet J, 2004, J VIROL, V78, P9446, DOI 10.1128/JVI.78.17.9446-9457.2004; Bernet J, 2003, J BIOSCIENCES, V28, P249, DOI 10.1007/BF02970145; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Cabanillas JA, 2002, CLIN EXP IMMUNOL, V127, P366, DOI 10.1046/j.1365-2249.2002.01716.x; Cooper N., 1998, HUMAN COMPLEMENT SYS, P393; DESROSIERS RC, 1982, J VIROL, V43, P352, DOI 10.1128/JVI.43.1.352-356.1982; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FODOR WL, 1995, J VIROL, V69, P3889, DOI 10.1128/JVI.69.6.3889-3892.1995; Gewurz BE, 2001, CURR OPIN IMMUNOL, V13, P442, DOI 10.1016/S0952-7915(00)00239-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Kapadia SB, 2002, IMMUNITY, V17, P143, DOI 10.1016/S1074-7613(02)00369-2; Kapadia SB, 1999, J VIROL, V73, P7658, DOI 10.1128/JVI.73.9.7658-7670.1999; Kirkitadze MD, 1999, BIOCHEMISTRY-US, V38, P7019, DOI 10.1021/bi982453a; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Kotwal GJ, 2000, IMMUNOL TODAY, V21, P242, DOI 10.1016/S0167-5699(00)01606-6; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x; Lachmann PJ, 2002, P NATL ACAD SCI USA, V99, P8461, DOI 10.1073/pnas.132284499; LAMBRIS JD, 1998, HUMAN COMPLEMENT SYS, P83; Liszewski MK, 2006, J IMMUNOL, V176, P3725, DOI 10.4049/jimmunol.176.6.3725; Mark L, 2004, J BIOL CHEM, V279, P45093, DOI 10.1074/jbc.M407558200; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; Means RE, 2002, CURR TOP MICROBIOL, V269, P187; Means RE, 2002, FRONT BIOSCI-LANDMRK, V7, pE185, DOI 10.2741/means; Mullick J, 2005, J VIROL, V79, P12382, DOI 10.1128/JVI.79.19.12382-12393.2005; Mullick J, 2005, J VIROL, V79, P5850, DOI 10.1128/JVI.79.9.5850-5856.2005; Mullick J, 2003, TRENDS IMMUNOL, V24, P500, DOI 10.1016/S1471-4906(03)00207-2; Mullick J, 2003, J VIROL, V77, P3878, DOI 10.1128/JVI.77.6.3878-3881.2003; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; Pan Q, 2000, J IMMUNOL, V165, P2518, DOI 10.4049/jimmunol.165.5.2518; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; PRYZDIAL ELG, 1986, MOL IMMUNOL, V23, P87, DOI 10.1016/0161-5890(86)90175-6; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; SAHU A, 1994, J BIOL CHEM, V269, P28997; Sahu A, 1998, J IMMUNOL, V160, P5596; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; SEYA T, 1990, J BIOCHEM, V107, P310, DOI 10.1093/oxfordjournals.jbchem.a123044; Sfyroera G, 2005, J IMMUNOL, V174, P2143, DOI 10.4049/jimmunol.174.4.2143; Spiller OB, 2003, J BIOL CHEM, V278, P9283, DOI 10.1074/jbc.M211579200; Stehle T, 2003, INFEC DIS S, P231; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604; Zhang L, 2006, BIOPHYS J, V90, P3106, DOI 10.1529/biophysj.105.068130	56	26	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23119	23128		10.1074/jbc.M603085200	http://dx.doi.org/10.1074/jbc.M603085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760474	hybrid			2022-12-25	WOS:000239542600076
J	Zhao, BH; Katagiri, T; Toyoda, H; Takada, T; Yanai, T; Fukuda, T; Chung, UI; Koike, T; Takaoka, K; Kamijo, R				Zhao, Baohong; Katagiri, Takenobu; Toyoda, Hiromitsu; Takada, Takatora; Yanai, Takako; Fukuda, Toru; Chung, Ung-il; Koike, Tatsuya; Takaoka, Kunio; Kamijo, Ryutaro			Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; SULFATE PROTEOGLYCAN; INDUCTIVE PROTEIN; GROWTH-FACTOR; BETA FAMILY; DIFFERENTIATION; OSTEOBLAST; VERTEBRATES; EXPRESSION; REGULATORS	Although bone morphogenetic proteins (BMPs) are clinically useful for bone regeneration, large amounts are required to induce new bone formation in monkeys and humans. We found recently that heparin stimulates BMP activity in vitro (Takada, T., Katagiri, T., Ifuku, M., Morimura, N., Kobayashi, M., Hasegawa, K., Ogamo, A., and Kamijo, R. (2003) J. Biol. Chem. 278, 43229-43235). In the present study, we examined whether heparin enhances bone formation induced by BMPs in vivo and attempted to determine the molecular mechanism by which heparin stimulates BMP activity using C2C12 myoblasts. Heparin enhanced BMP-2-induced gene expression and Smad1/5/8 phosphorylation at 24 h and thereafter, although not within 12 h. Heparitinase treatment did not affect the response of cells to BMP-2. In the presence of heparin, degradation of BMP-2 was blocked, and the half-life of BMP-2 in the culture medium was prolonged by nearly 20-fold. Although noggin mRNA was induced by BMP-2 within 1 h regardless of the presence of heparin, noggin failed to inhibit BMP-2 activity in the presence of heparin. Furthermore, simultaneous administration of BMP-2 and heparin in vivo dose-dependently induced larger amounts of mineralized bone tissue compared with BMP-2 alone. These findings clearly indicate that heparin enhances BMP-induced osteoblast differentiation not only in vitro but also in vivo. This study indicates that heparin enhances BMP-induced osteoblast differentiation in vitro and in vivo by protecting BMPs from degradation and inhibition by BMP antagonists.	Saitama Med Univ, Res Ctr Genom Med, Div Pathophysiol, Hidaka, Saitama 3501241, Japan; Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Dent, Dept Periodontol, Shinagawa Ku, Tokyo 1428555, Japan; Osaka City Univ, Sch Med, Dept Orthopaed Surg, Osaka 5458585, Japan; Univ Tokyo, Fac Med, Div Tissue Engn, Tokyo 1138655, Japan	Saitama Medical University; Showa University; Showa University; Osaka Metropolitan University; University of Tokyo	Katagiri, T (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Pathophysiol, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan.	katagiri@saitama-med.ac.jp						Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Kusumoto K, 2002, J INT MED RES, V30, P251, DOI 10.1177/147323000203000305; Ladd AN, 1998, DEV BIOL, V204, P407, DOI 10.1006/dbio.1998.9094; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; OLWIN BB, 1991, ANN NY ACAD SCI, V638, P195, DOI 10.1111/j.1749-6632.1991.tb49030.x; Pacifici M, 2005, J BONE MINER METAB, V23, P191, DOI 10.1007/s00774-004-0584-1; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; Sykaras Nikitas, 2003, J Oral Sci, V45, P57; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Toyoda H, 2005, BONE, V37, P555, DOI 10.1016/j.bone.2005.04.042; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yanai T, 2001, J BONE MINER METAB, V19, P345, DOI 10.1007/s007740170003; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoon BS, 2004, J CELL BIOCHEM, V93, P93, DOI 10.1002/jcb.20211	31	232	242	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23246	23253		10.1074/jbc.M511039200	http://dx.doi.org/10.1074/jbc.M511039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754660	hybrid			2022-12-25	WOS:000239542600087
J	Gao, XX; Harris, TK				Gao, Xinxin; Harris, Thomas K.			Steady-state kinetic mechanism of PDK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RIBOSOMAL S6 KINASE; CATALYTIC MECHANISM; BINDING POCKET; DOCKING-SITE; IN-VIVO; ACTIVATION; PHOSPHORYLATION; ISOFORMS; 3-KINASE	PDK1 catalyzes phosphorylation of Thr in the conserved activation loop region of a number of its downstream AGC kinase family members. In addition to the consensus sequence at the site of phosphorylation, a number of PDK1 substrates contain a PIF sequence ( PDK1-interacting fragment), which binds and activates the kinase domain of PDK1 (PDK1(Delta PH)). To gain further insight to PIF-dependent catalysis, steady-state kinetic and inhibition studies were performed for His6-PDK1(Delta PH)-catalyzed phosphorylation of PDK1-Tide ( Tide), which contains an extended "PIF" sequence C-terminal to the consensus sequence for PDK1 phosphorylation. In two-substrate kinetics, a large degree of negative binding synergism was observed to occur on formation of the active ternary complex (alpha K-d(ATP) = 40 mu M and alpha K-d(Tide) = 80 mu M) from individual transitory binary complexes (K-d(ATP) = 0.6 mu M and K-d(Tide) = 1 mu M). On varying ATP concentrations, the ADP product and the (T/E)-PDK1-Tide product analog (p' Tide) behaved as competitive and noncompetitive inhibitors, respectively; on varying Tide concentrations, ADP and p' Tide behaved as noncompetitive and competitive inhibitors, respectively. Also, negative binding synergism was associated with formation of dead-end inhibited ternary complexes. Time progress curves in pre-steady-state studies under "saturating" or k(cat) conditions showed (i) no burst or lag phenomena, ( ii) no change in reaction velocity when adenosine 5'-O(thiotriphosphate) was used as a phosphate donor, and (iii) no change in reaction velocity on increasing relative microviscosity ( 0 <= eta/eta(0) 0 <= 3). Taken together, PDK1-catalyzed trans-phosphorylation of PDK1-Tide approximates a Rapid Equilibrium Random Bi Bi system, where motions in the central ternary complex are largely rate-determining.	Univ Miami, Dept Biochem & Mol Biol, Miller Sch Med, Miami, FL 33136 USA; Univ Miami, Dept Chem, Coral Gables, FL 33124 USA	University of Miami; University of Miami	Harris, TK (corresponding author), Univ Miami, Dept Biochem & Mol Biol, Miller Sch Med, POB 016129, Miami, FL 33101 USA.	tkharris@miami.edu	Gao, Xinxin/D-3795-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069868] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069868, GM69868, R01 GM069868-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Aubol BE, 2004, J BIOL CHEM, V279, P30182, DOI 10.1074/jbc.M402797200; Aubol BE, 2002, BIOCHEMISTRY-US, V41, P10002, DOI 10.1021/bi020233y; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Biondi RM, 2004, TRENDS BIOCHEM SCI, V29, P136, DOI 10.1016/j.tibs.2004.01.005; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COLE PA, 1994, J BIOL CHEM, V269, P30880; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Enke DK, 2000, J BIOL CHEM, V275, P33267, DOI 10.1074/jbc.M004748200; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Gao XX, 2005, PROTEIN EXPRES PURIF, V43, P44, DOI 10.1016/j.pep.2005.03.017; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leatherbarrow R. J., 1998, GRAFIT VERSION 4 0; LEISER SA, 2005, BIOCHIM BIOPHYS ACTA, V1754, P191; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; MANNING BD, 2002, SCI STKE, V162, pPE49; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Obenauer John C, 2004, Methods Mol Biol, V261, P445; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; POSNER I, 1992, J BIOL CHEM, V267, P20638; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rainey MA, 2005, J AM CHEM SOC, V127, P10494, DOI 10.1021/ja052915p; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Segel I.H., 1975, ENZYME KINETICS; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Szafranska AE, 2005, FEBS J, V272, P4631, DOI 10.1111/j.1742-4658.2005.04827.x; Torbett NE, 2003, J BIOL CHEM, V278, P32344, DOI 10.1074/jbc.M303532200; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P8948, DOI 10.1021/bi0258243; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Waas WF, 2004, BBA-PROTEINS PROTEOM, V1697, P81, DOI 10.1016/j.bbapap.2003.11.015; Waas WF, 2003, BIOCHEMISTRY-US, V42, P12273, DOI 10.1021/bi0348617; Waas WF, 2002, J BIOL CHEM, V277, P12532, DOI 10.1074/jbc.M110523200; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l	52	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21670	21681		10.1074/jbc.M602448200	http://dx.doi.org/10.1074/jbc.M602448200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737971	hybrid, Green Accepted			2022-12-25	WOS:000239387100012
J	Browne, RO; Ben Moyal-Segal, L; Zumsteg, D; David, Y; Kofman, O; Berger, A; Soreq, H; Friedman, A				Browne, R. Orie; Ben Moyal-Segal, Liat; Zumsteg, Dominik; David, Yaron; Kofman, Ora; Berger, Andrea; Soreq, Hermona; Friedman, Alon			Coding region paraoxonase polymorphisms dictate accentuated neuronal reactions in chronic, sub-threshold pesticide exposure	FASEB JOURNAL			English	Article						acetylcholinesterase; electroencephalography; LORETA; organophosphates; subthreshold exposure	CORTICAL CHOLINERGIC INPUTS; ELECTROMAGNETIC TOMOGRAPHY; BASAL FOREBRAIN; ORGANOPHOSPHATE PESTICIDES; CARDIOVASCULAR-DISEASE; ATTENTIONAL FUNCTIONS; AFFERENT-PROJECTIONS; PON1 POLYMORPHISMS; SERUM PARAOXONASE; OXIDATIVE STRESS	Organophosphate pesticides (OPs), known inhibitors of acetylcholinesterase (AChE), are used extensively throughout the world. Recent studies have focused on the ACHE/PON1 locus as a determinant of inherited susceptibility to environmental OP exposure. To explore the relationship of the corresponding gene-environment interactions with brain activity, we integrated neurophysiologic, neuropsychological, biochemical, and genetic methods. Importantly, we found that subthreshold OP exposure leads to discernible physiological consequences that are significantly influenced by inherited factors. Cortical EEG analyses by LORETA revealed significantly decreased theta activity in the hippocampus, parahippocampal regions, and the cingulate cortex, as well as increased beta activity in the prefrontal cortex of exposed individuals-areas known to play a role in cholinergic-associated cognitive functions. Through neuropsychological testing, we identified an appreciable deficit in the visual recall in exposed individuals. Other neuropsychological tests revealed no significant differences between exposed and non-exposed individuals, attesting to the specificity of our findings. Biochemical analyses of blood samples revealed increases in paraoxonase and arylesterase activities and reduced serum acetylcholinesterase activity in chronically exposed individuals. Notably, specific paraoxonase genotypes were found to be associated with these exposure-related changes in blood enzyme activities and abnormal EEG patterns. Thus, gene-environment interactions involving the ACHE/PON1 locus may be causally involved in determining the physiological response to OP exposure.	Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Behav Sci, IL-84105 Beer Sheva, Israel; Hebrew Univ Jerusalem, Soroka Univ Med Ctr, Dept Physiol, IL-91905 Jerusalem, Israel; Hebrew Univ Jerusalem, Soroka Univ Med Ctr, Dept Neurosurg, IL-91905 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91905 Jerusalem, Israel; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M4X 1K9, Canada	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem; Ben Gurion University; Soroka Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Friedman, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel.	alonf@bgu.ac.il	Berger, Andrea/F-1427-2012	Berger, Andrea/0000-0001-5557-4114; Soreq, Hermona/0000-0002-0955-526X				Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Benmoyal-Segal L, 2005, FASEB J, V19, P452, DOI 10.1096/fj.04-2106fje; BESWICK FW, 1987, OXFORD TXB MED; BOWERS MB, 1964, J NERV MENT DIS, V138, P383; Brophy VH, 2001, AM J HUM GENET, V68, P1428, DOI 10.1086/320600; Brown MA, 1998, J APPL TOXICOL, V18, P393, DOI 10.1002/(SICI)1099-1263(199811/12)18:6<393::AID-JAT528>3.0.CO;2-0; Bryk B, 2005, J NEUROCHEM, V92, P1216, DOI 10.1111/j.1471-4159.2004.02959.x; Bucci DJ, 1998, J NEUROSCI, V18, P8038; BURCHFIEL JL, 1982, NEUROBEH TOXICOL TER, V4, P767; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Chiba AA, 1999, NEUROREPORT, V10, P3119, DOI 10.1097/00001756-199909290-00044; Costa LG, 2003, ANNU REV MED, V54, P371, DOI 10.1146/annurev.med.54.101601.152421; Dale AM, 2000, NEURON, V26, P55, DOI 10.1016/S0896-6273(00)81138-1; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; DUBOIS KP, 1949, J PHARMACOL EXP THER, V95, P79; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Fiedler N, 1997, AM J IND MED, V32, P487, DOI 10.1002/(SICI)1097-0274(199711)32:5&lt;487::AID-AJIM8&gt;3.0.CO;2-P; FURLONG CE, 1989, ANAL BIOCHEM, V180, P242, DOI 10.1016/0003-2697(89)90424-7; Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; Gill TM, 2000, J NEUROSCI, V20, P4745, DOI 10.1523/JNEUROSCI.20-12-04745.2000; GLICK D, 2003, BUTYRYLCHOLINESTERAS, P55; Hernandez AF, 2004, J TOXICOL ENV HEAL A, V67, P1095, DOI 10.1080/15287390490452371; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kaufer D, 1999, CURR OPIN NEUROL, V12, P739, DOI 10.1097/00019052-199912000-00014; Kocsis B, 2001, EUR J NEUROSCI, V13, P381, DOI 10.1046/j.0953-816X.2000.01392.x; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kozak R, 2006, CEREB CORTEX, V16, P9, DOI 10.1093/cercor/bhi079; LEVIN HS, 1976, ARCH GEN PSYCHIAT, V33, P225; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Martinez V, 2004, BEHAV NEUROSCI, V118, P984, DOI 10.1037/0735-7044.118.5.984; McGaughy J, 2002, J NEUROSCI, V22, P1905, DOI 10.1523/JNEUROSCI.22-05-01905.2002; McGaughy J, 2000, BEHAV BRAIN RES, V115, P251, DOI 10.1016/S0166-4328(00)00262-X; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; Metcalf D R, 1969, Ann N Y Acad Sci, V160, P357, DOI 10.1111/j.1749-6632.1969.tb15857.x; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P91; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; Pavlovsky L, 2005, J NEUROL, V252, P42, DOI 10.1007/s00415-005-0596-3; Ray DE, 2001, TOXICOL LETT, V120, P343, DOI 10.1016/S0378-4274(01)00266-1; RICHTER ED, 1992, ISRAEL J MED SCI, V28, P584; RODNITZKY RL, 1975, ARCH ENVIRON HEALTH, V30, P98, DOI 10.1080/00039896.1975.10666651; Rodrigo L, 2001, CHEM-BIOL INTERACT, V137, P123, DOI 10.1016/S0009-2797(01)00225-3; Sarter M, 1999, ANN NY ACAD SCI, V877, P368, DOI 10.1111/j.1749-6632.1999.tb09277.x; Sarter M, 2005, BRAIN RES REV, V48, P98, DOI 10.1016/j.brainresrev.2004.08.006; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; Schmidt R, 2002, CEREBROVASC DIS, V13, P16, DOI 10.1159/000049145; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SOREQ H, 2005, ENCY STRESS; Steenland K, 2000, ENVIRON HEALTH PERSP, V108, P293, DOI 10.2307/3454346; STEWART M, 1990, TRENDS NEUROSCI, V13, P163, DOI 10.1016/0166-2236(90)90040-H; Strik WK, 1998, EVOKED POTENTIAL, V108, P406, DOI 10.1016/S0168-5597(98)00021-5; Sukov W, 1998, J NEUROPHYSIOL, V79, P2875, DOI 10.1152/jn.1998.79.6.2875; Talairach J., 1988, COPLANAR STEREOTAXIC; TAYLOR P, 2001, GOODMAN GILMANS PHAR, P131; Turchi J, 2000, EUR J NEUROSCI, V12, P4505, DOI 10.1111/j.1460-9568.2000.01347.x; Vertes Robert P, 2004, Behav Cogn Neurosci Rev, V3, P173, DOI 10.1177/1534582304273594; Vertes RP, 1997, NEUROSCIENCE, V81, P893; VINOGRADOVA OS, 1995, PROG NEUROBIOL, V45, P523, DOI 10.1016/0301-0082(94)00051-I; WEINER L, 1994, BIOCHEM BIOPH RES CO, V198, P915, DOI 10.1006/bbrc.1994.1130	67	39	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1733	+		10.1096/fj.05-5576fje	http://dx.doi.org/10.1096/fj.05-5576fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807370				2022-12-25	WOS:000240266600031
J	Lee, SJ; Marintcheva, B; Hamdan, SM; Richardson, CC				Lee, Seung-Joo; Marintcheva, Boriana; Hamdan, Samir M.; Richardson, Charles C.			The C-terminal residues of bacteriophage T7 gene 4 helicase-primase coordinate helicase and DNA polymerase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DEOXYRIBONUCLEIC-ACID; STRAND-DISPLACEMENT; ESCHERICHIA-COLI; BINDING PROTEIN; PROCESSIVITY; REPLICATION; DOMAIN; REQUIREMENTS; HYDROLYSIS	The gene 4 protein of bacteriophage T7 plays a central role in DNA replication by providing both helicase and primase activities. The C-terminal helicase domain is not only responsible for DNA-dependent dTTP hydrolysis, translocation, and DNA unwinding, but it also interacts with T7 DNA polymerase to coordinate helicase and polymerase activities. The C-terminal 17 residues of gene 4 protein are critical for its interaction with the T7 DNA polymerase/thioredoxin complex. This C terminus is highly acidic; replacement of these residues with uncharged residues leads to a loss of interaction with T7 DNA polymerase/thioredoxin and an increase in oligomerization of the gene 4 protein. Such an alteration on the C terminus results in a reduced efficiency in strand displacement DNA synthesis catalyzed by gene 4 protein and T7 DNA polymerase/thioredoxin. Replacement of the C-terminal amino acid, phenylalanine, with non-aromatic residues also leads to a loss of interaction of gene 4 protein with T7 DNA polymerase/ thioredoxin. However, neither of these modifications of the C terminus affects helicase and primase activities. A chimeric gene 4 protein containing the acidic C terminus of the T7 gene 2.5 single-stranded DNA-binding protein is more active in strand displacement synthesis. Gene 4 hexamers containing even one subunit of a defective C terminus are defective in their interaction with T7 DNA polymerase.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu		Hamdan, Samir/0000-0001-5192-1852	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andraos N, 2004, J BIOL CHEM, V279, P50609, DOI 10.1074/jbc.M408428200; Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027; Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102; HUBER HE, 1986, J BIOL CHEM, V261, P5006; Kamtekar S, 2004, MOL CELL, V16, P609, DOI 10.1016/j.molcel.2004.10.019; KIM YT, 1994, J BIOL CHEM, V269, P5270; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Marintcheva B, 2006, J BIOL CHEM, V281, P25831, DOI 10.1074/jbc.M604601200; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Rodriguez I, 2005, P NATL ACAD SCI USA, V102, P6407, DOI 10.1073/pnas.0500597102; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8	19	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25841	25849		10.1074/jbc.M604602200	http://dx.doi.org/10.1074/jbc.M604602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807231	Green Published, hybrid			2022-12-25	WOS:000240031300086
J	Kang, BH; Altieri, DC				Kang, Byoung Heon; Altieri, Dario C.			Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE COMPLEX; AH RECEPTOR; CELL-CYCLE; APOPTOSIS; LOCALIZATION; CHECKPOINT; CANCER; HSP90; XAP2	Survivin is a multifunctional member of the IAP ( inhibitor of apoptosis) family, but its molecular interactions in protection from cell death and regulation of cell division have not been completely elucidated. In a proteomics screening to identify novel survivin-binding partners, we found that the aryl hydrocarbon receptor-interacting protein (AIP) directly associates with survivin in vitro and in co-immunoprecipitation experiments in vivo. This interaction is mediated by the carboxyl-terminal end of AIP, which contains three tetratricopeptide motifs, and involves the carboxyl terminus coiled coil in survivin with critical roles of Asp142 in AIP recognition. A survivin mutant lacking only Asp142 fails to bind AIP and exhibits accelerated degradation in vivo in a reaction reversed by a proteasome inhibitor. Acute knock-down of AIP by short interference RNA or competition of the survivin AIP complex by peptidyl mimicry destabilizes survivin levels in cells, with enhanced apoptosis but no changes in cell cycle progression. Therefore, AIP regulates survivin stability, thus elevating a cellular anti-apoptotic threshold. The survivin-AIP complex may influence the cellular xenobiotic response to environmental toxin(s) and contribute to subcellular chaperone trafficking during cell death regulation.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Kang, Byoung Heon/E-6165-2010	Kang, Byoung Heon/0000-0001-5902-0549	NATIONAL CANCER INSTITUTE [R01CA078810, R01CA090917] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131] Funding Source: NIH RePORTER; NCI NIH HHS [CA78810, CA90917] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Andreola F, 1997, CANCER RES, V57, P2835; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Carver LA, 1997, J BIOL CHEM, V272, P11452; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Earnshaw WC, 2005, SCIENCE, V310, P1443, DOI 10.1126/science.1121952; Fortugno P, 2002, J CELL SCI, V115, P575; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wall NR, 2003, CANCER RES, V63, P230; Yang L, 2004, GENE THER, V11, P1215, DOI 10.1038/sj.gt.3302280; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	29	62	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24721	24727		10.1074/jbc.M603175200	http://dx.doi.org/10.1074/jbc.M603175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807248	hybrid			2022-12-25	WOS:000239847800068
J	Melloni, E; Averna, M; Stifanese, R; De Tullio, R; Defranchi, E; Salamino, F; Pontremoli, S				Melloni, Edon; Averna, Monica; Stifanese, Roberto; De Tullio, Roberta; Defranchi, Enrico; Salamino, Franca; Pontremoli, Sandro			Association of calpastatin with inactive calpain - A novel mechanism to control the activation of the protease?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE CALPAIN; ENDOGENOUS INHIBITOR; SKELETAL-MUSCLE; MU-CALPAIN; RAT-BRAIN; CRYSTAL-STRUCTURE; COMPLEX-FORMATION; RABBIT LIVER; KINASE-C; CALCIUM	It is generally accepted that the Ca2+-dependent interaction of calpain with calpastatin is the most relevant mechanism involved in the regulation of Ca2+-induced proteolysis. We now report that a calpain-calpastatin association can occur also in the absence of Ca2+ or at very low Ca2+ concentrations, reflecting the physiological conditions under which calpain retains its inactive conformational state. The calpastatin binding region is localized in the non-inhibitory L-domain containing the amino acid sequences encoded by exons 4 - 7. This calpastatin region recognizes a calpain sequence located near the end of the DII-domain. Interaction of calpain with calpastatins lacking these sequences becomes strictly Ca2+-dependent because, under these conditions, the transition to an active state of the protease is an obligatory requirement. The occurrence of the molecular association between Ca2+-free calpain and various recombinant calpastatin forms has been demonstrated by the following experimental results. Addition of calpastatin protected calpain from trypsin digestion. Calpain was coprecipitated when calpastatin was immunoprecipitated. The calpastatin molecular size increased following exposure to calpain. The two proteins comigrated in zymogram analysis. Furthermore, calpain-calpastatin interaction was perturbed by protein kinase C phosphorylation occurring at sites located at the exons involved in the association. At a functional level, calpain-calpastatin interaction at a physiological concentration of Ca2+ represents a novel mechanism for the control of the amount of the active form of the protease potentially generated in response to an intracellular Ca2+ influx.	Univ Genoa, Biochem Sect, Dept Expt Med, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy	University of Genoa; University of Genoa	Pontremoli, S (corresponding author), Univ Genoa, Biochem Sect, Dept Expt Med, Viale Benedetto 15, I-16132 Genoa, Italy.	pontremoli@unige.it	AVERNA, MONICA/R-5719-2019	AVERNA, MONICA/0000-0002-9463-7533; DE TULLIO, ROBERTA/0000-0001-6925-3207				ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; Averna M, 2006, FEBS J, V273, P1660, DOI 10.1111/j.1742-4658.2006.05180.x; Averna M, 1999, FEBS LETT, V450, P13, DOI 10.1016/S0014-5793(99)00461-5; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Barnoy S, 1999, J CELL BIOCHEM, V74, P522, DOI 10.1002/(SICI)1097-4644(19990915)74:4<522::AID-JCB2>3.0.CO;2-I; Betts R, 2004, BIOCHEMISTRY-US, V43, P2596, DOI 10.1021/bi0359832; Betts R, 2003, J BIOL CHEM, V278, P7800, DOI 10.1074/jbc.M208350200; Brandenburg K, 2002, EUR J BIOCHEM, V269, P5414, DOI 10.1046/j.1432-1033.2002.03225.x; COTTIN P, 1981, FEBS LETT, V136, P221, DOI 10.1016/0014-5793(81)80622-9; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dainese E, 2002, J BIOL CHEM, V277, P40296, DOI 10.1074/jbc.M204471200; De Tullio R, 1998, FEBS LETT, V422, P113, DOI 10.1016/S0014-5793(97)01588-3; De Tullio R, 1999, BIOCHEM J, V343, P467; Doroshenko N, 2004, BIOCHEM PHARMACOL, V67, P903, DOI 10.1016/j.bcp.2003.10.005; Dutt P, 2002, BIOCHEM J, V367, P263, DOI 10.1042/BJ20020485; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1988, J BIOL CHEM, V263, P2364; Fabrice R, 2006, INT J BIOCHEM CELL B, V38, P404, DOI 10.1016/j.biocel.2005.09.020; FAHIEN LA, 1974, J BIOL CHEM, V249, P2696; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; GOLL DE, 1992, BIOCHIMIE, V74, P225, DOI 10.1016/0300-9084(92)90121-T; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; IMAJOH S, 1985, FEBS LETT, V187, P47, DOI 10.1016/0014-5793(85)81211-4; ISHIDA S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LEE WJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P251, DOI 10.1016/0167-4781(92)90500-Y; MA H, 1994, J BIOL CHEM, V269, P24430; MACGREGOR JS, 1980, P NATL ACAD SCI-BIOL, V77, P3889, DOI 10.1073/pnas.77.7.3889; Maddock KR, 2005, J ANIM SCI, V83, P1370; Melloni E, 1998, FEBS LETT, V431, P55, DOI 10.1016/S0014-5793(98)00724-8; Michetti M, 1997, BIOCHEM J, V325, P721, DOI 10.1042/bj3250721; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2001, BBA-PROTEIN STRUCT M, V1545, P245, DOI 10.1016/S0167-4838(00)00286-7; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; MURACHI T, 1989, BIOCHEM INT, V18, P263; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; PALEJWALA S, 1992, P NATL ACAD SCI USA, V89, P4202, DOI 10.1073/pnas.89.9.4202; Parr T, 2001, ARCH BIOCHEM BIOPHYS, V395, P1, DOI 10.1006/abbi.2001.2546; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G; PONTREMOLI S, 1984, P NATL ACAD SCI-BIOL, V81, P53, DOI 10.1073/pnas.81.1.53; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; Salamino F, 1997, FEBS LETT, V412, P433, DOI 10.1016/S0014-5793(97)00819-3; SHIGETA K, 1984, BIOCHEM INT, V9, P327; Simon J., 2000, CALPAIN METHODS PROT, P109; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Takano J, 1999, BIOCHEM BIOPH RES CO, V260, P339, DOI 10.1006/bbrc.1999.0903; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Temm-Grove CJ, 1999, EXP CELL RES, V247, P293, DOI 10.1006/excr.1998.4362; Tompa P, 2002, J BIOL CHEM, V277, P9022, DOI 10.1074/jbc.C100700200; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wendt A, 2004, BIOL CHEM, V385, P465, DOI 10.1515/BC.2004.054	61	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24945	24954		10.1074/jbc.M601449200	http://dx.doi.org/10.1074/jbc.M601449200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803906	hybrid			2022-12-25	WOS:000239847800087
J	Myers, SA; Wang, SCM; Muscat, GEO				Myers, Stephen A.; Wang, S. -C. Mary; Muscat, George E. O.			The chicken ovalbumin upstream promoter-transcription factors modulate genes and pathways involved in skeletal muscle cell metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; OXYGEN SPECIES PRODUCTION; ACTIVATED RECEPTOR-ALPHA; RETINOID-X-RECEPTOR; UNCOUPLING PROTEIN-3; NUCLEAR RECEPTORS; LIPID-METABOLISM; COUP-TFII; ORPHAN RECEPTOR; CROSS-TALK	The chicken ovalbumin upstream promoter-transcription factors ( COUP-TFs) are "orphan" members of the nuclear hormone receptor ( NR) superfamily. COUP-TFs are involved in organogenesis and neurogenesis. However, their role in skeletal muscle ( and other major mass tissues) and metabolism remains obscure. Skeletal muscle accounts for similar to 40% of total body mass and energy expenditure. Moreover, this peripheral tissue is a primary site of glucose and fatty acid utilization. We utilize small interfering RNA ( siRNA)-mediated attenuation of Coup-TfI and II ( mRNA and protein) in a skeletal muscle cell culture model to understand the regulatory role of Coup-Tfs in this energy demanding tissue. This targeted NR repression resulted in the significant attenuation of genes that regulate lipid mobilization and utilization ( including Ppar alpha, Fabp3, and Cpt-1). This was coupled to reduced fatty acid beta-oxidation. Additionally we observed significant attenuation of Ucp1, a gene involved in energy expenditure. Concordantly, we observed a 5-fold increase in ATP levels in cells with siRNA-mediated repression of Coup-TfI and II. Furthermore, the expression of "classical" liver X receptor ( LXR) target genes involved in reverse cholesterol transport ( Abca1 and Abcg1) were both significantly repressed. Moreover, we observed that repression of the Coup-Tfs ablated the activation of Abca1, and Abcg1 mRNA expression by the selective LXR agonist, T0901317. In concordance, Coup-Tf-siRNA-transfected cells were refractory to Lxr-mediated reduction of total intracellular cholesterol levels in contrast to the negative control cells. In agreement Lxr-mediated activation of the Abca1 promoter in Coup-Tf-siRNA cells was attenuated. Collectively, these data suggest a pivotal role for Coup-Tfs in the regulation of lipid utilization/cholesterol homeostasis in skeletal muscle cells and the modulation of Lxr-dependent gene regulation.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Myers, SA (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	s.myers@imb.uq.edu.au; g.muscat@imb.uq.edu.au	; Muscat, George/A-6401-2017; Wang, Shu-Ching/C-6082-2017	Myers, Stephen/0000-0003-4793-3820; Muscat, George/0000-0002-5829-5695; Wang, Shu-Ching/0000-0002-7871-3735				Anderson SP, 2004, MOL PHARMACOL, V66, P1440, DOI 10.1124/mol.104.005496; Ando H, 2005, ATHEROSCLEROSIS, V178, P265, DOI 10.1016/j.atherosclerosis.2004.09.016; Bardoux P, 2005, DIABETES, V54, P1357, DOI 10.2337/diabetes.54.5.1357; Bevilacqua L, 2005, AM J PHYSIOL-ENDOC M, V289, pE429, DOI 10.1152/ajpendo.00435.2004; Blanco G, 2004, NEUROMUSCULAR DISORD, V14, P217, DOI 10.1016/j.nmd.2003.09.008; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Chabowski A, 2005, J PHYSIOL PHARMACOL, V56, P381; Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6; Crestani M, 1998, J LIPID RES, V39, P2192; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Ferrer-Martinez A, 2004, BBA-GENE STRUCT EXPR, V1678, P157, DOI 10.1016/j.bbaexp.2004.02.003; Furmanczyk PS, 2003, CELL BIOL INT, V27, P845, DOI 10.1016/S1065-6995(03)00172-0; Garcia-Martinez C, 2001, FASEB J, V15, P2033, DOI 10.1096/fj.00-0828fje; GAUDET F, 1995, J BIOL CHEM, V270, P29916; Gonzalez-Muniesa P, 2005, J PHYSIOL BIOCHEM, V61, P389, DOI 10.1007/BF03167056; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gupta S, 2002, BIOCHEM BIOPH RES CO, V293, P338, DOI 10.1016/S0006-291X(02)00229-2; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hegardt FG, 1998, BIOCHIMIE, V80, P803, DOI 10.1016/S0300-9084(00)88874-4; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; HOSHIZAKI DK, 1994, DEVELOPMENT, V120, P2489; Kontani Y, 2005, AGING CELL, V4, P147, DOI 10.1111/j.1474-9726.2005.00157.x; KontrogianniKonstantopoulos A, 1996, DEV BIOL, V177, P371, DOI 10.1006/dbio.1996.0171; Koonen DPY, 2005, BBA-MOL CELL BIOL L, V1736, P163, DOI 10.1016/j.bbalip.2005.08.018; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lau P, 2004, J BIOL CHEM, V279, P36828, DOI 10.1074/jbc.M404927200; Lee CT, 2004, MOL CELL BIOL, V24, P10835, DOI 10.1128/MCB.24.24.10835-10843.2004; Lengacher S, 2004, J CEREBR BLOOD F MET, V24, P780, DOI 10.1097/01.WCB.0000122743.72175.52; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; Menke JG, 2002, ENDOCRINOLOGY, V143, P2548, DOI 10.1210/en.143.7.2548; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; Muscat GEO, 2002, J BIOL CHEM, V277, P40722, DOI 10.1074/jbc.M206681200; Nakamura T, 1999, J LIPID RES, V40, P1709; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plomgaard P, 2005, EXERC IMMUNOL REV, V11, P53; QIU Y, 1995, GENOMICS, V29, P240, DOI 10.1006/geno.1995.1237; Quinn LBS, 2005, CELL BIOL INT, V29, P449, DOI 10.1016/j.cellbi.2005.02.005; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; Ramakrishnan SN, 2005, J BIOL CHEM, V280, P8651, DOI 10.1074/jbc.M413949200; Schmitt B, 2003, PHYSIOL GENOMICS, V15, P148, DOI 10.1152/physiolgenomics.00089.2003; Schmitz G, 2005, BBA-MOL CELL BIOL L, V1735, P1, DOI 10.1016/j.bbalip.2005.04.004; Schrauwen P, 2004, P NUTR SOC, V63, P287, DOI 10.1079/PNS2003336; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Smith AG, 2005, INT J BIOCHEM CELL B, V37, P2047, DOI 10.1016/j.biocel.2005.03.002; Stroup D, 2000, J LIPID RES, V41, P1; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Stroup D, 1997, J BIOL CHEM, V272, P9833; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Wang S, 2003, DIABETES OBES METAB, V5, P295, DOI 10.1046/j.1463-1326.2003.00273.x; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	55	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24149	24160		10.1074/jbc.M601941200	http://dx.doi.org/10.1074/jbc.M601941200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803904	hybrid			2022-12-25	WOS:000239847800009
J	Qiao, LP; MacDougald, OA; Shao, JH				Qiao, Liping; MacDougald, Ormond A.; Shao, Jianhua			CCAAT/enhancer-binding protein alpha mediates induction of hepatic phosphoenolpyruvate carboxykinase by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; GENE-TRANSCRIPTION; GTP GENE; LIVER; GLUCOSE; STRESS; GLUCONEOGENESIS; INFLAMMATION; EXPRESSION; ENHANCER	Excessive hepatic gluconeogenesis and glucose production are important contributors to hyperglycemia in both type 1 and type 2 diabetes. In diabetic humans and animal models, elevated levels of p38 mitogen-activated protein kinase (p38) are observed in several tissues. Our study shows that activity of p38 is significantly elevated in livers of db/db or streptozocin-induced type 1 diabetic mice. Using cultured hepatoma cells, we find that activation of p38 enhances expression of hepatic gluconeogenic gene phosphoenolpyruvate carboxykinase (PEPCK). Furthermore, our studies demonstrate that activation of p38 stimulates phosphorylation of CCAAT/enhancer-binding protein alpha (C/EBP alpha) at serine 21 and increases its transactivation activity in the context of PEPCK gene transcription. Our results indicate that C/EBP alpha mediates p38-stimulated PEPCK transcription in liver cells.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Kentucky; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shao, JH (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, 900 S Limestone, Lexington, KY 40536 USA.	JianhuaShao@uky.edu		MacDougald, Ormond/0000-0001-6907-7960				Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Feifel E, 2002, AM J PHYSIOL-RENAL, V283, pF678, DOI 10.1152/ajprenal.00097.2002; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; Hanson RW, 2005, J BIOL CHEM, V280, P1705, DOI 10.1074/jbc.X400009200; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; Kondo T, 2004, J BIOL CHEM, V279, P37997, DOI 10.1074/jbc.M401339200; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIU JS, 1991, J BIOL CHEM, V266, P19095; Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Qiao LP, 2006, ENDOCRINOLOGY, V147, P3060, DOI 10.1210/en.2005-1507; Qiao LP, 2005, DIABETES, V54, P1744, DOI 10.2337/diabetes.54.6.1744; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Shao JH, 2005, DIABETES, V54, P976, DOI 10.2337/diabetes.54.4.976; Srinivasan S, 2004, J BIOL CHEM, V279, P31930, DOI 10.1074/jbc.M400753200; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Wang D, 2006, ENDOCRINOLOGY, V147, P350, DOI 10.1210/en.2005-1014; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wei YR, 2004, AM J PHYSIOL-ENDOC M, V287, pE926, DOI 10.1152/ajpendo.00185.2004; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	39	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24390	24397		10.1074/jbc.M603038200	http://dx.doi.org/10.1074/jbc.M603038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807249	hybrid			2022-12-25	WOS:000239847800032
J	Conchaudron, AP; Didry, D; Le, KHD; Larquet, E; Boisset, N; Pantaloni, D; Carlier, MF				Conchaudron, Andrea Pelikan; Didry, Dominique; Le, Kim Ho Diep; Larquet, Eric; Boisset, Nicolas; Pantaloni, Dominique; Carlier, Marie-France			Analysis of tetramethylrhodamine-labeled actin polymerization and interaction with actin regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; STRUCTURAL BASIS; ARP2/3 COMPLEX; FILAMENT NUCLEATION; CRYSTAL-STRUCTURE; CAPPING PROTEINS; MONOMERIC ACTIN; ATP HYDROLYSIS; BETA-ACTIN; DYNAMICS	The hydrolysis of ATP accompanying actin polymerization destabilizes the filament, controls actin assembly dynamics in motile processes, and allows the specific binding of regulatory proteins to ATP- or ADP-actin. However, the relationship between the structural changes linked to ATP hydrolysis and the functional properties of actin is not understood. Labeling of actin Cys(374) by tetramethylrhodamine (TMR) has been reported to make actin non-polymerizable and enabled the crystal structures of ADP-actin and 5 '-adenylyl beta, gamma-imidodiphosphate-actin to be solved. TMR-actin has also been used to solve the structure of actin in complex with the formin homology 2 domain of mammalian Dia1. To understand how the covalent modification of actin by TMR may affect the structural changes linked to ATP hydrolysis and to evaluate the functional relevance of crystal structures of TMR-actin in complex with actin-binding proteins, we have analyzed the assembly properties of TMR-actin and its interaction with regulatory proteins. We show that TMR-actin polymerized in very short filaments that were destabilized by ATP hydrolysis. The critical concentrations for assembly of TMR-actin in ATP and ADP were only an order of magnitude higher than those for unlabeled actin. The functional interactions of actin with capping proteins, formin, actin-depolymerizing factor/cofilin, and the VCA-Arp2/3 filament branching machinery were profoundly altered by TMR labeling. The data suggest that TMR labeling hinders the intramolecular movements of actin that allow its specific adaptative recognition by regulatory proteins and that determine its function in the ATP- or ADP-bound state.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 06, Inst Mineral & Phys Mat Condensee, F-75252 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr	larquet, eric/ABB-3063-2021	larquet, eric/0000-0002-9994-6845				Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1985, J BIOL CHEM, V260, P6565; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CASELLA JF, 1995, CELL MOTIL CYTOSKEL, V30, P164, DOI 10.1002/cm.970300208; Chereau D, 2005, P NATL ACAD SCI USA, V102, P16644, DOI 10.1073/pnas.0507021102; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; Egelman EH, 2001, NAT STRUCT BIOL, V8, P735, DOI 10.1038/nsb0901-735; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Fujiwara I, 2002, NAT CELL BIOL, V4, P666, DOI 10.1038/ncb841; Galkin VE, 2003, J CELL BIOL, V163, P1057, DOI 10.1083/jcb.200308144; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Irobi E, 2004, EMBO J, V23, P3599, DOI 10.1038/sj.emboj.7600372; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Klenchin VA, 2003, NAT STRUCT BIOL, V10, P1058, DOI 10.1038/nsb1006; Kudryashov DS, 2003, BIOPHYS J, V85, P2466, DOI 10.1016/S0006-3495(03)74669-4; Kudryashov DS, 2004, BIOPHYS J, V87, P1136, DOI 10.1529/biophysj.104.042242; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Muhlrad A, 2004, J MOL BIOL, V342, P1559, DOI 10.1016/j.jmb.2004.08.010; Ojala PJ, 2001, BIOCHEMISTRY-US, V40, P15562, DOI 10.1021/bi0117697; OOSAWA F, 1975, THERMODYNAMICS POLYM, P47; Orlova A, 2004, P NATL ACAD SCI USA, V101, P17664, DOI 10.1073/pnas.0407525102; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; ROSS PD, 1975, J MOL BIOL, V96, P239, DOI 10.1016/0022-2836(75)90345-9; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; TAIT JF, 1982, ARCH BIOCHEM BIOPHYS, V216, P133, DOI 10.1016/0003-9861(82)90197-7; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048	50	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24036	24047		10.1074/jbc.M602747200	http://dx.doi.org/10.1074/jbc.M602747200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16757474	hybrid			2022-12-25	WOS:000239702900077
J	Yang, MH; Mailhot, G; Birnbaum, MJ; MacKay, CA; Mason-Savas, A; Odgren, PR				Yang, Meiheng; Mailhot, Genevieve; Birnbaum, Mark J.; MacKay, Carole A.; Mason-Savas, April; Odgren, Paul R.			Expression of and role for ovarian cancer G-protein-coupled receptor 1 (OGR1) during osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CAMP ACCUMULATION; IN-VITRO; BONE; RAT; LIGAND; ACID; SPHINGOSYLPHOSPHORYLCHOLINE; DIFFERENTIATION; IDENTIFICATION	Osteoclasts differentiate from hematopoietic mononuclear precursor cells under the control of both colony stimulating factor-1 (CSF-1, or M-CSF) and receptor activator of NF-kappa B ligand (RANKL, or TRANCE, TNFSF11) to carry out bone resorption. Using high density gene microarrays, we followed gene expression changes in long bone RNA when CSF-1 injections were used to restore osteoclast populations in the CSF1-null toothless (csf1(tl)/csf1(tl)) osteopetrotic rat. We found that ovarian cancer G-protein-coupled receptor 1 (OGR1, or GPR68) was strongly up-regulated, rising > 6-fold in vivo after 2 days of CSF-1 treatments. OGR1 is a dual membrane receptor for both protons (extracellular pH) and lysolipids. Strong induction of OGR1 mRNA was also observed by microarray, real-time RT-PCR, and immunoblotting when mouse bone marrow mononuclear cells and RAW 264.7 pre-osteoclast-like cells were treated with RANKL to induce osteoclast differentiation. Anti-OGR1 immunofluorescence showed intense labeling of RANKL-treated RAW cells. The time course of OGR1 mRNA expression suggests that OGR1 induction is early but not immediate, peaking 2 days after inducing osteoclast differentiation both in vivo and in vitro. Specific inhibition of OGR1 by anti-OGR1 antibody and by small inhibitory RNA inhibited RANKL-induced differentiation of both mouse bone marrow mononuclear cells and RAW cells in vitro, as evidenced by a decrease in tartrate-resistant acid phosphatase-positive osteoclasts. Taken together, these data indicate that OGR1 is expressed early during osteoclastogenesis both in vivo and in vitro and plays a role in osteoclast differentiation.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Merrimack Coll, Dept Biol, N Andover, MA 01845 USA	University of Massachusetts System; University of Massachusetts Worcester; Merrimack College	Odgren, PR (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, S7-242,55 Lake Ave N, Worcester, MA 01655 USA.	paul.odgren@umassmed.edu	Mailhot, Genevieve/AAL-1310-2020; Mailhot, Genevieve/AAB-8928-2020	Mailhot, Genevieve/0000-0002-2673-6492; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE007444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07444] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balemans W, 2005, CALCIFIED TISSUE INT, V77, P263, DOI 10.1007/s00223-005-0027-6; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Dobbins DE, 2002, BIOCHEM BIOPH RES CO, V294, P1114, DOI 10.1016/S0006-291X(02)00598-3; Frick KK, 2005, AM J PHYSIOL-RENAL, V289, pF1005, DOI 10.1152/ajprenal.00420.2004; Frick KK, 2003, J BONE MINER RES, V18, P1317, DOI 10.1359/jbmr.2003.18.7.1317; Jahr H, 2005, BIOCHEM BIOPH RES CO, V337, P349, DOI 10.1016/j.bbrc.2005.09.054; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102; Lemann J, 2003, AM J PHYSIOL-RENAL, V285, pF811, DOI 10.1152/ajprenal.00115.2003; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Mogi C, 2005, J PHARMACOL SCI, V99, P160, DOI 10.1254/jphs.FP0050599; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Tomura H, 2005, J BIOL CHEM, V280, P34458, DOI 10.1074/jbc.M505287200; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Van Wesenbeeck L, 2002, P NATL ACAD SCI USA, V99, P14303, DOI 10.1073/pnas.202332999; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Y, 2006, NAT CELL BIOL, V8, P299; Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood-2005-08-3365; Yang MH, 2005, CYTOKINE, V31, P94, DOI 10.1016/j.cyto.2005.04.001	20	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23598	23605		10.1074/jbc.M602191200	http://dx.doi.org/10.1074/jbc.M602191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787916	hybrid			2022-12-25	WOS:000239702900034
J	Balsara, RD; Castellino, FJ; Ploplis, VA				Balsara, Rashna D.; Castellino, Francis J.; Ploplis, Victoria A.			A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED-PROTEIN; GENE DEFICIENT MICE; NF-KAPPA-B; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; TUMOR-GROWTH; APOPTOSIS; SURVIVAL; KINASE; PROLIFERATION	Cell proliferation, an event associated with angiogenesis, involves coordinated activities of a number of proteins. The role of plasminogen activator inhibitor-1 (PAI-1) in angiogenesis remains controversial. Utilizing proliferating PAI-1(-/-) endothelial cells (EC), the impact of a host PAI-1 deficiency on Akt activation was evaluated. Hyperactivation of Akt(Ser(P)(473)) was observed in PAI-1(-/-) EC, and this was probably due to enhanced inactivation of tumor suppressor PTEN, thus rendering the cells resistant to apoptotic signals. Higher levels of inactivated caspase-9 in PAI-1(-/-) EC led to lower levels of procaspase-3 and cleaved caspase-3, thereby promoting survival. These effects were reversed when recombinant PAI-1 was added to PAI-1(-/-) EC. Additional studies demonstrated that regulation of proliferation is dependent on its interaction with low density lipoprotein receptor-related protein. Thus, PAI-1 is a negative regulator of cell growth, exerting its effect on the phosphatidylinositol 3-kinase/Akt pathway and allowing controlled cell proliferation.	Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Notre Dame Canc Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame	Ploplis, VA (corresponding author), Univ Notre Dame, WM Keck Ctr Transgene Res, 230 Raclin Carmicheal Hall, Notre Dame, IN 46556 USA.	vploplis@nd.edu						Al-Fakhri N, 2003, BIOL CHEM, V384, P423, DOI 10.1515/BC.2003.048; Almholt K, 2003, ONCOGENE, V22, P4389, DOI 10.1038/sj.onc.1206601; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Bajou K, 2004, ONCOGENE, V23, P6986, DOI 10.1038/sj.onc.1207859; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chen YB, 2004, J CELL BIOCHEM, V92, P178, DOI 10.1002/jcb.20058; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dimmeler S, 2000, CIRC RES, V87, P434; Eitzman DT, 1996, BLOOD, V87, P4718; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gutierrez LS, 2000, CANCER RES, V60, P5839; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khor TO, 2004, CANCER LETT, V210, P139, DOI 10.1016/j.canlet.2004.01.017; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Ploplis VA, 2004, J BIOL CHEM, V279, P6143, DOI 10.1074/jbc.M307297200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Salameh A, 2005, BLOOD, V106, P3423, DOI 10.1182/blood-2005-04-1388; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Soeda S, 2001, MOL BRAIN RES, V91, P96, DOI 10.1016/S0169-328X(01)00133-4; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Sudarshan C, 1998, J CELL PHYSIOL, V176, P67, DOI 10.1002/(SICI)1097-4652(199807)176:1<67::AID-JCP8>3.0.CO;2-6; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HT, 2005, HEPATOLOGY, V42, P1099, DOI 10.1002/hep.20903; WILLNOW TE, 1994, J CELL SCI, V107, P719; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	59	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22527	22536		10.1074/jbc.M512819200	http://dx.doi.org/10.1074/jbc.M512819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785241	hybrid			2022-12-25	WOS:000239542600013
J	Kannan-Thulasiraman, P; Katsoulidis, E; Tallman, MS; Arthur, JSC; Platanias, LC				Kannan-Thulasiraman, Padma; Katsoulidis, Efstratios; Tallman, Martin S.; Arthur, J. Simon C.; Platanias, Leonidas C.			Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PROTEIN-KINASE PATHWAY; NF-KAPPA-B; STRESS-INDUCED PHOSPHORYLATION; TRANSFORMED MOUSE FIBROBLASTS; P38-ALPHA MAP KINASE; HISTONE H3; MYELODYSPLASTIC SYNDROMES; SIGNAL-TRANSDUCTION; HEMATOPOIETIC SUPPRESSION	Arsenic trioxide (As2O3) is a potent inducer of apoptosis of leukemic cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. We provide evidence that As2O3 induces activation of the mitogen- and stress-activated kinase 1 (MSK1) and downstream phosphorylation of its substrate, histone H3, in leukemia cell lines. Such activation requires upstream engagement of p38 MAPK, as demonstrated by experiments using pharmacological inhibitors of p38 or p38 alpha knock-out cells. Arsenic-induced apoptosis was enhanced in cells in which MSK1 expression was decreased using small interfering RNA and in Msk1 knock-out mouse embryonic fibroblasts, suggesting that this kinase is activated in a negative feedback regulatory manner to regulate As2O3 responses. Consistent with this, pharmacological inhibition of MSK1 enhanced the suppressive effects of As2O3 on the growth of primary leukemic progenitors from chronic myelogenous leukemia patients. Altogether, these findings indicate an important role for MSK1 downstream of p38 in the regulation of As2O3 responses.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; Lakeside VA Hosp, Chicago, IL 60611 USA; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Dundee	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Lurie 3-107,303 E Super St, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Arthur, J. Simon/B-8058-2010	Arthur, J. Simon/0000-0002-8135-1958	MRC [MC_U127081014] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA094079, T32CA070085] Funding Source: NIH RePORTER; Medical Research Council [MC_U127081014] Funding Source: Medline; NCI NIH HHS [T32CA070085, CA94079] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2002, SEMIN HEMATOL, V39, P22, DOI 10.1053/shem.2002.33611; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davison K, 2004, BLOOD, V103, P3496, DOI 10.1182/blood-2003-05-1412; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Douer D, 2005, J CLIN ONCOL, V23, P2396, DOI 10.1200/JCO.2005.10.217; Duncan EA, 2006, J BIOL CHEM, V281, P12521, DOI 10.1074/jbc.M513333200; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Evens AM, 2004, LEUKEMIA RES, V28, P891, DOI 10.1016/j.leukres.2004.01.011; Gartenhaus RB, 2002, CLIN CANCER RES, V8, P566; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Katsoulidis E, 2005, CANCER RES, V65, P9029, DOI 10.1158/0008-5472.CAN-04-4555; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kerbauy DMB, 2005, BLOOD, V106, P3917, DOI 10.1182/blood-2005-04-1424; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; List A, 2003, LEUKEMIA, V17, P1499, DOI 10.1038/sj.leu.2403021; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182/blood.V98.13.3762; Mann KK, 2005, J CLIN INVEST, V115, P2924, DOI 10.1172/JCI23628; MARCHAND C, 2006, J CELL BIOCH; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; Miller WH, 2002, CANCER RES, V62, P3893; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick SC, 2000, SEMIN ONCOL, V27, P495; O'Dwyer ME, 2002, SEMIN HEMATOL, V39, P18, DOI 10.1053/shem.2002.33612; Park WH, 2000, CANCER RES, V60, P3065; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ramos AM, 2005, BLOOD, V105, P4013, DOI 10.1182/blood-2004-07-2802; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHILLER M, 2006, ONOCOGENE; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strelkov IS, 2002, CANCER RES, V62, P75; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Tabellini G, 2005, J CELL PHYSIOL, V202, P623, DOI 10.1002/jcp.20153; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tallman MS, 2001, BLOOD REV, V15, P133, DOI 10.1054/blre.2001.0160; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhu F, 2004, CARCINOGENESIS, V25, P1847, DOI 10.1093/carcin/bgh202	66	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22446	22452		10.1074/jbc.M603111200	http://dx.doi.org/10.1074/jbc.M603111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762916	hybrid			2022-12-25	WOS:000239542600005
J	Xu, WL; Dunn, CA; O'Handley, SF; Smith, DL; Bessman, MJ				Xu, Wenlian; Dunn, Christopher A.; O'Handley, Suzanne F.; Smith, Denise L.; Bessman, Maurice J.			Three new nudix hydrolases from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC DOMAIN; ADP-RIBOSE; STREPTOCOCCUS-PNEUMONIAE; MUTT FAMILY; GENE; PYROPHOSPHATASE; PURIFICATION; ENZYMES; IDENTIFICATION; SUBFAMILY	Three members of the Nudix (nucleoside diphosphate X) hydrolase superfamily have been cloned from Escherichia coli MG1655 and expressed. The proteins have been purified and identified as enzymes active on nucleoside diphosphate derivatives with the following specificities. Orf141 (yfaO) is a nucleoside triphosphatase preferring pyrimidine deoxynucleoside triphosphates. Orf153 (ymfB) is a nonspecific nucleoside tri- and diphosphatase and atypically releases inorganic orthophosphate from triphosphates instead of pyrophosphate. Orf191 (yffH) is a highly active GDP-mannose pyrophosphatase. All three enzymes require a divalent cation for activity and are optimally active at alkaline pH, characteristic of the Nudix hydrolase superfamily. The question of whether or not Orf1.9 (wcaH) is a bona fide member of the Nudix hydrolase superfamily is discussed.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	zoot@jhu.edu		O'Handley, Suzanne/0000-0001-8373-0065; Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Bessman MJ, 2001, J BIOL CHEM, V276, P37834; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Cartwright JL, 2000, J BIOL CHEM, V275, P32925, DOI 10.1074/jbc.M005015200; Ciesla WP, 1998, J BIOL CHEM, V273, P16021, DOI 10.1074/jbc.273.26.16021; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Legler PM, 2000, BIOCHEMISTRY-US, V39, P8603, DOI 10.1021/bi000537p; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ranatunga W, 2004, J MOL BIOL, V339, P103, DOI 10.1016/j.jmb.2004.01.065; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; Xu WL, 2004, J BIOL CHEM, V279, P24861, DOI 10.1074/jbc.M403272200; Xu WL, 2003, J BIOL CHEM, V278, P37492, DOI 10.1074/jbc.M307639200	25	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22794	22798		10.1074/jbc.M603407200	http://dx.doi.org/10.1074/jbc.M603407200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766526	hybrid			2022-12-25	WOS:000239542600040
J	Zhang, Y; Lyver, ER; Knight, SAB; Pain, D; Lesuisse, E; Dancis, A				Zhang, Yan; Lyver, Elise R.; Knight, Simon A. B.; Pain, Debkumar; Lesuisse, Emmanuel; Dancis, Andrew			Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST FRATAXIN; CRYSTAL-STRUCTURE; PROTEIN IMPORT; BIOGENESIS; DEFICIENCY; HOMOLOG; ACCUMULATION; ACONITASE; CARRIERS; YFH1P	Yeast Mrs3p and Mrs4p are evolutionarily conserved mitochondrial carrier proteins that transport iron into mitochondria under some conditions. Yeast frataxin (Yfh1p), the homolog of the human protein implicated in Friedreich ataxia, is involved in iron homeostasis. However, its precise functions are controversial. Anaerobically grown triple mutant cells (Delta mrs3/4/Delta yfh1) displayed a severe growth defect corrected by in vivo iron supplementation. Because anaerobically grown cells do not synthesize heme, and they do not experience oxidative stress, this growth defect was most likely due to Fe-S cluster deficiency. Fe-S cluster formation was assessed in anaerobically grown cells shifted to air for a brief period. In isolated mitochondria, Fe-S clusters were detected on newly imported yeast ferredoxin precursor and on endogenous aconitase by means of [S-35]cysteine labeling and native gel separation. New cluster formation was dependent on iron addition to mitochondria, and the iron concentration dependence was shifted dramatically upward in the Delta mrs3/4 mutant, indicating a role of Mrs3/4p in iron transport. The frataxin mutant strain lacked protein import capacity because of low mitochondrial membrane potential, although this was partially restored by growth in the presence of high iron. Under these conditions, a kinetic defect in new Fe-S cluster formation was still noted. Import of frataxin into frataxin-minus isolated mitochondria promptly corrected the Fe-S cluster assembly defect without further iron addition. These findings show that Mrs3/4p transports iron into mitochondria, whereas frataxin makes iron already within mitochondria available for Fe-S cluster synthesis.	Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07101 USA; Univ Paris 06, CNRS, Lab Ingn Prot & Controle Metab, Dept Biol Genomes,Inst Jacques Monod,UMR 7592, F-75251 Paris 05, France; Univ Paris 07, CNRS, Lab Ingn Prot & Controle Metab, Dept Biol Genomes,Inst Jacques Monod,UMR 7592, F-75251 Paris 05, France	University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu	Zhang, Yan/K-1638-2015	Zhang, Yan/0000-0003-2031-0631; Knight, Simon/0000-0001-7407-3390	NIDDK NIH HHS [DK43593] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Aloria K, 2004, EMBO REP, V5, P1096, DOI 10.1038/sj.embor.7400272; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gakh O, 2006, HUM MOL GENET, V15, P467, DOI 10.1093/hmg/ddi461; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; He YN, 2004, BIOCHEMISTRY-US, V43, P16254, DOI 10.1021/bi0488193; Huynen MA, 2001, HUM MOL GENET, V10, P2463, DOI 10.1093/hmg/10.21.2463; Irazusta V, 2006, J BIOL CHEM, V281, P12227, DOI 10.1074/jbc.M511649200; Jacobson ES, 2005, MYCOPATHOLOGIA, V159, P1, DOI 10.1007/s11046-004-2223-8; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Robinson AJ, 2006, P NATL ACAD SCI USA, V103, P2617, DOI 10.1073/pnas.0509994103; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Yang M, 2006, EMBO J, V25, P1775, DOI 10.1038/sj.emboj.7601064; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	42	81	82	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22493	22502		10.1074/jbc.M604246200	http://dx.doi.org/10.1074/jbc.M604246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769722	hybrid			2022-12-25	WOS:000239542600010
J	Zwicker, K; Galkin, A; Drose, S; Grgic, L; Kerscher, S; Brandt, U				Zwicker, Klaus; Galkin, Alexander; Droese, Stefan; Grgic, Ljuban; Kerscher, Stefan; Brandt, Ulrich			The redox-Bohr group associated with iron-sulfur cluster N2 of complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NUCLEAR-ENCODED SUBUNITS; YARROWIA-LIPOLYTICA; PROTON-TRANSLOCATION; CONFORMATION-DRIVEN; ELECTRON-TRANSFER; 49-KDA SUBUNIT; PHOSPHORYLATION; STOICHIOMETRY; MITOCHONDRIA	Proton pumping respiratory complex I (NADH: ubiquinone oxidoreductase) is a major component of the oxidative phosphorylation system in mitochondria and many bacteria. In mammalian cells it provides 40% of the proton motive force needed to make ATP. Defects in this giant and most complicated membrane-bound enzyme cause numerous human disorders. Yet the mechanism of complex I is still elusive. A group exhibiting redox-linked protonation that is associated with iron-sulfur cluster N2 of complex I has been proposed to act as a central component of the proton pumping machinery. Here we show that a histidine in the 49-kDa subunit that resides near iron-sulfur cluster N2 confers this redox-Bohr effect. Mutating this residue to methionine in complex I from Yarrowia lipolytica resulted in a marked shift of the redox midpoint potential of iron-sulfur cluster N2 to the negative and abolished the redox-Bohr effect. However, the mutation did not significantly affect the catalytic activity of complex I and protons were pumped with an unchanged stoichiometry of 4 H+/2e(-). This finding has significant implications on the discussion about possible proton pumping mechanism for complex I.	Univ Frankfurt, Zentrum Mol Chem, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brandt, U (corresponding author), Univ Frankfurt, Zentrum Mol Chem, Theodor Stern Kai 7,Hau 26, D-60590 Frankfurt, Germany.	brandt@zbc.kgu.de	Brandt, Ulrich/GLV-1242-2022; Dröse, Stefan/E-4903-2010; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Dröse, Stefan/0000-0002-9361-9034; Brandt, Ulrich/0000-0003-1869-6811				ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 1999, BIOFACTORS, V9, P95, DOI 10.1002/biof.5520090203; Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539; CHANCE B, 1972, FEBS LETT, V23, P3, DOI 10.1016/0014-5793(72)80272-2; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Galkin AS, 1999, FEBS LETT, V451, P157, DOI 10.1016/S0014-5793(99)00575-X; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Mamedova AA, 2004, J BIOL CHEM, V279, P23830, DOI 10.1074/jbc.M401539200; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; Mitchell P, 1979, Methods Enzymol, V55, P627; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Ohnishi T, 2005, FEBS LETT, V579, P4555, DOI 10.1016/j.febslet.2005.06.086; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Vinogradov AD, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1086, DOI 10.1023/A:1012476728710; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; Yano T, 2005, BIOCHEMISTRY-US, V44, P1744, DOI 10.1021/bi048132i; Zvyagilskaya R, 2001, J MEMBRANE BIOL, V183, P39, DOI 10.1007/s00232-001-0054-9	31	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23013	23017		10.1074/jbc.M603442200	http://dx.doi.org/10.1074/jbc.M603442200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760472	hybrid			2022-12-25	WOS:000239542600063
J	Kanematsu, T; Yasunaga, A; Mizoguchi, Y; Kuratani, A; Kittler, JT; Jovanovic, JN; Takenaka, K; Nakayama, KI; Fukami, K; Takenawa, T; Moss, SJ; Nabekura, J; Hirata, M				Kanematsu, Takashi; Yasunaga, Atsushi; Mizoguchi, Yoshito; Kuratani, Akiko; Kittler, Josef T.; Jovanovic, Jasmina N.; Takenaka, Kei; Nakayama, Keiichi I.; Fukami, Kiyoko; Takenawa, Tadaomi; Moss, Stephen J.; Nabekura, Junichi; Hirata, Masato			Modulation of GABA(A) receptor phosphorylation and membrane trafficking by phospholipase C-related inactive protein/protein phosphatase 1 and 2A signaling complex underlying brain-derived neurotrophic factor-dependent regulation of GABAergic inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 1,4,5-TRISPHOSPHATE BINDING-PROTEIN; CELL-SURFACE STABILITY; 130 KDA PROTEIN; A RECEPTORS; RAT-BRAIN; SYNAPTIC-TRANSMISSION; FACTOR BDNF; P130; SUBUNIT	Brain-derived neurotrophic factor (BDNF) modulates several distinct aspects of synaptic transmission, including GABAergic transmission. Exposure to BDNF alters properties of GABA(A) receptors and induces changes in the expression level at the cell surface. Although phospholipase C-related inactive protein-1 (PRIP-1) plays an important role in GABA(A) receptor trafficking and function, its role in BDNF-dependent modulation of these receptors, together with the role of PRIP-2, was investigated using neurons cultured from PRIP double knock-out mice. The BDNF-dependent inhibition of whole cell GABA-evoked currents observed in wild type neurons was not detected in neurons cultured from knock-out mice. Instead, a gradual increase in GABA-evoked currents in these neurons correlated with a gradual increase in phosphorylation of GABA(A) receptor beta 3 subunit in response to BDNF. To characterize the specific role(s) that PRIP plays as components of underlying molecular machinery, we examined the recruitment of protein phosphatase(s) to GABA(A) receptors. We demonstrate that PRIP associates with phosphatases as well as with beta subunits. PRIP was found to colocalize with GABA(A) receptor clusters in cultured neurons and with recombinant GABA(A) receptors when co-expressed in HEK293 cells. Importantly, a peptide mimicking a domain of PRIP involved in binding to beta subunits disrupted the co-localization of these proteins in HEK293 cells and potently inhibited the BDNF-mediated attenuation of GABA(A) receptor currents in wild type neurons. Together, the results suggest that PRIP plays an important role in BDNF-dependent regulation of GABAA receptors by mediating the specific association between beta subunits of these receptors with protein phosphatases.	Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka 8128582, Japan; Natl Inst Physiol Sci, Dept Dev Physiol, Okazaki, Aichi 4448585, Japan; UCL, Dept Physiol, London WC1E 6BT, England; Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Tokyo Univ Pharm & Life Sci, Lab Genome & Biosignal, Hachioji, Tokyo 1920392, Japan; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	Kyushu University; Kyushu University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of London; University College London; University of London; University College London; University of London School of Pharmacy; University of Tokyo; Kyushu University; Tokyo University of Pharmacy & Life Sciences; University of Pennsylvania	Hirata, M (corresponding author), Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.	hirata1@dent.kyushu-u.ac.jp	Kittler, Josef/N-7589-2019; Kittler, Josef T/E-9113-2010	Kittler, Josef/0000-0002-3437-9456; Kittler, Josef T/0000-0002-3437-9456	MRC [G120/972] Funding Source: UKRI; Medical Research Council [G120/972] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Brandon NJ, 1999, J NEUROSCI, V19, P9228; Brunig I, 2001, EUR J NEUROSCI, V13, P1320, DOI 10.1046/j.0953-816x.2001.01506.x; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; Chen GJ, 2006, J NEUROSCI, V26, P2513, DOI 10.1523/JNEUROSCI.4712-05.2006; Cheng Q, 2003, J PHYSIOL-LONDON, V548, P711, DOI 10.1113/jphysiol.2002.037846; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; Filippova N, 2000, MOL PHARMACOL, V57, P847; Frerking M, 1998, J NEUROPHYSIOL, V80, P3383, DOI 10.1152/jn.1998.80.6.3383; Henneberger C, 2002, J NEUROPHYSIOL, V88, P595, DOI 10.1152/jn.2002.88.2.595; Herring D, 2005, NEUROPHARMACOLOGY, V48, P181, DOI 10.1016/j.neuropharm.2004.09.015; Jovanovic JN, 2004, J NEUROSCI, V24, P522, DOI 10.1523/JNEUROSCI.3606-03.2004; Kanematsu T, 1996, BIOCHEM J, V313, P319, DOI 10.1042/bj3130319; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kanematsu T, 2000, EUR J BIOCHEM, V267, P2731, DOI 10.1046/j.1432-1327.2000.01291.x; Kanematsu T, 2002, EMBO J, V21, P1004, DOI 10.1093/emboj/21.5.1004; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kittler JT, 2005, P NATL ACAD SCI USA, V102, P14871, DOI 10.1073/pnas.0506653102; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Kittler JT, 2000, J NEUROSCI, V20, P7972; Matsuda M, 1998, NEUROSCI LETT, V257, P97, DOI 10.1016/S0304-3940(98)00810-6; Mizoguchi Y, 2003, J PHYSIOL-LONDON, V548, P703, DOI 10.1113/jphysiol.2003.038935; Otsuki M, 1999, BIOCHEM BIOPH RES CO, V266, P97, DOI 10.1006/bbrc.1999.1784; Rose CR, 2004, BIOESSAYS, V26, P1185, DOI 10.1002/bies.20118; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Takenaka K, 2003, MOL CELL BIOL, V23, P7329, DOI 10.1128/MCB.23.20.7329-7338.2003; Takeuchi H, 2000, BIOCHEM J, V349, P357, DOI 10.1042/0264-6021:3490357; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Takeuchi H, 1996, BIOCHEM J, V318, P561, DOI 10.1042/bj3180561; Tanaka T, 1997, J NEUROSCI, V17, P2959; Terunuma M, 2004, J NEUROSCI, V24, P7074, DOI 10.1523/JNEUROSCI.1323-04.2004; Uji A, 2002, LIFE SCI, V72, P443, DOI 10.1016/S0024-3205(02)02275-0; Vicario-Abejon C, 2002, NAT REV NEUROSCI, V3, P965, DOI 10.1038/nrn988; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; YANAGIHORI S, 2006, IN PRESS ADV ENZ REG; YOSHIDA M, 1994, J BIOCHEM, V115, P973, DOI 10.1093/oxfordjournals.jbchem.a124447; Yoshimura K, 2001, J BIOL CHEM, V276, P17908, DOI 10.1074/jbc.M009677200	38	70	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22180	22189		10.1074/jbc.M603118200	http://dx.doi.org/10.1074/jbc.M603118200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754670	hybrid			2022-12-25	WOS:000239387100065
J	Cole, JN; McArthur, JD; McKay, FC; Sanderson-Smith, ML; Cork, AJ; Ranson, M; Rohde, M; Itzek, A; Sun, HM; Ginsburg, D; Kotb, M; Nizet, V; Chhatwal, GS; Walker, MJ				Cole, Jason N.; McArthur, Jason D.; McKay, Fiona C.; Sanderson-Smith, Martina L.; Cork, Amanda J.; Ranson, Marie; Rohde, Manfred; Itzek, Andreas; Sun, Hongmin; Ginsburg, David; Kotb, Malak; Nizet, Victor; Chhatwal, G. S.; Walker, Mark J.			Trigger for group A streptococcal M1T1 invasive disease	FASEB JOURNAL			English	Article						Streptococcus pyogenes; SpeB; plasminogen	HYALURONIC-ACID CAPSULE; CYSTEINE PROTEASE; PLASMINOGEN-BINDING; VIRULENCE FACTORS; SKIN INFECTION; IN-VIVO; PYOGENES; SURFACE; EXPRESSION; FIBRINOGEN	The globally disseminated Streptococcus pyogenes M1T1 clone causes a number of highly invasive human diseases. The transition from local to systemic infection occurs by an unknown mechanism; however invasive M1T1 clinical isolates are known to express significantly less cysteine protease SpeB than M1T1 isolates from local infections. Here, we show that in comparison to the M1T1 strain 5448, the isogenic mutant Delta speB accumulated 75-fold more human plasmin activity on the bacterial surface following incubation in human plasma. Human plasminogen was an absolute requirement for M1T1 strain 5448 virulence following subcutaneous (s.c.) infection of humanized plasminogen transgenic mice. S. pyogenes M1T1 isolates from the blood of infected humanized plasminogen transgenic mice expressed reduced levels of SpeB in comparison with the parental 5448 used as inoculum. We propose that the human plasminogen system plays a critical role in group A streptococcal M1T1 systemic disease initiation. SpeB is required for S. pyogenes M1T1 survival at the site of local infection, however, SpeB also disrupts the interaction of S. pyogenes M1T1 with the human plasminogen activation system. Loss of SpeB activity in a subpopulation of S. pyogenes M1T1 at the site of infection results in accumulation of surface plasmin activity thus triggering systemic spread.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; German Natl Ctr Biotechnol, Dept Microbial Pathogenesis & Vaccine Dev, Braunschweig, Germany; Univ Michigan, Dept Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Tennessee, Dept Mol Sci, Knoxville, TN 37996 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	University of Wollongong; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California San Diego	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Walker, Mark J./F-6940-2011; Ranson, Marie/A-6324-2008; Cork, Amanda/C-3830-2012; Ranson, Marie/GRO-5792-2022; Ranson, Marie/AAC-4468-2019; Sanderson-Smith, Martina/O-9387-2019; Nizet, Victor/AAF-3190-2019; Sanderson-Smith, Martina L/H-9614-2013	Ranson, Marie/0000-0002-5570-9645; Cork, Amanda/0000-0003-2207-6877; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Sanderson-Smith, Martina L/0000-0002-6366-4993; Walker, Mark/0000-0001-7423-2769; McKay, Fiona Catherine/0000-0002-9610-0668; Nizet, Victor/0000-0003-3847-0422	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL057346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashbaugh CD, 1998, J CLIN INVEST, V102, P550, DOI 10.1172/JCI3065; Aziz RK, 2004, MOL MICROBIOL, V51, P123, DOI 10.1046/j.1365-2958.2003.03797.x; BERGE A, 1993, J BIOL CHEM, V268, P25417; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cole JN, 2005, INFECT IMMUN, V73, P3137, DOI 10.1128/IAI.73.5.3137-3146.2005; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Gillen CM, 2002, MICROBIOL-SGM, V148, P169, DOI 10.1099/00221287-148-1-169; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Hynes W, 2004, FRONT BIOSCI-LANDMRK, V9, P3399, DOI 10.2741/1491; Hytonen J, 2001, MOL MICROBIOL, V39, P512, DOI 10.1046/j.1365-2958.2001.02269.x; Johnson DR, 2002, J INFECT DIS, V185, P1586, DOI 10.1086/340576; Kansal RG, 2000, INFECT IMMUN, V68, P6362, DOI 10.1128/IAI.68.11.6362-6369.2000; Kansal RG, 2003, J INFECT DIS, V187, P398, DOI 10.1086/368022; Kazmi SU, 2001, INFECT IMMUN, V69, P4988, DOI 10.1128/IAI.69.8.4988-4995.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; McMillan DJ, 2004, FEMS IMMUNOL MED MIC, V40, P249, DOI 10.1016/S0928-8244(04)00003-3; Musser JM, 1996, INFECT IMMUN, V64, P1913, DOI 10.1128/IAI.64.6.1913-1917.1996; Nyberg P, 2004, J BIOL CHEM, V279, P52820, DOI 10.1074/jbc.C400485200; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Raeder R, 1998, RES MICROBIOL, V149, P539, DOI 10.1016/S0923-2508(99)80001-1; Rezcallah MS, 2004, MICROBIOL-SGM, V150, P365, DOI 10.1099/mic.0.26826-0; Ringdahl U, 2000, MOL MICROBIOL, V37, P1318, DOI 10.1046/j.1365-2958.2000.02062.x; Rosch J, 2004, SCIENCE, V304, P1513, DOI 10.1126/science.1097404; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; STEVENS DL, 1992, CLIN INFECT DIS, V14, P2, DOI 10.1093/clinids/14.1.2; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 2000, MOL MICROBIOL, V38, P242, DOI 10.1046/j.1365-2958.2000.02144.x; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WANG H, 1995, MICROB PATHOGENESIS, V18, P153, DOI 10.1016/S0882-4010(95)90013-6; WANG H, 1994, J INFECT DIS, V169, P143, DOI 10.1093/infdis/169.1.143; WANG H, 1995, J INFECT DIS, V171, P85, DOI 10.1093/infdis/171.1.85; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	36	120	121	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1745	+		10.1096/fj.06-5804fje	http://dx.doi.org/10.1096/fj.06-5804fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790522	Green Submitted			2022-12-25	WOS:000240266600035
J	Shepherd, BR; Enis, DR; Wang, FY; Suarez, Y; Pober, JS; Schechner, JS				Shepherd, Benjamin R.; Enis, David R.; Wang, Feiya; Suarez, Yajaira; Pober, Jordan S.; Schechner, Jeffrey S.			Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells	FASEB JOURNAL			English	Article						endothelial progenitor cell; umbilical cord blood; leukapheresis; angiogenesis; tissue engineering	GROWTH; DIFFERENTIATION; TRANSPLANTATION; MICROVESSELS; FIBROBLASTS; EQUIVALENT; SIROLIMUS; APOPTOSIS; GRAFTS; ORIGIN	We seeded tissue engineered human skin substitutes with endothelial cells (EC) differentiated in vitro from progenitors from umbilical cord blood (CB-EC) or adult peripheral blood (AB-EC), comparing the results to previous work using cultured human umbilical vein EC (HUVEC) with or without Bcl-2 transduction. Vascularized skin substitutes were prepared by seeding Bcl-2-transduced or nontransduced HUVEC, CB-EC, or AB- EC on the deep surface of decellularized human dermis following keratinocyte coverage of the epidermal surface. These skin substitutes were transplanted onto C. B-17 SCID/beige mice receiving systemic rapamycin or vehicle control and were analyzed 21 d later. CB-EC and Bcl-2-HUVEC formed more human EC-lined vessels than AB- EC or control HUVEC; CB-EC, Bcl-2-HUVEC, and AB- EC but not control HUVEC promoted ingrowth of mouse EC-lined vessels. Bcl-2 transduction increased the number of human and mouse EC-lined vessels in grafts seeded with HUVEC but not with CB-EC or AB- EC. Both CB-EC and AB-EC-induced microvessels became invested by smooth muscle cell-specific alpha-actin-positive mural cells, indicative of maturation. Rapamycin inhibited ingrowth of mouse EC-lined vessels but did not inhibit formation of human EC-lined vessels. We conclude that EC differentiated from circulating progenitors can be utilized to vascularize human skin substitutes even in the setting of compromised host angiogenesis/vasculogenesis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Dermatol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, 295 Congress Ave,Rm 454, New Haven, CT 06510 USA.	jordan.pober@yale.edu		Suarez, Yajaira/0000-0003-4549-2953	NHLBI NIH HHS [T32 HL07950, R01 HL551014] Funding Source: Medline; NIAMS NIH HHS [P30 AR41942] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Curran MP, 2002, BIODRUGS, V16, P439, DOI 10.2165/00063030-200216060-00005; DEMARCHEZ M, 1992, TRANSPLANTATION, V54, P317, DOI 10.1097/00007890-199208000-00023; Drosou A, 2005, J AM ACAD DERMATOL, V52, P854, DOI 10.1016/j.jaad.2004.11.069; Enis DR, 2005, P NATL ACAD SCI USA, V102, P425, DOI 10.1073/pnas.0408357102; Gehling UM, 2000, BLOOD, V95, P3106; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Greenberg S, 2004, METH MOL B, V289, P425; Guilbeau JM, 2002, ANN PHARMACOTHER, V36, P1391; Harraz M, 2001, STEM CELLS, V19, P304, DOI 10.1634/stemcells.19-4-304; Hristov M, 2003, TRENDS CARDIOVAS MED, V13, P201, DOI 10.1016/S1050-1738(03)00077-X; Kearney JN, 2001, BURNS, V27, P545, DOI 10.1016/S0305-4179(01)00020-1; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; KREJCI NC, 1991, J INVEST DERMATOL, V97, P843, DOI 10.1111/1523-1747.ep12491522; Kuypers DRJ, 2005, DRUG SAFETY, V28, P153, DOI 10.2165/00002018-200528020-00006; LAMBERT PB, 1971, NATURE, V232, P279, DOI 10.1038/232279a0; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Marston WA, 2004, EXPERT REV MED DEVIC, V1, P21, DOI 10.1586/17434440.1.1.21; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; MORHENN VB, 1987, J INVEST DERMATOL, V89, P464, DOI 10.1111/1523-1747.ep12460913; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Phillips T, 2002, ARCH DERMATOL, V138, P1079, DOI 10.1001/archderm.138.8.1079; POBER JS, 1983, NATURE, V305, P726, DOI 10.1038/305726a0; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Schechner JS, 2003, FASEB J, V17, P2250, DOI 10.1096/fj.03-0257com; Sivan-Loukianova E, 2003, J VASC RES, V40, P368, DOI 10.1159/000072701; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; THOMSON AW, 1989, LANCET, V2, P443; Tremblay PL, 2005, AM J TRANSPLANT, V5, P1002, DOI 10.1111/j.1600-6143.2005.00790.x; Wu X, 2004, AM J PHYSIOL-HEART C, V287, pH480, DOI 10.1152/ajpheart.01232.2003; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665; Zheng L, 2004, J IMMUNOL, V173, P3020, DOI 10.4049/jimmunol.173.5.3020	39	102	112	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1739	+		10.1096/fj.05-5682fje	http://dx.doi.org/10.1096/fj.05-5682fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807367				2022-12-25	WOS:000240266600033
J	Bagaria, A; Surendranath, K; Ramagopal, UA; Ramakumar, S; Karande, AA				Bagaria, Ashima; Surendranath, Kalpana; Ramagopal, Udupi A.; Ramakumar, Suryanarayanarao; Karande, Anjali A.			Structure-function analysis and insights into the reduced toxicity of Abrus precatorius agglutinin I in relation to abrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEIN; RICIN A-CHAIN; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CELL-DEATH; MECHANISM; APOPTOSIS; TOXINS; REFINEMENT; ANGSTROM	Abrin and agglutinin-I from the seeds of Abrus precatorius are type II ribosome-inactivating proteins that inhibit protein synthesis in eukaryotic cells. The two toxins share a high degree of sequence similarity; however, agglutinin-I is weaker in its activity. We compared the kinetics of protein synthesis inhibition by abrin and agglutinin-I in two different cell lines and found that similar to 200-2000-fold higher concentration of agglutinin-I is needed for the same degree of inhibition. Like abrin, agglutinin-I also induced apoptosis in the cells by triggering the intrinsic mitochondrial pathway, although at higher concentrations as compared with abrin. The reason for the decreased toxicity of agglutinin-I became apparent on the analysis of the crystal structure of agglutinin-I obtained by us in comparison with that of the reported structure of abrin. The overall protein folding of agglutinin-I is similar to that of abrin-a with a single disulfide bond holding the toxic A subunit and the lectin-like B-subunit together, constituting a heterodimer. However, there are significant differences in the secondary structural elements, mostly in the A chain. The substitution of Asn-200 in abrin-a with Pro-199 in agglutinin-I seems to be a major cause for the decreased toxicity of agglutinin-I. This perhaps is not a consequence of any kink formation by a proline residue in the helical segment, as reported by others earlier, but due to fewer interactions that proline can possibly have with the bound substrate.	Indian Inst Sci, Dept Phys, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Bioinformat Ctr, Bangalore 560012, Karnataka, India; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore; Yeshiva University; Albert Einstein College of Medicine	Ramakumar, S (corresponding author), Indian Inst Sci, Dept Phys, Bangalore 560012, Karnataka, India.	ramak@physics.iisc.ernet.in; anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009	Bagaria, Ashima/0000-0003-0666-1945; surendranath, kalpana/0000-0002-2915-5001				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bantel H, 1999, CANCER RES, V59, P2083; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; Bolognesi A, 1996, INT J CANCER, V68, P349, DOI 10.1002/(SICI)1097-0215(19961104)68:3<349::AID-IJC13>3.0.CO;2-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Day PJ, 2001, J BIOL CHEM, V276, P7202, DOI 10.1074/jbc.M009499200; Delano W., 2002, PYMOL VERSION 0 99; EIKLID K, 1980, EXP CELL RES, V126, P321, DOI 10.1016/0014-4827(80)90270-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Foster DB, 2000, INFECT IMMUN, V68, P3108, DOI 10.1128/IAI.68.6.3108-3115.2000; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; HEGDE R, 1993, EUR J BIOCHEM, V215, P411, DOI 10.1111/j.1432-1033.1993.tb18048.x; HEGDE R, 1991, ANAL BIOCHEM, V194, P101, DOI 10.1016/0003-2697(91)90156-N; HOSUR MV, 1995, J MOL BIOL, V250, P368, DOI 10.1006/jmbi.1995.0383; HUNG CH, 1993, J MOL BIOL, V229, P263, DOI 10.1006/jmbi.1993.1029; HUSAIN J, 1994, FEBS LETT, V342, P154, DOI 10.1016/0014-5793(94)80491-5; Kim MK, 1999, PROTEIN SCI, V8, P1492, DOI 10.1110/ps.8.7.1492; Kitaoka Y, 1998, EUR J BIOCHEM, V257, P255, DOI 10.1046/j.1432-1327.1998.2570255.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LIN JY, 1981, TOXICON, V19, P41; Liu CL, 2000, J BIOL CHEM, V275, P1897, DOI 10.1074/jbc.275.3.1897; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Mishra V, 2004, ACTA CRYSTALLOGR D, V60, P2295, DOI 10.1107/S0907444904023534; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Narayanan S, 2004, BIOCHEM J, V377, P233, DOI 10.1042/BJ20030797; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niwa H, 2003, EUR J BIOCHEM, V270, P2739, DOI 10.1046/j.1432-1033.2003.03646.x; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Olsnes S, 2004, TOXICON, V44, P361, DOI 10.1016/j.toxicon.2004.05.003; Panneerselvam K, 2000, ACTA CRYSTALLOGR D, V56, P898, DOI 10.1107/S0907444900005047; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; READY M, 1984, J BIOL CHEM, V259, P5252; READY MP, 1991, PROTEINS, V10, P270, DOI 10.1002/prot.340100311; REDDY VVS, 1969, CANCER RES, V29, P1447; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharma S, 1999, MOL CELL BIOCHEM, V200, P133, DOI 10.1023/A:1007043218769; Shih SF, 2001, J BIOL CHEM, V276, P21870, DOI 10.1074/jbc.M100571200; SPERTI S, 1973, BIOCHEM J, V136, P813, DOI 10.1042/bj1360813; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; Thorburn J, 2003, CLIN CANCER RES, V9, P861; WEI CH, 1975, J BIOL CHEM, V250, P4790; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Zhu HB, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-27	58	63	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2006	281	45					34465	34474		10.1074/jbc.M601777200	http://dx.doi.org/10.1074/jbc.M601777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	101UZ	16772301	Green Accepted, hybrid			2022-12-25	WOS:000241767600067
J	Le Quere, AJL; Deakin, WJ; Schmeisser, C; Carlson, RW; Streit, WR; Broughton, WJ; Forsberg, LS				Le Quere, Antoine J. -L.; Deakin, William J.; Schmeisser, Christel; Carlson, Russell W.; Streit, Wolfgang R.; Broughton, William J.; Forsberg, L. Scott			Structural characterization of a K-antigen capsular polysaccharide essential for normal symbiotic infection in Rhizobium sp NGR234 - Deletion of the rkpMNO locus prevents synthesis of 5,7-diacetamido-3,5,7,9-tetradeoxy-non-2-ulosonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; PSEUDOMONAS-AERUGINOSA; SINORHIZOBIUM-FREDII; BACTERIAL LIPOPOLYSACCHARIDES; SURFACE POLYSACCHARIDE; PROTEIN SECRETION; SOMATIC ANTIGENS; STRAIN NGR234; LIPID-A; MELILOTI	Many early molecular events in symbiotic infection have been documented, although factors enabling Rhizobium to progress within the plant-derived infection thread and ultimately survive within the intracellular symbiosome compartment as mature nitrogen-fixing bacteroids are poorly understood. Rhizobial surface polysaccharides (SPS), including the capsular polysaccharides (K-antigens), exist in close proximity to plant-derived membranes throughout the infection process. SPSs are essential for bacterial survival, adaptation, and as potential determinants of nodulation and/ or host specificity. Relatively few studies have examined the role of K-antigens in these events. However, we constructed a mutant that lacks genes essential for the production of the K-antigen strain-specific sugar precursor, pseudaminicacid, in the broad host range Rhizobium sp. NGR234. The complete structure of the K-antigen of strain NGR234 was established, and it consists of disaccharide repeating units of glucuronic and pseudaminic acid having the structure -> 4)-beta-D-glucuronic acid-(1 -> 4)-beta-5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid-(2 ->. Deletion of three genes located in the rkp-3 gene cluster, rkpM, rkpN, and part of rkpO, abolished pseudaminic acid synthesis, yielding a mutant in which the strain-specific K-antigen was totally absent: other surface glycoconjugates, including the lipopolysaccharides, exopolysaccharides, and flagellin glycoprotein appeared unaffected. The NGR Delta rkpMNO mutant was symbiotically defective, showing reduced nodulation efficiency on several legumes. K-antigen production was found to decline after rhizobia were exposed to plant flavonoids, and the decrease coincided with induction of a symbiotically active (bacteroid-specific) rhamnan-LPS, suggesting an exchange of SPS occurs during bacterial differentiation in the developing nodule.	Univ Geneva, LBMPS, CH-1292 Geneva, Switzerland; Univ Hamburg, Inst Mikrobiol, D-22609 Hamburg, Germany; Univ Georgia, Complex Carbohydrate Res, Athens, GA 30602 USA	University of Geneva; University of Hamburg; University System of Georgia; University of Georgia	Broughton, WJ (corresponding author), Univ Geneva, LBMPS, CH-1292 Geneva, Switzerland.	william.broughton@bioveg.unige.ch	Streit, Wolfgang/S-3049-2019; Le Quere, antoine/GOH-0137-2022; Streit, Wolfgang R/K-1366-2012	Streit, Wolfgang/0000-0001-7617-7396; Le Quere, antoine/0000-0001-7470-5730; Deakin, William James/0000-0001-9338-0791	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALATTI PA, 1992, CAN J PLANT SCI, V72, P49, DOI 10.4141/cjps92-006; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Becker A, 2005, MOL PLANT MICROBE IN, V18, P899, DOI 10.1094/MPMI-18-0899; BecquartdeKozak I, 1997, MOL PLANT MICROBE IN, V10, P114, DOI 10.1094/MPMI.1997.10.1.114; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; BEYNON LM, 1994, CARBOHYD RES, V256, P303, DOI 10.1016/0008-6215(94)84215-9; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREWIN NJ, 1998, RHIZOBIACEAE, P415; Broughton WJ, 2000, J BACTERIOL, V182, P5641, DOI 10.1128/JB.182.20.5641-5652.2000; BROUGHTON WJ, 1971, BIOCHEM J, V125, P1075, DOI 10.1042/bj1251075; BROUGHTON WJ, 1986, J CELL BIOL, V102, P1173, DOI 10.1083/jcb.102.4.1173; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; Castric P, 2001, J BIOL CHEM, V276, P26479, DOI 10.1074/jbc.M102685200; CORZO J, 1991, ELECTROPHORESIS, V12, P439, DOI 10.1002/elps.1150120611; D'Haeze W, 2004, TRENDS MICROBIOL, V12, P555, DOI 10.1016/j.tim.2004.10.009; DABROWSKI U, 1979, TETRAHEDRON LETT, P4637; DAVIS AL, 1991, J MAGN RESON, V94, P637, DOI 10.1016/0022-2364(91)90154-L; Deakin WJ, 2005, MOL PLANT MICROBE IN, V18, P499, DOI 10.1094/MPMI-18-0499; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Forsberg LS, 2003, J BIOL CHEM, V278, P51347, DOI 10.1074/jbc.M309016200; Forsberg LS, 1997, J BACTERIOL, V179, P5366, DOI 10.1128/jb.179.17.5366-5371.1997; Fraysse N, 2005, GLYCOBIOLOGY, V15, P101, DOI 10.1093/glycob/cwh142; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; Fraysse N, 2002, GLYCOBIOLOGY, V12, P741, DOI 10.1093/glycob/cwf078; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; Gil-Serrano AM, 1999, BIOCHEM J, V342, P527, DOI 10.1042/0264-6021:3420527; Gryllos I, 2001, INFECT IMMUN, V69, P65, DOI 10.1128/IAI.69.1.65-74.2001; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Kereszt A, 1998, J BACTERIOL, V180, P5426, DOI 10.1128/JB.180.20.5426-5431.1998; Kiss E, 2001, MOL PLANT MICROBE IN, V14, P1395, DOI 10.1094/MPMI.2001.14.12.1395; Kiss E, 1997, J BACTERIOL, V179, P2132, DOI 10.1128/jb.179.7.2132-2140.1997; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1986, EUR J BIOCHEM, V157, P129, DOI 10.1111/j.1432-1033.1986.tb09648.x; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Kondakova AN, 2001, CARBOHYD RES, V333, P241, DOI 10.1016/S0008-6215(01)00145-8; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Marie C, 2004, MOL PLANT MICROBE IN, V17, P958, DOI 10.1094/MPMI.2004.17.9.958; Mathis R, 2005, P NATL ACAD SCI USA, V102, P2655, DOI 10.1073/pnas.0409816102; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; Parada M, 2006, MOL PLANT MICROBE IN, V19, P43, DOI 10.1094/MPMI-19-0043; Pellock BJ, 2000, J BACTERIOL, V182, P4310, DOI 10.1128/JB.182.15.4310-4318.2000; PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Pueppke SG, 1999, MOL PLANT MICROBE IN, V12, P293, DOI 10.1094/MPMI.1999.12.4.293; Putnoky M, 2004, J BACTERIOL, V186, P1591, DOI 10.1128/JB.186.6.1591-1597.2004; PUTNOKY P, 1988, J CELL BIOL, V106, P597, DOI 10.1083/jcb.106.3.597; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; REUHS BL, 1993, J BACTERIOL, V175, P3570, DOI 10.1128/jb.175.11.3570-3580.1993; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 2005, J BACTERIOL, V187, P6479, DOI 10.1128/JB.187.18.6479-6487.2005; REUHS BL, 1995, J BACTERIOL, V177, P4289, DOI 10.1128/jb.177.15.4289-4296.1995; Rodriguez-Carvajal MA, 2005, BIOMACROMOLECULES, V6, P1448, DOI 10.1021/bm049264u; Rodriguez-Carvajal MA, 2001, BIOCHEM J, V357, P505, DOI 10.1042/0264-6021:3570505; Roth L. E., 1991, Microbial cell-cell interactions., P255; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; Viprey V, 1998, MOL MICROBIOL, V28, P1381, DOI 10.1046/j.1365-2958.1998.00920.x; Viprey V, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-6-research0014; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WILLIAMS MNV, 1990, J BACTERIOL, V172, P6596, DOI 10.1128/jb.172.11.6596-6598.1990; YORK WS, 1986, METHOD ENZYMOL, V118, P3	71	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28981	28992		10.1074/jbc.M513639200	http://dx.doi.org/10.1074/jbc.M513639200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16772294	hybrid			2022-12-25	WOS:000240680500053
J	Gasper, R; Scrima, A; Wittinghofer, A				Gasper, Raphael; Scrima, Andrea; Wittinghofer, Alfred			Structural insights into HypB, a GTP-binding protein that regulates metal binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BRADYRHIZOBIUM-JAPONICUM; HYDROGENASE ISOENZYMES; HELICOBACTER-PYLORI; SIGNAL-TRANSDUCTION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; NICKEL; MATURATION; NITROGENASE	HypB is a prokaryotic metal-binding guanine nucleotide-binding protein that is essential for nickel incorporation into hydrogenases. Here we solved the x-ray structure of HypB from Methanocaldococcus jannaschii. It shows that the G-domain has a different topology than the Ras-like proteins and belongs to the SIMIBI (after Signal Recognition Particle, MinD and BioD) class of NTP-binding proteins. We show that HypB undergoes nucleotide-dependent dimerization, which is apparently a common feature of SIMIBI class G-proteins. The nucleotides are located in the dimer interface and are contacted by both subunits. The active site features residues from both subunits arguing that hydrolysis also requires dimerization. Two metal-binding sites are found, one of which is dependent on the state of bound nucleotide. A totally conserved ENV/IGNLV/ICP motif in switch II relays the nucleotide binding with the metal ion-binding site. The homology with NifH, the Fe protein subunit of nitrogenase, suggests a mechanistic model for the switch-dependent incorporation of a metal ion into hydrogenases.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de						Atanassova A, 2005, J BACTERIOL, V187, P4689, DOI 10.1128/JB.187.14.4689-4697.2005; BOCK A, 2006, IN PRESS ADV MICROBI, V51; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ermler U, 1998, CURR OPIN STRUC BIOL, V8, P749, DOI 10.1016/S0959-440X(98)80095-X; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; Hube M, 2002, J BACTERIOL, V184, P3879, DOI 10.1128/JB.184.14.3879-3885.2002; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Lammens A, 2004, CURR BIOL, V14, P1778, DOI 10.1016/j.cub.2004.09.044; Lanzilotta WN, 1997, J BIOL CHEM, V272, P4157, DOI 10.1074/jbc.272.7.4157; Leach MR, 2005, BIOCHEMISTRY-US, V44, P12229, DOI 10.1021/bi050993j; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Leonard TA, 2005, EMBO J, V24, P270, DOI 10.1038/sj.emboj.7600530; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; Ma LY, 2003, J BACTERIOL, V185, P4948, DOI 10.1128/JB.185.16.4948-4955.2003; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; Maier T, 1996, BIOCHEMISTRY-US, V35, P10089, DOI 10.1021/bi960567l; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mulrooney SB, 2003, FEMS MICROBIOL REV, V27, P239, DOI 10.1016/S0168-6445(03)00042-1; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Olson JW, 1997, MOL MICROBIOL, V24, P119, DOI 10.1046/j.1365-2958.1997.3251690.x; Olson JW, 2001, MOL MICROBIOL, V39, P176, DOI 10.1046/j.1365-2958.2001.02244.x; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; Quisel JD, 2000, J BACTERIOL, V182, P3446, DOI 10.1128/JB.182.12.3446-3451.2000; Quisel JD, 1999, MOL CELL, V4, P665, DOI 10.1016/S1097-2765(00)80377-9; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; Song HK, 2001, J BIOL CHEM, V276, P49359, DOI 10.1074/jbc.M108619200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WAUGH R, 1986, BIOCHIMIE, V68, P157, DOI 10.1016/S0300-9084(86)81080-X; Zhang JW, 2005, J BIOL CHEM, V280, P4360, DOI 10.1074/jbc.M411799200	45	113	116	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27492	27502		10.1074/jbc.M600809200	http://dx.doi.org/10.1074/jbc.M600809200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16807243	hybrid, Green Published			2022-12-25	WOS:000240397700076
J	Altheide, TK; Hayakawa, T; Mikkelsen, TS; Diaz, S; Varki, N; Varki, A				Altheide, Tasha K.; Hayakawa, Toshiyuki; Mikkelsen, Tarjei S.; Diaz, Sandra; Varki, Nissi; Varki, Ajit			System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents - Evidence for two modes of rapid evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; POLYSIALIC ACID; BINDING; GENE; EXPRESSION; DIVERSITY; MUTATION; OLIGOSACCHARIDE; CHROMATOGRAPHY; GLYCOSYLATION	Numerous vertebrate genes are involved in the biology of the oligosaccharide chains attached to glycoconjugates. These genes fall into diverse groups within the conventional Gene Ontology classification. However, they should be evaluated together from functional and evolutionary perspectives in a "biochemical systems" approach, considering each monosaccharide unit's biosynthesis, activation, transport, modification, transfer, recycling, degradation, and recognition. Sialic acid (Sia) residues are monosaccharides at the outer end of glycans on the cell-surface and secreted molecules of vertebrates, mediating recognition by intrinsic or extrinsic ( pathogen) receptors. The availability of multiple genome sequences allows a system-wide comparison among primates and rodents of all genes directly involved in Sia biology. Taking this approach, we present further evidence for accelerated evolution in Sia-binding domains of CD33-related Sia-recognizing Ig-like lectins. Other gene classes are more conserved, including those encoding the sialyltransferases that attach Sia residues to glycans. Despite this conservation, tissue sialylation patterns are shown to differ widely among these species, presumably because of rapid evolution of sialyltransferase expression patterns. Analyses of N- and O-glycans of erythrocyte and plasma glycopeptides from these and other mammalian taxa confirmed this phenomenon. Sia modifications on these glycopeptides also appear to be undergoing rapid evolution. This rapid evolution of the sialome presumably results from the ongoing need of organisms to evade microbial pathogens that use Sia residues as receptors. The rapid evolution of Sia-binding domains of the inhibitory CD33-related Sia-recognizing Ig-like lectins is likely to be a secondary consequence, as these inhibitory receptors presumably need to keep up with recognition of the rapidly evolving "self"-sialome.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; MIT, Broad Inst, Cambridge, MA 02141 USA; Harvard Univ, Cambridge, MA 02141 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Varki, A (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Mail Code 0687,9500 Gilman Dr, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Mikkelsen, Tarjei S/A-1306-2007	Mikkelsen, Tarjei S/0000-0002-8133-3135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL57345] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1998, GEN INF SER WORKSH G, V9, P131; Angata K, 2004, J BIOL CHEM, V279, P32603, DOI 10.1074/jbc.M403429200; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Angata T, 2004, P NATL ACAD SCI USA, V101, P13251, DOI 10.1073/pnas.0404833101; ANGATA T, 2006, IN PRESS FASEB J; Appenheimer MM, 2003, GLYCOBIOLOGY, V13, P591, DOI 10.1093/glycob/cwg066; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BEYER TA, 1979, J BIOL CHEM, V254, P2531; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Chiba A, 1997, J BIOL CHEM, V272, P2156; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; Dalziel M, 1999, GLYCOBIOLOGY, V9, P1003, DOI 10.1093/glycob/9.10.1003; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; Dorus S, 2004, CELL, V119, P1027, DOI 10.1016/j.cell.2004.11.040; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Gagneux P, 2003, J BIOL CHEM, V278, P48245, DOI 10.1074/jbc.M309813200; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; Gilad Y, 2003, P NATL ACAD SCI USA, V100, P3324, DOI 10.1073/pnas.0535697100; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; Goodman M, 1999, AM J HUM GENET, V64, P31, DOI 10.1086/302218; GOODMAN M, 1994, AM J PHYS ANTHROPOL, V94, P3, DOI 10.1002/ajpa.1330940103; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Hayakawa T, 2001, P NATL ACAD SCI USA, V98, P11399, DOI 10.1073/pnas.191268198; Irie A, 1998, J BIOL CHEM, V273, P15866, DOI 10.1074/jbc.273.25.15866; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jeanneau C, 2004, J BIOL CHEM, V279, P13461, DOI 10.1074/jbc.M311764200; Jukes T. H, 1969, MAMMALIAN PROTEIN ME, P21, DOI DOI 10.1093/BIOINFORMATICS/BTM404; Khaitovich P, 2004, PLOS BIOL, V2, P682, DOI 10.1371/journal.pbio.0020132; Kleene R, 2001, J BIOL CHEM, V276, P21656, DOI 10.1074/jbc.M101790200; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nguyen DH, 2006, P NATL ACAD SCI USA, V103, P7765, DOI 10.1073/pnas.0510484103; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Rausher MD, 1999, MOL BIOL EVOL, V16, P266, DOI 10.1093/oxfordjournals.molbev.a026108; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; Satta Y, 2000, MOL PHYLOGENET EVOL, V14, P259, DOI 10.1006/mpev.2000.0704; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; Sonnenburg JL, 2004, GLYCOBIOLOGY, V14, P339, DOI 10.1093/glycob/cwh039; Takashima S, 2000, J BIOCHEM-TOKYO, V127, P399, DOI 10.1093/oxfordjournals.jbchem.a022621; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; VANVALEN L, 1974, NATURE, V252, P298; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004	62	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25689	25702		10.1074/jbc.M604221200	http://dx.doi.org/10.1074/jbc.M604221200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16769723	hybrid			2022-12-25	WOS:000240031300072
J	Bernier, V; Stocco, R; Bogusky, MJ; Joyce, JG; Parachoniak, C; Grenier, K; Arget, M; Mathieu, MC; O'Neill, GP; Slipetz, D; Crackower, MA; Tan, CM; Therien, AG				Bernier, Virginie; Stocco, Rino; Bogusky, Michael J.; Joyce, Joseph G.; Parachoniak, Christine; Grenier, Karl; Arget, Michael; Mathieu, Marie-Claude; O'Neill, Gary P.; Slipetz, Deborah; Crackower, Michael A.; Tan, Christopher M.; Therien, Alex G.			Structure-function relationships in the neuropeptide S receptor - Molecular consequences of the asthma-associated mutation N107I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONFORMATION; POSITIONAL CLONING; SPECTROSCOPY; PEPTIDE; LOCUS; GENE	Neuropeptide S (NPS) and its receptor (NPSR) are thought to have a role in asthma pathogenesis; a number of single nucleotide polymorphisms within NPSR have been shown to be associated with an increased prevalance of asthma. One such single nucleotide polymorphism leads to the missense mutation N107I, which results in an increase in the potency of NPS for NPSR. To gain insight into structure-function relationships within NPS and NPSR, we first carried out a limited structural characterization of NPS and subjected the peptide to extensive mutagenesis studies. Our results show that the NH2-terminal third of NPS, in particular residues Phe-2, Arg-3, Asn-4, and Val-6, are necessary and sufficient for activation of NPSR. Furthermore, part of a nascent helix within the peptide, spanning residues 5 through 13, acts as a regulatory region that inhibits receptor activation. Notably, this inhibition is absent in the asthma-linked N107I variant of NPSR, suggesting that residue 107 interacts with the aforementioned regulatory region of NPS. Whereas this interaction may be at the root of the increase in potency associated with the N107I variant, we show here that the mutation also causes an increase in cell-surface expression of the mutant receptor, leading to a concomitant increase in the maximal efficacy (Emax) of NPS. Our results identify the key residues of NPS involved in NPSR activation and suggest a molecular basis for the functional effects of the N107I mutation and for its putative pathophysiological link with asthma.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H9L 3L1, Canada; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Kirkland, PQ H9L 3L1, Canada; Merck & Co Inc, Dept Med Chem, West Point, PA 19486 USA; Merck & Co Inc, Dept Vaccine & Biol Res, West Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Therien, AG (corresponding author), 16711 Trans Canada Hwy, Kirkland, PQ H9H 3L1, Canada.	alex_therien@merck.com	Therien, Alex/AAS-8437-2021					Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Beck B, 2005, BIOCHEM BIOPH RES CO, V332, P859, DOI 10.1016/j.bbrc.2005.05.029; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Gloriam DEI, 2005, BBA-GEN SUBJECTS, V1722, P235, DOI 10.1016/j.bbagen.2004.12.001; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Gupte J, 2004, P NATL ACAD SCI USA, V101, P1508, DOI 10.1073/pnas.0308250100; HOYER D, 1993, TRENDS PHARMACOL SCI, V14, P270, DOI 10.1016/0165-6147(93)90129-8; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LEVITT MH, 1982, J MAGN RESON, V47, P328, DOI 10.1016/0022-2364(82)90124-X; Lilly CM, 2005, J ALLERGY CLIN IMMUN, V115, pS526, DOI 10.1016/j.jaci.2005.01.028; Mathieu MC, 2005, IMMUNOL LETT, V100, P139, DOI 10.1016/j.imlet.2005.03.003; Melen E, 2005, AM J RESP CRIT CARE, V171, P1089, DOI 10.1164/rccm.200410-1317OC; Melnyk RA, 2002, J MOL BIOL, V315, P63, DOI 10.1006/jmbi.2001.5214; Reinscheid RK, 2005, J PHARMACOL EXP THER, V315, P1338, DOI 10.1124/jpet.105.093427; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vendelin J, 2005, AM J RESP CELL MOL, V33, P262, DOI 10.1165/rcmb.2004-0405OC; WUTHRICH K, 2005, NMR PROTEINS NUCL AC; Xu YL, 2004, NEURON, V43, P487, DOI 10.1016/j.neuron.2004.08.005; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	28	77	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24704	24712		10.1074/jbc.M603691200	http://dx.doi.org/10.1074/jbc.M603691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790440				2022-12-25	WOS:000239847800066
J	Datta, A; Sinha-Datta, U; Dhillon, NK; Buch, S; Nicot, C				Datta, Abhik; Sinha-Datta, Uma; Dhillon, Navneet Kaur; Buch, Shilpa; Nicot, Christophe			The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; GLYCOGEN-SYNTHASE KINASE-3; DOMAIN-DNA COMPLEX; HEPATITIS-C VIRUS; TRANSCRIPTION FACTOR; SPASTIC PARAPARESIS; IMMUNE-RESPONSE; EXPRESSION; TYPE-1	Whereas adaptive immunity has been extensively studied, very little is known about the innate immunity of the host to HTLV-I infection. HTLV-I-infected ATL patients have pronounced immunodeficiency associated with frequent opportunistic infections, and in these patients, concurrent infections with bacteria and/ or parasites are known to increase risks of progression to ATL. The Toll-like receptor-4 (TLR4) activation in response to bacterial infection is essential for dendritic cell maturation and links the innate and adaptive immune responses. Recent reports indicate that TLR4 is targeted by viruses such as RSV, HCV, and MMTV. Here we report that HTLV-I has also evolved a protein that interferes with TLR4 signaling; p30 interacts with and inhibits the DNA binding and transcription activity of PU.1 resulting in the down-regulation of the TLR4 expression from the cell surface. Expression of p30 hampers the release of pro-inflammatory cytokines MCP-1, TNF-alpha, and IL-8 and stimulates release of anti-inflammatory IL-10 following stimulation of TLR4 in human macrophage. Finally, we found that p30 increases phosphorylation and inactivation of GSK3-beta a key step for IL-10 production. Our study suggests a novel function of p30, which may instigate immune tolerance by reducing activation of adaptive immunity in ATL patients.	Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	cnicot@kumc.edu		Datta, Abhik/0000-0002-3442-5774; Buch, Shilpa/0000-0002-3103-6685	NCRR NIH HHS [P20 RR016443] Funding Source: Medline; NIAID NIH HHS [R01 AI058944, R01AI058944] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bangham CRM, 2005, ONCOGENE, V24, P6035, DOI 10.1038/sj.onc.1208970; Chen JL, 1995, AIDS RES HUM RETROV, V11, P1529, DOI 10.1089/aid.1995.11.1529; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Duesberg U, 2002, IMMUNOL LETT, V84, P89, DOI 10.1016/S0165-2478(02)00178-5; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; Feuer G, 1996, J VIROL, V70, P4038, DOI 10.1128/JVI.70.6.4038-4044.1996; Furukawa Y, 2006, INT J CANCER, V118, P381, DOI 10.1002/ijc.21328; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1985, LANCET, V2, P407; Hill SA, 1999, VIROLOGY, V263, P273, DOI 10.1006/viro.1999.9922; HOFFMAN PM, 1992, P NATL ACAD SCI USA, V89, P11784, DOI 10.1073/pnas.89.24.11784; Iwasaki Y, 2004, ACTA NEUROPATHOL, V108, P546, DOI 10.1007/s00401-004-0924-1; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; Jude BA, 2003, NAT IMMUNOL, V4, P573, DOI 10.1038/ni926; KANNAGI M, 1994, LEUKEMIA, V8, pS54; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KORALNIK IJ, 1992, AIDS RES HUM RETROV, V8, P1845, DOI 10.1089/aid.1992.8.1845; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Levin MC, 2001, J NEUROVIROL, V7, P61; Li CL, 2002, CELL GROWTH DIFFER, V13, P27; Makino M, 2000, VIROLOGY, V274, P140, DOI 10.1006/viro.2000.0445; MAKINO M, 2000, RYOIKIBETSU SHOKOGUN, V31, P9; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mori N, 2000, CANCER RES, V60, P4939; Mori N, 1999, BLOOD, V94, P2862, DOI 10.1182/blood.V94.8.2862.420k24_2862_2870; Mori N, 1996, BLOOD, V88, P1035; Mosley AJ, 2005, VIRAL IMMUNOL, V18, P293, DOI 10.1089/vim.2005.18.293; Mostoller K, 2004, J NEUROVIROL, V10, P358, DOI 10.1080/13550280490521104; Nagai M, 2001, J INFECT DIS, V183, P197, DOI 10.1086/317932; Nicot C, 2005, AM J HEMATOL, V78, P232, DOI 10.1002/ajh.20307; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nicot C, 2001, MOL CELL BIOL, V21, P7391, DOI 10.1128/MCB.21.21.7391-7402.2001; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; WANG JT, 1994, BLOOD, V84, P934; WHITE JD, 1995, CANCER, V75, P1598, DOI 10.1002/1097-0142(19950401)75:7<1598::AID-CNCR2820750708>3.0.CO;2-7; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000	52	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23414	23424		10.1074/jbc.M600684200	http://dx.doi.org/10.1074/jbc.M600684200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785240	hybrid			2022-12-25	WOS:000239702900016
J	Dong, C; Muriel, JM; Ramirez, S; Hutter, H; Hedgecock, EM; Breydo, L; Baskakov, IV; Vogel, BE				Dong, Chun; Muriel, Joaquin M.; Ramirez, Sarah; Hutter, Harald; Hedgecock, Edward M.; Breydo, Leonid; Baskakov, Ilia V.; Vogel, Bruce E.			Hemicentin assembly in the extracellular matrix is mediated by distinct structural modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-DOMAIN; FIBRONECTIN; RECOMBINATION; ELEGANS; LAMININ	Hemicentins are conserved extracellular matrix proteins characterized by a single von Willebrand A (VWA) domain at the amino terminus, a long stretch (> 40) of tandem immunoglobulin domains, multiple tandem epidermal growth factors (EGFs), and a single fibulin-like carboxyl-terminal module. In Caenorhabditis elegans, hemicentin is secreted from muscle and gonadal leader cells and assembles at multiple locations into discrete tracks that constrict broad regions of cell contact into adhesive and flexible line-shaped junctions. To determine hemicentin domains critical for function and assembly, we have expressed fragments of hemicentin as GFP tagged fusion proteins in C. elegans. We find that a hemicentin fragment containing the VWA domain can target to multiple assembly sites when expressed under the control of either endogenous hemicentin regulatory sequences or the muscle-specific unc-54 promoter. A hemicentin fragment containing the EGF and fibulin-like carboxyl-terminal modules can co-assemble with existing hemicentin polymers in wild-type animals but has no detectable function in the absence of endogenous hemicentin. The data suggest that the VWA domain is a cell binding domain whose function is to target hemicentin to sites of assembly and the EGF/fibulin-like carboxyl-terminal modules constitute an assembly domain that mediates direct interactions between hemicentin monomers during the hemicentin assembly process.	Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, Baltimore, MD 21201 USA; Max Planck Inst Med Res, D-69120 Heidelberg, Germany; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; Max Planck Society; Johns Hopkins University	Vogel, BE (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	vogel@umbi.umd.edu	Breydo, Leo/AAJ-7996-2020; Breydo, Leonid/E-6119-2010	Breydo, Leonid/0000-0003-4666-2301	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065184] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65184] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Hopf M, 2001, J MOL BIOL, V311, P529, DOI 10.1006/jmbi.2001.4878; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; Kumanovics A, 2001, IMMUNOGENETICS, V53, P64, DOI 10.1007/s002510100297; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Muriel JM, 2005, DEVELOPMENT, V132, P4223, DOI 10.1242/dev.02007; OKKEMA PG, 1993, GENETICS, V135, P385; Sasaki T, 2004, J CELL BIOL, V164, P959, DOI 10.1083/jcb.200401058; Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; Vogel BE, 2001, DEVELOPMENT, V128, P883; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006	18	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23606	23610		10.1074/jbc.M513589200	http://dx.doi.org/10.1074/jbc.M513589200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16798744	hybrid			2022-12-25	WOS:000239702900035
J	Guffanti, E; Ferrari, R; Preti, M; Forloni, M; Harismendy, O; Lefebvre, O; Dieci, G				Guffanti, Elisa; Ferrari, Roberto; Preti, Milena; Forloni, Matteo; Harismendy, Olivier; Lefebvre, Olivier; Dieci, Giorgio			A minimal promoter for TFIIIC-dependent in vitro transcription of snoRNA and tRNA genes by RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA3LEU GENE; TATA-BINDING PROTEIN; U6 SNRNA GENE; SACCHAROMYCES-CEREVISIAE; FACTOR-TAU; INTRAGENIC PROMOTER; MUTATIONAL ANALYSIS; POINT MUTATIONS; CONTROL REGIONS; S-CEREVISIAE	The Saccharomyces cerevisiae SNR52 gene is unique among the snoRNA coding genes in being transcribed by RNA polymerase III. The primary transcript of SNR52 is a 250-nucleotide precursor RNA from which a long leader sequence is cleaved to generate the mature snR52 RNA. We found that the box A and box B sequence elements in the leader region are both required for the in vivo accumulation of the snoRNA. As expected box B, but not box A, was absolutely required for stable TFIIIC, yet in vitro. Surprisingly, however, the box B was found to be largely dispensable for in vitro transcription of SNR52, whereas the box A-mutated template effectively recruited TFIIIB; yet it was transcriptionally inactive. Even in the complete absence of box B and both upstream TATA-like and T-rich elements, the box A still directed efficient, TFIIIC-dependent transcription. Box B-independent transcription was also observed for two members of the tRNAAsn (GTT) gene family, but not for two tRNA(Pro)(AGG) gene copies. Fully recombinant TFIIIC supported box B-independent transcription of both SNR52 and tRNAAsn genes, but only in the presence of TFIIIB reconstituted with a crude B '' fraction. Non-TFIIIB component(s) in this fraction were also required for transcription of wild-type SNR52. Transcription of the box B-less tRNA(Asn) genes was strongly influenced by their 5 '-flanking regions, and it was stimulated by TBP and Brf1 proteins synergistically. The box A can thus be viewed as a core TFIIIC-interacting element that, assisted by upstream TFIIIB- DNA contacts, is sufficient to promote class III gene transcription.	Univ Parma, Dipartimento Biochim & Biol Mol, I-43100 Parma, Italy; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); University of Parma; CEA; UDICE-French Research Universities; Universite Paris Saclay	Dieci, G (corresponding author), Univ Parma, Dipartimento Biochim & Biol Mol, Parco Area Sci 23-A, I-43100 Parma, Italy.	giorgio.dieci@unipr.it	Ferrari, Roberto/O-8143-2015; Harismendy, Olivier/AAM-2072-2021; LEFEBVRE, Olivier/C-3847-2014; Dieci, Giorgio/B-3434-2012	Ferrari, Roberto/0000-0002-0453-0899; Harismendy, Olivier/0000-0002-8098-9888; LEFEBVRE, Olivier/0000-0002-3903-9450; Dieci, Giorgio/0000-0002-8792-3961; Forloni, Matteo/0000-0003-4858-8491				ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; Bolchi A, 2005, BIOTECHNOL APPL BIOC, V42, P205, DOI 10.1042/BA20050050; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Braglia P, 2005, J BIOL CHEM, V280, P19551, DOI 10.1074/jbc.M412238200; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CARRARA G, 1981, CELL, V27, P371, DOI 10.1016/0092-8674(81)90420-7; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Cloutier TE, 2001, P NATL ACAD SCI USA, V98, P9581, DOI 10.1073/pnas.161292298; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; Dieci G, 2002, J BIOL CHEM, V277, P6903, DOI 10.1074/jbc.M105036200; DIECI G, 1993, J BIOL CHEM, V268, P11199; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; Ducrot C, 2006, J BIOL CHEM, V281, P11685, DOI 10.1074/jbc.M600101200; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; FRUSCOLONI P, 1995, NUCLEIC ACIDS RES, V23, P2914, DOI 10.1093/nar/23.15.2914; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Giuliodori S, 2003, J MOL BIOL, V333, P1, DOI 10.1016/j.jmb.2003.08.016; HALL BD, 1982, CELL, V29, P3, DOI 10.1016/0092-8674(82)90083-6; Hamada M, 2001, MOL CELL BIOL, V21, P6870, DOI 10.1128/MCB.21.20.6870-6881.2001; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Huet J, 1996, METHOD ENZYMOL, V273, P249; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; JOHNSON JD, 1984, MOL GEN GENET, V197, P55, DOI 10.1007/BF00327922; Kassavetis GA, 2006, J BIOL CHEM, V281, P7445, DOI 10.1074/jbc.M512810200; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOSKI RA, 1982, NUCLEIC ACIDS RES, V10, P8127, DOI 10.1093/nar/10.24.8127; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Kruszka K, 2003, EMBO J, V22, P621, DOI 10.1093/emboj/cdg040; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Marck C, 2006, NUCLEIC ACIDS RES, V34, P1816, DOI 10.1093/nar/gkl085; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARSOLIER MC, 1995, GENE DEV, V9, P410, DOI 10.1101/gad.9.4.410; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Moir RD, 2004, ADV PROTEIN CHEM, V67, P93; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; NEWMAN AJ, 1983, CELL, V35, P117, DOI 10.1016/0092-8674(83)90214-3; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; PAVESI A, 1994, NUCLEIC ACIDS RES, V22, P1247, DOI 10.1093/nar/22.7.1247; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; Yukawa Y, 2000, PLANT J, V22, P439, DOI 10.1046/j.1365-313X.2000.00752.x; Zecherle GN, 1996, MOL CELL BIOL, V16, P5801	66	23	25	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23945	23957		10.1074/jbc.M513814200	http://dx.doi.org/10.1074/jbc.M513814200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787917	hybrid			2022-12-25	WOS:000239702900069
J	Jayanthi, LD; Annamalai, B; Samuvel, DJ; Gether, U; Ramamoorthy, S				Jayanthi, Lankupalle D.; Annamalai, Balasubramaniam; Samuvel, Devadoss J.; Gether, Ulrik; Ramamoorthy, Sammanda			Phosphorylation of the norepinephrine transporter at threonine 258 and serine 259 is linked to protein kinase C-mediated transporter internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; HUMAN PLACENTAL SYNCYTIOTROPHOBLAST; SUBSTANCE-P RECEPTORS; DOPAMINE TRANSPORTER; SEROTONIN TRANSPORTER; LOCUS-COERULEUS; NEUROTRANSMITTER TRANSPORTERS; NEUROKININ-B; TYROSINE PHOSPHORYLATION; FUNCTIONAL REGULATION	Recently, we have demonstrated the phosphorylation- and lipid raft-mediated internalization of the native norepinephrine transporter (NET) following protein kinase C (PKC) activation (Jayanthi, L. D., Samuvel, D. J., and Ramamoorthy, S. (2004) J. Biol. Chem. 279, 19315 -19326). Here we tested an hypothesis that PKC-mediated phosphorylation of NET is required for transporter internalization. Phosphoamino acid analysis of P-32-labeled native NETs from rat placental trophoblasts and heterologously expressed wild type human NET (WT-hNET) from human placental trophoblast cells revealed that the phorbol ester (beta-PMA)-induced phosphorylation of NET occurs on serine and threonine residues. beta-PMA treatment inhibited NE transport, reduced plasma membrane hNET levels, and stimulated hNET phosphorylation in human placental trophoblast cells expressing the WT-hNET. Substance P-mediated activation of the G alpha(q)-coupled human neurokinin 1 (hNK-1) receptor coexpressed with the WT-hNET produced effects similar to beta-PMA via PKC stimulation. In striking contrast, an hNET double mutant harboring T258A and S259A failed to show NE uptake inhibition and plasma membrane redistribution by beta-PMA or SP. Most interestingly, the plasma membrane insertion of the WT-hNET and hNET double mutant were not affected by beta-PMA. Although the WT-hNET showed increased endocytosis and redistribution from caveolin-rich plasma membrane domains following beta-PMA treatment, the hNET double mutant was completely resistant to these PKC-mediated effects. In addition, the PKC-induced phosphorylation of hNET double mutant was significantly reduced. In the absence of T258A and S259A mutations, alanine substitution of all other potential phosphosites within the hNET did not block PKC-induced phosphorylation and down-regulation. These results suggest that Thr-258 and Ser-259 serve as a PKC-specific phospho-acceptor site and that phosphorylation of this motif is linked to PKC-induced NET internalization.	Med Univ S Carolina, Div Neurosci Res, Dept Neurosci, Charleston, SC 29425 USA; Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark	Medical University of South Carolina; University of Copenhagen	Jayanthi, LD (corresponding author), Med Univ S Carolina, Div Neurosci Res, Dept Neurosci, Charleston, SC 29425 USA.	jayanthi@musc.edu		Gether, Ulrik/0000-0002-0020-3807	NIDA NIH HHS [DA016753] Funding Source: Medline; NIMH NIH HHS [MH62612] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA016753] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; ASTONJONES G, 1981, J NEUROSCI, V1, P887; Axelrod J, 1969, Prog Brain Res, V31, P21; Bauman PA, 2002, ARCH BIOCHEM BIOPHYS, V404, P80, DOI 10.1016/S0003-9861(02)00232-1; Becher A, 2001, J NEUROCHEM, V79, P787, DOI 10.1046/j.1471-4159.2001.00614.x; BELISLE S, 1988, J CLIN ENDOCR METAB, V66, P283, DOI 10.1210/jcem-66-2-283; Bert L, 2002, SYNAPSE, V43, P62, DOI 10.1002/syn.10021; Boileau P, 2001, ENDOCRINOLOGY, V142, P3974, DOI 10.1210/en.142.9.3974; Bonisch H, 1998, Adv Pharmacol, V42, P183; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; GANGULY PK, 1986, CIRC RES, V59, P684, DOI 10.1161/01.RES.59.6.684; Goldberg NR, 2003, EUR J PHARMACOL, V479, P3, DOI 10.1016/j.ejphar.2003.08.052; GRAHAM D, 1992, LIFE SCI, V51, P631, DOI 10.1016/0024-3205(92)90236-I; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Hahn MK, 2005, MOL PHARMACOL, V68, P457, DOI 10.1124/mol.105.011270; HALLIDAY GM, 1988, J COMP NEUROL, V273, P301, DOI 10.1002/cne.902730303; Holton KL, 2005, NAT NEUROSCI, V8, P881, DOI 10.1038/nn1478; IVERSEN LL, 1978, HDB PSYCHOPHARMACOLO, P381; Jasmin L, 2002, P NATL ACAD SCI USA, V99, P1029, DOI 10.1073/pnas.012598599; Jayanthi LD, 2005, MOL PHARMACOL, V67, P2077, DOI 10.1124/mol.104.009555; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; JAYANTHI LD, 1993, BIOCHEMISTRY-US, V32, P12178, DOI 10.1021/bi00096a030; Jayanthi LD, 2002, BRIT J PHARMACOL, V135, P1927, DOI 10.1038/sj.bjp.0704658; Karl PI, 1996, BIOCHEM J, V320, P831, DOI 10.1042/bj3200831; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; Klimek V, 1997, J NEUROSCI, V17, P8451; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Lee-Kwon W, 2003, J BIOL CHEM, V278, P16494, DOI 10.1074/jbc.M300580200; Lin ZC, 2003, J BIOL CHEM, V278, P20162, DOI 10.1074/jbc.M209584200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; MERLET P, 1992, J CARDIOVASC PHARM, V19, P10, DOI 10.1097/00005344-199201000-00002; Miranda M, 2005, J BIOL CHEM, V280, P35617, DOI 10.1074/jbc.M506618200; Monastyrskaya K, 2005, J BIOL CHEM, V280, P7135, DOI 10.1074/jbc.M405806200; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Page NM, 2000, NATURE, V405, P797, DOI 10.1038/35015579; Page NM, 2001, HOSP MED, V62, P343, DOI 10.12968/hosp.2001.62.6.1589; Page NM, 2001, REGUL PEPTIDES, V98, P97, DOI 10.1016/S0167-0115(00)00239-1; PAVCOVICH LA, 1990, BRAIN RES BULL, V24, P293, DOI 10.1016/0361-9230(90)90219-P; PETIT A, 1990, J RECEPTOR RES, V10, P205, DOI 10.3109/10799899009064666; Prasad HC, 2005, P NATL ACAD SCI USA, V102, P11545, DOI 10.1073/pnas.0501432102; Quick MW, 2004, J BIOL CHEM, V279, P15961, DOI 10.1074/jbc.M306924200; Ramamoorthy JD, 1995, AM J OBSTET GYNECOL, V173, P1782, DOI 10.1016/0002-9378(95)90427-1; RAMAMOORTHY JD, 1995, ENDOCRINOLOGY, V136, P924, DOI 10.1210/en.136.3.924; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; Ripley TL, 2002, NEUROPHARMACOLOGY, V43, P1258, DOI 10.1016/S0028-3908(02)00295-2; Robertson D, 2001, ANN NY ACAD SCI, V940, P527; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; SCHOCKEN DD, 1980, J CLIN ENDOCR METAB, V50, P1082, DOI 10.1210/jcem-50-6-1082; SHULTS CW, 1984, PEPTIDES, V5, P1097, DOI 10.1016/0196-9781(84)90177-3; SIMSON PE, 1988, NEUROPSYCHOPHARMACOL, V1, P287; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sung U, 2003, J NEUROSCI, V23, P1697; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Uhl GR, 2003, EUR J PHARMACOL, V479, P71, DOI 10.1016/j.ejphar.2003.08.058; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Wang D, 2005, J BIOL CHEM, V280, P18703, DOI 10.1074/jbc.M500381200; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2005, J BIOL CHEM, V280, P30807, DOI 10.1074/jbc.M504087200	66	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23326	23340		10.1074/jbc.M601156200	http://dx.doi.org/10.1074/jbc.M601156200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16740633	hybrid			2022-12-25	WOS:000239702900007
J	Peshenko, IV; Dizhoor, AM				Peshenko, Igor V.; Dizhoor, Alexander M.			Ca2+ and Mg2+ binding properties of GCAP-1 - Evidence that Mg2+-bound form is the physiological activator of photoreceptor guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE-ROD DYSTROPHY; CA2+-BINDING PROTEINS; EF-HAND; CALCIUM-CONCENTRATION; MOLECULAR-MECHANISMS; OUTER SEGMENTS; RETINAL RODS; SPECIFICITY; DIMERIZATION; RECOVERIN	Guanylyl cyclase-activating protein 1 (GCAP-1) is an EF-hand protein that activates retinal guanylyl cyclase ( RetGC) in photoreceptors at low free Ca2+ in the light and inhibits it in the dark when Ca2+ concentrations rise. We present the first direct evidence that Mg2+-bound form of GCAP-1, not its cation-free form, is the true activator of RetGC-1 under physiological conditions. Of four EF-hand structures in GCAP-1, three bound Ca2+ ions and could exchange Ca2+ for Mg2+. At concentrations of free Ca2+ and Mg2+ typical for the light-adapted photoreceptors, all three metal-binding EF-hands were predominantly occupied by Mg-2, and the presence of bound Mg2+ in GCAP-1 was essential for its ability to stimulate RetGC-1. In the Mg2+- bound form of GCAP-1 all three Trp residues became more exposed to the polar environment compared with its apo form. The replacement of Mg2+ by Ca2+ in the EF-hands 2 and 3 further exposed Trp-21 to the solution in a non-metal-binding EF-hand domain 1 that interacts with RetGC. Contrary to that, replacement of Mg2+ by Ca2+ in the EF-hand 4 moved Trp-94 in the entering alpha-helix of the EF-hand 3 back to the non-polar environment. Our results demonstrate that Mg2+ regulates GCAP-1 not only by adjusting its Ca2+ sensitivity to the physiological conditions in photoreceptors but also by creating the conformation required for RetGC stimulation.	Penn Coll Optometry, Hafter Res Labs, Elkins Pk, PA 19027 USA		Dizhoor, AM (corresponding author), Penn Coll Optometry, Hafter Res Labs, Elkins Pk, PA 19027 USA.	adizhoor@pco.edu		Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011522-11, EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allouche D, 1999, J MOL BIOL, V285, P857, DOI 10.1006/jmbi.1998.2329; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 2002, ADV EXP MED BIOL, V514, P333; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BABU A, 1992, J BIOL CHEM, V267, P15469; Blumenschein TMA, 2000, BIOCHEMISTRY-US, V39, P3603, DOI 10.1021/bi9924718; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; Cates MS, 2002, BIOPHYS J, V82, P1133, DOI 10.1016/S0006-3495(02)75472-6; Chen CH, 2003, J PHYSIOL-LONDON, V553, P125, DOI 10.1113/jphysiol.2003.053280; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorczyca WA, 2003, ACTA BIOCHIM POL, V50, P367; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Hwang JY, 2004, EUR J BIOCHEM, V271, P3785, DOI 10.1111/j.1432-1033.2004.04320.x; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; MARKS PW, 1991, ANAL BIOCHEM, V193, P61, DOI 10.1016/0003-2697(91)90044-T; Olshevskaya EV, 2004, J NEUROSCI, V24, P6078, DOI 10.1523/JNEUROSCI.0963-04.2004; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Peshenko IV, 2004, BIOCHEMISTRY-US, V43, P13796, DOI 10.1021/bi048943m; Peshenko IV, 2004, J BIOL CHEM, V279, P16903, DOI 10.1074/jbc.C400065200; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; Ramamurthy V, 2001, J BIOL CHEM, V276, P26218, DOI 10.1074/jbc.M010495200; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1999, J GEN PHYSIOL, V113, P267, DOI 10.1085/jgp.113.2.267; Sokal I, 2001, J BIOL CHEM, V276, P43361, DOI 10.1074/jbc.M103614200; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Tucker CL, 1999, P NATL ACAD SCI USA, V96, P9039, DOI 10.1073/pnas.96.16.9039; Wilkie SE, 2000, HUM MOL GENET, V9, P3065, DOI 10.1093/hmg/9.20.3065; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; Yu H, 1999, J BIOL CHEM, V274, P15547, DOI 10.1074/jbc.274.22.15547	48	95	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23830	23841		10.1074/jbc.M600257200	http://dx.doi.org/10.1074/jbc.M600257200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793776	hybrid			2022-12-25	WOS:000239702900059
J	Agromayor, M; Martin-Serrano, J				Agromayor, Monica; Martin-Serrano, Juan			Interaction of AMSH with ESCRT-III and deubiquitination of endosomal cargo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDERMAL-GROWTH-FACTOR; MULTIVESICULAR BODY PATHWAY; RECEPTOR DOWN-REGULATION; PROTEIN INTERACTIONS; L-DOMAIN; UBIQUITIN; COMPLEX; GAG; TRANSPORT	The "class E" vacuolar protein sorting (VPS) pathway mediates sorting of ubiquitinated cargo into the forming vesicles of the multivesicular bodies (MVB), and it is essential for down-regulation of signaling by growth factors and budding of enveloped viruses such as Ebola and HIV-1. Work in yeast has identified DOA4 as a gene that is recruited by the class E machinery to remove ubiquitin from the endosomal cargo before it is incorporated into MVB vesicles, but the identity of the mammalian counterpart is unclear. Here we report the interaction of AMSH (associated molecule with the SH3 domain of STAM), an endosomal deubiquitinating enzyme, with the endodomal sorting complex required for transport (ESCRT-III) subunits CHMP1A, CHMP1B, CHMP2A, and CHMP3. We also show that a catalytically inactive AMSH inhibits retroviral budding in a dominant-negative manner and induces the accumulation of ubiquitinated forms of an endosomal cargo, namely murine leukemia virus Gag. Finally, VPS4 and AMSH compete for binding to the C-terminal regions of CHMP1A and CHMP1B, revealing a coordinated interaction with ESCRT-III. Taken together, these results are consistent with a role of AMSH in the deubiquitination of the endosomal cargo preceding lysosomal degradation.	Kings Coll London, Sch Med, Guys Hosp, Dept Infect Dis, London SE1 9RT, England; Kings Coll London, Sch Med, Univ London Kings Coll Hosp, Dept Infect Dis, London SE1 9RT, England; Kings Coll London, Sch Med, St Thomas Hosp, Dept Infect Dis, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Martin-Serrano, J (corresponding author), Kings Coll London, Sch Med, Guys Hosp, Dept Infect Dis, 2nd Floor New Guys House, London SE1 9RT, England.	juan.martin_serrano@kcl.ac.uk		Agromayor, Monica/0000-0001-6477-1750; Martin-Serrano, Juan/0000-0002-8183-3914	Medical Research Council [G0400207] Funding Source: Medline; MRC [G0400207] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gottwein E, 2005, J VIROL, V79, P9134, DOI 10.1128/JVI.79.14.9134-9144.2005; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Heidecker G, 2004, J VIROL, V78, P6636, DOI 10.1128/JVI.78.12.6636-6648.2004; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; Losko S, 2001, MOL BIOL CELL, V12, P1047, DOI 10.1091/mbc.12.4.1047; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Martin-Serrano J, 2004, J VIROL, V78, P5554, DOI 10.1128/JVI.78.11.5554-5563.2004; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Onishi M, 2003, BIOSCI BIOTECH BIOCH, V67, P1772, DOI 10.1271/bbb.67.1772; Ott DE, 2003, J VIROL, V77, P3384, DOI 10.1128/JVI.77.6.3384-3393.2003; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Scott A, 2005, P NATL ACAD SCI USA, V102, P13813, DOI 10.1073/pnas.0502165102; Scott A, 2005, EMBO J, V24, P3658, DOI 10.1038/sj.emboj.7600818; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000	51	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23083	23091		10.1074/jbc.M513803200	http://dx.doi.org/10.1074/jbc.M513803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760479	hybrid			2022-12-25	WOS:000239542600072
J	El Ghachi, M; Bouhss, A; Barreteau, H; Touze, T; Auger, G; Blanot, D; Mengin-Lecreulx, D				El Ghachi, Meriem; Bouhss, Ahmed; Barreteau, Helene; Touze, Thierry; Auger, Genevieve; Blanot, Didier; Mengin-Lecreulx, Dominique			Colicin M exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked peptidoglycan precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; CELL-WALL PEPTIDOGLYCAN; REQUIREMENTS ALLOWING DETECTION; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; LIPID INTERMEDIATE; MICROCOCCUS-LYSODEIKTICUS; C55-ISOPRENOID ALCOHOL; STAPHYLOCOCCUS-AUREUS; MUREIN BIOSYNTHESIS	Colicin M was earlier demonstrated to provoke Escherichia coli cell lysis via inhibition of cell wall peptidoglycan (murein) biosynthesis. As the formation of the O-antigen moiety of lipopolysaccharides was concomitantly blocked, it was hypothesized that the metabolism of undecaprenyl phosphate, an essential carrier lipid shared by these two pathways, should be the target of this colicin. However, the exact target and mechanism of action of colicin M was unknown. Colicin M was now purified to near homogeneity, and its effects on cell wall peptidoglycan metabolism reinvestigated. It is demonstrated that colicin M exhibits both in vitro and in vivo enzymatic properties of degradation of lipid I and lipid II peptidoglycan intermediates. Free undecaprenol and either 1-pyrophospho-MurNAc-pentapeptide or 1-pyrophospho-MurNAc-(pentapeptide)-Glc-NAc were identified as the lipid I and lipid II degradation products, respectively, showing that the cleavage occurred between the lipid moiety and the pyrophosphoryl group. This is the first time such an activity is described. Neither undecaprenyl pyrophosphate nor the peptidoglycan nucleotide precursors were substrates of colicin M, indicating that both undecaprenyl and sugar moieties were essential for activity. The bacteriolytic effect of colicin M therefore appears to be the consequence of an arrest of peptidoglycan polymerization steps provoked by enzymatic degradation of the undecaprenyl phosphate-linked peptidoglycan precursors.	Univ Paris 11, CNRS, UMR 8619, IBBMC,Lab Enveloppes Bacteriennes & Antibiot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, CNRS, UMR 8619, IBBMC,Lab Enveloppes Bacteriennes & Antibiot, Batiment 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr	Touzé, Thierry/GLT-1308-2022	Touze, Thierry/0000-0002-2176-6537; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				ABOGHALIA M, 1985, EUR J BIOCHEM, V153, P81, DOI 10.1111/j.1432-1033.1985.tb09269.x; ALEXANDER DC, 1994, J BACTERIOL, V176, P7079, DOI 10.1128/JB.176.22.7079-7084.1994; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Auger G, 2003, FEMS MICROBIOL LETT, V219, P115, DOI 10.1016/S0378-1097(02)01203-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLANOSGARCIA VM, 2006, IN PRESS BIOCH BIOPH; Bouhss A, 2004, J BIOL CHEM, V279, P29974, DOI 10.1074/jbc.M314165200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN V, 1973, BIOCHIM BIOPHYS ACTA, V323, P87, DOI 10.1016/0005-2736(73)90433-1; Crouvoisier M, 1999, FEBS LETT, V449, P289, DOI 10.1016/S0014-5793(99)00412-3; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; DAI D, 1988, J BACTERIOL, V170, P2197, DOI 10.1128/jb.170.5.2197-2201.1988; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DREHER R, 1985, ARCH MICROBIOL, V140, P343, DOI 10.1007/BF00446975; El Ghachi M, 2005, J BIOL CHEM, V280, P18689, DOI 10.1074/jbc.M412277200; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; HARKNESS RE, 1990, MOL GEN GENET, V222, P37, DOI 10.1007/BF00283020; HARKNESS RE, 1989, J BIOL CHEM, V264, P14716; HARKNESS RE, 1989, J BIOL CHEM, V264, P6177; HIGASHI Y, 1970, J BIOL CHEM, V245, P3697; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; JOHNSON JG, 1977, J BACTERIOL, V129, P225, DOI 10.1128/JB.129.1.225-236.1977; KALIN JR, 1979, BIOCHIM BIOPHYS ACTA, V574, P112, DOI 10.1016/0005-2760(79)90090-0; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; KOCK J, 1987, J BACTERIOL, V169, P3358; KOHLRAUSCH U, 1989, J GEN MICROBIOL, V135, P1499; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; LOWE PN, 1982, BIOCHEMISTRY-US, V21, P4073, DOI 10.1021/bi00260a025; Maillard AP, 2005, J BACTERIOL, V187, P3833, DOI 10.1128/JB.187.11.3833-3838.2005; MENGINLECREULX D, 1989, J BACTERIOL, V171, P3282, DOI 10.1128/jb.171.6.3282-3287.1989; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; OLSCHLAGER T, 1984, MOL GEN GENET, V196, P482, DOI 10.1007/BF00436196; PILSL H, 1993, MOL GEN GENET, V240, P103, DOI 10.1007/BF00276889; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P203; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAMEY WD, 1978, J BACTERIOL, V135, P71, DOI 10.1128/JB.135.1.71-77.1978; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Rick PD, 1998, GLYCOBIOLOGY, V8, P557, DOI 10.1093/glycob/8.6.557; ROHR TE, 1977, J BIOL CHEM, V252, P3460; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SCHALLER K, 1982, J BACTERIOL, V152, P994; SCHALLER K, 1981, J BACTERIOL, V146, P54, DOI 10.1128/JB.146.1.54-63.1981; SCHER M, 1968, P NATL ACAD SCI USA, V59, P1313, DOI 10.1073/pnas.59.4.1313; Schiller J, 1999, ANAL BIOCHEM, V267, P46, DOI 10.1006/abio.1998.3001; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; Stenbak CR, 2004, J IMMUNOL, V173, P7339, DOI 10.4049/jimmunol.173.12.7339; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1973, J BIOL CHEM, V248, P3940; TROY FA, 1975, J BIOL CHEM, V250, P156; TROY FA, 1971, J BIOL CHEM, V246, P118; Uehara T, 2006, J BACTERIOL, V188, P1660, DOI 10.1128/JB.188.4.1660-1662.2006; UMBREIT JN, 1972, J BACTERIOL, V112, P1306, DOI 10.1128/JB.112.3.1306-1309.1972; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; VANHEIJENOORT Y, 1971, FEBS LETT, V15, P137, DOI 10.1016/0014-5793(71)80041-8; WATKINSON RJ, 1971, NATURE-NEW BIOL, V229, P57, DOI 10.1038/newbio229057a0; WIENTJES FB, 1985, J BACTERIOL, V164, P331, DOI 10.1128/JB.164.1.331-337.1985; WILLOUGHBY E, 1972, J BIOL CHEM, V247, P5113; WRIGHT A, 1967, P NATL ACAD SCI USA, V57, P1798, DOI 10.1073/pnas.57.6.1798	67	91	93	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22761	22772		10.1074/jbc.M602834200	http://dx.doi.org/10.1074/jbc.M602834200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16777846	hybrid			2022-12-25	WOS:000239542600037
J	Pontarin, G; Ferraro, P; Valentin, ML; Hirano, M; Reichard, P; Bianchi, V				Pontarin, Giovanna; Ferraro, Paola; Valentin, Maria L.; Hirano, Michio; Reichard, Peter; Bianchi, Vera			Mitochondrial DNA depletion and thymidine phosphate pool dynamics in a cellular model of mitochondrial neurogastrointestinal encephalomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-DEFICIENCY; DEOXYRIBONUCLEIC ACID; DELETIONS; MNGIE; TRIPHOSPHATE; FIBROBLASTS; MUTATIONS; KINASE; CELLS; MTDNA	Mitochondrial (mt) neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disease associated with depletion, deletions, and point mutations of mtDNA. Patients lack a functional thymidine phosphorylase and their plasma contains high concentrations of thymidine and deoxyuridine; elevation of the corresponding triphosphates probably impairs normal mtDNA replication and repair. To study metabolic events leading to MNGIE we used as model systems skin and lung fibroblasts cultured in the presence of thymidine and/or deoxyuridine at concentrations close to those in the plasma of the patients, a more than 100-fold excess relative to controls. The two deoxynucleosides increased the mt and cytosolic dTTP pools of skin fibroblasts almost 2-fold in cycling cells and 8-fold in quiescent cells. During up to a two-month incubation of quiescent fibroblasts with thymidine (but not with deoxyuridine), mtDNA decreased to similar to 50% without showing deletions or point mutations. When we removed thymidine, but maintained the quiescent state, mtDNA recovered rapidly. With thymidine in the medium, the dTTP pool of quiescent cells turned over rapidly at a rate depending on the concentration of thymidine, due to increased degradation and resynthesis of dTMP in a substrate (=futile) cycle between thymidine kinase and 5'-deoxyribonucleotidase. The cycle limited the expansion of the dTTP pool at the expense of ATP hydrolysis. We propose that the substrate cycle represents a regulatory mechanism to protect cells from harmful increases of dTTP. Thus MNGIE patients may increase their consumption of ATP to counteract an unlimited expansion of the dTTP pool caused by circulating thymidine.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Columbia Univ, Ctr Med, Dept Neurol, New York, NY 10032 USA	University of Padua; Columbia University	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@bio.unipd.it		VALENTINO, MARIA LUCIA/0000-0001-5323-0115	Telethon [GFP03004] Funding Source: Medline	Telethon(Fondazione Telethon)		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BERK AJ, 1973, J BIOL CHEM, V248, P2722; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BJURSELL G, 1973, J BIOL CHEM, V248, P3904; Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99; Chabes A, 2003, CELL CYCLE, V2, P172, DOI 10.4161/cc.2.3.354; Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309; COHEN A, 1985, P SOC EXP BIOL MED, V179, P437; Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200; FRIEDKIN M, 1954, J BIOL CHEM, V207, P245; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; Marti R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192	28	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22720	22728		10.1074/jbc.M604498200	http://dx.doi.org/10.1074/jbc.M604498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774911	hybrid			2022-12-25	WOS:000239542600032
J	Rodriguez, JM; Glozak, MA; Ma, YH; Cress, WD				Rodriguez, Jose M.; Glozak, Michele A.; Ma, Yihong; Cress, W. Douglas			Bok, Bcl-2-related ovarian killer, is cell cycle-regulated and sensitizes to stress-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F FAMILY-MEMBER; DNA-DAMAGE RESPONSE; S-PHASE; TRANSCRIPTION FACTOR; BCL-2 FAMILY; GROWTH SUPPRESSION; BINDING PROTEIN; UP-REGULATION; EXPRESSION; IDENTIFICATION	Bok/Mtd (Bcl-2-related ovarian killer/Matador) is considered a pro-apoptotic member of the Bcl-2 family. Although identified in 1997, little is known about its biological role. We have previously demonstrated that Bok mRNA is up-regulated following E2F1 overexpression. In the current work, we demonstrate that Bok RNA is low in quiescent cells and rises upon serum stimulation. To determine the mechanism underlying this regulation, we cloned and characterized the mouse Bok promoter. We find that the mouse promoter contains a conserved E2F binding site (-43 to -49) and that a Bok promoter-driven luciferase reporter is activated by serum stimulation dependent on this site. Chromatin immunoprecipitation assays demonstrate that endogenous E2F1 and E2F3 associate with the Bok promoter in vivo. Surprisingly, we find that H1299 cells can stably express high levels of exogenous Bok protein. However, these cells are highly sensitive to chemotherapeutic drug treatment. Taken together these results demonstrate that Bok represents a cell cycle-regulated pro-apoptotic member of the Bcl-2 family, which may predispose growing cells to chemotherapeutic treatment.	Univ Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33612 USA; Univ Florida, Res Inst, Tampa, FL 33612 USA; Univ Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ Florida, Canc Biol PhD Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cress, WD (corresponding author), 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA090489] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA090489, R01 CA090489-05S1, R01 CA090489-04S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Brown CY, 2004, DEV COMP IMMUNOL, V28, P619, DOI 10.1016/j.dci.2003.09.017; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Gross A, 2006, CELL CYCLE, V5, P582, DOI 10.4161/cc.5.6.2575; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Ha SH, 2001, MOL CELLS, V12, P368; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Humbert PO, 2000, GENE DEV, V14, P690; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, MOL CANCER THER, V2, P73; Maglott D, 2005, NUCLEIC ACIDS RES, V33, pD54, DOI 10.1093/nar/gki031; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Neuman E, 1996, GENE, V173, P163, DOI 10.1016/0378-1119(96)00184-9; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Suominen JS, 2001, EUR J ENDOCRINOL, V145, P771, DOI 10.1530/eje.0.1450771; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	64	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22729	22735		10.1074/jbc.M604705200	http://dx.doi.org/10.1074/jbc.M604705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772296	Green Accepted, hybrid			2022-12-25	WOS:000239542600033
J	Sherman, EL; Taylor, RD; Go, NE; Nargang, FE				Sherman, E. Laura; Taylor, Rebecca D.; Go, Nancy E.; Nargang, Frank E.			Effect of mutations in Tom40 on stability of the translocase of the outer mitochondrial membrane (TOM) complex, assembly of Tom40, and import of mitochondrial preproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROTEIN IMPORT; INTERMEMBRANE SPACE; PRESEQUENCE TRANSLOCASE; BIOGENESIS; CHANNEL; PORE; PATHWAY; COMPONENT; TIM50	Mitochondrial preproteins synthesized in the cytosol are imported through the mitochondrial outer membrane by the translocase of the outer mitochondrial membrane (TOM) complex. Tom40 is the major component of the complex and is essential for cell viability. We generated 21 different mutations in conserved regions of the Neurospora crassa Tom40 protein. The mutant genes were transformed into a tom40 null nucleus maintained in a sheltered heterokaryon, and 17 of the mutant genes gave rise to viable strains. All mutations reduced the efficiency of the altered Tom40 molecules to assemble into the TOM complex. Mitochondria isolated from seven of the mutant strains had defects for importing mitochondrial preproteins. Only one strain had a general import defect for all preproteins examined. Another mutation resulted in defects in the import of a matrix-destined preprotein and an outer membrane beta-barrel protein, but import of the ADP/ATP carrier to the inner membrane was unaffected. Five strains showed deficiencies in the import of beta-barrel proteins. The latter results suggest that the TOM complex distinguishes beta-barrel proteins from other classes of preprotein during import. This supports the idea that the TOM complex plays an active role in the transfer of preproteins to subsequent translocases for insertion into the correct mitochondrial subcompartment.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Nargang, FE (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.	frank.nargang@ualberta.ca	Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; Allen S, 2005, J MOL BIOL, V353, P937, DOI 10.1016/j.jmb.2005.08.049; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Becker L, 2005, J MOL BIOL, V353, P1011, DOI 10.1016/j.jmb.2005.09.019; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; COURT DA, 1995, CAN J BOT, V73, pS193; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Descheneau AT, 2005, GENETICS, V169, P123, DOI 10.1534/genetics.104.034017; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Esaki M, 2003, NAT STRUCT BIOL, V10, P988, DOI 10.1038/nsb1008; Gabriel K, 2003, EMBO J, V22, P2380, DOI 10.1093/emboj/cdg229; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; GOOD AG, 1989, PLANT PHYSIOL, V90, P1305, DOI 10.1104/pp.90.4.1305; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hofmann S, 2005, J MOL BIOL, V353, P517, DOI 10.1016/j.jmb.2005.08.064; Hoppins SC, 2004, MYCOTA, V3, P33; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Humphries AD, 2005, J BIOL CHEM, V280, P11535, DOI 10.1074/jbc.M413816200; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kunkele KP, 1998, J BIOL CHEM, V273, P31032, DOI 10.1074/jbc.273.47.31032; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; MARGOLIN BS, 2000, FUNGAL GENET NEWSL, V47, P112; Margolin BS, 1997, FUNGAL GENET NEWSLET, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; Meisinger C, 2004, DEV CELL, V7, P61, DOI 10.1016/j.devcel.2004.06.003; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Mokranjac D, 2005, BIOCHEM SOC T, V33, P1019, DOI 10.1042/BST0331019; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 2004, TOP CURR GENET, V8, P37; Rapaport D, 1998, MOL CELL BIOL, V18, P5256, DOI 10.1128/MCB.18.9.5256; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rissler M, 2005, J MOL BIOL, V353, P485, DOI 10.1016/j.jmb.2005.08.051; Ryan MT, 2000, INT J BIOCHEM CELL B, V32, P13, DOI 10.1016/S1357-2725(99)00114-4; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schmitt S, 2005, J BIOL CHEM, V280, P14499, DOI 10.1074/jbc.M413667200; Sherman EL, 2005, MOL BIOL CELL, V16, P4172, DOI 10.1091/mbc.E05-03-0187; Stan T, 2000, EMBO J, V19, P4895, DOI 10.1093/emboj/19.18.4895; Suzuki H, 2004, J BIOL CHEM, V279, P50619, DOI 10.1074/jbc.M408604200; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Waizengger T, 2005, EMBO REP, V6, P57, DOI 10.1038/sj.embor.7400318; Wendland J., 1996, FUNGAL GENETICS REPO, V43, P54; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	66	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22554	22565		10.1074/jbc.M601630200	http://dx.doi.org/10.1074/jbc.M601630200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757481	hybrid			2022-12-25	WOS:000239542600016
J	Brennan, JP; Bardswell, SC; Burgoyne, JR; Fuller, W; Schroder, E; Wait, R; Begum, S; Kentish, JC; Eaton, P				Brennan, Jonathan P.; Bardswell, Sonya C.; Burgoyne, Joseph R.; Fuller, William; Schroder, Ewald; Wait, Robin; Begum, Shajna; Kentish, Jonathan C.; Eaton, Philip			Oxidant-induced activation of type I protein kinase a is mediated by RI subunit interprotein disulfide bond formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; HYDROGEN-PEROXIDE; REGULATORY SUBUNIT; IDENTIFICATION; OXIDATION; DOMAIN; ENDOTHELIN-1; STIMULATION; SUBSTRATE; ISCHEMIA	Here we demonstrate that type I protein kinase A is redoxactive, forming an interprotein disulfide bond between its two regulatory RI subunits in response to cellular hydrogen peroxide. This oxidative disulfide formation causes a subcellular translocation and activation of the kinase, resulting in phosphorylation of established substrate proteins. The translocation is mediated at least in part by the oxidized form of the kinase having an enhanced affinity for alpha-myosin heavy chain, which serves as a protein kinase A ( PKA) anchor protein and localizes the PKA to its myofilament substrates troponin I and myosin binding protein C. The functional consequence of these events in cardiac myocytes is that hydrogen peroxide increases contractility independently of beta-adrenergic stimulation and elevations of cAMP. The oxidant-induced phosphorylation of substrate proteins and increased contractility is blocked by the kinase inhibitor H89, indicating that these events involve PKA activation. In essence, type I PKA contains protein thiols that operate as redox sensors, and their oxidation by hydrogen peroxide directly activates the kinase.	St Thomas Hosp, Rayne Inst, Dept Cardiol, Kings Coll London, London SE1 7EH, England; St Thomas Hosp, Rayne Inst, Div Cardiovasc, Kings Coll London, London SE1 7EH, England; Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, Fac Med, London W6 8LH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; University of Oxford	Eaton, P (corresponding author), St Thomas Hosp, Rayne Inst, Dept Cardiol, Kings Coll London, London SE1 7EH, England.	philip.eaton@kcl.ac.uk	Eaton, Philip/I-5444-2015	Eaton, Philip/0000-0003-0748-2367; Fuller, William/0000-0002-5883-4433; Burgoyne, Joseph/0000-0001-7325-7382	MRC [G9900166, G0001112] Funding Source: UKRI; Medical Research Council [G9900166, G0001112, G0600785] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; Boeshans KM, 1999, PROTEIN SCI, V8, P1515, DOI 10.1110/ps.8.7.1515; Brennan JP, 2006, MOL CELL PROTEOMICS, V5, P215, DOI 10.1074/mcp.M500212-MCP200; Brennan JP, 2004, J BIOL CHEM, V279, P41352, DOI 10.1074/jbc.M403827200; DRUMMOND GI, 1981, ARCH BIOCHEM BIOPHYS, V211, P30, DOI 10.1016/0003-9861(81)90425-2; Eaton P, 2003, J AM SOC NEPHROL, V14, pS290, DOI 10.1097/01.ASN.0000078024.50060.C6; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; GOLDHABER JI, 1994, J PHYSIOL-LONDON, V477, P135, DOI 10.1113/jphysiol.1994.sp020178; Humphries KM, 2005, J BIOL CHEM, V280, P2750, DOI 10.1074/jbc.M410242200; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; James AF, 2001, BIOCHEM BIOPH RES CO, V284, P1048, DOI 10.1006/bbrc.2001.5083; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Knight PJ, 2005, J BIOL CHEM, V280, P34702, DOI 10.1074/jbc.M504887200; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Persad S, 1998, MOL CELL BIOCHEM, V186, P99, DOI 10.1023/A:1006823531286; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Rhee S G, 2000, Sci STKE, V2000, ppe1; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Snabaitis AK, 2005, CELL SIGNAL, V17, P655, DOI 10.1016/j.cellsig.2004.10.008; Snabaitis AK, 2006, J BIOL CHEM, V281, P20252, DOI 10.1074/jbc.M600268200; Thomas GP, 1998, J PHARMACOL EXP THER, V286, P1208; Vigil D, 2004, BIOCHEMISTRY-US, V43, P5629, DOI 10.1021/bi0499157; Viste K, 2005, J BIOL CHEM, V280, P13279, DOI 10.1074/jbc.M413065200; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; WARD CA, 1995, J MOL CELL CARDIOL, V27, P1089, DOI 10.1016/0022-2828(95)90077-2; Yao K, 2003, J PHARM PHARMACOL, V55, P109, DOI 10.1111/j.2042-7158.2003.tb02440.x	30	181	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21827	21836		10.1074/jbc.M603952200	http://dx.doi.org/10.1074/jbc.M603952200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754666	hybrid			2022-12-25	WOS:000239387100029
J	Lesnefsky, EJ; He, DC; Moghaddas, S; Hoppel, CL				Lesnefsky, Edward J.; He, DingChao; Moghaddas, Shadi; Hoppel, Charles L.			Reversal of mitochondrial defects before ischemia protects the aged heart	FASEB JOURNAL			English	Article						oxidative phosphorylation; reperfusion; cytochrome oxidase; ubiquinol-cytochrome c oxidoreductase (complex III)	ACETYL-L-CARNITINE; PROPIONYL-L-CARNITINE; ELECTRON-TRANSPORT; COMPLEX-III; REPERFUSION INJURY; LIPID-PEROXIDATION; CYTOCHROME-OXIDASE; RAT HEARTS; TRANSCRIPTION; DYSFUNCTION	Myocardial injury is increased in the aged heart during ischemia and reperfusion. Aging decreases oxidative metabolism in interfibrillar mitochondria (IFM) located between the myofibrils. We asked whether reversal of aging defects in IFM before ischemia would decrease injury in the aged heart following ischemia and reperfusion. Treatment with acetylcarnitine (AcCN) increases the activity of cytochrome oxidase in the aged heart. Aged (24 months) and adult ( 6 months) Fischer 344 rats were treated with AcCN (300 mg/ kg i. p. 3 h before excision of the heart) or served as controls. AcCN restored oxidative phosphorylation and the activity of complexes III and IV in IFM from aged hearts to rates present in adults. Isolated hearts underwent 25 min global ischemia and 30 min reperfusion without additional treatment. Contractile recovery during reperfusion improved in hearts from AcCN-treated aged rats compared to aged controls and were similar to adults in recovery. AcCN-treated aged hearts sustained less damage, indicated by decreased lactate dehydrogenase (LDH) release during reperfusion. AcCN treatment did not alter functional recovery or LDH release in adults. Restoration of mitochondrial function in the aged heart before ischemia was accompanied by enhanced contractile recovery and decreased tissue injury following ischemia and reperfusion.	Louis Stokes VA Med Ctr, Med Serv, Cardiol Sect, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Div Clin Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Lesnefsky, EJ (corresponding author), Louis Stokes VA Med Ctr, Med Serv, Cardiol Sect, 111W,10701 E Blvd, Cleveland, OH 44106 USA.	EXL9@cwru.edu			NIA NIH HHS [1K04AG00676, 1P01AG15885, 1R01AG12447] Funding Source: Medline; NIDDK NIH HHS [1R01DK36069] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000676, R01AG012447, P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ATAKA K, 1992, CIRCULATION, V86, P371; BAHL JJ, 1987, ANNU REV PHARMACOL, V27, P257, DOI 10.1146/annurev.pa.27.040187.001353; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; CARREA FP, 1991, CIRC RES, V68, P1652, DOI 10.1161/01.RES.68.6.1652; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Demin OV, 1998, MOL CELL BIOCHEM, V184, P21, DOI 10.1023/A:1006849920918; DILISA F, 1994, AM J PHYSIOL, V267, pH455, DOI 10.1152/ajpheart.1994.267.2.H455; DUAN J, 1989, BRIT J PHARMACOL, V98, P1319, DOI 10.1111/j.1476-5381.1989.tb12680.x; Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508; FERRARI R, 1991, CARDIOVASC DRUG THER, V5, P57, DOI 10.1007/BF00128244; FROLKIS VV, 1991, GERONTOLOGY, V37, P233; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GADALETA MN, 1994, ANN NY ACAD SCI, V717, P150, DOI 10.1111/j.1749-6632.1994.tb12082.x; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P7184; HEARSE DJ, 1980, THORAC CARDIOV SURG, V28, P253, DOI 10.1055/s-2007-1022090; Horwitz LD, 1999, J CARDIOVASC PHARM, V33, P19, DOI 10.1097/00005344-199901000-00004; Kadenbach B, 2000, FREE RADICAL BIO MED, V29, P211, DOI 10.1016/S0891-5849(00)00305-1; Lesnefsky EJ, 1996, J AM COLL CARDIOL, V28, P331, DOI 10.1016/0735-1097(96)00148-9; Lesnefsky EJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P287, DOI 10.1016/j.abb.2003.09.046; Lesnefsky EJ, 2003, FASEB J, V17, pA518; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; LESNEFSKY EJ, 1994, J LAB CLIN MED, V124, P843; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P37, DOI 10.1006/jmcc.2000.1273; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lesnefsky EJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P117, DOI 10.1006/abbi.2000.2066; Liu LX, 1998, AM J PHYSIOL-REG I, V275, pR315, DOI 10.1152/ajpregu.1998.275.1.R315; Loster H, 1998, MOL CELL BIOCHEM, V185, P65, DOI 10.1023/A:1006891208220; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8; Moghaddas S, 2002, J GERONTOL A-BIOL, V57, pB22, DOI 10.1093/gerona/57.1.B22; PALMER JW, 1977, J BIOL CHEM, V252, P8731; PARADIES G, 1993, ARCH GERONTOL GERIAT, V16, P263, DOI 10.1016/0167-4943(93)90037-I; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; PARADIES G, 1992, BIOCHIM BIOPHYS ACTA, V1103, P324, DOI 10.1016/0005-2736(92)90103-S; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; PARADIES G, 1994, ANN NY ACAD SCI, V717, P233, DOI 10.1111/j.1749-6632.1994.tb12093.x; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; SUGIOKA K, 1988, BIOCHIM BIOPHYS ACTA, V936, P377, DOI 10.1016/0005-2728(88)90014-X; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VIK SB, 1977, BIOCHEMISTRY-US, V16, P5755, DOI 10.1021/bi00645a016	43	46	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1543	+		10.1096/fj.05-4535fje	http://dx.doi.org/10.1096/fj.05-4535fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793872				2022-12-25	WOS:000240266000045
J	Sanz, A; Caro, P; Ayala, V; Portero-Otin, M; Pamplona, R; Barja, G				Sanz, Alberto; Caro, Pilar; Ayala, Victoria; Portero-Otin, Manuel; Pamplona, Reinald; Barja, Gustavo			Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins	FASEB JOURNAL			English	Article						mitochondria; methionine restriction; caloric restriction; free radicals; aging; DNA damage; oxidative damage	LOW-DENSITY-LIPOPROTEIN; MAXIMUM LIFE-SPAN; CALORIC RESTRICTION; RAT-HEART; SULFOXIDE REDUCTASE; DIETARY-PROTEIN; COMPLEX-I; INCREASES; STRESS; HOMOCYSTEINE	Previous studies have consistently shown that caloric restriction (CR) decreases mitochondrial reactive oxygen species (ROS) (mitROS) generation and oxidative damage to mtDNA and mitochondrial proteins, and increases maximum longevity, although the mechanisms responsible for this are unknown. We recently found that protein restriction ( PR) also produces these changes independent of energy restriction. Various facts link methionine to aging, and methionine restriction (MetR) without energy restriction increases, like CR, maximum longevity. We have thus hypothesized that MetR is responsible for the decrease in mitROS generation and oxidative stress in PR and CR. In this investigation we subjected male rats to exactly the same dietary protocol of MetR that is known to increase their longevity. We have found, for the first time, that MetR profoundly decreases mitROS production, decreases oxidative damage to mtDNA, lowers membrane unsaturation, and decreases all five markers of protein oxidation measured in rat heart and liver mitochondria. The concentration of complexes I and IV also decreases in MetR. The decrease in mitROS generation occurs in complexes I and III in liver and in complex I in heart mitochondria, and is due to an increase in efficiency of the respiratory chain in avoiding electron leak to oxygen. These changes are strikingly similar to those observed in CR and PR, suggesting that the decrease in methionine ingestion is responsible for the decrease in mitochondrial ROS production and oxidative stress, and possibly part of the decrease in aging rate, occurring during caloric restriction.	Univ Complutense, Fac Ciencias Biol, Dept Fisiol Anim 2, E-28040 Madrid, Spain; Univ Lleida, Dept Basic Med Sci, Lleida, Spain	Complutense University of Madrid; Universitat de Lleida	Barja, G (corresponding author), Univ Complutense, Fac Ciencias Biol, Dept Fisiol Anim 2, C Antonio Novais 2, E-28040 Madrid, Spain.	gbarja@bio.ucm.es	Portero-Otin, Manuel/B-7122-2009; Ayala, Maria Victoria/A-7391-2010; Barja, Gustavo/AAA-5903-2019; Pamplona, Reinald/A-7359-2010; Gustavo, Barja/B-5591-2012; Sanz, Alberto/O-2329-2015; SANZ, ALBERTO/F-8432-2011	Portero-Otin, Manuel/0000-0002-1823-0299; Ayala, Maria Victoria/0000-0002-1496-966X; Barja, Gustavo/0000-0001-5736-4735; Pamplona, Reinald/0000-0003-4337-6107; Sanz, Alberto/0000-0003-2149-1753; Caro, Pilar/0000-0002-7531-3234				Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; ASUNCION JG, 1996, FASEB J, V10, P333; Barja G, 2004, BIOL REV, V79, P235, DOI 10.1017/S1464793103006213; Barja G, 2002, J BIOENERG BIOMEMBR, V34, P227, DOI 10.1023/A:1016039604958; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; BARROWS CH, 1975, GROWTH, V39, P525; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Chang L, 2004, CLIN EXP PHARMACOL P, V31, P237, DOI 10.1111/j.1440-1681.2004.03983.x; FAU D, 1988, J NUTR, V118, P128, DOI 10.1093/jn/118.1.128; GOODRICK CL, 1978, J GERONTOL, V33, P184, DOI 10.1093/geronj/33.2.184; Gredilla R, 2005, ENDOCRINOLOGY, V146, P3713, DOI 10.1210/en.2005-0378; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190; Hidiroglou N, 2004, J NUTR BIOCHEM, V15, P730, DOI 10.1016/j.jnutbio.2004.04.009; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; LETO S, 1976, J GERONTOL, V31, P144, DOI 10.1093/geronj/31.2.144; Loft S, 1999, METHOD ENZYMOL, V300, P166; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Mitsui A, 2002, ANTIOXID REDOX SIGN, V4, P693, DOI 10.1089/15230860260220201; Mori N, 2000, J NUTR, V130, P2349, DOI 10.1093/jn/130.9.2349; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Ninomiya T, 2004, AM J KIDNEY DIS, V44, P437, DOI 10.1053/j.ajkd.2004.05.024; Pamplona R, 2005, J BIOL CHEM, V280, P21522, DOI 10.1074/jbc.M502255200; Pamplona R, 2002, ANN NY ACAD SCI, V959, P475, DOI 10.1111/j.1749-6632.2002.tb02118.x; Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3; Pamplona R, 2002, FREE RADICAL RES, V36, P47, DOI 10.1080/10715760210165; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; ROSS MH, 1961, J NUTR, V75, P197, DOI 10.1093/jn/75.2.197; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Ruiz MC, 2005, MECH AGEING DEV, V126, P1106, DOI 10.1016/j.mad.2005.04.005; Sanz A, 2004, J BIOENERG BIOMEMBR, V36, P545, DOI 10.1007/s10863-004-9001-7; SANZ A, 2006, IN PRESS ANN NY ACAD; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Uthus EO, 2003, EXP GERONTOL, V38, P491, DOI 10.1016/S0531-5565(03)00008-1; Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3	40	165	177	3	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1064	1073		10.1096/fj.05-5568com	http://dx.doi.org/10.1096/fj.05-5568com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770005				2022-12-25	WOS:000240210300006
J	Singh, AP; Chauhan, SC; Andrianifahanana, M; Moniaux, N; Meza, JL; Copin, MC; van Seuningen, I; Hollingsworth, MA; Aubert, JP; Batra, SK				Singh, A. P.; Chauhan, S. C.; Andrianifahanana, M.; Moniaux, N.; Meza, J. L.; Copin, M. C.; van Seuningen, I.; Hollingsworth, M. A.; Aubert, J. P.; Batra, S. K.			MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms	ONCOGENE			English	Article						MUC4; CFTR; pancreatic adenocarcinoma	KAPPA-B ACTIVATION; GENE-EXPRESSION; MUC4/SIALOMUCIN COMPLEX; SIALOMUCIN COMPLEX; SIGNALING PATHWAY; EPITHELIAL-CELLS; CANCER-CELLS; TUMOR-CELLS; DUCT CELLS; T84 CELLS	MUC4 mucin is a high molecular weight transmembrane glycoprotein that plays important roles in tumour biology. It is aberrantly expressed in pancreatic adenocarcinoma, while not being detectable in the normal pancreas. Previous studies have demonstrated that the cystic. brosis transmembrane conductance regulator (CFTR), a chloride channel that is defective in CF, is implicated in multiple cellular functions, including gene regulation. In the present study, using a CFTR-defective pancreatic cancer cell line and its derived subline expressing functional CFTR, we report that MUC4 expression is negatively regulated by CFTR. Short-interfering RNA (siRNA)mediated silencing of CFTR also leads to an increased expression of MUC4. Additionally, our results suggest that CFTR-mediated regulation of MUC4 is cell density-dependent and is achieved by transcriptional and post-translational mechanisms. Moreover, in a panel of pancreatic cancer cell lines and normal pancreas, we observed that CFTR was downregulated in pancreatic cancer cells and negatively correlated with MUC4 in most cases. An aberrant expression of MUC4 was also detected in the CF pancreas. Downregulation of CFTR in pancreatic adenocarcinoma and its inverse association with the tumour-linked mucin, MUC4, indicate novel function(s) of CFTR in pancreatic tumour biology and suggest the implication of new signalling pathway(s) in MUC4 regulation.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Biostat Sect, Omaha, NE 68198 USA; INSERM, U560, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018; Singh, Ajay/AAF-4414-2020; VAN SEUNINGEN, Isabelle/N-6176-2016	Moniaux, Nicolas/0000-0001-9718-1386; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [R01 CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; BREUER W, 1993, J BIOL CHEM, V268, P13935; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1667, DOI 10.1177/002215540004801210; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Davenport SE, 1996, BIOCHEM BIOPH RES CO, V229, P663, DOI 10.1006/bbrc.1996.1861; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estell K, 2003, MOL CELL BIOL, V23, P594, DOI 10.1128/MCB.23.2.594-606.2003; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hinojosa-Kurtzberg AM, 2003, AM J PHYSIOL-GASTR L, V284, pG853, DOI 10.1152/ajpgi.00326.2002; Hokari R, 2005, AM J PHYSIOL-GASTR L, V289, pG949, DOI 10.1152/ajpgi.00142.2005; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Karan D, 2003, BIOCHEM BIOPH RES CO, V305, P598, DOI 10.1016/S0006-291X(03)00823-4; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Malats N, 2001, GUT, V48, P70, DOI 10.1136/gut.48.1.70; MALMBERG EK, 2006, IN PRESS AM J PHYSL; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; McWilliams R, 2005, GUT, V54, P1661, DOI 10.1136/gut.2005.074534; Namkung W, 2003, J BIOL CHEM, V278, P200, DOI 10.1074/jbc.M207199200; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHELDON CD, 1993, BRIT J CANCER, V68, P1025, DOI 10.1038/bjc.1993.474; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Steagall WK, 2000, AM J RESP CELL MOL, V22, P45, DOI 10.1165/ajrcmb.22.1.3789; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tabary O, 1999, AM J PATHOL, V155, P473, DOI 10.1016/S0002-9440(10)65143-7; Thomsson KA, 2002, BIOCHEM J, V367, P609, DOI 10.1042/BJ20020371; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINPENNY JP, 1995, AM J PHYSIOL-CELL PH, V268, pC823, DOI 10.1152/ajpcell.1995.268.4.C823; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	49	46	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					30	41		10.1038/sj.onc.1209764	http://dx.doi.org/10.1038/sj.onc.1209764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799633				2022-12-25	WOS:000243236500004
J	Kamei, N; Tobe, K; Suzuki, R; Ohsugi, M; Watanabe, T; Kubota, N; Ohtsuka-Kowatari, N; Kumagai, K; Sakamoto, K; Kobayashi, M; Yamauchi, T; Ueki, K; Oishi, Y; Nishimura, S; Manabe, I; Hashimoto, H; Ohnishi, Y; Ogata, H; Tokuyama, K; Tsunoda, M; Ide, T; Murakami, K; Nagai, R; Kadowaki, T				Kamei, Nozomu; Tobe, Kazuyuki; Suzuki, Ryo; Ohsugi, Mitsuru; Watanabe, Taku; Kubota, Naoto; Ohtsuka-Kowatari, Norie; Kumagai, Katsuyoshi; Sakamoto, Kentaro; Kobayashi, Masatoshi; Yamauchi, Toshimasa; Ueki, Kohjiro; Oishi, Yumiko; Nishimura, Satoshi; Manabe, Ichiro; Hashimoto, Haruo; Ohnishi, Yasuyuki; Ogata, Hitomi; Tokuyama, Kumpei; Tsunoda, Masaki; Ide, Tomohiro; Murakami, Koji; Nagai, Ryozo; Kadowaki, Takashi			Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; INFLAMMATORY CHANGES; OBESITY; EXPRESSION; ADIPOCYTES; GENE; SUBSTRATE; IDENTIFICATION; DISRUPTION; LIVER	Adipose tissue expression and circulating concentrations of monocyte chemoattractant protein-1 (MCP-1) correlate positively with adiposity. To ascertain the roles of MCP-1 overexpression in adipose, we generated transgenic mice by utilizing the adipocyte P2 (aP2) promoter (aP2-MCP-1 mice). These mice had higher plasma MCP-1 concentrations and increased macrophage accumulation in adipose tissues, as confirmed by immunochemical, flow cytometric, and gene expression analyses. Tumornecrosis factor-alpha and interleukin-6 mRNA levels in white adipose tissue and plasma non-esterified fatty acid levels were increased in transgenic mice. aP2-MCP-1 mice showed insulin resistance, suggesting that inflammatory changes in adipose tissues may be involved in the development of insulin resistance. Insulin resistance in aP2-MCP-1 mice was confirmed by hyperinsulinemic euglycemic clamp studies showing that transgenic mice had lower rates of glucose disappearance and higher endogenous glucose production than wild-type mice. Consistent with this, insulin-induced phosphorylations of Akt were significantly decreased in both skeletal muscles and livers of a P2-MCP-1 mice. MCP-1 pretreatment of isolated skeletal muscle blunted insulin-stimulated glucose uptake, which was partially restored by treatment with the MEK inhibitor U0126, suggesting that circulating MCP-1 may contribute to insulin resistance in aP2MCP-1 mice. We concluded that both paracrine and endocrine effects of MCP-1 may contribute to the development of insulin resistance in aP2-MCP-1 mice.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Hiroshima 7348551, Japan; Natl Inst Hlth & Nutr, Div Appl Nutr, Tokyo 1628636, Japan; CREST Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Dis, Tokyo 1138655, Japan; Cent Inst Expt Anim, Kawasaki, Kanagawa 2160001, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; KYORIN Pharmaceut Co Ltd, Shimotsuga 3290114, Japan	University of Tokyo; Hiroshima University; National Institute of Health & Nutrition - Japan; Japan Science & Technology Agency (JST); University of Tokyo; University of Tsukuba	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Suzuki, Ryo/AAA-2736-2019; Manabe, Ichiro/E-1529-2014; Kubota, Naoto/N-7892-2015; Manabe, Ichiro/AAE-5105-2021	Suzuki, Ryo/0000-0002-2965-6906; Kumagai, Katsuyoshi/0000-0003-4072-9907; Watanabe, Taku/0000-0002-3195-2413; Kamei, Nozomu/0000-0002-7686-437X				Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Barlow C, 1997, NUCLEIC ACIDS RES, V25, P2543, DOI 10.1093/nar/25.12.2543; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Christiansen T, 2005, INT J OBESITY, V29, P146, DOI 10.1038/sj.ijo.0802839; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Fernandez-Real JM, 2003, ENDOCR REV, V24, P278, DOI 10.1210/er.2002-0010; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; GRAVES RA, 1992, J CELL BIOCHEM, V49, P219, DOI 10.1002/jcb.240490303; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kamei N, 2005, METABOLISM, V54, P713, DOI 10.1016/j.metabol.2004.12.016; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; Linton MF, 2003, INT J OBESITY, V27, pS35, DOI 10.1038/sj.ijo.0802498; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Murakami K, 1999, METABOLISM, V48, P1450, DOI 10.1016/S0026-0495(99)90158-0; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Soukas A, 2000, GENE DEV, V14, P963; Suganami T, 2005, ARTERIOSCL THROM VAS, V25, P2062, DOI 10.1161/01.ATV.0000183883.72263.13; Suzuki R, 2004, J BIOL CHEM, V279, P25039, DOI 10.1074/jbc.M311956200; Suzuki R, 2003, J BIOL CHEM, V278, P43691, DOI 10.1074/jbc.M307004200; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	42	648	674	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26602	26614		10.1074/jbc.M601284200	http://dx.doi.org/10.1074/jbc.M601284200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809344	hybrid			2022-12-25	WOS:000240249500078
J	Izadi-Pruneyre, N; Huche, F; Lukat-Rodgers, GS; Lecroisey, A; Gilli, R; Rodgers, KR; Wandersman, C; Delepelaire, P				Izadi-Pruneyre, Nadia; Huche, Frederic; Lukat-Rodgers, Gudrun S.; Lecroisey, Anne; Gilli, Robert; Rodgers, Kenton R.; Wandersman, Cecile; Delepelaire, Philippe			The heme transfer from the soluble HasA hemophore to its membrane-bound receptor HasR is driven by protein-protein interaction from a high to a lower affinity binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RESONANCE RAMAN; RESIDUES; IDENTIFICATION; HAEMOPHORE; TRANSPORT; PLUG	HasA is an extracellular heme binding protein, and HasR is an outer membrane receptor protein from Serratia marcescens. They are the initial partners of a heme internalization system allowing S. marcescens to scavenge heme at very low concentrations due to the very high affinity of HasA for heme (K-a = 5,3 x 10(10) M-1). Heme is then transferred to HasR, which has a lower affinity for heme. The mechanism of the heme transfer between HasA and HasR is largely unknown. HasR has been overexpressed and purified in holo and apo forms. It binds one heme molecule with a Ka of 5 x 10(6) M-1 and shows the characteristic absorbance spectrum of a low spin heme iron. Both holoHasA and apoHasA bind tightly to apoHasR in a 1:1 stoichiometry. In this study we show that heme transfer occurs in vitro in the purified HasA (.) HasR complex, demonstrating that heme transfer is energy- and TonB complex-independent and driven by a protein-protein interaction. We also show that heme binding to HasR involves two conserved histidine residues.	Inst Pasteur, CNRS URA 2172, Unite Membranes Bacteriennes, Dept Microbiol, F-75724 Paris 15, France; Inst Pasteur, CNRS URA 2185, Dept Biol Struct & Chim, Unite Resonance Magnet Nucl Biomol, F-75724 Paris 15, France; Univ Aix Marseille 2, CNRS FRE 2737, Fac Pharm, F-13385 Marseille 05, France; N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Aix-Marseille Universite; North Dakota State University Fargo	Delepelaire, P (corresponding author), Inst Pasteur, CNRS URA 2172, Unite Membranes Bacteriennes, Dept Microbiol, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	pdelep@pasteur.fr		Izadi-Pruneyre, Nadia/0000-0002-6864-2961; Delepelaire, Philippe/0000-0002-5190-7118	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015566] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015566, P20 RR15556] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Annamalai R, 2004, J BACTERIOL, V186, P3578, DOI 10.1128/JB.186.11.3578-3589.2004; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Caillet-Saguy C, 2006, J AM CHEM SOC, V128, P150, DOI 10.1021/ja054902h; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; Cornelissen CN, 2003, FRONT BIOSCI-LANDMRK, V8, pD836, DOI 10.2741/1076; Cwerman H, 2006, J BACTERIOL, V188, P3357, DOI 10.1128/JB.188.9.3357-3364.2006; Deniau C, 2003, BIOCHEMISTRY-US, V42, P10627, DOI 10.1021/bi030015k; Ferguson AD, 2004, CELL, V116, P15, DOI 10.1016/S0092-8674(03)01030-4; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; HURST JK, 1991, J BIOL CHEM, V266, P1627; Izadi N, 1997, BIOCHEMISTRY-US, V36, P7050, DOI 10.1021/bi962577s; Krell T, 2003, J BIOL CHEM, V278, P14712, DOI 10.1074/jbc.M204461200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lansky IB, 2006, J BIOL CHEM, V281, P13652, DOI 10.1074/jbc.M600824200; Letoffe S, 2005, J BACTERIOL, V187, P4637, DOI 10.1128/JB.187.13.4637-4645.2005; Letoffe S, 2004, J BACTERIOL, V186, P4067, DOI 10.1128/JB.186.13.4067-4074.2004; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 2003, MOL MICROBIOL, V50, P77, DOI 10.1046/j.1365-2958.2003.03686.x; Letoffe S, 2001, MOL MICROBIOL, V41, P439, DOI 10.1046/j.1365-2958.2001.02530.x; Liu MY, 2005, INFECT IMMUN, V73, P5086, DOI 10.1128/IAI.73.8.5086-5092.2005; Liu XY, 2006, INFECT IMMUN, V74, P1222, DOI 10.1128/IAI.74.2.1222-1232.2006; MAITI NC, 1995, J PHYS CHEM-US, V99, P10708, DOI 10.1021/j100027a006; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; Retzer MD, 1999, MOL MICROBIOL, V32, P111, DOI 10.1046/j.1365-2958.1999.01331.x; Schalk IJ, 2001, MOL MICROBIOL, V39, P351, DOI 10.1046/j.1365-2958.2001.02207.x; Sprencel C, 2000, J BACTERIOL, V182, P5359, DOI 10.1128/JB.182.19.5359-5364.2000; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	34	84	86	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25541	25550		10.1074/jbc.M603698200	http://dx.doi.org/10.1074/jbc.M603698200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16774915	hybrid			2022-12-25	WOS:000240031300057
J	Koleva, RI; Conley, BA; Romero, D; Riley, KS; Marto, JA; Lux, A; Vary, CPH				Koleva, Rositsa I.; Conley, Barbara A.; Romero, Diana; Riley, Kristin S.; Marto, Jarrod A.; Lux, Andreas; Vary, Calvin P. H.			Endoglin structure and function - Determinants of endoglin phosphorylation by transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; I RECEPTORS; EXPRESSION ANALYSIS; MASS-SPECTROMETRY; EPITHELIAL-CELLS; KINASE-1 GENE; COMPLEX; ANGIOGENESIS	Determination of the functional relationship between the transforming growth factor-beta(TGF beta) receptor proteins endoglin and ALK1 is essential to the understanding of the human vascular disease, hereditary hemorrhagic telangiectasia. TGF beta 1 caused recruitment of ALK1 into a complex with endoglin in human umbilical vein endothelial cells (HUVECs). Therefore, we examined TGF beta receptor-dependent phosphorylation of endoglin by the constitutively active forms of the TGF beta type I receptors ALK1, ALK5, and the TGF beta type II receptor, T beta RII. Of these receptors, T beta RII preferentially phosphorylated endoglin on cytosolic domain serine residues Ser(634) and Ser(635). Removal of the carboxyl-terminal tripeptide of endoglin, which comprises a putative PDZ-liganding motif, dramatically increased endoglin serine phosphorylation by all three receptors, suggesting that the PDZ-liganding motif is important for the regulation of endoglin phosphorylation. Constitutively active (ca) ALK1, but not caALK5, phosphorylated endoglin on cytosolic domain threonine residues. caALK1-mediated threonine phosphorylation required prior serine phosphorylation, suggesting a sequential mechanism of endoglin phosphorylation. Wild-type, but not a threonine phosphorylation-defective endoglin mutant blocked cell detachment and the antiproliferative effects of caALK1 expressed inHUVECs. These results suggest that ALK1 is a preferred TGF beta receptor kinase for endoglin threonine phosphorylation in HUVECs and indicate a role for endoglin phosphorylation in the regulation of endothelial cell adhesion and growth by ALK1.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Univ Hosp, D-68163 Mannheim, Germany; Univ Appl Sci, Inst Cell & Mol Biol, D-68163 Mannheim, Germany	Maine Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Ruprecht Karls University Heidelberg	Vary, CPH (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	varyc@mmc.org	Romero, Diana/GWU-9250-2022		PHS HHS [P20 15555] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; BLOBE GC, 2001, J BIOL CHEM, V23, P23; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Ficarro S, 2003, J BIOL CHEM, V278, P11579, DOI 10.1074/jbc.M202325200; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Ma XL, 2000, ARTERIOSCL THROM VAS, V20, P2546, DOI 10.1161/01.ATV.20.12.2546; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Meurer SK, 2005, J BIOL CHEM, V280, P3078, DOI 10.1074/jbc.M405411200; Muenzner P, 2005, J CELL BIOL, V170, P825, DOI 10.1083/jcb.200412151; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Raab U, 1999, BIOCHEM J, V339, P579, DOI 10.1042/0264-6021:3390579; Sanz-Rodriguez F, 2004, CLIN CHEM, V50, P2003, DOI 10.1373/clinchem.2004.035287; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Schmidt-Weber CB, 2005, INT IMMUNOL, V17, P921, DOI 10.1093/intimm/dxh272; Seki T, 2006, LAB INVEST, V86, P116, DOI 10.1038/labinvest.3700376; Seki T, 2004, CIRC RES, V94, pE72, DOI 10.1161/01.RES.0000127048.81744.31; Steen H, 2001, J MASS SPECTROM, V36, P782, DOI 10.1002/jms.174; Tang H, 2005, BLOOD, V105, P1977, DOI 10.1182/blood-2004-08-3308; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995	60	84	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25110	25123		10.1074/jbc.M601288200	http://dx.doi.org/10.1074/jbc.M601288200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16785228	hybrid			2022-12-25	WOS:000240031300012
J	LaVallie, ER; Chockalingam, PS; Collins-Racie, LA; Freeman, BA; Keohan, CC; Leitges, M; Dorner, AJ; Morris, EA; Majumdar, MK; Arai, M				LaVallie, Edward R.; Chockalingam, Priya S.; Collins-Racie, Lisa A.; Freeman, Bethany A.; Keohan, Cristin C.; Leitges, Michael; Dorner, Andrew J.; Morris, Elisabeth A.; Majumdar, Manas K.; Arai, Maya			Protein kinase C zeta is up-regulated in osteoarthritic cartilage and is required for activation of NF-kappa B by tumor necrosis factor and interleukin-1 in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TNF-ALPHA; METALLOPROTEINASE EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PROINFLAMMATORY CYTOKINE; GENE-EXPRESSION; POTENTIAL ROLE; ADAMTS FAMILY; ATYPICAL PKCS; CELLS	Protein kinase C zeta(PKC zeta) is an intracellular serine/threonine protein kinase that has been implicated in the signaling pathways for certain inflammatory cytokines,including interleukin-1 (IL-1) and tumor necrosis factor alpha(TNF-alpha), in some cell types. A study of gene expression in articular chondrocytes from osteoarthritis (OA) patients revealed that PKC zeta is transcriptionally up-regulated in human OA articular cartilage clinical samples. This finding led to the hypothesis that PKC zeta may be an important signaling component of cytokine-mediated cartilage matrix destruction in articular chondrocytes, believed to be an underlying factor in the pathophysiology of OA. IL-1 treatment of chondrocytes in culture resulted in rapidly increased phosphorylation of PKC zeta, implicating PKC zeta activation in the signaling pathway. Chondrocyte cell-based assays were used to evaluate the contribution of PKC zeta activity in NF-kappa B activation and extracellular matrix degradation mediated by IL-1, TNF, or sphingomyelinase. In primary chondrocytes, IL-1 and TNF-alpha caused an increase in NF-kappa B activity resulting in induction of aggrecanase-1 and aggrecanase-2 expression, with consequent increased proteoglycan degradation. This effect was blocked by the pan-specific PKC inhibitors RO 31-8220 and bisindolylmaleimide I, partially blocked by Go 6976, and was unaffected by the PKC zeta- sparing inhibitor calphostin C. A cell-permeable PKC zeta pseudosubstrate peptide inhibitor was capable of blocking TNF- and IL-1-mediated NF-kappa B activation and proteoglycan degradation in chondrocyte pellet cultures. In addition, overexpression of a dominant negative PKC zeta protein effectively prevented cytokine-mediated NF-kappa B activation in primary chondrocytes. These data implicate PKC zeta as a necessary component of the IL-1 and TNF signaling pathways in chondrocytes that result in catabolic destruction of extracellular matrix proteins in osteoarthritic cartilage.	Wyeth Ayerst Res, Dept Biol Technol, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Dept Womens Hlth & Musculoskeletal Biol, Cambridge, MA 02140 USA; Hannover Med Sch, D-30625 Hannover, Germany; Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Pfizer; Pfizer; Hannover Medical School; Boston University	LaVallie, ER (corresponding author), Wyeth Ayerst Res, Dept Biol Technol, 35 Cambridge Pk Dr,Rm Y1106, Cambridge, MA 02140 USA.	elavallie@wyeth.com	Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Aigner T, 2002, CURR OPIN RHEUMATOL, V14, P578, DOI 10.1097/00002281-200209000-00018; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Alden TD, 1999, HUM GENE THER, V10, P2245, DOI 10.1089/10430349950017220; Arai M, 2004, OSTEOARTHR CARTILAGE, V12, P599, DOI 10.1016/j.joca.2004.05.001; Attur MG, 2002, OSTEOARTHR CARTILAGE, V10, P1, DOI 10.1053/joca.2001.0488; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; BRANDT KD, 2000, DIAGNOSIS NONSURGICA; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Domm C, 2002, OSTEOARTHR CARTILAGE, V10, P13, DOI 10.1053/joca.2001.0477; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; FARAHAT MN, 1993, ANN RHEUM DIS, V52, P870, DOI 10.1136/ard.52.12.870; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Fernandes JC, 2002, BIORHEOLOGY, V39, P237; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926-000-0021-y; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Goldring MB, 2001, EXPERT OPIN BIOL TH, V1, P817, DOI 10.1517/14712598.1.5.817; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HARDINGHAM TE, 1986, CIBA F SYMP, V124, P30; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hauselmann HJ, 1996, ARTHRITIS RHEUM, V39, P478, DOI 10.1002/art.1780390316; Hedbom E, 2002, CELL MOL LIFE SCI, V59, P45, DOI 10.1007/s00018-002-8404-z; Hernandez AI, 2003, J BIOL CHEM, V278, P40305, DOI 10.1074/jbc.M307065200; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Kim HY, 2002, INFECT IMMUN, V70, P4132, DOI 10.1128/IAI.70.8.4132-4141.2002; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lisby S, 2002, EXP DERMATOL, V11, P592, DOI 10.1034/j.1600-0625.2002.110612.x; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Martin P, 2002, EMBO J, V21, P4049, DOI 10.1093/emboj/cdf407; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscat J, 2001, ADV ENZYME REGUL, V41, P99, DOI 10.1016/S0065-2571(00)00009-1; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nee LE, 2004, KIDNEY INT, V66, P1376, DOI 10.1111/j.1523-1755.2004.00900.x; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Oster H, 2004, MOL BRAIN RES, V127, P79, DOI 10.1016/j.molbrainres.2004.05.009; Pattoli MA, 2005, J PHARMACOL EXP THER, V315, P382, DOI 10.1124/jpet.105.087569; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Roshak AK, 2002, CURR OPIN PHARMACOL, V2, P316, DOI 10.1016/S1471-4892(02)00165-0; Rybakina E G, 2001, Neurosci Behav Physiol, V31, P439, DOI 10.1023/A:1010448930994; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schneider C, 2001, CYTOKINE, V13, P174, DOI 10.1006/cyto.2000.0817; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shi J, 2004, INFLAMM RES, V53, P377, DOI 10.1007/s00011-004-1271-3; Shibakawa A, 2003, OSTEOARTHR CARTILAGE, V11, P133, DOI 10.1053/joca.2002.0871; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Verbruggen G, 2006, RHEUMATOLOGY, V45, P129, DOI 10.1093/rheumatology/kei171; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Xie ZL, 2003, J BIOL CHEM, V278, P48546, DOI 10.1074/jbc.M302727200; YOSHIMICHI G, 2006, BONE ELMSFORD, V38, P853; Zhang MK, 2000, J CELL BIOCHEM, V76, P290, DOI 10.1002/(SICI)1097-4644(20000201)76:2<290::AID-JCB12>3.0.CO;2-V	76	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24124	24137		10.1074/jbc.M601905200	http://dx.doi.org/10.1074/jbc.M601905200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798739	hybrid			2022-12-25	WOS:000239847800007
J	Denisov, IG; Grinkova, YV; Baas, BJ; Sligar, SG				Denisov, Ilia G.; Grinkova, Yelena V.; Baas, Bradley J.; Sligar, Stephen G.			The ferrous-dioxygen intermediate in human cytochrome P450 3A4 - Substrate dependence of formation and decay kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; OXYGEN ACTIVATION; P450 REDUCTASE; MICROSOMAL CYTOCHROME-P450; MOLECULAR-OXYGEN; LOW-TEMPERATURE; LIGAND-BINDING; ACTIVE-SITE; MECHANISM; MYOGLOBIN	The oxy-ferrous complex is the first of three branching intermediates in the catalytic cycle of cytochrome P450, in which the total efficiency of substrate turnover is curtailed by the side reaction of autoxidation. For human membrane-bound cytochromes P450, the oxy complex is believed to be the primary source of cytotoxic superoxide and peroxide, although information on the properties and stability of this intermediate is lacking. Here we document stopped-flow spectroscopic studies of the formation and decay of the oxy-ferrous complex in the most abundant human cytochrome P450 (CYP3A4) as a function of temperature in the substrate-free and substrate-bound form. CYP3A4 solubilized in purified monomeric form in nanoscale POPC bilayers is functionally and kinetically homogeneous. In substrate-free CYP3A4, the oxy complex is extremely unstable with a half-life of similar to 30msat 5 degrees C. Saturation with testosterone or bromocriptine stabilizes the oxy-ferrous intermediate. Comparison of the autoxidation rates with the available data on CYP3A4 turnover kinetics suggests that the oxy complex may be an important route for uncoupling.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Dept Biochem, 116 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.	s-sligar@uiuc.edu	Denisov, Ilia G/J-6590-2013; Denisov, Gleb S/J-6549-2013	Denisov, Ilia G/0000-0002-7878-2626; Denisov, Gleb S/0000-0002-1246-0552	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775, R01GM031756, R37GM031756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31756, GM33775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; BANGCHAROENPAURPONG O, 1986, J BIOL CHEM, V261, P8089; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; Clark JP, 2006, J INORG BIOCHEM, V100, P1075, DOI 10.1016/j.jinorgbio.2005.11.020; Dabrowski MJ, 2002, J AM CHEM SOC, V124, P11866, DOI 10.1021/ja027552x; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; Davydov DR, 2005, BIOCHEMISTRY-US, V44, P13902, DOI 10.1021/bi0509346; Davydov DR, 2003, BIOCHEM BIOPH RES CO, V312, P121, DOI 10.1016/j.bbrc.2003.09.247; DAWSON JH, 1986, J AM CHEM SOC, V108, P8114, DOI 10.1021/ja00285a052; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Denisov IG, 2001, J INORG BIOCHEM, V87, P215, DOI 10.1016/S0162-0134(01)00328-2; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; EISENSTEIN L, 1977, BIOCHEM BIOPH RES CO, V77, P1377, DOI 10.1016/S0006-291X(77)80131-9; FISHER MT, 1987, BIOCHEMISTRY-US, V26, P4797, DOI 10.1021/bi00389a029; Franke A, 2004, J AM CHEM SOC, V126, P4181, DOI 10.1021/ja038774d; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; Guengerich F.P., 2005, CYTOCHROME P450 STRU, V3rd ed., P377, DOI [10.1007/0-387-27447-2_10, DOI 10.1007/0-387-27447-2_10]; Guengerich FP, 2002, BIOL CHEM, V383, P1553, DOI 10.1515/BC.2002.175; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; Henry ER, 1997, BIOPHYS J, V72, P652, DOI 10.1016/S0006-3495(97)78703-4; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; Hosea NA, 1998, ARCH BIOCHEM BIOPHYS, V353, P365, DOI 10.1006/abbi.1998.0659; HUME R, 1984, EUR J BIOCHEM, V140, P583, DOI 10.1111/j.1432-1033.1984.tb08142.x; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; Isin EM, 2006, J BIOL CHEM, V281, P9127, DOI 10.1074/jbc.M511375200; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; Makris TM, 2002, DRUG METAB REV, V34, P691, DOI 10.1081/DMR-120015691; MCKENNA CE, 1991, BIOCHIM BIOPHYS ACTA, V1075, P109, DOI 10.1016/0304-4165(91)90082-R; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SEVRIOUKOVA IF, 1995, ARCH BIOCHEM BIOPHYS, V317, P397, DOI 10.1006/abbi.1995.1180; Shaw PM, 1997, ARCH BIOCHEM BIOPHYS, V348, P107, DOI 10.1006/abbi.1997.0378; SHIKAMA K, 1990, BIOL REV, V65, P517, DOI 10.1111/j.1469-185X.1990.tb01236.x; Shikama K, 2006, PROG BIOPHYS MOL BIO, V91, P83, DOI 10.1016/j.pbiomolbio.2005.04.001; Shikama K, 1998, CHEM REV, V98, P1357, DOI 10.1021/cr970042e; SHIRO Y, 1991, BIOCHIM BIOPHYS ACTA, V1115, P101, DOI 10.1016/0304-4165(91)90018-C; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; SONO M, 1985, J BIOL CHEM, V260, P5530; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sudhamsu J, 2006, J BIOL CHEM, V281, P9623, DOI 10.1074/jbc.M510062200; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; ULLRICH V, 1980, DEV BIOCHEM, V13, P267; Wei CC, 2005, J BIOL CHEM, V280, P8929, DOI 10.1074/jbc.M409737200; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2005, J BIOL CHEM, V280, P12279, DOI 10.1074/jbc.M411019200; Zangar RC, 2004, TOXICOL APPL PHARM, V199, P316, DOI 10.1016/j.taap.2004.01.018; Zhang HM, 2005, BIOCHEM BIOPH RES CO, V338, P499, DOI 10.1016/j.bbrc.2005.09.022; Zhao B, 2005, J BIOL CHEM, V280, P42188, DOI 10.1074/jbc.M509220200	64	66	68	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23313	23318		10.1074/jbc.M605511200	http://dx.doi.org/10.1074/jbc.M605511200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16762915	hybrid			2022-12-25	WOS:000239702900005
J	Ghosh, AK; Steele, R; Ray, RB				Ghosh, Asish K.; Steele, Robert; Ray, Ratna B.			Knockdown of MBP-1 in human prostate cancer cells delays cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-BINDING PROTEIN; C-MYC; NUDE-MICE; GROWTH; B1; OVEREXPRESSION; LOCALIZATION; ACTIVATION; EXPRESSION; RNAS	We have previously shown that MBP-1 acts as a general transcriptional repressor, and forced expression of MBP-1 exerts an anti-proliferative effect on a number of human cancer cells. In this report, we have investigated the role of endogenous MBP-1 in cell growth regulation. For this, we generated human prostate cancer cells (PC3) stably transfected with short hairpin RNA targeting MBP-1. We have observed retarded growth and longer doubling time of MBP-1 knockdown PC3 cells as compared with control mock-transfected PC3 cells. Fluorescence-activated cell sorter analysis suggested that PC3 cells expressing MBP-1-specific small interfering RNA accumulated during G2/M phase of the cell cycle. Further analysis suggested that depletion of MBP-1 was associated with reduction of cyclin A and cyclin B1 expression when compared with that of the control cells. A delayed induction of cyclin A and B1 expression was observed in MBP-1-depleted PC3 cells (PC3-4.2) upon serum stimulation, although the level of expression was much lower than that of control PC3 cells. Supplementation of MBP-1 in PC3-4.2 cells restored cyclin A and cyclin B1 expression. Together, these results suggest that knockdown of MBP-1 in prostate cancer cells perturbs cell proliferation by inhibiting cyclin A and cyclin B1 expression.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Ctr Canc, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rayrb@slu.edu			NCI NIH HHS [CA52799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052799, R01CA052799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ghosh AK, 2005, CANCER RES, V65, P718; Ghosh AK, 1999, MOL CELL BIOL, V19, P2880; Ghosh AK, 2002, ONCOGENE, V21, P2775, DOI 10.1038/sj.onc.1205384; Ghosh AK, 2005, J BIOL CHEM, V280, P14325, DOI 10.1074/jbc.M413313200; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Machida YJ, 2005, J BIOL CHEM, V280, P6253, DOI 10.1074/jbc.R400037200; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Park M, 2000, CANCER RES, V60, P542; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; RAY RB, 1995, CANCER RES, V55, P3747; RAY RB, 1994, INT J ONCOL, V5, P1433; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; White RA, 1997, GENOMICS, V39, P406, DOI 10.1006/geno.1996.4499; Yin XY, 2001, CANCER RES, V61, P6487	22	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23652	23657		10.1074/jbc.M602930200	http://dx.doi.org/10.1074/jbc.M602930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16762917	hybrid			2022-12-25	WOS:000239702900040
J	Gong, P; Martin, CT				Gong, Peng; Martin, Craig T.			Mechanism of instability in abortive cycling by T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; INITIAL BUBBLE COLLAPSE; ELONGATION COMPLEX; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; DNA; RELEASE; BACTERIOPHAGE-T7; STABILITY; FLUORESCENCE	Abortive transcription, the premature release of short transcripts 2-8 bases in length, is a unique feature of transcription, accompanying the transition from initiation to elongation in all RNA polymerases. The current study focuses on major factors that relate to the stability of initially transcribing abortive complexes in T7 RNA polymerase. Building on previous studies, results reveal that collapse of the DNA from the downstream end of the bubble is a major contributor to the characteristic instability of abortive complexes. Furthermore, transcription from a novel DNA construct containing a nick between positions -14 and -13 of the nontemplate strand suggests that the more flexible promoter reduces somewhat the strain inherent in initially transcribing complexes, with a resulting decrease in abortive product release. Finally, as assessed by exonuclease III footprinting and transcription profiles, a DNA construct defective in bubble collapse specifically from the downstream end exhibits less abortive cycling and little perturbation of the final transition to elongation, including the process of promoter release.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 710 N Pleasant St,LGRT 701, Amherst, MA 01003 USA.	CMartin@chem.umass.edu	Gong, Peng/ABD-6333-2021; Martin, Craig T/L-3596-2013	Martin, Craig T/0000-0003-1029-5239	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055002] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM55002, R01 GM055002] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; Esposito EA, 2004, J BIOL CHEM, V279, P44270, DOI 10.1074/jbc.M407688200; Gong P, 2004, J BIOL CHEM, V279, P44277, DOI 10.1074/jbc.M409118200; Guo Q, 2005, J BIOL CHEM, V280, P14956, DOI 10.1074/jbc.M500518200; Guo Q, 2005, J BIOL CHEM, V280, P3474, DOI 10.1074/jbc.M412287200; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Kuzmine I, 2001, J MOL BIOL, V305, P559, DOI 10.1006/jmbi.2000.4316; LESCURE B, 1981, NUCLEIC ACIDS RES, V9, P31, DOI 10.1093/nar/9.1.31; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Martin CT, 2005, PROG NUCLEIC ACID RE, V80, P323, DOI 10.1016/S0079-6603(05)80008-X; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Tang GQ, 2006, BIOCHEMISTRY-US, V45, P4936, DOI 10.1021/bi0522910; Theis K, 2004, BIOCHEMISTRY-US, V43, P12709, DOI 10.1021/bi0486987; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	34	19	19	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23533	23544		10.1074/jbc.M604023200	http://dx.doi.org/10.1074/jbc.M604023200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790422	hybrid			2022-12-25	WOS:000239702900028
J	Rapti, M; Knauper, V; Murphy, G; Williamson, RA				Rapti, Magdalini; Knauper, Vera; Murphy, Gillian; Williamson, Richard A.			Characterization of the AB loop region of TIMP-2 - Involvement in pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; I-MATRIX-METALLOPROTEINASE; C-TERMINAL DOMAIN; GELATINASE-A; COMPLEX-FORMATION; 1-MATRIX METALLOPROTEINASE; EFFICIENT ACTIVATION; PROGELATINASE; BINDING; COLLAGENASE	Tissue inhibitor of metalloproteinases-2 (TIMP-2) is unique as it is the only member of the TIMP family that is involved in the cellular activation of promatrix metalloproteinase-2 (proMMP-2) by virtue of forming a trimolecular complex with membrane type 1 matrix metalloproteinase (MT1-MMP) on the cell surface. TIMP-4 is similar in structure to TIMP-2 but is unable to support the activation of the proenzyme. Several reports have highlighted the importance of the TIMP-2 C-terminal domain in the pro-MMP-2 activation complex; however, very little is known about the role of the extended AB loop of TIMP-2 in this mechanism even though it has been shown to interact with MT1-MMP. In this study we show by mutagenesis and kinetic analysis that it is possible to transfer the MT1-MMP binding affinity of the TIMP-2 AB loop to TIMP-4 but that its transplantation into TIMP-4 does not endow the inhibitor with proMMP-2 activating activity. However, transfer of both the AB loop and C-terminal domain of TIMP-2 to TIMP-4 generates a mutant that can activate pro-MMP-2 and so demonstrates that both these regions of TIMP-2 are important for the activation process.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of Kent; University of Cambridge; University of York - UK	Williamson, RA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	r.a.williamson@kent.ac.uk		Knauper, Vera/0000-0002-3965-9924	MRC [G0400637] Funding Source: UKRI; Medical Research Council [G0400637] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DORTHO MP, 1997, EUR J BIOCHEM, V250, P51; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagase H, 1998, Cell Res, V8, P179; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573	36	9	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23386	23394		10.1074/jbc.M604423200	http://dx.doi.org/10.1074/jbc.M604423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777853	hybrid			2022-12-25	WOS:000239702900013
J	Wild-Bode, C; Fellerer, K; Kugler, J; Haass, C; Capell, A				Wild-Bode, Christine; Fellerer, Katrin; Kugler, Johanna; Haass, Christian; Capell, Anja			A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; DARBY CANINE KIDNEY; GAMMA-SECRETASE; EPITHELIAL-CELLS; MDCK CELLS; E-CADHERIN; CLEAVAGE; ADHESION; RECEPTOR; METALLOPROTEASE	ADAM10 ( a disintegrin and metalloprotease) initiates regulated intramembrane proteolysis by shedding the ectodomain of a number of different substrates. Shedding is followed by subsequent intramembrane proteolysis leading to the liberation of intracellular domains capable of nuclear signaling. ADAM10 substrates have been found at cell-cell contacts and are apparently involved in cell-cell interaction and cell migration. Here we have investigated the cellular mechanism that guides ADAM10 to substrates at cell-cell contacts. We demonstrate that intracellular trafficking of ADAM10 critically requires a novel sorting signal within its cytoplasmic domain. Sequential deletion of the cytoplasmic domain and site-directed mutagenesis suggest that a potential Src homology 3-binding domain is essential for ADAM10 sorting. In a polarized epithelial cell line this motif not only targets ADAM10 to adherens junctions but is also strictly required for ADAM10 function in E-cadherin processing and cell migration.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Munich	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaass@med.uni-muenchen.de						Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Murai M, 2004, INT J ONCOL, V25, P831; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001	30	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23824	23829		10.1074/jbc.M601542200	http://dx.doi.org/10.1074/jbc.M601542200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777847	hybrid			2022-12-25	WOS:000239702900058
J	Karagiannides, I; Thomou, T; Tchkonia, T; Pirtskhalava, T; Kypreos, KE; Cartwright, A; Dalagiorgou, G; Lash, TL; Farmer, SR; Timchenko, NA; Kirkland, JL				Karagiannides, Iordanes; Thomou, Thomas; Tchkonia, Tamara; Pirtskhalava, Tamar; Kypreos, Kyriakos E.; Cartwright, Andrew; Dalagiorgou, Georgia; Lash, Timothy L.; Farmer, Stephen R.; Timchenko, Nikolai A.; Kirkland, James L.			Increased CUG triplet repeat-binding protein-1 predisposes to impaired adipogenesis with aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL INHIBITORY PROTEIN; ADIPOCYTE PRECURSOR CLONES; C/EBP-BETA; ADIPOSE-TISSUE; PPAR-GAMMA; ANATOMIC SITE; MESSENGER-RNA; DIFFERENTIATION	Preadipocyte differentiation capacity declines between middle and old age. Expression of the adipogenic transcription factors, CCAAT/enhancer-binding protein (C/EBP) alpha and peroxisome proliferator-activated receptor gamma (PPAR gamma), is lower in differentiating preadipocytes from old than young animals, although no age-related changes occur in C/EBP beta mRNA, which is upstream of C/EBP alpha and PPAR gamma. C/EBP beta-liver-enriched inhibitory protein (C/EBP beta-LIP), a truncated C/EBP beta isoform that is a dominant inhibitor of differentiation, increases with aging in rat fat tissue and preadipocytes. CUG triplet repeat-binding protein-1 (CUGBP1) binds to C/EBP beta mRNA, increasing C/EBP beta-LIP translation. Abundance and nucleotide binding activity of CUGBP1 increased with aging in preadipocytes. CUGBP1 overexpression in preadipocytes from young animals increased C/EB beta-LIP and impaired adipogenesis. Decreasing CUGBP1 in preadipocytes from old rats by RNA interference reduced C/EB beta-LIP abundance and promoted adipogenesis. Tumor necrosis factor-alpha, levels of which are elevated in fat tissue with aging, increased CUGBP1 protein, CUGBP1 binding activity, and C/EBP beta-LIP in preadipocytes from young rats. Thus, CUGBP1 contributes to regulation of adipogenesis in primary preadipocytes and is responsive to tumor necrosis factor-alpha. With aging, preadipocyte CUGBP1 abundance and activity increases, resulting in enhanced translation of the C/EBP beta-LIP isoform, thereby blocking effects of adipogenic transcription factors, predisposing preadipocytes from old animals to resist adipogenesis. Altered translational processing, possibly related to changes in cytokine milieu and activation of stress responses, may contribute to changes in progenitor differentiation and tissue function with aging.	Boston Univ, Dept Med, Boston, MA 02118 USA; Boston Univ, Dept Biochem, Boston, MA 02118 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Pathol, Houston, TX 77030 USA	Boston University; Boston University; Baylor College of Medicine	Kirkland, JL (corresponding author), Boston Univ, Dept Med, 88 E Newton St,Robinson 2, Boston, MA 02118 USA.	kirkland@bu.edu	Kirkland, James/F-9159-2016; KYPREOS, KYRIAKOS/AAN-4485-2020; Kypreos, Kyriakos/AAG-1745-2020	Kypreos, Kyriakos/0000-0001-6784-2710; Tchkonia, Tamar/0000-0003-4623-7145; Farmer, Stephen/0000-0003-2483-2795	NATIONAL INSTITUTE ON AGING [R01AG013925] Funding Source: NIH RePORTER; NIA NIH HHS [AG13925] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bae EJ, 2005, MOL PHARMACOL, V68, P660, DOI 10.1124/mol.105.012997; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Baldwin BR, 2004, MOL CELL BIOL, V24, P3682, DOI 10.1128/MCB.24.9.3682-3691.2004; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BERTRAND HA, 1980, J GERONTOL, V35, P827, DOI 10.1093/geronj/35.6.827; BERTRAND HA, 1978, SCIENCE, V201, P1234, DOI 10.1126/science.151328; Chae GN, 2003, EXP MOL MED, V35, P431, DOI 10.1038/emm.2003.56; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; Curat CA, 2004, DIABETES, V53, P1285, DOI 10.2337/diabetes.53.5.1285; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DJIAN P, 1983, J CLIN INVEST, V72, P1200, DOI 10.1172/JCI111075; DJIAN P, 1985, METABOLISM, V34, P880, DOI 10.1016/0026-0495(85)90114-3; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Garcia E, 1999, J ENDOCRINOL, V161, P89, DOI 10.1677/joe.0.1610089; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREGERMAN RI, 1994, J GERONTOL, V49, pB135, DOI 10.1093/geronj/49.4.B135; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; HAZZARD DG, 1988, EXP AGING RES, V14, P59, DOI 10.1080/03610738808259727; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLENBERG CH, 1968, J CLIN INVEST, V47, P2485, DOI 10.1172/JCI105930; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hughes KA, 2002, P NATL ACAD SCI USA, V99, P14286, DOI 10.1073/pnas.222326199; Iakova P, 2004, EMBO J, V23, P406, DOI 10.1038/sj.emboj.7600052; Kachigan S.K., 1986, STAT ANAL; Kang KW, 2003, J NATL CANCER I, V95, P53, DOI 10.1093/jnci/95.1.53; Karagiannides I, 2001, AM J PHYSIOL-REG I, V280, pR1772, DOI 10.1152/ajpregu.2001.280.6.R1772; Keppel G., 2004, DESIGN ANAL RES HDB; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; KIRKLAND JL, 1990, AM J PHYSIOL, V258, pC206, DOI 10.1152/ajpcell.1990.258.2.C206; Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531-5565(02)00014-1; KIRKLAND JL, 1992, ENDOCRINOLOGY, V131, P2769, DOI 10.1210/en.131.6.2769; Kirkland JL, 1996, INT J OBESITY, V20, pS102; KIRKLAND JL, 1994, J GERONTOL, V49, pB31, DOI 10.1093/geronj/49.1.B31; KLYDE BJ, 1979, J LIPID RES, V20, P691; Ladd AN, 2005, DEV DYNAM, V233, P783, DOI 10.1002/dvdy.20382; MILLER WH, 1984, J LIPID RES, V25, P336; Morin CL, 1997, J GERONTOL A-BIOL, V52, pB190, DOI 10.1093/gerona/52A.4.B190; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Poleev A, 2000, EUR J BIOCHEM, V267, P4002, DOI 10.1046/j.1432-1327.2000.01431.x; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SAMBROOKJ, 2001, MOL CLONING LAB MANU; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990; Strawford A, 2004, AM J PHYSIOL-ENDOC M, V286, pE577, DOI 10.1152/ajpendo.00093.2003; Tchkonia T, 2005, AM J PHYSIOL-ENDOC M, V288, pE267, DOI 10.1152/ajpendo.00265.2004; Tchkonia T, 2002, AM J PHYSIOL-REG I, V282, pR1286, DOI 10.1152/ajpregu.00653.2001; Tchkonia T, 2006, ENDOCR UPDAT, V26, P105; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2004, J BIOL CHEM, V279, P13129, DOI 10.1074/jbc.M312923200; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; WANG H, 1989, J CLIN INVEST, V83, P1741, DOI 10.1172/JCI114075; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Welm AL, 2000, J BIOL CHEM, V275, P27406; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YKIJARVINEN H, 1986, ACTA ENDOCRINOL-COP, V113, P88, DOI 10.1530/acta.0.1130088; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	69	54	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23025	23033		10.1074/jbc.M513187200	http://dx.doi.org/10.1074/jbc.M513187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754681	hybrid			2022-12-25	WOS:000239542600065
J	LoVerme, J; Guzman, M; Gaetani, S; Piomelli, D				LoVerme, Jesse; Guzman, Manuel; Gaetani, Silvana; Piomelli, Daniele			Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID PRECURSOR; SYMPATHETIC-NERVOUS-SYSTEM; PPAR-ALPHA; ACID AMIDASE; RECEPTOR; BIOSYNTHESIS; ANANDAMIDE; LIPOLYSIS; PHOSPHATIDYLETHANOLAMINE; PALMITOYLETHANOLAMIDE	Oleoylethanolamide (OEA) is an endogenous lipid mediator that inhibits feeding and stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activating receptor-alpha. Little is known about the physiological regulation of this compound outside of the gastrointestinal tract, where its production is regulated by feeding. Here we show that cold exposure increases OEA levels in rat white adipose tissue but not in liver or intestine. This change is accompanied by parallel elevations in the activity of N-acyltransferase, a key enzyme responsible for OEA synthesis, without concomitant changes in fatty acid amide hydrolase, an enzyme responsible for OEA degradation. Moreover, cold stimulates the production of two species of N-oleoylphosphatidylethanolamine OEA precursors. The changes in OEA biosynthesis are reversed by pretreatment with the beta-receptor antagonist propranolol, suggesting a role for beta-adrenoreceptors in this response. In agreement with these findings, the beta-agonists noradrenaline and isoproterenol stimulate OEA production in isolated adipocytes, an effect that is mimicked by the adenylyl cyclase activator forskolin. Collectively, these results identify cold exposure as a natural stimulus for OEA formation in white fat and suggest a role for the sympathetic nervous system in regulating OEA biosynthesis.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Drug Discovery, Irvine, CA 92697 USA; Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, Madrid 28040, Spain; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; Complutense University of Madrid; Sapienza University Rome	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, 360 MSRII, Irvine, CA 92697 USA.	piomelli@uci.edu	Gaetani, Silvana/D-3455-2009					Bamshad M, 1998, AM J PHYSIOL-REG I, V275, pR291, DOI 10.1152/ajpregu.1998.275.1.R291; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cinti S, 2001, P NUTR SOC, V60, P319, DOI 10.1079/PNS200192; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DAVIDOVIC V, 1981, ARCH INT PHYSIOL BIO, V89, P457, DOI 10.3109/13813458109082642; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Garofalo MAR, 1996, J AUTONOM NERV SYST, V60, P206, DOI 10.1016/0165-1838(96)00037-9; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Guzman M, 2004, J BIOL CHEM, V279, P27849, DOI 10.1074/jbc.M404087200; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Lo Verme J, 2005, CELL MOL LIFE SCI, V62, P708, DOI 10.1007/s00018-004-4494-0; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Murillo-Rodniguez E, 2006, LIFE SCI, V79, P30, DOI 10.1016/j.lfs.2005.12.028; Overton HA, 2006, CELL METAB, V3, P167, DOI 10.1016/j.cmet.2006.02.004; Petersen G, 2006, BBA-MOL CELL BIOL L, V1761, P143, DOI 10.1016/j.bbalip.2005.12.011; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rayner DV, 2001, P NUTR SOC, V60, P357, DOI 10.1079/PNS2001101; RODBELL M, 1964, J BIOL CHEM, V239, P375; Rosen ED, 2003, CURR BIOL, V13, pR961, DOI 10.1016/j.cub.2003.11.043; SCHMID PC, 1985, J BIOL CHEM, V260, P4145; Sun YX, 2005, BBA-MOL CELL BIOL L, V1736, P211, DOI 10.1016/j.bbalip.2005.08.010; Ueda N, 2001, J BIOL CHEM, V276, P35552, DOI 10.1074/jbc.M106261200; Wang DH, 2005, ACTA PHARMACOL SIN, V26, P286, DOI 10.1111/j.1745-7254.2005.00057.x; YOUNGSTROM TG, 1995, AM J PHYSIOL, V268, P744; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c	29	27	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22815	22818		10.1074/jbc.M604751200	http://dx.doi.org/10.1074/jbc.M604751200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785227	hybrid, Green Published			2022-12-25	WOS:000239542600043
J	Nicoll, DA; Sawaya, MR; Kwon, S; Cascio, D; Philipson, KD; Abramson, J				Nicoll, Debora A.; Sawaya, Michael R.; Kwon, Seunghyug; Cascio, Duilio; Philipson, Kenneth D.; Abramson, Jeff			The crystal structure of the primary Ca2+ sensor of the Na+/Ca2+ exchanger reveals a novel Ca2+ binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; CA2+-BINDING DOMAIN; MUTATIONAL ANALYSIS; SYNAPTOTAGMIN; CALMODULIN; SEQUENCE; MODEL	The Na+/Ca2+ exchanger is a plasma membrane protein that regulates intracellular Ca2+ levels in cardiac myocytes. Transport activity is governed by Ca2+, and the primary Ca2+ sensor (CBD1) is located in a large cytoplasmic loop connecting two transmembrane helices. The binding of Ca2+ to the CBD1 sensory domain results in conformational changes that stimulate the exchanger to extrude Ca2+. Here, we present a crystal structure of CBD1 at 2.5 A resolution, which reveals a novel Ca2+ binding site consisting of four Ca2+ ions arranged in a tight planar cluster. This intricate coordination pattern for a Ca2+ binding cluster is indicative of a highly sensitive Ca2+ sensor and may represent a general platform for Ca2+ sensing.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Dept Energy, Ctr Genom & Proteom,Mol Biol Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Abramson, J (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	jabramson@mednet.ucla.edu			NHLBI NIH HHS [HL-49101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, CELL, V30, P349, DOI 10.1016/0092-8674(82)90232-X; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; Bers D. M., 2001, EXCITATION CONTRACTI, V2nd, P133, DOI [10.1007/978-94-010-0658-3_6, DOI 10.1007/978-94-010-0658-3_6]; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dai H, 2004, NAT STRUCT MOL BIOL, V11, P844, DOI 10.1038/nsmb817; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; Hilge M, 2006, MOL CELL, V22, P15, DOI 10.1016/j.molcel.2006.03.008; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levitan IB, 2004, SCIENCE, V304, P394, DOI 10.1126/science.1097507; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; Levitsky DO, 1996, MOL CELL BIOCHEM, V161, P27, DOI 10.1007/BF00240027; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Ottolia M, 2005, J BIOL CHEM, V280, P1061, DOI 10.1074/jbc.M411899200; Ottolia M, 2004, BIOPHYS J, V87, P899, DOI 10.1529/biophysj.104.043471; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park S, 2006, PROTEIN SCI, V15, P200, DOI 10.1110/ps.051814306; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; Ponting CP, 1997, PROTEIN SCI, V6, P464; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	34	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21577	21581		10.1074/jbc.C600117200	http://dx.doi.org/10.1074/jbc.C600117200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16774926	hybrid			2022-12-25	WOS:000239387100002
J	West, MB; Hill, BG; Xuan, YT; Bhatnagar, A				West, Matthew B.; Hill, Bradford G.; Xuan, Yu-Ting; Bhatnagar, Aruni			Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification	FASEB JOURNAL			English	Article						iNOS-TG mice; aortic rings; endothelium-dependent relaxation; posttranslational modification; rat aortic smooth muscle cells	MITOCHONDRIAL PERMEABILITY TRANSITION; VASCULAR SMOOTH-MUSCLE; ADENINE-NUCLEOTIDE TRANSLOCASE; THIOL-DISULFIDE EXCHANGE; CYTOCHROME-C-OXIDASE; S-GLUTATHIONYLATION; RESPIRATORY BURST; ALDOSE REDUCTASE; MIXED DISULFIDES; OXIDATIVE STRESS	This study was designed to examine whether NO regulates protein glutathiolation. Exposure to NO donors increased protein glutathiolation in COS-7 or rat aortic smooth muscle cells as detected by anti-protein glutathione (GSH) antibodies. This process was reversible and saturable. Stimulation with acetylcholine (ACh) increased protein glutathiolation in isolated rat aortic rings. This was prevented by inhibiting endothelial NO synthase (eNOS). In ACh-treated rings, proteins showing positive immunoreactivity with the anti-PSSG antibody (Ab) were identified by matrix assisted laser desorption-time-of-flight mass spectrometry to be actin, vimentin, and heat shock protein 70. Purified actin was more readily glutathiolated by S-nitrosoglutathione than by oxidized GSH as determined by electrospray-ionization mass spectrometry, and nitrosylated actin was glutathiolated by reduced GSH. Relative to wild-type (WT) mice, increased protein glutathiolation was observed in hearts of mice with cardiac-specific expression of inducible NO synthase (iNOS). Proteins immunoprecipitated from transgenic hearts revealed GSH-adducted peptides corresponding to adenine nucleotide translocator and the alpha-subunit of F(1)F(0)ATPase. These data suggest that exogenous NO or NO generated by eNOS or iNOS regulates protein adduction with GSH. This could be due to a direct reaction of proteins with S-nitrosoglutathione or deni-trosylation of S-nitrosylated proteins by reduced GSH. Glutathiolation of cytoskeletal and mitochondrial proteins may be a significant feature of NO bioreactivity.	Univ Louisville, Dept Biochem & Mol Biol, Div Cardiol, Louisville, KY 40202 USA; Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Bhatnagar, A (corresponding author), Univ Louisville, Dept Med, Div Cardiol, Delia Baxter Bldg,580 S Preston St,Rm 421F, Louisville, KY 40202 USA.	aruni@louisville.edu	Hill, Bradford/F-9228-2011; Bhatnagar, Aruni/H-7791-2013; Hill, Bradford/I-4154-2013	Hill, Bradford/0000-0001-5332-8286	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059378, R01HL065660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59378, HL-65660] Funding Source: Medline; NIEHS NIH HHS [ES-11860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Craghill J, 2004, BIOCHEM J, V379, P595, DOI 10.1042/BJ20031367; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V35, P1185, DOI 10.1016/S0891-5849(03)00504-5; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Fratelli M, 2003, PROTEOMICS, V3, P1154, DOI 10.1002/pmic.200300436; FURCHGOTT RF, 1995, ANNU REV PHARMACOL, V35, P1; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; HILL B, 1992, IONIC CHANNELS EXCIT; Hoppe G, 2004, EXP EYE RES, V78, P1085, DOI 10.1016/j.exer.2004.02.001; Ignarro L., 1995, NITRIC OXIDE BIOCH M; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Jensen ON, 1999, METH MOL B, V112, P513; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mawatari S, 2004, ARCH BIOCHEM BIOPHYS, V421, P108, DOI 10.1016/j.abb.2003.10.012; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; MURAD F, 1994, RECENT PROG HORM RES, V49, P239; Padgett Christine M., 1995, Cell Biochemistry and Biophysics, V27, P157; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramana KV, 2003, FASEB J, V17, P417, DOI 10.1096/fj.02-0722com; ROKUTAN K, 1994, AM J PHYSIOL, V266, P247; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; Seres T, 1996, J IMMUNOL, V156, P1973; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; SRIVASTAVA SK, 1973, EXP EYE RES, V17, P33, DOI 10.1016/0014-4835(73)90165-6; STADLER J, 1994, P NATL ACAD SCI USA, V91, P3559, DOI 10.1073/pnas.91.9.3559; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Tao LM, 2004, BIOCHEMISTRY-US, V43, P4028, DOI 10.1021/bi035924o; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; Wang GW, 2005, AM J PHYSIOL-HEART C, V288, pH1290, DOI 10.1152/ajpheart.00796.2004; West MB, 2004, FASEB J, V18, pC276; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; Xian M, 2000, J BIOL CHEM, V275, P20467, DOI 10.1074/jbc.M001054200; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102; Zech B, 1999, J BIOL CHEM, V274, P20931, DOI 10.1074/jbc.274.30.20931; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	71	92	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1715	+		10.1096/fj.06-5843fje	http://dx.doi.org/10.1096/fj.06-5843fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809435				2022-12-25	WOS:000240266600025
J	Fischer, TW; Sweatman, TW; Semak, I; Sayre, RM; Wortsman, J; Slominski, A				Fischer, Tobias W.; Sweatman, Trevor W.; Semak, Igor; Sayre, Robert M.; Wortsman, Jacobo; Slominski, Andrzej			Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems	FASEB JOURNAL			English	Article						AFMK; 2-hydroxymelatonin; 4-hydroxymelatonin; melatonin; skin; UVR	TANDEM MASS-SPECTROMETRY; INDUCED DNA-DAMAGE; INDUCED ERYTHEMA; BONE-MARROW; OXIDATION; SKIN; N-1-ACETYL-N-2-FORMYL-5-METHOXYKYNURAMINE; ANTIOXIDANT; IDENTIFICATION; EXPRESSION	Melatonin, which can be produced in the skin, exerts a protective effect against damage induced by UV radiation (UVR). We have investigated the effect of UVB, the most damaging component of UVR, on melatonin metabolism in HaCaT keratinocytes and in a cell-free system. Four metabolites were identified by HPLC and LC-MS: 6-hydroxymelatonin, N-1-acetyl-N-2-formyl- 5-methoxykynuramine (AFMK), 2-hydroxymelatonin (the main intermediate between melatonin and AFMK), and 4-hydroxymelatonin. Concentrations of these photoproducts were directly proportional to UVR-dose and to melatonin substrate content, and their accumulation was time-dependent. The UVR-dependent increase of AFMK and 2-hydroxymelatonin was also detected in keratinocytes, where it was accompanied by simultaneous consumption of intracellular melatonin. Of note, melatonin and its two major metabolites, 2-hydroxymelatonin and AFMK, were also detected in untreated keratinocytes, neither irradiated nor preincubated with melatonin. Thus, intracellular melatonin metabolism is enhanced under exposure to UVR. The additional biological activity of these individual melatonin metabolites increases the spectrum of potential actions of the recently identified cutaneous melatoninergic system.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Div Dermatol, Memphis, TN 38163 USA; Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; Belarusian State Univ, Dept Biochem, Minsk 220050, BELARUS; So Illinois Univ, Dept Internal Med, Springfield, IL 62708 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; Belarusian State University; Southern Illinois University System; Southern Illinois University	Slominski, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, 930 Madison Ave, Memphis, TN 38163 USA.	aslominski@utmem.edu	Semak, Igor/AAT-9273-2020	Semak, Igor/0000-0001-9430-8492; Slominski, Andrzej/0000-0001-8963-3995				Almeida EA, 2004, J PINEAL RES, V36, P64, DOI 10.1046/j.1600-079X.2003.00098.x; ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; Bangha E, 1997, DERMATOLOGY, V195, P248, DOI 10.1159/000245953; Berman B, 2001, INT J DERMATOL, V40, P573, DOI 10.1046/j.1365-4362.2001.01280.x; Bubenik GA, 1999, J PINEAL RES, V26, P56, DOI 10.1111/j.1600-079X.1999.tb00567.x; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; CAHILL GM, 1992, VISUAL NEUROSCI, V8, P487, DOI 10.1017/S0952523800005009; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Collier M, 2004, PLOUGHSHARES, V30, P23; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; Costa EJX, 1995, J PINEAL RES, V19, P123, DOI 10.1111/j.1600-079X.1995.tb00180.x; de Almeida EA, 2003, J PINEAL RES, V35, P131; de Vries E, 2004, EUR J CANCER PREV, V13, P387, DOI 10.1097/00008469-200410000-00006; Dellegar SM, 1999, BIOCHEM BIOPH RES CO, V257, P431, DOI 10.1006/bbrc.1999.0438; Dreher F, 1998, BRIT J DERMATOL, V139, P332, DOI 10.1046/j.1365-2133.1998.02447.x; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; Fischer TW, 2006, J PINEAL RES, V40, P18, DOI 10.1111/j.1600-079X.2005.00273.x; Fischer TW, 2004, SKIN PHARMACOL PHYS, V17, P190, DOI 10.1159/000078822; Fischer TW, 2004, J PINEAL RES, V37, P107, DOI 10.1111/j.1600-079X.2004.00142.x; Fischer TW, 2001, J PINEAL RES, V31, P39, DOI 10.1034/j.1600-079X.2001.310106.x; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HARDELAND R, 2005, INT J BIOCHEM CELL B, DOI DOI 10.1016/JBIOCEL.2005.1008.1020; Hasse S, 2004, J INVEST DERMATOL, V122, P307, DOI 10.1046/j.0022-202X.2004.22230.x; Hipler UC, 2003, SKIN PHARMACOL APPL, V16, P379, DOI 10.1159/000072933; Horstman JA, 2002, BIOORG CHEM, V30, P371, DOI 10.1016/S0045-2068(02)00511-4; Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Kadekaro AL, 2004, J PINEAL RES, V36, P204, DOI 10.1111/j.1600-079X.2004.00119.x; Karasek M, 2002, NEUROENDOCRINOL LETT, V23, P1; Karbownik M, 2002, NEUROENDOCRINOL LETT, V23, P39; KELLY RW, 1984, BIOCHEM BIOPH RES CO, V121, P372, DOI 10.1016/0006-291X(84)90732-0; Kim YO, 1999, ARCH PHARM RES, V22, P143, DOI 10.1007/BF02976538; Kobayashi H, 2005, FASEB J, V19, P1710, DOI 10.1096/fj.04-2293fje; Krutmann J, 2001, EUR J DERMATOL, V11, P170; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; LERNER AB, 1978, J NEURAL TRANSM, P339; Lisby S, 2005, EXP DERMATOL, V14, P349, DOI 10.1111/j.0906-6705.2005.00282.x; Ma XC, 2005, DRUG METAB DISPOS, V33, P489, DOI 10.1124/dmd.104.002410; Maestroni GJM, 2001, EXPERT OPIN INV DRUG, V10, P467, DOI 10.1517/13543784.10.3.467; Maharaj DS, 2002, J PINEAL RES, V32, P257, DOI 10.1034/j.1600-079X.2002.01866.x; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Nickel A, 2000, ARCH DERMATOL RES, V292, P366, DOI 10.1007/s004030000141; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter RJ, 2005, J PINEAL RES, V39, P215, DOI 10.1111/j.1600-079X.2005.00261.x; Reiter RJ, 2002, ANN NY ACAD SCI, V957, P341, DOI 10.1111/j.1749-6632.2002.tb02938.x; Reiter RJ, 2003, J PINEAL RES, V34, P79, DOI 10.1034/j.1600-079X.2003.2e114.x; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Rozov SV, 2003, J PINEAL RES, V35, P245, DOI 10.1034/j.1600-079X.2003.00081.x; SCHALLREUTER KU, 1994, SCIENCE, V263, P1444, DOI 10.1126/science.8128228; Schallreuter KU, 2001, J PHOTOCH PHOTOBIO B, V64, P179, DOI 10.1016/S1011-1344(01)00235-4; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Semak I, 2005, BIOCHEMISTRY-US, V44, P9300, DOI 10.1021/bi050202d; Silva SO, 2004, J NEUROIMMUNOL, V156, P146, DOI 10.1016/j.jneuroim.2004.07.015; Silva SO, 2004, J PINEAL RES, V37, P171, DOI 10.1111/j.1600-079X.2004.00149.x; Skinner DC, 1999, ENDOCRINOLOGY, V140, P4399, DOI 10.1210/endo.140.10.7074; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2004, BBA-GENE STRUCT EXPR, V1680, P67, DOI 10.1016/j.bbaexp.2004.09.002; Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Stasica P, 2000, J PINEAL RES, V29, P125, DOI 10.1034/j.1600-079X.2000.290209.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 1999, LIFE SCI, V65, P2523, DOI 10.1016/S0024-3205(99)00519-6; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tesoriere L, 2001, FREE RADICAL RES, V35, P633, DOI 10.1080/10715760100301161; VAKKURI O, 1987, ENDOCRINOLOGY, V120, P2453, DOI 10.1210/endo-120-6-2453; Wong PSH, 1999, RAPID COMMUN MASS SP, V13, P407, DOI 10.1002/(SICI)1097-0231(19990315)13:5<407::AID-RCM500>3.0.CO;2-I; XIMENES VF, 2005, J BIOL CHEM	79	134	144	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1564	+		10.1096/fj.05-5227fje	http://dx.doi.org/10.1096/fj.05-5227fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793870				2022-12-25	WOS:000240266000052
J	Garcia, P; Ucurum, Z; Bucher, R; Svergun, DI; Huber, T; Lustig, A; Konarev, PV; Marino, M; Mayans, O				Garcia, Pilar; Ucurum, Zohre; Bucher, Rainer; Svergun, Dmitri I.; Huber, Thomas; Lustig, Ariel; Konarev, Petr V.; Marino, Marco; Mayans, Olga			Molecular insights into the self-assembly mechanism of dystrophia myotonica kinase	FASEB JOURNAL			English	Article						kinase; coiled-coil; protein assembly; protein structure; X-ray crystallography; multiangle static light scattering; small angle X-ray scattering	RAY SOLUTION SCATTERING; HELICAL COILED COILS; GCN4 LEUCINE-ZIPPER; PROTEIN-KINASE; CYTOSKELETAL REORGANIZATION; BIOLOGICAL MACROMOLECULES; MYOSIN PHOSPHATASE; SALT BRIDGE; RHO-KINASE; PROGRAM	Self-assembly via coiled-coil domains (CC) is crucial for the regulation of the dystrophia myotonica kinase ( DMPK)-related family of kinases. These CC domains are thought to form dimeric arrangements and thus to mediate dimerization in these enzymes. Using size exclusion chromatography combined with multiangle static light scattering, we analyzed the oligomeric state of DMPK as well as that of a truncated variant lacking the CC fraction. Remarkably, both forms were found to assemble into robust dimers. In contrast, the CC domain in isolation yielded trimeric assemblies, indicating that the oligomerization properties of CC domains from this kinase family are more diversified than anticipated. The crystal structure of this CC has been elucidated to 1.6 angstrom resolution and its properties in solution established using sedimentation equilibrium and thermal denaturation. These data show that, contrary to expectations, the self-assembly of DMPK is not dictated by the association properties of its CC domain. Instead, it appears to be driven by sequence segments flanking both N and C termini of the catalytic kinase fraction, as suggested by models of head-to-head dimers based on small angle X-ray scattering data. Our findings support a shared pattern of assembly across DMPK, ROCKs, and MRCK members of this family.	Univ Basel, Biozentrum, Div Struct Biol, CH-4056 Basel, Switzerland; DESY, Hamburg Outstn, European Mol Biol Lab, D-2000 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow, Russia; Univ Zurich, Inst Biochem, CH-8006 Zurich, Switzerland	University of Basel; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of Zurich	Mayans, O (corresponding author), Univ Basel, Biozentrum, Div Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	olga.mayans@unibas.ch	Konarev, Petr V/W-1380-2017; Mayans, Olga/A-3954-2008	Mayans, Olga/0000-0001-6876-8532; Svergun, Dmitri/0000-0003-0830-5696; Konarev, Petr/0000-0002-5606-1596				Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Burkhard P, 2002, J MOL BIOL, V318, P901, DOI 10.1016/S0022-2836(02)00114-6; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Doran JD, 2004, BIOCHEM J, V384, P255, DOI 10.1042/BJ20040344; Dvorsky R, 2004, J BIOL CHEM, V279, P7098, DOI 10.1074/jbc.M311911200; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Garcia P, 2004, ACTA CRYSTALLOGR D, V60, P2336, DOI 10.1107/S0907444904026873; Gonzalez L, 1996, NAT STRUCT BIOL, V3, P1011, DOI 10.1038/nsb1296-1011; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harper P.S., 1989, MYOTONIC DYSTROPHY; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JACOBS MD, 2005, J BIOL CHEM     1024; Jiang H, 2004, HUM MOL GENET, V13, P3079, DOI 10.1093/hmg/ddh327; Jin S, 2000, CELL MOTIL CYTOSKEL, V45, P133, DOI 10.1002/(SICI)1097-0169(200002)45:2<133::AID-CM5>3.0.CO;2-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kammerer RA, 2001, J BIOL CHEM, V276, P13685, DOI 10.1074/jbc.M010492200; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee HC, 2003, PHYSIOL GENOMICS, V12, P147, DOI 10.1152/physiolgenomics.00095.2002; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Luo LQ, 1997, P NATL ACAD SCI USA, V94, P12963, DOI 10.1073/pnas.94.24.12963; Lupas AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Meier M, 2002, J STRUCT BIOL, V137, P65, DOI 10.1006/jsbi.2002.4467; Mounsey JP, 2000, HUM MOL GENET, V9, P2313, DOI 10.1093/oxfordjournals.hmg.a018923; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petoukhov MV, 2005, BIOPHYS J, V89, P1237, DOI 10.1529/biophysj.105.064154; Petoukhov MV, 2002, BIOPHYS J, V83, P3113, DOI 10.1016/S0006-3495(02)75315-0; Piekny AJ, 2002, J CELL SCI, V115, P2271; Porod G., 1982, SMALL ANGLE XRAY SCA; Schulz PE, 2003, J NEUROPHYSIOL, V89, P1177, DOI 10.1152/jn.00504.2002; Shimizu M, 2000, FEBS LETT, V475, P273, DOI 10.1016/S0014-5793(00)01692-6; Shimizu T, 2003, J BIOL CHEM, V278, P46046, DOI 10.1074/jbc.M306458200; Strelkov SV, 2002, J STRUCT BIOL, V137, P54, DOI 10.1006/jsbi.2002.4454; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zhang RX, 2003, FEBS LETT, V546, P281, DOI 10.1016/S0014-5793(03)00601-X	55	18	19	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1142	1151		10.1096/fj.05-5262com	http://dx.doi.org/10.1096/fj.05-5262com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770013				2022-12-25	WOS:000240210300014
J	Hwang, SI; Thumar, J; Lundgren, DH; Rezaul, K; Mayya, V; Wu, L; Eng, J; Wright, ME; Han, DK				Hwang, S-I; Thumar, J.; Lundgren, D. H.; Rezaul, K.; Mayya, V.; Wu, L.; Eng, J.; Wright, M. E.; Han, D. K.			Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues	ONCOGENE			English	Article						direct tissue proteomics (DTP); LC-MS/MS; prostate cancer; Wnt; formalin-fixed paraffin-embedded tissues; prostate-specific antigen (PSA)	PROSTATE-SPECIFIC ANTIGEN; ANDROGEN RECEPTOR; MASS-SPECTROMETRY; STATISTICAL-MODEL; GENE-EXPRESSION; LUNG-CANCER; PROTEIN; IDENTIFICATION; SPECIFICITY; PREVENTION	Successful treatment of multiple cancer types requires early detection and identification of reliable biomarkers present in specific cancer tissues. To test the feasibility of identifying proteins from archival cancer tissues, we have developed a methodology, termed direct tissue proteomics (DTP), which can be used to identify proteins directly from formalin-fixed paraffin-embedded prostate cancer tissue samples. Using minute prostate biopsy sections, we demonstrate the identification of 428 prostate-expressed proteins using the shotgun method. Because the DTP method is not quantitative, we employed the absolute quanti. cation method and demonstrate picogram level quantification of prostate-specific antigen. In depth bioinformatics analysis of these expressed proteins affords the categorization of metabolic pathways that may be important for distinct stages of prostate carcinogenesis. Furthermore, we validate Wnt-3 as an upregulated protein in cancerous prostate cells by immunohistochemistry. We propose that this general strategy provides a roadmap for successful identification of critical molecular targets of multiple cancer types.	Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Cell Biol, Farmington, CT 06030 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University of Connecticut; Fred Hutchinson Cancer Center; University of California System; University of California Davis	Han, DK (corresponding author), Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Cell Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	han@nso.uchc.edu	Eng, Jimmy K/I-4202-2012	Eng, Jimmy K/0000-0001-6352-6737; Mayya, Viveka/0000-0001-5668-9124; Wright, Michael/0000-0002-4243-2931	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694, R01HL067569] Funding Source: NIH RePORTER; NCRR NIH HHS [RR019436] Funding Source: Medline; NHLBI NIH HHS [HL 67569, P01 HL70694] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cantin GT, 2004, J CHROMATOGR A, V1053, P7, DOI 10.1016/j.chroma.2004.06.046; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Cronauer MV, 2005, INT J ONCOL, V26, P1033; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FORD TF, 1985, BRIT J UROL, V57, P50, DOI 10.1111/j.1464-410X.1985.tb08984.x; George DJ, 2002, UROLOGY, V60, P115, DOI 10.1016/S0090-4295(02)01589-3; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Gleason D F, 1988, NCI Monogr, P15; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Griffin TJ, 2003, ANAL CHEM, V75, P867, DOI 10.1021/ac026127j; Gupta A, 2004, J UROLOGY, V171, P2384, DOI 10.1097/01.ju.0000124331.16739.12; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hood BL, 2005, MOL CELL PROTEOMICS, V4, P1741, DOI 10.1074/mcp.M500102-MCP200; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Lundgren DH, 2003, MOL CELL PROTEOMICS, V2, P1164, DOI 10.1074/mcp.M300059-MCP200; Mayya V, 2005, MOL CELL PROTEOMICS, V4, P214, DOI 10.1074/mcp.T400015-MCP200; Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nelson PS, 2000, ELECTROPHORESIS, V21, P1823; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Parnes HL, 2005, J CLIN ONCOL, V23, P368, DOI 10.1200/JCO.2005.08.027; Patterson SD, 2004, ARTHRITIS RHEUM-US, V50, P3741, DOI 10.1002/art.20796; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Petricoin EF, 2002, NAT REV DRUG DISCOV, V1, P683, DOI 10.1038/nrd891; Posadas EM, 2005, ANN ONCOL, V16, P16, DOI 10.1093/annonc/mdi004; Raben David, 2004, Clin Lung Cancer, V6, P48, DOI 10.3816/CLC.2004.n.021; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Smith RA, 2005, CA-CANCER J CLIN, V55, P31, DOI 10.3322/canjclin.55.1.31; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Sweat GT, 2005, POSTGRAD MED, V117, P45, DOI 10.3810/pgm.2005.04.1618; TANNEBERGER S, 1977, ARCH GESCHWULSTFORSC, V47, P755; Tarro G, 2005, J CELL PHYSIOL, V203, P1, DOI 10.1002/jcp.20195; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Wardwell NR, 2005, SEMIN ONCOL, V32, P259, DOI 10.1053/j.seminoncol.2005.02.009; Wilson JF, 2004, ANN INTERN MED, V140, P317, DOI 10.7326/0003-4819-140-4-200402170-00036; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wright ME, 2005, MOL CELL PROTEOMICS, V4, P545, DOI 10.1074/mcp.R500008-MCP200; Wright ME, 2004, GENOME BIOL, V5; Zangar RC, 2004, DIS MARKERS, V20, P135, DOI 10.1155/2004/754640; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	47	105	110	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					65	76		10.1038/sj.onc.1209755	http://dx.doi.org/10.1038/sj.onc.1209755			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799640				2022-12-25	WOS:000243236500007
J	Tsumura, H; Yoshida, T; Saito, H; Imanaka-Yoshida, K; Suzuki, N				Tsumura, H.; Yoshida, T.; Saito, H.; Imanaka-Yoshida, K.; Suzuki, N.			Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice	ONCOGENE			English	Article						pleomorphic rhabdomyosarcoma; K-ras; p53	SOFT-TISSUE SARCOMAS; N-RAS; SKELETAL-MUSCLE; H-RAS; P53-DEFICIENT MICE; POINT MUTATIONS; CRE RECOMBINASE; STEM-CELL; IN-VIVO; GENE	Human rhabdomyosarcomas (RMSs) frequently demonstrate genetic alterations in ras and p53. To investigate their possible involvement in the tumorigenesis, we generated a knock- in mouse line with oncogenic K- ras, conditionally expressed by Cre/ LoxP system on a background of p53 alteration. Electroporation of Cre expression vector in skeletal muscle tissues resulted in the generation of tumor in adults with tumor incidences of 100% at 10 weeks and 40% at 15 weeks, in p53(-/-) and p53(-/-) backgrounds, respectively. The tumor histology was pleomorphic RMS with characteristic bizarre giant cells, positive for desmin and alpha-sarcomeric actin and exhibiting remarkable increase in total and phosphorylated extracellular signal- regulated protein kinase (ERK) 1 and ERK2. Loss of the wild- type p53 was detected in K- rasG12V- expressed tumors of p53(-/+) mice. Early lesions 3 weeks after electroporation consisted of proliferating populations of myogenic progenitors, including stem cells positive for ScaI antigen, immature cells positive for desmin and neural cell adhesion molecule- positive myotubes. Thus, cooperation of oncogenic K- ras and p53 deficiency resulted in the development of pleomorphic RMS in adult mice, providing a useful mouse model for further detailed studies.	Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, Tsu, Mie 5148507, Japan; Mie Univ, Grad Sch Med, Tsu, Mie 5148507, Japan	Mie University; Mie University	Suzuki, N (corresponding author), Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	nsuzuki@doc.medic.mie-u.ac.jp	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217				BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Durieux AC, 2004, J GENE MED, V6, P809, DOI 10.1002/jgm.534; Fedorov YV, 2002, MOL CELL BIOL, V22, P1140, DOI 10.1128/MCB.22.4.1140-1149.2002; FELIX CA, 1992, CANCER RES, V52, P2243; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hawkins WG, 2001, CANCER-AM CANCER SOC, V91, P794, DOI 10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KOYABU S, 1994, CELL MOTIL CYTOSKEL, V29, P259, DOI 10.1002/cm.970290309; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Linardic CM, 2005, CANCER RES, V65, P4490, DOI 10.1158/0008-5472.CAN-04-3194; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nanni P, 2003, CANCER RES, V63, P2728; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Patel S R, 2000, Curr Treat Options Oncol, V1, P258, DOI 10.1007/s11864-000-0037-6; Saito H, 2005, BIOCHEM BIOPH RES CO, V331, P1216, DOI 10.1016/j.bbrc.2005.04.043; Sakai K, 1995, BIOCHEM BIOPH RES CO, V217, P393, DOI 10.1006/bbrc.1995.2789; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; STRATTON MR, 1989, CANCER RES, V49, P6324; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; TSUKADA T, 1993, ONCOGENE, V8, P3313; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; White JD, 2002, INT J DEV BIOL, V46, P577; WILKE W, 1993, MODERN PATHOL, V6, P129; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yoo J, 1999, CANCER, V86, P58, DOI 10.1002/(SICI)1097-0142(19990701)86:1<58::AID-CNCR10>3.3.CO;2-J	38	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7673	7679		10.1038/sj.onc.1209749	http://dx.doi.org/10.1038/sj.onc.1209749			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785989				2022-12-25	WOS:000242830800002
J	Li, WG; Yu, SW; Kong, ANT				Li, Wenge; Yu, Si-Wang; Kong, A. -N. Tony			Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-MEDIATED EXPRESSION; TRANSCRIPTION FACTOR NRF2; INDUCIBLE EXPRESSION; FUNCTIONAL-CHARACTERIZATION; ANTIOXIDANT INDUCTION; RESPONSIVE ELEMENT; GENE-EXPRESSION; SMALL-INTESTINE; DNA-BINDING; KEAP1	NF-E2-related factor 2 (Nrf2) is the key transcription factor regulating the antioxidant response. Previous studies identified a nuclear localization signal (NLS) in the basic region and a nuclear exporting signal (NES) in the leucine zipper domain of Nrf2. In this study, we characterize a new functional NES ((175)LLSIPELQCLNI(186)) in the transactivation (TA) domain of Nrf2. A green fluorescence protein (GFP)-tagged Nrf2 segment (amino acids162-295) called GFP-NESTA exhibited a cytosolic distribution that could be disrupted by L184A mutation or leptomycin B treatment. Chimeric expression of this NESTA with a nuclear protein GAL4DBD could expel GAL4DBD into the cytoplasm. A variety of oxidants, including sulforaphane, tert-butylhydroquinone, and H2O2, could effectively induce nuclear translocation of GFP-NESTA. Mutational studies showed that cysteine 183 may mediate the redox response of NESTA. The discovery of multiple NLS/NES motifs in Nrf2 and the redox sensitivity of NESTA imply Nrf2 may be self-sufficient to sense and transduce oxidative signals into the nucleus, consequently initiating antioxidant gene transcription.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	KongT@rci.rutgers.edu	Kong, Ah-Ng Tony/AAX-2828-2020	Yu, Siwang/0000-0002-3336-202X	NCI NIH HHS [R01 CA94828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee TD, 2005, BIOCHEM J, V390, P521, DOI 10.1042/BJ20050439; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Magin TM, 2003, NAT GENET, V35, P202, DOI 10.1038/ng1103-202; McMahon M, 2001, CANCER RES, V61, P3299; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; NISHI K, 1994, J BIOL CHEM, V269, P6320; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Shen GX, 2006, MOL CANCER THER, V5, P39, DOI 10.1158/1535-7163.MCT-05-0293; Shen GX, 2005, PHARM RES-DORDR, V22, P1805, DOI 10.1007/s11095-005-7546-8; Shen GX, 2004, J BIOL CHEM, V279, P23052, DOI 10.1074/jbc.M401368200; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; YOUVAN DC, 1984, CELL, V39, P1, DOI 10.1016/0092-8674(84)90185-5; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	62	121	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27251	27263		10.1074/jbc.M602746200	http://dx.doi.org/10.1074/jbc.M602746200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16790425	hybrid			2022-12-25	WOS:000240397700052
J	Marintcheva, B; Hamdan, SM; Lee, SJ; Richardson, CC				Marintcheva, Boriana; Hamdan, Samir M.; Lee, Seung-Joo; Richardson, Charles C.			Essential residues in the C terminus of the bacteriophage T7 gene 2.5 single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; LAGGING-STRAND; LIMITED PROTEOLYSIS; HELICASE-PRIMASE; REPLICATION; DOMAIN; POLYMERASE; PURIFICATION; PROCESSIVITY	Gene 2.5 of bacteriophage T7 encodes a single-stranded DNA (ssDNA)-binding protein (gp2.5) that is an essential component of the phage replisome. Similar to other prokaryotic ssDNA-binding proteins, gp2.5 has an acidic C terminus that is involved in protein-protein interactions at the replication fork and in modulation of the ssDNA binding properties of the molecule. We have used genetic and biochemical approaches to identify residues critical for the function of the C terminus of gp2.5. The presence of an aromatic residue in the C-terminal position is essential for gp2.5 function. Deletion of the C-terminal residue, phenylalanine, is detrimental to its function, as is the substitution of this residue with non-aromatic amino acids. Placing the C-terminal phenylalanine in the penultimate position also results in loss of function. Moderate shortening of the length of the acidic portion of the C terminus is tolerated when the aromatic nature of the C-terminal residue is preserved. Gradual removal of the acidic C terminus of gp2.5 results in a higher affinity for ssDNA and a decreased ability to interact with T7 DNA polymerase/thioredoxin. The replacement of the charged residues in the C terminus with neutral amino acids abolishes gp2.5 function. Our data show that both the C-terminal aromatic residue and the overall acidic charge of the C terminus of gp2.5 are critical for its function.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu		Hamdan, Samir/0000-0001-5192-1852	NIGMS NIH HHS [F32GM72305, GM 54397] Funding Source: Medline; OHS HRSA HHS [ST32A107245-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072305, R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BURKE RL, 1980, J BIOL CHEM, V255, P1484; Hamdan SM, 2005, P NATL ACAD SCI USA, V102, P5096, DOI 10.1073/pnas.0501637102; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; HOSODA J, 1978, J BIOL CHEM, V253, P7547; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2006, J BIOL CHEM, V281, P25841, DOI 10.1074/jbc.M604602200; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Milburn CC, 2004, NAT STRUCT MOL BIOL, V11, P193, DOI 10.1038/nsmb716; NAKAI H, 1986, J BIOL CHEM, V261, P5217; Pant K, 2005, J MOL BIOL, V349, P317, DOI 10.1016/j.jmb.2005.03.065; Rezende LF, 2003, J BIOL CHEM, V278, P29098, DOI 10.1074/jbc.M303374200; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; TABOR S, 1987, J BIOL CHEM, V262, P16212; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346	32	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25831	25840		10.1074/jbc.M604601200	http://dx.doi.org/10.1074/jbc.M604601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807232	hybrid, Green Published			2022-12-25	WOS:000240031300085
J	Spurgers, KB; Gold, DL; Coombes, KR; Bohnenstiehl, NL; Mullins, B; Meyn, RE; Logothetis, CJ; McDonnell, TJ				Spurgers, Kevin B.; Gold, David L.; Coombes, Kevin R.; Bohnenstiehl, Nicole L.; Mullins, Brian; Meyn, Raymond E.; Logothetis, Christopher J.; McDonnell, Timothy J.			Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NEGATIVE REGULATION; DOWN-REGULATION; DIRECT BINDING; CANCER CELLS; EXPRESSION; PROSTATE; BCL-2; MUTATIONS; MICROARRAYS	Historically, most studies attribute p53 function to the transactivation of target genes. That p53 can selectively repress genes to affect a cellular response is less widely appreciated. Available evidence suggests that repression is important for p53-induced apoptosis and cell cycle arrest. To better establish the scope of p53-repressed target genes and the cellular processes they may affect, a global expression profiling strategy was used to identify p53-responsive genes following adenoviral p53 gene transfer (Ad-p53) in PC3 prostate cancer cells. A total of 111 genes, 0.77% of the 14,500 genes represented on the Affymetrix U133A microarray, were repressed more than 2-fold (p <= 0.05). Validation of the array data, using reverse transcription-PCR of 20 randomly selected genes, yielded a confirmation rate of > 95.5% for the complete data set. Functional over-representation analysis revealed that cell cycle regulatory genes exhibited a highly significant enrichment (p <= 5 x 10(-28)) within the transrepressed targets. 41% of the repressed targets are cell cycle regulators. A subset of these genes exhibited repression following DNA damage, preceding cell cycle arrest, in LNCaP cells. The use of a p53 small interfering RNA strategy in LNCaP cells and the use of p53-null cell lines demonstrated that this repression is p53-dependent. These findings identify a set of genes not known previously to be down-regulated by p53 and indicate that p53induced cell cycle arrest is a function of not only the transactivation of cell cycle inhibitors (e.g. p21) but also the repression of targets that regulate proliferation at several distinct phases of the cell cycle.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 089, Houston, TX 77030 USA.	tmcdonne@mdanderson.org		Coombes, Kevin/0000-0002-7630-2123	NCI NIH HHS [P50 CA90270, CA16672, R01 CA69003-9] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069003, P30CA016672, P50CA090270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badie C, 2000, BRIT J CANCER, V82, P642; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Damia G, 2004, CELL CYCLE, V3, P46; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Gold D, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-2; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lei M, 2001, J CELL SCI, V114, P1447; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li C, 2004, ONCOGENE, V23, P9336, DOI 10.1038/sj.onc.1208114; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1994, CANCER RES, V54, P3131; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Spurgers KB, 2004, ONCOGENE, V23, P1712, DOI 10.1038/sj.onc.1207293; St Clair S, 2004, MOL CELL, V16, P725; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZHANG WW, 1994, CANCER GENE THER, V1, P5	51	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25134	25142		10.1074/jbc.M513901200	http://dx.doi.org/10.1074/jbc.M513901200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16798743	hybrid			2022-12-25	WOS:000240031300014
J	Babbar, N; Hacker, A; Huang, Y; Casero, RA				Babbar, Naveen; Hacker, Amy; Huang, Yi; Casero, Robert A., Jr.			Tumor necrosis factor alpha induces spermidine/spermine N-1-acetyltransferase through nuclear factor kappa B in non-small cell lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; POLYAMINE DEPLETION; INDUCED APOPTOSIS; SPERMINE N1-ACETYLTRANSFERASE; BREAST-CANCER; COLON-CANCER; BIS(ETHYL)POLYAMINE ANALOGS; DRUG-ACTION; ACTIVATION; INDUCTION	Tumor necrosis factor alpha( TNF alpha) is a potent pleiotropic cytokine produced by many cells in response to inflammatory stress. The molecular mechanisms responsible for the multiple biological activities of TNF alpha are due to its ability to activate multiple signal transduction pathways, including nuclear factor kappa B ( NF kappa B), which plays critical roles in cell proliferation and survival. TNF alpha displays both apoptotic and antiapoptotic properties, depending on the nature of the stimulus and the activation status of certain signaling pathways. Here we show that TNF alpha can lead to the induction of NF kappa B signaling with a concomitant increase in spermidine/spermine N-1-acetyltransferase ( SSAT) expression in A549 and H157 non-small cell lung cancer cells. Induction of SSAT, a stress-inducible gene that encodes a rate-limiting polyamine catabolic enzyme, leads to lower intracellular polyamine contents and has been associated with decreased cell growth and increased apoptosis. Stable overexpression of a mutant, dominant negative I kappa B alpha protein led to the suppression of SSAT induction by TNF alpha in these cells, thereby substantiating a role of NF kappa B in the induction of SSAT by TNF alpha. SSAT promoter deletion constructs led to the identification of three potential NF kappa B response elements in the SSAT gene. Electromobility shift assays, chromatin immunoprecipitation experiments and mutational studies confirmed that two of the three NF kappa B response elements play an important role in the regulation of SSAT in response to TNF alpha. The results of these studies indicate that a common mediator of inflammation can lead to the induction of SSAT expression by activating the NF kappa B signaling pathway in non-small cell lung cancer cells.	Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Casero, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA.	rcasero@jhmi.edu	Huang, Yi/AAW-7892-2021	Huang, Yi/0000-0002-9982-117X; Casero, Robert/0000-0001-5653-3306	NCI NIH HHS [CA 51085, CA 98454] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098454, R01CA051085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Babbar N, 2006, BIOCHEM J, V394, P317, DOI 10.1042/BJ20051298; Babbar N, 2003, BIOCHEM SOC T, V31, P388, DOI 10.1042/BST0310388; Babbar N, 2003, J BIOL CHEM, V278, P47762, DOI 10.1074/jbc.M307265200; BABBAR N, 2005, BIOCH J; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beutler BA, 1999, J RHEUMATOL, V26, P16; Bu DX, 2005, FASEB J, V19, P1293, DOI 10.1096/fj.04-2645fje; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1989, CANCER RES, V49, P639; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P183, DOI 10.1007/BF00686309; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cvetkovic I, 2004, CELL MOL LIFE SCI, V61, P1167, DOI 10.1007/s00018-004-3408-5; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; FULLER DJM, 1990, BIOCHEM J, V267, P601, DOI 10.1042/bj2670601; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Hector S, 2004, MOL CANCER THER, V3, P813; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Hughes A, 2003, BIOCHEM J, V374, P481, DOI 10.1042/BJ20030280; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; KHAN AU, 1992, P NATL ACAD SCI USA, V89, P11426, DOI 10.1073/pnas.89.23.11426; Kim K, 2005, BIOCHEM BIOPH RES CO, V331, P78, DOI 10.1016/j.bbrc.2005.03.121; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Kostadinova RM, 2005, FASEB J, V19, P650, DOI 10.1096/fj.04-2820fje; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; Li L, 2001, AM J PHYSIOL-GASTR L, V280, pG992, DOI 10.1152/ajpgi.2001.280.5.G992; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lovaas E, 1997, Adv Pharmacol, V38, P119; Mabuchi S, 2004, CLIN CANCER RES, V10, P7645, DOI 10.1158/1078-0432.CCR-04-0958; Maxwell PJ, 2003, CANCER RES, V63, P4602; McCloskey DE, 1996, CLIN CANCER RES, V2, P441; Pazdrak K, 2004, GASTROENTEROLOGY, V127, P1096, DOI 10.1053/j.gastro.2004.07.008; Pfeffer LM, 2001, J BIOL CHEM, V276, P45909, DOI 10.1074/jbc.M108097200; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1993, CANCER RES, V53, P581; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Sanlioglu AD, 2006, CANCER GENE THER, V13, P21, DOI 10.1038/sj.cgt.7700877; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Scorcioni F, 2001, BIOCHEM J, V354, P217, DOI 10.1042/0264-6021:3540217; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Shah N, 2001, ONCOGENE, V20, P1715, DOI 10.1038/sj.onc.1204247; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stefanelli C, 2001, BIOCHEM J, V355, P199, DOI 10.1042/0264-6021:3550199; Stuhlmeier KM, 2005, J BIOL CHEM, V280, P42766, DOI 10.1074/jbc.M503374200; Turchanowa L, 2001, EUR J CLIN INVEST, V31, P887, DOI 10.1046/j.1365-2362.2001.00901.x; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Yokochi T, 1998, PROG CLIN BIOL RES, V397, P235; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zou TT, 2004, AM J PHYSIOL-CELL PH, V286, pC1009, DOI 10.1152/ajpcell.00480.2003	64	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24182	24192		10.1074/jbc.M601871200	http://dx.doi.org/10.1074/jbc.M601871200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16757480	hybrid			2022-12-25	WOS:000239847800012
J	Bhattacharyya, N; Pechhold, K; Shahjee, H; Zappala, G; Elbi, C; Raaka, B; Wiench, M; Hong, J; Rechler, MM				Bhattacharyya, Nisan; Pechhold, Klaus; Shahjee, Hanief; Zappala, Giovanna; Elbi, Cem; Raaka, Bruce; Wiench, Malgorzata; Hong, Jiang; Rechler, Matthew M.			Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; HORMONE-RELATED PEPTIDE; FACTOR-BETA; FACTOR-I; SURFACE BINDING; TARGETED DISRUPTION; TGF-BETA; INHIBITION; RECEPTOR; EXPRESSION	Insulin-like growth factor binding protein-3 (IGFBP-3), a secreted protein, has the intrinsic ability to induce apoptosis directly without binding insulin-like growth factors. Previous studies suggested that IGFBP-3 must be secreted to exert its biological functions. IGFBP-3 contains a nuclear localization signal (NLS), and exogenous IGFBP-3 is translocated into the nucleus, suggesting that both secretion and nuclear localization may play important roles in IGFBP-3 action. To address these questions, we fused yellow fluorescent protein (YFP) to mature IGFBP-3 lacking its signal peptide so that it would remain intracellular and mutated the C-terminal NLS of IGFBP-3, 228KGRKR232, to MDGEA. Following transfection of PC-3 human prostate cancer cells with these constructs, Western blots indicated that YFP-IGFBP-3 lacking a signal peptide was cell-associated and not present in the extracellular media. Moreover, the fusion protein was not N- glycosylated, indicating that it had not entered the secretory pathway. Confocal imaging showed that intracellular YFP-MDGEA-IGFBP-3 was predominantly cytoplasmic. Transient transfection of nonsecreted YFP-wild-type IGFBP-3 decreased cell viability, as assessed by staining with annexin V followed by flow cytometry. Induction of cell death was caspase-dependent, indicative of apoptosis. Apoptosis also was induced by the nonsecreted NLS mutant (YFP-MDGEA-IGFBP-3) alone and when the IGF-binding site also had been mutated. These results indicate that IGFBP-3 can induce apoptosis in an IGF-independent manner without being secreted or concentrated in the nucleus.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Islet Autoimmun Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rechler, MM (corresponding author), NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA.	mrechler@helix.nih.gov		Wiench, Malgorzata/0000-0002-0202-9881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055006] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Baker KM, 2004, REGUL PEPTIDES, V120, P5, DOI 10.1016/j.regpep.2004.04.004; Besset V, 1996, ENDOCRINOLOGY, V137, P296, DOI 10.1210/en.137.1.296; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2005, ENDOCRINOLOGY, V146, P3113, DOI 10.1210/en.2004-1408; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chang YS, 2002, CLIN CANCER RES, V8, P3796; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274; Devi GR, 2002, PROSTATE, V51, P141, DOI 10.1002/pros.10068; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Firth SM, 1999, J ENDOCRINOL, V160, P379, DOI 10.1677/joe.0.1600379; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Giovannucci E, 2000, CANCER EPIDEM BIOMAR, V9, P345; Grimberg A, 2002, INT J ONCOL, V21, P327; Gucev ZS, 1996, CANCER RES, V56, P1545; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Hanafusa T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-9; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hochscheid R, 2000, J ENDOCRINOL, V166, P553, DOI 10.1677/joe.0.1660553; Hong J, 2002, J BIOL CHEM, V277, P10489, DOI 10.1074/jbc.M109604200; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; INGERMANN AR, 2000, GROWTH HORM IGF RES, V10, pA27; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Johnson HM, 2004, BIOESSAYS, V26, P993, DOI 10.1002/bies.20086; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim HS, 2004, CANCER RES, V64, P2229, DOI 10.1158/0008-5472.CAN-03-1675; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; Lillis AP, 2005, J THROMB HAEMOST, V3, P1884, DOI 10.1111/j.1538-7836.2005.01371.x; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu BR, 2005, CLIN CANCER RES, V11, P4851, DOI 10.1158/1078-0432.CCR-04-2160; LOGAN A, 1990, J ENDOCRINOL, V125, P339, DOI 10.1677/joe.0.1250339; Lu XF, 2005, J BIOL CHEM, V280, P22606, DOI 10.1074/jbc.M412073200; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Nguyen MTA, 2001, ENDOCRINOLOGY, V142, P694, DOI 10.1210/en.142.2.694; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rajah R, 2002, CELL GROWTH DIFFER, V13, P163; Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Ricort JM, 2004, GROWTH HORM IGF RES, V14, P277, DOI 10.1016/j.ghir.2004.02.002; Rozen F, 1998, INT J ONCOL, V13, P865; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270; Singh B, 2004, J BIOL CHEM, V279, P477, DOI 10.1074/jbc.M307322200; SMITH EP, 1992, ENDOCRINOLOGY, V131, P2733, DOI 10.1210/en.131.6.2733; Spagnoli A, 2002, J BIOL CHEM, V277, P18860, DOI 10.1074/jbc.M200218200; Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vasylyeva TL, 2005, GROWTH HORM IGF RES, V15, P207, DOI 10.1016/j.ghir.2005.02.008; Wang LZ, 2003, CANCER RES, V63, P4407; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886; Yang YWH, 1996, ENDOCRINOLOGY, V137, P4363, DOI 10.1210/en.137.10.4363; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819	86	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24588	24601		10.1074/jbc.M509463200	http://dx.doi.org/10.1074/jbc.M509463200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793770	hybrid			2022-12-25	WOS:000239847800054
J	Chen, YR; Glabe, CG				Chen, Yun-Ru; Glabe, Charles G.			Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides A beta 40 and A beta 42 - Stable trimer or tetramer formation by A beta 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; PROTEIN; DISEASE; OLIGOMERIZATION; THERMODYNAMICS; PATHOGENESIS; DENATURANTS; NUCLEATION; DEPOSITION; MECHANISM	The amyloid beta peptide (A beta), composed of 40 or 42 amino acids, is a critical component in the etiology of the neurodegenerative Alzheimer disease. A beta is prone to aggregate and forms amyloid fibrils progressively both in vitro and in vivo. To understand the process of amyloidogenesis, it is pivotal to examine the initial stages of the folding process. We examined the equilibrium folding properties, assembly states, and stabilities of the early folding stages of A beta 40 and A beta 42 prior to fibril formation. We found that A beta 40 and A beta 42 have different conformations and assembly states upon refolding from their unfolded ensembles. A beta 40 is predominantly an unstable and collapsed monomeric species, whereas A beta 42 populates a stable structured trimeric or tetrameric species at concentrations above similar to 12.5 mu M. Thermodynamic analysis showed that the free energies of A beta 40 monomer and A beta 42 trimer/tetramer are similar to 1.1 and similar to 15/similar to 22kcal/mol, respectively. The early aggregation stages of A beta 40 and A beta 42 contain different solvent-exposed hydrophobic surfaces that are located at the sequences flanking its protease-resistant segment. The amyloidogenic folded structure of A beta is important for the formation of spherical beta oligomeric species. However, beta oligomers are not an obligatory intermediate in the process of fibril formation because oligomerization is inhibited at concentrations of urea that have no effect on fibril formation. The distinct initial folding properties of A beta 40 and A beta 42 may play an important role in the higher aggregation potential and pathological significance of A beta 42.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3438 McGaugh Hall, Irvine, CA 92697 USA.	cglabe@uci.edu	Chen, Yun-Ru/C-9304-2014; Taylor, Graham/A-4027-2012	Chen, Yun-Ru/0000-0002-6596-6338; 	NINDS NIH HHS [NS31320] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Backmann J, 1998, J MOL BIOL, V284, P817, DOI 10.1006/jmbi.1998.2216; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Borreguero JM, 2005, P NATL ACAD SCI USA, V102, P6015, DOI 10.1073/pnas.0502006102; BURDICK D, 1992, J BIOL CHEM, V267, P546; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Ferrao-Gonzales AD, 2005, J BIOL CHEM, V280, P34747, DOI 10.1074/jbc.M501651200; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Ghosh M, 2001, INT J BIOL MACROMOL, V29, P273, DOI 10.1016/S0141-8130(01)00175-1; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HONG HY, 2002, PROTEIN PROTOCOLS HD, P387; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Jelesarov I, 2001, J MOL BIOL, V307, P637, DOI 10.1006/jmbi.2001.4469; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim JR, 2004, PROTEIN SCI, V13, P2888, DOI 10.1110/ps.04847404; Lazo ND, 2005, PROTEIN SCI, V14, P1581, DOI 10.1110/ps.041292205; LeVine H, 2004, ANAL BIOCHEM, V335, P81, DOI 10.1016/j.ab.2004.08.014; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sciarretta KL, 2005, BIOCHEMISTRY-US, V44, P6003, DOI 10.1021/bi0474867; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; Younkin S G, 1997, Rinsho Shinkeigaku, V37, P1099; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	41	172	182	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24414	24422		10.1074/jbc.M602363200	http://dx.doi.org/10.1074/jbc.M602363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16809342	hybrid			2022-12-25	WOS:000239847800035
J	Cheng, SJ; Gallie, DR				Cheng, Shijun; Gallie, Daniel R.			Wheat eukaryotic initiation factor 4B organizes assembly of RNA and eIFiso4G, eIF4A, and poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; CAP-DEPENDENT TRANSLATION; MESSENGER-RNA; HELICASE ACTIVITY; RECOGNITION MOTIF; IN-VITRO; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; BINDING-PROTEIN; RIBOSOMAL ENTRY	The eukaryotic translation initiation factor ( eIF) 4B promotes the RNA-dependent ATP hydrolysis activity and ATP-dependent RNA helicase activity of eIF4A and eIF4F during translation initiation. Although this function is conserved among plants, animals, and yeast, eIF4B is one of the least conserved of initiation factors at the sequence level. To gain insight into its functional conservation, the organization of the functional domains of eIF4B from wheat has been investigated. Plant eIF4B contains three RNA binding domains, one more than reported for mammalian or yeast eIF4B, and each domain exhibits a preference for purine-rich RNA. In addition to a conserved RNA recognition motif and a C-terminal RNA binding domain, wheat eIF4B contains a novel N-terminal RNA binding domain that requires a short, lysine-rich containing sequence. Both the lysine-rich motif and an adjacent, C-proximal motif are conserved with an N-proximal sequence in human and yeast eIF4B. The C-proximal motif within the N-terminal RNA binding domain in wheat eIF4B is required for interaction with eIFiso4G, an interaction not reported for other eIF4B proteins. Moreover, each RNA binding domain requires dimerization for binding activity. Two binding sites for the poly( A)-binding protein were mapped to a region within each of two conserved 41-amino acid repeat domains on either side of the C-terminal RNA binding domain. eIF4A bound to an adjacent region within each repeat, supporting a central role for these conserved eIF4B domains in facilitating interaction with other components of the translational machinery. These results support the notion that eIF4B functions by organizing multiple components of the translation initiation machinery and RNA.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu						ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BENNE R, 1978, J BIOL CHEM, V253, P3078; Bi XP, 2000, J BIOL CHEM, V275, P17740, DOI 10.1074/jbc.M909464199; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; Bushell M, 2001, J BIOL CHEM, V276, P23922, DOI 10.1074/jbc.M100384200; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; Dmitriev SE, 2003, MOL CELL BIOL, V23, P8925, DOI 10.1128/MCB.23.24.8925-8933.2003; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 2004, BIOCHEM SOC T, V32, P585, DOI 10.1042/BST0320585; Gallie DR, 2001, J BIOL CHEM, V276, P36951, DOI 10.1074/jbc.M103869200; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Khan MA, 2005, BIOCHEMISTRY-US, V44, P4510, DOI 10.1021/bi047298g; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 2000, J BIOL CHEM, V275, P17452, DOI 10.1074/jbc.M001186200; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Luo YJ, 2001, J BIOL CHEM, V276, P43083, DOI 10.1074/jbc.M104970200; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1996, RNA, V2, P38; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; Metz AM, 1999, BIOCHEM BIOPH RES CO, V266, P314, DOI 10.1006/bbrc.1999.1814; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; NARANDA T, 1994, J BIOL CHEM, V269, P14465; Neff CL, 1999, MOL CELL BIOL, V19, P5557; Niederberger N, 1998, RNA, V4, P1259, DOI 10.1017/S1355838298980487; Park HS, 2004, EMBO J, V23, P1381, DOI 10.1038/sj.emboj.7600140; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TRAKSHEL GM, 1988, BIOCHEM J, V252, P127, DOI 10.1042/bj2520127; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Wei CC, 1998, BIOCHEMISTRY-US, V37, P1910, DOI 10.1021/bi9724570; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	54	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24351	24364		10.1074/jbc.M605404200	http://dx.doi.org/10.1074/jbc.M605404200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803875	hybrid			2022-12-25	WOS:000239847800028
J	Kar, A; Havlioglu, N; Tarn, WY; Wu, JY				Kar, Amar; Havlioglu, Necat; Tarn, Woan-Yuh; Wu, Jane Y.			RBM4 interacts with an intronic element and stimulates tau exon 10 inclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAUSES FRONTOTEMPORAL DEMENTIA; SPLICING REGULATORY ELEMENT; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; MICROTUBULE DYNAMICS; ALZHEIMERS-DISEASE; PROTEIN TAU; MUTATIONS; EXPRESSION; FTDP-17	Tau protein, which binds to and stabilizes microtubules, is critical for neuronal survival and function. In the human brain, tau pre-mRNA splicing is regulated to maintain a delicate balance of exon 10-containing and exon 10-skipping isoforms. Splicing mutations affecting tau exon 10 alternative splicing lead to tauopathies, a group of neurodegenerative disorders including dementia. Molecular mechanisms regulating tau alternative splicing remain to be elucidated. In this study, we have developed an expression cloning strategy to identify splicing factors that stimulate tau exon 10 inclusion. Using this expression cloning approach, we have identified a previously unknown tau exon 10 splicing regulator, RBM4 (RNA binding motif protein 4). In cells transfected with a tau minigene, RBM4 overexpression leads to an increased inclusion of exon 10, whereas RBM4 down-regulation decreases exon 10 inclusion. The activity of RBM4 in stimulating tau exon 10 inclusion is abolished by mutations in its RNA- binding domain. A putative intronic splicing enhancer located in intron 10 of the tau gene is required for the splicing stimulatory activity of RBM4. Immunohistological analyses reveal that RBM4 is expressed in the human brain regions affected in tauopathy, including the hippocampus and frontal cortex. Our study demonstrates that RBM4 is involved in tau exon 10 alternative splicing. Our work also suggests that down-regulating tau exon 10 splicing activators, such as RBM4, may be of therapeutic potential in tauopathies involving excessive tau exon 10 inclusion.	Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Dept Neurol,Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; St Louis Univ, Dept Pathol, St Louis, MO 63103 USA; Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Saint Louis University; Academia Sinica - Taiwan	Wu, JY (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Dept Neurol,Lurie Comprehens Canc Ctr, 303 e Super St,Lurie 6-117, Chicago, IL 60611 USA.	jane-wu@northwestern.edu	Tarn, Woan-Yuh/N-8464-2018	Kar, Amar/0000-0003-2380-7504	NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017518] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197, R01 CA114197-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03, EY014576] Funding Source: Medline; NIA NIH HHS [AG17518, R01 AG017518] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, GM070967, R01 GM070967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Andreadis A, 2005, BBA-MOL BASIS DIS, V1739, P91, DOI 10.1016/j.bbadis.2004.08.010; Bernert G, 2002, PROTEOMICS, V2, P1752, DOI 10.1002/1615-9861(200212)2:12<1752::AID-PROT1752>3.0.CO;2-Y; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Bunker JM, 2004, MOL BIOL CELL, V15, P2720, DOI 10.1091/mbc.E04-01-0062; Cairns NJ, 2004, J PATHOL, V204, P438, DOI 10.1002/path.1650; COUCHIE D, 1986, J NEUROCHEM, V47, P1255; D'Souza I, 2006, J BIOL CHEM, V281, P2460, DOI 10.1074/jbc.M505809200; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; Diederichs S, 2004, J BIOL CHEM, V279, P33727, DOI 10.1074/jbc.M401708200; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Gromak N, 2003, EMBO J, V22, P6356, DOI 10.1093/emboj/cdg609; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KAR A, 2005, ALZ DIS ASSOC DIS S1, V19, P29; Lai MC, 2003, EMBO J, V22, P1359, DOI 10.1093/emboj/cdg126; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lin JC, 2005, MOL CELL BIOL, V25, P10111, DOI 10.1128/MCB.25.22.10111-10121.2005; Makrides V, 2003, J BIOL CHEM, V278, P33298, DOI 10.1074/jbc.M305207200; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Spillantini MG, 2001, ADV EXP MED BIOL, V487, P21; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Varani L, 2000, NUCLEIC ACIDS RES, V28, P710, DOI 10.1093/nar/28.3.710; Wang JN, 2004, J NEUROCHEM, V88, P1078, DOI 10.1046/j.1471-4159.2003.02232.x; WU JY, 2004, ALTERNATIVELY SPLICE, P125	39	41	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24479	24488		10.1074/jbc.M603971200	http://dx.doi.org/10.1074/jbc.M603971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16777844	Green Accepted, hybrid			2022-12-25	WOS:000239847800043
J	Martinez-Fleites, C; Guerreiro, CIPD; Baumann, MJ; Taylor, EJ; Prates, JAM; Ferreira, LMA; Fontes, CMGA; Brumer, H; Davies, GJ				Martinez-Fleites, Carlos; Guerreiro, Catarina I. P. D.; Baumann, Martin J.; Taylor, Edward J.; Prates, Jose A. M.; Ferreira, Luis M. A.; Fontes, Carlos M. G. A.; Brumer, Harry; Davies, Gideon J.			Crystal structures of Clostridium thermocellum xyloglucanase, XGH74A, reveal the structural basis for xyloglucan recognition and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOSE SURFACES; EXPRESSION; CLONING; CLASSIFICATION; BIOSYNTHESIS; PURIFICATION; NOMENCLATURE; MOLSCRIPT; ALIGNMENT; TOOLS	The enzymatic degradation of the plant cell wall is central both to the natural carbon cycle and, increasingly, to environmentally friendly routes to biomass conversion, including the production of biofuels. The plant cell wall is a complex composite of cellulose microfibrils embedded in diverse polysaccharides collectively termed hemicelluloses. Xyloglucan is one such polysaccharide whose hydrolysis is catalyzed by diverse xyloglucanases. Here we present the structure of the Clostridium thermocellum xyloglucanase Xgh74A in both apo and ligand-complexed forms. The structures, in combination with mutagenesis data on the catalytic residues and the kinetics and specificity of xyloglucan hydrolysis reveal a complex subsite specificity accommodating seventeen monosaccharide moieties of the multibranched substrate in an open substrate binding terrain.	Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Tecn Lisboa, CIISA, Fac Vet Med, P-1300477 Lisbon, Portugal; Royal Inst Technol, AlbaNova Univ Ctr, Sch Biotechnol, S-10691 Stockholm, Sweden	University of York - UK; Universidade de Lisboa; Royal Institute of Technology	Davies, GJ (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Prates, José A M/K-9934-2013; Davies, Gideon J/A-9042-2011; Martinez Fleites, Carlos/F-8526-2010	Prates, José A M/0000-0003-1032-5987; Davies, Gideon J/0000-0002-7343-776X; Ferreira, Luis/0000-0002-3543-9166; Taylor, Edward/0000-0003-4024-0976; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BB/D522511/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		[Anonymous], 2003, Current Trends in Polymer Science, V8, P27; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer S, 2005, CARBOHYD RES, V340, P2590, DOI 10.1016/j.carres.2005.09.014; BAYER EA, 1985, J BACTERIOL, V163, P552, DOI 10.1128/JB.163.2.552-559.1985; Bayer EA, 1998, J STRUCT BIOL, V124, P221, DOI 10.1006/jsbi.1998.4065; Brumer H, 2004, J AM CHEM SOC, V126, P5715, DOI 10.1021/ja0316770; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Chhabra SR, 2002, FEBS LETT, V531, P375, DOI 10.1016/S0014-5793(02)03493-2; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Demain AL, 2005, MICROBIOL MOL BIOL R, V69, P124, DOI 10.1128/MMBR.69.1.124-154.2005; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Irwin DC, 2003, EUR J BIOCHEM, V270, P3083, DOI 10.1046/j.1432-1033.2003.03695.x; KATO Y, 1985, J BIOCHEM, V97, P801, DOI 10.1093/oxfordjournals.jbchem.a135120; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Milkowski K, 2004, GREEN CHEM, V6, P189, DOI 10.1039/b316322a; Miyazaki S, 1998, J CONTROL RELEASE, V56, P75, DOI 10.1016/S0168-3659(98)00079-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nelson N, 1944, J BIOL CHEM, V153, P375; Reiter WD, 2002, CURR OPIN PLANT BIOL, V5, P536, DOI 10.1016/S1369-5266(02)00306-0; Scheible WR, 2004, CURR OPIN PLANT BIOL, V7, P285, DOI 10.1016/j.pbi.2004.03.006; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Thompson DS, 2005, J EXP BOT, V56, P2275, DOI 10.1093/jxb/eri247; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; VINCKEN JP, 1995, PLANT PHYSIOL, V108, P1579, DOI 10.1104/pp.108.4.1579; Yaoi K, 2005, APPL ENVIRON MICROB, V71, P7670, DOI 10.1128/AEM.71.12.7670-7678.2005; Yaoi K, 2004, STRUCTURE, V12, P1209, DOI 10.1016/j.str.2004.04.020; Yaoi K, 2004, FEBS LETT, V560, P45, DOI 10.1016/S0014-5793(04)00068-7; Yaoi K, 2002, J BIOL CHEM, V277, P48276, DOI 10.1074/jbc.M208443200; Yokoyama R, 2004, PLANT PHYSIOL, V134, P1088, DOI 10.1104/pp.103.035261; Zhou Q, 2005, MACROMOLECULES, V38, P3547, DOI 10.1021/ma047712k; Zhou Q, 2006, BIOCATAL BIOTRANSFOR, V24, P107, DOI 10.1080/10242420500538217; Zverlov VV, 2005, PROTEOMICS, V5, P3646, DOI 10.1002/pmic.200401199; Zverlov VV, 2005, MICROBIOL-SGM, V151, P3395, DOI 10.1099/mic.0.28206-0	44	75	76	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24922	24933		10.1074/jbc.M603583200	http://dx.doi.org/10.1074/jbc.M603583200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16772298	hybrid			2022-12-25	WOS:000239847800085
J	McMahon, S; Charbonneau, M; Grandmont, S; Richard, DE; Dubois, CM				McMahon, Stephanie; Charbonneau, Martine; Grandmont, Sebastien; Richard, Darren E.; Dubois, Claire M.			Transforming growth factor beta 1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; REGULATES GENE-EXPRESSION; SMOOTH-MUSCLE-CELLS; HUMAN BREAST-CANCER; TGF-BETA; FACTOR 1-ALPHA; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNALING PATHWAY; CARCINOMA-CELLS; E-CADHERIN	The hypoxia-inducible transcription factor-1 ( HIF-1) is central to a number of pathological processes through the induction of specific genes such as vascular endothelial growth factor ( VEGF). Even though HIF-1 is highly regulated by cellular oxygen levels, other elements of the inflammatory and tumor microenvironment were shown to influence its activity under normal oxygen concentration. Among others, recent studies indicated that transforming growth factor ( TGF) beta increases the expression of the regulatory HIF-1 alpha subunit, and induces HIF-1 DNA binding activity. Here, we demonstrate that TGF beta acts on HIF-1 alpha accumulation and activity by increasing HIF-1 alpha protein stability. In particular, we demonstrate that TGF beta markedly and specifically decreases both mRNA and protein levels of a HIF-1 alpha-associated prolyl hydroxylase ( PHD), PHD2, through the Smad signaling pathway. As a consequence, the degradation of HIF-1 alpha was inhibited as determined by impaired degradation of a reporter protein containing the HIF-1 alpha oxygen-dependent degradation domain encompassing the PHD-targeted prolines. Moreover, inhibition of the TGF beta 1 converting enzyme, furin, resulted in increased PHD2 expression, and decreased basal HIF-1 alpha and VEGF levels, suggesting that endogenous production of bioactive TGF beta 1 efficiently regulates HIF-1-targeted genes. This was reinforced by results from HIF-1 alpha knock-out or HIF-1 alpha-inhibited cells that show impairment in VEGF production in response to TGF beta. This study reveals a novel mechanism by which a growth factor controls HIF-1 stability, and thereby drives the expression of specific genes, through the regulation of PHD2 levels.	Univ Sherbrooke, Fac Med, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada; Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada	University of Sherbrooke	Dubois, CM (corresponding author), 3001,12th N Ave, Sherbrooke, PQ J1H 5N4, Canada.	Claire.M.Dubois@USherbrooke.ca	Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Benckert C, 2003, CANCER RES, V63, P1083; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blancher C, 2000, CANCER RES, V60, P7106; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427; Breier G, 2002, INT J CANCER, V97, P142, DOI 10.1002/ijc.1599; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Chiu C, 2001, INT J MOL MED, V8, P251; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chua CC, 2000, BBA-MOL CELL RES, V1497, P69, DOI 10.1016/S0167-4889(00)00040-9; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; Donovan D, 1997, ANN SURG ONCOL, V4, P621, DOI 10.1007/BF02303745; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuchi M, 2004, CLIN CANCER RES, V10, P2738, DOI 10.1158/1078-0432.CCR-1096-03; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Herrera B, 2004, FREE RADICAL BIO MED, V36, P16, DOI 10.1016/j.freeradbiomed.2003.09.020; Hu B, 2006, ONCOGENE, V25, P1030, DOI 10.1038/sj.onc.1209140; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janssen HLK, 2002, INT J RADIAT ONCOL, V54, P1537, DOI 10.1016/S0360-3016(02)03935-4; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kim ES, 2004, INT J ONCOL, V25, P1375; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Laprise MH, 2002, BLOOD, V100, P3578, DOI 10.1182/blood.V100.10.3578; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McMahon S, 2005, J BIOL CHEM, V280, P6561, DOI 10.1074/jbc.M413248200; McMahon S, 2003, EXP CELL RES, V291, P326, DOI 10.1016/S0014-4827(03)00407-5; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 2000, J BIOL CHEM, V275, P26765; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Shimizu S, 1996, CANCER RES, V56, P3366; Siegfried G, 2003, CANCER RES, V63, P1458; Stoeltzing O, 2004, JNCI-J NATL CANCER I, V96, P946, DOI 10.1093/jnci/djh168; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tacchini L, 2004, CARCINOGENESIS, V25, P2089, DOI 10.1093/carcin/bgh227; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Vukovic V, 2001, CANCER RES, V61, P7394; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	87	249	266	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24171	24181		10.1074/jbc.M604507200	http://dx.doi.org/10.1074/jbc.M604507200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16815840	hybrid			2022-12-25	WOS:000239847800011
J	He, XQ; Chen, MG; Lin, GX; Ma, Q				He, Xiaoqing; Chen, Michael G.; Lin, Gary X.; Ma, Qiang			Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 center dot Keap1 center dot CuI3 complex and recruiting Nrf2 center dot Maf to the antioxidant response element enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ARYL-HYDROCARBON RECEPTOR; SUBSTRATE ADAPTER PROTEIN; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; QUINONE REDUCTASE; ENZYME INDUCERS; GENE-EXPRESSION; KEAP1; INDUCTION	The ubiquitous toxic metalloid arsenic elicits pleiotropic adverse and adaptive responses in mammalian species. The biological targets of arsenic are largely unknown at present. We analyzed the signaling pathway for induction of detoxification gene NAD(P)H-quinone oxidoreductase (Nqo1) by arsenic. Genetic and biochemical evidence revealed that induction required cap 'n' collar basic leucine zipper transcription factor Nrf2 and the antioxidant response element (ARE) of Nqo1. Arsenic stabilized Nrf2 protein, extending the t(1/2) of Nrf2 from 21 to 200 min by inhibiting the Keap1(.)Cul3-dependent ubiquitination and proteasomal turnover of Nrf2. Arsenic markedly inhibited the ubiquitination of Nrf2 but did not disrupt the Nrf2(.)Keap1(.)Cul3 association in the cytoplasm. In the nucleus, arsenic, but not phenolic antioxidant tert-butylhydroquinone, dissociated Nrf2 from Keap1 and Cul3 followed by dimerization of Nrf2 with a Maf protein (Maf G/Maf K). Chromatin immunoprecipitation demonstrated that Nrf2 and Maf associated with the endogenous Nqo1 ARE enhancer constitutively. Arsenic substantially increased the ARE occupancy by Nrf2 and Maf. In addition, Keap1 was shown to be ubiquitinated in the cytoplasm and deubiquitinated in the nucleus in the presence of arsenic without changing the protein level, implicating nuclear-cytoplasmic recycling of Keap1. Our data reveal that arsenic activates the Nrf2/Keap1 signaling pathway through a distinct mechanism from that by antioxidants and suggest an "onswitch" model of Nqo1 transcription in which the binding of Nrf2(.)Maf to ARE controls both the basal and inducible expression of Nqo1.	NIOSH, Ctr Dis Control & Prevent, HELD, TMBB,Receptor Biol Lab, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Ma, Q (corresponding author), NIOSH, CDC, HELD, TMBB,Receptor Biol Lab, Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	qam1@cdc.gov	ma, qiang/HCI-1013-2022					Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chappell WR, 1997, ENVIRON HEALTH PERSP, V105, P1060, DOI 10.1289/ehp.971051060; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Duker AA, 2005, ENVIRON INT, V31, P631, DOI 10.1016/j.envint.2004.10.020; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Evens AM, 2004, LEUKEMIA RES, V28, P891, DOI 10.1016/j.leukres.2004.01.011; FARBER EM, 1992, J AM ACAD DERMATOL, V27, P640, DOI 10.1016/0190-9622(92)70232-5; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Golub MS, 1998, J TOXICOL ENV HEAL B, V1, P199, DOI 10.1080/10937409809524552; Gomez-Caminero A. P., 2001, ENV HLTH CRITERIA, V224; Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; LEONARD A, 1980, MUTAT RES, V75, P49, DOI 10.1016/0165-1110(80)90027-5; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Mastin JP, 2005, CARDIOVASC TOXICOL, V5, P91, DOI 10.1385/CT:5:2:091; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Pi JB, 2003, EXP CELL RES, V290, P234, DOI 10.1016/S0014-4827(03)00341-0; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; Tabacova S, 1996, TOXICOL APPL PHARM, V138, P298, DOI 10.1006/taap.1996.0128; TAYLOR PR, 1989, BRIT J IND MED, V46, P881; Tseng CH, 2005, J ENVIRON SCI HEAL C, V23, P55, DOI 10.1081/GNC-200051860; Wood TC, 2006, J BIOL CHEM, V281, P7364, DOI 10.1074/jbc.M512227200; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	41	131	138	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23620	23631		10.1074/jbc.M604120200	http://dx.doi.org/10.1074/jbc.M604120200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785233	hybrid			2022-12-25	WOS:000239702900037
J	Lee, JW; Helmann, JD				Lee, Jin-Won; Helmann, John D.			Biochemical characterization of the structural Zn2+ site in the Bacillus subtilis peroxide sensor PerR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATOR; MASS-SPECTROMETRY ANALYSIS; ANTI-SIGMA FACTOR; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; FUR PROTEIN; METAL-IONS; STREPTOMYCES-COELICOLOR; CRYSTAL-STRUCTURE; ZINC RELEASE	In Bacillus subtilis most peroxide-inducible oxidative stress genes are regulated by a metal-dependent repressor, PerR. PerR is a dimeric, Zn2+-containing metalloprotein with a regulatory metal-binding site that binds Fe2+ (PerR:Zn,Fe) or Mn2+ (PerR:Zn,Mn). Reaction of PerR:Zn,Fe with low levels of hydrogen peroxide (H2O2) leads to oxidation of two His residues thereby leading to derepression. When bound to Mn2+, the resulting PerR: Zn, Mn is much less sensitive to oxidative inactivation. Here we demonstrate that the structural Zn2+ is coordinated in a highly stable, intrasubunit Cys(4):Zn2+ site. Oxidation of this Cys(4):Zn2+ site by H2O2 leads to the formation of intrasubunit disulfide bonds. The rate of oxidation is too slow to account for induction of the peroxide stress response by micromolar levels of H2O2 but could contribute to induction under severe oxidative stress conditions. In vivo studies demonstrated that inactivation of PerR:Zn,Mn required 10 mM H2O2, a level at least 1000 times greater than that needed for inactivation of PerR:Zn,Fe. Surprisingly even under these severe oxidation conditions there was little if any detectable oxidation of cysteine residues in vivo: derepression was correlated with oxidation of the regulatory site. Because oxidation at this site required bound Fe2+ in vitro, we suggest that treatment of cells with 10 mM H2O2 released sufficient Fe2+ into the cytosol to effect a transition of PerR from the PerR:Zn,Mn form to the peroxide-sensitive PerR:Zn,Fe form. This model is supported by metal ion affinity measurements demonstrating that PerR bound Fe2+ with higher affinity than Mn2+.	Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA	Cornell University	Helmann, JD (corresponding author), Cornell Univ, Dept Microbiol, 370 Wing Hall, Ithaca, NY 14853 USA.	jdh9@cornell.edu	LEE, JIN-WON/L-1116-2016	LEE, JIN-WON/0000-0002-1201-8254; Helmann, John/0000-0002-3832-3249				Bae JB, 2004, J MOL BIOL, V335, P425, DOI 10.1016/j.jmb.2003.10.065; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; Bsat N, 1999, J BACTERIOL, V181, P4299, DOI 10.1128/JB.181.14.4299-4307.1999; CHEN L, 1995, P NATL ACAD SCI USA, V92, P8190, DOI 10.1073/pnas.92.18.8190; CHEN L, 1993, J BACTERIOL, V175, P5428, DOI 10.1128/JB.175.17.5428-5437.1993; COY M, 1994, BIOMETALS, V7, P292; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; Friedman YE, 2004, J BIOL CHEM, V279, P32100, DOI 10.1074/jbc.M404924200; Fuangthong M, 2003, J BACTERIOL, V185, P6348, DOI 10.1128/JB.185.21.6348-6357.2003; Fuangthong M, 2002, J BACTERIOL, V184, P3276, DOI 10.1128/JB.184.12.3276-3286.2002; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Green J, 2004, NAT REV MICROBIOL, V2, P954, DOI 10.1038/nrmicro1022; Hahn JS, 2000, J BIOL CHEM, V275, P38254, DOI 10.1074/jbc.M006079200; Harvie DR, 2005, CURR MICROBIOL, V50, P246, DOI 10.1007/s00284-004-4442-0; Helmann JD, 2003, J BACTERIOL, V185, P243, DOI 10.1128/JB.185.1.243-253.2003; Herbig AF, 2001, MOL MICROBIOL, V41, P849, DOI 10.1046/j.1365-2958.2001.02543.x; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Imlay JA, 2006, MOL MICROBIOL, V59, P1073, DOI 10.1111/j.1365-2958.2006.05028.x; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Janda I, 2004, STRUCTURE, V12, P1901, DOI 10.1016/j.str.2004.08.003; Kaltwasser M, 2002, APPL ENVIRON MICROB, V68, P2624, DOI 10.1128/AEM.68.5.2624-2628.2002; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; Kliegman JI, 2006, BIOCHEMISTRY-US, V45, P3493, DOI 10.1021/bi0524215; Lee JW, 2006, NATURE, V440, P363, DOI 10.1038/nature04537; Lucana DOD, 2000, MOL GEN GENET, V264, P341; MichaudSoret I, 1997, FEBS LETT, V413, P473, DOI 10.1016/S0014-5793(97)00963-0; Moore CM, 2004, J BACTERIOL, V186, P4655, DOI 10.1128/JB.186.14.4655-4664.2004; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538; PECQUEUR L, 2006, J BIOL CHEM; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sen KI, 2006, BIOCHEMISTRY-US, V45, P4295, DOI 10.1021/bi052288g; Stone JR, 2004, ARCH BIOCHEM BIOPHYS, V422, P119, DOI 10.1016/j.abb.2003.12.029; Winter J, 2005, MOL CELL, V17, P381, DOI 10.1016/j.molcel.2004.12.027; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Woodmansee AN, 2002, METHOD ENZYMOL, V349, P3, DOI 10.1016/S0076-6879(02)49316-0	42	102	105	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23567	23578		10.1074/jbc.M603968200	http://dx.doi.org/10.1074/jbc.M603968200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766519	hybrid			2022-12-25	WOS:000239702900031
J	Perez-Victoria, FJ; Sanchez-Canete, MP; Castanys, S; Gamarro, F				Perez-Victoria, F. Javier; Sanchez-Canete, Maria P.; Castanys, Santiago; Gamarro, Francisco			Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PLASMA-MEMBRANE; PUTATIVE AMINOPHOSPHOLIPID TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; VISCERAL LEISHMANIASIS; POLARIZED GROWTH; BETA-SUBUNITS; ATPASE; GENE; IDENTIFICATION; EXPRESSION	The antitumor drug miltefosine has been recently approved as the first oral drug active against visceral leishmaniasis. We have previously identified the L. donovani miltefosine transporter (LdMT) as a P-type ATPase involved in phospholipid translocation at the plasma membrane of Leishmania parasites. Here we show that this protein is essential but not sufficient for the phospholipid translocation activity and, thus, for the potency of the drug. Based on recent findings in yeast, we have identified the putative beta subunit of LdMT, named LdRos3, as another protein factor required for the translocation activity. LdRos3 belongs to the CDC50/Lem3 family, proposed as likely beta subunits for P-4-ATPases. The phenotype of LdRos3-defective parasites was identical to that of the LdMT-/-, including a defect in the uptake of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-amino)phosphatidylserine, generally considered as not affected in Lem3p-deficient yeast. Both LdMT and LdRos3 normally localized to the plasma membrane but were retained inside the endoplasmic reticulum in the absence of the other protein or when inactivating point mutations were introduced in LdMT. Modulating the expression levels of either protein independently, we show that any one of them could behave as the protein limiting the level of flippase activity. Thus, LdMT and LdRos3 seem to form part of the same translocation machinery that determines flippase activity and miltefosine sensitivity in Leishmania, further supporting the consideration of CDC50/Lem3 proteins as beta subunits required for the normal functioning of P-4-ATPases.	CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18100, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Gamarro, F (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Avda Conocimiento S-N, Granada 18100, Spain.	gamarro@ipb.csic.es	Castanys, Santiago/Y-3981-2019	Castanys, Santiago/0000-0002-3460-844X; Sanchez-Canete, Maria P./0000-0002-9418-8942; Gamarro, Francisco/0000-0003-1347-3440				Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BANGS JD, 1993, J CELL SCI, V105, P1101; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Ding JT, 2000, J BIOL CHEM, V275, P23378, DOI 10.1074/jbc.M910319199; DWYER DM, 1983, J CELL BIOCHEM, V23, P35, DOI 10.1002/jcb.240230105; Ganguly N., 2002, TDR NEWS, V68, P2; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Graham TR, 2004, TRENDS CELL BIOL, V14, P670, DOI 10.1016/j.tcb.2004.10.008; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; Katoh Y, 2004, ONCOL REP, V12, P939; Meguro M, 2001, NAT GENET, V28, P19, DOI 10.1038/ng0501-19; Misu K, 2003, MOL BIOL CELL, V14, P730, DOI 10.1091/mbc.E02-06-0314; Noguchi S, 2003, J CELL SCI, V116, P1875, DOI 10.1242/jcs.00392; Perez-Victoria FJ, 2003, J BIOL CHEM, V278, P49965, DOI 10.1074/jbc.M308352200; Perez-Victoria FJ, 2003, ANTIMICROB AGENTS CH, V47, P2397, DOI 10.1128/AAC.47.8.2397-2403.2003; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Saito K, 2004, MOL BIOL CELL, V15, P3418, DOI 10.1091/mbc.E03-11-0829; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Singh Sarman, 2004, Journal of Infection and Chemotherapy, V10, P307, DOI 10.1007/s10156-004-0348-9; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Sundar S, 2003, J Postgrad Med, V49, P29; Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Wang QQ, 2002, P NATL ACAD SCI USA, V99, P12853, DOI 10.1073/pnas.202115499; WHO, 2001, WORLD HLTH REPORT 20	33	119	120	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23766	23775		10.1074/jbc.M605214200	http://dx.doi.org/10.1074/jbc.M605214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785229	hybrid			2022-12-25	WOS:000239702900052
J	Stiehl, DP; Wirthner, R; Koditz, J; Spielmann, P; Camenisch, G; Wenger, RH				Stiehl, Daniel P.; Wirthner, Renato; Koeditz, Jens; Spielmann, Patrick; Camenisch, Gieri; Wenger, Roland H.			Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels - Evidence for an autoregulatory oxygen-sensing system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; MESSENGER-RNA EXPRESSION; TRANSCRIPTIONAL ACTIVITY; DEPENDENT DEGRADATION; HYDROXYLASE-ACTIVITY; HYPOXIA; HIF; GENE; FACTOR-1-ALPHA; HIF-1-ALPHA	Prolyl 4-hydroxylase domain (PHD) proteins are oxygen-dependent enzymes that hydroxylate hypoxia-inducible transcription factor (HIF) alpha-subunits, leading to their subsequent ubiquitination and degradation. Paradoxically, the expression of two family members (PHD2 and PHD3) is induced in hypoxic cell culture despite the reduced availability of the oxygen co-substrate, and it has been suggested that they become functionally relevant following re-oxygenation to rapidly terminate the HIF response. Here we show that PHDs are also induced in hypoxic mice in vivo, albeit in a tissue-specific manner. As demonstrated under chronically hypoxic conditions in vitro, PHD2 and PHD3 show a transient maximum but remain upregulated over more than 10 days, suggesting a feedback down-regulation of HIF-1 alpha which then levels off at a novel set point. Indeed, hypoxic induction of PHD2 and PHD3 is paralleled by the attenuation of endogenous HIF-1 alpha. Using an engineered oxygen-sensitive reporter gene in a cellular background lacking endogenous HIF-1 alpha and hence inducible PHD expression, we could show that increased exogenous PHD levels can compensate for a wide range of hypoxic conditions. Similar data were obtained in a reconstituted cell-free system in vitro. In summary, these results suggest that due to their high O-2 K-m values, PHDs have optimal oxygen-sensing properties under all physiologically relevant oxygen concentrations; increased PHDs play a functional role even under oxygen-deprived conditions, allowing the HIF system to adapt to a novel oxygen threshold and to respond to another hypoxic insult. Furthermore, such an autoregulatory oxygen-sensing system would explain how a single mechanism works in a wide variety of differently oxygenated tissues.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; Univ Gottingen, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Gottingen	Stiehl, DP (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	daniel.stiehl@access.unizh.ch	Stiehl, Daniel/A-3622-2008; Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Stiehl, Daniel/0000-0002-0076-4874; Spielmann, Patrick/0000-0001-7056-0351				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chilov D, 1999, J CELL SCI, V112, P1203; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Karhausen J, 2005, J CELL BIOCHEM, V95, P1264, DOI 10.1002/jcb.20489; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martin F, 2005, BLOOD, V105, P4613, DOI 10.1182/blood-2004-10-3980; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Masson N, 2004, FEBS LETT, V570, P166, DOI 10.1016/j.febslet.2004.06.040; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Oehme F, 2004, ANAL BIOCHEM, V330, P74, DOI 10.1016/j.ab.2004.03.066; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Safran M, 2006, P NATL ACAD SCI USA, V103, P105, DOI 10.1073/pnas.0509459103; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, INT J MOL MED, V2, P317; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WENGER RH, 1999, ENV STRESS GENE REGU, P25; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; WOLFF M, 1993, AM J PHYSIOL, V265, pC1266, DOI 10.1152/ajpcell.1993.265.5.C1266	43	226	233	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23482	23491		10.1074/jbc.M601719200	http://dx.doi.org/10.1074/jbc.M601719200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790428	hybrid, Green Published			2022-12-25	WOS:000239702900023
J	Umlauf, E; Mairhofer, M; Prohaska, R				Umlauf, Ellen; Mairhofer, Mario; Prohaska, Rainer			Characterization of the stomatin domain involved in homo-oligomerization and lipid raft association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; C-TERMINAL DOMAIN; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CELL-MEMBRANES; LIVING CELLS; SPFH DOMAIN; BAND 7.2B; IN-VIVO; PHOSPHORYLATION	The cytoplasmically oriented monotopic integral membrane protein stomatin forms high-order oligomers and associates with lipid rafts. To characterize the domains that are involved in oligomerization and detergent-resistant membrane (DRM) association, we expressed truncation and point mutants of stomatin and analyzed their size and buoyancy by ultracentrifugation methods. A small C-terminal region of stomatin that is largely hydrophobic, Ser-Thr-Ile-Val-Phe-Pro-Leu-Pro-Ile (residues 264-272), proved to be crucial for oligomerization, whereas the N-terminal domain (residues 1-20) and the last 12 C-terminal amino acids (residues 276 287) were not essential. The introduction of alanine substitutions in the region 264-272 resulted in the appearance of monomers. Remarkably, only three of these residues, Ile-Val-Phe (residues 266-268), were found to be indispensable for the DRM association. Interestingly, the exchange of Pro-269 and to some extent the residues 270-272, which are essential for oligomerization, did not affect the DRM association of stomatin. This suggests that the formation of oligomers is not necessary for the association of stomatin with DRMs. Internal deletions near the membrane anchoring domain resulted in the formation of intermediate size oligomers suggesting a conformational interdependence of large parts of the C-terminal region. Fluorescence recovery after photobleaching analysis of the tagged, monomeric, non-DRM mutant ST-(1-262)-green fluorescent protein and wild type stomatin Stom GFP showed a significantly higher lateral mobility of the truncation mutant in the plasma membrane suggesting a membrane interaction of the respective C-terminal region also in vivo.	Med Univ Vienna, Dept Biochem Med, Max F Perutz Labs, Vienna Bioctr, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Prohaska, R (corresponding author), Med Univ Vienna, Dept Biochem Med, Max F Perutz Labs, Vienna Bioctr, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.	rainer.prohaska@meduniwien.ac.at		Mairhofer, Mario/0000-0002-7218-6284				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Back JW, 2002, PROTEIN SCI, V11, P2471, DOI 10.1110/ps.0212602; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; Falk J, 2004, MOL BIOL CELL, V15, P4695, DOI 10.1091/mbc.E04-03-0171; Fernandez I, 2002, P NATL ACAD SCI USA, V99, P11193, DOI 10.1073/pnas.172196599; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; GALLAGHER PG, 1995, J BIOL CHEM, V270, P26358, DOI 10.1074/jbc.270.44.26358; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Goodwin JS, 2005, METHODS, V37, P154, DOI 10.1016/j.ymeth.2005.05.013; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1065, P195, DOI 10.1016/0005-2736(91)90230-6; HIEBLDIRSCHMIED CM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P123, DOI 10.1016/0167-4781(91)90047-P; Huber TB, 2003, HUM MOL GENET, V12, P3397, DOI 10.1093/hmg/ddg360; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Khan TK, 2003, BIOCHEMISTRY-US, V42, P4780, DOI 10.1021/bi0265877; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Lee H, 2002, J BIOL CHEM, V277, P34556, DOI 10.1074/jbc.M204367200; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Morrow IC, 2005, TRAFFIC, V6, P725, DOI 10.1111/j.1600-0854.2005.00318.x; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Rivera-Milla E, 2006, CELL MOL LIFE SCI, V63, P343, DOI 10.1007/s00018-005-5434-3; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Snyers L, 1997, EUR J CELL BIOL, V73, P281; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; Snyers L, 1999, EUR J CELL BIOL, V78, P802, DOI 10.1016/S0171-9335(99)80031-4; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; Suchanek M, 2005, NAT METHODS, V2, P261, DOI 10.1038/NMETH752; Suzuki K, 2001, BIOPHYS J, V81, P2181, DOI 10.1016/S0006-3495(01)75866-3; Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.e04-09-0807; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Unfried I, 1995, GENOMICS, V30, P521, DOI 10.1006/geno.1995.1273; Wang XB, 2004, BIOCHEMISTRY-US, V43, P13694, DOI 10.1021/bi049295+	54	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23349	23356		10.1074/jbc.M513720200	http://dx.doi.org/10.1074/jbc.M513720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16766530	hybrid			2022-12-25	WOS:000239702900009
J	Beloqui, A; Pita, M; Polaina, J; Martinez-Arias, A; Golyshina, OV; Zumarraga, M; Yakimov, MM; Garcia-Arellano, H; Alcalde, M; Fernandez, VM; Elborough, K; Andreu, JM; Ballesteros, A; Plou, FJ; Timmis, KN; Ferrer, M; Golyshin, PN				Beloqui, Ana; Pita, Marcos; Polaina, Julio; Martinez-Arias, Arturo; Golyshina, Olga V.; Zumarraga, Miren; Yakimov, Michail M.; Garcia-Arellano, Humberto; Alcalde, Miguel; Fernandez, Victor M.; Elborough, Kieran; Andreu, Jose M.; Ballesteros, Antonio; Plou, Francisco J.; Timmis, Kenneth N.; Ferrer, Manuel; Golyshin, Peter N.			Novel polyphenol oxidase mined from a metagenome expression library of bovine rumen - Biochemical properties, structural analysis, and phylogenetic relationships	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE-ROT FUNGI; CRYSTAL-STRUCTURE; TRAMETES-VERSICOLOR; LACCASE; LIGNIN; PURIFICATION; DEGRADATION; OXIDATION; DECOLORIZATION; RECOGNITION	RL5, a gene coding for a novel polyphenol oxidase, was identified through activity screening of a metagenome expression library from bovine rumen microflora. Characterization of the recombinant protein produced in Escherichia coli revealed a multipotent capacity to oxidize a wide range of substrates (syringaldazine > 2,6-dimethoxyphenol > veratryl alcohol > guaiacol > tetramethylbenzidine > 4-methoxybenzyl alcohol > 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) >> phenol red) over an unusually broad range of pH from 3.5 to 9.0. Apparent K-m and k(cat) values for ABTS, syringaldazine, and 2,6-dimetoxyphenol obtained from steady-state kinetic measurements performed at 40 degrees C, pH 4.5, yielded values of 26, 0.43, and 0.45 mu M and 18, 660, and 1175 s(-1), respectively. The K-m values for syringaldazine and 2,6-dimetoxyphenol are up to 5 times lower, and the kcat values up to 40 times higher, than values previously reported for this class of enzyme. RL5 is a 4-copper oxidase with oxidation potential values of 745, 400, and 500 mV versus normal hydrogen electrode for the T1, T2, and T3 copper sites. A three-dimensional model of RL5 and site-directed mutants were generated to identify the copper ligands. Bioinformatic analysis of the gene sequence and the sequences and contexts of neighboring genes suggested a tentative phylogenetic assignment to the genus Bacteroides. Kinetic, electrochemical, and EPR analyses provide unequivocal evidence that the hypothetical proteins from Bacteroides thetaiotaomicron and from E. coli, which are closely related to the deduced protein encoded by the RL5 gene, are also multicopper proteins with polyphenol oxidase activity. The present study shows that these three newly characterized enzymes form a new family of functional multicopper oxidases with laccase activity related to conserved hypothetical proteins harboring the domain of unknown function DUF152 and suggests that some other of these proteins may also be laccases.	CSIC, Inst Catalysis, E-28049 Madrid, Spain; CNR, Inst Ambiente Marino Costiero, I-98100 Messina, Italy; CSIC, Inst Agroquim & Tecnol Alimentos, Valencia 46980, Spain; ViaLactia Biosci Ltd, Auckland 1031, New Zealand; GBF German Res Ctr Biotechnol, Div Microbiol, D-38124 Braunschweig, Germany; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain; Tech Univ Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP); Consiglio Nazionale delle Ricerche (CNR); L'Istituto per l'Ambiente Marino Costiero (IAMC-CNR); Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Helmholtz Association; Helmholtz-Center for Infection Research; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Braunschweig University of Technology	Ferrer, M (corresponding author), CSIC, Inst Catalysis, Marie Curie 2, E-28049 Madrid, Spain.	mferrer@icp.csic.es	Garcia-Arellano, Humberto/G-7516-2018; Beloqui, Ana/C-4512-2012; Polaina, Julio/H-4498-2012; Pita, Marcos/AAB-9772-2020; Pita, Marcos/F-3547-2015; Ferrer, Manuel/K-4535-2014; Yakimov, Michail/H-1829-2016	Garcia-Arellano, Humberto/0000-0002-7018-7080; Beloqui, Ana/0000-0002-7693-4163; Pita, Marcos/0000-0002-6714-3669; Pita, Marcos/0000-0002-6714-3669; Plou, Francisco J./0000-0003-0831-893X; Andreu, Jose M/0000-0001-8064-6933; Golyshina, Olga/0000-0001-5132-6850; Ferrer, Manuel/0000-0003-4962-4714; Golyshin, Peter/0000-0002-5433-0350; BALLESTEROS, ANTONIO olmo/0000-0002-1967-2056; Yakimov, Michail/0000-0003-1418-363X; Alcalde, Miguel/0000-0001-6780-7616; Polaina, Julio/0000-0001-9912-0640				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antorini M, 2002, BBA-PROTEIN STRUCT M, V1594, P109, DOI 10.1016/S0167-4838(01)00289-8; Arias ME, 2003, APPL ENVIRON MICROB, V69, P1953, DOI 10.1128/AEM.69.4.1953-1958.2003; Bertrand T, 2002, ACTA CRYSTALLOGR D, V58, P319, DOI 10.1107/S0907444901019898; Bertrand T, 2002, BIOCHEMISTRY-US, V41, P7325, DOI 10.1021/bi0201318; Besemer J, 1999, NUCLEIC ACIDS RES, V27, P3911, DOI 10.1093/nar/27.19.3911; BOURBONNAIS R, 1990, FEBS LETT, V267, P99, DOI 10.1016/0014-5793(90)80298-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camarero S, 2005, APPL ENVIRON MICROB, V71, P1775, DOI 10.1128/AEM.71.4.1775-1784.2005; Chefetz B, 1998, APPL ENVIRON MICROB, V64, P3175; Claus H, 2004, MICRON, V35, P93, DOI 10.1016/j.micron.2003.10.029; Claus H, 2003, ARCH MICROBIOL, V179, P145, DOI 10.1007/s00203-002-0510-7; Cowan D, 2005, TRENDS BIOTECHNOL, V23, P321, DOI 10.1016/j.tibtech.2005.04.001; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Duran N, 2002, ENZYME MICROB TECH, V31, P907, DOI 10.1016/S0141-0229(02)00214-4; Eggert C, 1996, FEBS LETT, V391, P144, DOI 10.1016/0014-5793(96)00719-3; Ferrer M, 2005, CURR OPIN BIOTECH, V16, P588, DOI 10.1016/j.copbio.2005.09.001; Ferrer M, 2005, ENVIRON MICROBIOL, V7, P1996, DOI 10.1111/j.1462-2920.2005.00920.x; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakulinen N, 2002, NAT STRUCT BIOL, V9, P601, DOI 10.1038/nsb823; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; KAWAI S, 1988, FEBS LETT, V236, P309, DOI 10.1016/0014-5793(88)80043-7; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Klonowska A, 2002, EUR J BIOCHEM, V269, P6119, DOI 10.1046/j.1432-1033.2002.03324.x; Krause DO, 2003, FEMS MICROBIOL REV, V27, P663, DOI 10.1016/S0168-6445(03)00072-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machczynski MC, 2004, PROTEIN SCI, V13, P2388, DOI 10.1110/ps.04759104; Martins LO, 2002, J BIOL CHEM, V277, P18849, DOI 10.1074/jbc.M200827200; Mayer AM, 2002, PHYTOCHEMISTRY, V60, P551, DOI 10.1016/S0031-9422(02)00171-1; McGuirl MA, 1999, CURR OPIN CHEM BIOL, V3, P138, DOI 10.1016/S1367-5931(99)80025-8; Piontek K, 2002, J BIOL CHEM, V277, P37663, DOI 10.1074/jbc.M204571200; Reyes-Duarte D, 2005, ANGEW CHEM INT EDIT, V44, P7553, DOI 10.1002/anie.200502461; Ruijssenaars HJ, 2004, APPL MICROBIOL BIOT, V65, P177, DOI 10.1007/s00253-004-1571-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARIASLANI FS, 1989, CRIT REV BIOTECHNOL, V9, P171, DOI 10.3109/07388558909036736; Shah V, 2002, CAN J MICROBIOL, V48, P857, DOI 10.1139/W02-090; Shleev S, 2005, BIOCHEM J, V385, P745, DOI 10.1042/BJ20041015; Solano F, 2001, FEMS MICROBIOL LETT, V204, P175, DOI 10.1111/j.1574-6968.2001.tb10882.x; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stolz A, 2001, APPL MICROBIOL BIOT, V56, P69, DOI 10.1007/s002530100686; Valderrama B, 2003, ANTON LEEUW INT J G, V84, P289, DOI 10.1023/A:1026070122451; Wesenberg D, 2003, BIOTECHNOL ADV, V22, P161, DOI 10.1016/j.biotechadv.2003.08.011	43	133	149	3	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22933	22942		10.1074/jbc.M600577200	http://dx.doi.org/10.1074/jbc.M600577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16740638	hybrid, Green Published			2022-12-25	WOS:000239542600055
J	Dance, M; Montagner, A; Yart, A; Masri, B; Audigier, Y; Perret, B; Salles, JP; Raynal, P				Dance, Marie; Montagner, Alexandra; Yart, Armelle; Masri, Bernard; Audigier, Yves; Perret, Bertrand; Salles, Jean-Pierre; Raynal, Patrick			The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-REGULATED KINASE; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPIDERMAL-GROWTH; TYROSINE KINASE; C-MET; EPITHELIAL MORPHOGENESIS; LYSOPHOSPHATIDIC ACID; TUMOR ANGIOGENESIS	Phosphoinositide 3-kinase (PI3K) mediates essential functions of vascular endothelial growth factor (VEGF), including the stimulation of endothelial cell proliferation and migration. Nevertheless, the mechanisms coupling the receptor VEGFR-2 to PI3K remain obscure. We observed that the Grb2-bound adapter Gab1 is tyrosine-phosphorylated and relocated to membrane fractions upon VEGF stimulation of endothelial cells. We could detect the PI3K regulatory subunit p85 in immunoprecipitates of endogenous Gab1, and vice versa, and measure a Gab1-associated lipid kinase activity upon VEGF stimulation. Furthermore, transfection of the Gab1-YF3 mutant lacking all p85-binding sites strongly repressed PI3K activation measured in vitro. Moreover, Gab1-YF3 severely decreased the cellular amount of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) generated in response to VEGF. Furthermore, adenoviral expression of Gab1-YF3 suppressed both Akt phosphorylation and recovery of wounded human umbilical vein endothelial cell monolayers, a VEGF-dependent process involving cell migration and proliferation under PI3K control. Transfection of other Gab1 mutants, lacking Grb2-binding sites or the pleckstrin homology (PH) domain, also prevented Akt activation, further demonstrating Gab1 involvement in PI3K activation. These mutants were also used to show that interactions with both Grb2 and PtdIns(3,4,5)P-3 mediate Gab1 recruitment by VEGFR-2. Importantly, Gab1 mobilization was impaired by (i) PI3K inhibitors, (ii) deletion of Gab1 PH domain, (iii) PTEN (phosphatase and tensin homolog deleted on chromosome 10) overexpression to repress PtdIns(3,4,5)P-3 production, and (iv) overexpression of a competitor PH domain for PtdIns(3,4,5)P-3 binding, which altogether demonstrated that PI3K is also an upstream regulator of Gab1. Gab1 thus appears as a primary actor in coupling VEGFR-2 to PI3K/Akt, recruited through an amplification loop involving PtdIns(3,4,5)P-3 and its PH domain.	Hop Purpan, Fac Med Toulouse, INSERM, Dept Lipoprot & Mediateurs Lipid,U563, F-31024 Toulouse, France; Hop Rangueil, INSERM, U589, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Raynal, P (corresponding author), Hop Purpan, Fac Med Toulouse, INSERM, Dept Lipoprot & Mediateurs Lipid,U563, Bat C,BP 3028, F-31024 Toulouse, France.	raynal@toulouse.inserm.fr	SALLES, Jean Pierre/K-2998-2014; Masri, Bernard/N-9856-2018; PERRET, Bertrand/Y-2326-2019; YART, Armelle/A-5656-2016; Raynal, Patrick/O-1926-2018	Masri, Bernard/0000-0002-4027-2604; YART, Armelle/0000-0002-2412-9840; Bertrand, PERRET/0000-0001-7568-445X; Raynal, Patrick/0000-0002-6731-3007; Montagner, Alexandra/0000-0002-4800-5105				ABID MR, 2004, ARTERIOSCLER THROMB, V24, P294, DOI DOI 10.1161/01.ATV.0000110502.10593.06; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dixit M, 2005, CIRC RES, V97, P1236, DOI 10.1161/01.RES.0000195611.59811.ab; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Matsumoto T, 2005, EMBO J, V24, P2342, DOI 10.1038/sj.emboj.7600709; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vincent L, 2005, J CLIN INVEST, V115, P2992, DOI 10.1172/JCI24586; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yart A, 2003, CURR CANCER DRUG TAR, V3, P177, DOI 10.2174/1568009033481976	49	52	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23285	23295		10.1074/jbc.M600987200	http://dx.doi.org/10.1074/jbc.M600987200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16787925	hybrid			2022-12-25	WOS:000239542600091
J	Kheifets, V; Bright, R; Inagaki, K; Schechtman, D; Mochly-Rosen, D				Kheifets, Viktoria; Bright, Rachel; Inagaki, Koichi; Schechtman, Deborah; Mochly-Rosen, Daria			Protein kinase C delta (delta PKC)-annexin V interaction - A required step in delta PKC translocation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ANNEXIN-V; INTRACELLULAR RECEPTORS; EPSILON TRANSLOCATION; REPERFUSION INJURY; CARDIAC ISCHEMIA; PLASMA-MEMBRANE; RAT HEARTS; ALPHA; CELLS	Protein kinase C (PKC) plays a critical role in diseases such as cancer, stroke, and cardiac ischemia, and participates in a variety of signal transduction pathways such as apoptosis, cell proliferation, and tumor suppression. Though much is known about PKC downstream signaling events, the mechanisms of regulation of PKC activation and subsequent translocation have not been elucidated. Protein-protein interactions regulate and determine the specificity of many cellular signaling events. Such a specific protein-protein interaction is described here between delta PKC and annexin V. We demonstrate, at physiologically relevant conditions, that a transient interaction between annexin V and delta PKC occurs in cells after delta PKC stimulation, but before delta PKC translocates to the particulate fraction. Evidence of delta PKC-annexin V binding is provided also by FRET and by in vitro binding studies. Dissociation of the delta PKC-annexin V complex requires ATP and microtubule integrity. Furthermore, depletion of endogenous annexin V, but not annexin IV, with siRNA inhibits delta PKC translocation following PKC stimulation. A rationally designed eight amino acid peptide, corresponding to the interaction site for delta PKC on annexin V, inhibits delta PKC translocation and delta PKC-mediated function as evidenced by its protective effect in a model of myocardial infarction. Our data indicate that translocation of delta PKC is not simply a diffusion-driven process, but is instead a multi-step event regulated by protein-protein interactions. We show that following cell activation, delta PKC-annexin V binding is a transient and an essential step in the function of delta PKC, thus identifying a new role for annexin V in PKC signaling and a new step in PKC activation.	Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol,CCSR, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol,CCSR, Rm 3145A,269 Campus Dr, Stanford, CA 94305 USA.	mochly@stanford.edu	schechtman, deborah/B-7572-2012	Mochly-Rosen, Daria/0000-0002-6691-8733; Schechtman, Deborah/0000-0002-8874-7023	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONICELLI F, 1990, REPROD NUTR DEV, V30, P297, DOI 10.1051/rnd:19900302; BARNES JA, 1991, BIOCHEM CELL BIOL, V69, P163, DOI 10.1139/o91-024; Battistella-Patterson AS, 2000, ACTA PHYSIOL SCAND, V170, P87, DOI 10.1046/j.1365-201x.2000.00755.x; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Chen L, 2001, CHEM BIOL, V8, P1123, DOI 10.1016/S1074-5521(01)00076-X; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Gerke V, 2005, NAT REV MOL CELL BIO, V6, P449, DOI 10.1038/nrm1661; Hayes MJ, 2004, TRAFFIC, V5, P571, DOI 10.1111/j.1600-0854.2004.00210.x; HONDEGHEM LM, 1978, AM J PHYSIOL, V235, pH574, DOI 10.1152/ajpheart.1978.235.5.H574; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Inagaki K, 2000, CARDIOVASC DRUG THER, V14, P489, DOI 10.1023/A:1007884905461; Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Inagaki K, 2000, CIRCULATION, V101, P797, DOI 10.1161/01.CIR.101.7.797; John C, 2002, ENDOCRINOLOGY, V143, P3060, DOI 10.1210/en.143.8.3060; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kaneko N, 1997, BBA-BIOMEMBRANES, V1330, P1, DOI 10.1016/S0005-2736(97)00132-6; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; KONDO T, 1979, J LAB CLIN MED, V94, P617; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Miettinen S, 1996, J NEUROSCI, V16, P6236; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Prevostel C, 2000, J CELL SCI, V113, P2575; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; Schechtman D, 2004, J BIOL CHEM, V279, P15831, DOI 10.1074/jbc.M310696200; Schechtman D, 2002, METHOD ENZYMOL, V345, P470; Schechtman Deborah, 2003, Methods Mol Biol, V233, P351; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; Scott JD, 1997, SOC GEN PHY, V52, P227; Shirai Y, 1998, JPN J PHARMACOL, V78, P411, DOI 10.1254/jjp.78.411; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; STOEHR SJ, 1990, J IMMUNOL, V144, P3936; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Weinstein I B, 1991, Princess Takamatsu Symp, V22, P277; Xu TR, 2004, FEBS LETT, V570, P20, DOI 10.1016/j.febslet.2004.05.080; Yoshida K, 1997, J BIOCHEM, V122, P506; Zal T, 2004, BIOPHYS J, V86, P3923, DOI 10.1529/biophysj.103.022087	62	54	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23218	23226		10.1074/jbc.M602075200	http://dx.doi.org/10.1074/jbc.M602075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785226	hybrid			2022-12-25	WOS:000239542600084
J	Maroun, M; Delelis, O; Coadou, G; Bader, T; Segeral, E; Mbemba, G; Petit, C; Sonigo, P; Rain, JC; Mouscadet, JF; Benarous, R; Emiliani, S				Maroun, Marlene; Delelis, Olivier; Coadou, Gael; Bader, Thomas; Segeral, Emmanuel; Mbemba, Gladys; Petit, Caroline; Sonigo, Pierre; Rain, Jean-Christophe; Mouscadet, Jean-Francois; Benarous, Richard; Emiliani, Stephane			Inhibition of early steps of HIV-1 replication by SNF5/Ini1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHROMATIN-REMODELING COMPLEX; STRAND BREAK REPAIR; PREINTEGRATION COMPLEXES; SWI/SNF COMPLEX; HUMAN-CELLS; HUMAN GENOME; DNA-BINDING; IN-VITRO; RETROVIRAL INFECTION	To replicate, human immunodeficiency virus, type 1 (HIV-1) needs to integrate a cDNA copy of its RNA genome into a chromosome of the host cell, a step controlled by the viral integrase (IN) protein. Viral integration involves the participation of several cellular proteins. SNF5/Ini1, a subunit of the SWI/SNF chromatin remodeling complex, was the first cofactor identified to interact with IN. We report here that SNF5/Ini1 interferes with early steps of HIV-1 replication. Inhibition of SNF5/Ini1 expression by RNA interference increases HIV-1 replication. Using quantitative PCR, we show that both the 2-long terminal repeat circle and integrated DNA forms accumulate upon SNF5/Ini1 knock down. By yeast two-hybrid assay, we screened a library of HIV-1 IN random mutants obtained by PCR random mutagenesis using SNF5/Ini1 as prey. Two different mutants of interaction, IN E69G and IN K71R, were impaired for SNF5/Ini1 interaction. The E69G substitution completely abolished integrase catalytic activity, leading to a replication-defective virus. On the contrary, IN K71R retained in vitro integrase activity. K71R substitution stimulates viral replication and results in higher infectious titers. Taken together, these results suggest that, by interacting with IN, SNF5/Ini1 interferes with early steps of HIV-1 infection.	Inst Cochin, Dept Maladies Infect, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France; CNRS, Unite Mixte Rech 8104, F-75014 Paris, France; Univ Paris Descartes, Fac Med Rene Descartes, UMR S 8104, F-75014 Paris, France; CNRS, UMR 8532, Ecole Normale Super Cachan, Lab Biotechnol & Genet Appl, F-94235 Cachan, France; Hybrigenics SA, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Emiliani, S (corresponding author), Inst Cochin, Dept Maladies Infect, 27 Rue Faubourg St Jacques Bat Gustave Roussy, F-75014 Paris, France.	emiliani@cochin.inserm.fr	COADOU, Gael/M-3042-2015	COADOU, Gael/0000-0003-0979-6706; RAIN, Jean-Christophe/0000-0001-8110-0641; Sonigo, Pierre/0000-0003-2686-1303				Berthoux L, 2003, J VIROL, V77, P3167, DOI 10.1128/JVI.77.5.3167-3180.2003; Boese A, 2004, FEBS LETT, V578, P291, DOI 10.1016/j.febslet.2004.11.016; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Busschots K, 2005, J BIOL CHEM, V280, P17841, DOI 10.1074/jbc.M411681200; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Emiliani S, 2005, J BIOL CHEM, V280, P25517, DOI 10.1074/jbc.M501378200; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Imbalzano AN, 2005, CANCER CELL, V7, P294, DOI 10.1016/j.ccr.2005.04.001; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kilzer JM, 2003, VIROLOGY, V314, P460, DOI 10.1016/S0042-6822(03)00455-0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUIKEN CL, 2002, HIV SEQUENCE COMPEND; Lau A, 2004, EMBO J, V23, P3421, DOI 10.1038/sj.emboj.7600348; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Lu R, 2005, J VIROL, V79, P2493, DOI 10.1128/JVI.79.4.2493-2505.2005; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Mahmoudi T, 2006, J BIOL CHEM, V281, P19960, DOI 10.1074/jbc.M603336200; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Mulder LCF, 2002, J BIOL CHEM, V277, P27489, DOI 10.1074/jbc.M203061200; Parissi V, 2001, J VIROL, V75, P11344, DOI 10.1128/JVI.75.23.11344-11353.2001; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Treand C, 2006, EMBO J, V25, P1690, DOI 10.1038/sj.emboj.7601074; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Violot S, 2003, J VIROL, V77, P12507, DOI 10.1128/JVI.77.23.12507-12522.2003; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yung E, 2004, J VIROL, V78, P2222, DOI 10.1128/JVI.78.5.2222-2231.2004; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959; Zhou GC, 2001, METHODS, V25, P54, DOI 10.1006/meth.2001.1215	57	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22736	22743		10.1074/jbc.M604849200	http://dx.doi.org/10.1074/jbc.M604849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772295	Green Published, hybrid			2022-12-25	WOS:000239542600034
J	Miyauchi, Y; Daiho, T; Yamasaki, K; Takahashi, H; Ishida-Yamamoto, A; Danko, S; Suzuki, H; Iizuka, H				Miyauchi, Yuki; Daiho, Takashi; Yamasaki, Kazuo; Takahashi, Hidetoshi; Ishida-Yamamoto, Akemi; Danko, Stefania; Suzuki, Hiroshi; Iizuka, Hajime			Comprehensive analysis of expression and function of 51 sarco(endo) plasmic reticulum Ca2+-ATPase mutants associated with Darier disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE PHOSPHOENZYME INTERMEDIATE; MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; AMINO-ACIDS; ATP2A2 MUTATIONS; CA2+ OCCLUSION; CATALYTIC SITE; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL CHANGE; TRANSMEMBRANE DOMAIN	We examined possible defects of sarco(endo) plasmic reticulum Ca2+-ATPase 2b (SERCA2b) associated with its 51 mutations found in Darier disease (DD) pedigrees, i.e. most of the substitution and deletion mutations of residues reported so far. COS-1 cells were transfected with each of the mutant cDNAs, and the expression and function of the SERCA2b protein was analyzed with microsomes prepared from the cells and compared with those of the wild type. Fifteen mutants showed markedly reduced expression. Among the other 36, 29 mutants exhibited completely abolished or strongly inhibited Ca2+-ATPase activity, whereas the other seven possessed fairly high or normal ATPase activity. In four of the aforementioned seven mutants, Ca2+ transport activity was significantly reduced or almost completely lost, therefore uncoupled from ATP hydrolysis. The other three were exceptional cases as they were seemingly normal in protein expression and Ca2+ transport function, but were found to have abnormalities in the kinetic properties altered by the three mutations, which happened to be in the three DD pedigrees found by us previously (Sato, K., Yamasaki, K., Daiho, T., Miyauchi, Y., Takahashi, H., Ishida-Yamamoto, A., Nakamura, S., Iizuka, H., and Suzuki, H. (2004) J. Biol. Chem. 279, 35595 - 35603). Collectively, our results indicated that in most cases (48 of 51) DD mutations cause severe disruption of Ca2+ homeostasis by the defects in protein expression and/or transport function and hence DD, but even a slight disturbance of the homeostasis will result in the disease. Our results also provided further insight into the structure-function relationship of SERCAs and revealed critical regions and residues of the enzyme.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CAMPBELL AM, 1992, J BIOL CHEM, V267, P9321; Chao SC, 2002, BRIT J DERMATOL, V146, P958, DOI 10.1046/j.1365-2133.2002.04786.x; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Clausen JD, 2004, J BIOL CHEM, V279, P54426, DOI 10.1074/jbc.M410204200; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; Dhitavat J, 2003, J INVEST DERMATOL, V121, P486, DOI 10.1046/j.1523-1747.2003.12410.x; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ikeda S, 2003, J INVEST DERMATOL, V121, P475, DOI 10.1046/j.1523-1747.2003.12400.x; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Ma HL, 2005, BIOCHEMISTRY-US, V44, P8090, DOI 10.1021/bi050332m; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Montigny C, 2004, J BIOL CHEM, V279, P43971, DOI 10.1074/jbc.M407142200; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Onozuka T, 2004, BRIT J DERMATOL, V150, P652, DOI 10.1111/j.0007-0963.2004.05868.x; Peeraer Y, 2004, EUR J BIOCHEM, V271, P3421, DOI 10.1111/j.0014-2956.2004.04277.x; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 2000, J INVEST DERMATOL, V115, P1144, DOI 10.1046/j.1523-1747.2000.00182.x; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; Sato K, 2004, J BIOL CHEM, V279, P35595, DOI 10.1074/jbc.M404887200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; Takahashi H, 2001, J DERMATOL SCI, V26, P169, DOI 10.1016/S0923-1811(00)00173-0; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wada T, 2003, BRIT J DERMATOL, V149, P185, DOI 10.1046/j.1365-2133.2003.05412.x; Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200; Yang Y, 2001, J INVEST DERMATOL, V116, P482, DOI 10.1046/j.1523-1747.2001.127910.x; Youngburg GE, 1930, J LAB CLIN MED, V16, P158; Zhang YL, 1995, GENOMICS, V30, P415, DOI 10.1006/geno.1995.1259; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	78	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22882	22895		10.1074/jbc.M601966200	http://dx.doi.org/10.1074/jbc.M601966200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766529	Green Submitted, hybrid			2022-12-25	WOS:000239542600051
J	Shibagaki, N; Grossman, AR				Shibagaki, Nakako; Grossman, Arthur R.			The role of the STAS domain in the function and biogenesis of a sulfate transporter as probed by random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL CHLORIDE DIARRHEA; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; FACTOR SPOIIAB; MUTATIONS; GENE; FAMILY; ROOTS; CHONDRODYSPLASIA; EXPRESSION	Sulfate transporters in plants represent a family of proteins containing transmembrane domains that constitute the catalytic part of the protein and a short linking region that joins this catalytic moiety with a C-terminal STAS domain. The STAS domain resembles an anti-sigma factor antagonist of Bacillus subtilis, which is one distinguishing feature of the SLC26 transporter family; this family includes transporters for sulfate and other anions such as iodide and carbonate. Recent work has demonstrated that this domain is critical for the activity of Arabidopsis thaliana sulfate transporters, and specific lesions in this domain, or the exchange of STAS domains between different sulfate transporters, can severely impair transport activity. In this work we generated a Saccharomyces cerevisiae expression library of the A. thaliana Sultr1;2 gene with random mutations in the linking region-STAS domain and identified STAS domain lesions that altered Sultr1;2 biogenesis and/or function. A number of mutations in the beta-sheet that forms the core of the STAS domain prevented intracellular accumulation of Sultr1;2. In contrast, the linking region and one surface of the STAS domain containing N termini of the first and second alpha-helices have a number of amino acids critical for the function of the protein; mutations in these regions still allow protein accumulation in the plasmamembrane, but the protein is no longer capable of efficiently transporting sulfate into cells. These results suggest that the STAS domain is critical for both the activity and biosynthesis/stability of the transporter, and that STAS sub-domains correlate with these specific functions.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Shibagaki, N (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	snakako@stanford.edu						Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Burke D, 2000, METHODS YEAST GENETI, P103; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cherest H, 1997, GENETICS, V145, P627; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Everett LA, 1999, HUM MOL GENET, V8, P1883, DOI 10.1093/hmg/8.10.1883; Hastbacka J, 1996, ANN NY ACAD SCI, V785, P131; Ho MS, 2003, J BIOL CHEM, V278, P20898, DOI 10.1074/jbc.M302305200; Hoglund P, 2001, HUM MUTAT, V18, P233, DOI 10.1002/humu.1179; Karniski LP, 2004, HUM MOL GENET, V13, P2165, DOI 10.1093/hmg/ddh242; Ko SBH, 2004, NAT CELL BIOL, V6, P343, DOI 10.1038/ncb1115; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Leung DW, 1989, TECHNIQUE, V1, P11; Lohi H, 2003, AM J PHYSIOL-CELL PH, V284, pC769, DOI 10.1152/ajpcell.00270.2002; Masuda S, 2004, J MOL BIOL, V340, P941, DOI 10.1016/j.jmb.2004.05.040; Mount DB, 2004, PFLUG ARCH EUR J PHY, V447, P710, DOI 10.1007/s00424-003-1090-3; Rouached H, 2005, J BIOL CHEM, V280, P15976, DOI 10.1074/jbc.M501635200; Seavers PR, 2001, STRUCTURE, V9, P605, DOI 10.1016/S0969-2126(01)00623-2; Shibagaki N, 2002, PLANT J, V29, P475, DOI 10.1046/j.0960-7412.2001.01232.x; Shibagaki N, 2004, J BIOL CHEM, V279, P30791, DOI 10.1074/jbc.M403248200; Smith FW, 1997, PLANT J, V12, P875, DOI 10.1046/j.1365-313X.1997.12040875.x; SupertiFurga A, 1996, AM J MED GENET, V63, P144, DOI 10.1002/(SICI)1096-8628(19960503)63:1<144::AID-AJMG25>3.0.CO;2-N; Takahashi H, 2000, PLANT J, V23, P171, DOI 10.1046/j.1365-313x.2000.00768.x; Takahashi H, 1997, P NATL ACAD SCI USA, V94, P11102, DOI 10.1073/pnas.94.20.11102; Usami S, 1999, HUM GENET, V104, P188, DOI 10.1007/s004390050933; Vidmar JJ, 1999, PLANT MOL BIOL, V40, P883, DOI 10.1023/A:1006230131841; Zheng J, 2005, J CELL SCI, V118, P2987, DOI 10.1242/jcs.02431; Zheng J, 2001, NEUROREPORT, V12, P1929, DOI 10.1097/00001756-200107030-00032	31	75	78	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22964	22973		10.1074/jbc.M603462200	http://dx.doi.org/10.1074/jbc.M603462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754669	hybrid			2022-12-25	WOS:000239542600058
J	Werner, E; Kowalczyk, AP; Faundez, V				Werner, Erica; Kowalczyk, Andrew P.; Faundez, Victor			Anthrax toxin receptor 1/tumor endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRAX TOXIN RECEPTOR; CAPILLARY MORPHOGENESIS; SIGNAL-TRANSDUCTION; TUMOR ENDOTHELIUM; GENE-EXPRESSION; COLLAGEN; INTEGRINS; ADHESION; BINDING; MATRIX	Tumor endothelial marker 8 (TEM8) is induced in tumor-associated vasculature and acts as a receptor for Protective Antigen (PA), the cell-binding component of the anthrax toxin determinant for toxin entrance into cells. However, the normal function for TEM8 remains unknown. We show that TEM8 functions as an adhesion molecule mediating cell spreading on immobilized PA and collagen I. The mechanism for TEM8 interaction with collagen I was cell type-specific, because binding to collagen I was abrogated by beta 1 integrin function blocking antibody in HEK293 cells, but not in primary synovial rabbit fibroblasts. Binding to PA remained unaffected by the addition of beta 1 integrin function blocking antibody. Whereas the extracellular and transmembrane domains of TEM8 were sufficient to provide cell attachment, the intracellular domain was critical for spreading. Fusion of the cytosolic domain of TEM8 to the IL-2 receptor, conferred cell-spreading capability on IL-2 receptor antibody substrates. The cytoplasmic domain mediated linkage with the actin cytoskeleton as it co-precipitated actin and determined partitioning of TEM8 to the actin-containing detergent insoluble cellular fraction. TEM8 anchorage to actin was relevant as spreading was inhibited by the cytoskeleton-disrupting drug cytochalasin D, but persisted in the presence of the microtubule-depolymerizing drug nocodazole, and in cells lacking intermediate filaments. Thus, our results indicate that TEM8 is a new adhesion molecule linking collagen I or PA to the actin cytoskeleton.	Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Dept Dermatol, Atlanta, GA 30322 USA	Emory University; Emory University	Werner, E (corresponding author), Emory Univ, Dept Cell Biol, Whitehead Biomed Res Bldg,Rm 455,615 Michael St, Atlanta, GA 30322 USA.	ericaw@cellbio.emory.edu		Faundez, Victor/0000-0002-2114-5271; Werner, Erica/0000-0002-8183-1601	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042599] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR050501] Funding Source: Medline; NINDS NIH HHS [R01NS42599] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Bell SE, 2001, J CELL SCI, V114, P2755; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bradley KA, 2003, J BIOL CHEM, V278, P49342, DOI 10.1074/jbc.M307900200; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Dowling O, 2003, AM J HUM GENET, V73, P957, DOI 10.1086/378781; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Feng XD, 2002, J IMMUNOL, V168, P2441, DOI 10.4049/jimmunol.168.5.2441; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; Hotchkiss KA, 2005, EXP CELL RES, V305, P133, DOI 10.1016/j.yexcr.2004.12.025; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Liu SH, 2005, NAT BIOTECHNOL, V23, P725, DOI 10.1038/nbt1091; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; MOONEY DJ, 1995, J CELL SCI, V108, P2311; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; St Croix B, 2000, SCIENCE, V289, P1197; Styers ML, 2004, MOL BIOL CELL, V15, P5369, DOI 10.1091/mbc.E04-03-0272; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wei W, 2006, CELL, V124, P1141, DOI 10.1016/j.cell.2005.12.045; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200	49	63	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23227	23236		10.1074/jbc.M603676200	http://dx.doi.org/10.1074/jbc.M603676200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762926	hybrid			2022-12-25	WOS:000239542600085
J	Germano, S; Barberis, D; Santoro, MM; Penengo, L; Citri, A; Yarden, Y; Gaudino, G				Germano, Serena; Barberis, Davide; Santoro, Massimo M.; Penengo, Lorenza; Citri, Ami; Yarden, Yosef; Gaudino, Giovanni			Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MACROPHAGE-STIMULATING PROTEIN; GROWTH-FACTOR RECEPTOR; UBIQUITIN LIGASE CHIP; HEAT-SHOCK PROTEINS; PROTEASOMAL DEGRADATION; MOLECULAR CHAPERONE; BREAST-CANCER; C-CBL; HSP90	Ron, the tyrosine kinase receptor for macrophage-stimulating protein is responsible for proliferation and migration of cells from different tissues. Ron can acquire oncogenic potential by single point mutations in the kinase domain, and dysregulated Ron signaling has been involved in the development of different human cancers. We have previously shown that ligand-activated Ron recruits the negative regulator c-Cbl, which mediates its ubiquitylation and degradation. Here we report that Ron is ubiquitylated also by the U-box E3 ligase C-terminal Hsc70-interacting protein ( CHIP), recruited via chaperone intermediates Hsp90 and Hsc70. Gene silencing shows that CHIP activity is necessary to mediate Ron degradation upon cell treatment with Hsp90 inhibitors geldanamycins. The oncogenic Ron(M1254T) receptor escapes from c-Cbl negative regulation but retains a strong association with CHIP. This constitutively active mutant of Ron displays increased sensitivity to geldanamycins, enhanced physical interaction with Hsp90, and more rapid degradation rate. Cell growth and migration, as well as the transforming potential evoked by Ron(M1254T), are abrogated upon Hsp90 inhibition. These data highlight a novel mechanism for Ron degradation and propose Hsp90 antagonists like geldanamycins as suitable pharmacological agents for therapy of cancers where altered Ron signaling is involved.	Univ PIemonte Orientale A Avogadro, Dept DISCAFF, I-28100 Novara, Italy; Univ PIemonte Orientale A Avogadro, DFB Ctr, I-28100 Novara, Italy; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	University of Eastern Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro; Weizmann Institute of Science	Gaudino, G (corresponding author), Univ PIemonte Orientale A Avogadro, Dept DISCAFF, Via Bovio 6, I-28100 Novara, Italy.	giovanni.gaudino@unipmn.it	Citri, Ami/R-8973-2019; YARDEN, YOSEF/K-1467-2012	Citri, Ami/0000-0002-9914-0278; SANTORO, Massimo Mattia/0000-0003-4605-5085; PENENGO, Lorenza/0000-0001-7888-4473				Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cheng HL, 2005, BRIT J CANCER, V92, P1906, DOI 10.1038/sj.bjc.6602593; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119; Gorre ME, 2002, BLOOD, V100, P3041, DOI 10.1182/blood-2002-05-1361; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lerdrup M, 2006, J CELL SCI, V119, P85, DOI 10.1242/jcs.02707; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Maulik G, 2002, CLIN CANCER RES, V8, P620; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Penengo L, 2003, ONCOGENE, V22, P3669, DOI 10.1038/sj.onc.1206585; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Rowinsky EK, 2004, ANNU REV MED, V55, P433, DOI 10.1146/annurev.med.55.091902.104433; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; Santoro MM, 2000, ONCOGENE, V19, P5208, DOI 10.1038/sj.onc.1203819; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Webb CP, 2000, CANCER RES, V60, P342; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Wei X, 2005, J BIOL CHEM, V280, P40241, DOI 10.1074/jbc.M506806200; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Xie Q, 2005, ONCOGENE, V24, P3697, DOI 10.1038/sj.onc.1208499; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Xu XM, 2004, ONCOGENE, V23, P8464, DOI 10.1038/sj.onc.1207907; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	52	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21710	21719		10.1074/jbc.M602014200	http://dx.doi.org/10.1074/jbc.M602014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16740632	hybrid, Green Accepted			2022-12-25	WOS:000239387100016
J	Li, XD; Jung, HS; Mabuchi, K; Craig, R; Ikebe, M				Li, Xiang-dong; Jung, Hyun Suk; Mabuchi, Katsuhide; Craig, Roger; Ikebe, Mitsuo			The globular tail domain of myosin Va functions as an inhibitor of the myosin Va motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONVENTIONAL MYOSIN; MELANOSOME TRANSPORT; LINKS RAB27A; MELANOPHILIN; CALMODULIN; ACTIN; CONFORMATION; TROPOMYOSIN; ACTIVATION; COMPLEX	The actin-activated ATPase activity of full-length mammalian myosin Va is well regulated by Ca2+, whereas that of truncated myosin Va without the C-terminal globular tail domain ( GTD) is not. Here, we have found that exogenous GTD is capable of inhibiting the actin-activated ATPase activity of GTD-deleted myosin Va. A series of truncated constructs of myosin Va further showed that the entire length of the first coiled-coil ( coil-1) of the tail domain is critical for GTD-dependent regulation of myosin Va and that deletion of 58 residues from the C-terminal end of coil-1 markedly hampered regulation. Negative staining electron microscopy revealed that GTD-deleted myosin Va formed a "Y"-shaped structure, which was converted to a triangular shape, similar to the structure of full-length myosin Va in the inhibited state, by addition of exogenous GTD. In contrast, the triangular shape was not observed when the C-terminal 58 residues of coil-1 were deleted, even in the presence of exogenous GTD. Based on these results, we propose a model for the formation of the inhibited state of myosin Va. GTD binds to the C-terminal end of coil-1. The neck-tail junction of myosin Va is flexible, and the long neck enables the head domain to reach the GTD associated with the end of coil-1. Once the head interacts with the GTD, the triangular inhibited conformation is stabilized. Consistent with this model, we found that shortening of the neck of myosin Va by two IQ motifs abolished the regulation by GTD, whereas regulation was partially restored by shortening of coil-1 by an amount comparable to that of the two IQ motifs.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Boston Biomed Res Inst, Muscle Res Grp, Watertown, MA 02472 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Boston Biomedical Research Institute	Li, XD (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Xiangdong.Li@umassmed.edu			NIAMS NIH HHS [AR34711, AR048526, AR41653] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048526, R01AR041653, R01AR034711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Burgess SA, 2004, J STRUCT BIOL, V147, P247, DOI 10.1016/j.jsb.2004.04.004; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; IKURA M, 1990, BIOCHEM PHARMACOL, V40, P153; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Li XD, 2005, J BIOL CHEM, V280, P17815, DOI 10.1074/jbc.M413295200; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Pashkova N, 2006, EMBO J, V25, P693, DOI 10.1038/sj.emboj.7600965; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Rodriguez OC, 2002, J CELL SCI, V115, P991; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stachelek SJ, 2000, J BIOL CHEM, V275, P31701, DOI 10.1074/jbc.M004221200; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Terrak M, 2005, P NATL ACAD SCI USA, V102, P12718, DOI 10.1073/pnas.0503899102; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wu XF, 1997, J CELL SCI, V110, P847; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	33	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21789	21798		10.1074/jbc.M602957200	http://dx.doi.org/10.1074/jbc.M602957200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16757473	hybrid			2022-12-25	WOS:000239387100025
J	Stiernet, P; Guiot, Y; Gilon, P; Henquin, JC				Stiernet, Patrick; Guiot, Yves; Gilon, Patrick; Henquin, Jean-Claude			Glucose acutely decreases pH of secretory granules in mouse pancreatic islets - Mechanisms and influence on insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ELECTRICAL-ACTIVITY; K-ATP CHANNELS; BETA-CELLS; B-CELLS; CYTOPLASMIC CA2+; ENDOCRINE PANCREAS; MOLECULAR-BIOLOGY; EXOCYTOSIS; RELEASE; STIMULATION	Glucose-induced insulin secretion requires a rise in beta-cell cytosolic Ca2+ ([Ca2(+)](c)) that triggers exocytosis and a mechanistically unexplained amplification of the action of [Ca2+](c). Insulin granules are kept acidic by luminal pumping of protons with simultaneous Cl- uptake to maintain electroneutrality. Experiments using patched, dialyzed beta-cells prompted the suggestion that acute granule acidification by glucose underlies amplification of insulin secretion. However, others found glucose to increase granular pH in intact islets. In this study, we measured islet granular pH with Lysosensor DND-160, a fluorescent dye that permits ratiometric determination of pH < 6 in acidic compartments. Stimulation of mouse islets with glucose reversibly decreased granular pH by mechanisms that are dependent on metabolism and Cl- ions but independent of changes in [Ca2+](c) and protein kinase A or C activity. Granular pH was increased by concanamycin (blocker of the vesicular type H+-ATPase) > methylamine (weak base) > Cl- omission. Concanamycin and methylamine did not alter glucose-induced [Ca2+](c) increase in islets but strongly inhibited the two phases of insulin secretion. Omission of Cl- did not affect the first phase but decreased the second phase of both [Ca2+](c) and insulin responses. Neither experimental condition affected the [Ca2+](c) rise induced by 30mM KCl, but the insulin responses were inhibited by concanamycin > methylamine and not affected by Cl- omission. The amplification of insulin secretion by glucose was not suppressed. We conclude that an acidic granular pH is important for insulin secretion but that the acute further acidification produced by glucose is not essential for the augmentation of secretion via the amplifying pathway.	Univ Louvain, Fac Med, Unit Endocrinol & Metab, B-1200 Brussels, Belgium; Univ Louvain, Fac Med, Unit Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Henquin, JC (corresponding author), UCL, Unite Endocrinol & Metab, 55-30 Ave Hippocrate 55, B-1200 Brussels, Belgium.	henquin@endo.ucl.ac.be						ABRAHAMSSON H, 1980, ACTA PHYSIOL SCAND, V109, P113, DOI 10.1111/j.1748-1716.1980.tb06573.x; Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aspinwall CA, 1997, J BIOL CHEM, V272, P31308, DOI 10.1074/jbc.272.50.31308; Bankers-Fulbright JL, 2004, J CELL SCI, V117, P5749, DOI 10.1242/jcs.01498; Barg S, 2001, J CELL SCI, V114, P2145; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; DECLERCQ L, 1988, MECH AGEING DEV, V43, P25, DOI 10.1016/0047-6374(88)90095-4; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; Drose S, 1997, J EXP BIOL, V200, P1; EDDLESTONE GT, 1983, AM J PHYSIOL, V244, pC188, DOI 10.1152/ajpcell.1983.244.3.C188; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Eto K, 2003, AM J PHYSIOL-ENDOC M, V285, pE262, DOI 10.1152/ajpendo.00542.2002; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Geng XH, 2003, DIABETES, V52, P767, DOI 10.2337/diabetes.52.3.767; Gerbino A, 2004, GASTROENTEROLOGY, V126, P182, DOI 10.1053/j.gastro.2003.10.068; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; GILON P, 1992, J BIOL CHEM, V267, P20713; GOMIS R, 1984, CELL BIOCHEM FUNCT, V2, P161, DOI 10.1002/cbf.290020309; Guiot Y, 2005, DIABETOLOGIA, V48, pA175; Hauge-Evans AC, 1999, DIABETES, V48, P1402, DOI 10.2337/diabetes.48.7.1402; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; Henquin JC, 2006, DIABETES, V55, P441, DOI 10.2337/diabetes.55.02.06.db05-1051; Henquin JC, 2003, EUR J CLIN INVEST, V33, P742, DOI 10.1046/j.1365-2362.2003.01207.x; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HERMANS MP, 1986, BIOCHIM BIOPHYS ACTA, V889, P262, DOI 10.1016/0167-4889(86)90112-6; Holopainen JM, 2001, EUR J BIOCHEM, V268, P5851, DOI 10.1046/j.0014-2956.2001.02530.x; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Jonkers FC, 2001, BRIT J PHARMACOL, V133, P575, DOI 10.1038/sj.bjp.0704108; Jonkers FC, 1999, J PHYSIOL-LONDON, V520, P839, DOI 10.1111/j.1469-7793.1999.00839.x; Komatsu M, 2001, ENDOCR J, V48, P275, DOI 10.1507/endocrj.48.275; LANDSTROM AHS, 1991, METABOLISM, V40, P399, DOI 10.1016/0026-0495(91)90151-L; LEBRUN P, 1985, METABOLISM, V34, P1122, DOI 10.1016/0026-0495(85)90157-X; Lin HJ, 2001, ANAL BIOCHEM, V294, P118, DOI 10.1006/abio.2001.5155; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PACE CS, 1983, J MEMBRANE BIOL, V73, P39, DOI 10.1007/BF01870339; PACE CS, 1982, AM J PHYSIOL, V242, pC382, DOI 10.1152/ajpcell.1982.242.5.C382; Perez JF, 2001, J PHYSIOL-LONDON, V537, P735; Renstrom E, 2002, DIABETES, V51, pS33, DOI 10.2337/diabetes.51.2007.S33; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Sato Y, 1998, DIABETES, V47, P1713, DOI 10.2337/diabetes.47.11.1713; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; SEHLIN J, 1988, BIOCHIM BIOPHYS ACTA, V937, P309, DOI 10.1016/0005-2736(88)90253-2; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; SOMERS G, 1980, PFLUG ARCH EUR J PHY, V388, P249, DOI 10.1007/BF00658490; STEINER DF, 1992, DIABETOLOGIA, V35, pS41, DOI 10.1007/BF00586278; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Takahashi N, 1999, P NATL ACAD SCI USA, V96, P760, DOI 10.1073/pnas.96.2.760; TAMAGAWA T, 1983, DIABETES, V32, P416, DOI 10.2337/diabetes.32.5.416; Tompkins LS, 2002, AM J PHYSIOL-CELL PH, V283, pC429, DOI 10.1152/ajpcell.01066.2000; Watkins S, 2002, TRAFFIC, V3, P461, DOI 10.1034/j.1600-0854.2002.30703.x; Yajima H, 2000, DIABETES, V49, P712, DOI 10.2337/diabetes.49.5.712; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	60	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22142	22151		10.1074/jbc.M513224200	http://dx.doi.org/10.1074/jbc.M513224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16760469	hybrid			2022-12-25	WOS:000239387100061
J	Yazawa, S; Tsuchiya, H; Hori, H; Makino, R				Yazawa, Shinsuke; Tsuchiya, Hidemi; Hori, Hiroshi; Makino, Ryu			Functional characterization of two nucleotide-binding sites in soluble guanylate cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN ADENYLYL-CYCLASE; NITRIC-OXIDE; RESONANCE RAMAN; CARBON-MONOXIDE; BOVINE LUNG; SMOOTH-MUSCLE; HEME-BINDING; CYCLIC-GMP; RAT LUNG; ACTIVATION	Soluble guanylate cyclase is a heterodimeric hemoprotein composed of alpha- and beta-subunits with a homologous motif to the nucleotide-binding sites of adenylate cyclases. Homology modeling of guanylate cyclase, based on the crystal structure of adenylate cyclase, reveals a single GTP-binding site and a putative second site pseudosymmetric to the GTP-binding site. However, the role of this pseudosymmetric site has remained unclear. Using equilibrium dialysis, we identified two nucleotide-binding sites with high and low affinity for alpha, beta-methylene guanosine 5'-triphosphate (GMP-CPP). In contrast, 2'-dADP occupied both sites with equivalent affinities. Adenosine-5'-beta,gamma-imido triphosphate (AMPPNP), which competitively inhibited the cyclase reaction, bound solely to the high affinity site, indicating the role of this site as the catalytic site. The function of the low affinity site was examined using allosteric activators YC-1 and BAY 41-2272. YC-1 significantly reduced the affinity of 2'-dADP, probably by competing for the same site as 2'-dADP. BAY 41-2272 totally inhibited the specific binding of one molecule of 2'-dADP as well as GMP-CPP. This suggests that the activators compete with these nucleotides for the low affinity site. Infrared and EPR analyses of the enzymic CO- and NO-hemes also supported the suggested role of the low affinity site as a target for the activators. Our results imply that the low affinity site is the pseudosymmetric site, which binds YC-1 or BAY 41- 2272.	Rikkyo Univ, Dept Life Sci, Coll Sci, Toshima Ku, Tokyo 1718501, Japan; Osaka Univ, Div Bioengn, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan	Rikkyo University; Osaka University	Makino, R (corresponding author), Rikkyo Univ, Dept Life Sci, Coll Sci, Toshima Ku, Nishi Ikebukuro 3-34-1, Tokyo 1718501, Japan.	rmakino@rikkyo.ne.jp						Bischoff E, 2003, UROLOGY, V61, P464, DOI 10.1016/S0090-4295(02)02121-0; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Cary SPL, 2005, P NATL ACAD SCI USA, V102, P13064, DOI 10.1073/pnas.0506289102; Chang FJ, 2005, J BIOL CHEM, V280, P11513, DOI 10.1074/jbc.M412203200; Chien WL, 2003, MOL PHARMACOL, V63, P1322, DOI 10.1124/mol.63.6.1322; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Friebe A, 1996, EMBO J, V15, P6863, DOI 10.1002/j.1460-2075.1996.tb01078.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Koglin M, 2003, J BIOL CHEM, V278, P12590, DOI 10.1074/jbc.M212740200; Lamothe M, 2004, BIOCHEMISTRY-US, V43, P3039, DOI 10.1021/bi0360051; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Makino R, 2003, J BIOL CHEM, V278, P11130, DOI 10.1074/jbc.M209026200; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Martin E, 2005, J AM CHEM SOC, V127, P4625, DOI 10.1021/ja0440912; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; NAKANE M, 1990, J BIOL CHEM, V265, P16841; Ruiz-Stewart I, 2004, P NATL ACAD SCI USA, V101, P37, DOI 10.1073/pnas.0305080101; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Russwurm M, 2002, J BIOL CHEM, V277, P24883, DOI 10.1074/jbc.M110570200; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Segel I. H., 1975, ENZYME KINETICS, p[176, 387]; SMIT MJ, 1997, ADV 2 MESSENGER PHOS, V32, P1; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Suzuki T, 2001, FEBS LETT, V507, P49, DOI 10.1016/S0014-5793(01)02943-X; Tang Wei-Jen, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P137; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	44	44	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21763	21770		10.1074/jbc.M508983200	http://dx.doi.org/10.1074/jbc.M508983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754683	hybrid			2022-12-25	WOS:000239387100022
J	Pulukuri, SM; Rao, JS				Pulukuri, S. M.; Rao, J. S.			CpG island promoter methylation and silencing of 14-3-3 sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2	ONCOGENE			English	Article						CpG methylation; 14-3-3 sigma; MBD2; prostate cancer	DNA METHYLATION; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; EPIGENETIC INACTIVATION; UPA PROMOTER; HYPERMETHYLATION; CARCINOMA; CHROMATIN; MECHANISM; GROWTH	14-3-3 sigma proteins regulate numerous cellular processes that are important to cancer development. One of its biological roles involves G2 cell-cycle arrest following DNA damage. It has also been reported that the loss of 14-3-3 sigma expression via CpG methylation may contribute to malignant transformation by impairing the G2 cell-cycle checkpoint function, thereby allowing an accumulation of genetic defects. However, how the CpG methylation-dependent silencing mechanism works in relation to promoter methylation associated with methyl-CpG-binding proteins (MeCPs) is still unclear. To better understand the mechanism, we first examined the methylation status of the 14-3-3 sigma promoter-associated CpG islands and 14-33 sigma gene expression in a subset of prostate cancer cell lines using methylation-specific PCR (MSP), an HhaI-based DNA methylation assay, and reverse transcription-PCR (RT-PCR). We found that the 14-3-3 sigma expression is lost in LNCaP and Tramp-Cl prostate cancer cell lines and that this expression is restored after treatment with epigenetic silencing modifiers 5-aza-2'-deoxycytidine (5-aza) and trichostatin A (TSA). These results imply transcriptional silencing via promoter-associated CpG methylation. Chromatin immunroprecipitation analysis revealed that methyl-CpG-binding protein 2 (MBD2) is associated preferentially to the methylated CpG island in the 14-3-3 sigma promoter in LNCaP and Tramp-Cl cells but not in 14-3-3 sigma-expressing PC3 and DU145 cells, which contain an unmethylated CpG island in the 14-3-3 sigma promoter region. The 14-3-3 sigma gene silencing because of CpG methylation correlates with binding of MBD2. In addition, the activation of 14-3-3 sigma gene expression by a combination of 5-aza and TSA also involves the release of the MBD2 from the 14-3-3 sigma promoter-methylated CpG island in LNCaP and Tramp-C1 cells. Furthermore, MBD2 knockdown by siRNA stimulated 14-3-3 sigma expression in LNCaP cells. We also investigated whether the loss of 14-3-3 sigma expression in LNCaP and Tramp-Cl cells affects cell proliferation by MTT assays. Interestingly, we observed that 14-3-3 sigma-inactivated LNCaP and Tramp-Cl cells had markedly decreased cell proliferation and protein expression of proliferation cell nuclear antigen (PCNA) after restoration of 14-3-3 sigma expression with 5-aza and TSA treatment. On the other hand, the same treatment did not significantly affect 14-3-3 sigma-active PC3 and DU145 cells, which normally express 14-3-3 sigma. Finally, 14-3-3 sigma knockdown by siRNA resulted in increased proliferation in PC3 and DU145 cells. These findings suggest that the transcriptional silencing of the 14-3-3 sigma gene is caused by promoter CpG island methylation associated with MBD2, and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NCI NIH HHS [R01 CA095058, R01 CA092393, R01 CA116708, R01 CA075557, CA 75557, CA 116708, CA 95058, CA 92393] Funding Source: Medline; NINDS NIH HHS [NS 47699, R01 NS047699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095058, R01CA092393, R01CA116708, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Darwanto A, 2003, CANCER SCI, V94, P442, DOI 10.1111/j.1349-7006.2003.tb01462.x; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Ego T, 2005, ONCOGENE, V24, P1914, DOI 10.1038/sj.onc.1208394; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599; Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Lin XH, 2003, CANCER RES, V63, P498; Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004; Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854; Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291; Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5; Relchelt J, 2002, J CELL SCI, V115, P2639; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Tanaka K, 2004, INT J ONCOL, V25, P1591; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Yatabe Y, 2002, ONCOGENE, V21, P8310, DOI 10.1038/sj.onc.1206014; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200	57	34	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4559	4572		10.1038/sj.onc.1209462	http://dx.doi.org/10.1038/sj.onc.1209462			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16786000	Green Accepted			2022-12-25	WOS:000239457500006
J	Barre, L; Venkatesan, N; Magdalou, J; Netter, P; Fournel-Gigleux, S; Ouzzine, M				Barre, Lydia; Venkatesan, Narayanan; Magdalou, Jacques; Netter, Patrick; Fournel-Gigleux, Sylvie; Ouzzine, Mohamed			Evidence of calcium-dependent pathway in the regulation of human beta 1,3-glucuronosyltransferase-1 (GlcAT-I) gene expression: a key enzyme in proteoglycan synthesis	FASEB JOURNAL			English	Article						glycosyltransferase; glycosaminoglycan; promoter activation	HEPARAN-SULFATE PROTEOGLYCANS; GRANULOSA-CELLS INVITRO; GLUCURONOSYLTRANSFERASE-I; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCE; MOLECULAR-BASIS; SP1 BINDING; DNA-BINDING; TRANSCRIPTION	The importance of heparan-and chondroitinsulfate proteoglycans in physiological and pathological processes led to the investigation of the regulation of beta 1,3-glucuronosyltransferase I (GlcAT-I), responsible for the completion of glycosaminoglycan-protein linkage tetrasaccharide, a key step prior to polymerization of chondroitin-and heparan-sulfate chains. We have cloned and functionally characterized GlcAT-I 5'-flanking regulatory region. Mutation analysis and electrophoretic mobility shift assays demonstrated the importance of Sp1 motif located at -65/-56 position in promoter activity. Furthermore, we found that elevation of intracellular calcium concentration by the calcium ionophore ionomycin stimulated GlcAT-I gene expression as well as glycosaminoglycan chain synthesis in HeLa cells. Bisanthracycline, an anti-Sp1 compound, inhibited GlcAT-I basal promoter activity and suppressed ionomycin induction, suggesting the importance of Sp1 in calcium induction of GlcAT-I gene expression. Nuclear protein extracts from ionomycin-induced cells exhibited an increased DNA binding of Sp1 factor to the consensus sequence at position -65/-56. Signaling pathway analysis and MEK inhibition studies revealed the important role of p42/p44 MAPK in the stimulation of GlcAT-I promoter activity by ionomycin. The present study identifies, for the first time, GlcAT-I as a target of calcium-dependent signaling pathway and evidences the critical role of Sp1 transcription factor in the activation of GlcAT-I expression.	Univ Nancy 1, CNRS, UMR 7561, Fac Med, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Nancy 1, CNRS, UMR 7561, Fac Med, BP 184, F-54505 Vandoeuvre Les Nancy, France.	ouzzine@medecine.uhp-nancy.fr	Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950				Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; BELLIN ME, 1983, MOL CELL ENDOCRINOL, V29, P51, DOI 10.1016/0303-7207(83)90004-7; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Bontemps Y, 2003, J BIOL CHEM, V278, P21566, DOI 10.1074/jbc.M209366200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Czuwara-Ladykowska J, 2001, J BIOL CHEM, V276, P20839, DOI 10.1074/jbc.M010133200; Daidouji K, 2002, DIGEST DIS SCI, V47, P331, DOI 10.1023/A:1013718021713; DEVRIES BJ, 1986, RHEUMATOL INT, V6, P273, DOI 10.1007/BF00541319; DITTMER J, 1994, J BIOL CHEM, V269, P21428; Dittmer J, 2003, MOL CANCER, V2, P1; Fagnen G, 2000, J CELL BIOCHEM, V76, P322; Hapgood JP, 2001, CELL BIOL INT, V25, P17, DOI 10.1006/cbir.2000.0674; Heegaard AM, 2004, J CELL BIOCHEM, V93, P463, DOI 10.1002/jcb.20189; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Kang-Park S, 2001, BIOCHEM BIOPH RES CO, V283, P303, DOI 10.1006/bbrc.2001.4767; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, BIOCHEM J, V358, P539, DOI 10.1042/0264-6021:3580539; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kopp JL, 2004, J BIOL CHEM, V279, P19407, DOI 10.1074/jbc.M314115200; LATTARD V, 2005, IN PRESS PROTEIN EXP; LENZ RW, 1982, ENDOCRINOLOGY, V110, P1052, DOI 10.1210/endo-110-3-1052; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; McCormick C, 1999, MOL MED TODAY, V5, P481, DOI 10.1016/S1357-4310(99)01593-2; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Mukaratirwa S, 2004, J COMP PATHOL, V131, P259, DOI 10.1016/j.jcpa.2004.04.007; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Ouzzine M, 1999, FEBS LETT, V454, P187, DOI 10.1016/S0014-5793(99)00797-8; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Prydz K, 2000, J CELL SCI, V113, P193; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Valhmu WB, 1998, J BIOL CHEM, V273, P6196, DOI 10.1074/jbc.273.11.6196; VANDEWALLE B, 1994, J CANCER RES CLIN, V120, P389, DOI 10.1007/BF01240136; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; Vijayagopal P, 2001, ATHEROSCLEROSIS, V157, P353, DOI 10.1016/S0021-9150(00)00742-5; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wegrowski Y, 2004, CRIT REV ONCOL HEMAT, V49, P259, DOI 10.1016/j.critrevonc.2003.10.005; Wendt CH, 2000, J BIOL CHEM, V275, P41396, DOI 10.1074/jbc.M004759200; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6; Zhuang Y, 2000, J BIOL CHEM, V275, P24173, DOI 10.1074/jbc.M002953200	54	19	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1692	+		10.1096/fj.05-5073fje	http://dx.doi.org/10.1096/fj.05-5073fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807373				2022-12-25	WOS:000240266600017
J	Mercado, ML; Amenta, AR; Hagiwara, H; Rafii, MS; Lechner, BE; Owens, RT; McQuillan, DJ; Froehner, SC; Fallon, JR				Mercado, Mary Lynn; Amenta, Alison R.; Hagiwara, Hiroki; Rafii, Michael S.; Lechner, Beatrice E.; Owens, Rick T.; McQuillan, David J.; Froehner, Stanley C.; Fallon, Justin R.			Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS	FASEB JOURNAL			English	Article						dystrophin-associated protein complex; alpha-dystrobrevin-2; sarcoglycans; beta 1-syntrophin	NITRIC-OXIDE SYNTHASE; LEUCINE-RICH PROTEOGLYCANS; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; TARGETED DISRUPTION; ALPHA-DYSTROBREVIN; DEFICIENT MUSCLE; DECORIN; COMPLEX; MICE	The dystrophin-associated protein complex (DAPC) provides a linkage between the cytoskeleton and the extracellular matrix (ECM) and is also a scaffold for a host of signaling molecules. The constituents of the DAPC must be targeted to the sarcolemma in order to properly function. Biglycan is an ECM molecule that associates with the DAPC. Here, we show that biglycan null mice exhibit a mild dystrophic phenotype and display a selective reduction in the localization of alpha-dystrobrevin-1 and -2, alpha- and beta 1-syntrophin, and nNOS at the sarcolemma. Purified biglycan induces nNOS redistribution to the plasma membrane in cultured muscle cells. Biglycan protein injected into muscle becomes stably associated with the sarcolemma and ECM for at least 2 wk. This injected biglycan restores the sarcolemmal expression of alpha-dystrobrevin-1 and -2, and beta 1- and beta 2-syntrophin in biglycan null mice. We conclude that biglycan is important for the maintenance of muscle cell integrity and plays a direct role in regulating the expression and sarcolemmal localization of the intracellular signaling proteins dystrobrevin-1 and -2, alpha- and beta 1-syntrophin and nNOS.	Brown Univ, Dept Neurosci, Providence, RI 02912 USA; LifeCell Corp, Branchburg, NJ USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	Brown University; University of Washington; University of Washington Seattle	Fallon, JR (corresponding author), Brown Univ, Dept Neurosci, 190 Thayer St,Box 1953, Providence, RI 02912 USA.	Justin_Fallon@brown.edu			NCRR NIH HHS [RR15578, P20 RR015578] Funding Source: Medline; NIAMS NIH HHS [AR42826, R01 AR042826] Funding Source: Medline; NICHD NIH HHS [R01 HD023924-14S1, R01 HD023924-14, HD23924, R01 HD023924, R01 HD023924-13A1, R01 HD023924-17, R01 HD023924-15, R01 HD023924-12, R01 HD023924-16] Funding Source: Medline; NIMH NIH HHS [T32 MH020068, T32 MH020068-02, T32MH20068, T32 MH020068-03, T32 MH020068-01, T32 MH020068-05, T32 MH020068-04] Funding Source: Medline; NINDS NIH HHS [R01 NS033145, NS4678, NS33145, R44 NS045432] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023924] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033145, R44NS045432] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdelmoity A, 2000, FEBS LETT, V482, P65, DOI 10.1016/S0014-5793(00)02038-X; Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Casar JC, 2004, DEV BIOL, V268, P358, DOI 10.1016/j.ydbio.2003.12.025; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Compton AG, 2005, J NEUROPATH EXP NEUR, V64, P350, DOI 10.1093/jnen/64.4.350; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Crosbie RH, 2002, FASEB J, V16, P1786, DOI 10.1096/fj.02-0519com; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Goldberg M, 2005, CALCIFIED TISSUE INT, V77, P297, DOI 10.1007/s00223-005-0026-7; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hack AA, 2000, MICROSC RES TECHNIQ, V48, P167, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<167::AID-JEMT5>3.0.CO;2-T; Hayashi Y, 2005, DEV BIOL, V277, P222, DOI 10.1016/j.ydbio.2004.09.022; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; Marchand S, 2001, EUR J NEUROSCI, V13, P221, DOI 10.1046/j.1460-9568.2001.01373.x; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181; SAXON DW, 1994, NEUROREPORT, V5, P809, DOI 10.1097/00001756-199403000-00018; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yoshida M, 2000, HUM MOL GENET, V9, P1033, DOI 10.1093/hmg/9.7.1033	32	48	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1724	+		10.1096/fj.05-5124fje	http://dx.doi.org/10.1096/fj.05-5124fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807372	Green Accepted			2022-12-25	WOS:000240266600028
J	Li, B; Sharpe, EE; Maupin, AB; Teleron, AA; Pyle, AL; Carmeliet, P; Young, PP				Li, Bin; Sharpe, Emerson E.; Maupin, Amanda B.; Teleron, Amylynn A.; Pyle, Amy L.; Carmeliet, Peter; Young, Pampee P.			VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization	FASEB JOURNAL			English	Article						VEGF receptors; BM transplant models; angiogenesis; placental growth factor	ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR RECEPTOR-1; BETA-GLUCURONIDASE; MURINE MODEL; MOBILIZATION; ANGIOGENESIS; MUCOPOLYSACCHARIDOSIS; REVASCULARIZATION; PROLIFERATION; HEMATOPOIESIS	There are growing data to suggest that tissue hypoxia represents a critical force that drives adult vasculogenesis. Vascular endothelial growth factor (VEGF) expression is dramatically up-regulated by hypoxia and results in enhanced neovascularization. Although the role of VEGF in angiogenesis has been well characterized, its role in adult vasculogenesis remains poorly understood. We used two distinct murine bone marrow transplantation (BMT) models to demonstrate that increased VEGF levels at the site of tumor growth promoted vasculogenesis in vivo. This effect of VEGF was downstream of its effect to enhance either mobilization or survival of circulating endothelial progenitor cells (EPCs). Both VEGFR1 (flt1) and VEGFR2 (flk1) are expressed on culture expanded human EPCs. Previous studies suggest that the effect of VEGF on endothelial cell migration is primarily mediated via VEGFR2; however, VEGF-induced EPC migration in vitro was mediated by both receptors, suggesting that VEGF-VEGFR1 interactions in EPCs are distinct from differentiated endothelial cells. We used specific blocking antibodies to these receptors to demonstrate that VEGFR1 plays an important role in human EPC recruitment to tumors. These findings were further supported by our finding that tumor-associated placental growth factor (PlGF), a VEGFR1-specific agonist, increased tumor vasculogenesis in a murine BMT model. We further showed that both VEGF receptors were necessary for the formation of functional vessels derived from exogenously administered human ex vivo expanded EPCs. Our data suggest local VEGF and/or PlGF expression promote vasculogenesis; VEGF plays a role in EPC recruitment and subsequent formation of functional vessels.	Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN USA; Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Vanderbilt University; Vanderbilt University; Flanders Institute for Biotechnology (VIB); KU Leuven	Young, PP (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, 1161 21st Ave S,C2217 MCN, Nashville, TN 37232 USA.	pampee.young@vanderbilt.edu	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821	NHLBI NIH HHS [KO8HL84020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL084020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Argraves WS, 2002, DEV DYNAM, V225, P298, DOI 10.1002/dvdy.10162; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Asaumi N, 2001, ANN HEMATOL, V80, P387, DOI 10.1007/s002770100309; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bautch VL, 2000, BLOOD, V95, P1979, DOI 10.1182/blood.V95.6.1979; Boyer M, 2000, J VASC SURG, V31, P181, DOI 10.1016/S0741-5214(00)70080-2; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; Drake CJ, 2000, DEV BIOL, V224, P178, DOI 10.1006/dbio.2000.9744; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; Feng D, 2000, MICROVASC RES, V59, P24, DOI 10.1006/mvre.1999.2207; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FISHMAN WH, 1967, NATURE, V213, P457, DOI 10.1038/213457a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fragoso R, 2006, BLOOD, V107, P1608, DOI 10.1182/blood-2005-06-2530; Freeman BJ, 1999, BLOOD, V94, P2142, DOI 10.1182/blood.V94.6.2142.418k16_2142_2150; Gill M, 2001, CIRC RES, V88, P167; GLASER JH, 1973, J LAB CLIN MED, V82, P969; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hofling AA, 2004, MOL THER, V9, P856, DOI 10.1016/j.ymthe.2004.03.013; Hofling AA, 2003, BLOOD, V101, P2054, DOI 10.1182/blood-2002-08-2597; Hristov M, 2004, J CELL MOL MED, V8, P498, DOI 10.1111/j.1582-4934.2004.tb00474.x; Ii M, 2005, CIRCULATION, V111, P1114, DOI 10.1161/01.CIR.0000157144.24888.7E; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jiang SG, 2004, P NATL ACAD SCI USA, V101, P16891, DOI 10.1073/pnas.0404398101; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Moore XL, 2004, GENE THER, V11, P811, DOI 10.1038/sj.gt.3302151; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022; Poole TJ, 2001, DEV DYNAM, V220, P1, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2; RABELINK TJ, 2004, ARTERIOSCL THROM VAS, V24, P1; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Rumpold H, 2004, J CELL MOL MED, V8, P509, DOI 10.1111/j.1582-4934.2004.tb00475.x; Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Solanilla A, 2003, BRIT J HAEMATOL, V120, P782, DOI 10.1046/j.1365-2141.2003.04155.x; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Teleron AA, 2005, TRANSFUSION, V45, P21, DOI 10.1111/j.1537-2995.2005.04191.x; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Thomas J, 2002, CURR OPIN HEMATOL, V9, P183, DOI 10.1097/00062752-200205000-00002; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Vincent L, 2005, CANCER RES, V65, P3185, DOI 10.1158/0008-5472.CAN-04-3598; Xie KP, 2004, CYTOKINE GROWTH F R, V15, P297, DOI 10.1016/j.cytogfr.2004.04.003; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Young PP, 2005, CIRCULATION, V111, P2382, DOI 10.1161/01.CIR.0000164235.26339.78; Young PP, 2003, MOL THER, V7, P52, DOI 10.1016/S1525-0016(02)00016-5; Young PP, 2002, P NATL ACAD SCI USA, V99, P11951, DOI 10.1073/pnas.182215799; Zhang Lijian, 2005, World J Surg Oncol, V3, P68, DOI 10.1186/1477-7819-3-68	67	272	310	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1495	+		10.1096/fj.05-5137fje	http://dx.doi.org/10.1096/fj.05-5137fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754748				2022-12-25	WOS:000240266000029
J	Du, QY; Jovanovic, S; Clelland, A; Sukhodub, A; Budas, G; Phelan, K; Murray-Tait, V; Malone, L; Jovanovic, A				Du, Qingyou; Jovanovic, Sofija; Clelland, Allyson; Sukhodub, Andrey; Budas, Grant; Phelan, Karen; Murray-Tait, Victoria; Malone, Lorraine; Jovanovic, Aleksandar			Overexpression of SUR2A generates a cardiac phenotype resistant to ischemia	FASEB JOURNAL			English	Article						SUR2A; K-ATP channel; cardioprotection; hypoxia; heart	K-ATP CHANNELS; SENSITIVE POTASSIUM CHANNEL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; VENTRICULAR MYOCYTES; H9C2 CELLS; HYPOXIA; HEART; CARDIOMYOCYTES; EXPRESSION; PROTECTION	ATP-sensitive K+ (K-ATP) channels are present in the sarcolemma of cardiac myocytes where they link membrane excitability with the cellular bioenergetic state. These channels are in vivo composed of Kir6.2, a pore-forming subunit, SUR2A, a regulatory subunit, and at least four accessory proteins. In the present study, real-time RT-PCR has demonstrated that of all six sarcolemmal K-ATP channel-forming proteins, SUR2A was probably the least expressed protein. We have generated mice where the SUR2A was under the control of a cytomegalovirus promoter, a promoter that is more efficient than the native promoter. These mice had an increase in SUR2A mRNA/protein levels in the heart whereas levels of mRNAs of other channel-forming proteins were not affected at all. Imunoprecipitation/ Western blot and patch clamp electrophysiology has shown an increase in K-ATP channel numbers in the sarcolemma of transgenic mice. Cardiomyocytes from transgenic mice responded to hypoxia with shortening of action membrane potential and were significantly more resistant to this insult than cardiomyocytes from the wild-type. The size of myocardial infarction in response to ischemia-reperfusion was much smaller in hearts from transgenic mice compared to those in wild-type. We conclude that overexpression of SUR2A generates cardiac phenotype resistant to hypoxia/ischemia/reperfusion injury due at least in part to increase in levels of sarcolemmal K-ATP channels.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318; Clelland, Allyson/0000-0003-3637-8497	Biotechnology and Biological Sciences Research Council [S18744] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Medical Research Council [G0400608(71317), G0400608] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline; MRC [G0400608] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Babiker FA, 2002, CARDIOVASC RES, V53, P709, DOI 10.1016/S0008-6363(01)00526-0; BILLMAN GE, 1994, CARDIOVASC RES, V28, P762, DOI 10.1093/cvr/28.6.762; Budas GR, 2004, FASEB J, V18, P1046, DOI 10.1096/fj.04-1602fje; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Crawford RM, 2003, J BIOL CHEM, V278, P31444, DOI 10.1074/jbc.M303051200; Crawford RM, 2002, EMBO J, V21, P3936, DOI 10.1093/emboj/cdf388; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; Dhar-Chowdhury P, 2005, J BIOL CHEM, V280, P38464, DOI 10.1074/jbc.M508744200; Gogelein H, 2001, N-S ARCH PHARMACOL, V364, P33, DOI 10.1007/s002100000391; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jovanovic S, 2006, BIOCHEM BIOPH RES CO, V341, P57, DOI 10.1016/j.bbrc.2005.12.147; Jovanovic S, 2005, DIABETES, V54, P383, DOI 10.2337/diabetes.54.2.383; Jovanovic S, 2005, EMBO REP, V6, P848, DOI 10.1038/sj.embor.7400489; Kane GC, 2005, J MOL CELL CARDIOL, V38, P937, DOI 10.1016/j.yjmcc.2005.02.026; Kang YH, 2004, J BIOL CHEM, V279, P47125, DOI 10.1074/jbc.M404954200; Kloner RA, 2004, J AM COLL CARDIOL, V44, P276, DOI 10.1016/j.jacc.2004.03.068; Kloner RA, 2001, CIRCULATION, V104, P3158, DOI 10.1161/hc5001.100039; Kolar F, 2004, PHYSIOL RES, V53, pS3; Lacza Z, 2003, J MOL CELL CARDIOL, V35, P1339, DOI 10.1016/S0022-2828(03)00249-9; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Shibasaki T, 2004, DIABETES, V53, pS59, DOI 10.2337/diabetes.53.suppl_3.S59; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Singh H, 2003, J MOL CELL CARDIOL, V35, P445, DOI 10.1016/S0022-2828(03)00041-5; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; van Bever L, 2004, AM J PHYSIOL-HEART C, V287, pH850, DOI 10.1152/ajpheart.00054.2004; Verkerk AO, 1996, J MOL CELL CARDIOL, V28, P2443, DOI 10.1006/jmcc.1996.0237; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	34	74	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1131	1141		10.1096/fj.05-5483com	http://dx.doi.org/10.1096/fj.05-5483com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770012	Green Accepted			2022-12-25	WOS:000240210300013
J	Huang, Y; Li, X; Jiang, J; Frank, SJ				Huang, Y.; Li, X.; Jiang, J.; Frank, S. J.			Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells	ONCOGENE			English	Article; Proceedings Paper	86th Annual Meeting of the Endocrine-Society	JUN 12-15, 2004	New Orleans, LA	Endocrine Soc		prolactin; EGFR; signaling; phosphorylation; synergy	JAK2 TYROSINE KINASE; EGF-RECEPTOR; MAMMARY-GLAND; ERBB RECEPTORS; ACTIVATING PROTEIN-1; EPITHELIAL-CELLS; MESSENGER-RNA; HORMONE; INVOLVEMENT; EXPRESSION	Prolactin (PRL) is a polypeptide hormone produced by the anterior pituitary gland and other sites that acts both systemically and locally to cause lactation and other biological effects by interacting with the PRL receptor, a Janus kinase (JAK)2-coupled cytokine receptor family member, and activating downstream signal pathways. Recent evidence suggests PRL is a player in the pathogenesis and progression of breast cancer. Epidermal growth factor (EGF) also has effects on breast tissue, working through its receptors, epidermal growth factor receptor (EGFR) and ErbB-2 (c-neu, HER2), both intrinsic tyrosine kinase growth factor receptors. EGFR promotes pubertal breast ductal morphogenesis in mice, and both EGFR and ErbB-2 are relevant in pathogenesis and behavior of breast and other human cancers. Previous studies showed that PRL and EGF synergize to enhance motility in the human breast cancer cell line, T47D. In this study, we explored crosstalk between the PRL and EGF signaling pathways in T47D cells, with an ultimate aim of understanding how these two important factors might work together in vivo to affect breast cancer behavior. Both PRL and EGF caused robust signaling in T47D cells; PRL acutely activated JAK2, signal transducer and activator of transcription-5 (STAT5), and extracellular signal-regulated kinase-1 and -2 (ERK1 and ERK2), whereas EGF caused EGFR activation and consequent src homology collagen (SHC) activation and ERK activation. Notably, PRL also caused phosphorylation of the EGFR and ErbB-2 at sites detected by PTP101, an antibody that recognizes threonine phosphorylation at consensus motifs for ERK-induced phosphorylation. PRL-induced PTP101-reactive phosphorylation was prevented by pretreatment with PD98059, an ERK pathway inhibitor. Furthermore, PRL synergized with EGF in activating SHC and ERK and transactivating a luciferase reporter driven by c-fos gene enhancer elements, suggesting that PRL allowed markedly enhanced EGF signaling. This was accompanied by substantial inhibition of EGF-induced EGFR downregulation when PRL and EGF cotreatment was compared to EGF treatment alone. This effect of PRL was abrogated by ERK pathway inhibitor pretreatment. Our data suggest that PRL synergistically augments EGF signaling in T47D breast cancer cells at least in part by lessening EGF-induced EGFR downregulation and that this effect requires PRL-induced ERK activity and threonine phosphorylation of EGFR.	Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Endocrinol Sect, Med Serv, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R29DK046395, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANDERSON E, 1993, EUR J CANCER, V29A, P209, DOI 10.1016/0959-8049(93)90178-I; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Badache A, 2001, CANCER RES, V61, P383; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BERGER MS, 1988, CANCER RES, V48, P1238; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chen NY, 2002, INT J ONCOL, V20, P813; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Clevenger CV, 2001, LUPUS, V10, P706, DOI 10.1191/096120301717164949; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; Das R, 1996, ONCOGENE, V13, P1139; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FENTON SE, 1993, MOL BIOL CELL, V4, P773, DOI 10.1091/mbc.4.8.773; Fenton SE, 1997, EXP CELL RES, V236, P285, DOI 10.1006/excr.1997.3727; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Horseman ND, 1999, J MAMMARY GLAND BIOL, V4, P79, DOI 10.1023/A:1018708704335; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Huang Y, 2004, ENDOCRINOLOGY, V145, P3297, DOI 10.1210/en.2003-1658; Huang Y, 2004, MOL ENDOCRINOL, V18, P1471, DOI 10.1210/me.2003-0418; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laskin JJ, 2004, CANCER TREAT REV, V30, P1, DOI 10.1016/j.ctrv.2003.10.002; LI X, 2005, ENDOCRINE SOC PROGRA, P3; Lichtner RB, 2003, BIOMED PHARMACOTHER, V57, P447, DOI 10.1016/j.biopha.2003.09.006; Lichtner RB, 2001, CANCER RES, V61, P5790; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; MCMURRAY RW, 1995, J RHEUMATOL, V22, P2084; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Quijano VJ, 1998, J BIOL CHEM, V273, P1200, DOI 10.1074/jbc.273.2.1200; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 2000, CYTOKINE REFERENCE O, P267; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wiepz GJ, 1997, J CELL PHYSIOL, V173, P44, DOI 10.1002/(SICI)1097-4652(199710)173:1<44::AID-JCP6>3.0.CO;2-J; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, ENDOCR J, V45, pS27, DOI 10.1507/endocrj.45.Suppl_S27	100	47	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7565	7576		10.1038/sj.onc.1209740	http://dx.doi.org/10.1038/sj.onc.1209740			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16785991				2022-12-25	WOS:000242655500002
J	Shimazu, T; Komatsu, Y; Nakayama, KI; Fukazawa, H; Horinouchi, S; Yoshida, M				Shimazu, T.; Komatsu, Y.; Nakayama, K. I.; Fukazawa, H.; Horinouchi, S.; Yoshida, M.			Regulation of SV40 large T-antigen stability by reversible acetylation	ONCOGENE			English	Article						SV40 T-Ag; acetylation; TSA; HDAC	ANCHORAGE-INDEPENDENT GROWTH; HISTONE DEACETYLASE; DNA-REPLICATION; TRICHOSTATIN-A; IN-VIVO; P53; PHOSPHORYLATION; SIMIAN-VIRUS-40; PROTEIN; P300	Reversible acetylation on protein lysine residues has been shown to regulate the function of both nuclear proteins such as histones and p53 and cytoplasmic proteins such as alpha-tubulin. To identify novel acetylated proteins, we purified several proteins by the affinity to an anti-acetylated-lysine antibody from cells treated with trichostatin A (TSA). Among the proteins identified, here we report acetylation of the SV40 large T antigen (T-Ag). The acetylation site was determined to be lysine-697, which is located adjacent to the C-terminal Cdc4 phosphodegron (CPD). Overexpression of the CBP acetyltransferase acetylated T-Ag, whereas HDAC1, HDAC3 and SIRT1 bound and deacetylated T-Ag. The acetylation and deacetylation occurred independently of p53, a binding partner of T-Ag, but the acetylation was enhanced in the presence of p53. T-Ag in the cells treated with TSA and NA or the acetylation mimic mutant (K697Q) became unstable in COS-7 cells, suggesting that acetylation regulates stability of T-Ag. Indeed, NIH3T3 cells stably expressing K697Q showed decreased anchorage-independent growth compared with those expressing wild type or the K697R mutant. These results demonstrate that acetylation destabilizes T-Ag and regulates the transforming activity of T-Ag in NIH3T3 cells.	RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo, Japan; Adv Life Sci Inst Inc, Wako, Saitama, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 812, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo, Japan	RIKEN; University of Tokyo; Kyushu University; National Institute of Infectious Diseases (NIID)	Yoshida, M (corresponding author), RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	yoshidam@riken.jp	SHIMAZU, Tadahiro/ABC-3950-2020; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Komatsu, Yasuhiko/0000-0003-1739-8222				Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Komatsu Y, 2003, J IMMUNOL METHODS, V272, P161, DOI 10.1016/S0022-1759(02)00500-8; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LEDUC C, 2006, IN PRESS ONCOGENE; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Poulin DL, 2004, J VIROL, V78, P8245, DOI 10.1128/JVI.78.15.8245-8253.2004; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; STACY T, 1989, J VIROL, V63, P5208, DOI 10.1128/JVI.63.12.5208-5215.1989; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; Xie AY, 2002, MOL CELL BIOL, V22, P7907, DOI 10.1128/MCB.22.22.7907-7918.2002; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	41	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7391	7400		10.1038/sj.onc.1209731	http://dx.doi.org/10.1038/sj.onc.1209731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767160				2022-12-25	WOS:000242419100008
J	Wang, J; Ou, ZL; Hou, YF; Luo, JM; Shen, ZZ; Ding, J; Shao, ZM				Wang, J.; Ou, Z-L; Hou, Y-F; Luo, J-M; Shen, Z-Z; Ding, J.; Shao, Z-M			Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential	ONCOGENE			English	Article						breast cancer; metastasis; Duffy antigen receptor for chemokines (DARC)	ENDOTHELIAL-CELLS; PROSTATE-CANCER; NEGATIVE INDIVIDUALS; TUMOR REJECTION; BINDING PROTEIN; ANGIOGENESIS; INTERLEUKIN-8; TUMORIGENICITY; IDENTIFICATION; GENE	In addition to the role in regulating leukocyte trafficking, chemokines recently have been shown to be involved in cancer growth and metastasis. Chemokine network in tumor neovascularity may be regulated by decoy receptors. Duffy antigen receptor for chemokines (DARC) is a specific decoy receptor binding with the angiogenic CC and CXC chemokines. To investigate the effects of DARC on the tumorigenesis and the metastasis potential of human breast cancer cells, human DARC cDNA was reintroduced into the MDA-MB-231 and MDA-MB-435HM cells which have a high capability of spontaneous pulmonary metastasis. We demonstrated that DARC overexpression induced inhibition of tumorigenesis and/ or metastasis through interfering with the tumor angiogenesis in vivo. This inhibition is associated with decreasing CCL2 protein levels, and MVD and MMP-9 expression in xenograft tumors. In human breast cancer samples, we also demonstrated that low expression of the DARC protein is significantly associated with estrogen receptor (ER) status, MVD, lymph node metastasis, distant metastasis and poor survival. Our results suggest for the first time that DARC is a negative regulator of growth in breast cancer, mainly by sequestration of angiogenic chemokines and subsequent inhibition of tumor neovascularity.	Fudan Univ, Canc Hosp,Shanghai Med Coll, Inst Canc,Dept Oncol, Dept Breast Surg,Breast Canc Inst, Shanghai 200032, Peoples R China; Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Shao, ZM (corresponding author), Fudan Univ, Canc Hosp,Shanghai Med Coll, Inst Canc,Dept Oncol, Dept Breast Surg,Breast Canc Inst, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com						Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Braun SE, 2000, J IMMUNOL, V164, P4025, DOI 10.4049/jimmunol.164.8.4025; Castilho L, 2004, VOX SANG, V87, P190, DOI 10.1111/j.1423-0410.2004.00554.x; Chaudhuri A, 2004, BRIT J HAEMATOL, V127, P356, DOI 10.1111/j.1365-2141.2004.05208.x; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; Comerford L, 2005, IMMUNOL LETT, V96, P163, DOI 10.1016/j.imlet.2004.08.018; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; Giovarelli M, 2000, J IMMUNOL, V164, P3200, DOI 10.4049/jimmunol.164.6.3200; HORUK R, 1994, J BIOL CHEM, V269, P17730; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Lentsch AB, 2002, FASEB J, V16, P1093, DOI 10.1096/fj.02-0066hyp; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Nibbs R, 2003, SEMIN IMMUNOL, V15, P287, DOI 10.1016/j.smim.2003.08.006; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Schutyser E, 2002, J BIOL CHEM, V277, P24584, DOI 10.1074/jbc.M112275200; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; Tang T, 1998, DNA SEQUENCE, V9, P129, DOI 10.3109/10425179809072188; Tournamille C, 2004, IMMUNOGENETICS, V55, P682, DOI 10.1007/s00251-003-0633-2; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Vicari AP, 2002, CYTOKINE GROWTH F R, V13, P143, DOI 10.1016/S1359-6101(01)00033-8	32	105	115	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7201	7211		10.1038/sj.onc.1209703	http://dx.doi.org/10.1038/sj.onc.1209703			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16785997				2022-12-25	WOS:000242046900009
J	Kobrossy, L; Rastegar, M; Featherstone, M				Kobrossy, Laila; Rastegar, Mojgan; Featherstone, Mark			Interplay between chromatin and trans-acting factors regulating the Hoxd4 promoter during neural differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RESPONSE ELEMENT; TRANSCRIPTION FACTOR YY1; RETINOIC ACID; GENE-EXPRESSION; POLYCOMB GROUP; 5'-FLANKING REGION; DNA-BINDING; REQUIRES; ANTERIOR; PROTEIN	Correct patterning of the antero-posterior axis of the embryonic trunk is dependent on spatiotemporally restricted Hox gene expression. In this study, we identified components of the Hoxd4 P1 promoter directing expression in neurally differentiating retinoic acid-treated P19 cells. We mapped three nucleosomes that are subsequently remodeled into an open chromatin state upon retinoic acid-induced Hoxd4 transcription. These nucleosomes spanned the Hoxd4 transcriptional start site in addition to a GC-rich positive regulatory element located 3' to the initiation site. We further identified two major cis-acting regulatory elements. An autoregulatory element was shown to recruit HOXD4 and its cofactor PBX1 and to positively regulate Hoxd4 expression in differentiating P19 cells. Conversely, the Polycomb group (PcG) protein Ying-Yang 1 (YY1) binds to an internucleosomal linker and represses Hoxd4 transcription before and during transcriptional activation. Sequential chromatin immunoprecipitation studies revealed that the PcG protein MEL18 was co-recruited with YY1 only in undifferentiated P19 cells, suggesting a role for MEL18 in silencing Hoxd4 transcription in undifferentiated P19 cells. This study links for the first time local chromatin remodeling events that take place during transcriptional activation with the dynamics of transcription factor association and DNA accessibility at a Hox regulatory region.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University	Featherstone, M (corresponding author), McGill Univ, Ctr Canc, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	mark.featherstone@mcgill.ca	Rastegar, Mojgan/T-9394-2019; Featherstone, Mark/E-8057-2010	Rastegar, Mojgan/0000-0003-3619-6116; Featherstone, Mark/0000-0003-1576-046X				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Akasaka T, 2001, DEVELOPMENT, V128, P1587; Akiyama H, 2002, INVEST OPHTH VIS SCI, V43, P1367; Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Brend T, 2003, DEVELOPMENT, V130, P2717, DOI 10.1242/dev.00471; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; CAREY M, 2000, TRANSCRIPTIONAL REGU, P338; Chambeyron S, 2005, DEVELOPMENT, V132, P2215, DOI 10.1242/dev.01813; Deschamps J, 2005, DEVELOPMENT, V132, P2931, DOI 10.1242/dev.01897; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Duboule D, 2004, DEV CELL, V6, P738, DOI 10.1016/j.devcel.2004.05.016; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; Dupe V, 1997, DEVELOPMENT, V124, P399; Fan HY, 2005, MOL CELL, V17, P805, DOI 10.1016/j.molcel.2005.02.024; Featherstone M, 2003, AD DEV BIOL, V13, P1; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; Folberg A, 1997, J BIOL CHEM, V272, P29151, DOI 10.1074/jbc.272.46.29151; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; Gilthorpe J, 2002, DEVELOPMENT, V129, P3887; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; Haller K, 2004, J BIOL CHEM, V279, P49384, DOI 10.1074/jbc.M406046200; Horie S, 2001, J BIOL CHEM, V276, P2440, DOI 10.1074/jbc.M004942200; Houle M, 2000, MOL CELL BIOL, V20, P6579, DOI 10.1128/MCB.20.17.6579-6586.2000; Huang DY, 2002, DEV DYNAM, V223, P353, DOI 10.1002/dvdy.10057; Kim MH, 1998, SOMAT CELL MOLEC GEN, V24, P371, DOI 10.1023/A:1024446625716; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Maconochie M, 1999, DEVELOPMENT, V126, P1483; Maconochie M, 1996, ANNU REV GENET, V30, P529, DOI 10.1146/annurev.genet.30.1.529; Manzanares M, 2000, NATURE, V408, P854, DOI 10.1038/35048570; Manzanares M, 1999, DEV BIOL, V211, P220, DOI 10.1006/dbio.1999.9318; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; Meccia E, 2003, BBA-GENE STRUCT EXPR, V1626, P1, DOI 10.1016/S0167-4781(03)00018-6; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032; Mohd-Sarip A, 2005, GENE DEV, V19, P1755, DOI 10.1101/gad.347005; Morrison A, 1997, DEVELOPMENT, V124, P3135; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nolte C, 2003, MECH DEVELOP, V120, P325, DOI 10.1016/S0925-4773(02)00442-2; Nonchev S, 1996, P NATL ACAD SCI USA, V93, P9339, DOI 10.1073/pnas.93.18.9339; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oosterveen T, 2003, EMBO J, V22, P262, DOI 10.1093/emboj/cdg029; Packer AI, 1998, DEVELOPMENT, V125, P1991; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1993, MOL CELL BIOL, V13, P257; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; Roelen BAJ, 2002, MECH DEVELOP, V119, P81, DOI 10.1016/S0925-4773(02)00329-5; Ross JM, 2003, DEV CELL, V4, P891, DOI 10.1016/S1534-5807(03)00135-7; Srinivasan L, 2004, GENE DEV, V18, P2596, DOI 10.1101/gad.1228204; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; Szutorisz H, 2005, TRENDS BIOCHEM SCI, V30, P593, DOI 10.1016/j.tibs.2005.08.006; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Tour E, 2005, DEVELOPMENT, V132, P5271, DOI 10.1242/dev.02138; Weill L, 2003, J VIROL, V77, P2903, DOI 10.1128/JVI.77.5.2903-2914.2003; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Zhang F, 2000, MECH DEVELOP, V96, P79, DOI 10.1016/S0925-4773(00)00377-4; Zhang F, 1997, MECH DEVELOP, V67, P49, DOI 10.1016/S0925-4773(97)00104-4	70	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25926	25939		10.1074/jbc.M602555200	http://dx.doi.org/10.1074/jbc.M602555200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16757478	hybrid			2022-12-25	WOS:000240249500007
J	Karbowniczek, M; Robertson, GP; Henske, EP				Karbowniczek, Magdalena; Robertson, Gavin P.; Henske, Elizabeth Petri			Rheb inhibits C-Raf activity and B-Raf/C-Raf heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; FACIO-CUTANEOUS SYNDROME; CELL-GROWTH; MAMMALIAN PROTEIN; KINASE-ACTIVITY; GERMLINE KRAS; DIRECT TARGET; ACTIVATION; MUTATIONS; BRAF	The Ras-Raf-MEK signaling cascade is critical for normal development and is activated in many forms of cancer. We have recently shown that B-Raf kinase interacts with and is inhibited by Rheb, the target of the GTPase-activating domain of the tuberous sclerosis complex 2 gene product tuberin. Here, we demonstrate for the first time that activation of Rheb is associated with decreased B-Raf and C-Raf phosphorylation at residues Ser-446 and Ser-338, respectively, concomitant with a decrease in the activities of both kinases and decreased heterodimerization of B-Raf and C-Raf. Importantly, the impact of Rheb on B-Raf/C-Raf heterodimerization and kinase activity are rapamycin-insensitive, indicating that they are independent of Rheb activation of the mammalian target of rapamycin-Raptor complex. In addition, we found that Rheb inhibits the association of B-Raf with H-Ras. Taken together, these results support a central role of Rheb in the regulation of the Ras/B-Raf/C-Raf/MEK signaling network.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Henske, EP (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Elizabeth.Henske@fccc.edu	Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051052, R29DK051052] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51052] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Astrinidis A, 2004, J CHILD NEUROL, V19, P710, DOI 10.1177/08830738040190091201; Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036; Brose MS, 2002, CANCER RES, V62, P6997; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mizutani S, 2001, FEBS LETT, V507, P295, DOI 10.1016/S0014-5793(01)02992-1; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; Staehler M, 2006, UROLOGE, V45, P99, DOI 10.1007/s00120-005-0982-6; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yoon SH, 2004, BIOCHEMISTRY-MOSCOW+, V69, P799, DOI 10.1023/B:BIRY.0000040206.71415.6f; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	38	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25447	25456		10.1074/jbc.M605273200	http://dx.doi.org/10.1074/jbc.M605273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803888	hybrid			2022-12-25	WOS:000240031300047
J	Liu, HB; Carlsson, L; Grundstrom, T				Liu, Hebin; Carlsson, Leif; Grundstrom, Thomas			Identification of an N-terminal transactivation domain of Runx1 that separates molecular function from global differentiation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ROOT GANGLION NEURONS; CORE-BINDING-FACTOR; TRANSCRIPTION FACTOR; DNA-BINDING; ADULT HEMATOPOIESIS; DISTINCT ROLES; FAMILY-MEMBERS; IN-VITRO	RUNX1, or AML1, is a transcription factor that is the most frequent target for chromosomal gene translocations in acute leukemias. RUNX1 is essential for definitive hematopoiesis in embryos and profoundly influences adult steady-state hematopoiesis both positively and negatively. To investigate this wide range of normal activities and the pathological role of RUNX1, it is important to define the functions of different domains of the protein. RUNX1, RUNX2, and RUNX3 are highly conserved in their DNA binding runt homology domain and contain divergent sequences of unknown function N-terminal to this domain. Here we analyzed the role of the N-terminal sequence and the alpha-helix of the runt homology domain of Runx1 in DNA binding, transactivation, and megakaryocytopoiesis. Both the N terminus and the alpha-helix were found to reduce DNA binding of Runx1 and be essential for transactivation of the granulocyte-macrophage colony-stimulating factor and I alpha 1 promoters by Runx1. The N terminus of Runx1, including the alpha-helix, was also required for transactivation of a Gal4 reporter when expressed as fusion proteins with a Gal4 DNA binding domain, and the N terminus alone was capable of stimulating transcription when fused to the Gal4DNAbinding domain. The N terminus and the alpha-helix, however, were not required for megakaryocyte development from embryonic stem cells differentiated in vitro. Thus, our findings define a second transactivation domain of Runx1 that is differentially required for activation of transcription of some Runx1-dependent promoters and megakaryocytopoiesis.	Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden; Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden	Umea University; Umea University	Grundstrom, T (corresponding author), Umea Univ, Dept Mol Biol, SE-90187 Umea, Sweden.	Thomas.Grundstrom@molbiol.umu.se						Anglin Ian, 2004, Cancer Treat Res, V119, P189; Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Carlsson L, 2003, METHOD ENZYMOL, V365, P202; Carnicer MJ, 2002, LEUKEMIA, V16, P2329, DOI 10.1038/sj.leu.2402656; Cohen MM, 2001, AM J MED GENET, V104, P185, DOI 10.1002/ajmg.10064; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fukushima-Nakase Y, 2005, BLOOD, V105, P4298, DOI 10.1182/blood-2004-08-3372; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; HAWLEY RG, 1994, GENE THER, V1, P136; Hughes K, 1998, FEBS LETT, V441, P132, DOI 10.1016/S0014-5793(98)01537-3; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Inoue K, 2003, BLOOD CELL MOL DIS, V30, P157, DOI 10.1016/S1079-9796(03)00032-9; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kundu M, 2005, BLOOD, V106, P3621, DOI 10.1182/blood-2005-04-1447; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; Liu HB, 2004, J BIOL CHEM, V279, P29398, DOI 10.1074/jbc.M403173200; Nakao M, 2004, BRIT J HAEMATOL, V125, P709, DOI 10.1111/j.1365-2141.2004.04966.x; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pinto do O P, 1998, EMBO J, V17, P5744, DOI 10.1093/emboj/17.19.5744; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P384, DOI 10.1038/87531; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Taketani T, 2003, GENE CHROMOSOME CANC, V38, P1, DOI 10.1002/gcc.10246; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; Telfer JC, 2004, J IMMUNOL, V172, P4359, DOI 10.4049/jimmunol.172.7.4359; Telfer JC, 2001, DEV BIOL, V229, P363, DOI 10.1006/dbio.2000.9991; THORNELL A, 1993, J BIOL CHEM, V268, P21946; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Wolf-Watz M, 1999, EUR J BIOCHEM, V261, P251, DOI 10.1046/j.1432-1327.1999.00269.x; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Xu MJ, 2001, BLOOD, V97, P2016, DOI 10.1182/blood.V97.7.2016; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	62	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25659	25669		10.1074/jbc.M603249200	http://dx.doi.org/10.1074/jbc.M603249200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803898	hybrid			2022-12-25	WOS:000240031300069
J	Kingma, PS; Zhang, LQ; Ikegami, M; Hartshorn, K; McCormack, FX; Whitsett, JA				Kingma, Paul S.; Zhang, Liqian; Ikegami, Machiko; Hartshorn, Kevan; McCormack, Francis X.; Whitsett, Jeffrey A.			Correction of pulmonary abnormalities in Sftpd(-/-) mice requires the collagenous domain of surfactant protein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ALVEOLAR MACROPHAGE APOPTOSIS; TERMINAL DOMAINS; LUNG COLLECTINS; SP-A; HOMEOSTASIS; BINDING; EXPRESSION; DISTINCT; LIPOPOLYSACCHARIDES	Surfactant protein D (SP-D) is a member of the collectin family of innate defense proteins. Members of this family share four distinct structural domains: an N-terminal crosslinking domain, a collagenous domain, a neck region, and a carbohydrate recognition domain. In this study, the function of the collagenous domain was evaluated by expressing a SP-D collagen deletion mutant protein (rSftpdCDM) in wild type and SP-D null mice (Sftpd(-/-)). rSftpdCDM formed disulfide-linked trimers that further oligomerized into higher order structures. The mutant protein effectively bound carbohydrate and aggregated bacteria in vitro. Whereas rSftpdCDM did not disrupt pulmonary morphology or surfactant phospholipid levels in wild type mice, the mutant protein failed to rescue the emphysema or enlarged foamy macrophages that are characteristic of Sftpd(-/-) mice. Moreover, rSftpdCDM partitioned with small aggregate surfactant in a manner similar to SP- D, but rSftpdCDM did not correct the abnormal surfactant ultrastructure or phospholipid levels observed in Sftpd(-/-) mice. In contrast, rSftpdCDM completely corrected viral clearance and the abnormal inflammatory response that occurs following pulmonary influenza A challenge in Sftpd(-/-) mice. Our findings indicate that the collagen domain of SP-D is not required for assembly of disulfide-stabilized oligomers or the innate immune response to viral pathogens. The collagen domain of SP- D is required for the regulation of pulmonary macrophage activation, airspace remodeling, and surfactant lipid homeostasis.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Univ Cincinnati, Med Ctr, Pulm Crit Care Div, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; Boston University; Boston University; University System of Ohio; University of Cincinnati	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Hartshorn, Kevan/0000-0002-7196-7433	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060931, R01HL063329, P01HL056387, P50HL056387, R01HL068861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56387, HL60931, HL63329, HL68861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; Clark H, 2003, ANN NY ACAD SCI, V1010, P113, DOI 10.1196/annals.1299.019; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; DeSilva NS, 2003, AM J RESP CELL MOL, V29, P757, DOI 10.1165/rcmb.2003-0186OC; Ferguson JS, 2002, J IMMUNOL, V168, P1309, DOI 10.4049/jimmunol.168.3.1309; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; Hartshorn KL, 2002, INFECT IMMUN, V70, P6129, DOI 10.1128/IAI.70.11.6129-6139.2002; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Hartshorn KL, 2000, AM J PHYSIOL-LUNG C, V278, pL90, DOI 10.1152/ajplung.2000.278.1.L90; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Ikegami M, 2005, AM J PHYSIOL-LUNG C, V288, pL552, DOI 10.1152/ajplung.00142.2004; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Kishore U, 1996, BIOCHEM J, V318, P505, DOI 10.1042/bj3180505; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; Reed JA, 2000, AM J PHYSIOL-LUNG C, V278, pL1164, DOI 10.1152/ajplung.2000.278.6.L1164; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; Strong P, 1998, J IMMUNOL METHODS, V220, P139, DOI 10.1016/S0022-1759(98)00160-4; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; Wert S, 2000, CHEST, V117, p248S, DOI 10.1378/chest.117.5_suppl_1.248S; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Whitsett JA, 2005, BIOL NEONATE, V88, P175, DOI 10.1159/000087580; Zhang LQ, 2006, AM J PHYSIOL-LUNG C, V291, pL181, DOI 10.1152/ajplung.00015.2006; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200; Zhang LQ, 2002, J BIOL CHEM, V277, P38709, DOI 10.1074/jbc.M206200200; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	45	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24496	24505		10.1074/jbc.M600651200	http://dx.doi.org/10.1074/jbc.M600651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787926	hybrid			2022-12-25	WOS:000239847800045
J	Pham, XH; Farge, G; Shi, YH; Gaspari, M; Gustafsson, CM; Falkenberg, M				Pham, Xuan Hoi; Farge, Geraldine; Shi, Yonghong; Gaspari, Martina; Gustafsson, Claes M.; Falkenberg, Maria			Conserved sequence box II directs transcription termination and primer formation in mitochondriaw2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; DNA-REPLICATION; MAMMALIAN-CELLS; RNASE-H; PURIFIED PROTEINS; PRIMARY ORIGIN; HUMAN MTDNA; IN-VITRO; POLYMERASE; INITIATION	The human mitochondrial transcription machinery generates the RNA primers needed for initiation of heavy strand DNA synthesis. Most DNA replication events from the heavy strand origin are prematurely terminated, forming a persistent RNA-DNA hybrid, which remains annealed to the parental DNA strand. This triple-stranded structure is called the D-loop and encompasses the conserved sequence box II, a DNA element required for proper primer formation. We here use a purified recombinant mitochondrial transcription system and demonstrate that conserved sequence box II is a sequence-dependent transcription termination element in vitro. Transcription from the light strand promoter is prematurely terminated at positions 300-282 in the mitochondrial genome, which coincide with the major RNA-DNA transition points in the D-loop of human mitochondria. Based on our findings, we propose a model for primer formation at the origin of heavy strand DNA replication.	Novum, Karolinska Inst, Div Metab Dis, Dept Lab Med, SE-14186 Stockholm, Sweden	Karolinska Institutet	Falkenberg, M (corresponding author), Novum, Karolinska Inst, Div Metab Dis, Dept Lab Med, SE-14186 Stockholm, Sweden.	maria.falkenberg@ki.se	farge, geraldine/M-2803-2018; shi, yonghong/E-8254-2017	shi, yonghong/0000-0002-5265-7982; farge, geraldine/0000-0003-1054-4274; Gustafsson, Claes/0000-0003-3531-8468; Pham, Xuan Hoi/0000-0002-9629-2970				BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; BROWN WM, 1978, P NATL ACAD SCI USA, V75, P735, DOI 10.1073/pnas.75.2.735; CANTATORE P, 1995, J BIOL CHEM, V270, P25020, DOI 10.1074/jbc.270.42.25020; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; Chapados BR, 2001, J MOL BIOL, V307, P541, DOI 10.1006/jmbi.2001.4494; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CREWS S, 1979, NATURE, V277, P192, DOI 10.1038/277192a0; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FULLER CW, 1985, J BIOL CHEM, V260, P3197; FULLER CW, 1985, J BIOL CHEM, V260, P3185; Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003; Gaspari M, 2004, EMBO J, V23, P4606, DOI 10.1038/sj.emboj.7600465; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275; KISS T, 1992, EMBO J, V11, P3737, DOI 10.1002/j.1460-2075.1992.tb05459.x; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; TAPPER DP, 1981, J BIOL CHEM, V256, P5109; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9; Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	35	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24647	24652		10.1074/jbc.M602429200	http://dx.doi.org/10.1074/jbc.M602429200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790426	hybrid			2022-12-25	WOS:000239847800059
J	Sahin, B; Shu, HJ; Fernandez, J; El-Armouche, A; Molkentin, JD; Nairn, AC; Bibb, JA				Sahin, Bogachan; Shu, Hongjun; Fernandez, Joseph; El-Armouche, Ali; Molkentin, Jeffery D.; Nairn, Angus C.; Bibb, James A.			Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CAMP-REGULATED PHOSPHOPROTEIN; IMMUNOCYTOCHEMICAL LOCALIZATION; ACETYLCHOLINE-RECEPTOR; MOLECULAR-MECHANISMS; CARDIAC-FUNCTION; HEART-FAILURE; DARPP-32; DOPAMINE; RAT	Inhibitor-1 becomes a potent inhibitor of protein phosphatase 1 when phosphorylated by cAMP-dependent protein kinase at Thr(35). Moreover, Ser(67) of inhibitor-1 serves as a substrate for cyclin-dependent kinase 5 in the brain. Here, we report that dephosphoinhibitor-1 but not phospho-Ser(67) inhibitor-1 was efficiently phosphorylated by protein kinase C at Ser(65) in vitro. In contrast, Ser(67) phosphorylation by cyclin-dependent kinase 5 was unaffected by phospho-Ser(65). Protein kinase C activation in striatal tissue resulted in the concomitant phosphorylation of inhibitor-1 at Ser(65) and Ser(67), but not Ser(65) alone. Selective pharmacological inhibition of protein phosphatase activity suggested that phospho-Ser(65) inhibitor-1 is dephosphorylated by protein phosphatase 1 in the striatum. In vitro studies confirmed these findings and suggested that phospho-Ser(67) protects phospho-Ser(65) inhibitor-1 from dephosphorylation by protein phosphatase 1 in vivo. Activation of group I metabotropic glutamate receptors resulted in the up-regulation of diphospho-Ser(65)/Ser(67) inhibitor-1 in this tissue. In contrast, the activation of N-methyl-D-aspartate-type ionotropic glutamate receptors opposed increases in striatal diphospho-Ser(65)/Ser(67) inhibitor-1 levels. Phosphomimetic mutation of Ser(65) and/or Ser(67) did not convert inhibitor-1 into a protein phosphatase 1 inhibitor. On the other hand, in vitro and in vivo studies suggested that diphospho-Ser(65)/Ser(67) inhibitor-1 is a poor substrate for cAMP-dependent protein kinase. These observations extend earlier studies regarding the function of phospho-Ser(67) and underscore the possibility that phosphorylation in this region of inhibitor-1 by multiple protein kinases may serve as an integrative signaling mechanism that governs the responsiveness of inhibitor-1 to cAMP-dependent protein kinase activation.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Prot Chem Lab, Alliance Cellular Signaling, Dallas, TX 75390 USA; Rockefeller Univ, Prot DNA Technol Ctr, New York, NY 10021 USA; Rockefeller Univ, Lab Cellular & Mol Neurosci, New York, NY 10021 USA; Univ Hamburg, Hosp Eppendorf, Inst Expt & Clin Pharmacol, D-20246 Hamburg, Germany; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Yale Univ, Sch Med, New Haven, CT 06519 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rockefeller University; Rockefeller University; University of Hamburg; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Yale University	Bibb, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.bibb@utsouthwestern.edu	El-Armouche, Ali/H-3161-2018	El-Armouche, Ali/0000-0003-2514-9429; Molkentin, Jeffery/0000-0002-3558-6529; Nairn, Angus/0000-0002-7075-0195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044, R01DA016672] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL077101] Funding Source: Medline; NIDA NIH HHS [P01 DA010044, R01 DA016672, DA10044, DA16672] Funding Source: Medline; NIMH NIH HHS [MH67777, R01 MH067777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Barford D, 1996, TRENDS BIOCHEM SCI, V21, P407, DOI 10.1016/S0968-0004(96)10060-8; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Coe IR, 1996, J BIOL CHEM, V271, P29468, DOI 10.1074/jbc.271.46.29468; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1978, FEBS S, V54, P161; Cohen PTW, 2002, J CELL SCI, V115, P241; CZERNIK AJ, 1997, REGULATORY PROTEIN M, P219; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Genoux D, 2002, NATURE, V418, P970, DOI 10.1038/nature00928; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kennelly PJ, 2001, CHEM REV, V101, P2291, DOI 10.1021/cr0002543; Li MX, 2001, NAT NEUROSCI, V4, P871, DOI 10.1038/nn0901-871; Liu QR, 2005, PROG NUCLEIC ACID RE, V79, P371, DOI 10.1016/S0079-6603(04)79008-X; Liu QR, 2004, BIOCHEM J, V377, P171, DOI 10.1042/BJ20030128; Lovinger DM, 1996, INT REV NEUROBIOL, V39, P77, DOI 10.1016/S0074-7742(08)60664-9; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MILES K, 1987, P NATL ACAD SCI USA, V84, P6591, DOI 10.1073/pnas.84.18.6591; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nelson PG, 2003, J NEUROCYTOL, V32, P803, DOI 10.1023/B:NEUR.0000020625.70284.a6; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; OUIMET CC, 1984, J NEUROSCI, V4, P111; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; Pi YQ, 2003, J PHYSIOL-LONDON, V552, P845, DOI 10.1113/jphysiol.2003.045260; Poisbeau P, 1999, J NEUROSCI, V19, P674; SAFRAN A, 1990, BIOCHEMISTRY-US, V29, P6730, DOI 10.1021/bi00480a024; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; SHEA TB, 1992, J NEUROSCI RES, V33, P398, DOI 10.1002/jnr.490330306; SHENOLIKAR S, 1991, ADV 2 MESSENGER PHOS, V23, P1; SIKES S, 2005, CELLSCI REV, V2, P175; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Wei FY, 2005, J NEUROCHEM, V93, P502, DOI 10.1111/j.1471-4159.2005.03058.x; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; Zachariou V, 2002, BIOL PSYCHIAT, V51, P612, DOI 10.1016/S0006-3223(01)01318-X	55	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24322	24335		10.1074/jbc.M603282200	http://dx.doi.org/10.1074/jbc.M603282200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16772299	Green Accepted, hybrid			2022-12-25	WOS:000239847800025
J	Wang, Y; Li, D; Fan, H; Tian, LJ; Zhong, YC; Zhang, YM; Yuan, L; Jin, CN; Yin, CH; Ma, DL				Wang, Ying; Li, Dan; Fan, Hui; Tian, Linjie; Zhong, Yingcheng; Zhang, Yingmei; Yuan, Lan; Jin, Caining; Yin, Caihua; Ma, Dalong			Cellular uptake of exogenous human PDCD5 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PROFILES; MEMBRANE DOMAINS; LIPID RAFTS; TAT PROTEIN; CAVEOLAR ENDOCYTOSIS; GROWTH-FACTOR; INTERNALIZATION; CLATHRIN; CELLS; MICRODOMAINS	PDCD5 (human programmed cell death 5) plays a significant role in apoptotic and paraptotic cell deaths. However, it was found that recombinant PDCD5 added exogenously to culture medium could also enhance programmed cell death triggered by certain stimuli. Here we show that PDCD 5 has a remarkable role in intercellular transport in various cells (endogenous caveolin-1-positive and - negative cells) through a clathrin-independent endocytic pathway that originates from heparan sulfate proteoglycan binding and lipid rafts. These conclusions are supported by the studies of slow internalization kinetics of PDCD5 endosomes, by the resistance of endosomes to nonionic detergents, by the overexpression of the clathrin dominant negative mutant form, which did not block PDCD5-fluorescein isothiocyanate uptake, and by PDCD5 localization in lipid rafts by immunofluorescence, electron microscopy techniques, and sucrose density centrifugation. This is further supported by the findings that certain drugs that disrupt lipid rafts, compete with cell membrane heparan sulfate proteoglycans, or block the caveolae pathway, impair the PDCD5 internalization process. The translocation activity of PDCD5 may possess physiological significance and be a potential mechanism for its programmed cell death-promoting activity. PDCD5 protein also has the ability to drive the internalization of large protein cargo, depending on the residues 109 - 115 mapped by deletion mutagenesis, and can introduce the Mdm-2 binding domain of human p53 into living cells to induce cell death in human cancer cells, indicating that PDCD5 may serve as a vehicle and thus have potential in the field of protein delivery to the cells. This is the first evidence of such findings.	Peking Univ, Ctr Human Dis Genom, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Lab Med Immunol, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Peking Univ Med & Hlth Anal Ctr, Beijing 100083, Peoples R China	Peking University; Peking University; Peking University	Ma, DL (corresponding author), Peking Univ, Ctr Human Dis Genom, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	madl@bjmu.edu.cn	Jin, Caining/A-1870-2010; Tian, Linjie/E-6878-2014					ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Chen YY, 2001, FEBS LETT, V509, P191, DOI 10.1016/S0014-5793(01)03062-9; Colin S, 1999, MOL PHARMACOL, V55, P74, DOI 10.1124/mol.55.1.74; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HEYNINGEN SV, 1974, SCIENCE, V183, P656, DOI DOI 10.1126/SCIENCE.183.4125.656; Hinrichs JWJ, 2004, J BIOL CHEM, V279, P5734, DOI 10.1074/jbc.M306857200; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; [李现亭 Li Xianting], 2002, [中国生物化学与分子生物学报, Chinese Journal of Biochemistry and Molecular Biology], V18, P411; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu DS, 2004, BIOCHEM BIOPH RES CO, V318, P391, DOI 10.1016/j.bbrc.2004.04.044; Liu HT, 1999, BIOCHEM BIOPH RES CO, V254, P203, DOI 10.1006/bbrc.1998.9893; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; Liu Zhao-hui, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P407; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Ma X, 2005, CLIN CANCER RES, V11, P8592, DOI 10.1158/1078-0432.CCR-05-0039; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MASSEYEFF RF, 1993, METHODS IMMUNOLOGICA, V3, P237; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Rakheja D, 2004, BIOCHEM BIOPH RES CO, V317, P988, DOI 10.1016/j.bbrc.2004.03.146; Roseberry AG, 2001, J CELL SCI, V114, P739; Rostand KS, 1997, INFECT IMMUN, V65, P1; Rui M, 2002, LIFE SCI, V71, P1771, DOI 10.1016/S0024-3205(02)01943-4; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Sacchetti A, 2001, J CELL BIOCHEM, P117; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Spinola M, 2006, J CLIN ONCOL, V24, P1672, DOI 10.1200/JCO.2005.04.4339; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang Lu, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P360; Wang Y, 2004, J CELL SCI, V117, P1525, DOI 10.1242/jcs.00994; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Yang YH, 2006, APOPTOSIS, V11, P993, DOI 10.1007/s10495-006-6714-6; Zhang YM, 2000, J CHIN IMMUNOL, V16, P8; 宋清华, 2003, [中华风湿病学杂志, Chinese Journal of Rheumatology], V7, P563	71	33	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24803	24817		10.1074/jbc.M600183200	http://dx.doi.org/10.1074/jbc.M600183200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16754680	hybrid			2022-12-25	WOS:000239847800076
J	Arnaud, N; Murgia, I; Boucherez, J; Briat, JF; Cellier, F; Gaymard, F				Arnaud, Nicolas; Murgia, Irene; Boucherez, Jossia; Briat, Jean-Francois; Cellier, Francoise; Gaymard, Frederic			An iron-induced nitric oxide burst precedes ubiquitin-dependent protein degradation for Arabidopsis AtFer1 ferritin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DIFFERENTIAL EXPRESSION; S-NITROSYLATION; IN-VIVO; NO; METABOLISM; IDENTIFICATION; TRANSFERRIN; STABILITY; COMPLEXES	Ferritins play an essential role in iron homeostasis by sequestering iron in a bioavailable and non-toxic form. In plants, ferritin mRNAs are highly and quickly accumulated in response to iron overload. Such accumulation leads to a subsequent ferritin protein synthesis and iron storage, thus avoiding oxidative stress to take place. By combining pharmacological and imaging approaches in an Arabidopsis cell culture system, we have identified several elements in the signal transduction pathway leading to the increase of AtFer1 transcript level after iron treatment. Nitric oxide quickly accumulates in the plastids after iron treatment. This compound acts downstream of iron and upstream of a PP2A-type phosphatase to promote an increase of AtFer1 mRNA level. The AtFer1 gene transcription has been previously shown to be repressed under low iron conditions with the involvement of the cis-acting element iron-dependent regulatory sequence identified within the AtFer1 promoter sequence. We show here that the repressor is unlikely a transcription factor directly bound to the iron-dependent regulatory sequence; such a repressor is ubiquitinated upon iron treatment and subsequently degraded through a 26 S proteasome-dependent pathway.	Univ Montpellier 2, CNRS,UMR 5004, INRA, Lab Biochim & Physiol Mol Plantes, F-34060 Montpellier 1, France; Univ Milan, Dipartimento Biol, Sez Fisiol & Biochim Piante, I-20133 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; University of Milan	Gaymard, F (corresponding author), Univ Montpellier 2, CNRS,UMR 5004, INRA, Lab Biochim & Physiol Mol Plantes, Bat 7,2 Pl Viala, F-34060 Montpellier 1, France.	gaymard@ensam.inra.fr	Murgia, Irene/ABD-7070-2020	Murgia, Irene/0000-0002-3193-6325; ARNAUD, Nicolas/0000-0001-8571-5862				Barroso JB, 1999, J BIOL CHEM, V274, P36729, DOI 10.1074/jbc.274.51.36729; Beligni MV, 2000, PLANTA, V210, P215, DOI 10.1007/PL00008128; Bethke PC, 2004, PLANTA, V219, P847, DOI 10.1007/s00425-004-1282-x; Bethke PC, 2004, PLANT CELL, V16, P332, DOI 10.1105/tpc.017822; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; Bright J, 2006, PLANT J, V45, P113, DOI 10.1111/j.1365-313X.2005.02615.x; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; Chiou TJ, 2006, PLANT CELL, V18, P412, DOI 10.1105/tpc.105.038943; Crawford NM, 2006, J EXP BOT, V57, P471, DOI 10.1093/jxb/erj050; Crawford NM, 2005, TRENDS PLANT SCI, V10, P195, DOI 10.1016/j.tplants.2005.02.008; Dellagi A, 2005, PLANT J, V43, P262, DOI 10.1111/j.1365-313X.2005.02451.x; Delledonne M, 2005, CURR OPIN PLANT BIOL, V8, P390, DOI 10.1016/j.pbi.2005.05.002; Dordas C, 2003, ANN BOT-LONDON, V91, P173, DOI 10.1093/aob/mcf115; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; FOBISLOISY I, 1995, EUR J BIOCHEM, V231, P609, DOI 10.1111/j.1432-1033.1995.0609d.x; Foissner I, 2000, PLANT J, V23, P817, DOI 10.1046/j.1365-313X.2000.00835.x; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gaymard F, 1996, BIOCHEM J, V318, P67, DOI 10.1042/bj3180067; Gould KS, 2003, PLANT CELL ENVIRON, V26, P1851, DOI 10.1046/j.1365-3040.2003.01101.x; Graziano M, 2005, TRENDS PLANT SCI, V10, P4, DOI 10.1016/j.tplants.2004.12.004; Graziano M, 2002, PLANT PHYSIOL, V130, P1852, DOI 10.1104/pp.009076; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Guo FQ, 2005, PLANT CELL, V17, P3436, DOI 10.1105/tpc.105.037770; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HAUSER M, 1995, PLANT PHYSIOL, V108, P1059, DOI 10.1104/pp.108.3.1059; Hellmann H, 2002, SCIENCE, V297, P793, DOI 10.1126/science.1072831; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hershko DD, 2004, J CELL BIOCHEM, V91, P951, DOI 10.1002/jcb.20014; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huang X, 2004, PLANTA, V218, P938, DOI 10.1007/s00425-003-1178-1; Ishikawa H, 2005, MOL CELL, V19, P171, DOI 10.1016/j.molcel.2005.05.027; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; Kim S, 2004, MOL CELL BIOL, V24, P330, DOI 10.1128/MCB.24.1.330-337.2004; Kim S, 2003, BIOMETALS, V16, P125, DOI 10.1023/A:1020788603046; Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220; Kim SW, 2002, P NATL ACAD SCI USA, V99, P12214, DOI 10.1073/pnas.192316099; KLEPPER L, 1990, PLANT PHYSIOL, V93, P26, DOI 10.1104/pp.93.1.26; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; Lamotte O, 2005, PLANTA, V221, P1, DOI 10.1007/s00425-005-1494-8; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; Lindermayr C, 2005, PLANT PHYSIOL, V137, P921, DOI 10.1104/pp.104.058719; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Millar AH, 1996, FEBS LETT, V398, P155, DOI 10.1016/S0014-5793(96)01230-6; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; Murgia I, 2004, J PLANT PHYSIOL, V161, P777, DOI 10.1016/j.jplph.2003.12.004; Murgia I, 2002, PLANT J, V30, P521, DOI 10.1046/j.1365-313X.2002.01312.x; Murgia I, 2001, PLANT PHYSIOL BIOCH, V39, P797, DOI 10.1016/S0981-9428(01)01297-9; Navarre DA, 2000, PLANT PHYSIOL, V122, P573, DOI 10.1104/pp.122.2.573; Neill SJ, 2003, NEW PHYTOL, V159, P11, DOI 10.1046/j.1469-8137.2003.00804.x; NISHIMURA H, 1986, ENVIRON SCI TECHNOL, V20, P413, DOI 10.1021/es00146a017; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Petit JM, 2001, J BIOL CHEM, V276, P5584, DOI 10.1074/jbc.M005903200; Petit JM, 2001, BIOCHEM J, V359, P575, DOI 10.1042/0264-6021:3590575; RICHARDSON DR, 1995, BBA-MOL CELL RES, V1266, P250, DOI 10.1016/0167-4889(95)00022-K; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; Savino G, 1997, J BIOL CHEM, V272, P33319, DOI 10.1074/jbc.272.52.33319; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Severina IS, 2003, NITRIC OXIDE-BIOL CH, V8, P155, DOI 10.1016/S1089-8603(03)00002-8; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Song CP, 2004, P NATL ACAD SCI USA, V101, P10211, DOI 10.1073/pnas.0403709101; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tarantino D, 2003, PLANTA, V217, P709, DOI 10.1007/s00425-003-1038-z; Vanin AF, 2004, J BIOL CHEM, V279, P24100, DOI 10.1074/jbc.M312601200; VANIN AF, 1995, BIOCHEMISTRY-MOSCOW+, V60, P225; Vanin AF, 1996, BBA-PROTEIN STRUCT M, V1295, P5, DOI 10.1016/0167-4838(95)00247-2; Vierstra RD, 2003, TRENDS PLANT SCI, V8, P135, DOI 10.1016/S1360-1385(03)00014-1; WATTS RN, 2002, EUR J BIOCHEM, V290, P693; Wendehenne D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI 10.1016/j.pbi.2004.04.002; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Zancani M, 2004, EUR J BIOCHEM, V271, P3657, DOI 10.1111/j.1432-1033.2004.04300.x	82	141	148	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23579	23588		10.1074/jbc.M602135200	http://dx.doi.org/10.1074/jbc.M602135200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782706	Green Published, hybrid			2022-12-25	WOS:000239702900032
J	Jolliffe, NA; Di Cola, A; Marsden, CJ; Lord, JM; Ceriotti, A; Frigerio, L; Roberts, LM				Jolliffe, Nicholas A.; Di Cola, Alessandra; Marsden, Catherine J.; Lord, J. Michael; Ceriotti, Aldo; Frigerio, Lorenzo; Roberts, Lynne M.			The N-terminal ricin propeptide influences the fate of ricin A-chain in tobacco protoplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEINS; VACUOLAR PROCESSING ENZYME; ENDOPLASMIC-RETICULUM; ACTIVE-SITE; B-CHAIN; INTRACELLULAR-TRANSPORT; COMMUNIS AGGLUTININ; TRANSGENIC TOBACCO; PRECURSORS; INHIBITION	The plant toxin ricin is synthesized in castor bean seeds as an endoplasmic reticulum (ER)-targeted precursor. Removal of the signal peptide generates proricin in which the mature A- and B-chains are joined by an intervening propeptide and a 9-residue propeptide persists at the N terminus. The two propeptides are ultimately removed in protein storage vacuoles, where ricin accumulates. Here we have demonstrated that the N-terminal propeptide of proricin acts as a nonspecific spacer to ensure efficient ER import and glycosylation. Indeed, when absent from the N terminus of ricin A-chain, the non-imported material remained tethered to the cytosolic face of the ER membrane, presumably by the signal peptide. This species appeared toxic to ribosomes. The propeptide does not, however, influence catalytic activity per se or the vacuolar targeting of proricin or the rate of retrotranslocation/degradation of A-chain in the cytosol. The likely implications of these findings to the survival of the toxin-producing tissue are discussed.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; CNR, Ist Biol & Biotecnol Agr, I-20133 Milan, Italy	University of Warwick; Consiglio Nazionale delle Ricerche (CNR)	Roberts, LM (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	lynne.roberts@warwick.ac.uk	Frigerio, Lorenzo/D-2685-2009; Ceriotti, Aldo/A-1448-2016; Frigerio, Lorenzo/M-6013-2019	Frigerio, Lorenzo/0000-0003-4100-6022; Ceriotti, Aldo/0000-0002-8230-8863; Frigerio, Lorenzo/0000-0003-4100-6022				Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bismuth C, 2004, TOXICOL LETT, V149, P11, DOI 10.1016/j.toxlet.2003.12.016; BUSTOS MM, 1991, PLANT MOL BIOL, V16, P381, DOI 10.1007/BF00023990; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; Daubenfeld T, 2005, BIOCHEM BIOPH RES CO, V333, P984, DOI 10.1016/j.bbrc.2005.06.008; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Di Cola A, 2005, PLANT PHYSIOL, V137, P287, DOI 10.1104/pp.104.055434; Di Cola A, 2001, P NATL ACAD SCI USA, V98, P14726, DOI 10.1073/pnas.251386098; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FERRINI JB, 1995, EUR J BIOCHEM, V233, P772, DOI 10.1111/j.1432-1033.1995.772_3.x; Frigerio L, 1998, J BIOL CHEM, V273, P14194, DOI 10.1074/jbc.273.23.14194; Frigerio L, 2001, PLANT PHYSIOL, V126, P167, DOI 10.1104/pp.126.1.167; Gietl C, 2001, NATURWISSENSCHAFTEN, V88, P49, DOI 10.1007/s001140000203; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1995, SEIKAGAKU, V67, P372; HARLEY SM, 1985, PLANT SCI, V41, P111, DOI 10.1016/0168-9452(85)90111-6; Hartley MR, 1996, TRENDS PLANT SCI, V1, P254, DOI 10.1016/1360-1385(96)10030-3; Higy M, 2004, BIOCHEMISTRY-US, V43, P12716, DOI 10.1021/bi048368m; Lord J M, 1991, Semin Cell Biol, V2, P15; LORD JM, 1985, EUR J BIOCHEM, V146, P403, DOI 10.1111/j.1432-1033.1985.tb08666.x; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; Pedrazzini E, 1997, PLANT CELL, V9, P1869, DOI 10.1105/tpc.9.10.1869; RICHARDSON PT, 1989, FEBS LETT, V255, P15, DOI 10.1016/0014-5793(89)81052-X; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Schmid M, 2001, P NATL ACAD SCI USA, V98, P5353, DOI 10.1073/pnas.061038298; SEHNKE PC, 1994, J BIOL CHEM, V269, P22473; Slominska-Wojewodzka M, 2006, MOL BIOL CELL, V17, P1664, DOI 10.1091/mbc.E05-10-0961; Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004; Tabe L, 1998, TRENDS PLANT SCI, V3, P282, DOI 10.1016/S1360-1385(98)01267-9; Tagge EP, 1996, PROTEIN EXPRES PURIF, V8, P109, DOI 10.1006/prep.1996.0080; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; TULLY RE, 1976, PLANT PHYSIOL, V58, P710, DOI 10.1104/pp.58.6.710; WALES R, 1991, J BIOL CHEM, V266, P19172; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563; YUOLE RJ, 1976, PLANT PHYSIOL, V58, P703	40	17	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23377	23385		10.1074/jbc.M602678200	http://dx.doi.org/10.1074/jbc.M602678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774920	hybrid			2022-12-25	WOS:000239702900012
J	Kouvela, EC; Petropoulos, AD; Kalpaxis, DL				Kouvela, Ekaterini C.; Petropoulos, Alexandros D.; Kalpaxis, Dimitrios L.			Unraveling new features of clindamycin interaction with functional ribosomes and dependence of the drug potency on polyamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND FORMATION; ESCHERICHIA-COLI; TRANSFER-RNA; ANTIBIOTIC INHIBITORS; TRANSFERASE-ACTIVITY; NASCENT PEPTIDE; BINDING-SITES; LINCOMYCIN; PEPTIDYLTRANSFERASE; CHLORAMPHENICOL	The effect of spermine on the inhibition of peptide-bond formation by clindamycin, an antibiotic of the Macrolide-Lincosamide-Streptogramins(B) family, was investigated in a cell-free system derived from Escherichia coli. In this system peptide bond is formed between puromycin, a pseudo-substrate of the A-site, and acetylphenylalanyl-tRNA, bound at the P-site of poly(U)-programmed 70 S ribosomes. Biphasic kinetics revealed that one molecule of clindamycin, after a transient interference with the A-site of ribosomes, is slowly accommodated near the P-site and perturbs the 70 S/acetylphenylalanyl-tRNA complex so that a peptide bond is still formed but with a lower velocity compared with that observed in the absence of the drug. The above mechanism requires a high temperature (25 degrees C as opposed to 5 degrees C). If this is not met, the inhibition is simple competitive. ;It was found that at 25 degrees C spermine favors the clindamycin binding to ribosomes; the affinity of clindamycin for the A-site becomes 5 times higher, whereas the overall inhibition constant undergoes a 3-fold decrease. Similar results were obtained when ribosomes labeled with N-1-azidobenzamidino-spermine, a photo-reactive analogue of spermine, were used or when a mixture of spermine and spermidine was added in the reaction mixture instead of spermine alone. Polyamines cannot compensate for the loss of biphasic kinetics at 5 degrees C nor can they stimulate the clindamycin binding to ribosomes. Our kinetic results correlate well with photoaffinity labeling data, suggesting that at 25 degrees C polyamines bound at the vicinity of the drug binding pocket affect the tertiary structure of ribosomes and influence their interaction with clindamycin.	Univ Patras, Sch Med, Biochem Lab, Patras 26500, Greece	University of Patras	Kalpaxis, DL (corresponding author), Univ Patras, Sch Med, Biochem Lab, Patras 26500, Greece.	dimkal@med.upatras.gr	Kalpaxis, Dimitrios L./A-5195-2008					Amarantos I, 2001, BIOCHEMISTRY-US, V40, P7641, DOI 10.1021/bi010010s; Athamna A, 2004, J ANTIMICROB CHEMOTH, V53, P609, DOI 10.1093/jac/dkh130; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; Blanchard SC, 2004, P NATL ACAD SCI USA, V101, P12893, DOI 10.1073/pnas.0403884101; CELMA ML, 1971, FEBS LETT, V13, P247, DOI 10.1016/0014-5793(71)80546-X; CERNA J, 1972, BIOCHIM BIOPHYS ACTA, V287, P292, DOI 10.1016/0005-2787(72)90378-4; Champney WS, 2000, CURR MICROBIOL, V41, P126, DOI 10.1007/s002840010106; CHANG FN, 1967, BIOCHEMISTRY-US, V6, P836, DOI 10.1021/bi00855a025; CHENEY BV, 1974, J MED CHEM, V17, P590, DOI 10.1021/jm00252a005; CLARK E, 1991, BIOCHEMISTRY-US, V30, P4009, DOI 10.1021/bi00230a028; Dinos G, 2005, NUCLEIC ACIDS RES, V33, P5291, DOI 10.1093/nar/gki833; DOUTHWAITE S, 1992, NUCLEIC ACIDS RES, V20, P4717, DOI 10.1093/nar/20.18.4717; Fitzhugh AL, 1998, BIOORG MED CHEM LETT, V8, P87, DOI 10.1016/S0960-894X(97)10196-2; Gaggelli E, 2002, INORG CHEM, V41, P1518, DOI 10.1021/ic010388e; HARRIS RJ, 1973, BIOORG CHEM, V2, P266, DOI 10.1016/0045-2068(73)90028-X; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; KAKEGAWA T, 1991, J BIOCHEM, V109, P627, DOI 10.1093/oxfordjournals.jbchem.a123431; KALLIARAFTOPOULOS S, 1992, ARCH BIOCHEM BIOPHYS, V298, P332, DOI 10.1016/0003-9861(92)90419-W; KALLIARAFTOPOULOS S, 1994, MOL PHARMACOL, V46, P1009; KALPAXIS DL, 1989, MOL PHARMACOL, V36, P615; Karahalios P, 1998, EUR J BIOCHEM, V258, P437, DOI 10.1046/j.1432-1327.1998.2580437.x; Katunin VI, 2002, MOL CELL, V10, P339, DOI 10.1016/S1097-2765(02)00566-X; Kehrenberg C, 2005, MOL MICROBIOL, V57, P1064, DOI 10.1111/j.1365-2958.2005.04754.x; Kirillov SV, 1999, RNA, V5, P1003, DOI 10.1017/S1355838299990568; MENNINGER JR, 1993, ANTIMICROB AGENTS CH, V37, P2027, DOI 10.1128/AAC.37.9.2027; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; PESTKA S, 1972, J BIOL CHEM, V247, P4669; Petropoulos AD, 2004, J BIOL CHEM, V279, P26518, DOI 10.1074/jbc.M313634200; Polacek N, 2003, MOL CELL, V11, P103, DOI 10.1016/S1097-2765(02)00825-0; Polacek N, 2002, BIOCHEMISTRY-US, V41, P11602, DOI 10.1021/bi026040s; REUSSER F, 1975, ANTIMICROB AGENTS CH, V7, P32, DOI 10.1128/AAC.7.1.32; Roberts MC, 2004, MOL BIOTECHNOL, V28, P47, DOI 10.1385/MB:28:1:47; SAARMA U, 1992, NUCLEIC ACIDS RES, V20, P3147, DOI 10.1093/nar/20.12.3147; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; SEGEL IH, 1993, ENZYME KINETICS, P39; Spizek J, 2004, APPL MICROBIOL BIOT, V64, P455, DOI 10.1007/s00253-003-1545-7; STERN S, 1988, METHOD ENZYMOL, V164, P481; SYNETOS D, 1987, BIOCHIM BIOPHYS ACTA, V923, P275, DOI 10.1016/0304-4165(87)90014-6; Tenson T, 2003, J MOL BIOL, V330, P1005, DOI 10.1016/S0022-2836(03)00662-4; Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005; VAARA M, 1983, ANTIMICROB AGENTS CH, V24, P107, DOI 10.1128/AAC.24.1.107; Verdier L, 2000, BIOORGAN MED CHEM, V8, P1225, DOI 10.1016/S0968-0896(00)00081-X; VOGEL Z, 1971, J MOL BIOL, V60, P339, DOI 10.1016/0022-2836(71)90298-1; Xaplanteri MA, 2005, NUCLEIC ACIDS RES, V33, P2792, DOI 10.1093/nar/gki557	44	7	7	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23103	23110		10.1074/jbc.M603263200	http://dx.doi.org/10.1074/jbc.M603263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760473	hybrid			2022-12-25	WOS:000239542600074
J	Ryu, JH; Chun, JS				Ryu, Je-Hwang; Chun, Jang-Soo			Opposing roles of WNT-5A and WNT-11 in interleukin-1 beta regulation of type II collagen expression in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENE-EXPRESSION; FRIZZLED HOMOLOGS; PATTERN-FORMATION; DIFFERENTIATION; CHONDROGENESIS; CARTILAGE; WNTS; ANTAGONIST; PHENOTYPE	Interleukin (IL)-1 beta is a major catabolic cytokine that plays a pivotal role in cartilage destruction. This study examined the possible involvement and regulatory mechanisms of Wnt signaling in IL-1 beta-induced inhibition of type II collagen expression in chondrocytes. Treatment of chondrocytes with IL-1 beta up-regulated Wnt-5a and down-regulated Wnt-11 expression. Conditioned medium from Wnt-5a-expressing cells inhibited type II collagen expression, whereas knockdown of Wnt-5a by siRNA blocked the inhibitory effects of IL-1 beta on type II collagen expression. In contrast to the inhibitory effects of Wnt-5a, Wnt-11 stimulated type II collagen expression. Wnt-5a and Wnt-11 did not cause accumulation of beta-catenin or activation of the beta-catenin-Tcf/Lef transcriptional complex. Instead, we found that Wnt-5a activated c-Jun N-terminal kinase and that an inhibitor of this kinase blocked Wnt-5a inhibition of type II collagen expression. In contrast, Wnt-11 activated protein kinase C and an inhibitor of this kinase blocked Wnt-11 stimulation of type II collagen expression. Collectively, these results indicate that Wnt-5a and Wnt-11 signaling through distinct non-canonical Wnt pathways have opposing effects on type II collagen expression by chondrocytes.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea.	jschun@gist.ac.kr						ASKEW GR, 1991, J BIOL CHEM, V266, P16834; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bergwitz C, 2001, BBA-MOL CELL RES, V1538, P129, DOI 10.1016/S0167-4889(00)00123-3; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152; Church VL, 2002, INT J DEV BIOL, V46, P927; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Enomoto-Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hwang SG, 2005, FEBS LETT, V579, P4837, DOI 10.1016/j.febslet.2005.07.067; Hwang SG, 2005, J BIOL CHEM, V280, P29780, DOI 10.1074/jbc.M411793200; Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200; Jin EJ, 2006, INT J BIOCHEM CELL B, V38, P183, DOI 10.1016/j.biocel.2005.08.013; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Koyanagi M, 2005, J BIOL CHEM, V280, P16838, DOI 10.1074/jbc.M500323200; Kozaci LD, 1997, ARTHRITIS RHEUM-US, V40, P164, DOI 10.1002/art.1780400121; Loganathan PG, 2005, HISTOCHEM CELL BIOL, V123, P195, DOI 10.1007/s00418-005-0756-7; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Roman-Roman S, 2004, J BIOL CHEM, V279, P5725, DOI 10.1074/jbc.M309233200; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsao WC, 2005, EXP CELL RES, V304, P234, DOI 10.1016/j.yexcr.2004.11.004; Tufan AC, 2001, FASEB J, V15, P1436, DOI 10.1096/fj.00-0784fje; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	36	92	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22039	22047		10.1074/jbc.M601804200	http://dx.doi.org/10.1074/jbc.M601804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754689	hybrid			2022-12-25	WOS:000239387100051
J	Schaaf, MJM; Willetts, L; Hayes, BP; Maschera, B; Stylianou, E; Farrow, SN				Schaaf, Marcel J. M.; Willetts, Lynsey; Hayes, Brian P.; Maschera, Barbara; Stylianou, Eleni; Farrow, Stuart N.			The relationship between intranuclear mobility of the NF-kappa B subunit p65 and its DNA binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR; LIVING CELLS; DISTINCT MECHANISMS; CRYSTAL-STRUCTURE; SITES; ACETYLATION; CHROMATIN; PROTEINS	It has been hypothesized that the main determinant of the intranuclear mobility of transcription factors is their ability to bind DNA. In the present study, we have extensively tested the relationship between the intranuclear mobility of the NF-kappa B subunit p65 and binding to its consensus target sequence. The affinity of p65 for this binding site is altered by mutation of specific acetylation sites, so these mutants provide a model system to study the relationship between specific DNA binding affinity and intranuclear mobility. DNA binding affinity was measured in vitro using an enzyme-linked immunosorbent assay-based method, and intranuclear mobility was measured using the fluorescence recovery after photobleaching technique on yellow fluorescent protein-tagged p65 constructs. A negative correlation was observed between DNA binding affinity and intranuclear mobility of p65 acetylation site mutants. However, moving the yellow fluorescent protein tag from the C terminus of p65 to the N terminus resulted in an increased mobility but did not significantly affect DNA binding affinity. Thus, all changes in DNA binding affinity produce alterations in mobility, but not vice versa. Finally, a positive correlation was observed between mobility and the randomness of the intranuclear distribution of p65. Our data are in line with a model in which the intranuclear mobility and distribution of a transcription factor are determined by its affinity for specific DNA sequences, which may be altered by protein-protein interactions.	GlaxoSmithKline, Dept Asthma Biol, Stevenage SG1 2NY, Herts, England; Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	GlaxoSmithKline; University of Nottingham	Schaaf, MJM (corresponding author), Leiden Univ, Inst Biol, Clusius Lab, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	schaaf@rulbim.leidenuniv.nl		Schaaf, Marcel/0000-0002-5859-8936				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; Euskirchen G, 2004, MOL CELL BIOL, V24, P3804, DOI 10.1128/MCB.24.9.3804-3814.2004; Farla P, 2004, J STRUCT BIOL, V147, P50, DOI 10.1016/j.jsb.2004.01.002; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Greene Warner C, 2004, Novartis Found Symp, V259, P208; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Hsu J.C., 1996, MULTIPLE COMPARISONS, P13; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Karpova TS, 2004, EMBO REP, V5, P1064, DOI 10.1038/sj.embor.7400281; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Laricchia-Robbio L, 2005, P NATL ACAD SCI USA, V102, P14368, DOI 10.1073/pnas.0504014102; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Mayr BM, 2005, J BIOL CHEM, V280, P15103, DOI 10.1074/jbc.M414144200; Nelson G, 2003, J CELL SCI, V116, P2495, DOI 10.1242/jcs.00461; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Schaaf MJM, 2005, MOL ENDOCRINOL, V19, P1501, DOI 10.1210/me.2005-0050; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Sprague BL, 2004, BIOPHYS J, V86, P3473, DOI 10.1529/biophysj.103.026765; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	41	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22409	22420		10.1074/jbc.M511086200	http://dx.doi.org/10.1074/jbc.M511086200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16760470	Green Published, hybrid			2022-12-25	WOS:000239387100086
J	Suzuki, T; Hara, I; Nakano, M; Zhao, G; Lennarz, WJ; Schindelin, H; Taniguchi, N; Totani, K; Matsuo, I; Ito, Y				Suzuki, Tadashi; Hara, Izumi; Nakano, Miyako; Zhao, Gang; Lennarz, William J.; Schindelin, Hermann; Taniguchi, Naoyuki; Totani, Kiichiro; Matsuo, Ichiro; Ito, Yukishige			Site-specific labeling of cytoplasmic peptide : N-glycanase by N,N '-diacetylchitobiose-related compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL-SYSTEM; ENDOPLASMIC-RETICULUM; DEGLYCOSYLATING ENZYME; GLYCOPROTEIN TURNOVER; MEMBRANE-PROTEIN; DEGRADATION; CELLS; YEAST; IDENTIFICATION; INHIBITION	Peptide: N-glycanase ( PNGase) is the deglycosylating enzyme, which releases N-linked glycan chains from N-linked glyco peptides and glycoproteins. Recent studies have revealed that the cytoplasmic PNGase is involved in the degradation of misfolded/unassembled glycoproteins. This enzyme has a Cys, His, and Asp catalytic triad, which is required for its enzymatic activity and can be inhibited by "free" N-linked glycans. These observations prompted us to investigate the possible use of haloacetamidyl derivatives of N-glycans as potent inhibitors and labeling reagents of this enzyme. Using a cytoplasmic PNGase from budding yeast (Png1), Man(9)GlcNAc(2)-iodoacetoamide was shown to be a strong inhibitor of this enzyme. The inhibition was found to be through covalent binding of the carbohydrate to a single Cys residue on Png1, and the binding was highly selective. The mutant enzyme in which Cys(191) of the catalytic triad was changed to Ala did not bind to the carbohydrate probe, suggesting that the catalytic Cys is the binding site for this compound. Precise determination of the carbohydrate attachment site by mass spectrometry clearly identified Cys191 as the site of covalent attachment. Molecular modeling of N, N'-diacetylchitobiose (chitobiose) binding to the protein suggests that the carbohydrate binding site is distinct from but adjacent to that of Z-VAD-fmk, a peptide-based inhibitor of this enzyme. These results suggest that cytoplasmic PNGase has a separate binding site for chitobiose and other carbohydrates, and haloacetamide derivatives can irreversibly inhibit that catalytic Cys in a highly specific manner.	Osaka Univ, Grad Sch Med, Dept Biochem, Ctr Excellence Program 21, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Univ Wurzburg, Klinikum Rudolf Ctr Expt Biomed, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Biol Struct, D-97078 Wurzburg, Germany; Osaka Univ, Res Inst Microbial Dis, Dept Dis Glycom, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	Osaka University; Japan Science & Technology Agency (JST); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wurzburg; University of Wurzburg; Osaka University; RIKEN	Suzuki, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, Ctr Excellence Program 21, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsuzuki@biochem.med.osaka-u.ac.jp	Ito, Yukishige/M-5119-2014; Ito, Yukishige/ACL-6203-2022; Schindelin, Hermann/Q-2697-2019; Suzuki, Tadashi/AAX-5707-2021; Suzuki, Tadashi/I-4536-2014; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Ito, Yukishige/0000-0001-6251-7249; Ito, Yukishige/0000-0001-6251-7249; Suzuki, Tadashi/0000-0003-1030-7631; Taniguchi, Naoyuki/0000-0001-5889-5968; 	NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM33814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Brown JR, 2003, J BIOL CHEM, V278, P23352, DOI 10.1074/jbc.M303093200; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; Foster MM, 2003, CANCER RES, V63, P2775; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Ito Y, 2005, CURR OPIN STRUC BIOL, V15, P481, DOI 10.1016/j.sbi.2005.08.012; Katiyar S, 2002, J BIOL CHEM, V277, P12953, DOI 10.1074/jbc.M111383200; Kim I, 2006, J CELL BIOL, V172, P211, DOI 10.1083/jcb.200507149; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; Lederkremer GZ, 2005, TRENDS BIOCHEM SCI, V30, P297, DOI 10.1016/j.tibs.2005.04.010; Lee JH, 2005, P NATL ACAD SCI USA, V102, P9144, DOI 10.1073/pnas.0502082102; Macmillan D, 2001, CHEM BIOL, V8, P133, DOI 10.1016/S1074-5521(00)90065-6; Makarova KS, 1999, PROTEIN SCI, V8, P1714, DOI 10.1110/ps.8.8.1714; Matsuo I, 2003, J AM CHEM SOC, V125, P3402, DOI 10.1021/ja021288q; Matsuo I, 2003, CARBOHYD RES, V338, P2163, DOI 10.1016/S0008-6215(03)00357-4; Misaghi S, 2006, CELL DEATH DIFFER, V13, P163, DOI 10.1038/sj.cdd.4401716; Misaghi S, 2004, CHEM BIOL, V11, P1677, DOI 10.1016/j.chembiol.2004.11.010; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; Seko A, 1999, GLYCOBIOLOGY, V9, P887, DOI 10.1093/glycob/9.9.887; Suzuki T, 2002, FASEB J, V16, DOI 10.1096/fj.01-0889rev; Suzuki T, 2005, METHODS, V35, P360, DOI 10.1016/j.ymeth.2004.10.008; Suzuki T, 2003, BIOCHEM BIOPH RES CO, V304, P326, DOI 10.1016/S0006-291X(03)00600-4; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; Suzuki T, 1998, J BIOL CHEM, V273, P21526, DOI 10.1074/jbc.273.34.21526; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; Totani K, 2004, GLYCOCONJUGATE J, V21, P69, DOI 10.1023/B:GLYC.0000043751.18027.c1; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Zhao G, 2006, J BIOL CHEM, V281, P13751, DOI 10.1074/jbc.M600137200	38	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22152	22160		10.1074/jbc.M603236200	http://dx.doi.org/10.1074/jbc.M603236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16740630	hybrid			2022-12-25	WOS:000239387100062
J	Ying, BW; Taguchi, H; Ueda, T				Ying, Bei-Wen; Taguchi, Hideki; Ueda, Takuya			Co-translational binding of GroEL to nascent polypeptides is followed by post-translational encapsulation by GroES to mediate protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROTEINS; TRIGGER FACTOR; CHAPERONIN GROEL; ESCHERICHIA-COLI; IN-VIVO; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; SUBSTRATE PROTEIN; APICAL DOMAIN; RIBOSOME	The eubacterial chaperonins GroEL and GroES are essential chaperones and primarily assist protein folding in the cell. Although the molecular mechanism of the GroEL system has been examined previously, the mechanism by which GroEL and GroES assist folding of nascent polypeptides during translation is still poorly understood. We previously demonstrated a co-translational involvement of the Escherichia coli GroEL in folding of newly synthesized polypeptides using a reconstituted cell-free translation system ( Ying, B. W., Taguchi, H., Kondo, M., and Ueda, T. ( 2005) J. Biol. Chem. 280, 12035 - 12040). Employing the same system here, we further characterized the mechanism by which GroEL assists folding of translated proteins via encapsulation into the GroEL-GroES cavity. The stable co-translational association between GroEL and the newly synthesized polypeptide is dependent on the length of the nascent chain. Furthermore, GroES is capable of interacting with the GroEL-nascent peptide-ribosome complex, and experiments using a single-ring variant of GroEL clearly indicate that GroES association occurs only at the trans-ring, not the cis-ring, of GroEL. GroEL holds the nascent chain on the ribosome in a polypeptide length-dependent manner and post-translationally encapsulates the polypeptide using the GroES cap to accomplish the chaperonin-mediated folding process.	Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan; PRESTO, Japan Sci & Technol Agcy, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Taguchi, H (corresponding author), Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, FSB-401,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	taguchi@k.u-tokyo.ac.jp; ueda@k.u-tokyo.ac.jp	Taguchi, Hideki/B-6946-2009; Ueda, Takuya/K-5217-2014; Ying, Bei-Wen/Q-9750-2019; taguchi, hideki/AAM-2663-2021	Taguchi, Hideki/0000-0002-6612-9339; Ueda, Takuya/0000-0002-7760-8271; Ying, Bei-Wen/0000-0003-2517-5686; taguchi, hideki/0000-0002-6612-9339				Ashcroft AE, 2002, J BIOL CHEM, V277, P33115, DOI 10.1074/jbc.M203398200; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chaudhuri TK, 2001, CELL, V107, P235, DOI 10.1016/S0092-8674(01)00523-2; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Etchells SA, 2005, J BIOL CHEM, V280, P28118, DOI 10.1074/jbc.M504110200; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 2003, EMBO J, V22, P3220, DOI 10.1093/emboj/cdg313; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Hoffmann A, 2006, J BIOL CHEM, V281, P6539, DOI 10.1074/jbc.M512345200; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; Koike-Takeshita A, 2006, J BIOL CHEM, V281, P962, DOI 10.1074/jbc.M506298200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARKHAM GD, 1984, J BIOL CHEM, V259, P4505; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Shimizu Y, 2005, METHODS, V36, P299, DOI 10.1016/j.ymeth.2005.04.006; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Taguchi H, 2005, J BIOCHEM, V137, P543, DOI 10.1093/jb/mvi069; Taguchi H, 2001, NAT BIOTECHNOL, V19, P861, DOI 10.1038/nbt0901-861; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Tomic S, 2006, FEBS LETT, V580, P72, DOI 10.1016/j.febslet.2005.11.050; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3; Wang JM, 2003, J MOL BIOL, V334, P489, DOI 10.1016/j.jmb.2003.09.074; Wei YH, 2002, MOL MICROBIOL, V43, P1651, DOI 10.1046/j.1365-2958.2002.02856.x; WEISS C, 1995, J BIOL CHEM, V270, P13956, DOI 10.1074/jbc.270.23.13956; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; Ying BW, 2004, BIOCHEM BIOPH RES CO, V320, P1359, DOI 10.1016/j.bbrc.2004.06.095; Ying BW, 2005, J BIOL CHEM, V280, P12035, DOI 10.1074/jbc.M500364200	58	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21813	21819		10.1074/jbc.M603091200	http://dx.doi.org/10.1074/jbc.M603091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754671	hybrid			2022-12-25	WOS:000239387100027
J	Obeid, D; Nguyen, J; Lesavre, P; Bauvois, B				Obeid, D.; Nguyen, J.; Lesavre, P.; Bauvois, B.			Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells	ONCOGENE			English	Article						interferon; ACE; TACE; monocyte; leukemia; ADAM-17	ENDOTHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; IFN-GAMMA; INHIBITORS; CANCER; MATRIX-METALLOPROTEINASE-9; ADHESION; GROWTH; INTERNALIZATION	The transmembrane metalloproteases angiotensin-converting enzyme (ACE) and tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE/ADAM-17) have been associated with inflammation, cancer progression and angiogenesis. Few investigations into the regulation of these enzymes by physiological stimuli have been reported. In this study, we investigated the influence of interferons (IFNs) type I (alpha, beta) and II (gamma) on ACE and TACE expression of human leukemic NB4 cells and monocytes. We assessed the expression of proteases by reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay and immunofluorescence analyses. IFN gamma, but not type I IFNs, upregulated membrane ACE in a dose- and time-dependency and this was reflected by the increase of ACE enzymatic activity and ACE mRNA. ACE upregulation was dependent on protein synthesis. Treatment of the interferon responsive factor 1 (IRF1)-unresponsive HepG2 cell line with IFN gamma did not affect ACE expression, thus suggesting the participation of the IRF1 signaling pathway in IFN gamma-mediated ACE upregulation in myeloid cells. In contrast, both types of IFNs, in a dose- and time-dependent manner, downregulated surface TACE without affecting TACE transcript. Soluble TACE was not detected in the medium of IFN-treated cells. IFN gamma-mediated decrease of surface TACE in NB4 cells was reversible, and correlated with an increase in intracellular TACE, suggesting that cell surface TACE was internalized in response to IFNs. These findings, showing the presence of IFN-dependent controlled mechanisms by which ACE and TACE levels are regulated in human normal and leukemic myeloid cells, may have implications in the context of current investigations on the therapeutic potential of IFNs.	Hop Necker Enfants Malad, INSERM 507, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bauvois, B (corresponding author), Hop Necker Enfants Malad, INSERM 507, Batiment Lavoisier,161 Rue Sevres, F-75015 Paris, France.	bauvois@necker.fr	Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922				Bauvois B, 1996, EXP CELL RES, V222, P209, DOI 10.1006/excr.1996.0026; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Borden EC, 2005, J INTERF CYTOK RES, V25, P511, DOI 10.1089/jir.2005.25.511; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Caceres William, 2003, P R Health Sci J, V22, P149; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Eyries M, 2002, CIRC RES, V91, P899, DOI 10.1161/01.RES.0000042703.39845.B4; Fuchs S, 2004, CURR HYPERTENS REP, V6, P124, DOI 10.1007/s11906-004-0087-4; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Golikov P P, 1998, Klin Lab Diagn, P11; Guilhot F, 2004, HEMATOL ONCOL CLIN N, V18, P585, DOI 10.1016/j.hoc.2004.03.002; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KAPLAN G, 1982, J EXP MED, V156, P1101, DOI 10.1084/jem.156.4.1101; Le Page C, 2000, Rev Immunogenet, V2, P374; Levin JI, 2004, CURR TOP MED CHEM, V4, P1289, DOI 10.2174/1568026043387935; Lindberg H, 2004, ACTA ONCOL, V43, P142, DOI 10.1080/02841860310022346; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; Lovering F, 2005, CNS NEUROL DISORD-DR, V4, P161, DOI 10.2174/1568007053544147; MAGUIRE GA, 1985, ANN CLIN BIOCHEM, V22, P204, DOI 10.1177/000456328502200218; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Moschos S, 2005, CANC TREAT, V126, P207, DOI 10.1007/0-387-24361-5_9; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; NEWTON RC, 2001, ANN RHEUM DIS     S3, V60, P25; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nguyen J, 2005, FEBS LETT, V579, P5487, DOI 10.1016/j.febslet.2005.09.012; OHMANN HB, 1990, LYMPHOKINE RES, V9, P43; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; Rocken C, 2005, CLIN CANCER RES, V11, P2526, DOI 10.1158/1078-0432.CCR-04-1922; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Saijonmaa O, 2001, J VASC RES, V38, P370, DOI 10.1159/000051068; Saijonmaa O, 2001, AM J PHYSIOL-HEART C, V280, pH885, DOI 10.1152/ajpheart.2001.280.2.H885; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taki S, 2002, CYTOKINE GROWTH F R, V13, P379, DOI 10.1016/S1359-6101(02)00023-0; Tnani M, 1999, BBA-MOL CELL RES, V1451, P59, DOI 10.1016/S0167-4889(99)00089-0; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; Worley JR, 2003, J BIOL CHEM, V278, P51340, DOI 10.1074/jbc.M310865200; Yoshiji H, 2004, CURR CANCER DRUG TAR, V4, P555, DOI 10.2174/1568009043332790	50	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					102	110		10.1038/sj.onc.1209779	http://dx.doi.org/10.1038/sj.onc.1209779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799629				2022-12-25	WOS:000243236500010
J	Gonsiorek, W; Hesk, D; Chen, SC; Kinsley, D; Fine, JS; Jackson, JV; Bober, LA; Deno, G; Bian, H; Fossetta, J; Lunn, CA; Kozlowski, JA; Lavey, B; Piwinski, J; Narula, SK; Lundell, DJ; Hipkin, RW				Gonsiorek, Waldemar; Hesk, David; Chen, Shu-Cheng; Kinsley, David; Fine, Jay S.; Jackson, James V.; Bober, Loretta A.; Deno, Gregory; Bian, Hong; Fossetta, James; Lunn, Charles A.; Kozlowski, Joseph A.; Lavey, Brian; Piwinski, John; Narula, Satwant K.; Lundell, Daniel J.; Hipkin, R. William			Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [S-35]Sch225336	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CB2 RECEPTOR; HL-60 CELLS; PHENYLMETHYLSULFONYL FLUORIDE; SOMATOSTATIN RECEPTOR; SELECTIVE ANTAGONIST; GROWTH-FACTOR; IN-VIVO; ANANDAMIDE; RAT; BINDING	Studies to characterize the endogenous expression and pharmacology of peripheral human cannabinoid receptor (hCB2) have been hampered by the dearth of authentic anti-hCB2 antibodies and the lack of radioligands with CB2 selectivity. We recently described a novel CB2 inverse agonist, N-[1(S)-[4-[[4- methoxy2-[(4-methoxyphenyl) sulfonyl] phenyl] sulfonyl] phenyl] ethyl] methane-sulfonamide (Sch225336), that binds hCB2 with high affinity and excellent selectivity versus hCB1. The precursor primary amine of Sch225336 was prepared and reacted directly with [S-35] mesyl chloride ( synthesized from commercially obtained [S-35] methane sulfonic acid) to generate [S-35] Sch225336. [ 35S] Sch225336 has high specific activity (> 1400 Ci/mmol) and affinity for hCB2( 65 pM). Using [S-35] Sch225336, we assayed hemopoietic cells and cell lines to quantitate the expression and pharmacology of hCB2. Lastly, we used [S-35] Sch225336 for detailed autoradiographic analysis of CB2 in lymphoid tissues. Based on these data, we conclude that [S-35] Sch225336 represents a unique radioligand for the study of CB2 endogenously expressed in blood cells and tissues.	Schering Plough Corp, Res Inst, Dept Inflammat, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Radiochem, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Chem, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, High Throughput Screening, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Hipkin, RW (corresponding author), Schering Plough Corp, Res Inst, Dept Inflammat, K15 E332C-3845, Kenilworth, NJ 07033 USA.	william.hipkin@spcorp.com		Hesk, David/0000-0003-4059-4168				Abood ME, 1997, BIOCHEM PHARMACOL, V53, P207, DOI 10.1016/S0006-2952(96)00727-7; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckley NE, 1998, NEUROSCIENCE, V82, P1131; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chou CC, 2002, BRIT J PHARMACOL, V137, P663, DOI 10.1038/sj.bjp.0704907; Compton DR, 1997, J PHARMACOL EXP THER, V283, P1138; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Dean DC, 1996, J MED CHEM, V39, P1767, DOI 10.1021/jm960054c; Derocq JM, 1998, FEBS LETT, V425, P419, DOI 10.1016/S0014-5793(98)00275-0; Derocq JM, 2000, J BIOL CHEM, V275, P15621, DOI 10.1074/jbc.275.21.15621; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fossetta J, 2004, BRIT J PHARMACOL, V142, P851, DOI 10.1038/sj.bjp.0705856; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9; GOLLOB KJ, 1993, EUR J IMMUNOL, V23, P2565, DOI 10.1002/eji.1830231028; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; Gonsiorek W, 2003, J IMMUNOL METHODS, V273, P15, DOI 10.1016/S0022-1759(02)00415-5; Gu YZ, 1997, MOL ENDOCRINOL, V11, P527, DOI 10.1210/me.11.5.527; Ha ES, 2004, BIOL PHARM BULL, V27, P1348, DOI 10.1248/bpb.27.1348; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Kishimoto S, 2003, J BIOL CHEM, V278, P24469, DOI 10.1074/jbc.M301359200; Lavey BJ, 2005, BIOORG MED CHEM LETT, V15, P783, DOI 10.1016/j.bmcl.2004.11.007; Lunn CA, 2006, J PHARMACOL EXP THER, V316, P780, DOI 10.1124/JPET.105.093500; LYNN AB, 1994, J PHARMACOL EXP THER, V268, P1612; Maestroni GJM, 2004, FASEB J, V18, P1914, DOI 10.1096/fj.04-2190fje; Massi P, 1997, PHARMACOL BIOCHEM BE, V58, P73, DOI 10.1016/S0091-3057(96)00379-6; McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood-2002-01-0098; Mossman SP, 1999, J MED PRIMATOL, V28, P206, DOI 10.1111/j.1600-0684.1999.tb00271.x; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NAGELKERKEN L, 1993, EUR J IMMUNOL, V23, P2306, DOI 10.1002/eji.1830230938; Oka S, 2004, J LEUKOCYTE BIOL, V76, P1002, DOI 10.1189/jlb.0404252; PERTWEE RG, 1995, EUR J PHARMACOL, V272, P73, DOI 10.1016/0014-2999(94)00618-H; Pettit DAD, 1996, ADV EXP MED BIOL, V402, P119; Rayman N, 2004, J IMMUNOL, V172, P2111, DOI 10.4049/jimmunol.172.4.2111; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Tonks AJ, 2003, CYTOKINE, V21, P242, DOI 10.1016/S1043-4666(03)00092-9; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Zavitsanou K, 2004, PROG NEURO-PSYCHOPH, V28, P355, DOI 10.1016/j.pnpbp.2003.11.005	46	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28143	28151		10.1074/jbc.M602364200	http://dx.doi.org/10.1074/jbc.M602364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16754676	hybrid			2022-12-25	WOS:000240534400052
J	Lee, H; Zeng, SYX; Lu, H				Lee, Hunjoo; Zeng, Shelya X.; Lu, Hua			UV induces p21 rapid turnover independently of ubiquitin and Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DEGRADATION; PROTEASOMAL TURNOVER; CYCLIN KINASES; DNA-DAMAGE; CELL-CYCLE; P53; MDM2; P21(WAF1/CIP1); EXPRESSION; INHIBITOR	It was previously reported that low doses, but not high doses, of UV trigger the Skp2-mediated proteasomal degradation of the cyclin-dependent kinase inhibitor p21 in mammalian cells. Here we show that both UV-C and UV-B lead to decrease of p21 protein, but not mRNA, level in a dose-dependent fashion in all of six human cell lines and five mouse cell lines tested. Also, high doses of UV reduce the half-life of p21. High doses, but not low doses, of UV induced p21 degradation in both skp2-proficient and -deficient murine embryonic fibroblast cells. UV-induced p21 reduction was rescued by proteasome inhibitors in all human and mouse cell lines tested. Neither a caspase inhibitor nor small interfering RNA against skp2 had an effect on the UV-induced p21 decrease, suggesting that this p21 degradation pathway may not involve caspases, or Skp2. Finally, UV did not induce p21 ubiquitination but still induced its degradation when the E1-activating enzyme was inactivated in an E1 temperature-sensitive mouse embryonic fibroblast cell line. Altogether, these results demonstrate that UV induces p21 degradation through an Skp2- and ubiquitin-independent pathway.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [CA079721, CA095441, CA93614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095441, R01CA093614, R01CA079721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; HARPER JW, 1993, CELL, V75, P805; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; LANDAIS I, 2006, CELL DEATH DIFFER, P1; LI Y, 1994, ONCOGENE, V9, P2261; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Nakanishi Y, 2000, AM J RESP CELL MOL, V22, P747, DOI 10.1165/ajrcmb.22.6.3877; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schwartz GK, 2002, CELL CYCLE, V1, P122, DOI 10.4161/cc.1.2.112; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zeng XY, 2000, CANCER RES, V60, P6184; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26876	26883		10.1074/jbc.M605366200	http://dx.doi.org/10.1074/jbc.M605366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16803887	hybrid			2022-12-25	WOS:000240397700014
J	Fosset, C; Chauveau, MJ; Guillon, B; Canal, F; Drapier, JC; Bouton, C				Fosset, Cedric; Chauveau, Marie-Jeanne; Guillon, Blanche; Canal, Frederic; Drapier, Jean-Claude; Bouton, Cecile			RNA silencing of mitochondrial m-Nfs1 reduces Fe-S enzyme activity both in mitochondria and cytosol of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; REGULATORY PROTEIN-1; CYSTEINE DESULFURASE; ESCHERICHIA-COLI; FRIEDREICH ATAXIA; SCAFFOLD PROTEIN; DOWN-REGULATION; BINDING; NFS1P; NIFS	In prokaryotes and yeast, the general mechanism of biogenesis of iron-sulfur (Fe-S) clusters involves activities of several proteins among which IscS and Nfs1p provide, through cysteine desulfuration, elemental sulfide for Fe-S core formation. Although these proteins have been well characterized, the role of their mammalian homolog in Fe-S cluster biogenesis has never been evaluated. We report here the first functional study that implicates the putative cysteine desulfurase m-Nfs1 in the biogenesis of both mitochondrial and cytosolic mammalian Fe-S proteins. Depletion of m-Nfs1 in cultured fibroblasts through small interfering RNA-based gene silencing significantly inhibited the activities of mitochondrial NADH-ubiquinone oxidoreductase (complex I) and succinate-ubiquinone oxidoreductase (complex II) of the respiratory chain, as well as aconitase of the Krebs cycle, with no alteration in their protein levels. Activity of cytosolic xanthine oxidase, which holds a [2Fe2S] cluster, was also specifically reduced, and iron-regulatory protein-1 was converted from its [4Fe-4S] aconitase form to its apo- or RNA-binding form. Reduction of Fe-S enzyme activities occurred earlier and more markedly in the cytosol than in mitochondria, suggesting that there is a mechanism that primarily dedicates m-Nfs1 to the biogenesis of mitochondrial Fe-S clusters in order to maintain cell survival. Finally, depletion of m-Nfs1, which conferred on apo-IRP-1 a high affinity for ferritin mRNA, was associated with the down-regulation of the iron storage protein ferritin.	CNRS, Inst Chim Subst Nat, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouton, C (corresponding author), CNRS, Inst Chim Subst Nat, Ave Terrasse, F-91190 Gif Sur Yvette, France.	cecile.bouton@icsn.cnrs-gif.fr	Bouton, Cecile/J-8663-2013					Anderson PR, 2005, HUM MOL GENET, V14, P3397, DOI 10.1093/hmg/ddi367; Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Bekri S, 2000, BLOOD, V96, P3256; Bouton C, 1999, CELL MOL LIFE SCI, V55, P1043, DOI 10.1007/s000180050355; Bouton C, 2002, J BIOL CHEM, V277, P31220, DOI 10.1074/jbc.M203276200; BOUTON C, 2003, SCI STKE, pPE17; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Demple B, 1996, GENE, V179, P53, DOI 10.1016/S0378-1119(96)00329-0; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fillebeen C, 2002, REDOX REP, V7, P15, DOI 10.1179/135100002125000136; Fillebeen C, 2003, MOL CELL BIOL, V23, P6973, DOI 10.1128/MCB.23.19.6973-6981.2003; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li KY, 2006, J BIOL CHEM, V281, P12344, DOI 10.1074/jbc.M600582200; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Oliveira L, 2000, P NATL ACAD SCI USA, V97, P6550, DOI 10.1073/pnas.120571797; PANTOPOULOS K, 1995, RNA, V1, P155; Pondarre C, 2006, HUM MOL GENET, V15, P953, DOI 10.1093/hmg/ddl012; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schueck ND, 2001, MITOCHONDRION, V1, P51, DOI 10.1016/S1567-7249(01)00004-6; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; SIEGEL L, 1962, BIOCHIM BIOPHYS ACTA, V64, P101, DOI 10.1016/0006-3002(62)90763-1; Starzynski RR, 2005, J BIOL CHEM, V280, P4207, DOI 10.1074/jbc.M411055200; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Unden G, 1997, MOL MICROBIOL, V25, P205, DOI 10.1046/j.1365-2958.1997.4731841.x; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; Wingert RA, 2005, NATURE, V436, P1035, DOI 10.1038/nature03887; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	50	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25398	25406		10.1074/jbc.M602979200	http://dx.doi.org/10.1074/jbc.M602979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16787928	hybrid			2022-12-25	WOS:000240031300042
J	Held, DM; Kissel, JD; Saran, D; Michalowski, D; Burke, DH				Held, Daniel M.; Kissel, Jay D.; Saran, Dayal; Michalowski, Daniel; Burke, Donald H.			Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STRAND DISPLACEMENT SYNTHESIS; NONNUCLEOSIDE INHIBITORS; DNA-SYNTHESIS; STEADY-STATE; IN-VITRO; NUCLEOTIDE INCORPORATION; AVIAN-MYELOBLASTOSIS; PSEUDOKNOT INHIBITOR; MOLECULAR-MECHANISM	Nucleic acid aptamers to HIV-1 reverse transcriptase (RT) are potent inhibitors of DNA polymerase function in vitro, and they have been shown to inhibit viral replication when expressed in cultured T-lymphoid lines. We monitored RT inhibition by five RNA pseudoknot RNA aptamers in a series of biochemical assays designed to mimic discrete steps of viral reverse transcription. Our results demonstrate potent aptamer inhibition (IC50 values in the low nanomolar range) of all RT functions assayed, including RNA- and DNA-primed DNA polymerization, strand displacement synthesis, and polymerase-independent RNase H activity. Additionally, we observe differences in the time dependence of aptamer inhibition. Polymerase-independent RNase H activity is the most resistant to long term aptamer suppression, and RNA- dependent DNA polymerization is the most susceptible. Finally, when DNA polymerization was monitored in the presence of an RNA aptamer in combination with each of four different small molecule inhibitors, significant synergy was observed between the aptamer and the two nucleoside analog RT inhibitors (azidothymidine triphosphate or ddCTP), whereas two non-nucleoside analog RT inhibitors showed either weak synergy (efavirenz) or antagonism (nevirapine). Together, these results support a model wherein aptamers suppress viral replication by cumulative inhibition of RT at every stage of genome replication.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA; Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Burke, DH (corresponding author), 471h Life Sci Ctr, 1201 E Rollins Rd, Columbia, MO 65211 USA.	burkedh@missouri.edu			NIAID NIH HHS [AI62513] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599; Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; Avidan O, 1998, NUCLEIC ACIDS RES, V26, P1713, DOI 10.1093/nar/26.7.1713; Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003; BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1; Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667; Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522; CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016; Chen H, 1996, BIOCHEMISTRY-US, V35, P6923, DOI 10.1021/bi9600106; CHONG KT, 1994, ANTIMICROB AGENTS CH, V38, P288, DOI 10.1128/AAC.38.2.288; Cruchaga C, 2005, BIOCHEMISTRY-US, V44, P3535, DOI 10.1021/bi048129z; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Fisher TS, 2002, J VIROL, V76, P4068, DOI 10.1128/JVI.76.8.4068-4072.2002; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; Gerondelis P, 1999, J VIROL, V73, P5803, DOI 10.1128/JVI.73.7.5803-5813.1999; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; Hannoush RN, 2004, CHEMBIOCHEM, V5, P527, DOI 10.1002/cbic.200300831; Held DM, 2006, FRONT BIOSCI-LANDMRK, V11, P89, DOI 10.2741/1782; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535; Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002; Joshi P. J., 2003, Current Drug Targets - Infectious Disorders, V3, P383, DOI 10.2174/1568005033481060; Joshi PJ, 2005, MOL THER, V11, P677, DOI 10.1016/j.ymthe.2005.01.013; KATI WM, 1992, J BIOL CHEM, V267, P25988; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Maga G, 2001, J BIOL CHEM, V276, P44653, DOI 10.1074/jbc.M106702200; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037; Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22; Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Temiz NA, 2002, PROTEINS, V49, P61, DOI 10.1002/prot.10183; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; Witvrouw M, 1998, ANTIMICROB AGENTS CH, V42, P618, DOI 10.1128/AAC.42.3.618; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; Yazdanpanah Y, 2004, BMJ-BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6	49	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25712	25722		10.1074/jbc.M604460200	http://dx.doi.org/10.1074/jbc.M604460200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16798747	hybrid			2022-12-25	WOS:000240031300074
J	Mayanil, CSK; Pool, A; Nakazaki, H; Reddy, AC; Mania-Farnell, B; Yun, B; George, D; McLone, DG; Bremer, EG				Mayanil, Chandra S. K.; Pool, Angela; Nakazaki, Hiromichi; Reddy, Anvesh C.; Mania-Farnell, Barbara; Yun, Beth; George, David; McLone, David G.; Bremer, Eric G.			Regulation of murine TGF beta 2 by Pax3 during early embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL-TUBE; P53; EXPRESSION; ACTIVATION; PROMOTER; DEFECTS; MICE; IDENTIFICATION; MIGRATION; MUTATION	Previously our laboratory identified TGF beta 2 as a potential downstream target of Pax3 by utilizing microarray analysis and promoter data base mining (Mayanil, C.S.K., George, D., Freilich, L., Miljan, E. J., Mania-Farnell, B. J., McLone, D. G., and Bremer, E. G. (2001) J. Biol. Chem. 276, 49299-49309). Here we report that Pax3 directly regulates TGF beta 2 transcription by binding to cis-regulatory elements within its promoter. Chromatin immunoprecipitation revealed that Pax3 bound to the cis-regulatory elements on the TGF beta 2 promoter (GenBank (TM) accession number AF118263). Both TGF beta 2 promoter-luciferase activity measurements in transient cotransfection experiments and electromobility shift assays supported the idea that Pax3 regulates TGF beta 2 by directly binding to its cis-regulatory regions. Additionally, by using a combination of co-immunoprecipitation and chromatin immunoprecipitation, we show that the TGF beta 2 cis-regulatory elements between bp 741-940 and bp 1012-1212 bind acetylated Pax3 and are associated with p300/CBP and histone deacetylases. The cis-regulatory elements between bp 741 and 940 in addition to associating with acetylated Pax3 and HDAC1 also associated with SIRT1. Whole mount in situ hybridization and quantitative real time reverse transcription-PCR showed diminished levels of TGF beta 2 transcripts in Pax3(-/-) mouse embryos (whose phenotype is characterized by neural tube defects) as compared with Pax3(+/+) littermates (embryonic day 10.0; 30 somite stage), suggesting that Pax3 regulation of TGF beta 2 may play a pivotal role during early embryonic development.	Northwestern Univ, Neurobiol Program, Childrens Mem Res Ctr, Lab Neural Tube Res,Dept Pediat Neurosurg, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60614 USA; Purdue Univ Calumet, Dept Biol, Hammond, IN 46323 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60616 USA	Northwestern University; Northwestern University; Feinberg School of Medicine; Purdue University System; Purdue University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Mayanil, CSK (corresponding author), Northwestern Univ, Neurobiol Program, Childrens Mem Res Ctr, Lab Neural Tube Res,Dept Pediat Neurosurg, M-c 226,2430 N Halsted, Chicago, IL 60614 USA.	smayanil@northwestern.edu						Basch Martin L, 2004, Birth Defects Res C Embryo Today, V72, P109, DOI 10.1002/bdrc.20015; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Colas JF, 2001, DEV DYNAM, V221, P117, DOI 10.1002/dvdy.1144; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Corry GN, 2005, PIGM CELL RES, V18, P427, DOI 10.1111/j.1600-0749.2005.00275.x; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 2000, DEVELOPMENT, V127, P1869; EPSTEIN JA, 1996, J BIOL CHEM, V93, P4213; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; Gammill LS, 2003, NAT REV NEUROSCI, V4, P795, DOI 10.1038/nrn1219; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Itokawa M, 2003, NEUROSCI LETT, V345, P53, DOI 10.1016/S0304-3940(03)00501-9; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; Lang D, 2003, HUM MOL GENET, V12, P937, DOI 10.1093/hmg/ddg107; Lang D, 2000, J CLIN INVEST, V106, P963, DOI 10.1172/JCI10828; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; LEBLANC GG, 1995, J NEUROBIOL, V26, P497, DOI 10.1002/neu.480260404; Levine M, 2005, P NATL ACAD SCI USA, V102, P4936, DOI 10.1073/pnas.0408031102; LOU J, 2001, CELL, V107, P137; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mayanil CSK, 2000, J BIOL CHEM, V275, P23259, DOI 10.1074/jbc.M002975200; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Meulemans D, 2004, DEV CELL, V7, P291, DOI 10.1016/j.devcel.2004.08.007; Monsoro-Burq AH, 2005, DEV CELL, V8, P167, DOI 10.1016/j.devcel.2004.12.017; Mori-Akiyama Y, 2003, P NATL ACAD SCI USA, V100, P9360, DOI 10.1073/pnas.1631288100; Pani L, 2002, GENE DEV, V16, P676, DOI 10.1101/gad.969302; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sato T, 2005, DEVELOPMENT, V132, P2355, DOI 10.1242/dev.01823; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Serbedzija GN, 1997, DEV BIOL, V185, P139, DOI 10.1006/dbio.1997.8551; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955-0674(02)00375-7; Wilder PJ, 2001, GENE, V270, P201, DOI 10.1016/S0378-1119(01)00475-9; Wilkinson D.G., 1992, SITU HYBRIDIZATION P, P1; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	45	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24544	24552		10.1074/jbc.M512449200	http://dx.doi.org/10.1074/jbc.M512449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787918	hybrid			2022-12-25	WOS:000239847800050
J	Rondard, P; Liu, JF; Huang, SL; Malhaire, F; Vol, C; Pinault, A; Labesse, G; Pin, JP				Rondard, Philippe; Liu, Jianfeng; Huang, Siluo; Malhaire, Fanny; Vol, Claire; Pinault, Alexia; Labesse, Gilles; Pin, Jean-Philippe			Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; GABA(B) RECEPTOR; ALLOSTERIC MODULATOR; HEPTAHELICAL DOMAIN; LIGAND-BINDING; DIMERIZATION; CHANNEL; GLUTAMATE-RECEPTOR-1-ALPHA; IDENTIFICATION; EXPRESSION	Many membrane receptors are made of a ligand binding domain and an effector domain mediating intracellular signaling. This is the case for the metabotropic glutamate-like G-protein-coupled receptors. How ligand binding leads to the active conformation of the effector domain in such receptors is largely unknown. Here, we used an evolutionary trace analysis and mutagenesis to identify critical residues involved in the allosteric coupling between the Venus flytrap ligand binding domain (VFT) and the heptahelical G-protein activating domain of the metabotropic glutamate-like receptors. We have shown that a conserved interdomain disulfide bridge is required for this allosteric interaction. Taking into account that these receptors are homodimers, this finding provides important new information explaining how the different conformations of the dimer of VFT lead to different signaling of such dimeric receptors.	Univ Montpellier 1, CNRS, UMR 5203, INSERM,U661, F-34094 Montpellier, France; Univ Montpellier 2, F-34094 Montpellier, France; Inst Geom Fonct, Dept Mol Pharmacol, F-34094 Montpellier, France; Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Wuhan 430074, Hubei, Peoples R China; Univ Montpellier 1, INSERM, CNRS, U414,UMR 5048,Plate Forme RIO Biol Struct,Ctr Bio, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Huazhong University of Science & Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Rondard, P (corresponding author), Univ Montpellier 1, CNRS, UMR 5203, INSERM,U661, F-34094 Montpellier, France.	prondard@igf.cnrs.fr	Rondard, Philippe/N-9720-2018	Pin, Jean-Philippe/0000-0002-1423-345X; RONDARD, Philippe/0000-0003-1134-2738; Labesse, Gilles/0000-0002-6861-3300; MALHAIRE, Fanny/0000-0001-5930-9879				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Goudet C., 2004, DRUG DISCOV TODAY TH, V1, P125, DOI DOI 10.1016/J.DDSTR.2004.08.017; Guo W, 2005, P NATL ACAD SCI USA, V102, P17495, DOI 10.1073/pnas.0508950102; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Johnson MP, 2005, PSYCHOPHARMACOLOGY, V179, P271, DOI 10.1007/s00213-004-2099-9; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; O'Brien JA, 2004, J PHARMACOL EXP THER, V309, P568, DOI 10.1124/jpet.103.061747; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Ray K, 2000, J BIOL CHEM, V275, P34245, DOI 10.1074/jbc.M005581200; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Tateyama M, 2006, P NATL ACAD SCI USA, V103, P1124, DOI 10.1073/pnas.0505925103; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Yu L, 2004, TRENDS BIOCHEM SCI, V29, P458, DOI 10.1016/j.tibs.2004.07.009; Zhang PS, 1999, MOL BRAIN RES, V72, P195, DOI 10.1016/S0169-328X(99)00241-7	33	65	82	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24653	24661		10.1074/jbc.M602277200	http://dx.doi.org/10.1074/jbc.M602277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787923	hybrid			2022-12-25	WOS:000239847800060
J	Jesch, SA; Liu, P; Zhao, X; Wells, MT; Henry, SA				Jesch, Stephen A.; Liu, Peng; Zhao, Xin; Wells, Martin T.; Henry, Susan A.			Multiple endoplasmic reticulum-to-nucleus signaling pathways coordinate phospholipid metabolism with gene expression by distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							UNFOLDED-PROTEIN RESPONSE; ENCODING PEROXISOMAL PROTEINS; FATTY-ACID DESATURASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSCRIPTION FACTOR; MICROARRAY EXPERIMENTS; TRANSMEMBRANE PROTEIN; LIPID BIOSYNTHESIS; HYPOXIC INDUCTION	In many organisms the coordinated synthesis of membrane lipids is controlled by feedback systems that regulate the transcription of target genes. However, a complete description of the transcriptional changes that accompany the remodeling of membrane phospholipids has not been reported. To identify metabolic signaling networks that coordinate phospholipid metabolism with gene expression, we profiled the sequential and temporal changes in genome-wide expression that accompany alterations in phospholipid metabolism induced by inositol supplementation in yeast. This analysis identified six distinct expression responses, which included phospholipid biosynthetic genes regulated by Opi1p, endoplasmic reticulum (ER) luminal protein folding chaperone and oxidoreductase genes regulated by the unfolded protein response pathway, lipid-remodeling genes regulated by Mga2p, as well as genes involved in ribosome biogenesis, cytosolic stress response, and purine and amino acid metabolism. We also report that the unfolded protein response pathway is rapidly inactivated by inositol supplementation and demonstrate that the response of the unfolded protein response pathway to inositol is separable from the response mediated by Opi1p. These data indicate that altering phospholipid metabolism produces signals that are relayed through numerous distinct ER-to-nucleus signaling pathways and, thereby, produce an integrated transcriptional response. We propose that these signals are generated in the ER by increased flux through the pathway of phosphatidylinositol synthesis.	Cornell Univ, Coll Agr & Life Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Henry, SA (corresponding author), Cornell Univ, Coll Agr & Life Sci, 260 Roberts Hall, Ithaca, NY 14853 USA.	sah42@cornell.edu	Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFEEL W, 1992, P NATL ACAD SCI USA, V89, P4534, DOI 10.1073/pnas.89.10.4534; Almaguer C, 2004, J BIOL CHEM, V279, P31937, DOI 10.1074/jbc.M403648200; Almaguer C, 2003, EUKARYOT CELL, V2, P729, DOI 10.1128/EC.2.4.729-736.2003; Alvarez-Vasquez F, 2005, NATURE, V433, P425, DOI 10.1038/nature03232; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Bedalov A, 2003, MOL CELL BIOL, V23, P7044, DOI 10.1128/MCB.23.19.7044-7054.2003; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; Boumann HA, 2006, FEMS MICROBIOL LETT, V258, P297, DOI 10.1111/j.1574-6968.2006.00233.x; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Brachmann CB, 1998, YEAST, V14, P115; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Burnett WV, 1997, BIOTECHNIQUES, V22, P668, DOI 10.2144/97224st01; Carman GM, 2005, BIOCHEM SOC T, V33, P1150, DOI 10.1042/BST0331150; Chang HJ, 2004, GENETICS, V168, P1899, DOI 10.1534/genetics.104.032961; Chang HJ, 2002, GENETICS, V162, P29; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Chellappa R, 2001, J BIOL CHEM, V276, P43548, DOI 10.1074/jbc.M107845200; CONZELMANN A, 2005, CELL BIOL DYNAMICS Y, P133; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Dudoit S, 2002, STAT SINICA, V12, P111; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gardenour KR, 2004, MOL MICROBIOL, V52, P1271, DOI 10.1111/j.1365-2958.2004.04069.x; GASPAR ML, 2006, J BIOL CHEM; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Han SH, 2005, J BIOL CHEM, V280, P29017, DOI 10.1074/jbc.M505881200; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Heyken WT, 2005, MOL MICROBIOL, V56, P696, DOI 10.1111/j.1365-2958.2004.04499.x; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Horsted MW, 1998, YEAST, V14, P793, DOI 10.1002/(SICI)1097-0061(19980630)14:9<793::AID-YEA277>3.3.CO;2-5; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; JESCH SA, 2005, CELL BIOL DYNAMICS Y, P105; Jiang YD, 2002, EUKARYOT CELL, V1, P481, DOI 10.1128/EC.1.3.481-490.2002; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kandasamy P, 2004, J BIOL CHEM, V279, P36586, DOI 10.1074/jbc.M401557200; Karpichev IV, 1998, MOL CELL BIOL, V18, P6560, DOI 10.1128/MCB.18.11.6560; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kersting MC, 2006, J BIOL CHEM, V281, P13110, DOI 10.1074/jbc.M601612200; Kimata Y, 2004, J CELL BIOL, V167, P445, DOI 10.1083/jcb.200405153; Kimata Y, 2003, MOL BIOL CELL, V14, P2559, DOI 10.1091/mbc.E02-11-0708; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; Lyons TJ, 2004, P NATL ACAD SCI USA, V101, P5506, DOI 10.1073/pnas.0306324101; Martin CE, 2002, BIOCHEM SOC T, V30, P1080, DOI 10.1042/bst0301080; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MORI K, 1993, CELL, V74, P743; Natter K, 2005, MOL CELL PROTEOMICS, V4, P662, DOI 10.1074/mcp.M400123-MCP200; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; Ogawa N, 2004, GENES CELLS, V9, P95, DOI 10.1111/j.1365-2443.2004.00704.x; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Patil CK, 2004, PLOS BIOL, V2, P1208, DOI 10.1371/journal.pbio.0020246; Resnick AC, 2005, P NATL ACAD SCI USA, V102, P12783, DOI 10.1073/pnas.0506184102; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shcherbik N, 2004, J BIOL CHEM, V279, P53892, DOI 10.1074/jbc.M410325200; Shcherbik N, 2003, CURR BIOL, V13, P1227, DOI 10.1016/S0960-9822(03)00457-3; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SPASSIEVA S, 2005, CELL BIOL DYNAMICS Y, P201; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P269, DOI 10.1080/10409230500315352; Van der Sanden MHM, 2003, BIOCHEM J, V369, P643, DOI 10.1042/BJ20020285; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Vemula M, 2003, J BIOL CHEM, V278, P45269, DOI 10.1074/jbc.M308812200; Verstrepen KJ, 2004, YEAST, V21, P367, DOI 10.1002/yea.1100; Wang XJ, 2003, BIOINFORMATICS, V19, P1341, DOI 10.1093/bioinformatics/btg154; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yeung KY, 2001, BIOINFORMATICS, V17, P763, DOI 10.1093/bioinformatics/17.9.763; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200; Zhang SR, 1999, GENETICS, V151, P473; Zhang SR, 1997, MOL CELL BIOL, V17, P4718, DOI 10.1128/MCB.17.8.4718; Zhao X, 2004, STAT SINICA, V14, P789	106	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24070	24083		10.1074/jbc.M604541200	http://dx.doi.org/10.1074/jbc.M604541200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777852	hybrid			2022-12-25	WOS:000239702900080
J	Magnusdottir, A; Stenmark, P; Flodin, S; Nyman, T; Hammarstrom, M; Ehn, M; Bakali-H, MA; Berglund, H; Nordlund, P				Magnusdottir, Audur; Stenmark, Pal; Flodin, Susanne; Nyman, Tomas; Hammarstrom, Martin; Ehn, Maria; Bakali H, M. Amin; Berglund, Helena; Nordlund, Par			The crystal structure of a human PP2A phosphatase activator reveals a novel fold and highly conserved cleft implicated in protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE PHOSPHATASES; SACCHAROMYCES-CEREVISIAE; 2A PHOSPHATASES; CELL-GROWTH; IDENTIFICATION; TRANSFORMATION; REFINEMENT; COMPLEXES; MECHANISM; CANCER	Protein phosphatase 2A (PP2A) is a heterotrimeric Ser/Thr phosphatase that is involved in regulating a plethora of signaling pathways in the cell, making its regulation a critical part of the well being of the cell. For example, three of the non-catalytic PP2A subunits have been linked to carcinogenic events. Therefore, the molecular basis for the complicated protein-protein interaction pattern of PP2A and its regulators is of special interest. The PP2A phosphatase activator (PTPA) protein is highly conserved from humans to yeast. It is an activator of PP2A and has been shown to be essential for a fully functional PP2A, but its mechanism of activation is still not well defined. We have solved the crystal structure of human PTPA to 1.6 angstrom. It reveals a two-domain protein with a novel fold comprised of 13 alpha-helices. We have identified a highly conserved cleft as a potential region for interaction with peptide segments of other proteins. Binding studies with ATP and its analogs are not consistent with ATP being a cofactor/substrate for PTPA as had previously been proposed. The structure of PTPA can serve as a basis for structure-function studies directed at elucidating its mechanism as an activator of PP2A.	Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, S-17177 Stockholm, Sweden; Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, S-17177 Stockholm, Sweden.	par.nordlund@mbb.ki.se		Stenmark, Pal/0000-0003-4777-3417	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fanghanel J, 2004, FRONT BIOSCI-LANDMRK, V9, P3453, DOI 10.2741/1494; Fellner T, 2003, GENE DEV, V17, P2138, DOI 10.1101/gad.259903; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2000, EUR J BIOCHEM, V267, P4406, DOI 10.1046/j.1432-1327.2000.01486.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jordens J, 2006, J BIOL CHEM, V281, P6349, DOI 10.1074/jbc.M507760200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Laskowski RA, 2005, J MOL BIOL, V351, P614, DOI 10.1016/j.jmb.2005.05.067; Longin S, 2004, BIOCHEM J, V380, P111, DOI 10.1042/BJ20031643; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rempola B, 2000, MOL GEN GENET, V262, P1081, DOI 10.1007/PL00008651; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; Van Hoof C, 2000, J MOL BIOL, V302, P103, DOI 10.1006/jmbi.2000.4062; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Zheng Y, 2005, MOL BIOL CELL, V16, P2119, DOI 10.1091/mbc.e04-09-0797	35	13	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22434	22438		10.1074/jbc.C600100200	http://dx.doi.org/10.1074/jbc.C600100200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782712	Green Published, hybrid			2022-12-25	WOS:000239542600003
J	Zhang, D; Chen, J; Saraf, A; Cassar, S; Han, P; Rogers, JC; Brioni, JD; Sullivan, JP; Gopalakrishnan, M				Zhang, Di; Chen, Jun; Saraf, Anita; Cassar, Steven; Han, Ping; Rogers, John C.; Brioni, Jorge D.; Sullivan, James P.; Gopalakrishnan, Murali			Association of Catsper1 or -2 with Ca(v)3.3 leads to suppression of T-type calcium channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERACTIVATED SPERM MOTILITY; ENERGY-TRANSFER; MALE-FERTILITY; CA2+ CHANNELS; MOUSE SPERM; EXPRESSION; IDENTIFICATION; SPERMATOZOA; SUBUNITS; REVEAL	Sperm-specific CatSper1 and CatSper2 proteins are critical to sperm-hyperactivated motility and male fertility. Although architecturally resembling voltage-gated ion channels, neither CatSper1 nor CatSper2 alone forms functional ion channels in heterologous expression systems, which may be related to the absence of yet unidentified accessory subunits. Here we isolated CatSper1- and CatSper2-associated protein(s) from human sperm and analyzed their identities by a multidimensional protein identification technology approach. We identified the T-type voltage-gated calcium channel Ca(v)3.3 as binding to both CatSper1 and CatSper2. The specificity of their interactions was verified by co-immunoprecipitation in transfected mammalian cells. Electrophysiological studies revealed that the co-expression of CatSper1 or CatSper2 specifically inhibited the amplitude of Ca(v)3.3-evoked T-type calcium current without altering other biophysical properties of Ca(v)3.3. Immunostaining studies revealed co-localization of CatSper1 and Ca(v)3.3 on the principal piece of human sperm tail. Furthermore, fluorescence resonance energy transfer analysis revealed close proximity and physical association of these two proteins on the sperm tail. These studies demonstrate that CatSper1 and CatSper2 can associate with and modulate the function of the Ca(v)3.3 channel, which might be important in the regulation of sperm function.	Abbott Labs, Neurosci Res & Adv Technol, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA	Abbott Laboratories	Zhang, D (corresponding author), Abbott Labs, Neurosci Res, Dept R4PM, Bldg AP9-1125,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	di.zhang@abbott.com	Cassar, Steven/AAW-3201-2020					Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Breitbart H, 2003, CELL MOL BIOL, V49, P321; Carlson AE, 2005, J BIOL CHEM, V280, P32238, DOI 10.1074/jbc.M501430200; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Day RN, 2001, METHODS, V25, P4, DOI 10.1006/meth.2001.1211; Dubel SJ, 2004, J BIOL CHEM, V279, P29263, DOI 10.1074/jbc.M313450200; Hansen JP, 2004, J MOL CELL CARDIOL, V37, P1147, DOI 10.1016/j.yjmcc.2004.08.005; Ho HC, 2003, BIOL REPROD, V68, P1590, DOI 10.1095/biolreprod.102.011320; Kirichok Y, 2006, NATURE, V439, P737, DOI 10.1038/nature04417; LINDEMANN CB, 1988, CELL MOTIL CYTOSKEL, V10, P420, DOI 10.1002/cm.970100309; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lobley Anna, 2003, Reprod Biol Endocrinol, V1, P53, DOI 10.1186/1477-7827-1-53; Okunande GW, 2004, J BIOL CHEM, V279, P33742, DOI 10.1074/jbc.M404628200; Park JY, 2003, EXP MOL MED, V35, P285, DOI 10.1038/emm.2003.39; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Schuh K, 2004, J BIOL CHEM, V279, P28220, DOI 10.1074/jbc.M312599200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Suarez SS, 2003, CELL MOL BIOL, V49, P351; SUAREZ SS, 1987, J EXP ZOOL, V244, P331, DOI 10.1002/jez.1402440218; Trevino CL, 2004, FEBS LETT, V563, P87, DOI 10.1016/S0014-5793(04)00257-1; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yunker AMR, 2003, NEUROSCIENCE, V117, P321, DOI 10.1016/S0306-4522(02)00936-3; Zhang D, 2005, J ANDROL, V26, P643, DOI 10.2164/jandrol.05009	30	14	18	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22332	22341		10.1074/jbc.M511288200	http://dx.doi.org/10.1074/jbc.M511288200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16740636	hybrid			2022-12-25	WOS:000239387100078
J	Rumbaugh, J; Turchan-Cholewo, J; Galey, D; Hillaire, CS; Anderson, C; Conant, K; Nath, A				Rumbaugh, J.; Turchan-Cholewo, J.; Galey, D.; Hillaire, C. St.; Anderson, C.; Conant, K.; Nath, A.			Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism	FASEB JOURNAL			English	Article						human; immunodeficiency diseases; neuroimmunology; neurotoxicity; viral	IMMUNODEFICIENCY-VIRUS TYPE-1; BLOOD-BRAIN-BARRIER; SYNERGISTIC NEUROTOXICITY; PROTEIN; EXPRESSION; APOPTOSIS; AIDS; METHAMPHETAMINE; ACTIVATION; DEMENTIA	Tat, the HIV transactivating protein, and matrix metalloproteinases ( MMPs), a family of extracellular matrix (ECM) endopeptidases, have been implicated in the pathogenesis of HIV-associated dementia. However, the possibility that MMPs interact with viral proteins has remained unexplored. We therefore treated mixed human fetal neuronal cultures with recombinant Tat and select MMPs. Neurotoxicity was determined by measuring mitochondrial membrane potential and neuronal cell death. Previous studies have shown that Tat and MMP independently cause neurotoxicity. Surprisingly, we found the combination of Tat and MMP produced significant attenuation of neurotoxicity. To determine whether there was a physical interaction between Tat and MMP, we used protein electrophoresis and Western blot techniques, and found that MMP-1 can degrade Tat. This effect was blocked by MMP inhibitors. Furthermore, MMP-1 decreased Tat-mediated transactivation of the HIV long terminal repeat region, and this functionality was restored when MMP-1 activity was inhibited. These results suggest that the decrease in Tat-induced neurotoxicity and HIV transactivation is due to Tat's enzymatic cleavage by MMP-1. The direct interaction of human MMPs with viral proteins has now been demonstrated, with resultant modulation of Tat-mediated neurotoxicity and transactivation. This study elucidates a unique viral-host interaction that may serve as an innate host defense mechanism.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21218 USA; Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40506 USA	Johns Hopkins University; Johns Hopkins University; University of Kentucky	Nath, A (corresponding author), 600 N Wolfe St,Pathol 509, Baltimore, MD 21287 USA.	anath1@jhmi.edu						Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019; Bansal AK, 2000, BRAIN RES, V879, P42, DOI 10.1016/S0006-8993(00)02725-6; Bozzo C, 1997, EXP CELL RES, V237, P326, DOI 10.1006/excr.1997.3777; Chauhan A, 2003, J BIOL CHEM, V278, P13512, DOI 10.1074/jbc.M209381200; Checler F, 2002, TRENDS NEUROSCI, V25, P616, DOI 10.1016/S0166-2236(02)02263-4; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Chung KKK, 2001, TRENDS NEUROSCI, V24, pS7, DOI 10.1016/S0166-2236(00)01998-6; Conant K, 2004, J BIOL CHEM, V279, P8056, DOI 10.1074/jbc.M307051200; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Culley FJ, 2000, J IMMUNOL, V165, P6447, DOI 10.4049/jimmunol.165.11.6447; Dore GJ, 2003, AIDS, V17, P1539, DOI 10.1097/00002030-200307040-00015; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Flora G, 2003, EXP NEUROL, V179, P60, DOI 10.1006/exnr.2002.8048; Fox L, 1997, J NEUROPATH EXP NEUR, V56, P360, DOI 10.1097/00005072-199704000-00004; Gartner S, 2000, SCIENCE, V287, P602, DOI 10.1126/science.287.5453.602; Gelbard HA, 1999, ANN NY ACAD SCI, V890, P312, DOI 10.1111/j.1749-6632.1999.tb08008.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gurwell JA, 2001, NEUROSCIENCE, V102, P555, DOI 10.1016/S0306-4522(00)00461-9; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Kim TA, 2003, J IMMUNOL, V170, P2629, DOI 10.4049/jimmunol.170.5.2629; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Langford D, 2002, J NEUROIMMUNOL, V127, P115, DOI 10.1016/S0165-5728(02)00068-1; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; Libby RT, 1999, J NEUROSCI, V19, P9399; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Liu YQ, 2001, PLANT PHYSIOL, V127, P1788, DOI 10.1104/pp.010593; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Ma MH, 1997, J VIROL, V71, P2495, DOI 10.1128/JVI.71.3.2495-2499.1997; MAGNAN A, 1995, ENFANCE, V1, P37; MALISSA H, 1991, MIKROCHIM ACTA, V1, P1; Maragos WF, 2002, J NEUROCHEM, V83, P955, DOI 10.1046/j.1471-4159.2002.01212.x; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P585; McArthur JC, 2003, J NEUROVIROL, V9, P205, DOI 10.1080/13550280390194109; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; McManus CM, 2000, AM J PATHOL, V156, P1441, DOI 10.1016/S0002-9440(10)65013-4; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Montaner J, 2001, STROKE, V32, P2762, DOI 10.1161/hs1201.99512; Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V; Nath A, 1998, PROG NEUROBIOL, V54, P19, DOI 10.1016/S0301-0082(97)00053-1; Nath A, 1999, SEMIN NEUROL, V19, P113, DOI 10.1055/s-2008-1040830; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nath A, 2002, JAIDS-J ACQ IMM DEF, V31, pS62, DOI 10.1097/00126334-200210012-00006; Nath A, 2002, J INFECT DIS, V186, pS193, DOI 10.1086/344528; Neuenburg JK, 2002, JAIDS-J ACQ IMM DEF, V31, P171, DOI 10.1097/00126334-200210010-00007; New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806; NICHOL KA, 1995, BRAIN RES, V697, P1, DOI 10.1016/0006-8993(95)00695-M; Olsen C, 1999, BRAIN RES, V850, P144, DOI 10.1016/S0006-8993(99)02115-0; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005; Sacktor N, 2002, J NEUROVIROL, V8, P115, DOI 10.1080/13550280290101094; SASAGURI Y, 1994, LAB INVEST, V71, P261; SATO H, 1993, ONCOGENE, V8, P395; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; Tikhonov I, 2004, FEBS LETT, V565, P89, DOI 10.1016/j.febslet.2004.03.079; Turchan J, 2003, NEUROLOGY, V60, P307, DOI 10.1212/01.WNL.0000042048.85204.3D; Turchan J, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-3; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wang P, 1999, NEUROSCIENCE, V88, P585, DOI 10.1016/S0306-4522(98)00242-5; Weiss JM, 1999, J IMMUNOL, V163, P2953; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	66	38	41	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1736	+		10.1096/fj.05-5619fje	http://dx.doi.org/10.1096/fj.05-5619fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807369				2022-12-25	WOS:000240266600032
J	Liu, W; Cao, DZ; Oh, SF; Serhan, CN; Kulmacz, RJ				Liu, Wen; Cao, Dazhe; Oh, Sungwhan F.; Serhan, Charles N.; Kulmacz, Richard J.			Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases	FASEB JOURNAL			English	Article						cyclooxygenase substrate specificity; cyclooxygenase activation by peroxide; aspirin-induced lipoxygenase catalysis	TURBOT SCOPHTHALMUS-MAXIMUS; SALMON SALMO-SALAR; ACTIVE-SITE RESIDUES; RAINBOW-TROUT; ONCORHYNCHUS-MYKISS; EICOSANOID PRODUCTION; LIPID HYDROPEROXIDES; ARACHIDONIC-ACID; EXPRESSION; PLASMA	Prostanoid synthesis in mammalian tissues is regulated at the level of prostaglandin H synthase ( PGHS) cyclooxygenase catalysis by the availability and structure of substrate fatty acid and the availability of peroxide activator. Two major PGHS isoforms, with distinct pathophysiological functions and catalytic regulation, have been characterized in mammals; a functionally homologous PGHS isoform pair has been cloned from an evolutionarily distant vertebrate, brook trout. The cyclooxygenase activities of recombinant brook trout PGHS-1 and -2 were characterized to test the generality of mammalian regulatory paradigms for substrate specificity, peroxide activation, and product shifting by aspirin. Both trout cyclooxygenases had much more restrictive substrate specificities than their mammalian counterparts, with pronounced discrimination toward arachidonate ( 20: 4n-6) and against eicosapentaenoate (20: 5n-3) and docosahexaenoate ( 22: 6n-3), the latter two prominent in trout tissue lipids. Aspirin treatment did not increase lipoxygenase-type catalysis by either trout enzyme. Both trout enzymes had higher requirements for peroxide activator than their mammalian counterparts, though the preferential peroxide activation of PGHS-2 over PGHS-1 seen in mammals was conserved in the fish enzymes. The divergence in cyclooxygenase characteristics between the trout and mammalian PGHS proteins may reflect accomodations to differences among vertebrates in tissue lipid composition and general redox state.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA; Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Texas System; University of Texas Health Science Center Houston; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kulmacz, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, 6431 Fannin St, Houston, TX 77030 USA.	kulmacz@uth.tmc.edu		Cao, Dazhe/0000-0003-2775-8527	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R37GM038765, R01GM052170, R01GM038765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 074448] Funding Source: Medline; NIGMS NIH HHS [GM 52170, GM 38765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKMAN RG, 1967, COMP BIOCHEM PHYSIOL, V22, P907, DOI 10.1016/0010-406X(67)90781-5; Bambai B, 2000, J BIOL CHEM, V275, P27608; Bambai B, 2004, J BIOL CHEM, V279, P4084, DOI 10.1074/jbc.M304762200; BELL JG, 1995, PROSTAG LEUKOTR ESS, V53, P279, DOI 10.1016/0952-3278(95)90128-0; BELL JG, 1994, BBA-LIPID LIPID MET, V1211, P335, DOI 10.1016/0005-2760(94)90158-9; Bell JG, 1996, LIPIDS, V31, P1163, DOI 10.1007/BF02524291; Bell JG, 1997, LIPIDS, V32, P515, DOI 10.1007/s11745-997-0066-4; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Brubacher JL, 2000, DEV COMP IMMUNOL, V24, P565, DOI 10.1016/S0145-305X(00)00019-7; Buonocore F, 2005, AQUACULTURE, V245, P301, DOI 10.1016/j.aquaculture.2004.11.015; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Frein D, 2005, BIOCHEM PHARMACOL, V70, P811, DOI 10.1016/j.bcp.2005.04.012; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Ghioni C, 1997, PROSTAG LEUKOTR ESS, V56, P479, DOI 10.1016/S0952-3278(97)90603-7; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Gorog DA, 2002, CARDIOVASC PATHOL, V11, P153, DOI 10.1016/S1054-8807(02)00103-5; Grosser T, 2002, P NATL ACAD SCI USA, V99, P8418, DOI 10.1073/pnas.112217799; GUNTHER SJ, 2003, THESIS U GUELPH GUEL; HENDERSON RJ, 1987, PROG LIPID RES, V26, P281, DOI 10.1016/0163-7827(87)90002-6; Henderson RJ, 1996, BBA-LIPID LIPID MET, V1299, P289, DOI 10.1016/0005-2760(95)00213-8; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Holland JW, 2003, PARASITOLOGY, V126, pS95, DOI 10.1017/S0031182003003767; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Holub DJ, 2004, MOL CELL BIOCHEM, V263, P217, DOI 10.1023/B:MCBI.0000041863.11248.8d; Jarving R, 2004, J BIOL CHEM, V279, P13624, DOI 10.1074/jbc.M313258200; Kaewsrithong J, 2000, FISHERIES SCI, V66, P768, DOI 10.1046/j.1444-2906.2000.00125.x; Kovacs IB, 1997, AM HEART J, V134, P572, DOI 10.1016/S0002-8703(97)70097-8; Kozak KR, 2001, J BIOL CHEM, V276, P36993, DOI 10.1074/jbc.M105854200; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KULMACZ RJ, 1985, PROSTAGLANDINS, V29, P175, DOI 10.1016/0090-6980(85)90200-X; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MELNIKOVA VI, 1983, BIOMED MASS SPECTROM, V10, P399, DOI 10.1002/bms.1200100703; MIYAZAWA T, 1989, FREE RADICAL BIO MED, V7, P209, DOI 10.1016/0891-5849(89)90017-8; Mori Trevor A, 2004, Curr Atheroscler Rep, V6, P461, DOI 10.1007/s11883-004-0087-5; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; Ornberg RL, 1999, ADV EXP MED BIOL, V469, P131; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PENDLETON R, 1990, THESIS U ILLINOIS UR; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Roberts SB, 2000, MOL CELL ENDOCRINOL, V160, P89, DOI 10.1016/S0303-7207(99)00252-X; Rowley AF, 1997, THROMB HAEMOSTASIS, V77, P227; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; Schneider C, 2004, J BIOL CHEM, V279, P4404, DOI 10.1074/jbc.M307431200; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; SECOMBES CJ, 1994, VET IMMUNOL IMMUNOP, V42, P367, DOI 10.1016/0165-2427(94)90080-9; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Smith WL, 2005, CURR OPIN CELL BIOL, V17, P174, DOI 10.1016/j.ceb.2005.02.005; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sorbera LA, 2001, BIOL REPROD, V64, P382, DOI 10.1095/biolreprod64.1.382; SPRECHER H, 1982, J BIOL CHEM, V257, P3912; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; Tocher DR, 1996, COMP BIOCHEM PHYS B, V115, P215, DOI 10.1016/0305-0491(96)00113-7; Tocher DR, 1997, PROSTAG LEUKOTR ESS, V57, P125, DOI 10.1016/S0952-3278(97)90002-8; UENO R, 1982, J BIOL CHEM, V257, P5584; WADE MG, 1994, BIOL REPROD, V51, P131, DOI 10.1095/biolreprod51.1.131; WATANABE T, 1982, COMP BIOCHEM PHYS B, V73, P3, DOI 10.1016/0305-0491(82)90196-1; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; Yang TX, 1998, AM J PHYSIOL-RENAL, V274, pF481, DOI 10.1152/ajprenal.1998.274.3.F481; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181; ZAMBURLINI A, 1995, ANAL BIOCHEM, V232, P107, DOI 10.1006/abio.1995.9953; Zou J, 1999, BIOCHEM J, V340, P153, DOI 10.1042/bj3400153	80	33	33	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1097	1108		10.1096/fj.05-5273com	http://dx.doi.org/10.1096/fj.05-5273com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770009				2022-12-25	WOS:000240210300010
J	Novac, N; Baus, D; Dostert, A; Heinzel, T				Novac, Natalia; Baus, Daniela; Dostert, Anja; Heinzel, Thorsten			Competition between glucocorticoid receptor and NF kappa B for control of the human FasL promoter	FASEB JOURNAL			English	Article						nGRE; AICD; inflammation; glucocorticoid receptor; cis-repression	INDUCED APOPTOSIS; NUCLEAR FACTOR; T-LYMPHOCYTES; LIGAND GENE; CD95 LIGAND; CELL-DEATH; INHIBITION; ACTIVATION; REPRESSION; DNA	Glucocorticoids mediate a variety of biological effects via binding their intracellular receptor. Ligand-bound glucocorticoid receptor (GR) translocates to the nucleus and regulates gene transcription in a DNA binding-dependent or independent manner. The predominant biological effect of glucocorticoids on peripheral T cells is immunosupression via transcriptional repression of genes induced during T cell activation. Glucocorticoids have been implicated in the inhibition of activation-induced T cell apoptosis by virtue of their down-regulation of Fas ligand (fasL) expression. It is believed that FasL, similar to other cytokines, is repressed by glucocorticoids via GR interaction with other transcription factors, interfering with their transactivation ability. Here, we show that human fasL is directly regulated by GR in a DNA binding-dependent manner. A negative GR element found at position -990 in the fasL promoter binds GR in vitro as well as in the chromatin context. This negative glucocorticoid response element overlaps with a known NF kappa B binding site. GR down- regulates fasL promoter by competing with NF kappa B for binding to the common response element. Thus, fasL is the first gene described whose repression by GR is mediated by sterical occlusion of NF kappa B DNA binding. This type of repression represents an additional mechanism for the GR-NF kappa B mutual antagonism.	Univ Jena, Inst Biochem & Biophys, D-07743 Jena, Germany; Biomed Res Inst, Frankfurt, Germany	Friedrich Schiller University of Jena	Heinzel, T (corresponding author), Univ Jena, Inst Biochem & Biophys, Philosophenweg 12, D-07743 Jena, Germany.	t.heinzel@uni-jena.de	Heinzel, Thorsten/B-1013-2015					Baumann S, 2005, BLOOD, V106, P617, DOI 10.1182/blood-2004-11-4390; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Buttgereit F, 2005, LANCET, V365, P801; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Devitt A., 2004, METH MOL B, V282, P207; Dostert A, 2004, CURR PHARM DESIGN, V10, P2807; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Lucas M, 2003, J IMMUNOL, V171, P2610, DOI 10.4049/jimmunol.171.5.2610; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; NAKAI Y, 1991, J STEROID BIOCHEM, V40, P301, DOI 10.1016/0960-0760(91)90195-B; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; PALIOGIANNI F, 1993, J IMMUNOL, V151, P4081; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2004, CURR PHARM DESIGN, V10, P2797, DOI 10.2174/1381612043383575; Schacke Heike, 2005, Curr Opin Investig Drugs, V6, P503; Schleimer Robert P., 2000, Journal of Allergy and Clinical Immunology, V106, pS270; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Yerramasetti R, 2002, J CLIN IMMUNOL, V22, P37, DOI 10.1023/A:1014256603539; Zipp F, 2000, J NEUROIMMUNOL, V110, P214, DOI 10.1016/S0165-5728(00)00337-4	37	46	47	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1074	1081		10.1096/fj.05-5457com	http://dx.doi.org/10.1096/fj.05-5457com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770006				2022-12-25	WOS:000240210300007
J	Cowell, LN; D Graham, J; Bouton, AH; Clarke, CL; O'Neill, GM				Cowell, L. N.; D Graham, J.; Bouton, A. H.; Clarke, C. L.; O'Neill, G. M.			Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway	ONCOGENE			English	Article						p130Cas/BCAR1; Src kinase; estrogen receptor; adhesion; tamoxifen; FAK	BREAST-CANCER CELLS; CRK-ASSOCIATED SUBSTRATE; DOMAIN TYROSINE PHOSPHORYLATION; HUMAN ESTROGEN-RECEPTOR; DOCKING PROTEIN HEF1; C-SRC; ANTIESTROGEN RESISTANCE; TRANSFORMED-CELLS; FAMILY KINASES; IN-VIVO	Reports that the adhesion-associated molecule p130Cas/BCAR1 promotes resistance to tamoxifen suggested that adhesion-mediated signalling may be altered by tamoxifen treatment. We find that p130Cas/BCAR1 phosphorylation is enhanced in tamoxifen-treated estrogen receptor (ER)positive MCF-7 breast cancer cells. The effects of estrogen and tamoxifen were assessed independently and in combination, and the results demonstrate that tamoxifen antagonizes estrogen regulation of p130Cas/BCAR1 phosphorylation. Phosphorylation correlates with tamoxifen ER antagonist effects, as phosphorylation effects are replicated by the pure antiestrogen ICI 182, 780. Correspondingly, phosphorylation is not changed in ER-negative cells exposed to tamoxifen. We show that deletion of the p130Cas/BCAR1 substrate domain substantially reduces tamoxifen-induced phosphorylation of p130Cas/BCAR1 and confers enhanced sensitivity to tamoxifen. P130Cas/BCAR1 forms a phosphorylation-dependent signalling complex with focal adhesion kinase (FAK) and Src kinase that promotes adhesion-mediated cell survival. Therefore, we examined the kinetics of p130Cas/BCAR1, Src and FAK phosphorylation over a 14-day time course and find sustained phosphorylation of these molecules after 7 days exposure to tamoxifen. Inhibition of Src kinase is shown to reduce tamoxifen-promoted p130Cas/BCAR1 phosphorylation and reduce cell viability. Stimulation of the Src/FAK/p130Cas/BCAR1 adhesion signalling pathway in tamoxifen-treated MCF-7 cells does not cause increased migration; however, there is Src-dependent phosphorylation of the cell survival molecule Akt. Correspondingly, Akt inhibition reduces cell viability in cells treated with tamoxifen. We propose that prolonged activation of adhesion-dependent signalling may confer a survival advantage in response to additional cellular insults or alternatively, may poise cells to develop a migratory phenotype in response to additional cellular cues.	Univ Sydney, Focal Adhes Biol Grp, Oncol Res Unit, Childrens Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Discipline Paediat & Child Hlth, Westmead, NSW 2145, Australia; Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA USA	University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Virginia; University of Virginia	O'Neill, GM (corresponding author), Univ Sydney, Focal Adhes Biol Grp, Oncol Res Unit, Childrens Hosp, Westmead, NSW 2145, Australia.	geraldio@chw.edu.au	O'Neill, Geraldine/F-3112-2014	O'Neill, Geraldine/0000-0001-9997-8794; Clarke, Christine/0000-0001-7568-111X	NCI NIH HHS [CA096846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bartholomew PJ, 1998, J STEROID BIOCHEM, V67, P241, DOI 10.1016/S0960-0760(98)00098-3; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cai DP, 1999, J IMMUNOL, V163, P2104; Cai DP, 2003, CANCER RES, V63, P6802; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Clemons M, 2002, CANCER TREAT REV, V28, P165, DOI 10.1016/S0305-7372(02)00036-1; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GIERTHY JF, 1991, J CELL BIOCHEM, V45, P177, DOI 10.1002/jcb.240450209; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hiscox S, 2004, CLIN EXP METASTAS, V21, P201, DOI 10.1023/B:CLIN.0000037697.76011.1d; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vuori K, 1996, MOL CELL BIOL, V16, P2606	56	42	45	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7597	7607		10.1038/sj.onc.1209747	http://dx.doi.org/10.1038/sj.onc.1209747			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16799644				2022-12-25	WOS:000242655500005
J	Evans, EJ; Castro, MAA; O'Brien, R; Kearney, A; Walsh, H; Sparks, LM; Tucknott, MG; Davies, EA; Carmo, AM; van der Merwe, PA; Stuart, DI; Jones, EY; Ladbury, JE; Ikemizu, S; Davis, SJ				Evans, Edward J.; Castro, Monica A. A.; O'Brien, Ronan; Kearney, Alice; Walsh, Heather; Sparks, Lisa M.; Tucknott, Michael G.; Davies, Elizabeth A.; Carmo, Alexandre M.; van der Merwe, P. Anton; Stuart, David I.; Jones, E. Yvonne; Ladbury, John E.; Ikemizu, Shinji; Davis, Simon J.			Crystal structure and binding properties of the CD2 and CD244 (2B4)-binding protein, CD48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE CD2; LINKED LYMPHOPROLIFERATIVE-DISEASE; CELL ANTIGEN RECOGNITION; VERY-LOW AFFINITY; T-CELLS; NATURAL-KILLER; PEPTIDE-MHC; IMMUNE-RESPONSES; SLAM FAMILY; SUBTLE ROLE	The structural analysis of surface proteins belonging to the CD2 subset of the immunoglobulin superfamily has yielded important insights into transient cellular interactions. In mice and rats, CD2 and CD244 (2B4), which are expressed predominantly on T cells and natural killer cells, respectively, bind the same, broadly expressed ligand, CD48. Structures of CD2 and CD244 have been solved previously, and we now present the structure of the receptor-binding domain of rat CD48. The receptor-binding surface of CD48 is unusually flat, as in the case of rat CD2, and shares a high degree of electrostatic complementarity with the equivalent surface of CD2. The relatively simple arrangement of charged residues and this flat topology explain why CD48 cross-reacts with CD2 and CD244 and, in rats, with the CD244-related protein, 2B4R. Comparisons of modeled complexes of CD2 and CD48 with the complex of human CD2 and CD58 are suggestive of there being substantial plasticity in the topology of ligand binding by CD2. Thermodynamic analysis of the native CD48-CD2 interaction indicates that binding is driven by equivalent, weak enthalpic and entropic effects, in contrast to the human CD2-CD58 interaction, for which there is a large entropic barrier. Overall, the structural and biophysical comparisons of the CD2 homologues suggest that the evolutionary diversification of interacting cell surface proteins is rapid and constrained only by the requirement that binding remains weak and specific.	Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 9DS, England; John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Univ Porto, Grp Cell Activat & Gene Express, IBMC, P-4099003 Oporto, Portugal; Univ Porto, ICBAS, P-4099003 Oporto, Portugal; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Kumamoto Univ, Grad Sch Pharmaceut Sci, Div Struct Biol, Kumamoto 8620973, Japan	University of Oxford; University of Oxford; Universidade do Porto; Universidade do Porto; University of London; University College London; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Kumamoto University	Ikemizu, S (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Oxford OX3 9DS, England.	ikemizu@gpo.kumamoto-u.ac.jp; simon.davis@ndm.ox.ac.uk	Lima, Marta T/C-7042-2009; van der Merwe, P. Anton/F-8539-2011; Jones, Yvonne/J-2293-2016; Carmo, Alexandre/B-5191-2011; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Carmo, Alexandre/0000-0002-2508-9799; Jones, Yvonne/0000-0002-3834-1893; Ladbury, John/0000-0002-6328-7200; Stuart, David/0000-0002-3426-4210	MRC [G9722488, G0500365, G9900061] Funding Source: UKRI; Medical Research Council [G9722488, G19/31, G0500365, G9900061] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ames JB, 2005, BIOCHEMISTRY-US, V44, P6416, DOI 10.1021/bi050139s; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butters TD, 1999, PROTEIN SCI, V8, P1696, DOI 10.1110/ps.8.8.1696; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; Davis SJ, 2003, NAT IMMUNOL, V4, P217, DOI 10.1038/ni0303-217; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Dumont C, 2001, TRANSPLANT P, V33, P199, DOI 10.1016/S0041-1345(00)01974-6; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; Gonzalez-Cabrero J, 1999, P NATL ACAD SCI USA, V96, P1019, DOI 10.1073/pnas.96.3.1019; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; KILLEEN N, 1992, EMBO J, V11, P4329, DOI 10.1002/j.1460-2075.1992.tb05532.x; Kitao A, 2000, P NATL ACAD SCI USA, V97, P2064, DOI 10.1073/pnas.030540397; Kumaresan PR, 2000, IMMUNOGENETICS, V51, P306, DOI 10.1007/s002510050624; Kumaresan PR, 2000, MOL IMMUNOL, V37, P735, DOI 10.1016/S0161-5890(00)00103-6; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SCHUHMACHERS G, 1995, EUR J IMMUNOL, V25, P1117, DOI 10.1002/eji.1830250440; SCHUHMACHERS G, 1995, J INVEST DERMATOL, V105, P592, DOI 10.1111/1523-1747.ep12323533; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; Teh SJ, 1997, BLOOD, V89, P1308, DOI 10.1182/blood.V89.4.1308; van der Merwe PA, 1999, J EXP MED, V190, P1371, DOI 10.1084/jem.190.10.1371; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Veillette A, 2003, CURR OPIN IMMUNOL, V15, P277, DOI 10.1016/S0952-7915(03)00041-4; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wang N, 2001, IMMUNOGENETICS, V53, P382, DOI 10.1007/s002510100337; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	64	28	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					29309	29320		10.1074/jbc.M601314200	http://dx.doi.org/10.1074/jbc.M601314200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16803907	hybrid			2022-12-25	WOS:000240680500086
J	Loeb, CRK; Harris, JL; Craik, CS				Loeb, Carly R. K.; Harris, Jennifer L.; Craik, Charles S.			Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; MEDIATED APOPTOSIS; CELL-DEATH; INTRAEPITHELIAL NEOPLASIA; LYMPHOCYTE PROTEASE; T-LYMPHOCYTES; KEY MEDIATORS; ACTIVATION; CLEAVAGE; SPECIFICITY	Granzyme B is critical to the ability of natural killer cells and cytotoxic T lymphocytes to induce efficient cell death of virally infected or tumor cell targets. Although granzyme B can cleave and activate caspases to induce apoptosis, granzyme B can also cause caspase-independent cell death. Thirteen prospective granzyme B substrates were identified from a cDNA expression-cleavage screen, including Hsp70, Notch1, fibroblast growth factor receptor-1 (FGFR1), poly-A-binding protein, cAbl, heterogeneous nuclear ribonucleoprotein H', Br140, and intersectin-1. Validation revealed that Notch1 is a substrate of both granzyme B and caspases, whereas FGFR1 is a caspase-independent substrate of granzyme B. Proteolysis of FGFR1 in prostate cancer cells has functionally relevant consequences that indicate its cleavage may be advantageous for granzyme B to kill prostate cancer cells. Therefore, granzyme B not only activates pro-death functions within a target, but also has a previously unidentified role in inactivating pro-growth signals to cause cell death.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94131 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Tetrad Grad Program, San Francisco, CA 94131 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, MC 2280,Genentech Hall,Rm S512,600 16th St, San Francisco, CA 94131 USA.	craik@cgl.ucsf.edu			NCI NIH HHS [CA072006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Casciola-Rosen L, 1999, J EXP MED, V190, P815, DOI 10.1084/jem.190.6.815; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Freeman KW, 2003, CANCER RES, V63, P8256; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Gorak-Stolinska P, 2001, J LEUKOCYTE BIOL, V70, P756; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Jehn BM, 1999, J IMMUNOL, V162, P635; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Kwabi-Addo B, 2001, PROSTATE, V46, P163, DOI 10.1002/1097-0045(20010201)46:2<163::AID-PROS1020>3.0.CO;2-T; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Opferman JT, 2001, INT IMMUNOL, V13, P411, DOI 10.1093/intimm/13.4.411; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Polnaszek N, 2003, CANCER RES, V63, P5754; Ropiquet F, 1997, INT J CANCER, V72, P543, DOI 10.1002/(SICI)1097-0215(19970729)72:3<543::AID-IJC26>3.0.CO;2-B; Rotonda J, 2001, CHEM BIOL, V8, P357, DOI 10.1016/S1074-5521(01)00018-7; Ruchalski K, 2006, J BIOL CHEM, V281, P7873, DOI 10.1074/jbc.M513728200; Rugles SW, 2004, J BIOL CHEM, V279, P30751, DOI 10.1074/jbc.M400949200; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Thiery J, 2003, J IMMUNOL, V170, P5919, DOI 10.4049/jimmunol.170.12.5919; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Willoughby CA, 2002, BIOORG MED CHEM LETT, V12, P2197, DOI 10.1016/S0960-894X(02)00363-3; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598	48	61	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28326	28335		10.1074/jbc.M604544200	http://dx.doi.org/10.1074/jbc.M604544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16798735	hybrid			2022-12-25	WOS:000240534400070
J	Hothorn, M; Wachter, A; Gromes, R; Stuwe, T; Rausch, T; Scheffzek, K				Hothorn, Michael; Wachter, Andreas; Gromes, Roland; Stuwe, Tobias; Rausch, Thomas; Scheffzek, Klaus			Structural basis for the redox control of plant glutamate cysteine ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ARABIDOPSIS-THALIANA; GLUTATHIONE HOMEOSTASIS; MACROMOLECULAR STRUCTURES; MODIFIER SUBUNIT; GENE-EXPRESSION; MECHANISM; BIOSYNTHESIS; METABOLISM; REFINEMENT	Glutathione (GSH) plays a crucial role in plant metabolism and stress response. The rate-limiting step in the biosynthesis of GSH is catalyzed by glutamate cysteine ligase (GCL) the activity of which is tightly regulated. The regulation of plant GCLs is poorly understood. The crystal structure of substrate-bound GCL from Brassica juncea at 2.1-angstrom resolution reveals a plant-unique regulatory mechanism based on two intramolecular redox-sensitive disulfide bonds. Reduction of one disulfide bond allows a beta-hairpin motif to shield the active site of B. juncea GCL, thereby preventing the access of substrates. Reduction of the second disulfide bond reversibly controls dimer to monomer transition of B. juncea GCL that is associated with a significant inactivation of the enzyme. These regulatory events provide a molecular link between high GSH levels in the plant cell and associated down-regulation of its biosynthesis. Furthermore, known mutations in the Arabidopsis GCL gene affect residues in the close proximity of the active site and thus explain the decreased GSH levels in mutant plants. In particular, the mutation in rax1-1 plants causes impaired binding of cysteine.	European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany; Heidelberg Inst Plant Sci, Dept Mol Ecophysiol, D-69120 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Scheffzek, K (corresponding author), European Mol Biol Lab, Struct & Computat Biol Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	scheffzek@embl.de	Gromes, Roland/H-9041-2012; Hothorn, Michael/C-6807-2011; Wachter, Andreas/P-9038-2014	Gromes, Roland/0000-0002-4693-6491; Wachter, Andreas/0000-0002-3132-5161; Hothorn, Michael/0000-0002-3597-5698				Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; Ball L, 2004, PLANT CELL, V16, P2448, DOI 10.1105/tpc.104.022608; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Cobbett CS, 1998, PLANT J, V16, P73, DOI 10.1046/j.1365-313x.1998.00262.x; Dall'Antonia F, 2003, ACTA CRYSTALLOGR D, V59, P1987, DOI 10.1107/S0907444903017670; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dixon DP, 2005, PLANT PHYSIOL, V138, P2233, DOI 10.1104/pp.104.058917; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Foyer CH, 2005, PLANT CELL, V17, P1866, DOI 10.1105/tpc.105.033589; Fraser JA, 2003, J BIOL CHEM, V278, P46369, DOI 10.1074/jbc.M308035200; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Grosse-Kunstleve RW, 2003, ACTA CRYSTALLOGR D, V59, P1966, DOI 10.1107/S0907444903018043; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HELL R, 1990, PLANTA, V180, P603, DOI 10.1007/BF02411460; Hibi T, 2004, P NATL ACAD SCI USA, V101, P15052, DOI 10.1073/pnas.0403277101; Hothorn M, 2003, ACTA CRYSTALLOGR D, V59, P2279, DOI 10.1107/S0907444903021036; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; Kopriva S, 2004, J EXP BOT, V55, P1831, DOI 10.1093/jxb/erh203; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; May MJ, 1998, P NATL ACAD SCI USA, V95, P12049, DOI 10.1073/pnas.95.20.12049; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Meyer AJ, 2005, PHOTOSYNTH RES, V86, P435, DOI 10.1007/s11120-005-8425-1; Michelet L, 2005, P NATL ACAD SCI USA, V102, P16478, DOI 10.1073/pnas.0507498102; Milla MAR, 2003, PLANT J, V36, P602, DOI 10.1046/j.1365-313X.2003.01901.x; Mullineaux PM, 2005, PHOTOSYNTH RES, V86, P459, DOI 10.1007/s11120-005-8811-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noctor G, 1998, PLANT PHYSIOL, V118, P471, DOI 10.1104/pp.118.2.471; Peltier JB, 2006, MOL CELL PROTEOMICS, V5, P114, DOI 10.1074/mcp.M500180-MCP200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rausch T, 2005, TRENDS PLANT SCI, V10, P503, DOI 10.1016/j.tplants.2005.08.006; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; SanchezFernandez R, 1997, P NATL ACAD SCI USA, V94, P2745, DOI 10.1073/pnas.94.6.2745; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tu ZH, 1998, BIOCHEM J, V336, P675, DOI 10.1042/bj3360675; Ullmann P, 1996, EUR J BIOCHEM, V236, P662, DOI 10.1111/j.1432-1033.1996.00662.x; Vernoux T, 2000, PLANT CELL, V12, P97, DOI 10.1105/tpc.12.1.97; Wachter A, 2005, PLANT J, V41, P15, DOI 10.1111/j.1365-313X.2004.02269.x; Wagner U, 2002, PLANT MOL BIOL, V49, P515, DOI 10.1023/A:1015557300450; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539	50	83	87	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27557	27565		10.1074/jbc.M602770200	http://dx.doi.org/10.1074/jbc.M602770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16766527	Green Published, hybrid			2022-12-25	WOS:000240397700081
J	Vaid, A; Sharma, P				Vaid, Ankush; Sharma, Pushkar			PfPKB, a protein kinase B-like enzyme from Plasmodium falciparum II. Identification of calcium/calmodulin as its upstream activator and dissection of a novel signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MALARIA PARASITES; CALCIUM HOMEOSTASIS; GAMETE FORMATION; CALMODULIN; INVASION; ERYTHROCYTES; MECHANISM; SEQUENCE; PEPTIDE; INSULIN	Intracellular cell signaling cascades of protozoan parasite Plasmodium falciparum are not clearly understood. We have reported previously (Kumar, A., Vaid, A., Syin, C., and Sharma, P. (2004) J. Biol. Chem. 279, 24255-24264) the identification and characterization of a protein kinase B-like enzyme in P. falciparum (PfPKB). PfPKB lacks the phosphoinositide-interacting pleckstrin homology domain present in mammalian protein kinase B. Therefore, the mechanism of PfPKB regulation was expected to be different from that of the host and had remained unknown. We have identified calmodulin (CaM) as the regulator of PfPKB activity. A CaM binding domain was mapped in the N-terminal region of PfPKB. CaM, in a calcium-dependent manner, interacts with this domain and activates PfPKB. CaM associates with PfPKB in the parasite and regulates its activity. Furthermore phospholipase C acts as an upstream regulator of this cascade as it facilitates the release of calcium from intracellular stores. This is one of the first multicomponent signaling pathways to be dissected in the malaria parasite.	Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sharma, P (corresponding author), Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India.	pushkar@nii.res.in			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Biagini GA, 2003, J BIOL CHEM, V278, P27910, DOI 10.1074/jbc.M304193200; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; COWMAN AF, 1991, EXP PARASITOL, V73, P269, DOI 10.1016/0014-4894(91)90098-H; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Garcia CRS, 1996, EUR J CELL BIOL, V71, P409; Garcia CRS, 1999, PARASITOL TODAY, V15, P488, DOI 10.1016/S0169-4758(99)01571-9; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gazarini ML, 2003, J CELL BIOL, V161, P103, DOI 10.1083/jcb.200212130; Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hotta CT, 2003, BRAZ J MED BIOL RES, V36, P1583, DOI 10.1590/S0100-879X2003001100016; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Kumar A, 2004, J BIOL CHEM, V279, P24255, DOI 10.1074/jbc.M312855200; MATSUMOTO Y, 1987, EUR J CELL BIOL, V45, P36; MCCALLUMDEIGHTON N, 1992, MOL BIOCHEM PARASIT, V50, P317, DOI 10.1016/0166-6851(92)90229-D; Merckx A, 2003, J BIOL CHEM, V278, P39839, DOI 10.1074/jbc.M301625200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Reininger L, 2005, J BIOL CHEM, V280, P31957, DOI 10.1074/jbc.M504523200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROBSON KJH, 1993, PHILOS T R SOC B, V340, P39, DOI 10.1098/rstb.1993.0047; SCHEIBEL LW, 1987, P NATL ACAD SCI USA, V84, P7310, DOI 10.1073/pnas.84.20.7310; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sun XT, 2000, PLANT CELL PHYSIOL, V41, P804, DOI 10.1093/pcp/41.6.804; Tewari R, 2005, MOL MICROBIOL, V58, P1253, DOI 10.1111/j.1365-2958.2005.04793.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WARD GE, 1994, EXP PARASITOL, V79, P480, DOI 10.1006/expr.1994.1109; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Yamauchi E, 2003, NAT STRUCT BIOL, V10, P226, DOI 10.1038/nsb900	31	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27126	27133		10.1074/jbc.M601914200	http://dx.doi.org/10.1074/jbc.M601914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16809343	hybrid			2022-12-25	WOS:000240397700040
J	Bhor, VM; Dev, S; Vasanthakumar, GR; Kumar, P; Sinha, S; Surolia, A				Bhor, Vikrant M.; Dev, Sagarika; Vasanthakumar, Ganga Ramu; Kumar, Parimal; Sinha, Sharmistha; Surolia, Avadhesha			Broad substrate stereospecificity of the Mycobacterium tuberculosis 7-keto-8-aminopelargonic acid synthase - Spectroscopic and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							8-AMINO-7-OXONONANOATE SYNTHASE; 8-AMINO-7-OXOPELARGONATE SYNTHASE; CRYSTAL-STRUCTURE; BIOTIN; BIOSYNTHESIS; BINDING; ENZYME; INTERMEDIATE; SPECIFICITY; INHIBITION	Biotin is an essential enzyme cofactor required for carboxylation and transcarboxylation reactions. The absence of the biotin biosynthesis pathway in humans suggests that it can be an attractive target for the development of novel drugs against a number of pathogens. 7-Keto-8-aminopelargonic acid (KAPA) synthase (EC 2.3.1.47), the enzyme catalyzing the first committed step in the biotin biosynthesis pathway, is believed to exhibit high substrate stereospecificity. A comparative kinetic characterization of the interaction of the Mycobacterium tuberculosis KAPA synthase with both L- and D-alanine was carried out to investigate the basis of the substrate stereospecificity exhibited by the enzyme. The formation of the external aldimine with D-alanine (k = 82.63 M-1 s(-1)) is similar to 5 times slower than that with L-alanine (k = 399.4 M-1 s(-1)). In addition to formation of the external aldimine, formation of substrate quinonoid was also observed upon addition of pimeloyl-CoA to the preformed D-alanine external aldimine complex. However, the formation of this intermediate was extremely slow compared with the substrate quinonoid with L- alanine and pimeloyl-CoA (k = 16.9 x 10(4) M-1 s(-1)). Contrary to earlier reports, these results clearly show that D-alanine is not a competitive inhibitor but a substrate for the enzyme and thereby demonstrate the broad substrate stereospecificity of the M. tuberculosis KAPA synthase. Further, D-KAPA, the product of the reaction utilizing D-alanine inhibits both KAPA synthase (K-i = 114.83 mu M) as well as 7,8-diaminopelargonic acid synthase (IC50 = 43.9 mu M), the next enzyme of the pathway.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Inst Immunol, New Delhi 110067, India	Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Aruna Asaf Ali Marg, Bangalore 560012, Karnataka, India.	surolia@nii.res.in	SUROLIA, AVADESHA/C-5442-2009; Kumar, Parimal/AAG-9653-2019	BHOR, VIKRANT/0000-0001-9897-4505; Sinha, Sharmistha/0000-0003-2459-650X				ACHARYA S, 1990, J BIOL CHEM, V265, P11586; Alexeev D, 2006, ORG BIOMOL CHEM, V4, P1209, DOI 10.1039/b517922j; Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Astner I, 2005, EMBO J, V24, P3166, DOI 10.1038/sj.emboj.7600792; Bhor VM, 2006, IUBMB LIFE, V58, P225, DOI 10.1080/15216540600746997; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; CRAMER F, 1967, J AM CHEM SOC, V89, P14, DOI 10.1021/ja00977a003; EISENBERG M, 1987, ESCHERICHIA COLI SAL, P544; EISENBERG MA, 1971, J BACTERIOL, V108, P1135, DOI 10.1128/JB.108.3.1135-1140.1971; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FEDERIUK CS, 1983, J BIOL CHEM, V258, P5372; Hiromi K., 1979, KINETICS FAST ENZYME; Hunter GA, 1999, J BIOL CHEM, V274, P12222, DOI 10.1074/jbc.274.18.12222; Kerbarh O, 2006, CHEM COMMUN, P60, DOI 10.1039/b511837a; KLOSS RA, 1963, BIOCHIM BIOPHYS ACTA, V70, P90; KRMER L, 2002, EXPERT OPIN INV DRUG, V11, P1; Lim YH, 1998, J BIOL CHEM, V273, P4001, DOI 10.1074/jbc.273.7.4001; Malthouse JPG, 2003, BBA-PROTEINS PROTEOM, V1647, P138, DOI 10.1016/S1570-9639(03)00080-3; Marquet A, 2001, VITAM HORM, V61, P51; Nudelman A, 1998, BIOORG CHEM, V26, P157, DOI 10.1006/bioo.1998.1094; Pinon V, 2005, PLANT PHYSIOL, V139, P1666, DOI 10.1104/pp.105.070144; Ploux O, 1996, EUR J BIOCHEM, V236, P301, DOI 10.1111/j.1432-1033.1996.00301.x; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; Schmidt A, 2001, BIOCHEMISTRY-US, V40, P5151, DOI 10.1021/bi002204y; Schneider G, 2001, FEBS LETT, V495, P7, DOI 10.1016/S0014-5793(01)02325-0; Segel IH, 1993, ENZYME KINETICS BEHA, P161; SILVERMAN RB, 1987, J BIOL CHEM, V262, P3192; Soda K, 2001, CHEM REC, V1, P373, DOI 10.1002/tcr.1021; WATANABE Y, 1980, BIOCHEM J, V189, P393, DOI 10.1042/bj1890393; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j	32	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25076	25088		10.1074/jbc.M604477200	http://dx.doi.org/10.1074/jbc.M604477200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16769720	hybrid			2022-12-25	WOS:000240031300009
J	Jeske, M; Meyer, S; Temme, C; Freudenreich, D; Wahle, E				Jeske, Mandy; Meyer, Sylke; Temme, Claudia; Freudenreich, Dorian; Wahle, Elmar			Rapid ATP-dependent deadenylation of nanos mRNA in a cell-free system from Drosophila embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) TAIL LENGTH; AU-RICH ELEMENTS; BINDING-PROTEIN; TRANSLATIONAL REPRESSION; POSTERIOR DETERMINANT; CAF1 PROTEINS; YEAST; DEGRADATION; SMAUG; COMPLEX	Shortening of the poly(A) tail (deadenylation) is the first and often rate-limiting step in the degradation pathway of most eukaryotic mRNAs and is also used as a means of translational repression, in particular in early embryonic development. The nanos mRNA is translationally repressed by the protein Smaug in Drosophila embryos. The RNA has a short poly(A) tail at steady state and decays gradually during the first 2-3 h of development. Smaug has recently also been implicated in mRNA deadenylation. To study the mechanism of sequence-dependent deadenylation, we have developed a cell-free system from Drosophila embryos that displays rapid deadenylation of nanos mRNA. The Smaug response elements contained in the nanos 3'-untranslated region are necessary and sufficient to induce deadenylation; thus, Smaug is likely to be involved. Unexpectedly, deadenylation requires the presence of an ATP regenerating system. The activity can be pelleted by ultracentrifugation, and both the Smaug protein and the CCR4(.)NOT complex, a known deadenylase, are enriched in the active fraction. The same extracts show pronounced translational repression mediated by the Smaug response elements. RNAs lacking a poly(A) tail are poorly translated in the extract; therefore, SRE-dependent deadenylation contributes to translational repression. However, repression is strong even with RNAs either bearing a poly(A) tract that cannot be removed or lacking poly(A) altogether; thus, an additional aspect of translational repression functions independently of deadenylation.	Univ Halle, Inst Biochem, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg	Wahle, E (corresponding author), Univ Halle, Inst Biochem, Kurt Mothes Str 3, D-06120 Halle, Germany.	ewahle@biochemtech.uni-halle.de		Wahle, Elmar/0000-0003-2504-0677; Jeske, Mandy/0000-0002-1107-9442				Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Bashirullah A, 1999, EMBO J, V18, P2610, DOI 10.1093/emboj/18.9.2610; Bergsten SE, 1999, DEVELOPMENT, V126, P659; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Chagnovich D, 2001, P NATL ACAD SCI USA, V98, P11359, DOI 10.1073/pnas.201284398; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chekulaeva M, 2006, CELL, V124, P521, DOI 10.1016/j.cell.2006.01.031; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Clark IE, 2000, CURR BIOL, V10, P1311, DOI 10.1016/S0960-9822(00)00754-5; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; Crucs S, 2000, MOL CELL, V5, P457, DOI 10.1016/S1097-2765(00)80440-2; Dahanukar A, 1996, GENE DEV, V10, P2610, DOI 10.1101/gad.10.20.2610; Dahanukar A, 1999, MOL CELL, V4, P209, DOI 10.1016/S1097-2765(00)80368-8; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Dean KA, 2002, TRENDS GENET, V18, P572, DOI 10.1016/S0168-9525(02)02792-0; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Forrest KM, 2004, DEVELOPMENT, V131, P5849, DOI 10.1242/dev.01460; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Gavis ER, 1996, DEVELOPMENT, V122, P2791; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; GOLSTROHM AC, 2006, NAT STRUCT MOL BIOL, V13, P533; Gorgoni Barbara, 2004, Briefings in Functional Genomics & Proteomics, V3, P125, DOI 10.1093/bfgp/3.2.125; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GRONER B, 1974, BIOCHEMISTRY-US, V13, P5378, DOI 10.1021/bi00723a020; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kalifa Y, 2006, DEV CELL, V10, P291, DOI 10.1016/j.devcel.2006.01.001; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Legagneux V, 1995, RNA, V1, P1001; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; Markesich DC, 2000, DEVELOPMENT, V127, P559; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Morris JZ, 2005, DEVELOPMENT, V132, P1165, DOI 10.1242/dev.01672; Muhlrad D, 2005, EMBO J, V24, P1033, DOI 10.1038/sj.emboj.7600560; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Nelson MR, 2004, EMBO J, V23, P150, DOI 10.1038/sj.emboj.7600026; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Paillard L, 2003, BIOL CELL, V95, P107, DOI 10.1016/S0248-4900(03)00010-8; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Reverdatto SV, 2004, RNA, V10, P1200, DOI 10.1261/rna.7540204; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Smibert CA, 1999, RNA, V5, P1535, DOI 10.1017/S1355838299991392; Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Temme C, 2004, EMBO J, V23, P2862, DOI 10.1038/sj.emboj.7600273; Thompson SR, 2000, MOL CELL BIOL, V20, P2129, DOI 10.1128/MCB.20.6.2129-2137.2000; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Till DD, 1998, MECH DEVELOP, V79, P51, DOI 10.1016/S0925-4773(98)00173-7; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wickens M, 2000, TRANSLATIONAL CONTRO; Wilhelm JE, 2003, J CELL BIOL, V163, P1197, DOI 10.1083/jcb.200309088; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wreden C, 1997, DEVELOPMENT, V124, P3015; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; Zappavigna V, 2004, P NATL ACAD SCI USA, V101, P14800, DOI 10.1073/pnas.0406451101	88	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25124	25133		10.1074/jbc.M604802200	http://dx.doi.org/10.1074/jbc.M604802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16793774	hybrid			2022-12-25	WOS:000240031300013
J	Yoon, D; Pastore, YD; Divoky, V; Liu, EL; Mlodnicka, AE; Rainey, K; Ponka, P; Semenza, GL; Schumacher, A; Prchal, JT				Yoon, Donghoon; Pastore, Yves D.; Divoky, Vladimir; Liu, Enli; Mlodnicka, Agnieszka E.; Rainey, Karin; Ponka, Premysl; Semenza, Gregg L.; Schumacher, Armin; Prchal, Josef T.			Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSCRIPTION; EMBRYOS LACKING; YOLK-SAC; OXYGEN; VEGF; POLYCYTHEMIA; ACTIVATION; EXPRESSION; HEPCIDIN; GROWTH	Hypoxia-inducible factor-1 (HIF-1) regulates the transcription of genes whose products play critical roles in energy metabolism, erythropoiesis, angiogenesis, and cell survival. Limited information is available concerning its function in mammalian hematopoiesis. Previous studies have demonstrated that homozygosity for a targeted null mutation in the Hif1 alpha gene, which encodes the hypoxia-responsive alpha subunit of HIF-1, causes cardiac, vascular, and neural malformations resulting in lethality by embryonic day 10.5 (E10.5). This study revealed reduced myeloid multilineage and committed erythroid progenitors in HIF-1 alpha-deficient embryos, as well as decreased hemoglobin content in erythroid colonies from HIF-1 alpha-deficient yolk sacs at E9.5. Dysregulation of erythropoietin (Epo) signaling was evident from a significant decrease in mRNA levels of Epo receptor (EpoR) in Hif1 alpha(-/-) yolk sac as well as Epo and EpoR mRNA in Hif1 alpha(-/-) embryos. The erythropoietic defects in HIF-1 alpha-deficient erythroid colonies could not be corrected by cytokines, such as vascular endothelial growth factor and Epo, but were ameliorated by Fe-SIH, a compound delivering iron into cells independently of iron transport proteins. Consistent with profound defects in iron homeostasis, Hif1 alpha(-/-) yolk sac and/or embryos demonstrated aberrant mRNA levels of hepcidin, Fpn1, Irp1, and frascati. We conclude that dysregulated expression of genes encoding Epo, EpoR, and iron regulatory proteins contributes to defective erythropoiesis in Hif1 alpha(-/-) yolk sacs. These results identify a novel role for HIF-1 in the regulation of iron homeostasis and reveal unexpected regulatory differences in Epo/EpoR signaling in yolk sac and embryonic erythropoiesis.	Univ Utah, Hematol Sect, Salt Lake City, UT 84132 USA; CHU Vaudois, CH-1005 Lausanne, Switzerland; Palacky Univ, Fac Med, Olomouc 77200, Czech Republic; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Vasc Biol Program,Inst Cell Engn,Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; McGill Univ, Montreal, PQ H3T 1E2, Canada	Utah System of Higher Education; University of Utah; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Palacky University Olomouc; Baylor College of Medicine; Baylor College of Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; McGill University	Prchal, JT (corresponding author), Univ Utah, Hematol Sect, 30 North 1900 E,4C416 SOM, Salt Lake City, UT 84132 USA.	Josef.Prchal@hsc.utah.edu	Pastore, Yves Dominique/AAE-2427-2019; Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338, R01HL050077] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55338, R01HL50077-11] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Ang SO, 2002, BLOOD CELL MOL DIS, V28, P57, DOI 10.1006/bcmd.2002.0488; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bichet S, 1999, FASEB J, V13, P285, DOI 10.1096/fasebj.13.2.285; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Choi K, 1998, DEVELOPMENT, V125, P725; Cianetti L, 2005, HAEMATOLOGICA, V90, P1595; Compernolle V, 2003, CARDIOVASC RES, V60, P569, DOI 10.1016/j.cardiores.2003.07.003; CORREA PN, 1991, BLOOD, V78, P2823; Dallalio G, 2006, BLOOD, V107, P2702, DOI 10.1182/blood-2005-07-2854; Damert A, 2002, DEVELOPMENT, V129, P1881; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lee R, 2001, BLOOD, V98, P1408, DOI 10.1182/blood.V98.5.1408; Liu XB, 2002, BLOOD CELL MOL DIS, V29, P315, DOI 10.1006/bcmd.2002.0572; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 2004, CELL CYCLE, V3, P156; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Mok H, 2006, J BIOL CHEM, V281, P7946, DOI 10.1074/jbc.M509857200; Mok H, 2004, DEVELOPMENT, V131, P4871, DOI 10.1242/dev.01342; Mok H, 2004, DEVELOPMENT, V131, P1859, DOI 10.1242/dev.01081; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Palis J, 1999, DEVELOPMENT, V126, P5073; PONKA P, 1979, BIOCHIM BIOPHYS ACTA, V586, P278, DOI 10.1016/0304-4165(79)90100-4; PONKA P, 1985, J BIOL CHEM, V260, P4717; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Scortegagna M, 2005, BLOOD, V105, P3133, DOI 10.1182/blood-2004-05-1695; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xie XD, 2003, BLOOD, V101, P1329, DOI 10.1182/blood-2002-05-1468	47	166	184	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25703	25711		10.1074/jbc.M602329200	http://dx.doi.org/10.1074/jbc.M602329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16787915	hybrid			2022-12-25	WOS:000240031300073
J	Carneiro, AMD; Blakely, RD				Carneiro, Ana Marin D.; Blakely, Randy D.			Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; MEMBRANE SKELETON; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; TERMINAL REGION; UP-REGULATION; LIPID RAFTS; PHOSPHORYLATION; TRAFFICKING; HIC-5	Emerging data indicate the existence of multiple regulatory processes supporting serotonin (5HT) transporter (SERT) capacity including regulated trafficking and catalytic activation, influenced by post-translational modifications and transporter-associated proteins. In the present study, using differential extraction and sedimentation procedures optimized for the purification of cytoskeletal and membrane-skeletal associated proteins, we analyze SERT localization in platelets. Wefind that most of the plasma membrane SERT is associated with themembrane skeleton. This association can be enhanced by both transporter activation and 5HT2A receptor activation. Inactivation of transport activity by phorbol ester treatment of intact platelets relocates SERT to the cytoskeleton fraction, consequently leading to transporter internalization. The translocation of SERT between these compartments is correlated with changes in the interaction with the LIM domain adaptor protein Hic-5. Co-immunoprecipitation and uptake activity studies suggest that Hic-5 is a determinant of transporter inactivation and relocation to a compartment subserving endocytic regulation. Associations of SERT with Hic-5 are evident in brain synaptosomes, suggesting the existence of parallel mechanisms operating to regulate SERT at serotonergic synapses.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Psychiat, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu		MD Carneiro, Ana/0000-0002-7470-7047; Marin Dias Carneiro, Ana/0000-0002-1204-9202	NCI NIH HHS [P30 CA068485] Funding Source: Medline; NIDA NIH HHS [R01 DA007390, R01 DA007390-10, DA07390] Funding Source: Medline; NIDDK NIH HHS [P60 DK020593, P30 DK020593] Funding Source: Medline; NIMH NIH HHS [T32 MH065215, T32 MH065782, T32 MH65782, T32 MH65215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH065782, T32MH065215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bauman AL, 2000, J NEUROSCI, V20, P7571; Blakely RD, 1998, BIOL PSYCHIAT, V44, P169, DOI 10.1016/S0006-3223(98)00124-3; Carneiro AM, 2002, J NEUROSCI, V22, P7045; DASH D, 1995, FEBS LETT, V363, P231, DOI 10.1016/0014-5793(95)00320-9; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; Duan SM, 1999, J NEUROSCI, V19, P10193; Fox JEB, 2001, THROMB HAEMOSTASIS, V86, P198; FOX JEB, 1993, J BIOL CHEM, V268, P25973; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Jayanthi LD, 2005, MOL PHARMACOL, V67, P2077, DOI 10.1124/mol.104.009555; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Koob GF, 2000, ANN NY ACAD SCI, V909, P170, DOI 10.1111/j.1749-6632.2000.tb06682.x; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; Lohi O, 1998, FEBS LETT, V436, P419, DOI 10.1016/S0014-5793(98)01171-5; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Melikian HE, 2004, PHARMACOL THERAPEUT, V104, P17, DOI 10.1016/j.pharmthera.2004.07.006; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; MIYAMOTO S, 1995, JPN CIRC J, V59, P693, DOI 10.1253/jcj.59.693; Mochizuki H, 2005, NEUROCHEM INT, V46, P93, DOI 10.1016/j.neuint.2004.08.008; Murphy DL, 2003, GENES BRAIN BEHAV, V2, P350, DOI 10.1046/j.1601-1848.2003.00049.x; Murphy DL, 2004, MOL INTERV, V4, P109, DOI 10.1124/mi.4.2.8; Najimi M, 2002, FEBS LETT, V523, P224, DOI 10.1016/S0014-5793(02)02981-2; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Nishiya N, 2002, J BIOCHEM, V132, P279, DOI 10.1093/oxfordjournals.jbchem.a003222; Osada M, 2001, BIOCHEM J, V355, P691, DOI 10.1042/bj3550691; Pollock B G, 2001, Expert Opin Pharmacother, V2, P681, DOI 10.1517/14656566.2.4.681; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Quick MW, 2003, NEURON, V40, P537, DOI 10.1016/S0896-6273(03)00605-6; Quick MW, 2002, INT J DEV NEUROSCI, V20, P219, DOI 10.1016/S0736-5748(02)00021-7; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; RUDNICK G, 1977, J BIOL CHEM, V252, P2170; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; Sakai N, 2000, NEUROCHEM INT, V36, P567, DOI 10.1016/S0197-0186(99)00160-6; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Scanlon SM, 2001, BIOCHEMISTRY-US, V40, P10507, DOI 10.1021/bi010730z; Schatzberg AF, 2000, J CLIN PSYCHIAT, V61, P9; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Sur C, 1996, EUR J NEUROSCI, V8, P2753, DOI 10.1111/j.1460-9568.1996.tb01570.x; TOLLEFSON GD, 1989, PSYCHOPATHOLOGY, V22, P37, DOI 10.1159/000284625; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Wang JW, 2004, BIOCHEMISTRY-US, V43, P1010, DOI 10.1021/bi035696y; Zhou FC, 1996, MOL BRAIN RES, V43, P267, DOI 10.1016/S0169-328X(96)00209-4; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462; Zohar J, 2000, World J Biol Psychiatry, V1, P92, DOI 10.3109/15622970009150571	52	84	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24769	24780		10.1074/jbc.M603877200	http://dx.doi.org/10.1074/jbc.M603877200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803896	Green Accepted, hybrid			2022-12-25	WOS:000239847800073
J	Le Gac, G; Esteve, PO; Ferec, C; Pradhan, S				Le Gac, Gerald; Esteve, Pierre-Olivier; Ferec, Claude; Pradhan, Sriharsa			DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; CPG-BINDING-PROTEIN; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; HISTONE METHYLTRANSFERASE; CANCER-CELLS; METHYLATION; COMPLEX; DNMT1; EXPRESSION	The Cdc25C phosphatase mediates cellular entry into mitosis in mammalian cells. Cdc25C activates Cdc2 for entry into mitosis by dephosphorylating Thr and Tyr at the site of inhibitory phosphorylation. The Cdc25C gene contains tumor suppressor p53 binding sites and is demonstrated to contribute to the p53-dependent cell cycle arrest upon DNA damage. Here we show that both Cdc25C and Cdc2 were down-regulated in wild-type HCT116 cells but not in p53-null, DNMT1-null or DNMT1- and DNMT3b-null cells, upon p53 stabilization following doxorubicin-mediated DNA damage. Furthermore, zebularine, a drug that selectively traps and depletes nuclear DNMT1 and DNMT3b, relieved p53-mediated repression of endogenous Cdc25C and Cdc2. Methylation analysis of the Cdc25C and Cdc2 promoter displayed internal CG methylation proximal to the p53 binding site upon DNA damage in a p53-dependent manner. Chromatin immunoprecipitation of doxorubicin treated wild- type HCT116 cells showed the presence of DNMT1, p53, H3K9me2, and the transcriptional repressor HDAC1 on the Cdc25C and Cdc2 promoters, suggesting their involvement as repressive complexes in Cdc25C and Cdc2 gene silencing. Thus, the general mechanism of p53-mediated gene repression may involve recruitment of other repressive factors.	New England Biolabs Inc, Ipswich, MA 01938 USA; INSERM, U613, Dept Genet, Etab Francais Sang, F-29275 Brest, France	New England Biolabs; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale	Pradhan, S (corresponding author), New England Biolabs Inc, 240 Cty Rd, Ipswich, MA 01938 USA.	pradhan@neb.com	Le Gac, Gérald/AFQ-1679-2022; Ferec, Claude/ABG-9699-2020	Ferec, Claude/0000-0002-2325-0710; LE GAC, Gerald/0000-0003-3236-7280				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pradhan S, 2003, CLIN IMMUNOL, V109, P6, DOI 10.1016/S1521-6616(03)00204-3; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; St Clair S, 2004, MOL CELL, V16, P725; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; TAN NW, 1990, BIOCHEMISTRY-US, V29, P9234, DOI 10.1021/bi00491a018; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9	46	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24161	24170		10.1074/jbc.M603724200	http://dx.doi.org/10.1074/jbc.M603724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807237	hybrid			2022-12-25	WOS:000239847800010
J	Hodel, AE; Harreman, MT; Pulliam, KF; Harben, ME; Holmes, JS; Hodel, MR; Berland, KM; Corbett, AH				Hodel, Alec E.; Harreman, Michelle T.; Pulliam, Kanika F.; Harben, Mary Elizabeth; Holmes, Jordan S.; Hodel, Mary R.; Berland, Keith M.; Corbett, Anita H.			Nuclear localization signal receptor affinity correlates with in vivo localization in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTIN-ALPHA; KARYOPHERIN-ALPHA; STRUCTURAL BASIS; SYSTEMS-ANALYSIS; TERMINAL DOMAIN; PROTEIN IMPORT; TRANSPORT; BETA; EXPORT; COMPLEX	Nuclear localization signals (NLSs) target proteins into the nucleus through mediating interactions with nuclear import receptors. Here, we perform a quantitative analysis of the correlation between NLS receptor affinity and the steady-state distribution of NLS-bearing cargo proteins between the cytoplasm and the nucleus of live yeast, which reflects the relative import rates of various NLS sequences. We find that there is a complicated, but monotonic quantitative relationship between the affinity of an NLS for the import receptor, importin alpha, and the steady-state accumulation of the cargo in the nucleus. This analysis takes into consideration the impact of protein size. In addition, the hypothetical upper limit to an NLS affinity for the receptors is explored through genetic approaches. Overall, our results indicate that there is a correlation between the binding affinity of an NLS cargo for the NLS receptor, importin alpha, and the import rate for this cargo. This correlation, however, is not maintained for cargoes that bind to the NLS receptor with very weak or very strong affinity.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Dept Phys, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE,Rm 4117, Atlanta, GA 30322 USA.	acorbe2@emory.edu	Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Gilchrist D, 2003, J BIOL CHEM, V278, P51937, DOI 10.1074/jbc.M307371200; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Matsuura Y, 2003, EMBO J, V22, P5358, DOI 10.1093/emboj/cdg538; Matsuura Y, 2004, NATURE, V432, P872, DOI 10.1038/nature03144; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Quimby BB, 2001, J BIOL CHEM, V276, P38820, DOI 10.1074/jbc.M105054200; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	53	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23545	23556		10.1074/jbc.M601718200	http://dx.doi.org/10.1074/jbc.M601718200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785238	hybrid			2022-12-25	WOS:000239702900029
J	Noordeen, NA; Carafoli, F; Hohenester, E; Horton, MA; Leitinger, B				Noordeen, Nafeesa A.; Carafoli, Federico; Hohenester, Erhard; Horton, Michael A.; Leitinger, Birgit			A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCOIDIN DOMAIN RECEPTOR; GROWTH-FACTOR RECEPTORS; ERYTHROPOIETIN RECEPTOR; PROLIFERATION; ASSOCIATION; BINDING; MOTIF; OLIGOMERIZATION; IDENTIFICATION; EXPRESSION	Receptor tyrosine kinases of the discoidin domain family, DDR1 and DDR2, are activated by different types of collagen and play important roles in cell adhesion, migration, proliferation, and matrix remodeling. In a previous study, we found that collagen binding by the discoidin domain receptors (DDRs) requires dimerization of their extracellular domains (Leitinger, B. (2003) J. Biol. Chem. 278, 16761 - 16769), indicating that the paradigm of ligand-induced receptor dimerization may not apply to the DDRs. Using chemical cross-linking and co-immunoprecipitation of differently tagged DDRs, we now show that the DDRs form ligand-independent dimers in the biosynthetic pathway and on the cell surface. We further show that both the extracellular and the cytoplasmic domains are individually dispensable for DDR1 dimerization. The DDR1 transmembrane domain contains two putative dimerization motifs, a leucine zipper and a GXXXG motif. Mutations disrupting the leucine zipper strongly impaired collagen-induced transmembrane signaling, although the mutant DDR1 proteins were still able to dimerize, whereas mutation of the GXXXG motif had no effect. A bacterial reporter assay (named TOXCAT) showed that the DDR1 transmembrane domain has a strong potential for self-association in a biological membrane and that this interaction occurs via the leucine zipper and not the GXXXG motif. Our results demonstrate that the DDRs exist as stable dimers in the absence of ligand and that receptor activation requires specific interactions made by the transmembrane leucine zipper.	UCL, Dept Med, London WC1E 6JJ, England; Univ London Imperial Coll Sci & Technol, Div Cell & Mol Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci & Technol, Div Biomed Sci, London SW7 2AZ, England	University of London; University College London; Imperial College London; Imperial College London	Leitinger, B (corresponding author), UCL, Dept Med, 5 Univ St, London WC1E 6JJ, England.	b.leitinger@imperial.ac.uk			Wellcome Trust [054334] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brown RJ, 2005, NAT STRUCT MOL BIOL, V12, P814, DOI 10.1038/nsmb977; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Curat CA, 2001, J BIOL CHEM, V276, P45952, DOI 10.1074/jbc.M104360200; Dejmek J, 2005, CLIN CANCER RES, V11, P520; Evtimova V, 2003, TUMOR BIOL, V24, P189, DOI 10.1159/000074429; Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Gerber D, 2004, J BIOL CHEM, V279, P21177, DOI 10.1074/jbc.M400847200; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Huber O, 1999, J CELL SCI, V112, P4415; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; Leitinger B, 2004, J MOL BIOL, V344, P993, DOI 10.1016/j.jmb.2004.09.089; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Martin-Fernandez M, 2002, BIOPHYS J, V82, P2415, DOI 10.1016/S0006-3495(02)75585-9; Mason JM, 2004, CHEMBIOCHEM, V5, P170, DOI 10.1002/cbic.200300781; Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Ram R, 2006, J NEURO-ONCOL, V76, P239, DOI 10.1007/s11060-005-6874-1; Ruan WM, 2004, J BIOL CHEM, V279, P3273, DOI 10.1074/jbc.M309311200; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2002, FEBS LETT, V514, P175, DOI 10.1016/S0014-5793(02)02360-8; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Wall SJ, 2005, J BIOL CHEM, V280, P40187, DOI 10.1074/jbc.M508226200; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	42	88	91	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22744	22751		10.1074/jbc.M603233200	http://dx.doi.org/10.1074/jbc.M603233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774916	hybrid			2022-12-25	WOS:000239542600035
J	Stewart, JJ; Fischbeck, JA; Chen, X; Stargell, LA				Stewart, Jennifer J.; Fischbeck, Julie A.; Chen, Xu; Stargell, Laurie A.			Non-optimal TATA elements exhibit diverse mechanistic consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROMOTER DATABASE; BOX-BINDING PROTEIN; GENE-EXPRESSION; HAPLOINSUFFICIENCY; SEQUENCE; COMPLEX	To reveal mechanistic differences in transcription initiation between variant TATA elements, in vivo and in vitro assays of the functional activity of 14 different sequences were compared. Variant elements exhibited particular degrees of activation in vivo but universally were unable to support the -fold activation observed for an element consisting of TATAAA. Each element was classified by its functional activity for in vitro interaction with TATA-binding protein (TBP), TFIIA, and TFIIB. Certain off-consensus TATA elements form poor binding sites for TBP and this compromised interaction interferes with higher order complex formation with TFIIA and/or TFIIB. Other elements are only modestly decreased for TBP binding but dramatically affected for higher order complex formation. Another distinct category is comprised of two elements (CATAAA and TATAAG), which are not affected in the initial formation of the TBP, TFIIA-TBP, or TFIIB-TBP complexes. However, CATAAA and TATAAG are unable to form a stable TFIIA-TBP-DNA complex in vitro. Moreover, fusion of TFIIA to TBP specifically restores activity from these two elements in vivo. Taken together, these results indicate that the interplay between the sequence of the TATA element and the components of the general transcription machinery can lead to variations in the formation of functional complexes and/or the stability of these complexes. These differences offer distinct opportunities for an organism to exploit diverse steps in the regulation of gene expression depending on the precise TATA element sequence at a given gene.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Stargell, LA (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA.	Laurie.Stargell@Colostate.edu	Stargell, Laurie/GWC-7423-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056884] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56884] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bernues J, 1996, NUCLEIC ACIDS RES, V24, P2950, DOI 10.1093/nar/24.15.2950; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Cabelof DC, 2003, CANCER RES, V63, P5799; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; Chirala SS, 2003, P NATL ACAD SCI USA, V100, P6358, DOI 10.1073/pnas.0931394100; Deutschbauer AM, 2005, GENETICS, V169, P1915, DOI 10.1534/genetics.104.036871; Diagana TT, 1997, J MOL BIOL, V265, P480, DOI 10.1006/jmbi.1996.0752; Gershenzon NI, 2005, BIOINFORMATICS, V21, P1295, DOI 10.1093/bioinformatics/bti172; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IYER V, 1995, MOL CELL BIOL, V15, P7059; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Kim JW, 2004, MOL CELL BIOL, V24, P8104, DOI 10.1128/MCB.24.18.8104-8112.2004; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Molina C, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-25; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; Ohler U, 2002, GENOME BIOL, V3, DOI [10.1186/gb-2002-3-12-research0087, DOI 10.1186/GB-2002-3-12-RESEARCH0087]; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Powell RM, 2001, J BIOL CHEM, V276, P29782, DOI 10.1074/jbc.M104099200; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Stewart JJ, 2001, J BIOL CHEM, V276, P30078, DOI 10.1074/jbc.M105276200; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200	32	17	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22665	22673		10.1074/jbc.M603237200	http://dx.doi.org/10.1074/jbc.M603237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772290	hybrid			2022-12-25	WOS:000239542600027
J	Asikainen, TM; Chang, LY; Coalson, JJ; Schneider, BK; Waleh, NS; Ikegami, M; Shannon, JM; Winter, VT; Grubb, P; Clyman, RI; Yoder, BA; Crapo, JD; White, CW				Asikainen, Tiina M.; Chang, Ling-Yi; Coalson, Jacqueline J.; Schneider, Barbara K.; Waleh, Nahid S.; Ikegami, Machiko; Shannon, John M.; Winter, Vicki T.; Grubb, Peter; Clyman, Ronald I.; Yoder, Bradley A.; Crapo, James D.; White, Carl W.			Improved lung growth and function through hypoxia-inducible factor in primate chronic lung disease of prematurity	FASEB JOURNAL			English	Article						bronchopulmonary dysplasia; preterm neonate; angiogenesis; alveolization; lung development	BRONCHOPULMONARY DYSPLASIA; RESPIRATORY-DISTRESS; VASCULAR DEVELOPMENT; DUCTUS-ARTERIOSUS; IMMATURE BABOONS; NITRIC-OXIDE; MICE; VEGF; ANGIOGENESIS; ALVEOLARIZATION	Bronchopulmonary dysplasia (BPD), a chronic lung disease affecting preterm neonates, is associated with significant childhood and adult health problems. Histopathologic features of BPD include impaired vascular and distal airway development. We previously showed that activation of hypoxia-inducible factors (HIFs) by inhibition of prolyl hydroxylase domain-containing proteins (PHDs) is feasible and that it stimulates vascular endothelial growth factor (VEGF)-dependent angiogenesis in vitro. We tested the hypothesis that enhancement of angiogenesis by activation of HIFs improves lung growth and function in prematurely born neonates in vivo. Preterm baboons (125 day + 14 day pro re nata O(2) model, corresponding to 27 human gestational weeks) were treated for 14 days with intravenous (i. v.) FG-4095, a PHD inhibitor. Notably, 77% of diminished total alveolar surface area in untreated controls was recovered by FG-4095 treatment. Functional significance of the structural changes was indicated by improved oxygenation and lung compliance in FG-4095-treated newborns. Surfactant proteins B and C and saturated phosphatidylcholine were unchanged. Incidence of spontaneous ductus arteriosus closure was increased, likely contributing to lower ratio of pulmonary to systemic blood flow in FG-4095 group. These findings indicate that HIF stimulation by PHD inhibition ameliorates pathological and physiological consequences of BPD.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA; SW Fdn Biomed Res, San Antonio, TX 78284 USA; Univ Calif San Francisco, SRI Int, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH USA; Vanderbilt Univ, Med Ctr, Div Neonatol, Nashville, TN USA	National Jewish Health; University of Texas System; University of Texas Health San Antonio; Texas Biomedical Research Institute; SRI International; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Vanderbilt University	White, CW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Rm J-318, Denver, CO 80206 USA.	whitec@njc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR013986] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL052636, U10HL052636, U01HL056263, R10HL052636, U01HL063397] Funding Source: NIH RePORTER; NCRR NIH HHS [P51RR13986] Funding Source: Medline; NHLBI NIH HHS [HL63397, U01 HL56263, HL52636] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afshar S, 2003, AM J PHYSIOL-LUNG C, V284, pL749, DOI 10.1152/ajplung.00334.2002; Asikainen TM, 2005, PEDIATR PULM, V40, P538, DOI 10.1002/ppul.20321; Asikainen TM, 2005, P NATL ACAD SCI USA, V102, P10212, DOI 10.1073/pnas.0504520102; Asikainen TM, 2005, FREE RADICAL BIO MED, V38, P1002, DOI 10.1016/j.freeradbiomed.2004.12.004; ASIKAINEN TM, 2006, AM J PHYSL LUNG CELL; ASIKAINEN TM, 2005, LUNG INJURY MECH PAT, V196, P665; Bhatt AJ, 2001, AM J RESP CRIT CARE, V164, P1971, DOI 10.1164/ajrccm.164.10.2101140; Bland RD, 2005, BIOL NEONATE, V88, P181, DOI 10.1159/000087581; Bourbon J, 2005, PEDIATR RES, V57, p38R, DOI 10.1203/01.PDR.0000159630.35883.BE; BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; Clyman RI, 2002, AM J PHYSIOL-REG I, V282, pR199, DOI 10.1152/ajpregu.00298.2001; Coalson JJ, 1999, AM J RESP CRIT CARE, V160, P1333, DOI 10.1164/ajrccm.160.4.9810071; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; De Paepe ME, 2006, AM J RESP CRIT CARE, V173, P204, DOI 10.1164/rccm.200506-927OC; Dulak J, 2003, ANTIOXID REDOX SIGN, V5, P123, DOI 10.1089/152308603321223612; Ehrenkranz RA, 2005, PEDIATRICS, V116, P1353, DOI 10.1542/peds.2005-0249; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Gebb SA, 2000, DEV DYNAM, V217, P159, DOI 10.1002/(SICI)1097-0177(200002)217:2<159::AID-DVDY3>3.0.CO;2-9; GUNZLER V, 2006, KEYST S HYP DEV PHYS, pA216; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Ikegami M, 2005, AM J PHYSIOL-LUNG C, V289, pL34, DOI 10.1152/ajplung.00407.2004; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00007; KLAUS S, 2006, KEYST S HYP DEV PHYS, pA241; Kunig AM, 2005, AM J PHYSIOL-LUNG C, V289, pL529, DOI 10.1152/ajplung.00336.2004; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Lassus P, 2001, AM J RESP CRIT CARE, V164, P1981, DOI 10.1164/ajrccm.164.10.2012036; Le Cras TD, 2004, AM J PHYSIOL-LUNG C, V287, pL134, DOI 10.1152/ajplung.00050.2004; Levin M, 2006, AM J PHYSIOL-REG I, V290, pR359, DOI 10.1152/ajpregu.00629.2005; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maniscalco WM, 2002, AM J PHYSIOL-LUNG C, V282, pL811, DOI 10.1152/ajplung.00325.2001; MASON RJ, 1976, J LIPID RES, V17, P281; McCurnin DC, 2005, AM J RESP CRIT CARE, V172, P1569, DOI 10.1164/rccm.200502-230OC; McCurnin DC, 2005, AM J PHYSIOL-LUNG C, V288, pL450, DOI 10.1152/ajplung.00347.2004; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Ohlsson A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003481.pub2; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; Stenmark KR, 2005, ANNU REV PHYSIOL, V67, P623, DOI 10.1146/annurev.physiol.67.040403.102229; Thebaud B, 2005, CIRCULATION, V112, P2477, DOI 10.1161/CIRCULATIONAHA.105.541524; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tschanz SA, 2002, EXP LUNG RES, V28, P457, DOI 10.1080/01902140290096719; van Tuyl M, 2005, AM J PHYSIOL-LUNG C, V288, pL167, DOI 10.1152/ajplung.00185.2004; Waleh N, 2004, CIRCULATION, V110, P2326, DOI 10.1161/01.CIR.0000145159.16637.5D; Walisser JA, 2004, J BIOL CHEM, V279, P16326, DOI 10.1074/jbc.M400784200; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Yoder BA, 2002, PEDIATR RES, V51, P426, DOI 10.1203/00006450-200204000-00006	51	62	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1698	+		10.1096/fj.06-5887fje	http://dx.doi.org/10.1096/fj.06-5887fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807366				2022-12-25	WOS:000240266600019
J	Mainieri, D; Summermatter, S; Seydoux, J; Montani, JP; Rusconi, S; Russell, AP; Boss, O; Buchala, AJ; Dulloo, AG				Mainieri, Davide; Summermatter, Serge; Seydoux, Josiane; Montani, Jean-Pierre; Rusconi, Sandro; Russell, Aaron P.; Boss, Olivier; Buchala, Antony J.; Dulloo, Abdul G.			A role for skeletal muscle stearoyl-CoA desaturase 1 in control of thermogenesis	FASEB JOURNAL			English	Article						obesity; weight cycling; catch-up growth; low birth weight; insulin resistance	DE-NOVO LIPOGENESIS; CATCH-UP FAT; DIRECTLY STIMULATES THERMOGENESIS; WEIGHT-LOSS; ENERGY-EXPENDITURE; LIPID OXIDATION; UNCOUPLING PROTEIN-3; METABOLIC EFFICIENCY; INSULIN-RESISTANCE; ADIPOSE-TISSUE	An enhanced metabolic efficiency for accelerating the recovery of fat mass (or catch-up fat) is a characteristic feature of body weight regulation after weight loss or growth retardation and is the outcome of an "adipose-specific" suppression of thermogenesis, i.e., a feedback control system in which signals from the depleted adipose tissue fat stores exert a suppressive effect on thermogenesis. Using a previously described rat model of semistarvation-refeeding in which catch-up fat results from suppressed thermogenesis per se, we report here that the gene expression of stearoyl-coenzyme A desaturase 1 (SCD1) is elevated in skeletal muscle after 2 wk of semistarvation and remains elevated in parallel to the phase of suppressed thermogenesis favoring catch-up fat during refeeding. These elevations in the SCD1 transcript are skeletal muscle specific and are associated with elevations in microsomal Delta 9 desaturase enzyme activity, in the Delta 9 desaturation index, and in the relative content of SCD1-derived monounsaturates in several lipid fractions extracted from skeletal muscle. An elevated skeletal muscle SCD1, by desaturating the products of de novo lipogenesis and diverting them away from mitochondrial oxidation, would inhibit substrate cycling between de novo lipogenesis and lipid oxidation, thereby leading to a state of suppressed thermogenesis that regulates the body's fat stores.	Univ Fribourg, Fac Sci, Div Physiol, Dept Med, CH-1700 Fribourg, Switzerland; Univ Fribourg, Fac Sci, Div Biochem, Dept Med, CH-1700 Fribourg, Switzerland; SUVA Care, Clin Readaptat, Sion, Switzerland; Endocrinol Energy Metab, Boston, MA USA; Univ Fribourg, Fac Sci, Dept Biol, CH-1700 Fribourg, Switzerland	University of Fribourg; University of Fribourg; University of Fribourg	Dulloo, AG (corresponding author), Univ Fribourg, Fac Sci, Div Physiol, Dept Med, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	abdul.dulloo@unifr.ch	Buchala, Antony/A-2656-2012	Summermatter, Serge/0000-0003-4870-0148; DULLOO, Abdul/0000-0003-3877-6149; Russell, Aaron/0000-0002-7323-9501; MAINIERI, DAVIDE/0000-0003-0797-5794				ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOYLE PC, 1978, PHYSIOL BEHAV, V21, P261, DOI 10.1016/0031-9384(78)90050-1; Cettour-Rose P, 2005, DIABETES, V54, P751, DOI 10.2337/diabetes.54.3.751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Crescenzo R, 2003, FEBS LETT, V544, P138, DOI 10.1016/S0014-5793(03)00491-5; Crescenzo R, 2003, DIABETES, V52, P1090, DOI 10.2337/diabetes.52.5.1090; Dobrzyn A, 2005, AM J PHYSIOL-ENDOC M, V288, pE599, DOI 10.1152/ajpendo.00439.2004; Dulloo AG, 1998, AM J CLIN NUTR, V68, P599, DOI 10.1093/ajcn/68.3.599; DULLOO AG, 1988, AM J PHYSIOL, V255, pE180, DOI 10.1152/ajpendo.1988.255.2.E180; Dulloo AG, 2005, ACTA PHYSIOL SCAND, V184, P295, DOI 10.1111/j.1365-201X.2005.01466.x; Dulloo AG, 2004, INT J OBESITY, V28, pS29, DOI 10.1038/sj.ijo.0802861; DULLOO AG, 1990, AM J CLIN NUTR, V52, P415, DOI 10.1093/ajcn/52.3.415; Dulloo AG, 2001, INT J OBESITY, V25, pS22, DOI 10.1038/sj.ijo.0801907; Dulloo AG, 2002, INT J OBESITY, V26, pS46, DOI 10.1038/sj.ijo.0802127; Dulloo AG, 2002, FEBS LETT, V515, P109, DOI 10.1016/S0014-5793(02)02449-3; DULLOO AG, 1995, AM J PHYSIOL-REG I, V269, pR365, DOI 10.1152/ajpregu.1995.269.2.R365; DULLOO AG, 1993, INT J OBESITY, V17, P115; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Evans SA, 2005, AM J PHYSIOL-REG I, V288, pR1468, DOI 10.1152/ajpregu.00602.2004; Harper ME, 2001, BIOCHEM SOC T, V29, P768, DOI 10.1042/bst0290768; HARRIS RBS, 1984, J NUTR, V114, P1143, DOI 10.1093/jn/114.6.1143; HILL JO, 1984, AM J PHYSIOL, V247, pR318, DOI 10.1152/ajpregu.1984.247.2.R318; Houdali B, 2003, DIABETOLOGIA, V46, P203, DOI 10.1007/s00125-002-1015-2; Hulver MW, 2005, CELL METAB, V2, P251, DOI 10.1016/j.cmet.2005.09.002; Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962; Keys A, 1950, BIOL HUMAN STARVATIO; LANDSBERG L, 1984, AM J PHYSIOL, V247, pE181, DOI 10.1152/ajpendo.1984.247.2.E181; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; MacLean PS, 2004, AM J PHYSIOL-REG I, V287, pR1306, DOI 10.1152/ajpregu.00463.2004; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; MORRISON WR, 1964, J LIPID RES, V5, P600; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Ntambi JM, 2004, LIPIDS, V39, P1061, DOI 10.1007/s11745-004-1331-2; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Ong KK, 2004, EUR J ENDOCRINOL, V151, pU131, DOI 10.1530/eje.0.151U131; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rahman SM, 2003, P NATL ACAD SCI USA, V100, P11110, DOI 10.1073/pnas.1934571100; Russell AP, 2003, FEBS LETT, V551, P104, DOI 10.1016/S0014-5793(03)00875-5; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Simonides WS, 2001, BIOSCIENCE REP, V21, P139, DOI 10.1023/A:1013692023449; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Smith WS, 2002, BIOCHEM J, V361, P277, DOI 10.1042/0264-6021:3610277; Solinas G, 2006, ENDOCRINOLOGY, V147, P31, DOI 10.1210/en.2005-1033; Solinas G, 2004, FEBS LETT, V577, P539, DOI 10.1016/j.febslet.2004.10.066; Verca MSB, 1998, BIOTECHNIQUES, V24, P374, DOI 10.2144/98243bm08; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Weyer C, 2000, AM J CLIN NUTR, V72, P946; Wylie AA, 2000, GENOME RES, V10, P1711, DOI 10.1101/gr.161600; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	28	29	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1751	+		10.1096/fj.06-5934fje	http://dx.doi.org/10.1096/fj.06-5934fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809433	Green Submitted			2022-12-25	WOS:000240266600037
J	Semkova, I; Fauser, S; Lappas, A; Smyth, N; Kociok, N; Kirchhof, B; Paulsson, M; Poulaki, V; Joussen, AM				Semkova, Irina; Fauser, Sascha; Lappas, Alexandra; Smyth, Neil; Kociok, Norbert; Kirchhof, Bernd; Paulsson, Mats; Poulaki, Vassiliki; Joussen, Antonia M.			Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization	FASEB JOURNAL			English	Article						choroidal neovascularization; apoptosis; inflammation	ENDOTHELIAL GROWTH-FACTOR; DISCIFORM MACULAR DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TARGETED DISRUPTION; IMMUNE PRIVILEGE; APOPTOSIS; LIGAND; MEMBRANES; EXPRESSION; RETINOPATHY	Choroidal neovascularization (CNV) is responsible for the severe visual loss in age-related macular degeneration. CNV formation is considered to be due to an imbalance between pro-and antiangiogenic factors that lead to neovascular growth from the choriocapillaris into the subretinal space. To define whether FasL overexpression in retinal pigment epithelial cells (RPE) can inhibit choroidal neovascularization through Fas-FasL-mediated apoptosis, we examined the role of this pathway in a mouse model of laser-induced choroidal neovascularization. FasL was expressed in the retinal pigment epithelium of transgenic mice. Polymerase chain reaction (PCR), immunoblot, and immunohistochemistry confirmed that the transgene FasL was specifically expressed in RPE. The established laser model was used to induce choroidal neovascularization (CNV) in wild-type (WT) and transgenic mice. CNV formation was compared with respect to fluorescein angiographic leakage (at days 0 and 14 after laser injury) and histological appearance. The lesions were assessed on RPE-choroidal flatmounts after CD31-labeling and with confocal microscopy after perfusion with rhodamine-labeled concanavalin A (Con A). Apoptosis was quantified by TUNEL positivity and caspase activation. FasL mRNA and protein were highly expressed in the RPE of the transgenic mice before and after laser photocoagulation. In contrast, FasL was only weakly expressed in the RPE layer of WT C57BL/ 6J mice. While ruptures of Bruch's membrane and CNV formation were observed histologically two weeks after laser photocoagulation in transgenic as well as control eyes, the shape and size of CNV lesions were reduced in the transgenic mice. The area of leakage was decreased by 70% in FasL transgenic mice compared with WT mice (P < 0.005). The number of TUNEL-positive cells was greater in FasL-overexpressing mice and correlated with the expression of activated caspases. Th expression of other antiangiogenic factors such as PEDF remained unchanged. The specific overexpression of FasL in RPE layer reduced CNV formation in our laser model. Our results strongly point to the FasL-Fas pathway as a potential therapeutic target in controlling pathological choroidal neovascularization.	Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Southampton, Ctr Biochem, Southampton, Hants, England; Univ Southampton, Sch Biol Sci, Southampton, Hants, England; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA	University of Cologne; University of Cologne; University of Southampton; University of Southampton; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Joussen, AM (corresponding author), Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Joseph Stelzmannstr 9, D-50931 Cologne, Germany.	joussena@googlemail.com	Joussen, Antonia/AAA-6901-2022	Smyth, Neil/0000-0002-3734-2149				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Barreiro R, 2003, INVEST OPHTH VIS SCI, V44, P1282, DOI 10.1167/iovs.02-0478; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397; CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2; Chang CW, 1997, INVEST OPHTH VIS SCI, V38, P1082; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DAS A, 1992, OPHTHALMOLOGY, V99, P1368; Davies MH, 2003, INVEST OPHTH VIS SCI, V44, P3202, DOI 10.1167/iovs.03-0050; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907; FERGUSON TA, 1997, IMMUNOL REV, V156, P176; FINE SL, 1976, AM J OPHTHALMOL, V82, P352, DOI 10.1016/0002-9394(76)90483-9; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; GRAGOUDAS ES, 1976, ARCH OPHTHALMOL-CHIC, V94, P755, DOI 10.1001/archopht.1976.03910030365003; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180; GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; HOLZ FG, 1995, Z PRAKT AUGENHEILKUN, V16, P87; Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; LEIBOWITZ H, 1984, SURV OPHTHALMOL S, V25, P335; LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Lucas R, 1998, BLOOD, V92, P4730; Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466; MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899; Murata T, 1996, LAB INVEST, V74, P68; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Neff TA, 2005, AM J PATHOL, V166, P685, DOI 10.1016/S0002-9440(10)62290-0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246; Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walsh K, 1999, MOL MED TODAY, V5, P61, DOI 10.1016/S1357-4310(98)01415-4; Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467; Wigginton JM, 2001, J CLIN INVEST, V108, P51	63	33	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1689	+		10.1096/fj.05-5653fje	http://dx.doi.org/10.1096/fj.05-5653fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807368				2022-12-25	WOS:000240266600016
J	Gooz, M; Gooz, P; Luttrell, LM; Raymond, JR				Gooz, Monika; Gooz, Pal; Luttrell, Louis M.; Raymond, John R.			5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DIPHTHERIA-TOXIN RECEPTOR; METALLOPROTEASE-DISINTEGRINS; LYSOPHOSPHATIDIC ACID; CARDIAC-HYPERTROPHY; TNF-ALPHA; BINDING; TRANSACTIVATION; EXPRESSION; CLEAVAGE	In this study, we present multiple lines of evidence to support a critical role for heparin-boundEGF( epidermal growth factor)like growth factor (HB-EGF) and tumor necrosis factor-alpha-converting enzyme (TACE) (ADAM17) in the transactivation of EGF receptor (EGFR), ERK phosphorylation, and cellular proliferation induced by the 5-HT2A receptor in renal mesangial cells. 5-hydroxy-tryptamine (5-HT) resulted in rapid activation of TACE, HB-EGF shedding, EGFR activation, ERK phosphorylation, and longer term increases in DNA content in mesangial cells. ERK phosphorylation was attenuated by 1) neutralizing EGFR antibodies and the EGFR kinase inhibitor, AG1478, 2) neutralizing HB-EGF, but not amphiregulin, antibodies, heparin, or CM197, and 3) pharmacological inhibitors of matrix-degrading metalloproteinases or TACE small interfering RNA. Exogenously administered HB-EGF stimulated ERK phosphorylation. Additionally, TACE was co-immunoprecipitated with HB-EGF. Small interfering RNA against TACE also blocked 5-HT-induced increases in ERK phosphorylation, HB-EGF shedding, and DNA content. In aggregate, this work supports a pathway map that can be depicted as follows: 5-HT -> 5-HT2A receptor -> TACE -> HB-EGF shedding -> EGFR -> ERK -> increased DNA content. To our knowledge, this is the first time that TACE has been implicated in 5-HT-induced EGFR transactivation or in proliferation induced by a G protein-coupled receptor in native cells in culture.	Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Rheumatol, Charleston, SC 29425 USA; Med Univ S Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Gooz, M (corresponding author), Med Univ S Carolina, Div Nephrol, CSB 829,96 Jonathan Lucas St, Charleston, SC 29425 USA.	beckm@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK070054, R01DK055524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063909] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR016434] Funding Source: Medline; NIDDK NIH HHS [DK070054-01, R01 DK55524] Funding Source: Medline; NIGMS NIH HHS [R01 GM-63909] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dell KM, 2001, KIDNEY INT, V60, P1240, DOI 10.1046/j.1523-1755.2001.00963.x; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; GARNOVSKAYA MN, 1995, MOL PHARMACOL, V48, P230; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Gschwind A, 2002, CANCER RES, V62, P6329; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hao L, 2004, CIRC RES, V94, P68, DOI 10.1161/01.RES.0000109413.57726.91; HOMMA T, 1995, J CLIN INVEST, V96, P1018, DOI 10.1172/JCI118087; Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003; Hua H, 2003, AM J PHYSIOL-RENAL, V284, pF303, DOI 10.1152/ajprenal.00127.2002; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; LEE YJ, 1995, BIOCHEM BIOPH RES CO, V207, P216, DOI 10.1006/bbrc.1995.1175; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Mishra R, 2002, AM J PHYSIOL-RENAL, V283, pF1151, DOI 10.1152/ajprenal.00103.2002; Miura S, 2003, J CARDIOVASC PHARM, V42, P174, DOI 10.1097/00005344-200308000-00004; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NEBIGIL CG, 1995, AM J PHYSIOL, V268, P122; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sagel SD, 2005, PEDIATR PULM, V39, P224, DOI 10.1002/ppul.20165; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; Schlondorff J, 1999, J CELL SCI, V112, P3603; Takemura T, 1999, J PATHOL, V189, P431; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101; Zhao JS, 2001, INT J DEV BIOL, V45, P623; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	50	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21004	21012		10.1074/jbc.M512096200	http://dx.doi.org/10.1074/jbc.M512096200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737974	hybrid			2022-12-25	WOS:000239187300037
J	Godzich, M; Hodnett, M; Frank, JA; Su, G; Pespeni, M; Angel, A; Howard, MB; Matthay, MA; Pittet, JF				Godzich, M.; Hodnett, M.; Frank, J. A.; Su, G.; Pespeni, M.; Angel, A.; Howard, M. B.; Matthay, M. A.; Pittet, J. F.			Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats	FASEB JOURNAL			English	Article							ENDOTHELIAL GROWTH-FACTOR; UP-REGULATION; ISCHEMIA/REPERFUSION INJURY; HEMORRHAGIC-SHOCK; EXPRESSION; MEDIATORS; CADHERIN; SWITCH; DAMAGE	Lung endothelial damage is a characteristic morphological feature of ischemia-reperfusion (I/R) injury, although the molecular steps involved in the loss of endothelial integrity are still poorly understood. We tested the hypothesis that the activation of vascular endothelial growth factor (VEGF) cell signaling would be responsible for the increase in lung vascular permeability seen early after the onset of I/R in rats. Furthermore, we hypothesized that the I/R-induced pulmonary edema would be significantly attenuated in rats by the activation of the stress protein response. Pretreatment with Ad Flk-1, an adenovirus encoding for the soluble VEGF receptor type II, prevented I/R-mediated increase in lung vascular permeability in rats. Furthermore, the I/R-induced lung injury was significantly decreased by prior activation of the stress protein response with geldanamycin or pyrrolidine dithiocarbamate. In vitro studies demonstrated that VEGF caused an increase in protein permeability across primary cultures of bovine macro- and microvascular lung endothelial cell monolayers that were associated with a phosphorylation of VE- and E-cadherin and the formation of actin stress fibers. Activation of the stress protein response prevented the VEGF-mediated changes in protein permeability across these cell monolayers and reduced the phosphorylation of VE- and E-cadherins, as well as the formation of actin stress fibers in these cells.	Univ Calif San Francisco, Surg Res Lab, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Surg Res Lab, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Surg Res Lab, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pittet, JF (corresponding author), San Francisco Gen Hosp, Div Anesthesia, Rm 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	pittetj@anesthesia.ucsf.edu	Frank, Joseph/W-2021-2019		NHLBI NIH HHS [K08 HL069900, HL-51854, R56 HL088440, K08 HL069900-05, P50HL74005] Funding Source: Medline; NIGMS NIH HHS [GM-62188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL088440, P50HL074005, R01HL051854, K08HL069900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Becker PM, 2000, AM J RESP CELL MOL, V22, P272, DOI 10.1165/ajrcmb.22.3.3814; Belotti D, 2003, CANCER RES, V63, P5224; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; de Perrot M, 2003, AM J RESP CRIT CARE, V167, P490, DOI 10.1164/rccm.200207-670SO; EPPINGER MJ, 1995, J SURG RES, V58, P713, DOI 10.1006/jsre.1995.1112; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; Esser S, 1998, J CELL SCI, V111, P1853; Farivar AS, 2004, J HEART LUNG TRANSPL, V23, P585, DOI 10.1016/S1053-2498(03)00300-0; Fehrenbach A, 2003, J HEART LUNG TRANSPL, V22, P967, DOI 10.1016/S1053-2498(02)01157-9; Fujita T, 2004, J CLIN INVEST, V113, P1615, DOI 10.1172/JCI200419225; Hedge Ramanujan S., 1995, Journal of Cellular Physiology, V165, P186; Hiratsuka M, 1998, J HEART LUNG TRANSPL, V17, P1238; Hiratsuka M, 1999, ANN THORAC SURG, V67, P1421, DOI 10.1016/S0003-4975(99)00164-2; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ito K, 2003, SHOCK, V19, P462, DOI 10.1097/01.shk.0000055240.25446.16; Javadpour M, 1998, BRIT J SURG, V85, P943; Kanellis J, 2002, KIDNEY INT, V61, P1696, DOI 10.1046/j.1523-1755.2002.00329.x; Kaner RJ, 2001, MOL MED, V7, P240, DOI 10.1007/BF03401843; Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779; Kazi AA, 2000, AM J PHYSIOL-LUNG C, V279, pL460, DOI 10.1152/ajplung.2000.279.3.L460; Long SM, 2003, J SURG RES, V112, P12, DOI 10.1016/S0022-4804(03)00139-2; McCormick PH, 2003, J SURG RES, V109, P24, DOI 10.1016/S0022-4804(02)00035-5; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; Modelska K, 1999, AM J PHYSIOL-LUNG C, V276, pL844, DOI 10.1152/ajplung.1999.276.5.L844; Modelska K, 1997, AM J PHYSIOL-LUNG C, V273, pL305, DOI 10.1152/ajplung.1997.273.2.L305; Morimoto RI, 1990, STRESS PROTEINS BIOL; Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Pittet JF, 2002, J PHYSIOL-LONDON, V538, P583, DOI 10.1113/jphysiol.2001.013102; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272; Safdar Z, 2003, J CLIN INVEST, V112, P1541, DOI 10.1172/JCI200318370; Sakuma T, 1999, AM J PHYSIOL-LUNG C, V276, pL137, DOI 10.1152/ajplung.1999.276.1.L137; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Serraf A, 2003, J THORAC CARDIOV SUR, V125, P1050, DOI 10.1067/mtc.2003.402; Soccal PM, 2004, AM J TRANSPLANT, V4, P41, DOI 10.1046/j.1600-6135.2003.00277.x; Tseng JF, 2002, SURGERY, V132, P857, DOI 10.1067/msy.2002.127680; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang J, 2002, J CELL PHYSIOL, V190, P238, DOI 10.1002/JCP.10059; Ware LB, 2005, EUR RESPIR J, V26, P101, DOI 10.1183/09031936.05.00106604; Wright TJ, 2002, EXP CELL RES, V280, P159, DOI 10.1006/excr.2002.5636; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168	44	37	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1519	+		10.1096/fj.05-4708fje	http://dx.doi.org/10.1096/fj.05-4708fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793871				2022-12-25	WOS:000240266000037
J	Hsieh, YC; Choudhry, MA; Yu, HP; Shimizu, T; Yang, SL; Suzuki, T; Chen, JG; Bland, KI; Chaudry, IH				Hsieh, Ya-Ching; Choudhry, Mashkoor A.; Yu, Huang-Ping; Shimizu, Tomoharu; Yang, Shaolong; Suzuki, Takao; Chen, Jianguo; Bland, Kirby I.; Chaudry, Irshad H.			Inhibition of cardiac PGC-1 alpha expression abolishes ER beta agonist-mediated cardioprotection following trauma-hemorrhage	FASEB JOURNAL			English	Article						hemorrhagic shock; heart; estrogen receptor; mitochondria	PROLIFERATOR-ACTIVATED RECEPTOR; ESTROGEN-RECEPTORS; UP-REGULATION; PPAR-ALPHA; MECHANISM; LIVER; SHOCK; PHOSPHORYLATION; COACTIVATOR; LIGANDS	PGC-1 alpha (peroxisome proliferator-activated receptor [PPAR gamma] coactivator-1 alpha) activates PPAR alpha and mitochondrial transcription factor A ( Tfam), which regulate proteins, fatty acid and ATP metabolism (i.e., FAT/CD36, MCAD, and COX I). Recently we found that the salutary effects of estradiol (E2) on cardiac function following trauma-hemorrhage (T-H) are mediated via estrogen receptor (ER)beta. In this study we tested the hypothesis that ER beta-mediated cardioprotection is induced via up-regulation of PGC-1 alpha through PPAR alpha or Tfam-dependent pathway. Male rats underwent T-H and received ER alpha agonist propylpyrazole-triol (PPT), ER beta agonist diarylpropionitrile (DPN), E2, or vehicle. Another group was treated with antisense PGC-1 alpha oligonucleotides prior to administration of DPN. E2 and DPN treatments attenuated the decrease in cardiac mitochondrial ATP, abrogated the T-H-induced lipid accumulation, and normalized PGC-1 alpha, PPAR alpha, FAT/CD36, MCAD, Tfam, and COX I after T-H. In contrast, PPT administration did not abrogate lipid accumulation. Moreover, in PPT-treated animals mitochondrial ATP remained significantly lower than those observed in DPN- or E2-treated animals. Prior administration of antisense PGC-1 alpha prevented DPN- mediated cardioprotection and increase in ATP levels and Tfam but not in PPAR alpha following T-H. These findings suggest that the salutary effects of E2 on cardiac function following T-H are mediated via ER beta up-regulation of PGC-1 alpha through Tfam-dependent pathway.	Univ Alabama Birmingham, Surg Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chaudry, IH (corresponding author), Univ Alabama Birmingham, Surg Res Ctr, 1670 Univ Blvd,Volker Hall,Rm G094, Birmingham, AL 35294 USA.	ichaudry@surg.uab.edu			NIGMS NIH HHS [R37 GM-39519] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM039519] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexaki VI, 2004, FASEB J, V18, P1594, DOI 10.1096/fj.04-1495fje; Asano Goro, 2003, Journal of Nippon Medical School, V70, P384, DOI 10.1272/jnms.70.384; Ba ZF, 2000, CRIT CARE MED, V28, P2837, DOI 10.1097/00003246-200008000-00026; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Cobb JP, 2001, SHOCK, V15, P165; De Souza CT, 2005, DIABETOLOGIA, V48, P1860, DOI 10.1007/s00125-005-1866-4; De Souza CT, 2003, DIABETOLOGIA, V46, P1522, DOI 10.1007/s00125-003-1222-5; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; Erol E, 2003, FASEB J, V17, P347, DOI 10.1096/fj.03-0330fje; Gabel Scott A, 2005, J Mol Cell Cardiol, V38, P289, DOI 10.1016/j.yjmcc.2004.11.013; HAUPTMAN JG, 1989, AM J PHYSIOL, V257, pR439, DOI 10.1152/ajpregu.1989.257.2.R439; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hsieh YC, 2005, AM J PHYSIOL-HEART C, V289, pH2665, DOI 10.1152/ajpheart.00682.2005; Huss JM, 2004, CIRC RES, V95, P568, DOI 10.1161/01.RES.0000141774.29937.e3; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Jarrar D, 2000, SURGERY, V128, P246, DOI 10.1067/msy.2000.107376; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015, DOI 10.1152/ajpheart.2000.279.3.H1015; Jeschke MG, 2005, ANN SURG, V241, P759, DOI 10.1097/01.sla.0000161028.43338.cd; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Kanda N, 2004, J INVEST DERMATOL, V123, P319, DOI 10.1111/j.0022-202X.2004.12645.x; Kher A, 2005, SHOCK, V23, P1, DOI 10.1097/01.shk.0000148055.12387.15; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; McCloskey CA, 2003, SHOCK, V20, P316, DOI 10.1097/01.shk.0000084341.58020.c5; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Mizushima Y, 2000, ANN SURG, V232, P673, DOI 10.1097/00000658-200011000-00009; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Oliveira RLGS, 2004, AM J PHYSIOL-ENDOC M, V287, pE686, DOI 10.1152/ajpendo.00103.2004; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Pelzer T, 2005, CIRCULATION, V111, P1492, DOI 10.1161/01.CIR.0000159262.18512.46; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Remmers DE, 1997, AM J PHYSIOL-HEART C, V273, pH2919, DOI 10.1152/ajpheart.1997.273.6.H2919; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Skavdahl M, 2005, AM J PHYSIOL-HEART C, V288, pH469, DOI 10.1152/ajpheart.00723.2004; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; van Raalte DH, 2004, PHARM RES-DORDR, V21, P1531, DOI 10.1023/B:PHAM.0000041444.06122.8d; Wade CNB, 2003, ENDOCRINOLOGY, V144, P832, DOI 10.1210/en.2002-220899; Wu LL, 2001, AM J PHYSIOL-REG I, V281, pR408, DOI 10.1152/ajpregu.2001.281.2.R408; Yu HP, 2006, J MOL CELL CARDIOL, V40, P185, DOI 10.1016/j.yjmcc.2005.10.001; Zuckerbraun BS, 2005, SHOCK, V23, P527, DOI 10.1097/01.shk.0000163206.22032.a1	42	64	66	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1109	1117		10.1096/fj.05-5549com	http://dx.doi.org/10.1096/fj.05-5549com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770010				2022-12-25	WOS:000240210300011
J	Vigetti, D; Moretto, P; Viola, M; Genasetti, A; Rizzi, M; Karousou, E; Pallotti, F; De Luca, G; Passi, A				Vigetti, Davide; Moretto, Paola; Viola, Manuela; Genasetti, Anna; Rizzi, Manuela; Karousou, Evgenia; Pallotti, Francesco; De Luca, Giancarlo; Passi, Alberto			Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging	FASEB JOURNAL			English	Article						senescence; extracellular matrix (ECM); siRNA; gene expression	TYPE-1 MATRIX-METALLOPROTEINASE; IV COLLAGENASE ACTIVITY; AGE-RELATED-CHANGES; GELATINASE-A; EXTRACELLULAR-MATRIX; TIMP-2; PROTEOGLYCANS; BINDING; MMP-2; PROLIFERATION	As a direct correlation between aging and the risk of onset of vascular disease has been universally accepted, we prepared an in vitro aging model consisting in sequential passages of human aortic smooth muscle cells (AoSMC) in order to evaluate the cell behavior changes during aging. Because matrix metalloproteinases (MMP) are actively involved in matrix remodeling and disease outcome, in our model we found active MMP-2 only in the conditioned medium of young AoSMCs, whereas aged cells showed only the inactive zymogen form of MMP-2 (pro-MMP2). We ascribed the pro-MMP-2 activation in young cells to an increase in membrane type 1 matrix metalloproteinase (MT1-MMP) content. Furthermore, we found that transcripts coding for tissue inhibitor of metalloproteinases (TIMPs) were up-regulated in aged cells, and this increase of TIMPs could also prevent pro-MMP-2 activation in aged cells. Moreover, we demonstrated that young AoSMCs possess higher migratory capabilities than aged cells. The young AoSMC migration can be inhibited by adding TIMP-1 and TIMP-2 to the cells reproducing aged AoSMC migratory behavior. Finally, the role of MMP-2 and TIMP-2 in AoSMC migration was confirmed silencing MMP-2 and TIMP-2 in young and aged AoSMCs, respectively; therefore, in this study we showed that these enzymes play a pivotal role in the regulation of the AoSMC migration during in vitro aging.	Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, I-21100 Varese, Italy	University of Insubria	Passi, A (corresponding author), Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, Via JH Dunant 5, I-21100 Varese, Italy.	alberto.passi@uninsubria.it	Rizzi, Manuela/AAE-9202-2021; Vigetti, Davide/C-9861-2010; passi, alberto g/A-1752-2018; Viola, Manuela/B-7120-2011	Rizzi, Manuela/0000-0002-6174-7111; Vigetti, Davide/0000-0002-6339-8453; passi, alberto g/0000-0003-3328-3089; Viola, Manuela/0000-0002-0634-6390; Pallotti, Francesco/0000-0001-9946-8516				Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Cheng L, 1998, CIRCULATION, V98, P2195, DOI 10.1161/01.CIR.98.20.2195; Cheng XW, 2004, CARDIOVASC RES, V62, P594, DOI 10.1016/j.cardiores.2004.01.023; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; Galis ZS, 1997, ARTERIOSCL THROM VAS, V17, P483, DOI 10.1161/01.ATV.17.3.483; Giannelli G, 2002, HISTOL HISTOPATHOL, V17, P339, DOI 10.14670/HH-17.339; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Halayko AJ, 2001, J APPL PHYSIOL, V90, P358, DOI 10.1152/jappl.2001.90.1.358; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Iannone F, 2003, AGING CLIN EXP RES, V15, P364, DOI 10.1007/BF03327357; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Johnson C, 2004, ARTERIOSCL THROM VAS, V24, P54, DOI 10.1161/01.ATV.0000100402.69997.C3; Kadoglou NP, 2004, CURR MED RES OPIN, V20, P419, DOI 10.1185/030079904125003143; Kanda S, 2000, ARTERIOSCL THROM VAS, V20, P998, DOI 10.1161/01.ATV.20.4.998; Katsuda Shogo, 2003, J Atheroscler Thromb, V10, P267; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kipling D, 2004, SCIENCE, V305, P1426, DOI 10.1126/science.1102587; Kuzuya M, 2003, CIRCULATION, V108, P1375, DOI 10.1161/01.CIR.0000086463.15540.3C; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li ZH, 1997, EXP MOL PATHOL, V64, P1, DOI 10.1006/exmp.1997.2204; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Lijnen HR, 2003, PATHOPHYSIOL HAEMO T, V33, P275, DOI 10.1159/000083814; Liu SQ, 1998, ANN BIOMED ENG, V26, P86, DOI 10.1114/1.52; Lundberg MS, 1999, EXP GERONTOL, V34, P549, DOI 10.1016/S0531-5565(99)00036-4; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; MARTIN GM, 1983, AM J PATHOL, V110, P236; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MCCAFFREY TA, 1988, J EXP MED, V167, P163, DOI 10.1084/jem.167.1.163; McNulty M, 2005, AM J HYPERTENS, V18, P504, DOI 10.1016/j.amjhyper.2004.11.011; Myers JE, 2005, HYPERTENS PREGNANCY, V24, P103, DOI 10.1081/PRG-200059836; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Nour N, 2005, MOL BIOL CELL, V16, P5215, DOI 10.1091/mbc.E05-06-0504; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Partridge L, 2002, CURR BIOL, V12, pR544, DOI 10.1016/S0960-9822(02)01048-5; Passi A, 1997, FEBS LETT, V402, P286, DOI 10.1016/S0014-5793(97)00008-2; Passi A, 1999, FEBS LETT, V456, P93, DOI 10.1016/S0014-5793(99)00929-1; PAULY RR, 1994, CIRC RES, V75, P41, DOI 10.1161/01.RES.75.1.41; Perez-Martinez L, 2005, J NEUROSCI, V25, P4917, DOI 10.1523/JNEUROSCI.5066-04.2005; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruiz-Torres A, 2003, J GERONTOL A-BIOL, V58, P1074; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sounni NE, 2003, MATRIX BIOL, V22, P55, DOI 10.1016/S0945-053X(03)00003-9; SPERTI G, 1992, CIRC RES, V71, P385, DOI 10.1161/01.RES.71.2.385; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Troen BR, 2003, MT SINAI J MED, V70, P3; van der Loo B, 1998, EXP CELL RES, V241, P309, DOI 10.1006/excr.1998.4035; van Oostrom O, 2005, CARDIOVASC PATHOL, V14, P126, DOI 10.1016/j.carpath.2005.03.002; Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Whatling C, 2004, ARTERIOSCL THROM VAS, V24, P10, DOI 10.1161/01.ATV.0000100562.63144.C1; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573	57	41	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1118	1130		10.1096/fj.05-4504com	http://dx.doi.org/10.1096/fj.05-4504com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770011	Green Submitted			2022-12-25	WOS:000240210300012
J	Ohashi, S; Sakashita, G; Ban, R; Nagasawa, M; Matsuzaki, H; Murata, Y; Taniguchi, H; Shima, H; Furukawa, K; Urano, T				Ohashi, S.; Sakashita, G.; Ban, R.; Nagasawa, M.; Matsuzaki, H.; Murata, Y.; Taniguchi, H.; Shima, H.; Furukawa, K.; Urano, T.			Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies	ONCOGENE			English	Article						aurora-A; autophosphorylation; upstream kinase; phospho-specific antibody; monoclonal antibody; substrate specificity	CELL-CYCLE; SUSCEPTIBILITY GENE; CATALYTIC SUBUNIT; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CLEAVAGE FURROW; CENP-A; PHOSPHORYLATION; ACTIVATION	Mammalian Aurora- A is related to a serine/threonine protein kinase that was originally identified by its close homology with Saccharomyces cerevisiae IpI1p and Drosophila melanogaster aurora that are key regulators in the orchestration of mitotic events. The protein level of Aurora-A, its peak kinase activity during mitosis, and its activation have been attributed to phosphorylation. Here we show that this enzyme is an arginine-directed kinase and de. ne its substrate specificity. We also found that Thr288 within the activation loop is a critical residue for activating phosphorylation events in vitro and that it is spatiotemporally restricted to a brief window at mitosis on duplicated centrosomes and on spindle microtubules proximal to the poles in vivo. Immunodepletion assays indicated that an upstream kinase( s) of Aurora- A might exist in mammalian cells in addition to autophosphorylation. Furthermore, human activated Aurora- A forms complexes with the negative regulator protein serine/ threonine phosphatase type 1 ( PP1) that was negatively phosphorylated on Thr320. Interestingly, phospho- specific Aurora- A monoclonal antibodies restrain Aurora- A kinase activity in vitro, providing further therapeutic avenues to explore.	Nagoya Univ, Dept Biochem 2, Grad Sch Med, Showa Ku, 65 Tsurumai Machi, Nagoya, Aichi 4668550, Japan; RIKEN, Harima Inst, Spring 8, Synchrotron Radiat Res Network,Membrane Dynam Pro, Sayo, Hyogo, Japan; Miyagi Prefectural Canc Ctr, Inst Res, Div Canc Chemotherapy, Natori, Miyagi, Japan	Nagoya University; Japan Synchrotron Radiation Research Institute; RIKEN	Urano, T (corresponding author), Nagoya Univ, Dept Biochem 2, Grad Sch Med, Showa Ku, 65 Tsurumai Machi, Nagoya, Aichi 4668550, Japan.	turano@med.nagoya-u.ac.jp	Murata, Yasunobu/Y-5799-2019	Murata, Yasunobu/0000-0001-5757-2497; Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Ban R, 2004, J BIOL CHEM, V279, P16394, DOI 10.1074/jbc.M313257200; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Du J, 2004, P NATL ACAD SCI USA, V101, P8975, DOI 10.1073/pnas.0308484101; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Puntoni F, 1997, MOL CELL BIOCHEM, V171, P115, DOI 10.1023/A:1006892103306; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Sakai H, 2002, J BIOL CHEM, V277, P48714, DOI 10.1074/jbc.M208461200; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	79	75	79	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7691	7702		10.1038/sj.onc.1209754	http://dx.doi.org/10.1038/sj.onc.1209754			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785988				2022-12-25	WOS:000242830800004
J	Darbro, BW; Lee, KM; Nguyen, NK; Domann, FE; Klingelhutz, AJ				Darbro, B. W.; Lee, K. M.; Nguyen, N. K.; Domann, F. E.; Klingelhutz, A. J.			Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-culturedwith feeder cells	ONCOGENE			English	Article						hTERT; CDKN2A; senescence; epigenetic; Rb; telomeres	MAMMARY EPITHELIAL-CELLS; HUMAN UROEPITHELIAL CELLS; HUMAN ORAL KERATINOCYTES; DNA METHYLATION; PROGNOSTIC-SIGNIFICANCE; P16 EXPRESSION; HUMAN CANCER; REPLICATIVE SENESCENCE; GROWTH-CONDITIONS; P16/PRB PATHWAY	Human keratinocytes grown in co-culture with fibroblast feeder cells have an extended in vitro lifespan and delayed accumulation of the tumor suppressor protein p16(INK4a) when compared to the same cells grown on tissue culture plastic alone. Previous studies have indicated that human keratinocytes can be immortalized by telomerase activity alone when grown in co-culture with feeder cells, suggesting that loss of the p16(INK4a)/Rb pathway is not required for immortalization. Using two independent human keratinocyte cell strains, we found that exogenous telomerase expression and co-culture with feeder cells results in efficient extension of lifespan without an apparent crisis. However, when these cells were transferred from the co-culture environment to plastic alone they experienced only a brief period of slowed growth before continuing to proliferate indefinitely. Examination of immortal cell lines demonstrated p16(INK4a) promoter methylation had occurred in both the absence and presence of feeder cells. Reintroduction of p16INK4a into immortal cell lines resulted in rapid growth arrest. Our results suggest that p16(INK4a)/Rb-induced telomere-independent senescence, although delayed in the presence of feeders, still provides a proliferation barrier to human keratinocytes in this culture system and that extended culture of telomerase-transduced keratinocytes on feeders can lead to the methylation of p16(INK4a).	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Holden Canc Ctr, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Med Scientist Training Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Klingelhutz, AJ (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	al-klingelhutz@uiowa.edu	Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046; Darbro, Benjamin/0000-0001-9279-356X; Domann, Frederick/0000-0002-0489-2179	NATIONAL CANCER INSTITUTE [R01CA073612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73612, R01 CA073612] Funding Source: Medline; NHLBI NIH HHS [T32 HL07638, T32 HL007638] Funding Source: Medline; NIA NIH HHS [R01 AG18265, R01 AG018265] Funding Source: Medline; NIGMS NIH HHS [T32 GM07337, T32 GM007337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek JH, 2003, INT J MOL MED, V12, P319; BLANTON RA, 1991, AM J PATHOL, V138, P673; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Cody DT, 1999, ORAL ONCOL, V35, P516, DOI 10.1016/S1368-8375(99)00026-3; Curtis CD, 2005, METH MOLEC MED, V103, P123; Darbro BW, 2005, J INVEST DERMATOL, V125, P499, DOI 10.1111/j.0022-202X.2005.23844.x; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Esteller M, 2001, J CLIN ONCOL, V19, P299, DOI 10.1200/JCO.2001.19.2.299; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1996, ONCOGENE, V12, P1773; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Fu BJ, 2003, CANCER RES, V63, P7815; Govindarajan B, 2002, MOL MED, V8, P1; Groeger AM, 1999, J THORAC CARDIOV SUR, V118, P529, DOI 10.1016/S0022-5223(99)70192-3; Harada H, 2003, MOL CANCER RES, V1, P729; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Jarmalaite S, 2003, INT J CANCER, V106, P913, DOI 10.1002/ijc.11322; Jarrard DF, 1999, CANCER RES, V59, P2957; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 2005, VIROLOGY, V340, P237, DOI 10.1016/j.virol.2005.06.027; Korkolopoulou P, 2001, EUR UROL, V39, P167, DOI 10.1159/000052432; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Liu LM, 2005, INT J ONCOL, V26, P275; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Natarajan E, 2003, AM J PATHOL, V163, P477, DOI 10.1016/S0002-9440(10)63677-2; Nilsson K, 2004, MODERN PATHOL, V17, P1464, DOI 10.1038/modpathol.3800220; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; Partridge M, 2005, CANCER METAST REV, V24, P71, DOI 10.1007/s10555-005-5048-0; Paz MF, 2003, CANCER RES, V63, P1114; Puthenveettil JA, 1999, ADV EXP MED BIOL, V462, P83; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Romanenko A, 2002, DIAGN MOL PATHOL, V11, P163, DOI 10.1097/00019606-200209000-00007; Sandhu C, 2000, CANCER RES, V60, P2616; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Svensson S, 2003, CANCER RES, V63, P1737; Taylor LM, 2004, J BIOL CHEM, V279, P43634, DOI 10.1074/jbc.M402388200; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Weinberger PM, 2004, CLIN CANCER RES, V10, P5684, DOI 10.1158/1078-0432.CCR-04-0448; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Wong DJ, 1997, CANCER RES, V57, P2619; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zongaro S, 2005, CANCER RES, V65, P11411, DOI 10.1158/0008-5472.CAN-05-1140	66	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7421	7433		10.1038/sj.onc.1209729	http://dx.doi.org/10.1038/sj.onc.1209729			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767161	Green Accepted			2022-12-25	WOS:000242419100011
J	Winograd-Katz, SE; Levitzki, A				Winograd-Katz, S. E.; Levitzki, A.			Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor	ONCOGENE			English	Article						therapy; cisplatin; p38; EGPR; phosphorylation	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; THREONINE PHOSPHORYLATION; INDEPENDENT MECHANISMS; PI3K/AKT PATHWAY; CELLS; P38; RESISTANCE; SIGNAL	Cisplatin is an effective DNA-damaging antitumor agent employed for the treatment of various human cancers. In this study, we report that Cisplatin activates PKB/Akt in several cancer cell lines and that this activation is mediated by EGFR, Src and PI3-kinase. Inhibition of PI3-kinase activity decreases the survival of the cells exposed to Cisplatin, suggesting that Cisplatin-induced PKB/Akt activation may lead to Cisplatin resistance. While investigating the EGFR-dependent PKB/Akt activation in MDA-MB-468 cells, we found that the EGFR receptor undergoes a gel mobility shift upon Cisplatin treatment, which is mediated by p38(MAPK). An EGFR, in which threonine 669 was mutated to alanine (A669), is phosphorylated by p38MAPK to a much lesser extent, suggesting that threonine 669 is a p38 phosphorylation site. We found that Cisplatin induces EGFR internalization, which is mediated by p38(MAPK-) dependent phosphorylation of the receptor on threonine 669. Our results identify the EGFR as a new substrate of p38 and identify threonine 669 as a new phosphorylation site that regulates EGFR internalization. Together, these results suggest that Cisplatin has side effects, which may alter the signaling pattern of cancer cells and modulate the desired effects of Cisplatin treatment.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il						Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hayakawa J, 2000, CANCER RES, V60, P5988; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LITMAN P, 2006, UNPUB; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	37	143	148	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7381	7390		10.1038/sj.onc.1209737	http://dx.doi.org/10.1038/sj.onc.1209737			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785992	Bronze			2022-12-25	WOS:000242419100007
J	Renart, ML; Barrera, FN; Molina, ML; Encinar, JA; Poveda, JA; Fernandez, AM; Gomez, J; Gonzalez-Ros, JM				Renart, Maria L.; Barrera, Francisco N.; Molina, Maria L.; Encinar, Jose A.; Poveda, Jose A.; Fernandez, Asia M.; Gomez, Javier; Gonzalez-Ros, Jose M.			Effects of conducting and blocking ions on the structure and stability of the potassium channel KcsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; PROKARYOTIC K+ CHANNEL; C-TYPE-INACTIVATION; STREPTOMYCES-LIVIDANS; MONOVALENT CATIONS; PROTEIN; PORE; BINDING; SELECTIVITY; AFFINITY	This article reports on the interaction of conducting ( K (+)) and blocking (Na+) monovalent metal ions with detergent- solubilized and lipid-reconstituted forms of the K (+) channel KcsA. Monitoring of the protein intrinsic fluorescence reveals that the two ions bind competitively to KcsA with distinct affinities ( dissociation constants for the KcsA . K+ and KcsA(+) Na+ complexes of similar to 8 and 190mM, respectively) and induce different conformations of the ion- bound protein. The differences in binding affinity as well as the higher K+ concentration bathing the intracellular mouth of the channel, through which the cations gain access to the protein binding sites, should favor that only KcsA . K+ complexes are formed under physiological- like conditions. Nevertheless, despite such prediction, it was also found that concentrations of Na+ well below its dissociation constant and even in the presence of higher K+ concentrations, cause a remarkable decrease in the protein thermal stability and facilitate thermal dissociation into subunits of the tetrameric KcsA, as concluded from the temperature dependence of the protein infrared spectra and from gel electrophoresis, respectively. These latter observations cannot be explained based on the occupancy of the binding sites from above and suggest that there must be additional ion binding sites, whose occupancy could not be detected by fluorescence and in which the affinity for Na+ must be higher or at least similar to that of K+. Moreover, cation binding as reported by means of fluorescence does not suffice to explain the large differences in free energy of stabilization involved in the formation of the KcsA(+) Na+ and KcsA . K+ complexes, which for the most part should arise from synergistic effects of the ion- mediated intersubunit interactions.	Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain	Universidad Miguel Hernandez de Elche	Gonzalez-Ros, JM (corresponding author), Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain.	gonzalez.ros@umh.es	Carvajal, Asia Fernandez/G-8877-2015; Encinar, José A/F-2946-2013; Gallego, María Luisa Molina/K-4810-2017; Encinar, José Antonio/AAE-9141-2020; Gomez, Javier/N-9820-2013; Poveda Larrosa, Jose Antonio/H-5925-2015	Encinar, José A/0000-0002-7219-3863; Gallego, María Luisa Molina/0000-0001-9190-6948; Encinar, José Antonio/0000-0002-7219-3863; Gomez, Javier/0000-0001-9612-5075; Poveda Larrosa, Jose Antonio/0000-0003-0722-3752; Barrera, Francisco N./0000-0002-5200-7891; Gonzalez Ros, Jose Manuel/0000-0002-4804-6855; Fernandez-Carvajal, Asia/0000-0003-2741-1427; Renart, Maria Lourdes/0000-0002-6717-4756				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Barrera FN, 2005, BIOCHEMISTRY-US, V44, P14344, DOI 10.1021/bi050845t; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Echabe I, 1997, BIOSPECTROSCOPY, V3, P469; Encinar JA, 2005, FEBS LETT, V579, P5199, DOI 10.1016/j.febslet.2005.08.038; FRENCH RJ, 1977, J GEN PHYSIOL, V70, P707, DOI 10.1085/jgp.70.6.707; Gomez-Lagunas F, 2001, J GEN PHYSIOL, V118, P639, DOI 10.1085/jgp.118.6.639; GomezLagunas F, 1997, J PHYSIOL-LONDON, V499, P3, DOI 10.1113/jphysiol.1997.sp021907; GONZALEZROS JM, 1984, BIOCHEM BIOPH RES CO, V120, P368, DOI 10.1016/0006-291X(84)91263-4; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 1992, IONIC CHANNELS EXCIT; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Krishnan MN, 2005, J GEN PHYSIOL, V126, P271, DOI 10.1085/jgp.200509323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MacKinnon R, 2003, FEBS LETT, V555, P62, DOI 10.1016/S0014-5793(03)01104-9; Martell A., 1982, CRITICAL STABILITY C, V5; Meuser D, 1999, FEBS LETT, V462, P447, DOI 10.1016/S0014-5793(99)01579-3; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Nimigean CM, 2002, J GEN PHYSIOL, V120, P323, DOI 10.1085/jgp.20028614; Ogielska EM, 1999, J GEN PHYSIOL, V113, P347, DOI 10.1085/jgp.113.2.347; Pace C. N., 1997, PROTEIN STRUCTURE PR; RIQUELME G, 1990, BIOCHEMISTRY-US, V29, P11215, DOI 10.1021/bi00503a009; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Royer C A, 1995, Methods Mol Biol, V40, P65; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Shrivastava IH, 2002, EUR BIOPHYS J BIOPHY, V31, P207, DOI 10.1007/s00249-002-0209-3; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Splitt H, 2000, FEBS LETT, V472, P83, DOI 10.1016/S0014-5793(00)01429-0; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; van den Brink-van der Laan E, 2004, BIOCHEMISTRY-US, V43, P4240, DOI 10.1021/bi036129d; WANG ZX, 1995, FEBS LETT, V360, P111, DOI 10.1016/0014-5793(95)00062-E; Yellen G, 1997, J GEN PHYSIOL, V110, P83, DOI 10.1085/jgp.110.2.83; Zhou Y, 2004, BIOCHEMISTRY-US, V43, P4978, DOI 10.1021/bi049876z; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	48	24	24	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2006	281	40					29905	29915		10.1074/jbc.M602636200	http://dx.doi.org/10.1074/jbc.M602636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	089QT	16815844	hybrid, Green Published			2022-12-25	WOS:000240896300052
J	Marx, A; Nugoor, C; Muller, J; Panneerselvam, S; Timm, T; Bilang, M; Mylonas, E; Svergun, DI; Mandelkow, EM; Mandelkow, E				Marx, Alexander; Nugoor, Chanakya; Mueller, Jens; Panneerselvam, Saravanan; Timm, Thomas; Bilang, Matthias; Mylonas, Efstratios; Svergun, Dmitri I.; Mandelkow, Eva-Maria; Mandelkow, Eckhard			Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; UBA DOMAIN; C-SRC; MARK/PAR-1; POLARITY; ACTIVATION; FAMILY; RECOGNITION; SCATTERING	The microtubule-associated protein (MAP)/microtubule affinity regulating kinase (MARK)/Par-1 phosphorylates microtubule-associated proteins tau, MAP2, and MAP4 and is involved in the regulation of microtubule-based transport. Par-1, a homologue of MARK in Drosophila and Caenorhabditis elegans, is essential for the development of embryonic polarity. Four isoforms of MARK are found in humans. Recently, we reported the crystal structure of the catalytic and ubiquitin-associated domains of MARK2, an isoform enriched in brain (Panneerselvam, S., Marx, A., Mandelkow, E.-M., and Mandelkow, E. (2006) Structure 14, 173-183). It showed that the ubiquitin-associated domain (UBA) domain has an unusual fold and binds to the N-terminal lobe of the catalytic domain. This is at variance with a previous low resolution structure derived from small angle solution scattering (Jaleel, M., Villa, F., Deak, M., Toth, R., Prescott, A. R., Van Aalten, D. M., and Alessi, D. R. (2006) Biochem. J. 394, 545-555), which predicts binding of the UBA domain to the larger, C-terminal lobe. Here we report the crystal structure of the catalytic and UBA domain of another isoform, MARK1. Although the crystal packing of the two isoforms are unrelated, the overall conformations of the molecules are similar. Notably, the UBA domain has the same unusual conformation as in MARK2, and it binds at the same site. Remarkable differences occur in the catalytic domain at helix C, the catalytic loop, and the activation segment.	Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	Max Planck Society; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Mandelkow, E (corresponding author), DESY, MPG ASMB, Notkestr 85, D-22607 Hamburg, Germany.	mand@mpasmb.desy.de		Mylonas, Efstratios/0000-0003-4476-3010; Svergun, Dmitri/0000-0003-0830-5696				Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Benton R, 2002, DEV CELL, V3, P659, DOI 10.1016/S1534-5807(02)00320-9; Beullens M, 2005, J BIOL CHEM, V280, P40003, DOI 10.1074/jbc.M507274200; Biernat J, 2002, MOL BIOL CELL, V13, P4013, DOI 10.1091/mbc.02-03-0046; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007; Jaleel M, 2006, BIOCHEM J, V394, P545, DOI 10.1042/BJ20051844; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kusakabe M, 2004, EMBO J, V23, P4190, DOI 10.1038/sj.emboj.7600381; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matenia D, 2005, MOL BIOL CELL, V16, P4410, DOI 10.1091/mbc.E05-01-0081; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Munro EM, 2006, CURR OPIN CELL BIOL, V18, P86, DOI 10.1016/j.ceb.2005.12.007; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nayak V, 2006, STRUCTURE, V14, P477, DOI 10.1016/j.str.2005.12.008; Ohno A, 2005, STRUCTURE, V13, P521, DOI 10.1016/j.str.2005.01.011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Panneerselvam S, 2006, STRUCTURE, V14, P173, DOI 10.1016/j.str.2005.09.022; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Rudolph MJ, 2005, BIOCHEM BIOPH RES CO, V337, P1224, DOI 10.1016/j.bbrc.2005.09.181; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Timm T, 2003, EMBO J, V22, P5090, DOI 10.1093/emboj/cdg447; Varadan R, 2005, MOL CELL, V18, P687, DOI 10.1016/j.molcel.2005.05.013; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	42	47	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27586	27599		10.1074/jbc.M604865200	http://dx.doi.org/10.1074/jbc.M604865200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16803889	Green Published, hybrid			2022-12-25	WOS:000240397700084
J	Kelly, P; Stemmle, LN; Madden, JF; Fields, TA; Daaka, Y; Casey, PJ				Kelly, Patrick; Stemmle, Laura N.; Madden, John F.; Fields, Timothy A.; Daaka, Yehia; Casey, Patrick J.			A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; RHO; ACTIVATION; RECEPTOR; CELLS; G-ALPHA(13); MOTILITY; PATHWAY; KINASE; DOMAIN	Many studies have suggested a role for the members of the G(12) family of heterotrimeric G proteins (G alpha(12) and G alpha(13)) in oncogenesis and tumor cell growth. However, few studies have examined G(12) signaling in actual human cancers. In this study, we examined the role of G(12) signaling in prostate cancer. We found that expression of the G(12) proteins is significantly elevated in prostate cancer. Interestingly, expression of the activated forms of G alpha(12) or G alpha(13) in the PC3 and DU145 prostate cancer cell lines did not promote cancer cell growth. Instead, expression of the activated forms of G alpha(12) or G alpha(13) in these cell lines induced cell invasion through the activation of the RhoA family of G proteins. Furthermore, inhibition of G(12) signaling by expression of the RGS domain of the p115-Rho-specific guanine nucleotide exchange factor (p115-RGS) in the PC3 and DU145 cell lines did not reduce cancer cell growth. However, inhibition of G(12) signaling with p115-RGS in these cell lines blocked thrombin-and thromboxane A2-stimulated cell invasion. These observations identify the G(12) family proteins as important regulators of prostate cancer invasion and suggest that these proteins may be targeted to limit invasion- and metastasis-induced prostate cancer patient mortality.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA	Duke University; Duke University; University System of Georgia; Augusta University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NCI NIH HHS [CA100869] Funding Source: Medline; NIA NIH HHS [AG17952] Funding Source: Medline; NIDDK NIH HHS [DK60917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Caceres M, 2005, EXP CELL RES, V309, P229, DOI 10.1016/j.yexcr.2005.05.020; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chen Z, 2003, J BIOL CHEM, V278, P9912, DOI 10.1074/jbc.M212695200; Chunthapong J, 2004, J CELL BIOCHEM, V91, P649, DOI 10.1002/jcb.20032; DAAKA Y, 2004, SCI STKE, pRE2; DASSESSE T, 2006, IN PRESS EUR UROL; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hodge JC, 2003, CANCER RES, V63, P1359; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hwang YS, 2006, MOL CARCINOGEN, V45, P518, DOI 10.1002/mc.20183; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kaushal V, 2006, PROSTATE, V66, P273, DOI 10.1002/pros.20326; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Lin F, 2005, J CELL BIOL, V169, P777, DOI 10.1083/jcb.200501104; Liu J, 2006, BIOCHEM BIOPH RES CO, V343, P183, DOI 10.1016/j.bbrc.2006.02.136; Liu J, 2003, UROL RES, V31, P163, DOI 10.1007/s00240-003-0309-2; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; Ruppel KM, 2005, P NATL ACAD SCI USA, V102, P8281, DOI 10.1073/pnas.0503326102; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shi XL, 2004, MOL CANCER RES, V2, P395; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Taichman RS, 2002, CANCER RES, V62, P1832; Tantivejkul K, 2005, J CELL BIOCHEM, V96, P641, DOI 10.1002/jcb.20533; Taub JS, 2003, CANCER RES, V63, P2037; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van Golen KL, 2002, CLIN EXP METASTAS, V19, P301, DOI 10.1023/A:1015518114931; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yao H, 2006, ONCOGENE, V25, P2285, DOI 10.1038/sj.onc.1209260; YOSHIDA E, 1994, CANCER RES, V54, P3300; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	56	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26483	26490		10.1074/jbc.M604376200	http://dx.doi.org/10.1074/jbc.M604376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16787920	hybrid			2022-12-25	WOS:000240249500066
J	Collins, QF; Xiong, Y; Lupo, EG; Liu, HY; Cao, WH				Collins, Qu Fan; Xiong, Yan; Lupo, Edgar G., Jr.; Liu, Hui-Yu; Cao, Wenhong			p38 mitogen-activated protein kinase mediates free fatty acid-induced gluconeogenesis in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC INSULIN-RESISTANCE; MAP KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOSE-PRODUCTION; SKELETAL-MUSCLE; INDUCED APOPTOSIS; BINDING-PROTEIN; POTENTIAL ROLE; METABOLISM; LIVER	Free fatty acids ( FFA) are considered as a causative link between obesity and diabetes. In various animal models and in humans FFA can stimulate hepatic gluconeogenesis. Although the in vivo role of FFA in hepatic gluconeogenesis has been clearly established, the intracellular role of FFA and related signaling pathway remain unclear in the regulation of hepatic gluconeogenic gene transcription. In this study, we have identified p38 mitogen-activated protein kinase ( p38) as a critical signaling component in FFA-induced transcription of key gluconeogenic genes. We show in primary hepatocytes that both mid- and long-chain fatty acids ( saturated or unsaturated) could activate p38 and increase levels of phosphoenolpyruvate carboxykinase ( PEPCK), glucose-6-phosphatase, and peroxisome proliferator-activated receptor gamma coactivator alpha( PGC-1 alpha) gene transcripts. The FFA-induced expression of PEPCK and PGC-1 alpha genes and gluconeogenesis in isolated hepatocytes could be blocked by the inhibition of p38. Furthermore, PGC-1 alpha phosphorylation by p38 was necessary for FFA-induced activation of the PEPCK promoter. Additionally, FFA stimulated phosphorylation of cAMP-response element-binding protein ( CREB) through p38. The overexpression of the dominant-negative CREB prevented FFA-induced activation of the PEPCK promoter. Finally, we show that FFA activation of p38 requires protein kinase C delta. Together, our results indicate that p38 plays a critical role in FFA-induced transcription of gluconeogenic genes, and the known gluconeogenic regulators, PGC-1 alpha and CREB, are also integral parts of FFA-stimulated transcription of gluconeogenic genes.	Chem Ind Inst Toxicol, Ctr Hlth Res, Div Biol Sci, Endocrine Biol Program, Res Triangle Pk, NC 27709 USA; Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China; Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27708 USA	Central South University; Duke University	Cao, WH (corresponding author), Chem Ind Inst Toxicol, Ctr Hlth Res, Div Biol Sci, Endocrine Biol Program, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	wcao@ciit.org						Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Al-Regaiey KA, 2005, ENDOCRINOLOGY, V146, P851, DOI 10.1210/en.2004-1120; ANTRASFERRY J, 1994, BIOCHEM BIOPH RES CO, V203, P385, DOI 10.1006/bbrc.1994.2194; Baldeweg SE, 2000, EUR J CLIN INVEST, V30, P45; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; BEVILACQUA S, 1987, METABOLISM, V36, P502, DOI 10.1016/0026-0495(87)90051-5; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bizeau ME, 1999, J NUTR BIOCHEM, V10, P709, DOI 10.1016/S0955-2863(99)00060-1; Blaak EE, 2003, P NUTR SOC, V62, P753, DOI 10.1079/PNS2003290; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 2003, LIFE SCI, V72, P977, DOI 10.1016/S0024-3205(02)02350-0; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden Guenther, 2005, Curr Diab Rep, V5, P167, DOI 10.1007/s11892-005-0004-5; Bolinder J, 2000, DIABETES, V49, P797, DOI 10.2337/diabetes.49.5.797; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Bysted A, 2005, EUR J CLIN NUTR, V59, P24, DOI 10.1038/sj.ejcn.1602028; Cahill GF., 1976, GLUCONEOGENESIS ITS, P515; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; COPPACK SW, 1992, METABOLISM, V41, P264, DOI 10.1016/0026-0495(92)90269-G; De Almeida IT, 2002, CLIN NUTR, V21, P219, DOI 10.1054/clnu.2001.0529; Dersch K, 2005, CELL DEATH DIFFER, V12, P1107, DOI 10.1038/sj.cdd.4401633; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gum RJ, 2003, MOL ENDOCRINOL, V17, P1131, DOI 10.1210/me.2002-0288; Hakimi Parvin, 2005, Nutr Metab (Lond), V2, P33, DOI 10.1186/1743-7075-2-33; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HENRY RR, 1995, J CLIN INVEST, V95, P1427, DOI 10.1172/JCI117812; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Iglesias MA, 2002, DIABETES, V51, P2886, DOI 10.2337/diabetes.51.10.2886; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Katsuma S, 2005, J BIOL CHEM, V280, P19507, DOI 10.1074/jbc.M412385200; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kobayashi M, 2004, BIOCHEMISTRY-US, V43, P7522, DOI 10.1021/bi035966c; Lam TKT, 2005, NAT MED, V11, P320, DOI 10.1038/nm1201; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE281, DOI 10.1152/ajpendo.00332.2002; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Miller TA, 2005, BIOCHEM BIOPH RES CO, V336, P309, DOI 10.1016/j.bbrc.2005.08.088; Nguyen MTA, 2005, J BIOL CHEM, V280, P35361, DOI 10.1074/jbc.M504611200; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; Robidoux J, 2005, MOL CELL BIOL, V25, P5466, DOI 10.1128/MCB.25.13.5466-5479.2005; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; SALORANTA C, 1993, AM J PHYSIOL, V264, pE599, DOI 10.1152/ajpendo.1993.264.4.E599; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Tordjman J, 2003, BIOCHIMIE, V85, P1213, DOI 10.1016/j.biochi.2003.11.010; Uji Yoshinori, 2004, Nihon Rinsho, V62 Suppl 12, P57; Wiesenthal SR, 1999, DIABETES, V48, P766, DOI 10.2337/diabetes.48.4.766; Wyne KL, 2003, AM J MED, V115, P29, DOI 10.1016/j.amjmed.2003.09.004; Yamaguchi H, 2004, ARTERIOSCL THROM VAS, V24, P2095, DOI 10.1161/01.ATV.0000144009.35400.65; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhou H, 2005, BIOCHEM BIOPH RES CO, V338, P793, DOI 10.1016/j.bbrc.2005.10.007	71	98	103	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24336	24344		10.1074/jbc.M602177200	http://dx.doi.org/10.1074/jbc.M602177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803882	hybrid			2022-12-25	WOS:000239847800026
J	Loughnan, M; Nicke, A; Jones, A; Schroeder, CI; Nevin, ST; Adams, DJ; Alewood, PF; Lewis, RJ				Loughnan, Marion; Nicke, Annette; Jones, Alun; Schroeder, Christina I.; Nevin, Simon T.; Adams, David J.; Alewood, Paul F.; Lewis, Richard J.			Identification of a novel class of nicotinic receptor antagonists - Dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-BINDING PROTEIN; CRYSTAL-STRUCTURE; ALPHA-CONOTOXINS; BIOLOGICAL-ACTIVITY; KAPPA-BUNGAROTOXIN; POLYPEPTIDE TOXIN; VENOM NEUROTOXINS; MASS-SPECTROMETRY; NMR-SPECTROSCOPY; PLATYPUS VENOM	The venoms of predatory marine snails ( Conus spp.) contain diverse mixtures of peptide toxins with high potency and selectivity for a variety of voltage-gated and ligand-gated ion channels. Here we describe the chemical and functional characterization of three novel conotoxins, alpha D-VxXIIA, alpha D-VxXIIB, and alpha D-VxXIIC, purified from the venom of Conus vexillum. Each toxin was observed as an similar to 11-kDa protein by LC/MS, size exclusion chromatography, and SDS-PAGE. After reduction, the peptide sequences were determined by Edman degradation chemistry and tandem MS. Combining the sequence data together with LC/MS and NMR data revealed that in solution these toxins are pseudo-homodimers of paired 47-50-residue peptides. The toxin subunitsexhibited a novel arrangement of 10 conserved cystine residues, and additional post-translational modifications contributed heterogeneity to the proteins. Binding assays and two-electrode voltage clamp analyses showed that alpha D-VxXIIA, alpha D-VxXIIB, and alpha D-VxXIIC are potent inhibitors of nicotinic acetylcholine receptors (nAChRs) with selectivity for alpha 7 and alpha 2 containing neuronal nAChR subtypes. These dimeric conotoxins represent a fifth and highly divergent structural class of conotoxins targeting nAChRs.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany	University of Queensland; University of Queensland; Max Planck Society	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard/T-8763-2019; Adams, David/J-9125-2014; Alewood, Paul F/J-2412-2014; Lewis, Richard J/E-8674-2013; Schroeder, Cristina I./K-2042-2014; Loughnan, Marion/B-4508-2009; Nevin, Simon/B-2663-2014; Adams, David John/K-3578-2019	Lewis, Richard/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Lewis, Richard J/0000-0003-3470-923X; Schroeder, Cristina I./0000-0002-6737-6374; Adams, David John/0000-0002-7030-2288; Alewood, Paul/0000-0001-7454-6522; Nicke, Annette/0000-0001-6798-505X				Arias HR, 2000, INT J BIOCHEM CELL B, V32, P1017, DOI 10.1016/S1357-2725(00)00051-0; Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brandwijk RJMGE, 2005, BIOCHEM BIOPH RES CO, V333, P1261, DOI 10.1016/j.bbrc.2005.06.029; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Campopiano DJ, 2004, J BIOL CHEM, V279, P48671, DOI 10.1074/jbc.M404690200; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; Corona M, 2001, TOXICON, V39, P1893, DOI 10.1016/S0041-0101(01)00174-X; Craig AG, 1999, EUR J BIOCHEM, V264, P271, DOI 10.1046/j.1432-1327.1999.00624.x; Craig AG, 2000, J TOXICOL-TOXIN REV, V19, P53, DOI 10.1081/TXR-100100315; Czerwiec E, 2002, EUR J BIOCHEM, V269, P6162, DOI 10.1046/j.1432-1033.2002.03335.x; Davies NW, 2004, TOXICON, V43, P173, DOI 10.1016/j.toxicon.2003.11.021; Decker MW, 2004, CURR TOP MED CHEM, V4, P369, DOI 10.2174/1568026043451447; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; England LJ, 1998, SCIENCE, V281, P575, DOI 10.1126/science.281.5376.575; Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4; Escoubas P, 2003, PROTEIN SCI, V12, P1332, DOI 10.1110/ps.0307003; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; Gawade SP, 2004, J TOXICOL-TOXIN REV, V23, P37, DOI 10.1081/TXR-120030647; GLOOR S, 1995, GENE, V160, P213, DOI 10.1016/0378-1119(95)00226-V; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; Grant GA, 1997, BIOCHEMISTRY-US, V36, P3353, DOI 10.1021/bi9629687; Grant GA, 1998, J TOXICOL-TOXIN REV, V17, P239, DOI 10.3109/15569549809009251; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Hao CJ, 2005, BIOTECHNOL LETT, V27, P1929, DOI 10.1007/s10529-005-3905-0; Jacobsen R, 1997, J BIOL CHEM, V272, P22531, DOI 10.1074/jbc.272.36.22531; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kashiwagi T, 2000, J AM SOC MASS SPECTR, V11, P54, DOI 10.1016/S1044-0305(99)00119-1; Kauferstein S, 2004, TOXICON, V44, P539, DOI 10.1016/j.toxicon.2004.07.006; KOBAYASHI J, 1985, TOXICON, V23, P783, DOI 10.1016/0041-0101(85)90009-1; KOBAYASHI J, 1982, BIOCHEM BIOPH RES CO, V105, P1389, DOI 10.1016/0006-291X(82)90941-X; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197; Lewis RJ, 2004, IUBMB LIFE, V56, P89, DOI 10.1080/15216540410001668055; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; Loughnan ML, 2004, EUR J BIOCHEM, V271, P2294, DOI 10.1111/j.1432-1033.2004.04146.x; Loughnan ML, 2004, J MED CHEM, V47, P1234, DOI 10.1021/jm031010o; Maggio F, 2002, J BIOL CHEM, V277, P22806, DOI 10.1074/jbc.M202297200; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; Milne TJ, 2003, J BIOL CHEM, V278, P31105, DOI 10.1074/jbc.M304843200; Moffatt F, 2000, J CHROMATOGR A, V891, P235, DOI 10.1016/S0021-9673(00)00620-8; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Nirthanan S, 2004, J PHARMACOL SCI, V94, P1, DOI 10.1254/jphs.94.1; Olivera BM, 2002, ANNU REV ECOL SYST, V33, P25, DOI 10.1146/annurev.ecolsys.33.010802.150424; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POSSANI LD, 1992, TOXICON, V30, P1343, DOI 10.1016/0041-0101(92)90511-3; Santos AD, 2004, J BIOL CHEM, V279, P17596, DOI 10.1074/jbc.M309654200; SAXENA VK, 1992, NEUROCHEM INT, V20, P69, DOI 10.1016/0197-0186(92)90127-D; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Smit AB, 2003, ANN NY ACAD SCI, V998, P81, DOI 10.1196/annals.1254.010; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Teichert RW, 2004, TOXICON, V44, P207, DOI 10.1016/j.toxicon.2004.05.026; Teichertt RW, 2005, BIOCHEMISTRY-US, V44, P7897, DOI 10.1021/bi047274+; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Torres AM, 2000, BIOCHEM J, V348, P649, DOI 10.1042/0264-6021:3480649; Torres AM, 1999, BIOCHEM J, V341, P785, DOI 10.1042/0264-6021:3410785; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; Valdez-Cruz NA, 2004, EUR J BIOCHEM, V271, P1453, DOI 10.1111/j.1432-1033.2004.04047.x; Van Wagoner RM, 2003, BIOCHEMISTRY-US, V42, P6353, DOI 10.1021/bi0272757; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wu JJ, 2002, BIOCHEMISTRY-US, V41, P2844, DOI 10.1021/bi011367z; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yuki Y, 2005, BIOTECHNOL BIOENG, V92, P803, DOI 10.1002/bit.20654; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5	70	65	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24745	24755		10.1074/jbc.M603703200	http://dx.doi.org/10.1074/jbc.M603703200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790424	hybrid			2022-12-25	WOS:000239847800071
J	Nakanishi, K; Aono, S; Hirano, K; Kuroda, Y; Ida, M; Tokita, Y; Matsui, F; Oohira, A				Nakanishi, Keiko; Aono, Sachiko; Hirano, Kanako; Kuroda, Yoshiyuki; Ida, Michiru; Tokita, Yoshihito; Matsui, Fumiko; Oohira, Atsuhiko			Identification of neurite outgrowth-promoting domains of neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, and involvement of phosphatidylinositol 3-kinase and protein kinase C signaling pathways in neuritogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TENASCIN-C; NEOCORTICAL NEURONS; SMI CORTEX; EXPRESSION; ACTIVATION; MOUSE; RAT; DIFFERENTIATION; FAMILY; CALEB	Neuroglycan C (NGC) is a transmembrane-type chondroitin sulfate proteoglycan that is exclusively expressed in the central nervous system. We report that the recombinant ectodomain of NGC core protein enhances neurite outgrowth from rat neocortical neurons in culture. Both protein kinase C (PKC) inhibitors and phosphatidylinositol 3-kinase (PI3K) inhibitors attenuated the NGC-mediated neurite outgrowth in a dose-dependent manner, suggesting that NGC promotes neurite outgrowth via PI3K and PKC pathways. The active sites of NGC for neurite outgrowth existed in the epidermal growth factor (EGF)-like domain and acidic amino acid (AA)-domain of the NGC ectodomain. The EGF-domain caused cells to extend preferentially one neurite from a soma, whereas the AA-domain caused several neurites to develop. The EGF-domain also enhanced neurite outgrowth from GABA-positive neurons, but the AA-domain did not. These results suggest that the EGF-domain and AA-domain have distinct functions in terms of neuritogenesis. From these findings, NGC can be considered to be involved in neuritogenesis in the developing central nervous system.	Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Kasugai, Aichi 4800392, Japan		Nakanishi, K (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Kasugai, Aichi 4800392, Japan.	nakanishi@inst-hsc.jp		Ida-Eto, Michiru/0000-0002-2469-4006				Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOU CL, 1994, J NEUROSCI, V14, P7616; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Garwood J, 1999, J NEUROSCI, V19, P3888; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Hoffman-Kim D, 2002, MOL CELL NEUROSCI, V21, P81, DOI 10.1006/mcne.2002.1157; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kinugasa Y, 2004, BIOCHEM BIOPH RES CO, V321, P1045, DOI 10.1016/j.bbrc.2004.07.066; Kornblum HI, 2000, DEV NEUROSCI-BASEL, V22, P16, DOI 10.1159/000017423; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; LIN CS, 1985, J NEUROSCI, V5, P1934; Martinez MC, 2003, J CELL BIOL, V162, P99, DOI 10.1083/jcb.200211025; Matsui Fumiko, 2004, Congenital Anomalies, V44, P181, DOI 10.1111/j.1741-4520.2004.00038.x; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Menager C, 2004, J NEUROCHEM, V89, P109, DOI 10.1046/j.1471-4159.2004.02302.x; Mercado MLT, 2004, J NEUROSCI, V24, P238, DOI 10.1523/JNEUROSCI.4519-03.2004; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nakanishi K, 1999, BRAIN RES PROTOC, V4, P105, DOI 10.1016/S1385-299X(99)00003-3; Nakanishi K, 2001, NEUROSCI LETT, V304, P85, DOI 10.1016/S0304-3940(01)01767-0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Oohira A, 2004, GLYCOCONJUGATE J, V21, P53, DOI 10.1023/B:GLYC.0000043748.90896.83; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Rigato F, 2002, J NEUROSCI, V22, P6596; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; SIMONS DJ, 1984, J COMP NEUROL, V230, P119, DOI 10.1002/cne.902300111; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; TOKITA Y, 2001, NEUROSCI RES, V25, pS4; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; White EL, 1997, SOMATOSENS MOT RES, V14, P34, DOI 10.1080/08990229771204; Wu YJ, 2004, MOL BIOL CELL, V15, P2093, DOI 10.1091/mbc.E03-09-0667; Yamagata M, 2005, J NEUROSCI, V25, P8457, DOI 10.1523/JNEUROSCI.1976-05.2005; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200	46	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24970	24978		10.1074/jbc.M601498200	http://dx.doi.org/10.1074/jbc.M601498200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803884	hybrid			2022-12-25	WOS:000239847800089
J	Osvath, S; Herenyi, L; Zavodszky, P; Fidy, J; Kohler, G				Osvath, Szabolcs; Herenyi, Levente; Zavodszky, Peter; Fidy, Judit; Koehler, Gottfried			Hierarchic finite level energy landscape model - To describe the refolding kinetics of phosphoglycerate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING RATES; COLD DENATURATION; MICROSCOPIC THEORY; BIPHASIC KINETICS; DOMAIN; RELAXATION; TRYPTOPHAN; INTENSITY; DYNAMICS; PROLINE	One of the most intriguing predictions of energy landscape models is the existence of non-exponential protein folding kinetics caused by hierarchical structures in the landscapes. Here we provide the strongest evidence so far of such hierarchy and determine the time constants and weights of the kinetic components of the suggested hierarchic energy landscape. To our knowledge, the idea of hierarchical folding energy barriers has never been tested over such a broad timescale. Refolding of yeast phosphoglycerate kinase was initiated from the guanidine-unfolded state by stopped-flow or manual mixing and monitored by tryptophan fluorescence from 1 ms to 15 min. The strategy to build a model that describes folding of yeast phosphoglycerate kinase was to start from the simplest paradigm and modify it stepwise to the necessary minimal extent after repeated comparisons with the experiments. We made no a priori assumptions about the folding landscape. The result was a hierarchic finite level landscape model that quantitatively describes the refolding of yeast phosphoglycerate kinase from 1 ms to 15 min. The early steps of the folding process happen in the upper region of the landscape, where the surface has a hierarchic structure. This leads to stretched kinetics in the early phase of the folding. The lower region of the energy landscape is dominated by a trap that reflects the accumulation of molten globule intermediate state. From this intermediate, the protein can reach the global energy minimum corresponding to the native state through a cross-barrier folding step.	Semmelweis Univ, Dept Biophys & Radiat Biol, H-1088 Budapest, Hungary; Biol Res Ctr Szeged, Inst Enzymol, H-1113 Budapest, Hungary; Semmelweis Univ, Hungarian Acad Sci, Res Grp Biophys, H-1088 Budapest, Hungary; Univ Vienna, Max F Perutz Labs, Dept Chem, A-1090 Vienna, Austria	Semmelweis University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Hungarian Academy of Sciences; Semmelweis University; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Osvath, S (corresponding author), Semmelweis Univ, Dept Biophys & Radiat Biol, Puskin 9, H-1088 Budapest, Hungary.	osvath@puskin.sote.hu	Osváth, Szabolcs/H-6823-2012	Osvath, Szabolcs/0000-0003-2304-3284				Basharov MA, 2003, J CELL MOL MED, V7, P223, DOI 10.1111/j.1582-4934.2003.tb00223.x; BEECHEM JM, 1995, BIOCHEMISTRY-US, V34, P13943, DOI 10.1021/bi00042a028; BETTON JM, 1992, ARCH BIOCHEM BIOPHYS, V296, P95, DOI 10.1016/0003-9861(92)90549-C; Brooks CL, 1998, P NATL ACAD SCI USA, V95, P11037, DOI 10.1073/pnas.95.19.11037; Bustamante C, 2004, ANNU REV BIOCHEM, V73, P705, DOI 10.1146/annurev.biochem.72.121801.161542; Cecconi C, 2005, SCIENCE, V309, P2057, DOI 10.1126/science.1116702; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; CHARDOT T, 1988, FEBS LETT, V228, P65, DOI 10.1016/0014-5793(88)80586-6; Damaschun G, 1998, BIOCHEMISTRY-MOSCOW+, V63, P259; DAMASCHUN G, 1993, BIOCHEMISTRY-US, V32, P7739, DOI 10.1021/bi00081a019; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Finkelstein AV, 2004, PHYS LIFE REV, V1, P23, DOI 10.1016/j.plrev.2004.03.001; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Gast K, 1997, EUR BIOPHYS J BIOPHY, V25, P211, DOI 10.1007/s002490050033; GAST K, 1993, BIOCHEMISTRY-US, V32, P7747, DOI 10.1021/bi00081a020; Gillespie B, 2004, ANNU REV BIOCHEM, V73, P837, DOI 10.1146/annurev.biochem.73.011303.073904; GRIKO YV, 1989, FEBS LETT, V244, P276, DOI 10.1016/0014-5793(89)80544-7; Gruebele M, 1999, ANNU REV PHYS CHEM, V50, P485, DOI 10.1146/annurev.physchem.50.1.485; Karanicolas J, 2004, P NATL ACAD SCI USA, V101, P3432, DOI 10.1073/pnas.0304825101; Karanicolas J, 2003, P NATL ACAD SCI USA, V100, P3954, DOI 10.1073/pnas.0731771100; KLAFTER J, 1986, P NATL ACAD SCI USA, V83, P848, DOI 10.1073/pnas.83.4.848; Lee JC, 2002, J MOL BIOL, V320, P159, DOI 10.1016/S0022-2836(02)00466-7; Lillo MP, 1998, BIOPHYS J, V74, pA168; Lyubovitsky JG, 2002, J AM CHEM SOC, V124, P5481, DOI 10.1021/ja017399r; Ma HR, 2005, P NATL ACAD SCI USA, V102, P2283, DOI 10.1073/pnas.0409270102; McHarg J, 1999, EUR J BIOCHEM, V259, P939, DOI 10.1046/j.1432-1327.1999.00133.x; Metzler R, 1999, P NATL ACAD SCI USA, V96, P11085, DOI 10.1073/pnas.96.20.11085; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Onuchic JN, 1997, ANNU REV PHYS CHEM, V48, P545, DOI 10.1146/annurev.physchem.48.1.545; Osvath S, 2005, PROTEIN SCI, V14, P1609, DOI 10.1110/ps.051359905; Osvath S, 2003, J MOL BIOL, V333, P187, DOI 10.1016/j.jmb.2003.08.011; Osvath S, 2003, BIOPHYS J, V85, P1215, DOI 10.1016/S0006-3495(03)74557-3; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Plotkin SS, 2002, J CHEM PHYS, V116, P5263, DOI 10.1063/1.1449866; Portman JJ, 2001, J CHEM PHYS, V114, P5082, DOI 10.1063/1.1334663; Portman JJ, 2001, J CHEM PHYS, V114, P5069, DOI 10.1063/1.1334662; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Sabelko J, 1999, P NATL ACAD SCI USA, V96, P6031, DOI 10.1073/pnas.96.11.6031; SABELKO JJ, 2000, THESIS U ILLINOIS UR; Tezcan FA, 2002, P NATL ACAD SCI USA, V99, P8626, DOI 10.1073/pnas.132254499; Wolynes PG, 2005, PHILOS T R SOC A, V363, P453, DOI 10.1098/rsta.2004.1502; Yang WY, 2004, J MOL BIOL, V336, P241, DOI 10.1016/j.jmb.2003.11.033	45	13	13	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24375	24380		10.1074/jbc.M601915200	http://dx.doi.org/10.1074/jbc.M601915200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807241	hybrid, Green Published			2022-12-25	WOS:000239847800030
J	Shen, F; Hu, ZH; Goswami, J; Gaffen, SL				Shen, Fang; Hu, Zihua; Goswami, Jaya; Gaffen, Sarah L.			Identification of common transcriptional regulatory elements in interleukin-17 target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; T-CELL INTERLEUKIN-17; NECROSIS-FACTOR-ALPHA; AIRWAY SMOOTH-MUSCLE; CXC CHEMOKINE; MESSENGER-RNA; INFLAMMATORY CYTOKINE; DESTRUCTIVE ARTHRITIS; IL-17; EXPRESSION	Interleukin (IL)-17 is the founding member of a novel family of inflammatory cytokines. Although produced by T cells, IL-17 activates genes and signals typical of innate immune mediators such as tumor necrosis factor (TNF)-alpha and IL-1 beta. Most IL-17 target genes characterized to date are cytokines or neutrophilattractive chemokines. Our recent microarray studies identified an acute phase response gene, 24p3/lipocalin 2, as a novel IL-17-induced gene. Here we describe a detailed analysis of the 24p3 promoter. We find that, unlike cytokine or chemokine gene target genes, 24p3 is regulated primarily at the level of transcription rather than mRNA stability and that synergy between IL-17 and TNF alpha occurs at the level of the 24p3 promoter. Two key transcription factor binding sites (TFBS) were identified, corresponding to NF-kappa B and CCAAT/enhancer-binding protein (C/EBP). Deletion of either site eliminated 24p3 promoter activity in response to IL-17. These findings were strikingly similar to the IL-6 promoter, where IL-17-mediated regulation of both NF-kappa B and C/EBP is essential. To determine whether joint use of NF-kappa B and C/EBP is common to all IL-17 target genes, we performed a computational analysis on 18 well documented IL-17 target promoters to assess statistical enrichment of specific TFBSs. Indeed, NF-kappa B and C/EBP sites were over-represented in these genes, as were AP1 and OCT1 sites. Moreover, these promoters fell into three definable subcategories based on TFBS location and usage. Analysis of IL-17 target gene regulation is key for understanding this important host-defense molecule and also contributes to an understanding of upstream signaling mechanisms used by IL-17, either alone or in concert with TNF alpha.	SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biostat, Ctr Computat Res, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Gaffen, SL (corresponding author), 36 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041; Shen, Fang/0000-0003-0084-7933	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050458] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050458] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Bettelli E, 2005, J EXP MED, V201, P169, DOI 10.1084/jem.20042279; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Cowland JB, 2006, J IMMUNOL, V176, P5559, DOI 10.4049/jimmunol.176.9.5559; Cowland JB, 2003, J IMMUNOL, V171, P6630, DOI 10.4049/jimmunol.171.12.6630; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Frith MC, 2004, NUCLEIC ACIDS RES, V32, P1372, DOI 10.1093/nar/gkh299; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hata K, 2002, AM J PHYSIOL-GASTR L, V282, pG1035, DOI 10.1152/ajpgi.00494.2001; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kelly MN, 2005, INFECT IMMUN, V73, P617, DOI 10.1128/IAI.73.1.617-621.2005; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Lubberts E, 2002, INFLAMM RES, V51, P102, DOI 10.1007/BF02684010; Lubberts E, 2005, ARTHRITIS RES THER, V7, P29, DOI 10.1186/ar1478; Lubberts Erik, 2003, Curr Opin Investig Drugs, V4, P572; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Miljkovic D, 2004, CYTOKINE GROWTH F R, V15, P21, DOI 10.1016/j.cytogfr.2003.10.003; Miossec P, 2003, ARTHRITIS RHEUM-US, V48, P594, DOI 10.1002/art.10816; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Nardone J, 2004, NAT IMMUNOL, V5, P768, DOI 10.1038/ni0804-768; Nilsen-Hamilton M, 2003, ANN NY ACAD SCI, V995, P94, DOI 10.1111/j.1749-6632.2003.tb03213.x; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rahman MS, 2005, CLIN IMMUNOL, V115, P268, DOI 10.1016/j.clim.2005.01.014; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; Richardson DR, 2005, CELL, V123, P1175, DOI 10.1016/j.cell.2005.12.008; Ruddy MJ, 2004, J LEUKOCYTE BIOL, V76, P135, DOI 10.1189/jlb.0204065; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Shimada M, 2002, J IMMUNOL, V168, P861, DOI 10.4049/jimmunol.168.2.861; Smith JB, 2002, IMMUNOGENETICS, V54, P599, DOI 10.1007/s00251-002-0501-5; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Tokuda H, 2004, J CELL BIOCHEM, V91, P1053, DOI 10.1002/jcb.20004; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Xuan ZY, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r72; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamashita R, 2006, NUCLEIC ACIDS RES, V34, pD86, DOI 10.1093/nar/gkj129; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404	63	231	244	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24138	24148		10.1074/jbc.M604597200	http://dx.doi.org/10.1074/jbc.M604597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798734	hybrid			2022-12-25	WOS:000239847800008
J	Lin, Y; Yang, QF; Wang, X; Liu, ZG				Lin, Yong; Yang, Qingfeng; Wang, Xia; Liu, Zheng-gang			The essential role of the death domain kinase receptor-interacting protein in insulin growth factor-I-induced c-Jun N-terminal kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; TNF-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CELL-DEATH; DNA-DAMAGE; NH2-TERMINAL KINASE; MEDIATED APOPTOSIS; GENE-EXPRESSION; IGF-1 RECEPTOR; JNK ACTIVATION	Insulin-like growth factor I (IGF-I) plays an important role in cell survival, proliferation, and differentiation. Diverse kinases, including AKT/ protein kinase B, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), can be activated by IGF-I. Here, we show that the receptor-interacting protein (RIP), a key mediator of tumor necrosis factor-induced NF-kappa B and JNK activation, plays a key role in IGF-I receptor signaling. IGF-I induced a robust JNK activation in wild type but not RIP null (RIP-/-) mouse embryonic fibroblast cells. Reconstitution of RIP expression in the RIP-/- cells restored the induction of JNK by IGF-I, suggesting that RIP is essential in IGF-I-induced JNK activation. Reconstitution experiments with different RIP mutants further revealed that the death domain and the kinase activity of RIP are not required for IGF-I-induced JNK activation. Interestingly, the AKT and ERK activation by IGF-I was normal in RIP-/- cells. The phosphatidylinositol 3-kinase inhibitor, wortmannin, did not affect IGF-I-induced JNK activation. These results agree with previous studies showing that the IGF-I-induced JNK activation pathway is distinct from that of ERK and AKT activation. Additionally, physical interaction of ectopically expressed RIP and IGF-IR beta was detected by co-immunoprecipitation assays. More importantly, RIP was recruited to the IGF-I receptor complex during IGF-I-induced signaling. Furthermore, we found that IGF-I-induced cell proliferation was impaired in RIP-/- cells. Taken together, our results indicate that RIP, a key factor in tumor necrosis factor signaling, also plays a pivotal role in IGF-I-induced JNK activation and cell proliferation.	Lovelace Fdn Med Educ & Res, Mol Biol & Lung Canc Program, Albuquerque, NM 87108 USA; NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA	Lovelace Respiratory Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lin, Y (corresponding author), Lovelace Fdn Med Educ & Res, Mol Biol & Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	ylin@lrri.org	Yang, Heroine/GRY-2630-2022		NATIONAL CANCER INSTITUTE [Z01SC010376, ZIASC010376] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FANG P, 2004, NOVART FDN SYMP, V262, P230; FANG P, 2004, NOVART FDN SYMP, V262, P265; Fang Peng, 2004, Novartis Found Symp, V262, P215; Fischer-Posovszky P, 2004, ENDOCRINOLOGY, V145, P1849, DOI 10.1210/en.2003-0985; Grimberg A, 2003, CANCER BIOL THER, V2, P630; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Krajcik RA, 2002, CANCER EPIDEM BIOMAR, V11, P1566; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Meylan E, 2005, TRENDS BIOCHEM SCI, V30, P151, DOI 10.1016/j.tibs.2005.01.003; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sekharam M, 2003, CANCER RES, V63, P7708; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vallee S, 2003, BIOCHEM BIOPH RES CO, V305, P831, DOI 10.1016/S0006-291X(03)00866-0; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Vivarelli MS, 2004, J EXP MED, V200, P399, DOI 10.1084/jem.20040446; Wajant H, 2004, VITAM HORM, V67, P101; Walsh PT, 2002, IMMUNOLOGY, V107, P461, DOI 10.1046/j.1365-2567.2002.01525.x; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	53	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23525	23532		10.1074/jbc.M601487200	http://dx.doi.org/10.1074/jbc.M601487200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793775	hybrid			2022-12-25	WOS:000239702900027
J	Shafat, I; Vlodavsky, I; Ilan, N				Shafat, Itay; Vlodavsky, Israel; Ilan, Neta			Characterization of mechanisms involved in secretion of active heparanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; FIBROBLAST-GROWTH-FACTOR; MAMMALIAN HEPARANASE; SULFATE DEGRADATION; BINDING DOMAINS; CELL-SURFACE; EXPRESSION; PROTEIN; GENE; ACTIVATION	Heparanase is an endo-beta-D-glucuronidase involved in extracellular matrix remodeling and degradation and implicated in tumor metastasis, angiogenesis, inflammation, and autoimmunity. The enzyme is synthesized as a latent 65-kDa protein and is processed in the lysosomal compartment to an active 58-kDa heterodimer, where it is stored in a stable form. In contrast, its heparan sulfate substrate is localized extracellularly, suggesting the existence of mechanisms that trigger heparanase secretion. Here we show that secretion of the active enzyme is mediated by the protein kinase A and C pathways. Moreover, secretion of active heparanase was observed upon cell stimulation with physiological concentrations of adenosine, ADP, and ATP, as well as by the noncleavable ATP analogue adenosine 5'-O-( thiotriphosphate). Indeed, heparanase secretion was noted upon cell stimulation with a specific P2Y1 receptor agonist and was inhibited by P2Y receptor antagonists. The kinetics of heparanase secretion resembled the secretion of cathepsin D, a lysosomal enzyme, indicating that the secreted heparanase is of lysosomal origin. We suggest that secretion of active heparanase is initiated by extracellular cues activating the protein kinase A and C signaling pathways. The secreted enzyme(s) then facilitate cell invasion associated with cancer metastasis, angiogenesis, and inflammation.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01-CA106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Abbracchio MP, 1998, JPN J PHARMACOL, V78, P113, DOI 10.1254/jjp.78.113; Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Baraz L, 2006, ONCOGENE, V25, P3939, DOI 10.1038/sj.onc.1209425; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chen JQ, 2004, WORLD J GASTROENTERO, V10, P776; Cohen E, 2005, FEBS LETT, V579, P2334, DOI 10.1016/j.febslet.2005.03.030; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; de Mestre AM, 2005, J BIOL CHEM, V280, P35136, DOI 10.1074/jbc.M503414200; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Munoz EM, 2004, ARTERIOSCL THROM VAS, V24, P1549, DOI 10.1161/01.ATV.0000137189.22999.3f; Nadav L, 2002, J CELL SCI, V115, P2179; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; van der Weyden L, 2000, IMMUNOL CELL BIOL, V78, P369, DOI 10.1046/j.1440-1711.2000.00918.x; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Vreys V, 2005, J BIOL CHEM, V280, P33141, DOI 10.1074/jbc.M503007200; Werry TD, 2002, BRIT J PHARMACOL, V135, P1199, DOI 10.1038/sj.bjp.0704566; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zetser A, 2003, CANCER RES, V63, P7733	47	57	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23804	23811		10.1074/jbc.M602762200	http://dx.doi.org/10.1074/jbc.M602762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790442	hybrid			2022-12-25	WOS:000239702900056
J	Amado, L; Kuzminov, A				Amado, Luciana; Kuzminov, Andrei			The replication intermediates in Escherichia coli are not the product of DNA processing or uracil excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; CHAIN GROWTH; DEOXYRIBONUCLEIC-ACID; LEADING-STRAND; POLYMERASE-I; RECBC ENZYME; NASCENT DNA; RNASE-H; MECHANISM; MUTANTS	The current model of DNA replication in Escherichia coli postulates continuous synthesis of the leading strand, based on in vitro experiments with purified enzymes. In contrast, in vivo experiments in E. coli and its bacteriophages, in which maturation of replication intermediates was blocked, report discontinuous DNA synthesis of both the lagging and the leading strands. To address this discrepancy, we analyzed nascent DNA species from ThyA(+) E. coli cells replicating their DNA in ligase-deficient conditions to block maturation of replication intermediates. We report here that the bulk of the newly synthesized DNA isolated from ligase-deficient cells have a length between 0.3 and 3 kb, with a minor fraction being longer that 11 kb but shorter than the chromosome. The low molecular weight of the replication intermediates is unchanged by blocking linear DNA processing with a recBCD mutation or by blocking uracil excision with an ung mutation. These results are consistent with the previously proposed discontinuous replication of the leading strand in E. coli.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kuzminov, A (corresponding author), Univ Illinois, Dept Microbiol, B103 C&LSL,601 S Goodwin Ave, Urbana, IL 61801 USA.	kuzminov@life.uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283, F31GM075425] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07283, F31 GM075425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad SI, 1998, ANNU REV MICROBIOL, V52, P591, DOI 10.1146/annurev.micro.52.1.591; ALBERTS B, 1977, NATURE, V269, P655, DOI 10.1038/269655a0; BIRD RE, 1970, J MOL BIOL, V49, P343, DOI 10.1016/0022-2836(70)90249-4; BOYCE RP, 1962, BIOCHIM BIOPHYS ACTA, V61, P618, DOI 10.1016/0926-6550(62)90117-2; CHA TA, 1989, J BIOL CHEM, V264, P12220; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; DUNCAN BK, 1985, J BACTERIOL, V164, P689, DOI 10.1128/JB.164.2.689-695.1985; Gottesman M. M., 1973, DNA SYNTHESIS IN VIT, P107; HANAWALT PC, 1964, P NATL ACAD SCI USA, V52, P125, DOI 10.1073/pnas.52.1.125; HERRMANN R, 1972, NATURE-NEW BIOL, V240, P235, DOI 10.1038/newbio240235a0; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOCHHAUSER SJ, 1978, J BACTERIOL, V134, P157, DOI 10.1128/JB.134.1.157-166.1978; IYER VN, 1970, P NATL ACAD SCI USA, V67, P629, DOI 10.1073/pnas.67.2.629; JACOBSON MK, 1973, J MOL BIOL, V73, P371, DOI 10.1016/0022-2836(73)90088-0; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; JOHNSTON LH, 1978, NATURE, V274, P891, DOI 10.1038/274891a0; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KONRAD EB, 1973, J MOL BIOL, V77, P519, DOI 10.1016/0022-2836(73)90220-9; KONRAD EB, 1975, P NATL ACAD SCI USA, V72, P2150, DOI 10.1073/pnas.72.6.2150; Kornberg A., 1992, DNA REPLICATION; Kornberg Arthur, 1974, DNA SYNTHESIS; Kouzminova EA, 2006, J MOL BIOL, V355, P20, DOI 10.1016/j.jmb.2005.10.044; Kouzminova EA, 2004, MOL MICROBIOL, V51, P1279, DOI 10.1111/j.1365-2958.2003.03924.x; KUEMPEL PL, 1970, BIOCHEM BIOPH RES CO, V41, P973, DOI 10.1016/0006-291X(70)90180-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUROSAWA Y, 1975, J MOL BIOL, V94, P229, DOI 10.1016/0022-2836(75)90080-7; KUROSAWA Y, 1975, J MOL BIOL, V96, P653, DOI 10.1016/0022-2836(75)90144-8; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LOUARN JM, 1974, P NATL ACAD SCI USA, V71, P329, DOI 10.1073/pnas.71.2.329; MACKAY V, 1976, J BIOL CHEM, V251, P3716; MACKAY V, 1974, J BIOL CHEM, V249, P4286; Maniatis T., 1982, MOL CLONING LAB MANU; MANOR H, 1969, J MOL BIOL, V39, P1, DOI 10.1016/0022-2836(69)90329-5; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; OISHI M, 1968, P NATL ACAD SCI USA, V60, P329, DOI 10.1073/pnas.60.1.329; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; OKAZAKI R, 1968, COLD SPRING HARB SYM, V33, P129, DOI 10.1101/SQB.1968.033.01.017; OKAZAKI R, 1971, P NATL ACAD SCI USA, V68, P2954, DOI 10.1073/pnas.68.12.2954; OKAZAKI R, 1974, METHOD MOL BIOL, V7, P1; OKAZAKI T, 1969, P NATL ACAD SCI USA, V64, P1242, DOI 10.1073/pnas.64.4.1242; OLIVERA BM, 1972, NATURE-NEW BIOL, V240, P233, DOI 10.1038/newbio240233a0; OLIVERA BM, 1978, P NATL ACAD SCI USA, V75, P238, DOI 10.1073/pnas.75.1.238; OLIVERA BM, 1979, J MOL BIOL, V128, P265, DOI 10.1016/0022-2836(79)90087-1; ROWEN L, 1978, J BIOL CHEM, V253, P758; SAKABE K, 1966, BIOCHIM BIOPHYS ACTA, V129, P651, DOI 10.1016/0005-2787(66)90088-8; SILVERSTEIN JL, 1976, VIROLOGY, V72, P212, DOI 10.1016/0042-6822(76)90324-X; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; STENT GS, 1978, MOL GENET, P248; SUGIMOTO K, 1969, P NATL ACAD SCI USA, V63, P1343, DOI 10.1073/pnas.63.4.1343; SUGIMOTO K, 1968, P NATL ACAD SCI USA, V60, P1356, DOI 10.1073/pnas.60.4.1356; TAMANOI F, 1978, P NATL ACAD SCI USA, V75, P2195, DOI 10.1073/pnas.75.5.2195; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; TYE BK, 1977, J MOL BIOL, V117, P293, DOI 10.1016/0022-2836(77)90128-0; Wang TCV, 2005, BIOESSAYS, V27, P633, DOI 10.1002/bies.20233; WANG TCV, 1989, BIOCHEM BIOPH RES CO, V165, P685, DOI 10.1016/S0006-291X(89)80020-8; WARNER HR, 1981, J BACTERIOL, V145, P687, DOI 10.1128/JB.145.2.687-695.1981; WERNER R, 1971, NATURE-NEW BIOL, V233, P99, DOI 10.1038/newbio233099a0; WICKNER W, 1972, P NATL ACAD SCI USA, V69, P965, DOI 10.1073/pnas.69.4.965; WU CA, 1992, J BIOL CHEM, V267, P4030; YUDELEVICH A, 1968, P NATL ACAD SCI USA, V61, P1129, DOI 10.1073/pnas.61.3.1129	68	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22635	22646		10.1074/jbc.M602320200	http://dx.doi.org/10.1074/jbc.M602320200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772291	hybrid			2022-12-25	WOS:000239542600024
J	Baker, DL; Fujiwara, Y; Pigg, KR; Tsukahara, R; Kobayashi, S; Murofushi, H; Uchiyama, A; Murakami-Murofushi, K; Koh, E; Bandle, RW; Byun, HS; Bittman, R; Fan, D; Murph, M; Mills, GB; Tigyi, G				Baker, Daniel L.; Fujiwara, Yuko; Pigg, Kathryn R.; Tsukahara, Ryoko; Kobayashi, Susumu; Murofushi, Hiromu; Uchiyama, Ayako; Murakami-Murofushi, Kimiko; Koh, Eunjin; Bandle, Russell W.; Byun, Hoe-Sup; Bittman, Robert; Fan, Dominic; Murph, Mandi; Mills, Gordon B.; Tigyi, Gabor			Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY ALCOHOL PHOSPHATES; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPASE-D; PPAR-GAMMA; IDENTIFICATION; MOTILITY; EXPRESSION; RECEPTOR; PHYLPA; SERUM	Autotaxin (ATX, nucleotide pyrophosphate/phosphodiesterase-2) is an autocrine motility factor initially characterized from A2058 melanoma cell-conditioned medium. ATX is known to contribute to cancer cell survival, growth, and invasion. Recently ATX was shown to be responsible for the lysophospholipase D activity that generates lysophosphatidic acid (LPA). Production of LPA is sufficient to explain the effects of ATX on tumor cells. Cyclic phosphatidic acid (cPA) is a naturally occurring analog of LPA in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate. Cellular responses to cPA generally oppose those of LPA despite activation of apparently overlapping receptor populations, suggesting that cPA also activates cellular targets distinct from LPA receptors. cPA has previously been shown to inhibit tumor cell invasion in vitro and cancer cell metastasis in vivo. However, the mechanism governing this effect remains unresolved. Here we show that 3-carba analogs of cPA lack significant agonist activity at LPA receptors yet are potent inhibitors of ATX activity, LPA production, and A2058 melanoma cell invasion in vitro and B16F10 melanoma cell metastasis in vivo.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Vasc Biol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Genom, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Bioinformat Ctr Excellence, Memphis, TN 38163 USA; Tokyo Univ Sci, Fac Pharmaceut, Dept Med Chem, Chiba 2788510, Japan; Yamaguchi Univ, Fac Nat Sci, Dept Biol Sci, Yamaguchi 7538511, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Tokyo 1128610, Japan; NCI, Lab Pathol, NIH, Bethesda, MD 20892 USA; City Univ New York, Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA; Univ Texas, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, Dept Mol Therapeut, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Tokyo University of Science; Yamaguchi University; Ochanomizu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City University of New York (CUNY) System; Queens College NY (CUNY); University of Texas System; University of Texas System; UTMD Anderson Cancer Center	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		Koh, Eunjin/0000-0001-8967-6266; Baker, Daniel/0000-0003-1482-0416	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA92160, P01 CA064602, P01 CA64602, R01 CA092160-08, R01 CA092160] Funding Source: Medline; NHLBI NIH HHS [R01 HL061469, HL61469, HL79004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010673, P01CA064602, R01CA092160] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079004, R01HL061469] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Clair T, 2003, CANCER RES, V63, P5446; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Debies MT, 2001, J MAMMARY GLAND BIOL, V6, P441, DOI 10.1023/A:1014739131690; Deissler H, 1999, FASEB J, V13, P657, DOI 10.1096/fasebj.13.6.657; Durgam GG, 2005, J MED CHEM, V48, P4919, DOI 10.1021/jm049609r; ERUKULLA RK, 1994, TETRAHEDRON LETT, V35, P5783; Euer N, 2002, ANTICANCER RES, V22, P733; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Friedman P, 1996, J BIOL CHEM, V271, P953, DOI 10.1074/jbc.271.2.953; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; Ishihara R, 2004, INT J CANCER, V110, P188, DOI 10.1002/ijc.20069; Klominek J, 1998, ANTICANCER RES, V18, P759; KOBAYASHI S, 1993, TETRAHEDRON LETT, V34, P4047, DOI 10.1016/S0040-4039(00)60612-3; KOBAYASHI S, 2004, Patent No. 1402894; Kobayashi T, 1999, LIFE SCI, V65, P2185, DOI 10.1016/S0024-3205(99)00483-X; KOHN EC, 1993, INT J CANCER, V53, P968; Liliom K, 1996, AM J PHYSIOL-CELL PH, V270, pC772, DOI 10.1152/ajpcell.1996.270.3.C772; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukai M, 2000, FEBS LETT, V484, P69, DOI 10.1016/S0014-5793(00)02129-3; Mukai M, 1999, INT J CANCER, V81, P918, DOI 10.1002/(SICI)1097-0215(19990611)81:6<918::AID-IJC13>3.0.CO;2-E; Murakami-Murofushi K, 2002, BBA-MOL CELL BIOL L, V1582, P1, DOI 10.1016/S1388-1981(02)00131-2; MURAKAMIMUROFUSHI K, 1992, J BIOL CHEM, V267, P21512; MURAKAMIMUROFUSHI K, 1993, CELL STRUCT FUNCT, V18, P363, DOI 10.1247/csf.18.363; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tokumura A, 2002, J LIPID RES, V43, P307; Tokumura A, 2000, ANN NY ACAD SCI, V905, P347; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; Virag T, 2003, MOL PHARMACOL, V63, P1032, DOI 10.1124/mol.63.5.1032; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Yang Y, 1999, AM J RESP CELL MOL, V21, P216, DOI 10.1165/ajrcmb.21.2.3667; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330	54	136	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22786	22793		10.1074/jbc.M512486200	http://dx.doi.org/10.1074/jbc.M512486200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782709	hybrid, Green Accepted			2022-12-25	WOS:000239542600039
J	Vitagliano, D; Portella, G; Troncone, G; Francione, A; Rossi, C; Bruno, A; Giorgini, A; Coluzzi, S; Nappi, TC; Rothstein, JL; Pasquinelli, R; Chiappetta, G; Terracciano, D; Macchia, V; Melillo, RM; Fusco, A; Santoro, M				Vitagliano, D.; Portella, G.; Troncone, G.; Francione, A.; Rossi, C.; Bruno, A.; Giorgini, A.; Coluzzi, S.; Nappi, T. C.; Rothstein, J. L.; Pasquinelli, R.; Chiappetta, G.; Terracciano, D.; Macchia, V.; Melillo, R. M.; Fusco, A.; Santoro, M.			Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas	ONCOGENE			English	Article						kinase; carcinoma; thyroid; ras; progression; differentiation	TISSUE-SPECIFIC EXPRESSION; PAPILLARY CARCINOMAS; RAS ONCOGENE; THYROGLOBULIN PROMOTER; RET/PTC1 ONCOGENE; PCCL3 CELLS; MUTATIONS; CANCER; INSTABILITY; DEDIFFERENTIATION	Ras oncogenes are frequently mutated in thyroid carcinomas. To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells.Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and similar to 40% developed invasive follicular carcinomas, in some cases with a mixed papillary/follicular morphology. About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases. N-ras(Gln61Lys) express ion in cultured PC Cl 3 thyrocytes induced thyroid-stimulating hormone-independent proliferation and genomic instability with micronuclei formation and centrosome amplification. These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med, CNR,Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Sci Biomorfol & Funzionali, I-80131 Naples, Italy; Consorzio Mario Negri Sud, Chieti, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA; Fdn Pascale, Ist Nazl Tumori, Funt Genom Unit, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; Consorzio Mario Negri Sud; Jefferson University; Jefferson University; IRCCS Fondazione Pascale	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med, CNR,Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Portella, Giuseppe/AFU-6826-2022; vitagliano, donata/B-8976-2012; melillo, rosa marina/O-5255-2015; Terracciano, Daniela/AAB-9521-2022	Terracciano, Daniela/0000-0003-4296-429X; PORTELLA, Giuseppe/0000-0001-8276-9769; Fusco, Alfredo/0000-0003-3332-5197; Coluzzi, Sabrina/0000-0003-4483-6232; MELILLO, Rosa Marina/0000-0002-9233-5275				CARCANGIU ML, 1984, AM J SURG PATHOL, V8, P655, DOI 10.1097/00000478-198409000-00005; DELELLIS RA, 2004, TUMOURS ENDOCRINE OR, P51; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Fagin JA, 2004, J ENDOCRINOL, V183, P249, DOI 10.1677/joe.1.05895; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Garcia-Rostan G, 2003, J CLIN ONCOL, V21, P3226, DOI 10.1200/JCO.2003.10.130; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GRECO A, 1992, ONCOGENE, V7, P237; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JOKINEN MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; Ledent C, 1996, EXP CLIN ENDOCR DIAB, V104, P43, DOI 10.1055/s-0029-1211683; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Motoi O, 2000, PATHOL RES PRACT, V196, P1; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Powell DJ, 1998, CANCER RES, V58, P5523; Rochefort P, 1996, ONCOGENE, V12, P111; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; SANTELLI G, 1993, CANCER RES, V53, P5523; Santoro M, 1996, ONCOGENE, V12, P1821; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Vasko V, 2003, J CLIN ENDOCR METAB, V88, P2745, DOI 10.1210/jc.2002-021186; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	35	55	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5467	5474		10.1038/sj.onc.1209527	http://dx.doi.org/10.1038/sj.onc.1209527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16785999				2022-12-25	WOS:000240144900011
J	Razeghi, P; Buksinska-Lisik, M; Palanichamy, N; Stepkowski, S; Frazier, OH; Taegtmeyer, H				Razeghi, Peter; Buksinska-Lisik, Malgorzata; Palanichamy, Nanthini; Stepkowski, Stanislaw; Frazier, O. Howard; Taegtmeyer, Heinrich			Transcriptional regulators of ribosomal biogenesis are increased in the unloaded heart	FASEB JOURNAL			English	Article						failing human heart; LVAD; reverse remodeling c-myc	C-MYC; INCREASED EXPRESSION; RNA; HYPERTROPHY; ACTIVATION; GROWTH; GENES; UBF; DNA	Mechanical unloading of the rat heart increases both protein synthesis and protein degradation. The transcriptional mechanism underlying increased protein synthesis during atrophic remodeling is not known. The aim of this study was to identify transcriptional regulators and the gene expression profile regulating protein synthesis in the unloaded rat heart and in the unloaded failing human heart. We measured DNA binding activity, transcript levels, and protein expression of transcriptional regulators of protein synthesis in a model of atrophic remodeling induced by heterotopic transplantation of the rat heart ( duration 1 and 7 days). Using microarray analysis and quantitative RT-polymerase chain reaction, we found an increase in c-myc-regulated gene expression including an induction of ribosomal subunit messenger RNA's (RPS 10, RPL 21) and rRNA (18S). Consistent with the gene expression profile, DNA binding activity of c-myc and the nuclear protein concentration of its coactivator, upstream binding factor (UBF), increased in the atrophied heart whereas protein levels of the c-myc inhibitor MAD1 decreased. We found the same increase of ribosomal subunit messenger RNA and rRNA in 21 paired samples of failing human hearts obtained before and after left ventricular assist device treatment ( mean duration: 157 +/- 31 days). In summary, mechanical unloading increases c-myc activity and c-myc regulated gene expression in the rat heart. Changes in transcript levels of genes regulating ribosomal biogenesis in the unloaded rat heart resemble those found in the unloaded failing human heart. We concluded c-myc and c-myc-regulated gene expression are transcriptional regulators of protein synthesis during atrophic remodeling of the heart.	Univ Texas, Houston Med Sch, Div Cardiol, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Div Organ Transplantat, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Saint Lukes Episcopal Hospital; Texas Heart Institute	Taegtmeyer, H (corresponding author), Univ Texas, Houston Med Sch, Div Cardiol, Dept Internal Med, 6431 Fannin,MSB 1-222, Houston, TX 77030 USA.	heinrich.taegtmeyer@uth.tmc.edu		Buksinska-Lisik, Malgorzata/0000-0001-7738-1049	NHLBI NIH HHS [R01-HL 61483] Funding Source: Medline; NIA NIH HHS [R01-AG 61483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Barton PJR, 2005, CIRCULATION, V112, pI46, DOI 10.1161/01.CIRCULATIONAHA.105.525873; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; MCCARTHY PM, 1995, ANN THORAC SURG, V59, P609, DOI 10.1016/0003-4975(94)00953-8; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nader GA, 2005, AM J PHYSIOL-CELL PH, V289, pC1457, DOI 10.1152/ajpcell.00165.2005; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Razeghi P, 2005, CIRC RES, V97, P964, DOI 10.1161/01.RES.0000193563.53859.3e; Razeghi P, 2003, CIRCULATION, V108, P2536, DOI 10.1161/01.CIR.0000096481.45105.13; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SCHEININ SA, 1992, ASAIO J, V38, pM271, DOI 10.1097/00002480-199207000-00035; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schnabel P, 2000, BIOCHEM BIOPH RES CO, V275, P1, DOI 10.1006/bbrc.2000.3255; Sharma S, 2006, CARDIOLOGY, V105, P128, DOI 10.1159/000090550; Uray IP, 2002, J HEART LUNG TRANSPL, V21, P771, DOI 10.1016/S1053-2498(02)00390-X; Xiao GS, 2001, CIRC RES, V89, P1122, DOI 10.1161/hh2401.100742	20	16	16	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1090	1096		10.1096/fj.06-5718com	http://dx.doi.org/10.1096/fj.06-5718com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770008				2022-12-25	WOS:000240210300009
J	Holcomb, VB; Vogel, H; Marple, T; Kornegay, RW; Hasty, P				Holcomb, V. B.; Vogel, H.; Marple, T.; Kornegay, R. W.; Hasty, P.			Ku80 and p53 suppress medulloblastoma that arise independent of Rag-1-induced DSBs	ONCOGENE			English	Article						Ku80; p53; nonhomologous end joining; Rag-1; medulloblastoma; DNA double-strand breaks	MAJOR BREAKPOINT REGION; END-JOINING PATHWAY; V(D)J RECOMBINATION; EMBRYONIC LETHALITY; DNA-REPAIR; GENOMIC STABILITY; MICE; DEFICIENT; CELLS; GENE	Ku80 maintains the genome by repairing DNA double-strand breaks (DSBs) through nonhomologous end joining (NHEJ), a pathway that repairs nonspecific DSBs and Rag-1 Rag-2 (Rag)-specific DSBs. As a result, Ku80 deletion results in phenotypes characteristic of defective repair for both nonspecific DSBs (c-radiation hypersensitivity and genomic instability) and Rag-specific DSBs (immunodeficiency). ku80(-/)-mice also exhibit neuronal apoptosis, but we do not know the type of DSBs responsible for this response. In spite of genomic instability and immunodeficiency, cancer incidence is not increased in ku80(-/-)mice. However, deletion of the tumor suppressor, p53 greatly increases pro-B-cell lymphoma in ku80(-/-)mice due to IgH/ c-Myc translocations suggesting that responses to Rag-specific DNA DSBs suppress cancer. Like suppression of pro-B-cell lymphoma, neuronal apoptosis requires p53 presenting the intriguing possibility that Rag-specific DSBs mediate neuronal development as they do lymphocyte development. Here we delete Rag-1 from ku80(-/)-p53(-/-)mice to differentiate the impact nonspecific vs Rag-specific DSBs have on ku80(-/-)mice. We find that deleting Rag-1 prevents pro-B cell lymphoma confirming Rag-induced DSBs induce this form of cancer. Both the triple mutant mice and the p53(-/-)rag-1(-/)-mice exhibit T-cell lymphoma and medulloblastoma; incidence of T-cell lymphoma is the same for both cohorts whereas incidence of medulloblastoma is higher for the triple-mutant cohort. Thus, p53-mediated neuronal apoptosis likely suppresses medulloblastoma in Ku80-deleted mice and Ku80 likely suppresses medulloblastoma by repairing nonspecific DNA DSBs instead of Rag-specific DSBs. Our observations are the first to show that Ku80 suppresses cancer caused by nonspecific DNA damage and we present a novel mouse model for medulloblastoma.	Univ Texas, Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr San Antonio, Lab Anim Resources, San Antonio, TX 78245 USA; Stanford Univ, Med Ctr, Dept Pathol, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University	Hasty, P (corresponding author), Univ Texas, Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	hastye@uthscsa.edu		Hasty, Paul/0000-0003-3046-0131; Vogel, Otto Hannes/0000-0002-0960-3508	NATIONAL CANCER INSTITUTE [R01CA076317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76317-05A1] Funding Source: Medline; NIA NIH HHS [P01 AG17242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535-6108(02)00236-2; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Karanjawala ZE, 2002, DNA REPAIR, V1, P1017, DOI 10.1016/S1568-7864(02)00151-9; Lee CJ, 2005, J NEURO-ONCOL, V73, P101, DOI 10.1007/s11060-004-4598-2; Lee Y, 2002, CANCER RES, V62, P6395; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Maser RS, 2003, CANCER CELL, V3, P4, DOI 10.1016/S1535-6108(02)00243-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Raghavan SC, 2005, MOL CELL BIOL, V25, P6475, DOI 10.1128/MCB.25.15.6475-6484.2005; Raghavan SC, 2005, MOL CELL BIOL, V25, P5904, DOI 10.1128/MCB.25.14.5904-5919.2005; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	46	34	36	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7159	7165		10.1038/sj.onc.1209704	http://dx.doi.org/10.1038/sj.onc.1209704			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16751807				2022-12-25	WOS:000242046900005
J	Watari, A; Takaki, K; Higashiyama, S; Li, Y; Satomi, Y; Takao, T; Tanemura, A; Yamaguchi, Y; Katayama, I; Shimakage, M; Miyashiro, I; Takami, K; Kodama, K; Yutsudo, M				Watari, A.; Takaki, K.; Higashiyama, S.; Li, Y.; Satomi, Y.; Takao, T.; Tanemura, A.; Yamaguchi, Y.; Katayama, I.; Shimakage, M.; Miyashiro, I.; Takami, K.; Kodama, K.; Yutsudo, M.			Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG	ONCOGENE			English	Article						CapG; tumor suppressor gene; multistep tumorigenesis; gastric cancer; lung cancer	GELSOLIN; PROTEIN; EXPRESSION	Previously, we isolated a series of cell lines from a human diploid fibroblast lineage as a model for multistep tumorigenesis in humans. After passaging a single LT-transfected fibroblast clone, differently progressed cell lines were obtained, including immortalized, anchorage-independent and tumorigenic cell lines. In the present paper, we analysed the gene expression profiles of these model cell lines, and observed that expression of the CapG protein was lost in the tumorigenic cell line. To examine the possibility that loss of CapG protein expression was required for tumorigenic progression, we transfected CapG cDNA into the tumorigenic cell line and tested for tumor-forming ability in nude mice. Results showed that ectopic expression of CapG suppressed tumorigenicity, but not growth in soft agar or liquid medium. We also found that certain cancer cell lines including stomach cancer, lung cancer and melanoma had also lost CapG expression. One such cancer cell line AZ521 also became non-tumorigenic after the introduction of CapG cDNA. Moreover, we showed that CapG expression was repressed in small-cell lung cancer tissues. Together, our findings indicated that CapG is a new tumor suppressor gene involved in the tumorigenic progression of certain cancers.	Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Natl Hosp, Chuo, Osaka, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka National Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases	Yutsudo, M (corresponding author), Osaka Univ, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	yutsudo@biken.osaka-u.ac.jp	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019	Satomi, Yoshinori/0000-0002-8991-1040; Yamaguchi, Yuji/0000-0003-4338-2662				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Corte V, 2004, J CELL SCI, V117, P5283, DOI 10.1242/jcs.01410; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Lal A, 1999, CANCER RES, V59, P5403; Oka K, 1999, GENE CHROMOSOME CANC, V26, P47, DOI 10.1002/(SICI)1098-2264(199909)26:1<47::AID-GCC7>3.0.CO;2-8; Pellieux C, 2003, J BIOL CHEM, V278, P29136, DOI 10.1074/jbc.M300598200; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Sagawa N, 2003, BRIT J CANCER, V88, P606, DOI 10.1038/sj.bjc.6600739; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; TANAKA M, 1995, CANCER RES, V55, P3228; Van Ginkel PR, 1998, BBA-MOL CELL RES, V1448, P290, DOI 10.1016/S0167-4889(98)00133-5; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	16	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7373	7380		10.1038/sj.onc.1209732	http://dx.doi.org/10.1038/sj.onc.1209732			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767159				2022-12-25	WOS:000242419100006
J	Dobi, A; Szemes, M; Lee, C; Palkovits, M; Lim, F; Gyorgy, A; Mahan, MA; Agoston, DV				Dobi, Albert; Szemes, Marianna; Lee, Cheol; Palkovits, Miklos; Lim, Francis; Gyorgy, Andrea; Mahan, Mark A.; Agoston, Denes V.			AUF1 ls expressed in the developing brain, binds to AT-rich double-stranded DNA, and regulates enkephalin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MESSENGER-RNA DECAY; TRANSCRIPTION FACTORS; CHROMATIN DOMAINS; PROTEIN ISOFORMS; HNRNP PROTEINS; ARID PROTEINS; IN-VIVO; MATRIX; REGION	During our search for transcriptional regulators that control the developmentally regulated expression of the enkephalin (ENK) gene, we identified AUF1. ENK, a peptide neurotransmitter, displays precise cell-specific expression in the adult brain. AUF1 (also known as heterogeneous nuclear ribonucleoprotein D) has been known to regulate gene expression through altering the stability of AU-rich mRNAs. We show here that in the developing brain AUF1 proteins are expressed in a spatiotemporally defined manner, and p37 and p40/42 isoforms bind to an AT-rich double-stranded (ds) DNA element of the rat ENK (rENK) gene. This AT-rich dsDNA sequence acts as a cis-regulatory DNA element and is involved in regulating the cell-specific expression of the ENK gene in primary neuronal cultures. The AT-rich dsDNA elements are present at similar to 2.5 kb 5' upstream of the rat, human, and mouse ENK genes. AUF1 proteins are shown here to provide direct interaction between these upstream AT-rich DNA sequences and the TATA region of the rENK gene. Double immunohistochemistry demonstrated that in the developing brain AUF1 proteins are expressed by proliferating neural progenitors and by differentiating neurons populating brain regions, which will not express the ENK gene in the adult, suggesting a repressor role for AUF1 proteins during enkephalinergic differentiation. Their subnuclear distribution and interactions with AT-rich DNA suggest that in the developing brain they can be involved in complex nuclear regulatory mechanisms controlling the development- and cell-specific expression of the ENK gene.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; NIMH, Bethesda, MD 20892 USA; Univ New Mexico, Dept Biochem, Albuquerque, NM 87131 USA; Columbia Univ, Dept Neurol, New York, NY 10027 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of New Mexico; Columbia University	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, B2036, Bethesda, MD 20814 USA.	vagoston@usuhs.mil	Palkovits, Miklos/F-2707-2013	Palkovits, Miklos/0000-0003-0578-0387				AGOSTON D, 1998, DNA SEQUENCE, V9, P217; AGOSTON DV, 1991, J NEUROSCI RES, V28, P140, DOI 10.1002/jnr.490280115; Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Bernstein BE, 2004, METHOD ENZYMOL, V376, P349; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Boulikas T, 1995, INT REV CYTOL, V162A, P279; Boussif O, 1996, GENE THER, V3, P1074; Brewer G, 2002, AGEING RES REV, V1, P607, DOI 10.1016/S1568-1637(02)00023-5; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Comb M J, 1992, NIDA Res Monogr, V126, P98; Comings DE, 1999, NEUROREPORT, V10, P1133, DOI 10.1097/00001756-199904060-00042; Comings DE, 2000, PROG BRAIN RES, V126, P325; Cremer T, 2000, CRIT REV EUKAR GENE, V10, P179; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dobi A, 2002, BIOTECHNIQUES, V33, P868, DOI 10.2144/02334rr03; Dobi A, 1997, MOL BRAIN RES, V52, P98, DOI 10.1016/S0169-328X(97)00238-6; Dobi A, 2000, J NEUROSCI, V20, P1073, DOI 10.1523/JNEUROSCI.20-03-01073.2000; Dobi A, 1998, P NATL ACAD SCI USA, V95, P5981, DOI 10.1073/pnas.95.11.5981; DONOVAN DM, 1992, P NATL ACAD SCI USA, V89, P2345, DOI 10.1073/pnas.89.6.2345; Gindullis F, 1999, PLANT CELL, V11, P1117, DOI 10.1105/tpc.11.6.1117; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Hyman S E, 1996, NIDA Res Monogr, V161, P59; Ishii K, 2003, MOL CELL, V11, P237, DOI 10.1016/S1097-2765(03)00010-8; Johnson TA, 2001, BIOTECHNIQUES, V31, P740, DOI 10.2144/01314bm05; JOSHI J, 1991, MOL ENDOCRINOL, V5, P1069, DOI 10.1210/mend-5-8-1069; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Kumar NV, 2001, ANAL BIOCHEM, V299, P203, DOI 10.1006/abio.2001.5433; Laemmli UK, 1996, CURR OPIN CELL BIOL, V8, P299, DOI 10.1016/S0955-0674(96)80001-9; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; PAULI U, 1989, J CELL PHYSIOL, V139, P320, DOI 10.1002/jcp.1041390214; PAXINOS G, 1995, ATLAS DEV RAT NERVOU; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; Sarkar B, 2003, J BIOL CHEM, V278, P20700, DOI 10.1074/jbc.M301176200; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; SONG DD, 1994, DEV BRAIN RES, V83, P247, DOI 10.1016/0165-3806(94)00145-6; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; SUMMERS RW, 1993, DEV BRAIN RES, V73, P185, DOI 10.1016/0165-3806(93)90137-Y; Szemes M, 2006, NEUROCHEM RES, V31, P237, DOI 10.1007/s11064-005-9012-8; Taylor A, 1997, MOL CELL BIOCHEM, V169, P61, DOI 10.1023/A:1006898812618; Tolnay M, 2000, BIOCHEM J, V348, P151, DOI 10.1042/0264-6021:3480151; Tolnay M, 2002, BIOCHEM J, V363, P127, DOI 10.1042/0264-6021:3630127; Vaccarino AL, 1999, PEPTIDES, V20, P1527, DOI 10.1016/S0196-9781(99)00166-7; Von Agoston D, 2000, BIOCHEM SOC T, V28, P446; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; Woynarowski JM, 2004, CURR CANCER DRUG TAR, V4, P219, DOI 10.2174/1568009043481524; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	65	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28889	28900		10.1074/jbc.M511858200	http://dx.doi.org/10.1074/jbc.M511858200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16769718	hybrid			2022-12-25	WOS:000240680500043
J	Debela, M; Magdolen, V; Schechter, N; Valachova, M; Lottspeich, F; Craik, CS; Choe, Y; Bode, W; Goettig, P				Debela, Mekdes; Magdolen, Viktor; Schechter, Norman; Valachova, Martina; Lottspeich, Friedrich; Craik, Charles S.; Choe, Youngchool; Bode, Wolfram; Goettig, Peter			Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; CORNEUM CHYMOTRYPTIC ENZYME; RAY CRYSTAL-STRUCTURE; SERINE-PROTEASE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; PLASMINOGEN-ACTIVATOR; GENE FAMILY; CRYSTALLOGRAPHIC REFINEMENT; GENOMIC ORGANIZATION	Human tissue kallikreins (hKs) form a family of 15 closely related (chymo) trypsin-like serine proteinases. These tissue kallikreins are expressed in a wide range of tissues including the central nervous system, the salivary gland, and endocrine-regulated tissues, such as prostate, breast, or testis, and may have diverse physiological functions. For several tissue kallikreins, a clear correlation has been established between expression and different types of cancer. For example, the prostate-specific antigen (PSA or hK3) serves as tumor marker and is used to monitor therapy response. Using a novel strategy, we have cloned, expressed in Escherichia coli or in insect cells, refolded, activated, and purified the seven human tissue kallikreins hK3/PSA, hK4, hK5, hK6, hK7, hK10, and hK11. Moreover, we have determined their extended substrate specificity for the nonprime side using a positional scanning combinatorial library of tetrapeptide substrates. hK3/PSA and hK7 exhibited a chymotrypsin-like specificity preferring large hydrophobic or polar residues at the P1 position. In contrast, hK4, hK5, and less stringent hK6 displayed a trypsin-like specificity with strong preference for P1-Arg, whereas hK10 and hK11 showed an ambivalent specificity, accepting both basic and large aliphatic P1 residues. The extended substrate specificity profiles are in good agreement with known substrate cleavage sites but also in accord with experimentally solved ( hK4, hK6, and hK7) or modeled structures. The specificity profiles may lead to a better understanding of human tissue kallikrein functions and assist in identifying their physiological protein substrates as well as in designing more selective inhibitors.	Max Planck Inst Biochem, Proteinase Res Grp, D-82152 Martinsried, Germany; Tech Univ Munich, Klinikum Rechts Isar, Frauenklin, Klin Forschergrp, D-81675 Munich, Germany; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Max Planck Society; Technical University of Munich; University of Pennsylvania; Max Planck Society; University of California System; University of California San Francisco	Bode, W (corresponding author), Max Planck Inst Biochem, Proteinase Res Grp, Klopferspitz 18, D-82152 Martinsried, Germany.	bode@biochem.mpg.de; goettig@biochem.mpg.de	Goettig, Peter/R-7996-2017; Goettig, Peter/K-4508-2019	Goettig, Peter/0000-0002-2430-1970; Goettig, Peter/0000-0002-2430-1970	NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelo PF, 2006, J BIOL CHEM, V281, P3116, DOI 10.1074/jbc.M510096200; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Barrett AJ, 2003, BIOL CHEM, V384, P873, DOI 10.1515/BC.2003.098; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; Beaufort N, 2006, BIOL CHEM, V387, P217, DOI 10.1515/BC.2006.029; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Borgono CA, 2004, MOL CANCER RES, V2, P257; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; BRILLARDBOURDET M, 1995, BBA-PROTEIN STRUCT M, V1246, P47, DOI 10.1016/0167-4838(94)00179-K; Carvalho AL, 2002, J MOL BIOL, V322, P325, DOI 10.1016/S0022-2836(02)00705-2; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; Chao J., 2004, HDB PROTEOLYTIC ENZY, V2, P1577; CHEN ZG, 1983, J MOL BIOL, V164, P283, DOI 10.1016/0022-2836(83)90078-5; Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200; Clements J, 2001, BIOL CHEM, V382, P5, DOI 10.1515/BC.2001.002; Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931; CLEMENTS JA, 2004, HDB PROTEOLYTIC ENZY, V2, P1569; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Denmeade SR, 2001, PROSTATE, V48, P1; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Diamandis EP, 2000, CLIN CHEM, V46, P1855; Egelrud T, 2005, BRIT J DERMATOL, V153, P1200, DOI 10.1111/j.1365-2133.2005.06834.x; EGELRUD T, 2004, HDB PROTEOLYTIC ENZY, V2, P1556; Felber LM, 2005, BIOL CHEM, V386, P291, DOI 10.1515/BC.2005.035; FUJINAGA M, 1987, J MOL BIOL, V195, P373, DOI 10.1016/0022-2836(87)90658-9; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hachem JP, 2005, J INVEST DERMATOL, V125, P510, DOI 10.1111/j.0022-202X.2005.23838.x; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HAREL M, 1991, BIOCHEMISTRY-US, V30, P5217, DOI 10.1021/bi00235a015; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Hart PS, 2004, J MED GENET, V41, P545, DOI 10.1136/jmg.2003.017657; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; Hooper JD, 2001, GENOMICS, V73, P117, DOI 10.1006/geno.2000.6490; Hu JCC, 2000, GENE, V251, P1, DOI 10.1016/S0378-1119(00)00203-1; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; Kumar A, 1997, CANCER RES, V57, P3111; Laxmikanthan G, 2005, PROTEINS, V58, P802, DOI 10.1002/prot.20368; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; Liu XL, 1996, CANCER RES, V56, P3371; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; Luo LY, 2006, CLIN CANCER RES, V12, P742, DOI 10.1158/1078-0432.CCR-05-1696; Malm J, 2000, PROSTATE, V45, P132, DOI 10.1002/1097-0045(20001001)45:2<132::AID-PROS7>3.0.CO;2-3; Matsumura M, 2005, PROSTATE, V62, P1, DOI 10.1002/pros.20101; Michael IP, 2006, J BIOL CHEM, V281, P12743, DOI 10.1074/jbc.M600326200; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Mitsui S, 2000, BIOCHEM BIOPH RES CO, V272, P205, DOI 10.1006/bbrc.2000.2761; Nakamura T, 2003, PROSTATE, V54, P299, DOI 10.1002/pros.10191; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Obiezu CV, 2005, CANCER LETT, V224, P1, DOI 10.1016/j.canlet.2004.09.024; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Parry MAA, 1998, STRUCT FOLD DES, V6, P1195, DOI 10.1016/S0969-2126(98)00119-1; Pimenta DC, 2002, BIOL CHEM, V383, P853, DOI 10.1515/BC.2002.091; Rehault S, 2002, BBA-PROTEIN STRUCT M, V1596, P55, DOI 10.1016/S0167-4838(02)00204-2; Rehault S, 2001, EUR J BIOCHEM, V268, P2960, DOI 10.1046/j.1432-1327.2001.02185.x; Robert M, 1997, BIOCHEMISTRY-US, V36, P3811, DOI 10.1021/bi9626158; Schechter NM, 2005, BIOL CHEM, V386, P1173, DOI 10.1515/BC.2005.134; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; Simmer JP, 1998, J DENT RES, V77, P377, DOI 10.1177/00220345980770020601; SKYTT A, 1995, BIOCHEM BIOPH RES CO, V211, P586, DOI 10.1006/bbrc.1995.1853; Takayama TK, 2001, BIOCHEMISTRY-US, V40, P15341, DOI 10.1021/bi015775e; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; YAMAGUCHI N, 2004, HDB PROTEOLYTIC ENZY, V2, P1595; YAMAGUCHI N, 2004, HDB PROTEOLYTIC ENZY, V2, P1585; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7; Yousef GM, 2000, J BIOL CHEM, V275, P11891, DOI 10.1074/jbc.275.16.11891; Yousef GM, 2000, BIOCHEM BIOPH RES CO, V276, P125, DOI 10.1006/bbrc.2000.3448; Yousef GM, 2002, TUMOR BIOL, V23, P185, DOI 10.1159/000064027; Yousef GM, 2002, BIOL CHEM, V383, P1045, DOI 10.1515/BC.2002.113; Yousef GM, 2003, CLIN BIOCHEM, V36, P443, DOI 10.1016/S0009-9120(03)00055-9; Yousef GM, 2003, THROMB HAEMOSTASIS, V90, P7, DOI 10.1055/s-0037-1613593; Yousef GM, 1999, ANTICANCER RES, V19, P2843; Yousef GM, 2001, J BIOL CHEM, V276, P53, DOI 10.1074/jbc.M005432200	86	137	142	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25678	25688		10.1074/jbc.M602372200	http://dx.doi.org/10.1074/jbc.M602372200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16740631	hybrid			2022-12-25	WOS:000240031300071
J	Hsieh, CF; Chang, BJ; Pai, CH; Chen, HY; Tsai, JW; Yi, YH; Chiang, YT; Wang, DW; Chi, S; Hsu, L; Lin, CH				Hsieh, Chia-Fen; Chang, Bo-Jui; Pai, Chyi-Huey; Chen, Hsuan-Yi; Tsai, Jin-Wu; Yi, Yung-Hsiang; Chiang, Yi-Ting; Wang, Da-Wei; Chi, Sien; Hsu, Long; Lin, Chi-Hung			Stepped changes of monovalent ligand-binding force during ligand-induced clustering of integrin alpha(IIB)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; PLATELET-AGGREGATION INHIBITOR; GLYCOPROTEIN IB-IX; RECOMBINANT RHODOSTOMIN; CALCIUM OSCILLATION; SIGNAL-TRANSDUCTION; AVIDITY REGULATION; ADHESION FORCE; CELL-ADHESION; OUTSIDE-IN	Recent evidence demonstrated that conformational changes of the integrin during receptor activation affected its binding to extracellular matrix; however, experimental assessment of ligand-receptor binding following the initial molecular interaction has rarely been carried out at a single-molecule resolution. In the present study, laser tweezers were used to measure the binding force exerted by a live Chinese hamster ovary cell that expressed integrin alpha(IIb)beta(3) (CHO alpha(IIb)beta(3)), to the bead carrier coated with the snake venom rhodostomin that served as an activated ligand for integrin alpha(IIb)beta(3). A progressive increase of total binding force over time was noticed when the bead interacted with the CHO alpha(IIb)beta(3) cell; such an increase was due mainly to the recruitment of more integrin molecules to the bead-cell interface. When the binding strength exerted by a single ligand-receptor pair was derived from the "polyvalent" measurements, surprisingly, a stepped decrease of the "monovalent binding force" was noted (from 4.15 to 2.54 piconewtons (pN)); such decrease appeared to occur during the ligand-induced integrin clustering process. On the other hand, the mutant rhodostomin defective in clustering integrins exhibited only one (1.81 pN) unit binding strength.	Natl Yang Ming Univ, Inst Biophoton Engn, Inst Microbiol & Immunol, Taipei, Taiwan; Natl Chiao Tung Univ, Dept Photon, Hsinchu, Taiwan; Natl Chiao Tung Univ, Inst Electroopt Engn, Hsinchu 30050, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Inst Sci Informat, Taipei 115, Taiwan; Natl Cent Univ, Dept Phys, Taoyuan, Taiwan; Yuan Ze Univ, Dept Elect Engn, Taoyuan, Taiwan; Natl Chiao Tung Univ, Dept Electrophys, Hsinchu 30050, Taiwan; Natl Yang Ming Univ, Inst Biophoton Engn, Taipei 112, Taiwan; Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan; Taipei City Hosp, Div Med Res, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Central University; Yuan Ze University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei City Hospital	Lin, CH (corresponding author), Natl Yang Ming Univ, Inst Biophoton Engn, Inst Microbiol & Immunol, Taipei, Taiwan.	linch@ym.edu.tw	Tsai, Jin W/A-6428-2009	Chang, Bo-Jui/0000-0002-5513-7106; Chi, Sien/0000-0002-8674-1963; Tsai, Jin-Wu/0000-0003-0135-759X				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; Arya M, 2005, BIOPHYS J, V88, P4391, DOI 10.1529/biophysj.104.046318; Arya M, 2003, J THROMB HAEMOST, V1, P1150, DOI 10.1046/j.1538-7836.2003.00295.x; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; CANTARERO LA, 1980, ANAL BIOCHEM, V105, P375, DOI 10.1016/0003-2697(80)90473-X; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chang CP, 2001, BIOCHEM J, V357, P57, DOI 10.1042/0264-6021:3570057; Chang HH, 1999, EXP CELL RES, V250, P387, DOI 10.1006/excr.1999.4547; Chang HH, 1997, TOXICON, V35, P195, DOI 10.1016/S0041-0101(96)00121-3; Chang HH, 1998, TOXICON, V36, P1087, DOI 10.1016/S0041-0101(98)00088-9; CHIANG HS, 1995, BRIT J CANCER, V71, P265, DOI 10.1038/bjc.1995.54; CLEVELAND WS, 1988, J ECONOMETRICS, V37, P87, DOI 10.1016/0304-4076(88)90077-2; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Gergely C, 2000, P NATL ACAD SCI USA, V97, P10802, DOI 10.1073/pnas.180293097; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; HUANG TF, 1987, BIOCHIM BIOPHYS ACTA, V925, P248, DOI 10.1016/0304-4165(87)90189-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KAUFMAN L, 1990, FINDING GROUPS DATA, P69; Larrucea S, 2002, BLOOD, V99, P2819, DOI 10.1182/blood.V99.8.2819; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; Mekrache M, 2002, BRIT J HAEMATOL, V116, P636, DOI 10.1046/j.0007-1048.2001.03332.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Payrastre B, 2000, BIOCHEM PHARMACOL, V60, P1069, DOI 10.1016/S0006-2952(00)00417-2; Sagvolden G, 1999, BIOPHYS J, V77, P526, DOI 10.1016/S0006-3495(99)76909-2; SHETZ MP, 1999, LASER TWEEZERS CELL, P1; Sun DS, 2005, J BIOMED SCI, V12, P321, DOI 10.1007/s11373-005-0979-6; SUNG KLP, 1993, BLOOD, V81, P419; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tsai JW, 2000, P SOC PHOTO-OPT INS, V4082, P213, DOI 10.1117/12.390549; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351	41	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25466	25474		10.1074/jbc.M601793200	http://dx.doi.org/10.1074/jbc.M601793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16793773	hybrid			2022-12-25	WOS:000240031300049
J	Jones, LL; Brophy, SE; Bankovich, AJ; Colf, LA; Hanick, NA; Garcia, KC; Kranz, DM				Jones, Lindsay L.; Brophy, Susan E.; Bankovich, Alexander J.; Colf, Leremy A.; Hanick, Nicole A.; Garcia, K. Christopher; Kranz, David M.			Engineering and characterization of a stabilized alpha 1/alpha 2 module of the class I major histocompatibility complex product L-d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; YEAST SURFACE-DISPLAY; SINGLE-CHAIN TRIMERS; HIGH-AFFINITY; DIRECTED EVOLUTION; MONOCLONAL-ANTIBODIES; PEPTIDE SPECIFICITY; MHC MOLECULES; ANTIGEN; CD8	The major histocompatibility complex (MHC) is the most polymorphic locus known, with thousands of allelic variants. There is considerable interest in understanding the diversity of structures and peptide-binding features represented by this class of proteins. Although many MHC proteins have been crystallized, others have not been amenable to structural or biochemical studies due to problems with expression or stability. In the present study, yeast display was used to engineer stabilizing mutations into the class I MHC molecule, L-d. The approach was based on previous studies that showed surface levels of yeast-displayed fusion proteins are directly correlated with protein stability. To engineer a more stable L-d, we selected L-d mutants with increased surface expression from randomly mutated yeast display libraries using anti-L-d antibodies or high affinity, soluble T-cell receptors (TCRs). The most stable L-d mutant, L-d-m31, consisted of a single-chain MHC module containing only the alpha 1 and alpha 2 domains. The enhanced stability was in part due to a single mutation (Trp-973 -> Arg), shown previously to be present in the allele L-q. Mutant Ld-m31 could bind to L-d peptides, and the specific peptide (.) L-d-m31 complex (QL9(.)L(d)-m31) was recognized by alloreactive TCR2C. A soluble form of the L-d-m31 protein was expressed in Escherichia coli and refolded from inclusion bodies at high yields. Surface plasmon resonance showed that TCRs bound to peptide(.)L(d)-m31 complexes with affinities similar to those of native full-length L-d. The TCR and QL9(.)L(d)-m31 formed complexes that could be resolved by native gel electrophoresis, suggesting that stabilized alpha 1/alpha 2 class I platforms may enable various structural studies.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of Illinois System; University of Illinois Urbana-Champaign; Stanford University	Kranz, DM (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	d-kranz@uiuc.edu		Jones, Lindsay/0000-0003-4360-6451; Bankovich, Alexander/0000-0003-2368-4479	NIAID NIH HHS [T32 AI007290, AI048540] Funding Source: Medline; NIGMS NIH HHS [GM55767] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI048540, R01AI048540, T32AI007290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055767] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; BECK JC, 1986, J IMMUNOL, V137, P916; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Boder ET, 2005, BIOTECHNOL BIOENG, V92, P485, DOI 10.1002/bit.20616; Brophy SE, 2003, J IMMUNOL METHODS, V272, P235, DOI 10.1016/S0022-1759(02)00439-8; Buonpane RA, 2005, J MOL BIOL, V353, P308, DOI 10.1016/j.jmb.2005.08.041; Burrows GG, 1999, PROTEIN ENG, V12, P771, DOI 10.1093/protein/12.9.771; Chang JW, 2001, J BIOL CHEM, V276, P24170, DOI 10.1074/jbc.M101808200; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; Cull MG, 2000, METHOD ENZYMOL, V326, P430; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; DOWER SK, 1985, J IMMUNOL, V134, P431; Esteban O, 2004, J MOL BIOL, V340, P81, DOI 10.1016/j.jmb.2004.04.054; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hansen NJV, 2001, EUR J IMMUNOL, V31, P32, DOI 10.1002/1521-4141(200101)31:1<32::AID-IMMU32>3.0.CO;2-6; Hansen T, 2000, IMMUNOL TODAY, V21, P83, DOI 10.1016/S0167-5699(98)01426-1; Hansen TH, 2006, CANCER IMMUNOL IMMUN, V55, P235, DOI 10.1007/s00262-005-0091-9; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Holman PO, 2005, J IMMUNOL, V174, P3986, DOI 10.4049/jimmunol.174.7.3986; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kieke MC, 1999, P NATL ACAD SCI USA, V96, P5651, DOI 10.1073/pnas.96.10.5651; Kulski JK, 2002, IMMUNOL REV, V190, P95, DOI 10.1034/j.1600-065X.2002.19008.x; Kurokawa MS, 2002, IMMUNOL LETT, V80, P163, DOI 10.1016/S0165-2478(01)00325-X; Le Doussal JM, 2000, J IMMUNOL METHODS, V241, P147, DOI 10.1016/S0022-1759(00)00211-8; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; Lybarger L, 2003, J BIOL CHEM, V278, P27105, DOI 10.1074/jbc.M303716200; MAGE MG, 1992, P NATL ACAD SCI USA, V89, P10658, DOI 10.1073/pnas.89.22.10658; Maile R, 2005, J IMMUNOL, V174, P619, DOI 10.4049/jimmunol.174.2.619; Mason PM, 1998, TISSUE ANTIGENS, V51, P417; Maynard J, 2005, J IMMUNOL METHODS, V306, P51, DOI 10.1016/j.jim.2005.07.022; Maynard J, 2005, IMMUNITY, V22, P81, DOI 10.1016/j.immuni.2004.11.015; MOTTEZ E, 1995, J EXP MED, V181, P493, DOI 10.1084/jem.181.2.493; MOTTEZ E, 1991, EUR J IMMUNOL, V21, P467, DOI 10.1002/eji.1830210232; OZATO K, 1980, J IMMUNOL, V125, P2473; POTTER TA, 1981, J IMMUNOL, V127, P580; Reche PA, 2003, J MOL BIOL, V331, P623, DOI 10.1016/S0022-2836(03)00750-2; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; Smith RA, 2002, J IMMUNOL, V169, P3105, DOI 10.4049/jimmunol.169.6.3105; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; Starwalt SE, 2003, PROTEIN ENG, V16, P147, DOI 10.1093/proeng/gzg018; Stones JD, 2006, J IMMUNOL, V176, P1498, DOI 10.4049/jimmunol.176.3.1498; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Vukmanovic S, 2003, TRENDS MOL MED, V9, P139, DOI 10.1016/S1471-4914(03)00029-7; Weber KS, 2005, P NATL ACAD SCI USA, V102, P19033, DOI 10.1073/pnas.0507554102; Wooldridge L, 2005, J BIOL CHEM, V280, P27491, DOI 10.1074/jbc.M500555200; Yu YYL, 2002, J IMMUNOL, V168, P3145, DOI 10.4049/jimmunol.168.7.3145	59	42	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25734	25744		10.1074/jbc.M604343200	http://dx.doi.org/10.1074/jbc.M604343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815841	hybrid			2022-12-25	WOS:000240031300076
J	Li, H; Xu, DK; Li, JH; Berndt, MC; Liu, JP				Li, He; Xu, Dakang; Li, Jinhua; Berndt, Michael C.; Liu, Jun-Ping			Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; BREAST-CANCER CELLS; TGF-BETA; CATALYTIC SUBUNIT; SIGNALING PATHWAY; LYMPHOBLASTIC-LEUKEMIA; TARGETED DISRUPTION; DIRECT ACTIVATION; STEM-CELLS; DIFFERENTIATION	Telomerase underpins stem cell renewal and proliferation and is required for most neoplasia. Recent studies suggest that hormones and growth factors play physiological roles in regulating telomerase activity. In this report we show a rapid repression of the telomerase reverse transcriptase ( TERT) gene by transforming growth factor beta(TGF-beta) in normal and neoplastic cells by a mechanism depending on the intracellular signaling protein Smad3. In human breast cancer cells TGF-beta induces rapid entry of Smad3 into the nucleus where it binds to the TERT gene promoter and represses TERT gene transcription. Silencing Smad3 gene expression or genetically deleting the Smad3 gene disrupts TGF-beta repression of TERT gene expression. Expression of the Smad3 antagonist, Smad7, also interrupts TGF-beta-mediated Smad3-induced repression of the TERT gene. Mutational analysis identified the Smad3 site on the TERT gene promoter, mediating TERT repression. In response to TGF-beta, Smad3 binds to c-Myc; knocking down c-Myc, Smad3 does not bind to the TERT gene, suggesting that c-Myc recruits Smad3 to the TERT promoter. Thus, TGF-beta negatively regulates telomerase activity via Smad3 interactions with c-Myc and the TERT gene promoter. Modifying the interaction between Smad3 and TERT gene may, thus, lead to novel strategies to regulate telomerase.	Monash Univ, Dept Immunol, Melbourne, Vic 3181, Australia; Monash Univ, Monash Inst Med Res, Melbourne, Vic 3181, Australia	Monash University; Monash University	Liu, JP (corresponding author), Monash Univ Sch Med, AMREP, Dept Immunol, Commercial Rd, Prahran, Vic 3181, Australia.	jun-ping.liu@med.monash.edu.au	Berndt, Michael C/D-5580-2012; Liu, Jun-Ping/AAA-5521-2020; Li, Jinhua/I-2741-2014	Liu, Jun-Ping/0000-0001-7442-2116; Li, Jinhua/0000-0003-4039-5759; Xu, Dakang/0000-0003-2415-4920				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Armstrong L, 2005, STEM CELLS, V23, P516, DOI 10.1634/stemcells.2004-0269; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Budiyanto A, 2003, J INVEST DERMATOL, V121, P1088, DOI 10.1046/j.1523-1747.2003.12529.x; Cerezo A, 2002, J CELL SCI, V115, P1305; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chiang YJ, 2004, MOL CELL BIOL, V24, P7024, DOI 10.1128/MCB.24.16.7024-7031.2004; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Debacq-Chainlaux F, 2005, J CELL SCI, V118, P743, DOI 10.1242/jcs.01651; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Downing JR, 2004, NEW ENGL J MED, V351, P528, DOI 10.1056/NEJMp048121; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ebisui O, 1999, J HYPERTENS, V17, P1535, DOI 10.1097/00004872-199917110-00005; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Hahn WC, 2005, CURR MOL MED, V5, P227, DOI 10.2174/1566524053586572; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Hu B, 2006, ONCOGENE, V25, P1030, DOI 10.1038/sj.onc.1209140; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Li H, 2005, J NEUROCHEM, V95, P891, DOI 10.1111/j.1471-4159.2005.03439.x; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Nosek J, 2005, J BIOL CHEM, V280, P10840, DOI 10.1074/jbc.M409295200; Prior RL, 2002, FASEB J, V16, pA1009; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Vijayachandra K, 2003, CANCER RES, V63, P3447; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yago M, 2002, FEBS LETT, V520, P40, DOI 10.1016/S0014-5793(02)02757-6; Yang H, 2001, CELL GROWTH DIFFER, V12, P119; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	66	102	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25588	25600		10.1074/jbc.M602381200	http://dx.doi.org/10.1074/jbc.M602381200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16785237	hybrid			2022-12-25	WOS:000240031300062
J	Schaaf, G; Honsbein, A; Meda, AR; Kirchner, S; Wipf, D; von Wiren, N				Schaaf, Gabriel; Honsbein, Annegret; Meda, Anderson R.; Kirchner, Silvia; Wipf, Daniel; von Wiren, Nicolaus			AtIREG2 encodes a tonoplast transport protein involved in iron-dependent nickel detoxification in Arabidopsis thaliana roots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; METAL TRANSPORTER; CONFERRING RESISTANCE; PLANT TRANSFORMATION; YEAST; CLONING; DEFICIENCY; EXPRESSION; FAMILY; ACCUMULATION	dIron acquisition in Arabidopsis depends mainly on AtIRT1, a Fe2+ transporter in the plasma membrane of root cells. However, substrate specificity of AtIRT1 is low, leading to an excess accumulation of other transition metals in iron-deficient plants. In the present study we describe AtIREG2 as a nickel transporter at the vacuolar membrane that counterbalances the low substrate specificity of AtIRT1 and possibly other iron transport systems in iron-deficient root cells. AtIREG2 is co-regulated with AtIRT1 by the transcription factor FRU/FIT1, encodes a membrane protein, which has 10 putative transmembrane domains and shares homology with vertebrate Fe2+ exporters. Heterologous expression of AtIREG2 in various yeast mutants, however, did not demonstrate an iron transport function. Instead, expression in wild-type and nickel-sensitive cot1 yeast cells conferred enhanced tolerance to elevated concentrations of nickel at acidic pH. A role in vacuolar substrate transport was further supported by localization of AtIREG2-GFP fusion proteins to the tonoplast in Arabidopsis suspension cells and root cells of intact plants. Transgenic plants overexpressing AtIREG2 showed an increased tolerance to elevated concentrations of nickel, whereas T-DNA insertion lines lacking AtIREG2 expression were more sensitive to nickel, particularly under iron deficiency, and accumulated less nickel in roots. We therefore propose a role of AtIREG2 in vacuolar loading of nickel under iron deficiency and thus identify it as a novel component in the iron deficiency stress response.	Univ Hohenheim, Inst Pflanzenernahrung, D-70593 Stuttgart, Germany; Univ Bonn, Inst Zellulare & Mol Bot, D-53115 Bonn, Germany	University Hohenheim; University of Bonn	von Wiren, N (corresponding author), Univ Hohenheim, Inst Pflanzenernahrung, Postfach 700562, D-70593 Stuttgart, Germany.	vonwiren@uni-hohenheim.de	Schaaf, Gabriel/F-1956-2014	Schaaf, Gabriel/0000-0001-9022-4515; Wipf, Daniel/0000-0001-7197-5612; von Wiren, Nicolaus/0000-0002-4966-425X				AGARWALA SC, 1977, CAN J BOT, V55, P1299, DOI 10.1139/b77-151; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Cheng NH, 2003, J BIOL CHEM, V278, P6503, DOI 10.1074/jbc.M210883200; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cohen CK, 1998, PLANT PHYSIOL, V116, P1063, DOI 10.1104/pp.116.3.1063; Colangelo EP, 2004, PLANT CELL, V16, P3400, DOI 10.1105/tpc.104.024315; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; CROOKE WM, 1954, ANN APPL BIOL, V41, P311, DOI 10.1111/j.1744-7348.1954.tb01124.x; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Fontes RLF, 1998, J PLANT NUTR, V21, P1723, DOI 10.1080/01904169809365517; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Jakoby M, 2004, FEBS LETT, V577, P528, DOI 10.1016/j.febslet.2004.10.062; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Kim S, 2005, PLANT CELL PHYSIOL, V46, P1809, DOI 10.1093/pcp/pci196; Kukier U, 2001, J ENVIRON QUAL, V30, P1949, DOI 10.2134/jeq2001.1949; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liu LH, 2003, PLANT CELL, V15, P790, DOI 10.1105/tpc.007120; Loque D, 2005, PLANT PHYSIOL, V137, P671, DOI 10.1104/pp.104.051268; Marschner H., 1995, MINERAL NUTR HIGHER, P313, DOI DOI 10.1016/B978-012473542-2/50011-0; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2004, PFLUG ARCH EUR J PHY, V447, P801, DOI 10.1007/s00424-003-1102-3; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; Pianelli K, 2005, TRANSGENIC RES, V14, P739, DOI 10.1007/s11248-005-7159-3; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAAF G, 2005, PLANT CELL PHYSL, V46, P672; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; Takano J, 2005, P NATL ACAD SCI USA, V102, P12276, DOI 10.1073/pnas.0502060102; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; Vacchina V, 2003, ANAL CHEM, V75, P2740, DOI 10.1021/ac020704m; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Vert GA, 2003, PLANT PHYSIOL, V132, P796, DOI 10.1104/pp.102.016089; VONWIREN N, 1994, PLANT PHYSIOL, V106, P71, DOI 10.1104/pp.106.1.71	44	157	164	4	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25532	25540		10.1074/jbc.M601062200	http://dx.doi.org/10.1074/jbc.M601062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16790430	hybrid			2022-12-25	WOS:000240031300056
J	Clark, SJ; Higman, VA; Mulloy, B; Perkins, SJ; Lea, SM; Sim, RB; Day, AJ				Clark, Simon J.; Higman, Victoria A.; Mulloy, Barbara; Perkins, Stephen J.; Lea, Susan M.; Sim, Robert B.; Day, Anthony J.			His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; BOUND C3B; SULFATE; IDENTIFICATION; POLYMORPHISM; PROTEIN; COMMON; MEMBRANE	A polymorphism in complement factor H has recently been associated with age-related macular degeneration (AMD), the leading cause of blindness in the elderly. A histidine rather than a tyrosine at residue position 384 in the mature protein increases the risk of AMD. Here, using a recombinant construct, we show that amino acid 384 is adjacent to a heparin-binding site in CCP7 of factor H and demonstrate that the allotypic variants differentially recognize heparin. This functional alteration may affect binding of factor H to polyanionic patterns on host surfaces, potentially influencing complement activation, immune complex clearance, and inflammation in the macula of AMD patients.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England; Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of Manchester; University of Oxford; University of Oxford; National Institute for Biological Standards & Control; University of London; University College London	Day, AJ (corresponding author), Univ Manchester, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	anthony.day@manchester.ac.uk	Sim, Bob/A-1354-2008; Lea, Susan M/B-7678-2009; Day, Anthony/O-1658-2015; Higman, Victoria/H-3795-2011	Sim, Bob/0000-0002-2855-7455; Lea, Susan M/0000-0001-9287-8053; Day, Anthony/0000-0002-1415-3134; Higman, Victoria/0000-0002-3204-2665; Clark, Simon/0000-0001-8394-8355	Medical Research Council [MC_U138274352] Funding Source: Medline; MRC [MC_U138274352] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126; Carrino DA, 2003, J BIOL CHEM, V278, P17566, DOI 10.1074/jbc.M300124200; Cavallotti C, 2004, OPHTHALMIC RES, V36, P211, DOI 10.1159/000078779; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Girardin EP, 2005, J BIOL CHEM, V280, P38059, DOI 10.1074/jbc.M507997200; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86; Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021; Lauder RM, 1998, BIOCHEM J, V330, P753; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Mahoney DJ, 2004, ANAL BIOCHEM, V330, P123, DOI 10.1016/j.ab.2004.03.055; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6; Mulloy B, 2000, THROMB HAEMOSTASIS, V84, P1052; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Saito A, 2005, J BIOCHEM, V137, P225, DOI 10.1093/jb/mvi025; SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205; SIM RB, 1993, METHOD ENZYMOL, V223, P13; THOMAS DP, 1984, THROMB HAEMOSTASIS, V52, P148; White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604	44	148	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24713	24720		10.1074/jbc.M605083200	http://dx.doi.org/10.1074/jbc.M605083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787919	hybrid			2022-12-25	WOS:000239847800067
J	Dai, MS; Shi, DD; Jin, YT; Sun, XX; Zhang, YP; Grossman, SR; Lu, H				Dai, Mu-Shui; Shi, Dingding; Jin, Yetao; Sun, Xiao-Xin; Zhang, Yanping; Grossman, Steven R.; Lu, Hua			Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; AUTOREGULATORY FEEDBACK LOOP; DNA-DAMAGE; ONCOPROTEIN MDM2; P53-MDM2 INTERACTION; GENE AMPLIFICATION; LIGASE ACTIVITY; GROWTH-CONTROL; CELL-CYCLE; IN-VIVO	Inhibition of the MDM2-p53 feedback loop is critical for p53 activation in response to cellular stresses. The ribosomal proteins L5, L11, and L23 can block this loop by inhibiting MDM2-mediated p53 ubiquitination and degradation in response to ribosomal stress. Here, we show that L11, but not L5 and L23, leads to a drastic accumulation of ubiquitinated and native MDM2. This effect is dependent on the ubiquitin ligase activity of MDM2, but not p53, and requires the central MDM2 binding domain ( residues 51-108) of L11. We further show that L11 inhibited 26 S proteasome-mediated degradation of ubiquitinated MDM2 in vitro and consistently prolonged the half-life of MDM2 in cells. These results suggest that L11, unlike L5 and L23, differentially regulates the levels of ubiquitinated p53 and MDM2 and inhibits the turnover and activity of MDM2 through a post-ubiquitination mechanism.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Sch Med, Portland, OR 97239 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	Oregon Health & Science University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of North Carolina; University of North Carolina Chapel Hill	Lu, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Sch Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	luh@ohsu.edu			NCI NIH HHS [R01 CA100302, R01 CA095441, CA107532, CA93614, R01 CA093614, R01 CA107532, CA095441, CA079721, R01 CA079721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100302, R01CA107532, R01CA093614, R01CA079721, R01CA095441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chene P, 2004, MOL CANCER RES, V2, P20; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; CORDONCARDO C, 1994, CANCER RES, V54, P794; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Deb SP, 2003, MOL CANCER RES, V1, P1009; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Dworakowska D, 2004, LUNG CANCER, V43, P285, DOI 10.1016/j.lungcan.2003.09.010; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moss T, 2004, CURR OPIN GENET DEV, V14, P210, DOI 10.1016/j.gde.2004.02.005; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	57	91	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24304	24313		10.1074/jbc.M602596200	http://dx.doi.org/10.1074/jbc.M602596200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803902	hybrid, Green Submitted, Green Accepted			2022-12-25	WOS:000239847800023
J	Flemming, D; Hellwig, P; Lepper, S; Kloer, DP; Friedrich, T				Flemming, Dirk; Hellwig, Petra; Lepper, Simone; Kloer, Daniel P.; Friedrich, Thorsten			Catalytic importance of acidic amino acids on subunit NuoB of the Escherichia coli NADH: Ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; PROTON-TRANSLOCATING NADH; RESPIRATORY-CHAIN; YARROWIA-LIPOLYTICA; PARACOCCUS-DENITRIFICANS; QUINONE OXIDOREDUCTASE; CONFORMATION-DRIVEN; MODULAR EVOLUTION; 49-KDA SUBUNIT; CYTOCHROME-C	The NADH:ubiquinone oxidoreductase (complex I) from Escherichia coli is composed of 13 subunits called NuoA through NuoN and contains one FMN and 9 iron-sulfur clusters as redox groups. Electron transfer from NADH to ubiquinone is coupled with the translocation of protons across the membrane by a yet unknown mechanism. Redox-induced Fourier transform infrared difference spectroscopy showed that the oxidation of iron-sulfur cluster N2 located on NuoB is accompanied by the protonation of acidic amino acid(s). Here, we describe the effect of mutating the conserved acidic amino acids on NuoB. The complex was assembled in all mutants but the electron transfer activity was completely abolished in the mutants E67Q, D77N, and D94N. The complex isolated from these mutants contained N2 although in diminished amounts. The protonation of acidic amino acid(s) coupled with the oxidation of N2 was not detectable in the complex from the mutant E67Q. However, the conservative mutations E67D and D77E did not disturb the enzymatic activity, and the signals because of the protonation of acidic amino acid(s) were detectable in the E67D mutant. We discuss the possible participation of Glu(67) in a proton pathway coupled with the redox reaction of N2.	Univ Freiburg, Inst Org Chem & Biochem, D-79104 Freiburg, Germany; Univ Strasbourg 1, Lab Electrochim, UMR7177 LC3, Inst Chim, F-67000 Strasbourg, France	University of Freiburg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Friedrich, T (corresponding author), Univ Freiburg, Inst Org Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	tfriedri@uni-freiburg.de	Flemming, Dirk/AAP-3274-2021	hellwig, petra/0000-0001-6294-5163				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; Bertsova YV, 2004, FEBS LETT, V563, P207, DOI 10.1016/S0014-5793(04)00312-6; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P1; Flemming D, 2005, J MOL MICROB BIOTECH, V10, P208, DOI 10.1159/000091566; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Flemming D, 2003, J BIOL CHEM, V278, P3055, DOI 10.1074/jbc.M208849200; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Grgic L, 2004, J BIOL CHEM, V279, P21193, DOI 10.1074/jbc.M313180200; Gurrath M, 2004, PROTEINS, V56, P556, DOI 10.1002/prot.20155; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hellwig P, 1998, BIOCHEMISTRY-US, V37, P7390, DOI 10.1021/bi9725576; Hellwig P, 2000, BIOCHEMISTRY-US, V39, P10884, DOI 10.1021/bi000842a; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Marshall D, 2006, BIOCHEMISTRY-US, V45, P5458, DOI 10.1021/bi052561e; Mathiesen C, 2003, FEBS LETT, V549, P7, DOI 10.1016/S0014-5793(03)00767-1; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Nakamaru-Ogiso E, 2005, J BIOL CHEM, V280, P301, DOI 10.1074/jbc.M410377200; OHNISHI T, 1985, J BIOL CHEM, V260, P2782; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Ohnishi T, 2005, FEBS LETT, V579, P4555, DOI 10.1016/j.febslet.2005.06.086; Ohnishi T, 2005, FEBS LETT, V579, P500, DOI 10.1016/j.febslet.2004.11.107; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Stolpe S, 2004, J BIOL CHEM, V279, P18377, DOI 10.1074/jbc.M311242200; TOWBIN H, 1979, P NATL ACAD SCI USA, V1320, P217; Uhlmann M, 2005, BIOCHEMISTRY-US, V44, P1653, DOI 10.1021/bi048136n; vanBelzen R, 1997, BIOCHEMISTRY-US, V36, P886, DOI 10.1021/bi9612982; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yano T, 2005, BIOCHEMISTRY-US, V44, P1744, DOI 10.1021/bi048132i; Yano T, 2003, J BIOL CHEM, V278, P15514, DOI 10.1074/jbc.M212275200; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	51	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24781	24789		10.1074/jbc.M602499200	http://dx.doi.org/10.1074/jbc.M602499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807239	hybrid			2022-12-25	WOS:000239847800074
J	Song, M; Balakrishnan, M; Chen, Y; Roques, BP; Bambara, RA				Song, Min; Balakrishnan, Mini; Chen, Yan; Roques, Bernard P.; Bambara, Robert A.			Stimulation of HIV-1 minus strand strong stop DNA transfer by genomic sequences 3 ' of the primer binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 NUCLEOCAPSID PROTEIN; ACID-CHAPERONE ACTIVITY; RNA SECONDARY STRUCTURE; ZINC-FINGER STRUCTURES; REVERSE-TRANSCRIPTASE; LEADER RNA; IN-VITRO; CONFORMATIONAL-CHANGES; INVASION MECHANISM; INFECTED-CELLS	The mechanism of human immunodeficiency virus 1 ( HIV-1) minus strand transfer was examined using a genomic RNA sequence-based donor-acceptor template system. The donor RNA, D199, was a 199- nucleotide sequence from the 5'-end of the genome to the primer binding site ( PBS) and shared 97 nucleotides of homology with the acceptor RNA. To investigate the influence of RNA structure on transfer, a second donor RNA, D520, was generated by extending the 3'-end of D199 to include an additional 321 nucleotides of the genome. The position of priming, length of homology with the acceptor, and length of cDNA synthesized were identical with the two donors. Interestingly, at 200% NC coating, donor D520 yielded a transfer efficiency of about 75% compared with about 35% with D199. A large proportion of the D520 promoted transfers occurred after the donor RNA was copied to the end. Analysis of donor RNA cleavage, the acceptor invasion site and R homology requirements indicated that transfers with D520 involved a similar but more efficient acceptor invasion mechanism compared with D199. RNA structure probing by RNase T1 and the RT pause profile during synthesis indicated conformational differences between D199 and D520 in the starting structure, and in dynamic structures formed during synthesis within the R region. Overall observations suggest that regions 3' of the primer binding site influence the conformation of the R region of D520 to facilitate steps that promote strand transfer.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA; CNRS, UMR 8600, Fac Pharm, INSERM,U266,Dept Pharmacochim Mol & Struct, F-75270 Paris, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	Robert_bambara@urmc.rochester.edu	so, strawberry/F-6515-2012		NIGMS NIH HHS [GM 049573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Berkhout B, 2002, J BIOL CHEM, V277, P19967, DOI 10.1074/jbc.M200950200; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Chen Y, 2005, J BIOL CHEM, V280, P14443, DOI 10.1074/jbc.M412190200; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Cui Y, 1999, J VIROL, V73, P6171, DOI 10.1128/JVI.73.7.6171-6176.1999; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; Das AT, 1998, J VIROL, V72, P9217, DOI 10.1128/JVI.72.11.9217-9223.1998; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Harrich D, 2000, J VIROL, V74, P5639, DOI 10.1128/JVI.74.12.5639-5646.2000; Heath MJ, 2005, BIOCHEMISTRY-US, V44, P3915, DOI 10.1021/bi0477945; Heilman-Miller SL, 2004, J BIOL CHEM, V279, P44154, DOI 10.1074/jbc.M401646200; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Lanciault C, 2005, J BIOL CHEM, V280, P2413, DOI 10.1074/jbc.M410718200; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6; Lodmell JS, 2001, J MOL BIOL, V311, P475, DOI 10.1006/jmbi.2001.4879; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Ooms M, 2004, NUCLEIC ACIDS RES, V32, P819, DOI 10.1093/nar/gkh206; Paillart JC, 2004, J BIOL CHEM, V279, P48397, DOI 10.1074/jbc.M408294200; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Sakuragi J, 2003, J VIROL, V77, P4060, DOI 10.1128/JVI.77.7.4060-4069.2003; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Telesnitsky A., 1997, P121; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Topping R, 1998, J MOL BIOL, V281, P1, DOI 10.1006/jmbi.1998.1929; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; VARMUS H, 1989, MOBILE DNA, P53; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; YOU JC, 1994, J BIOL CHEM, V269, P31491	55	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24227	24235		10.1074/jbc.M603097200	http://dx.doi.org/10.1074/jbc.M603097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16782713	hybrid			2022-12-25	WOS:000239847800016
J	Yan, P; Hu, XY; Song, HW; Yin, KJ; Bateman, RJ; Cirrito, JR; Xiao, QL; Hsu, FF; Turk, JW; Xu, J; Hsu, CY; Holtzman, DM; Lee, JM				Yan, Ping; Hu, Xiaoyan; Song, Haowei; Yin, Kejie; Bateman, Randall J.; Cirrito, John R.; Xiao, Qingli; Hsu, Fong F.; Turk, John W.; Xu, Jan; Hsu, Chung Y.; Holtzman, David M.; Lee, Jin-Moo			Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-CONVERTING ENZYME; FOCAL CEREBRAL-ISCHEMIA; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; A-BETA; MATRIX METALLOPROTEINASES; SENILE PLAQUES; GELATINASE-B; MULTIPLE-SCLEROSIS; SPINAL-CORD	The pathological hallmark of Alzheimer disease is the senile plaque principally composed of tightly aggregated amyloid-beta fibrils (fA beta), which are thought to be resistant to degradation and clearance. In this study, we explored whether proteases capable of degrading soluble A beta (sA beta) could degrade fA beta as well. We demonstrate that matrix metalloproteinase-9 (MMP-9) can degrade fA beta and that this ability is not shared by other sA beta-degrading enzymes examined, including endothelin-converting enzyme, insulin-degrading enzyme, and neprilysin. fA beta was decreased in samples incubated with MMP-9compared with other proteases, assessed using thioflavin-T. Furthermore, fA beta breakdown with MMP-9 but not with other proteases was demonstrated by transmission electron microscopy. Proteolytic digests of purified fA beta were analyzed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry to identify sites of A beta that are cleaved during its degradation. Only MMP-9 digests contained fragments (A beta(1-20) and A beta(1-30)) from fA beta(1-42) substrate; the corresponding cleavage sites are thought to be important for beta-pleated sheet formation. To determine whether MMP-9 can degrade plaques formed in vivo, fresh brain slices from aged APP/PS1 mice were incubated with proteases. MMP-9 digestion resulted in a decrease in thioflavin-S (ThS) staining. Consistent with a role for endogenous MMP-9 in this process in vivo, MMP-9 immunoreactivity was detected in astrocytes surrounding amyloid plaques in the brains of aged APP/PS1 and APPsw mice, and increased MMP activity was selectively observed in compact ThS-positive plaques. These findings suggest that MMP-9 can degrade fA beta and may contribute to ongoing clearance of plaques from amyloid-laden brains.	Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Hope Ctr Neurol Disorders, Sch Med, St Louis, MO 63110 USA; Washington Univ, Div Endocrinol Diabet Metab & Lipid Res, Dept Internal Med, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, Sch Med, St Louis, MO 63110 USA; Taipei Med Univ, Taipei, Taiwan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Taipei Medical University	Lee, JM (corresponding author), Washington Univ, Dept Neurol, Sch Med, 660 S Euclid Ave,Campus Box 8111, St Louis, MO 63110 USA.	leejm@neuro.wustl.edu	; Lee, Jin-Moo/K-2024-2015	Yin, Ke-Jie/0000-0002-7169-3858; Lee, Jin-Moo/0000-0002-3979-0906; Hsu, Chung Y./0000-0002-5632-2733; Hsu, Fong-Fu/0000-0001-5368-0183; Bateman, Randall/0000-0002-7729-1702	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013956, K08AG027091, R37AG013956] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR00954] Funding Source: Medline; NIA NIH HHS [K08 AG027091-01, AG13956, L30 AG024455-01, K08 AG027091, L30 AG024455] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341, P30 DK056341-06, P30 DK056341-05S2, P30-DK56341, P60-DK20579] Funding Source: Medline; NINDS NIH HHS [NS048283] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0; Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Betsuyaku T, 2000, AM J PATHOL, V157, P525, DOI 10.1016/S0002-9440(10)64563-4; Bond JP, 2003, J STRUCT BIOL, V141, P156, DOI 10.1016/S1047-8477(02)00625-1; Christie RH, 2001, J NEUROSCI, V21, P858, DOI 10.1523/JNEUROSCI.21-03-00858.2001; Cruz L, 1997, P NATL ACAD SCI USA, V94, P7612, DOI 10.1073/pnas.94.14.7612; Deb S, 2003, BRAIN RES, V970, P205, DOI 10.1016/S0006-8993(03)02344-8; Dubois B, 1999, ACTA NEUROL BELG, V99, P53; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Goussev S, 2003, J NEUROSURG, V99, P188, DOI 10.3171/spi.2003.99.2.0188; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; Iannone F, 2003, J RHEUMATOL, V30, P2294; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kelly EA, 2003, CURR OPIN PULM MED, V9, P28, DOI 10.1097/00063198-200301000-00005; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; LeVine H, 1997, ARCH BIOCHEM BIOPHYS, V342, P306, DOI 10.1006/abbi.1997.0137; Liu RT, 2004, J NEUROSCI RES, V75, P162, DOI 10.1002/jnr.10859; Lorenzl S, 2003, J NEUROL SCI, V207, P71, DOI 10.1016/S0022-510X(02)00398-2; Lorenzo A, 1996, ANN NY ACAD SCI, V777, P89, DOI 10.1111/j.1749-6632.1996.tb34406.x; Maier CM, 2004, STROKE, V35, P1169, DOI 10.1161/01.STR.0000125861.55804.f2; McGeer E G, 2001, Mol Interv, V1, P22; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SHIRAHAMA T, 1967, J CELL BIOL, V33, P679, DOI 10.1083/jcb.33.3.679; Shivaprasad S, 2004, BIOCHEMISTRY-US, V43, P15310, DOI 10.1021/bi048019s; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Sun AY, 2002, J HISTOCHEM CYTOCHEM, V50, P463, DOI 10.1177/002215540205000403; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Thal DR, 1998, NEUROBIOL AGING, V19, P517, DOI 10.1016/S0197-4580(98)00090-6; Tucker HM, 2000, J NEUROSCI, V20, P3937; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yan P, 1999, J NEUROSCI, V19, P9355; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Zhang X, 2004, NEUROSCI LETT, V356, P140, DOI 10.1016/j.neulet.2003.10.084	58	271	275	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24566	24574		10.1074/jbc.M602440200	http://dx.doi.org/10.1074/jbc.M602440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787929	hybrid			2022-12-25	WOS:000239847800052
J	Yoda, A; Xu, XZ; Onishi, N; Toyoshima, K; Fujimoto, H; Kato, N; Oishi, I; Kondo, T; Minami, Y				Yoda, Akinori; Xu, Xiao Zhou; Onishi, Nobuyuki; Toyoshima, Kyoko; Fujimoto, Hiroko; Kato, Naoko; Oishi, Isao; Kondo, Takeshi; Minami, Yasuhiro			Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; TUMOR-SUPPRESSOR; THREONINE-68 PHOSPHORYLATION; GENOMIC INSTABILITY; IONIZING-RADIATION; PPM1D; ACTIVATION; APOPTOSIS; CDS1	The anti-oncogenic Chk2 kinase plays a crucial role in DNA damage-induced cell cycle checkpoint regulation. Recently, we have shown that Chk2 associates with the oncogenic Wip1 (PPM1D) phosphatase and that Wip1 acts as a negative regulator of Chk2 during DNA damage response by dephosphorylating phosphorylated Thr-68 in activated Chk2 (Fujimoto, H., Onishi, N., Kato, N., Takekawa, M., Xu, X. Z., Kosugi, A., Kondo, T., Imamura, M., Oishi, I., Yoda, A., and Minami, Y. (2006) Cell Death Differ. 13, 1170 - 1180). Here, we performed structure-function analyses of Chk2 and Wip1 by using a series of deletion or amino acid-substituted mutant proteins of Chk2 and Wip1. We show that nuclear localization of both Chk2 and Wip1 is required for their association in cultured cells and that the serine-glutamine(SQ)/threonine-glutamine (TQ) domain of Chk2, containing Thr-68, and the N-terminal domain of Wip1, comprising about 100 amino acids, are necessary and sufficient for the association of both molecules. However, it was found that an intrinsic kinase activity of Chk2, but not phosphatase activity of Wip1, is required for the association of full-length Chk2 and Wip1. Interestingly, we also show that the mutant Wip1 proteins, bearing the N-terminal domain of Wip1 alone or lacking an intrinsic phosphatase activity, exhibit dominant negative effects on the functions of the wild-type Wip1, i.e. ectopic expression of either of these Wip1 mutants inhibits dephosphorylation of Thr-68 in Chk2 by Wip1 and anti-apoptotic function of Wip1. These results provide a molecular basis for developing novel anti-cancer drugs, targeting oncogenic Wip1 phosphatase.	Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Kobe University; Hokkaido University	Minami, Y (corresponding author), Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci,Chuo Ku, 7-5-1,Kusunokicho, Kobe, Hyogo 6500017, Japan.	minami@kobe-u.ac.jp	ONISHI, Nobuyuki/L-6296-2013; Oishi, Isao/L-8639-2018; Kondo, Takeshi/G-2103-2012	Oishi, Isao/0000-0003-3682-5349; Kondo, Takeshi/0000-0001-7455-5824				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Kato N, 2004, CELL DEATH DIFFER, V11, pS153, DOI 10.1038/sj.cdd.4401461; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; Oishi I, 2001, MOL CELL BIOL, V21, P1329, DOI 10.1128/MCB.21.4.1329-1335.2001; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shieh SY, 2000, GENE DEV, V14, P289; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zannini L, 2003, J BIOL CHEM, V278, P42346, DOI 10.1074/jbc.M303304200	59	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24847	24862		10.1074/jbc.M600403200	http://dx.doi.org/10.1074/jbc.M600403200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798742	hybrid			2022-12-25	WOS:000239847800079
J	Li, WQ; Miller, WT				Li, Wanqing; Miller, W. Todd			Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DOMAIN; AUTOPHOSPHORYLATION; INHIBITION; SPECIFICITY; MUTATIONS; CANCER; IGF-1	The tyrosine kinase activity of insulin-like growth factor I receptor (IGF1R) is under tight control. Ligand binding to the extracellular portion of IGF1R stimulates autophosphorylation at three sites (Tyr(1131), Tyr(1135), and Tyr(1136)) in the activation loop within the tyrosine kinase catalytic domain. Autophosphorylation at all three sites is required for maximum enzyme activity, and for IGF1-stimulated cellular activity of the receptor. Previous studies have not clarified the contributions of the individual tyrosines to enzymatic activation. Here, we produced single Tyr-to-Phe mutations at these positions, and compared activities of the purified kinase domains (unphosphorylated and phosphorylated) with wild-type IGF1R. Rates of autophosphorylation of the three mutants were more rapid than for wild-type IGF1R; this was most apparent for the Y1135F mutant. Substrate phosphorylation studies on the unphosphorylated forms of IGF1R confirmed that the value of Vmax for Y1135F was elevated relative to wild- type IGF1R, consistent with a disruption of an autoinhibitory interaction. In contrast, activity measurements on the fully phosphorylated enzymes indicated that k(cat)/K-m values were lowered relative to wild- type IGF1R; this effect was most dramatic for Y1136F. We confirmed these findings using limited proteolysis and tryptophan fluorescence experiments. The results demonstrate that Tyr1135 plays a particularly important role in stabilizing the autoinhibited conformation of the activation loop, while Tyr1136 plays the key role in stabilizing the open, activated conformation of IGF1R.	SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Frankel M, 1999, PROTEIN SCI, V8, P2158, DOI 10.1110/ps.8.10.2158; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leroith Derek, 1992, Biological Signals, V1, P173; LI SW, 1994, J BIOL CHEM, V269, P32558; Li WQ, 2004, BIOCHEM PHARMACOL, V68, P145, DOI 10.1016/j.bcp.2004.03.013; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Munshi S, 2002, J BIOL CHEM, V277, P38797, DOI 10.1074/jbc.M205580200; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065	29	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23785	23791		10.1074/jbc.M605269200	http://dx.doi.org/10.1074/jbc.M605269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16793764	hybrid			2022-12-25	WOS:000239702900054
J	Safiulina, VF; Afzalov, R; Khiroug, L; Cherubini, E; Giniatullin, R				Safiulina, Victoria F.; Afzalov, Ramil; Khiroug, Leonard; Cherubini, Enrico; Giniatullin, Rashid			Reactive oxygen species mediate the potentiating effects of ATP on GABAergic synaptic transmission in the immature hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIANT DEPOLARIZING POTENTIALS; CENTRAL-NERVOUS-SYSTEM; FROG NEUROMUSCULAR-JUNCTION; NEONATAL-RAT HIPPOCAMPUS; NITRIC-OXIDE; HYDROGEN-PEROXIDE; GLUTAMATERGIC SYNAPSES; NEURONAL NETWORKS; EXTRACELLULAR ATP; PROTEIN-KINASE	Reactive oxygen species (ROS) constitute important signaling molecules in the central nervous system. They regulate a number of different functions both under physiological conditions and under pathological conditions. Here we tested the hypothesis that in the immature hippocampus ATP, the most diffuse neurotransmitter in the brain, modulates synaptic transmission via ROS. We show that ATP, acting on metabotropic P2Y(1) receptors, increased the frequency of GABA(A)-mediated spontaneous postsynaptic currents (SPSCs) in CA3 principal cells, an effect that was prevented by the antioxidant N-acetyl-cysteine or by catalase, an enzyme that breaks down H2O2. The effect of ATP on SPSCs was mimicked by H2O2 or by the pro-oxidant, Fe2+, which, through the Fentol reaction, catalyzes the conversion of H2O2 into highly reactive hydroxyl radicals. MRS-2179, a P2Y(1) receptor antagonist, removed the facilitatory action of Fe2+ on SPSCs, suggesting that endogenous ATP acting on P2Y(1) receptors is involved in Fe2+-induced modulation of synaptic transmission. Imaging ROS with the H2O2-sensitive dye DCF revealed that ATP induces generation of peroxide in astrocytes via activation of P2Y(1) receptors coupled to intracellular calcium rise. Neither N-acetyl-cysteine nor catalase prevented Ca2+ transients induced by ATP in astrocytes. Since a single hippocampal astrocyte can contact many neurons, ATP-induced ROS signaling may control thousands of synapses. This may be crucial for information processing in the immature brain when GABAergic activity is essential for the proper wiring of the hippocampal network.	Scuola Int Super Studi Avanzati, Dept Neurobiol, I-34014 Trieste, Italy; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	International School for Advanced Studies (SISSA); University of Helsinki	Giniatullin, R (corresponding author), Scuola Int Super Studi Avanzati, Dept Neurobiol, Via Beirut 2-4, I-34014 Trieste, Italy.	rashid@sissa.it	Giniatullin, Rashid/Y-9687-2018	Giniatullin, Rashid/0000-0002-1580-6280	Telethon [GGP04037] Funding Source: Medline	Telethon(Fondazione Telethon)		Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; Arbogast S, 2004, AM J PHYSIOL-REG I, V287, pR698, DOI 10.1152/ajpregu.00072.2004; Auerbach JM, 1997, J NEUROSCI, V17, P8695; Avshalumov MV, 2005, J NEUROSCI, V25, P4222, DOI 10.1523/JNEUROSCI.4701-04.2005; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Buonocore G, 2001, BIOL NEONATE, V79, P180; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Chen BT, 2001, J NEUROPHYSIOL, V85, P2468, DOI 10.1152/jn.2001.85.6.2468; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Eder C, 2005, J NEUROSCI RES, V81, P314, DOI 10.1002/jnr.20476; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Fabbro A, 2004, J PHYSIOL-LONDON, V560, P505, DOI 10.1113/jphysiol.2004.068924; FERRARI G, 1995, J NEUROSCI, V15, P2857; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Giniatullin AR, 2005, J PHYSIOL-LONDON, V565, P229, DOI 10.1113/jphysiol.2005.084186; Giniatullin AR, 2003, J PHYSIOL-LONDON, V552, P283, DOI 10.1113/jphysiol.2003.050690; GINIATULLIN AR, 2006, IN PRESS J NEUROCHEM; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; He ML, 2003, J BIOL CHEM, V278, P46270, DOI 10.1074/jbc.M309005200; Hennou S, 2002, EUR J NEUROSCI, V16, P197, DOI 10.1046/j.1460-9568.2002.02073.x; Hirase H, 2004, PLOS BIOL, V2, P494, DOI 10.1371/journal.pbio.0020096; HOSOKAWA Y, 1994, EUR J NEUROSCI, V6, P805, DOI 10.1111/j.1460-9568.1994.tb00991.x; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; Illes P, 2004, EUR J PHARMACOL, V483, P5, DOI 10.1016/j.ejphar.2003.10.030; Kasyanov AM, 2004, P NATL ACAD SCI USA, V101, P3967, DOI 10.1073/pnas.0305974101; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Knapp LT, 2002, J NEUROSCI, V22, P674, DOI 10.1523/JNEUROSCI.22-03-00674.2002; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Li NZ, 2003, J NEUROSCI, V23, P10302; Maggi L, 2001, J PHYSIOL-LONDON, V536, P89, DOI 10.1111/j.1469-7793.2001.00089.x; Murakami K, 2003, NEUROSCIENCE, V117, P37, DOI 10.1016/S0306-4522(02)00804-7; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Peng TI, 2004, ANN NY ACAD SCI, V1011, P112, DOI 10.1196/annals.1293.012; Poisbeau P, 1996, J NEUROSCI, V16, P4835; Ralevic V, 1998, PHARMACOL REV, V50, P413; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Safiulina VF, 2006, J NEUROSCI, V26, P597, DOI 10.1523/JNEUROSCI.4493-05.2006; Safiulina VF, 2005, J NEUROPHYSIOL, V94, P2797, DOI 10.1152/jn.00445.2005; Safiulina VF, 2005, J PHYSIOL-LONDON, V565, P981, DOI 10.1113/jphysiol.2005.085621; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Tyzio R, 1999, J NEUROSCI, V19, P10372; Verderio C, 2004, NEURON, V41, P599, DOI 10.1016/S0896-6273(04)00077-7; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Winterbourn CC, 1995, TOXICOL LETT, V82-3, P969, DOI 10.1016/0378-4274(95)03532-X	51	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23464	23470		10.1074/jbc.M601627200	http://dx.doi.org/10.1074/jbc.M601627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787924	hybrid			2022-12-25	WOS:000239702900021
J	Guiot, E; Carayon, K; Delelis, O; Simon, F; Tauc, P; Zubin, E; Gottikh, M; Mouscadet, JF; Brochon, JC; Deprez, E				Guiot, Elvire; Carayon, Kevin; Delelis, Olivier; Simon, Francoise; Tauc, Patrick; Zubin, Evgenii; Gottikh, Marina; Mouscadet, Jean-Francois; Brochon, Jean-Claude; Deprez, Eric			Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESOLVED FLUORESCENCE ANISOTROPY; VIRAL-DNA; IN-VITRO; CONCERTED INTEGRATION; PREINTEGRATION COMPLEXES; COOPERATIVE BINDING; TERMINAL DOMAINS; ENERGY-TRANSFER; PROTEIN	The 3'-processing of the extremities of viral DNA is the first of two reactions catalyzed by HIV-1 integrase (IN). High order IN multimers (tetramers) are required for complete integration, but it remains unclear which oligomer is responsible for the 3'-processing reaction. Moreover, IN tends to aggregate, and it is unknown whether the polymerization or aggregation of this enzyme on DNA is detrimental or beneficial for activity. We have developed a fluorescence assay based on anisotropy for monitoring release of the terminal dinucleotide product in real-time. Because the initial anisotropy value obtained after DNA binding and before catalysis depends on the fractional saturation of DNA sites and the size of IN center dot DNA complexes, this approach can be used to study the relationship between activity and binding/multimerization parameters in the same assay. By increasing the IN: DNA ratio, we found that the anisotropy increased but the 3'-processing activity displayed a characteristic bell-shaped behavior. The anisotropy values obtained in the first phase were predictive of subsequent activity and accounted for the number of complexes. Interestingly, activity peaked and then decreased in the second phase, whereas anisotropy continued to increase. Time-resolved fluorescence anisotropy studies showed that the most competent form for catalysis corresponds to a dimer bound to one viral DNA end, whereas higher order complexes such as aggregates predominate during the second phase when activity drops off. We conclude that a single IN dimer at each extremity of viral DNA molecules is required for 3'-processing, with a dimer of dimers responsible for the subsequent full integration.	Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France; Moscow MV Lomonosov State Univ, Belozersky Inst Phys Chem Biol, Moscow 119992, Russia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Lomonosov Moscow State University	Deprez, E (corresponding author), Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, 61 Av President Wilson, F-94235 Cachan, France.	deprez@lbpa.ens-cachan.fr	Zubin, Evgeny/I-3880-2012; Gottikh, Marina/D-7575-2012					Agapkina J, 2006, J BIOL CHEM, V281, P11530, DOI 10.1074/jbc.M512271200; AGRAWAL S, 1986, NUCLEIC ACIDS RES, V14, P6227, DOI 10.1093/nar/14.15.6227; ANTSYPOVICH SI, 1995, BIOORG KHIM+, V21, P774; Bera S, 2005, BIOCHEMISTRY-US, V44, P15106, DOI 10.1021/bi0508340; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; Chen AP, 2006, J BIOL CHEM, V281, P4173, DOI 10.1074/jbc.M510628200; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Cherepanov P, 2005, P NATL ACAD SCI USA, V102, P17308, DOI 10.1073/pnas.0506924102; Ciubotaru M, 2003, J BIOL CHEM, V278, P5584, DOI 10.1074/jbc.M209758200; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85; Deprez E, 2001, P NATL ACAD SCI USA, V98, P10090, DOI 10.1073/pnas.181024498; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Etzkorn C, 2004, BIOCHEMISTRY-US, V43, P13256, DOI 10.1021/bi0490082; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; HAWKINS ME, 1995, NUCLEIC ACIDS RES, V23, P2872, DOI 10.1093/nar/23.15.2872; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Holman AG, 2005, P NATL ACAD SCI USA, V102, P6103, DOI 10.1073/pnas.0501646102; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; KUZNETSOVA LG, 1993, BIOORG KHIM+, V19, P455; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10205, DOI 10.1021/bi00032a014; LEE SP, 1995, ANAL BIOCHEM, V227, P295, DOI 10.1006/abio.1995.1284; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005; Li M, 2005, J BIOL CHEM, V280, P29334, DOI 10.1074/jbc.M505367200; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Pinskaya M, 2004, BIOCHEMISTRY-US, V43, P8735, DOI 10.1021/bi049706m; Podtelezhnikov AA, 2003, BIOPOLYMERS, V68, P110, DOI 10.1002/bip.10217; Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002; Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005; Smolov M, 2006, FEBS J, V273, P1137, DOI 10.1111/j.1742-4658.2006.05139.x; Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o; van den Ent FMI, 1999, J VIROL, V73, P3176, DOI 10.1128/JVI.73.4.3176-3183.1999; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wang Y, 2005, J BIOMOL SCREEN, V10, P456, DOI 10.1177/1087057105275212; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wielens J, 2005, J COMPUT AID MOL DES, V19, P301, DOI 10.1007/s10822-005-5256-2; Wu XL, 2005, J VIROL, V79, P5211, DOI 10.1128/JVI.79.8.5211-5214.2005; Yang JS, 2005, J BIOL CHEM, V280, P25416, DOI 10.1074/jbc.M501847200; Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o	54	127	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22707	22719		10.1074/jbc.M602198200	http://dx.doi.org/10.1074/jbc.M602198200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774912	hybrid			2022-12-25	WOS:000239542600031
J	Murata, T; Tsuboi, M; Hikita, K; Kaneda, N				Murata, Tomiyasu; Tsuboi, Masaru; Hikita, Kiyomi; Kaneda, Norio			Protective effects of neurotrophic factors on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of murine adrenal chromaffin cell line tsAM5D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CD120A P55; PHOSPHATIDYLINOSITOL 3-KINASE; NEURONAL DIFFERENTIATION; SIGNALING COMPLEX; TYROSINE-HYDROXYLASE; CASPASE-8 CLEAVAGE; DIRECT ACTIVATION; DEATH RECEPTORS; GROWTH-FACTOR; TRAIL	We previously established the murine adrenal chromaffin cell line tsAM5D, which was immortalized with the temperature-sensitive simian virus 40 large T-antigen. tsAM5D cells have the capacity to differentiate into neuron-like cells in response to neurotrophic factors when the culture temperature is shifted from 33 to 39 degrees C. In this model system, the temperature shift in the absence of neurotrophic factors led to cell death. Hoechst staining analysis revealed that typical apoptotic nuclei appeared in a time-dependent manner after the temperature shift. Upon shifting to 39 degrees C, the degradation of T-antigen was accompanied by the transcriptional activation of p53 protein. Among the p53 target genes, death receptor 5 (DR5), which is the receptor for tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL), showed the highest level of induction. Interestingly, TRAIL-neutralizing antibody protected tsAM5D cells from the temperature shift-induced apoptotic cell death by blocking the activation of caspase-8 and -3, indicating the involvement of TRAIL-mediated death signaling in the temperature shift-induced apoptosis. Glial cell line-derived neurotrophic factor (GDNF) inhibited the TRAIL-mediated activation of caspase-8 in tsAM5D cells exposed to 39 degrees C and cooperated with basic fibroblast growth factor and ciliary neurotrophic factor. Interestingly, the temperature shift induced oligomerization of DR5, which is the earliest process necessary for transduction of the death signal. This oligomerization was inhibited by treatment with GDNF plus ciliary neurotrophic factor but not by that with GDNF alone or GDNF plus basic fibroblast growth factor. These results are discussed with respect to the intracellular mechanism underlying the protective function of neurotrophic factors against TRAIL-mediated death signaling.	Meijo Univ, Fac Pharm, Dept Analyt Neurobiol, Tempa Ku, Nagoya, Aichi 4688503, Japan	Meijo University	Kaneda, N (corresponding author), Meijo Univ, Fac Pharm, Dept Analyt Neurobiol, Tempa Ku, Nagoya, Aichi 4688503, Japan.	nkaneda@ccmfs.meijo-u.ac.jp						Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Barber RD, 2000, J NEUROSCI, V20, P3695, DOI 10.1523/JNEUROSCI.20-10-03695.2000; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Cantarella G, 2003, CELL DEATH DIFFER, V10, P134, DOI 10.1038/sj.cdd.4401143; CHOU JY, 1989, MOL ENDOCRINOL, V3, P1511, DOI 10.1210/mend-3-10-1511; Cottin V, 1999, J BIOL CHEM, V274, P32975, DOI 10.1074/jbc.274.46.32975; Cottin V, 2001, J BIOL CHEM, V276, P17252, DOI 10.1074/jbc.M010681200; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; Dorr J, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-04-j0001.2002; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Frankel SK, 2001, BIOCHEM BIOPH RES CO, V288, P313, DOI 10.1006/bbrc.2001.5761; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Hilliard B, 2001, J IMMUNOL, V166, P1314, DOI 10.4049/jimmunol.166.2.1314; Hossain MA, 2002, J NEUROCHEM, V81, P365, DOI 10.1046/j.1471-4159.2002.00837.x; Huang WX, 2000, NEUROLOGY, V55, P928, DOI 10.1212/WNL.55.7.928; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Jones RG, 2002, J EXP MED, V196, P335, DOI 10.1084/jem.20020307; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; Mao YW, 2005, J CELL BIOL, V170, P305, DOI 10.1083/jcb.200505061; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; McManus MF, 1999, J NEUROSCI, V19, P9004, DOI 10.1523/JNEUROSCI.19-20-09004.1999; Miura Y, 2003, P NATL ACAD SCI USA, V100, P2777, DOI 10.1073/pnas.2628048100; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Murata T, 2003, J NEUROCHEM, V85, P1126, DOI 10.1046/j.1471-4159.2003.01765.x; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Obinata M, 1997, GENES CELLS, V2, P235, DOI 10.1046/j.1365-2443.1997.1160314.x; Obinata M, 2001, BIOCHEM BIOPH RES CO, V286, P667, DOI 10.1006/bbrc.2001.5247; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Ryan LA, 2004, J NEUROIMMUNOL, V148, P127, DOI 10.1016/j.jneuroim.2003.11.019; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Soler RM, 1999, J NEUROSCI, V19, P9160; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 2000, HEPATOLOGY, V32, P796, DOI 10.1053/jhep.2000.17738; Tavelin S, 1999, J PHARMACOL EXP THER, V290, P1212; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; Uberti D, 2004, NEUROREPORT, V15, P579, DOI 10.1097/00001756-200403220-00002; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade SB, 1999, J NEUROSCI, V19, P6994, DOI 10.1523/JNEUROSCI.19-16-06994.1999; Walther N, 1999, BIOL REPROD, V60, P1078, DOI 10.1095/biolreprod60.5.1078; WHITE LA, 1994, J NEUROSCI, V14, P6744; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; ZHENG DQ, 1994, ONCOGENE, V9, P3345	74	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22503	22516		10.1074/jbc.M602579200	http://dx.doi.org/10.1074/jbc.M602579200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772303	hybrid			2022-12-25	WOS:000239542600011
J	Stefansson, B; Brautigan, DL				Stefansson, Bjarki; Brautigan, David L.			Protein phosphatase 6 subunit with conserved sit4-associated protein domain targets I kappa B epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHOSPHATASE 2A; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SIT4; IDENTIFICATION; APOPTOSIS; RECEPTOR; KINASE; ASSOCIATION	Protein Ser/Thr phosphatases compose a PPP family that includes type-2 PP2A, PP4, and PP6, each with essential functions. The human PP6 gene rescues sit4(ts) mutants of Saccharomyces cerevisiae, and Sit4 phosphatase function depends on multiple Sit4-associated protein (SAP) subunits. We report here finding a SAPS sequence domain encoded in only a single gene each in Schizosaccharomyces pombe, Caenorhabditis elegans, and Drosophila but in three distinct open reading frames in Xenopus, Mus musculus, and Homo sapiens. The SAPS proteins are more divergent in sequence than PP6. Northern hybridization showed differential distribution of the human SAPS-related mRNA in multiple human tissues, named as PP6R1, PP6R2, and PP6R3. Antibodies were generated, distribution of endogenous PP6, PP6R1, PP6R2, and PP6R3 proteins was examined by immunoblotting, and the abundance of mRNA and protein in various tissues did not match. FLAG-tagged PP6R1 and PP6R2 expressed in HEK293 cells co-precipitated endogenous PP6, but not PP2A or PP4, showing specificity for recognition of phosphatases. The SAPS domain of PP6R1 alone was sufficient for association with PP6, and this predicts that conserved sequence motifs in the SAPS domain accounts for the specificity. FLAG-PP6R1 and FLAG-PP6R2 co-precipitated HA-I kappa B epsilon. Knockdown of PP6 or PP6R1 but not PP6R3 with siRNA significantly enhanced degradation of endogenous I kappa B epsilon in response to tumor necrosis factor-alpha. The results show SAPS domain subunits recruit substrates such as I kappa B epsilon as one way to determine specific functions for PP6.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577,W Complex MSB 7225, Charlottesville, VA 22908 USA.	db8g@virginia.edu		Stefansson, Bjarki/0000-0002-0363-5162	NATIONAL CANCER INSTITUTE [R01CA077584] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Astier AL, 2003, BLOOD, V101, P1118, DOI 10.1182/blood-2002-05-1519; Bastians H, 1996, J CELL SCI, V109, P2865; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Clotet J, 1999, MOL CELL BIOL, V19, P2408; Cohen PTW, 2005, FEBS LETT, V579, P3278, DOI 10.1016/j.febslet.2005.04.070; Ferguson RE, 2005, PROTEOMICS, V5, P566, DOI 10.1002/pmic.200400941; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hastie CJ, 2000, BIOCHEM J, V347, P845, DOI 10.1042/0264-6021:3470845; Hayashi N, 2005, CURR GENET, V47, P359, DOI 10.1007/s00294-005-0577-1; Jablonowski D, 2001, GENETICS, V159, P1479; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jarai G, 2004, EUR J PHARMACOL, V497, P255, DOI 10.1016/j.ejphar.2004.06.055; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Luke MM, 1996, MOL CELL BIOL, V16, P2744; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manlandro CMA, 2005, EUKARYOT CELL, V4, P1041, DOI 10.1128/EC.4.6.1041-1049.2005; MANN DJ, 1993, EMBO J, V12, P4833, DOI 10.1002/j.1460-2075.1993.tb06173.x; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Moynagh Paul N, 2005, J Cell Sci, V118, P4589, DOI 10.1242/jcs.02579; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; Prickett TD, 2004, J BIOL CHEM, V279, P38912, DOI 10.1074/jbc.M401444200; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Shirra MK, 2005, GENETICS, V169, P1957, DOI 10.1534/genetics.104.038075; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Tackels-Horne D, 2001, CANCER-AM CANCER SOC, V92, P395, DOI 10.1002/1097-0142(20010715)92:2<395::AID-CNCR1335>3.0.CO;2-U; Twells RCJ, 2001, GENOMICS, V72, P231, DOI 10.1006/geno.2000.6492; UHLER MD, 1987, J BIOL CHEM, V262, P15202; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Zabrocki P, 2002, MOL MICROBIOL, V43, P835, DOI 10.1046/j.1365-2958.2002.02786.x	48	86	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22624	22634		10.1074/jbc.M601772200	http://dx.doi.org/10.1074/jbc.M601772200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769727	hybrid			2022-12-25	WOS:000239542600023
J	Masuoka, N; Sugiyama, H; Ishibashi, N; Wang, DH; Masuoka, T; Kodama, H; Nakano, T				Masuoka, Noriyoshi; Sugiyama, Hitoshi; Ishibashi, Naoki; Wang, Da-Hong; Masuoka, Takayoshi; Kodama, Hiroyuki; Nakano, Taku			Characterization of acatalasemic erythrocytes treated with low and high dose hydrogen peroxide - Hemolysis and aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE ACTIVITY; NITRIC-OXIDE; BLOOD-CELLS; HEMOGLOBIN; REMOVAL; FERRYLHEMOGLOBIN; FERRYLMYOGLOBIN; MYOGLOBIN; OXIDATION; JAPANESE	The effects of hydrogen peroxide on normal and acatalasemic erythrocytes were examined. Severe hemolysis of acatalasemic erythrocytes and a small tyrosine radical signal ( g = 2.005) associated with the formation of ferryl hemoglobin were observed upon the addition of less than 0.25mM hydrogen peroxide. However, when the concentration of hydrogen peroxide was increased to 0.5 mM, acatalasemic erythrocytes became insoluble in water and increased the tyrosine radical signal. Polymerization of hemoglobin and aggregation of the erythrocytes were observed. On the other hand, normal erythrocytes exhibited only mild hemolysis by the addition of hydrogen peroxide under similar conditions. From these results, the scavenging of hydrogen peroxide by hemoglobin generates the ferryl hemoglobin species (H-Hb-Fe(IV) = O) plus protein-based radicals ((center dot)HbFe(IV) =O). These species induce hemolysis of erythrocytes, polymerization of hemoglobin, and aggregation of the acatalasemic erythrocytes. A mechanism for the onset of Takarara disease is proposed.	Okayama Univ Sci, Dept Life Sci, Okayama 7000005, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Biochem, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Med & Clin Sci, Okayama 7008558, Japan; Okayama Univ, Sch Med, Okayama 7008558, Japan; Okayama Univ Sci, Grad Sch Med & Dent, Dept Publ Hlth, Okayama 7000005, Japan; Okayama Univ, Dept Pharmacol, Fac Pharmaceut Sci, Okayama 7008530, Japan; Kochi Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Kochi 7838505, Japan; Toyama Univ, Dept Pharmaceut Sci, Toyama 9300194, Japan	Okayama University of Science; Okayama University; Okayama University; Okayama University; Okayama University of Science; Okayama University; Kochi University; University of Toyama	Masuoka, N (corresponding author), Okayama Univ Sci, Dept Life Sci, 1-1 Ridai Cho, Okayama 7000005, Japan.	masuokan@dls.ous.ac.jp	Masuoka, Takayoshi/AAI-8785-2020; Sugiyama, Hitoshi/B-2252-2011	Masuoka, Takayoshi/0000-0002-1689-8762; Sugiyama, Hitoshi/0000-0002-4127-6471				Drabkin DL, 1935, J BIOL CHEM, V112, P51; EATON JW, 1995, METABOLIC MOL BASES, V2, P2371; FEINSTEI.RN, 1967, ARCH BIOCHEM BIOPHYS, V120, P165, DOI 10.1016/0003-9861(67)90609-1; GAETANI GF, 1994, BLOOD, V84, P325; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; Goth L, 2001, BLOOD CELL MOL DIS, V27, P512, DOI 10.1006/bcmd.2001.0415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuoka N, 1996, CLIN CHIM ACTA, V254, P101, DOI 10.1016/0009-8981(96)06374-7; Masuoka N, 1997, BBA-MOL BASIS DIS, V1361, P131, DOI 10.1016/S0925-4439(97)00024-0; Masuoka N, 2003, BBA-MOL BASIS DIS, V1637, P46, DOI 10.1016/S0925-4439(02)00213-2; MIKI M, 1987, ARCH BIOCHEM BIOPHYS, V258, P373, DOI 10.1016/0003-9861(87)90358-4; OGATA M, 1986, P JPN ACAD B-PHYS, V62, P367, DOI 10.2183/pjab.62.367; OGATA M, 1966, P JPN ACAD, V42, P828, DOI 10.2183/pjab1945.42.828; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Svistunenko DA, 1997, J BIOL CHEM, V272, P7114, DOI 10.1074/jbc.272.11.7114; TAKAHARA S, 1952, LANCET, V263, P1101; Takahara S., 1977, BIOCH MED ASPECTS AC, P275; Wakimoto M, 1998, ACTA MED OKAYAMA, V52, P233; WALTERS FP, 1983, FEBS LETT, V163, P292, DOI 10.1016/0014-5793(83)80838-2; WU F, 1994, BBA-MOL BASIS DIS, V1225, P158, DOI 10.1016/0925-4439(94)90073-6	22	12	12	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21728	21734		10.1074/jbc.M513818200	http://dx.doi.org/10.1074/jbc.M513818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751193	hybrid			2022-12-25	WOS:000239387100018
J	Lin, HY; Lansing, L; Merillon, JM; Davis, FB; Tang, HY; Shih, A; Vitrac, X; Krisa, S; Keating, T; Cao, HJ; Bergh, J; Quackenbush, S; Davis, PJ				Lin, Hung-Yun; Lansing, Lawrence; Merillon, Jean-Michel; Davis, Faith B.; Tang, Heng-Yuan; Shih, Ai; Vitrac, Xavier; Krisa, Stephanie; Keating, Travis; Cao, H. James; Bergh, Joel; Quackenbush, Steven; Davis, Paul J.			Integrin alpha V beta 3 contains a receptor site for resveratrol	FASEB JOURNAL			English	Article						resveratrol; integrin alpha V beta 3; apoptosis; breast cancer cell; extracellular-regulated kinases 1 and 2	ACTIVATED PROTEIN-KINASE; THYROID-HORMONE; GROWTH-FACTOR; APOPTOSIS; CANCER; P53; PHOSPHORYLATION; CELLS	Resveratrol is a naturally occurring polyphenol, which causes apoptosis in cultured cancer cells. We describe a cell surface resveratrol receptor on the extracellular domain of hetero-dimeric alpha V beta 3 integrin in MCF-7 human breast cancer cells. This receptor is linked to induction by resveratrol of extracellular-regulated kinases 1 and 2 (ERK1/2)- and serine-15-p53-dependent phosphorylation leading to apoptosis. The integrin receptor is near the Arg-Gly-Asp (RGD) recognition site on the integrin; an integrin-binding RGD peptide inhibits induction by resveratrol of ERK1/2 and p53-dependent apoptosis. Antibody (Ab) to integrin alpha V beta 3, but not to alpha V beta 5, inhibits activation by resveratrol of ERK1/2 and p53 and consequent apoptosis in estrogen receptor-alpha (ER alpha) positive MCF-7, and ER alpha-negative MDA-MB231 cells. Resveratrol is displaced from the purified integrin by an RGD, but not RGE, peptide, and by alpha V beta 3 integrin-specific Ab. Resveratrol action is blocked by siRNA beta 3, but not by siRNA alpha V. [C-14]-Resveratrol binds to commercially purified integrin alpha V beta 3 and to alpha V beta 3 prepared from MCF-7 cells; binding of [C-14]- resveratrol to the beta 3, but not to the alpha V monomer, is displaced by unlabeled resveratrol. In conclusion, binding of resveratrol to integrin alpha V beta 3, principally to the beta 3 monomer, is essential for transduction of the stilbene signal into p53-dependent apoptosis of breast cancer cells.	Ordway Res Inst, Albany, NY 12208 USA; Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA; Univ Bordeaux 1, Lab Mycol & Biotechnol Vegetale, F-33405 Talence, France; New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	Ordway Research Institute; UDICE-French Research Universities; Universite de Bordeaux; State University of New York (SUNY) System; Wadsworth Center	Davis, PJ (corresponding author), Ordway Res Inst, 150 New Scotland Ave, Albany, NY 12208 USA.	fdavis@ordwayresearch.org						Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Belvisi L, 2005, MOL CANCER THER, V4, P1670, DOI 10.1158/1535-7163.MCT-05-0120; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Bhat KPL, 2001, CANCER RES, V61, P6137; Castro MR, 1999, J CLIN ENDOCR METAB, V84, P2957, DOI 10.1210/jc.84.8.2957; Gao ZB, 2005, BRAIN RES, V1056, P68, DOI 10.1016/j.brainres.2005.07.013; Hattangadi DK, 2004, BIOCHEM PHARMACOL, V68, P1699, DOI 10.1016/j.bcp.2004.06.033; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; She QB, 2002, MOL CARCINOGEN, V33, P244, DOI 10.1002/mc.10041; Shih A, 2004, MOL CANCER THER, V3, P1355; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Vitrac X, 2002, J BIOTECHNOL, V95, P49, DOI 10.1016/S0168-1656(01)00441-2; Zhang S, 2004, BRIT J CANCER, V91, P178, DOI 10.1038/sj.bjc.6601902	21	114	128	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1742	+		10.1096/fj.06-5743fje	http://dx.doi.org/10.1096/fj.06-5743fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790523				2022-12-25	WOS:000240266600034
J	Guan, XL; He, X; Ong, WY; Yeo, WK; Shui, GH; Wenk, MR				Guan, Xue Li; He, Xin; Ong, Wei-Yi; Yeo, Wee Kiang; Shui, Guanghou; Wenk, Markus R.			Non-targeted profiling of lipids during kainate-induced neuronal injury	FASEB JOURNAL			English	Article						lipidomics; neurotoxicity; mass spectrometry; ceramide; N-acylated phosphatidylethanolamine	PHOSPHOLIPASE A(2) INHIBITORS; IONIZATION MASS-SPECTROMETRY; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; CELL-DEATH; BRAIN; LIPIDOMICS; INVOLVEMENT; PATHOPHYSIOLOGY	Kainate is a glutamate analog that has been widely used in pharmacological studies of neuronal injury related to ischemic conditions and epilepsy. While altered lipid metabolism has been implicated in kainate action, no study has yet investigated the associated changes in lipid metabolites on a systems scale. Here we describe a mass spectrometry-based approach for profiling of lipid mixtures in a nontargeted fashion. Combined with tandem mass spectrometry, this method aims to identify lipids that are altered between two conditions, the kainate-treated and the control hippocampal tissues. In addition to reductions in major phospholipids with mainly polyunsaturated fatty acyl chains, we find elevated levels of ions that correspond to acylated forms of phosphatidylethanolamines and ceramides. Acylated phosphatidylethanolamines are neuroprotective lipids and precursors for anandamide, which signals via cannabinoid receptors. Quantitative analysis of ceramides shows that many molecular species with different acyl compositions are increased during kainate treatment. This increase is mainly restricted to neurons rather than other brain cells in the hippocampus as revealed by immunohistochemistry of brain slices.	Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117548, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biol Sci, Singapore 117548, Singapore; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Wenk, MR (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, 8 Med Dr,Block MD7, Singapore 117548, Singapore.	antongwy@nus.edu.sg; bchmrw@nus.edu.sg	Yeo, Wee Kiang/A-4566-2009; Guan, Xue Li/D-2935-2014	Guan, Xue Li/0000-0002-5189-8178; Shui, Guanghou/0000-0002-1621-9643; Yeo, Wee Kiang/0000-0002-5329-1062				Adibhatla RM, 2003, ANTIOXID REDOX SIGN, V5, P647, DOI 10.1089/152308603770310329; Balazy M, 2004, PROSTAG OTH LIPID M, V73, P173, DOI 10.1016/j.prostaglandins.2004.03.003; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cole-Edwards KK, 2005, NEUROCHEM RES, V30, P847, DOI 10.1007/s11064-005-6878-4; Cowart LA, 2002, J LIPID RES, V43, P2042, DOI 10.1194/jlr.M200241-JLR200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Farooqui AA, 2004, PROSTAG LEUKOTR ESS, V71, P161, DOI 10.1016/j.plefa.2004.03.004; Farooqui AA, 2001, BRAIN RES REV, V38, P61, DOI 10.1016/S0169-328X(01)00214-5; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; Farooqui Akhlaq A, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P85, DOI 10.2174/1568006043481239; Forrester JS, 2004, MOL PHARMACOL, V65, P813, DOI 10.1124/mol.65.4.813; Han XL, 2004, ANAL BIOCHEM, V330, P317, DOI 10.1016/j.ab.2004.04.004; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 1999, J MASS SPECTROM, V34, P761, DOI 10.1002/(SICI)1096-9888(199907)34:7<761::AID-JMS832>3.0.CO;2-R; Hisaki H, 2004, BRAIN RES, V1018, P73, DOI 10.1016/j.brainres.2004.05.042; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lu XR, 2001, FREE RADICAL BIO MED, V30, P1263, DOI 10.1016/S0891-5849(01)00528-7; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Nakane M, 2000, NEUROSCI LETT, V296, P89, DOI 10.1016/S0304-3940(00)01655-4; Nielsen NPV, 1998, J CHROMATOGR A, V805, P17, DOI 10.1016/S0021-9673(98)00021-1; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ong WY, 2003, BRAIN PATHOL, V13, P250; Ong WY, 2003, EXP BRAIN RES, V148, P521, DOI 10.1007/s00221-002-1315-2; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rapaka RS, 2005, PROSTAG OTH LIPID M, V77, P223, DOI 10.1016/j.prostaglandins.2005.06.005; Rohrbough J, 2005, NAT REV NEUROSCI, V6, P139, DOI 10.1038/nrn1608; Schaub TM, 2003, ANAL CHEM, V75, P2172, DOI 10.1021/ac020627v; Serhan CN, 2005, PROSTAG OTH LIPID M, V77, P4, DOI 10.1016/j.prostaglandins.2004.09.016; Sturley SL, 2004, BBA-MOL CELL BIOL L, V1685, P83, DOI 10.1016/j.bbalip.2004.08.014; SULLARDS MC, 2001, SCI STKE; Thwin MM, 2003, EXP BRAIN RES, V150, P427, DOI 10.1007/s00221-003-1476-7; Ueda N, 2005, CURR MED CHEM, V12, P1413, DOI 10.2174/0929867054020918; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Wenk MR, 2003, NAT BIOTECHNOL, V21, P813, DOI 10.1038/nbt837; Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776; Wolozin B, 2004, CNS DRUG REV, V10, P127	42	72	79	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1152	1161		10.1096/fj.05-5362com	http://dx.doi.org/10.1096/fj.05-5362com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770014				2022-12-25	WOS:000240210300015
J	Bacon, AL; Fox, S; Turley, H; Harris, AL				Bacon, A. L.; Fox, S.; Turley, H.; Harris, A. L.			Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer	ONCOGENE			English	Article						BNIP3; hypoxia; histone deacetylation; HIF; silencing	CELL-DEATH; PROTEIN BNIP3; TUMOR HYPOXIA; EXPRESSION; NECROSIS; BREAST; P53; MEDIATOR; GROWTH; HEAD	Hypoxia, via the hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2), upregulates many genes involved in cell survival. However, proapoptotic pathways are also induced. BCL-2/adenovirus E1B-19kDa-interacting protein 3 (BNIP3) represents a paradigm of a cell death protein that is hypoxically upregulated via HIF-1 in most cancers. We found that in contrast to many other cell types, 6/8 colorectal cancer (CRC) cell lines show little hypoxic induction of BNIP3 despite an intact HIF signalling system. Colorectal tumour tissue also loses BNIP3 expression relative to matched normal samples. Downregulation of hypoxic BNIP3 in CRC cells was independent of the expression of other BCL-2 family members, or BNIP3L. That BNIP3 plays a functional role in hypoxic survival in CRC cells was demonstrated by the fact that CRC cell lines that do not upregulate BNIP3 or have been treated with BNIP3 RNA interference were insensitive to hypoxia-induced cell death. Promoter methylation and histone deacetylation were shown to silence BNIP3 in these CRC cell lines. Of significance, hypoxic induction of BNIP3 was restored in 4/6 cell lines by trichostatin-A treatment alone. These data suggest that BNIP3 plays an important role in hypoxic cell death and epigenetic mechanisms selectively silence its expression in CRC.	Univ Oxford, John Radcliffe Hosp, Mol Oncol Lab, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Mol Oncol Lab, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DU, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020; Fox, Stephen/G-9719-2016	Harris, Adrian L/0000-0003-1376-8409; Fox, Stephen/0000-0002-7648-8896				Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Beasley NJP, 2002, CANCER RES, V62, P2493; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hockel M, 1998, INT J CANCER, V79, P365; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rubin H, 2001, ADV CANCER RES, V83, P159, DOI 10.1016/S0065-230X(01)83006-2; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Stadler P, 1999, INT J RADIAT ONCOL, V44, P749, DOI 10.1016/S0360-3016(99)00115-7; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wykoff CC, 2000, CANCER RES, V60, P7075; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	39	53	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					132	141		10.1038/sj.onc.1209761	http://dx.doi.org/10.1038/sj.onc.1209761			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799636				2022-12-25	WOS:000243236500013
J	Wang, G; Jones, SJM; Marra, MA; Sadar, MD				Wang, G.; Jones, S. J. M.; Marra, M. A.; Sadar, M. D.			Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen receptor; Affymetrix; LNCaP hollow fiber model; cross-talk; PKA	PROTEIN-KINASE; MOLECULAR CHARACTERIZATION; HORMONAL-REGULATION; EXPRESSION PROFILE; RESPONSIVE GENES; TUMOR-SUPPRESSOR; REGULATED GENES; DOWN-REGULATION; AMINO-TERMINUS; RECEPTOR	Progression of prostate cancer to androgen independence is suspected to involve the androgen and protein kinase A (PKA) signaling pathways. Here for the first time, the transcriptomes associated with each pathway and common transcriptional targets in response to stimulation of both pathways were identified in human prostate cancer cells using Affymetrix GeneChip technology (Human Genome U133 plus2). Statistically significant changes in the levels of 858 genes in response to androgen and 303 genes in response to activation of the PKA pathway were determined using GeneSpring software. Expression of a subset of these genes (22) that were transcriptional targets for the androgen and/or PKA pathways were validated by reverse transcriptase-polymerase chain reaction and Western blot analyses. Application of small interfering RNAs to the androgen receptor (AR) revealed that in addition to KLK3, levels of expression of KLK2 and SESN1 were regulated by AR activated by both the androgen and PKA signaling pathways. SESN1 was identified as a gene repressed by activated AR. These results provide a broad view of the effects of the androgen and PKA signaling pathways on the transcriptional program of prostate cancer cells and indicate that only a limited number of genes are targeted by cross-talk between AR and PKA pathways.	British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Genome Sci Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	msadar@bcgsc.ca	Sadar, Marianne/E-9136-2012; Jones, Steven J/C-3621-2009; Marra, Marco A/B-5987-2008	Sadar, Marianne/0000-0003-0599-9215; Jones, Steven J/0000-0003-3394-2208; Marra, Marco A/0000-0001-7146-7175	NCI NIH HHS [CA105403] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Amler LC, 2000, CANCER RES, V60, P6134; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bouchal J, 2005, J PHARM PHARMACOL, V57, P83, DOI 10.1211/0022357055164; Chen TS, 1999, CANCER RES, V59, P213; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culig Z, 1997, PROSTATE, V32, P106, DOI 10.1002/(SICI)1097-0045(19970701)32:2<106::AID-PROS5>3.0.CO;2-K; DAGA A, 1993, J BIOL CHEM, V268, P8123; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Day CL, 2004, BIOCHEM J, V377, P597, DOI 10.1042/BJ20031251; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; DePrimo SE, 2002, GENOME BIOL, V3; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Farini D, 2003, ENDOCRINOLOGY, V144, P1631, DOI 10.1210/en.2002-221009; Gobert GN, 2001, HISTOCHEM CELL BIOL, V115, P381; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jung M, 2003, PROSTATE, V55, P89, DOI 10.1002/pros.10194; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; MORRIS DI, 1991, J BIOL CHEM, V266, P13377; Nakhla AM, 1999, STEROIDS, V64, P213, DOI 10.1016/S0039-128X(98)00084-1; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Prins G S, 2000, Mayo Clin Proc, V75 Suppl, pS32; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robles LD, 2002, J BIOL CHEM, V277, P25431, DOI 10.1074/jbc.M201199200; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadar MD, 2002, MOL CANCER THER, V1, P629; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tepper CG, 2002, CANCER RES, V62, P6606; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Vilaboa N, 2004, NUCLEIC ACIDS RES, V32, P6454, DOI 10.1093/nar/gkh981; Waghray A, 2001, PROTEOMICS, V1, P1327, DOI 10.1002/1615-9861(200110)1:10<1327::AID-PROT1327>3.3.CO;2-2; Wang G, 2006, J CELL BIOCHEM, V98, P36, DOI 10.1002/jcb.20802; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zou ZQ, 2002, CLIN CANCER RES, V8, P1172; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	63	54	64	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7311	7323		10.1038/sj.onc.1209715	http://dx.doi.org/10.1038/sj.onc.1209715			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751804				2022-12-25	WOS:000242244700010
J	Thomson, JM; Distler, AM; Prati, F; Bonomo, RA				Thomson, Jodi M.; Distler, Anne M.; Prati, Fabio; Bonomo, Robert A.			Probing active site chemistry in SHV beta-lactamase variants at ambler position 244 - Understanding unique properties of inhibitor resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLAVULANIC ACID; CLINICAL ISOLATE; TAZOBACTAM; MECHANISM; ARGININE-244; INACTIVATION; CEFTAZIDIME; RECOGNITION; RESOLUTION	Inhibitor-resistant class A beta-lactamases are an emerging threat to the use of beta-lactam/beta-lactamase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bacterial infections. In the TEM family of Class A beta-lactamases, single amino acid substitutions at Arg-244 confer resistance to clavulanate inactivation. To understand the amino acid sequence requirements in class A beta-lactamases that confer resistance to clavulanate, we performed site-saturation mutagenesis of Arg-244 in SHV-1, a related class A beta-lactamase found in Klebsiella pneumoniae. Twelve SHV enzymes with amino acid substitutions at Arg-244 resulted in significant increases in minimal inhibitory concentrations to ampicillin/clavulanate when expressed in Escherichia coli. Kinetic analyses of SHV-1, R244S, R244Q, R244L, and R244E beta-lactamases revealed that the main determinant of clavulanate resistance was reduced inhibitor affinity. In contrast to studies in the highly similar TEM enzyme, we observed increases in clavulanate k(inact) for all mutants. Electrospray ionization mass spectrometry of clavulanate inhibited SHV-1 and R244S showed nearly identical mass adducts, arguing against a difference in the inactivation mechanism. Testing a wide range of substrates with C3-4 carboxylates in different stereochemical orientations, we observed impaired affinity for all substrates among inhibitor resistant variants. Lastly, we synthesized two boronic acid transition state analogs that mimic cephalothin and found substitutions at Arg-244 markedly affect both the affinity and kinetics of binding to the chiral, deacylation transition state inhibitor. These data define a role for Arg-244 in substrate and inhibitor binding in the SHV beta-lactamase.	Louis Stokes Cleveland Vet Affairs Med Ctr, Div Res Serv, Cleveland, OH 44106 USA; Univ Modena, Dept Chem, I-41100 Modena, Italy; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Universita di Modena e Reggio Emilia; Case Western Reserve University	Bonomo, RA (corresponding author), Louis Stokes Cleveland Vet Affairs Med Ctr, Div Res Serv, 10701 E Blvd, Cleveland, OH 44106 USA.	robert.bonomo@med.va.gov	Prati, Fabio/B-7532-2015	Prati, Fabio/0000-0002-0650-9540	NIGMS NIH HHS [T32 GM07250] Funding Source: Medline; PHS HHS [1R01 A1063517-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; Buynak JD, 2004, CURR MED CHEM, V11, P1951, DOI 10.2174/0929867043364847; Caselli E, 2001, CHEM BIOL, V8, P17, DOI 10.1016/S1074-5521(00)00052-1; Chen Y, 2006, J AM CHEM SOC, V128, P2970, DOI 10.1021/ja056806m; Chen Y, 2005, J AM CHEM SOC, V127, P5423, DOI 10.1021/ja042850a; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DELAIRE M, 1992, J BIOL CHEM, V267, P20600; Hall DG, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P1, DOI 10.1002/3527606548.ch1; Helfand MS, 2003, BIOCHEMISTRY-US, V42, P13386, DOI 10.1021/bi035716w; Hujer AM, 2002, ANTIMICROB AGENTS CH, V46, P3971, DOI 10.1128/AAC.46.12.3971-3977.2002; IMTIAZ U, 1994, ANTIMICROB AGENTS CH, V38, P1134, DOI 10.1128/AAC.38.5.1134; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Lin S, 1998, BIOCHEM J, V333, P395, DOI 10.1042/bj3330395; Morandi F, 2003, J AM CHEM SOC, V125, P685, DOI 10.1021/ja0288338; Pagan-Rodriguez D, 2004, J BIOL CHEM, V279, P19494, DOI 10.1074/jbc.M311669200; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; Rice LB, 2000, ANTIMICROB AGENTS CH, V44, P362, DOI 10.1128/AAC.44.2.362-367.2000; Sulton D, 2005, J BIOL CHEM, V280, P35528, DOI 10.1074/jbc.M501251200; Sun T, 2004, BIOCHEMISTRY-US, V43, P14111, DOI 10.1021/bi0487903; Thomson JM, 2005, CURR OPIN MICROBIOL, V8, P518, DOI 10.1016/j.mib.2005.08.014; Wang XJ, 2003, BIOCHEMISTRY-US, V42, P8434, DOI 10.1021/bi034242y; Weiss WJ, 2004, ANTIMICROB AGENTS CH, V48, P4589, DOI 10.1128/AAC.48.12.4589-4596.2004; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016; ZHOU XY, 1994, ANTIMICROB AGENTS CH, V38, P1085, DOI 10.1128/AAC.38.5.1085	29	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26734	26744		10.1074/jbc.M603222200	http://dx.doi.org/10.1074/jbc.M603222200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16803899	hybrid			2022-12-25	WOS:000240249500091
J	Polychronopoulos, S; Verykokakis, M; Yazicioglu, MN; Sakarellos-Daitsiotis, M; Cobb, MH; Mavrothalassitis, G				Polychronopoulos, Sarantis; Verykokakis, Mihalis; Yazicioglu, Mustafa N.; Sakarellos-Daitsiotis, Maria; Cobb, Melanie H.; Mavrothalassitis, George			The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ERK2; DOCKING SITES; CELL-CYCLE; PROTEIN-KINASES; SIGNAL; PHOSPHORYLATION; SPECIFICITY; BINDING; IDENTIFICATION; ACTIVATION	The transcriptional ETS2 repressor factor (ERF) is phosphorylated by Erks both in vivo and in vitro. This phosphorylation determines the subcellular localization and biological function of ERF. Here, we show that active and inactive Erk2 proteins bind ERF with high affinity through a hydrophobic pocket formed by the alpha F and alpha G helices and the activation loop of Erk2. We have identified two FXF motifs on ERF that mediate the specific interaction with Erks. One of these motifs is utilized only by active Erks, whereas the other mediates the association with inactive Erks but also contributes to interaction with active Erks. Mutation of the phenylalanines of these motifs to alanines resulted in decreased association and phosphorylation of ERF by Erks both in cells and in vitro. ERF proteins carrying these mutations exhibited increased nuclear accumulation and increased inhibition of cellular proliferation. Expression of ERF regions harboring these motifs could inhibit Erk activity in cells. Our data suggest that, in the proper context, FXF motifs can mediate a strong and specific interaction not only with active but also inactive Erks and that these interactions determine protein function in vivo.	Univ Crete, Sch Med, Iraklion 71003, Crete, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71003, Crete, Greece; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Ioannina, Dept Chem, Sect Organ Chem & Biochem, GR-45110 Ioannina, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Ioannina	Mavrothalassitis, G (corresponding author), Univ Crete, Sch Med, Iraklion 71003, Crete, Greece.	mavro@imbb.forth.gr		Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Le Gallic L, 2004, MOL CELL BIOL, V24, P1206, DOI 10.1128/MCB.24.3.1206-1218.2004; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pawson T, 2000, GENE DEV, V14, P1027; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Robinson MJ, 2002, J BIOL CHEM, V277, P5094, DOI 10.1074/jbc.M110935200; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stewart M, 2000, CELL STRUCT FUNCT, V25, P217, DOI 10.1247/csf.25.217; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Volmat V, 2001, J CELL SCI, V114, P3433; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	48	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25601	25611		10.1074/jbc.M605185200	http://dx.doi.org/10.1074/jbc.M605185200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16799155	hybrid			2022-12-25	WOS:000240031300063
J	Dizin, E; Gressier, C; Magnard, C; Ray, H; Decimo, D; Ohlmann, T; Dalla Venezia, N				Dizin, Eva; Gressier, Celine; Magnard, Clemence; Ray, Hind; Decimo, Didier; Ohlmann, Theophile; Dalla Venezia, Nicole			BRCA1 interacts with poly(A)-binding protein - Implication of BRCA1 in translation regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; NUCLEAR EXPORT SEQUENCE; SPORADIC BREAST-CANCER; ACETYL-COA CARBOXYLASE; MESSENGER-RNA; INITIATION-FACTOR; SUBCELLULAR-LOCALIZATION; DNA-REPAIR; FUNCTIONAL INTERACTION; TUMOR-FORMATION	BRCA1 has been implicated in a number of cellular processes, including transcription regulation, DNA damage repair, cell cycle control, and apoptosis. We identified poly( A)-binding protein 1 ( PABP) as a novel BRCA1-interacting protein in a yeast two-hybrid screen and confirmed the interaction by in vitro assays and coimmunoprecipitation in mammalian cells. Endogenous interaction between BRCA1 and PABP was also observed. This interaction was abolished by BRCA1 cancer-associated mutations, suggesting that it may be physiologically relevant. Deletion mapping demonstrated that the RNA recognition motifs 1-4 region of PABP is required to mediate the interaction with BRCA1. To understand the biological function of the BRCA1-PABP complex, we sought to determine whether BRCA1 is a modulator of translation. We showed here that inhibition of endogenous BRCA1 using a small interfering RNA-based approach decreased protein synthesis. Conversely, overexpression of BRCA1 activated translation. Using a RNA transfection approach, we clearly showed that BRCA1 modulates translation, independently of any transcriptional activity. The data presented here suggest that BRCA1 modulates protein synthesis via its interaction with PABP, providing a novel mechanism by which BRCA1 may exert its tumor suppressor function.	Univ Lyon 1, Fac Med Rockefeller, CNRS, UMR 5201,Lab Genet Mol Signalisat & Canc, F-69373 Lyon 08, France; Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Dalla Venezia, N (corresponding author), Univ Lyon 1, Fac Med Rockefeller, CNRS, UMR 5201,Lab Genet Mol Signalisat & Canc, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	ohlmann, Theophile/M-4463-2014; VENEZIA, Nicole DALLA/C-6542-2017; Ohlmann, Theophile/H-6522-2016	ohlmann, Theophile/0000-0002-2001-8916; VENEZIA, Nicole DALLA/0000-0002-4553-3535; Decimo, Didier/0000-0002-0390-1205				Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Collier B, 2005, EMBO J, V24, P2656, DOI 10.1038/sj.emboj.7600738; Copeland PR, 2001, RNA, V7, P875, DOI 10.1017/S1355838201010020; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Koloteva-Levine N, 2004, MOL CELL BIOL, V24, P3577, DOI 10.1128/MCB.24.9.3577-3587.2004; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magnard C, 2002, ONCOGENE, V21, P6729, DOI 10.1038/sj.onc.1205915; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moreau K, 2006, J BIOL CHEM, V281, P3172, DOI 10.1074/jbc.M504652200; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shuda M, 2000, ANTICANCER RES, V20, P2489; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	62	22	22	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24236	24246		10.1074/jbc.M602176200	http://dx.doi.org/10.1074/jbc.M602176200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16782705	hybrid			2022-12-25	WOS:000239847800017
J	Guo, MX; Wang, D; Shao, HJ; Qiu, HL; Xue, L; Zhao, ZZ; Zhu, CG; Shi, YB; Li, WX				Guo, Ming-Xiong; Wang, Di; Shao, Huan-Jie; Qiu, Hong-Ling; Xue, Lu; Zhao, Zhou-Zhou; Zhu, Chen-Gang; Shi, Yun-Bo; Li, Wen-Xin			Transcription of human zinc finger ZNF268 gene requires an intragenic promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; CANDIDATE GENE; NUCLEAR FACTOR; HUMAN EMBRYO; CYCLIC-AMP; DNA; CREB; LEUKEMIA; IDENTIFICATION; CAMP	Human ZNF268 gene is a typical Kruppel-associated box/C2H2 zinc finger gene whose homolog has been found only in higher mammals and not in lower mammals such as mouse. Its expression profiles have suggested that it plays a role in the differentiation of blood cells during early human embryonic development and the pathogenesis of leukemia. To gain additional insight into the molecular mechanisms controlling the expression of the ZNF268 gene and to provide the necessary tools for further genetic studies of leukemia, we have mapped the 5'-end of the human ZNF268 mRNA by reverse transcription-PCR and primer extension assays. We then cloned the 5'-flanking genomic-DNA-containing the putative ZNF268 gene promoter and analyzed its function in several different human and mouse tissue culture cell lines. Interestingly, our studies show that the ZNF268 gene lacks a typical eukaryotic promoter that is present upstream of the transcription start site and directs a basal level of transcription. Instead, the functional promoter requires an essential element that is located within the first exon of the gene. Deletion and mutational analysis reveals the requirement for a cAMP response-element-binding protein (CREB)-binding site within this element for promoter function. Gel mobility shift and chromatin immunoprecipitation assays confirm that CREB-2 binds to the site in vitro and in vivo. Furthermore, overexpression of CREB-2 enhances the promoter activity. These results demonstrate that the human ZNF268 gene promoter is atypical and requires an intragenic element located within the first exon that mediates the effect of CREB for its activity.	Wuhan Univ, Coll Life Sci, State Key Virol, Wuhan 430072, Peoples R China; NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Wuhan University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Li, WX (corresponding author), Wuhan Univ, Coll Life Sci, State Key Virol, Wuhan 430072, Peoples R China.	Liwxlab@whu.edu.cn	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Shi, Yun-Bo/0000-0002-6330-0639				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, P425; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CAREY M, 2000, TRANSCRIPTIONAL REGU, P99; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Courtes C, 2000, J BIOL CHEM, V275, P949, DOI 10.1074/jbc.275.2.949; Dai KS, 1999, J MOL CELL CARDIOL, V31, P1749, DOI 10.1006/jmcc.1999.1011; Dreyer SD, 1998, MAMM GENOME, V9, P458; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Gou DM, 2001, GENE, V278, P141, DOI 10.1016/S0378-1119(01)00701-6; Gou DM, 2001, BBA-GENE STRUCT EXPR, V1518, P306, DOI 10.1016/S0167-4781(01)00194-4; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraiwa N, 2003, BLOOD, V101, P3615, DOI 10.1182/blood-2002-07-2301; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JEFFERS M, 1994, BBA-GENE STRUCT EXPR, V1219, P623, DOI 10.1016/0167-4781(94)90221-6; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; Krackhardt AM, 2002, BLOOD, V100, P2123, DOI 10.1182/blood-2002-02-0513; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Mora-Garcia P, 2003, STEM CELLS, V21, P123, DOI 10.1634/stemcells.21-2-123; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; Peng Xiao, 2004, Acta Genetica Sinica, V31, P221; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Riese U, 2000, MOL CELL BIOCHEM, V212, P45, DOI 10.1023/A:1007196602659; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Rousseau-Merck MF, 2002, CYTOGENET GENOME RES, V98, P147, DOI 10.1159/000069802; Sambrook J., 2001, MOL CLONING LAB MANU, P463; Shankar DB, 2005, CANCER-AM CANCER SOC, V104, P1819, DOI 10.1002/cncr.21401; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sun Y, 2004, INT J MOL MED, V14, P971; Sun Y, 2003, IUBMB LIFE, V55, P127, DOI 10.1080/1521654031000110208; Takase K, 2001, SCHIZOPHR RES, V52, P161, DOI 10.1016/S0920-9964(00)00191-2; TOMMERUP N, 1993, HUM MOL GENET, V2, P1571, DOI 10.1093/hmg/2.10.1571; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHENG YW, 1994, J BIOL CHEM, V269, P22593; Zhou L, 2002, BIOCHEM BIOPH RES CO, V295, P862, DOI 10.1016/S0006-291X(02)00759-3	54	15	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24623	24636		10.1074/jbc.M602753200	http://dx.doi.org/10.1074/jbc.M602753200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787922	Green Submitted, hybrid			2022-12-25	WOS:000239847800057
J	Masuda, Y; Kamiya, K				Masuda, Yuji; Kamiya, Kenji			Role of single-stranded DNA in targeting REV1 to primer termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYCYTIDYL TRANSFERASE-ACTIVITY; POLYMERASE-ZETA; ABASIC SITES; YEAST REV1; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS; CATALYTIC SUBUNIT; Y-FAMILY; IN-VIVO; ESCHERICHIA-COLI	Cellular functions of the REV1 gene have been conserved in evolution and appear important for maintaining genetic integrity through translesion DNA synthesis. This study documents a novel biochemical activity of human REV1 protein, due to higher affinity for single-stranded DNA ( ssDNA) than the primer terminus. Preferential binding to long ssDNA regions of the template strand means that REV1 is targeted specifically to the included primer termini, a property not shared by other DNA polymerases, including human DNA polymerases alpha, beta, and eta. Furthermore, a mutant REV1 lacking N- and C-terminal domains, but catalytically active, lost this function, indicating that control is not due to the catalytic core. The novel activity of REV1 protein might imply a role for ssDNA in the regulation of translesion DNA synthesis.	Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Kamiya, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	kkamiya@hiroshima-u.ac.jp	Masuda, Yuji/I-6315-2014	Masuda, Yuji/0000-0002-6229-1988				Acharya N, 2005, MOL CELL BIOL, V25, P9734, DOI 10.1128/MCB.25.21.9734-9740.2005; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Auerbach P, 2005, P NATL ACAD SCI USA, V102, P17711, DOI 10.1073/pnas.0504643102; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Clark DR, 2003, NUCLEIC ACIDS RES, V31, P4981, DOI 10.1093/nar/gkg725; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Guo DY, 2004, NUCLEIC ACIDS RES, V32, P1122, DOI 10.1093/nar/gkh279; Haracska L, 2002, J BIOL CHEM, V277, P15546, DOI 10.1074/jbc.M112146200; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Jansen JG, 2005, NUCLEIC ACIDS RES, V33, P356, DOI 10.1093/nar/gki189; Jansen JG, 2003, DNA REPAIR, V2, P1075, DOI 10.1016/S1568-7864(03)00119-8; LAWRENCE CW, 1985, MOL GEN GENET, V200, P80, DOI 10.1007/BF00383316; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LEMONTT JF, 1971, GENETICS, V68, P21; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Masuda Y, 2003, J BIOL CHEM, V278, P12356, DOI 10.1074/jbc.M211765200; Masuda Y, 2002, FEBS LETT, V520, P88, DOI 10.1016/S0014-5793(02)02773-4; Masuda Y, 2002, J BIOL CHEM, V277, P3040, DOI 10.1074/jbc.M110149200; Masuda Y, 2001, J BIOL CHEM, V276, P15051, DOI 10.1074/jbc.M008082200; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nelson JR, 2000, MOL MICROBIOL, V37, P549, DOI 10.1046/j.1365-2958.2000.01997.x; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Niimi A, 2004, MOL CELL BIOL, V24, P2734, DOI 10.1128/MCB.24.7.2734-2746.2004; Ohashi E, 2004, GENES CELLS, V9, P523, DOI 10.1111/j.1356-9597.2004.00747.x; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Okada T, 2005, MOL CELL BIOL, V25, P6103, DOI 10.1128/MCB.25.14.6103-6111.2005; Otsuka C, 2005, MUTAT RES-FUND MOL M, V578, P79, DOI 10.1016/j.mrfmmm.2005.03.005; Otsuka C, 2002, NUCLEIC ACIDS RES, V30, P5129, DOI 10.1093/nar/gkf666; Otsuka C, 2002, MUTAT RES-FUND MOL M, V502, P53, DOI 10.1016/S0027-5107(02)00023-4; Poltoratsky V, 2005, DNA REPAIR, V4, P1182, DOI 10.1016/j.dnarep.2005.05.002; Ross AL, 2005, NUCLEIC ACIDS RES, V33, P1280, DOI 10.1093/nar/gki279; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simpson LJ, 2003, EMBO J, V22, P1654, DOI 10.1093/emboj/cdg161; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tissier A, 2004, DNA REPAIR, V3, P1503, DOI 10.1016/j.dnarep.2004.06.015; Van Sloun PPH, 1999, MUTAT RES-DNA REPAIR, V433, P109, DOI 10.1016/S0921-8777(98)00067-6; Waters LS, 2006, P NATL ACAD SCI USA, V103, P8971, DOI 10.1073/pnas.0510167103; YASUDA S, 1983, J BACTERIOL, V154, P1153, DOI 10.1128/JB.154.3.1153-1161.1983; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630; Zhao B, 2004, NUCLEIC ACIDS RES, V32, P3984, DOI 10.1093/nar/gkh710	52	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24314	24321		10.1074/jbc.M602967200	http://dx.doi.org/10.1074/jbc.M602967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803901	hybrid			2022-12-25	WOS:000239847800024
J	Talley, TT; Olivera, BM; Han, KH; Christensen, SB; Dowell, C; Tsigelny, I; Ho, KY; Taylor, P; McIntosh, JM				Talley, Todd T.; Olivera, Baldomero M.; Han, Kyou-Hoon; Christensen, Sean B.; Dowell, Cheryl; Tsigelny, Igor; Ho, Kwok-Yiu; Taylor, Palmer; McIntosh, J. Michael			alpha-Conotoxin OmIA is a potent ligand for the acetylcholine-binding protein as well as alpha 3 beta 2 and alpha 7 nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; REVEALS; ACHBP; COMPLEX; INHIBITION; ANTAGONIST; AGONISTS; PEPTIDE	The molluskan acetylcholine-binding protein ( AChBP) is a homolog of the extracellular binding domain of the pentameric ligand-gated ion channel family. AChBP most closely resembles the alpha-subunit of nicotinic acetylcholine receptors and in particular the homomeric alpha 7 nicotinic receptor. We report the isolation and characterization of an alpha-conotoxin that has the highest known affinity for the Lymnaea AChBP and also potently blocks the alpha 7 nAChR subtype when expressed in Xenopus oocytes. Remarkably, the peptide also has high affinity for the alpha 3 beta 2 nAChR indicating that alpha-conotoxin OmIA in combination with the AChBP may serve as a model system for understanding the binding determinants of alpha 3 beta 2 nAChRs. alpha-Conotoxin OmIA was purified from the venom of Conus omaria. It is a 17-amino-acid, two-disulfide bridge peptide. The ligand is the first alpha-conotoxin with higher affinity for the closely related receptor subtypes, alpha 3 beta 2 versus alpha 6 beta 2, and selectively blocks these two subtypes when compared with alpha 2 beta 2, alpha 4 beta 2, and alpha 1 beta 1 delta epsilon nAChRs.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Calif La Jolla, Dept Pharmacol, La Jolla, CA 92093 USA; Korea Res Inst Biosci & Biotechnol, Mol Anti Canc Res Ctr, Div Mol Therapeut, Taejon, South Korea; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; University of California System; University of California San Diego; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Utah System of Higher Education; University of Utah	McIntosh, JM (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E, Salt Lake City, UT 84112 USA.	mcintosh.mike@gmail.com	Talley, Todd/B-3630-2010	Talley, Todd/0000-0002-1077-1947	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053631, R01MH053631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U01DA019372] Funding Source: NIH RePORTER; NIDA NIH HHS [U01 DA019372, U01-DA019372] Funding Source: Medline; NIGMS NIH HHS [GM48677, R37-GM18360, P01 GM048677, R37 GM018360] Funding Source: Medline; NIMH NIH HHS [R29 MH053631, MH53631, R01 MH053631-11S1, R01 MH053631-11, R01 MH053631] Funding Source: Medline; NINDS NIH HHS [NS 043063, F32 NS043063-01, F32 NS043063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Azam L, 2005, J BIOL CHEM, V280, P80, DOI 10.1074/jbc.M406281200; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Changeux J-P, 2005, NICOTINIC ACETYLCHOL; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chi SW, 2006, BIOCHEM BIOPH RES CO, V345, P248, DOI 10.1016/j.bbrc.2006.04.099; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; Dowell C, 2003, J NEUROSCI, V23, P8445; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; Dutertre S, 2004, J MOL RECOGNIT, V17, P339, DOI 10.1002/jmr.683; Ellison M, 2003, J BIOL CHEM, V278, P757, DOI 10.1074/jbc.M204565200; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Hibbs RE, 2005, BIOCHEMISTRY-US, V44, P16602, DOI 10.1021/bi051735p; Hibbs RE, 2004, J BIOL CHEM, V279, P28483, DOI 10.1074/jbc.M403713200; Hogg RC, 1999, J BIOL CHEM, V274, P36559, DOI 10.1074/jbc.274.51.36559; Janes RW, 2005, CURR OPIN PHARMACOL, V5, P280, DOI 10.1016/j.coph.2005.01.013; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Kehoe J, 1998, J NEUROSCI, V18, P8198; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; Luo SQ, 1998, J NEUROSCI, V18, P8571; McIntosh JM, 2005, J BIOL CHEM, V280, P30107, DOI 10.1074/jbc.M504102200; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; McIntosh JM, 2002, J BIOL CHEM, V277, P33610, DOI 10.1074/jbc.M205102200; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; Nicke A, 2004, EUR J BIOCHEM, V271, P2305, DOI 10.1111/j.1432-1033.2004.04145.x; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Quik M, 2005, MOL PHARMACOL, V67, P32, DOI 10.1124/mol.104.006015; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; Shi JX, 2006, J BIOL CHEM, V281, P12170, DOI 10.1074/jbc.M600154200; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Taylor P, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P271; Vulfius CA, 2005, NEUROSCI LETT, V373, P232, DOI 10.1016/j.neulet.2004.10.010; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664	43	49	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24678	24686		10.1074/jbc.M602969200	http://dx.doi.org/10.1074/jbc.M602969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803900	Green Accepted, hybrid			2022-12-25	WOS:000239847800063
J	Allison, SJ; Baldock, P; Sainsbury, A; Enriquez, R; Lee, NJ; Lin, EJD; Klugman, M; During, M; Eisman, JA; Li, M; Pan, LC; Herzog, H; Gardiner, EM				Allison, Susan J.; Baldock, Paul; Sainsbury, Amanda; Enriquez, Ronaldo; Lee, Nicola J.; Lin, En-Ju Deborah; Klugman, Matthias; During, Matthew; Eisman, John A.; Li, Mei; Pan, Lydia C.; Herzog, Herbert; Gardiner, Edith M.			Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; Y2 RECEPTORS; OB/OB MICE; OSTEOPOROSIS; BODY; EXPRESSION; OSTEOBLASTS; OVARIECTOMY; ALENDRONATE	Reduction in levels of sex hormones at menopause in women is associated with two common, major outcomes, the accumulation of white adipose tissue, and the progressive loss of bone because of excess osteoclastic bone resorption exceeding osteoblastic bone formation. Current antiresorptive therapies can reduce osteoclastic activity but have only limited capacity to stimulate osteoblastic bone formation and restore lost skeletal mass. Likewise, the availability of effective pharmacological weight loss treatments is currently limited. Here we demonstrate that conditional deletion of hypothalamic neuropeptide Y2 receptors can prevent ongoing bone loss in sex hormone-deficient adult male and female mice. This benefit is attributable solely to activation of an anabolic osteoblastic bone formation response that counterbalances persistent elevation of bone resorption, suggesting the Y2-mediated anabolic pathway to be independent of sex hormones. Furthermore, the increase in fat mass that typically occurs after ovariectomy is prevented by germ line deletion of Y2 receptors, whereas in male mice body weight and fat mass were consistently lower than wild-type regardless of sex hormone status. Therefore, this study indicates a role for Y2 receptors in the accumulation of adipose tissue in the hypogonadal state and demonstrates that hypothalamic Y2 receptors constitutively restrain osteoblastic activity even in the absence of sex hormones. The increase in bone formation after release of this tonic inhibition suggests a promising new avenue for osteoporosis treatment.	St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia; Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand; Univ Queensland, Princess Alexandra Hosp, Sch Med, Brisbane, Qld 4120, Australia; Pfizer Global Res & Dev Inc, Groton, CT 06340 USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Auckland; University of Queensland; Pfizer	Herzog, H (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	h.herzog@garvan.org.au	During, Matthew/AAC-1388-2020; /E-2900-2010; Baldock, Paul/B-3840-2012; Eisman, John A/C-2886-2014; /B-2038-2013; Salis, Amanda/A-3187-2011; Herzog, Herbert/B-8294-2008	/0000-0001-7766-6095; Salis, Amanda/0000-0001-9176-1574; , Herbert/0000-0002-1713-1029				Ainslie DA, 2001, INT J OBESITY, V25, P1680, DOI 10.1038/sj.ijo.0801806; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Baldock PAJ, 1998, J BONE MINER RES, V13, P1451, DOI 10.1359/jbmr.1998.13.9.1451; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Denes A, 2005, NEUROSCIENCE, V134, P947, DOI 10.1016/j.neuroscience.2005.03.060; Escobar CM, 2004, J CLIN ENDOCR METAB, V89, P2338, DOI 10.1210/jc.2003-031899; Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725; Godsland IF, 2004, CLIN ENDOCRINOL, V60, P541, DOI 10.1111/j.1365-2265.2004.02017.x; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Inoue K, 1997, J BONE MINER RES, V12, P989, DOI 10.1359/jbmr.1997.12.6.989; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; McCarthy TL, 2001, GROWTH HORM IGF RES, V11, P213, DOI 10.1054/ghir.2001.0236; Naveilhan P, 2002, PEPTIDES, V23, P1087, DOI 10.1016/S0196-9781(02)00042-6; POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003-4819-123-9-199511010-00005; REHMAN MTA, 1994, J CLIN PATHOL, V47, P529, DOI 10.1136/jcp.47.6.529; REID IR, 1992, J CLIN ENDOCR METAB, V75, P45, DOI 10.1210/jc.75.1.45; ROHOLL PJM, 1994, J BONE MINER RES, V9, P355; Sainsbury A, 2002, P NATL ACAD SCI USA, V99, P8938, DOI 10.1073/pnas.132043299; Sainsbury A, 2002, DIABETES, V51, P3420, DOI 10.2337/diabetes.51.12.3420; Shimizu H, 1996, NEUROSCI LETT, V204, P81, DOI 10.1016/0304-3940(96)12322-3; Toth MJ, 2000, ANN NY ACAD SCI, V904, P502; Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002-9343(99)00420-9; WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756-3282(86)90683-6; WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453	26	51	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23436	23444		10.1074/jbc.M604839200	http://dx.doi.org/10.1074/jbc.M604839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785231	Green Published, hybrid			2022-12-25	WOS:000239702900018
J	Hinoi, E; Ueshima, T; Hojo, H; Iemata, M; Takarada, T; Yoneda, Y				Hinoi, Eiichi; Ueshima, Taichi; Hojo, Hironori; Iemata, Mika; Takarada, Takeshi; Yoneda, Yukio			Up-regulation of per mRNA expression by parathyroid hormone through a protein kinase A-CREB-dependent mechanism in chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE; CIRCADIAN CLOCK; GENE-EXPRESSION; GROWTH-PLATE; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; MOLECULAR CLOCK; IN-VIVO; CELLS; TRANSCRIPTION	In bone, clock genes are involved in the circadian oscillation of bone formation and extracellular matrix expression. However, to date little attention has been paid to circadian rhythm in association with expression of clock genes during chondrogenesis in cartilage. In this study, we investigated the functional expression of different clock genes by chondrocytes in the course of cartilage development. The mRNA expression of types I, II, and X collagens exhibited a 24-h rhythm with a peak at zeitgeber time 6, in addition to a 24-h rhythmicity of all the clock genes examined in mouse femurs in vivo. Marked expression of different clock genes was seen in both osteoblastic MC3T3-E1 and chondrogenic ATDC5 cells in vitro, whereas parathyroid hormone (PTH) transiently increased period 1 (per1) mRNA expression at 1 h inboth cell lines. Similar increases were seen in the mRNA levels for both per1 and per2 in prehypertrophic chondrocytes in metatarsal organotypic cultures within 2 h of exposure to PTH. PTH significantly activated the mouse per1 (mper1) and mper2 promoters but not the mper3 promoter in a manner sensitive to both a protein kinase A inhibitor and deletion of the cAMP-responsive element sequence (CRE) in ATDC5cells. In HEK293 cells, introduction of brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1 (bmal1)/clock enhanced mouse type II collagen first intron reporter activity without affecting promoter activity, with reduction effected by either per1 or per2. These results suggest that PTH directly stimulates mper expression through a protein kinase A-CRE-binding protein signaling pathway for subsequent regulation of bmal1/clock-dependent extracellular matrix expression in cartilage.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.	yyoneda@p.kanazawa-u.ac.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X; Takarada-Iemata, Mika/0000-0002-2113-0707; Takarada, Takeshi/0000-0002-2363-7704; Hojo, Hironori/0000-0003-2245-6853				BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534-5807(02)00218-6; Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02-0820fje; Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Muhlbauer E, 2004, FEBS LETT, V564, P91, DOI 10.1016/S0014-5793(04)00322-9; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; Oishi K, 2005, BIOCHEM J, V386, P575, DOI 10.1042/BJ20041150; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; Ripperger JA, 2000, GENE DEV, V14, P679; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz Z, 1997, BONE, V21, P249, DOI 10.1016/S8756-3282(97)00123-3; Shimba S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI 10.1073/pnas.0502383102; SIMMONS DJ, 1966, AM J PHYSIOL, V210, P411, DOI 10.1152/ajplegacy.1966.210.2.411; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358; Yamaguchi S, 2000, CURR BIOL, V10, P873, DOI 10.1016/S0960-9822(00)00602-3; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Yoshida E, 2001, EXP CELL RES, V265, P64, DOI 10.1006/excr.2001.5161; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200	34	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23632	23642		10.1074/jbc.M512362200	http://dx.doi.org/10.1074/jbc.M512362200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777848	hybrid			2022-12-25	WOS:000239702900038
J	Bieganowski, P; Seidle, HF; Wojcik, M; Brenner, C				Bieganowski, Pawel; Seidle, Heather F.; Wojcik, Marzena; Brenner, Charles			Synthetic lethal and biochemical analyses of NAD and NADH kinases in Saccharomyces cerevisiae establish separation of cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIPHOSPHOPYRIDINE NUCLEOTIDE; YEAST MITOCHONDRIA; GENE; IDENTIFICATION; EXPRESSION; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; BIOSYNTHESIS; VECTORS; SYSTEM	Production of NADP and NADPH depends on activity of NAD and NADH kinases. Here we characterized all combinations of mutants in yeast NAD and NADH kinases to determine their physiological roles. We constructed a diploid strain heterozygous for disruption of POS5, encoding mitochondrial NADH kinase, UTR1, cytosolic NAD kinase, and YEF1, a UTR1-homologous gene we characterized as encoding a low specific activity cytosolic NAD kinase. pos5 utr1 is a synthetic lethal combination rescued by plasmid-borne copies of the POS5 or UTR1 genes or by YEF1 driven by the ADH1 promoter. Respiratory-deficient and oxidative damage-sensitive defects in pos5 mutants were not made more deleterious by yef1 deletion, and a quantitative growth phenotype of pos5 and its arginine auxotrophy were repaired by plasmid-borne POS5 but not UTR1 or ADH1-driven YEF1. utr1 haploids have a slow growth phenotype on glucose not exacerbated by yef1 deletion but reversed by either plasmid-borne UTR1 or ADH1-driven YEF1. The defect in fermentative growth of utr1 mutants renders POS5 but not POS5-dependent mitochondrial genome maintenance essential because rho-utr1 derivatives are viable. Purified Yef1 has similar nucleoside triphosphate specificity but substantially lower specific activity and less discrimination in favor of NAD versus NADH phosphorylation than Utr1. Low expression and low intrinsic NAD kinase activity of Yef1 and the lack of phenotype associated with yef1 suggest that Utr1 and Pos5 are responsible for essentially all NAD/NADH kinase activity in vivo. The data are compatible with a model in which there is no exchange of NADP, NADPH, or cytoplasmic NAD/NADH kinase between nucleocytoplasmic and mitochondrial compartments, but the cytoplasm is exposed to mitochondrial NAD/NADH kinase during the transit of the molecule.	Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Int Inst Moll & Cell Biol, PL-02109 Warsaw, Poland; Polish Acad Sci, Ctr Mol & Macromol Studies, Dept Bioorgan Chem, PL-90363 Lodz, Poland	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences; Centre of Molecular & Macromolecular Studies of the Polish Academy of Sciences	Brenner, C (corresponding author), Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Wojcik, Marzena/S-9411-2016; Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; wojcik, marzena/0000-0001-5563-8122; Brenner, Charles/0000-0002-4955-3226				APPS DK, 1970, EUR J BIOCHEM, V13, P223, DOI 10.1111/j.1432-1033.1970.tb00921.x; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BARRY K, 1987, MOL CELL BIOL, V7, P632, DOI 10.1128/MCB.7.2.632; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7; Bieganowski P, 2003, J BIOL CHEM, V278, P33049, DOI 10.1074/jbc.M302257200; Brachmann CB, 1998, YEAST, V14, P115; Butcher RA, 2004, P NATL ACAD SCI USA, V101, P7868, DOI 10.1073/pnas.0402317101; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; Emanuelli M, 2003, PROTEIN EXPRES PURIF, V27, P357, DOI 10.1016/S1046-5928(02)00645-9; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; Grabowska D, 2003, J BIOL CHEM, V278, P13984, DOI 10.1074/jbc.M210076200; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; Kawai S, 2001, FEMS MICROBIOL LETT, V200, P181, DOI 10.1111/j.1574-6968.2001.tb10712.x; Kerr KM, 2000, BIOCHEMISTRY-US, V39, P9804, DOI 10.1021/bi0005409; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; Kmita H, 2000, BBA-BIOMEMBRANES, V1509, P86, DOI 10.1016/S0005-2736(00)00284-4; KREHL WA, 1945, SCIENCE, V101, P489, DOI 10.1126/science.101.2628.489; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; MAAYAN ML, 1964, NATURE, V204, P1169, DOI 10.1038/2041169a0; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MUNSON M, 1994, GENE, V144, P59, DOI 10.1016/0378-1119(94)90203-8; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; PREISS J, 1958, J BIOL CHEM, V233, P488; PREISS J, 1958, J BIOL CHEM, V233, P493; Raffaelli N, 2004, BIOCHEMISTRY-US, V43, P7610, DOI 10.1021/bi049650w; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; Rutter Guy A, 2003, Biochem J, V373, pe3, DOI 10.1042/BJ20030472COM; SCHUTZ G, 1972, J BIOL CHEM, V247, P5327; Shi F, 2005, FEBS J, V272, P3337, DOI 10.1111/j.1742-4658.2005.04749.x; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; SLONIMSKI PP, 1968, BIOCHEM BIOPH RES CO, V30, P232, DOI 10.1016/0006-291X(68)90440-3; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Strand MK, 2003, EUKARYOT CELL, V2, P809, DOI 10.1128/EC.2.4.809-820.2003; Tamura T, 1997, BIOCHEM BIOPH RES CO, V237, P419, DOI 10.1006/bbrc.1997.7153; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; Todisco S, 2006, J BIOL CHEM, V281, P1524, DOI 10.1074/jbc.M510425200; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; TSENG YM, 1979, BIOCHIM BIOPHYS ACTA, V568, P205, DOI 10.1016/0005-2744(79)90287-0; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	50	43	45	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22439	22445		10.1074/jbc.M513919200	http://dx.doi.org/10.1074/jbc.M513919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760478	hybrid			2022-12-25	WOS:000239542600004
J	Bittencourt, VCB; Figueiredo, RT; da Silva, RB; Mourao-Sa, DS; Fernandez, PL; Sassaki, GL; Mulloy, B; Bozza, MT; Barreto-Bergter, E				Bittencourt, Vera Carolina B.; Figueiredo, Rodrigo T.; da Silva, Rosana B.; Mourao-Sa, Diego S.; Fernandez, Patricia L.; Sassaki, Guilherme L.; Mulloy, Barbara; Bozza, Marcelo T.; Barreto-Bergter, Eliana			An alpha-glucan of Pseudallescheria boydii is involved in fungal phagocytosis and toll-like receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE CELLS; CANDIDA; TLR4; RECOGNITION; DECTIN-1; MICE; CD14; SUSCEPTIBILITY; INDUCTION; RESPONSES	The host response to fungi is in part dependent on activation of evolutionarily conserved receptors, including toll-like receptors and phagocytic receptors. However, the molecular nature of fungal ligands responsible for this activation is largely unknown. Herein, we describe the isolation and structural characterization of an alpha-glucan from Pseudallescheria boydii cell wall and evaluate its role in the induction of innate immune response. These analyses indicate that alpha-glucan of P. boydii is a glycogen-like polysaccharide consisting of linear 4-linked alpha-D-Glcp residues substituted at position 6 with alpha-D-Glcp branches. Soluble alpha-glucan, but not alpha-glucan, led to a dose-dependent inhibition of conidia phagocytosis. Furthermore, a significant decrease in the phagocytic index occurred when alpha-glucan from conidial surface was removed by enzymatic treatment with alpha-amyloglucosidase, thus indicating an essential role of alpha-glucan in P. boydii internalization by macrophages. alpha-Glucan stimulates the secretion of inflammatory cytokines by macrophages and dendritic cells; again this effect is abolished by treatment with alpha-amyloglucosidase. Finally, alpha-glucan induces cytokine secretion by cells of the innate immune system in a mechanism involving toll-like receptor 2, CD14, and MyD88. These results might have relevance in the context of infections with P. boydii and other fungi, and alpha-glucan could be a target for intervention during fungal infections.	Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Microbiol Geral, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Parana, Dept Bioquim, BR-81531990 Curitiba, Parana, Brazil; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Parana; National Institute for Biological Standards & Control	Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Ave Brigadeiro Trompowsky S-N,CCS Bloco 1, BR-21941590 Rio De Janeiro, Brazil.	mbozza@micro.ufrj.br; eliana.bergter@micro.ufrj.br	Sassaki, Guilherme/AAM-1112-2020; Mourao-Sa, Diego/C-5977-2009; Bergter, Eliana Barreto/E-2664-2013; Bittencourt, Vera CB/A-7921-2019; Figueiredo, Rodrigo/F-5176-2016	Sassaki, Guilherme/0000-0001-7420-168X; Bozza, Marcelo/0000-0003-3683-7550; Mourao, Diego/0000-0001-6618-6969; bittencourt, vera/0000-0002-7403-9747; Llanes Fernandez, Patricia/0000-0002-0762-0566; Figueiredo, Rodrigo/0000-0002-7551-8782				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bahia MCFD, 1997, MYCOPATHOLOGIA, V137, P17, DOI 10.1023/A:1006862420963; Balloy V, 2005, INFECT IMMUN, V73, P5420, DOI 10.1128/IAI.73.9.5420-5425.2005; Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059; BJORNDAL H, 1967, U STOCKOL CHEM COMMU, V8, P1; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Cano LE, 1998, INFECT IMMUN, V66, P800, DOI 10.1128/IAI.66.2.800-806.1998; Cenci E, 1998, J IMMUNOL, V161, P3543; Cenci E, 1999, J INFECT DIS, V180, P1957, DOI 10.1086/315142; CHEETHAM NWH, 1991, CARBOHYD RES, V215, P59, DOI 10.1016/0008-6215(91)84007-2; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; Flo TH, 2000, INFECT IMMUN, V68, P6770, DOI 10.1128/IAI.68.12.6770-6776.2000; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gil-Lamaignere C, 2003, INFECT IMMUN, V71, P6472, DOI 10.1128/IAI.71.11.6472-6478.2003; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511; NEWMAN SL, 1995, J IMMUNOL, V154, P753; Park JM, 2004, J EXP MED, V200, P1647, DOI 10.1084/jem.20041215; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Popi AF, 2002, CELL IMMUNOL, V218, P87, DOI 10.1016/S0008-8749(02)00576-2; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Tischer CA, 2002, CARBOHYD POLYM, V47, P151, DOI 10.1016/S0144-8617(01)00173-4; Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020; WANG RH, 1995, BIOCHEM J, V311, P867, DOI 10.1042/bj3110867; WASHBURN RG, 1987, INFECT IMMUN, V55, P2088, DOI 10.1128/IAI.55.9.2088-2092.1987; ZANG LH, 1991, CARBOHYD RES, V220, P1, DOI 10.1016/0008-6215(91)80001-4	53	106	109	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22614	22623		10.1074/jbc.M511417200	http://dx.doi.org/10.1074/jbc.M511417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766532	hybrid			2022-12-25	WOS:000239542600022
J	Clark, RJ; Fischer, H; Nevin, ST; Adams, DJ; Craik, DJ				Clark, Richard J.; Fischer, Harald; Nevin, Simon T.; Adams, David J.; Craik, David J.			The synthesis, structural characterization, and receptor specificity of the alpha-conotoxin Vc1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC-ACETYLCHOLINE-RECEPTOR; 3-DIMENSIONAL SOLUTION STRUCTURE; NMR STRUCTURE CALCULATION; 1.1 ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; SUBTYPE SELECTIVITY; PEPTIDE ANTAGONIST; CONUS-EPISCOPATUS; CHROMAFFIN CELLS; HOMOLOG ACHBP	The alpha-conotoxin Vc1.1 is a small disulfide-bonded peptide currently in development as a treatment for neuropathic pain. This study describes the synthesis, determination of the disulfide connectivity, and the determination of the three-dimensional structure of Vc1.1 using NMR spectroscopy. Vc1.1 was shown to inhibit nicotine-evoked membrane currents in isolated bovine chromaffin cells in a concentration-dependent manner and preferentially targets peripheral nicotinic acetylcholine receptor (nAChR) subtypes over central subtypes. Specifically, Vc1.1 is selective for alpha 3-containing nAChR subtypes. The three-dimensional structure of Vc1.1 comprises a small alpha-helix spanning residues Pro(6) to Asp(11) and is braced by the I-III, II-IV disulfide connectivity seen in other alpha-conotoxins. A comparison of the structure of Vc1.1 with other alpha-conotoxins, taken together with nAChR selectivity data, suggests that the conserved proline at position 6 is important for binding, whereas a number of residues in the C-terminal portion of the peptide contribute toward the selectivity. The structure reported here should open new opportunities for further development of Vc1.1 or analogues as analgesic agents.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Adams, David John/K-3578-2019; Craik, David/B-1695-2010; Clark, Richard J/G-8848-2012; Adams, David/J-9125-2014; Nevin, Simon/B-2663-2014	Adams, David John/0000-0002-7030-2288; Craik, David/0000-0003-0007-6796; Clark, Richard J/0000-0002-6807-5426; Adams, David/0000-0002-7030-2288; 				Abdrakhmanova G, 2004, MOL PHARMACOL, V66, P347, DOI 10.1124/mol.66.2.347; Adams DJ, 1999, DRUG DEVELOP RES, V46, P219; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Broxton N, 2000, EUR J PHARMACOL, V390, P229, DOI 10.1016/S0014-2999(00)00023-6; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Dutertre S, 2005, J BIOL CHEM, V280, P30460, DOI 10.1074/jbc.M504229200; Dutton JL, 2001, CURR MED CHEM, V8, P327, DOI 10.2174/0929867013373453; Ellison M, 2004, BIOCHEMISTRY-US, V43, P16019, DOI 10.1021/bi048918g; Ellison M, 2003, J BIOL CHEM, V278, P757, DOI 10.1074/jbc.M204565200; Everhart D, 2004, BIOCHEMISTRY-US, V43, P2732, DOI 10.1021/bi036180h; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; Fischer H, 2005, J NEUROSCI, V25, P3571, DOI 10.1523/JNEUROSCI.4971-04.2005; Gayler K, 2005, IEEE ENG MED BIOL, V24, P79, DOI 10.1109/MEMB.2005.1411352; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hill JM, 1998, BIOCHEMISTRY-US, V37, P15621, DOI 10.1021/bi981535w; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; Hu SH, 1997, BIOCHEMISTRY-US, V36, P11323, DOI 10.1021/bi9713052; Hu SH, 1998, BIOCHEMISTRY-US, V37, P11425, DOI 10.1021/bi9806549; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jakubowski JA, 2004, J MASS SPECTROM, V39, P548, DOI 10.1002/jms.624; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kuryatov A, 2000, NEUROPHARMACOLOGY, V39, P2570, DOI 10.1016/S0028-3908(00)00144-1; Lang PM, 2005, NEUROREPORT, V16, P479, DOI 10.1097/00001756-200504040-00012; Lang PM, 2003, J NEUROPHYSIOL, V90, P3295, DOI 10.1152/jn.00512.2003; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Livett B., 2002, Patent, Patent No. [02079236, WO 02/079236 A1]; Livett BG, 2004, CURR MED CHEM, V11, P1715, DOI 10.2174/0929867043364928; Loughnan M, 1998, J BIOL CHEM, V273, P15667, DOI 10.1074/jbc.273.25.15667; Luo S, 1999, BIOCHEMISTRY-US, V38, P14542, DOI 10.1021/bi991252j; McIntosh JM, 2004, MOL PHARMACOL, V65, P944, DOI 10.1124/mol.65.4.944; McIntosh JM, 2002, J BIOL CHEM, V277, P33610, DOI 10.1074/jbc.M205102200; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Nicke A, 2003, FEBS LETT, V554, P219, DOI 10.1016/S0014-5793(03)01161-X; Nicke A, 2003, J BIOL CHEM, V278, P3137, DOI 10.1074/jbc.M210280200; NUTTER TJ, 1995, J GEN PHYSIOL, V105, P701, DOI 10.1085/jgp.105.6.701; Quiram PA, 2000, J BIOL CHEM, V275, P4889, DOI 10.1074/jbc.275.7.4889; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; Sandall DW, 2003, BIOCHEMISTRY-US, V42, P6904, DOI 10.1021/bi034043e; Satkunanathan N, 2005, BRAIN RES, V1059, P149, DOI 10.1016/j.brainres.2005.08.009; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Shon KJ, 1997, BIOCHEMISTRY-US, V36, P15693, DOI 10.1021/bi971443r; Terlau H, 2004, PHYSIOL REV, V84, P41, DOI 10.1152/physrev.00020.2003; Ulens C, 2006, P NATL ACAD SCI USA, V103, P3615, DOI 10.1073/pnas.0507889103; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471	50	120	129	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23254	23263		10.1074/jbc.M604550200	http://dx.doi.org/10.1074/jbc.M604550200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754662	hybrid			2022-12-25	WOS:000239542600088
J	Cooper, BJ; Key, B; Carter, A; Angel, NZ; Hart, DNJ; Kato, M				Cooper, Benjamine J.; Key, Brian; Carter, Adrian; Angel, Nicola Z.; Hart, Derek N. J.; Kato, Masato			Suppression and overexpression of adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) influences zebrafish embryo development A - Possible role for AHCYL1 in inositol phospholipid signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELLS; IP3 RECEPTOR; XENOPUS-EMBRYOS; HUMAN MONOCYTES; DIFFERENTIATION; TRISPHOSPHATE; LOCALIZATION; PATHWAYS; BINDING; LAEVIS	Adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) is a novel intracellular protein with similar to 50% protein identity to adenosyl homocysteine hydrolase (AHCY), an important enzyme for metabolizing S-adenosyl-L-homocysteine, the by-product of S-adenosyl-L-homomethionine-dependent methylation. AHCYL1 binds to the inositol 1,4,5-trisphosphate receptor, suggesting that AHCYL1 is involved in intracellular calcium release. We identified two zebrafish AHCYL1 orthologs(zAHCYL1A and -B) by bioinformatics and reverse transcription-PCR. Unlike the ubiquitously present AHCY genes, AHCYL1 genes were only detected in segmented animals, and AHCYL1 proteins were highly conserved among species. Phylogenic analysis suggested that the AHCYL1 gene diverged early from AHCY and evolved independently. Quantitative reverse transcription-PCR showed that zAHCYL1A and -B mRNA expression was regulated differently from the other AHCY-like protein zAHCYL2 and zAHCY during zebrafish embryogenesis. Injection of morpholino antisense oligonucleotides against zAHCYL1A and -B into zebrafish embryos inhibited zAHCYL1A and -B mRNA translation specifically and induced ventralized morphologies. Conversely, human and zebrafish AHCYL1A mRNA injection into zebrafish embryos induced dorsalized morphologies that were similar to those obtained by depleting intracellular calcium with thapsigargin. Human AHCY mRNA injection showed little effect on the embryos. These data suggest that AHCYL1 has a different function from AHCY and plays an important role in embryogenesis by modulating inositol 1,4,5-trisphosphate receptor function for the intracellular calcium release.	Mater Med Res Inst, Dendrit Cell Program, Brisbane, Qld 4101, Australia; Univ Queensland, Discipline Anat & Dev Biol, Sch Biomed Sci, Brisbane, Qld 4172, Australia; Univ Queensland, Sch Med, Herston, Qld 4006, Australia	Mater Research; University of Queensland; University of Queensland	Kato, M (corresponding author), Mater Med Res Inst, Aubigny Pl, Brisbane, Qld 4101, Australia.	mkato@mmri.mater.org.au	Hart, Derek NJ/B-9505-2014; Carter, Adrian/AAG-2830-2020; Carter, Adrian N/A-1282-2008	Carter, Adrian/0000-0002-3593-0772; Carter, Adrian N/0000-0002-3593-0772; Key, Brian/0000-0002-1150-3848				Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baric I, 2004, P NATL ACAD SCI USA, V101, P4234, DOI 10.1073/pnas.0400658101; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Dekker JW, 2002, IMMUNOGENETICS, V53, P993, DOI 10.1007/s00251-001-0402-z; Devogelaere B, 2006, BIOCHEM BIOPH RES CO, V343, P49, DOI 10.1016/j.bbrc.2006.02.119; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Koski GK, 1999, J IMMUNOL, V163, P82; Koulen P, 2000, J NEUROSCI RES, V61, P493, DOI 10.1002/1097-4547(20000901)61:5<493::AID-JNR3>3.0.CO;2-9; Kume S, 1997, SCIENCE, V278, P1940, DOI 10.1126/science.278.5345.1940; Lyakh LA, 2005, J IMMUNOL, V174, P2061, DOI 10.4049/jimmunol.174.4.2061; Mikoshiba Katsuhiko, 1994, Seminars in Cell Biology, V5, P273, DOI 10.1006/scel.1994.1033; MILLER MW, 1994, EMBO J, V13, P1806, DOI 10.1002/j.1460-2075.1994.tb06449.x; Mullins MC, 1996, DEVELOPMENT, V123, P81; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nardelli B, 1999, J IMMUNOL, V162, P435; Radomski N, 1999, MOL BIOL CELL, V10, P4283, DOI 10.1091/mbc.10.12.4283; Radomski N, 2002, BBA-MOL CELL RES, V1590, P93, DOI 10.1016/S0167-4889(02)00205-7; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Swatton JE, 2001, BIOCHEM J, V359, P435, DOI 10.1042/0264-6021:3590435; Tenca C, 2005, J IMMUNOL, V174, P6757, DOI 10.4049/jimmunol.174.11.6757; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Turner MA, 2000, CELL BIOCHEM BIOPHYS, V33, P101, DOI 10.1385/CBB:33:2:101; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Westfall TA, 2003, DEV BIOL, V259, P380, DOI 10.1016/S0012-1606(03)00209-4	28	22	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22471	22484		10.1074/jbc.M602520200	http://dx.doi.org/10.1074/jbc.M602520200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754674	hybrid			2022-12-25	WOS:000239542600008
J	Harrison-Findik, DD; Schafer, D; Klein, E; Timchenko, NA; Kulaksiz, H; Clemens, D; Fein, E; Andriopoulos, B; Pantopoulos, K; Gollan, J				Harrison-Findik, Duygu Dee; Schafer, Denise; Klein, Elizabeth; Timchenko, Nikolai A.; Kulaksiz, Hasan; Clemens, Dahn; Fein, Evelyn; Andriopoulos, Billy; Pantopoulos, Kostas; Gollan, John			Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE; LIVER; ANEMIA; ABSORPTION; INFLAMMATION; OVERLOAD; ETHANOL; GENE; LOCALIZATION; HYPOFERREMIA	Patients with alcoholic liver disease frequently exhibit iron overload in association with increased hepatic fibrosis. Even moderate alcohol consumption elevates body iron stores; however, the underlying molecular mechanisms are unknown. Hepcidin, a circulatory peptide synthesized in the liver, is a key mediator of iron metabolism. Ethanol metabolism significantly down-regulated both in vitro and in vivo hepcidin mRNA and protein expression. 4-Methylpyrazole, a specific inhibitor of the alcohol-metabolizing enzymes, abolished the effects of ethanol on hepcidin. However, ethanol did not alter the expression of transferrin receptor1 and ferritin or the activation of iron regulatory RNA-binding proteins, IRP1 and IRP2. Mice maintained on 10-20% ethanol for 7 days displayed down-regulation of liver hepcidin expression without changes in liver triglycerides or histology. This was accompanied by elevated duodenal divalent metal transporter1 and ferroportin protein expression. Injection of hepcidin peptide negated the effect of ethanol on duodenal iron transporters. Ethanol down-regulated hepcidin promoter activity and the DNA binding activity of CCAAT/enhancer-binding protein alpha(C/EBP alpha) but not beta. Interestingly, the antioxidants vitamin E and N-acetylcysteine abolished both the alcohol-mediated down-regulation of C/EBP alpha binding activity and hepcidin expression in the liver and the up-regulation of duodenal divalent metal transporter 1. Collectively, these findings indicate that alcohol metabolism-mediated oxidative stress regulates hepcidin transcription via C/EBP alpha, which in turn leads to increased duodenal iron transport.	Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Heidelberg Univ, Dept Internal Med, Div Gastroenterol, D-6900 Heidelberg, Germany; Vet Adm Med Ctr, Omaha, NE 68105 USA; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Nebraska System; University of Nebraska Medical Center; Baylor College of Medicine; Baylor College of Medicine; Ruprecht Karls University Heidelberg; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lady Davis Institute; McGill University	Harrison-Findik, DD (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, 95820, Omaha, NE 68198 USA.	dharrisonfindik@unmc.edu	Pantopoulos, Kostas/A-9668-2008	Pantopoulos, Kostas/0000-0002-2305-0057				Andrews NC, 2004, J CLIN INVEST, V113, P1251, DOI 10.1172/JCI200421441; Andrews NC, 2002, SEMIN HEMATOL, V39, P227, DOI 10.1053/shem.2002.35632; Arteel GE, 2003, GASTROENTEROLOGY, V124, P778, DOI 10.1053/gast.2003.50087; Barry-Lane PA, 2001, J CLIN INVEST, V108, P1513, DOI 10.1172/JCI11927; BLOMSTRAND R, 1970, LIFE SCI 2-BIOCH GEN, V9, P631, DOI 10.1016/0024-3205(70)90214-6; Bonkovsky HL, 2003, ALCOHOL, V30, P137, DOI 10.1016/S0741-8329(03)00127-7; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1524, DOI 10.1016/S0891-5849(01)00741-9; CHAPMAN RW, 1982, DIGEST DIS SCI, V27, P909, DOI 10.1007/BF01316575; Courselaud B, 2002, J BIOL CHEM, V277, P41163, DOI 10.1074/jbc.M202653200; Courselaud B, 2004, BLOOD CELL MOL DIS, V32, P283, DOI 10.1016/j.bcmd.2003.11.003; De Feo TM, 2001, ALCOHOL CLIN EXP RES, V25, P1494, DOI 10.1097/00000374-200110000-00013; Donohue TM, 2006, INT J BIOCHEM CELL B, V38, P92, DOI 10.1016/j.biocel.2005.07.010; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; DUANE P, 1992, ALCOHOL ALCOHOLISM, V27, P539; Fletcher LM, 2002, GASTROENTEROLOGY, V122, P281, DOI 10.1053/gast.2002.30992; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; Ganz T, 2004, CURR OPIN HEMATOL, V11, P251, DOI 10.1097/00062752-200407000-00004; Gunshin H, 2005, J CLIN INVEST, V115, P1258, DOI [10.1172/JCI200524356, 10.1172/JCI24356]; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Ioannou GN, 2004, GASTROENTEROLOGY, V126, P1293, DOI 10.1053/j.gastro.2004.01.020; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Kulaksiz H, 2004, GUT, V53, P735, DOI 10.1136/gut.2003.022863; Kulaksiz H, 2005, J ENDOCRINOL, V184, P361, DOI 10.1677/joe.1.05729; Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Liu HJ, 2005, CIRC RES, V97, P967, DOI 10.1161/01.RES.0000188210.72062.10; Liu WH, 2002, ANAL BIOCHEM, V302, P52, DOI 10.1006/abio.2001.5530; Lou DQ, 2004, BLOOD, V103, P2816, DOI 10.1182/blood-2003-07-2524; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Nicolas G, 2002, BLOOD CELL MOL DIS, V29, P327, DOI 10.1006/bcmd.2002.0573; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Rao RK, 2004, AM J PHYSIOL-GASTR L, V286, pG881, DOI 10.1152/ajpgi.00006.2004; Rivera S, 2005, BLOOD, V106, P2196, DOI 10.1182/blood-2005-04-1766; Sun AY, 2001, ALCOHOL CLIN EXP RES, V25, p237S, DOI 10.1097/00000374-200105051-00038; Tavill AS, 2004, SEMIN LIVER DIS, V24, P317, DOI 10.1055/s-2004-832943; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Whitfield JB, 2001, ALCOHOL CLIN EXP RES, V25, P1037, DOI 10.1097/00000374-200107000-00014; Yamaji S, 2004, BLOOD, V104, P2178, DOI 10.1182/blood-2004-03-0829; Yeh KY, 2004, AM J PHYSIOL-GASTR L, V286, pG385, DOI 10.1152/ajpgi.00246.2003	51	220	235	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22974	22982		10.1074/jbc.M602098200	http://dx.doi.org/10.1074/jbc.M602098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16737972	hybrid			2022-12-25	WOS:000239542600059
J	Hsieh, JY; Liu, GY; Chang, GG; Hung, HC				Hsieh, Ju-Yi; Liu, Guang-Yaw; Chang, Gu-Gang; Hung, Hui-Chih			Determinants of the dual cofactor specificity and substrate cooperativity of the human mitochondrial NAD(P)(+)-dependent malic enzyme - Functional roles of glutamine 362	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCARIS-SUUM; OXIDATIVE DECARBOXYLASES; REGULATORY PROPERTIES; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; ADRENAL-CORTEX; CDNA CLONING; RAT-LIVER; NAD; PURIFICATION	The human mitochondrial NAD(P)(+)-dependent malic enzyme (m-NAD-ME) is a malic enzyme isoform with dual cofactor specificity and substrate binding cooperativity. Previous kinetic studies have suggested that Lys(362) in the pigeon cytosolic NADP(+)-dependent malic enzyme has remarkable effects on the binding of NADP(+) to the enzyme and on the catalytic power of the enzyme (Kuo, C. C., Tsai, L. C., Chin, T. Y., Chang, G.-G., and Chou, W. Y. (2000) Biochem. Biophys. Res. Commun. 270, 821-825). In this study, we investigate the important role of Gln(362) in the transformation of cofactor specificity from NAD(+) to NADP(+) in human m-NAD-ME. Our kinetic data clearly indicate that the Q362K mutant shifted its cofactor preference from NAD(+) to NADP(+). The K-m(NADP) and k(cat(NADP)) values for this mutant were reduced by 4-6-fold and increased by 5-10-fold, respectively, compared with those for the wild-type enzyme. Furthermore, up to a 2-fold reduction in Km(NADP)/Km(NAD) and elevation of k(cat(NADP))/k(cat(NAD)) were observed for the Q362K enzyme. Mutation of Gln(362) to Ala or Asn did not shift its cofactor preference. The K-m(NADP)/K-m(NAD) and k(cat(NADP))/k(cat(NAD)) values for Q362A and Q362N were comparable with those for the wild-type enzyme. The Delta G values for Q362A and Q362N with either NAD(+) or NADP(+) were positive, indicating that substitution of Gln with Ala or Asn at position 362 brings about unfavorable cofactor binding at the active site and thus significantly reduces the catalytic efficiency. Our data also indicate that the cooperative binding of malate became insignificant in human m-NAD-ME upon mutation of Gln(362) to Lys because the sigmoidal phenomenon appearing in the wildtype enzyme was much less obvious that that in Q362K. Therefore, mutation of Gln(362) to Lys in human m-NAD-ME alters its kinetic properties of cofactor preference, malate binding cooperativity, and allosteric regulation by fumarate. However, the other Gln(362) mutants, Q362A and Q362N, have conserved malate binding cooperativity and NAD(+) specificity. In this study, we provide clear evidence that the single mutation of Gln(362) to Lys in human m-NAD-ME changes it to an NADP(+)-dependent enzyme, which is characteristic because it is non-allosteric, non-cooperative, and NADP(+)-specific.	Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; Chung Shan Med Univ, Inst Immunol, Taichung 40201, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan	National Chung Hsing University; Chung Shan Medical University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Hung, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hchung@dragon.nchu.edu.tw	Hung, Hui-Chih/L-8061-2019; Hung, Hui-Chih/G-4485-2013	Hung, Hui-Chih/0000-0003-0180-1822; Hung, Hui-Chih/0000-0003-0180-1822				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Bhargava G, 1999, J STRUCT BIOL, V127, P72, DOI 10.1006/jsbi.1999.4126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG GG, 1991, EUR J BIOCHEM, V202, P681, DOI 10.1111/j.1432-1033.1991.tb16423.x; Chang GG, 2003, BIOCHEMISTRY-US, V42, P12721, DOI 10.1021/bi035251+; Cleland WW, 2000, PROTEIN PEPTIDE LETT, V7, P305; Coleman DE, 2002, BIOCHEMISTRY-US, V41, P6928, DOI 10.1021/bi0255120; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HSU RY, 1982, MOL CELL BIOCHEM, V43, P3; Hsu WC, 2004, BIOCHEMISTRY-US, V43, P7382, DOI 10.1021/bi049600r; Hung HC, 2005, BIOCHEM J, V392, P39, DOI 10.1042/BJ20050641; Hung HC, 2005, BIOCHEMISTRY-US, V44, P12737, DOI 10.1021/bi050510b; Karsten WE, 2005, BIOCHEMISTRY-US, V44, P3626, DOI 10.1021/bi047826o; Karsten WE, 2003, BIOCHEMISTRY-US, V42, P9712, DOI 10.1021/bi034101w; Kuo CC, 2000, BIOCHEM BIOPH RES CO, V270, P821, DOI 10.1006/bbrc.2000.2502; LAI CJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P214, DOI 10.1016/0003-9861(92)90266-Y; LANDSPERGER WJ, 1976, J BIOL CHEM, V251, P3599; LOEBER G, 1994, BIOCHEM J, V304, P687, DOI 10.1042/bj3040687; LOEBER G, 1994, FEBS LETT, V344, P181, DOI 10.1016/0014-5793(94)00386-6; LOEBER G, 1991, J BIOL CHEM, V266, P3016; MANDELLA RD, 1975, J BIOL CHEM, V250, P5877; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; Rao GSJ, 2003, J BIOL CHEM, V278, P38051, DOI 10.1074/jbc.M305145200; Sanz N, 1997, BRIT J CANCER, V75, P487, DOI 10.1038/bjc.1997.85; SAUER LA, 1973, BIOCHEM BIOPH RES CO, V50, P524, DOI 10.1016/0006-291X(73)90871-1; SAUER LA, 1980, J BIOL CHEM, V255, P3844; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Tao X, 2003, STRUCTURE, V11, P1141, DOI 10.1016/S0969-2126(03)00168-0; Teller J K, 1990, Protein Expr Purif, V1, P151, DOI 10.1016/1046-5928(90)90009-N; TELLER JK, 1992, J BIOL CHEM, V267, P10423; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2000, NAT STRUCT BIOL, V7, P251; Yang ZR, 2002, PROTEIN SCI, V11, P332, DOI 10.1110/ps.38002; Yang ZR, 2002, STRUCTURE, V10, P951, DOI 10.1016/S0969-2126(02)00788-8; ZDNIEROWICZ S, 1988, BIOCHEM MED METAB B, V39, P208	43	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23237	23245		10.1074/jbc.M603451200	http://dx.doi.org/10.1074/jbc.M603451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757477	hybrid			2022-12-25	WOS:000239542600086
J	Meisinger, C; Wiedemann, N; Rissler, M; Strub, A; Milenkovic, D; Schonfisch, B; Muller, H; Kozjak, V; Pfanner, N				Meisinger, Chris; Wiedemann, Nils; Rissler, Michael; Strub, Andreas; Milenkovic, Dusanka; Schoenfisch, Birgit; Mueller, Hanne; Kozjak, Vera; Pfanner, Nikolaus			Mitochondrial protein sorting - Differentiation of beta-barrel assembly by Tom7-mediated segregation of Mdm10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL IMPORT PORE; INTERMEMBRANE SPACE PROTEINS; OUTER-MEMBRANE; TOM COMPLEX; PREPROTEIN TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; BIOGENESIS; MACHINERY; PATHWAY	The mitochondrial outer membrane contains two distinct machineries for protein import and protein sorting that function in a sequential manner: the general translocase of the outer membrane (TOM complex) and the sorting and assembly machinery (SAM complex), which is dedicated to beta-barrel proteins. The SAM(core) complex consists of three subunits, Sam35, Sam37, and Sam50, that can associate with a fourth subunit, the morphology component Mdm10, to form the SAM(holo) complex. Whereas the SAMcore complex is required for the biogenesis of all beta-barrel proteins, Mdm10 and the SAMholo complex play a selective role in beta-barrel biogenesis by promoting assembly of Tom40 but not of porin. We report that Tom7, a conserved subunit of the TOM complex, functions in an antagonistic manner to Mdm10 in biogenesis of Tom40 and porin. We show that Tom7 promotes segregation of Mdm10 from the SAMholo complex into a low molecular mass form. Upon deletion of Tom7, the fraction of Mdm10 in the SAMholo complex is significantly increased, explaining the opposing functions of Tom7 and Mdm10 in beta-barrel sorting. Thus the role of Tom7 is not limited to the TOM complex. Tom7 functions in mitochondrial protein biogenesis by a new mechanism, segregation of a sorting component, leading to a differentiation of beta-barrel assembly.	Univ Freiburg, Inst Biochem & Molekularbiol, D-79104 Freiburg, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Molekularbiol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	nikolaus.pfanner@biochemie.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014; Kozjak-Pavlovic, Vera/E-1494-2013	Meisinger, Chris/0000-0002-8326-3548; Kozjak-Pavlovic, Vera/0000-0001-9658-7018; Wiedemann, Nils/0000-0001-8305-6728; Rissler, Michael/0000-0002-4539-3341				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Allen S, 2005, J MOL BIOL, V353, P937, DOI 10.1016/j.jmb.2005.08.049; Berger KH, 1997, J CELL BIOL, V136, P545, DOI 10.1083/jcb.136.3.545; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; BURGESS SM, 1994, J CELL BIOL, V126, P1375, DOI 10.1083/jcb.126.6.1375; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dembowski M, 2001, J BIOL CHEM, V276, P17679, DOI 10.1074/jbc.M009653200; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Esaki M, 2004, J BIOL CHEM, V279, P45701, DOI 10.1074/jbc.M404591200; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Gentle I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/jcb.200310092; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Herrmann JM, 2003, TRENDS MICROBIOL, V11, P74, DOI 10.1016/S0966-842X(02)00033-1; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; Hoppins SC, 2004, J BIOL CHEM, V279, P12396, DOI 10.1074/jbc.M313037200; Humphries AD, 2005, J BIOL CHEM, V280, P11535, DOI 10.1074/jbc.M413816200; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; Jensen RE, 2005, CURR OPIN CELL BIOL, V17, P384, DOI 10.1016/j.ceb.2005.06.011; Jensen RE, 2002, BBA-MOL CELL RES, V1592, P25, DOI 10.1016/S0167-4889(02)00261-6; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; Kozjak V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/jbc.C300442200; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Meisinger C, 2004, DEV CELL, V7, P61, DOI 10.1016/j.devcel.2004.06.003; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Meisinger C, 1999, CELL MOL LIFE SCI, V56, P817, DOI 10.1007/s000180050028; Meisinger Chris, 2006, Methods Mol Biol, V313, P33; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Mihara K, 2003, NATURE, V424, P505, DOI 10.1038/424505a; Milenkovic D, 2004, J BIOL CHEM, V279, P22781, DOI 10.1074/jbc.C400120200; Model K, 2001, NAT STRUCT BIOL, V8, P361, DOI 10.1038/86253; Mokranjac D, 2005, BIOCHEM SOC T, V33, P1019, DOI 10.1042/BST0331019; Naoe M, 2004, J BIOL CHEM, V279, P47815, DOI 10.1074/jbc.M410272200; Oka T, 2005, MOL CELL, V18, P145, DOI 10.1016/j.molcel.2005.03.022; Okamoto K, 2001, METHOD CELL BIOL, V65, P277, DOI 10.1016/S0091-679X(01)65017-9; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Paschen SA, 2005, TRENDS BIOCHEM SCI, V30, P575, DOI 10.1016/j.tibs.2005.08.009; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Prokisch H, 2004, PLOS BIOL, V2, P795, DOI 10.1371/journal.pbio.0020160; Rapaport D, 2005, J CELL BIOL, V171, P419, DOI 10.1083/jcb.200507147; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Rissler M, 2005, J MOL BIOL, V353, P485, DOI 10.1016/j.jmb.2005.08.051; Ryan MT, 2004, CURR BIOL, V14, pR207, DOI 10.1016/j.cub.2004.02.024; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schleiff E, 2005, EMBO REP, V6, P1023, DOI 10.1038/sj.embor.7400563; Schmitt S, 2005, J BIOL CHEM, V280, P14499, DOI 10.1074/jbc.M413667200; Scott SV, 2003, CURR OPIN CELL BIOL, V15, P482, DOI 10.1016/S0955-0674(03)00070-X; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Sherman EL, 2005, MOL BIOL CELL, V16, P4172, DOI 10.1091/mbc.E05-03-0187; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; Stojanovski D, 2003, EXP PHYSIOL, V88, P57, DOI 10.1113/eph8802501; Taylor RD, 2004, BBA-BIOENERGETICS, V1658, P37, DOI 10.1016/j.bbabio.2004.04.017; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Waizenegger T, 2004, EMBO REP, V5, P704, DOI 10.1038/sj.embor.7400183; Webb CT, 2006, MOL CELL, V21, P123, DOI 10.1016/j.molcel.2005.11.010; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wiedemann N, 2006, MOL CELL, V21, P145, DOI 10.1016/j.molcel.2006.01.001; Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200; Wiedemann Nils, 2006, Methods Mol Biol, V313, P373; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	71	85	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22819	22826		10.1074/jbc.M602679200	http://dx.doi.org/10.1074/jbc.M602679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760475	hybrid			2022-12-25	WOS:000239542600044
J	Roman, LJ; Masters, BSS				Roman, Linda J.; Masters, Bettie Sue S.			Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOINHIBITORY CONTROL ELEMENT; LIGHT-CHAIN KINASE; REDUCTASE DOMAIN; BINDING DOMAIN; FLOW-THROUGH; FLAVIN; ACTIVATION; ISOFORMS; NADPH; IDENTIFICATION	The nitric-oxide synthases (NOSs) are modular, cofactor-containing enzymes, divided into a heme-containing oxygenase domain and an FMN- and FAD-containing reductase domain. The domains are connected by a calmodulin (CaM)-binding sequence, occupancy of which is required for nitric oxide (NO) production. Two additional CaM-modulated regulatory elements are present in the reductase domains of the constitutive isoforms, the autoregulatory region (AR) and the C-terminal tail region. Deletion of the AR reduces CaM stimulation of electron flow through the reductase domain from 10-fold in wild-type nNOS to 2-fold in the mutant. Deletion of the C terminus yields an enzyme with greatly enhanced reductase activity in the absence of CaM but with activity equivalent to that of wild-type enzyme in its presence. A mutant in which both the AR and C terminus were deleted completely loses CaM modulation through the reductase domain. Thus, transduction of the CaM effect through the reductase domain of nNOS is dependent on these elements. Formation of nitric oxide is, however, still stimulated by CaM in all three mutants. A CaM molecule in which the N-terminal lobe was replaced by the C-terminal lobe (CaMCC) supported NO synthesis by the deletion mutants but not by wild-type nNOS. We propose a model in which the AR, the C-terminal tail, and CaM interact directly to regulate the conformational state of the reductase domain of nNOS.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Roman, LJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	roman@uthscsa.edu			NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALEXANDER LM, 1980, MICROSOMES DRUG OXID, P285; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Bruckdorfer Richard, 2005, Molecular Aspects of Medicine, V26, P3, DOI 10.1016/j.mam.2004.09.002; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Craig DH, 2002, J BIOL CHEM, V277, P33987, DOI 10.1074/jbc.M203118200; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Jones RJ, 2004, J BIOL CHEM, V279, P36876, DOI 10.1074/jbc.M402808200; Knight K, 2002, BIOCHEM J, V367, P19, DOI 10.1042/BJ20020667; Knudsen GM, 2003, J BIOL CHEM, V278, P31814, DOI 10.1074/jbc.M303267200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; LINSE S, 1991, J BIOL CHEM, V266, P8050; Martasek P, 1999, METHOD ENZYMOL, V301, P70; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; MUNRO AW, 1999, METHODS MOL BIOL FLA, P1; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Persechini A, 1996, J BIOL CHEM, V271, P32217, DOI 10.1074/jbc.271.50.32217; PIETTA P, 1982, J CHROMATOGR, V229, P445, DOI 10.1016/S0378-4347(00)84288-7; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Roman LJ, 2003, J BIOL CHEM, V278, P25700, DOI 10.1074/jbc.M212309200; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Tiso M, 2005, J BIOL CHEM, V280, P39208, DOI 10.1074/jbc.M507775200; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901	53	74	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23111	23118		10.1074/jbc.M603671200	http://dx.doi.org/10.1074/jbc.M603671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782703	hybrid			2022-12-25	WOS:000239542600075
J	Wei, JH; Zhai, L; Xu, J; Wang, HB				Wei, Jianhua; Zhai, Ling; Xu, Jun; Wang, Hengbin			Role of Bmi1 in H2A ubiquitylation and Hox gene silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC TRANSGENIC MICE; HISTONE H2B; TRANSCRIPTIONAL ACTIVATION; STEM-CELLS; POLYCOMB; UBIQUITINATION; METHYLATION; CHROMATIN; H3; PROLIFERATION	Posttranslational histone modifications play a crucial role in the regulation of chromatin structure and gene activity. In previous studies, we identified the histone H2A ubiquitin ligase as Ring2, together in a complex with Ring1, Bmi1, and HPH2 (human polyhomeotic 2). We report here that the oncogene Bmi1 stimulates H2A ubiquitylation both in vitro and in vivo and that Bmi1-regulated H2A ubiquitylation is required for Hox gene silencing and normal cell growth. Our studies indicate that Bmi1 maintains the integrity of the complex through simultaneous interactions with the other subunits. We reconstituted the functional human H2A ubiquitin ligase complex and a panel of subcomplexes of different subunits. Comparisons of the H2A ubiquitin ligase activities of these different complexes revealed that Bmi1 stimulates the H2A ubiquitin ligase activity of Ring2 (and Ring1). Additionally, we demonstrated that the HoxC5 gene is regulated by ubiquitylated H2A in HeLa cells and that ubiquitylated H2A is localized on 5' regulatory regions of the HoxC5 gene. The role of Bmi1 in H2A ubiquitylation and HoxC5 gene expression in vivo was analyzed by RNA interference experiments. Knockdown of Bmi1 causes a global and loci-specific loss of H2A ubiquitylation, up-regulation of the HoxC5 gene, and slower cell growth. Intriguingly, Ring2 binds to its target regions in Bmi1 knockdown cells. Therefore, our studies reveal that Bmi1 is required for H2A ubiquitylation and suggest that H2A ubiquitylation regulates Bmi1-mediated gene expression.	Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Wang, HB (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Kaul Human Genet Bldg,Rm 402A,720 20th St, Birmingham, AL 35294 USA.	hbwang@uab.edu		Wang, Hengbin/0000-0003-2414-0609				Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Emre NCT, 2005, MOL CELL, V17, P585, DOI 10.1016/j.molcel.2005.01.007; Fleming A, 2004, CELL, V119, P449, DOI 10.1016/j.cell.2004.11.001; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Gardner RG, 2005, MOL CELL BIOL, V25, P6123, DOI 10.1128/MCB.25.14.6123-6139.2005; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Osley MA, 2004, BBA-GENE STRUCT EXPR, V1677, P74, DOI 10.1016/j.bbaexp.2003.10.013; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005	35	68	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22537	22544		10.1074/jbc.M600826200	http://dx.doi.org/10.1074/jbc.M600826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16751658	hybrid			2022-12-25	WOS:000239542600014
J	Wehner, A; Grasses, T; Jahns, P				Wehner, Antje; Grasses, Thomas; Jahns, Peter			De-epoxidation of violaxanthin in the minor antenna proteins of photosystem II, LHCB4, LHCB5, and LHCB6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CAROTENOID-BINDING-SITES; IN-VITRO RECONSTITUTION; RESOLVED FLUORESCENCE ANALYSIS; XANTHOPHYLL-CYCLE; ENERGY-DISSIPATION; PIGMENT-BINDING; PEA-PLANTS; ZEAXANTHIN; DYNAMICS	The conversion of violaxanthin to zeaxanthin is essentially required for the pH-regulated dissipation of excess light energy in the antenna of photosystem II. Violaxanthin is bound to each of the antenna proteins of both photosystems. Former studies with recombinant Lhcb1 and different Lhca proteins implied that each antenna protein contributes specifically to violaxanthin conversion related to protein-specific affinities of the different violaxanthin binding sites. We investigated the violaxanthin de-epoxidation in the minor antenna proteins of photosystem II, Lhcb4-6. Recombinant proteins were reconstituted with different xanthophyll mixtures to study the conversion of violaxanthin at different xanthophyll binding sites in these proteins. The extent and kinetics of violaxanthin de-epoxidation were found to be dependent on the respective protein and, for each protein, also on the binding site of violaxanthin. In particular, violaxanthin bound to Lhcb4 was nearly inconvertible for de-epoxidation, whereas violaxanthin bound to Lhcb5 was fully convertible but with slow kinetics. Lhcb6 exhibited heterogeneous violaxanthin conversion characteristics, which could be assigned to different populations of reconstituted Lhcb6 complexes with respect to violaxanthin binding sites. The results support the proposed different binding affinities of violaxanthin to the three putative violaxanthin binding sites (V1, N1, and L2) in antenna proteins. Under consideration of former studies with Lhcb1 and Lhca proteins, the data imply that violaxanthin bound to the V1 and N1 binding site of antenna proteins is easily accessible for de-epoxidation in all antenna proteins, whereas violaxanthin bound to L2 is either only slowly or not convertible to zeaxanthin, depending on the respective protein.	Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Jahns, P (corresponding author), Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany.	pjahns@uni-duesseldorf.de						Aspinall-O'Dea M, 2002, P NATL ACAD SCI USA, V99, P16331, DOI 10.1073/pnas.252500999; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Chow WS, 2000, INDIAN J BIOCHEM BIO, V37, P395; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Dall'Osto L, 2005, PLANT CELL, V17, P1217, DOI 10.1105/tpc.104.030601; Das SK, 2002, BIOCHEMISTRY-US, V41, P13087, DOI 10.1021/bi0204802; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x; FALK S, 1994, PHYSIOL PLANTARUM, V91, P551, DOI 10.1111/j.1399-3054.1994.tb02987.x; Farber A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/pp.115.4.1609; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Gastaldelli M, 2003, J BIOL CHEM, V278, P19190, DOI 10.1074/jbc.M212125200; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GREEN BR, 2003, LIGHT HARVESTING ANT, P1; Hartel H, 1996, PLANT PHYSIOL, V110, P471, DOI 10.1104/pp.110.2.471; HARTEL H, 1995, BBA-BIOENERGETICS, V1228, P91, DOI 10.1016/0005-2728(94)00172-2; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 1998, TRENDS PLANT SCI, V3, P147, DOI 10.1016/S1360-1385(98)01200-X; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Holt NE, 2005, SCIENCE, V307, P433, DOI 10.1126/science.1105833; Horton P, 2005, FEBS LETT, V579, P4201, DOI 10.1016/j.febslet.2005.07.003; JAHNS P, 1995, PLANT PHYSIOL, V108, P149, DOI 10.1104/pp.108.1.149; JAHNS P, 1994, PLANTA, V192, P176, DOI 10.1007/BF01089032; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Kalituho L, 2006, PLANTA, V223, P532, DOI 10.1007/s00425-005-0093-z; Li XP, 2004, J BIOL CHEM, V279, P22866, DOI 10.1074/jbc.M402461200; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Ma YZ, 2003, P NATL ACAD SCI USA, V100, P4377, DOI 10.1073/pnas.0736959100; Macko S, 2002, PLANTA, V216, P309, DOI 10.1007/s00425-002-0848-8; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; Morosinotto T, 2003, PHYSIOL PLANTARUM, V119, P347, DOI 10.1034/j.1399-3054.2003.00213.x; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Niyogi KK, 1998, PLANT CELL, V10, P1121, DOI 10.1105/tpc.10.7.1121; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Paulsen H, 1999, ADV PHOTOSYNTH, V8, P123; PAULSEN H, 2002, HEME CHLOROPHYLL BIL, P235; PETER GF, 1991, J BIOL CHEM, V266, P16745; PFUNDEL E, 1994, PHOTOSYNTH RES, V42, P89, DOI 10.1007/BF02187121; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; Scheer H, 2003, LIGHT HARVESTING ANT, P29; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Storf S, 2004, BIOCHEMISTRY-US, V43, P9214, DOI 10.1021/bi0498196; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Wehner A, 2004, J BIOL CHEM, V279, P26823, DOI 10.1074/jbc.M402399200; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1996, OXYGENIC PHOTOSYNTHE, P539, DOI DOI 10.1007/0-306-48127-8_30	58	41	43	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21924	21933		10.1074/jbc.M602915200	http://dx.doi.org/10.1074/jbc.M602915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754673	hybrid			2022-12-25	WOS:000239387100039
J	Bondjers, C; He, LQ; Takemoto, M; Norlin, J; Asker, N; Mats, HRM; Lindahl, P; Betsholtz, C				Bondjers, Cecilia; He, Liqun; Takemoto, Minoru; Norlin, Jenny; Asker, Noomi; Mats, Hellstro R. M.; Lindahl, Per; Betsholtz, Christer			Microarray analysis of blood microvessels from PDGF-RB and PDGF-R beta mutant mice identifies novel markers for brain pericytes	FASEB JOURNAL			English	Article						vascular stability; Kir6.1; SUR2; DLK1; RGS5	SMOOTH-MUSCLE-CELLS; RETINAL VASCULAR PATTERNS; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CORONARY-ARTERIES; MURAL CELLS; ANGIOGENESIS; TUMORS; RECEPTOR	Normal blood microvessels are lined by pericytes, which contribute to microvessel development and stability through mechanisms that are poorly understood. Pericyte deficiency has been implicated in the pathogenesis of microvascular abnormalities associated with diabetes and tumors. However, the unambiguous identification of pericytes is still a problem because of cellular heterogeneity and few available molecular markers. Here we describe an approach to identify pericyte markers based on transcription profiling of pericyte-deficient brain microvessels isolated from platelet-derived growth factor (PDGF-B)-/- and PDGF beta receptor (PDGFR beta)-/- mouse mutants. The approach was validated by the identification of known pericyte markers among the most down-regulated genes in PDGF-B-/- and PDGFR beta-/- microvessels. Of candidates for novel pericyte markers, we selected ATP-sensitive potassium-channel Kir6.1 (also known as Kcnj8) and sulfonylurea receptor 2, (SUR2, also known as Abcc9), both part of the same channel complex, as well as delta homologue 1 (DLK1) for in situ hybridization, which demonstrated their specific expression in brain pericytes of mouse embryos. We also show that Kir6.1 is highly expressed in pericytes in brain but undetectable in pericytes in skin and heart. The three new brain pericyte markers are signaling molecules implicated in ion transport and intercellular signaling, potentially opening new windows on pericyte function in brain microvessels.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, SE-17177 Stockholm, Sweden; Gothenburg Univ, Sahlgrenska Acad, Dept Med Biochem, S-41124 Gothenburg, Sweden	Karolinska Institutet; University of Gothenburg	Betsholtz, C (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, SE-17177 Stockholm, Sweden.	christer.betsholtz@ki.se		Hellstrom, Mats/0000-0002-7088-9533; He, Liqun/0000-0003-2127-7597				Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Alliot F, 1999, J NEUROSCI RES, V58, P367; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P1127; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger M, 2005, BLOOD, V105, P1094, DOI 10.1182/blood-2004-06-2315; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bondjers C, 2003, AM J PATHOL, V162, P721, DOI 10.1016/S0002-9440(10)63868-0; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cho H, 2003, FASEB J, V17, P440, DOI 10.1096/fj.02-0340fje; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; CUEVAS P, 1984, ANAT EMBRYOL, V170, P155, DOI 10.1007/BF00319000; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fisher SA, 1995, BIOCHEM BIOPH RES CO, V217, P696, DOI 10.1006/bbrc.1995.2829; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; FUNK JL, 2002, BIOCHEM BIOPH RES CO, V297, P980; Furuhashi M, 2004, CANCER RES, V64, P2725, DOI 10.1158/0008-5472.CAN-03-1489; Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107; Heldin CH, 2002, ARCH BIOCHEM BIOPHYS, V398, P284, DOI 10.1006/abbi.2001.2707; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; Hirschi KK, 2003, CIRC RES, V93, P429, DOI 10.1161/01.RES.0000091259.84556.D5; Hogan B, 1994, MANIPULATING MOUSE E; Ikedo H, 2003, INT J MOL MED, V11, P645; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jensen CH, 2001, NEUROREPORT, V12, P3959, DOI 10.1097/00001756-200112210-00021; Kale S, 2004, FASEB J, V18, P270, DOI 10.1096/fj.04-1604fje; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; Laborda J, 2000, HISTOL HISTOPATHOL, V15, P119, DOI 10.14670/HH-15.119; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li X, 2001, AM J PHYSIOL-HEART C, V281, pH1890, DOI 10.1152/ajpheart.2001.281.5.H1890; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu Q, 1997, BRIT J PHARMACOL, V120, P728, DOI 10.1038/sj.bjp.0700939; Mazurais D, 2002, J HISTOCHEM CYTOCHEM, V50, P661, DOI 10.1177/002215540205000507; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; Nelander S, 2003, GENOME RES, V13, P1838, DOI 10.1101/gr.1197303; Okamoto M, 1997, STEROIDS, V62, P73, DOI 10.1016/S0039-128X(96)00162-6; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Scheidl SJ, 2002, AM J PATHOL, V160, P801, DOI 10.1016/S0002-9440(10)64903-6; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Shaheen RM, 2001, CANCER RES, V61, P1464; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Song WW, 2005, INVEST OPHTH VIS SCI, V46, P2974, DOI 10.1167/iovs.04-1505; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takemoto M, 2006, EMBO J, V25, P1160, DOI 10.1038/sj.emboj.7601014; Tidhar A, 2001, DEV DYNAM, V220, P60, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1089>3.0.CO;2-X; Uemura A, 2002, J CLIN INVEST, V110, P1619, DOI 10.1172/JCI200215621; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	78	139	139	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1703	+		10.1096/fj.05-4944fje	http://dx.doi.org/10.1096/fj.05-4944fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807374				2022-12-25	WOS:000240266600021
J	Pan, GJ; Li, J; Zhou, YL; Zheng, H; Pei, DQ				Pan, Guangjin; Li, Jun; Zhou, Yali; Zheng, Hui; Pei, Duanqing			A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal	FASEB JOURNAL			English	Article						embryonic stem cells	SUSTAINING FACTOR; GENE-EXPRESSION; FACTOR NANOG; FACTOR OCT4; ES CELLS; IDENTIFICATION; EMBRYO	Embryonic stem (ES) cells possess the ability to renew themselves while maintaining the capacity to differentiate into virtually all cell types of the body. Current evidence suggests that ES cells maintain their pluripotent state by expressing a battery of transcription factors including Oct4 and Nanog. However, little is known about how ES cells maintain the expression of these pluripotent factors in ES cells. Here we present evidence that Oct4, Nanog, and FoxD3 form a negative feedback loop to maintain their expression in pluripotent ES cells. First, Oct4 maintains Nanog activity by directly activating its promoter at sub-steady-state concentration but repressing it at or above steady-state levels. On the other hand, FoxD3 behaves as a positive activator of Nanog to counter the repressive effect of Oct4. The expression of Oct4 is activated by FoxD3 and Nanog but repressed by Oct4 itself, thus, exerting an important negative feedback loop to limit its own activity. Indeed, overexpression of either FoxD3 or Nanog in ES cells failed to increase the concentration of Oct4 beyond the steady-state concentration, whereas knocking down either FoxD3 or Nanog reduces the expression of Oct4 in ES cells. Finally, overexpression of Oct4 or Nanog failed to compensate the loss of Nanog or Oct4, respectively, suggesting that both are required for ES self-renewal and pluripotency. Our results suggest the FoxD3-Nanog-Oct4 loop anchors an interdependent network of transcription factors that regulate stem cell pluripotency.	Tsinghua Univ, Sch Med, Inst Pharmacol,Inst Biomed, Dept Biol Sci & Biotechnol,State Key Lab Biomembr, Beijing 100084, Peoples R China	Tsinghua University	Pei, DQ (corresponding author), Chinese Acad Sci, GIBH, Guangzhou 510663, Guangdong, Peoples R China.	pei-duanqing@gibh.ac.cn	zhou, xingru/G-4442-2012	Pan, Guangjin/0000-0002-2378-7198; Zheng, Hui/0000-0001-6801-0529				Audet J, 2004, EXPERT OPIN BIOL TH, V4, P631, DOI 10.1517/eobt.4.5.631.31058; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Constantinescu S, 2003, J CELL MOL MED, V7, P103, DOI 10.1111/j.1582-4934.2003.tb00209.x; Guo JH, 2002, ASIAN J ANDROL, V4, P3; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Koike N, 2004, NATURE, V428, P138, DOI 10.1038/428138a; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Pan GJ, 2003, CELL RES, V13, P499, DOI 10.1038/sj.cr.7290193; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	22	167	200	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1730	+		10.1096/fj.05-5543fje	http://dx.doi.org/10.1096/fj.05-5543fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790525				2022-12-25	WOS:000240266600030
J	Ding, QX; Dimayuga, E; Markesbery, WR; Keller, JN				Ding, Qunxing; Dimayuga, Edgardo; Markesbery, William R.; Keller, Jeffrey N.			Proteasome inhibition induces reversible impairments in protein synthesis	FASEB JOURNAL			English	Article						aging; Alzheimer's disease; neurodegeneration; Parkinson's disease; protein aggregation	OXIDATIVE STRESS; GENE-EXPRESSION; DYSFUNCTION; APOPTOSIS; BRAIN; DEATH; CELLS; INCLUSIONS; INDUCTION; TOXICITY	Proteasome inhibition occurs during normal aging and in a variety of age-related diseases, with inhibition of proteasome function sufficient to induce physiological and pathological alterations observed in each of these conditions. It is presumed that proteasome inhibition induces cellular alterations by promoting rapid protein accumulation, as the direct result of impairments in protein removal, which assumes protein synthesis remains relatively unchanged during proteasome inhibition. We conducted experimentation using established proteasome inhibitors and primary rat neuron cultures in order to elucidate whether proteasome inhibition had any effect on neuronal protein synthesis. Proteasome inhibition impaired neuronal protein synthesis, with concentrations of inhibitor necessary to significantly inhibit protein synthesis similar to the concentrations necessary to induce subsequent neuron death. The inhibition of protein synthesis was reversible during the first 6 h of treatment, with the neurotoxicity of proteasome inhibition reversible during the first 12 h of treatment. These studies are the first to demonstrate a potentially important interplay between the proteasome and protein synthesis in neurons, and the first to identify that some effects of proteasome inhibition are reversible in neurons. Together these findings have important implications for understanding proteasome inhibition as a potential contributor to aging and age-related disease.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol & Neuropathol, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Keller, JN (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 205 Sanders Brown,800 S Limestone, Lexington, KY 40536 USA.	jnkell0@uky.edu	Keller, Jeffrey N/N-1975-2017	keller, jeffrey/0000-0002-9892-7423	NIA NIH HHS [AG018437, 5P01 AG05114] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018437] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; Chondrogianni N, 2005, EXP GERONTOL, V40, P931, DOI 10.1016/j.exger.2005.09.004; Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200; COSGROVE JW, 1986, NEUROCHEM RES, V11, P1289, DOI 10.1007/BF00966123; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Dietrich P, 2003, MOL CELL NEUROSCI, V24, P430, DOI 10.1016/S1044-7431(03)00201-X; Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005; Ding QX, 2004, J NEUROCHEM, V91, P1211, DOI 10.1111/j.1471-4159.2004.02802.x; Ding QX, 2004, FREE RADICAL BIO MED, V36, P445, DOI 10.1016/j.freeradbiomed.2003.10.025; Ding QX, 2003, FEBS LETT, V546, P228, DOI 10.1016/S0014-5793(03)00582-9; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Halliwell B, 2002, ANN NY ACAD SCI, V962, P182, DOI 10.1111/j.1749-6632.2002.tb04067.x; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Hyun DH, 2003, J NEUROCHEM, V86, P363, DOI 10.1046/j.1471-4159.2003.01841.x; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Keller JN, 1999, J NEUROSCI RES, V58, P823, DOI 10.1002/(SICI)1097-4547(19991215)58:6<823::AID-JNR9>3.0.CO;2-T; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Keller JN, 1999, J NEUROCHEM, V72, P2601, DOI 10.1046/j.1471-4159.1999.0722601.x; KIM TS, 2005, IN PRESS MOL BIOL CE; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Lang-Rollin I, 2005, APOPTOSIS, V10, P809, DOI 10.1007/s10495-005-0378-5; Lang-Rollin I, 2004, J NEUROCHEM, V90, P1511, DOI 10.1111/j.1471-4159.2004.02684.x; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; McNaught KSP, 2004, INT REV NEUROBIOL, V62, P95, DOI 10.1016/S0074-7742(04)62003-4; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; Rattan SIS, 1996, BIOCHEM SOC T, V24, P1043, DOI 10.1042/bst0241043; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Robertson JD, 1999, BIOCHEM J, V344, P477, DOI 10.1042/0264-6021:3440477; Seo H, 2004, ANN NEUROL, V56, P319, DOI 10.1002/ana.20207; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Stolzing A, 2001, CLIN EXP DERMATOL, V26, P566, DOI 10.1046/j.1365-2230.2001.00867.x; Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200; Yew EHJ, 2005, J NEUROCHEM, V94, P943, DOI 10.1111/j.1471-4159.2005.03220.x	39	81	92	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1055	1063		10.1096/fj.05-5495com	http://dx.doi.org/10.1096/fj.05-5495com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770004				2022-12-25	WOS:000240210300005
J	Saxena, A; Rorie, CJ; Dimitrov, D; Daniely, Y; Borowiec, JA				Saxena, A.; Rorie, C. J.; Dimitrov, D.; Daniely, Y.; Borowiec, J. A.			Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization	ONCOGENE			English	Article						ARF; Mdm2; nucleolin; p53; ubiquitination	ARF TUMOR-SUPPRESSOR; PRE-RIBOSOMAL-RNA; REPLICATION PROTEIN-A; UBIQUITIN LIGASE ACTIVITY; DNA-DAMAGE; ONCOPROTEIN MDM2; GENOTOXIC STRESS; IN-VITRO; P53-DEPENDENT APOPTOSIS; EMBRYONIC LETHALITY	Nucleolin is a c-Myc-induced gene product with defined roles in ribosomal RNA processing and the inhibition of chromosomal DNA replication following stress. Here we find that changes in nucleolin protein levels in unstressed cells cause parallel changes in the amount of p53 protein. Alterations in p53 levels arise from nucleolin binding to the p53 antagonist Hdm2, resulting in the inhibition of both p53 ubiquitination and Hdm2 auto-ubiquitination. Nucleolin does not alter p53 ubiquitination by human papillomavirus E6, indicating that the effect is specific for Hdm2. Although the inhibition of ligase activity would be expected to stabilize Hdm2, we instead find that nucleolin also reduces Hdm2 protein levels, demonstrating that nucleolin inhibits Hdm2 using multiple mechanisms. Increases in nucleolin levels in unstressed cells led to higher expression of p21(cip1/waf1), a reduced rate of cellular proliferation, and an increase in apoptosis. Thus, nucleolin has a number of properties in common with the tumor suppressor ARF (alternate reading frame). We propose that nucleolin, like ARF, responds to hyperproliferative signals by upregulation of p53 through Hdm2 inhibition.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Borowiec, JA (corresponding author), NYU, Sch Med, Dept Biochem, 550 1St Ave, New York, NY 10016 USA.	james.borowiec@med.nyu.edu	Saxena, Anjana/AAZ-5244-2020	Saxena, Anjana/0000-0001-8884-5179; Borowiec, James/0000-0003-4117-0826	NIAID NIH HHS [AI29963] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Anderson-Cook CM, 2004, PHARM STAT, V3, P247, DOI 10.1002/pst.138; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borovjagin AV, 2004, RNA, V10, P942, DOI 10.1261/rna.5256704; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; Brooks CL, 2004, CELL CYCLE, V3, P895; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; GULLI MP, 1995, NUCLEIC ACIDS RES, V23, P1912, DOI 10.1093/nar/23.11.1912; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kim K, 2005, MOL CELL BIOL, V25, P2463, DOI 10.1128/MCB.25.6.2463-2474.2005; KONDO K, 1992, J BIOL CHEM, V267, P16252; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moss T, 2004, CURR OPIN GENET DEV, V14, P210, DOI 10.1016/j.gde.2004.02.005; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saez-Vasquez J, 2004, MOL CELL BIOL, V24, P7284, DOI 10.1128/MCB.24.16.7284-7297.2004; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Sirri V, 1997, CYTOMETRY, V28, P147, DOI 10.1002/(SICI)1097-0320(19970601)28:2<147::AID-CYTO8>3.3.CO;2-G; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang YZ, 2001, J BIOL CHEM, V276, P20579, DOI 10.1074/jbc.M100874200; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wesierska-Gadek J, 2003, ANN NY ACAD SCI, V1010, P266, DOI 10.1196/annals.1299.046; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zheng X, 2005, BIOCHEM BIOPH RES CO, V329, P95, DOI 10.1016/j.bbrc.2005.01.105; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	93	67	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7274	7288		10.1038/sj.onc.1209714	http://dx.doi.org/10.1038/sj.onc.1209714			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751805				2022-12-25	WOS:000242244700006
J	Senn, JJ				Senn, Joseph J.			Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACID; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; INFLAMMATORY CYTOKINES; SKELETAL-MUSCLE; ACTIVATION; INTERLEUKIN-6; EXPRESSION; POLYMORPHISM; RECOGNITION	Fatty acids can activate proinflammatory pathways leading to the development of insulin resistance, but the mechanism is undiscovered. Toll like receptor 2 (TLR2) recognizes lipids, activates proinflammatory pathways, and is genetically associated with inflammatory diseases. This study aimed to examine the role of TLR2 in palmitate-induced insulin resistance in C2C12 myotubes. Treatment with palmitate rapidly induced the association of myeloid differentiation factor 88 (MyD88) with the TLR2 receptor, activated the stress-linked kinases p38, JNK, and protein kinase C, induced degradation of I kappa B alpha, and increased NF-kappa B DNA binding. The activation of these pathways by palmitate was sensitive and temporally regulated and occurred within the upper physiologic range of saturated fatty acid concentrations in vivo, suggesting a receptor-mediated event and not simple lipotoxicity. When compared with an equimolar concentration of palmitate, fibroblast-stimulating lipopeptide-1, a known TLR2 ligand, was a slightly more potent activator of signal transduction and interleukin (IL)-6 production. Palmitate inhibited insulin signal transduction in C2C12 cells beginning 1-2 h after exposure and reached a maximum at 12-16 h. An antagonist TLR2 antibody, mAb 2.5, led to a 50-60% decrease in palmitate- induced IL-6 production and partially restored insulin signal transduction, whereas an isotype-matched control antibody had no effect. RNA interference-resulted in a near complete inhibition of palmitate- induced insulin resistance and IL-6 production. This study provides strong evidence that TLR2 mediates the initial events of fatty acid-induced insulin resistance in muscle.	Med Univ S Carolina, Dept Pediat, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA	Medical University of South Carolina	Senn, JJ (corresponding author), Med Univ S Carolina, Dept Pediat Endocrinol, Rm 316,Clin Sci Bldg,96 Jonathon Lucas St, Charleston, SC 29425 USA.	sennj@musc.edu						Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Ajuwon KM, 2005, J NUTR, V135, P1841, DOI 10.1093/jn/135.8.1841; Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bajaj M, 2005, DIABETES, V54, P3148, DOI 10.2337/diabetes.54.11.3148; Belfort R, 2005, DIABETES, V54, P1640, DOI 10.2337/diabetes.54.6.1640; Boden G, 2003, EXP CLIN ENDOCR DIAB, V111, P121, DOI 10.1055/s-2003-39781; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Fraser DA, 1999, RHEUMATOLOGY, V38, P948, DOI 10.1093/rheumatology/38.10.948; Frost RA, 2005, ALCOHOL CLIN EXP RES, V29, P1247, DOI 10.1097/01.ALC.0000171935.06914.5D; Frost RA, 2004, AM J PHYSIOL-CELL PH, V287, pC1605, DOI 10.1152/ajpcell.00010.2004; Fujita M, 2003, J IMMUNOL, V171, P3675, DOI 10.4049/jimmunol.171.7.3675; Ghanim H, 2004, CIRCULATION, V110, P1564, DOI 10.1161/01.CIR.0000142055.53122.FA; Illig T, 2003, DIABETES, V52, P2861, DOI 10.2337/diabetes.52.11.2861; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jimenez R, 2005, P NATL ACAD SCI USA, V102, P4637, DOI 10.1073/pnas.0407655101; Jove M, 2005, ENDOCRINOLOGY, V146, P3087, DOI 10.1210/en.2004-1560; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Lang CH, 2003, SHOCK, V19, P538, DOI 10.1097/01.shk.0000055237.25446.80; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Liu RH, 2002, INT J OBESITY, V26, P318, DOI 10.1038/sj.ijo.0801924; Miller YI, 2003, CURR OPIN LIPIDOL, V14, P437, DOI 10.1097/00041433-200310000-00004; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Muller SDC, 2004, INT IMMUNOPHARMACOL, V4, P1287, DOI 10.1016/j.intimp.2004.04.012; Muzio M, 2000, MICROBES INFECT, V2, P251, DOI 10.1016/S1286-4579(00)00303-8; Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563; Nakao Y, 2005, J IMMUNOL, V174, P1566, DOI 10.4049/jimmunol.174.3.1566; Netea MG, 2004, J LEUKOCYTE BIOL, V75, P749, DOI 10.1189/jlb.1103543; Nishimura M, 2005, BIOL PHARM BULL, V28, P886, DOI 10.1248/bpb.28.886; Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004; Park Y, 2004, ANN NY ACAD SCI, V1037, P170, DOI 10.1196/annals.1337.028; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; RIETSCHEL ET, 1987, REV INFECT DIS, V9, pS527; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rook GAW, 2003, CURR OPIN ALLERGY CL, V3, P337, DOI [10.1097/00130832-200310000-00003, 10.1097/01.all.0000092602.76804.ad]; Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; Sewter CP, 1999, J ENDOCRINOL, V163, P33, DOI 10.1677/joe.0.1630033; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Tomas E, 2004, P NUTR SOC, V63, P381, DOI 10.1079/PNS2004356; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Yang X, 2005, AM J PHYSIOL-HEART C, V289, pH1069, DOI 10.1152/ajpheart.00143.2005; Yim JJ, 2004, FEMS IMMUNOL MED MIC, V40, P163, DOI 10.1016/S0928-8244(03)00342-0; Zuany-Amorim C, 2002, NAT REV DRUG DISCOV, V1, P797, DOI 10.1038/nrd914	53	204	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26865	26875		10.1074/jbc.M513304200	http://dx.doi.org/10.1074/jbc.M513304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16798732	hybrid			2022-12-25	WOS:000240397700013
J	Frank, DJ; Martin, SR; Gruender, BNT; Lee, YSR; Simonette, RA; Bayley, PM; Miller, KG; Beckingham, KM				Frank, Deborah J.; Martin, Stephen R.; Gruender, Bridget N. T.; Lee, Yung-Sheng R.; Simonette, Rebecca A.; Bayley, Peter M.; Miller, Kathryn G.; Beckingham, Kathleen M.			Androcam is a tissue-specific light chain for myosin VI in the Drosophila testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-RELATED PROTEIN; UNCONVENTIONAL MYOSIN; MOTOR FUNCTION; CA2+ BINDING; HAIR-CELLS; SPERMATOGENESIS; SEQUENCE; SITES; TRANSLOCATION; LOCALIZATION	Myosin VI, a ubiquitously expressed unconventional myosin, has roles in a broad array of biological processes. Unusual for this motor family, myosin VI moves toward the minus (pointed) end of actin filaments. Myosin VI has two light chain binding sites that can both bind calmodulin (CaM). However unconventional myosins could use tissue-specific light chains to modify their activity. In the Drosophila testis, myosin VI is important for maintenance of moving actin structures, called actin cones, which mediate spermatid individualization. ACaM-related protein, Androcam (Acam), is abundantly expressed in the testis and like myosin VI, accumulates on these cones. We have investigated the possibility that Acam is a testis-specific light chain of Drosophila myosin VI. We find that Acam and myosin VI precisely colocalize at the leading edge of the actin cones and that myosin VI is necessary for this Acam localization. Further, myosin VI and Acam co-immunoprecipitate from the testis and interact in yeast two-hybrid assays. Finally Acam binds with high affinity to peptide versions of both myosin VI light chain binding sites. In contrast, although Drosophila CaM also shows high affinity interactions with these peptides, we cannot detect a CaM/myosin VI interaction in the testis. We conclude that Acam and not CaM acts as a myosin VI light chain in the Drosophila testis and hypothesize that it may alter the regulation of myosin VI in this tissue.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Washington Univ, Dept Biol, St Louis, MO 63130 USA; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	Rice University; Washington University (WUSTL); MRC National Institute for Medical Research	Beckingham, KM (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,POB 1892, Houston, TX 77251 USA.	kate@bioc.rice.edu			Medical Research Council [MC_U117570592] Funding Source: Medline; NICHD NIH HHS [HD39766] Funding Source: Medline; NIGMS NIH HHS [GM 60494] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060494] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Andruss BF, 2004, GENESIS, V38, P93, DOI 10.1002/gene.20002; ANDRUSS BF, 1997, THESIS RICE U; Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Bahloul A, 2004, P NATL ACAD SCI USA, V101, P4787, DOI 10.1073/pnas.0306892101; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; DOYLE KE, 1990, J MOL BIOL, V213, P599, DOI 10.1016/S0022-2836(05)80245-1; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frank DJ, 2004, CURR OPIN CELL BIOL, V16, P189, DOI 10.1016/j.ceb.2004.02.001; FYRBERG C, 1994, BIOCHEM GENET, V32, P119, DOI 10.1007/BF00554420; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; Hicks JL, 1999, MOL BIOL CELL, V10, P4341, DOI 10.1091/mbc.10.12.4341; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Kelleher JF, 2000, CURR BIOL, V10, P1489, DOI 10.1016/S0960-9822(00)00828-9; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Lu AQ, 2000, MECH DEVELOP, V94, P171, DOI 10.1016/S0925-4773(00)00262-8; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; Martin SR, 2000, PROTEIN SCI, V9, P2477, DOI 10.1110/ps.9.12.2477; Martin SR, 1999, PROTEIN SCI, V8, P2444; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; Morris CA, 2003, J BIOL CHEM, V278, P23324, DOI 10.1074/jbc.M208957200; Petritsch C, 2003, DEV CELL, V4, P273, DOI 10.1016/S1534-5807(03)00020-0; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rogat AD, 2002, J CELL SCI, V115, P4855, DOI 10.1242/jcs.00149; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200; Zhu T, 1998, J BIOL CHEM, V273, P20481, DOI 10.1074/jbc.273.32.20481	39	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24728	24736		10.1074/jbc.M602094200	http://dx.doi.org/10.1074/jbc.M602094200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790438	hybrid			2022-12-25	WOS:000239847800069
J	Nikolaev, VO; Hoffmann, C; Bunemann, M; Lohse, MJ; Vilardaga, JP				Nikolaev, Viacheslav O.; Hoffmann, Carsten; Buenemann, Moritz; Lohse, Martin J.; Vilardaga, Jean-Pierre			Molecular basis of partial agonism at the neurotransmitter alpha(2A)-adrenergic receptor and G(i)-protein heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIVING CELLS; CONFORMATIONS; ACTIVATION; MODEL	To characterize the mechanism by which heterotrimeric G-proteins interpret the signals coming from various neurotransmitters of diverse efficacies (agonists and partial agonists) acting on alpha(2A)-adrenergic receptors, we used a fluorescent resonance energy transfer-based approach to study the effects of these partial agonists on the activation process of both the alpha(2A)-adrenergic receptor and its cognate G(i)-protein. We show that ligands of different efficacies switch the receptor into distinct conformational states, which in turn set the speed and extent of the G(i)-protein signaling. Thus, in cells the efficacy by which a receptor responds to diverse ligands is caused by the ability of the G-protein to differentiate between distinct receptor conformations. The data provide a new key characteristic underlying the mechanism of partial agonism at G-protein-coupled receceptors.	Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Nephrol, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	University of Wurzburg; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Vilardaga, JP (corresponding author), Simches Res Ctr, Program Membrane Biol, 185 Cambridge St,CPZN-8218, Boston, MA 02114 USA.	jvilardaga@partners.org	Lohse, Martin J/A-7160-2012; Nikolaev, Vyacheslav/AAT-7746-2020	Lohse, Martin J/0000-0002-0599-3510; Vilardaga, Jean-Pierre/0000-0002-1217-1435				Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; Watson C, 2000, MOL PHARMACOL, V58, P1230, DOI 10.1124/mol.58.6.1230; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005	16	87	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24506	24511		10.1074/jbc.M603266200	http://dx.doi.org/10.1074/jbc.M603266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787921	hybrid			2022-12-25	WOS:000239847800046
J	Sakamoto, K; Ito, Y; Mori, T; Sugimura, K				Sakamoto, Kotaro; Ito, Yuji; Mori, Toshiyuki; Sugimura, Kazuhisa			Interaction of human lactoferrin with cell adhesion molecules through RGD motif elucidated by lactoferrin-binding epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; PROTEIN; LIPOPOLYSACCHARIDE; ANGIOGENESIS; ACTIVATION; COMPLEX; CLONING; ARG(4); FAMILY	Lactoferrin (LF) is an iron-binding secretory protein, which is distributed in the secondary granules of polynuclear lymphocytes as well as in the milk produced by female mammals. Although it has multiple functions, for example antimicrobial, immunomodulatory, antiviral, and anti-tumor metastasis activities, the receptors responsible for these activities are not fully understood. In this study, the binding epitopes for human LF were first isolated from a hexameric random peptide library displayed on T7 phage. Interestingly, two of the four isolated peptides had a representative cell adhesion motif, Arg-Gly-Asp (RGD), implying that human LF interacts with proteins with the RGD motif. We found that human LF bound to the RGD-containing human extracellular matrix proteins, fibronectin and vitronectin. Furthermore, human LF inhibited cell adhesion to these matrix proteins in a concentration-dependent manner but not to the RGD-independent cell adhesion molecule like laminin or collagen. These results indicate that a function of human LF is to block the various interactions between the cell surface and adhesion molecules. This may explain the multifunctionality of LF.	Kagoshima Univ, Fac Engn, Kagoshima 8900065, Japan; NCI, Mol Targets Dev Program, Canc Res Ctr, NIH, Frederick, MD 21702 USA	Kagoshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ito, Y (corresponding author), Kagoshima Univ, Fac Engn, Kagoshima 8900065, Japan.	yito@be.kagoshima-u.ac.jp			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Caccavo D, 2002, J ENDOTOXIN RES, V8, P403, DOI 10.1179/096805102125001000; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Elass-Rochard E, 1998, INFECT IMMUN, V66, P486, DOI 10.1128/IAI.66.2.486-491.1998; Haversen L, 2002, CELL IMMUNOL, V220, P83, DOI 10.1016/S0008-8749(03)00006-6; Iigo M, 2004, CYTOKINE, V25, P36, DOI 10.1016/j.cyto.2003.09.009; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kawabata H, 2004, BRIT J HAEMATOL, V127, P464, DOI 10.1111/j.1365-2141.2004.05224.x; Legrand D, 1997, BIOCHEM J, V327, P841, DOI 10.1042/bj3270841; Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x; Li RH, 2003, PROTEIN ENG, V16, P65, DOI 10.1093/proeng/gzg002; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; Na YJ, 2004, INT IMMUNOPHARMACOL, V4, P1187, DOI 10.1016/j.intimp.2004.05.009; Norrby K, 2001, INT J CANCER, V91, P236, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1024&gt;3.3.CO;2-K; Salcedo R, 1997, EXP CELL RES, V233, P25, DOI 10.1006/excr.1997.3544; Shimamura M, 2004, INT J CANCER, V111, P111, DOI 10.1002/ijc.20187; Suzuki YA, 2001, BIOCHEMISTRY-US, V40, P15771, DOI 10.1021/bi0155899; van der Strate BWA, 2001, ANTIVIR RES, V52, P225, DOI 10.1016/S0166-3542(01)00195-4; van Well RM, 2003, BIOORG MED CHEM LETT, V13, P331, DOI 10.1016/S0960-894X(02)01022-3; vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; Weng TY, 2005, ANTIVIR RES, V67, P31, DOI 10.1016/j.antiviral.2005.03.005; Yi MY, 1997, J VIROL, V71, P5997, DOI 10.1128/JVI.71.8.5997-6002.1997; Zhao TM, 2001, J CELL BIOL, V152, P65, DOI 10.1083/jcb.152.1.65	24	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24472	24478		10.1074/jbc.M604974200	http://dx.doi.org/10.1074/jbc.M604974200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16787913	hybrid			2022-12-25	WOS:000239847800042
J	Binder, M; Liebisch, G; Langmann, T; Schmitz, G				Binder, Marion; Liebisch, Gerhard; Langmann, Thomas; Schmitz, Gerd			Metabolic profiling of glycerophospholipid synthesis in fibroblasts loaded with free cholesterol and modified low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HIGH-THROUGHPUT QUANTIFICATION; PHOSPHATIDYLCHOLINE SYNTHESIS; PHOSPHOLIPID BIOSYNTHESIS; MEMBRANE CURVATURE; MAMMALIAN-CELLS; UP-REGULATION; FATTY-ACIDS; MACROPHAGES	Currently, the detailed regulation of major pathways of glycerophospholipid synthesis upon cholesterol loading is largely unknown. Therefore, a detailed lipid metabolic profiling using stable isotope-labeled choline, ethanolamine, and serine was performed by quantitative electrospray ionization tandem mass spectrometry (ESI-MS/MS) in free cholesterol (FC), oxidized (Ox-LDL) and enzymatically modified LDL (E-LDL)-loaded primary human skin fibroblasts. As previously described, an adaptive induction of phosphatidylcholine ( PC) synthesis via CDP-choline was found upon FC loading. In contrast to PC, CDP-ethanolamine-mediated phosphatidylethanolamine ( PE) synthesis was inhibited by FC incubation. Furthermore, FC induced a shift toward polyunsaturated PE and PC species, which was mediated primarily by PE biosynthesis but not PE remodeling, whereas PC species were shifted mainly by fatty acid ( FA) remodeling of existing PC. Modified lipoprotein incubation revealed rather different effects on glycerophospholipid synthesis. E-LDL greatly enhanced PC synthesis, whereas OxLDL did not change PC synthesis. Addition of different free FAs (FFA) with and without FC coincubation, as major components of E-LDL, clearly indicated an incorporation of FFA into newly synthesized PC and PE species as well as FFA as important driving force for PC synthesis. Because FC and FFA are known to affect lipid membrane properties including membrane curvature, these data support that CTP: phosphocholine cytidylyltransferase activity and consequently PC synthesis are regulated by modulation of membrane characteristics at the cellular level. In conclusion, the application of high throughput metabolic profiling of major glycerophospholipid pathways by ES-IMS/MS is a powerful tool to unravel mechanisms underlying the regulation of cellular lipid metabolism.	Univ Regensburg, Inst Clin Chem, D-93042 Regensburg, Germany	University of Regensburg	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	gerd.schmitz@klinik.uni-regensburg.de	Liebisch, Gerhard/G-6130-2010; Langmann, Thomas/HHZ-9814-2022	Liebisch, Gerhard/0000-0003-4886-0811; Langmann, Thomas/0000-0001-6826-529X; Schmitz, Gerd/0000-0002-1325-1007				Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Baird SK, 2004, FEBS LETT, V578, P169, DOI 10.1016/j.febslet.2004.11.007; Bhakdi S, 2004, THROMB HAEMOSTASIS, V91, P639, DOI 10.1160/TH-03-12-d733; Bhakdi S, 2004, CIRCULATION, V109, P1870, DOI 10.1161/01.CIR.0000124228.08972.26; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; Boumann HA, 2006, MOL BIOL CELL, V17, P1006, DOI 10.1091/mbc.E05-04-0344; Boumann HA, 2005, BIOCHEM SOC T, V33, P1146, DOI 10.1042/BST0331146; Brown AJ, 2000, J LIPID RES, V41, P226; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; de Boschero MGI, 2000, EXP GERONTOL, V35, P653, DOI 10.1016/S0531-5565(00)00104-2; Dhaliwal BS, 2000, J LIPID RES, V41, P1658; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Giusto NM, 2000, PROG LIPID RES, V39, P315, DOI 10.1016/S0163-7827(00)00009-6; Huang CH, 1999, BBA-REV BIOMEMBRANES, V1422, P273, DOI 10.1016/S0005-2736(99)00099-1; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X; Johnson CA, 2005, BBA-MOL CELL BIOL L, V1735, P230, DOI 10.1016/j.bbalip.2005.06.002; JONES HE, 1992, LIPIDS, V27, P984, DOI 10.1007/BF02535576; Kapinsky M, 2001, ARTERIOSCL THROM VAS, V21, P1004, DOI 10.1161/01.ATV.21.6.1004; Leppimaki P, 2000, EUR J BIOCHEM, V267, P6385, DOI 10.1046/j.1432-1327.2000.01726.x; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; Liebisch G, 2006, BBA-MOL CELL BIOL L, V1761, P121, DOI 10.1016/j.bbalip.2005.12.007; Liebisch G, 2002, CLIN CHEM, V48, P2217; Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Salvayre R, 2002, BBA-MOL CELL BIOL L, V1585, P213, DOI 10.1016/S1388-1981(02)00343-8; SCHMITZ G, 1990, J LIPID RES, V31, P1741; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; Suriyaphol P, 2002, CIRCULATION, V106, P2581, DOI 10.1161/01.CIR.0000038366.11851.D0; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073; WIELAND E, 1993, P NATL ACAD SCI USA, V90, P5929, DOI 10.1073/pnas.90.13.5929; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; Yu A, 2000, BBA-MOL CELL BIOL L, V1487, P296, DOI 10.1016/S1388-1981(00)00100-1	47	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21869	21877		10.1074/jbc.M603025200	http://dx.doi.org/10.1074/jbc.M603025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16766520	hybrid			2022-12-25	WOS:000239387100033
J	Canto, C; Chibalin, AV; Barnes, BR; Glund, S; Suarez, E; Ryder, JW; Palacin, M; Zierath, JR; Zorzano, A; Guma, A				Canto, Carles; Chibalin, Alexander V.; Barnes, Brian R.; Glund, Stephan; Suarez, Elisabet; Ryder, Jeffrey W.; Palacin, Manuel; Zierath, Juleen R.; Zorzano, Antonio; Guma, Anna			Neuregulins mediate calcium-induced glucose transport during muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; ACTIVATED PROTEIN-KINASE; SOLEUS MUSCLE; INSULIN; GLUT4; TRANSLOCATION; METABOLISM; EXPRESSION; EXERCISE; DISSOCIATION	Neuregulin, a growth factor involved in myogenesis, has rapid effects on muscle metabolism. In a manner analogous to insulin and exercise, neuregulins stimulate glucose transport through recruitment of glucose transporters to surface membranes in skeletal muscle. Like muscle contraction, neuregulins have additive effects with insulin on glucose uptake. Therefore, we examined whether neuregulins are involved in the mechanism by which muscle contraction regulates glucose transport. We show that caffeine-induced increases in cytosolic Ca2+ mediate a metalloproteinase-dependent release of neuregulins, which stimulates tyrosine phosphorylation of ErbB4 receptors. Activation of ErbB4 is necessary for Ca2+-derived effects on glucose transport. Furthermore, blockage of ErbB4 abruptly impairs contraction-induced glucose uptake in slow twitch muscle fibers, and to a lesser extent, in fast twitch muscle fibers. In conclusion, we provide evidence that contraction-induced activation of neuregulin receptors is necessary for the stimulation of glucose transport and a key element of energetic metabolism during muscle contraction.	Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, E-08028 Barcelona, Spain; Inst Recerca Biomed, E-08028 Barcelona, Spain; Karolinska Inst, Dept Mol Med & Surg, Sect Integrat Physiol, SE-17177 Stockholm, Sweden	University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Karolinska Institutet	Guma, A (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, Avda Diagonal,645,Parc Cient Barcelona, E-08028 Barcelona, Spain.	aguma@ub.edu	Zorzano, Antonio/R-5479-2018; Gumà, Anna/C-5165-2017	Gumà, Anna/0000-0001-9390-5252; Zierath, Juleen/0000-0001-6891-7497; Chibalin, Alexander/0000-0002-6339-6271; Palacin, Manuel/0000-0002-8670-293X; Canto, Carles/0000-0002-5167-7922				Ai H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1291, DOI 10.1152/ajpendo.00167.2001; Barnes BR, 2002, DIABETES, V51, P2703, DOI 10.2337/diabetes.51.9.2703; Canto C, 2004, J BIOL CHEM, V279, P12260, DOI 10.1074/jbc.M308554200; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; Holloszy JO, 2003, AM J PHYSIOL-ENDOC M, V284, pE453, DOI 10.1152/ajpendo.00463.2002; Jessen N, 2005, J APPL PHYSIOL, V99, P330, DOI 10.1152/japplphysiol.00175.2005; Kaushik VK, 2001, AM J PHYSIOL-ENDOC M, V281, pE335, DOI 10.1152/ajpendo.2001.281.2.E335; Koistinen HA, 2002, ANN MED, V34, P410, DOI 10.1080/078538902321012351; KOUMANOV F, 1998, BIOCHEM J, V330, P109; Lebrasseur NK, 2003, AM J PHYSIOL-CELL PH, V284, pC1149, DOI 10.1152/ajpcell.00487.2002; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; OJTASZEWSKI JF, 1998, AM J PHYSIOL, V274, pE184; Ozcelik C, 2002, P NATL ACAD SCI USA, V99, P8880, DOI 10.1073/pnas.122249299; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; Rimer M, 2003, J NEUROCYTOL, V32, P665, DOI 10.1023/B:NEUR.0000020615.79831.51; Rose AJ, 2005, PHYSIOLOGY, V20, P260, DOI 10.1152/physiol.00012.2005; Roy D, 1996, BIOCHEM BIOPH RES CO, V223, P147, DOI 10.1006/bbrc.1996.0860; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Suarez E, 2001, J BIOL CHEM, V276, P18257, DOI 10.1074/jbc.M008100200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Ueda H, 2005, J HISTOCHEM CYTOCHEM, V53, P87, DOI 10.1369/jhc.4A6341.2005; Wojtaszewski JFP, 1996, J APPL PHYSIOL, V81, P1501, DOI 10.1152/jappl.1996.81.4.1501; Wright DC, 2006, AM J PHYSIOL-ENDOC M, V290, pE123, DOI 10.1152/ajpendo.00280.2005; Wright DC, 2005, AM J PHYSIOL-ENDOC M, V288, pE1062, DOI 10.1152/ajpendo.00561.2004; Wright DC, 2004, DIABETES, V53, P330, DOI 10.2337/diabetes.53.2.330; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x; Zorzano A, 2005, ACTA PHYSIOL SCAND, V183, P43, DOI 10.1111/j.1365-201X.2004.01380.x	33	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21690	21697		10.1074/jbc.M600475200	http://dx.doi.org/10.1074/jbc.M600475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16740635	hybrid			2022-12-25	WOS:000239387100014
J	Finnson, KW; Tam, BYY; Liu, K; Marcoux, A; Lepage, P; Roy, S; Bizet, AA; Philip, A				Finnson, Kenneth W.; Tam, Betty Y. Y.; Liu, Kai; Marcoux, Anne; Lepage, Pierre; Roy, Stephane; Bizet, Albane A.; Philip, Anie			Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes	FASEB JOURNAL			English	Article						TGF-beta; receptor; CD109; signaling; keratinocyte	GROWTH-FACTOR-BETA; LIGAND-BINDING; II RECEPTORS; EXPRESSION; PROTEINS; CELLS; BETAGLYCAN; TGF-BETA-1; COMPLEXES; EPIDERMIS	We have previously reported that keratinocytes defective in glycosylphosphatidylinositol (GPI)-anchor biosynthesis display enhanced TGF-beta responses. These studies implicated the involvement of a 150 kDa GPI-anchored TGF-beta 1 binding protein, r150, in modulating TGF-beta signaling. Here, we sought to determine the molecular identity of r150 by affinity purification and microsequencing. Our results identify r150 as CD109, a novel member of the alpha 2-macroglobulin (alpha 2M)/complement superfamily, whose function has remained obscure. In addition, we have identified a novel CD109 isoform that occurs in the human placenta but not keratinocytes. Biochemical studies show that r150 contains an internal thioester bond, a defining feature of the alpha 2M/complement family. Loss and gain of function studies demonstrate that CD109 is a component of the TGF-beta receptor system, and a negative modulator of TGF-beta responses in keratinocytes, as implicated for r150. Our data suggest that CD109 can inhibit TGF-beta signaling independently of ligand sequestration and may exert its effect on TGF-beta signaling by direct modulation of receptor activity. Together, our results linking CD109 function to regulation of TGF-beta signaling suggest that CD109 plays a unique role in the regulation of isoform-specific TGF-beta signaling in keratinocytes.	McGill Univ, Dept Surg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Stomatol, Montreal, PQ H3G 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ, Canada	McGill University; McGill University	Philip, A (corresponding author), McGill Univ, Montreal Gen Hosp, 1650 Cedar Ave,Rm C9-177, Montreal, PQ H3G 1A4, Canada.	anie.philip@mcgill.ca	; Bizet, Albane/L-2622-2017	Finnson, Kenneth/0000-0003-2930-0595; Bizet, Albane/0000-0003-4187-9659				BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Choi ME, 1999, AM J PHYSIOL-RENAL, V276, pF88, DOI 10.1152/ajprenal.1999.276.1.F88; Cowin AJ, 2001, J INVEST DERMATOL, V117, P1282, DOI 10.1046/j.0022-202x.2001.01501.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Dodds AW, 1998, IMMUNOL REV, V166, P15; DUMONT N, 1995, MOL CELL ENDOCRINOL, V111, P57, DOI 10.1016/0303-7207(95)03548-L; Ferguson MWJ, 2004, PHILOS T R SOC B, V359, P839, DOI 10.1098/rstb.2004.1475; FURLEY AJ, 1986, BLOOD, V68, P1101; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Guo BQ, 2004, ANTICANCER RES, V24, P1337; HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hashimoto M, 2004, ONCOGENE, V23, P3716, DOI 10.1038/sj.onc.1207418; Hussein MR, 2005, J CUTAN PATHOL, V32, P389, DOI 10.1111/j.0303-6987.2005.00356.x; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li AG, 2004, EMBO J, V23, P1770, DOI 10.1038/sj.emboj.7600183; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MACKAY K, 1991, J BIOL CHEM, V266, P9907; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; SCHMID P, 1993, J PATHOL, V171, P191, DOI 10.1002/path.1711710307; Schuh AC, 2002, BLOOD, V99, P1692, DOI 10.1182/blood.V99.5.1692; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SMITH JW, 1995, BLOOD, V86, P2807; Solomon KR, 2004, GENE, V327, P171, DOI 10.1016/j.gene.2003.11.025; SUTHERLAND DR, 1991, BLOOD, V77, P84; Tam BYY, 2003, J BIOL CHEM, V278, P49610, DOI 10.1074/jbc.M308492200; Tam BYY, 1998, J CELL BIOCHEM, V70, P573, DOI 10.1002/(SICI)1097-4644(19980915)70:4<573::AID-JCB13>3.0.CO;2-I; Tam BYY, 2001, J CELL BIOCHEM, V83, P494, DOI 10.1002/jcb.1074; Tam BYY, 1998, J CELL PHYSIOL, V176, P553, DOI 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.3.CO;2-A; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; WRANA JL, 1992, COLD SPRING HARB SYM, V57, P81, DOI 10.1101/SQB.1992.057.01.011; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	108	116	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1525	+		10.1096/fj.05-5229fje	http://dx.doi.org/10.1096/fj.05-5229fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754747				2022-12-25	WOS:000240266000039
J	Zhang, JS; Gong, A; Young, CYF				Zhang, J-S; Gong, A.; Young, C. Y. F.			ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer	ONCOGENE			English	Article						LIM domain protein; filamentous actin; prostate cancer; tumor suppressor	GENE; DOMAIN; DIFFERENTIATION; HOMEODOMAIN; TARGETS; EPLIN; CELLS; MOTIF; LOST	We have recently identified ZNF185 as a gene that is downregulated in prostate cancer (PCa), in part via epigenetic alteration, and maybe associated with disease progression. In this study, we cloned the ZNF185 cDNA from normal human prostate tissues and investigated its biological function. We show that ZNF185 is a novel actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain-containing protein that localizes to F-actin structures, and is enriched at focal adhesions. We find that the NH2-terminal region, which we designate the actin-targeting domain, facilitates ZNF185 binding to actin ;in vitro and is both necessary and sufficient to mediate actin - cytoskeleton targeting of ZNF185, whereas the LIM domain, which is localized in the COOH-terminus is dispensable for this phenomenon. Interestingly, ectopic expression of full-length ZNF185, but not a mutant lacking the actin-targeting domain, could suppress proliferation and anchorage-independent growth of PCa cells. Together, our data suggest that ZNF185 may function as a tumor-suppressor protein by associating with the actin cytoskeleton.	Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA	Mayo Clinic	Zhang, JS (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.	zhang.jinsan@mayo.edu			NCI NIH HHS [CA70892, CA91956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA091956, R01CA070892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Garvalov BK, 2003, J CELL BIOL, V161, P33, DOI 10.1083/jcb.200211015; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Heiss NS, 1997, GENOMICS, V43, P329, DOI 10.1006/geno.1997.4810; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Labouesse M, 2003, CURR BIOL, V13, pR528, DOI 10.1016/S0960-9822(03)00448-2; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; PAN Y, 2003, CANCER EPIDEM BIOMAR, V8, P769; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Song YH, 2002, MOL BIOL CELL, V13, P1408, DOI 10.1091/mbc.01-08-0414; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Vanaja DK, 2003, CANCER RES, V63, P3877; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Welsh JB, 2001, CANCER RES, V61, P5974; Wong N, 2005, CLIN CANCER RES, V11, P1319; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188	30	32	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					111	122		10.1038/sj.onc.1209769	http://dx.doi.org/10.1038/sj.onc.1209769			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799630				2022-12-25	WOS:000243236500011
J	Hui, L; Zheng, Y; Yan, Y; Bargonetti, J; Foster, DA				Hui, L.; Zheng, Y.; Yan, Y.; Bargonetti, J.; Foster, D. A.			Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D	ONCOGENE			English	Article						phospholipase D; p53; survival signals; apoptosis; breast cancer	GAIN-OF-FUNCTION; TUMOR-SUPPRESSOR GENE; WILD-TYPE; FUNCTION MUTATIONS; EXPRESSION; BINDING; MDM2; TRANSFORMATION; ACTIVATION; RESISTANCE	p53 is the most commonly mutated gene in human cancer. Although the loss of tumor suppressor functions for p53 in tumorigenesis is well characterized, gain-of-function p53 mutations observed in most cancers are not as widely appreciated. The human breast cancer cell line MDA-MB-231, which has high levels of a mutant p53, has high levels of phospholipase D (PLD) activity, which provides a survival signal in these cells when deprived of serum growth factors. We report here that the mutant p53 in MDA-MB-231 cells is stabilized by the elevated PLD activity in these cells. Surprisingly, the survival of MDA-MB-231 cells deprived of serum was dependent on the mutant p53. These data indicate that a mutant p53, stabilized by elevated PLD activity, can contribute to the suppression of apoptosis in a human breast cancer cell line and suggest a rationale for the selection of p53 mutations early in tumorigenesis to suppress apoptosis in an emerging tumor.	CUNY, Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY, Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu		Bargonetti, Jill/0000-0003-2692-0991	NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asher G, 2003, P NATL ACAD SCI USA, V100, P15065, DOI 10.1073/pnas.2436329100; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; FOSTER DA, 2006, IN PRESS CURR SIGNAL, V1; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HSIAO M, 1994, AM J PATHOL, V145, P702; Hui L, 2005, J BIOL CHEM, V280, P35829, DOI 10.1074/jbc.M504192200; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Irwin MS, 2004, CELL CYCLE, V3, P319; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Katayose D, 1995, CLIN CANCER RES, V1, P889; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Moll UM, 2003, MOL CANCER RES, V1, P1001; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Strano S, 2003, CELL CYCLE, V2, P348, DOI 10.4161/cc.2.4.426; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	44	145	149	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7305	7310		10.1038/sj.onc.1209735	http://dx.doi.org/10.1038/sj.onc.1209735			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16785993				2022-12-25	WOS:000242244700009
J	Wang, W; Mulakala, C; Ward, SC; Jung, G; Luong, H; Pham, D; Waring, AJ; Kaznessis, Y; Lu, WY; Bradley, KA; Lehrer, RI				Wang, Wei; Mulakala, Chandrika; Ward, Sabrina C.; Jung, Grace; Luong, Hai; Pham, Duy; Waring, Alan J.; Kaznessis, Yiannis; Lu, Wuyuan; Bradley, Kenneth A.; Lehrer, Robert I.			Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THETA-DEFENSINS; ANTIMICROBIAL PEPTIDES; PROTECTIVE ANTIGEN; LIPID-BILAYERS; PROTEOLYTIC ACTIVATION; ADENYLATE-CYCLASE; EDEMA FACTOR; BINDING; MEMBRANE; PROTEINS	theta-defensins are cyclic octadecapeptides encoded by the modified alpha-defensin genes of certain nonhuman primates. The recent demonstration that human alpha-defensins could prevent deleterious effects of anthrax lethal toxin in vitro and in vivo led us to examine the effects of theta-defensins on Bacillus anthracis (Sterne). We tested rhesus theta-defensins 1-3, retrocyclins 1-3, and several analogues of RC-1. Low concentrations of theta-defensins not only killed vegetative cells of B. anthracis (Sterne) and rendered their germinating spores nonviable, they also inactivated the enzymatic activity of anthrax lethal factor and protected murine RAW-264.7 cells from lethal toxin, a mixture of lethal factor and protective antigen. Structure-function studies indicated that the cyclic backbone, intramolecular tri-disulfide ladder, and arginine residues of theta-defensins contributed substantially to these protective effects. Surface plasmon resonance studies showed that retrocyclins bound the lethal factor rapidly and with high affinity. Retrocyclin-mediated inhibition of the enzymatic activity of lethal factor increased substantially if the enzyme and peptide were preincubated before substrate was added. The temporal discrepancy between the rapidity of binding and the slowly progressive extent of lethal factor inhibition suggest that post-binding events, perhaps in situ oligomerization, contribute to the antitoxic properties of retrocyclins. Overall, these findings suggest that theta-defensins provide molecular templates that could be used to create novel agents effective against B. anthracis and its toxins.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Minnesota System; University of Minnesota Twin Cities; University System of Maryland; University of Maryland Baltimore	Lehrer, RI (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10833 LeConte Ave, Los Angeles, CA 90095 USA.	rlehrer@mednet.ucla.edu	Lu, Wuyuan/B-2268-2010; Lu, Wuyuan/J-8452-2017; Kaznessis, Yiannis N/H-1795-2015	Lu, Wuyuan/0000-0003-1318-9968; Kaznessis, Yiannis/0000-0002-5088-1104	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057870, R01AI061482, R01AI056921, R21AI056921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070989] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 061482, AI 056921, R01 AI061482, R01 AI056921, R21 AI056921, AI 057870, R01 AI057870] Funding Source: Medline; NIGMS NIH HHS [GM 070989, R01 GM070989, R01 GM070989-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banks DJ, 2005, CELL MICROBIOL, V7, P1173, DOI 10.1111/j.1462-5822.2005.00545.x; Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Buffy JJ, 2004, BIOCHEMISTRY-US, V43, P9800, DOI 10.1021/bi036243w; Buffy JJ, 2003, BIOCHEMISTRY-US, V42, P13725, DOI 10.1021/bi035187w; Buffy JJ, 2003, BIOPHYS J, V85, P2363, DOI 10.1016/S0006-3495(03)74660-8; Chong-Cerrillo C, 2003, J PEPT RES, V61, P237, DOI 10.1034/j.1399-3011.2003.00053.x; COHN EJ, 1943, PROTEINS AMINO ACIDS, P374; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Demchick P, 1996, J BACTERIOL, V178, P768, DOI 10.1128/jb.178.3.768-773.1996; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Friedlander AM, 2002, CURR TOP MICROBIOL, V271, P33; Ganz T, 2004, CR BIOL, V327, P539, DOI 10.1016/j.crvi.2003.12.007; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; GREEN BD, 1985, INFECT IMMUN, V49, P291, DOI 10.1128/IAI.49.2.291-297.1985; Heller WT, 2000, BIOCHEMISTRY-US, V39, P139, DOI 10.1021/bi991892m; Kim C, 2005, P NATL ACAD SCI USA, V102, P4830, DOI 10.1073/pnas.0500508102; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEHRER RI, 1992, CIBA F SYMP, V171, P276; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248; Leonova L, 2001, J LEUKOCYTE BIOL, V70, P461; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Mani R, 2004, BIOCHEMISTRY-US, V43, P13839, DOI 10.1021/bi048650t; Mayer-Scholl A, 2005, PLOS PATHOG, V1, P179, DOI 10.1371/journal.ppat.0010023; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mulvenna JP, 2006, NUCLEIC ACIDS RES, V34, pD192, DOI 10.1093/nar/gkj005; Nguyen TX, 2003, PEPTIDES, V24, P1647, DOI 10.1016/j.peptides.2003.07.023; Okinaka RT, 1999, J BACTERIOL, V181, P6509, DOI 10.1128/JB.181.20.6509-6515.1999; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; RICE WG, 1987, BLOOD, V70, P757; Scheetz T, 2002, IMMUNOL REV, V190, P137, DOI 10.1034/j.1600-065X.2002.19010.x; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Selsted ME, 2004, CURR PROTEIN PEPT SC, V5, P365, DOI 10.2174/1389203043379459; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Shoop WL, 2005, P NATL ACAD SCI USA, V102, P7958, DOI 10.1073/pnas.0502159102; SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19; STOTE RH, 1995, PROTEINS, V23, P12, DOI 10.1002/prot.340230104; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Tran D, 2002, J BIOL CHEM, V277, P3079, DOI 10.1074/jbc.M109117200; Turk BE, 2004, NAT STRUCT MOL BIOL, V11, P60, DOI 10.1038/nsmb708; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang W, 2003, J IMMUNOL, V170, P4708, DOI 10.4049/jimmunol.170.9.4708; Weiss TM, 2002, BIOCHEMISTRY-US, V41, P10070, DOI 10.1021/bi025853d; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wu ZB, 2003, J AM CHEM SOC, V125, P2402, DOI 10.1021/ja0294257; Yasin B, 2004, J VIROL, V78, P5147, DOI 10.1128/JVI.78.10.5147-5156.2004	64	69	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2006	281	43					32755	32764		10.1074/jbc.M603614200	http://dx.doi.org/10.1074/jbc.M603614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	096ZB	16790431	hybrid, Green Accepted			2022-12-25	WOS:000241414500074
J	Belotserkovskii, BP; Arimondo, PB; Cozzarelli, NR				Belotserkovskii, Boris P.; Arimondo, Paola B.; Cozzarelli, Nicholas R.			Topoisomerase action on short DNA duplexes reveals requirements for gate and transfer DNA segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; ESCHERICHIA-COLI; II TOPOISOMERASES; NALIDIXIC-ACID; BINDING-SITE; SUBUNIT-A; GYRASE; MECHANISM; CLEAVAGE; IV	Type II topoisomerases change DNA topology by passage of one DNA duplex (the transfer, T-segment) through a transient double-stranded break in another (the gate, G-segment). Here we monitor the passage between short double-stranded DNA segments within long single-stranded DNA circles that leads to catenation of the circles. To facilitate catenation, the circles were brought into close proximity using a tethering oligonucleotide, which was removed after the reaction was complete. We varied the length and the composition of the reacting DNA segments. The minimal DNA duplex length at which we detected catenation was 50-60 bp for DNA gyrase and 40 bp for topoisomerase IV (Topo IV). For Topo IV, catenation was observed when one, but not both, of the DNA-DNA duplexes was replaced by a DNA-RNA duplex. Topo IV cleaved the DNA-DNA duplex, but not the DNA-RNA duplex implying that the DNA-RNA duplex can be a T-segment but not a G-segment.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Arimondo, PB (corresponding author), Museum Natl Hist Nat, USM0503, INSERM, CNRS,UMR 5153,UR565, 43 Rue Cuvier, F-75231 Paris 05, France.	arimondo@mnhn.fr	Arimondo, Paola B/R-9095-2017	Arimondo, Paola B/0000-0001-5175-4396; Belotserkovskii, Boris/0000-0002-1570-9923	NCI NIH HHS [R37 CM31657] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; CHUNG IK, 1992, NUCLEIC ACIDS RES, V20, P1973, DOI 10.1093/nar/20.8.1973; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Cove ME, 1997, NUCLEIC ACIDS RES, V25, P2716, DOI 10.1093/nar/25.14.2716; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Gmunder H, 1997, NUCLEIC ACIDS RES, V25, P604, DOI 10.1093/nar/25.3.604; Hardy CD, 2004, PHILOS T R SOC B, V359, P39, DOI 10.1098/rstb.2003.1363; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KHODURSKY AB, 2000, P NATL ACAD SCI USA, V97, P9149; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; LEE MP, 1989, J BIOL CHEM, V264, P21779; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; LUND K, 1990, J BIOL CHEM, V265, P13856; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; ORPHANIDES G, 1994, NUCLEIC ACIDS RES, V22, P1567, DOI 10.1093/nar/22.9.1567; PATO ML, 1990, P NATL ACAD SCI USA, V87, P8716, DOI 10.1073/pnas.87.22.8716; Pong H, 1999, METH MOL B, V94, P163; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Ruthenburg AJ, 2005, J BIOL CHEM, V280, P26177, DOI 10.1074/jbc.M502838200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schoeffler AJ, 2005, BIOCHEM SOC T, V33, P1465, DOI 10.1042/BST0331465; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Y, 1999, J BIOL CHEM, V274, P22839, DOI 10.1074/jbc.274.32.22839; Wang Y, 2000, NUCLEIC ACIDS RES, V28, P4815, DOI 10.1093/nar/28.24.4815; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25407	25415		10.1074/jbc.M603977200	http://dx.doi.org/10.1074/jbc.M603977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16798730	hybrid			2022-12-25	WOS:000240031300043
J	Singh, RR; Kaluarachchi, K; Chen, MZ; Rayala, SK; Balasenthil, S; Ma, JP; Kumar, R				Singh, Rajesh R.; Kaluarachchi, Kumaralal; Chen, Mingzhi; Rayala, Suresh K.; Balasenthil, Seetharaman; Ma, Jianpeng; Kumar, Rakesh			Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURGICAL ADJUVANT BREAST; HUMAN ESTROGEN-RECEPTOR; CANCER; TAMOXIFEN; SUPPRESSION; EXPRESSION; RESOLUTION; PROTEIN-1; BINDING; GROWTH	Metastasis tumor-associated 1 short form (MTA1s) is a naturally occurring, alternatively spliced variant of MTA1 that functions as a repressor of estrogen receptor ( ER) alpha transcriptional functions, at least in part by binding and sequestering ER alpha in the cytoplasm. A unique C-terminal 33-amino acid region containing a nuclear receptor (NR)-box motif (-LRILL-) mediates binding of MTA1s with ER alpha and is indispensable in this interaction. Here, we elucidated the solution structure of this 33-amino acid region by NMR spectroscopy. We found a predominance of the alpha-helical region toward the N-terminal region, which includes the NR-box motif. In silico docking and comparison studies showed similarities between the NR-box motif of MTA1s and a similar motif of coregulators, both in structure and mode of ER alpha binding. In MCF-7 breast cancer cells, the MTA1s peptide effectively repressed ER alpha transactivation function, as evidenced by the estrogen response element-luc assay and down-regulation of estrogen-induced genes. In mechanistic studies, we found that the antiestrogenic effects of the MTA1s peptide were due to its ability to compete with the coactivator recruitment to ER alpha. Furthermore, the peptide efficiently repressed estrogen-induced proliferation and anchorage-independent growth of MCF-7 cells. In addition, the MTA1s peptide blocked the progression of tumors formed by MCF-7 cells overexpressing an ER alpha coactivator in a xenograft-based assay. In brief, the characterization of structure and antiestrogenic activity of MTA1s peptide highlight its therapeutic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct & Computat Biol, Houston, TX 77030 USA; Rice Univ, Dept Bioengn, Houston, TX 77251 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Rice University; Baylor College of Medicine; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Rayala, Suresh/0000-0003-4394-4450	NCI NIH HHS [CA65746, CA98823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746, R01CA098823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Chang CY, 1999, MOL CELL BIOL, V19, P8226; COLE MP, 1971, BRIT J CANCER, V25, P270, DOI 10.1038/bjc.1971.33; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MCGUIRE WL, 1975, ESTROGEN RECEPTOR HU, P57; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Singh RR, 2005, J CELL BIOCHEM, V96, P490, DOI 10.1002/jcb.20566; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Warnmark A, 2002, J BIOL CHEM, V277, P21862, DOI 10.1074/jbc.M200764200; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	37	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25612	25621		10.1074/jbc.M604444200	http://dx.doi.org/10.1074/jbc.M604444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807247	Green Published, hybrid			2022-12-25	WOS:000240031300064
J	Cook, AC; Chambers, AF; Turley, EA; Tuck, AB				Cook, Amy C.; Chambers, Ann F.; Turley, Eva A.; Tuck, Alan B.			Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; MAMMARY EPITHELIAL-CELLS; METASTATIC PROSTATE; PERICELLULAR MATRIX; MIGRATION; RECEPTOR; ACTIVATION; ADHESION; INVASIVENESS; PROGRESSION	Osteopontin (OPN) is a tumor-associated, secreted phosphoprotein that has been implicated in breast cancer progression and metastasis. Research concerning how OPN functions in tumor progression has led to the identification of a limited number of genes that contribute functionally to OPN-induced cellular behaviors. Recent microarray analysis, comparing 21NT breast cancer cells transfected to constitutively overexpress OPN with control cells, revealed hyaluronan synthase 2 (HAS2) to be a gene highly up-regulated in OPN-overexpressing cells. In this study, we further examined the relationship between OPN and HAS2. We show that 21NT OPN-transfected cells express high levels of HAS2, which is associated with increased HA production and matrix retention and is necessary for tumor cell adhesion to bone marrow endothelial cells and anchorage-independent growth. Finally, stable transfection of antisense HAS2 into 21NT cells overexpressing OPN resulted in a reduction in HAS2 expression, HA production, and pericellular retention. Antisense-mediated down-regulation of HAS2 also resulted in a significant decrease in cellular proliferation and colony growth in soft agar. To our knowledge, this is the first report of the ability of OPN to regulate HAS2 expression and HA production in breast cancer cells and further illustrates a unique functional relationship by which enhanced HA production facilitates OPN-mediated cell behaviors.	Univ Western Ontario, Dept Pathol, London, ON N6A 5C1, Canada; London Hlth Sci Ctr, London Reg Canc Program, London, ON N6A 4L6, Canada; London Hlth Sci Ctr, Dept Pathol, London, ON N6A 5A5, Canada	Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre	Tuck, AB (corresponding author), Univ Hosp London, Dept Pathol, London Hlth Sci Ctr, London, ON N6A 5A5, Canada.	Alan.Tuck@Lhsc.on.ca	Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Adwan H, 2004, CANCER GENE THER, V11, P109, DOI 10.1038/sj.cgt.7700659; Allan AL, 2005, CANC DRUG DISC DEV, P107; BAND V, 1990, CANCER RES, V50, P7351; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HE B, 2005, ONCOGENE; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, IUBMB LIFE, V54, P195, DOI 10.1080/15216540214929; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KNUDSON W, 1991, J CELL SCI, V99, P227; Kosaki R, 1999, CANCER RES, V59, P1141; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Liu NF, 2001, CANCER RES, V61, P5207; McDonald JA, 2002, GLYCOCONJUGATE J, V19, P331, DOI 10.1023/A:1025369004783; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; Senger DR, 1996, AM J PATHOL, V149, P293; Simpson MA, 2002, J BIOL CHEM, V277, P10050, DOI 10.1074/jbc.M110069200; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Singhal H, 1997, CLIN CANCER RES, V3, P605; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, BREAST CANCER RES TR, V70, P197, DOI 10.1023/A:1013095329825; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zeng CX, 1998, INT J CANCER, V77, P396; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	38	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24381	24389		10.1074/jbc.M602694200	http://dx.doi.org/10.1074/jbc.M602694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807238	hybrid			2022-12-25	WOS:000239847800031
J	Sanchez, M; Galy, B; Dandekar, T; Bengert, P; Vainshtein, Y; Stolte, J; Muckenthaler, MU; Hentze, MW				Sanchez, Mayka; Galy, Bruno; Dandekar, Thomas; Bengert, Peter; Vainshtein, Yevhen; Stolte, Jens; Muckenthaler, Martina U.; Hentze, Matthias W.			Iron regulation and the cell cycle - Identification of an iron-responsive element in the 3 '-untranslated region of human cell division cycle 14A mRNA by a refined microarray-based screening strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT METAL TRANSPORTER-1; HUMAN CDC14A PHOSPHATASE; CHROMOSOME SEGREGATION; HIGH-AFFINITY; EXPRESSION; BINDING; PROTEIN; ISOFORMS; MUTATION; MURINE	Iron regulatory proteins (IRPs) 1 and 2 post-transcriptionally control mammalian iron homeostasis by binding to iron-responsive elements (IREs), conserved RNA stem-loop structures located in the 5'- or 3'-untranslated regions of genes involved in iron metabolism (e. g. FTH1, FTL, and TFRC). To identify novel IRE-containing mRNAs, we integrated biochemical, biocomputational, and microarray-based experimental approaches. IRP/IRE messenger ribonucleoproteins were immunoselected, and their mRNA composition was analyzed using an IronChip microarray enriched for genes predicted computationally to contain IRE- like motifs. Among different candidates, this report focuses on a novel IRE located in the 3'-untranslated region of the cell division cycle 14A mRNA. We show that this IRE motif efficiently binds both IRP1 and IRP2. Differential splicing of cell division cycle 14A produces IRE- and non-IRE-containing mRNA isoforms. Interestingly, only the expression of the IRE-containing mRNA isoforms is selectively increased by cellular iron deficiency. This work describes a new experimental strategy to explore the IRE/IRP regulatory network and uncovers a previously unrecognized regulatory link between iron metabolism and the cell cycle.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; Univ Wurzburg, Biozentrum, Dept Bioinformat, D-97074 Wurzburg, Germany; Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; University of Wurzburg; Ruprecht Karls University Heidelberg	Muckenthaler, MU (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	martina.muckenthaler@med.uni-heidelberg.de; hentze@embl.de	Hentze, Matthias W/V-3980-2017; Sanchez, Mayka/F-5140-2010; Dandekar, Thomas/A-4431-2017	Hentze, Matthias W/0000-0002-4023-7876; Sanchez, Mayka/0000-0002-6499-5989; Dandekar, Thomas/0000-0003-1886-7625; Vainshtein, Yevhen/0000-0001-7944-8892; Galy, Bruno/0000-0002-0501-6357; Muckenthaler, Martina/0000-0002-3778-510X				BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; Benes V, 2003, TRENDS BIOCHEM SCI, V28, P244, DOI 10.1016/S0968-0004(03)00068-9; Bengert P, 2003, NUCLEIC ACIDS RES, V31, P3441, DOI 10.1093/nar/gkg568; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cmejla R, 2006, BIOCHEM BIOPH RES CO, V341, P158, DOI 10.1016/j.bbrc.2005.12.155; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Eisenstein RS, 2003, J NUTR, V133, p1510S, DOI 10.1093/jn/133.5.1510S; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Galy B, 2005, GENESIS, V43, P181, DOI 10.1002/gene.20169; Galy B, 2005, BLOOD, V106, P2580, DOI 10.1182/blood-2005-04-1365; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; Hubert N, 2002, P NATL ACAD SCI USA, V99, P12345, DOI 10.1073/pnas.192423399; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kato J, 2001, AM J HUM GENET, V69, P191, DOI 10.1086/321261; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; Kohler SA, 1999, J BIOL CHEM, V274, P2401, DOI 10.1074/jbc.274.4.2401; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; Liang SX, 2003, CARCINOGENESIS, V24, P1601, DOI 10.1093/carcin/bgg116; Lis A, 2005, BIOCHEM PHARMACOL, V69, P1647, DOI 10.1016/j.bcp.2005.03.023; Lymboussaki A, 2003, J HEPATOL, V39, P710, DOI 10.1016/S0168-8278(03)00408-2; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Meehan HA, 2001, J BIOL CHEM, V276, P14791, DOI 10.1074/jbc.M010295200; Meyron-Holtz EG, 2004, EMBO J, V23, P386, DOI 10.1038/sj.emboj.7600041; Mignone F, 2005, NUCLEIC ACIDS RES, V33, pD141, DOI 10.1093/nar/gki021; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Paramar PN, 2006, BIOCHEM J, V394, P173, DOI 10.1042/BJ20051296; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Schneider B D, 2000, Curr Opin Clin Nutr Metab Care, V3, P267, DOI 10.1097/00075197-200007000-00005; Smith SR, 2006, BLOOD CELL MOL DIS, V36, P283, DOI 10.1016/j.bcmd.2005.12.006; Tabuchi M, 2002, MOL BIOL CELL, V13, P4371, DOI 10.1091/mbc.E02-03-0165; Tchernitchko D, 2002, BIOCHEM J, V363, P449, DOI 10.1042/0264-6021:3630449; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; TSEUNG SLY, 2006, BIOCHEMISTRY-US, V45, P2294; Wang XC, 2005, AM J PHYSIOL-LUNG C, V289, pL24, DOI 10.1152/ajplung.00428.2003; Wong AKC, 1999, GENOMICS, V59, P248, DOI 10.1006/geno.1999.5863; Zoller H, 2002, BLOOD CELL MOL DIS, V29, P488, DOI 10.1006/bcmd.2002.0587	50	85	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22865	22874		10.1074/jbc.M603876200	http://dx.doi.org/10.1074/jbc.M603876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760464	hybrid			2022-12-25	WOS:000239542600049
J	Chen, J; Carcamo, JM; Golde, DW				Chen, Jian; Carcamo, Juan M.; Golde, David W.			The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; MOLECULAR-CLONING; TYROSINE KINASE; HEMATOPOIETIC STEM; CELL-LINE; EXPRESSION; ERYTHROPOIETIN; RECONSTITUTION; ACTIVATION; APOPTOSIS	The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates hematopoiesis and the function of mature host defense cells through the GM-CSF receptor (GMR), which is composed of alpha(alpha GMR) and beta(beta GMR) subunits. Stem cell factor is another important hematopoietic cytokine that signals through c-Kit, a receptor tyrosine kinase, and regulates hematopoietic stem cell maintenance and erythroid development. Like other cytokine receptors, GMR and c-Kit are generally deemed as independent adaptor molecules capable of transducing cytokine-specific signals. We found that the alpha GMR directly interacts with c-Kit and that the interaction is mediated by the cytoplasmic domains. Furthermore, alpha GMR inhibited c-Kit auto-phosphorylation induced by the ligand stem cell factor. Consistent with the inhibitory effect, the expression of alpha GMR was suppressed in cells whose viability was dependent on c- Kit signaling. In contrast, the alternatively spliced alpha 2 isoform of the alpha GMR could not inhibit c-Kit signaling, providing a rationale for the existence of the alpha 2 isoform. Our results suggest that in addition to having the commonly appreciated roles in cytokine signal transduction, the receptors alpha GMR and c-Kit could interact to coordinate their signal initiation.	Cornell Univ, Weill Grad Sch Med Sci, Dept Pharmacol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Chen, J (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Dept Pharmacol, New York, NY 10021 USA.	jchen10021@yahoo.com; jcarcamo@enzobio.com			NATIONAL CANCER INSTITUTE [R37CA030388, R01CA030388] Funding Source: NIH RePORTER; NCI NIH HHS [CA30388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1993, DEVELOPMENT, P125; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chen J, 2003, P NATL ACAD SCI USA, V100, P14000, DOI 10.1073/pnas.2334584100; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707; Doyle SE, 1998, BLOOD, V92, P867; Ebner K, 2003, BLOOD, V102, P192, DOI 10.1182/blood-2002-12-3753; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; HIRSCH T, 1995, BIOCHEM BIOPH RES CO, V217, P138, DOI 10.1006/bbrc.1995.2755; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Lilly MB, 2001, BLOOD, V97, P1662, DOI 10.1182/blood.V97.6.1662; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; MARKS DC, 1995, BIOCHEM PHARMACOL, V50, P475, DOI 10.1016/0006-2952(95)00157-U; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Slater NJ, 2003, BRIT J HAEMATOL, V122, P150, DOI 10.1046/j.1365-2141.2003.04383.x; Tanaka S, 1997, BBA-GENE STRUCT EXPR, V1352, P151, DOI 10.1016/S0167-4781(97)00055-9; Tu JL, 2000, BLOOD, V96, P794, DOI 10.1182/blood.V96.3.794.015k31_794_799; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	35	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22421	22426		10.1074/jbc.M604644200	http://dx.doi.org/10.1074/jbc.M604644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16760463	hybrid			2022-12-25	WOS:000239387100087
J	Chade, AR; Zhu, XY; Mushin, OP; Napoli, C; Lerman, A; Lerman, LO				Chade, Alejandro R.; Zhu, Xiangyang; Mushin, Oren P.; Napoli, Claudio; Lerman, Amir; Lerman, Lilach O.			Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia	FASEB JOURNAL			English	Article						kidney; ischemia; simvastatin; angiogenesis; microvessels; remodeling	EXPERIMENTAL RENOVASCULAR DISEASE; INCREASED OXIDATIVE STRESS; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL HYPERCHOLESTEROLEMIA; ARTERY STENOSIS; MYOCARDIAL NEOVASCULARIZATION; TISSUE TRANSGLUTAMINASE; STENOTIC KIDNEY; RAT MODEL	We tested the hypothesis that statins would decrease renal injury in renal artery stenosis (RAS) by restoring angiogenesis and attenuating intrarenal microvascular (IMV) remodeling. Single-kidney hemodynamics and function were quantified using electronbeam- computed tomography (CT) in normocholesterolemic pigs after 12 wk of experimental RAS, RAS supplemented with simvastatin (RAS+simvastatin), and normal controls. Renal circulation was also studied in vivo using angiography and ex vivo using a unique 3D micro-CT imaging technique. Angiogenic and remodeling pathways were subsequently explored in renal tissue. Blood pressure and the degree of stenosis were similarly increased in RAS groups. Simvastatin in RAS enhanced both intrarenal angiogenesis and peri-steno-sis arteriogenesis and increased the expression of angiogenic growth factors and hypoxia-inducible factor-1 alpha . Furthermore, simvastatin decreased tissue-transglutaminase expression and IMV inward remodeling, restored IMV endothelial function, decreased fibrogenic activity, and improved renal function. Chronic simvastatin supplementation promoted angiogenesis in vivo, decreased ischemia-induced IMV remodeling, and improved IMV function in the stenotic kidney, independent of lipid lowering. These novel renoprotective effects suggest a role for simvastatin in preserving the ischemic kidney in chronic RAS.	Mayo Clin, Coll Med, Div Nephrol & Hypertens, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Univ Naples Federico 2, Res Ctr Excellence Cardiovasc Dis, I-80138 Naples, Italy; Univ Naples Federico 2, Dept Gen Pathol, I-80138 Naples, Italy; Univ Naples Federico 2, Dept Med, I-80138 Naples, Italy; Boston Univ, Evans Dept Med, Boston, MA 02215 USA; Boston Univ, Whitaker Cardiovasc Inst, Boston, MA 02215 USA	Mayo Clinic; Mayo Clinic; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Boston University; Boston University	Lerman, LO (corresponding author), Mayo Clin, Coll Med, Div Nephrol & Hypertens, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	lerman.lilach@mayo.edu	Lerman, Lilach/M-4962-2017	Napoli, Claudio/0000-0002-5455-555X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073608] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-77131] Funding Source: Medline; NIBIB NIH HHS [EB 000305] Funding Source: Medline; NIDDK NIH HHS [DK-73608] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakker ENTP, 2005, CIRC RES, V96, P119, DOI 10.1161/01.RES.0000151333.56089.66; Bentley MD, 2002, KIDNEY INT, V61, P1056, DOI 10.1046/j.1523-1755.2002.00211.x; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Carey GB, 1997, MED SCI SPORT EXER, V29, P1437, DOI 10.1097/00005768-199711000-00008; Chade AR, 2003, HYPERTENSION, V42, P605, DOI 10.1161/01.HYP.0000089880.32275.7C; Chade AR, 2004, J AM SOC NEPHROL, V15, P1816, DOI 10.1097/01.ASN.0000130428.85603.6B; Chade AR, 2004, AM J PHYSIOL-RENAL, V286, pF1079, DOI 10.1152/ajprenal.00385.2003; Chade AR, 2004, J AM SOC NEPHROL, V15, P958, DOI 10.1097/01.ASN.0000117774.83396.E9; Chade AR, 2003, ARTERIOSCL THROM VAS, V23, P1295, DOI 10.1161/01.ATV.0000077477.40824.52; Chade AR, 2002, CIRCULATION, V106, P1165, DOI 10.1161/01.CIR.0000027105.02327.48; Chen CH, 2000, CIRCULATION, V101, P171, DOI 10.1161/01.CIR.101.2.171; Cheng JF, 2002, EXP BIOL MED, V227, P943, DOI 10.1177/153537020222701102; Edwards MS, 2005, ARCH INTERN MED, V165, P207, DOI 10.1001/archinte.165.2.207; Eickelberg O, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022008.30175.5B; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; Gueler F, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000026609.45827.3D; HaslerRapacz J, 1996, ARTERIOSCL THROM VAS, V16, P137, DOI 10.1161/01.ATV.16.1.137; Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5; Imanishi T, 2003, CLIN EXP PHARMACOL P, V30, P665, DOI 10.1046/j.1440-1681.2003.03894.x; Inman SR, 2003, AM J MED SCI, V326, P117, DOI 10.1097/00000441-200309000-00002; Johnson TS, 2003, J AM SOC NEPHROL, V14, P2052, DOI 10.1097/01.ASN.0000079614.63463.DD; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Krier JD, 2001, AM J PHYSIOL-RENAL, V281, pF630, DOI 10.1152/ajprenal.2001.281.4.F630; Landmesser U, 2004, CIRCULATION, V110, P1933, DOI 10.1161/01.CIR.0000143232.67642.7A; Langille BL, 2005, CIRC RES, V96, P9, DOI 10.1161/01.RES.0000153883.55971.81; Lerman L, 2001, UROL CLIN N AM, V28, P793, DOI 10.1016/S0094-0143(01)80034-3; Lerman LO, 1999, J AM SOC NEPHROL, V10, P1455; Lerman LO, 2001, HYPERTENSION, V37, P541, DOI 10.1161/01.HYP.37.2.541; Levy AP, 1999, CORONARY ARTERY DIS, V10, P427, DOI 10.1097/00019501-199909000-00013; Manotham K, 2005, KIDNEY INT, V67, P1428, DOI 10.1111/j.1523-1755.2005.00220.x; Moriyama T, 2001, KIDNEY INT, V59, P2095, DOI 10.1046/j.1523-1755.2001.0590062095.x; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Pourati I, 2003, AM HEART J, V146, P876, DOI 10.1016/S0002-8703(03)00413-7; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; Rizzoni D, 2003, CIRCULATION, V108, P2230, DOI 10.1161/01.CIR.0000095031.51492.C5; Safian RD, 2001, NEW ENGL J MED, V344, P431, DOI 10.1056/NEJM200102083440607; Sata M, 2004, HYPERTENSION, V43, P1214, DOI 10.1161/01.HYP.0000126186.29571.41; Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F; Smith RS, 2002, ARTERIOSCL THROM VAS, V22, P1279, DOI 10.1161/01.ATV.0000026613.18742.67; Sottile J, 2004, BBA-REV CANCER, V1654, P13, DOI 10.1016/j.bbcan.2003.07.002; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; Usui H, 2003, NEPHROL DIAL TRANSPL, V18, P265, DOI 10.1093/ndt/18.2.265; Vaughan CJ, 2004, CIRCULATION, V110, P886, DOI 10.1161/01.CIR.0000139312.10076.BA; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wilson SH, 2002, CIRCULATION, V105, P415, DOI 10.1161/hc0402.104119; Wilson SH, 2003, NEPHROL DIAL TRANSPL, V18, P703, DOI 10.1093/ndt/gfg143; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhu XY, 2004, ARTERIOSCL THROM VAS, V24, P1854, DOI 10.1161/01.ATV.0000142443.52606.81; Zhu XY, 2004, CIRCULATION, V109, P2109, DOI 10.1161/01.CIR.0000125742.65841.8B	50	104	107	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1706	+		10.1096/fj.05-5680fje	http://dx.doi.org/10.1096/fj.05-5680fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790524				2022-12-25	WOS:000240266600022
J	Pignatelli, P; Di Santo, S; Buchetti, B; Sanguigni, V; Brunelli, A; Violi, F				Pignatelli, P.; Di Santo, S.; Buchetti, B.; Sanguigni, V.; Brunelli, A.; Violi, F.			Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment	FASEB JOURNAL			English	Article						oxidative stress; polyphenols; platelet recruitment	CORONARY-HEART-DISEASE; FLAVONOID INTAKE; RISK; WINE; PHOSPHORYLATION; AGGREGATION; EXPRESSION; THROMBOSIS; QUERCETIN; JUICE	Several studies demonstrated an inverse association between polyphenol intake and cardiovascular events. Platelet recruitment is an important phase of platelet activation at the site of vascular injury, but it has never been investigated whether polyphenols influence platelet recruitment. The aim of the study was to analyze in vitro whether two polyphenols, quercetin and catechin, were able to affect platelet recruitment. Platelet recruitment was reduced by NO donors and by NADPH oxidase inhibitors and was enhanced by L-NAME, an inhibitor of NO synthase. Quercetin and catechin, but not single polyphenol, significantly inhibited platelet recruitment in a concentration- dependent fashion. The formation of superoxide anion was significantly inhibited in platelets incubated with quercetin and catechin but was unaffected by a single polyphenol. Incubation of platelets with quercetin and catechin resulted in inhibition of PKC and NADPH oxidase activation. Treatment of platelets with quercetin and catechin resulted in an increase of NO and also down-regulated the expression of GpIIb/IIIa glycoprotein. This study shows that the polyphenols quercetin and catechin synergistically act in reducing platelet recruitment via inhibition of PKC-dependent NADPH oxidase activation. This effect, resulting in NO-mediated platelet glycoprotein GpIIb/IIIa down-regulation, could provide a novel mechanism through which polyphenols reduce cardiovascular disease.	Univ Roma La Sapienza, Div Clin Med 4, Dipartimento Med Sperimentale & Patol, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Med Interna, I-00173 Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata	Violi, F (corresponding author), Univ Roma La Sapienza, Div Clin Med 4, Dipartimento Med Sperimentale & Patol, Policlin Umberto 1, I-00185 Rome, Italy.	francesco.violi@uniroma1.it	Sanguigni, Valerio/AAH-2515-2020; Violi, Francesco/K-1509-2016; pignatelli, pasquale/K-2116-2016	Violi, Francesco/0000-0002-6610-7068; pignatelli, pasquale/0000-0002-2265-7455				Al-Awwadi NA, 2005, J AGR FOOD CHEM, V53, P151, DOI 10.1021/jf048919f; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; BEGONIA AJ, 2005, BLOOD, V15, P2757; Burns J, 2000, J AGR FOOD CHEM, V48, P220, DOI 10.1021/jf9909757; Casani L, 2004, CIRCULATION, V110, P460, DOI 10.1161/01.CIR.0000136027.98303.4D; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; DEMROW HS, 1995, CIRCULATION, V91, P1182, DOI 10.1161/01.CIR.91.4.1182; Fichtlscherer S, 2004, CURR OPIN PHARMACOL, V4, P124, DOI 10.1016/j.coph.2004.01.002; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Freedman JE, 2001, CIRCULATION, V103, P2792, DOI 10.1161/01.CIR.103.23.2792; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hertog MGL, 1997, AM J CLIN NUTR, V65, P1489, DOI 10.1093/ajcn/65.5.1489; Janssen PLTMK, 1998, AM J CLIN NUTR, V67, P255, DOI 10.1093/ajcn/67.2.255; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; Krotz F, 2002, BLOOD, V100, P917, DOI 10.1182/blood.V100.3.917; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Miura T, 2003, FOOD CHEM TOXICOL, V41, P759, DOI 10.1016/S0278-6915(03)00005-X; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; Pignatelli P, 2000, AM J CLIN NUTR, V72, P1150; Pignatelli P, 2004, CIRCULATION, V110, P1326, DOI 10.1161/01.CIR.0000134963.77201.55; Pignatelli P, 2003, AM J PHYSIOL-HEART C, V284, pH41, DOI 10.1152/ajpheart.00249.2002; Poolman TM, 2005, FREE RADICAL BIO MED, V39, P118, DOI 10.1016/j.freeradbiomed.2005.02.036; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; Stocker R, 2004, AM J CLIN NUTR, V79, P123; Violi F, 2002, CIRCULATION, V105, pE53; Watala C, 2003, THROMB RES, V109, P299, DOI 10.1016/S0049-3848(03)00238-X; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.243S, 10.1093/ajcn/81.1.230S]; WOLLNY T, 1999, BRIT J PHARMACOL, V127, P147; Woodman OL, 2004, CLIN EXP PHARMACOL P, V31, P786, DOI 10.1111/j.1440-1681.2004.04072.x; Xu JW, 2005, LIFE SCI, V76, P2861, DOI 10.1016/j.lfs.2004.11.015	35	103	108	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1082	1089		10.1096/fj.05-5269com	http://dx.doi.org/10.1096/fj.05-5269com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770007				2022-12-25	WOS:000240210300008
J	Chen, H; Yong, WD; Ren, SX; Shen, WH; He, YZ; Cox, KA; Zhu, WQ; Li, W; Soonpaa, M; Payne, RM; Franco, D; Field, LJ; Rosen, V; Wang, YB; Shou, WN				Chen, Hanying; Yong, Weidong; Ren, Shuxun; Shen, Weihua; He, Yongzheng; Cox, Karen A.; Zhu, Wuqiang; Li, Wei; Soonpaa, Mark; Payne, R. Mark; Franco, Diego; Field, Loren J.; Rosen, Vicki; Wang, Yibin; Shou, Weinian			Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOMYOCYTE DNA-SYNTHESIS; SIGNALING PATHWAYS; PHYSIOLOGICAL LOADS; GENE-EXPRESSION; TRANSGENIC MICE; HEART-FAILURE; CELL-CYCLE; RAT-HEART; IN-VIVO; RECEPTOR	Postnatal cardiac hypertrophies have traditionally been classified into physiological or pathological hypertrophies. Both of them are induced by hemodynamic load. Cardiac postnatal hypertrophic growth is regarded as a part of the cardiac maturation process that is independent of the cardiac working load. However, the functional significance of this biological event has not been determined, mainly because of the difficulty in creating an experimental condition for testing the growth potential of functioning heart in the absence of hemodynamic load. Recently, we generated a novel transgenic mouse model (alpha MHC-BMP10) in which the cardiac-specific growth factor bone morphogenetic protein 10 (BMP10) is overexpressed in postnatal myocardium. These alpha MHC-BMP10 mice appear to have normal cardiogenesis throughout embryogenesis, but develop to smaller hearts within 6 weeks after birth. alpha MHC-BMP10 hearts are about half the normal size with 100% penetrance. Detailed morphometric analysis of cardiomyocytes clearly indicated that the compromised cardiac growth in alpha MHC-BMP10 mice was solely because of defect in cardiomyocyte postnatal hypertrophic growth. Physiological analysis further demonstrated that the responses of these hearts to both physiological (e.g. exercise-induced hypertrophy) and pathological hypertrophic stimuli remain normal. In addition, the alpha MHC-BMP10 mice develop subaortic narrowing and concentric myocardial thickening without obstruction by four weeks of age. Systematic analysis of potential intracellular pathways further suggested a novel genetic pathway regulating this previously undefined cardiac postnatal hypertrophic grow the vent. This is the first demonstration that cardiac postnatal hypertrophic growth can be specifically modified genetically and dissected out from physiological and pathological hypertrophies.	Indiana Univ, Sch Med, Dept Pediat, Hermann B Wells Ctr Pediat Res,Div Pediat Cardiol, Indianapolis, IN 46202 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Med, Los Angeles, CA 90095 USA; Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Univ Jaen, Dept Expt Biol, Jaen 23071, Spain	Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Harvard School of Dental Medicine; Universidad de Jaen	Shou, WN (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Hermann B Wells Ctr Pediat Res,Div Pediat Cardiol, Indianapolis, IN 46202 USA.	wshou@iupui.edu		Franco, Diego/0000-0002-5669-7164; Wang, Yibin/0000-0003-0852-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070259, P01HL085098, R01HL081092] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL070259-04, R01 HL070259, R01 HL081092, P01 HL085098-01A1, R01 HL081092-01A2, P01 HL085098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BISHOP SP, 1990, CIRC RES, V66, P84, DOI 10.1161/01.RES.66.1.84; BUTTRICK PM, 1994, J MOL CELL CARDIOL, V26, P61, DOI 10.1006/jmcc.1994.1008; Chen HY, 2004, DEVELOPMENT, V131, P2219, DOI 10.1242/dev.01094; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Cohn JN, 1997, CIRCULATION, V95, P766; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dorn GW, 2003, CIRC RES, V92, P1171, DOI 10.1161/01.RES.0000077012.11088.BC; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; Field LJ, 2004, ANN NY ACAD SCI, V1015, P160, DOI 10.1196/annals.1302.013; Gaussin V, 2005, CIRC RES, V97, P219, DOI 10.1161/01.RES.0000177862.85474.63; Gaussin V, 2002, P NATL ACAD SCI USA, V99, P2878, DOI 10.1073/pnas.042390499; Gerdes A M, 1998, J Card Fail, V4, P343, DOI 10.1016/S1071-9164(98)90240-8; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; JACKSON T, 1990, MOL CELL BIOL, V10, P3709, DOI 10.1128/MCB.10.7.3709; KAPLAN ML, 1994, AM J PHYSIOL, V267, pH1167, DOI 10.1152/ajpheart.1994.267.3.H1167; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Luo J, 2005, MOL CELL BIOL, V25, P9491, DOI 10.1128/MCB.25.21.9491-9502.2005; MacLellan WB, 1999, HEART DEV, P405; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mazerbourg S, 2005, J BIOL CHEM, V280, P32122, DOI 10.1074/jbc.M504629200; McMullen JR, 2004, J BIOL CHEM, V279, P4782, DOI 10.1074/jbc.M310405200; McMullen JR, 2003, P NATL ACAD SCI USA, V100, P12355, DOI 10.1073/pnas.1934654100; Nakajima H, 2000, CIRC RES, V86, P571, DOI 10.1161/01.RES.86.5.571; Neuhaus H, 1999, MECH DEVELOP, V80, P181, DOI 10.1016/S0925-4773(98)00221-4; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rodriguez P, 2005, ARCH MAL COEUR VAISS, V98, P1239; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; RUMYANTSEV PP, 1991, SOVIET MED REV S SER; SCHEUER J, 1987, CIRCULATION, V75, P63; Shen WH, 2005, J ENDOCRINOL, V185, P275, DOI 10.1677/joe.1.06080; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1997, AM J PHYSIOL-HEART C, V272, pH220, DOI 10.1152/ajpheart.1997.272.1.H220; SOONPAA MH, 1994, AM J PHYSIOL, V266, pH1439, DOI 10.1152/ajpheart.1994.266.4.H1439; TUCKER DC, 1995, J MOL CELL CARDIOL, V27, P1415, DOI 10.1006/jmcc.1995.0134; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Yi SE, 2000, DEVELOPMENT, V127, P621; Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102	45	44	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27481	27491		10.1074/jbc.M604818200	http://dx.doi.org/10.1074/jbc.M604818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16798733	Green Accepted, hybrid			2022-12-25	WOS:000240397700075
J	El-Tanani, MK; Campbell, FC; Crowe, P; Erwin, P; Harkin, DP; Pharoah, P; Ponder, B; Rudland, PS				El-Tanani, Mohamed K.; Campbell, Frederick Charles; Crowe, Paul; Erwin, Pauline; Harkin, Denis Paul; Pharoah, Paul; Ponder, Bruce; Rudland, Philip S.			BRCA1 suppresses osteopontin-mediated breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE TUMOR-SUPPRESSOR; GENE-EXPRESSION; NEOPLASTIC TRANSFORMATION; OVARIAN-CANCER; ESTROGEN; GROWTH; TRANSCRIPTION; METASTASIS; INHIBITION; PROTEIN	BRCA1 is a well described breast cancer susceptibility gene thought to be involved primarily in DNA repair. However, mutation within the BRCA1 transcriptional domain is also implicated in neoplastic transformation of mammary epithelium, but responsible mechanisms are unclear. Here we show in a rat mammary model system that wild type (WT) BRCA1 specifically represses the expression of osteopontin (OPN), a multifunctional estrogen-responsive gene implicated in oncogenic transformation, particularly that of the breast. WT. BRCA1 selectively binds OPN-activating transcription factors estrogen receptor alpha, AP-1, and PEA3, inhibits OPN promoter transactivation, and suppresses OPN mRNA and protein both from an endogenous gene and a relevant model inducible gene. WT. BRCA1 also inhibits OPN-mediated neoplastic transformation characterized by morphology change, anchorage-independent growth, adhesion to fibronectin, and invasion through Matrigel. A mutant BRCA1 allele (Mut. BRCA1) associated with familial breast cancer lacks OPN suppressor effects, binds to WT. BRCA1, and impedes WT. BRCA1 suppression of OPN. Stable transfection of rat breast tumor cell lines with Mut. BRCA1 dramatically up-regulates OPN protein and induces anchorage-independent growth. In human primary breast cancer, BRCA1 mutation is significantly associated with OPN overexpression. Taken together, these data suggest that BRCA1 mutation may confer increased tissue-specific cancer risk, in part by disruption of BRCA1 suppression of OPN gene transcription.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT12 6BJ, Antrim, North Ireland; Univ Cambridge, Strangeways Res Lab, Cambridge CB1 8RN, England; Univ Liverpool, Sch Biol Sci, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England	Queens University Belfast; University of Cambridge; University of Liverpool	El-Tanani, MK (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.	m.el-tanani@qub.ac.uk	Pharoah, Paul/V-6658-2019	Pharoah, Paul/0000-0001-8494-732X; El-Tanani, Mohamed/0000-0002-4735-5445; Campbell, Frederick/0000-0002-0363-9964	Medical Research Council [G0200103] Funding Source: Medline; MRC [G0200103] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Al-Mulla F, 2005, J HISTOCHEM CYTOCHEM, V53, P621, DOI 10.1369/jhc.4A6544.2005; BEHREND EI, 1994, CANCER RES, V54, P832; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; Chan YJ, 1996, J VIROL, V70, P8590, DOI 10.1128/JVI.70.12.8590-8605.1996; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Chen YM, 1996, CANCER RES, V56, P3168; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Devoll RE, 1999, J ORAL PATHOL MED, V28, P97; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; Euer N, 2002, ANTICANCER RES, V22, P733; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Gayther SA, 1999, AM J HUM GENET, V65, P1021, DOI 10.1086/302583; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kachhap SK, 2000, CANCER LETT, V154, P115, DOI 10.1016/S0304-3835(00)00371-2; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Kurpios NA, 2003, J MAMMARY GLAND BIOL, V8, P177, DOI 10.1023/A:1025948823955; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Meier JL, 1996, INTERVIROLOGY, V39, P331, DOI 10.1159/000150504; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2003, TRENDS GENET, V19, P312, DOI 10.1016/S0168-9525(03)00110-0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Oates AJ, 1996, ONCOGENE, V13, P97; Oates AJ, 1996, BIOCHEM SOC T, V24, pS353, DOI 10.1042/bst024353s; Orian-Rousseau V, 1998, J CELL SCI, V111, P1993; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rao VN, 1996, ONCOGENE, V12, P523; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; Rudland PS, 2002, CANCER RES, V62, P3417; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; SENGER DR, 1985, CANCER RES, V45, P5818; SENGER DR, 1988, CANCER RES, V48, P5770; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Sun Xian-jun, 2005, Zhonghua Zhongliu Zazhi, V27, P292; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, BREAST CANCER RES TR, V70, P197, DOI 10.1023/A:1013095329825; Uht Rosalie M, 2004, Nucl Recept, V2, P2, DOI 10.1186/1478-1336-2-2; Zhang Dong-tao, 2005, Zhonghua Zhongliu Zazhi, V27, P167; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	66	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26587	26601		10.1074/jbc.M604403200	http://dx.doi.org/10.1074/jbc.M604403200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16807234	hybrid			2022-12-25	WOS:000240249500077
J	Quick, M; Yano, H; Goldberg, NR; Duan, LH; Beuming, T; Shi, L; Weinstein, H; Javitch, JA				Quick, Matthias; Yano, Hideaki; Goldberg, Naomi R.; Duan, Lihua; Beuming, Thijs; Shi, Lei; Weinstein, Harel; Javitch, Jonathan A.			State-dependent conformations of the translocation pathway in the tyrosine transporter Tyt1, a novel neurotransmitter : sodium symporter from Fusobacterium nucleatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE TRANSPORT; ISOLATED MEMBRANE-VESICLES; NA+ GLUCOSE COTRANSPORTER; AMINO-ACID TRANSPORTER; ESCHERICHIA-COLI; MELIBIOSE PERMEASE; SEROTONIN TRANSPORTER; NA+/PROLINE PERMEASE; DOPAMINE TRANSPORTER; BACTERIAL HOMOLOG	The gene of a novel prokaryotic member (Tyt1) of the neurotransmitter: sodium symporter (NSS) family has been cloned from Fusobacterium nucleatum. In contrast to eukaryotic and some prokaryotic NSSs, which contain 12 transmembrane domains (TMs), Tyt1 contains only 11 TMs, a characteristic shared by similar to 70% of prokaryotic NSS homologues. Nonetheless upon heterologous expression in an engineered Escherichia coli host, Tyt1 catalyzes robust Na+-dependent, highly selective L-tyrosine transport. Genetic engineering of Tyt1 variants devoid of cysteines or with individually retained endogenous cysteines at positions 18 or 238, at the cytoplasmic ends of TM1 and TM6, respectively, preserved normal transport activity. Whereas cysteine-less Tyt1 was resistant to the inhibitory effect of sulfhydryl-alkylating reagents, N-ethylmaleimide inhibited transport by Tyt1 variants containing either one or both of the endogenous cysteines, and this inhibition was altered by the substrates sodium and tyrosine, consistent with substrate-induced dynamics in the transport pathway. Our findings support a binding model of Tyt1 function in which an ordered sequence of substrate-induced structural changes reflects distinct conformational states of the transporter. This work identifies Tyt1 as the first functional bacterial NSS member putatively consisting of only 11 TMs and shows that Tyt1 is a suitable model for the study of NSS dynamics with relevance to structure/function relationships of human NSSs, including the dopamine, norepinephrine, serotonin, and gamma-aminobutyric acid transporters.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Cornell Univ, Dept Physiol & Biophys, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Dept Physiol & Biophys, Weill Med Coll, His Royal Highness Prince Alwaleed Bin Talal Bin, New York, NY 10021 USA	Columbia University; Columbia University; Columbia University; Cornell University; Cornell University	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, P&S 11-401,Box 7, New York, NY 10032 USA.	jaj2@columbia.edu	Shi, Lei/AAV-1321-2020; WEINSTEIN, HAREL/O-8245-2019	Shi, Lei/0000-0002-4137-096X; WEINSTEIN, HAREL/0000-0003-3473-9818; Yano, Hideaki/0000-0001-9242-3884; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408, R01DA017293] Funding Source: NIH RePORTER; NIDA NIH HHS [DA17293, DA12408] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amara SG, 1998, DRUG ALCOHOL DEPEN, V51, P87, DOI 10.1016/S0376-8716(98)00068-4; Androutsellis-Theotokis A, 2003, J BIOL CHEM, V278, P12703, DOI 10.1074/jbc.M206563200; BARNES EM, 1970, P NATL ACAD SCI USA, V66, P1190, DOI 10.1073/pnas.66.4.1190; BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Broer A, 2006, BIOCHEM J, V393, P421, DOI 10.1042/BJ20051273; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Do CB, 2005, GENOME RES, V15, P330, DOI 10.1101/gr.2821705; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Feldman DH, 2000, J BIOL CHEM, V275, P24518, DOI 10.1074/jbc.M907582199; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Goldberg NR, 2003, EUR J PHARMACOL, V479, P3, DOI 10.1016/j.ejphar.2003.08.052; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; Iversen L, 2006, BRIT J PHARMACOL, V147, pS82, DOI 10.1038/sj.bjp.0706428; Jensdottir T, 2005, CARIES RES, V39, P468, DOI 10.1159/000088181; KABACK HR, 1971, J BIOL CHEM, V246, P5523; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KRUEGER BK, 1990, J NEUROCHEM, V55, P260, DOI 10.1111/j.1471-4159.1990.tb08847.x; Li LB, 2002, N-S ARCH PHARMACOL, V365, P303, DOI 10.1007/s00210-001-0526-6; Loo DDF, 2005, J GEN PHYSIOL, V125, P13, DOI 10.1085/jgp.200409150; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Masson J, 1999, PHARMACOL REV, V51, P439; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; Quick M, 2002, P NATL ACAD SCI USA, V99, P8597, DOI 10.1073/pnas.132266599; Quick M, 2001, J BIOL CHEM, V276, P1728, DOI 10.1074/jbc.M005521200; Rees DC, 2000, J BIOL CHEM, V275, P713, DOI 10.1074/jbc.275.2.713; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 2002, NEUROTRANSMITTER TRA; Saier MH, 1999, J CELL BIOCHEM, P84; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schenk JO, 2005, J NEUROSCI METH, V143, P41, DOI 10.1016/j.jneumeth.2004.09.021; Sonders MS, 2005, CURR OPIN NEUROBIOL, V15, P296, DOI 10.1016/j.conb.2005.05.009; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Tate CG, 2003, BBA-BIOMEMBRANES, V1610, P141, DOI 10.1016/S0005-2736(02)00719-8; Tate CG, 2001, FEBS LETT, V504, P94, DOI 10.1016/S0014-5793(01)02711-9; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VANDERREST ME, 1992, J BACTERIOL, V174, P4893, DOI 10.1128/JB.174.15.4893-4898.1992; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991	64	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26444	26454		10.1074/jbc.M602438200	http://dx.doi.org/10.1074/jbc.M602438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16798738	hybrid			2022-12-25	WOS:000240249500062
J	Eble, JA; Kassner, A; Niland, S; Morgelin, M; Grifka, J; Grassel, S				Eble, Johannes A.; Kassner, Anja; Niland, Stephan; Moergelin, Matthias; Grifka, Joachim; Graessel, Susanne			Collagen XVI harbors an integrin alpha 1 beta 1 recognition site in its C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; BINDING-SITE; A-DOMAIN; ALPHA(2)BETA(1) INTEGRIN; MONOCLONAL-ANTIBODIES; IV COLLAGEN; RECEPTOR; MIGRATION; SKIN; ALPHA(1)BETA(1)	Collagen XVI is integrated tissue-dependently into distinct fibrillar aggregates, such as D-banded cartilage fibrils and fibrillin-1-containing microfibrils. In skin, the distribution of collagen XVI overlaps that of the collagen-binding integrins alpha 1 beta 1 and alpha 2 beta 1. Basal layer keratinocytes express integrin alpha 2 beta 1, whereas integrin alpha 1 beta 1 occurs in smooth muscle cells surrounding blood vessels, in hair follicles, and on adipocytes. Cells bearing the integrins alpha 1 beta 1 and alpha 2 beta 1 attach and spread on recombinant collagen XVI. Furthermore, collagen XVI induces the recruitment of these integrins into focal adhesion plaques, a principal step in integrin signaling. Of potential physiological relevance, these integrin-collagen XVI interactions may connect cells with specialized fibrils, thus contributing to the organization of fibrillar and cellular components within connective tissues. In cell-free binding assays, collagen XVI is more avidly bound by alpha 1 beta 1 integrin than by alpha 2 beta 1 integrin. Both integrins interact with collagen XVI via the A domain of their alpha subunits. A tryptic collagen XVI fragment comprising the collagenous domains 1 - 3 is recognized by alpha 1 beta 1 integrin. Electron microscopy of complexes of alpha 1 beta 1 integrin with this tryptic collagen XVI fragment or with full-length collagen XVI revealed a unique alpha 1 beta 1 integrin-binding site within collagen XVI located close to its C-terminal end.	Muenster Univ Hosp, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Lund Univ, Biomed Ctr, S-22184 Lund, Sweden; Univ Regensburg, Dept Orthopaed, D-93077 Bad Abbach, Germany	University of Munster; Lund University; University of Regensburg	Eble, JA (corresponding author), Muenster Univ Hosp, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.	eble@uni-muenster.de						AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Eble JA, 2005, CURR PHARM DESIGN, V11, P867, DOI 10.2174/1381612053381738; Eble JA, 2003, BIOCHEM J, V376, P77, DOI 10.1042/BJ20030373; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Eble JA, 2002, METHOD CELL BIOL, V69, P223, DOI 10.1016/S0091-679X(02)69015-6; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; EIKENBERRY EF, 1999, DYNAMICS BONE CARTIL, P289; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fleischmajer R, 1998, J CELL SCI, V111, P1929; Fleischmajer R, 1998, ANN NY ACAD SCI, V857, P212, DOI 10.1111/j.1749-6632.1998.tb10118.x; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; Grassel S, 1999, MATRIX BIOL, V18, P309, DOI 10.1016/S0945-053X(99)00019-0; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kassner A, 2004, J MOL BIOL, V339, P835, DOI 10.1016/j.jmb.2004.03.042; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Kern A, 1998, J CELL PHYSIOL, V176, P634, DOI 10.1002/(SICI)1097-4652(199809)176:3<634::AID-JCP20>3.3.CO;2-J; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; Patrick CW, 2003, ANN BIOMED ENG, V31, P505, DOI 10.1114/1.1566446; Perret S, 2003, J BIOL CHEM, V278, P29873, DOI 10.1074/jbc.M304073200; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RYYNANEN J, 1992, J CLIN INVEST, V89, P163, DOI 10.1172/JCI115557; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Tuckwell DS, 2000, BIOCHEM J, V350, P485, DOI 10.1042/0264-6021:3500485; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200	42	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25745	25756		10.1074/jbc.M509942200	http://dx.doi.org/10.1074/jbc.M509942200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16754661	hybrid			2022-12-25	WOS:000240031300077
J	Badyal, SK; Joyce, MG; Sharp, KH; Seward, HE; Mewies, M; Basran, J; Macdonald, IK; Moody, PCE; Raven, EL				Badyal, Sandip K.; Joyce, M. Gordon; Sharp, Katherine H.; Seward, Harriet E.; Mewies, Martin; Basran, Jaswir; Macdonald, Isabel K.; Moody, Peter C. E.; Raven, Emma Lloyd			Conformational mobility in the active site of a heme peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; ASCORBATE PEROXIDASE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURES; SUBSTRATE-BINDING; COMPOUND-II; PH; CHEMISTRY; VARIANT; OXYGEN	Conformational mobility of the distal histidine residue has been implicated for several different heme peroxidase enzymes, but unambiguous structural evidence is not available. In this work, we present mechanistic, spectroscopic, and structural evidence for peroxide- and ligand-induced conformational mobility of the distal histidine residue (His-42) in a site-directed variant of ascorbate peroxidase (W41A). In this variant, His-42 binds "on" to the heme in the oxidized form, duplicating the active site structure of the cytochromes b but, in contrast to the cytochromes b, is able to swing "off" the iron during catalysis. This conformational flexibility between the on and off forms is fully reversible and is used as a means to overcome the inherently unreactive nature of the on form toward peroxide, so that essentially complete catalytic activity is maintained. Contrary to the widely adopted view of heme enzyme catalysis, these data indicate that strong coordination of the distal histidine to the heme iron does not automatically undermine catalytic activity. The data add a new dimension to our wider appreciation of structure/activity correlations in other heme enzymes.	Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Leicester, Henry Wellcome Labs Struct Biol, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester; University of Leicester	Raven, EL (corresponding author), Univ Leicester, Dept Chem, Henry Wellcome Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	emma.raven@le.ac.uk	Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238; Raven, Emma/0000-0002-1643-8694	Biotechnology and Biological Sciences Research Council [B19083] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASADA K, 1984, METHOD ENZYMOL, V105, P422; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Bonagura CA, 2003, BIOCHEMISTRY-US, V42, P5600, DOI 10.1021/bi034058c; Bursey EH, 2000, BIOCHEMISTRY-US, V39, P7374, DOI 10.1021/bi000446s; Cheek J, 1999, J BIOL INORG CHEM, V4, P64, DOI 10.1007/s007750050290; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dunford H. B., 1999, HEME PEROXIDASES; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Everse J., 1991, PEROXIDASES CHEM BIO, V2; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FERRER JC, 1994, BIOCHEMISTRY-US, V33, P7819, DOI 10.1021/bi00191a009; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Hersleth HP, 2002, J BIOL INORG CHEM, V7, P299, DOI 10.1007/s007750100296; Jones DK, 1998, ARCH BIOCHEM BIOPHYS, V360, P173, DOI 10.1006/abbi.1998.0941; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KELLY GJ, 1979, NATURWISSENSCHAFTEN, V66, P617, DOI 10.1007/BF00405128; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; Lad L, 2002, BIOCHEMISTRY-US, V41, P13774, DOI 10.1021/bi0261591; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Leys D, 2000, J BIOL CHEM, V275, P16050, DOI 10.1074/jbc.275.21.16050; Metcalfe CL, 2004, J AM CHEM SOC, V126, P16242, DOI 10.1021/ja048242c; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raven EL, 2003, NAT PROD REP, V20, P367, DOI 10.1039/b210426c; SANTIMONE M, 1975, CAN J BIOCHEM CELL B, V53, P649, DOI 10.1139/o75-090; Sasakura Y, 2006, ACCOUNTS CHEM RES, V39, P37, DOI 10.1021/ar0501525; Sharp KH, 2004, BIOCHEMISTRY-US, V43, P8644, DOI 10.1021/bi049343q; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; Tatum E.L., 1971, HEMOGLOBIN MYOGLOBIN; TURANO P, 1995, BIOCHEMISTRY-US, V34, P13895, DOI 10.1021/bi00042a022; VITELLO LB, 1992, BIOCHEMISTRY-US, V31, P11524, DOI 10.1021/bi00161a034; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; VITELLO LB, 1990, BIOCHEMISTRY-US, V29, P4283, DOI 10.1021/bi00470a004; Youngs HL, 2000, BIOCHEMISTRY-US, V39, P9994, DOI 10.1021/bi000679j	41	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24512	24520		10.1074/jbc.M602602200	http://dx.doi.org/10.1074/jbc.M602602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16762924	Green Submitted, hybrid, Green Published			2022-12-25	WOS:000239847800047
J	Ohana, L; Barchad, O; Parnas, I; Parnas, H				Ohana, Lily; Barchad, Ofra; Parnas, Itzchak; Parnas, Hanna			The metabotropic glutamate G-protein-coupled receptors mGluR3 and mGluR1a are voltage-sensitive	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNEL; FROG NEUROMUSCULAR-JUNCTION; BETA-ADRENERGIC-RECEPTOR; 2ND INTRACELLULAR LOOP; LONG-TERM DEPRESSION; XENOPUS-OOCYTES; PHARMACOLOGICAL CHARACTERIZATION; ACETYLCHOLINE-RELEASE; DEACTIVATION KINETICS; RAT-BRAIN	G-protein-coupled receptors play a key role in signal transduction processes. Despite G-protein-coupled receptors being transmembrane proteins, the notion that they exhibit voltage sensitivity is rather novel. Here we examine whether two metabotropic glutamate receptors, mGluR3 and mGluR1a, both involved in fundamental physiological processes, exhibit, by themselves, voltage sensitivity. Measuring mGluR3-induced K+ currents and mGluR1a-induced Ca2+-activated Cl- currents in Xenopus oocytes, we show that the apparent affinity toward glutamate decreases ( mGluR3) or increases ( mGluR1a) upon depolarization. Measurements of binding of [ H-3] glutamate to oocytes expressing either mGluR3 or mGluR1a corroborated the electrophysiological results. Using the chimeric G alpha subunit, we further show that the voltage sensitivity does not reside in the G-protein. To locate sites within the receptors that are involved in the voltage sensitivity, we used chimeric mGluR1a, where the intracellular loops that couple to the G-protein were replaced by those of mGluR3. The voltage sensitivity of the chimeric mGluR1a resembled that of mGluR3 and not that of the parental mGluR1a. The cumulative results indicate that the voltage sensitivity does not reside downstream to the activation of the receptors but rather in the mGluR3 and mGluR1a themselves. Furthermore, the intracellular loops play a crucial role in relaying changes in membrane potential to changes in the affinity of the receptors toward glutamate.	Hebrew Univ Jerusalem, Dept Neurobiol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Parnas, H (corresponding author), Hebrew Univ Jerusalem, Dept Neurobiol, IL-91904 Jerusalem, Israel.	hanna@vms.huji.ac.il						BAUD C, 1984, J PHYSIOL-LONDON, V356, P275, DOI 10.1113/jphysiol.1984.sp015464; Ben-Chaim Y, 2003, J BIOL CHEM, V278, P22482, DOI 10.1074/jbc.M301146200; Benians A, 2003, P NATL ACAD SCI USA, V100, P6239, DOI 10.1073/pnas.1037595100; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOTON R, 1990, PFLUG ARCH EUR J PHY, V416, P1, DOI 10.1007/BF00370214; Bradley SR, 2000, J NEUROSCI, V20, P3085, DOI 10.1523/JNEUROSCI.20-09-03085.2000; Bunemann M, 2001, J BIOL CHEM, V276, P47512, DOI 10.1074/jbc.M108652200; Callamaras N, 2000, AM J PHYSIOL-CELL PH, V278, pC667, DOI 10.1152/ajpcell.2000.278.4.C667; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; GANITKEVICH VY, 1993, J PHYSIOL-LONDON, V470, P35, DOI 10.1113/jphysiol.1993.sp019845; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Havlickova M, 2003, J BIOL CHEM, V278, P35063, DOI 10.1074/jbc.M306555200; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; ITOH T, 1992, J PHYSIOL-LONDON, V451, P307, DOI 10.1113/jphysiol.1992.sp019166; Kammermeier PJ, 2005, J PHARMACOL EXP THER, V312, P502, DOI 10.1124/jpet.104.073155; KENT RS, 1980, MOL PHARMACOL, V17, P14; Kew JNC, 2001, NEUROPHARMACOLOGY, V40, P20, DOI 10.1016/S0028-3908(00)00118-0; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; Martinez-Pinna J, 2005, J BIOL CHEM, V280, P1490, DOI 10.1074/jbc.M407783200; Mason MJ, 2000, J PHYSIOL-LONDON, V524, P437, DOI 10.1111/j.1469-7793.2000.00437.x; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; Mutel V, 2000, J NEUROCHEM, V75, P2590, DOI 10.1046/j.1471-4159.2000.0752590.x; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; PERIER F, 1992, J NEUROCHEM, V59, P1971, DOI 10.1111/j.1471-4159.1992.tb11036.x; Perroy J, 2002, J BIOL CHEM, V277, P1223, DOI 10.1074/jbc.M109141200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Saugstad JA, 1996, J NEUROSCI, V16, P5979; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; Schweitzer C, 2000, NEUROPHARMACOLOGY, V39, P1700, DOI 10.1016/S0028-3908(99)00265-8; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; Slutsky I, 1999, J PHYSIOL-LONDON, V514, P769, DOI 10.1111/j.1469-7793.1999.769ad.x; Slutsky I, 2003, J NEUROPHYSIOL, V89, P1954, DOI 10.1152/jn.00668.2002; Slutsky I, 2002, J NEUROSCI, V22, P3426; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; Tamaru Y, 2001, NEUROSCIENCE, V106, P481, DOI 10.1016/S0306-4522(01)00305-0; THOMSEN C, 1993, BRAIN RES, V619, P22, DOI 10.1016/0006-8993(93)91592-G; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Wigmore MA, 1998, BRIT J PHARMACOL, V123, P667, DOI 10.1038/sj.bjp.0701662; Wright RA, 2001, J PHARMACOL EXP THER, V298, P453	52	55	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24204	24215		10.1074/jbc.M513447200	http://dx.doi.org/10.1074/jbc.M513447200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16760467	hybrid			2022-12-25	WOS:000239847800014
J	Utepbergenov, DI; Fanning, AS; Anderson, JM				Utepbergenov, Darkhan I.; Fanning, Alan S.; Anderson, James M.			Dimerization of the scaffolding protein ZO-1 through the second PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION; MEDIATED MULTIMERIZATION; CRYSTAL-STRUCTURE; COMPLEX REVEALS; EXPRESSION; OCCLUDIN; CELLS; ASSOCIATION; PSD-95; ACTIN	The tight junction protein ZO-1 is known to link the transmembrane proteins occludin, claudins, and JAMs to many cytoplasmic proteins and the actin cytoskeleton. Although specific roles for ZO-1 at the tight junction are unknown, it is widely assumed that ZO-1, together with its homologs ZO-2 and ZO-3, serves as a platform to scaffold various transmembrane and cytoplasmic tight junction proteins. Thus the manner in which the zonula occludens (ZO) proteins multimerize has implications for the protein networks they can coordinate. The purpose of our study was to determine whether ZO-1 forms homodimers and to determine the protein interaction region. Using laser light scattering and analytical centrifugation, we show that protein sequences corresponding to the NH2- terminal half of ZO-1 form stable homodimers with a submicromolar equilibrium dissociation constant. Analysis of the molecular weight of different truncated forms of ZO-1 revealed that the second PDZ domain is both necessary and sufficient for dimerization. This interaction does not use the beta-finger motif described for other PDZ dimers. Furthermore, ZO-1 does not dimerize via an Src homology 3 to Guk domain interaction as was demonstrated previously for MAGUKs, like PSD-95. Results from immunoprecipitation experiments with polarized Madin-Darby canine kidney epithelial cells stably transfected with full-length GFP-ZO-1 indicate that a substantial portion of ZO-1 forms homodimers in vivo. As described previously, ZO-1 also forms heterodimers with ZO-2 and ZO-3. We conclude that the dimerization of ZO proteins is unlike that of other MAGUKs and that the previously unrecognized ZO-1 homodimers may allow formation of protein networks distinct from those of heterodimers with ZO-2 and ZO-3.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Anderson, JM (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Med & Biomol Res Bldg,CB 7545, Chapel Hill, NC 27599 USA.	jandersn@med.unc.edu	Utepbergenov, Darkhan/N-9881-2014; Utepbergenov, Darkhan/AAA-1249-2021	Utepbergenov, Darkhan/0000-0002-9005-4103; Utepbergenov, Darkhan/0000-0002-9005-4103; Anderson, James/0000-0003-2765-7996	NIDDK NIH HHS [DK61397, R01 DK061397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061397, R56DK061397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gonzalez-Mariscal L, 2000, KIDNEY INT, V57, P2386, DOI 10.1046/j.1523-1755.2000.00098.x; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Im YJ, 2003, J BIOL CHEM, V278, P48099, DOI 10.1074/jbc.M306919200; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; Inoko A, 2003, GENES CELLS, V8, P837, DOI 10.1046/j.1365-2443.2003.00681.x; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Nielsen PA, 2003, MOL BIOL CELL, V14, P2470, DOI 10.1091/mbc.E02-10-0637; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Riesen FK, 2002, HISTOCHEM CELL BIOL, V117, P307, DOI 10.1007/s00418-002-0398-y; Ryeom SW, 2000, MOL BIOL CELL, V11, P1687, DOI 10.1091/mbc.11.5.1687; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Umeda K, 2004, J BIOL CHEM, V279, P44785, DOI 10.1074/jbc.M406563200; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179	23	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24671	24677		10.1074/jbc.M512820200	http://dx.doi.org/10.1074/jbc.M512820200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790439	Green Published, hybrid			2022-12-25	WOS:000239847800062
J	Turanov, AA; Su, D; Gladyshev, VN				Turanov, Anton A.; Su, Dan; Gladyshev, Vadim N.			Characterization of alternative cytosolic forms and cellular targets of mouse mitochondrial thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; ESCHERICHIA-COLI; SPLICING VARIANT; CRYSTAL-STRUCTURES; RAT-LIVER; SELENOCYSTEINE; EXPRESSION; SELENOPROTEINS; MECHANISM; CLONING	Thioredoxin reductase (TR) and thioredoxin (Trx) define a major cellular redox system that maintains cysteine residues in numerous proteins in the reduced state. Both cytosolic (TR1 and Trx1) and mitochondrial (TR3 and Trx2) enzymes are essential in mammals, but the function of the mitochondrial system is less understood. In this study, we characterized subcellular localization of three TR3 forms that are generated by alternative first exon splicing and that differ in their N-terminal sequences. Only one of these forms resides in mitochondria, whereas the two other isoforms are cytosolic. Consistent with this finding, TR3 did not have catalytic preferences for mitochondrial Trx2 versus cytosolic Trx1, both of which could serve as TR3 substrates. Similarly, TR1 was equally active with Trx1, Trx2, or a bacterial Trx. We generated recombinant selenoprotein forms of TR1 and TR3 and found that these enzymes were inhibited by zinc, but not by calcium or cobalt ions. We further developed a proteomic method for identification of targets of TRs in mammalian cells utilizing affinity columns containing recombinant TR3 forms differing in C-terminal sequences. Using this procedure, we found that Trx1 was the major target of TR3 in both rat and mouse liver cytosol. The truncated form of TR3 lacking selenocysteine was particularly efficient in binding Trx1, consistent with the previously observed role of truncated TR1 in apoptosis. Overall, these data establish that the function of TR3 is not limited to its role in Trx2 reduction.	Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Gladyshev, VN (corresponding author), Univ Nebraska, Beadle Ctr, Dept Biochem, N151, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013; Su, Dan/B-1972-2010	Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM065204, R01GM065204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 2002, METHOD ENZYMOL, V347, P226; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Chang EY, 2005, FREE RADICAL BIO MED, V39, P1666, DOI 10.1016/j.freeradbiomed.2005.08.008; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Damdimopoulos AE, 2004, J BIOL CHEM, V279, P38721, DOI 10.1074/jbc.M402753200; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V379, P5; Gitler C, 2002, BIOCHEM BIOPH RES CO, V290, P624, DOI 10.1006/bbrc.2001.6214; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Halvey PJ, 2005, BIOCHEM J, V386, P215, DOI 10.1042/BJ20041829; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Miranda-Vizuete A, 2002, MOL CELLS, V13, P488; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; OBLONG JE, 1993, FEBS LETT, V334, P1, DOI 10.1016/0014-5793(93)81667-O; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Rigobello MP, 2006, BIOCHEM BIOPH RES CO, V343, P873, DOI 10.1016/j.bbrc.2006.03.050; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SCHALLREUTER KU, 1989, BIOCHEM BIOPH RES CO, V162, P1311, DOI 10.1016/0006-291X(89)90816-4; SCHALLREUTER KU, 1989, BIOCHIM BIOPHYS ACTA, V967, P242; Smeets A, 2005, PROTEIN SCI, V14, P2610, DOI 10.1110/ps.051632905; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Su D, 2004, BIOCHEMISTRY-US, V43, P12177, DOI 10.1021/bi048478t; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; Yamamoto M, 2003, J CLIN INVEST, V112, P1395, DOI 10.1172/JCI200317700; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	41	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22953	22963		10.1074/jbc.M604326200	http://dx.doi.org/10.1074/jbc.M604326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774913	Green Submitted, hybrid			2022-12-25	WOS:000239542600057
J	Luo, SH; Fang, JM; Docampo, R				Luo, Shuhong; Fang, Jianmin; Docampo, Roberto			Molecular characterization of Trypanosoma brucei p-type H+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; DOUBLE-STRANDED-RNA; BLOOD-STREAM FORMS; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; AFRICAN TRYPANOSOMES; ENZYMATIC-PROPERTIES; PROTON PUMPS; YEAST; INTERFERENCE	Previous studies in Trypanosoma brucei have shown that intracellular pH homeostasis is affected by inhibitors of H+-ATPases, suggesting a major role for these pumps in this process (Vander-Heyden, N., Wong, J., and Docampo, R., ( 2000) Biochem. J. 346, 53-62). Here, we report the cloning and sequencing of three genes (TbHA1, TbHA2, and TbHA3) present in the genome of T. brucei that encode proteins with homology to fungal and plant P-type proton-pumping ATPases. Northern and Western blot analyses revealed that these genes are up-regulated in procyclic trypomastigotes. TbHA1, TbHA2, and TbHA3 complemented a Saccharomyces cerevisiae strain deficient in P-type H+-ATPase activity, providing genetic evidence for their function. Indirect immunofluorescence analysis showed that TbHA proteins are localized mainly in the plasma membrane of procyclic forms and in the plasma membrane and flagellum of bloodstream forms. T. brucei H+-ATPase genes were functionally characterized using double-stranded RNA interference methodology. The induction of double-stranded RNA ( RNA interference) caused growth inhibition, which was more accentuated in procyclic forms and when expression of all TbHA proteins was decreased. Knockdown of TbHA1 and TbHA3, but not of TbHA2, resulted in cells with a lower steady-state pH(i) and a slower rate of pHi recovery from acidification. No evidence was found of an intracellular P-type H+-ATPase activity. These results establish that T. brucei H+-ATPases are plasma membrane enzymes essential for parasite viability.	Univ Georgia, Ctr Trop & Emerging Global Dis, Paul D Coverdell Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Cellular Biol, Paul D Coverdell Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Docampo, R (corresponding author), Univ Georgia, Ctr Trop & Emerging Global Dis, Paul D Coverdell Ctr, 500 DW Brooks Dr,, Athens, GA 30602 USA.	rdocampo@cb.uga.edu			NIAID NIH HHS [R01 AI068647-01, R01 AI068647, AI-68647] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068647] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BARNARD JP, 1994, ARCH BIOCHEM BIOPHYS, V313, P77, DOI 10.1006/abbi.1994.1361; BRUN R, 1979, ACTA TROP, V36, P387; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grigore D, 2006, INT J PARASITOL, V36, P381, DOI 10.1016/j.ijpara.2005.11.001; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Jaisser F, 1999, AM J PHYSIOL-RENAL, V276, pF812, DOI 10.1152/ajprenal.1999.276.6.F812; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; Luo SH, 2002, J BIOL CHEM, V277, P44497, DOI 10.1074/jbc.M202267200; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Miranda K, 2005, J EUKARYOT MICROBIOL, V52, P55, DOI 10.1111/j.1550-7408.2005.3309rr.x; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MONK BC, 1994, CRIT REV MICROBIOL, V20, P209, DOI 10.3109/10408419409114555; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; Scott DA, 1998, BIOCHEM J, V331, P583, DOI 10.1042/bj3310583; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SUPPLY P, 1993, J BIOL CHEM, V268, P19753; Van der Heyden N, 2002, J EUKARYOT MICROBIOL, V49, P407, DOI 10.1111/j.1550-7408.2002.tb00220.x; Van Der Heyden N, 2002, MOL BIOCHEM PARASIT, V120, P127, DOI 10.1016/S0166-6851(01)00444-3; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vanderheyden N, 2000, BIOCHEM J, V346, P53, DOI 10.1042/0264-6021:3460053; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Vieira M, 2005, BIOCHEM J, V392, P467, DOI 10.1042/BJ20051319; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; Wang CC, 1997, PARASITOLOGY, V114, pS31; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WIGGLESWORTH V. B., 1929, PARASITOLOGY, V21, P288, DOI 10.1017/S0031182000022988; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835	45	11	11	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21963	21973		10.1074/jbc.M601057200	http://dx.doi.org/10.1074/jbc.M601057200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16757482	hybrid			2022-12-25	WOS:000239387100043
J	Riojas, RA; Kikani, CK; Wang, CH; Mao, XM; Zhou, LJ; Langlais, PR; Hu, DR; Roberts, JL; Dong, LQ; Liu, F				Riojas, Ramon A.; Kikani, Chintan K.; Wang, Changhua; Mao, Xuming; Zhou, Lijun; Langlais, Paul R.; Hu, Derong; Roberts, James L.; Dong, Lily Q.; Liu, Feng			Fine tuning PDK1 activity by phosphorylation at Ser(163)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; TYROSINE PHOSPHORYLATION; TRANSLOCATION; SITE; IDENTIFICATION; MECHANISM; RECEPTOR; DEFINES; MOTIFS; TISSUE	3-Phosphoinositide-dependent protein kinase-1 ( PDK1) mediates phosphorylation and activation of members of the AGC protein kinase family and plays an essential role in insulin signaling and action. However, whether and how PDK1 activity is regulated in cells remains largely uncharacterized. In the present study, we show that PDK1 undergoes insulin-stimulated and phosphatidylinositol 3-kinase-dependent phosphorylation at Ser(244) in the activation loop and at a novel site: Ser(163) in the hinge region between the two lobes of the kinase domain. Sequence alignment studies revealed that the residue corresponding to Ser(163) of PDK1 in all other AGC kinases is glutamate, suggesting that a negative charge at this site may be important for PDK1 function. Replacing Ser(163) with a negatively charged residue, glutamate, led to a 2-fold increase in PDK1 activity. Molecular modeling studies suggested that phosphorylated Ser163 may form additional hydrogen bonds with Tyr(149) and Gln(223). In support of this, mutation of Tyr(149) to Ala is sufficient to reduce PDK1 activity. Taken together, our results suggest that PDK1 phosphorylation of Ser(163) may provide a mechanism to fine-tune PDK1 activity and function in cells.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), UTHSCSA, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Zhou, Lijun/H-2229-2011	Kikani, Chintan/0000-0003-1140-0192	NIDDK NIH HHS [F31DK068874] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK068874] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen H, 2001, BIOCHEMISTRY-US, V40, P11851, DOI 10.1021/bi010743c; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Fiory F, 2005, MOL CELL BIOL, V25, P10803, DOI 10.1128/MCB.25.24.10803-10814.2005; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kondo T, 2004, J BIOL CHEM, V279, P37997, DOI 10.1074/jbc.M401339200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; Seong HA, 2005, J BIOL CHEM, V280, P42897, DOI 10.1074/jbc.M507539200; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200	33	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21588	21593		10.1074/jbc.M600393200	http://dx.doi.org/10.1074/jbc.M600393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751192	hybrid			2022-12-25	WOS:000239387100004
J	Wang, JH; Simonavicius, N; Wu, XS; Swaminath, G; Reagan, J; Tian, H; Ling, L				Wang, Jinghong; Simonavicius, Nicole; Wu, Xiaosu; Swaminath, Gayathri; Reagan, Jeff; Tian, Hui; Ling, Lei			Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; CHAIN FATTY-ACIDS; TRYPTOPHAN CATABOLISM; QUINOLINIC ACID; IDENTIFICATION; CELLS; ACTIVATION; RELAXIN-3/INSL7; ANTAGONIST; SECRETION	Local catabolism of the essential amino acid tryptophan is considered an important mechanism in regulating immunological and neurological responses. The kynurenine pathway is the main route for the non-protein metabolism of tryptophan. The intermediates of the kynurenine pathway are present at micromolar concentrations in blood and are regulated by inflammatory stimuli. Here we show that GPR35, a previously orphan G protein-coupled receptor, functions as a receptor for the kynurenine pathway intermediate kynurenic acid. Kynurenic acid elicits calcium mobilization and inositol phosphate production in a GPR35-dependent manner in the presence of G(qi/o) chimeric G proteins. Kynurenic acid stimulates [S-35] guanosine 5'-O-(3-thiotriphosphate) binding in GPR35-expressing cells, an effect abolished by pertussis toxin treatment. Kynurenic acid also induces the internalization of GPR35. Expression analysis indicates that GPR35 is predominantly detected in immune cells and the gastrointestinal tract. Furthermore, we show that kynurenic acid inhibits lipopolysaccharide-induced tumor necrosis factor-alpha secretion in peripheral blood mononuclear cells. Our results suggest unexpected signaling functions for kynurenic acid through GPR35 activation.	Amgen Inc, San Francisco, CA 94080 USA	Amgen	Ling, L (corresponding author), Amgen Inc, San Francisco, CA 94080 USA.	lling@amgen.com						AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; Ellinger A, 1904, H-S Z PHYSIOL CHEM, V43, P325; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; Forrest CM, 2003, ADV EXP MED BIOL, V527, P395; Forrest CM, 2002, J BIOMED SCI, V9, P436, DOI 10.1007/BF02256538; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Hauck Andrew L, 2005, Birth Defects Res C Embryo Today, V75, P58, DOI 10.1002/bdrc.20032; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Homer A, 1914, J BIOL CHEM, V17, P509; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; KESSLER M, 1989, J NEUROCHEM, V52, P1319, DOI 10.1111/j.1471-4159.1989.tb01881.x; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; O'Dowd BF, 1998, GENOMICS, V47, P310, DOI 10.1006/geno.1998.5095; Okumura S, 2004, CANCER SCI, V95, P131, DOI 10.1111/j.1349-7006.2004.tb03193.x; Pereira EFR, 2002, J NEUROBIOL, V53, P479, DOI 10.1002/neu.10146; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; Schwarcz R, 2004, CURR OPIN PHARMACOL, V4, P12, DOI 10.1016/j.coph.2003.10.006; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Stone TW, 2003, CLIN CHEM LAB MED, V41, P852, DOI 10.1515/CCLM.2003.129; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; SWARTZ KJ, 1990, J NEUROSCI, V10, P2965; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866	41	449	472	5	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22021	22028		10.1074/jbc.M603503200	http://dx.doi.org/10.1074/jbc.M603503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754668	hybrid			2022-12-25	WOS:000239387100049
J	Wang, N; Li, Z; Ding, RH; Frank, GD; Senbonmatsu, T; Landon, EJ; Inagami, T; Zhao, ZJ				Wang, Ning; Li, Zhe; Ding, Ronghua; Frank, Gerald D.; Senbonmatsu, Takaaki; Landon, Erwin J.; Inagami, Tadashi; Zhao, Zhizhuang Joe			Antagonism or synergism - Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; NOONAN-SYNDROME; CELL LYMPHOMA; SH2 DOMAINS; MOTH-EATEN; PROTEIN; MUTATIONS; ACTIVATION; GENE; PTPN11	SHP-1 and SHP-2 are two Src homology 2 domain-containing tyrosine phosphatases with major pathological implications in cell growth regulating signaling. They share significant overall sequence identity, but their biological functions are often opposite. SHP-1 is generally considered as a negative signal transducer and SHP-2 as a positive one. However, the precise role of each enzyme in shared signaling pathways is not well defined. In this study, we investigated the interaction of these two enzymes in a single cell system by knocking down their expressions with small interfering RNAs and analyzing the effects on epidermal growth factor signaling. Interestingly, knockdown of either SHP-1 or SHP-2 caused significant reduction in the activation of ERK1/2 but not Akt. Furthermore, SHP-1, SHP-2, and Gab1 formed a signaling complex, and SHP-1 and SHP-2 interact with each other. The interaction of SHP-1 with Gab1 is mediated by SHP-2 because it was abrogated by knockdown of SHP-2, and SHP-2, but not SHP-1, binds directly to tyrosine-phosphorylated Gab1. Together, the data revealed that both SHP-1 and SHP-2 have a positive role in epidermal growth factor-induced ERK1/2 activation and that they act cooperatively rather than antagonistically. The interaction of SHP-1 and SHP-2 may be responsible for previously unexpected novel regulatory mechanism of cell signaling by tyrosine phosphatases.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Jilin Univ, Edmond H Fischer Signal Transduct Lab, Coll Life Sci, Changchun 130023, Peoples R China	Vanderbilt University; Vanderbilt University; University of Oklahoma System; University of Oklahoma Health Sciences Center; Jilin University	Inagami, T (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.	tadashi.inagami@vanderbilt.edu; joe-zhao@ouhsc.edu	li, zhe/B-6882-2011		NHLBI NIH HHS [R37 HL058205, HL058205, R01 HL076309, HL076309, R01 HL076309-04, R01 HL058205] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058205, R01HL076309, R01HL058205] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chen DH, 2004, J IMMUNOL, V172, P3535, DOI 10.4049/jimmunol.172.6.3535; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Gutch MJ, 1998, GENE DEV, V12, P571, DOI 10.1101/gad.12.4.571; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishida K, 2003, CANCER SCI, V94, P1029, DOI 10.1111/j.1349-7006.2003.tb01396.x; Oka T, 2001, AM J PATHOL, V159, P1495, DOI 10.1016/S0002-9440(10)62535-7; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Xu FP, 2001, J BIOL CHEM, V276, P29479, DOI 10.1074/jbc.M104428200; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Zhang Q, 2000, AM J PATHOL, V157, P1137, DOI 10.1016/S0002-9440(10)64629-9; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; Zhao RX, 2003, J BIOL CHEM, V278, P42893, DOI 10.1074/jbc.M306136200; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	35	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21878	21883		10.1074/jbc.M605018200	http://dx.doi.org/10.1074/jbc.M605018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16762922	Green Accepted, hybrid			2022-12-25	WOS:000239387100034
J	Zhu, L; Imanishi, Y; Filipek, S; Alekseev, A; Jastrzebska, B; Sun, WY; Saperstein, DA; Palczewski, K				Zhu, Li; Imanishi, Yoshikazu; Filipek, Slawomir; Alekseev, Andrei; Jastrzebska, Beata; Sun, Wenyu; Saperstein, David A.; Palczewski, Krzysztof			Autosomal recessive retinitis pigmentosa and E150K mutation in the opsin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR RHODOPSIN; GOLGI-LOCALIZATION; CYTOPLASMIC LOOP; AMINO-ACIDS; PROTEIN; ACTIVATION; MUTANTS; DIMERS; TRANSDUCIN; CELLS	Retinitis pigmentosa (RP) is a heterogeneous group of hereditary disorders of the retina caused by mutation in genes of the photoreceptor proteins with an autosomal dominant (adRP), autosomal recessive (arRP), or X-linked pattern of inheritance. Although there are over 100 identified mutations in the opsin gene associated with RP, only a few of them are inherited with the arRP pattern. E150K is the first reported missense mutation associated with arRP. This opsin mutation is located in the second cytoplasmic loop of this G protein-coupled receptor. E150K opsin expressed in HEK293 cells and reconstituted with 11-cis-retinal displayed an absorption spectrum similar to the wild type (WT) counterpart and activated G protein transducin slightly faster than WT receptor. However, the majority of E150K opsin showed a higher apparent molecular mass in SDS-PAGE and was resistant to endoglycosidase H deglycosidase. Instead of being transported to the plasma membrane, E150K opsin is partially colocalized with the cis/medial Golgi compartment markers such as GM130 and Vti1b but not with the trans-Golgi network. In contrast to the endoplasmic reticulum-retained adRP mutant, P23H opsin, Golgi-retained E150K opsin did not influence the proper transport of the WT opsin when coexpressed in HEK293 cells. This result is consistent with the recessive pattern of inheritance of this mutation. Thus, our study reveals a novel molecular mechanism for retinal degeneration that results from deficient export of opsin from the Golgi apparatus.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Case Western Reserve University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu	Imanishi, Yoshikazu/E-8178-2010; Filipek, Slawomir/A-2985-2008	Imanishi, Yoshikazu/0000-0003-4696-4836; Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, P30EY011373] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Andres A, 2003, BIOCHEM BIOPH RES CO, V303, P294, DOI 10.1016/S0006-291X(03)00328-0; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Dempski RE, 2002, CURR OPIN CHEM BIOL, V6, P844, DOI 10.1016/S1367-5931(02)00390-3; Deretic D, 2005, P NATL ACAD SCI USA, V102, P3301, DOI 10.1073/pnas.0500095102; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fasick JI, 1999, BIOCHEMISTRY-US, V38, P11593, DOI 10.1021/bi991600h; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Imai H, 1997, P NATL ACAD SCI USA, V94, P2322, DOI 10.1073/pnas.94.6.2322; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kota P, 2006, P NATL ACAD SCI USA, V103, P3054, DOI 10.1073/pnas.0510982103; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KUMARAMANICKAVEL G, 1994, NAT GENET, V8, P10, DOI 10.1038/ng0994-10; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Liang Y, 2004, J BIOL CHEM, V279, P48189, DOI 10.1074/jbc.M408362200; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOW SH, 1994, J BIOL CHEM, V269, P1985; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mansoor SE, 2006, P NATL ACAD SCI USA, V103, P3060, DOI 10.1073/pnas.0511010103; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Rajan RS, 2005, J BIOL CHEM, V280, P1284, DOI 10.1074/jbc.M406448200; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; Ridge KD, 1996, J BIOL CHEM, V271, P7860, DOI 10.1074/jbc.271.13.7860; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; Rozell TG, 1998, ENDOCRINOLOGY, V139, P1588, DOI 10.1210/en.139.4.1588; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Saliba RS, 2002, J CELL SCI, V115, P2907; Siffroi-Fernandez S, 2002, EUR J BIOCHEM, V269, P4930, DOI 10.1046/j.1432-1033.2002.03192.x; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Ungar D, 2006, TRENDS CELL BIOL, V16, P113, DOI 10.1016/j.tcb.2005.12.004; Zhu L, 2004, J BIOL CHEM, V279, P53828, DOI 10.1074/jbc.M408472200	60	19	19	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22289	22298		10.1074/jbc.M602664200	http://dx.doi.org/10.1074/jbc.M602664200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16737970	Green Accepted, hybrid			2022-12-25	WOS:000239387100074
J	Nakayama, S; Ito, Y; Sato, S; Kamijo, A; Liu, HN; Kajioka, S				Nakayama, Shinsuke; Ito, Yasushi; Sato, Shinji; Kamijo, Atsushi; Liu, Hong-Nian; Kajioka, Shunichi			Tyrosine kinase inhibitors and ATP modulate the conversion of smooth muscle L-type Ca2+ channels toward a second open state	FASEB JOURNAL			English	Article						persistent Ca2+ channel current; genistein; genistin	BETA-ADRENERGIC STIMULATION; MULTIPLE OPEN STATES; C-SRC; GENISTEIN; CELLS; INACTIVATION; CURRENTS; MECHANISM; PHOSPHORYLATION; MYOCYTES	Properties of smooth and cardiac L-type Ca2+ channels differ prominently in several physiological aspects, including sympathetic modulation. To assess the possible underlying mechanisms, we applied the whole cell patch-clamp technique to guinea pig detrusor smooth muscle cells, in which only L-type Ca2+ channel currents are observed in practice. During depolarization to large positive potentials, the conformation of the majority of L-type Ca2+ channels is converted from the normal (O-1) to a second open state (O-2), which undergoes little inactivation during depolarization. Extracellular application of genistein, a known tyrosine kinase inhibitor, significantly attenuated the voltage-dependent conversion of Ca2+ channels to O-2, accompanied by reduction of availability, whereas genistin, an inactive analog, had little effect. In the absence of ATP in the patch pipette, intracellular application of either genistein or tyrphostin-47 suppressed the conversion to O-2. Computer calculation revealed that the acceleration of the O-1 to an inactivated state qualitatively reconstructs the unique effects of PTK inhibitors antagonized by ATP. We concluded that under normal conditions smooth muscle L-type Ca2+ channels are already modulated by tyrosine-kinase and ATP-related mechanism(s) and thereby easily achieve the second conversion, which yields voltage-dependent modulation of L-type Ca2+ current analogous to that in cardiac myocytes during beta-adrenoceptor stimulation.	Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan	Nagoya University; Nagoya University	Nakayama, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.	h44673a@nucc.cc.nagoya-u.ac.jp						AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Aoyama M, 2003, BIOPHYS J, V84, P709, DOI 10.1016/S0006-3495(03)74890-5; Beech D. J., 1996, P39; Belevych AE, 2002, MOL PHARMACOL, V62, P554, DOI 10.1124/mol.62.3.554; BULBRING E, 1981, SMOOTH MUSCLE ASSESS, P219; CAVALIE A, 1991, PFLUG ARCH EUR J PHY, V419, P433, DOI 10.1007/BF00370785; Chow KY, 2003, NEUROUROL URODYNAM, V22, P77, DOI 10.1002/nau.10081; Du XL, 2004, J GEN PHYSIOL, V123, P427, DOI 10.1085/jgp.200409013; Findlay I, 2004, J PHYSIOL-LONDON, V554, P275, DOI 10.1113/jphysiol.2003.047902; Findlay I, 2002, J PHYSIOL-LONDON, V541, P741, DOI 10.1113/jphysiol.2002.019737; Flatman PW, 1996, AM J PHYSIOL-CELL PH, V271, pC255, DOI 10.1152/ajpcell.1996.271.1.C255; Fry C H, 1998, Int Urogynecol J Pelvic Floor Dysfunct, V9, P291, DOI 10.1007/BF01901509; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; IMAIZUMI Y, 1991, METHODS NEUROSCI, V4, P44; Jin XC, 2002, GASTROENTEROLOGY, V123, P827, DOI 10.1053/gast.2002.35388; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; Liu HY, 1997, CAN J PHYSIOL PHARM, V75, P1058, DOI 10.1139/cjpp-75-9-1058; MARKS TN, 1992, J GEN PHYSIOL, V99, P367, DOI 10.1085/jgp.99.3.367; Mitarai S, 2000, AM J PHYSIOL-CELL PH, V279, pC603, DOI 10.1152/ajpcell.2000.279.3.C603; Murakami M, 2003, MOL CELL BIOCHEM, V254, P217, DOI 10.1023/A:1027316017156; Murakami M, 2003, J BIOL CHEM, V278, P43261, DOI 10.1074/jbc.M211380200; NAKAYAMA S, 1995, AM J PHYSIOL-CELL PH, V269, pC48, DOI 10.1152/ajpcell.1995.269.1.C48; Nakayama S, 1995, J GEN PHYSIOL, V106, P1211, DOI 10.1085/jgp.106.6.1211; Nakayama S., 1996, P13; NAKAYAMA S, 1993, J PHYSIOL-LONDON, V471, P107, DOI 10.1113/jphysiol.1993.sp019893; NAKAYAMA S, 1993, J PHYSIOL-LONDON, V471, P87, DOI 10.1113/jphysiol.1993.sp019892; Nakayama S, 2000, J PHYSIOL-LONDON, V526, P47, DOI 10.1111/j.1469-7793.2000.00047.x; OCHI R, 1993, JPN J PHYSIOL, V43, P571, DOI 10.2170/jjphysiol.43.571; Ogura T, 1999, AM J PHYSIOL-HEART C, V276, pH1724, DOI 10.1152/ajpheart.1999.276.5.H1724; Rothberg BS, 2001, BIOPHYS J, V80, P3025, DOI 10.1016/S0006-3495(01)76268-6; Schafer M, 2000, AM J PHYSIOL-CELL PH, V279, pC495, DOI 10.1152/ajpcell.2000.279.2.C495; Sears CL, 1995, AM J PHYSIOL-GASTR L, V269, pG874, DOI 10.1152/ajpgi.1995.269.6.G874; Seki T, 1999, PFLUG ARCH EUR J PHY, V437, P317, DOI 10.1007/s004240050785; Smith LM, 1999, EUR J PHARMACOL, V370, P187, DOI 10.1016/S0014-2999(99)00119-3; Tsang F, 2002, BIOCHEM BIOPH RES CO, V293, P72, DOI 10.1016/S0006-291X(02)00170-5; Wang YG, 1998, AM J PHYSIOL-HEART C, V275, pH204, DOI 10.1152/ajpheart.1998.275.1.H204; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; Wijetunge S, 2000, BRIT J PHARMACOL, V129, P1347, DOI 10.1038/sj.bjp.0703186; Yamamoto K, 2003, AUTOIMMUN REV, V2, P13, DOI 10.1016/S1568-9972(02)00121-0; Yazawa K, 1997, PFLUG ARCH EUR J PHY, V433, P557, DOI 10.1007/s004240050314; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753	44	12	13	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1492	+		10.1096/fj.05-5049fje	http://dx.doi.org/10.1096/fj.05-5049fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16738256				2022-12-25	WOS:000240266000028
J	Zhao, Y; Patzer, A; Herdegen, T; Gohlke, P; Culman, J				Zhao, Yi; Patzer, Andreas; Herdegen, Thomas; Gohlke, Peter; Culman, Juraj			Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats	FASEB JOURNAL			English	Article						cerebral ischemia; PPAR gamma; pioglitazone; cyclooxygenase-2; cyclooxygenase-1; rat	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; PPAR-GAMMA; CELL-DEATH; CORTICAL-NEURONS; GENE-EXPRESSION; BRAIN ISCHEMIA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GLOBAL-ISCHEMIA; ACID-RECEPTORS	Up-regulation of cyclooxygenase (COX)-2 exacerbates neuronal injury after cerebral ischemia and contributes to neuronal cell death. The present study clarifies the function of cerebral peroxisome-proliferator-activated receptor(s) gamma (PPAR gamma) in the expression of COX-2 in neurons of the rat brain after middle cerebral artery occlusion (MCAO) with reperfusion by immunohistochemistry, Western blot, and immunofluorescence staining. In peri-infarct cortical areas the PPAR gamma was located in both microglia and neurons, whereas COX-2 was almost exclusively expressed in neurons. PPAR gamma immunolabeling reached the peak 12 h after MCAO, whereas the number of COX-2 immunostained cells gradually rose and reached its peak at 48 h. Intracerebroventricular infusion of pioglitazone, an agonist of the PPAR gamma, over a 5-day period before and 2 days after MCAO, reduced the infarct size, the expression of tumor necrosis factor alpha (TNF-alpha), COX-2, and the number of cells positively stained for COX-1 and COX-2 in the peri-infarct cortical regions. COX-2 induction was also attenuated in the ipsilateral but not in the contralateral hippocampus. In primary cortical neurons expressing the PPAR gamma, pioglitazone suppressed COX-2 expression in response to oxidative stress. This protective effect was reversed after cotreatment with GW 9662, a selective antagonist of the PPAR gamma, clearly demonstrating a PPAR gamma-dependent mechanism. Our data provide evidence that activation of neuronal PPAR gamma considerably contributes to neuroprotection by prevention of COX-2 up-regulation in vitro and in peri-infarct brain areas.	Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Culman, J (corresponding author), Univ Hosp Schleswig Holstein, Inst Pharmacol, Campus Kiel Hosp Str 4, D-24105 Kiel, Germany.	juraj.culman@pharmakologie.uni-kiel.de	Zhao, Yi/A-8806-2010; herdegen, thomas/E-5135-2010					Araki E, 2001, STROKE, V32, P2370, DOI 10.1161/hs1001.096057; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-3; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cimini A, 2005, NEUROSCIENCE, V130, P325, DOI 10.1016/j.neuroscience.2004.09.043; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Cristiano L, 2001, J NEUROCYTOL, V30, P671, DOI 10.1023/A:1016525716209; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dobrian AD, 2004, HYPERTENSION, V43, P48, DOI 10.1161/01.HYP.0000103629.01745.59; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Drew PD, 2005, BRAIN RES REV, V48, P322, DOI 10.1016/j.brainresrev.2004.12.020; Graham SH, 2003, ARCH NEUROL-CHICAGO, V60, P628, DOI 10.1001/archneur.60.4.628; Han SW, 2003, CLIN CANCER RES, V9, P4627; Heneka MT, 2000, J NEUROSCI, V20, P6862, DOI 10.1523/JNEUROSCI.20-18-06862.2000; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Iadecola C, 2001, J CEREBR BLOOD F MET, V21, P1436, DOI 10.1097/00004647-200112000-00008; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Kim EJ, 2002, BRAIN RES, V941, P1, DOI 10.1016/S0006-8993(02)02480-0; Koistinaho J, 1999, STROKE, V30, P1900, DOI 10.1161/01.STR.30.9.1900; Koizumi J., 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Lin BJ, 2003, J MICROLITH MICROFAB, V2, P5, DOI 10.1117/1.1536623; Lou M, 2004, J CEREBR BLOOD F MET, V24, P536, DOI 10.1097/00004647-200405000-00008; Luna-Medina R, 2005, J BIOL CHEM, V280, P21453, DOI 10.1074/jbc.M414390200; Mendez M, 2003, HYPERTENSION, V42, P844, DOI 10.1161/01.HYP.0000085332.69777.D1; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Niwa K, 2001, CIRC RES, V88, P600, DOI 10.1161/01.RES.88.6.600; Nogawa S, 1997, J NEUROSCI, V17, P2746; Pepicelli O, 2002, J NEUROCHEM, V81, P1028, DOI 10.1046/j.1471-4159.2002.00897.x; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sasaki T, 2004, J CEREBR BLOOD F MET, V24, P107, DOI 10.1097/01.WCB.0000100065.36077.4A; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schwab JM, 2003, ARCH NEUROL-CHICAGO, V60, P630, DOI 10.1001/archneur.60.4.630; SHIRAZ T, 2005, STROKE, V36, P353; Smith SA, 2003, J NEUROSCI RES, V72, P747, DOI 10.1002/jnr.10613; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Sundararajan S, 2004, DRUG NEWS PERSPECT, V17, P229, DOI 10.1358/dnp.2004.17.4.829049; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Vasudevan Abu R, 2004, Diabetes Technol Ther, V6, P850, DOI 10.1089/dia.2004.6.850; Xu JH, 2003, STROKE, V34, P1287, DOI 10.1161/01.STR.0000066308.25088.64; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yokota C, 2004, NEUROSCI LETT, V357, P219, DOI 10.1016/j.neulet.2003.12.109; Zhao Y, 2005, J NEUROCHEM, V94, P1395, DOI 10.1111/j.1471-4159.2005.03275.x; Zhao Y, 2005, EUR J NEUROSCI, V22, P278, DOI 10.1111/j.1460-9568.2005.04200.x	60	162	171	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2006	20	8					1162	1175		10.1096/fj.05-5007com	http://dx.doi.org/10.1096/fj.05-5007com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079XD	16770015				2022-12-25	WOS:000240210300016
J	Camilleri-Broet, S; Cremer, I; Marmey, B; Comperat, E; Viguie, F; Audouin, J; Rio, MC; Fridman, WH; Sautes-Fridman, C; Regnier, CH				Camilleri-Broet, S.; Cremer, I.; Marmey, B.; Comperat, E.; Viguie, F.; Audouin, J.; Rio, M-C; Fridman, W-H; Sautes-Fridman, C.; Regnier, C. H.			TRAF4 overexpression is a common characteristic of human carcinomas	ONCOGENE			English	Article						TRAF4; chromosome 17q11; ERBB2; amplification; lung	HUMAN BREAST-TUMORS; GENE-EXPRESSION; CDNA MICROARRAYS; COPY NUMBER; CANCER; ACTIVATION; RECEPTOR; FAMILY; IDENTIFICATION; CHROMOSOME-17	Tumor necrosis factor receptor (TNFR) associated factor 4 (TRAF4) was initially identified as a gene amplified and overexpressed in breast carcinomas. Our aim was to evaluate whether TRAF4 protein overexpression exists in other cancer types. Immunohistochemistry analysis of tumor samples from 623 patients with 20 different tumor types showed that TRAF4 was overexpressed in 268 tumors (43%), including 82 of 137 lung adenocarcinomas (60%). Interestingly, 32 primary tumors and their matching metastases exhibited mostly similar TRAF4 expression pattern. TRAF4 protein overexpression was limited to cancer cells and the subcellular localization was consistently cytoplasmic in a large majority of cases. To investigate changes in TRAF4 gene copy number, 125 cases from six different types of carcinomas were also analysed by fluorescence in situ hybridization. Out of the 28 cases (22%) showing an increased TRAF4 gene copy number, 23 (82%) were overexpressing the protein. Thus, TRAF4 gene amplification is one of the mechanisms responsible for TRAF4 protein overexpression in human cancers. Considering that TRAF4 is located at 17q11.2 in a region of amplification devoid of known oncogenes and is commonly overexpressed in cancer, our data support an oncogenic role for TRAF4.	Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM,Univ Paris Descartes, U255,Fac Med,Ctr Rech Biomed Cordeliers, F-75006 Paris, France; Univ Paris Descartes, Fac Med, AP HP Hotel Dieu, Paris, France; Univ Paris 06, Fac Med, AP HA La Pitie Salpetriere, Paris, France; Univ Strasbourg 1, INSERM, U596,Dept Pathol Mol,IGBMC, CNRS,UPR 6520, Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Regnier, CH (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM,Univ Paris Descartes, U255,Fac Med,Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	catherine.regnier@u255.bhdc.jussieu.fr	Cremer, Isabelle/D-4278-2017	Cremer, Isabelle/0000-0002-0963-1031; fridman, wolf herman/0000-0002-1332-0973; sautes-fridman, catherine/0000-0003-1735-8722; Regnier, Catherine/0000-0002-4386-1324				Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bieche I, 1996, CANCER RES, V56, P3886; Bowers AJ, 2004, GENE, V328, P135, DOI 10.1016/j.gene.2003.12.002; Chung JY, 2002, J CELL SCI, V115, P679; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Glauner H, 2002, EUR J BIOCHEM, V269, P4819, DOI 10.1046/j.1432-1033.2002.03180.x; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj.bjc.6600286; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; Krajewska M, 1998, AM J PATHOL, V152, P1549; Li JM, 2005, MOL CELL BIOL, V25, P2320, DOI 10.1128/MCB.25.6.2320-2330.2005; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takeshita F, 2005, EUR J IMMUNOL, V35, P2477, DOI 10.1002/eji.200526151; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Wu RF, 2005, J CELL BIOL, V171, P893, DOI 10.1083/jcb.200507004; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	29	61	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					142	147		10.1038/sj.onc.1209762	http://dx.doi.org/10.1038/sj.onc.1209762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799635				2022-12-25	WOS:000243236500014
J	Zhang, G; Luo, X; Sumithran, E; Pua, VSC; Barnetson, RSC; Halliday, GM; Khachigian, LM				Zhang, G.; Luo, X.; Sumithran, E.; Pua, V. S. C.; Barnetson, R. St C.; Halliday, G. M.; Khachigian, L. M.			Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression	ONCOGENE			English	Article						c-Jun; squamous cell carcinoma; matrix metalloproteinases; angiogenesis; tumor growth	TRANSCRIPTION FACTOR; SKIN CARCINOGENESIS; TUMOR-GROWTH; DNA ENZYME; ANGIOGENESIS; ACTIVATION; AP-1; DEOXYRIBOZYMES; PROLIFERATION; PROGRESSION	Squamous cell carcinoma (SCC) is an invasive malignancy of epidermal keratinocytes. Surgical excision is currently the main treatment; however, this can cause scarring and disfigurement. There is accordingly, an acute need for alternative strategies to treat SCC. The transcription factor c-Jun is expressed in human SCC and another common form of invasive skin cancer, basal cell carcinoma together with the mitogenic marker-proliferating cell nuclear antigen. Here, we have employed DNAzymes (catalytic DNA molecules) targeting c-Jun (Dz13) to inhibit c-Jun expression in SCC cells. Dz13 inhibits SCC proliferation and suppresses solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. We further demonstrate that Dz13 inhibits c-Jun, together with matrix metalloproteinase (MMP)-2 and MMP-9 expression in the tumors, consistent with DNAzyme inhibition of MMP-2 and MMP-9 gelatinolytic activity by zymography. Dz13 also suppressed the expression of vascular endothelial growth factor and fibroblast growth factor-2 in the tumors. These findings demonstrate that c-Jun regulates SCC growth and suggest that DNAzymes targeting this transcription factor may potentially be useful as inhibitors of cutaneous carcinoma.	Univ New S Wales, Ctr Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia; Gribbles Pathol, Melbourne, Vic, Australia; Royal Prince Alfred Hosp, Dermatol Res Labs, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of New South Wales Sydney; University of Sydney; University of Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia.	l.khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Bernstein SC, 1996, DERMATOL SURG, V22, P243, DOI 10.1111/j.1524-4725.1996.tb00315.x; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1; Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Fuchs Shmuel, 2001, Int J Cardiovasc Intervent, V4, P3; Halliday GM, 2001, INT IMMUNOL, V13, P1147, DOI 10.1093/intimm/13.9.1147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Karamouzis M, 2004, EUR J CANCER, V40, P761, DOI 10.1016/j.ejca.2003.12.002; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Khachigian LM, 2000, J CLIN INVEST, V106, P1189, DOI 10.1172/JCI11620; Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kraus S, 1998, J AM ACAD DERMATOL, V38, P438, DOI 10.1016/S0190-9622(98)70502-X; Lowe HC, 2002, THROMB HAEMOSTASIS, V87, P134, DOI 10.1055/s-0037-1612956; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Patel BP, 2005, J SURG ONCOL, V90, P81, DOI 10.1002/jso.20240; Ro Young-Suck, 1995, Journal of Korean Medical Science, V10, P85; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; Schubert S, 2003, NUCLEIC ACIDS RES, V31, P5982, DOI 10.1093/nar/gkg791; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120	36	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7260	7266		10.1038/sj.onc.1209726	http://dx.doi.org/10.1038/sj.onc.1209726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16785994	Bronze			2022-12-25	WOS:000242244700004
J	Schumacher, MA; Mizuno, K; Bachinger, HP				Schumacher, Maria A.; Mizuno, Kazunori; Bachinger, Hans Peter			The crystal structure of a collagen-like polypeptide with 3(S)-hydroxyproline residues in the Xaa position forms a standard 7/2 collagen triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL 4-HYDROXYLASES; ANGSTROM RESOLUTION; MOLECULAR-STRUCTURE; REPEATING SEQUENCE; MODEL PEPTIDE; PROLINE RING; X-RAY; STABILITY; HYDRATION; ENZYMES	Collagen has a triple helical structure comprising strands with a repeating Xaa-Yaa-Gly sequence. L-Proline (Pro) and 4(R)-hydroxyl-L-proline (4(R)Hyp) residues are found most frequently in the Xaa and Yaa positions. However, in natural collagen, 3(S)hydroxyl-L-proline ( 3( S) Hyp) occurs in the Xaa positions to varying extents and is most common in collagen types IV and V. Although 4(R) Hyp residues in the Yaa positions have been shown to be critical for the formation of a stable triple helix, the role of 3(S) Hyp residues in the Xaa position is not well understood. Indeed, recent studies have demonstrated that the presence of 3(S) Hyp in the Xaa positions of collagen-like peptides actually has a destabilizing effect relative to peptides with Pro in these locations. Whether this destabilization is reflected in a local unfolding or in other structural alterations of the collagen triple helix is unknown. Thus, to determine what effect the presence of 3(S) Hyp residues in the Xaa positions has on the overall conformation of the collagen triple helix, we determined the crystal structure of the polypeptide H-(Gly-Pro-4(R)Hyp)(3)(Gly-3(S)Hyp-4(R)Hyp)(2)-(Gly-Pro-4(R)Hyp)(4)-OH to 1.80 angstrom resolution. The structure shows that, despite the presence of the 3(S) Hyp residues, the peptide still adopts a typical 7/2 superhelical symmetry similar to that observed in other collagen structures. The puckering of the Xaa position 3( S) Hyp residues, which are all down (C gamma-endo), and the phi/psi dihedral angles of the Xaa 3(S) Hyp residues are also similar to those of typical collagen Pro Xaa residues. Thus, the presence of 3(S) Hyp in the Xaa positions does not lead to large structural alterations in the collagen triple helix.	Shriners Hosp Children, Res Dept, Portland, OR 97239 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Dept, Portland, OR 97239 USA.	hpb@shcc.org	Mizuno, Kazunori/AAY-7613-2021	Mizuno, Kazunori/0000-0003-3354-6264; Brennan, Richard/0000-0001-7647-485X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Berisio R, 2002, PROTEIN SCI, V11, P262, DOI 10.1110/ps.32602; Bos KJ, 1999, MATRIX BIOL, V18, P149, DOI 10.1016/S0945-053X(99)00015-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DeRider ML, 2002, J AM CHEM SOC, V124, P2497, DOI 10.1021/ja0166904; Engel J, 1998, MATRIX BIOL, V17, P679, DOI 10.1016/S0945-053X(98)90119-6; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Holmgren SK, 1998, NATURE, V392, P666, DOI 10.1038/33573; Holmgren SK, 1999, CHEM BIOL, V6, P63, DOI 10.1016/S1074-5521(99)80003-9; Hongo C, 2001, POLYM J, V33, P812; Improta R, 2002, J AM CHEM SOC, V124, P7857, DOI 10.1021/ja020187p; Jenkins CL, 2003, J AM CHEM SOC, V125, P6422, DOI 10.1021/ja034015j; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawahara K, 2005, BIOCHEMISTRY-US, V44, P15812, DOI 10.1021/bi051619m; Kefalides N A, 1973, Int Rev Connect Tissue Res, V6, P63; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Kramer RZ, 2000, J MOL BIOL, V301, P1191, DOI 10.1006/jmbi.2000.4017; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Kramer RZ, 2001, J MOL BIOL, V311, P131, DOI 10.1006/jmbi.2001.4849; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EAMC, V26; Mayo KH, 1996, BIOPOLYMERS, V40, P359, DOI 10.1002/(SICI)1097-0282(1996)40:4<359::AID-BIP2>3.0.CO;2-V; Mizuno K, 2004, J BIOL CHEM, V279, P282, DOI 10.1074/jbc.M308181200; Mogilner IG, 2002, J MOL GRAPH MODEL, V21, P209, DOI 10.1016/S1093-3263(02)00145-6; MORELLO R, 2006, IN PRESS CELL; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagarajan V, 1998, J BIOCHEM-TOKYO, V124, P1117, DOI 10.1093/oxfordjournals.jbchem.a022229; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; Okuyama K, 2004, BIOPOLYMERS, V76, P367, DOI 10.1002/bip.20107; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; RHODES RK, 1978, BIOCHEMISTRY-US, V17, P3442, DOI 10.1021/bi00610a003; Schumacher M, 2005, J BIOL CHEM, V280, P20397, DOI 10.1074/jbc.M501453200; Vranka JA, 2004, J BIOL CHEM, V279, P23615, DOI 10.1074/jbc.M312807200; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	45	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27566	27574		10.1074/jbc.M602797200	http://dx.doi.org/10.1074/jbc.M602797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16798737	hybrid			2022-12-25	WOS:000240397700082
J	Allen, MD; Buchberger, A; Bycroft, M				Allen, Mark D.; Buchberger, Alexander; Bycroft, Mark			The PUB domain functions as a p97 binding module in human peptide N-glycanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBX DOMAIN; AAA-ATPASE; PROTEIN; UBIQUITIN; COMPLEX; IDENTIFICATION; DEGLYCOSYLATION; DEGRADATION; MECHANISM; SUBSTRATE	The AAA ATPase p97 is a ubiquitin-selective molecular machine involved in multiple cellular processes, including protein degradation through the ubiquitin-proteasome system and homotypic membrane fusion. Specific p97 functions are mediated by a variety of cofactors, among them peptide N-glycanase, an enzyme that removes glycans from misfolded glycoproteins. Here we report the three-dimensional structure of the amino-terminal PUB domain of human peptide N-glycanase. We demonstrate that the PUB domain is a novel p97 binding module interacting with the D1 and/or D2 ATPase domains of p97 and identify an evolutionary conserved surface patch required for p97 binding. Furthermore, we show that the PUB and UBX domains do not bind to p97 in a mutually exclusive manner. Our results suggest that PUB domain-containing proteins constitute a widespread family of diverse p97 cofactors.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	Max Planck Society; University of Cambridge	Buchberger, A (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	buchberg@biochem.mpg.de; mb10031@cus.cam.ac.uk	Buchberger, Alexander/J-4070-2019; Bycroft, Mark/D-9446-2017; Buchberger, Alexander/AAF-4728-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Bycroft, Mark/0000-0002-0673-2216	MRC [MC_U105459896] Funding Source: UKRI; Medical Research Council [MC_U105459896] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; BEURON F, 2006, EMBO J; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Carim-Todd L, 2001, BBA-GENE STRUCT EXPR, V1517, P298, DOI 10.1016/S0167-4781(00)00248-7; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Dreveny I, 2004, BIOCHEM SOC T, V32, P715, DOI 10.1042/BST0320715; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Iyer LM, 2004, CELL CYCLE, V3, P1440, DOI 10.4161/cc.3.11.1206; Katiyar S, 2005, MOL BIOL CELL, V16, P4584, DOI 10.1091/mbc.E05-04-0345; Katiyar S, 2004, P NATL ACAD SCI USA, V101, P13774, DOI 10.1073/pnas.0405663101; Kim I, 2006, J CELL BIOL, V172, P211, DOI 10.1083/jcb.200507149; Lee JH, 2005, P NATL ACAD SCI USA, V102, P9144, DOI 10.1073/pnas.0502082102; LESLIE AGW, 1991, CCP4 ESF EACMB NEWSL; Li GT, 2005, P NATL ACAD SCI USA, V102, P15809, DOI 10.1073/pnas.0507155102; McNeill H, 2004, BIOCHEM J, V384, P391, DOI 10.1042/BJ20041498; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Olsen BB, 2003, FEBS LETT, V546, P218, DOI 10.1016/S0014-5793(03)00575-1; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Suzuki T, 2001, BIOCHEM BIOPH RES CO, V287, P1083, DOI 10.1006/bbrc.2001.5688; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TURK D, 1992, THESIS TU MUNCHEN; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Weihl CC, 2006, HUM MOL GENET, V15, P189, DOI 10.1093/hmg/ddi426; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhao G, 2006, J BIOL CHEM, V281, P13751, DOI 10.1074/jbc.M600137200	37	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25502	25508		10.1074/jbc.M601173200	http://dx.doi.org/10.1074/jbc.M601173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807242	hybrid			2022-12-25	WOS:000240031300053
J	Black, LW; Peng, GH				Black, Lindsay W.; Peng, Guihong			Mechanistic coupling of bacteriophage T4 DNA packaging to components of the replication-dependent late transcription machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAD MATURATION PATHWAY; PHAGE-T4 TERMINASE; LARGE SUBUNIT; PROTEIN; GP17; T4; INITIATION; PARTICLES; MUTANTS; PURIFICATION	Regulation of the terminal stage of viral DNA development, DNA packaging, is poorly understood. A new phage T4 in vitro DNA packaging assay employed purified proheads, terminase (gp17 + gp16), and ATP to encapsidate DNA resistant to nuclease. Mature phage T4 DNA and linearized plasmid DNAs containing or lacking a cloned T4 gene were packaged with high (similar to 10%) efficiency. Supercoiled, relaxed covalently closed, and nicked circular plasmid DNAs were packaged inefficiently, if at all, by these components. However, efficient packaging is achieved for nicked circular plasmid DNA, but not covalently closed plasmid DNA, upon addition to packaging mixtures of the purified T4 late transcription-replication machinery proteins: gp45 ( sliding clamp), gp44/gp62 ( clamp loader complex), gp55 ( late sigma-factor), and gp33 ( transcriptional co-activator). The small terminase subunit ( gp16) is inhibitory for packaging linear DNAs, but enhances the transcription-replication protein packaging of nicked plasmid DNA. Taken together with genetic and biochemical evidence of a requirement for gp55 for concatemer packaging to assemble active wild-type phage particles ( 1), the plasmid packaging results show that initiation of phage T4 packaging on "endless" concatemeric DNA in vivo by terminase depends upon interaction with the DNA loaded gp45 coupled late transcription-replication machinery. The results suggest a close mechanistic connection in vivo between DNA packaging and developmentally concurrent replication-dependent late transcription.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Black, LW (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Rm 408,108 N Greene St, Baltimore, MD 21201 USA.	lblack@umaryland.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011676, R21AI011676, R37AI011676] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baumann RG, 2003, J BIOL CHEM, V278, P4618, DOI 10.1074/jbc.M208574200; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; BLACK LW, 1986, GENE, V46, P97, DOI 10.1016/0378-1119(86)90171-X; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1981, VIROLOGY, V113, P336, DOI 10.1016/0042-6822(81)90160-4; BLACK LW, 1994, MOL BIOL BACTERIOP T, V4, P481; CARRASCOSA JL, 1978, J VIROL, V25, P831, DOI 10.1128/JVI.25.3.831-844.1978; CARRASCOSA JL, 1978, J VIROL, V26, P420, DOI 10.1128/JVI.26.2.420-428.1978; CASJENS S, 1992, J MOL BIOL, V227, P1086, DOI 10.1016/0022-2836(92)90523-M; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; CHUNG YB, 1990, J MOL BIOL, V216, P939, DOI 10.1016/S0022-2836(99)80012-6; Geiduschek E.P., 1997, MECH TRANSCRIPTION, P135; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; Jardine PJ, 1998, J MOL BIOL, V284, P661, DOI 10.1006/jmbi.1998.2179; Kanamaru S, 2004, J BIOL CHEM, V279, P40795, DOI 10.1074/jbc.M403647200; Kreuzer KN, 2005, ANNU REV MICROBIOL, V59, P43, DOI 10.1146/annurev.micro.59.030804.121255; Leffers G, 1996, J MOL BIOL, V258, P839, DOI 10.1006/jmbi.1996.0291; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; Lin H, 1997, J BIOL CHEM, V272, P3495, DOI 10.1074/jbc.272.6.3495; Lin HC, 1998, VIROLOGY, V242, P118, DOI 10.1006/viro.1997.9019; Malys N, 2002, J MOL BIOL, V319, P289, DOI 10.1016/S0022-2836(02)00298-X; Mitchell MS, 2002, NUCLEIC ACIDS RES, V30, P4009, DOI 10.1093/nar/gkf524; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; RAO VB, 1985, J MOL BIOL, V185, P565, DOI 10.1016/0022-2836(85)90072-5; Rao Venigalla B., 2005, P40; Rentas FJ, 2003, J MOL BIOL, V334, P37, DOI 10.1016/j.jmb.2003.09.028; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; SANDERS GM, 1994, P NATL ACAD SCI USA, V91, P7703, DOI 10.1073/pnas.91.16.7703; WILLIAMS KP, 1994, MOL BIOL BACTERIOP T, V4, P161; Wong K, 1998, J MOL BIOL, V284, P195, DOI 10.1006/jmbi.1998.2166; WU CHH, 1995, J MOL BIOL, V247, P523; YOUNG MC, 1994, MOL BIOL BACTERIOP T, V4, P313; Zhang X, 2004, J MOL BIOL, V340, P707, DOI 10.1016/j.jmb.2004.05.006	36	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25635	25643		10.1074/jbc.M602093200	http://dx.doi.org/10.1074/jbc.M602093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807240	hybrid			2022-12-25	WOS:000240031300066
J	Estrada, M; Varshney, A; Ehrlich, BE				Estrada, Manuel; Varshney, Anurag; Ehrlich, Barbara E.			Elevated testosterone induces apoptosis in neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ANABOLIC-ANDROGENIC STEROIDS; MESSENGER-RIBONUCLEIC-ACID; SENSITIVE G-PROTEIN; CYTOCHROME-C; KENNEDYS-DISEASE; CALCIUM SIGNALS; GENE-EXPRESSION; SPINAL NUCLEUS; DEATH	Testosterone plays a crucial role in neuronal function, but elevated concentrations can have deleterious effects. Here we show that supraphysiological levels of testosterone (micromolar range) initiate the apoptotic cascade. We used three criteria, annexin V labeling, caspase activity, and DNA fragmentation, to determine that apoptotic pathways were activated by testosterone. Micromolar, but not nanomolar, testosterone concentrations increased the response in all three assays of apoptosis. In addition, testosterone induced different concentration-dependent Ca2+ signaling patterns: at low concentrations of testosterone (100 nM), Ca2+ oscillations were produced, whereas high concentrations (1-10 mu M) induced a sustained Ca2+ increase. Elevated testosterone concentrations increase cell death, and this effect was abolished in the presence of either inhibitors of caspases or the inositol 1,4,5-trisphosphate receptor (InsP(3)R)-mediated Ca2+ release. Knockdown of InsP(3)R type 1 with specific small interfering RNA also abolished the testosterone-induced cell death and the prolonged Ca2+ signals. In contrast, knockdown of InsP(3)R type 3 modified neither the apoptotic response nor the Ca2+ signals. These results support our hypothesis that elevated testosterone alters InsP(3)R type 1-mediated intracellular Ca2+ signaling and that the prolonged Ca2+ signals lead to apoptotic cell death. These effects of testosterone on neurons will have long term effects on brain function.	Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Ehrlich, BE (corresponding author), Yale Univ, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	iestrada@med.uchile.cl; barbara.ehrlich@yale.edu	Estrada, Manuel/AAS-5605-2020; Varshney, Anurag/Y-6381-2019; /AAX-8408-2021; Estrada, Manuel/C-1269-2014	Estrada, Manuel/0000-0001-7877-8160; Varshney, Anurag/0000-0001-8509-0882; /0000-0001-9657-9704; Estrada, Manuel/0000-0001-7877-8160	NIDDK NIH HHS [DK61747] Funding Source: Medline; NIGMS NIH HHS [GM63496] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063496] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Aragno M, 2000, DIABETES, V49, P1924, DOI 10.2337/diabetes.49.11.1924; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/nejm199607043350101; Bhuyan AK, 2001, CELL DEATH DIFFER, V8, P63, DOI 10.1038/sj.cdd.4400773; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Boehning D, 2004, CELL CYCLE, V3, P252; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Darrington RS, 2002, NEUROREPORT, V13, P2117, DOI 10.1097/00001756-200211150-00025; DUVAL D, 1983, BIOCHIM BIOPHYS ACTA, V737, P409, DOI 10.1016/0304-4157(83)90008-4; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Estrada M, 2006, J CELL SCI, V119, P733, DOI 10.1242/jcs.02775; Estrada M, 2003, ENDOCRINOLOGY, V144, P3586, DOI 10.1210/en.2002-0164; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; Freeman LM, 1996, HORM BEHAV, V30, P424, DOI 10.1006/hbeh.1996.0047; Frye CA, 2004, PSYCHONEUROENDOCRINO, V29, P1019, DOI 10.1016/j.psyneuen.2003.10.004; Garic-Stankovic A, 2005, ALCOHOL CLIN EXP RES, V29, P1237, DOI 10.1097/01.ALC.0000172460.05756.D9; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; Greenland KJ, 2004, INTERN MED J, V34, P279, DOI 10.1111/j.1444-0903.2004.00588.x; Guo Q, 1997, J NEUROSCI, V17, P4212; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Jacob SN, 2005, J NEUROSCI, V25, P2853, DOI 10.1523/JNEUROSCI.4313-04.2005; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Johenning FW, 2004, BIOCHEM J, V382, P687, DOI 10.1042/BJ20040418; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; KERR JE, 1995, ENDOCRINOLOGY, V136, P3213, DOI 10.1210/en.136.8.3213; Lafevre-Bernt MA, 2003, J BIOL CHEM, V278, P34918, DOI 10.1074/jbc.M302841200; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Lipton SA, 1998, CELL CALCIUM, V23, P165, DOI 10.1016/S0143-4160(98)90115-4; Marron TU, 2005, J NEUROCHEM, V92, P10, DOI 10.1111/j.1471-4159.2004.02836.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUMOTO A, 1993, J NEUROENDOCRINOL, V5, P357, DOI 10.1111/j.1365-2826.1993.tb00495.x; MATSUMOTO A, 1994, HORM BEHAV, V28, P357, DOI 10.1006/hbeh.1994.1032; McEwen B S, 1972, Adv Behav Biol, V4, P41; McEwen BS, 1997, ANN NY ACAD SCI, V823, P201, DOI 10.1111/j.1749-6632.1997.tb48392.x; MENDES CC, 2005, J BIOL CHEM; Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200; Mong JA, 1999, J NEUROSCI, V19, P1464; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; Nagata S, 2005, ANNU REV IMMUNOL, V23, P853, DOI 10.1146/annurev.immunol.23.021704.115811; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; Rubinow DR, 1996, AM J PSYCHIAT, V153, P974; SAR M, 1990, ENDOCRINOLOGY, V127, P3180, DOI 10.1210/endo-127-6-3180; Sharp AH, 1999, J COMP NEUROL, V406, P207; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tabori NE, 2005, NEUROSCIENCE, V130, P151, DOI 10.1016/j.neuroscience.2004.08.048; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Thiblin I, 2000, J FORENSIC SCI, V45, P16; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tirassa P, 1997, J NEUROSCI RES, V47, P198, DOI 10.1002/(SICI)1097-4547(19970115)47:2<198::AID-JNR8>3.0.CO;2-A; Tovey SC, 2001, J CELL SCI, V114, P3979; Varshney A, 2003, NEURON, V39, P195, DOI 10.1016/S0896-6273(03)00425-2; Verkhratsky A, 2003, J CELL MOL MED, V7, P351, DOI 10.1111/j.1582-4934.2003.tb00238.x; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wozniak A, 1998, STEROIDS, V63, P263, DOI 10.1016/S0039-128X(98)00029-4; YERRAMILLIRAO P, 1995, J NEUROL SCI, V129, P131, DOI 10.1016/0022-510X(95)00083-E	68	110	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25492	25501		10.1074/jbc.M603193200	http://dx.doi.org/10.1074/jbc.M603193200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803879	hybrid			2022-12-25	WOS:000240031300052
J	Hu, ZH; Wang, YM; Graham, WV; Su, LP; Musch, MW; Turner, JR				Hu, Zhihong; Wang, Yingmin; Graham, W. Vallen; Su, Liping; Musch, Mark W.; Turner, Jerrold R.			MAPKAPK-2 is a critical signaling intermediate in NHE3 activation following Na+-glucose cotransport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAPK; AKT ACTIVATION; CANCER CELLS; KINASE; PROTEIN; TRANSLOCATION; ABSORPTION; PATHWAY; EZRIN; DIFFERENTIATION	Villus enterocyte nutrient absorption occurs via precisely orchestrated interactions among multiple transporters. For example, transport by the apical Na+-glucose cotransporter, SGLT1, triggers translocation of NHE3, Na+-H+ antiporter isoform 3, to the plasma membrane. This translocation requires activation of p38 mitogen-activated protein kinase ( MAPK), Akt2, and ezrin. Akt2 directly phosphorylates ezrin, but the precise role of p38 MAPK in this process remains to be defined. Sequence analysis suggested that p38 MAPK could not directly phosphorylate Akt2. We hypothesized that MAPKAPK-2 might link p38 MAPK and Akt2 activation. MAPKAPK-2 was phosphorylated after initiation of Na+-glucose cotransport with kinetics that paralleled activation of p38 MAPK, Akt2, and ezrin. MAPKAPK-2, Akt2, and ezrin phosphorylation were all attenuated by p38 MAPK inhibition but were unaffected by dominant negative ezrin expression. Akt2 inhibition blocked ezrin but not p38 MAPK or MAPKAPK-2 phosphorylation, suggesting that MAPKAPK-2 could be an intermediate in p38 MAPK-dependent Akt2 activation. Consistent with this, MAPKAPK-2 could phosphorylate an Akt2-derived peptide in vitro. siRNA-mediated MAPKAPK-2 knockdown inhibited phosphorylation of Akt2 and ezrin but not p38 MAPK. MAPKAPK-2 knockdown also blocked NHE3 translocation. Thus, MAPKAPK-2 controls Akt2 phosphorylation. In so doing, MAPKAPK-2 links p38 MAPK to Akt2, ezrin, and NHE3 activation after SGLT1-mediated transport.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Turner, JR (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 1089, Chicago, IL 60637 USA.	jturner@bsd.uchicago.edu	wang, yingying/GRS-3058-2022; Graham, W Vallen/C-4315-2019; Turner, Jerrold/H-1502-2019; Graham, W/L-2301-2019; Turner, Jerrold R/A-6895-2009	Graham, W Vallen/0000-0003-3815-7532; Graham, W/0000-0003-3815-7532; Turner, Jerrold R/0000-0003-0627-9455	NCI NIH HHS [CA14599] Funding Source: Medline; NIDDK NIH HHS [DK42086, DK61931, DK68271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068271, R01DK061931, P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn EH, 2006, ANTICANCER RES, V26, P121; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; De la Horra MC, 1998, PFLUG ARCH EUR J PHY, V436, P112, DOI 10.1007/s004240050611; Duggan C, 2004, JAMA-J AM MED ASSOC, V291, P2628, DOI 10.1001/jama.291.21.2628; Gawenis LR, 2002, AM J PHYSIOL-GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001; Gueorguiev VD, 2006, J BIOL CHEM, V281, P10188, DOI 10.1074/jbc.M513806200; Hokari R, 2005, AM J PHYSIOL-GASTR L, V289, pG949, DOI 10.1152/ajpgi.00142.2005; HUNT JB, 1992, GUT, V33, P479, DOI 10.1136/gut.33.4.479; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lluis F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002; MacCorkle RA, 2005, CELL BIOCHEM BIOPHYS, V43, P451, DOI 10.1385/CBB:43:3:451; Maher MM, 1997, GASTROENTEROLOGY, V112, P174, DOI 10.1016/S0016-5085(97)70232-4; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Segarra J, 2006, J BIOL CHEM, V281, P4771, DOI 10.1074/jbc.M508298200; Shiue H, 2005, J BIOL CHEM, V280, P1688, DOI 10.1074/jbc.M409471200; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Taniyama Y, 2004, AM J PHYSIOL-CELL PH, V287, pC494, DOI 10.1152/ajpcell.00439.2003; Thwaites DT, 2002, GASTROENTEROLOGY, V122, P1322, DOI 10.1053/gast.2002.32992; Tilly BC, 1996, FEBS LETT, V395, P133, DOI 10.1016/0014-5793(96)01028-9; Turner JR, 2000, ADV DRUG DELIVER REV, V41, P265, DOI 10.1016/S0169-409X(00)00046-6; Turner JR, 2001, AM J PHYSIOL-CELL PH, V281, pC1533, DOI 10.1152/ajpcell.2001.281.5.C1533; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; Xia Q, 2006, CLIN EXP DERMATOL, V31, P260, DOI 10.1111/j.1365-2230.2006.02050.x; Zhao HR, 2004, P NATL ACAD SCI USA, V101, P9485, DOI 10.1073/pnas.0308400101	35	29	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24247	24253		10.1074/jbc.M602898200	http://dx.doi.org/10.1074/jbc.M602898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793766	hybrid			2022-12-25	WOS:000239847800018
J	Marques, JM; Rodrigues, RJ; de Magalhaes-Sant'Ana, AC; Goncalves, T				Marques, Joana M.; Rodrigues, Ricardo J.; de Magalhaes-Sant'Ana, Augusto C.; Goncalves, Teresa			Saccharomyces cerevisiae Hog1 protein phosphorylation upon exposure to bacterial endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE CASCADE; OSMOSENSING SIGNAL-TRANSDUCTION; OSMOTIC-STRESS RESPONSE; TYROSINE PHOSPHATASES; OXIDATIVE STRESS; GENE-EXPRESSION; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; TRANSCRIPTIONAL RESPONSE; 2-COMPONENT SYSTEM; BUDDING YEAST	The yeast Hog1 protein is both functionally and structurally similar to the mammalian p38, belonging to the same family of mitogen-activated protein (MAP) kinases and responding to extracellular changes in osmolarity. Since p38 mediates lipopolysaccharide (LPS) effects in mammalian cells, we now tested the responsiveness of Hog1 upon exposure of the yeast Saccharomyces cerevisiae to bacterial LPS. In the presence of Escherichia coli LPS (100 ng/ml) and an endotoxically active, hexaacylated, synthetic lipid A (compound 506; 100 ng/ml), Hog1 becomes phosphorylated with a maximum of phosphorylation between 3 and 6 h, whereas a tetraacylated, inactive form of lipid A (compound 406) did not cause any modification in the phosphorylation state of Hog1. A triple labeling immunocytochemical study showed that phosphorylated Hog1 translocates into the nucleus after a 90-min incubation and becomes sparsely located in the cytoplasm. The translocation of the phospho-Hog1 is preceded by an increased expression of the HOG1gene and concomitant with the expression of the Hog1 target gene, GPD1. We also observed that cells unable to synthesize Hog1 do not resist LPS as efficiently as wild-type cells. We conclude that the yeast S. cerevisiae is able to respond to the presence of Gram-negative bacteria endotoxin and that Hog1 is involved in this response.	Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3004504 Coimbra, Portugal; Univ Coimbra, Inst Microbiol, P-3004504 Coimbra, Portugal; Univ Coimbra, Inst Biochem, Fac Med, P-3004504 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Goncalves, T (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol Coimbra, P-3004504 Coimbra, Portugal.	tmfog@ci.uc.pt	Marques, Joana M/AAW-2711-2020; Gonçalves, Teresa/F-5146-2011; Rodrigues, Ricardo J/B-3847-2008	Marques, Joana M/0000-0002-7234-9477; Gonçalves, Teresa/0000-0001-9347-0535; Rodrigues, Ricardo J/0000-0002-7631-743X				Akhtar N, 2000, FEBS LETT, V483, P87, DOI 10.1016/S0014-5793(00)02087-1; ALBERTYN J, 1994, CURR GENET, V25, P12, DOI 10.1007/BF00712960; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alonso-Monge R, 2003, EUKARYOT CELL, V2, P351, DOI 10.1128/EC.2.2.351-361.2003; Bilsland E, 2004, MOL MICROBIOL, V53, P1743, DOI 10.1111/j.1365-2958.2004.04238.x; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Bohm M, 2002, CELL TISSUE RES, V308, P431, DOI 10.1007/s00441-002-0535-x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GASCH AP, 2000, FUNCT INTEGR GENOMIC, V2, P181; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; Lawrence CL, 2004, MOL CELL BIOL, V24, P3307, DOI 10.1128/MCB.24.8.3307-3323.2004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Mattison CP, 2000, GENE DEV, V14, P1229; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; Ogura M, 1998, J IMMUNOL, V161, P3569; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; PRINTEN JA, 1994, GENETICS, V138, P609; Proft M, 2004, CELL, V118, P351, DOI 10.1016/j.cell.2004.07.016; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Seydel U, 2005, FEBS J, V272, P327, DOI 10.1111/j.1742-4658.2004.04471.x; Sharma P, 2005, CURR GENET, V48, P162, DOI 10.1007/s00294-005-0010-9; Sheikh-Hamad D, 2004, AM J PHYSIOL-RENAL, V287, pF1102, DOI 10.1152/ajprenal.00225.2004; Singh KK, 2000, FREE RADICAL BIO MED, V29, P1043, DOI 10.1016/S0891-5849(00)00432-9; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tamas MJ, 2000, FEBS LETT, V472, P159, DOI 10.1016/S0014-5793(00)01445-9; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002	56	20	21	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24687	24694		10.1074/jbc.M603753200	http://dx.doi.org/10.1074/jbc.M603753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790423	Green Published, hybrid			2022-12-25	WOS:000239847800064
J	Contreras-Alcantara, S; Godby, JA; Delos, SE				Contreras-Alcantara, Susana; Godby, Jesse A.; Delos, Sue E.			The single ligand-binding repeat of Tva, a low density lipoprotein receptor-related protein, contains two ligand-binding surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-A MODULE; VIRUS ENVELOPE GLYCOPROTEIN; GROUP HUMAN RHINOVIRUS; CYSTEINE-RICH REPEAT; SUBGROUP-A; APOLIPOPROTEIN-E; LEUKOSIS VIRUS; AVIAN-SARCOMA; ALPHA-2-MACROGLOBULIN RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA	The receptor for avian sarcoma/leukosis virus subtype A (ASLV-A), Tva, is the simplest member of the low density lipoprotein receptor family containing a single ligand-binding repeat (LBR). Most LBRs contain a central Trp (Trp(33) in Tva) that is important for ligand binding and, for the low density lipoprotein receptor, is associated with familial hypercholesterolemia. The Tva ligand-binding module contains a second Trp (Trp(48)) that is part of a DEW motif present in a subset of LBRs. Trp(48) is important for ASLV-A infectivity. A soluble Tva (sTva) ligand-binding module is sufficient for ASLV-A infectivity. Tva interacts with the viral glycoprotein, and a soluble receptor-binding domain (SUA) binds sTva with picomolar affinity. We investigated whether Tva, a retroviral receptor, could behave as a classic LBR by assessing sTva interactions with the universal receptor-associated protein (RAP) and comparing these interactions with those between sTva and its viral ligand (SUA). To address the role of the two Trp residues in Tva function, we prepared sTva harboring mutations of Trp(33), Trp(48), or both and determined the binding kinetics with RAP and SUA. We found that sTva behaved as a "normal" receptor toward RAP, requiring both calcium and Trp(33) for binding. However, sTva binding to SUA required neither calcium nor Trp(33). Furthermore, sTva could bind both RAP and SUA simultaneously. These results show that the single LBR of Tva has two ligand-binding sites, raising the possibility that other LBRs may also.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Delos, SE (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	sed7a@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022470] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdul-Aziz D, 2005, BIOCHEMISTRY-US, V44, P5075, DOI 10.1021/bi047575j; Adler A J, 1973, Methods Enzymol, V27, P675; Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andersen OM, 2003, CHEMBIOCHEM, V4, P1137, DOI 10.1002/cbic.200300580; Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; Andersen OM, 2001, BIOCHEM J, V357, P289, DOI 10.1042/0264-6021:3570289; Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Bu GJ, 2001, INT REV CYTOL, V209, P79; Croy JE, 2003, BIOCHEMISTRY-US, V42, P13049, DOI 10.1021/bi034752s; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Damico RL, 1998, P NATL ACAD SCI USA, V95, P2580, DOI 10.1073/pnas.95.5.2580; Delos SE, 2000, J VIROL, V74, P9738, DOI 10.1128/JVI.74.20.9738-9741.2000; Delos SE, 2005, J VIROL, V79, P3488, DOI 10.1128/JVI.79.6.3488-3499.2005; Delos SE, 2002, VIROLOGY, V294, P354, DOI 10.1006/viro.2001.1339; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; Earp LJ, 2003, METHOD ENZYMOL, V372, P428; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher C, 2004, BIOCHEMISTRY-US, V43, P1037, DOI 10.1021/bi035529y; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GRUENBERGER M, 1995, J VIROL, V69, P7244, DOI 10.1128/JVI.69.11.7244-7247.1995; Guo Y, 2004, J BIOL CHEM, V279, P16629, DOI 10.1074/jbc.M400157200; Hernandez LD, 1997, J CELL BIOL, V139, P1455, DOI 10.1083/jcb.139.6.1455; Herz J, 2003, CELL, V112, P289, DOI 10.1016/S0092-8674(03)00073-4; Herz J, 2000, CURR OPIN LIPIDOL, V11, P161, DOI 10.1097/00041433-200004000-00009; Hiesberger T, 1996, J BIOL CHEM, V271, P28792, DOI 10.1074/jbc.271.46.28792; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Jensen HK, 1996, ATHEROSCLEROSIS, V120, P57, DOI 10.1016/0021-9150(95)05680-7; Koduri V, 2001, BIOCHEMISTRY-US, V40, P12801, DOI 10.1021/bi011344k; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Kurniawan ND, 2000, PROTEIN SCI, V9, P1282, DOI 10.1110/ps.9.7.1282; Kvaratskhelia M, 2004, VIROLOGY, V326, P171, DOI 10.1016/j.virol.2004.05.020; Lazic A, 2003, BIOCHEMISTRY-US, V42, P14913, DOI 10.1021/bi035779e; LEITERSDORF E, 1990, J CLIN INVEST, V85, P1014, DOI 10.1172/JCI114531; Matsuyama S, 2004, J VIROL, V78, P8201, DOI 10.1128/JVI.78.15.8201-8209.2004; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; McCormick LM, 2005, BIOCHEMISTRY-US, V44, P5794, DOI 10.1021/bi047652a; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; North CL, 2000, BIOCHEMISTRY-US, V39, P13127, DOI 10.1021/bi0015156; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Nykjaer A, 2002, TRENDS CELL BIOL, V12, P273, DOI 10.1016/S0962-8924(02)02282-1; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Prevost M, 2004, PROTEINS, V55, P874, DOI 10.1002/prot.20080; Raffai R, 2000, J BIOL CHEM, V275, P7109, DOI 10.1074/jbc.275.10.7109; Rai T, 2005, J VIROL, V79, P14962, DOI 10.1128/JVI.79.23.14962-14966.2005; Rai T, 2004, J VIROL, V78, P683, DOI 10.1128/JVI.78.2.683-691.2004; RALL SC, 1983, J CLIN INVEST, V72, P1288, DOI 10.1172/JCI111085; Rong LJ, 1997, J VIROL, V71, P3458, DOI 10.1128/JVI.71.5.3458-3465.1997; Rong LJ, 1998, J VIROL, V72, P4552, DOI 10.1128/JVI.72.6.4552-4559.1998; Rong LJ, 1998, P NATL ACAD SCI USA, V95, P8467, DOI 10.1073/pnas.95.15.8467; Rudenko G, 2003, CURR OPIN STRUC BIOL, V13, P683, DOI 10.1016/j.sbi.2003.10.001; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Simonovic M, 2001, BIOCHEMISTRY-US, V40, P15127, DOI 10.1021/bi015688m; Smith JG, 2004, J VIROL, V78, P1403, DOI 10.1128/JVI.78.3.1403-1410.2004; Tonelli M, 2001, FEBS LETT, V509, P161, DOI 10.1016/S0014-5793(01)03086-1; Verdaguer N, 2004, NAT STRUCT MOL BIOL, V11, P429, DOI 10.1038/nsmb753; Vlasak M, 2003, J VIROL, V77, P6923, DOI 10.1128/JVI.77.12.6923-6930.2003; Wang QY, 2002, PROTEIN SCI, V11, P2596, DOI 10.1110/ps.0219802; Wang QY, 2001, J VIROL, V75, P2051, DOI 10.1128/JVI.75.5.2051-2058.2001; Weaver AM, 1997, J LIPID RES, V38, P1841; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993; Yu XM, 2003, J VIROL, V77, P7517, DOI 10.1128/JVI.77.13.7517-7526.2003; Zaiou M, 2000, J LIPID RES, V41, P1087; Zingler K, 1996, J VIROL, V70, P7510, DOI 10.1128/JVI.70.11.7510-7516.1996	76	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22827	22838		10.1074/jbc.M512599200	http://dx.doi.org/10.1074/jbc.M512599200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769730	hybrid			2022-12-25	WOS:000239542600045
J	Zimny, J; Sikora, M; Guranowski, A; Jakubowski, H				Zimny, Jaroslaw; Sikora, Marta; Guranowski, Andrzej; Jakubowski, Hieronim			Protective mechanisms against homocysteine toxicity - The role of bleomycin hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN HOMOCYSTEINYLATION; PATHOLOGICAL CONSEQUENCES; CYSTEINE PROTEASE; ENDOTHELIAL-CELLS; AMINO-ACID; THIOLACTONE; METABOLISM; HUMANS; AUTOANTIBODIES	Homocysteine (Hcy) editing by methionyl-tRNA synthetase results in the formation of Hcy-thiolactone and initiates a pathway that has been implicated in human disease. In addition to being cleared from the circulation by urinary excretion, Hcy-thiolactone is detoxified by the serum Hcy-thiolactonase/paraoxonase carried on high density lipoprotein. Whether Hcy-thiolactone is detoxified inside cells was unknown. Here we show that Hcy-thiolactone is hydrolyzed by an intracellular enzyme, which we have purified to homogeneity from human placenta and identified by proteomic analyses as human bleomycin hydrolase (hBLH). We have also purified an Hcy-thiolactonase from the yeast Saccharomyces cerevisiae and identified it as yeast bleomycin hydrolase (yBLH). BLH belongs to a family of evolutionarily conserved cysteine aminopeptidases, and its only known biologically relevant function was deamidation of the anticancer drug bleomycin. Recombinant hBLH or yBLH, expressed in Escherichia coli, exhibits Hcy-thiolactonase activity similar to that of the native enzymes. Active site mutations, C73A for hBLH and H369A for yBLH, inactivate Hcy-thiolactonase activities. Yeast blh1 mutants are deficient in Hcy-thiolactonase activity in vitro and in vivo, produce more Hcy-thiolactone, and exhibit greater sensitivity to Hcy toxicity than wild type yeast cells. Our data suggest that BLH protects cells against Hcy toxicity by hydrolyzing intracellular Hcy-thiolactone.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Univ Agr, Dept Biochem & Biotechnol, PL-60637 Poznan, Poland; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Poznan University of Life Sciences; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; Zimny, Jaroslaw/0000-0001-6236-8562; Guranowski, Andrzej/0000-0002-8515-5153				Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; Chwatko G, 2005, CLIN CHEM, V51, P408, DOI 10.1373/clinchem.2004.042531; Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; DOMAGALA TB, 2006, IN PRESS CELL MOL BI, V52; EACINSKI M, 2004, CELL MOL BIOL, V50, P885; Glowacki R, 2004, J BIOL CHEM, V279, P10864, DOI 10.1074/jbc.M313268200; Hossain GS, 2003, J BIOL CHEM, V278, P30317, DOI 10.1074/jbc.M212897200; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2005, CLIN CHEM LAB MED, V43, P1011, DOI 10.1515/CCLM.2005.177; Jakubowski H, 2004, CELL MOL LIFE SCI, V61, P470, DOI 10.1007/s00018-003-3204-7; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 2003, J BIOL CHEM, V278, P6765, DOI 10.1074/jbc.M211819200; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; JAKUBOWSKI H, 2005, CELL MOL LIFE SCI, P384; Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S; Jakubowsky H., 2005, AMINOACYL TRNA SYNTH, P384; Koldamova RP, 1998, MOL PHARMACOL, V54, P954, DOI 10.1124/mol.54.6.954; Koldamova RP, 1998, BIOCHEMISTRY-US, V37, P2282, DOI 10.1021/bi9722204; Koldamova RP, 1999, BIOCHEMISTRY-US, V38, P7111, DOI 10.1021/bi990135l; Lefterov IM, 2001, BIOCHEM BIOPH RES CO, V283, P994, DOI 10.1006/bbrc.2001.4860; Lefterov IM, 2000, FASEB J, V14, P1837, DOI 10.1096/fj.99-0938com; Lentz SR, 2005, J THROMB HAEMOST, V3, P1646, DOI 10.1111/j.1538-7836.2005.01364.x; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Niemer I, 1997, CURR GENET, V32, P41, DOI 10.1007/s002940050246; O'Farrell PA, 1999, STRUCT FOLD DES, V7, P619, DOI 10.1016/S0969-2126(99)80083-5; PEI ZD, 1995, MOL PHARMACOL, V48, P676; PERDZIAK M, 2005, ACTA BIOCH POL S1, V50, P184; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Schwartz DR, 1999, P NATL ACAD SCI USA, V96, P4680, DOI 10.1073/pnas.96.8.4680; Senger B, 2001, J MOL BIOL, V311, P205, DOI 10.1006/jmbi.2001.4844; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Spence JD, 2005, STROKE, V36, P2404, DOI 10.1161/01.STR.0000185929.38534.f3; Tuite NL, 2005, J BACTERIOL, V187, P4362, DOI 10.1128/JB.187.13.4362-4371.2005; Undas A, 2005, THROMB HAEMOSTASIS, V93, P346, DOI 10.1160/TH04-08-0493; Undas A, 2004, STROKE, V35, P1299, DOI 10.1161/01.STR.0000128412.59768.6e; Wang HJ, 2002, BIOCHEM CELL BIOL, V80, P789, DOI 10.1139/O02-167; Zhang C, 2001, J BIOL CHEM, V276, P35867, DOI 10.1074/jbc.M100747200; Zheng WJ, 1998, CELL, V93, P103, DOI 10.1016/S0092-8674(00)81150-2; Zheng WJ, 1998, MOL CELL BIOL, V18, P3580, DOI 10.1128/MCB.18.6.3580; ZIMNY J, 2005, CLIN CHEM LAB MED, V43, pA23	49	74	75	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22485	22492		10.1074/jbc.M603656200	http://dx.doi.org/10.1074/jbc.M603656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769724	hybrid			2022-12-25	WOS:000239542600009
J	Chen, I; Provvedi, R; Dubnau, D				Chen, Ines; Provvedi, Roberta; Dubnau, David			A macromolecular complex formed by a pilin-like protein in competent Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PSEUDOMONAS-AERUGINOSA; TRANSCRIPTION FACTOR; MEMBRANE-PROTEIN; TYPE-4 FIMBRIAE; PILUS-STRUCTURE; TRANSFORMATION; SECRETION; BIOGENESIS; ENCODES	In competent Bacillus subtilis, the ComG proteins are required to allow exogenous DNA to access to membrane-bound receptor ComEA during transformation. Here we describe a multimeric complex containing the pilin-like protein ComGC. Due to similarities to the type 4 pilus and the type 2 secretion system pseudopilus, we have tentatively named it the "competence pseudopilus." The ComGC multimer is released from cells upon digestion of the cell wall with lysozyme and has a heterogeneous size, estimated to range between 40 and 100 monomers, covalently linked by disulfide bonds. We determined that the prepilin peptidase ComC, the thiol-disulfide oxidoreductase pair BdbDC, and all seven ComG proteins are necessary to form the pseudopilus. Furthermore, these proteins are also sufficient to form a functional complex, i.e. able to facilitate binding of exogenous DNA to ComEA. The initial steps of pseudopilus biogenesis include the processing of ComGC in the cytoplasmic membrane and consist of two independent events, proteolytic cleavage by ComC and formation of an intramolecular disulfide bond by BdbDC. The other ComG proteins are required to assemble the mature ComGC monomers in the membrane into a multimeric complex proposed to span the cell envelope. We discuss the possible role of the competence pseudopilus in DNA binding and uptake during transformation.	Publ Hlth Res Inst, Newark, NJ 07103 USA		Dubnau, D (corresponding author), Publ Hlth Res Inst, 225 Warren St, Newark, NJ 07103 USA.	dubnau@phri.org	Provvedi, Roberta/I-8430-2012	Chen, Ines/0000-0002-1405-9703; PROVVEDI, ROBERTA/0000-0003-1164-9676	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43756, R01 GM043756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANO M, 1987, J BACTERIOL, V169, P3110, DOI 10.1128/jb.169.7.3110-3117.1987; ALBANO M, 1989, J BACTERIOL, V171, P5386, DOI 10.1128/jb.171.10.5386-5404.1989; Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BREITLING R, 1990, J BACTERIOL, V172, P1499, DOI 10.1128/jb.172.3.1499-1508.1990; Chen I, 2004, NAT REV MICROBIOL, V2, P241, DOI 10.1038/nrmicro844; CHUNG YS, 1995, MOL MICROBIOL, V15, P543, DOI 10.1111/j.1365-2958.1995.tb02267.x; Chung YS, 1998, MOL MICROBIOL, V29, P905, DOI 10.1046/j.1365-2958.1998.00989.x; Chung YS, 1998, J BACTERIOL, V180, P41, DOI 10.1128/JB.180.1.41-45.1998; Craig L, 2004, NAT REV MICROBIOL, V2, P363, DOI 10.1038/nrmicro885; Draskovic I, 2005, MOL MICROBIOL, V55, P881, DOI 10.1111/j.1365-2958.2004.04430.x; Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217; Durand E, 2003, J BACTERIOL, V185, P2749, DOI 10.1128/JB.185.9.2749-2758.2003; Filloux A, 2004, BBA-MOL CELL RES, V1694, P163, DOI 10.1016/j.bbamcr.2004.05.003; Forest KT, 1997, GENE, V192, P165, DOI 10.1016/S0378-1119(97)00008-5; HAHN J, 1995, J BACTERIOL, V177, P3601, DOI 10.1128/jb.177.12.3601-3605.1995; Hahn J, 2005, CELL, V122, P59, DOI 10.1016/j.cell.2005.04.035; Hahn J, 1995, MOL MICROBIOL, V18, P755, DOI 10.1111/j.1365-2958.1995.mmi_18040755.x; Hahn J, 1996, MOL MICROBIOL, V21, P763, DOI 10.1046/j.1365-2958.1996.371407.x; HAHN J, 1987, J BACTERIOL, V169, P3104, DOI 10.1128/jb.169.7.3104-3109.1987; HAHN J, 1993, MOL MICROBIOL, V10, P99, DOI 10.1111/j.1365-2958.1993.tb00907.x; Haijema BJ, 2001, MOL MICROBIOL, V40, P52, DOI 10.1046/j.1365-2958.2001.02363.x; Hamoen LW, 2003, MICROBIOL-SGM, V149, P9, DOI 10.1099/mic.0.26003-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; INAMINE GS, 1995, J BACTERIOL, V177, P3045, DOI 10.1128/jb.177.11.3045-3051.1995; Kohler R, 2004, MOL MICROBIOL, V54, P647, DOI 10.1111/j.1365-2958.2004.04307.x; LONDONOVALLEJO JA, 1993, MOL MICROBIOL, V9, P119, DOI 10.1111/j.1365-2958.1993.tb01674.x; Maier B, 2004, NAT STRUCT MOL BIOL, V11, P643, DOI 10.1038/nsmb783; Matias VRF, 2005, MOL MICROBIOL, V56, P240, DOI 10.1111/j.1365-2958.2005.04535.x; Meima R, 2002, J BIOL CHEM, V277, P6994, DOI 10.1074/jbc.M111380200; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; Nunn D, 1999, TRENDS CELL BIOL, V9, P402, DOI 10.1016/S0962-8924(99)01634-7; Provvedi R, 1999, MOL MICROBIOL, V31, P271, DOI 10.1046/j.1365-2958.1999.01170.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sauvonnet N, 2000, EMBO J, V19, P2221, DOI 10.1093/emboj/19.10.2221; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; VANSINDEREN D, 1995, MOL MICROBIOL, V15, P455; Vignon G, 2003, J BACTERIOL, V185, P3416, DOI 10.1128/JB.185.11.3416-3428.2003	40	86	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21720	21727		10.1074/jbc.M604071200	http://dx.doi.org/10.1074/jbc.M604071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751195	Green Accepted, hybrid			2022-12-25	WOS:000239387100017
J	Pal, G; Kouadio, JLK; Artis, DR; Kossiakoff, AA; Sidhu, SS				Pal, Gabor; Kouadio, Jean-Louis K.; Artis, Dean R.; Kossiakoff, Anthony A.; Sidhu, Sachdev S.			Comprehensive and quantitative mapping of energy landscapes for protein-protein interactions by rapid combinatorial scanning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; HIGH-AFFINITY VARIANT; EXTRACELLULAR DOMAIN; PHAGE DISPLAY; BETA-LACTAMASE; BINDING-ENERGY; RECEPTOR; SPECIFICITY; MUTAGENESIS; ENERGETICS	A novel, quantitative saturation (QS) scanning strategy was developed to obtain a comprehensive data base of the structural and functional effects of all possible mutations across a large protein-protein interface. The QS scan approach was applied to the high affinity site of human growth hormone (hGH) for binding to its receptor (hGHR). Although the published structure-function data base describing this system is probably the most extensive for any large protein-protein interface, it is nonetheless too sparse to accurately describe the nature of the energetics governing the interaction. Our comprehensive data base affords a complete view of the binding site and provides important new insights into the general principles underlying protein-protein interactions. The hGH binding interface is highly adaptable to mutations, but the nature of the tolerated mutations challenges generally accepted views about the evolutionary and biophysical pressures governing protein-protein interactions. Many substitutions that would be considered chemically conservative are not tolerated, while conversely, many non-conservative substitutions can be accommodated. Furthermore, conservation across species is a poor predictor of the chemical character of tolerated substitutions across the interface. Numerous deviations from generally accepted expectations indicate that mutational tolerance is highly context dependent and, furthermore, cannot be predicted by our current knowledge base. The type of data produced by the comprehensive QS scan can fill the gaps in the structure-function matrix. The compilation of analogous data bases from studies of other protein-protein interactions should greatly aid the development of computational methods for explaining and designing molecular recognition.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Inst Biophys Dynam, Cummings Life Sci Ctr, Chicago, IL 60637 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	University of Chicago; University of Chicago; Roche Holding; Genentech	Kossiakoff, AA (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.	koss@cummings.uchicago; sidhu@gene.com	Pal, Gabor/A-6244-2009	Pal, Gabor/0000-0001-7868-7971				Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Bernat B, 2004, BIOCHEMISTRY-US, V43, P6076, DOI 10.1021/bi036069b; Bernat B, 2003, P NATL ACAD SCI USA, V100, P952, DOI 10.1073/pnas.0235023100; Bond CJ, 2005, J MOL BIOL, V348, P699, DOI 10.1016/j.jmb.2005.02.063; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; HILL MO, 1973, ECOLOGY, V54, P427, DOI 10.2307/1934352; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Kossiakoff AA, 2004, ADV PROTEIN CHEM, V68, P147; Kouadio JLK, 2005, J BIOL CHEM, V280, P25524, DOI 10.1074/jbc.M502167200; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Pal G, 2005, PROTEIN SCI, V14, P2405, DOI 10.1110/ps.051519805; Pal G, 2005, J MOL BIOL, V347, P489, DOI 10.1016/j.jmb.2005.01.040; Pal G, 2003, J MOL BIOL, V332, P195, DOI 10.1016/S0022-2836(03)00898-2; Schiffer C, 2002, J MOL BIOL, V316, P277, DOI 10.1006/jmbi.2001.5348; Schwehm JM, 1998, BIOCHEMISTRY-US, V37, P6939, DOI 10.1021/bi9725069; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SHENKIN PS, 1991, PROTEINS, V11, P297, DOI 10.1002/prot.340110408; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Skelton NJ, 2003, J BIOL CHEM, V278, P7645, DOI 10.1074/jbc.M209751200; Stewart JJ, 1997, MOL IMMUNOL, V34, P1067, DOI 10.1016/S0161-5890(97)00130-2; Thorn KS, 2001, BIOINFORMATICS, V17, P284, DOI 10.1093/bioinformatics/17.3.284; Vajdos FF, 2002, J MOL BIOL, V320, P415, DOI 10.1016/S0022-2836(02)00264-4; Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Yang JY, 2003, J BIOL CHEM, V278, P50412, DOI 10.1074/jbc.M306848200; Yi SJ, 2002, MOL BIOL EVOL, V19, P1083, DOI 10.1093/oxfordjournals.molbev.a004166; Zhang Z, 2004, J BIOL CHEM, V279, P42860, DOI 10.1074/jbc.M406157200; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200	38	93	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22378	22385		10.1074/jbc.M603826200	http://dx.doi.org/10.1074/jbc.M603826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16762925	hybrid			2022-12-25	WOS:000239387100083
J	Massiello, A; Roesser, JR; Chalfant, CE				Massiello, Autumn; Roesser, James R.; Chalfant, Charles E.			SAP155 binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5 ' splice site selection of Bcl-x pre-mRNA	FASEB JOURNAL			English	Article						Bcl-x; alternative splicing; A549 cells; daunorubicin; chemotherapy	PROTEIN PHOSPHATASE-1; CELL-DIFFERENTIATION; SPHINGOMYELIN TURNOVER; IDENTIFICATION; DEPENDENCE; COMPLEXES; DEATH; CYCLE; SITE	Two splice variants are derived from the BCL-x gene, proapoptotic Bcl-x(s) and antiapoptotic Bcl-x(L), via alternative 5' splice site selection. In previous studies, our laboratory identified an RNA cis-element within exon 2 of Bcl-x pre-mRNA that is a ceramide responsive termed CRCE 1. In this study, mass spectrometric analysis identified the splicing factor SAP155, as an RNA trans-acting factor binding to the purine-rich CRCE 1. The interaction of SAP155 with CRCE 1 was confirmed by the addition of an anti-SAP155 antibody (Ab) to EMSA decreasing the mobility of a protein: CRCE 1 complex (SuperShift). Furthermore, the down-regulation of SAP155 in A549 cells by RNA interference (RNAi) technology resulted in the loss of a 155 kDa protein complexed with CRCE 1. Moreover, this down-regulation of SAP155 induced an increase in the Bcl-x(s) with a concomitant decrease in the Bcl-x(L) splice variants and immunoreactive protein levels, thereby decreasing the Bcl-x(L)/Bcl-x(s) ratio. Specific down-regulation of SAP155 also inhibited the ability of exogenous ceramide treatment to further induce the activation of the Bcl-x(s) 5' splice site. Additionally, the specific downregulation of SAP155 sensitized cells to undergo apoptosis in response to daunorubicin in a manner similar to ceramide. Therefore, we have identified SAP155 as an RNA trans-acting factor that binds to CRCE 1, functions to regulate the alternative 5' splice site selection of Bcl-x pre-mRNA, and is required for ceramide to induce the activation of the Bcl-x(s) 5' splice site. Furthermore, we have demonstrated that activation of the Bcl-x(s) 5' splice site can increase the effectiveness of chemotherapeutic drug treatment, thus establishing a role for the alternative splicing mechanism of Bcl-x in chemotherapeutic sensitivity.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA	Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Rm 2-016,Sanger Hall,1101 E Marshall St,POB 98061, Richmond, VA 23298 USA.	cechalfant@vcu.edu	, Proteomics Core UNC/AFQ-7201-2022		NCRR NIH HHS [1C06-RR-17393] Funding Source: Medline; NHLBI NIH HHS [R01-HL-072925] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017393] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Das BK, 1999, MOL CELL BIOL, V19, P6796; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gozani O, 1998, MOL CELL BIOL, V18, P4752, DOI 10.1128/MCB.18.8.4752; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; Massiello A, 2004, J BIOL CHEM, V279, P15799, DOI 10.1074/jbc.M313950200; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Parker Carol E., 2005, V301, P117; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Tran HT, 2004, MOL CELL PROTEOMICS, V3, P257, DOI 10.1074/mcp.M300115-MCP200	23	66	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1680	+		10.1096/fj.05-5021fje	http://dx.doi.org/10.1096/fj.05-5021fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790528				2022-12-25	WOS:000240266600013
J	Maurelli, R; Zambruno, G; Guerra, L; Abbruzzese, C; Dimri, G; Gellini, M; Bondanza, S; Dellambra, E				Maurelli, Riccardo; Zambruno, Giovanna; Guerra, Liliana; Abbruzzese, Claudia; Dimri, Goberdhan; Gellini, Mara; Bondanza, Sergio; Dellambra, Elena			Inactivation of p16(INK4a) (inhibitor of cyclin-dependent kinase 4A) immortalizes primary human keratinocytes by maintaining cells in the stem cell compartment	FASEB JOURNAL			English	Article						Bmi-; telomerase; keratinocyte clonal evolution; keratinocyte senescence	TELOMERASE ACTIVITY; LIFE-SPAN; REPLICATIVE SENESCENCE; TRANSCRIPTIONAL SUPPRESSION; TUMOR SUPPRESSION; HAIR-FOLLICLES; BASAL LAYER; EXPRESSION; SKIN; INK4A	Replicative senescence of human keratinocytes is determined by a progressive decline of clonogenic and dividing cells, and its timing is controlled by clonal evolution (i.e., the transition from stem cells to transient amplifying and postmitotic cells). Progressive increase of p16(INK4a) (inhibitor of cyclin-dependent kinase 4A) expression has been shown to correlate with keratinocyte clonal evolution. Thus, the aim of our study is to understand whether p16(INK4a) accumulation is a triggering mechanism of epidermal clonal evolution or a secondary event. We show that inactivation of p16(INK4a), by an antisense strategy, allows primary human keratinocytes to escape replicative senescence. Specifically, p16(INK4a) inactivation alone blocks clonal evolution and maintains keratinocytes in the stem cell compartment. Antisense excision is followed by keratinocyte senescence, confirming that persistent p16(INK4a) inactivation is required for maintenance of clonal evolution block. Immortalization is accompanied by resumption of B-Cell Specific Moloney murine leukemia virus site 1 (Bmi-1) expression and telomerase activity, hallmarks of tissue regenerative capacity. In turn, Bmi-1 expression is necessary to maintain the impairment of clonal evolution induced by p16(INK4a) inactivation. Finally, p16(INK4a) down-regulation in transient amplifying keratinocytes does not affect clonal evolution, and cells undergo senescence. Thus, p16(INK4a) inactivation appears to selectively prevent clonal conversion in cells endowed with a high proliferative potential. These data indicate that p16(INK4a) regulates keratinocyte clonal evolution and that inactivation of p16(INK4a) in epidermal stem cells is necessary for maintaining stemness.	IDI, Lab Tissue Engn & Cutaneous Physiopathol, IRCCS, I-00040 Pomezia, Roma, Italy; IDI, Lab Mol & Cell Biol, IRCCS, I-00040 Pomezia, Roma, Italy; Dept Med, Div Canc Biol, Evanston, IL USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Dellambra, E (corresponding author), IDI, Lab Tissue Engn & Cutaneous Physiopathol, IRCCS, Via Castelli Romani 83-85, I-00040 Pomezia, Roma, Italy.	e.dellambra@idi.it	Dellambra, Elena/A-4005-2014; Guerra, Liliana/G-8849-2016; Maurelli, Riccardo/AAA-7723-2020; Zambruno, Giavanna/K-2933-2018; Abbruzzese, Claudia/U-7576-2017; Dimri, Goberdhan/AAO-4210-2021; GELLINI, MARA/D-7954-2016	Dellambra, Elena/0000-0002-4329-3312; Abbruzzese, Claudia/0000-0003-3301-9421; GELLINI, MARA/0000-0002-6243-7836; Guerra, Liliana/0000-0001-6274-6607; Zambruno, Giovanna/0000-0002-1295-056X				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Barrandon Y., 1993, SEMIN DEV BIOL, V4, P209, DOI [DOI 10.1006/SEDB.1993.1025, 10.1006/sedb.1993.1025]; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Berghella L, 1999, HUM GENE THER, V10, P1607, DOI 10.1089/10430349950017617; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; Bickenbach JR, 1998, J INVEST DERMATOL, V111, P1045, DOI 10.1046/j.1523-1747.1998.00420.x; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; Bond JA, 1999, MOL CELL BIOL, V19, P3103; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Campisi J, 1998, J Investig Dermatol Symp Proc, V3, P1; Claudinot S, 2005, P NATL ACAD SCI USA, V102, P14677, DOI 10.1073/pnas.0507250102; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Dimri GP, 2002, CANCER RES, V62, P4736; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Harada H, 2003, MOL CANCER RES, V1, P729; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; JONES P, 1996, CELL, V73, P713; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Munro J, 1999, CANCER RES, V59, P2516; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pellegrini G, 2004, EUR J CELL BIOL, V83, P691, DOI 10.1078/0171-9335-00424; QUELLE DE, 1995, CELL, V83, P993; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel RR, 2001, J CLIN INVEST, V108, P665, DOI 10.1172/JCI200113818; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; ROOP DR, 1988, CANCER RES, V48, P3245; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Saito M, 2004, INT J ONCOL, V24, P1213; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2	67	42	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1516	+		10.1096/fj.05-4480fje	http://dx.doi.org/10.1096/fj.05-4480fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754749				2022-12-25	WOS:000240266000036
J	Salatino, M; Beguelin, W; Peters, MG; Carnevale, R; Proietti, CJ; D Galigniana, M; Vedoy, CG; Schillaci, R; Charreau, EH; Sogayar, MC; Elizalde, PV				Salatino, M.; Beguelin, W.; Peters, M. G.; Carnevale, R.; Proietti, C. J.; D Galigniana, M.; Vedoy, C. G.; Schillaci, R.; Charreau, E. H.; Sogayar, M. C.; Elizalde, P. V.			Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation	ONCOGENE			English	Article						caveolin-1; breast cancer; progesterone receptor	ACTIVATED PROTEIN-KINASE; ONCOGENICALLY TRANSFORMED-CELLS; MOUSE MAMMARY ADENOCARCINOMAS; INSENSITIVE PROSTATE-CANCER; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; MEDROXYPROGESTERONE ACETATE	Progestin regulation of gene expression was assessed in the progestin- dependent murine tumor line C4HD which requires MPA, a synthetic progestin, for in vivo growth and expresses high levels of progesterone receptor ( PR). By using suppressive subtractive hybridization, caveolin-1 was identified as a gene whose expression was increased with in vivo MPA treatment. By Northern and Western blot analysis, we further confirmed that caveolin-1 mRNA and protein expression increased in MPA- treated tumors as compared with untreated tumors. When primary cultures of C4H D cells were treated in vitro with MPA, caveolin-1 levels also increased, effect that was abolished by pre-treatment with progestin antagonist RU486. In addition, MPA promoted strong caveolin-1 promoter transcriptional activation both in mouse and human breast cancer cells. We also showed that MPA regulation of caveolin-1 expression involved in activation of two signaling pathways: MAPK and PI-3K. Short- term MPA treatment of C4HD cells led to tyrosine phosphorylation of caveolin-1 protein, where Src was the kinase involved. Additionally, we showed that MPA- induced association of caveolin- 1 and PR, which was detected by communoprecipitation and by confocal microscopy. Finally, we proved that MPA- induced proliferation of C4HD cells was inhibited by suppression ofcaveol in- 1 expression with antisense oligodeoxynucleotides to caveolin1 mRNA. Furthermore, we observed that inhibition of caveolin- 1 expression abrogated PR capacity to induced luciferase activity from a progesterone response elementdriven reporter plasmid. Comprehensively, our results demonstrated for the. rst time that caveolin- 1 expression is upregulated by progestin in breast cancer. We also demonstrated that caveolin- 1 is a downstream effector of MPA that is partially responsible for the stimulation of growth ofbreast cancer cells.	Consejo Nacl Invest Cient & Tecn, Lab Mol Mechanisms Carcinogenesis, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Inst Leloir, RA-1033 Buenos Aires, DF, Argentina; Univ Sao Paulo, Inst Quim, Sao Paulo, Brazil	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Universidade de Sao Paulo	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mechanisms Carcinogenesis, Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	elizalde@dna.uba.ar	Sogayar, Mari C/B-3980-2017	Sogayar, Mari C/0000-0003-4805-4609; Elizalde, Patricia V./0000-0002-5923-9898; GALIGNIANA, MARIO/0000-0002-9130-8574; Peters, Maria/0000-0002-9271-4590				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Galbiati F, 2001, TRENDS MOL MED, V7, P435, DOI 10.1016/S1471-4914(01)02105-0; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Hayashi K, 2001, CANCER RES, V61, P2361; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Kiss AL, 2005, MOL CELL ENDOCRINOL, V245, P128, DOI 10.1016/j.mce.2005.11.005; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KORDON E, 1990, BREAST CANCER RES TR, V17, P33, DOI 10.1007/BF01812682; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Li SW, 1996, J BIOL CHEM, V271, P3863; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lydon JP, 2000, J MAMMARY GLAND BIOL, V5, P325, DOI 10.1023/A:1009555013246; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Montecchia MF, 1999, J STEROID BIOCHEM, V68, P11, DOI 10.1016/S0960-0760(98)00166-6; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Proietti C, 2005, MOL CELL BIOL, V25, P4826, DOI 10.1128/MCB.25.12.4826-4840.2005; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Salatino M, 2004, ONCOGENE, V23, P5161, DOI 10.1038/sj.onc.1207659; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tahir SA, 2001, CANCER RES, V61, P3882; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Timme TL, 2003, CURR DRUG TARGETS, V4, P251, DOI 10.2174/1389450033491127; Trouet D, 1999, J PHYSIOL-LONDON, V520, P113, DOI 10.1111/j.1469-7793.1999.t01-1-00113.x; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Watson CS, 2003, EXP BIOL MED, V228, P1272, DOI 10.1177/153537020322801106; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; Williams TM, 2005, J BIOL CHEM, V280, P25134, DOI 10.1074/jbc.M501186200; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang G, 2000, CLIN CANCER RES, V6, P3430	66	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7723	7739		10.1038/sj.onc.1209757	http://dx.doi.org/10.1038/sj.onc.1209757			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799639				2022-12-25	WOS:000242830800007
J	Burks, J; Agazie, YM				Burks, J.; Agazie, Y. M.			Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3	ONCOGENE			English	Article						FGFR3; SHP2; alpha catenin; transformation; adhesion; migration	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE PHOSPHATASES; E-CADHERIN; KINASE ACTIVATION; SKELETAL DYSPLASIA; INSULIN-RECEPTOR; BETA-CATENIN; P120 CATENIN; SH2 DOMAINS; MAP KINASE	The Src homology 2 phosphotyrosyl phosphatase (SHP2) is a nonreceptor-type phosphatase that acts as a positive transducer of receptor Tyr kinase (RTK) signaling, particularly the Ras-REK and PI3K-Akt pathways. Recently, we have demonstrated that SHP2 is required for cell transformation induced by the constitutively active fibroblast growth factor receptor 3 (K/E-FR3) (Oncogene, 22, 6909 -6918). In that study, we had detected a phosphotyrosyl protein of similar to 100 KDa (p100) in cells expressing dominant-negative SHP2 (R/ E-SHP2), but its identity and relevance in SHP2-meditaed transformation was not known. Here, we report the identification of p100 as alpha-catenin, a vinculin-related protein involved in adherens junction-mediated intercellular adhesion. We show that a-catenin becomes Tyr phosphorylated in intercellular adhesion-dependent manner and this event is counteracted by SHP2. Substrate trapping in intact cells and immunocomplex phosphatse assays confirmed that a-catenin is in deed an SHP2 substrate. Tyr phosphorylation of alpha-catenin enhances its translocation to the plasma membrane and its interaction with beta-catenin, leading to enhanced actin polymerization and stabilization of adherens junction-mediated intercellular adhesion, a phenomenon commensurate with loss of the transformation phenotype. Site-directed mutagenesis studies also suggested that Tyr phosphorylation of a-catenin enhances its inhibitory role on cell transformation. Based on our previous work and the current report, we demonstrate that mediation of cell transformation by SHP2 is a complex process that involves modulation of the Ras-ERK and PI3K-Akt signaling pathways, intercellular adhesion, focal adhesion and actin cytoskeletal reorganization. To our knowledge, this is the first report showing regulation of a-catenin function by Tyr phosphorylation and its inhibitory effect on cell transformation.	W Virginia Univ, Dept Mol Pharmacol & Biochem, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Agazie, YM (corresponding author), W Virginia Univ, Dept Mol Pharmacol & Biochem, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu	Ladoux, Benoit/A-9879-2013					Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Abutaily AS, 2003, J PATHOL, V201, P355, DOI 10.1002/path.1458; Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; MORTON RA, 1993, CANCER RES, V53, P3585; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ozawa M, 2001, J CELL SCI, V114, P503; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Seki N, 2002, ARTERIOSCL THROM VAS, V22, P1081, DOI 10.1161/01.ATV.0000022878.37277.EC; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X	59	28	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7166	7179		10.1038/sj.onc.1209728	http://dx.doi.org/10.1038/sj.onc.1209728			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16767162				2022-12-25	WOS:000242046900006
J	Martel, V; Filhol, O; Colas, P; Cochet, C				Martel, V.; Filhol, O.; Colas, P.; Cochet, C.			p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2	ONCOGENE			English	Article						CK2 beta subunit; peptidic inhibitors; IE2 protein; p53 activation; cell apoptosis	HETEROGENEOUS RIBONUCLEOPROTEIN-K; BETA-SUBUNIT; ALPHA-SUBUNIT; DNA-DAMAGE; INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; CK2-BETA SUBUNIT; P53; EXPRESSION; BINDING	Based on the perturbation of its expression in human cancers and on its involvement in transformation and tumorigenesis, protein kinase CK2 has recently attracted attention as a potential therapeutic target. To assess the value of CK2 as a target for antiproliferative strategies, we have initiated a program aiming to develop inhibitors targeting specifically the regulatory CK2 beta subunit. Here, we use a two-hybrid approach to isolate from combinatorial libraries, peptide aptamers that specifically interact with CK2b. One of these (P1), which has significant sequence homology to the cytomegalovirus IE2 protein, binds with high affinity to the N-terminal domain of CK2b without disrupting the formation of the CK2 holoenzyme. Expression of green fluorescent protein (GFP)-P1 in different mammalian cell lines activates p53 phosphorylation on serine 15, induces an upregulation of p21 and the release of the Cyt-C and apoptosis-inducing factor proapoptotic proteins triggering caspase-dependent and caspase-independent apoptosis. GFP-P1-induced apoptosis is associated with a p53-dependent pathwayas cell death was abrogated in p53 knocked out cells. In summary, our data show that genetically selected peptide aptamers that specifically target CK2b can induce apoptosis in mammalian cells through the recruitment of a p53-dependent apoptosis pathway. They also emphasize the critical role of CK2b for cell survival and might allow the design of novel proapoptotic agents targeting this protein.	CEA, INSERM EMI0104, Dept Reponse & Dynam Cellulaire, F-38054 Grenoble, France; Aptanomics SA, Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cochet, C (corresponding author), CEA, INSERM EMI0104, Dept Reponse & Dynam Cellulaire, 17 Rue Martyrs, F-38054 Grenoble, France.	ccochet1@cea.fr	Martel-Frachet, Veronique/B-8657-2014; Filhol-Cochet, Odile/I-3962-2016; Frachet, Véronique/B-8418-2018	Frachet, Véronique/0000-0001-6739-7901; Filhol, Odile/0000-0003-1964-7958; Colas, Pierre/0000-0001-7436-3718; Cochet, Claude/0000-0002-1772-4270				Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Andreau K, 2004, J BIOL CHEM, V279, P55937, DOI 10.1074/jbc.M406411200; Bibby AC, 2005, INT J BIOL SCI, V1, P67; Bjorling-Poulsen M, 2005, ONCOGENE, V24, P6194, DOI 10.1038/sj.onc.1208762; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Chiou SH, 2001, J IMMUNOL, V167, P4098, DOI 10.4049/jimmunol.167.7.4098; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Colman-Lerner A, 2001, CELL, V107, P739, DOI 10.1016/S0092-8674(01)00596-7; Dagher MC, 1997, BIOTECHNIQUES, V22, P916, DOI 10.2144/97225st05; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Geyer CR, 2000, METHOD ENZYMOL, V328, P171, DOI 10.1016/S0076-6879(00)28398-5; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Grein S, 1999, MOL CELL BIOCHEM, V191, P105, DOI 10.1023/A:1006814428582; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Leroy D, 1999, MOL CELL BIOCHEM, V191, P43, DOI 10.1023/A:1006832312169; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Maizel A, 2002, DEVELOPMENT, V129, P3545; Martel V, 2002, ANN NY ACAD SCI, V973, P272, DOI 10.1111/j.1749-6632.2002.tb04648.x; MESSERLE M, 1991, J VIROL, V65, P1638, DOI 10.1128/JVI.65.3.1638-1643.1991; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Shimada K, 2004, MICROBIOL IMMUNOL, V48, P205, DOI 10.1111/j.1348-0421.2004.tb03507.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Wiebusch L, 2001, EMBO J, V20, P1086, DOI 10.1093/emboj/20.5.1086; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	60	20	21	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7343	7353		10.1038/sj.onc.1209722	http://dx.doi.org/10.1038/sj.onc.1209722			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751801				2022-12-25	WOS:000242419100003
J	MirAfzali, Z; Leipprandt, JR; McCracken, JL; DeWitt, DL				MirAfzali, Zahra; Leipprandt, Jeffrey R.; McCracken, John L.; DeWitt, David L.			Topography of the prostaglandin endoperoxide H-2 synthase-2 in membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-STRUCTURE; H SYNTHASES-1; C2 DOMAIN; SPIN; SITE; DYNAMICS; CYCLOOXYGENASES; ASSOCIATION; ORIENTATION	The topology of association of the monotopic protein cyclooxygenase-2 (COX-2) with membranes has been examined using EPR spectroscopy of spin-labeled recombinant human COX-2. Twenty-four mutants, each containing a single free cysteine substituted for an amino acid in the COX-2 membrane binding domain were expressed using the baculovirus system and purified, then conjugated with a nitroxide spin label and reconstituted into liposomes. Determining the relative accessibility of the nitroxide-tagged amino acid side chains for the solubilized COX-2 mutants, or COX-2 reconstituted into liposomes to nonpolar (oxygen) and polar (NiEDDA or CrOx) paramagnetic reagents allowed us to map the topology of COX-2 interaction with the lipid bilayer. When spin-labeled COX-2 was reconstituted into liposomes, EPR power saturation curves showed that side chains for all but two of the 24 mutants tested had limited accessibility to both polar and nonpolar paramagnetic relaxation agents, indicating that COX-2 associates primarily with the interfacial membrane region near the glycerol backbone and phospholipid head groups. Two amino acids, Phe(66) and Leu(67), were readily accessible to the non-polar relaxation agent oxygen, and thus likely inserted into the hydrophobic core of the lipid bilayer. However these residues are co-linear with amino acids in the interfacial region, so their extension into the hydrophobic core must be relatively shallow. EPR and structural data suggest that membrane interaction of COX-2 is also aided by partitioning of 4 aromatic amino acids, Phe(59), Phe(66), Tyr(76), and Phe(84) to the interfacial region, and by the electrostatic interactions of two basic amino acids, Arg(62) and Lys(64), with the phospholipid head groups.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Encapsula NanoSci, Nashville, TN 37203 USA	Michigan State University; Michigan State University	DeWitt, DL (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 519 Biochem Bldg, E Lansing, MI 48824 USA.	dewittd@msu.edu						ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Clayton AHA, 1999, EUR BIOPHYS J BIOPHY, V28, P133, DOI 10.1007/s002490050192; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; HUBBELL WL, 1994, MEMBRANE PROTEIN STR, P00224; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; KENNEDY TA, 1994, J BIOL CHEM, V269, P27357; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; MirAfzali Z, 2005, ARCH BIOCHEM BIOPHYS, V443, P60, DOI 10.1016/j.abb.2005.08.014; Otto JC, 1996, J BIOL CHEM, V271, P9906, DOI 10.1074/jbc.271.17.9906; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	23	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28354	28364		10.1074/jbc.M605206200	http://dx.doi.org/10.1074/jbc.M605206200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16809339	hybrid			2022-12-25	WOS:000240534400073
J	Ma, K; Forbes, JG; Gutierrez-Cruz, G; Wang, K				Ma, Kan; Forbes, Jeffrey G.; Gutierrez-Cruz, Gustavo; Wang, Kuan			Titin as a giant scaffold for integrating stress and Src homology domain 3-mediated signaling pathways - The clustering of novel overlap ligand motifs in the elastic PEVK segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TITIN; POLYPROLINE-II HELIX; SH3 DOMAIN; BINDING-SPECIFICITY; PEPTIDE RECOGNITION; MOLECULAR-DYNAMICS; AFFINITY PROFILES; KINASE DOMAIN; TERMINAL SH3; IN-VITRO	The richness of proline sequences in titins qualifies these giant proteins as the largest source of intrinsically disordered structures in nature. An extensive search and analysis for Src homology domain 3 (SH3) ligand motifs revealed a myriad of broadly distributed SH3 ligand motifs, with the highest density in the PEVK segments of human titin. Besides the canonical class I and II motifs with opposite orientations, novel overlapping motifs consisting of one or more of each canonical motif are abundant. Experimentally, the binding affinity and critical residues of these putative titin-based SH3 ligands toward nebulin SH3 and other SH3-containing proteins in muscle and non-muscle cell extracts were validated with peptide array technology and by the sarcomere distribution of SH3-containing proteins. A 28-mer overlapping motif-containing PEVK module binds to nebulin SH3 in and around the canonical cleft, especially to the acidic residues in the loops, as revealed by NMR titration. Molecular dynamics and molecular docking studies indicated that the overlapping motif can bind in opposite orientations with comparable energy and contact areas and predicts correctly orientation-specific contacts in NMR data. We propose that the overlap ligand motifs are a new class of ligands with innate ability to dictate SH3 domain orientation and to facilitate the rate, strength, and stereospecificity of receptor interactions. Proline-rich sequences of titins are candidates as major hubs of SH3- dependent signaling pathways. The interplay of elasticity and dense clustering of mixed receptor orientations in titin PEVK segment have important implications for the mechanical sensing, force sensitivity, and inter-adapter interactions in signaling pathways.	NIAMS, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Wang, K (corresponding author), NIAMS, Muscle Proteom & Nanotechnol Sect, Muscle Biol Lab, NIH, Bldg 50,Rm 1140, Bethesda, MD 20892 USA.	wangk@exchange.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041118, Z01AR041119, ZIAAR041118] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adhikari BB, 2001, FEBS LETT, V497, P95, DOI 10.1016/S0014-5793(01)02444-9; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Bullard B, 2004, J BIOL CHEM, V279, P7917, DOI 10.1074/jbc.M307473200; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fernandez-Ballester G, 2004, J MOL BIOL, V335, P619, DOI 10.1016/j.jmb.2003.10.060; Flaherty DB, 2002, J MOL BIOL, V323, P533, DOI 10.1016/S0022-2836(02)00970-1; Forbes JG, 2005, J MUSCLE RES CELL M, V26, P291, DOI 10.1007/s10974-005-9035-4; GAUTEL M, 1993, EMBO J, V12, P3827, DOI 10.1002/j.1460-2075.1993.tb06061.x; Granzier HL, 2005, ADV PROTEIN CHEM, V71, P89, DOI 10.1016/S0065-3233(04)71003-7; Greaser M, 2001, PROTEINS, V43, P145, DOI 10.1002/1097-0134(20010501)43:2<145::AID-PROT1026>3.0.CO;2-B; Gutierrez-Cruz G, 2001, J BIOL CHEM, V276, P7442, DOI 10.1074/jbc.M008851200; Ho BK, 2005, PROTEIN SCI, V14, P1011, DOI 10.1110/ps.041156905; Hoshijima M, 2006, AM J PHYSIOL-HEART C, V290, pH1313, DOI 10.1152/ajpheart.00816.2005; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kim K, 2002, J CELL BIOL, V156, P101, DOI 10.1083/jcb.200107037; Kontrogianni-Konstantopoulos A, 2004, AM J PHYSIOL-CELL PH, V287, pC209, DOI 10.1152/ajpcell.00497.2003; Kramer A, 1998, METH MOL B, V87, P25; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; Lange S, 2005, SCIENCE, V308, P1599, DOI 10.1126/science.1110463; Leake MC, 2004, BIOPHYS J, V87, P1112, DOI 10.1529/biophysj.103.033571; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Linke WA, 2002, J STRUCT BIOL, V137, P194, DOI 10.1006/jsbi.2002.4468; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Ma K, 2003, BIOCHEM J, V374, P687, DOI 10.1042/BJ20030702; Ma K, 2002, FEBS LETT, V532, P273, DOI 10.1016/S0014-5793(02)03655-4; Ma K, 2001, BIOCHEMISTRY-US, V40, P3427, DOI 10.1021/bi0022792; Mayer BJ, 2001, J CELL SCI, V114, P1253; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nagy A, 2005, BIOPHYS J, V89, P329, DOI 10.1529/biophysj.104.057737; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Nicholas G, 2002, J CELL PHYSIOL, V193, P120, DOI 10.1002/jcp.10158; Pires JR, 2003, J MOL BIOL, V326, P1427, DOI 10.1016/S0022-2836(03)00039-1; Politou AS, 2002, J MOL BIOL, V316, P305, DOI 10.1006/jmbi.2001.5312; Politou AS, 1998, J MOL BIOL, V276, P189, DOI 10.1006/jmbi.1997.1521; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SOMERVILLE LL, 1988, ARCH BIOCHEM BIOPHYS, V262, P118, DOI 10.1016/0003-9861(88)90174-9; Tskhovrebova L, 2003, NAT REV MOL CELL BIO, V4, P679, DOI 10.1038/nrm1198; Wang K, 1996, J BIOL CHEM, V271, P4304; Wang K, 1985, Cell Muscle Motil, V6, P315; Wang K, 2001, PROG BIOPHYS MOL BIO, V77, P1, DOI 10.1016/S0079-6107(01)00009-8; Watanabe K, 2002, J BIOL CHEM, V277, P11549, DOI 10.1074/jbc.M200356200; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zastrow MS, 2006, J CELL SCI, V119, P239, DOI 10.1242/jcs.02728	61	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					27539	27556		10.1074/jbc.M604525200	http://dx.doi.org/10.1074/jbc.M604525200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16766517	hybrid			2022-12-25	WOS:000240397700080
J	Li, LL; Heldin, CH; Heldin, P				Li, Lingli; Heldin, Carl-Henrik; Heldin, Paraskevi			Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL-MIGRATION; INTEGRIN; ADHESION; PHOSPHORYLATION; TRANSMEMBRANE; MECHANISMS; MESENCHYME; EXPRESSION; INCREASES	The extracellular matrix molecule hyaluronan was found to suppress platelet-derived growth factor (PDGF) beta-receptor activation and PDGF-BB-induced migration of primary human dermal fibroblasts. The suppressive effect of hyaluronan was neutralized by a monoclonal antibody that specifically inhibits hyaluronan binding to its receptor CD44. Moreover, co-immunoprecipitation experiments showed that the PDGF beta-receptor and CD44 can form a complex. Interestingly, the inhibitory effect of hyaluronan on PDGF beta-receptor activation was not seen in the presence of the tyrosine phosphatase inhibitor pervanadate. Our observations suggest that hyaluronan suppresses PDGF beta-receptor activation by recruiting a CD44-associated tyrosine phosphatase to the receptor.	Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, S-75123 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University	Heldin, P (corresponding author), Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden.	Paraskevi.Heldin@imbim.uu.se						Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cichy J, 2004, FEBS LETT, V556, P69, DOI 10.1016/S0014-5793(03)01370-X; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Greiling D, 1997, J CELL SCI, V110, P861; Hamada Jun-Ichi, 1998, Frontiers in Bioscience, V3, pD657; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Heldin P, 1996, ONCOL REP, V3, P1011; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Knudson W., 1998, FRONT BIOSCI, V3, P604; Kubens BS, 1997, CANCER LETT, V118, P189, DOI 10.1016/S0304-3835(97)00330-3; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Persson C, 2004, MOL CELL BIOL, V24, P2190, DOI 10.1128/MCB.24.5.2190-2201.2004; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; SARAS J, 1994, J BIOL CHEM, V269, P24082; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shenoi H, 1999, J IMMUNOL, V162, P7120; Sherman L, 1998, GENE DEV, V12, P1058, DOI 10.1101/gad.12.7.1058; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; TEDER P, 1995, CANCER RES, V55, P3908; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Wobus M, 2002, APPL IMMUNOHISTO M M, V10, P34, DOI 10.1097/00022744-200203000-00006; Woodard AS, 1998, J CELL SCI, V111, P469; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622	41	66	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26512	26519		10.1074/jbc.M605607200	http://dx.doi.org/10.1074/jbc.M605607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809345	hybrid			2022-12-25	WOS:000240249500069
J	Reynolds, KA; Thomson, JM; Corbett, KD; Bethel, CR; Berger, JM; Kirsch, JF; Bonomo, RA; Handel, TM				Reynolds, Kimberly A.; Thomson, Jodi M.; Corbett, Kevin D.; Bethel, Christopher R.; Berger, James M.; Kirsch, Jack F.; Bonomo, Robert A.; Handel, Tracy M.			Structural and computational characterization of the SHV-1 beta-lactamase-beta- lactamase inhibitor protein interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-AFFINITY; ENERGY FUNCTIONS; DESIGN; BACKBONE; RESIDUES; TEM-1; SPECIFICITY; REFINEMENT; RESISTANCE; COMPLEX	beta-Lactamase inhibitor protein (BLIP) binds a variety of class A beta-lactamases with affinities ranging from micromolar to picomolar. Whereas the TEM-1 and SHV-1 beta-lactamases are almost structurally identical, BLIP binds TEM-1 similar to 1000-fold tighter than SHV-1. Determining the underlying source of this affinity difference is important for understanding the molecular basis of beta-lactamase inhibition and mechanisms of protein-protein interface specificity and affinity. Here we present the 1.6 angstrom resolution crystal structure of SHV-1(.)BLIP. In addition, a point mutation was identified, SHV D104E, that increases (SHVBLIP)-B-. binding affinity from micromolar to nanomolar. Comparison of the SHV-1(.)BLIP structure with the published TEM-1(.)BLIP structure suggests that the increased volume of Glu-104 stabilizes a key binding loop in the interface. Solution of the 1.8 angstrom SHV D104K(.)BLIP crystal structure identifies a novel conformation in which this binding loop is removed from the interface. Using these structural data, we evaluated the ability of EGAD, a program developed for computational protein design, to calculate changes in the stability of mutant beta-lactamase(.)BLIP complexes. Changes in binding affinity were calculated within an error of 1.6 kcal/ mol of the experimental values for 112 mutations at the TEM-1(.) BLIP interface and within an error of 2.2 kcal/ mol for 24 mutations at the SHV-1(.)BLIP interface. The reasonable success of EGAD in predicting changes in interface stability is a promising step toward understanding the stability of the beta-lactamase(.)BLIP complexes and computationally assisted design of tight binding BLIP variants.	Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Calif Berkeley, Biophys Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Louis Stokes Vet Affaris Med Ctr, Res Serv, Cleveland, OH 44106 USA	University of California System; University of California San Diego; Case Western Reserve University; University of California System; University of California Berkeley; University of California System; University of California Berkeley; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Handel, TM (corresponding author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.	thandel@ucsd.edu		Corbett, Kevin/0000-0001-5854-2388; Reynolds, Kimberly/0000-0003-4805-0317	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, R01GM035393] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI635172] Funding Source: Medline; NIGMS NIH HHS [GM35393, T32 GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; Horn JR, 2004, J MOL BIOL, V336, P1283, DOI 10.1016/j.jmb.2003.12.068; Huang WZ, 2003, PROTEIN ENG, V16, P853, DOI 10.1093/protein/gzg108; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JONES TA, 1997, O MANUAL VERSION 7 0; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; Joughin BA, 2005, PROTEIN SCI, V14, P1363, DOI 10.1110/ps.041283105; KLEYWEGT GJ, 1994, JOINT CCP4 ESF EACBM, V31, P9; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Kuhlman B, 2002, J MOL BIOL, V315, P471, DOI 10.1006/jmbi.2001.5229; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Larson SM, 2002, PROTEIN SCI, V11, P2804, DOI 10.1110/ps.0203902; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Lin S, 1998, BIOCHEM J, V333, P395, DOI 10.1042/bj3330395; MacDowell AA, 2004, J SYNCHROTRON RADIAT, V11, P447, DOI 10.1107/S0909049504024835; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; Offredi F, 2003, J MOL BIOL, V325, P163, DOI 10.1016/S0022-2836(02)01206-8; OTWINOWSKI Z, 1997, METHOD ENZYMOL, V276, P472, DOI DOI 10.1016/S0076-6879(97)76073-7; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Pokala N, 2005, J MOL BIOL, V347, P203, DOI 10.1016/j.jmb.2004.12.019; Pokala N, 2004, PROTEIN SCI, V13, P925, DOI 10.1110/ps.03486104; Reichmann D, 2005, P NATL ACAD SCI USA, V102, P57, DOI 10.1073/pnas.0407280102; Rice LB, 2000, ANTIMICROB AGENTS CH, V44, P362, DOI 10.1128/AAC.44.2.362-367.2000; Rudgers GW, 1999, J BIOL CHEM, V274, P6963, DOI 10.1074/jbc.274.11.6963; Rudgers GW, 2001, PROTEIN ENG, V14, P487, DOI 10.1093/protein/14.7.487; Rudgers GW, 2001, ANTIMICROB AGENTS CH, V45, P3279, DOI 10.1128/AAC.45.12.3279-3286.2001; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; Sosa-Peinado A, 2000, PROTEIN EXPRES PURIF, V19, P235, DOI 10.1006/prep.2000.1243; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Zhang Z, 2004, J BIOL CHEM, V279, P42860, DOI 10.1074/jbc.M406157200; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200	45	44	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26745	26753		10.1074/jbc.M603878200	http://dx.doi.org/10.1074/jbc.M603878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809340	hybrid			2022-12-25	WOS:000240249500092
J	Li, L; Dworkowski, FSN; Cook, PF				Li, Lei; Dworkowski, Florian S. N.; Cook, Paul F.			Importance in catalysis of the 6-phosphate-binding site of 6-phosphogluconate in sheep liver 6-phosphogluconate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME MECHANISMS; ISOTOPE; SUBSTRATE; COENZYME; BINDING; NADP	The 6-phosphate of 6-phosphogluconate (6PG) is proposed to anchor the sugar phosphate in the active site and aid in orientating the substrate for catalysis. In order to test this hypothesis, alanine mutagenesis was used to probe the contribution of residues in the vicinity of the 6-phosphate to binding of 6PG and catalysis. The crystal structure of sheep liver 6-phosphogluconate dehydrogenase shows that Tyr-191, Lys-260, Thr-262, Arg-287, and Arg-446 contribute a mixture of ionic and hydrogen bonding interactions to the 6-phosphate, and these interactions are likely to provide the majority of the binding energy for 6PG. All mutant enzymes, with the exception of T262A, exhibit an increase in K-6PG that ranges from 5- to 800-fold. There is also a less pronounced increase in KNADP, ranging from 3- to 15-fold, with the exception of T262A. The R287A and R446A mutant enzymes exhibit a dramatic decrease in V/E-t (600- and 300-fold, respectively) as well as in V/K6PGEt(10(5)- and 10(4)- fold), and therefore no further characterization was carried out with these two mutant enzymes. No change in V/E-t was observed for the Y191A mutant enzyme, whereas 20 and 3- fold decreases were obtained for the K260A and T262A mutant enzymes, respectively, resulting in a decrease in V/K6PGEt range from 3- to 120-fold. All mutant enzymes also exhibit at least an order of magnitude increase in C-13-isotope effect -1, indicating that the decarboxylation step has become more rate-limiting. Data are consistent with significant roles for Tyr-191, Lys-260, Thr-262, Arg-287, and Arg-446 in providing the binding energy for 6PG. In addition, these residues also likely ensure proper orientation of 6PG for catalysis and aid in inducing the conformation change that precedes, and sets up the active site for, catalysis.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cook, PF (corresponding author), Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.	pcook@chemdept.chem.ou.edu	Dworkowski, Florian/D-2807-2011; Dworkowski, Florian/H-6017-2019	Dworkowski, Florian/0000-0001-5004-8684; Dworkowski, Florian/0000-0001-5004-8684				ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; BERDIS AJ, 1993, BIOCHEMISTRY-US, V32, P2036, DOI 10.1021/bi00059a021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cervellati C, 2005, BIOCHEMISTRY-US, V44, P2432, DOI 10.1021/bi0476679; Chooback L, 1998, PROTEIN EXPRES PURIF, V13, P251, DOI 10.1006/prep.1998.0896; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1980, BIOCHEMISTRY-US, V19, P4853, DOI 10.1021/bi00562a023; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; HERMES JD, 1982, BIOCHEMISTRY-US, V21, P5106, DOI 10.1021/bi00263a040; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P15698, DOI 10.1021/bi981288w; Hwang CC, 1998, BIOCHEMISTRY-US, V37, P12596, DOI 10.1021/bi980611s; Karsten WE, 1998, BIOCHEMISTRY-US, V37, P15691, DOI 10.1021/bi9812827; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; O'Leary M H, 1980, Methods Enzymol, V64, P83; PARKIN DW, 1991, ENZYME MECH ISOTOPE, P284; Price NE, 1996, ARCH BIOCHEM BIOPHYS, V336, P215, DOI 10.1006/abbi.1996.0551; Tetaud E, 1999, BIOCHEM J, V338, P55, DOI 10.1042/0264-6021:3380055; Weiss PM, 1991, ENZYME MECH ISOTOPE, P291; ZHANG L, 1999, BIOCHEMISTRY-US, V36, P11231	20	13	13	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25568	25576		10.1074/jbc.M601154200	http://dx.doi.org/10.1074/jbc.M601154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803886	hybrid			2022-12-25	WOS:000240031300060
J	Hayashida, K; Johnston, DR; Goldberger, O; Park, PW				Hayashida, Kazutaka; Johnston, Douglas R.; Goldberger, Olga; Park, Pyong Woo			Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; HEPARAN-SULFATE PROTEOGLYCANS; NECROSIS-FACTOR-ALPHA; PSEUDOMONAS-AERUGINOSA; SURFACE PROTEOGLYCAN; FACTOR RECEPTOR; MICE; PHOSPHORYLATION; ACTIVATION; MEMBRANE	Syndecans comprise a major family of cell surface heparan sulfate proteoglycans (HSPGs). Syndecans bind and modulate a wide variety of biological molecules through their heparan sulfate (HS) moiety. Although all syndecans contain the ligand binding HS chains, they likely perform specific functions in vivo because their temporal and spatial expression patterns are different. However, how syndecan expression is regulated has yet to be clearly defined. In this study, we examined how syndecan-1 expression is regulated in epithelial cells. Our results showed that among several bioactive agents tested, only forskolin and three isoforms of TGF beta (TGF beta 1-TGF beta 3) significantly induced syndecan-1, but not syndecan-4, expression on various epithelial cells. Steady-state syndecan-1 mRNA was not increased by TGF beta treatment and cycloheximide did not inhibit syndecan-1 induction by TGF beta, indicating that TGF beta induces syndecan-1 in a post-translational manner. However, TGF beta induction of syndecan-1 was inhibited by transient expression of a dominant-negative construct of protein kinase A (PKA) and by specific inhibitors of PKA. Further (i) syndecan-1 cytoplasmic domains were Ser-phosphorylated when cells were treated with TGF beta and this was inhibited by a PKA inhibitor, (ii) PKA was co-immunoprecipitated from cell lysates by anti-syndecan-1 antibodies, (iii) PKA phosphorylated recombinant syndecan-1 cytoplasmic domains in vitro, and (iv) expression of a syndecan-1 construct with its invariant Ser(286) replaced with a Gly was not induced by TGF beta. Together, these findings define a regulatory mechanism where TGF beta signals through PKA to phosphorylate the syndecan-1 cytoplasmic domain and increases syndecan-1 expression on epithelial cells.	Baylor Coll Med, Sect Infect Dis, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Boston Children's Hospital; Harvard Medical School	Park, PW (corresponding author), Baylor Coll Med, Sect Infect Dis, Dept Med, 1 Baylor Plaza,Rm N1319, Houston, TX 77030 USA.	pwpark@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073725, R01HL069050] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL069050, R01 HL073725, HL69050, HL73725] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Asundi VK, 1997, BIOCHEM BIOPH RES CO, V240, P502, DOI 10.1006/bbrc.1997.7684; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouchard JF, 2004, J NEUROSCI, V24, P3040, DOI 10.1523/JNEUROSCI.4934-03.2004; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; Carey DJ, 1997, BIOCHEM J, V327, P1; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Granes F, 2000, J CELL SCI, V113, P1267; Haynes A, 2005, INFECT IMMUN, V73, P7914, DOI 10.1128/IAI.73.12.7914-7921.2005; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; Kaksonen M, 2002, MOL CELL NEUROSCI, V21, P158, DOI 10.1006/mcne.2002.1167; Katsura T, 1997, Am J Physiol, V272, pF817; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Massague J, 2000, GENE DEV, V14, P627; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Murakami M, 2002, J BIOL CHEM, V277, P20367, DOI 10.1074/jbc.M202501200; Oh ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P67, DOI 10.1006/abbi.1997.0180; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; Salazar G, 2002, MOL BIOL CELL, V13, P1677, DOI 10.1091/mbc.01-08-0403; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; Varela LM, 1996, ENDOCRINOLOGY, V137, P4915, DOI 10.1210/en.137.11.4915; Wang LW, 1998, J BIOL CHEM, V273, P8522, DOI 10.1074/jbc.273.14.8522; Xu J, 2005, J IMMUNOL, V174, P5758, DOI 10.4049/jimmunol.174.9.5758; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941; Zhang LZ, 2004, MOL CELL BIOL, V24, P2169, DOI 10.1128/MCB.24.5.2169-2180.2004	54	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24365	24374		10.1074/jbc.M509320200	http://dx.doi.org/10.1074/jbc.M509320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807246	hybrid			2022-12-25	WOS:000239847800029
J	Finlin, BS; Correll, RN; Pang, CY; Crump, SM; Satin, J; Andres, DA				Finlin, Brian S.; Correll, Robert N.; Pang, Chunyan; Crump, Shawn M.; Satin, Jonathan; Andres, Douglas A.			Analysis of the complex between Ca2+ channel beta-subunit and the Rem GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RGK FAMILY; PROTEIN; BINDING; RAD; CALMODULIN; EXPRESSION; GEM; MEMBER; PHOSPHORYLATION; MODULATION	Voltage-gated calcium channels are multiprotein complexes that regulate calcium influx and are important contributors to cardiac excitability and contractility. The auxiliary beta-subunit (CaVB) binds a conserved domain (the alpha-interaction domain (AID)) of the pore-forming Ca-V alpha(1) subunit to modulate channel gating properties and promote cell surface trafficking. Recently, members of the RGK family of small GTPases (Rem, Rem2, Rad, Gem/Kir) have been identified as novel contributors to the regulation of L-type calcium channel activity. Here, we describe the Rem-association domain within Ca-V beta(2a). The Rem interaction module is located in a similar to 130-residue region within the highly conserved guanylate kinase domain that also directs AID binding. Importantly, Ca-V beta mutants were identified that lost the ability to bind AID but retained their association with Rem, indicating that the AID and Rem association sites of Ca-V beta(2a) are structurally distinct. In vitro binding studies indicate that the affinity of Rem for Ca-V beta(2a) interaction is lower than that of AID for Ca-V beta(2a). Furthermore, in vitro binding studies indicate that Rem association does not inhibit the interaction of Ca-V beta(2a) with AID. Instead, CaV beta can simultaneously associate with both Rem and Ca-V alpha(1)-AID. Previous studies had suggested that RGK proteins may regulate Ca2+ channel activity by blocking the association of Ca-V beta subunits with Ca-V alpha(1) to inhibit plasma membrane trafficking. However, surface biotinylation studies in HIT-T15 cells indicate that Rem can acutely modulate channel function without decreasing the density of L-type channels at the plasma membrane. Together these data suggest that Rem-dependent Ca2+ channel modulation involves formation of a Rem(.)Ca(V)beta(.)AID regulatory complex without the need to disrupt Ca-V alpha Ca-.(1)V beta association or alter Ca-V alpha(1) expression at the plasma membrane.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, BBSRB Rm R-179,741 S Limestone St, Lexington, KY 40536 USA.	dandres@pop.uky.edu			NCRR NIH HHS [P20 RR20171] Funding Source: Medline; NHLBI NIH HHS [HL072936, R01 HL072936, HL074091, R01 HL072936-04] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072936, R01HL074091, R56HL074091] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; Balijepalli RC, 2004, CIRC RES, V95, P337, DOI 10.1161/01.RES.0000141018.33292.21; Beguin P, 2005, BIOCHEM J, V390, P67, DOI 10.1042/BJ20050414; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Cohen RM, 2005, AM J PHYSIOL-HEART C, V288, pH2363, DOI 10.1152/ajpheart.00348.2004; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; CRUMP SM, 2006, IN PRESS AM J PHYSL; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Harry JB, 2004, J BIOL CHEM, V279, P46367, DOI 10.1074/jbc.M409523200; Hibino H, 2003, P NATL ACAD SCI USA, V100, P307, DOI 10.1073/pnas.0136791100; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richards MW, 2004, TRENDS PHARMACOL SCI, V25, P626, DOI 10.1016/j.tips.2004.10.008; ROUSSET M, 2005, SCI STKE, pPE11; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; Takahashi SX, 2004, P NATL ACAD SCI USA, V101, P7193, DOI 10.1073/pnas.0306665101; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; Yanuar A, 2005, ACTA CRYSTALLOGR F, V61, P978, DOI 10.1107/S1744309105031982	41	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23557	23566		10.1074/jbc.M604867200	http://dx.doi.org/10.1074/jbc.M604867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790445	hybrid			2022-12-25	WOS:000239702900030
J	Schilling, B; Gafni, J; Torcassi, C; Cong, X; Row, RH; LaFevre-Bernt, MA; Cusack, MP; Ratovitski, T; Hirschhorn, R; Ross, CA; Gibson, BW; Ellerby, LM				Schilling, Birgit; Gafni, Juliette; Torcassi, Cameron; Cong, Xin; Row, Richard H.; LaFevre-Bernt, Michelle A.; Cusack, Michael P.; Ratovitski, Tamara; Hirschhorn, Ricky; Ross, Christopher A.; Gibson, Bradford W.; Ellerby, Lisa M.			Huntingtin phosphorylation sites mapped by mass spectrometry - Modulation of cleavage and toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; CASPASE CLEAVAGE; PROTEIN-PHOSPHORYLATION; REDUCES TOXICITY; WIDE PREDICTION; DISEASE; IDENTIFICATION; FRAGMENTS; SEQUENCE; DEHYDROGENASE	Huntingtin (Htt) is a large protein of 3144 amino acids, whose function and regulation have not been well defined. Polyglutamine (polyQ) expansion in the N terminus of Htt causes the neurodegenerative disorder Huntington disease (HD). The cytotoxicity of mutant Htt is modulated by proteolytic cleavage with caspases and calpains generating N-terminal polyQ-containing fragments. We hypothesized that phosphorylation of Htt may modulate cleavage and cytotoxicity. In the present study, we have mapped the major phosphorylation sites of Htt using cell culture models (293T and PC12 cells) expressing full-length myc-tagged Htt constructs containing 23Q or 148Q repeats. Purified myc-tagged Htt was subjected to mass spectrometric analysis including matrix-assisted laser desorption/ionization mass spectrometry and nano- HPLC tandem mass spectrometry, used in conjunction with on-target alkaline phosphatase and protease digestions. We have identified more than six novel serine phosphorylation sites within Htt, one of which lies in the proteolytic susceptibility domain. Three of the sites have the consensus sequence for ERK1 phosphorylation, and addition of ERK1 inhibitor blocks phosphorylation at those sites. Other observed phosphorylation sites are possibly substrates for CDK5/CDC2 kinases. Mutation of amino acid Ser536, which is located in the proteolytic susceptibility domain, to aspartic acid, inhibited calpain cleavage and reduced mutant Htt toxicity. The results presented here represent the first detailed mapping of the phosphorylation sites in full-length Htt. Dissection of phosphorylation modifications in Htt may provide clues to Huntington disease pathogenesis and targets for therapeutic development.	Buck Inst Age Res, Novato, CA 94945 USA; Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Psychiat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Hood Coll, Frederick, MD 21701 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco	Ellerby, LM (corresponding author), 8001 Redwood Blvd, Novato, CA 94945 USA.	lellerby@buckinstitute.org	Ross, Christopher A/H-8395-2013		NINDS NIH HHS [NS40251A, F32 NS043937, RL1 NS062413, NS 38144, NS 16375] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251, RL1NS062413, F32NS043937, P50NS016375, R01NS038144, P01NS016375] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aronin N, 1999, PHILOS T ROY SOC B, V354, P995, DOI 10.1098/rstb.1999.0451; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Chang EJ, 2004, ANAL CHEM, V76, P4472, DOI 10.1021/ac049637h; Corthals GL, 2005, METHOD ENZYMOL, V405, P66, DOI 10.1016/S0076-6879(05)05004-4; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hermel E, 2004, CELL DEATH DIFFER, V11, P424, DOI 10.1038/sj.cdd.4401358; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Igarashi S, 2003, NEUROREPORT, V14, P565, DOI 10.1097/00001756-200303240-00007; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Kaytor MD, 2005, HUM MOL GENET, V14, P1095, DOI 10.1093/hmg/ddi122; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Lafevre-Bernt MA, 2003, J BIOL CHEM, V278, P34918, DOI 10.1074/jbc.M302841200; Larsen MR, 2001, PROTEOMICS, V1, P223; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Peters MF, 1999, MOL CELL NEUROSCI, V14, P121, DOI 10.1006/mcne.1999.0773; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rangone H, 2004, EUR J NEUROSCI, V19, P273, DOI 10.1111/j.0953-816X.2003.03131.x; Schilling B, 2006, BBA-MOL BASIS DIS, V1762, P213, DOI 10.1016/j.bbadis.2005.07.003; Schilling B, 2005, MOL CELL PROTEOMICS, V4, P84, DOI 10.1074/mcp.M400143-MCP200; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tanaka Y, 2006, NEUROBIOL DIS, V21, P381, DOI 10.1016/j.nbd.2005.07.014; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	41	98	100	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23686	23697		10.1074/jbc.M513507200	http://dx.doi.org/10.1074/jbc.M513507200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782707	hybrid			2022-12-25	WOS:000239702900044
J	Szatmari, I; Vamosi, G; Brazda, P; Balint, BL; Benko, S; Szeles, L; Jeney, V; Ozvegy-Laczka, C; Szanto, A; Barta, E; Balla, J; Sarkadi, B; Nagy, L				Szatmari, Istvan; Vamosi, Gyoergy; Brazda, Peter; Balint, Balint L.; Benko, Szilvia; Szeles, Lajos; Jeney, Viktoria; Oezvegy-Laczka, Csilla; Szanto, Attila; Barta, Endre; Balla, Jozsef; Balazs Sarkadi; Nagy, Laszlo			Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-RESISTANCE-PROTEIN; PPAR-GAMMA; TRANSPORTER; GENE; EFFLUX; ORGANIZATION; INFLAMMATION; CHOLESTEROL; MACROPHAGES; PROMOTER	ABCG2, a member of the ATP-binding cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells and variably regulated during cell differentiation. Here we demonstrate that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPAR gamma. We identified and characterized a 150-base pair long conserved enhancer region, containing three functional PPAR response elements (PPARE), upstream of the human ABCG2 gene. We confirmed the binding of the PPAR gamma(.) RXR heterodimer to this enhancer region, suggesting that PPAR gamma directly regulates the transcription of ABCG2. Consistent with these results, elevated expression of ABCG2 mRNA was coupled to enhanced protein production, resulting in increased xenobiotic extrusion capacity via ABCG2 in PPAR gamma-activated cells. Furthermore PPAR gamma instructed dendritic cells showed increased Hoechst dye extrusion and resistance to mitoxantrone. Collectively, these results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid-activated transcription factor, PPAR gamma. The increased expression of the promiscuous ABCG2 transporter can significantly modify the xenobiotic and drug resistance of human myeloid dendritic cells.	Hungarian Acad Sci, Dept Biochem & Mol Biol, H-4032 Debrecen, Hungary; Hungarian Acad Sci, Cell Biophys Res Grp, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Immunol, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Internal Med, Res Ctr Mol Med, Med & Hlth Sci Ctr, H-4032 Debrecen, Hungary; Hungarian Acad Sci, Membrane Res Grp, Inst Haematol & Immunol, Natl Med Ctr, H-1113 Budapest, Hungary; Ctr Agr Biotechnol, H-2100 Godollo, Hungary	Hungarian Academy of Sciences; Hungarian Academy of Sciences; University of Debrecen; University of Debrecen; Hungarian Academy of Sciences	Nagy, L (corresponding author), Hungarian Acad Sci, Dept Biochem & Mol Biol, Egyetem Ter 1, H-4032 Debrecen, Hungary.	lnagy@indi.biochem.dote.hu	Széles, Lajos/B-3309-2010; Sarkadi, Balazs/I-5024-2013; Balint, Balint/A-3853-2010; Nagy, Laszlo/A-3814-2008; Jeney, Viktoria/A-6779-2011; Szatmari, Istvan/B-3152-2010; Szanto, Attila/B-2198-2012; Széles, Lajos/B-4165-2012; Barta, Endre/B-1166-2008; Jeney, Viktória/AAF-5355-2019; Vamosi, Gyorgy/C-9351-2009; Laczka, Csilla/AAE-5543-2021	Nagy, Laszlo/0000-0001-6653-2155; Szatmari, Istvan/0000-0001-5260-1498; Barta, Endre/0000-0002-6753-0714; Balla, Jozsef/0000-0001-7923-2645; Vamosi, Gyorgy/0000-0002-7940-2787; Szeles, Lajos/0000-0003-1206-8515; Balint, Balint/0000-0002-6163-7190	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allikmets R, 1998, GENE, V215, P111, DOI 10.1016/S0378-1119(98)00269-8; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Dubsky P, 2005, J CLIN IMMUNOL, V25, P551, DOI 10.1007/s10875-005-8216-7; Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583; GERLIER D, 1986, J IMMUNOL METHODS, V94, P57, DOI 10.1016/0022-1759(86)90215-2; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nencioni A, 2002, J IMMUNOL, V169, P1228, DOI 10.4049/jimmunol.169.3.1228; Niemi M, 2004, CLIN PHARMACOL THER, V76, P239, DOI 10.1016/j.clpt.2004.05.001; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Sarkadi B, 2004, FEBS LETT, V567, P116, DOI 10.1016/j.febslet.2004.03.123; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Szanto A, 2004, MOL CELL BIOL, V24, P8154, DOI 10.1128/MCB.24.18.8154-8166.2004; Szatmari I, 2004, IMMUNITY, V21, P95, DOI 10.1016/j.immuni.2004.06.003; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; ZHOU S, 2004, BLOOD	34	142	149	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23812	23823		10.1074/jbc.M604890200	http://dx.doi.org/10.1074/jbc.M604890200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785230	hybrid			2022-12-25	WOS:000239702900057
J	Takata, K; Shimizu, T; Iwai, S; Wood, RD				Takata, Kei-ichi; Shimizu, Tatsuhiko; Iwai, Shigenori; Wood, Richard D.			Human DNA polymerase N (POLN) is a low fidelity enzyme capable of error-free bypass of 5S-thymine glycol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; HUMAN CELL-EXTRACTS; ESCHERICHIA-COLI; THYMINE GLYCOL; TRANSLESION SYNTHESIS; CROSS-LINK; PURIFIED PROTEINS; HELICASE ACTIVITY; OXIDATIVE DAMAGE; KLENOW FRAGMENT	Human DNA polymerase N (POLN or pol nu) is the most recently discovered nuclear DNA polymerase in the human genome. It is an A-family DNA polymerase related to Escherichia coli pol I, human POLQ, and Drosophila Mus308. We report the first purification of the recombinant enzyme and examination of its biochemical properties, as a step toward understanding the functions of POLN. Unusual for an A-family DNA polymerase, POLN is a low fidelity enzyme incorporating T opposite template G with a frequency of 0.45 and G opposite template T with a frequency of 0.021. The frequency of misincorporation of T opposite template G is higher than any other known DNA polymerase. POLN has a processivity of DNA synthesis (1-100 nucleotides) similar to the exonuclease-deficient Klenow fragment of E. coli pol I, is inhibited by dideoxynucleotides, and resistant to aphidicolin. The strand displacement activity of POLN was higher than exonuclease-deficient Klenow fragment. Furthermore, POLN can perform translesion synthesis past thymine glycol, a common endogenous and radiation-induced product of reactive oxygen species damage to DNA. Thymine glycol blocks DNA synthesis by most DNA polymerases, but POLN was particularly adept at efficient and accurate translesion synthesis past a 5S-thymine glycol.	Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA; Osaka Univ, Grad Sch Engn Sci, Div Chem, Toyonaka, Osaka 5608531, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Osaka University	Wood, RD (corresponding author), Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA.	rdwood@pitt.edu	; Wood, Richard/M-6319-2018	Takata, Kei-ichi/0000-0002-8272-3397; Wood, Richard/0000-0002-9495-6892	NCI NIH HHS [CA101980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn B, 2004, J BIOL CHEM, V279, P53465, DOI 10.1074/jbc.M409624200; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Camps M, 2003, P NATL ACAD SCI USA, V100, P9727, DOI 10.1073/pnas.1333928100; Cannistraro VJ, 2004, J BIOL CHEM, V279, P18288, DOI 10.1074/jbc.M400282200; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Harris PV, 1996, MOL CELL BIOL, V16, P5764; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Iwai S, 2001, CHEM-EUR J, V7, P4343, DOI 10.1002/1521-3765(20011015)7:20<4343::AID-CHEM4343>3.0.CO;2-H; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Katafuchi A, 2004, J BIOL CHEM, V279, P14464, DOI 10.1074/jbc.M400393200; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; McDonald JP, 2003, J EXP MED, V198, P635, DOI 10.1084/jem.20030767; McTigue MM, 2004, DNA REPAIR, V3, P313, DOI 10.1016/j.dnarep.2003.11.009; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Pang M, 2005, DNA REPAIR, V4, P971, DOI 10.1016/j.dnarep.2005.04.020; Parlanti E, 2004, DNA REPAIR, V3, P703, DOI 10.1016/j.dnarep.2003.12.009; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; Seki M, 2005, EMBO REP, V6, P1143, DOI 10.1038/sj.embor.7400582; Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424; Seki M, 2003, NUCLEIC ACIDS RES, V31, P6117, DOI 10.1093/nar/gkg814; Shimizu T, 2006, NUCLEIC ACIDS RES, V34, P313, DOI 10.1093/nar/gkj443; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Tissier A, 2000, GENE DEV, V14, P1642; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Yang GW, 2002, BIOCHEMISTRY-US, V41, P10256, DOI 10.1021/bi0202171	49	131	132	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23445	23455		10.1074/jbc.M604317200	http://dx.doi.org/10.1074/jbc.M604317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16787914	hybrid			2022-12-25	WOS:000239702900019
J	Camozzi, M; Rusnati, M; Bugatti, A; Bottazzi, B; Mantovani, A; Bastone, A; Inforzato, A; Vincenti, S; Bracci, L; Mastroianni, D; Presta, M				Camozzi, Maura; Rusnati, Marco; Bugatti, Antonella; Bottazzi, Barbara; Mantovani, Alberto; Bastone, Antonio; Inforzato, Antonio; Vincenti, Silvia; Bracci, Luisa; Mastroianni, Domenico; Presta, Marco			Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; LONG PENTRAXIN PTX3; C-REACTIVE PROTEIN; T-LYMPHOCYTES; CELLS; RELEASE; MATRIX	Long-pentraxin 3 (PTX3) is a soluble pattern recognition receptor with non-redundant functions in inflammation and innate immunity. PTX3 comprises a pentraxin-like C-terminal domain involved in complement activation via C1q interaction and an N-terminal extension with unknown functions. PTX3 binds fibroblast growth factor-2 (FGF2), inhibiting its pro-angiogenic and pro-restenotic activity. Here, retroviral transduced endothelial cells (ECs) overexpressing the N-terminal fragment PTX3-(1-178) showed reduced mitogenic activity in response to FGF2. Accordingly, purified recombinant PTX3-(1-178) binds FGF2, prevents PTX3/FGF2 interaction, and inhibits FGF2 mitogenic activity in ECs. Also, the monoclonal antibody mAb-MNB4, which recognizes the PTX3-(87-99) epitope, prevents FGF2/PTX3 interaction and abolishes the FGF2 antagonist activity of PTX3. Consistently, the synthetic peptides PTX3-(82-110) and PTX3-(97-110) bind FGF2 and inhibit the interaction of FGF2 with PTX3 immobilized to a BIAcore sensor chip, FGF2-dependent EC proliferation, and angiogenesis in vivo. Thus, the data identify a FGF2-binding domain in the N-terminal extension of PTX3 spanning the PTX3-(97-110) region, pointing to a novel function for the N-terminal extension of PTX3 and underlining the complexity of the PTX3 molecule for modular humoral pattern recognition.	Univ Brescia, Dept Biomed Sci & Biotechnol, Sch Med, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Milan, Inst Gen Pathol, I-20133 Milan, Italy; Ist Clin Humanitas, I-20089 Milan, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Sigma Tau Res Dept, I-0040 Rome, Italy; Univ Siena, Dept Mol Biol, I-53100 Siena, Italy; Tecnogen SCpA, I-81015 Piana Di Monte Verna, Caserta, Italy	University of Brescia; University of Milan; IRCCS Humanitas Research Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Rome Tor Vergata; University of Siena	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Sch Med, Unit Gen Pathol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	presta@med.unibs.it	Rusnati, Marco/F-1168-2010; Inforzato, Antonio/ABG-4513-2020; Inforzato, Antonio/K-6954-2012; Bracci, Luisa/V-9913-2018; Presta, Marco/B-4345-2010; Mantovani, Alberto/HCI-7449-2022; bottazzi, barbara/ABH-9274-2020	Rusnati, Marco/0000-0001-9968-5908; Inforzato, Antonio/0000-0001-8110-0027; Bracci, Luisa/0000-0002-0738-5746; Mantovani, Alberto/0000-0001-5578-236X; bottazzi, barbara/0000-0002-1930-9257; PRESTA, Marco/0000-0002-4398-8376				Basile A, 1997, J BIOL CHEM, V272, P8172, DOI 10.1074/jbc.272.13.8172; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; Camozzi M, 2005, ARTERIOSCL THROM VAS, V25, P1837, DOI 10.1161/01.ATV.0000177807.54959.7d; Frank R, 1996, Methods Mol Biol, V66, P149; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; Knoll A, 1999, MICROVASC RES, V58, P1, DOI 10.1006/mvre.1999.2149; LEE GW, 1993, J IMMUNOL, V150, P1804; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; Mantovani A, 2003, VACCINE, V21, pS43, DOI 10.1016/S0264-410X(03)00199-3; Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Peri G, 2000, CIRCULATION, V102, P636, DOI 10.1161/01.CIR.102.6.636; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; PRESTA M, 1989, J CELL PHYSIOL, V141, P517, DOI 10.1002/jcp.1041410310; Ravizza T, 2001, NEUROSCIENCE, V105, P43, DOI 10.1016/S0306-4522(01)00177-4; REIDY MA, 1992, CIRCULATION, V86, P43; Rolph MS, 2002, ARTERIOSCL THROM VAS, V22, pE10, DOI 10.1161/01.ATV.0000015595.95497.2F; Rusnati M, 2004, BLOOD, V104, P92, DOI 10.1182/blood-2003-10-3433; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4	26	96	99	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22605	22613		10.1074/jbc.M601023200	http://dx.doi.org/10.1074/jbc.M601023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769728	hybrid			2022-12-25	WOS:000239542600021
J	Hsu, JL; Rho, SB; Vannella, KM; Martinis, SA				Hsu, Jennifer L.; Rho, Seung Bae; Vannella, Kevin M.; Martinis, Susan A.			Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CRYSTAL-STRUCTURE; TRNA(LEU); CEREVISIAE; IDENTITY; SELECTION; PROTEINS; SEQUENCE; MATURASE; ELEMENTS	Leucyl-tRNA synthetase (LeuRS) performs dual essential roles in group I intron RNA splicing as well as protein synthesis within the yeast mitochondria. Deletions of the C terminus differentially impact the two functions of the enzyme in splicing and aminoacylation in vivo. Herein, we determined that a five-amino acid C-terminal deletion of LeuRS, which does not complement a null strain, can form a ternary complex with the bI4 intron and its maturase splicing partner. However, the complex fails to stimulate splicing activity. The x-ray co-crystal structure of LeuRS showed that a C-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the LeuRSs and interacts with the corner of the L-shaped tRNA(Leu). Interestingly, deletion of the entire yeast mitochondrial LeuRS C-terminal domain enhanced its aminoacylation and amino acid editing activities. In striking contrast, deletion of the corresponding C-terminal domain of Escherichia coli LeuRS abolished aminoacylation of tRNALeu and also amino acid editing of mischarged tRNA molecules. These results suggest that the role of the leucine-specific C-terminal domain in tRNA recognition for aminoacylation and amino acid editing has adapted differentially and with surprisingly opposite effects. We propose that the secondary role of yeast mitochondrial LeuRS in RNA splicing has impacted the functional evolution of this critical C-terminal domain.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Martinis, SA (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	martinis@life.uiuc.edu		Martinis, Susan/0000-0001-5730-8346	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063107, R01GM063789] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63107, GM63789] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahara H, 1998, J MOL BIOL, V283, P605, DOI 10.1006/jmbi.1998.2111; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; BREITSCHOPF K, 1995, NUCLEIC ACIDS RES, V23, P3633, DOI 10.1093/nar/23.18.3633; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fukunaga R, 2005, J MOL BIOL, V346, P57, DOI 10.1016/j.jmb.2004.11.060; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; Houman F, 2000, P NATL ACAD SCI USA, V97, P13743, DOI 10.1073/pnas.240465597; LABOUESSE M, 1984, EUR J BIOCHEM, V144, P85, DOI 10.1111/j.1432-1033.1984.tb08434.x; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; Larkin DC, 2002, NUCLEIC ACIDS RES, V30, P2103, DOI 10.1093/nar/30.10.2103; Li GY, 1996, MOL GEN GENET, V252, P667, DOI 10.1007/BF02173972; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; LINCECUM TL, 2005, AMINOACYL TRNA SYNTH, P36; Lue SW, 2005, BIOCHEMISTRY-US, V44, P3010, DOI 10.1021/bi047901v; Martinis S A, 1997, Nucleic Acids Symp Ser, V36, P125; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mursinna RS, 2002, J AM CHEM SOC, V124, P7286, DOI 10.1021/ja025879s; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Rho SB, 2000, RNA, V6, P1882, DOI 10.1017/S1355838200001254; Roy H, 2005, J BIOL CHEM, V280, P38186, DOI 10.1074/jbc.M508281200; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Soma A, 1996, J MOL BIOL, V263, P707, DOI 10.1006/jmbi.1996.0610; Tukalo M, 2005, NAT STRUCT MOL BIOL, V12, P923, DOI 10.1038/nsmb986; Zhai YX, 2005, BIOCHEMISTRY-US, V44, P15437, DOI 10.1021/bi0514461; Zheng YG, 2004, NUCLEIC ACIDS RES, V32, P3294, DOI 10.1093/nar/gkh665	35	31	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23075	23082		10.1074/jbc.M601606200	http://dx.doi.org/10.1074/jbc.M601606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774921	hybrid			2022-12-25	WOS:000239542600071
J	Amagasaki, K; Kaneto, H; Heldin, CH; Lennartsson, J				Amagasaki, Kenichi; Kaneto, Hideaki; Heldin, Carl-Henrik; Lennartsson, Johan			c-Jun N-terminal kinase is necessary for platelet-derived growth factor-mediated chemotaxis in primary fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-MIGRATION; SIGNAL-TRANSDUCTION; MAP KINASES; JNK; PROLIFERATION; 3-KINASE; REORGANIZATION; MECHANISMS; PATHWAYS	c-Jun N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase family. It has become clear that JNK does not only have a role in induction of stress responses but also in processes such as cell movement. In this report we demonstrate that JNK activity is necessary for platelet-derived growth factor (PDGF)-BB-induced chemotaxis of primary foreskin fibroblasts and in other cell types. PDGF-BB stimulation was found to lead to activation of JNK with a maximum after 30 min. Inhibition of JNK reduced Ser(178) phosphorylation of the focal adhesion component paxillin. Paxillin phosphorylation at this site has been shown to be involved in the dynamics of focal adhesions and consequently cell migration. Moreover, we observed localization of JNK to the actin-dense membrane ruffles induced by PDGF-BB stimulation both using immunofluorescence staining and green fluorescent protein-tagged JNK. This suggests a role for JNK at the leading edge of the cell compatible with a function in cell migration. Furthermore, we show that phosphatidylinositol 3-kinase (PI3-kinase), which has an established role in PDGF-stimulated cell migration, is necessary for PDGF-induced activation of JNK. In conclusion, JNK is a critical component downstream of PI3-kinase that may be involved in PDGF-stimulated chemotaxis presumably by modulating the integrity of focal adhesions by phosphorylating its components.	Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, SE-75124 Uppsala, Sweden; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut A8, Suita, Osaka 5650871, Japan	Ludwig Institute for Cancer Research; Uppsala University; Osaka University	Lennartsson, J (corresponding author), Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden.	Johan.Lennartsson@LICR.uu.se						Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BETSHOLTZ C, 1989, MOL CHEM NEUROPATHOL, V10, P27, DOI 10.1007/BF02969484; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ioroi T, 2003, J PHARMACOL SCI, V91, P145; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irani C, 2002, AM J PHYSIOL-LUNG C, V282, pL854, DOI 10.1152/ajplung.00291.2001; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; Kam AYF, 2004, J NEUROCHEM, V89, P391, DOI 10.1111/j.1471-4159.2004.02338.x; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kang YJ, 2005, J CELL BIOCHEM, V95, P1135, DOI 10.1002/jcb.20499; Kavurma MM, 2003, J CELL BIOCHEM, V89, P289, DOI 10.1002/jcb.10497; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ronnstrand L, 2001, INT J CANCER, V91, P757, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1136>3.0.CO;2-J; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651	27	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22173	22179		10.1074/jbc.M513307200	http://dx.doi.org/10.1074/jbc.M513307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16760468	hybrid			2022-12-25	WOS:000239387100064
J	Teixeira, PF; Cerca, F; Santos, SD; Saraiva, MJ				Teixeira, Pedro Filipe; Cerca, Filipe; Santos, Sofia D.; Saraiva, Maria Joao			Endoplasmic reticulum stress associated with extracellular aggregates - Evidence from transthyretin deposition in familial amyloid polyneuropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; UP-REGULATION; BIP	The hallmark of familial amyloid polyneuropathy (FAP) is the presence of extracellular deposits of transthyretin (TTR) aggregates and amyloid fibers in several tissues, particularly in the peripheral nervous system. The molecular pathways to neurodegeneration in FAP still remain elusive; activation of nuclear factor kappa B, pro-inflammatory cytokines, oxidative stress, and pro-apoptotic caspase-3 has been demonstrated "in vivo" in clinical samples and in cell culture systems. In this study, we investigated the involvement of endoplasmic reticulum ( ER) stress response in FAP by showing activation of the classical unfolded protein response pathways in tissues not specialized in TTR synthesis but presenting extracellular TTR aggregate and fibril deposition. We also proved cytotoxicity by Ca2+ efflux from the ER in cell cultures incubated with TTR oligomers. Taken together, these studies evidence ER stress associated with a extracellular signal in a misfolding disorder.	IBMC, P-4150 Oporto, Portugal; Univ Porto, ICBAS, P-4099 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Saraiva, MJ (corresponding author), IBMC, P-4150 Oporto, Portugal.	mjsaraiv@ibmc.up.pt	Santos, Sofia/I-7149-2013; Saraiva, Maria João/K-3907-2013; Lima, Marta T/C-7042-2009	Santos, Sofia/0000-0002-8086-3310; Saraiva, Maria João/0000-0002-3360-6899; Cerca, Filipe/0000-0002-8515-2892				Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; ANDRADE C, 1952, BRAIN, V75, P408, DOI 10.1093/brain/75.3.408; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Koike H, 2004, NEUROLOGY, V63, P129, DOI 10.1212/01.WNL.0000132966.36437.12; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Liu CY, 2003, J BIOL CHEM, V278, P17680, DOI 10.1074/jbc.M300418200; Paschen W, 2005, CELL CALCIUM, V38, P409, DOI 10.1016/j.ceca.2005.06.019; PUCHTLER H, 1965, J HISTOCHEM CYTOCHEM, V13, P693, DOI 10.1177/13.8.693; SANTOS SD, 2005, PROGRAM 6709 ABSTRAC; SARAIVA MJ, 1984, J CLIN INVEST, V76, P2171; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shendure J, 2002, GENOME BIOL, V3; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2004, FASEB J, V18, P124, DOI 10.1096/fj.04-2022fje; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1; Wootz H, 2004, BIOCHEM BIOPH RES CO, V322, P281, DOI 10.1016/j.bbrc.2004.07.118	23	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21998	22003		10.1074/jbc.M602302200	http://dx.doi.org/10.1074/jbc.M602302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751191	hybrid			2022-12-25	WOS:000239387100046
J	Wu, HJ; Sun, LY; Zhang, Y; Chen, YP; Shi, B; Li, RF; Wang, Y; Liang, J; Fan, DW; Wu, G; Wang, D; Li, SS; Shang, YF				Wu, Huijian; Sun, Luyang; Zhang, Ying; Chen, Yupeng; Shi, Bin; Li, Ruifang; Wang, Yan; Liang, Jing; Fan, Dongwei; Wu, Ge; Wang, Dan; Li, Shaosi; Shang, Yongfeng			Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; NUCLEAR RECEPTOR; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; BREAST-CANCER; ANDROGEN RECEPTOR; MODIFIER-1 SUMO-1; GENE-REGULATION; PROTEIN; SRC-1	AIB1, a member of the steroid receptor coactivator ( SRC) family that participates in gene transcriptional activation by nuclear receptors and other transcription factors, is required for animal growth and reproductive development and implicated in breast carcinogenesis. The mechanisms underlying the AIB1 pleiotropic functions are not fully understood and neither is the regulation of its activity. Here, we showed that AIB1 was a sumoylated protein and the sumoylation attenuated the transactivation activity of AIB1, which is in contrast to the sumoylation of its paralogs, GRIP1 and SRC-1. The transactivation activity of AIB1 is enhanced by its phosphorylation by several kinases, including mitogen-activated protein kinase. We demonstrated in this report that estrogen treatment led to an increased phosphorylation and decreased sumoylation of AIB1 and that the sumoylation coordinated with phosphorylation in regulating the transcriptional activity of AIB1, providing a mechanism for post-translational modifications in regulating the transcriptional output of AIB1.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Shang, YF (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	yshang@hsc.pku.edu.cn	Chen, Yupeng/T-5275-2019	Chen, Yupeng/0000-0001-8887-9547				Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Glass CK, 2000, GENE DEV, V14, P121; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; ONATE SA, 1995, SCIENCE, V270, P1654; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yin N, 2004, CANCER RES, V64, P5870, DOI 10.1158/0008-5472.CAN-04-0655; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	49	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21848	21856		10.1074/jbc.M603772200	http://dx.doi.org/10.1074/jbc.M603772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16760465	hybrid			2022-12-25	WOS:000239387100031
J	Myllykangas, S; Himberg, J; Bohling, T; Nagy, B; Hollmen, J; Knuutila, S				Myllykangas, S.; Himberg, J.; Bohling, T.; Nagy, B.; Hollmen, J.; Knuutila, S.			DNA copy number amplification profiling of human neoplasms	ONCOGENE			English	Article						cancer; gene amplification; fragile site; bioinformatics; data mining; molecular pathology	ACUTE LYMPHOBLASTIC-LEUKEMIA; DIHYDROFOLATE-REDUCTASE GENE; COMMON FRAGILE SITES; WILD-TYPE P53; MICROARRAY ANALYSIS; BREAST-CANCER; TUMORS; CELLS; CHROMOSOMES; IMBALANCES	DNA copy number amplications activate oncogenes and are hallmarks of nearly all advanced tumors. Amplified genes represent attractive targets for therapy, diagnostics and prognostics. To investigate DNA amplications in different neoplasms, we performed a bibliomics survey using 838 published chromosomal comparative genomic hybridization studies and collected amplification data at chromosome band resolution from more than 4500 cases. Amplification profiles were determined for 73 distinct neoplasms. Neoplasms were clustered according to the amplification profiles, and frequently amplificed chromosomal loci (amplification hot spots) were identified using computational modeling. To investigate the site specificity and mechanisms of gene amplifications, colocalization of amplification hot spots, cancer genes, fragile sites, virus integration sites and gene size cohorts were tested in a statistical framework. Amplification-based clustering demonstrated that cancers with similar etiology, cell-of-origin or topographical location have a tendency to obtain convergent amplification profiles. The identified amplification hot spots were colocalized with the known fragile sites, cancer genes and virus integration sites, but global statistical significance could not be ascertained. Large genes were significantly over-represented on the fragile sites and the reported amplifcation hot spots. These findings indicate that amplifications are selected in the cancer tissue environment according to the qualitative traits and localization of cancer genes.	Univ Helsinki, Haartman Inst, Dept Pathol, FI-00014 Helsinki, Finland; Univ Helsinki, HUSLAB, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Helsinki Univ Technol, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Scmmclwcis Univ, Dept Obstet & Gynecol 1, Budapest, Hungary	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aalto University	Myllykangas, S (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21, FI-00014 Helsinki, Finland.	samuel.myllykangas@helsinki.fi	Nagy, Balint/F-6943-2012					Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; [Anonymous], [No title captured]; Atiye J, 2005, GENE CHROMOSOME CANC, V42, P158, DOI 10.1002/gcc.20120; Bernasconi P, 2005, CANCER GENET CYTOGEN, V162, P146, DOI 10.1016/j.cancergencyto.2005.04.002; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Good P, 2000, PERMUTATION TESTS PR; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; HIMBERG J, 2001, 3 INT WORKSH IND COM, P552; Hyman E, 2002, CANCER RES, V62, P6240; ISCN, 1995, INT SYST HUM CYT NOM; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; Monni O, 1999, LEUKEMIA LYMPHOMA, V34, P45, DOI 10.3109/10428199909083379; Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045; Ozaki T, 2002, INT J CANCER, V102, P355, DOI 10.1002/ijc.10709; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rieker RJ, 2002, INT J CANCER, V99, P68, DOI 10.1002/ijc.10287; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Torchia EC, 2003, CANCER RES, V63, P3464; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Weng WH, 2003, BRIT J CANCER, V89, P720, DOI 10.1038/sj.bjc.6601069; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zatkova A, 2004, GENE CHROMOSOME CANC, V39, P263, DOI 10.1002/gcc.20002	41	81	85	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7324	7332		10.1038/sj.onc.1209717	http://dx.doi.org/10.1038/sj.onc.1209717			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751803				2022-12-25	WOS:000242244700011
J	Zhang, L; D'Costa, J; Kummalue, T; Civin, CI; Friedman, AD				Zhang, L.; D'Costa, J.; Kummalue, T.; Civin, C. I.; Friedman, A. D.			Identification of a region on the outer surface of the CBF beta-SMMHC myeloid oncoprotein assembly competence domain critical for multimerization	ONCOGENE			English	Article						CBF beta-SMMHC; myosin; ACD; proliferation; RUNX1	MYOSIN HEAVY-CHAIN; COILED-COIL ROD; CELL-CYCLE; TRANSCRIPTION FACTOR; GENE CBFB-MYH11; FUSION GENE; LEUKEMIA; BINDING; PROLIFERATION; HEMATOPOIESIS	In the core binding factor (CBF) beta-smooth muscle myosin heavy chain (SMMHC) acute myeloid leukemia (AML) oncoprotein, CBF beta lies N-terminal to the alpha-helical rod domain of SMMHC. Deletion of the SMMHC assembly competence domain (ACD), conserved among skeletal, smooth and nonmuscle myosins, prevents multimerization, inhibition of CBF and inhibition of cell proliferation. To de. ne the amino acids critical for ACD function, three outer surface residues of ACD helices A-D, the subsequent helices E-H or the more N-terminal X or Z helices were now mutated. Variants were assessed for multimerization in low ionic strength in vitro and for nuclear localization as a measure of in vivo multimerization. Mutation of individual helices C-H reduced multimerization, with alteration of the outer surface of helices D or E having the greatest effect. The ability of these SMMHC variants to slow murine myeloid progenitor proliferation largely paralleled their effects on multimerization. Divergence at the boundaries of the ACD may reflect quantitative differences between in vitro and in vivo filament assembly. Each helix mutant retained the ability to bind the mSin3A corepressor. Agents interacting with the outer surface of the CBF beta-SMMHC ACD that prevent multimerization may be effective as novel therapeutics in AML.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Div Immunol & Hematopoiesis, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA098805] Funding Source: NIH RePORTER; NCI NIH HHS [CA070970, CA098805] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON SJ, 1991, J CELL SCI, V99, P823; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; D'Costa J, 2005, LEUKEMIA, V19, P921, DOI 10.1038/sj.leu.2403755; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; FINER MH, 1994, BLOOD, V83, P43; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Hoppe PE, 1996, J CELL BIOL, V135, P371, DOI 10.1083/jcb.135.2.371; Kummalue T, 2002, MOL CELL BIOL, V22, P8278, DOI 10.1128/MCB.22.23.8278-8291.2002; Landrette SF, 2005, BLOOD, V105, P2900, DOI 10.1182/blood-2004-09-3630; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakasawa T, 2005, BIOCHEMISTRY-US, V44, P174, DOI 10.1021/bi048807h; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yang YD, 2002, CANCER RES, V62, P2232; Yoshida N, 2005, MOL CELL BIOL, V25, P1003, DOI 10.1128/MCB.25.3.1003-1012.2005	29	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7289	7296		10.1038/sj.onc.1209725	http://dx.doi.org/10.1038/sj.onc.1209725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16767164				2022-12-25	WOS:000242244700007
J	Crown, SE; Yu, YH; Sweeney, MD; Leary, JA; Handel, TM				Crown, Susan E.; Yu, Yonghao; Sweeney, Matthew D.; Leary, Julie A.; Handel, Tracy M.			Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; ICR MASS-SPECTROMETRY; CHEMOTACTIC PROTEIN-2; INCREASED EXPRESSION; RECEPTOR-BINDING; IN-VIVO; MCP-1; CELLS; PLATELET-FACTOR-4; OLIGOMERIZATION	Despite the wide range of sequence diversity among chemokines, their tertiary structures are remarkably similar. Furthermore, many chemokines form dimers or higher order oligomers, but all characterized oligomeric structures are based primarily on two dimerization motifs represented by CC-chemokine or CXC-chemokine dimer interfaces. These observations raise the possibility that some chemokines could form unique hetero-oligomers using the same oligomerization motifs. Such interactions could modulate the overall signaling response of the receptors, thereby providing a general mechanism for regulating chemokine function. For some chemokines, homo-oligomerization has also been shown to be coupled to glycosaminoglycan (GAG)-binding. However, the effect of GAG binding on chemokine hetero-oligomerization has not yet been demonstrated. In this report, we characterized the heterodimerization of the CCR2 ligands MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (CCL7), MCP-4 (CCL13), and eotaxin (CCL11), as well as the effects of GAG binding, using electrospray ionization Fourier transform ion cyclotron resonance (ESI-FTICR) mass spectrometry. Strong heterodimerization was observed between CCL2 and CCL8 at the expense of homodimer formation. Using NMR, we showed that the heterodimer is predominant in solution and forms a specific CC chemokine-like dimer. By contrast, only moderate heterodimer formation was observed between CCL2(.)CCL13, CCL2(.)CCL11 and CCL8(.)CCL13, and no heterodimerization was observed when any other CCR2 ligand was added to CCL7. To investigate the effect of a highly sulfated GAG on the formation of heterodimers, each chemokine pair was mixed with the heparin pentasaccharide, Arixtra, and assayed by ESI-FTICR mass spectrometry. Although no abundant ions corresponding to the ternary complex, CCL8(.)CCL11(.)Arixtra, were observed upon addition of Arixtra. Heterodimerization between CCL2 and CCL11 was also enhanced in the presence of Arixtra. In summary, these results indicate that some CCR2 ligands can form stable heterodimers in preference to homodimers and that these interactions, like those of homo-oligomers, can be influenced by some GAGs.	Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Mol Cell Biol, Genome Ctr, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Diego	Leary, JA (corresponding author), Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95616 USA.	jaleary@ucdavis.edu; thandel@ucsd.edu			NIAID NIH HHS [R01-AI37113-09] Funding Source: Medline; NIGMS NIH HHS [GM63581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Banisor I, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-7; Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Devalaraja MN, 1999, TRENDS PHARMACOL SCI, V20, P151, DOI 10.1016/S0165-6147(99)01342-5; Dudek AZ, 2003, BLOOD, V101, P4687, DOI 10.1182/blood-2002-08-2363; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fulkerson PC, 2004, J IMMUNOL, V173, P7565, DOI 10.4049/jimmunol.173.12.7565; Garcia G, 2005, CURR ALLERGY ASTHM R, V5, P155, DOI 10.1007/s11882-005-0090-0; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; GRZESIEK S, 1993, J AM CHEM SOC, V115, P4369, DOI 10.1021/ja00063a068; Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Inston NG, 2002, NEPHROL DIAL TRANSPL, V17, P1374, DOI 10.1093/ndt/17.8.1374; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Kawaguchi S, 2002, SPINE, V27, P1511, DOI 10.1097/00007632-200207150-00006; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau EK, 2004, ADV PROTEIN CHEM, V68, P351; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; McCornack MA, 2004, BIOCHEMISTRY-US, V43, P10090, DOI 10.1021/bi049751u; McCornack MA, 2003, J BIOL CHEM, V278, P1946, DOI 10.1074/jbc.M207440200; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Moore UM, 1997, J LEUKOCYTE BIOL, V62, P911, DOI 10.1002/jlb.62.6.911; Nasu K, 2003, FERTIL STERIL, V79, P821, DOI 10.1016/S0015-0282(02)04831-8; Nesmelova IV, 2005, J BIOL CHEM, V280, P4948, DOI 10.1074/jbc.M405364200; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Paoletti S, 2005, BLOOD, V105, P3405, DOI 10.1182/blood-2004-04-1648; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Renninger ML, 2005, EXP DERMATOL, V14, P906, DOI 10.1111/j.1600-0625.2005.00378.x; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Ruotolo BT, 2005, SCIENCE, V310, P1658, DOI 10.1126/science.1120177; Shaw JP, 2004, STRUCTURE, V12, P2081, DOI 10.1016/j.str.2004.08.014; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Struyf S, 1998, J LEUKOCYTE BIOL, V63, P364; Swaminathan GJ, 2003, STRUCTURE, V11, P521, DOI 10.1016/S0969-2126(03)00070-4; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2; VANDAMME J, 1994, J IMMUNOL, V152, P5495; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; von Hundelshausen P, 2005, BLOOD, V105, P924, DOI 10.1182/blood-2004-06-2475; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; Yu YH, 2006, J AM SOC MASS SPECTR, V17, P524, DOI 10.1016/j.jasms.2005.12.008; Yu YH, 2005, J BIOL CHEM, V280, P32200, DOI 10.1074/jbc.M505738200; Yu YH, 2004, J AM SOC MASS SPECTR, V15, P1400, DOI 10.1016/j.jasms.2004.06.002	56	87	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25438	25446		10.1074/jbc.M601518200	http://dx.doi.org/10.1074/jbc.M601518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803905	hybrid			2022-12-25	WOS:000240031300046
J	Leupold, D; Teuchner, K; Ehlert, J; Irrgang, KD; Renger, G; Lokstein, H				Leupold, Dieter; Teuchner, Klaus; Ehlert, Juergen; Irrgang, Klaus-Dieter; Renger, Gernot; Lokstein, Heiko			Stepwise two-photon excited fluorescence from higher excited states of chlorophylls in photosynthetic antenna complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; NONLINEAR POLARIZATION SPECTROSCOPY; PHOTOSYSTEM-II; CRYSTAL-STRUCTURE; ENERGY-TRANSFER; HIGHER-PLANTS; GREEN PLANTS; PROTEIN; CP29; ARCHITECTURE	Stepwise two-photon excited fluorescence (TPEF) spectra of the photosynthetic antenna complexes PCP, CP47, CP29, and light-harvesting complex II (LHCII) were measured. TPEF emitted from higher excited states of chlorophyll (Chl) a and b was elicited via consecutive absorption of two photons in the Chl a/b Q(y) range induced by tunable 100-fs laser pulses. Global analyses of the TPEF line shapes with a model function for monomeric Chl a in a proteinaceous environment allow distinction between contributions from monomeric Chls a and b, strongly excitonically coupled Chls a, and Chl a/b heterodimers/-oligomers. The analyses indicate that the longest wavelength-absorbing Chl species in the Qy region of LHC II is a Chl a homodimer with additional contributions from adjacent Chl b. Likewise, in CP47 a spectral form at similar to 680nm (that is, however, not the red-most species) is also due to strongly coupled Chls a. In contrast to LHC II, the red-most Chl subband of CP29 is due to a monomeric Chl a. The two Chls b in CP29 exhibit marked differences: a Chl b absorbing at similar to 650 nm is not excitonically coupled to other Chls. Based on this finding, the refractive index of its microenvironment can be determined to be 1.48. The second Chl b in CP29 (absorbing at similar to 640 nm) is strongly coupled to Chl a. Implications of the findings with respect to excitation energy transfer pathways and rates are discussed. Moreover, the results will be related to most recent structural analyses.	Univ Potsdam, Inst Biochem & Biol Pflanzenphysiol, D-14476 Golm, Germany; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; Max Born Inst Nichtlineare Opt & Kurzzeitspektros, D-12489 Berlin, Germany; Gesell Forderung Angew Opt Optoelekt Quantenelekt, D-12489 Berlin, Germany; Univ Potsdam, Inst Phys Photon, D-14415 Potsdam, Germany	University of Potsdam; Technical University of Berlin; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy; University of Potsdam	Lokstein, H (corresponding author), Univ Potsdam, Inst Biochem & Biol Pflanzenphysiol, Karl Liebknecht Str 24-25,Haus 20, D-14476 Golm, Germany.	lokstein@uni-potsdam.de	Lokstein, Heiko/H-7702-2013; Lokstein, Heiko/AAK-1930-2021; Lokstein, Heiko/P-2788-2019	Lokstein, Heiko/0000-0001-6739-4612; Lokstein, Heiko/0000-0001-6739-4612				Cinque G, 2000, BIOPHYS J, V79, P1706, DOI 10.1016/S0006-3495(00)76423-X; Croce R, 2003, BIOPHYS J, V84, P2508, DOI 10.1016/S0006-3495(03)75056-5; de Weerd FL, 2002, BIOPHYS J, V82, P1586, DOI 10.1016/S0006-3495(02)75510-0; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Eichwurzel I, 2000, PHOTOCHEM PHOTOBIOL, V72, P204, DOI 10.1562/0031-8655(2000)072<0204:PCOCBA>2.0.CO;2; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gradinaru CC, 1998, BIOCHEMISTRY-US, V37, P1143, DOI 10.1021/bi9722655; Gruszecki WI, 1999, BBA-BIOENERGETICS, V1412, P173, DOI 10.1016/S0005-2728(99)00055-9; Hofmann E, 1996, SCIENCE, V272, P1788, DOI 10.1126/science.272.5269.1788; Huyer J, 2004, J PHYS CHEM B, V108, P3326, DOI 10.1021/jp030944l; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Knox RS, 2002, J PHYS CHEM B, V106, P5289, DOI 10.1021/jp013927+; Krikunova M, 2002, BBA-BIOENERGETICS, V1556, P1, DOI 10.1016/S0005-2728(02)00326-2; Leupold D, 1996, PHYS REV LETT, V77, P4675, DOI 10.1103/PhysRevLett.77.4675; Leupold D, 2002, BIOPHYS J, V82, P1580, DOI 10.1016/S0006-3495(02)75509-4; LEUPOLD D, 1990, CHEM PHYS LETT, V170, P478, DOI 10.1016/S0009-2614(90)87088-9; Leupold D, 2000, FEBS LETT, V480, P73, DOI 10.1016/S0014-5793(00)01892-5; Leupold Dieter, 2006, V25, P413; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loll B, 2005, PHOTOSYNTH RES, V86, P175, DOI 10.1007/s11120-005-4117-0; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; Pieper J, 2000, PHOTOCHEM PHOTOBIOL, V71, P574, DOI 10.1562/0031-8655(2000)071<0574:AOTLQY>2.0.CO;2; Rogl H, 2002, BIOCHEMISTRY-US, V41, P2281, DOI 10.1021/bi015875k; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; Schubert A, 2002, BIOPHYS J, V82, P1030, DOI 10.1016/S0006-3495(02)75462-3; Sharples FP, 1996, BBA-BIOENERGETICS, V1276, P117, DOI 10.1016/0005-2728(96)00066-7; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Teuchner K, 2000, J FLUORESC, V10, P275, DOI 10.1023/A:1009453228102; Voigt B, 2002, BIOCHEMISTRY-US, V41, P3049, DOI 10.1021/bi0155854; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	31	8	8	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25381	25387		10.1074/jbc.M600080200	http://dx.doi.org/10.1074/jbc.M600080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16799157	hybrid			2022-12-25	WOS:000240031300040
J	Steger, HK; Root, MJ				Steger, H. Kirby; Root, Michael J.			Kinetic dependence to HIV-1 entry inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; POTENT INHIBITORS; MEMBRANE-FUSION; NONNEUTRALIZING ANTIBODIES; SYNTHETIC PEPTIDE; ATOMIC-STRUCTURE; 6-HELIX BUNDLE; HELICAL DOMAIN; COILED-COIL	Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41 trimer-of-hairpins. A designed protein, 5-Helix, targets the C-terminal region of the gp41 ectodomain, disrupting trimer-of-hairpins formation and blocking viral entry. Here we show that the nanomolar inhibitory potency of 5-Helix (IC50 similar to 6 nM) is 4 orders of magnitude larger than its subpicomolar binding affinity (K-D similar to 0.6 pm). This discrepancy results from the transient exposure of the 5-Helix binding site on gp41. As a consequence, inhibitory potency is determined by the association rate, not by binding affinity. For a series of 5-Helix variants with mutations in their gp41 binding sites, the IC50 and KD values poorly correlate. By contrast, an inverse relationship between IC50 values and association rate constants (kon) extends for over 2 orders of magnitude. The kinetic dependence to inhibition places temporal restrictions on an intermediate state of HIV-1 membrane fusion and suggests that access to the C-terminal region of the gp41 ectodomain is largely free from steric hindrance. Our results support the importance of association kinetics in the development of improved HIV-1 fusion inhibitors.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Root, MJ (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, 233 S 10th St,Rm 802, Philadelphia, PA 19107 USA.	mroot@mail.jci.tju.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066682] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066682, R01 GM66682] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahamyan LG, 2005, J VIROL, V79, P106, DOI 10.1128/JVI.79.1.106-115.2005; Bianchi E, 2005, P NATL ACAD SCI USA, V102, P12903, DOI 10.1073/pnas.0502449102; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Hamburger AE, 2005, J BIOL CHEM, V280, P12567, DOI 10.1074/jbc.M412770200; Herrera C, 2003, J VIROL, V77, P1084, DOI 10.1128/JVI.77.2.1084-1091.2003; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004; Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1; Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Root MJ, 2004, CURR PHARM DESIGN, V10, P1805, DOI 10.2174/1381612043384448; Root MJ, 2003, P NATL ACAD SCI USA, V100, P5016, DOI 10.1073/pnas.0936926100; Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024; Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	41	62	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25813	25821		10.1074/jbc.M601457200	http://dx.doi.org/10.1074/jbc.M601457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803885	hybrid			2022-12-25	WOS:000240031300083
J	Wang, LF; Rhodes, CJ; Lawrence, JC				Wang, Lifu; Rhodes, Christopher J.; Lawrence, John C., Jr.			Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; REPRESSOR PHAS-I; P70 S6 KINASE; PROTEIN-KINASE; MESSENGER-RNA; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; DEPENDENT PHOSPHORYLATION; TRANSLATIONAL REGULATOR; INDEPENDENT PATHWAY	Insulin stimulates protein synthesis by promoting phosphorylation of the eIF4E-binding protein, 4EBP1. This effect is rapamycin-sensitive and mediated by mammalian target of rapamycin ( mTOR) complex 1 ( mTORC1), a signaling complex containing mTOR, raptor, and mLST8. Here we demonstrate that insulin produces a stable increase in the kinase activity of mTORC1 in 3T3-L1 adipocytes. The response was associated with a marked increase in 4EBP1 binding to raptor in mTORC1, and it was abolished by disrupting the TOR signaling motif in 4EBP1. The stimulatory effects of insulin on both 4EBP1 kinase activity and binding occurred rapidly and at physiological concentrations of insulin, and both effects required an intact mTORC1. Results of experiments involving size exclusion chromatography and coimmunoprecipitation of epitope-tagged subunits provide evidence that the major insulin-responsive form is dimeric mTORC1, a structure containing two heterotrimers of mTOR, raptor, and mLST8.	Univ Virginia, Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Washington, Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Virginia; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lawrence, JC (corresponding author), Univ Virginia, Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu	wang, lifu/E-1436-2012		NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK052753] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Harris Thurl E, 2003, Sci STKE, V2003, pre15; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball SR, 2006, J NUTR, V136, p227S, DOI 10.1093/jn/136.1.227S; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979	51	92	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24293	24303		10.1074/jbc.M603566200	http://dx.doi.org/10.1074/jbc.M603566200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798736	hybrid			2022-12-25	WOS:000239847800022
J	Ayrapetov, MK; Wang, YH; Lin, XF; Gu, XF; Parang, K; Sun, GQ				Ayrapetov, Marina K.; Wang, Yue-Hao; Lin, Xiaofeng; Gu, Xianfeng; Parang, Keykavous; Sun, Gongqin			Conformational basis for SH2-Tyr(P)(527) binding in Src inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE HCK; CRYSTAL-STRUCTURE; C-SRC; SUBSTRATE-SPECIFICITY; STRUCTURAL BASIS; SH3 DOMAIN; PROTEIN; CSK; ACTIVATION; PHOSPHORYLATION	Src protein-tyrosine kinase contains a myristoylation motif, a unique region, an Src homology (SH) 3 domain, an SH2 domain, a catalytic domain, and a C-terminal tail. The C-terminal tail contains a Tyr residue, Tyr(527). Phosphorylation of Tyr(527) triggers Src inactivation, caused by Tyr(P)(527) binding to the SH2 domain. In this study, we demonstrated that a conformational contribution, not affinity, is the predominant force for the intramolecular SH2-Tyr(P)(527) binding, and we characterized the structural basis for this conformational contribution. First, a phosphopeptide mimicking the C-terminal tail is an 80-fold weaker ligand than the optimal phosphopeptide, pYEEI, and similar to a phosphopeptide containing three Ala residues following Tyr( P) in binding to the Src SH2 domain. Second, the SH2-Tyr(P)(527) binding is largely independent of the amino acid sequence surrounding Tyr(P)(527), and only slightly decreased by an inactivating mutation in the SH2 domain. Furthermore, even the unphosphorylated C-terminal tail with the sequence of YEEI suppresses Src activity by binding to the SH2 domain. These experiments demonstrate that very weak affinity is sufficient for the SH2-Tyr(P)(527) binding in Src inactivation. Third, the effective intramolecular SH2-Tyr(P)(527) binding is attributed to a conformational contribution that requires residues Trp(260) and Leu(255). Although the SH3 domain is essential for Src inactivation by Tyr(P)(527), it does not contribute to the SH2-Tyr(P)(527) binding. These findings suggest a conformation-based Src inactivation model, which provides a unifying framework for understanding Src activation by a variety of mechanisms.	Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA; Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA	University of Rhode Island; University of Rhode Island	Sun, GQ (corresponding author), Univ Rhode Isl, Dept Cell & Mol Biol, 117 Morrill Sci Bldg,45 Lower Coll Rd, Kingston, RI 02881 USA.	gsun@uri.edu	Parang, Keykavous/F-9236-2010; Parang, Keykavous/ABC-1584-2021	Parang, Keykavous/0000-0001-8600-0893	NATIONAL CANCER INSTITUTE [R01CA111687] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA111687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Ayrapetov MK, 2005, J BIOL CHEM, V280, P25780, DOI 10.1074/jbc.M504022200; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lee SS, 2006, J BIOL CHEM, V281, P8183, DOI 10.1074/jbc.M508120200; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Levin Victor A, 2004, Cancer Treat Res, V119, P89; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; OKADA M, 1991, J BIOL CHEM, V266, P24249; Parang K, 2004, CURR OPIN DRUG DISC, V7, P617; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Wang DX, 2002, J BIOL CHEM, V277, P40428, DOI 10.1074/jbc.M206467200; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P606, DOI 10.1016/j.bbrc.2006.05.180; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23776	23784		10.1074/jbc.M604219200	http://dx.doi.org/10.1074/jbc.M604219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790421	hybrid			2022-12-25	WOS:000239702900053
J	Okada, SF; Nicholas, RA; Kreda, SM; Lazarowski, ER; Boucher, RC				Okada, Seiko F.; Nicholas, Robert A.; Kreda, Silvia M.; Lazarowski, Eduardo R.; Boucher, Richard C.			Physiological regulation of ATP release at the apical surface of human airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL-VOLUME REGULATION; CYSTIC-FIBROSIS AIRWAYS; EXTRACELLULAR ATP; INTRACELLULAR CALCIUM; PERICILIARY LIQUID; ANION CHANNELS; RECEPTOR; CFTR; CONTRIBUTES	Extracellular ATP and its metabolite adenosine regulate mucociliary clearance in airway epithelia. Little has been known, however, regarding the actual ATP and adenosine concentrations in the thin (similar to 7 mu m) liquid layer lining native airway surfaces and the link between ATP release/metabolism and autocrine/paracrine regulation of epithelial function. In this study, chimeric Staphylococcus aureus protein A-luciferase (SPA-luc) was bound to endogenous antigens on primary human bronchial epithelial (HBE) cell surface and ATP concentrations assessed in real-time in the thin airway surface liquid (ASL). ATP concentrations on resting cells were 1-10 nM. Inhibition of ectonucleotidases resulted in ATP accumulation at a rate of similar to 250 fmol/min/cm(2), reflecting the basal ATP release rate. Following hypotonic challenge to promote cell swelling, cell-surface ATP concentration measured by SPA-luc transiently reached similar to 1 mu M independent of ASL volume, reflecting a transient 3-log increase in ATP release rates. In contrast, peak ATP concentrations measured in bulk ASL by soluble luciferase inversely correlated with volume. ATP release rates were intracellular calcium-independent, suggesting that non-exocytotic ATP release from ciliated cells, which dominate our cultures, mediated hypotonicity-induced nucleotide release. However, the cystic fibrosis transmembrane conductance regulator (CFTR) did not participate in this function. Following the acute swelling phase, HBE cells exhibited regulatory volume decrease which was impaired by apyrase and facilitated by ATP or UTP. Our data provide the first evidence that ATP concentrations at the airway epithelial surface reach the range for P2Y(2) receptor activation by physiological stimuli and identify a role for mucosal ATP release in airway epithelial cell volume regulation.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Okada, SF (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.	seiko_okada@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076303, R01HL071131, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071131, P01 HL034322-21A10012, R01 HL076303, P01 HL034322, R01 HL076303-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bahima L, 2006, J CELL PHYSIOL, V206, P95, DOI 10.1002/jcp.20440; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bell PD, 2003, P NATL ACAD SCI USA, V100, P4322, DOI 10.1073/pnas.0736323100; Boudreault F, 2004, J PHYSIOL-LONDON, V561, P499, DOI 10.1113/jphysiol.2004.072306; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; Cobb BR, 2002, AM J PHYSIOL-LUNG C, V282, pL12, DOI 10.1152/ajplung.2002.282.1.L12; DAVIS CW, 1992, AM J PHYSIOL, V262, pC1313, DOI 10.1152/ajpcell.1992.262.5.C1313; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Dezaki K, 2000, JPN J PHYSIOL, V50, P235, DOI 10.2170/jjphysiol.50.235; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; Dutta AK, 2004, J PHYSIOL-LONDON, V559, P799, DOI 10.1113/jphysiol.2004.069245; FLEISCHER B, 1981, ARCH BIOCHEM BIOPHYS, V212, P602, DOI 10.1016/0003-9861(81)90403-3; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; Furstenau CR, 2004, CHEM-BIOL INTERACT, V148, P93, DOI 10.1016/j.cbi.2004.04.003; Gatof D, 2004, AM J PHYSIOL-GASTR L, V286, pG538, DOI 10.1152/ajpgi.00355.2003; GEARY CA, 1995, AM J PHYSIOL-LUNG C, V268, pL1021, DOI 10.1152/ajplung.1995.268.6.L1021; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; HAYASHI S, 2004, SCI STKE, P114; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 1998, PFLUG ARCH EUR J PHY, V437, P31, DOI 10.1007/s004240050742; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; Hermoso M, 2004, J BIOL CHEM, V279, P17681, DOI 10.1074/jbc.M304506200; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Joseph SM, 2004, BRIT J PHARMACOL, V142, P1002, DOI 10.1038/sj.bjp.0705865; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Le KT, 1998, J NEUROSCI, V18, P7152; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; Liang LH, 2005, AM J PHYSIOL-CELL PH, V289, pC388, DOI 10.1152/ajpcell.00491.2004; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; May C, 2006, BIOCHEM PHARMACOL, V71, P1497, DOI 10.1016/j.bcp.2006.02.003; Okada SF, 2004, J GEN PHYSIOL, V124, P513, DOI 10.1085/jgp.200409154; Okada Y, 2004, CELL BIOCHEM BIOPHYS, V41, P233, DOI 10.1385/CBB:41:2:233; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Picher M, 2004, J BIOL CHEM, V279, P20234, DOI 10.1074/jbc.M400305200; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; PICHER M, 2005, PEDIAT PULMON S, V28, P274; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; Reigada D, 2005, AM J PHYSIOL-CELL PH, V288, pC132, DOI 10.1152/ajpcell.00201.2004; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Rich PB, 2003, J TRAUMA, V55, P290, DOI 10.1097/01.TA.0000078882.11919.AF; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Sabirov RZ, 2006, J BIOL CHEM, V281, P1897, DOI 10.1074/jbc.M509482200; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Schneider SW, 1999, P NATL ACAD SCI USA, V96, P12180, DOI 10.1073/pnas.96.21.12180; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Stojilkovic SS, 2005, TRENDS ENDOCRIN MET, V16, P81, DOI 10.1016/j.tem.2005.02.002; Sugita M, 1998, EMBO J, V17, P898, DOI 10.1093/emboj/17.4.898; Tarran R, 2005, J BIOL CHEM, V280, P35751, DOI 10.1074/jbc.M505832200; Townsend-Nicholson A, 1999, MOL BRAIN RES, V64, P246, DOI 10.1016/S0169-328X(98)00328-3; van der Wijk T, 1999, BIOCHEM J, V343, P579, DOI 10.1042/0264-6021:3430579; van der Wijk T, 2003, J BIOL CHEM, V278, P40020, DOI 10.1074/jbc.M307603200; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002; Zsembery A, 2004, J BIOL CHEM, V279, P10720, DOI 10.1074/jbc.M313391200; Zsembery A, 2003, J BIOL CHEM, V278, P13398, DOI 10.1074/jbc.M212277200; ZUO P, 2004, 4 INT S NUCL NUCL JU	72	159	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22992	23002		10.1074/jbc.M603019200	http://dx.doi.org/10.1074/jbc.M603019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754672	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000239542600061
J	Uchimura, Y; Ichimura, T; Uwada, J; Tachibana, T; Sugahara, S; Nakao, M; Saitoh, H				Uchimura, Yasuhiro; Ichimura, Takaya; Uwada, Junsuke; Tachibana, Taro; Sugahara, Satoko; Nakao, Mitsuyoshi; Saitoh, Hisato			Involvement of SUMO modification in MBD1- and MCAF1-mediated heterochromatin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN MBD1; E3 LIGASE ACTIVITY; TRANSCRIPTIONAL REPRESSION; DNA METHYLATION; UBIQUITIN; CHROMATIN; INTERACTS; LYSINE-9; COMPLEX; FAMILY	Small ubiquitin-related modifiers, SUMO-2/3 and SUMO-1, are involved in gene regulation and nuclear structures. However, little is known about the roles of SUMO, in heterochromatin formation of mammalian cells. Here we demonstrate that SUMOs directly interact with human MCAF1, which forms complexes with either the methyl-CpG-binding protein MBD1 or SETDB1, which trimethylates histone H3 at lysine 9 (H3-K9) in the presence of MCAF1. Modification of MBD1 with either SUMO-2/3 or SUMO-1 facilitated the interaction between MBD1 and MCAF1, suggesting that SUMOylation links the methylation of DNA and histones. In a cultured human cell line, SUMOs were localized in MBD1- and MCAF1-containing heterochromatin regions that were enriched in trimethyl-H3-K9 and the heterochromatin proteins HP1 beta and HP1 gamma. Specific knockdown of either SUMO-2/3 or SUMO-1 induced dissociation of MCAF1, trimethyl-H3-K9, and the HP1 proteins from the MBD1-containing heterochromatin foci, suggesting a requirement for SUMOs for heterochromatin assembly. These findings provide insights into the roles of SUMOylation in the regulation of heterochromatin formation and gene silencing.	Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan; Osaka City Univ, Grad Sch Engn, Dept Bioengn, Osaka 5588585, Japan	Kumamoto University; Osaka Metropolitan University	Saitoh, H (corresponding author), Kumamoto Univ, Grad Sch Sci & Technol, 2-39-1 Kurokami, Kumamoto 8608555, Japan.	hisa@gpo.kumamoto-u.ac.jp	Uwada, Junsuke/ABB-2131-2021	Uwada, Junsuke/0000-0002-6123-9061				Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; De Graeve F, 2000, ONCOGENE, V19, P1807, DOI 10.1038/sj.onc.1203492; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Ichimura T, 2005, J BIOL CHEM, V280, P13928, DOI 10.1074/jbc.M413654200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kawata H, 2003, BIOCHEM J, V373, P747, DOI 10.1042/BJ20030171; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Potts PR, 2005, MOL CELL BIOL, V25, P7021, DOI 10.1128/MCB.25.16.7021-7032.2005; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Reese BE, 2003, MOL CELL BIOL, V23, P3226, DOI 10.1128/MCB.23.9.3226-3236.2003; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sakaguchi N, 2003, HYBRIDOMA HYBRIDOM, V22, P397, DOI 10.1089/153685903771797110; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	37	75	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23180	23190		10.1074/jbc.M602280200	http://dx.doi.org/10.1074/jbc.M602280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757475	hybrid			2022-12-25	WOS:000239542600081
J	De Jesus, ML; Stope, MB; Weernink, PAO; Mahlke, Y; Borgermann, C; Ananaba, VN; Rimmbach, C; Rosskopf, D; Michel, MC; Jakobs, KH; Schmidt, M				De Jesus, Maider Lopez; Stope, Matthias B.; Weernink, Paschal A. Oude; Mahlke, Yvonne; Boergermann, Christof; Ananaba, Viktoria N.; Rimmbach, Christian; Rosskopf, Dieter; Michel, Martin C.; Jakobs, Karl H.; Schmidt, Martina			Cyclic AMP-dependent and Epac-mediated activation of R-ras by G protein-coupled receptors leads to phospholipase D stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; INTEGRIN ACTIVATION; ADP-RIBOSYLATION; C-EPSILON; RAP1; CAMP; FAMILY; IDENTIFICATION; CALCIUM; KINASES	The activation of the Ras-related GTPase R-Ras, which has been implicated in the regulation of various cellular functions, by G protein-coupled receptors (GPCRs) was studied in HEK293 cells stably expressing the M-3 muscarinic acetylcholine receptor ( mAChR), which can couple to several types of heterotrimeric G proteins. Activation of the receptor induced a very rapid and transient activation of R-Ras. Studies with inhibitors and activators of various signaling pathways indicated that R-Ras activation by the M-3 mAChR is dependent on cyclic AMP formation but is independent of protein kinase A. Similar to the rather promiscuous M-3 mAChR, two typical G(s)-coupled receptors also induced R-Ras activation. The receptor actions were mimicked by an Epac-specific cyclic AMP analog and suppressed by depletion of endogenous Epac1 by small interfering RNAs, as well as expression of a cyclic AMP binding-deficient Epac1 mutant, but not by expression of dominant negative Rap GTPases. In vitro studies demonstrated that Epac1 directly interacts with R-Ras and catalyzes GDP/GTP exchange at this GTPase. Finally, it is shown that the cyclic AMP- and Epac-activated R-Ras plays a major role in the M-3 mAChR-mediated stimulation of phospholipase D but not phospholipase C. Collectively, our data indicate that GPCRs rapidly activate R-Ras, that R-Ras activation by the GPCRs is apparently directly induced by cyclic AMP- regulated Epac proteins, and that activated R-Ras specifically controls GPCR-mediated phospholipase D stimulation.	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany; Univ Amsterdam, Dept Pharmacol & Pharmacotherapy, NL-1105 AZ Amsterdam, Netherlands	University of Duisburg Essen; University of Amsterdam	Schmidt, M (corresponding author), Univ Groningen, Dept Mol Pharmacol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	m.schmidt@rug.nl	Lopez De Jesus, Maider/F-2478-2016; Schmidt, Martina/C-5339-2018	Lopez De Jesus, Maider/0000-0002-5938-3590; Schmidt, Martina/0000-0003-3075-0630				Ada-Nguema AS, 2006, J CELL SCI, V119, P1307, DOI 10.1242/jcs.02835; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Holly SP, 2005, MOL BIOL CELL, V16, P2458, DOI 10.1091/mbc.E03-12-0917; Jeong HW, 2005, CANCER RES, V65, P507; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Keiper M, 2004, J BIOL CHEM, V279, P46497, DOI 10.1074/jbc.M403604200; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Komatsu M, 2005, NAT MED, V11, P1346, DOI 10.1038/nm1324; Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080; Koopman WJH, 2003, J BIOL CHEM, V278, P13672, DOI 10.1074/jbc.M211256200; Li Y, 2006, J BIOL CHEM, V281, P2506, DOI 10.1074/jbc.M508165200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; Lutz S, 2004, N-S ARCH PHARMACOL, V369, P540, DOI 10.1007/s00210-004-0926-5; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Riese MJ, 2001, BIOCHEMISTRY-US, V40, P3289, DOI 10.1021/bi002729q; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Schurmann A, 1999, J BIOL CHEM, V274, P9744, DOI 10.1074/jbc.274.14.9744; Self AJ, 2001, J CELL SCI, V114, P1357; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Stope MB, 2004, MOL CELL BIOL, V24, P4664, DOI 10.1128/MCB.24.11.4664-4676.2004; vom Dorp F, 2004, CELL SIGNAL, V16, P921, DOI 10.1016/j.cellsig.2004.01.009; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wozniak MA, 2005, MOL BIOL CELL, V16, P84, DOI 10.1091/mbc.E04-04-0277; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	52	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21837	21847		10.1074/jbc.M604156200	http://dx.doi.org/10.1074/jbc.M604156200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754664	hybrid, Green Published			2022-12-25	WOS:000239387100030
J	Yamaguchi, Y; Takahashi, K; Zmudzka, BZ; Kornhauser, A; Miller, SA; Tadokoro, T; Berens, W; Beer, JZ; Hearing, VJ				Yamaguchi, Yuji; Takahashi, Kaoruko; Zmudzka, Barbara Z.; Kornhauser, Andrija; Miller, Sharon A.; Tadokoro, Taketsugu; Berens, Werner; Beer, Janusz Z.; Hearing, Vincent J.			Human skin responses to UV radiation: pigment in the upper epidermis protects against DNA damage in the lower epidermis and facilitates apoptosis	FASEB JOURNAL			English	Article						pigmentation; melanocyte; melanosome; photoprotection	ULTRAVIOLET-RADIATION; MELANIN; P53; SUNBURN; PHOTOPRODUCTS; EXPRESSION; MUTATIONS; CANCER; DIMERS; REPAIR	Melanin plays an important role in protecting the skin against UV radiation, and melanomas and basal/squamous cell carcinomas occur more frequently in individuals with fair/light skin. We previously reported that levels of melanin correlate inversely with amounts of DNA damage induced by UV in normal human skin of different racial/ethnic groups. We have now separately examined DNA damage in the upper and lower epidermal layers in various types of skin before and after exposure to UV and have measured subsequent apoptosis and phosphorylation of p53. The results show that two major mechanisms underlie the increased photocarcinogenesis in fair/light skin. First, UV-induced DNA damage in the lower epidermis (including keratinocyte stem cells and melanocytes) is more effectively prevented in darker skin, suggesting that the pigmented epidermis is an efficient UV filter. Second, UV-induced apoptosis is significantly greater in darker skin, which suggests that UV-damaged cells may be removed more efficiently in pigmented epidermis. The combination of decreased DNA damage and more efficient removal of UV-damaged cells may play a critical role in the decreased photocarcinogenesis seen in individuals with darker skin.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	hearingv@nih.gov	Yamaguchi, Yuji/B-9312-2008; Yamaguchi, Yuji/X-6681-2019	Yamaguchi, Yuji/0000-0003-4338-2662	Intramural NIH HHS Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Bykov VJ, 2000, J INVEST DERMATOL, V114, P40, DOI 10.1046/j.1523-1747.2000.00821.x; Cario-Andre M, 2000, J INVEST DERMATOL, V115, P193, DOI 10.1046/j.1523-1747.2000.00007.x; English DR, 1997, CANCER CAUSE CONTROL, V8, P271, DOI 10.1023/A:1018440801577; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; HALDER RM, 1995, CANCER, V75, P667, DOI 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I; HALL PA, 1993, ONCOGENE, V8, P203; Hemminki K, 2002, CARCINOGENESIS, V23, P605, DOI 10.1093/carcin/23.4.605; Iyoda T, 2005, J IMMUNOL, V175, P3475, DOI 10.4049/jimmunol.175.6.3475; JOHNSON BE, 1972, NATURE-NEW BIOL, V235, P147, DOI 10.1038/newbio235147a0; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; KAIDBEY KH, 1979, J AM ACAD DERMATOL, V1, P249, DOI 10.1016/S0190-9622(79)70018-1; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; McKay BC, 2004, P NATL ACAD SCI USA, V101, P6582, DOI 10.1073/pnas.0308181101; Moan J, 1999, PHOTOCHEM PHOTOBIOL, V70, P243, DOI 10.1111/j.1751-1097.1999.tb07995.x; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; OLSON RL, 1974, J CUTAN PATHOL, V1, P120, DOI 10.1111/j.1600-0560.1974.tb00203.x; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ortonne JP, 2002, BRIT J DERMATOL, V146, P7, DOI 10.1046/j.1365-2133.146.s61.3.x; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Setlow RB, 1999, J INVEST DERM SYMP P, V4, P46, DOI 10.1038/sj.jidsp.5640180; Sheehan JM, 2002, J INVEST DERMATOL, V118, P825, DOI 10.1046/j.1523-1747.2002.01681.x; SZABO G, 1969, NATURE, V222, P1082, DOI 10.1038/2221081a0; Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Takeuchi S, 2004, P NATL ACAD SCI USA, V101, P15076, DOI 10.1073/pnas.0403994101; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; Wagner JK, 2002, PIGM CELL RES, V15, P385, DOI 10.1034/j.1600-0749.2002.02046.x; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yoon TJ, 2003, ANAL BIOCHEM, V318, P260, DOI 10.1016/S0003-2697(03)00172-6; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; ZEISE L, 1995, MELANIN ITS ROLE HUM; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	42	140	144	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1486	+		10.1096/fj.06-5725fje	http://dx.doi.org/10.1096/fj.06-5725fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16793869				2022-12-25	WOS:000240266000026
J	Timofeeva, OA; Plisov, S; Evseev, AA; Peng, S; Jose-Kampfner, M; Lovvorn, HN; Dome, JS; Perantoni, AO				Timofeeva, O. A.; Plisov, S.; Evseev, A. A.; Peng, S.; Jose-Kampfner, M.; Lovvorn, H. N.; Dome, J. S.; Perantoni, A. O.			Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis	ONCOGENE			English	Article						serine 727; STAT1; protein kinase CK2; MCL-1; HSP27; Wilms' tumor	PROTEIN-KINASE CK2; CHRONIC LYMPHOCYTIC-LEUKEMIA; TARGET GENE-EXPRESSION; SIGNAL TRANSDUCER; IFN-GAMMA; INTERFERON-GAMMA; INDUCED APOPTOSIS; CASEIN KINASE-2; CANCER-THERAPY; CELL LYMPHOMA	Wilms' tumor (WT), one of the most common pediatric solid cancers, arises in the developing kidney as a result of genetic and epigenetic changes that lead to the abnormal proliferation and differentiation of the metanephric blastema. As activation of signal transducers and activators of transcription (STATs) plays an important role in the maintenance/growth and differentiation of the metanephric blastema, and constitutively activated STATs facilitate neoplastic behaviors of a variety of cancers, we hypothesized that dysregulation of STAT signaling may also contribute to WT pathogenesis. Accordingly, we evaluated STAT phosphorylation patterns in tumors and found that STAT1 was constitutively phosphorylated on serine 727 (S727) in 19 of 21 primary WT samples and two WT cell lines. An inactivating mutation of S727 to alanine reduced colony formation of WT cells in soft agar by more than 80% and induced apoptosis under conditions of growth stress. S727-phosphorylated STAT1 provided apoptotic resistance for WT cells via upregulation of expression of the heat-shock protein (HSP) 27 and antiapoptotic protein myeloid cell leukemia (MCL)-1. The kinase responsible for STAT1 S727 phosphorylation in WT cells was identified based upon the use of selective inhibitors as protein kinase CK2, not p38, MAP-kinase kinase (MEK)1/2, phosphatidylinositol 3'-kinase, protein kinase C or Ca/calmodulin-dependent protein kinase II (CaMKII). The inhibition of CK2 blocked the anchorage-independent growth of WT cells and induced apoptosis under conditions of growth stress. Our findings suggest that serine-phosphorylated STAT1, as a downstream target of protein kinase CK2, plays a critical role in the pathogenesis of WT and possibly other neoplasms with similar STAT1 phosphorylation patterns.	NCI, Lab Comparat Carcinogenesis, Canc Res Ctr, Frederick, MD 21702 USA; Vanderbilt Univ, Dept Pediat Surg, Nashville, TN USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; St Jude Children's Research Hospital	Perantoni, AO (corresponding author), NCI, Lab Comparat Carcinogenesis, Canc Res Ctr, 1050 Boyless St,Bldg 538,R 205E, Frederick, MD 21702 USA.	peranton@ncifcrf.gov	Dome, Jeffrey/AAH-7825-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005093, ZIABC005093] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Friedberg JW, 2004, LEUKEMIA RES, V28, P139, DOI 10.1016/S0145-2126(03)00213-3; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Hudelist G, 2005, CANCER GENET CYTOGEN, V158, P35, DOI 10.1016/j.cancergencyto.2004.08.007; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kabakov AE, 2003, CELL STRESS CHAPERON, V8, P335, DOI 10.1379/1466-1268(2003)008<0335:HSPOHS>2.0.CO;2; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100; Koesters R, 1999, CANCER RES, V59, P3880; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koshikawa N, 2006, ONCOGENE, V25, P917, DOI 10.1038/sj.onc.1209128; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; Maiti S, 2000, CANCER RES, V60, P6288; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nishiu M, 2002, JPN J CANCER RES, V93, P894, DOI 10.1111/j.1349-7006.2002.tb01335.x; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Plisov SY, 2001, DEVELOPMENT, V128, P1045; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rigolet M, 2001, PEDIATR NEPHROL, V16, P1113, DOI 10.1007/s004670100040; Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447; Ruteshouser EC, 2004, AM J MED GENET C, V129C, P29, DOI 10.1002/ajmg.c.30025; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sarto C, 2004, PROTEOMICS, V4, P2252, DOI 10.1002/pmic.200300797; Seldin DC, 2005, MOL CELL BIOCHEM, V274, P63, DOI 10.1007/s11010-005-3078-0; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Terui K, 2004, BIOCHEM J, V380, P203, DOI 10.1042/BJ20031891; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wang GX, 2005, MOL CELL BIOCHEM, V274, P77, DOI 10.1007/s11010-005-3077-1; Widschwendter A, 2002, CLIN CANCER RES, V8, P3065; Xu WF, 2005, J INTERF CYTOK RES, V25, P113, DOI 10.1089/jir.2005.25.113; Yu J, 2004, CURR OPIN GENET DEV, V14, P550, DOI 10.1016/j.gde.2004.07.009; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zien P, 2005, BBA-PROTEINS PROTEOM, V1754, P271, DOI 10.1016/j.bbapap.2005.07.039; Zykova TA, 2005, CARCINOGENESIS, V26, P331, DOI 10.1093/carcin/bgh334	70	73	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7555	7564		10.1038/sj.onc.1209742	http://dx.doi.org/10.1038/sj.onc.1209742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16799645				2022-12-25	WOS:000242655500001
J	Masuda, K; Richter, M; Song, X; Berezov, A; Masuda, K; Murali, R; Greene, MI; Zhang, H				Masuda, K.; Richter, M.; Song, X.; Berezov, A.; Masuda, K.; Murali, R.; Greene, M. I.; Zhang, H.			AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185(her2/neu)	ONCOGENE			English	Article						AHNP; P185(her2/neu); streptavidin; tetramer	ESCHERICHIA-COLI; EXPRESSION; ONCOGENE; TUMOR; PHARMACOKINETICS; BIODISTRIBUTION; ADENOCARCINOMAS; PEPTIDES; C-ERBB-2; P185NEU	The anti-p185(her2/neu) peptidomimetic (AHNP) is a small exo-cyclic peptide derived from the anti-p185(her2/neu) rhumAb 4D5 (h4D5). AHNP mimics many but not all of the antitumor characteristics exhibited by h4D5. However, the pharmacokinetic profiles of AHNP are less than optimal for therapeutic or diagnostic purposes. To improve the binding affinity to p185(her2/neu) and the antitumor efficacy, we have engineered a fusion protein containing AHNP and a nonimmunoglobulin protein scaffold, streptavidin (SA). The recombinant protein, AHNP-SA (ASA) bound to p185(her2/neu) with high affinity, inhibited the proliferation of p185(her2/neu)-overexpressing cells, and reduced tumor growth induced by p185(her2/neu)-transformed cells. These data suggest that the bacterially produced tetrameric ASA can be used as an antibody-surrogate molecule. This class of molecule will play a role in the diagnosis and treatment of p185(her2/neu)-related tumors. Our studies establish a general principle by which a small biologically active synthetic exo-cyclic peptide can be engineered to enhance functional aspects by structured oligomerization and can be produced recombinantly using bacterial expression.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu		Murali, Ramachandran/0000-0002-8384-2793; Zhang, Hongtao/0000-0001-9173-0049	NCI NIH HHS [5P01 CA 89480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA089480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; Chinol M, 1998, BRIT J CANCER, V78, P189, DOI 10.1038/bjc.1998.463; COHEN JA, 1989, ONCOGENE, V4, P81; DI FP, 1987, CELL, V51, P1063; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; DREBIN JA, 1986, S FUND CANC RES, V381, P277; Farlow SJ, 2002, FEBS LETT, V516, P197, DOI 10.1016/S0014-5793(02)02565-6; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Jurado P, 2002, J MOL BIOL, V320, P1, DOI 10.1016/S0022-2836(02)00405-9; KALOFONOS HP, 1990, J NUCL MED, V31, P1791; KERN JA, 1990, CANCER RES, V50, P5184; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; KOKAI Y, 1988, PRINC TAK S, V191, P45; LODATO RF, 1990, MODERN PATHOL, V3, P449; Maynard J, 2000, ANNU REV BIOMED ENG, V2, P339, DOI 10.1146/annurev.bioeng.2.1.339; Meyer DL, 2001, PROTEIN SCI, V10, P491, DOI 10.1110/ps.19901; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; ROSEBROUGH SF, 1993, NUCL MED BIOL, V20, P663, DOI 10.1016/0969-8051(93)90037-U; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; Zhang HT, 2006, NAT MED, V12, P473, DOI 10.1038/nm1378	30	16	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7740	7746		10.1038/sj.onc.1209745	http://dx.doi.org/10.1038/sj.onc.1209745			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785990				2022-12-25	WOS:000242830800008
J	Barber, RC; Hickenbotham, P; Hatch, T; Kelly, D; Topchiy, N; Almeida, GM; Jones, GDD; Johnson, GE; Parry, JM; Rothkamm, K; Dubrova, YE				Barber, R. C.; Hickenbotham, P.; Hatch, T.; Kelly, D.; Topchiy, N.; Almeida, G. M.; Jones, G. D. D.; Johnson, G. E.; Parry, J. M.; Rothkamm, K.; Dubrova, Y. E.			Radiation-induced transgenerational alterations in genome stability and DNA damage	ONCOGENE			English	Editorial Material						radiation; transgenerational instability; mutations; DNA damage; mouse; germ line	F-1 MICE BORN; IONIZING-RADIATION; MULTIPLE MUTATIONS; DEFICIENT MICE; COMET ASSAY; IN-VITRO; INSTABILITY; CANCER; INDUCTION; EXPOSURE	Mutation induction in directly exposed cells is currently regarded as the main component of the genetic risk of ionizing radiation for humans. However, recent data on the transgenerational increases in mutation rates in the offspring of irradiated parents indicate that the genetic risk could be greater than predicted previously. Here, we have analysed transgenerational changes in mutation rates and DNA damage in the germline and somatic tissues of non-exposed first-generation offspring of irradiated inbred male CBA/Ca and BALB/c mice. Mutation rates at an expanded simple tandem repeat DNA locus and a protein-coding gene (hprt) were significantly elevated in both the germline (sperm) and somatic tissues of all the offspring of irradiated males. The transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous DNA lesions (double- and single-strand breaks), measured by the phosphorylated form of histone H2AX (gamma-H2AX) and alkaline Comet assays. Such remarkable transgenerational destabilization of the F-1 genome may have important implications for cancer aetiology and genetic risk estimates. Our data also provide important clues on the still unknown mechanisms of radiation-induced genomic instability.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 7RH, Leics, England; Univ Coll Swansea, Ctr Mol Genet & Toxicol, Swansea, W Glam, Wales; Gray Canc Inst, Northwood, Middx, England	University of Leicester; University of Leicester; Swansea University; University of Oxford	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Rothkamm, Kai/A-2164-2014; Almeida, Gabriela/A-8160-2012; Dubrova, Yuri/ABA-7148-2020; Topchiy, Nataliya/AAD-5215-2020; Barber, Ruth/A-1051-2008; Almeida, Gabriela/GXV-3687-2022; Johnson, George/J-2488-2014	Rothkamm, Kai/0000-0001-7414-5729; Almeida, Gabriela/0000-0001-8712-7394; Dubrova, Yuri/0000-0001-5281-7539; Johnson, George/0000-0001-5643-9942; Jones, George/0000-0002-9543-2206; Topchiy, Nataliya/0000-0003-4694-5707	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Almeida GM, 2006, DNA REPAIR, V5, P219, DOI 10.1016/j.dnarep.2005.09.010; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bol SAM, 1998, CANCER RES, V58, P2850; Breger KS, 2004, CANCER RES, V64, P8231, DOI 10.1158/0008-5472.CAN-04-0879; Collins Andrew R, 2002, Methods Mol Biol, V186, P147; Cosentino L, 2000, MUTAT RES-FUND MOL M, V454, P1, DOI 10.1016/S0027-5107(00)00125-1; Dubrova YE, 2005, RADIAT RES, V163, P200, DOI 10.1667/RR3296; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Dubrova YE, 2003, ONCOGENE, V22, P7087, DOI 10.1038/sj.onc.1206993; FRIEDBERG EC, 1995, DNA REPAIR REPAIR MU; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Garcia CL, 2001, MUTAT RES-GEN TOX EN, V492, P59, DOI 10.1016/S1383-5718(01)00149-8; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Kassie F, 2000, MUTAT RES-REV MUTAT, V463, P13, DOI 10.1016/S1383-5742(00)00041-7; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, ONCOGENE, V22, P7058, DOI 10.1038/sj.onc.1207044; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Nomura T, 2003, MUTAT RES-REV MUTAT, V544, P425, DOI 10.1016/j.mrrev.2003.06.006; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Tawn EJ, 2005, MUTAT RES-GEN TOX EN, V583, P198, DOI 10.1016/j.mrgentox.2005.03.007; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	33	98	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7336	7342		10.1038/sj.onc.1209723	http://dx.doi.org/10.1038/sj.onc.1209723			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751800				2022-12-25	WOS:000242419100002
J	Oddo, C; Freire, E; Frappier, L; de Prat-Gay, G				Oddo, Cristian; Freire, Eleonora; Frappier, Lori; de Prat-Gay, Gonzalo			Mechanism of DNA recognition at a viral replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; CRYSTAL-STRUCTURE; BINDING-PROTEIN; NUCLEAR ANTIGEN-1; SURFACE-AREAS; EBNA1; SEQUENCE; DOMAINS; TARGET; HEAT	Recognition of the DNA origin by the Epstein- Barr nuclear antigen 1 (EBNA1) protein is the primary event in latent-phase genome replication of the Epstein-Barr virus, a model for replication initiation in eukaryotes. We carried out an extensive thermodynamic and kinetic characterization of the binding mechanism of the DNA binding domain of EBNA1, EBNA1(452-641), to a DNA fragment containing a single specific origin site. The interaction displays a binding energy of 12.7 kcal mol(-1), with 11.9 kcal mol(-1) coming from the enthalpic change with a minimal entropic contribution. Formation of the EBNA1(452-641), DNA complex is accompanied by a heat capacity change of -1.22 kcal mol(-1) K-1, a very large value considering the surface area buried, which we assign to an unusually apolar protein-DNA interface. Kinetic dissociation experiments, including fluorescence anisotropy and a continuous native electrophoretic mobility shift assay, confirmed that two EBNA1(452-641)(.)DNA complex conformers are in slow equilibrium; one dissociates slowly (t(1/2)similar to 41 min) through an undissociated intermediate species and the other corresponds to a fast two-step dissociation route (t(1/2)similar to 0.8 min). In line with this, at least two parallel association events from two populations of protein conformers are observed, with on-rates of 0.25-1.6 x 10(8) M(-1)s(-1), which occur differentially either in excess protein or DNA molecules. Both parallel complexes undergo subsequent first-order rearrangements of similar to 2.0s(-1) to yield two consolidated complexes. These parallel association and dissociation routes likely allow additional flexible regulatory events for site recognition depending on site availability according to nucleus environmental conditions, which may lock a final recognition event, dissociate and re- bind, or slide along the DNA.	Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Leloir Institute; University of Toronto	de Prat-Gay, G (corresponding author), Inst Leloir, Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	gpratgay@leloir.org.ar		Prat Gay, Gonzalo/0000-0001-5748-6863; Freire Espeleta, Eleonora/0000-0002-6026-8696	Wellcome Trust [066649/Z/01/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bergqvist S, 2004, J MOL BIOL, V336, P829, DOI 10.1016/j.jmb.2003.12.061; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; Bochkarev A, 1998, J MOL BIOL, V284, P1273, DOI 10.1006/jmbi.1998.2247; Cruickshank J, 2000, J BIOL CHEM, V275, P22273, DOI 10.1074/jbc.M001414200; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P6218, DOI 10.1021/bi026866u; Ferreiro DU, 2005, J BIOL CHEM, V280, P32480, DOI 10.1074/jbc.M505706200; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; Ferreiro DU, 2003, J MOL BIOL, V331, P89, DOI 10.1016/S0022-2836(03)00720-4; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7964, DOI 10.1021/bi00191a025; Gray D. M., 1996, CIRCULAR DICHROISM C, P469; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; Kozlov AG, 1998, J MOL BIOL, V278, P999, DOI 10.1006/jmbi.1998.1738; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Lundback T, 2000, BIOCHEMISTRY-US, V39, P7570, DOI 10.1021/bi000377h; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26893	26903		10.1074/jbc.M602083200	http://dx.doi.org/10.1074/jbc.M602083200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16815848	hybrid, Green Published			2022-12-25	WOS:000240397700016
J	Jin, XS; Touhey, J; Gaudet, R				Jin, Xiangshu; Touhey, Jason; Gaudet, Rachelle			Structure of the N-terminal ankyrin repeat domain of the TRPV2 ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CAPSAICIN-RECEPTOR; VANILLOID RECEPTOR-1; CATION CHANNEL; HEAT; ARCHITECTURE; DESENSITIZATION; RECOGNITION; EXPRESSION; MICE	The TRPV ion channels mediate responses to many sensory stimuli including heat, low pH, neuropeptides, and chemical ligands. All TRPV subfamily members contain an intracellular N-terminal ankyrin repeat domain (ARD), a prevalent protein interaction motif. The 1.6-angstrom crystal structure of the TRPV2-ARD, with six ankyrin repeats, reveals several atypical structural features. Repeats one through three display unusually long and flexible fingers with a large number of exposed aromatic residues, whereas repeats five and six have unusually long outer helices. Furthermore, a large counterclockwise twist observed in the stacking of repeats four and five breaks the regularity of the domain, altering the shape of surfaces available for interactions with proteins or other cellular ligands. Both solution studies and crystal packing interactions indicate that the TRPV2-ARD does not form homo-oligomers, suggesting that the ARD of TRPV ion channels may be used for interactions with regulatory factors rather than in promoting tetrameric assembly of the ion channels.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Gaudet, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	gaudet@mcb.harvard.edu	Gaudet, Rachelle/I-4133-2014; Gaudet, Rachelle/Y-3985-2019	Gaudet, Rachelle/0000-0002-9177-054X; Gaudet, Rachelle/0000-0002-9177-054X; Jin, Xiangshu/0000-0002-6551-8850	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-15301] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barnhill JC, 2004, J CELL BIOCHEM, V91, P808, DOI 10.1002/jcb.10775; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cuajungco MP, 2006, J BIOL CHEM, V281, P18753, DOI 10.1074/jbc.M602452200; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; MCCLEVERTY CJ, 2006, IN PRESS PROTEIN SCI; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Mohapatra DP, 2005, J BIOL CHEM, V280, P13424, DOI 10.1074/jbc.M410917200; Moqrich A, 2005, SCIENCE, V307, P1468, DOI 10.1126/science.1108609; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037; Nijenhuis T, 2005, PFLUG ARCH EUR J PHY, V451, P181, DOI 10.1007/s00424-005-1430-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Stokes AJ, 2005, J CELL BIOCHEM, V94, P669, DOI 10.1002/jcb.20331; Stokes AJ, 2004, J EXP MED, V200, P137, DOI 10.1084/jem.20032082; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882; Zhang XM, 2005, EMBO J, V24, P4211, DOI 10.1038/sj.emboj.7600893	37	103	108	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25006	25010		10.1074/jbc.C600153200	http://dx.doi.org/10.1074/jbc.C600153200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809337	hybrid, Green Published			2022-12-25	WOS:000240031300002
J	Linggi, B; Carpenter, G				Linggi, Bryan; Carpenter, Graham			ErbB-4s80 intracellular domain abrogates ETO2-dependent transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NUCLEAR-LOCALIZATION; GENE; DIFFERENTIATION; PROTEINS; CLEAVAGE; FRAGMENT; BREAST; ERBB4; ETO	ErbB-4 is cleaved by alpha- and gamma-secretases to release a soluble 80-kDa intracellular domain, termed s80, which translocates to the nucleus. s80 is present in the nucleus of normal and cancerous mammary cells and is predicted to have a role in cell differentiation. To further investigate the mechanism by which s80 may mediate differentiation, we tested whether s80 regulates Eto2, a transcriptional corepressor that is involved in erythrocyte differentiation and is also implicated in human breast cancer. Here we show that ligand binding to ErbB-4 causes s80 translocation to the nucleus, where it colocalizes and interacts with Eto2. Expression of s80 blocks Eto2-mediated transcriptional repression of a heterologous promoter. This effect on Eto2 does not require s80 kinase activity and is mediated by the carboxyl-terminal region of s80. Although other cell surface receptors regulate transcription by activating signal transduction cascades, these data present a novel mechanism of corepressor regulation and suggest a role for Eto2 in ErbB-4 dependent differentiation.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu			NCI NIH HHS [CA97456, T32 CA009582, P30 CA6845] Funding Source: Medline; NIDDK NIH HHS [P30 DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582, R01CA097456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amann JM, 2005, MOL CELL BIOL, V25, P9576, DOI 10.1128/MCB.25.21.9576-9585.2005; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; Jankiewicz M, 2006, MOL ENDOCRINOL, V20, P2369, DOI 10.1210/me.2006-0071; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Kochetkova M, 2002, CANCER RES, V62, P4599; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; Takahashi S, 2004, BLOOD, V103, P4650, DOI 10.1182/blood-2003-08-2759; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532	31	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25373	25380		10.1074/jbc.M603998200	http://dx.doi.org/10.1074/jbc.M603998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815842	hybrid			2022-12-25	WOS:000240031300039
J	Morita, YS; Sena, CBC; Waller, RF; Kurokawa, K; Sernee, MF; Nakatani, F; Haites, RE; Billman-Jacobe, H; McConville, MJ; Maeda, Y; Kinoshita, T				Morita, Yasu S.; Sena, Chubert B. C.; Waller, Ross F.; Kurokawa, Ken; Sernee, M. Fleur; Nakatani, Fumiki; Haites, Ruth E.; Billman-Jacobe, Helen; McConville, Malcolm J.; Maeda, Yusuke; Kinoshita, Taroh			PimE is a polyprenol-phosphate-mannose-dependent mannosyltransferase that transfers the fifth mannose of phosphatidylinositol mannoside in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; LIPOARABINOMANNAN BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; GPI ANCHOR; GLYCOSYLPHOSPHATIDYLINOSITOL; IDENTIFICATION; TUBERCULOSIS; SMEGMATIS; PROTEIN; GROWTH	Phosphatidylinositol mannosides (PIMs) are a major class of glycolipids in all mycobacteria. AcPIM2, a dimannosyl PIM, is both an end product and a precursor for polar PIMs, such as hexamannosyl PIM (AcPIM6) and the major cell wall lipoglycan, lipoarabinomannan (LAM). The mannosyltransferases that convert AcPIM2 to AcPIM6 or LAM are dependent on polyprenol-phosphate-mannose (PPM), but have not yet been characterized. Here, we identified a gene, termed pimE that is present in all mycobacteria, and is required for AcPIM6 biosynthesis. PimE was initially identified based on homology with eukaryotic PIG-M mannosyltransferases. PimE-deleted Mycobacterium smegmatis was defective in AcPIM6 synthesis, and accumulated the tetramannosyl PIM, AcPIM4. Loss of PimE had no affect on cell growth or viability, or the biosynthesis of other intracellular and cell wall glycans. However, changes in cell wall hydrophobicity and plasma membrane organization were detected, suggesting a role for AcPIM6 in the structural integrity of the cell wall and plasma membrane. These defects were corrected by ectopic expression of the pimE gene. Metabolic pulse-chase radiolabeling and cell-free PIM biosynthesis assays indicated that PimE catalyzes the alpha 1,2-mannosyl transfer for the AcPIM5 synthesis. Mutation of an Asp residue in PimE that is conserved in and required for the activity of human PIG-M resulted in loss of PIM-biosynthetic activity, indicating that PimE is the catalytic component. Finally, PimE was localized to a distinct membrane fraction enriched in AcPIM4-6 biosynthesis. Taken together, PimE represents the first PPM-dependent mannosyltransferase shown to be involved in PIM biosynthesis, where it mediates the fifth mannose transfer.	Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Melbourne, Plant Cell Biol Res Ctr, Sch Bot, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Nara Inst Sci & Technol, Lab Comparat Genom, Grad Sch Informat Sci, Nara 6300192, Japan	Osaka University; University of Melbourne; University of Melbourne; University of Melbourne; Nara Institute of Science & Technology	Kinoshita, T (corresponding author), Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Kinoshita, Taroh/C-7353-2009; Waller, Ross F/D-5761-2016; Shingakujyutsu, Kurokawaken/G-1378-2011	Waller, Ross F/0000-0001-6961-9344; Sena, Chubert/0000-0002-2328-9885; Billman-Jacobe, Helen/0000-0001-5713-4657; Sernee, Marijke/0000-0002-4846-9268; Morita, Yasu/0000-0002-4514-9242				Alexander DC, 2004, J BIOL CHEM, V279, P18824, DOI 10.1074/jbc.M400791200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apostolou I, 1999, P NATL ACAD SCI USA, V96, P5141, DOI 10.1073/pnas.96.9.5141; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; Billman-Jacobe H, 1999, ANTIMICROB AGENTS CH, V43, P3011, DOI 10.1128/AAC.43.12.3011; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x; Burguiere A, 2005, J BIOL CHEM, V280, P42124, DOI 10.1074/jbc.M507500200; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chua J, 2004, CURR OPIN MICROBIOL, V7, P71, DOI 10.1016/j.mib.2003.12.011; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; de la Salle H, 2005, SCIENCE, V310, P1321, DOI 10.1126/science.1115301; Dinadayala P, 2006, J BIOL CHEM, V281, P20027, DOI 10.1074/jbc.M603395200; Dmitriev BA, 2000, INT J MED MICROBIOL, V290, P251; Fabre AL, 2005, FEBS J, V272, P1160, DOI 10.1111/j.1742-4658.2005.04551.x; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Haites RE, 2005, J BIOL CHEM, V280, P10981, DOI 10.1074/jbc.M413443200; HILL DL, 1966, J BIOL CHEM, V241, P895; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; Jeevarajah D, 2004, J BACTERIOL, V186, P6792, DOI 10.1128/JB.186.20.6792-6799.2004; Kang JY, 2005, J BIOL CHEM, V280, P9489, DOI 10.1074/jbc.M413867200; Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kovacevic S, 2006, J BIOL CHEM, V281, P9011, DOI 10.1074/jbc.M511709200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Marques MAM, 1998, INFECT IMMUN, V66, P2625, DOI 10.1128/IAI.66.6.2625-2631.1998; Morita YS, 2005, J BIOL CHEM, V280, P21645, DOI 10.1074/jbc.m414181200; Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Patterson JH, 2000, J BIOL CHEM, V275, P24900, DOI 10.1074/jbc.M000147200; Patterson JH, 2003, BIOCHEM J, V372, P77, DOI 10.1042/BJ20021700; ROSENBERG M, 1980, FEMS MICROBIOL LETT, V9, P29, DOI 10.1016/0378-1097(80)90106-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Taron BW, 2004, J BIOL CHEM, V279, P36083, DOI 10.1074/jbc.M405081200; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	54	100	107	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25143	25155		10.1074/jbc.M604214200	http://dx.doi.org/10.1074/jbc.M604214200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803893	hybrid			2022-12-25	WOS:000240031300015
J	Seyit, G; Rockel, B; Baumeister, W; Peters, J				Seyit, Goenuel; Rockel, Beate; Baumeister, Wolfgang; Peters, Juergen			Size matters for the tripeptidylpeptidase II complex from Drosophila - The 6-MDa spindle form stabilizes the activated state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS PROTEASE; PEPTIDASE-II; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; SERINE-PROTEASE; ENZYME-ACTIVITY; GIANT PROTEASE; DEGRADATION; SPECIFICITY; AMINOPEPTIDASE	Tripeptidylpeptidase II (TPP II) is an exopeptidase of the subtilisin type of serine proteases, a key component of the protein degradation cascade in many eukaryotes, which cleaves tripeptides from the N terminus of proteasome-released products. The Drosophila TPP II is a large homooligomeric complex (similar to 6 MDa) that is organized in a unique repetitive structure with two strands each composed of ten stacked homodimers; two strands intertwine to form a spindle-shaped structure. We report a novel procedure of preparing an active, structurally homogeneous TPP II holo-complex overexpressed in Escherichia coli. Assembly studies revealed that the specific activity of TPP II increases with oligomer size, which in turn is strongly concentration-dependent. At a TPP II concentration such as prevailing in Drosophila, equilibration of size and activity proceeds on a time scale of hours and leads to spindle formation at a TPP II concentration of >= 0.03 mg/ml. Before equilibrium is reached, activation lags behind assembly, suggesting that activation occurs in a two-step process consisting of (i) assembly and (ii) a subsequent conformational change leading to a switch from basal to full activity. We propose a model consistent with the hyperbolic increase of activity with oligomer size. Spindle formation by strand pairing causes both significant thermodynamic and kinetic stabilization. The strands inherently heterogeneous in length are thus locked into a discrete oligomeric state. Our data indicate that the unique spindle form of the holo-complex represents an assembly motif stabilizing a highly active state.	Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany	Max Planck Society	Peters, J (corresponding author), Max Planck Inst Biochem, Dept Mol Struct Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	Peters@biochem.mpg.de						BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Book AJ, 2005, PLANT PHYSIOL, V138, P1046, DOI 10.1104/pp.104.057406; Borissenko L, 2005, J MOL BIOL, V346, P1207, DOI 10.1016/j.jmb.2004.12.056; CHANDU D, 2002, APPL GENOM PROTEOM, V1, P235; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; EGAN RM, 1981, J BIOL CHEM, V256, P4877; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; HARRIS JR, 1990, MICRON MICROSC ACTA, V21, P77, DOI 10.1016/0739-6260(90)90008-4; Hasselgren PO, 2002, BIOCHEM BIOPH RES CO, V290, P1, DOI 10.1006/bbrc.2001.5849; Hilbi H, 2000, INFECT IMMUN, V68, P5502, DOI 10.1128/IAI.68.10.5502-5508.2000; Hong X, 2003, J EXP MED, V197, P1731, DOI 10.1084/jem.20020801; Levy F, 2002, J IMMUNOL, V169, P4161, DOI 10.4049/jimmunol.169.8.4161; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Mayr J, 1996, CURR BIOL, V6, P739, DOI 10.1016/S0960-9822(09)00455-2; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Pettit SC, 2003, J VIROL, V77, P366, DOI 10.1128/JVI.77.1.366-374.2003; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; Princiotta MF, 2001, P NATL ACAD SCI USA, V98, P513, DOI 10.1073/pnas.021132398; Ray K, 2004, J BIOL CHEM, V279, P20480, DOI 10.1074/jbc.M400795200; Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3; Renn SCP, 1998, J BIOL CHEM, V273, P19173, DOI 10.1074/jbc.273.30.19173; Rockel B, 2005, P NATL ACAD SCI USA, V102, P10135, DOI 10.1073/pnas.0504569102; Rockel B, 2002, EMBO J, V21, P5979, DOI 10.1093/emboj/cdf601; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Shieh HS, 1996, NATURE, V383, P279, DOI 10.1038/383279a0; Snoussi K, 2005, BIOPHYS J, V88, P2855, DOI 10.1529/biophysj.104.055871; Tomkinson B, 2005, INT J BIOCHEM CELL B, V37, P1933, DOI 10.1016/j.biocel.2005.02.009; Tomkinson B, 2000, ARCH BIOCHEM BIOPHYS, V376, P275, DOI 10.1006/abbi.2000.1713; Tomkinson B, 2002, EUR J BIOCHEM, V269, P1438, DOI 10.1046/j.1432-1033.2002.02783.x; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Voorhorst WGB, 1996, J BIOL CHEM, V271, P20426, DOI 10.1074/jbc.271.34.20426; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Warburton MJ, 2002, NEUROSCI LETT, V331, P99, DOI 10.1016/S0304-3940(02)00841-8; Wray CJ, 2002, BIOCHEM BIOPH RES CO, V296, P41, DOI 10.1016/S0006-291X(02)00834-3	43	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25723	25733		10.1074/jbc.M602722200	http://dx.doi.org/10.1074/jbc.M602722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16799156	hybrid			2022-12-25	WOS:000240031300075
J	Reynolds, PA; Sigaroudinia, M; Zardo, G; Wilson, MB; Benton, GM; Miller, CJ; Hong, CB; Fridlyand, J; Costello, JF; Tlsty, TD				Reynolds, Paul A.; Sigaroudinia, Mahvash; Zardo, Giuseppe; Wilson, Matthew B.; Benton, Geoffrey M.; Miller, Caroline J.; Hong, Chibo; Fridlyand, Jane; Costello, Joseph F.; Tlsty, Thea D.			Tumor suppressor p16(INK4A) regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN EZH2; P16 EXPRESSION; SELF-RENEWAL; METHYLATION; CANCER; GENE; GROWTH; SENESCENCE; RECEPTOR; TARGET	Alterations in DNA methylation are important in cancer, but the acquisition of these alterations is poorly understood. Using an unbiased global screen for CpG island methylation events, we have identified a non-random pattern of DNA hypermethylation acquired in p16-repressed cells. Interestingly, this pattern included loci located upstream of a number of homeobox genes. Upon removal of p16(INK4A) activity in primary human mammary epithelial cells, polycomb repressors, EZH2 and SUZ12, are upregulated and recruited to HOXA9, a locus expressed during normal breast development and epigenetically silenced in breast cancer. We demonstrate that at this targeted locus, the up-regulation of polycomb repressors is accompanied by the recruitment of DNA methyltransferases and the hypermethylation of DNA, an endpoint, which we show to be dependent on SUZ12 expression. These results demonstrate a causal role of p16INK4A disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression.	Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tlsty, TD (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW501, San Francisco, CA 94143 USA.	thea.tlsty@ucsf.edu		Reynolds, Paul/0000-0001-8738-1245	NCI NIH HHS [R01 CA97214, P50 CA58207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058207, R01CA097214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Belinsky SA, 2002, CANCER RES, V62, P2370; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, NAT GENET, V31, P123, DOI 10.1038/ng0602-123; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gadd M, 2001, CANCER RES, V61, P8811; Gauthier ML, 2005, CANCER RES, V65, P1792, DOI 10.1158/0008-5472.CAN-04-3507; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holst CR, 2003, CANCER RES, V63, P1596; Huschtscha LI, 1998, CANCER RES, V58, P3508; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim MH, 1998, DNA CELL BIOL, V17, P407, DOI 10.1089/dna.1998.17.407; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nikolova Z, 1998, J CELL SCI, V111, P2741; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shim YH, 2003, MODERN PATHOL, V16, P430, DOI 10.1097/01.mp.0000066799.99032.A7; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f; UNGER MA, 2002, THESIS U PENNSYLVANI; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Westfall P.H., 1993, RESAMPLING BASED MUL, V279; Wong DJ, 2001, CANCER RES, V61, P8284	58	103	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24790	24802		10.1074/jbc.M604175200	http://dx.doi.org/10.1074/jbc.M604175200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16766534	Green Published, hybrid			2022-12-25	WOS:000239847800075
J	Schug, ZT; Joseph, SK				Schug, Zachary T.; Joseph, Suresh K.			The role of the S4-S5 linker and C-terminal tail in inositol 1,4,5-trisphosphate receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; LIGAND-BINDING; POTASSIUM CHANNELS; K+ CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION GATE; FAMILY; DOMAIN; CA2+; OLIGOMERIZATION	In previous studies we have suggested that spatial proximity of the C- and N-terminal domains of inositol 1,4,5-trisphosphate receptors (IP3Rs) may be critical for the channel gating mechanism. In the present study we have examined the sites of C-N interaction in more detail. We report that deletion mutations within the S4-S5 linker (amino acids 2418-2437) prevent co-immunoprecipitation of the C- and N-terminal domains, inhibit channel activity and enhance IP3 binding. We also show that a region of the C- terminal tail (amino acids 2694-2721), predicted to be a coiled-coil, is also required for channel activity. Circular dichroism spectroscopy and gel filtration studies confirm that this region has a helical structure with the ability to form tetramers. We propose a model in which IP3-induced conformational changes in the N-terminal domain are mechanically transmitted to the opening of the pore through an attachment to the S4-S5 linker. The coiled-coil domain in the C- terminal tail may play a critical role in maintaining the structural integrity of the channel.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sch Med, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Sch Med, 1020 Locust St,JAH 230A, Philadelphia, PA 19107 USA.	suresh.joseph@mail.tju.edu		Schug, Zachary/0000-0003-4197-8227	NIAAA NIH HHS [T32-AA07463] Funding Source: Medline; NIDDK NIH HHS [R01-DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Decher N, 2004, J BIOL CHEM, V279, P13859, DOI 10.1074/jbc.M313704200; Engeland B, 1998, J PHYSIOL-LONDON, V513, P647, DOI 10.1111/j.1469-7793.1998.647ba.x; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Galvan DL, 2002, J BIOL CHEM, V277, P48248, DOI 10.1074/jbc.M209990200; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Joseph SK, 2005, CELL CALCIUM, V38, P539, DOI 10.1016/j.ceca.2005.07.007; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Kuo AL, 2005, STRUCTURE, V13, P1463, DOI 10.1016/j.str.2005.07.011; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Stewart R, 2003, BIOCHEM J, V376, P795, DOI 10.1042/BJ20030597; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Uchida K, 2003, J BIOL CHEM, V278, P16551, DOI 10.1074/jbc.M300646200; Varnai P, 2005, P NATL ACAD SCI USA, V102, P7859, DOI 10.1073/pnas.0407535102; Wang RW, 2004, J BIOL CHEM, V279, P3635, DOI 10.1074/jbc.M311367200; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	46	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24431	24440		10.1074/jbc.M604190200	http://dx.doi.org/10.1074/jbc.M604190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16815846	hybrid			2022-12-25	WOS:000239847800037
J	Wally, J; Halbrooks, PJ; Vonrhein, C; Rould, MA; Everse, SJ; Mason, AB; Buchanan, SK				Wally, Jeremy; Halbrooks, Peter J.; Vonrhein, Clemens; Rould, Mark A.; Everse, Stephen J.; Mason, Anne B.; Buchanan, Susan K.			The crystal structure of iron-free human serum transferrin provides insight into inter-lobe communication and receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGE; CARBOXYL-TERMINAL LOBES; C-LOBE; N-LOBE; ANION-BINDING; DUCK OVOTRANSFERRIN; MUTATIONAL ANALYSIS; HEN OVOTRANSFERRIN; HUMAN LACTOFERRIN; RELEASE	Serum transferrin reversibly binds iron in each of two lobes and delivers it to cells by a receptor-mediated, pH-dependent process. The binding and release of iron result in a large conformational change in which two subdomains in each lobe close or open with a rigid twisting motion around a hinge. We report the structure of human serum transferrin (hTF) lacking iron (apo-hTF), which was independently determined by two methods: 1) the crystal structure of recombinant non-glycosylated apo-hTF was solved at 2.7-angstrom resolution using a multiple wavelength anomalous dispersion phasing strategy, by substituting the nine methionines in hTF with selenomethionine and 2) the structure of glycosylated apo-hTF (isolated from serum) was determined to a resolution of 2.7 angstrom by molecular replacement using the human apo-N-lobe and the rabbit holo-C1-subdomain as search models. These two crystal structures are essentially identical. They represent the first published model for full-length human transferrin and reveal that, in contrast to family members (human lactoferrin and hen ovotransferrin), both lobes are almost equally open: 59.4 degrees and 49.5 degrees rotations are required to open the N- and C-lobes, respectively (compared with closed pig TF). Availability of this structure is critical to a complete understanding of the metal binding properties of each lobe of hTF; the apo-hTF structure suggests that differences in the hinge regions of the N- and C-lobes may influence the rates of iron binding and release. In addition, we evaluate potential interactions between apo-hTF and the human transferrin receptor.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Global Phasing Ltd, Cambridge CB3 0AX, England; Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Vermont; Global Phasing Limited; University of Vermont	Buchanan, SK (corresponding author), NIDDK, Mol Biol Lab, NIH, 50 S Dr,Rm 4503, Bethesda, MD 20892 USA.	skbuchan@helix.nih.gov	Mason, Anne B/A-6754-2008		Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R01 DK21739, Z01 DK011003-04, R01 DK021739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011003, Z01DK036143, R01DK021739] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdallah FB, 2000, J MOL BIOL, V303, P255, DOI 10.1006/jmbi.2000.4101; Abdallah FB, 1999, EUR J BIOCHEM, V263, P912, DOI 10.1046/j.1432-1327.1999.00596.x; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams TE, 2003, J BIOL CHEM, V278, P6027, DOI 10.1074/jbc.M210349200; AISEN P, 1978, J BIOL CHEM, V253, P1930; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Baker EN, 2002, BIOCHEM CELL BIOL, V80, P27, DOI 10.1139/o01-153; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BALDWIN DA, 1982, BIOCHIM BIOPHYS ACTA, V719, P140, DOI 10.1016/0304-4165(82)90317-8; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BALI PK, 1992, BIOCHEMISTRY-US, V31, P3963, DOI 10.1021/bi00131a011; BATES GW, 1967, J BIOL CHEM, V242, P2810; Beatty EJ, 1996, BIOCHEMISTRY-US, V35, P7635, DOI 10.1021/bi960684g; Bennett MJ, 2000, NATURE, V403, P46, DOI 10.1038/47417; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAHINE JME, 1994, EUR J BIOCHEM, V223, P581; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; Cheng YF, 2005, J STRUCT BIOL, V152, P204, DOI 10.1016/j.jsb.2005.10.006; DAY CL, 1992, J BIOL CHEM, V267, P13857; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; EVANS RW, 1994, BIOCHEMISTRY-US, V33, P12512, DOI 10.1021/bi00207a019; Giannetti AM, 2005, STRUCTURE, V13, P1613, DOI 10.1016/j.str.2005.07.016; Giannetti AM, 2003, PLOS BIOL, V1, P341, DOI 10.1371/journal.pbio.0000051; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guha Thakurta Piyali, 2003, Acta Crystallogr D Biol Crystallogr, V59, P1773, DOI 10.1107/S0907444903016652; Gumerov DR, 2003, BIOCHEMISTRY-US, V42, P5421, DOI 10.1021/bi020660b; Halbrooks PJ, 2005, BIOCHEMISTRY-US, V44, P15451, DOI 10.1021/bi0518693; Halbrooks PJ, 2003, BIOCHEMISTRY-US, V42, P3701, DOI 10.1021/bi027071q; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Hamilton DH, 2004, J BIOL INORG CHEM, V9, P936, DOI 10.1007/s00775-004-0592-6; HARRIS DC, 1989, IRON CARRIERS IRON P, P241; Harris WR, 2003, INORG CHEM, V42, P5880, DOI 10.1021/ic034009o; Harris WR, 2003, INORG CHEM, V42, P3262, DOI 10.1021/ic026027w; He QY, 2000, BIOCHEM J, V350, P909, DOI 10.1042/0264-6021:3500909; He QY, 1999, BIOCHEMISTRY-US, V38, P9704, DOI 10.1021/bi990134t; HE QY, 2002, MOL CELLULAR IRON TR, P95; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Khan JA, 2001, J MOL BIOL, V309, P751, DOI 10.1006/jmbi.2001.4692; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kurokawa H, 1999, J BIOL CHEM, V274, P28445, DOI 10.1074/jbc.274.40.28445; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; KUROKAWA H, 1994, J BIOL CHEM, V269, P6671; Lambert LA, 2005, COMP BIOCHEM PHYS B, V142, P129, DOI 10.1016/j.cbpb.2005.07.007; Lambert LA, 2005, COMP BIOCHEM PHYS B, V140, P11, DOI 10.1016/j.cbpc.2004.09.012; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESTAS AN, 1976, BRIT J HAEMATOL, V32, P341, DOI 10.1111/j.1365-2141.1976.tb00937.x; LIN LN, 1991, BIOCHEMISTRY-US, V30, P11660, DOI 10.1021/bi00114a008; LIN LN, 1994, BIOCHEMISTRY-US, V33, P1881, DOI 10.1021/bi00173a035; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MARQUES HM, 1991, INORG CHEM, V30, P3758, DOI 10.1021/ic00019a037; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; Mason AB, 2005, BIOCHEMISTRY-US, V44, P8013, DOI 10.1021/bi050015f; Mason AB, 2004, PROTEIN EXPRES PURIF, V36, P318, DOI 10.1016/j.pep.2004.04.013; Mason AB, 2002, BIOCHEMISTRY-US, V41, P9448, DOI 10.1021/bi025927l; Mason AB, 1998, BIOCHEM J, V330, P35; Mason AB, 2001, PROTEIN EXPRES PURIF, V23, P142, DOI 10.1006/prep.2001.1480; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Okamoto I, 2004, BIOCHEMISTRY-US, V43, P11118, DOI 10.1021/bi049147j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENHALLOW RC, 1986, J CELL PHYSIOL, V128, P251, DOI 10.1002/jcp.1041280217; PRINCIOTTO JV, 1975, NATURE, V255, P87, DOI 10.1038/255087a0; Rawas A, 1996, ACTA CRYSTALLOGR D, V52, P631, DOI 10.1107/S0907444996000212; Rawas A, 1997, ACTA CRYSTALLOGR D, V53, P464, DOI 10.1107/S0907444997000838; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Teh EM, 2005, FEBS J, V272, P6344, DOI 10.1111/j.1742-4658.2005.05028.x; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; VONRHEIN C, 2006, CRYSTALLOGRAPHIC MET, P215; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Ward PP, 1996, J BIOL CHEM, V271, P12790, DOI 10.1074/jbc.271.22.12790; WILLIAMS J, 1978, BIOCHEM J, V173, P535, DOI 10.1042/bj1730533; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu GZ, 2005, MOL CELL PROTEOMICS, V4, P1959, DOI 10.1074/mcp.M500095-MCP200; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505; YOUNG SP, 1990, BIOCHEM J, V265, P587, DOI 10.1042/bj2650587; Zak O, 2003, BIOCHEMISTRY-US, V42, P12330, DOI 10.1021/bi034991f; Zak O, 2002, BIOCHEMISTRY-US, V41, P7416, DOI 10.1021/bi0160258; Zak O, 1997, BIOCHEMISTRY-US, V36, P11036, DOI 10.1021/bi970628v; Zuccola H. J., 1993, CRYSTAL STRUCTURE MO	89	192	196	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24934	24944		10.1074/jbc.M604592200	http://dx.doi.org/10.1074/jbc.M604592200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793765	Green Accepted, hybrid			2022-12-25	WOS:000239847800086
J	Wang, LY; Hinoi, E; Takemori, A; Nakamichi, N; Yoneda, Y				Wang, Liyang; Hinoi, Eiichi; Takemori, Akihiro; Nakamichi, Noritaka; Yoneda, Yukio			Glutamate inhibits chondral mineralization through apoptotic cell death mediated by retrograde operation of the cystine/glutamate antiporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; HORMONE-RELATED PEPTIDE; FUNCTIONAL EXPRESSION; HUMAN OSTEOARTHRITIS; CHONDROCYTE DEATH; RODENT CARTILAGE; PLASMA-MEMBRANE; RAT; RECEPTORS; ARTHRITIS	Although we have previously demonstrated the functional significance of excitatory amino acid transporters as well as glutamate (Glu) receptors (GluRs) expressed by chondrocytes, little attention has been paid to the possible expression of the cystine/Glu antiporter responsible for the bi-directional transmembrane transport of Glu in chondrocytes to date. In organotypic cultured mouse embryonic metatarsals isolated before vascularization, the chondral mineralization was significantly decreased in the presence of Glu at a high concentration. Apoptotic cells were detected within the late proliferating and prehypertrophic chondrocytic layers in metatarsals cultured in the presence of Glu. A group III metabotropic GluR (mGluR) antagonist partially, but significantly, prevented the inhibition of mineralization by Glu in metatarsals without affecting the number of apoptotic cells. Both decreased mineralization and apoptosis by Glu were significantly prevented by the addition of the cystine/Glu antiporter inhibitor homocysteic acid, as well as reduced glutathione (GSH) and cystine. Expression of mRNA for xCT and 4F2hc subunits, which are components of the cystine/Glu antiporter, was seen in both cultured mouse metatarsals and rat costal chondrocytes. In chondrocytes cultured with Glu, a significant decrease was seen in intracellular GSH levels, together with increases in the number of apoptotic cells and the level of intracellular reactive oxygen species. These results suggest that Glu could regulate chondrogenic differentiation toward mineralization through a mechanism associated with apoptosis mediated by the depletion of intracellular GSH after the retrograde operation of the cystine/ Glu antiporter, in addition to the activation of group III mGluR, in chondrocytes.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Lab Mol Pharmacol, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Lab Mol Pharmacol, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan.	yyoneda@p.kanazawa-u.ac.jp	Nakamichi, Noritaka/D-8403-2015; Nakamichi, Noritaka/AAB-7388-2020; Yoneda, Yukio/ABI-1864-2020	Nakamichi, Noritaka/0000-0002-0283-3546; Yoneda, Yukio/0000-0002-4624-177X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00-0594fje; Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534-5807(02)00218-6; Haaijman A, 1999, BONE, V25, P397, DOI 10.1016/S8756-3282(99)00189-1; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Heraud F, 2000, ANN RHEUM DIS, V59, P959, DOI 10.1136/ard.59.12.959; HERLIN PM, 1982, J NEUROCHEM, V38, P1170, DOI 10.1111/j.1471-4159.1982.tb05367.x; Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P1744, DOI 10.1016/j.bcp.2005.09.010; Hinoi E, 2005, BIOCHEM PHARMACOL, V70, P70, DOI 10.1016/j.bcp.2005.04.025; Hinoi E, 2004, EUR J BIOCHEM, V271, P1, DOI 10.1046/j.1432-1033.2003.03907.x; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Kim HA, 1999, ARTHRITIS RHEUM, V42, P1528, DOI 10.1002/1529-0131(199907)42:7<1528::AID-ANR28>3.0.CO;2-9; Kim HA, 2000, J RHEUMATOL, V27, P455; KLEMENT BJ, 1993, J EXP ZOOL, V265, P285, DOI 10.1002/jez.1402650309; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lawand NB, 2000, PAIN, V86, P69, DOI 10.1016/S0304-3959(99)00311-5; Lawand NB, 1997, EUR J PHARMACOL, V324, P169, DOI 10.1016/S0014-2999(97)00072-1; MacLean HE, 2004, J CLIN INVEST, V113, P1334, DOI 10.1172/JCI200421252; McNearney T, 2000, J RHEUMATOL, V27, P739; Moriguchi N, 2006, HISTOL HISTOPATHOL, V21, P969, DOI 10.14670/HH-21.969; PLAITAKIS A, 1982, SCIENCE, V216, P193, DOI 10.1126/science.6121377; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang LY, 2005, BRIT J PHARMACOL, V146, P732, DOI 10.1038/sj.bjp.0706358; Wang LY, 2005, BIOL PHARM BULL, V28, P990, DOI 10.1248/bpb.28.990; Yoneda Y, 2001, PROG NEUROBIOL, V63, P697, DOI 10.1016/S0301-0082(00)00036-8	35	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24553	24565		10.1074/jbc.M600939200	http://dx.doi.org/10.1074/jbc.M600939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790444	hybrid			2022-12-25	WOS:000239847800051
J	Hou, JC; Shigematsu, S; Crawford, HC; Anastasiadis, PZ; Pessin, JE				Hou, June C.; Shigematsu, Satoshi; Crawford, Howard C.; Anastasiadis, Panos Z.; Pessin, Jeffrey E.			Dual regulation of Rho and Rac by p120 catenin controls adipocyte plasma membrane trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; TRANS-GOLGI NETWORK; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; 3T3L1 ADIPOCYTES; ACTIN-FILAMENTS; TYROSINE PHOSPHORYLATION; TRANSFERRIN RECEPTORS; SIGNALING PATHWAY	During 3T3L1 adipogenesis there is a marked reduction in beta-catenin and N-cadherin expression with a relatively small decrease in p120 catenin protein levels. Cell fractionation demonstrated a predominant decrease in the particulate (membrane-bound) pool of p120 catenin with little effect on the soluble pool, resulting in a large redistribution from the plasma membrane to the cytosol. Reexpression of p120 catenin inhibited constitutive ( transferrin receptor) and regulated mannose 6-phosphate receptor and GLUT4 trafficking to the plasma membrane. The inhibition of membrane trafficking was specific for p120 catenin function as this could be rescued by co-expression of N-cadherin. Moreover, overexpression of a p120 catenin deletion mutant (p120 Delta 622-628) or splice variant (p120-4A), neither of which could regulate Rho or Rac activity, showed no significant effect. The inhibition of GLUT4 translocation was also observed upon the simultaneous expression of a constitutively active Rac mutant (Rac1/Val(12)) in combination with a dominant-interfering Rho mutant (RhoA/Asn(19)). This was recapitulated by expression of the Rho ADP-ribosylation factor (C3ADP) in combination with constitutively active Rac1/Val(12). Moreover, siRNA-mediated knockdown of p120 catenin resulted in increased basal state accumulation of GLUT4 at the plasma membrane. Together, these data demonstrate that p120 catenin plays an important role in maintaining the basal tone of membrane protein trafficking in adipocytes through the dual regulation of Rho and Rac function and accounts for reports implicating Rho or Rac in the control of GLUT4 translocation.	Stony Brook Univ, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Shinshu Univ, Sch Med, Dept Aging Med & Geriatr, Matsumoto, Nagano 3908621, Japan; Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Shinshu University; Mayo Clinic	Pessin, JE (corresponding author), Stony Brook Univ, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	Pessin@pharm.stonybrook.edu	Crawford, Howard/A-2874-2008		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK055811, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55811, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Brozinick JT, 2004, J BIOL CHEM, V279, P40699, DOI 10.1074/jbc.M402697200; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; CHUNQIU HJ, 2003, MOL BIOL CELL, V14, P3578; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DOWNING JR, 1991, ONCOGENE, V6, P607; Ducluzeau PH, 2002, DIABETES METAB, V28, P85; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Grosheva I, 2001, J CELL SCI, V114, P695; Holman GD, 2001, TRENDS CELL BIOL, V11, P173, DOI 10.1016/S0962-8924(01)01953-5; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Kanzaki M, 2002, MOL BIOL CELL, V13, P2334, DOI 10.1091/mbc.01-10-0490; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Khayat ZA, 2000, J CELL SCI, V113, P279; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Martin S, 2000, J CELL SCI, V113, P3427; Martin S, 1997, J CELL SCI, V110, P2281; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OKA Y, 1985, J BIOL CHEM, V260, P9435; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Ploug T, 2002, MOL MEMBR BIOL, V19, P39, DOI 10.1080/09687680110119229; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Standaert M, 1998, J BIOL CHEM, V273, P7470, DOI 10.1074/jbc.273.13.7470; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Usui I, 2003, J BIOL CHEM, V278, P13765, DOI 10.1074/jbc.M208904200; Valderrama F, 2000, P NATL ACAD SCI USA, V97, P1560, DOI 10.1073/pnas.97.4.1560; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200	65	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23307	23312		10.1074/jbc.M603127200	http://dx.doi.org/10.1074/jbc.M603127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16754687	hybrid			2022-12-25	WOS:000239702900004
J	Sethi, G; Ahn, KS; Sandur, SK; Lin, X; Chaturvedi, MM; Aggarwal, BB				Sethi, Gautam; Ahn, Kwang Seok; Sandur, Santosh K.; Lin, Xin; Chaturvedi, Madan M.; Aggarwal, Bharat B.			Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; ALPHA KINASE; P65 PHOSPHORYLATION; DOWN-REGULATION; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; TNF-ALPHA; ACTIVATION; INHIBITOR; INDUCTION	Although indirubin is known to exhibit anti-cancer and antiinflammatory activities, very little is known about its mechanism of action. In this study, we investigated whether indirubin mediates its effects through interference with the NF-kappa B pathway. As examined by the DNA binding of NF-kappa B, we found that indirubin suppressed tumor necrosis factor (TNF)-induced NF-kappa B activation in a dose-and time-dependent manner. Indirubin also suppressed the NF-kappa B activation induced by various inflammatory agents and carcinogens. Further studies showed that indirubin blocked the phosphorylation and degradation of I kappa B alpha through the inhibition of activation of I kappa B alpha kinase and phosphorylation and nuclear translocation of p65. NF-kappa B reporter activity induced by TNFR1, TNF receptor-associated death domain, TRAF2, TAK1, NF-kappa B-inducing kinase, and IKK beta was inhibited by indirubin but not that induced by p65 transfection. We also found that indirubin inhibited the expression of NF-kappa B-regulated gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Bcl-x(L), and TRAF1), proliferation (cyclin D1 and c-Myc), and invasion (COX-2 and MMP-9). This correlated with enhancement of the apoptosis induced by TNF and the chemotherapeutic agent taxol in human leukemic KBM-5 cells. Indirubin also suppressed cytokine-induced cellular invasion. Overall, our results indicate that anti-cancer and anti-inflammatory activities previously assigned to indirubin may be mediated in part through the suppression of the NF-kappa B activation pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Sethi, Gautam/F-2372-2011; Ahn, Kwang Seok/G-4249-2013; Aggarwal, Bharat B/G-3388-2013	Sethi, Gautam/0000-0002-8677-8475; 	NATIONAL CANCER INSTITUTE [P50CA097007, P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844, P50CA97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Danz H, 2001, PLANTA MED, V67, P411, DOI 10.1055/s-2001-15805; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Eisenbrand G, 2004, J CANCER RES CLIN, V130, P627, DOI 10.1007/s00432-004-0579-2; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Kunikata T, 2000, EUR J PHARMACOL, V410, P93, DOI 10.1016/S0014-2999(00)00879-7; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee JW, 2005, BIOORG MED CHEM LETT, V15, P3948, DOI 10.1016/j.bmcl.2005.05.105; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Liu XM, 1996, BIOCHEM PHARMACOL, V51, P1545, DOI 10.1016/0006-2952(96)00098-6; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mak NK, 2004, BIOCHEM PHARMACOL, V67, P167, DOI 10.1016/j.bcp.2003.08.020; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Moon MJ, 2006, BIOORGAN MED CHEM, V14, P237, DOI 10.1016/j.bmc.2005.08.008; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shiraga M, 2002, CANCER RES, V62, P5967; Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008-5472.CAN-05-1585; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sugihara K, 2004, BIOCHEM BIOPH RES CO, V318, P571, DOI 10.1016/j.bbrc.2004.04.066; Suzuki K, 2005, BRIT J HAEMATOL, V130, P681, DOI 10.1111/j.1365-2141.2005.05655.x; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiao ZJ, 2002, LEUKEMIA LYMPHOMA, V43, P1763, DOI 10.1080/1042819021000006295; Xie YB, 2004, NEUROSCI LETT, V367, P355, DOI 10.1016/j.neulet.2004.06.044; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	69	92	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23425	23435		10.1074/jbc.M602627200	http://dx.doi.org/10.1074/jbc.M602627200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16785236	hybrid			2022-12-25	WOS:000239702900017
J	Bahi, N; Zhang, JS; Llovera, M; Ballester, M; Comella, JX; Sanchis, D				Bahi, Nuria; Zhang, Jisheng; Llovera, Marta; Ballester, Manel; Comella, Joan X.; Sanchis, Daniel			Switch from caspase-dependent to caspase-independent death during heart development - Essential role of endonuclease G in ischemia-induced DNA processing of differentiated cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-DEATH; MITOCHONDRIAL RELEASE; GENE-TRANSFER; POLY(ADP-RIBOSE) POLYMERASE; APOPTOSIS REPRESSOR; RECRUITMENT DOMAIN; OXIDATIVE STRESS; CARDIAC MYOCYTE; KEY FACTOR; FACTOR-I	Differentiated cardiomyocytes are resistant to caspase-dependent cell death; however, the mechanisms involved are still uncertain. We previously reported that low Apaf1 expression partially accounts for cardiomyocyte resistance to apoptosis. Here, we extend the knowledge on the molecular basis of cardiac resistance to caspase activation by showing that the whole caspase-dependent pathway is silenced during heart development. Experimental ischemia triggers caspase activation in embryonic cardiomyocytes and proliferating fibroblasts, but not in neonatal and adult cardiomyocytes. Ischemia induces the release of the proapoptotic factors cytochrome c, truncated-AIF, and EndoG from mitochondria in postnatal cardiomyocytes in the absence of caspase activation. On the one hand, lentiviral-driven knockdown of EndoG shows that this gene is essential for ischemia-induced DNA degradation in neonatal cardiomyocytes, but not in proliferating fibroblasts; on the other hand, the AIF gene is essential for high molecular DNA cleavage in fibroblasts, but not in postmitotic cardiomyocytes, where it plays a prosurvival role during reoxygenation. These results show the switch from caspase-dependent to caspase-independent death pathways after cardiac cell differentiation, and disclose the relevance of EndoG in the caspase-independent DNA processing of differentiated cardiomyocytes.	UdL, HUAV,Dept CMB, Lab Invest, Cell Signaling & Apoptosis Grp, Lleida 25198, Spain	Universitat de Lleida	Sanchis, D (corresponding author), UdL, HUAV,Dept CMB, Lab Invest, Cell Signaling & Apoptosis Grp, Av Rovira Roure 80, Lleida 25198, Spain.	daniel.sanchis@cmb.udl.es	Zhang, Jisheng/A-1928-2010; Sanchis, Daniel/C-8077-2009; Pla, Nuria Bahi/B-8022-2009; Llovera, Marta/AAE-4230-2021; Zhang, Jisheng/AAT-6495-2020; Comella, Joan/GQA-4279-2022; Comella, Joan X/D-7333-2012; Llovera, Marta/B-5585-2009; Bahi, Nuria/ABE-9680-2021; Sanchis, Daniel/B-5644-2009	Sanchis, Daniel/0000-0003-0047-8533; Pla, Nuria Bahi/0000-0003-2845-0313; Comella, Joan X/0000-0002-6218-0786; Llovera, Marta/0000-0001-8399-6867; Bahi, Nuria/0000-0003-2845-0313; 				Akao M, 2003, CIRC RES, V92, P186, DOI 10.1161/01.RES.0000051861.21316.E9; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Chatterjee S, 2002, CIRCULATION, V106, pI212, DOI 10.1161/01.cir.0000032907.33237.55; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; CUMMINGS OW, 1987, J BIOL CHEM, V262, P2005; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; David KK, 2006, CELL DEATH DIFFER, V13, P1147, DOI 10.1038/sj.cdd.4401787; Ekhterae D, 1999, CIRC RES, V85, pE70; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Hochhauser E, 2003, AM J PHYSIOL-HEART C, V284, pH2351, DOI 10.1152/ajpheart.00783.2002; Huang JH, 2003, BIOCHEM BIOPH RES CO, V311, P64, DOI 10.1016/j.bbrc.2003.09.160; Irvine RA, 2005, MOL CELL BIOL, V25, P294, DOI 10.1128/MCB.25.1.294-302.2005; Jayasankar V, 2003, CIRCULATION, V108, P230, DOI 10.1161/01.cir.0000087444.53354.66; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Mayorga M, 2004, J BIOL CHEM, V279, P34882, DOI 10.1074/jbc.M404616200; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Misra A, 2003, CIRCULATION, V108, P3075, DOI 10.1161/01.CIR.0000108929.93074.0B; Nakano M, 1997, CIRCULATION, V95, P1523; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Potts MB, 2005, J CELL BIOL, V171, P925, DOI 10.1083/jcb.200504082; Ravassa S, 2000, HYPERTENSION, V36, P1065, DOI 10.1161/01.HYP.36.6.1065; Sanchis D, 2003, CELL DEATH DIFFER, V10, P977, DOI 10.1038/sj.cdd.4401267; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Teshima Y, 2003, CIRCULATION, V108, P2275, DOI 10.1161/01.CIR.0000093277.20968.C7; van Empel VPM, 2005, CIRC RES, V96, pE92, DOI 10.1161/01.RES.0000172081.30327.28; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wright KM, 2004, J CELL BIOL, V167, P303, DOI 10.1083/jcb.200406073; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200	55	74	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22943	22952		10.1074/jbc.M601025200	http://dx.doi.org/10.1074/jbc.M601025200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754658	hybrid, Green Published			2022-12-25	WOS:000239542600056
J	Gaspar, ML; Aregullin, MA; Jesch, SA; Henry, SA				Gaspar, Maria L.; Aregullin, Manuel A.; Jesch, Stephen A.; Henry, Susan A.			Inositol induces a profound alteration in the pattern and rate of synthesis and turnover of membrane lipids in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPATHY TARGET ESTERASE; PROTEIN N-MYRISTOYLATION; CROSS-PATHWAY REGULATION; ACETYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; EXOGENOUS FATTY-ACIDS; PHOSPHOLIPID BIOSYNTHESIS; INO1 PROMOTER; YEAST; GENE	The addition of inositol to actively growing yeast cultures causes a rapid increase in the rate of synthesis of phosphatidylinositol and, simultaneously, triggers changes in the expression of hundreds of genes. We now demonstrate that the addition of inositol to yeast cells growing in the presence of choline leads to a dramatic reprogramming of cellular lipid synthesis and turnover. The response to inositol includes a 5-6-fold increase in cellular phosphatidylinositol content within a period of 30 min. The increase in phosphatidylinositol content appears to be dependent upon fatty acid synthesis. Phosphatidylcholine turnover increased rapidly following inositol addition, a response that requires the participation of Nte1p, an endoplasmic reticulum-localized phospholipase B. Mass spectrometry revealed that the acyl species composition of phosphatidylinositol is relatively constant regardless of supplementation with inositol or choline, whereas phosphatidylcholine acyl species composition is influenced by both inositol and choline. In medium containing inositol, but lacking choline, high levels of dimyristoylphos-phatidylcholine were detected. Within 60 min following the addition of inositol, dimyristoylphosphatidylcholine levels had decreased from similar to 40% of total phosphatidylcholine to a basal level of less than 5%. nte1 Delta cells grown in the absence of inositol and in the presence of choline exhibited lower levels of dimyristoylphosphatidylcholine than wild type cells grown under these same conditions, but these levels remained largely constant after the addition of inositol. These results are discussed in relationship to transcriptional regulation known to be linked to lipid metabolism in yeast.	Cornell Univ, Coll Agr & Life Sci, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; Cornell University	Henry, SA (corresponding author), Cornell Univ, Coll Agr & Life Sci, 260 Roberts Hall, Ithaca, NY 14853 USA.	sah42@cornell.edu	Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Vasquez F, 2005, NATURE, V433, P425, DOI 10.1038/nature03232; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; Athenstaedt K, 2005, J BIOL CHEM, V280, P37301, DOI 10.1074/jbc.M507261200; Athenstaedt K, 2003, J BIOL CHEM, V278, P23317, DOI 10.1074/jbc.M302577200; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1978, THESIS YESHIVA U NEW; Boumann HA, 2003, BIOCHEMISTRY-US, V42, P3054, DOI 10.1021/bi026801r; Brachmann CB, 1998, YEAST, V14, P115; Burnett WV, 1997, BIOTECHNIQUES, V22, P668, DOI 10.2144/97224st01; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Christie W.W., 2003, LIPID ANAL ISOLATION, P105; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Glynn P, 2005, BBA-MOL CELL BIOL L, V1736, P87, DOI 10.1016/j.bbalip.2005.08.002; GREENBERG ML, 1982, GENETICS, V100, P19; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; JESCH SA, 2005, CELL BIOL DYNAMICS Y, P105; Jesch SA, 2006, J BIOL CHEM, V281, P24070, DOI 10.1074/jbc.M604541200; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1973, FEBS LETT, V38, P29, DOI 10.1016/0014-5793(73)80505-8; KAMIRYO T, 1976, P NATL ACAD SCI USA, V73, P386, DOI 10.1073/pnas.73.2.386; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MCGRAW P, 1989, GENETICS, V122, P317; Natter K, 2005, MOL CELL PROTEOMICS, V4, P662, DOI 10.1074/mcp.M400123-MCP200; NOMURA S, 1972, J BIOCHEM-TOKYO, V71, P783, DOI 10.1093/oxfordjournals.jbchem.a129827; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Santiago TC, 2003, J BIOL CHEM, V278, P38723, DOI 10.1074/jbc.M303008200; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; Shirra MK, 2001, MOL CELL BIOL, V21, P5710, DOI 10.1128/MCB.21.17.5710-5722.2001; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUMMERS EF, 1988, GENETICS, V120, P909; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Weerheim AM, 2002, ANAL BIOCHEM, V302, P191, DOI 10.1006/abio.2001.5552; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WOODS A, 1994, J BIOL CHEM, V269, P19509; Zaccheo O, 2004, J BIOL CHEM, V279, P24024, DOI 10.1074/jbc.M400830200	47	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22773	22785		10.1074/jbc.M603548200	http://dx.doi.org/10.1074/jbc.M603548200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16777854	hybrid			2022-12-25	WOS:000239542600038
J	Markham, JE; Li, J; Cahoon, EB; Jaworski, JG				Markham, Jonathan E.; Li, Jia; Cahoon, Edgar B.; Jaworski, Jan G.			Separation and identification of major plant sphingolipid classes from leaves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; PROGRAMMED CELL-DEATH; PERFORMANCE LIQUID-CHROMATOGRAPHY; LONG-CHAIN BASES; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TOBACCO-LEAVES; LIPID RAFTS; FATTY-ACIDS; SPHINGOSINE-1-PHOSPHATE	Sphingolipids are major components of the plasma membrane, tonoplast, and other endomembranes of plant cells. Previous compositional analyses have focused only on individual sphingolipid classes because of the widely differing polarities of plant sphingolipids. Consequently, the total content of sphingolipid classes in plants has yet to be quantified. In addition, the major polar sphingolipid class in the model plant Arabidopsis thaliana has not been previously determined. In this report, we describe the separation and quantification of sphingolipid classes from A. thaliana leaves using hydrolysis of sphingolipids and high performance liquid chromatography (HPLC) analysis of o-phthaldialdehyde derivatives of the released long-chain bases to monitor the separation steps. An extraction solvent that contained substantial proportions of water was used to solubilized > 95% of the sphingolipids from leaves. Neutral and charged sphingolipids were then partitioned by anion exchange solid phase extraction. HPLC analysis of the charged lipid fraction from A. thaliana revealed only one major anionic sphingolipid class, which was identified by mass spectrometry as hexose-hexuronic-inositolphosphoceramide. The neutral sphingolipids were predominantly composed of monohexosylceramide with lesser amounts of ceramides. Extraction and separation of sphingolipids from soybean and tomato showed that, like A. thaliana, the neutral sphingolipids consisted of ceramide and monohexosylceramides; however, the major polar sphingolipid was found to be N-acetyl-hexosamine-hexuronic-inositolphosphoceramide. In extracts from A. thaliana leaves, hexose-hexuronic-inositolphosphoceramides, monohexosylceramides, and ceramides accounted for similar to 64, 34, and 2% of the total sphingolipids, respectively, suggesting an important role for the anionic sphingolipids in plant membranes.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; United State Dept Agr Agr Res Serv Plant, Genet Res Unit, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Markham, JE (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jmarkham@danforthcenter.org	Jaworski, Jan/N-2255-2014	Markham, Jennifer/0000-0003-2397-3131; Jaworski, Jan/0000-0003-3309-4915				[Anonymous], 2003, LIPID ANAL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonaventure G, 2003, PLANT CELL, V15, P1020, DOI 10.1105/tpc.008946; Borner GHH, 2005, PLANT PHYSIOL, V137, P104, DOI 10.1104/pp.104.053041; CAHOON EB, 1991, PLANT PHYSIOL, V95, P58, DOI 10.1104/pp.95.1.58; CARTER HE, 1969, BIOCHEMISTRY-US, V8, P383, DOI 10.1021/bi00829a053; CARTER HE, 1958, J BIOL CHEM, V233, P1309; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; Coursol S, 2005, PLANT PHYSIOL, V137, P724, DOI 10.1104/pp.104.055806; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dunn TM, 2004, ANN BOT-LONDON, V93, P483, DOI 10.1093/aob/mch071; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; HANSON BA, 1980, J LIPID RES, V21, P309; Imai H, 2000, J PLANT PHYSIOL, V157, P453, DOI 10.1016/S0176-1617(00)80031-0; IRO S, 1985, AGR BIOL CHEM TOKYO, V49, P539; KAUL K, 1978, BIOCHEMISTRY-US, V17, P3569, DOI 10.1021/bi00610a023; KAUL K, 1975, PLANT PHYSIOL, V55, P120, DOI 10.1104/pp.55.1.120; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; Levery SB, 2001, RAPID COMMUN MASS SP, V15, P2240, DOI 10.1002/rcm.505; Liang H, 2003, GENE DEV, V17, P2636, DOI 10.1101/gad.1140503; Maceyka M, 2005, PROSTAG OTH LIPID M, V77, P15, DOI 10.1016/j.prostaglandins.2004.09.010; Merrill AH, 2000, METHOD ENZYMOL, V312, P3; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Mongrand S, 2004, J BIOL CHEM, V279, P36277, DOI 10.1074/jbc.M403440200; MORRISON WR, 1970, BIOCHIM BIOPHYS ACTA, V202, P460, DOI 10.1016/0005-2760(70)90116-5; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; NICHOLS BW, 1963, BIOCHIM BIOPHYS ACTA, V70, P417, DOI 10.1016/0926-6542(63)90060-X; OHNISHI M, 1983, BIOCHIM BIOPHYS ACTA, V752, P416; OHNISHI M, 1982, LIPIDS, V17, P803, DOI 10.1007/BF02535357; SASTRY PS, 1964, BIOCHEMISTRY-US, V3, P1271, DOI 10.1021/bi00897a015; SINGH BN, 1991, ARCH BIOCHEM BIOPHYS, V286, P409, DOI 10.1016/0003-9861(91)90059-R; Spassieva SD, 2002, PLANT J, V32, P561, DOI 10.1046/j.1365-313X.2002.01444.x; Sperling P, 2005, PLANT PHYSIOL BIOCH, V43, P1031, DOI 10.1016/j.plaphy.2005.10.004; TOLEDO MS, 1995, J MED VET MYCOL, V33, P247; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996	37	239	248	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22684	22694		10.1074/jbc.M604050200	http://dx.doi.org/10.1074/jbc.M604050200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772288	hybrid			2022-12-25	WOS:000239542600029
J	Ogburn, KD; Figueiredo-Pereira, ME				Ogburn, Kenyon D.; Figueiredo-Pereira, Maria E.			Cytoskeleton/endoplasmic reticulum collapse induced by prostaglandin J2 parallels centrosomal deposition of ubiquitinated protein aggregates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; AMINO-ACID-SEQUENCE; CYCLOPENTENONE PROSTAGLANDINS; ENDOGENOUS ELECTROPHILE; INCLUSION-BODIES; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ENDOPLASMIC-RETICULUM; PARKINSONS-DISEASE; OXIDATIVE STRESS; NEURONAL CELLS	Many neurodegenerative disorders, such as Parkinson disease, exhibit inclusion bodies containing ubiquitinated proteins. The mechanisms implicated in this aberrant protein deposition remain elusive. In these disorders signs of inflammation are also apparent in the affected central nervous system areas. We show that prostaglandin-J2(PGJ2), an endogenous product of inflammation, disrupts the cytoskeleton in neuronal cells. Furthermore, PGJ2 perturbed microtubule polymerization in vitro and decreased the number of free sulfhydryl groups on tubulin cysteines. A direct effect of PGJ2 on actin was not apparent, although actin filaments were altered in cells treated with PGJ2. This cyclopentenone prostaglandin triggered endoplasmic reticulum (ER) collapse and the redistribution of ER proteins, such as calnexin and catechol-O-methyltransferase, into a large centrosomal aggregate containing ubiquitinated proteins and alpha-synuclein. The PGJ2-dependent cytoskeletal rearrangement paralleled the development of the large centrosomal aggregate. Both of these events were replicated by treating cells with colchicine, which disrupts the microtubule/ER network, but not with brefeldin A, which impairs ER/Golgi transport. PGJ2 also perturbed 26 S proteasome assembly and activity, which preceded the accumulation of ubiquitinated proteins as detergent/salt-insoluble aggregates. Our data support a mechanism by which, upon PGJ2 treatment, cytoskeleton/ER collapse coincides with the relocation of ER proteins, other potentially neighboring proteins, and ubiquitinated proteins into centrosomal aggregates. Development of these large perinuclear aggregates is associated with disruption of the microtubule/ER network. This aberrant protein deposition, triggered by a product of inflammation, may be common to other compounds that disrupt microtubules and induce protein aggregation, such as MPP+ and rotenone, found to be associated with neurodegeneration.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Figueiredo-Pereira, ME (corresponding author), 695 Pk Ave, New York, NY 10021 USA.	pereira@genectr.hunter.cuny.edu			NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM060665, GM60654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM060665, S06GM060654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldini G, 2005, J MASS SPECTROM, V40, P946, DOI 10.1002/jms.872; Alim MA, 2004, J ALZHEIMERS DIS, V6, P435; Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Bajorek M, 2003, CURR BIOL, V13, P1140, DOI 10.1016/S0960-9822(03)00417-2; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; BIEDLER JL, 1978, CANCER RES, V38, P3751; Cappelletti G, 2001, CELL BIOL INT, V25, P981, DOI 10.1006/cbir.2001.0772; Diaz-Corrales FJ, 2005, NEUROSCIENCE, V133, P117, DOI 10.1016/j.neuroscience.2005.01.044; Farooqui AA, 2006, NEUROSCIENTIST, V12, P245, DOI 10.1177/1073858405285923; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIMES RH, 1977, J BIOL CHEM, V252, P6222; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Ishii T, 2004, CHEM RES TOXICOL, V17, P1313, DOI 10.1021/tx049860+; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; Landino LM, 2002, ARCH BIOCHEM BIOPHYS, V398, P213, DOI 10.1006/abbi.2001.2729; Li ZM, 2004, J NEUROSCI RES, V78, P824, DOI 10.1002/jnr.20346; Li ZM, 2004, BIOCHEM BIOPH RES CO, V319, P1171, DOI 10.1016/j.bbrc.2004.05.098; Li ZM, 2003, INT J BIOCHEM CELL B, V35, P547, DOI 10.1016/S1357-2725(02)00384-9; Liu CL, 2005, NEUROSCIENCE, V134, P1273, DOI 10.1016/j.neuroscience.2005.05.015; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Ogburn KD, 2006, NEUROBIOL DIS, V22, P294, DOI 10.1016/j.nbd.2005.11.006; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; Pignatelli M, 2005, CARCINOGENESIS, V26, P81, DOI 10.1093/carcin/bgh308; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; Ren Y, 2003, J NEUROSCI, V23, P3316; Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Shibata T, 2003, BIOCHEMISTRY-US, V42, P13960, DOI 10.1021/bi035215a; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Wigley WC, 1999, J CELL BIOL, V145, P481; Yang F, 2005, J BIOL CHEM, V280, P17154, DOI 10.1074/jbc.M500843200; Zhu BT, 2004, INT J MOL MED, V13, P343	46	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23274	23284		10.1074/jbc.M600635200	http://dx.doi.org/10.1074/jbc.M600635200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774923	hybrid			2022-12-25	WOS:000239542600090
J	Reinehr, R; Becker, S; Braun, J; Eberle, A; Grether-Beck, S; Haussinger, D				Reinehr, Roland; Becker, Stephan; Braun, Juliane; Eberle, Andrea; Grether-Beck, Susanne; Haeussinger, Dieter			Endosomal acidification and activation of NADPH oxidase isoforms are upstream events in hyperosmolarity-induced hepatocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHIOCYANATE-DEXTRAN FLUORESCENCE; ACIDIC CELLULAR COMPARTMENTS; GROWTH-FACTOR RECEPTOR; RAT HEPATOCYTES; CL-CHANNELS; SIGNAL-TRANSDUCTION; CHLORIDE CHANNELS; VOLUME REGULATION; INTRACELLULAR PH; STRESS-RESPONSE	Hyperosmotic exposure of rat hepatocytes induced a rapid oxidativestress(ROS) response as an upstream signal for proapoptotic CD95 activation. This study shows that hyperosmotic ROS formation involves a rapid ceramide- and protein kinase C zeta (PKC zeta)-dependent serine phosphorylation of p47(phox) and subsequent activation of NADPH oxidase isoforms. Hyperosmotic p47(phox) phosphorylation and ROS formation were sensitive to inhibition of sphingomyelinases and were strongly blunted after knockdown of acidic sphingomyelinase (ASM) or of p47(phox) protein. Hyperosmolarity induced a rapid bafilomycin- and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid disodium salt (DIDS)-sensitive acidification of a vesicular compartment, which was accessible to endocytosed fluorescein isothiocyanate-dextran and colocalized with ASM, PKC zeta, and the NADPH oxidase isoform Nox 2 (gp91(phox)). Bafilomycin and DIDS prevented the hyperosmolarity-induced increase in ceramide formation, p47(phox) phosphorylation, and ROS formation. As shown recently (Reinehr, R., Becker, S., Hongen, A., and Haussinger, D. (2004) J. Biol. Chem. 279, 23977 - 23987), hyperosmolarity induced a Yes-dependent activation of JNK and the epidermal growth factor receptor (EGFR), followed by EGFR-CD95 association, EGFR-catalyzed CD95-tyrosine phosphorylation, and translocation of the EGFR-CD95 complex to the plasma membrane, where formation of the death-inducing signaling complex occurs. These proapoptotic responses were not only sensitive to inhibitors of sphingomyelinase, PKC zeta, or NADPH oxidases but also to ASM knock-down, bafilomycin, and DIDS, i.e. maneuvers largely preventing hyperosmolarity-induced endosomal acidification and/or ceramide formation. In hepatocytes from p47(phox) knock-out mice, hyperosmolarity failed to activate the CD95 system. The data suggest that hyperosmolarity induces endosomal acidification as an important upstream event for CD95 activation through stimulation of ASM-dependent ceramide formation and activation of NADPH oxidase isoforms.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany; Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Bataller R, 2003, J CLIN INVEST, V112, P1383, DOI 10.1172/JCI200318212; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; BUSCH GL, 1994, P NATL ACAD SCI USA, V91, P9165, DOI 10.1073/pnas.91.19.9165; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Dickinson ME, 2003, J BIOMED OPT, V8, P329, DOI 10.1117/1.1583734; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Eberle A, 2005, HEPATOLOGY, V41, P315, DOI 10.1002/hep.20564; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; Edwards JC, 2000, J BIOL CHEM, V275, P31826, DOI 10.1074/jbc.M005275200; Faundez Victor, 2004, Sci STKE, V2004, pre8, DOI 10.1126/stke.2332004re8; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Gomez-Munoz A, 1998, BBA-LIPID LIPID MET, V1391, P92, DOI 10.1016/S0005-2760(97)00201-4; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Graf J, 1996, J HEPATOL, V24, P53; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Gupta S, 2004, J BIOL CHEM, V279, P5821, DOI 10.1074/jbc.M310979200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1996, BIOCHEM J, V313, P697; HAUSSINGER D, 1990, HEPATOLOGY, V11, P243, DOI 10.1002/hep.1840110214; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KOJIMA S, 1993, FEBS LETT, V329, P125, DOI 10.1016/0014-5793(93)80207-B; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LANG F, 1993, RENAL PHYSIOL BIOCH, V16, P48; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li XH, 2002, ANNU REV PHYSIOL, V64, P609, DOI 10.1146/annurev.physiol.64.090501.145429; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Pazoles C J, 1980, Ann N Y Acad Sci, V358, P354, DOI 10.1111/j.1749-6632.1980.tb15417.x; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; Ramstedt B, 2002, FEBS LETT, V531, P33, DOI 10.1016/S0014-5793(02)03406-3; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2005, J BIOL CHEM, V280, P27179, DOI 10.1074/jbc.M414361200; Reinehr R, 2004, J BIOL CHEM, V279, P23977, DOI 10.1074/jbc.M401519200; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Reinehr R, 2005, GASTROENTEROLOGY, V129, P2009, DOI 10.1053/j.gastro.2005.09.023; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; SCHREIBER R, 1994, BIOCHEM J, V303, P113, DOI 10.1042/bj3030113; Schreiber R, 1996, BIOCHEM J, V315, P385, DOI 10.1042/bj3150385; SCHREIBER R, 1995, BIOCHEM J, V309, P19, DOI 10.1042/bj3090019; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TIMMER A, 2004, PLANAR CHROMATOGR, V93, P2; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; VOLKL H, 1994, FEBS LETT, V338, P27, DOI 10.1016/0014-5793(94)80110-X; VOLKL H, 1993, BIOCHEM J, V295, P11; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702; YOSHIDA Y, 1985, J BIOCHEM-TOKYO, V98, P1669, DOI 10.1093/oxfordjournals.jbchem.a135438; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423; Zsembery A, 2000, FASEB J, V14, P2345, DOI 10.1096/fj.99-0509com	80	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23150	23166		10.1074/jbc.M601451200	http://dx.doi.org/10.1074/jbc.M601451200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772302	hybrid			2022-12-25	WOS:000239542600079
J	Valdes, R; Liu, W; Ullman, B; Landfear, SM				Valdes, Raquel; Liu, Wei; Ullman, Buddy; Landfear, Scott M.			Comprehensive examination of charged intramembrane residues in a nucleoside transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE-GUANOSINE TRANSPORTER; TRYPANOSOMA-BRUCEI-BRUCEI; LEISHMANIA-DONOVANI; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; NUCLEOBASE TRANSPORTER; LACTOSE PERMEASE; PLASMODIUM-FALCIPARUM; CHIMERIC CONSTRUCTS; DEFICIENT MUTANT	Permeases of the equilibrative nucleoside transporter family mediate the uptake of nucleosides and/or nucleobases in a diverse array of eukaryotes and transport a host of drugs used for treatment of cancer, heart disease, AIDS, and parasitic infections. To identify residues that play central roles in transport function, we have systematically substituted by site-directed mutagenesis all the charged residues located within predicted transmembrane domains of the Leishmania donovani nucleoside transporter 1.1, LdNT1.1, which transports adenosine and the pyrimidine nucleosides. Substitution of three of these ten residues by uncharged amino acids resulted in loss of > 95% transport activity, and we hence designated them "key" residues. These amino acids were Glu(94), Lys(153), and Arg(404) located in transmembrane domains 2, 4, and 9, respectively. In addition, previous studies on the related LdNT2 inosine/guanosine transporter identified the highly conserved Asp(389) and Arg(393) (equivalent to Asp(374) and Arg(378) in LdNT1.1) in transmembrane domain 8 as key residues. Among these residues, the mutants in Arg(393) (LdNT2) and Arg(404) were strongly impaired in trafficking to the plasma membrane, but the other mutants were expressed with high to moderate efficiency at the cell surface, indicating that their mutation impaired transport activity per se. A conservative K153R substitution exhibited a change in substrate specificity, acquiring the ability to transport inosine, a nucleoside that is not a substrate for the wild-type LdNT1.1 permease. These results imply that the Glu(94), Lys(153), and Asp(374) residues may play central roles in the mechanism of substrate translocation in LdNT1.1.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Landfear, SM (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	landfear@ohsu.edu		Landfear, Scott/0000-0002-1643-6664	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138, R01AI025920] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25920, AI 44138, R01 AI044138] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Arastu-Kapur S, 2005, J BIOL CHEM, V280, P2213, DOI 10.1074/jbc.M408224200; Arastu-Kapur S, 2003, J BIOL CHEM, V278, P33327, DOI 10.1074/jbc.M305141200; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BERENS RL, 1995, BIOCH MOL BIOL PARAS; Burchmore RJS, 2003, J BIOL CHEM, V278, P23502, DOI 10.1074/jbc.M301252200; CARRASCO N, 1986, BIOCHEMISTRY-US, V25, P4486, DOI 10.1021/bi00364a004; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Carter NS, 2000, J BIOL CHEM, V275, P20935, DOI 10.1074/jbc.M002418200; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1995, DRUG TRANSPORT ANTIM, P404; Chaudary N, 2004, J PHARMACOL EXP THER, V310, P1190, DOI 10.1124/jpet.104.067157; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; De Koning HP, 1999, MOL PHARMACOL, V56, P1162, DOI 10.1124/mol.56.6.1162; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Henriques C, 2003, MOL BIOCHEM PARASIT, V130, P101, DOI 10.1016/S0166-6851(03)00167-1; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; Landfear SM, 2001, MOL BIOCHEM PARASIT, V115, P1, DOI 10.1016/S0166-6851(01)00262-6; LEBOWITZ JH, 1994, METHOD CELL BIOL, V45, P65; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Mackey JR, 1998, CANCER RES, V58, P4349; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; Sambrook J, 1989, MOL CLONING LAB MANU, V3, P18; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; Sanchez MA, 2004, MOL MEMBR BIOL, V21, P11, DOI 10.1080/0968768031000140845; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Snell BJ, 2004, LIFE SCI, V75, P225, DOI 10.1016/j.lfs.2003.12.012; Stein A, 2003, J BIOL CHEM, V278, P35127, DOI 10.1074/jbc.M306188200; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Taniguchi M, 2004, J AM COLL SURGEONS, V198, P758, DOI 10.1016/j.jamcollsurg.2003.12.002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valdes R, 2004, BIOCHEMISTRY-US, V43, P6793, DOI 10.1021/bi049873m; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22647	22655		10.1074/jbc.M602366200	http://dx.doi.org/10.1074/jbc.M602366200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769726	hybrid			2022-12-25	WOS:000239542600025
J	Hu, XQ; Sun, H; Peoples, RW; Hong, R; Zhang, L				Hu, Xiang-Qun; Sun, Hui; Peoples, Robert W.; Hong, Ren; Zhang, Li			An interaction involving an arginine residue in the cytoplasmic domain of the 5-HT3A receptor contributes to receptor desensitization mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL CONDUCTANCE; GATED ION-CHANNEL; SEROTONIN-RECEPTOR; AMINO-ACID; 5-HYDROXYTRYPTAMINE TYPE-3; SUBUNIT; PROTEIN; ACETYLCHOLINE; AGONIST; DETERMINANTS	A large cytoplasmic domain accounts for approximately one third of the entire protein of one superfamily of ligand-gated membrane ion channels, which includes nicotinic acetylcholine ( nACh), gamma-aminobutyric acid type A ( GABA(A)), serotonin type 3 ( 5-HT3), and glycine receptors. Desensitization is one functional feature shared by these receptors. Because most molecular studies of receptor desensitization have focused on the agonist binding and channel pore domains, relatively little is known about the role of the large cytoplasmic domain ( LCD) in this process. To address this issue, we sequentially deleted segments of the LCD of the 5-HT3A receptor and examined the function of the mutant receptors. Deletion of a small segment that contains three amino acid residues ( 425 - 427) significantly slowed the desensitization kinetics of the 5-HT3A receptor. Both deletion and point mutation of arginine 427 altered desensitization kinetics in a manner similar to that of the ( 425 - 427) deletion without significantly changing the apparent agonist affinity. The extent of receptor desensitization was positively correlated with the polarity of the amino acid residue at 427: the desensitization accelerates with increasing polarity. Whereas the R427L mutation produced the slowest desensitization, it did not significantly alter single channel conductance of 5-HT3A receptor. Thus, the arginine 427 residue in the LCD contributes to 5-HT3A receptor desensitization, possibly through forming an electrostatic interaction with its neighboring residues. Because the polarity of the amino acid residue at 427 is highly conserved, such a desensitization mechanism may occur in other members of the Cys-loop family of ligand-gated ion channels.	NIAAA, NIH, Lab Integrat Neurosci, Bethesda, MD 20892 USA; Marquette Univ, Dept Biomed Sci, Coll Hlth Sci, Milwaukee, WI 53201 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Marquette University	Zhang, L (corresponding author), NIAAA, NIH, Lab Integrat Neurosci, 5625 Fishers Lane, Bethesda, MD 20892 USA.	lzhang@mail.nih.gov	Zhang, Li/W-2104-2019					Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; Brownlow S, 2001, J CLIN INVEST, V108, P125, DOI 10.1172/JCI12935; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; Engel AG, 2003, ANN NY ACAD SCI, V998, P138, DOI 10.1196/annals.1254.016; GRANT KA, 1995, DRUG ALCOHOL DEPEN, V38, P155, DOI 10.1016/0376-8716(95)01120-N; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Gunthorpe MJ, 2000, J PHYSIOL-LONDON, V522, P187, DOI 10.1111/j.1469-7793.2000.00187.x; Hales TG, 2006, J BIOL CHEM, V281, P8062, DOI 10.1074/jbc.M513222200; Hapfelmeier G, 2003, BIOPHYS J, V84, P1720, DOI 10.1016/S0006-3495(03)74980-7; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Ilegems E, 2005, CHEMBIOCHEM, V6, P2180, DOI 10.1002/cbic.200500191; Jones MV, 1996, TRENDS NEUROSCI, V19, P96, DOI 10.1016/S0166-2236(96)80037-3; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lobitz N, 2001, MOL PHARMACOL, V59, P844, DOI 10.1124/mol.59.4.844; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Morales M, 2002, J NEUROSCI, V22, P6732; Mott DD, 2001, J PHYSIOL-LONDON, V535, P427, DOI 10.1111/j.1469-7793.2001.00427.x; Peters JA, 2005, TRENDS PHARMACOL SCI, V26, P587, DOI 10.1016/j.tips.2005.09.011; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Spier AD, 1999, MOL BRAIN RES, V67, P221; Sun H, 2003, J BIOL CHEM, V278, P34150, DOI 10.1074/jbc.M303584200; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; van Hooft JA, 2000, TRENDS NEUROSCI, V23, P605, DOI 10.1016/S0166-2236(00)01662-3; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326; YAKEL JL, 1988, NEURON, V1, P615, DOI 10.1016/0896-6273(88)90111-0	31	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21781	21788		10.1074/jbc.M600676200	http://dx.doi.org/10.1074/jbc.M600676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754678	hybrid			2022-12-25	WOS:000239387100024
J	Mikami, F; Lim, JH; Ishinaga, H; Ha, UH; Gu, H; Koga, T; Jono, H; Kai, H; Li, JD				Mikami, Fumi; Lim, Jae Hyang; Ishinaga, Hajime; Ha, Un-Hwan; Gu, He; Koga, Tomoaki; Jono, Hirofumi; Kai, Hirofumi; Li, Jian-Dong			The transforming growth factor-beta-Smad3/4 signaling pathway acts as a positive regulator for TLR2 induction by bacteria via a dual mechanism involving functional cooperation with NF-kappa B and MAPK phosphatase 1-dependent negative cross-talk with p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONTYPABLE HAEMOPHILUS-INFLUENZAE; TOLL-LIKE RECEPTOR; MUC5AC MUCIN TRANSCRIPTION; TGF-BETA; IN-VIVO; KINASE; EXPRESSION; ACTIVATION; GLUCOCORTICOIDS; INHIBITION	The transforming growth factor beta(TGF-beta) pathway represents an important signaling pathway involved in the regulation of diverse biological processes, including cell proliferation, differentiation, and apoptosis. Despite the known role of TGF-beta R-mediated signaling in suppressing immune response, its role in regulating human Toll-like receptors (TLRs), key host defense receptors that recognize invading bacterial pathogens, however, remains unknown. Here, we show for the first time that TGF-beta R-Smad3/4 signaling pathway acts as a positive regulator for TLR2 induction by bacterium nontypeable Hemophilus influenzae (NTHi) in vitro and in vivo. The positive regulation of TLR2 induction by TGF-beta R is mediated via a dual mechanism involving distinct signaling pathways. One mechanism involves functional cooperation between the TGF-beta R-Smad3/4 pathway and NF-kappa B pathway. Another involves MAP kinase phosphatase 1 (MKP-1)-dependent inhibition of p38MAPK, a known negative regulator for TLR2 induction. Moreover, we showed that T beta R-mediated signaling is probably activated by NTHi-derived TGF-beta mimicry molecule via an autocrine-independent mechanism. Thus, our study provides new insights into the role of TGF-beta signaling in positively regulating host defense response by tightly controlling the expression level of TLR2 during bacterial infections and may lead to new therapeutic strategies for modulating host defense and inflammatory response.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan	University of Rochester; House Research Institute; University of Southern California; Kumamoto University	Li, JD (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Box 672,601 Elmwood Ave, Rochester, NY 14642 USA.	Jian-Dong_Li@urmc.rochester.edu	Ha, Un-Hwan/ABH-8017-2020	Li, Jian-Dong/0000-0002-5593-050X; Lim, Jae Hyang/0000-0003-0972-9271; Ha, Un-Hwan/0000-0001-9182-7000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005843, R01DC004562] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070293] Funding Source: Medline; NIDCD NIH HHS [DC004562, DC005843] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; *APPL BIOS, 1997, US B APPL BIOS, V2; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jono H, 2003, J BIOL CHEM, V278, P27811, DOI 10.1074/jbc.M301773200; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Li JD, 2003, J PHARMACOL SCI, V91, P1, DOI 10.1254/jphs.91.1; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mikami F, 2005, J BIOL CHEM, V280, P36185, DOI 10.1074/jbc.M503941200; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reed SG, 1999, MICROBES INFECT, V1, P1313, DOI 10.1016/S1286-4579(99)00252-X; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Sakai A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-2; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; SHUTO T, 2006, IN PRESS FASEB J; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SPACCAPELO R, 1995, J IMMUNOL, V155, P1349; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Watanabe T, 2004, P NATL ACAD SCI USA, V101, P3563, DOI 10.1073/pnas.0400557101; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	43	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22397	22408		10.1074/jbc.M602124200	http://dx.doi.org/10.1074/jbc.M602124200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754688	hybrid			2022-12-25	WOS:000239387100085
J	Sackett, K; Wexler-Cohen, Y; Shai, Y				Sackett, Kelly; Wexler-Cohen, Yael; Shai, Yechiel			Characterization of the HIVN-terminal fusion peptide-containing region in context of key gp41 fusion conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRIMERIC COILED-COIL; ENVELOPE GLYCOPROTEIN; HEPTAD REPEAT; MEMBRANE-FUSION; CELL-FUSION; SIV GP41; TRANSMEMBRANE GLYCOPROTEIN; PHOSPHOLIPID-MEMBRANES; ACTIVE CONFORMATION	Central to our understanding of human immunodeficiency virus-induced fusion is the high resolution structure of fragments of the gp41 fusion protein folded in a low energy core conformation. However, regions fundamental to fusion, like the fusion peptide ( FP), have yet to be characterized in the context of the cognate protein regardless of its conformation. Based on conformation-specific monoclonal antibody recognition, we identified the polar region consecutive to the N36 fragment as a stabilizer of trimeric coiled-coil assembly, thereby enhancing inhibitory potency. This tertiary organization is retained in the context of the hydrophobic FP ( N70 fragment). Our data indicate that the N70 fragment recapitulates the expected organization of this region in the viral fusion intermediate ( N-terminal half of the pre- hairpin intermediate ( N-PHI)), which happens to be the prime target for fusion inhibitors. Regarding the low energy conformation, we show for the first time core formation in the context of the FP ( N70 core). The alpha-helical and coiled-coil stabilizing polar region confers substantial thermal stability to the core, whereas the hydrophobic FP does not add further stability. For the two key fusion conformations, N- PHI and N70 core, we find that the FP adopts a nonhelical structure and directs higher order assembly ( assembly of coiled coils in N- PHI and assembly of bundles in the N70 core). This supra-molecular organization of coiled coils or folded cores is seen only in the context of the FP. This study is the first to characterize the FP region in the context of the folded core and provides a basic understanding of the role of the elusive FP for key gp41 fusion conformations.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	yechiel.shai@weizmann.ac.il						BERNSTEIN HB, 1995, J VIROL, V69, P2745, DOI 10.1128/JVI.69.5.2745-2750.1995; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281, DOI 10.1089/aid.1990.6.1281; Curtain C, 1999, EUR BIOPHYS J BIOPHY, V28, P427, DOI 10.1007/s002490050225; Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2004, J MOL BIOL, V340, P9, DOI 10.1016/j.jmb.2004.04.027; GORDON LM, 1992, BIOCHIM BIOPHYS ACTA, V1139, P257, DOI 10.1016/0925-4439(92)90099-9; Hackeng TM, 1999, P NATL ACAD SCI USA, V96, P10068, DOI 10.1073/pnas.96.18.10068; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i; Pereira FB, 1997, BIOPHYS J, V73, P1977, DOI 10.1016/S0006-3495(97)78228-6; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322; Sackett K, 2003, J MOL BIOL, V333, P47, DOI 10.1016/j.jmb.2003.07.008; Sackett K, 2005, J MOL BIOL, V350, P790, DOI 10.1016/j.jmb.2005.05.030; SCHAAL H, 1995, J VIROL, V69, P3308, DOI 10.1128/JVI.69.6.3308-3314.1995; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SLEPUSHKIN VA, 1992, AIDS RES HUM RETROV, V8, P9, DOI 10.1089/aid.1992.8.9; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2005, BIOCHEMISTRY-US, V44, P5853, DOI 10.1021/bi047666g; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Wingfield PT, 1997, PROTEIN SCI, V6, P1653, DOI 10.1002/pro.5560060806; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; Yang J, 2004, BIOPHYS J, V87, P1951, DOI 10.1529/biophysj.103.028530	50	36	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21755	21762		10.1074/jbc.M603135200	http://dx.doi.org/10.1074/jbc.M603135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751188	hybrid			2022-12-25	WOS:000239387100021
J	Takahashi, Y; Chen, Y; Moiseyev, G; Ma, JX				Takahashi, Yusuke; Chen, Ying; Moiseyev, Gennadiy; Ma, Jian-Xing			Two point mutations of RPE65 from patients with retinal dystrophies decrease the stability of RPE65 protein and abolish its isomerohydrolase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEBER CONGENITAL AMAUROSIS; VISUAL CYCLE; PIGMENT EPITHELIUM; CHILDHOOD-ONSET; GENE-MUTATIONS; MESSENGER-RNA; BETA-CAROTENE; EXPRESSION; IDENTIFICATION; MOUSE	RPE65 is the isomerohydrolase in the retinoid visual cycle essential for recycling of 11-cis retinal, the chromophore for visual pigments in both rod and cone photoreceptors. Mutations in the RPE65 gene are associated with inherited retinal dystrophies with unknown mechanisms. Here we show that two point mutations of RPE65, R91W and Y368H, identified in patients with retinal dystrophies both abolished the isomerohydrolase activity of RPE65 after a subretinal injection into the Rpe65(-/-) mice and in the in vitro isomerohydrolase activity assay, independent of their protein levels. Further, the R91W and Y368H mutants showed significantly decreased protein levels but unchanged mRNA levels when compared with the wild-type RPE65 (wtRPE65). Protein stability analysis showed that wtRPE65 is a fairly stable protein, with an apparent half-life longer than 10 h, when expressed in 293A cells. Under the same conditions, mutants R91W and Y368H both showed substantially decreased protein stabilities, with half-lives less than 2 and 6 h, respectively. Subcellular fractionation and Western blot analysis demonstrated that wtRPE65 predominantly exists in the membrane fraction, while both of the mutants are primarily distributed in the cytosolic fraction, suggesting that these mutations disrupt the membrane association of RPE65. However, palmitoylation assay showed that wtRPE65 and both of the mutants were palmitoylated. These results suggest that these mutations may result in critical structural alterations of RPE65 protein, disrupt its membrane association, and consequently impair its isomerohydrolase activity, leading to retinal degeneration.	Univ Oklahoma, Hlth Sci Ctr, Dept Med Endocrinol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Ma, JX (corresponding author), 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.	jian-xing-ma@ouhsc.edu			NATIONAL EYE INSTITUTE [R33EY015650, R21EY015650, R01EY012231] Funding Source: NIH RePORTER; NEI NIH HHS [EY012231, EY015650] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aguirre G D, 1998, Mol Vis, V4, P23; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Boulanger A, 2001, MOL VIS, V7, P283; Bridges CDB, 1972, HDB SENSORY PHYSIOLO, P417, DOI DOI 10.1007/978-3-642-65066-6_11; Dharmaraj S R, 2000, Ophthalmic Genet, V21, P135; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Gal A., 1998, IOVS, V39, pS901; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Klein SL, 2002, DEV DYNAM, V225, P384, DOI 10.1002/dvdy.10174; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Lotery AJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P538; Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429; Ma JX, 1999, FEBS LETT, V452, P199, DOI 10.1016/S0014-5793(99)00606-7; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; Manes G, 1998, FEBS LETT, V423, P133, DOI 10.1016/S0014-5793(98)00081-7; Marlhens F, 1998, EUR J HUM GENET, V6, P527, DOI 10.1038/sj.ejhg.5200205; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; Perrault I, 1999, AM J HUM GENET, V64, P1225, DOI 10.1086/302335; Pittler SJ, 1999, INVEST OPHTH VIS SCI, V40, pS471; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Simovich M J, 2001, Hum Mutat, V18, P164, DOI 10.1002/humu.1168; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Thompson DA, 1999, INVEST OPHTH VIS SCI, V40, pS575; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Trudel E, 2006, BIOCHEMISTRY-US, V45, P3337, DOI 10.1021/bi0519405; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wada Y, 2000, INVEST OPHTH VIS SCI, V41, pS617; Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Yzer S, 2003, J MED GENET, V40, P709, DOI 10.1136/jmg.40.9.709; Znoiko SL, 2005, INVEST OPHTH VIS SCI, V46, P1473, DOI 10.1167/iovs.04-0653	41	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21820	21826		10.1074/jbc.M603725200	http://dx.doi.org/10.1074/jbc.M603725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754667	hybrid			2022-12-25	WOS:000239387100028
J	Yang, G; Thompson, MA; Brandt, SJ; Hiebert, SW				Yang, G.; Thompson, M. A.; Brandt, S. J.; Hiebert, S. W.			Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein	ONCOGENE			English	Article						RUNX1; ETO; MTG8; histone deacetylase; t(8;21); corepressor	ACUTE MYELOID-LEUKEMIA; T-CELL LYMPHOMA; ABL TYROSINE KINASE; TRANS-RETINOIC ACID; ALPHA ONCOPROTEIN; TUMOR-SUPPRESSOR; ARSENIC TRIOXIDE; NUCLEAR-BODIES; CANCER-THERAPY; MURINE MODEL	The t(8; 21) chromosomal translocation that generates the fusion oncoprotein RUNX1-ETO predominates in leukemia patients of the French-American-British (FAB) class M2 subtype. The oncoprotein has the capacity to promote expansion of hematopoietic stem/progenitor cells and induces leukemia in association with other genetic alterations. Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies. These compounds induce turnover of RUNX1-ETO without affecting the stability of RUNX1-ETO partner proteins. In addition, RUNX1-ETO physically interacts with heat shock protein 90 (HSP90). DEP treatment interrupts the association of RUNX1-ETO with HSP90 and induces proteasomal degradation of RUNX1-ETO. DEP and the HSP90 antagonist 17-allylamino-geldanamycin (17-AAG) both triggered RUNX1-ETO degradation, but without any additive or cooperative effects. These findings may stimulate the development of more rational and effective approaches for treating t(8; 21) patients using histone deacetylase inhibitors or HSP90 inhibitors.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Tennessee Valley VA Healthcare Syst, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 512 Preston Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NCI NIH HHS [R01-CA64140, CA68485] Funding Source: Medline; NHLBI NIH HHS [R01-HL49118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Byrd JC, 2005, BLOOD, V105, P959, DOI 10.1182/blood-2004-05-1693; Chen GQ, 1997, BLOOD, V89, P3345; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Fuino L, 2003, MOL CANCER THER, V2, P971; Garrido SM, 2001, EXP HEMATOL, V29, P448, DOI 10.1016/S0301-472X(01)00612-9; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kasashima K, 2004, BIOCHIMIE, V86, P713, DOI 10.1016/j.biochi.2004.08.003; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kozu T, 2000, GENES CELLS, V5, P637, DOI 10.1046/j.1365-2443.2000.00353.x; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Odenike OM, 2004, BLOOD, V104, p79A; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pichardo DA, 2004, LEUKEMIA LYMPHOMA, V45, P1755, DOI 10.1080/10428190410001693560; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; SANDRO V, 2002, CLIN CANCER RES, V8, P662; Sato N, 2004, INT J ONCOL, V24, P679; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; Szyrach M, 2001, EUR J BIOCHEM, V268, P3550, DOI 10.1046/j.1432-1327.2001.02259.x; Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yang GY, 2005, MOL CELL BIOL, V25, P5869, DOI 10.1128/MCB.25.14.5869-5879.2005; Yoshida H, 1996, CANCER RES, V56, P2945; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	68	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					91	101		10.1038/sj.onc.1209760	http://dx.doi.org/10.1038/sj.onc.1209760			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799637				2022-12-25	WOS:000243236500009
J	Kim, YM; Park, KI; Choi, KS; Alvarez, RA; Cummings, RD; Cho, M				Kim, Young Mee; Park, Kyung-Il; Choi, Kwang-Sik; Alvarez, Richard A.; Cummings, Richard D.; Cho, Moonjae			Lectin from the manila clam Ruditapes philippinarum is induced upon infection with the protozoan parasite Perkinsus olseni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; C-TYPE LECTIN; INVERTEBRATE CUCUMARIA ECHINATA; COLLECTIN-LIKE PROTEIN; BINDING LECTIN; INNATE IMMUNITY; MARINE MUSSEL; SEA-CUCUMBER; CEL-III; HEMOCYTES	Glycan-binding proteins (lectins) are widely expressed in many invertebrates, although the biosynthesis and functions of the lectins are not well understood. Here we report that Manila clam (Ruditapes philippinarum) synthesizes a lectin termed Manila clam lectin (MCL) upon infection with the protozoan parasite Perkinsus olseni. MCL is synthesized in hemocytes as a similar to 74-kDa precursor and secreted into hemolymph where it is converted to 30- and 34-kDa polypeptides. The synthesis of MCL in hemocytes is stimulated by one or more factors in Perkinsus-infected hemolymph, but not directly by Perkinsus itself. MCL can bind to the surfaces of purified hypnospores and zoospores of the parasite, and this binding is inhibitable by either EDTA or GalNAc. Fluorescent beads coated with purified MCL were actively phagocytosed by hemocytes from the clam. Immunohistochemistry showed that secreted MCL is concentrated within cyst-like structures. To define the glycan binding specificity of MCL we examined its binding to an array of biotinylated glycans. MCL recognizes terminal non-reducing beta-linked GalNAc as expressed within the LacdiNAc motif GalNAc beta 1-4GlcNAc beta 1-R and glycans with terminal, non-reducing beta-linked Gal residues. Our results show that the synthesis of MCL is specifically up-regulated upon parasite infection of the clams and may serve as an opsonin through recognition of terminal GalNAc/Gal residues on the parasites.	Jeju Natl Univ, Dept Med, Cheju 690756, South Korea; Jeju Natl Univ, Sch Appl Marine Sci, Cheju 690756, South Korea; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; O Wayne Rollins Res Ctr, Atlanta, GA 30322 USA	Jeju National University; Jeju National University; Emory University	Cho, M (corresponding author), Jeju Natl Univ, Dept Med, Cheju 690756, South Korea.	moonjcho@cheju.ac.kr	Choi, Kwang-Sik Albert/B-5367-2011		NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asokan R, 1997, DEV COMP IMMUNOL, V21, P1, DOI 10.1016/S0145-305X(97)00004-9; Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; Bulgakov AA, 2004, FISH SHELLFISH IMMUN, V16, P487, DOI 10.1016/j.fsi.2003.08.006; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; Choi KS, 2002, J SHELLFISH RES, V21, P119; Cremonte F, 2005, DIS AQUAT ORGAN, V64, P85, DOI 10.3354/dao064085; DAM TK, 1992, MOL CELL BIOCHEM, V117, P1; Dodds Alister W., 1996, P303; Dyrynda EA, 1997, CELL TISSUE RES, V289, P527, DOI 10.1007/s004410050898; Endo Y, 2003, J IMMUNOL, V170, P4701, DOI 10.4049/jimmunol.170.9.4701; FAYE I, 1990, RES IMMUNOL, V141, P927, DOI 10.1016/0923-2494(90)90195-5; FISHER WS, 1992, J EXP MAR BIOL ECOL, V162, P1, DOI 10.1016/0022-0981(92)90121-P; GAMULIN V, 1994, BIOL CHEM H-S, V375, P583; Gaphurov JM, 1999, TOXICON, V37, P1591, DOI 10.1016/S0041-0101(99)00107-5; GIGA Y, 1987, J BIOL CHEM, V262, P6197; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Green PL, 2003, DEV COMP IMMUNOL, V27, P3, DOI 10.1016/S0145-305X(02)00067-8; HATAKEYAMA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1314, DOI 10.1271/bbb.59.1314; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; HIMESHIMA T, 1994, J BIOCHEM-TOKYO, V115, P689, DOI 10.1093/oxfordjournals.jbchem.a124397; Hine PM, 1996, REV SCI TECH OIE, V15, P563, DOI 10.20506/rst.15.2.940; Jenny MJ, 2002, MAR BIOTECHNOL, V4, P81, DOI 10.1007/s10126-001-0072-8; Kawai F, 1999, J IND MICROBIOL BIOT, V23, P400, DOI 10.1038/sj.jim.2900730; Kenjo A, 2001, J BIOL CHEM, V276, P19959, DOI 10.1074/jbc.M011723200; Ling EJ, 2006, DEV COMP IMMUNOL, V30, P289, DOI 10.1016/j.dci.2005.05.005; Mann K, 2000, EUR J BIOCHEM, V267, P5257, DOI 10.1046/j.1432-1327.2000.01602.x; Marques MRF, 2000, AQUACULTURE, V191, P23, DOI 10.1016/S0044-8486(00)00417-8; MATSUI T, 1994, J BIOCHEM-TOKYO, V116, P1127, DOI 10.1093/oxfordjournals.jbchem.a124638; Miarons PB, 2000, J BIOL CHEM, V275, P29283, DOI 10.1074/jbc.M001366200; Mitta G, 1999, J CELL SCI, V112, P4233; Mitta G, 1999, EUR J BIOCHEM, V265, P71, DOI 10.1046/j.1432-1327.1999.00654.x; Montes JF, 1996, DIS AQUAT ORGAN, V26, P149, DOI 10.3354/dao026149; Muller WEG, 1999, TRANSPLANTATION, V68, P1215; Nair SV, 2001, COMP BIOCHEM PHYS C, V129, P11, DOI 10.1016/S1532-0456(01)00179-X; Nair SV, 2000, COMP BIOCHEM PHYS B, V125, P279, DOI 10.1016/S0305-0491(99)00180-7; NAVAS JI, 1992, AQUACULTURE, V107, P193, DOI 10.1016/0044-8486(92)90067-U; Oda T, 1997, J BIOCHEM, V121, P560; OLAFSEN JA, 1995, ADV EXP MED BIOL, V371, P343; Ordas MC, 2000, FISH SHELLFISH IMMUN, V10, P597, DOI 10.1006/fsim.2000.0274; Ordas MC, 1998, DIS AQUAT ORGAN, V33, P129, DOI 10.3354/dao033129; Park KI, 2001, AQUACULTURE, V203, P9, DOI 10.1016/S0044-8486(01)00619-6; Ray S.M., 1966, P NATL SHELLFISH ASS, V54, P55, DOI DOI 10.2983/0730-8000(2006)25; RENWRANTZ L, 1983, J COMP PHYSIOL, V149, P535, DOI 10.1007/BF00690013; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sekine H, 2001, J IMMUNOL, V167, P4504, DOI 10.4049/jimmunol.167.8.4504; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; SUH-CHAE Y A, 1988, Korean Biochemical Journal, V21, P46; TAKAHASHI Y, 1995, FISH PATHOL, V30, P141, DOI 10.3147/jsfp.30.141; Tunkijjanukij S, 1998, DEV COMP IMMUNOL, V22, P139, DOI 10.1016/S0145-305X(98)00017-2; VASTA GR, 1990, UCLA SYM BI, V121, P183; Wootton EC, 2003, AQUAT TOXICOL, V65, P13, DOI 10.1016/S0166-445X(03)00098-5	51	48	52	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26854	26864		10.1074/jbc.M601251200	http://dx.doi.org/10.1074/jbc.M601251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16785239	hybrid			2022-12-25	WOS:000240397700012
J	Tashiro, K; Konishi, H; Sano, E; Nabeshi, H; Yamauchi, E; Taniguchi, H				Tashiro, Kyoko; Konishi, Hiroaki; Sano, Etsuko; Nabeshi, Hiromi; Yamauchi, Emiko; Taniguchi, Hisaaki			Suppression of the ligand-mediated down-regulation of epidermal growth factor receptor by Ymer, a novel tyrosine-phosphorylated and ubiquitinated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING NETWORKS; ERBB RECEPTORS; CANCER-CELLS; RABEX-5; DOMAIN; DEGRADATION; PROTEOMICS; SITES; CBL	The ligand-mediated down-regulation of the growth factor receptors is preceded by the involvement of various other factors. In particular, a ubiquitin ligase, Cbl, plays a central role in this event. Several candidates that have potential effects on the negative control of the epidermal growth factor (EGF) receptor have now been identified by our recent studies in phospho-proteomics. Among these molecules, we focus on characterizing a novel protein, Ymer, which is a tyrosine-phosphorylated and ubiquitinated protein. Ymer is found to be phosphorylated at tyrosine 145 and 146 upon EGF stimulation, and lysine 129 of Ymer has been identified as a ubiquitination site. Ymer has two motifs interacting with the ubiquitin (MIU) domains that might function as a binding site for the ubiquitinated EGF receptor. Although Ymer and EGF receptors are associated in an EGF-dependent manner, their interaction is required not only for MIU domains but also for the tyrosine phosphorylation of Ymer. Phosphorylated Ymer is mainly located at the plasma membrane with EGF receptor and functions in its endocytosis and degradation. Furthermore, EGF-mediated secondary modifications of an activated-EGF receptor are inhibited by overexpressing Ymer in COS7 cells. Therefore, Ymer may have competitive effects on the activation of the EGF receptor. Our findings suggest that Ymer functions as a novel inhibitor for the down-regulation of the EGF receptor and plays a crucial role for regulating the amount of the EGF receptor on the cell surface membrane.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; RIKEN, Harima Inst, Spring 8, Hyogo 6795148, Japan	Tokushima University; RIKEN	Konishi, H (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	konishi@ier.tokushima-u.ac.jp	Taniguchi, Hisaaki/I-9171-2012					Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; de Hoog CL, 2004, ANNU REV GENOM HUM G, V5, P267, DOI 10.1146/annurev.genom.4.070802.110305; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Mattera R, 2006, J BIOL CHEM, V281, P6874, DOI 10.1074/jbc.M509939200; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Vazza G, 2003, GENE, V314, P113, DOI 10.1016/S0378-1119(03)00710-8; Zhang Y, 2005, MOL CELL PROTEOMICS, V4, P1240, DOI 10.1074/mcp.M500089-MCP200	26	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24612	24622		10.1074/jbc.M604184200	http://dx.doi.org/10.1074/jbc.M604184200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803894	hybrid			2022-12-25	WOS:000239847800056
J	Timmen, M; Bassler, BL; Jung, K				Timmen, Melanie; Bassler, Bonnie L.; Jung, Kirsten			AI-1 influences the kinase activity but not the phosphatase activity of LuxN of Vibrio harveyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT SIGNAL-TRANSDUCTION; QUORUM-SENSING SIGNAL; ESCHERICHIA-COLI; GENETIC-ANALYSIS; PROTEIN; PHOSPHORELAY; SYSTEM; EXPRESSION; SENSOR; LUMINESCENCE	The Gram-negative bacterium Vibrio harveyi produces and responds to three autoinducers, AI-1, AI-2, and CAI-1 to regulate cell density dependent gene expression by a process referred to as quorum sensing. The concentration of the autoinducers is sensed by three cognate hybrid sensor kinases, and information is channeled via the HPt protein LuxU to the response regulator LuxO. Here, a detailed biochemical study on the enzymatic activities of the membrane-integrated hybrid sensor kinase LuxN, the sensor for N-(D-3-hydroxybutanoyl) homoserine lactone (AI-1), is provided. LuxN was heterologously overproduced as the full-length protein in Escherichia coli. LuxN activities were characterized in vitro and are an autophosphorylation activity with an unusually high ATP turnover rate, stable LuxU phosphorylation, and a slow phosphatase activity with LuxU similar to P as substrate. The presence of AI-1 affected the kinase but not the phosphatase activity of LuxN. The influence of AI-1 on the LuxN -> LuxU signaling step was monitored, and in the presence of AI-1, the kinase activity of LuxN, and hence the amount of LuxU similar to P produced, were significantly reduced. Half-maximal inhibition of kinase activity by AI-1 occurred at 20 mu M. Together, these results indicate that AI-1 directly interacts with LuxN to down-regulate its autokinase activity and suggest that the key regulatory step of the AI-1 quorum sensing system of Vibrio harveyi is AI-1-mediated repression of the LuxN kinase activity.	Univ Munich, Dept Biol 1, Bereich Mikrobiol, D-80638 Munich, Germany; Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	University of Munich; Howard Hughes Medical Institute; Princeton University	Jung, K (corresponding author), Univ Munich, Dept Biol 1, Bereich Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.	kirsten.jung@lrz.uni-muenchen.de		Bassler, Bonnie/0000-0002-0043-746X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065859] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 065859] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSLER BL, 1994, MOL MICROBIOL, V13, P273, DOI 10.1111/j.1365-2958.1994.tb00422.x; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Freeman JA, 1999, J BACTERIOL, V181, P899, DOI 10.1128/JB.181.3.899-906.1999; Freeman JA, 1999, MOL MICROBIOL, V31, P665, DOI 10.1046/j.1365-2958.1999.01208.x; Freeman JA, 2000, MOL MICROBIOL, V35, P139, DOI 10.1046/j.1365-2958.2000.01684.x; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jung H, 2002, J BIOL CHEM, V277, P39251, DOI 10.1074/jbc.M206319200; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; Kremling A, 2004, BIOSYSTEMS, V78, P23, DOI 10.1016/j.biosystems.2004.06.003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenz DH, 2005, MOL MICROBIOL, V58, P1186, DOI 10.1111/j.1365-2958.2005.04902.x; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Mok KC, 2003, EMBO J, V22, P870, DOI 10.1093/emboj/cdg085; Neiditch MB, 2005, MOL CELL, V18, P507, DOI 10.1016/j.molcel.2005.04.020; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Qin L, 2001, P NATL ACAD SCI USA, V98, P908, DOI 10.1073/pnas.031383098; Schuster M, 2001, P NATL ACAD SCI USA, V98, P6003, DOI 10.1073/pnas.101571298; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; Ulrich DL, 2005, J MOL BIOL, V347, P297, DOI 10.1016/j.jmb.2005.01.039; Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	47	48	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24398	24404		10.1074/jbc.M604108200	http://dx.doi.org/10.1074/jbc.M604108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807235	hybrid			2022-12-25	WOS:000239847800033
J	Relic, B; Benoit, V; Franchimont, N; Kaiser, MJ; Hauzeur, JP; Gillet, P; Merville, MP; Bours, V; Malaise, MG				Relic, Biserka; Benoit, Valerie; Franchimont, Nathalie; Kaiser, Marie-Joelle; Hauzeur, Jean-Philippe; Gillet, Philippe; Merville, Marie-Paule; Bours, Vincent; Malaise, Michel G.			Peroxisome proliferator-activated receptor-gamma 1 is dephosphorylated and degraded during BAY11-7085-induced synovial fibroblast apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; MAP KINASE; RHEUMATOID-ARTHRITIS; CELLS; PHOSPHORYLATION; EXPRESSION; PROTEIN; DEGRADATION; AGONISTS; DIFFERENTIATION	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) plays a central role in whole body metabolism by regulating adipocyte differentiation and energy storage. Recently, however, PPAR-gamma has also been demonstrated to affect proliferation, differentiation, and apoptosis of different cell types. As we have previously shown that BAY 11-7085-induced synovial fibroblast apoptosis is prevented by PPAR-gamma agonist 15d-PGJ2; the expression of PPAR-gamma in these cells was studied. Both PPAR-gamma 1 and PPAR-gamma 2 isoforms were cloned from synovial fibroblast RNA, but only PPAR-gamma 1 was detected by Western blot, showing constitutive nuclear expression. Within minutes of BAY 11-7085 treatment, a PPAR-1 gamma-specific band was shifted into a form of higher mobility, suggesting dephosphorylation, as confirmed by phosphatase treatment of cell extracts. Of interest, BAY 11-7085-induced PPAR-gamma 1 dephosphorylation was followed by PARP and caspase-8 cleavage as well as by PPAR-gamma 1 protein degradation. PPAR-gamma 1 dephosphorylation was followed by the loss of PPAR-DNA binding activity ubiquitously present in synovial fibroblast nuclear extracts. Unlike the phosphorylated form, dephosphorylated PPAR-gamma 1 was found in insoluble membrane cell fraction and was not ubiquitinated before degradation. PPAR-gamma 1 dephosphorylation coincided with ERK1/2 phosphorylation that accompanies BAY 11-7085-induced synovial fibroblasts apoptosis. 15d-PGJ2, PGD2, and partially UO126, down-regulated ERK1/2 phosphorylation, protected cells from BAY 11-7085-induced apoptosis, and reversed both PPAR-gamma dephosphorylation and degradation. Furthermore, PPAR-gamma antagonist BADGE induced PPAR-gamma 1 degradation, ERK1/2 phosphorylation, and synovial fibroblasts apoptosis. The results presented suggest an anti-apoptotic role for PPAR-gamma 1 in synovial fibroblasts. Since apoptotic marker PARP is cleaved after PPAR-gamma 1 dephosphorylation but before PPAR-gamma 1 degradation, dephosphorylation event might be enough to mediate BAY 11-7085-induced apoptosis in synovial fibroblasts.	Univ Liege, Dept Rheumatol, B-4000 Liege, Belgium; Univ Liege, Dept Med Chem & Human Genet, B-4000 Liege, Belgium; Univ Liege, Dept Orthoped Surg, B-4000 Liege, Belgium; Univ Liege, CBIG, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege	Malaise, MG (corresponding author), CHU Sart Tilman, Dept Rheumatol, B35, B-4000 Liege, Belgium.	Michel.Malaise@ulg.ac.be		BENOIT, Valerie/0000-0002-1098-9452				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Al-Rasheed NM, 2004, J BIOL CHEM, V279, P49747, DOI 10.1074/jbc.M408268200; Appel S, 2005, BLOOD, V106, P3888, DOI 10.1182/blood-2004-12-4709; Baier A, 2003, CURR OPIN RHEUMATOL, V15, P274, DOI 10.1097/00002281-200305000-00015; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Bren-Mattison Y, 2005, ONCOGENE, V24, P1412, DOI 10.1038/sj.onc.1208333; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Compe E, 2005, MOL CELL BIOL, V25, P6065, DOI 10.1128/MCB.25.14.6065-6076.2005; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Desmet C, 2005, BIOCHEM PHARMACOL, V69, P255, DOI 10.1016/j.bcp.2004.09.017; Eucker J, 2004, ANTI-CANCER DRUG, V15, P955, DOI 10.1097/00001813-200411000-00004; Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Klotz L, 2005, J IMMUNOL, V175, P4948, DOI 10.4049/jimmunol.175.8.4948; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Liu HT, 2004, RHEUM DIS CLIN N AM, V30, P603, DOI 10.1016/j.rdc.2004.04.010; Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471-4892(03)00037-7; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Relic B, 2004, J BIOL CHEM, V279, P22399, DOI 10.1074/jbc.M314118200; Sabichi AL, 2004, CANCER EPIDEM BIOMAR, V13, P1704; Scaglia N, 2005, BBA-MOL CELL BIOL L, V1687, P141, DOI 10.1016/j.bbalip.2004.11.015; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Simonin MA, 2002, AM J PHYSIOL-CELL PH, V282, pC125, DOI 10.1152/ajpcell.2002.282.1.C125; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Takashima T, 2005, ONCOL REP, V13, P601; Tanabe Yoshiyuki, 2004, Nihon Yakurigaku Zasshi, V124, P337; Theocharis S, 2004, CANCER TREAT REV, V30, P545, DOI 10.1016/j.ctrv.2004.04.004; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Varley CL, 2004, J CELL SCI, V117, P2029, DOI 10.1242/jcs.01042; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yamasaki S, 2002, CLIN EXP IMMUNOL, V129, P379, DOI 10.1046/j.1365-2249.2002.01876.x; Zingarelli B, 2005, SHOCK, V23, P393, DOI 10.1097/01.shk.0000160521.91363.88	42	13	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22597	22604		10.1074/jbc.M512807200	http://dx.doi.org/10.1074/jbc.M512807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766531	hybrid			2022-12-25	WOS:000239542600020
J	Idkowiak-Baldys, J; Becker, KP; Kitatani, K; Hannun, YA				Idkowiak-Baldys, Jolanta; Becker, Kevin P.; Kitatani, Kazuyuki; Hannun, Yusuf A.			Dynamic sequestration of the recycling compartment by classical protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; BETA-II; REGULATED INTERNALIZATION; DOPAMINE TRANSPORTER; CHOLESTEROL; RECEPTOR; ENDOCYTOSIS; CAVEOLAE; ENDOSOMES; ACTIVATION	It has been previously shown that upon sustained stimulation (30-60 min) with phorbol esters, protein kinase C(PKC) alpha and beta II become sequestered in a juxtanuclear region, the pericentrion. The activation of PKC also results in sequestration of transferrin, suggesting a role for PKC in regulating endocytosis and sequestration of recycling components. In this work we characterize the pericentrion as a PKC-dependent subset of the recycling compartment. We demonstrate that upon sustained stimulation of PKC, both protein (CD59, caveolin) and possibly also lipid (Bodipy-GM1) cargo become sequestered in a PKC-dependent manner. This sequestration displayed a strict temperature requirement and was inhibited below 32 C. Treatment of cells with phorbol myristate acetate for 60 min led to the formation of a distinct membrane structure. PKC sequestration and pericentrion formation were blocked by hypertonic sucrose as well as by potassium depletion (inhibitors of clathrin-dependent endocytosis) but not by nystatin or filipin, which inhibit clathrin-independent pathways. Interestingly, it was also observed that some molecules that internalize through clathrin-independent pathways (CD59, Bodipy-GM1, caveolin) also sequestered to the pericentrion upon sustained PKC activation, suggesting that PKC acted distal to the site of internalization of endocytic cargo. Together these results suggest that PKC regulates sequestration of recycling molecules into this compartment, the pericentrion.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135	NHLBI NIH HHS [HL-43707] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker KP, 2005, J BIOL CHEM, V280, P2606, DOI 10.1074/jbc.M409066200; Becker KP, 2004, J BIOL CHEM, V279, P28251, DOI 10.1074/jbc.M400770200; Becker KP, 2003, J BIOL CHEM, V278, P52747, DOI 10.1074/jbc.M305228200; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Haberman Y, 2005, J CELL SCI, V118, P1641, DOI 10.1242/jcs.02276; Hailstones D, 1998, J LIPID RES, V39, P369; Jayanthi LD, 2004, J BIOL CHEM, V279, P19315, DOI 10.1074/jbc.M311172200; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kokubo H, 2003, BRAIN RES, V965, P83, DOI 10.1016/S0006-8993(02)04140-9; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pichler H, 2004, BBA-BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; Punnonen EL, 1998, EUR J CELL BIOL, V75, P344, DOI 10.1016/S0171-9335(98)80067-8; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Rotmann A, 2004, J BIOL CHEM, V279, P54185, DOI 10.1074/jbc.M409556200; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; So CH, 2005, MOL PHARMACOL, V68, P568, DOI 10.1124/mol.105.012229; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	42	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22321	22331		10.1074/jbc.M512540200	http://dx.doi.org/10.1074/jbc.M512540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751194	hybrid			2022-12-25	WOS:000239387100077
J	Qin, WP; Yang, TL; Ho, L; Zhao, Z; Wang, J; Chen, LH; Zhao, W; Thiyagarajan, M; MacGrogan, D; Rodgers, JT; Puigserver, P; Sadoshima, J; Deng, HT; Pedrini, S; Gandy, S; Sauve, AA; Pasinetti, GM				Qin, Weiping; Yang, Tianle; Ho, Lap; Zhao, Zhong; Wang, Jun; Chen, Linghong; Zhao, Wei; Thiyagarajan, Meenakshisundaram; MacGrogan, Donal; Rodgers, Joseph T.; Puigserver, Pere; Sadoshima, Junichi; Deng, Haiteng; Pedrini, Steven; Gandy, Samuel; Sauve, Anthony A.; Pasinetti, Giulio M.			Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTONE DEACETYLASE; TRANSGENIC MICE; PROTEIN; FAMILY; LONGEVITY; NICOTINAMIDE; INHIBITION; REGULATOR	Nicotinamide adenine dinucleotide(NAD)(+)-dependent sirtuins have been identified to be key regulators in the lifespan extending effects of calorie restriction (CR) in a number of species. In this study we report for the first time that promotion of the NAD(+)-dependent sirtuin, SIRT1-mediated deacetylase activity, may be a mechanism by which CR influences Alzheimer disease (AD)-type amyloid neuropathology. Most importantly, were port that the predicted attenuation of beta-amyloid content in the brain during CR can be reproduced in mouse neurons in vitro by manipulating cellular SIRT1 expression/activity through mechanisms involving the regulation of the serine/threonine Rho kinase ROCK1, known in part for its role in the inhibition of the non-amyloidogenic alpha-secretase processing of the amyloid precursor protein. Conversely, we found that the expression of constitutively active ROCK1 in vitro cultures significantly prevented SIRT1-mediated response, suggesting that alpha-secretase activity is required for SIRT1-mediated prevention of AD-type amyloid neuropathology. Consistently we found that the expression of exogenous human ( h) SIRT1 in the brain of hSIRT1 transgenics also resulted in decreased ROCK1 expression and elevated alpha-secretase activity in vivo. These results demonstrate for the first time a role for SIRT1 activation in the brain as a novel mechanism through which CR may influence AD amyloid neuropathology. The study provides a potentially novel pharmacological strategy for AD prevention and/or treatment.	Cornell Univ, Weill Med Coll, Dept Pharmacol, Tri Inst Program Chem Biol, New York, NY 10021 USA; Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA; Bronx Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY 10468 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Newark, NJ 07103 USA; Rockefeller Univ, Proteom Resource Ctr, New York, NY 10021 USA; Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA	Cornell University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rockefeller University; Jefferson University	Pasinetti, GM (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, Tri Inst Program Chem Biol, New York, NY 10021 USA.	as2004@med.cornell.edu; giulio.pasinetti@mssm.edu	Zhao, Wei/A-2206-2010; MacGrogan, Donal/AAR-7392-2021; MacGrogan, Donal/E-8604-2016	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Rodgers, Joseph/0000-0002-6598-5520; Sadoshima, Junichi/0000-0003-3724-4132; Pasinetti, Giulio/0000-0002-1524-5196; Zhao, Wei/0000-0002-3449-2395; Pedrini, Steve/0000-0002-6409-8022	NIA NIH HHS [P01 AG010491-14, P01 AG010491] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burns M, 2003, J NEUROSCI, V23, P5645; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Gandy S, 2002, NEUROBIOL AGING, V23, P1009, DOI 10.1016/S0197-4580(02)00125-2; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Lamming DW, 2004, MOL MICROBIOL, V53, P1003, DOI 10.1111/j.1365-2958.2004.04209.x; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Mattson MP, 2003, NEUROLOGY, V60, P690, DOI 10.1212/01.WNL.0000042785.02850.11; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Qin WP, 2003, J BIOL CHEM, V278, P50970, DOI 10.1074/jbc.M307699200; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sauve AA, 2005, MOL CELL, V17, P595, DOI 10.1016/j.molcel.2004.12.032; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang W, 2005, INT J MOD PHYS B, V19, P659, DOI 10.1142/S0217979205029262	31	504	524	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21745	21754		10.1074/jbc.M602909200	http://dx.doi.org/10.1074/jbc.M602909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751189	hybrid			2022-12-25	WOS:000239387100020
J	Choi, JY; Angel, KC; Guengerich, FP				Choi, Jeong-Yun; Angel, Karen C.; Guengerich, F. Peter			Translesion synthesis across bulky N-2-alkyl guanine DNA adducts by human DNA polymerase kappa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; STEADY-STATE KINETICS; POLYCYCLIC AROMATIC-HYDROCARBON; HUMAN DINB1 GENE; NUCLEOTIDE INCORPORATION; ESCHERICHIA-COLI; ERROR-FREE; BASE-PAIR; SACCHAROMYCES-CEREVISIAE; REPLICATION FIDELITY	DNA polymerase (pol) kappa is one of the so-called translesion polymerases involved in replication past DNA lesions. Bypass events have been studied with a number of chemical modifications with human pol kappa, and the conclusion has been presented, based on limited quantitative data, that the enzyme is ineffective at incorporating opposite DNA damage but proficient at extending beyond bases paired with the damage. Purified recombinant full-length human pol kappa was studied with a series of eight N2-guanyl adducts (in oligonucleotides) ranging in size from methyl- to -CH2(6-benzo[a] pyrenyl) (BP). Steady-state kinetic parameters (catalytic specificity, kcat/Km) were similar for insertion of dCTP opposite the lesions and for extension beyond the N-2-adduct G:C pairs. Mispairing of dGTP and dTTP was similar and occurred with k(cat)/K-m values similar to 10(-3) less than for dCTP with all adducts; a similar differential was found for extension beyond a paired adduct. Pre-steady-state kinetic analysis showed moderately rapid burst kinetics for dCTP incorporations, even opposite the bulky methyl(9-anthracenyl)- and BPG adducts (k(p) 5.9-10.3 s(-1)). The rapid bursts were abolished opposite BPG when alpha-thio-dCTP was used instead of dCTP, implying rate-limiting phosphodiester bond formation. Comparisons are made with similar studies done with human pols eta and iota; pol kappa is the most resistant to N-2-bulk and the most quantitatively efficient of these in catalyzing dCTP incorporation opposite bulky guanine N-2-adducts, particularly the largest (N-2-BPG).	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Ewha Womans Univ, Coll Med, Dept Pharmacol, Seoul 158710, South Korea	Vanderbilt University; Vanderbilt University; Ewha Womans University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [R01 ES10375, P30 ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avkin S, 2004, J BIOL CHEM, V279, P53298, DOI 10.1074/jbc.M409155200; Bavoux C, 2005, BIOCHIMIE, V87, P637, DOI 10.1016/j.biochi.2005.02.007; BORER PN, 1975, HDB BIOCH MOL BIOL, P589; Choi JY, 2006, J BIOL CHEM, V281, P12315, DOI 10.1074/jbc.M600112200; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; Guengerich FP, 2006, CHEM REV, V106, P420, DOI 10.1021/cr0404693; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Jarosz DF, 2006, NATURE, V439, P225, DOI 10.1038/nature04318; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson Kenneth A., 2003, P1; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Nair DT, 2005, STRUCTURE, V13, P1569, DOI 10.1016/j.str.2005.08.010; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; O-Wang J, 2001, CANCER RES, V61, P5366; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Ramos KS, 2005, DRUG METAB REV, V37, P595, DOI 10.1080/03602530500251253; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Schenten D, 2002, EUR J IMMUNOL, V32, P3152, DOI 10.1002/1521-4141(200211)32:11<3152::AID-IMMU3152>3.0.CO;2-2; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; Singer B, 2002, BIOCHEMISTRY-US, V41, P1778, DOI 10.1021/bi0119114; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Suzuki N, 2005, BIOCHEMISTRY-US, V44, P9238, DOI 10.1021/bi050276p; Suzuki N, 2004, BIOCHEMISTRY-US, V43, P6304, DOI 10.1021/bi0360298; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; Washington MT, 2004, MOL CELL BIOL, V24, P5687, DOI 10.1128/MCB.24.13.5687-5693.2004; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383; Wolfle WT, 2006, MOL CELL BIOL, V26, P381, DOI 10.1128/MCB.26.1.381-386.2006; Wolfle WT, 2005, MOL CELL BIOL, V25, P7137, DOI 10.1128/MCB.25.16.7137-7143.2005; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yasui M, 2004, J MOL BIOL, V344, P665, DOI 10.1016/j.jmb.2004.09.064; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200; Zang H, 2005, CHEM RES TOXICOL, V18, P389, DOI 10.1021/tx049683c; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	71	117	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21062	21072		10.1074/jbc.M602246200	http://dx.doi.org/10.1074/jbc.M602246200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16751196	hybrid			2022-12-25	WOS:000239187300043
J	Rockstroh, A; Kleinert, A; Kramer, M; Grosse, F; Soe, K				Rockstroh, A.; Kleinert, A.; Kramer, M.; Grosse, F.; Soe, K.			Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner	ONCOGENE			English	Article						apoptosis; damage response; p53; topoisomerase I; colcemid; TNF alpha	CLEAVAGE COMPLEXES; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; INDUCTION; CELLS; FRAGMENTATION; POLYMERASE; CASPASE-3; ADDUCTS; REPAIR	The 'human topoisomerase I (htopoI) damage response' was reported to be triggered by various kinds of DNA lesions. Also, a high and persistent level of htopoI cleavage complexes correlated with apoptosis. In the present study, we demonstrate that DNA damage-independent induction of cell death using colcemid and tumor necrosis factor a is also accompanied by a strong htopoI response that correlates with the onset of apoptotic hallmarks. Consequently, these results suggest that htopoI cleavage complex formation may be caused by signaling pathways independent of the kind of cellular stress. Thus, protein interactions or signaling cascades induced by DNA damage or cellular stress might lead to the formation of stabilized cleavage complexes rather than the DNA lesion itself. Finally, we show that p53 not only plays a key role in the regulation of the htopoI response to UV-C irradiation but also to treatment with colcemid.	Fritz Lipmann Inst eV, Leibniz Inst Age Res, Biochem, D-07745 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Soe, K (corresponding author), Fritz Lipmann Inst eV, Leibniz Inst Age Res, Biochem, Beutenbergstr 11, D-07745 Jena, Germany.	kent@fli-leibniz.de	Soe, Kent/N-3618-2017	Soe, Kent/0000-0001-7402-314X				ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Daroui P, 2004, J BIOL CHEM, V279, P14587, DOI 10.1074/jbc.M311370200; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2003, DNA REPAIR, V2, P1115, DOI 10.1016/S1568-7864(03)00122-8; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2002, CLIN CANCER RES, V8, P2499; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200; STEWART AF, 1990, CELL, V60, P141; Subramanian D, 1998, CANCER RES, V58, P976; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651	33	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					123	131		10.1038/sj.onc.1209766	http://dx.doi.org/10.1038/sj.onc.1209766			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799632				2022-12-25	WOS:000243236500012
J	Inomata, K; Noack, S; Hammam, MAS; Khawn, H; Kinoshita, H; Murata, Y; Michael, N; Scheerer, P; Krauss, N; Lamparter, T				Inomata, Katsuhiko; Noack, Steffi; Hammam, Mostafa A. S.; Khawn, Htoi; Kinoshita, Hideki; Murata, Yasue; Michael, Norbert; Scheerer, Patrick; Krauss, Norbert; Lamparter, Tilman			Assembly of synthetic locked chromophores with Agrobacterium phytochromes AGP1 and AGP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN DERIVATIVE BEARING; INDUCED PROTON RELEASE; HISTIDINE KINASES; EFFICIENT METHOD; OAT PHYTOCHROME; TUMEFACIENS; RING; BACTERIOPHYTOCHROME; FORM; PHYCOCYANOBILIN	Phytochromes are photoreceptors with a bilin chromophore in which light triggers the conversion between the red-absorbing form Pr and the far-red-absorbing form Pfr. Agrobacterium tumefaciens has two phytochromes, Agp1 and Agp2, with antagonistic properties: in darkness, Agp1 converts slowly from Pfr to Pr, whereas Agp2 converts slowly from Pr to Pfr. In a previous study, we have assembled Agp1 with synthetic locked chromophores 15Za, 15Zs, 15Ea, and 15Es in which the C15 = C16 double bond is fixed in either the E or Z configuration and the C14 - C15 single bond is fixed in either the syn(s) or anti ( a) conformation. In the present study, the locked chromophores 5Za and 5Zs were used for assembly with Agp1; in these chromophores, the C4 = C5 double bond is fixed in the Z configuration, and the C5 - C6 single bond is fixed in either the syn or anti conformation. All locked chromophores were also assembled with Agp2. The data showed that in both phytochromes the Pr chromophore adopts a C4 = C5 Z C5 - C6 syn C15 = C16 Z C14 - C15 anti stereochemistry and that in the Pfr chromophore the C15 = C16 double bond has isomerized to the E configuration, whereas the C14 - C15 single bond remains in the anti conformation. Photoconversion shifted the absorption maxima of the 5Zs adducts to shorter wavelengths, whereas the 5Za adducts were shifted to longer wavelengths. Thus, the C5 - C6 single bond of the Pfr chromophore is rather in an anti conformation, supporting the previous suggestion that during photoconversion of phytochromes, a rotation around the ring A-B connecting single bond occurs.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan; Free Univ Berlin, D-14195 Berlin, Germany; Univ Med Berlin, Charite, Inst Biochem, D-10117 Berlin, Germany	Kanazawa University; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Inomata, K (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan.	inomata@cacheibm.s.kanazawa-u.ac.jp; lamparte@zedat.fu-berlin.de	Lamparter, Tilman/E-4421-2013; Hammam, Mostafa/M-6126-2016	Lamparter, Tilman/0000-0003-4327-9737; Hammam, Mostafa/0000-0003-4299-2231; Scheerer, Patrick/0000-0001-5028-2075; Krauss, Norbert/0000-0002-7128-4632				Andel F, 1996, BIOCHEMISTRY-US, V35, P15997, DOI 10.1021/bi962175k; Andel F, 2000, BIOCHEMISTRY-US, V39, P2667, DOI 10.1021/bi991688z; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Blumenstein A, 2005, CURR BIOL, V15, P1833, DOI 10.1016/j.cub.2005.08.061; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen EF, 1996, BIOCHEMISTRY-US, V35, P843, DOI 10.1021/bi952115z; DeLano W.L., 2002, PYMOL MOL GRAPHICS S, DOI DOI 10.1007/S10822-016-9944-X; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; EILFELD P, 1985, Z NATURFORSCH C, V40, P109; FALK H, 1987, MONATSH CHEM, V118, P1301, DOI 10.1007/BF00816873; Falk H., 1989, CHEM LINEAR OLIGOPYR; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Giraud E, 2005, J BIOL CHEM, V280, P32389, DOI 10.1074/jbc.M506890200; Giraud E, 2004, PHOTOCH PHOTOBIO SCI, V3, P587, DOI 10.1039/b315770a; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Hammam MAS, 2004, CHEM LETT, V33, P1258, DOI 10.1246/cl.2004.1258; HAMMAM MAS, 2006, IN PRESS B CHEM SOC; Heyne K, 2002, BIOPHYS J, V82, P1004, DOI 10.1016/S0006-3495(02)75460-X; Hubschmann T, 2001, EUR J BIOCHEM, V268, P2055, DOI 10.1046/j.1432-1327.2001.02083.x; Inomata K, 2005, J BIOL CHEM, V280, P24491, DOI 10.1074/jbc.M504710200; Kakiuchi T, 1998, CHEM LETT, P1001, DOI 10.1246/cl.1998.1001; Kakiuchi T, 1999, SYNLETT, P901; Karniol B, 2003, P NATL ACAD SCI USA, V100, P2807, DOI 10.1073/pnas.0437914100; Kinoshita H, 2005, CHEM LETT, V34, P800, DOI 10.1246/cl.2005.800; Lamparter T, 2005, BIOCHEMISTRY-US, V44, P8461, DOI 10.1021/bi047510g; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Oberpichler I, 2006, FEBS LETT, V580, P437, DOI 10.1016/j.febslet.2005.12.035; Rentsch S, 1997, PHOTOCHEM PHOTOBIOL, V66, P585, DOI 10.1111/j.1751-1097.1997.tb03193.x; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; Rudiger W., 1994, PHOTOMORPHOGENESIS P, V2nd, P51; Sawamoto D, 2001, CHEM LETT, P588, DOI 10.1246/cl.2001.588; Scheerer P, 2006, J STRUCT BIOL, V153, P97, DOI 10.1016/j.jsb.2005.11.002; STAROSTZIK C, 1995, FEBS LETT, V370, P146, DOI 10.1016/0014-5793(95)00820-Y; Takeda S, 2001, CHEM LETT, P590, DOI 10.1246/cl.2001.590; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; Tu SL, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P121, DOI 10.1002/352760510X.ch6; van Thor JJ, 2001, BIOCHEMISTRY-US, V40, P11460, DOI 10.1021/bi002651d; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	43	48	48	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28162	28173		10.1074/jbc.M603983200	http://dx.doi.org/10.1074/jbc.M603983200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16803878	Green Submitted, hybrid			2022-12-25	WOS:000240534400054
J	Chakravarthy, S; Luger, K				Chakravarthy, Srinivas; Luger, Karolin			The histone variant macro-H2A preferentially forms "hybrid nucleosomes"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; CORE PARTICLE; MACROH2A; TRANSCRIPTION; CHROMATIN; BINDING; STABILITY; OCTAMER; COMPLEX	The histone domain of macro-H2A, which constitutes the N-terminal one third of this histone variant, is only 64% identical to major H2A. We have shown previously that the main structural differences in a nucleosome in which both H2A moieties have been replaced by macro-H2A reside in the only point of contact between the two histone dimers, the L1-L1 interface of macro-H2A. Here we show that the L1 loop of macro-H2A is responsible for the increased salt-dependent stability of the histone octamer, with implications for the nucleosome assembly pathway. It is unknown whether only one or both of the H2A-H2B dimers within a nucleosome are replaced with H2A variant containing nucleosomes in vivo. We demonstrate that macroH2A preferentially forms hybrid nucleosomes containing one chain each of major H2A and macro-HA in vitro. The 2.9-angstrom crystal structure of such a hybrid nucleosome shows significant structural differences in the L1-L1 interface when comparing with homotypic major H2A-and macro-H2A-containing nucleosomes. Both homotypic and hybrid macro-nucleosome core particles ( NCPs) are resistant to chaperone-assisted H2A-H2B dimer exchange. Together, our findings suggest that the histone domain of macro-H2A modifies the dynamic properties of the nucleosome. We propose that the possibility of forming hybrid macro-NCP adds yet another level of complexity to variant nucleosome structure and function.	Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University; Howard Hughes Medical Institute; Colorado State University	Luger, K (corresponding author), Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA.	karolin.luger@colostate.edu		SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331				Abbott DW, 2005, J BIOL CHEM, V280, P16437, DOI 10.1074/jbc.M500170200; Abbott DW, 2004, BIOCHEMISTRY-US, V43, P1352, DOI 10.1021/bi035859i; Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Bao YH, 2004, EMBO J, V23, P3314, DOI 10.1038/sj.emboj.7600316; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Chadwick BP, 2002, J CELL BIOL, V157, P1113, DOI 10.1083/jcb.200112074; Chadwick BP, 2001, NUCLEIC ACIDS RES, V29, P2699, DOI 10.1093/nar/29.13.2699; Chakravarthy S, 2004, COLD SPRING HARB SYM, V69, P227, DOI 10.1101/sqb.2004.69.227; Chakravarthy S, 2005, MOL CELL BIOL, V25, P7616, DOI 10.1128/MCB.25.17.7616-7624.2005; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; ENDO S, 1983, ANAL BIOCHEM, V131, P108, DOI 10.1016/0003-2697(83)90141-0; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Gautier T, 2004, EMBO REP, V5, P715, DOI 10.1038/sj.embor.7400182; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; Muthurajan UM, 2004, EMBO J, V23, P260, DOI 10.1038/sj.emboj.7600046; Muthurajan UM, 2003, BIOPOLYMERS, V68, P547, DOI 10.1002/bip.10317; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Rice LM, 1998, J APPL CRYSTALLOGR, V31, P798, DOI 10.1107/S0021889898006645; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Tsunaka Y, 2005, NUCLEIC ACIDS RES, V33, P3424, DOI 10.1093/nar/gki663	37	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25522	25531		10.1074/jbc.M602258200	http://dx.doi.org/10.1074/jbc.M602258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803903	hybrid			2022-12-25	WOS:000240031300055
J	Andreotti, G; Mendez, BL; Amodeo, P; Morelli, MAC; Nakamuta, H; Motta, A				Andreotti, Giuseppina; Mendez, Blanca Lopez; Amodeo, Pietro; Morelli, Maria A. Castiglione; Nakamuta, Hiromichi; Motta, Andrea			Structural determinants of salmon calcitonin bioactivity - The role of the Leu-based amphipathic alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECYL-SULFATE MICELLES; BIOLOGICAL POTENCY; 2-DIMENSIONAL NMR; CONFORMATIONAL FLEXIBILITY; MOLECULAR-DYNAMICS; ADENYLATE-CYCLASE; AMINO-TERMINUS; MODEL PEPTIDE; RECEPTOR; ANALOGS	Salmon calcitonin ( sCT) forms an amphipathic helix in the region 9 - 19, with the C-terminal decapeptide interacting with the helix ( Amodeo, P., Motta, A., Strazzullo, G., Castiglione Morelli, M. A. ( 1999) J. Biomol. NMR 13, 161 - 174). To uncover the structural requirements for the hormone bioactivity, we investigated several sCT analogs. They were designed so as to alter the length of the central helix by removal and/or replacement of flanking residues and by selectively mutating or deleting residues inside the helix. The helix content was assessed by circular dichroism and NMR spectroscopies; the receptor binding affinity in human breast cancer cell line T 47D and the in vivo hypocalcemic activity were also evaluated. In particular, by NMR spectroscopy and molecular dynamics calculations we studied Leu(23), Ala(24)-sCT in which Pro(23) and Arg(24) were replaced by helix inducing residues. Compared with sCT, it assumes a longer amphipathic alpha-helix, with decreased binding affinity and one-fifth of the hypocalcemic activity, therefore supporting the idea of a relationship between a definite helix length and bioactivity. From the analysis of other sCT mutants, we inferred that the correct helix length is located in the 9 - 19 region and requires long range interactions and the presence of specific regions of residues within the sequence for high binding affinity and hypocalcemic activity. Taken together, the structural and biological data identify well defined structural parameters of the helix for sCT bioactivity.	CNR, Ist Chim Biomol, Comprensorio Olivetti, I-80078 Pozzuoli, Napoli, Italy; Univ Basilicata, Dipartimento Chim, I-85100 Potenza, Italy; Hiroshima Int Univ, Fac Pharmaceut Sci, Dept Pharmaceut Sci, Pharmacol Lab, Hiroshima 7370112, Japan	Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Basilicata	Motta, A (corresponding author), CNR, Ist Chim Biomol, Comprensorio Olivetti, Edificio A,Via Campi Flegrei 34, I-80078 Pozzuoli, Napoli, Italy.	amotta@icmib.na.cnr.it	Amodeo, Pietro/P-1800-2015; ANDREOTTI, GIUSEPPINA/AAX-8952-2020	Amodeo, Pietro/0000-0002-6439-7575; ANDREOTTI, GIUSEPPINA/0000-0002-1594-0156; Castiglione Morelli, Maria Antonietta/0000-0003-3967-3117; Motta, Andrea/0000-0002-8643-658X				Amodeo P, 1999, J BIOMOL NMR, V13, P161, DOI 10.1023/A:1008365322148; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Andreotti G, 2004, J BIOL CHEM, V279, P6364, DOI 10.1074/jbc.M310882200; ARVINTE T, 1993, J BIOL CHEM, V268, P6415; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Chen WJ, 1997, MOL PHARMACOL, V52, P1164, DOI 10.1124/mol.52.6.1164; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dong MQ, 2004, J BIOL CHEM, V279, P31177, DOI 10.1074/jbc.M404113200; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; Epand RF, 2004, BIOPOLYMERS, V76, P258, DOI 10.1002/bip.20030; EPAND RM, 1985, INT J PEPT PROT RES, V25, P105; EPAND RM, 1988, BIOCHEM BIOPH RES CO, V152, P203, DOI 10.1016/S0006-291X(88)80700-9; EPAND RM, 1986, BIOCHEMISTRY-US, V25, P1964, DOI 10.1021/bi00356a019; EPAND RM, 1990, EUR J BIOCHEM, V188, P633, DOI 10.1111/j.1432-1033.1990.tb15444.x; EPAND RM, 1988, J MED CHEM, V31, P1595, DOI 10.1021/jm00403a019; EPAND RM, 1986, EUR J BIOCHEM, V159, P125, DOI 10.1111/j.1432-1033.1986.tb09841.x; EPAND RM, 1986, INT J PEPT PROT RES, V26, P501; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; FINDLAY DM, 1983, ENDOCRINOLOGY, V112, P1288, DOI 10.1210/endo-112-4-1288; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; GREEN FR, 1987, P NATL ACAD SCI USA, V84, P8340, DOI 10.1073/pnas.84.23.8340; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUNTERT P, 1989, J AM CHEM SOC, V111, P3997; HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Jourdan F, 2003, PROTEINS, V52, P534, DOI 10.1002/prot.10418; KAPURNIOTU A, 1995, J MED CHEM, V38, P836, DOI 10.1021/jm00005a011; Kazantzis A, 2002, EUR J BIOCHEM, V269, P780, DOI 10.1046/j.0014-2956.2001.02689.x; LAMP SJ, 1981, J BIOL CHEM, V256, P2269; LYBRAND TP, 1986, P NATL ACAD SCI USA, V83, P833, DOI 10.1073/pnas.83.4.833; MAIER R, 1976, CLIN ENDOCRINOL, V5, P327; Manicourt D.-H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P285; MEADOWS RP, 1991, BIOCHEMISTRY-US, V30, P1247, DOI 10.1021/bi00219a012; MEYER JP, 1991, BIOPOLYMERS, V31, P233, DOI 10.1002/bip.360310210; MOE GR, 1983, J AM CHEM SOC, V105, P4100, DOI 10.1021/ja00350a064; MOE GR, 1985, BIOCHEMISTRY-US, V24, P1971, DOI 10.1021/bi00329a026; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; MORELLI MAC, 1992, J BIOMOL NMR, V2, P335, DOI 10.1007/BF01874812; MOTTA A, 1991, BIOCHEMISTRY-US, V30, P10444, DOI 10.1021/bi00107a012; Motta A, 1998, PROTEINS, V32, P314, DOI 10.1002/(SICI)1097-0134(19980815)32:3<314::AID-PROT7>3.3.CO;2-J; NAKAMUTA H, 1990, ENDOCRINOLOGY, V127, P163, DOI 10.1210/endo-127-1-163; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pham V, 2004, J BIOL CHEM, V279, P6720, DOI 10.1074/jbc.M307214200; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Rajashankar KR, 1996, PROTEIN SCI, V5, P932; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; WADA S, 1995, ENDOCRINOLOGY, V136, P2611, DOI 10.1210/en.136.6.2611; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WURTICH K, 1986, NMR PROTEINS NUCLEIC, P162; ZAIDI M, 2002, PRINCIPLES BONE BIOL, V2, P1423	58	52	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24193	24203		10.1074/jbc.M603528200	http://dx.doi.org/10.1074/jbc.M603528200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16766525	hybrid			2022-12-25	WOS:000239847800013
J	Bassler, J; Kallas, M; Hurt, E				Bassler, Jochen; Kallas, Martina; Hurt, Ed			The NUG1 GTPase reveals an N-terminal RNA-binding domain that is essential for association with 60 S pre-ribosomal particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEXES; MESSENGER-RNA; ESCHERICHIA-COLI; 3-HYBRID SYSTEM; IN-VITRO; BIOGENESIS; SUBUNIT; MATURATION; CYTOPLASM	The putative yeast GTPase Nug1, which is associated with several pre-60 S particles in the nucleolus and nucleoplasm, consists of an N-terminal domain, which is found only in eukaryotic orthologues, and middle and C-terminal domains that are conserved throughout eukaryotes, bacteria, and archaea. Here, we analyzed the role of the eukaryote- specific Nug1 N-domain (Nug1-N). We show that the essential Nug1-N is sufficient and necessary for nucle(ol)ar targeting and association with pre-60 S particles. Nug1-N exhibits RNA binding activity and is genetically linked in an allele- specific way to the pre-60 S factors Noc2, Noc3, and Dbp10. In contrast, the middle domain, which exhibits a circularly permuted GTPase fold and an intrinsic GTP hydrolysis activity in vitro, is not essential for cell growth. The conserved Nug1 C-domain, which has a yet uncharacterized fold, is also essential for ribosome biogenesis. Our findings suggest that Nug1 associates with pre-60 S subunits via its essential N-terminal RNA-binding domain and exerts a non-essential regulative role in pre-60 S subunit biogenesis via its central GTPase domain.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Baßler, Jochen/AAC-5336-2021; Ed Hurt, Dr./AAE-8874-2019	Baßler, Jochen/0000-0002-7441-7867; Ed Hurt, Dr./0000-0002-4535-8255				Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; Barrientos A, 2003, MOL BIOL CELL, V14, P2292, DOI 10.1091/mbc.E02-10-0636; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Burger F, 2000, NUCLEIC ACIDS RES, V28, P2315, DOI 10.1093/nar/28.12.2315; Daigle DM, 2004, J BACTERIOL, V186, P1381, DOI 10.1128/JB.186.5.1381-1387.2004; Daigle DM, 2002, BIOCHEMISTRY-US, V41, P11109, DOI 10.1021/bi020355q; De Antoni A, 2002, J BIOL CHEM, V277, P41023, DOI 10.1074/jbc.M205783200; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Du XM, 2006, MOL BIOL CELL, V17, P460, DOI 10.1091/mbc.E05-09-0848; Fewell SW, 1999, MOL CELL BIOL, V19, P826; FISKE LM, 1925, J BIOL CHEM, V66, P375; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Granneman S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/j.yexcr.2004.03.016; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; Himeno H, 2004, NUCLEIC ACIDS RES, V32, P5303, DOI 10.1093/nar/gkh861; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kallstrom G, 2003, MOL CELL BIOL, V23, P4344, DOI 10.1128/MCB.23.12.4344-4355.2003; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Liu SJ, 2004, WORLD J GASTROENTERO, V10, P1246; Maniatis T., 1982, MOL CLONING LAB MANU; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Nissan TA, 2004, MOL CELL, V15, P295, DOI 10.1016/j.molcel.2004.06.033; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Osheim YN, 2004, MOL CELL, V16, P943, DOI 10.1016/j.molcel.2004.11.031; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saveanu C, 2003, MOL CELL BIOL, V23, P4449, DOI 10.1128/MCB.23.13.4449-4460.2003; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Schafer T, 2006, NATURE, V441, P651, DOI 10.1038/nature04840; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shin DH, 2004, P NATL ACAD SCI USA, V101, P13198, DOI 10.1073/pnas.0405202101; Sijin L, 2004, J EXP CLIN CANC RES, V23, P529; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tsai RYL, 2005, J CELL BIOL, V168, P179, DOI 10.1083/jcb.200409053; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Uicker WC, 2006, MOL MICROBIOL, V59, P528, DOI 10.1111/j.1365-2958.2005.04948.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; West M, 2005, MOL CELL BIOL, V25, P3802, DOI 10.1128/MCB.25.9.3802-3813.2005	44	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24737	24744		10.1074/jbc.M604261200	http://dx.doi.org/10.1074/jbc.M604261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803892	hybrid			2022-12-25	WOS:000239847800070
J	Culbert, AA; Skaper, SD; Howlett, DR; Evans, NA; Facci, L; Soden, PE; Seymour, ZM; Guillot, F; Gaestel, M; Richardson, JC				Culbert, Ainsley A.; Skaper, Stephen D.; Howlett, David R.; Evans, Nicholas A.; Facci, Laura; Soden, Peter E.; Seymour, Zoe M.; Guillot, Florence; Gaestel, Matthias; Richardson, Jill C.			MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity - Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; TNF-ALPHA; IN-VITRO; TAU-HYPERPHOSPHORYLATION; MAPKAP KINASE-2; P38 KINASE; MICE; BRAIN	MAPK-activated protein kinase 2 (MAPKAP K2 or MK2) is one of several kinases directly regulated by p38 MAPK. A role for p38 MAPK in the pathology of Alzheimer disease (AD) has previously been suggested. Here, we provide evidence to suggest that MK2 also plays a role in neuroinflammatory and neurodegenerative pathology of relevance to AD. MK2 activation and expression were increased in lipopolysaccharide (LPS) + interferon gamma-stimulated microglial cells, implicating a role for MK2 in eliciting a pro-inflammatory response. Microglia cultured ex vivo from MK2-deficient (MK2(-/-)) mice demonstrated significant inhibition in release of tumor necrosis factor alpha, KC (mouse chemokine with highest sequence identity to human GROs and interleukin-8), and macrophage inflammatory protein 1 alpha on stimulation with LPS + interferon gamma or amyloid-beta peptide (1-42) compared with MK2(+/+) wild-type microglia. Consistent with an inhibition in pro- inflammatory mediator release, cortical neurons co-cultured with LPS + interferon gamma-stimulated or amyloid-beta peptide (1-42) stimulated MK2(+/+) microglia were protected from microglial-mediated neuronal cell toxicity. In a transgenic mouse model of AD in which amyloid precursor protein and presenilin-1 harboring familial AD mutations are over-expressed in specific regions of the brain, elevated activation and expression of MK2 correlated with beta-amyloid deposition, microglial activation, and up-regulation of tumor necrosis factor alpha, macrophage inflammatory protein 1 alpha, and KC gene expression in the same brain regions. Our data propose a role for MK2 in AD brain pathology, for which neuroinflammation involving cytokines and chemokines and overt neuronal loss have been documented.	GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	GlaxoSmithKline; Hannover Medical School	Culbert, AA (corresponding author), GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	ainsley.a.culbert@gsk.com	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Richardson, Jill/0000-0001-6564-3187; Seymour, Zoe/0000-0002-8977-1519; , Florence/0000-0002-8491-4269				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aloe L, 1999, CYTOKINE, V11, P45, DOI 10.1006/cyto.1998.0397; Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; Atzori C, 2001, J NEUROPATH EXP NEUR, V60, P1190, DOI 10.1093/jnen/60.12.1190; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chessell IP, 1997, BRIT J PHARMACOL, V121, P1429, DOI 10.1038/sj.bjp.0701278; Cross D, 2000, METH MOL B, V124, P147; Diemel LT, 1998, NEUROCHEM RES, V23, P341, DOI 10.1023/A:1022405516630; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Flavin MP, 2000, GLIA, V29, P347, DOI 10.1002/(SICI)1098-1136(20000215)29:4<347::AID-GLIA5>3.3.CO;2-#; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Giovannini MG, 2002, NEUROBIOL DIS, V11, P257, DOI 10.1006/nbdi.2002.0538; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Golde S, 2002, J NEUROCHEM, V82, P269, DOI 10.1046/j.1471-4159.2002.00973.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Howlett DR, 2004, BRAIN RES, V1017, P130, DOI 10.1016/j.brainres.2004.05.029; Hwang DY, 2004, EXP NEUROL, V186, P20, DOI 10.1016/j.expneurol.2003.09.021; KARP HL, 1994, GLIA, V11, P284, DOI 10.1002/glia.440110310; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Koistinaho M, 2002, P NATL ACAD SCI USA, V99, P1610, DOI 10.1073/pnas.032670899; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kotlyarov A, 2002, BIOCHEM SOC T, V30, P959, DOI 10.1042/BST0300959; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Puig B, 2004, NEUROPATH APPL NEURO, V30, P491, DOI 10.1111/j.1365-2990.2004.00569.x; Reynolds LJ, 2001, TOXICOLOGY, V165, P145, DOI 10.1016/S0300-483X(01)00417-6; Richardson JC, 2003, NEUROSCIENCE, V122, P213, DOI 10.1016/S0306-4522(03)00389-0; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; Stein TD, 2002, J NEUROSCI, V22, P7380; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Streit WJ, 2001, NEUROBIOL AGING, V22, P909, DOI 10.1016/S0197-4580(01)00290-1; Sudo T, 2005, BIOCHEM BIOPH RES CO, V337, P415, DOI 10.1016/j.bbrc.2005.09.063; Vician LJ, 2004, J NEUROSCI RES, V78, P315, DOI 10.1002/jnr.20251; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang XK, 2002, J BIOL CHEM, V277, P43968, DOI 10.1074/jbc.M206837200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu YP, 2004, P NATL ACAD SCI USA, V101, P8425, DOI 10.1073/pnas.0400625101; Xia MQ, 2002, J NEUROIMMUNOL, V122, P55, DOI 10.1016/S0165-5728(01)00463-5; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	55	125	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23658	23667		10.1074/jbc.M513646200	http://dx.doi.org/10.1074/jbc.M513646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16774924	hybrid			2022-12-25	WOS:000239702900041
J	Li, XM; Thyssen, G; Beliakoff, J; Sun, ZJ				Li, Xiaomeng; Thyssen, Gregory; Beliakoff, Jason; Sun, Zijie			The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; RECEPTOR-MEDIATED TRANSCRIPTION; TGF-BETA; ANDROGEN RECEPTOR; DEPENDENT TRANSCRIPTION; INTERACTING PROTEIN-3; SIGNAL-TRANSDUCTION; TUMOR SUPPRESSORS; GENE-EXPRESSION; FAMILY-MEMBERS	Transforming growth factor beta (TGF-beta) plays critical roles in the control of cell proliferation, differentiation, and apoptosis. Smad proteins are substrates of the TGF-beta type I receptor and are responsible for transducing receptor signals to target genes in the nucleus. The PIAS (protein inhibitor of activated STAT) proteins were originally identified as transcriptional co-regulators of the JAK-STAT pathway. Subsequently, cross-talk between the PIAS proteins and other signaling pathways has been shown to be involved in various cellular processes. Importantly, PIAS proteins modulate TGF-beta signaling by regulating the transcriptional activity of Smad3. In this study we tested whether hZimp10, a novel PIAS-like protein, acts as other PIAS proteins to regulate Smad3-mediated transcription. We show that expression of exogenous hZimp10 enhances the transcriptional activity of Smad3, which appears to be Smad4-dependent and responsive to TGF-beta induction. Furthermore, knockdown of endogenous hZimp10 reduced the transcriptional activity of Smad3. A protein-protein interaction between Smad3 and Smad4 with hZimp10 was identified in glutathione S-transferase-pulldown and co-immunoprecipitation assays. The Miz domain of hZimp10 and the MH2 domains of Smad3 and Smad4 were mapped as the regions responsible for binding. Results from immunostaining assays further demonstrated that Smad3, Smad4, and hZimp10 co-localize within cell nuclei. Finally, we demonstrated that Smad3/4-mediated transcription is significantly impaired in response to TGF-beta induction in Zimp10 null (zimp10 -/-) embryonic fibroblasts. Taken together, these results provide the first line of evidence to demonstrate a role for Zimp10 in regulating the TGF-beta/Smad signaling pathway.	Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Sun, ZJ (corresponding author), Stanford Univ, Dept Urol, Sch Med, 300 Pasteur Dr,Grant Bldg,S287, Stanford, CA 94305 USA.	zsun@stanford.edu		Li, Xiaomeng/0000-0002-7811-3457	NATIONAL CANCER INSTITUTE [R29CA070297, R01CA087767, R01CA070297, T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061002, R56DK061002] Funding Source: NIH RePORTER; NCI NIH HHS [CA087767, R01 CA087767-04, R01 CA070297-08, R01 CA070297-12, R01 CA070297-09, R01 CA070297-10, R01 CA070297-06A1, R01 CA070297-07, R01 CA070297-11A2, R01 CA070297, CA070297, R01 CA087767-03, R01 CA087767-02, 5T32 CA09302-27, R01 CA087767, R01 CA087767-01A2, R01 CA087767-05] Funding Source: Medline; NIDDK NIH HHS [R56 DK061002, R01 DK061002-01A1, R01 DK061002, DK061002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gutierrez L, 2003, DEVELOPMENT, V130, P343, DOI 10.1242/dev.00222; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayes SA, 2001, CANCER RES, V61, P2112; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lange D, 1999, INT J ONCOL, V14, P1049; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ohshima T, 2003, J BIOL CHEM, V278, P50833, DOI 10.1074/jbc.M307533200; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sharma M, 2001, MOL ENDOCRINOL, V15, P1918, DOI 10.1210/me.15.11.1918; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; SUN ZJ, 1995, J BIOL CHEM, V270, P1462, DOI 10.1074/jbc.270.3.1462; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	52	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23748	23756		10.1074/jbc.M508365200	http://dx.doi.org/10.1074/jbc.M508365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16777850	hybrid			2022-12-25	WOS:000239702900050
J	Berteau, O; Guillot, A; Benjdia, A; Rabot, S				Berteau, Olivier; Guillot, Alain; Benjdia, Alhosna; Rabot, Sylvie			A new type of bacterial sulfatase reveals a novel maturation pathway in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLGLYCINE-GENERATING ENZYME; SULFUR PROTEIN ATSB; ARYLSULFATASE GENE; MOLECULAR-CLONING; BIOCHEMICAL-CHARACTERIZATION; POSTTRANSLATIONAL FORMATION; CHONDRODYSPLASIA PUNCTATA; SEA-URCHIN; MECHANISM; DEFICIENCY	Sulfatases are a highly conserved family of enzymes found in all three domains of life. To be active, sulfatases undergo a unique post-translational modification leading to the conversion of either a critical cysteine ("Cys-type" sulfatases) or a serine ("Ser-type" sulfatases) into a C alpha-formylglycine (FGly). This conversion depends on a strictly conserved sequence called "sulfatase signature" (C/S)XPXR. In a search for new enzymes from the human microbiota, we identified the first sulfatase from Firmicutes. Matrix-assisted laser desorption ionization time-of-flight analysis revealed that this enzyme undergoes conversion of its critical cysteine residue into FGly, even though it has a modified (C/S)XAXR sulfatase signature. Examination of the bacterial and archaeal genomes sequenced to date has identified many genes bearing this new motif, suggesting that the definition of the sulfatase signature should be expanded. Furthermore, we have also identified a new Cys-type sulfatase-maturating enzyme that catalyzes the conversion of cysteine into FGly, in anaerobic conditions, whereas the only enzyme reported so far to be able to catalyze this reaction is oxygen-dependent. The new enzyme belongs to the radical S-adenosyl-L-methionine enzyme superfamily and is related to the Ser-type sulfatase-maturating enzymes. This finding leads to the definition of a new enzyme family of sulfatase-maturating enzymes that we have named anSME (anaerobic sulfatase-maturating enzyme). This family includes enzymes able to maturate Cys-type as well as Ser-type sulfatases in anaerobic conditions. In conclusion, our results lead to a new scheme for the biochemistry of sulfatases maturation and suggest that the number of genes and bacterial species encoding sulfatase enzymes is currently underestimated.	INRA, Unite Ecol & Physiol Syst Digest, F-78352 Jouy En Josas, France; INRA, Unite Biochim Bacterienne, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Berteau, O (corresponding author), INRA, Unite Ecol & Physiol Syst Digest, F-78352 Jouy En Josas, France.	Olivier.Berteau@jouy.inra.fr	Benjdia, Alhosna/AAM-7415-2021; Berteau, Olivier/AAF-9080-2019	Benjdia, Alhosna/0000-0002-3544-2541; Berteau, Olivier/0000-0002-3434-5168; Rabot, Sylvie/0000-0002-4603-2038				BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Diez-Roux G, 2005, ANNU REV GENOM HUM G, V6, P355, DOI 10.1146/annurev.genom.6.080604.162334; DORFMAN A, 1976, P NATL ACAD SCI USA, V73, P630, DOI 10.1073/pnas.73.2.630; Dotson SB, 1996, J BIOL CHEM, V271, P25754, DOI 10.1074/jbc.271.42.25754; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fang QH, 2004, J BIOL CHEM, V279, P14570, DOI 10.1074/jbc.M313855200; Ferrante P, 2004, GENE, V336, P155, DOI 10.1016/j.gene.2004.04.001; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; Gieselmann V, 1998, J INHERIT METAB DIS, V21, P564, DOI 10.1023/A:1005471106088; HALLMANN A, 1994, EUR J BIOCHEM, V221, P143, DOI 10.1111/j.1432-1033.1994.tb18723.x; Hanson SR, 2004, ANGEW CHEM INT EDIT, V43, P5736, DOI 10.1002/anie.200300632; Haugen AC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-r95; Hernandez-Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200; Hoffman JA, 2000, INFECT IMMUN, V68, P5062, DOI 10.1128/IAI.68.9.5062-5067.2000; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; Leoni O, 1998, IND CROP PROD, V7, P335, DOI 10.1016/S0926-6690(97)00066-6; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Marquordt C, 2003, J BIOL CHEM, V278, P2212, DOI 10.1074/jbc.M209435200; MODARESSI S, 1993, BIOL CHEM H-S, V374, P327, DOI 10.1515/bchm3.1993.374.1-6.327; Morokuma J, 1997, DEV GROWTH DIFFER, V39, P469; Mougous JD, 2002, CHEM BIOL, V9, P767, DOI 10.1016/S1074-5521(02)00175-8; Myette JR, 2003, J BIOL CHEM, V278, P12157, DOI 10.1074/jbc.M211420200; PAIETTA JV, 1989, MOL CELL BIOL, V9, P3630, DOI 10.1128/MCB.9.9.3630; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Peng JH, 2003, J MASS SPECTROM, V38, P80, DOI 10.1002/jms.404; Preusser-Kunze A, 2005, J BIOL CHEM, V280, P14900, DOI 10.1074/jbc.M413383200; Quaiser A, 2003, MOL MICROBIOL, V50, P563, DOI 10.1046/j.1365-2958.2003.03707.x; Ravina CG, 2002, PLANT PHYSIOL, V130, P2076, DOI 10.1104/pp.012484; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sardiello M, 2005, HUM MOL GENET, V14, P3203, DOI 10.1093/hmg/ddi351; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YANG Q, 1989, DEV BIOL, V135, P53, DOI 10.1016/0012-1606(89)90157-7	46	81	92	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22464	22470		10.1074/jbc.M602504200	http://dx.doi.org/10.1074/jbc.M602504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766528	hybrid, Green Published			2022-12-25	WOS:000239542600007
J	York, SJ; Modrich, P				York, Sally J.; Modrich, Paul			Mismatch repair-dependent iterative excision at irreparable O-6-methylguanine lesions in human nuclear extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRO-N-NITROSOGUANIDINE; DNA-POLYMERASE ETA; COLORECTAL-CANCER; METHYLATING AGENTS; INDUCED APOPTOSIS; CELL-LINE; DAMAGE; ALKYLATION; ALPHA; RESISTANCE	The response of mammalian cells to S(n)1 DNA methylators depends on functional MutS alpha and MutL alpha. Cells deficient in either of these activities are resistant to the cytotoxic effects of this class of chemotherapeutic drug. Because killing by Sn1 methylators has been attributed to O-6-methylguanine (MeG), we have constructed nicked circular heteroduplexes that contain a single MeG-T mis-pair, and we have examined processing of these molecules by mismatch repair in nuclear extracts of human cells. Excision provoked by MeG-T is restricted to the incised heteroduplex strand, leading to removal of the MeG when it resides on this strand. However, when the MeG is located on the continuous strand, the heteroduplex is irreparable. MeG-T-dependent repair DNA synthesis is observed on both reparable and irreparable 3' and 5' heteroduplexes as judged by [P-32]dAMP incorporation. Labeling with [alpha-P-32]dATP followed by a cold dATP chase has demonstrated that newly synthesized DNA on irreparable molecules is subject to re-excision in a reaction that is MutL alpha-dependent, an effect attributable to the presence of MeG on the template strand. Processing of the irreparable 3' heteroduplex is also associated with incision of the discontinuous strand of a few percent of molecules near the thymidylate of the MeG-T base pair. These results provide the first direct evidence for mismatch repair-mediated iterative processing of DNA methylator damage, an effect that may be relevant to damage signaling events triggered by this class of chemotherapeutic agent.	Duke Univ, Ctr Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Med, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	York, SJ (corresponding author), Duke Univ, Ctr Med, Howard Hughes Med Inst, Box 3711, Durham, NC 27710 USA.	modrich@biochem.duke.edu	Classen, Scott/AAY-8176-2020	Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [P50CA108786, P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P01 CA092584, P01 CA92584, 1P50CA108786, P01 CA092584-060005, P50 CA108786] Funding Source: Medline; NIGMS NIH HHS [GM45190, R01 GM045190, R01 GM045190-16] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BROOKS P, 1989, P NATL ACAD SCI USA, V86, P4425, DOI 10.1073/pnas.86.12.4425; Caporali S, 2004, MOL PHARMACOL, V66, P478; Cejka P, 2005, CURR BIOL, V15, P1395, DOI 10.1016/j.cub.2005.07.032; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; FANG WH, 1993, J BIOL CHEM, V268, P11838; Friedman HS, 1997, CANCER RES, V57, P2933; Genschel J, 2003, MOL CELL, V12, P1077, DOI 10.1016/S1097-2765(03)00428-3; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Khare V, 2001, J BIOL CHEM, V276, P24286, DOI 10.1074/jbc.M011025200; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Li GM, 1999, ONCOL RES, V11, P393; Liu LL, 2002, CANCER RES, V62, P3070; Lynch HT, 1999, J MED GENET, V36, P801; Meira LB, 2002, DNA REPAIR, V1, P929, DOI 10.1016/S1568-7864(02)00143-X; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1036, DOI 10.1021/bi00353a013; Perrino FW, 2003, CHEM RES TOXICOL, V16, P1616, DOI 10.1021/tx034164f; Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Spratt TE, 1997, NUCLEIC ACIDS RES, V25, P3354, DOI 10.1093/nar/25.16.3354; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404; Surtees JA, 2004, CYTOGENET GENOME RES, V107, P146, DOI 10.1159/000080593; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; Wang HX, 2001, MOL BIOTECHNOL, V19, P133, DOI 10.1385/MB:19:2:133; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Yamane K, 2004, BIOCHEM BIOPH RES CO, V318, P297, DOI 10.1016/j.bbrc.2004.04.030	45	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22674	22683		10.1074/jbc.M603667200	http://dx.doi.org/10.1074/jbc.M603667200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772289	Green Accepted, hybrid			2022-12-25	WOS:000239542600028
J	Dhar, SK; Xu, Y; Chen, YM; Clair, DKS				Dhar, Sanjit Kumar; Xu, Yong; Chen, Yumin; Clair, Daret K. St.			Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ISCHEMIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; BOX-BINDING PROTEIN; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; ACTIVATION DOMAINS; TUMOR-SUPPRESSOR; DNA-BINDING; C/EBP-BETA	Manganese superoxide dismutase ( MnSOD) is a primary antioxidant enzyme necessary for the survival of aerobic life. Previously, we demonstrated that specificity protein 1 ( Sp1) is essential for the basal transcription of the MnSOD gene. We also identified nucleophosmin ( NPM), an RNA-binding protein, as an important co-activator of NF-kappa B in the induction of MnSOD by cytokine and tumor promoter. Here, using chromatin immunoprecipitation ( ChIP) analysis, we demonstrate that Sp1 and NPM interact in vivo to enhance NF-kappa B-mediated MnSOD induction. Interaction between NPM and Sp1 or NF-kappa B at the promoter and enhancer of the MnSOD gene in vivo were verified by the presence of the PCR products from the promoter and enhancer elements in the ChIP assay. Unexpectedly, we also found p53, another transcription factor, to be a component of the complex detected by ChIP assay. The presence of p53 in this transcription complex was verified by immunoprecipitation of p53 proteins with antibody to Sp1 in nuclear extracts. Using a vector expressing full-length p53 cDNA, we demonstrated that p53 overexpression suppresses MnSOD mRNA and protein levels. Consistent with the negative role of p53 in the expression of the MnSOD gene, expression of small interfering RNA for p53 leads to an increase of MnSOD mRNA and protein levels. Using ChIP assays and immunoprecipitation, we further demonstrated that p53 interacts with Sp1 to suppress both the constitutive and 12-O-tetradecanoylphorbol-13-acetate-stimulated expression of the MnSOD gene. Inhibition of the MnSOD gene by p53 was abolished when Sp1 sites on the MnSOD promoter were mutated or when the Sp1 protein was reduced by siRNA approaches. Because expression of MnSOD protects against cell death, our findings reveal a previously unrecognized mechanism of p53-mediated cell death and demonstrate an intricate relationship between the positive and negative control of MnSOD expression.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky	Clair, DKS (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	DSTL00@pop.uky.edu			NATIONAL CANCER INSTITUTE [R01CA094853, R01CA073599, R29CA049797, R01CA049797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG005119] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA049797-15, CA 49797, CA73599, CA 94853, R01 CA049797, R01 CA073599, R01 CA094853] Funding Source: Medline; NIA NIH HHS [P01 AG005119, AG 05119] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DHAR SK, 1994, J BIOL CHEM, V279, P28209; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2379; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; GRILLI M, 1993, INT REV CYTOL, V143, P1; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Josson S, 2006, ONCOGENE, V25, P1554, DOI 10.1038/sj.onc.1209186; Katayama K, 2002, HISTOL HISTOPATHOL, V17, P715, DOI 10.14670/HH-17.715; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; PASCAL D, 2001, ONCOGENE, V20, P430; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Porntadavity S, 2001, DNA CELL BIOL, V20, P473, DOI 10.1089/104454901316976109; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; St Clair DK, 2002, METHOD ENZYMOL, V349, P306, DOI 10.1016/S0076-6879(02)49345-7; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUZUKI K, 1993, AM J PHYSIOL, V265, pH1173, DOI 10.1152/ajpheart.1993.265.4.H1173; Tong X, 2004, MOL CELL BIOCHEM, V265, P171, DOI 10.1023/B:MCBI.0000044394.66951.4d; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; ZABEL U, 1991, J BIOL CHEM, V266, P252	38	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21698	21709		10.1074/jbc.M601083200	http://dx.doi.org/10.1074/jbc.M601083200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16740634	Green Accepted, hybrid			2022-12-25	WOS:000239387100015
J	Wozniak, RJ; Klimecki, WT; Lau, SS; Feinstein, Y; Futscher, BW				Wozniak, R. J.; Klimecki, W. T.; Lau, S. S.; Feinstein, Y.; Futscher, B. W.			5-Aza-2 '-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3K9 di-methylation levels are linked to tumor suppressor gene reactivation	ONCOGENE			English	Article						5-aza-2 '-deoxycytidine; H3K9 methylation; cytosine methylation; tumor suppressor; breast cancer; G9A histone methyltransferase	ABERRANT CYTOSINE METHYLATION; RISK MYELODYSPLASTIC SYNDROME; CPG-BINDING-PROTEIN; HUMAN BREAST-CANCER; DNA METHYLATION; PROMOTER HYPERMETHYLATION; HYPOMETHYLATING AGENT; COLORECTAL-CANCER; BRCA1 PROMOTER; LUNG-CANCER	The epigenetic silencing of tumor suppressor genes is a common event during carcinogenesis, and often involves aberrant DNA methylation and histone modi. cation of gene regulatory regions, resulting in the formation of a transcriptionally repressive chromatin state. Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (DSC3) and MASPIN, which are frequently silenced in this manner in human breast cancer. Treatment of the breast tumor cell lines MDA-MB-231 and UACC 1179 with 5-aza-20-deoxycytidine (5-aza-CdR) induced transcriptional reactivation of both genes in a dose-dependent manner. Importantly, DSC3 and MASPIN reactivation was closely and consistently linked with significant decreases in promoter H3 K9 di-methylation. Moreover, 5-aza-CdR treatment also resulted in global decreases in H3 K9 di-methylation, an effect that was linked to its ability to mediate dose-dependent, post-transcriptional decreases in the key enzyme responsible for this epigenetic modification, G9A. Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells. These results highlight an additional, complimentary mechanism of action for 5-aza-CdR in the reactivation of epigenetically silenced genes, in a manner that is independent of its effects on DNA methylation, further supporting an important role for H3 K9 methylation in the aberrant repression of tumor suppressor genes in human cancer.	Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Arizona, Arizona Resp Sci Ctr, Tucson, AZ USA; Univ Arizona, Arizona Canc Ctr, SW Environm Hlth Sci Ctr Prote Core, Tucson, AZ USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; Arizona Center Cancer Care; University of Arizona	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	bfutscher@azcc.arizona.edu			NCI NIH HHS [R01 CA065662, T32-CA09213, CA65662] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694, P30 ES06694, T32 ES007091, ES007091] Funding Source: Medline; PHS HHS [P30023074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065662, R29CA065662, T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694, T32ES007091] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Huang C, 2003, CURR OPIN GENET DEV, V13, P246, DOI 10.1016/S0959-437X(03)00054-6; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006; Kantarjian HM, 2003, CANCER, V98, P522, DOI 10.1002/cncr.11543; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lubbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Nguyen CT, 2002, CANCER RES, V62, P6456; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; PLIML J, 1964, COLLECT CZECH CHEM C, V29, P2576; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosenfeld CS, 2005, SEMIN ONCOL, V32, P465, DOI 10.1053/j.seminoncol.2005.07.002; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; TAMAME M, 1988, MOL CELL BIOL, V8, P3043, DOI 10.1128/MCB.8.8.3043; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	65	159	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					77	90		10.1038/sj.onc.1209763	http://dx.doi.org/10.1038/sj.onc.1209763			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799634				2022-12-25	WOS:000243236500008
J	Smith, APL; Henze, M; Lee, JA; Osborn, KG; Keck, JM; Tedesco, D; Bortner, DM; Rosenberg, MP; Reed, SI				Smith, A. P. L.; Henze, M.; Lee, J. A.; Osborn, K. G.; Keck, J. M.; Tedesco, D.; Bortner, D. M.; Rosenberg, M. P.; Reed, S. I.			Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland	ONCOGENE			English	Article						cyclin E; mammary tumorigenesis; genomic instability; p53; loss of heterozygosity	T-CELL LYMPHOMAGENESIS; WILD-TYPE P53; BREAST-CANCER; TRANSGENIC MICE; CHROMOSOMAL INSTABILITY; ENDOMETRIAL CANCER; PHASE-TRANSITION; E OVEREXPRESSION; GENE-EXPRESSION; ACTIVATION	Deregulation of cyclin E expression and/or high levels have been reported in a variety of tumors and have been used as indicators of poor prognosis. Although the role that cyclin E plays in tumorigenesis remains unclear, there is evidence that it confers genomic instability when deregulated in cultured cells. Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually. Most tumors and tumor-derived cell lines demonstrated loss of p53 heterozygosity. Furthermore, this tumor susceptibility is related to the number of times the transgene is induced indicating that it is directly attributable to the expression of the cyclin E transgene. An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy. These data support the hypothesis that deregulated expression of cyclin E stimulates p53 loss of heterozygosity by promoting genomic instability and provides specific evidence for this in vivo. Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Rotherham Gen Hosp, Dept Histopathol, Rotherham, S Yorkshire, England; Scripps Res Inst, Dept Anim Resources, La Jolla, CA 92037 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	Scripps Research Institute; Scripps Research Institute; GlaxoSmithKline	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu		Smith, Adrian/0000-0001-9732-1422	NCI NIH HHS [R01-CA78343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Calhoun ES, 2003, AM J PATHOL, V163, P1255, DOI 10.1016/S0002-9440(10)63485-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Covini G, 1997, HEPATOLOGY, V25, P75; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hamilton AS, 2003, NEW ENGL J MED, V348, P2313, DOI 10.1056/NEJMoa021293; Hosokawa Y, 2001, TRANSGENIC RES, V10, P471, DOI 10.1023/A:1012064911751; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; MOON RC, 1969, INT J CANCER, V4, P312, DOI 10.1002/ijc.2910040308; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Park M, 2000, CANCER RES, V60, P542; Qiu J, 2003, LEUKEMIA, V17, P1891, DOI 10.1038/sj.leu.2403073; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SWANSON SM, 1995, CANCER LETT, V90, P171, DOI 10.1016/0304-3835(95)03712-6; THORDARSON G, 1995, CARCINOGENESIS, V16, P2847, DOI 10.1093/carcin/16.11.2847; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yin XY, 2001, CANCER RES, V61, P6487; Yu M, 2002, MOL IMMUNOL, V38, P981, DOI 10.1016/S0161-5890(02)00026-3	56	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7245	7259		10.1038/sj.onc.1209713	http://dx.doi.org/10.1038/sj.onc.1209713			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751806				2022-12-25	WOS:000242244700003
J	Jastrebova, N; Vanwildemeersch, M; Rapraeger, AC; Gimenez-Gallego, G; Lindahl, U; Spillmann, D				Jastrebova, Nadja; Vanwildemeersch, Maarten; Rapraeger, Alan C.; Gimenez-Gallego, Guillermo; Lindahl, Ulf; Spillmann, Dorothe			Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR FGF; HEPARIN/HEPARAN SULFATE; CRYSTAL-STRUCTURE; BINDING-SITES; CELL-SURFACE; SEQUENCE; IDENTIFICATION; PROTEOGLYCANS; DIVERSITY; GLYPICAN	Biosynthesis of heparan sulfate (HS) is strictly regulated to yield products with cell/tissue-specific composition. Interactions between HS and a variety of proteins, including growth factors and morphogens, are essential for embryonic development and for homeostasis in the adult. Fibroblast growth factors (FGFs) and their various receptors (FRs) form ternary complexes with HS, as required for receptor signaling. Libraries of HS-related, radiolabeled oligosaccharides were generated by chemo-enzymatic modification of heparin and tested for affinity to immobilized FR ectodomains in the presence of FGF1 or FGF2. Experiments were designed to enable assessment of N-sulfated 8- and 10-mers with defined numbers of iduronic acid 2-O-sulfate and glucosamine 6-O-sulfate groups. FGF1 and FGF2 were found to require similar oligosaccharides in complex formation with FR1c-3c, FGF2 affording somewhat more efficient oligosaccharide recruitment than FGF1. FR4, contrary to FR1c-3c, bound oligosaccharides at physiological ionic conditions even in the absence of FGFs, and this interaction was further promoted by FGF1 but not by FGF2. In all systems studied, the stability of FGF-oligosaccharide-FR complexes correlated with the overall level of saccharide O-sulfation rather than on the precise distribution of sulfate groups.	Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Ctr Invest Biol, Madrid 28040, Spain	Uppsala University; University of Wisconsin System; University of Wisconsin Madison; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Spillmann, D (corresponding author), Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Dorothe.Spillmann@imbim.uu.se			NIGMS NIH HHS [R01 GM048850] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; Ford-Perriss M, 2001, CLIN EXP PHARMACOL P, V28, P493, DOI 10.1046/j.1440-1681.2001.03477.x; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Garcia-Maya M, 2006, J CELL PHYSIOL, V206, P386, DOI 10.1002/jcp.20483; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Kreuger J, 2004, DEV CELL, V7, P503, DOI 10.1016/j.devcel.2004.08.005; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavine KJ, 2005, DEV CELL, V8, P85, DOI 10.1016/j.devcel.2004.12.002; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Li JP, 2005, P NATL ACAD SCI USA, V102, P6473, DOI 10.1073/pnas.0502287102; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; ten Dam GB, 2006, J BIOL CHEM, V281, P4654, DOI 10.1074/jbc.M506357200; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Vanwildemeersch M, 2006, J BIOL CHEM, V281, P10298, DOI 10.1074/jbc.M508483200; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Wilson VA, 2002, GLYCOCONJUGATE J, V19, P347, DOI 10.1023/A:1025325222530; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZAZO M, 1992, GENE, V15, P231; Zhang XQ, 2006, DEVELOPMENT, V133, P173, DOI 10.1242/dev.02175	66	63	67	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26884	26892		10.1074/jbc.M600806200	http://dx.doi.org/10.1074/jbc.M600806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16807244	Green Published, hybrid			2022-12-25	WOS:000240397700015
J	Joly, D; Ishibe, S; Nickel, C; Yu, ZH; Somlo, S; Cantley, LG				Joly, Dominique; Ishibe, Shuta; Nickel, Christian; Yu, Zhiheng; Somlo, Stefan; Cantley, Lloyd G.			The polycystin 1-C-terminal fragment stimulates ERK-dependent spreading of renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; KIDNEY-DISEASE GENE; PKD1 GENE; EXTRACELLULAR-MATRIX; ADHESION; PROTEIN; PAXILLIN; PRODUCT; PHOSPHORYLATION; ACTIVATION	Polycystin 1, the product of the PKD1 gene, is mutated in autosomal dominant polycystic kidney disease, a disease characterized by renal cyst formation and progressive renal failure. We show that expression of the C-terminal domain of human polycystin-1 (PKD1-CT) triggers spreading of isolated inner medullary collecting duct cells, a process mediated by Erk. As inner medullary collecting duct cells spread, PKD1-CT localizes to cell-extracellular matrix contacts, interacts with focal adhesion proteins Fak and paxillin, and stimulates Fak phosphorylation, paxillin phosphorylation, Fak-paxillin association, and formation of small focal complexes. PKD1-CT-mediated spreading requires membrane localization and the integrity of the C-terminal protein binding sites. We additionally show that Pkd1 null proximal tubule cells generated from Pkd1(flox/-): TSLargeT mice by in vitro Cre recombinase transfection demonstrate diminished spreading when compared with Pkd(flox/-) heterozygous parental cells. These findings suggest that membrane-bound PC1 has a central role in regulating morphogenic protein signaling at cell-matrix interfaces in non-confluent cells.	Univ Paris 05, INSERM, Fac Med, Hop Necker Enfants Malad,U813, F-75743 Paris 15, France; Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA; Univ Freiburg, D-79085 Freiburg, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Yale University; University of Freiburg	Joly, D (corresponding author), Univ Paris 05, INSERM, Fac Med, Hop Necker Enfants Malad,U813, F-75743 Paris 15, France.	joly@necker.fr			NIDDK NIH HHS [DK065109, DK057328] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065109, P50DK057328] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnould T, 1999, MOL CELL BIOL, V19, P3423; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; ILLC D, 1995, NATURE, V377, P539; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; NAULI SM, 2003, NAT GENET; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ong ACM, 2003, LANCET, V361, P774, DOI 10.1016/S0140-6736(03)12662-1; Parr C, 2001, BIOCHEM BIOPH RES CO, V285, P1330, DOI 10.1006/bbrc.2001.5307; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Streets AJ, 2003, J AM SOC NEPHROL, V14, P1804, DOI 10.1097/01.ASN.0000076075.49819.9B; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wilson PD, 1999, LAB INVEST, V79, P1311; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25	42	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26329	26339		10.1074/jbc.M601373200	http://dx.doi.org/10.1074/jbc.M601373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16790429	hybrid			2022-12-25	WOS:000240249500050
J	Kitada, S; Abe, Y; Shimada, H; Kusaka, Y; Matsuo, Y; Katayama, H; Okumura, S; Akao, T; Mizuki, E; Kuge, O; Sasaguri, Y; Ohba, M; Ito, A				Kitada, Sakae; Abe, Yuichi; Shimada, Hiroyasu; Kusaka, Yoshitomo; Matsuo, Yoko; Katayama, Hideki; Okumura, Shiro; Akao, Tetsuyuki; Mizuki, Eiichi; Kuge, Osamu; Sasaguri, Yasuyuki; Ohba, Michio; Ito, Akio			Cytocidal actions of parasporin-2, an anti-tumor crystal toxin from Bacillus thuringiensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MISFOLDING DISEASES; SOLUBLE AMYLOID OLIGOMERS; HUMAN CANCER-CELLS; ENDOPLASMIC-RETICULUM; CYTOTOXIC PROTEIN; COMMON MECHANISM; LIPID-BILAYERS; PORE FORMATION; MEMBRANE; INCLUSIONS	Parasporin-2, a new crystal protein derived from noninsecticidal and nonhemolytic Bacillus thuringiensis, recognizes and kills human liver and colon cancer cells as well as some classes of human cultured cells. Here we report that a potent proteinase K-resistant parasporin-2 toxin shows specific binding to and a variety of cytocidal effects against human hepatocyte cancer cells. Cleavage of the N-terminal region of parasporin-2 was essential for the toxin activity, whereas C-terminal digestion was required for rapid cell injury. Protease-activated parasporin-2 induced remarkable morphological alterations, cell blebbing, cytoskeletal alterations, and mitochondrial and endoplasmic reticulum fragmentation. The plasma membrane permeability was increased immediately after the toxin treatment and most of the cytoplasmic proteins leaked from the cells, whereas mitochondrial and endoplasmic reticulum proteins remained in the intoxicated cells. Parasporin-2 selectively bound to cancer cells in slices of liver tumor tissues and susceptible human cultured cells and became localized in the plasma membrane until the cells were damaged. Thus, parasporin-2 acts as a cytolysin that permeabilizes the plasma membrane with target cell specificity and subsequently induces cell decay.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Fukuoka Ind Technol Ctr, Biotechnol & Food Res Inst, Fukuoka 8390861, Japan; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Fukuoka 8078555, Japan; Kyushu Univ, Fac Agr, Dept Appl Genet & Pest Management, Fukuoka 8128581, Japan	Kyushu University; University of Occupational & Environmental Health - Japan; Kyushu University	Kitada, S (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.	s.kitscc@mbox.nc.kyushu-u.ac.jp		Shimada, Hiroyasu/0000-0002-7120-5850; Kuge, Osamu/0000-0003-4962-3519				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Akiba T, 2006, PROTEINS, V63, P243, DOI 10.1002/prot.20843; Amano H, 2005, BIOSCI BIOTECH BIOCH, V69, P2063, DOI 10.1271/bbb.69.2063; BRAUNER T, 1984, BIOCHIM BIOPHYS ACTA, V771, P208, DOI 10.1016/0005-2736(84)90535-2; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cannon RJC, 1996, BIOL REV, V71, P561, DOI 10.1111/j.1469-185X.1996.tb01285.x; Crickmore N, 1998, MICROBIOL MOL BIOL R, V62, P807, DOI 10.1128/MMBR.62.3.807-813.1998; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; HOFTE H, 1989, MICROBIOL REV, V53, P242; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Ito A, 2004, J BIOL CHEM, V279, P21282, DOI 10.1074/jbc.M401881200; Katayama H, 2005, J BIOCHEM, V137, P17, DOI 10.1093/jb/mvi003; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HS, 2000, J APPL MICROBIOL, V89, P16, DOI 10.1046/j.1365-2672.2000.01087.x; Kondo S, 2002, PARASITOL RES, V88, P1090, DOI 10.1007/s00436-002-0692-6; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee DW, 2001, BBA-PROTEIN STRUCT M, V1547, P57, DOI 10.1016/S0167-4838(01)00169-8; MAHILLON J, 1994, GENETICA, V93, P13, DOI 10.1007/BF01435236; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; MEADOWS MP, 1992, APPL ENVIRON MICROB, V58, P1344, DOI 10.1128/AEM.58.4.1344-1350.1992; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; Miyata S, 2002, J BIOL CHEM, V277, P39463, DOI 10.1074/jbc.M206731200; Mizuki E, 1999, J APPL MICROBIOL, V86, P477, DOI 10.1046/j.1365-2672.1999.00692.x; Mizuki E, 2000, CLIN DIAGN LAB IMMUN, V7, P625, DOI 10.1128/CDLI.7.4.625-634.2000; OHBA M, 1986, J INVERTEBR PATHOL, V47, P12, DOI 10.1016/0022-2011(86)90158-8; Okumura S, 2005, J AGR FOOD CHEM, V53, P6313, DOI 10.1021/jf0506129; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; SASAGURI Y, 1992, AM J PATHOL, V141, P611; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033; Vie V, 2001, J MEMBRANE BIOL, V180, P195, DOI 10.1007/s002320010070; Wei JZ, 2003, P NATL ACAD SCI USA, V100, P2760, DOI 10.1073/pnas.0538072100; Yamashita S, 2005, J BIOCHEM, V138, P663, DOI 10.1093/jb/mvi177	36	49	56	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26350	26360		10.1074/jbc.M602589200	http://dx.doi.org/10.1074/jbc.M602589200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809341	hybrid			2022-12-25	WOS:000240249500052
J	Kotsyfakis, M; Sa-Nunes, A; Francischetti, IMB; Mather, TN; Andersen, JF; Ribeiro, JMC				Kotsyfakis, Michalis; Sa-Nunes, Anderson; Francischetti, Ivo M. B.; Mather, Thomas N.; Andersen, John F.; Ribeiro, Jose M. C.			Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; LYSOSOMAL CYSTEINE PROTEASES; CATHEPSIN-L; EXTRACELLULAR-MATRIX; IMMUNE-RESPONSES; STRUCTURAL BASIS; PROTEIN; INHIBITORS; EXPRESSION; COLLAGEN	Here we report the ability of the tick Ixodes scapularis, the main vector of Lyme disease in the United States, to actively and specifically affect the host proteolytic activity in the sites of infestation through the release of a cystatin constituent of its saliva. The cystatin presence in the saliva was verified both biochemically and immunologically. We named the protein sialostatin L because of its inhibitory action against cathepsin L. We also show that the proteases it targets, although limited in number, have a prominent role in the proteolytic cascades that take place in the extracellular and intracellular environment. As a result, sialostatin L displays an antiinflammatory role and inhibits proliferation of cytotoxic T lymphocytes. Beyond unraveling another component accounting for the properties of tick saliva, contributing to feeding success and pathogen transmission, we describe a novel tool for studying the role of papain-like proteases in diverse biologic phenomena and a protein with numerous potential pharmaceutical applications.	NIAID, Lab Malaria & Vector Res, Vector Biol Sect, NIH, Rockville, MD 20852 USA; Univ Rhode Isl, Ctr Vector Borne Dis, Kingston, RI 02881 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Rhode Island	Ribeiro, JMC (corresponding author), NIAID, Lab Malaria & Vector Res, Vector Biol Sect, NIH, 12735 Twinbrook Pkwy,Rm 2E-32, Rockville, MD 20852 USA.	jribeiro@niaid.nih.gov	Sa-Nunes, Anderson/M-5654-2019; Sa-Nunes, Anderson/D-8667-2012; Kotsyfakis, Michail/G-9525-2014	Sa-Nunes, Anderson/0000-0002-1859-4973; Sa-Nunes, Anderson/0000-0002-1859-4973; Kotsyfakis, Michail/0000-0002-7526-1876; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000810, ZIAAI001012, ZIAAI000810, Z01AI001012] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P4423, DOI 10.1021/bi9628883; BARNA JB, 1995, INFLAMMATION, V19, P561, DOI 10.1007/BF01539136; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, V2, P1051; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; BJORK I, 2006, BIOCHEMISTRY-US, V35, P10720; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; Dahl SW, 2001, BIOCHEMISTRY-US, V40, P1671, DOI 10.1021/bi001693z; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; FOSSUM K, 1968, ARCH BIOCHEM BIOPHYS, V125, P367, DOI 10.1016/0003-9861(68)90672-3; GERN L, 1993, J INFECT DIS, V167, P971, DOI 10.1093/infdis/167.4.971; Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x; Hartmann S, 2003, INT J PARASITOL, V33, P1291, DOI 10.1016/S0020-7519(03)00163-2; Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110; Honey K, 2002, NAT IMMUNOL, V3, P1069, DOI 10.1038/ni844; Houle S, 2005, BRIT J PHARMACOL, V146, P670, DOI 10.1038/sj.bjp.0706371; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Karim S, 2005, BIOCHEM BIOPH RES CO, V334, P1336, DOI 10.1016/j.bbrc.2005.07.036; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; Kotsyfakis M, 2005, INSECT MOL BIOL, V14, P555, DOI 10.1111/j.1365-2583.2005.00586.x; Kotsyfakis M, 2005, MOL MICROBIOL, V57, P171, DOI 10.1111/j.1365-2958.2005.04664.x; LEUNGTACK J, 1990, INFLAMMATION, V14, P247, DOI 10.1007/BF00915809; LEVY L, 1969, LIFE SCI PT 1 PHYSI, V8, P601, DOI 10.1016/0024-3205(69)90021-6; Lombardi G, 2005, J IMMUNOL, V174, P7022, DOI 10.4049/jimmunol.174.11.7022; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; Maniatis T., 1989, MOL CLONING LAB MAN; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; *NAT I HLTH, 1996, GUID CAR US LAB AN; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P107, DOI 10.1016/0003-9861(88)90618-2; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Oliveira F, 2006, VACCINE, V24, P374, DOI 10.1016/j.vaccine.2005.07.085; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; POL E, 1995, BIOCHEM J, V311, P275, DOI 10.1042/bj3110275; Puzer L, 2005, BIOL CHEM, V386, P699, DOI 10.1515/BC.2005.081; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; RIBEIRO JMC, 1985, J EXP MED, V161, P332, DOI 10.1084/jem.161.2.332; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SAUER JR, 1995, ANNU REV ENTOMOL, V40, P245, DOI 10.1146/annurev.en.40.010195.001333; Schonemeyer A, 2001, J IMMUNOL, V167, P3207, DOI 10.4049/jimmunol.167.6.3207; Serveau-Avesque C, 2006, BIOL CELL, V98, P15, DOI 10.1042/BC20040512; Thiele DL, 1997, J IMMUNOL, V158, P5200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; Vray B, 2002, CELL MOL LIFE SCI, V59, P1503, DOI 10.1007/s00018-002-8525-4; WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912; Wikel SK, 1997, PARASITOL TODAY, V13, P383, DOI 10.1016/S0169-4758(97)01126-5; Wille A, 2004, BIOL CHEM, V385, P665, DOI 10.1515/BC.2004.082; Williams J W, 1979, Methods Enzymol, V63, P437; Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200	64	165	172	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26298	26307		10.1074/jbc.M513010200	http://dx.doi.org/10.1074/jbc.M513010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16772304	hybrid, Green Published			2022-12-25	WOS:000240249500047
J	Midorikawa, Y; Yamamoto, S; Ishikawa, S; Kamimura, N; Igarashi, H; Sugimura, H; Makuuchi, M; Aburatani, H				Midorikawa, Y.; Yamamoto, S.; Ishikawa, S.; Kamimura, N.; Igarashi, H.; Sugimura, H.; Makuuchi, M.; Aburatani, H.			Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays	ONCOGENE			English	Article						liver cancer; oligonucleotide array; SNP; allelic imbalance; copy number	COMPARATIVE GENOMIC HYBRIDIZATION; UNIPARENTAL PATERNAL DISOMY; HIGH-RESOLUTION ANALYSIS; COPY NUMBER VARIATION; HETEROZYGOSITY ANALYSIS; MICROARRAY ANALYSIS; ANALYSIS REVEALS; CPG ISLANDS; CANCER; DNA	Genomic amplification of oncogenes and inactivation of suppressor genes are critical in the pathogenesis of human cancer. To identify chromosomal alterations associated with hepatocarcinogenesis, we performed allelic gene dosage analysis on 36 hepatocellular carcinomas (HCCs). Data from high-density single-nucleotide polymorphism arrays were analysed using the Genome Imbalance Map (GIM) algorithm, which simultaneously detects DNA copy number alterations and loss of heterozygosity (LOH) events. Genome Imbalance Map analysis identified allelic imbalance regions, including uniparental disomy, and predicted the coexistence of a heterozygous population of cancer cells. We observed that gains of 1q, 5p, 5q, 6p, 7q, 8q, 17q and 20q, and LOH of 1p, 4q, 6q, 8p, 10q, 13q, 16p, 16q and 17p were significantly associated with HCC. On 6q24-25, which contains imprinting gene clusters, we observed reduced levels of PLAGL1 expression owing to loss of the unmethylated allele. Finally, we integrated the copy number data with gene expression intensity, and found that genome dosage is correlated with alteration in gene expression. These observations indicated that high-resolution GIM analysis can accurately determine the localizations of genomic regions with allelic imbalance, and when integrated with epigenetic information, a mechanistic basis for inactivation of a tumor suppressor gene in HCC was elucidated.	Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Shizuoka, Japan; Univ Tokyo, Hepato Biliary Pancreat Surg Div, Tokyo, Japan	University of Tokyo; Hamamatsu University School of Medicine; University of Tokyo	Aburatani, H (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	haburata-tky@umin.ac.jp	幕内, 雅敏 m/A-2140-2012					Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Benetkiewicz M, 2005, GENE CHROMOSOME CANC, V42, P228, DOI 10.1002/g.cc.20128; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Boige V, 1997, CANCER RES, V57, P1986; Buckley PG, 2005, CANCER RES, V65, P2653, DOI 10.1158/0008-5472.CAN-04-3651; Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051; ENGEL E, 1993, AM J MED GENET, V46, P670, DOI 10.1002/ajmg.1320460613; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; GRUNDY P, 1994, AM J HUM GENET, V54, P282; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoque MO, 2003, CANCER RES, V63, P2216; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jou YS, 2004, CANCER RES, V64, P3030, DOI 10.1158/0008-5472.CAN-03-2320; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kano M, 2003, PHYSIOL GENOMICS, V13, P31, DOI 10.1152/physiolgenomics.00116.2002; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kitayama Y, 2003, LAB INVEST, V83, P1311, DOI 10.1097/01.LAB.0000087622.80751.C5; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Midorikawa Y, 2004, CANCER RES, V64, P7263, DOI 10.1158/0008-5472.CAN-04-1275; Murthy SK, 2002, MODERN PATHOL, V15, P1241, DOI 10.1097/01.MP.0000032535.62750.D1; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Patil MA, 2005, CARCINOGENESIS, V26, P2050, DOI 10.1093/carcin/bgi178; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Raghavan M, 2005, CANCER RES, V65, P375; Sano T, 2006, PATHOL INT, V56, P117, DOI 10.1111/j.1440-1827.2006.01940.x; TAGUCHI T, 1993, CANCER RES, V53, P4349; TEMPLE IK, 1995, NAT GENET, V9, P110, DOI 10.1038/ng0295-110; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Upender MB, 2004, CANCER RES, V64, P6941, DOI 10.1158/0008-5472.CAN-04-0474; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	53	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5581	5590		10.1038/sj.onc.1209537	http://dx.doi.org/10.1038/sj.onc.1209537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16785998				2022-12-25	WOS:000240370400012
J	Bajaj, SP; Schmidt, AE; Agah, S; Bajaj, MS; Padmanabhan, K				Bajaj, S. Paul; Schmidt, Amy E.; Agah, Sayeh; Bajaj, Madhu S.; Padmanabhan, Kaillathe			High resolution structures of p-aminobenzamidine- and benzamidine-VIIa soluble tissue factor - Unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+, and Zn2+ sites in factor VIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BLOOD-COAGULATION FACTOR; 1.7 ANGSTROM RESOLUTION; CALCIUM-BINDING SITE; ACTIVATED PROTEIN-C; FACTOR-LIKE DOMAIN; FACTOR-IX; CRYSTAL-STRUCTURE; FACTOR-X; SERINE-PROTEASE; PROTHROMBIN FRAGMENT-1	Factor VIIa (FVIIa) consists of a gamma-carboxyglutamic acid (Gla) domain, two epidermal growth factor-like domains, and a protease domain. FVIIa binds seven Ca2(+) ions in the Gla, one in the EGF1, and one in the protease domain. However, blood contains both Ca2+ and Mg2+, and the Ca2+ sites in FVIIa that could be specifically occupied by Mg2+ are unknown. Furthermore, FVIIa contains a Na+ and two Zn2+ sites, but ligands for these cations are undefined. We obtained p-aminobenzamidine-VIIa/ soluble tissue factor (sTF) crystals under conditions containing Ca2+, Mg2+, Na+, and Zn2+. The crystal diffracted to 1.8 angstrom resolution, and the final structure has an R-factor of 19.8%. In this structure, the Gla domain has four Ca2+ and three bound Mg2+. The EGF1 domain contains one Ca2+ site, and the protease domain contains one Ca2+, one Na+, and two Zn2+ sites. Ca-45(2+) binding in the presence/absence of Mg2+ to FVIIa, Gla-domainless FVIIa, and prothrombin fragment 1 supports the crystal data. Furthermore, unlike in other serine proteases, the amide N of Gly(193) in FVIIa points away from the oxyanion hole in this structure. Importantly, the oxyanion hole is also absent in the benzamidine-FVIIa/sTF structure at 1.87 angstrom resolution. However, soaking benzamidine-FVIIa/sTF crystals with D-Phe-Pro-Arg- chloromethyl ketone results in benzamidine displacement, D-Phe-Pro-Arg incorporation, and oxyanion hole formation by a flip of the 192 - 193 peptide bond in FVIIa. Thus, it is the substrate and not the TF binding that induces oxyanion hole formation and functional active site geometry in FVIIa. Absence of oxyanion hole is unusual and has biologic implications for FVIIa macromolecular substrate specificity and catalysis.	Univ Calif Los Angeles, Orthopaed Hosp, Dept Orthopaed Surg, Inst Mol Biol,Prot Sci Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Div Pulm, Los Angeles, CA 90095 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Michigan State University	Bajaj, SP (corresponding author), Univ Calif Los Angeles, Orthopaed Hosp, Dept Orthopaed Surg, Inst Mol Biol,Prot Sci Lab, Box 951795,Rehab 22-53, Los Angeles, CA 90095 USA.	pbajaj@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036365, R56HL036365, R01HL036365, R01HL070369] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36365, HL-70369] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Batsanov AS, 2000, ACTA CRYSTALLOGR C, V56, pE230; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLOOM JW, 1978, BIOCHEMISTRY-US, V17, P4430, DOI 10.1021/bi00614a012; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Butenas S, 1996, BIOCHEMISTRY-US, V35, P1904, DOI 10.1021/bi951768c; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Cavarelli J, 1997, STRUCTURE, V5, P813, DOI 10.1016/S0969-2126(97)00235-9; Chen SWW, 2002, THROMB HAEMOSTASIS, V88, P74; DANG QD, 1996, P NATL ACAD SCI USA, V93, P10563; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; EINSPAHR H, 1981, ACTA CRYSTALLOGR B, V37, P1044, DOI 10.1107/S0567740881005037; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; Gosalia DN, 2005, PROTEOMICS, V5, P1292, DOI 10.1002/pmic.200401011; Gosalia DN, 2005, MOL CELL PROTEOMICS, V4, P626, DOI 10.1074/mcp.M500004-MCP200; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; Hervio LS, 2000, CHEM BIOL, V7, P443, DOI 10.1016/S1074-5521(00)00125-3; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HIPPENMEYER P, 1993, BIO-TECHNOL, V11, P1037, DOI 10.1038/nbt0993-1037; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Huang MD, 1998, J MOL BIOL, V275, P873, DOI 10.1006/jmbi.1997.1512; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; Jin L, 2005, ACTA CRYSTALLOGR D, V61, P1418, DOI [10.1107/S0907444905024340, 10.1107/S090744905024340]; Johnson DJD, 2005, BIOCHEM J, V392, P21, DOI 10.1042/BJ20051217; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Klingler O, 2003, BIOORG MED CHEM LETT, V13, P1463, DOI 10.1016/S0960-894X(03)00168-9; Kosal ME, 2002, J PORPHYR PHTHALOCYA, V6, P377, DOI 10.1142/S1088424602000464; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH HC, 1979, J BIOL CHEM, V254, P268; MASYS DR, 1982, BLOOD, V60, P1143; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; Ndonwi M, 2005, J THROMB HAEMOST, V3, P112, DOI 10.1111/j.1538-7836.2004.01051.x; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; Norledge BV, 2003, PROTEINS, V53, P640, DOI 10.1002/prot.10445; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; Olivero AG, 2005, J BIOL CHEM, V280, P9160, DOI 10.1074/jbc.M409068200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Papageorgiou AC, 2000, PROTEIN SCI, V9, P610; PEDERSEN AH, 1991, THROMB HAEMOSTASIS, V65, P528; Petersen LC, 2000, PROTEIN SCI, V9, P859, DOI 10.1110/ps.9.5.859; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUF W, 1991, J BIOL CHEM, V266, P2158; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; Schmidt AE, 2005, J MOL BIOL, V350, P78, DOI 10.1016/j.jmb.2005.04.052; Schmidt AE, 2003, BLOOD, V102, p303A; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; Schmidt AE, 2004, BLOOD, V104, p122a; Sekiya F, 1996, FEBS LETT, V392, P205, DOI 10.1016/0014-5793(96)00813-7; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; Sekiya F, 1996, J BIOL CHEM, V271, P8541, DOI 10.1074/jbc.271.15.8541; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; Sichler K, 2002, J MOL BIOL, V322, P591, DOI 10.1016/S0022-2836(02)00747-7; Skelton BW, 2003, ACTA CRYSTALLOGR C, V59, pM435, DOI 10.1107/S0108270103020407; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; South MS, 2003, BIOORG MED CHEM LETT, V13, P2319, DOI 10.1016/S0960-894X(03)00410-4; Tang J, 2005, J BIOL CHEM, V280, P41077, DOI 10.1074/jbc.M506766200; Tranter R, 2000, STRUCTURE, V8, P1179, DOI 10.1016/S0969-2126(00)00523-2; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; van den Besselaar AMHP, 2002, BLOOD COAGUL FIBRIN, V13, P19, DOI 10.1097/00001721-200201000-00003; van den Besselaar AMHP, 2005, THROMB RES, V115, P239, DOI 10.1016/j.thromres.2004.08.019; Vath GM, 1999, BIOCHEMISTRY-US, V38, P10239, DOI 10.1021/bi990721e; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; Venkateswarlu D, 2003, J THROMB HAEMOST, V1, P2577, DOI 10.1111/j.1538-7836.2003.00421.x; Wang S, 2002, ARCH PATHOL LAB MED, V126, P947; Wang SX, 2003, BIOCHEMISTRY-US, V42, P7959, DOI 10.1021/bi027320a; WARNCRAMER BJ, 1986, BIOCHEM J, V239, P757, DOI 10.1042/bj2390757; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089; Zbinden KG, 2005, BIOORG MED CHEM LETT, V15, P5344, DOI 10.1016/j.bmcl.2005.04.079; Zbinden KG, 2005, BIOORG MED CHEM LETT, V15, P817, DOI 10.1016/j.bmcl.2004.10.092; Zehtabchi S, 2004, AM J HEMATOL, V77, P215, DOI 10.1002/ajh.20187; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574; Zhong DG, 2002, J BIOL CHEM, V277, P3622, DOI 10.1074/jbc.M111202200	103	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24873	24888		10.1074/jbc.M509971200	http://dx.doi.org/10.1074/jbc.M509971200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16757484	hybrid			2022-12-25	WOS:000239847800081
J	Ding, J; Li, JX; Xue, CF; Wu, KJ; Ouyang, WM; Zhang, DY; Yan, Y; Huang, CS				Ding, Jin; Li, Jingxia; Xue, Caifang; Wu, Kangjian; Ouyang, Weiming; Zhang, Dongyun; Yan, Yan; Huang, Chuanshu			Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; SODIUM ARSENITE; LUNG-CANCER; RAT LUNG; MOLECULAR-MECHANISMS; DRINKING-WATER; TUMOR PROMOTER; C/EBP-BETA; EXPRESSION	Arsenite is a well known metalloid human carcinogen, and epidemiological evidence has demonstrated its association with the increased incidence of lung cancer. However, the mechanism involved in its lung carcinogenic effect remains obscure. The current study demonstrated that exposure of human bronchial epithelial cells (Beas-2B) to arsenite resulted in a marked induction of cyclooxygenase (COX)-2, an important mediator for inflammation and tumor promotion. Exposure of the Beas-2B cells to arsenite also led to significant transactivation of nuclear factor of activated T-cells (NFAT), but not activator protein-1 (AP-1) and NF kappa B, suggesting that NFAT, rather than AP-1 or NF kappa B, is implicated in the responses of Beas-2B cells to arsenite exposure. Furthermore, we found that inhibition of the NFAT pathway by either chemical inhibitors, dominant negative mutants of NFAT, or NFAT3 small interference RNA resulted in the impairment of COX-2 induction and caused cell apoptosis in Beas-2B cells exposed to arsenite. Site- directed mutation of two putative NFAT binding sites between -111 to +65 in the COX-2 promoter region eliminated the COX-2 transcriptional activity induced by arsenite, confirming that those two NFAT binding sites in the COX-2 promoter region are critical for COX-2 induction by arsenite. Moreover, knockdown of COX-2 expression by COX-2-specific small interference RNA also led to an increased cell apoptosis in Beas-2B cells upon arsenite exposure. Together, our results demonstrate that COX-2 induction by arsenite is through NFAT3-dependent and AP-1- or NF kappa B-independent pathways and plays a crucial role in antagonizing arsenite-induced cell apoptosis in human bronchial epithelial Beas-2B cells.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Fourth Mil Med Univ, Dept Etiol, Xian 710032, Shaanxi, Peoples R China	New York University; Air Force Military Medical University	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NCI NIH HHS [CA112557, CA103180, CA094964] Funding Source: Medline; NIEHS NIH HHS [ES012451, ES000260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103180, R01CA112557, R01CA094964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451, P30ES000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali-Fehmi R, 2005, AM J OBSTET GYNECOL, V192, P819, DOI 10.1016/j.ajog.2004.10.587; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; BATES MN, 1995, AM J EPIDEMIOL, V141, P523, DOI 10.1093/oxfordjournals.aje.a117467; BETTLEY FR, 1975, BRIT J DERMATOL, V92, P563; Chakravortty D, 2001, J IMMUNOL, V166, P2011, DOI 10.4049/jimmunol.166.3.2011; Chappell WR, 1997, ENVIRON HEALTH PERSP, V105, P1060, DOI 10.1289/ehp.971051060; Chen J, 2005, J BIOL CHEM, V280, P16354, DOI 10.1074/jbc.M411134200; CHIOU HY, 1995, CANCER RES, V55, P1296; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Clarke A R, 2000, Symp Soc Exp Biol, V52, P265; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Correa P, 1998, BRIT MED BULL, V54, P151; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Daum G, 2001, MOL CELL BIOCHEM, V217, P131, DOI 10.1023/A:1007276812824; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; El-Bayoumy K, 1999, CANCER RES, V59, P1400; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; Harris RE, 2005, ONCOL REP, V13, P559; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang CS, 2004, MOL CELL BIOCHEM, V255, P57, DOI 10.1023/B:MCBI.0000007261.04684.78; Huang CS, 1999, CANCER RES, V59, P3053; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 2001, ANTICANCER RES, V21, P261; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; ISHINISHI N, 1977, ENVIRON HEALTH PERSP, V19, P191, DOI 10.2307/3428474; Khuri FR, 2001, CLIN CANCER RES, V7, P861; KNOWLES F C, 1984, Zeitschrift fuer die Gesamte Hygiene und ihre Grenzgebiete, V30, P625; Koyama Y, 1999, J NEUROCHEM, V73, P1004, DOI 10.1046/j.1471-4159.1999.0731004.x; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; LANDOLPH JR, 1994, ENVIRON HEALTH PERSP, V102, P119, DOI 10.2307/3431774; LEE TC, 1988, SCIENCE, V241, P79, DOI 10.1126/science.3388020; LI J-H, 1989, Molecular Toxicology, V2, P1; LI JH, 1989, BIOL TRACE ELEM RES, V21, P373, DOI 10.1007/BF02917278; Li JX, 2004, MOL CARCINOGEN, V40, P104, DOI 10.1002/mc.20020; Li LY, 2003, RADIAT RES, V160, P617, DOI 10.1667/RR3076; Liu ZG, 2005, CELL RES, V15, P24, DOI 10.1038/sj.cr.7290259; Liu ZG, 2001, METHOD CELL BIOL, V66, P187; Morris RD, 1995, ENVIRON HEALTH PERSP, V103, P225, DOI 10.2307/3432315; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Ouyang WM, 2005, CANCER RES, V65, P9287, DOI 10.1158/0008-5472.CAN-05-0469; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pold M, 2004, CANCER RES, V64, P6549, DOI 10.1158/0008-5472.CAN-04-1225; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Scott KA, 2003, MOL CANCER THER, V2, P445; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Subbaramaiah K, 2001, J BIOMOL SCREEN, V6, P101; Sugimoto T, 2001, J AM SOC NEPHROL, V12, P1359, DOI 10.1681/ASN.V1271359; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; TSUDA T, 1995, AM J EPIDEMIOL, V141, P198, DOI 10.1093/oxfordjournals.aje.a117421; Wijeweera JB, 2001, TOXICOL SCI, V61, P283, DOI 10.1093/toxsci/61.2.283; Wyllie AH, 1999, BRIT J CANCER, V80, P34; YAN Y, 2006, IN PRESS J CELL SCI; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	63	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24405	24413		10.1074/jbc.M600751200	http://dx.doi.org/10.1074/jbc.M600751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16809336	hybrid			2022-12-25	WOS:000239847800034
J	Durgan, DJ; Trexler, NA; Egbejimi, O; McElfresh, TA; Suk, HY; Petterson, LE; Shaw, CA; Hardin, PE; Bray, MS; Chandler, MP; Chow, CW; Young, ME				Durgan, David J.; Trexler, Nowice A.; Egbejimi, Oluwaseun; McElfresh, Tracy A.; Suk, Hee Yun; Petterson, Lauren E.; Shaw, Chad A.; Hardin, Paul E.; Bray, Molly S.; Chandler, Margaret P.; Chow, Chi-Wing; Young, Martin E.			The circadian clock within the cardiomyocyte is essential for responsiveness of the heart to fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; 24-HOUR BLOOD-PRESSURE; SHIFT WORKERS; DIURNAL-VARIATIONS; ENERGY-METABOLISM; GENE-EXPRESSION; INCREASED RISK; RHYTHMS; DISEASE; OXIDATION	Cells/organs must respond both rapidly and appropriately to increased fatty acid availability; failure to do so is associated with the development of skeletal muscle and hepatic insulin resistance, pancreatic beta-cell dysfunction, and myocardial contractile dysfunction. Here we tested the hypothesis that the intrinsic circadian clock within the cardiomyocytes of the heart allows rapid and appropriate adaptation of this organ to fatty acids by investigating the following: 1) whether circadian rhythms in fatty acid responsiveness persist in isolated adult rat cardiomyocytes, and 2) whether manipulation of the circadian clock within the heart, either through light/dark ( L/D) cycle or genetic disruptions, impairs responsiveness of the heart to fasting in vivo. We report that both the intramyocellular circadian clock and diurnal variations in fatty acid responsiveness observed in the intact rat heart in vivo persist in adult rat cardiomyocytes. Reversal of the 12-h/12-h L/D cycle was associated with a re-entrainment of the circadian clock within the rat heart, which required 5-8 days for completion. Fasting rats resulted in the induction of fatty acid-responsive genes, an effect that was dramatically attenuated 2 days after L/D cycle reversal. Similarly, a targeted disruption of the circadian clock within the heart, through overexpression of a dominant negative CLOCK mutant, severely attenuated induction of myocardial fatty acid-responsive genes during fasting. These studies expose a causal relationship between the circadian clock within the cardiomyocyte with responsiveness of the heart to fatty acids and myocardial triglyceride metabolism.	USDA ARS, Childrens Nutr Res Ctr, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77204 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Case Western Reserve University; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station	Young, ME (corresponding author), USDA ARS, Childrens Nutr Res Ctr, Baylor Coll Med, Dept Pediat, 1100 Bates St, Houston, TX 77030 USA.	meyoung@bcm.edu		Shaw, Chad/0000-0001-7267-5398; Hardin, Paul/0000-0002-3370-9011	NHLBI NIH HHS [HL-074259-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074259] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barger PM, 2000, TRENDS CARDIOVAS MED, V10, P238, DOI 10.1016/S1050-1738(00)00077-3; Carson PA, 2000, J AM COLL CARDIOL, V36, P541, DOI 10.1016/S0735-1097(00)00728-2; Chandler MP, 2002, AM J PHYSIOL-HEART C, V282, pH1871, DOI 10.1152/ajpheart.00976.2001; CHAU NP, 1989, CIRCULATION, V80, P341, DOI 10.1161/01.CIR.80.2.341; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Davidson AJ, 2005, CLIN EXP HYPERTENS, V27, P307, DOI 10.1081/CEH-200048933; DEGAUTE JP, 1994, HYPERTENSION, V23, P244, DOI 10.1161/01.HYP.23.2.244; DEGAUTE JP, 1991, HYPERTENSION, V18, P199, DOI 10.1161/01.HYP.18.2.199; Durgan DJ, 2005, AM J PHYSIOL-HEART C, V289, pH1530, DOI 10.1152/ajpheart.00406.2005; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Harma MI, 1999, SCAND J WORK ENV HEA, V25, P610; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Kassam A, 1999, J BIOL CHEM, V274, P22895, DOI 10.1074/jbc.274.32.22895; KHATRI IM, 1967, J APPL PHYSIOL, V22, P867, DOI 10.1152/jappl.1967.22.5.867; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNUTSSON A, 1986, LANCET, V2, P89; KOLLER M, 1983, INT ARCH OCC ENV HEA, V53, P59, DOI 10.1007/BF00406178; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; LOPASCHUK GD, 1994, BBA-LIPID LIPID MET, V1213, P263, DOI 10.1016/0005-2760(94)00082-4; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; MILLARCRAIG MW, 1978, LANCET, V1, P795; Mukamal KJ, 2000, AM HEART J, V140, P438, DOI 10.1067/mhj.2000.108830; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; PRINZ PN, 1979, J CLIN ENDOCR METAB, V49, P300, DOI 10.1210/jcem-49-2-300; RICHARDS AM, 1986, CLIN EXP HYPERTENS A, V8, P153, DOI 10.3109/10641968609074769; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Sharma S, 2004, FASEB J, V18, P1692, DOI 10.1096/fj.04-2263com; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Stavinoha MA, 2004, AM J PHYSIOL-ENDOC M, V287, pE878, DOI 10.1152/ajpendo.00189.2004; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; SUNDBERG S, 1988, J HYPERTENS, V6, P393; TURTON MB, 1974, CLIN CHIM ACTA, V55, P389, DOI 10.1016/0009-8981(74)90014-X; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; van den Buuse M, 1999, PHYSIOL BEHAV, V68, P9, DOI 10.1016/S0031-9384(99)00148-1; VEERMAN DP, 1995, HYPERTENSION, V26, P55, DOI 10.1161/01.HYP.26.1.55; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Wu PF, 2001, BIOCHEM BIOPH RES CO, V287, P391, DOI 10.1006/bbrc.2001.5608; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Young ME, 2001, CIRC RES, V89, P1199, DOI 10.1161/hh2401.100741; Young ME, 2006, AM J PHYSIOL-HEART C, V290, pH1, DOI 10.1152/ajpheart.00582.2005; Young ME, 2003, CURR HYPERTENS REP, V5, P445, DOI 10.1007/s11906-003-0051-8; Young ME, 2002, J MOL CELL CARDIOL, V34, P223, DOI 10.1006/jmcc.2001.1504; Young ME, 2002, CIRCULATION, V105, P1861, DOI 10.1161/01.CIR.0000012467.61045.87; Young ME, 2001, CIRC RES, V88, P1142, DOI 10.1161/hh1101.091190; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com; Zhang BL, 2000, AM J PHYSIOL-REG I, V279, pR169, DOI 10.1152/ajpregu.2000.279.1.R169	50	116	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24254	24269		10.1074/jbc.M601704200	http://dx.doi.org/10.1074/jbc.M601704200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798731	hybrid			2022-12-25	WOS:000239847800019
J	Harrison, NJ; Lummis, SCR				Harrison, Neil J.; Lummis, Sarah C. R.			Locating the carboxylate group of GABA in the homomeric rho GABA(A) receptor ligand-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; AGONIST-BINDING; 5-HT3 RECEPTOR; EXTRACELLULAR DOMAIN; XENOPUS OOCYTES; SITE; RESIDUES; CHANNELS; PHARMACOLOGY; ANTAGONISTS	gamma-Aminobutyric acid, type A (GABA(A)) receptors, of which the GABA(C) receptor family is a subgroup, are members of the Cys loop family of neurotransmitter receptors. Homology modeling of the extracellular domain of these proteins has revealed many molecular details, but it is not yet clear how GABA is orientated in the binding pocket. Here we have examined the role of arginine residues that the homology model locates in or close to the binding site of the GABA(C) receptor (Arg-104, Arg-170, Arg-158, and Arg-249) using mutagenesis and functional studies. The data suggest that Arg-158 is critical for GABA binding and/or function; substitution with Lys, Ala, or Glu resulted in nonfunctional receptors, and modeling placed the carboxylate of GABA within 3 angstrom of this residue. Substitution of Arg-104 with Ala or Glu resulted in > 10,000-fold increases in EC50 values compared with wild type receptors, and modeling indicated a role of this residue both in binding GABA and in the structure of the binding pocket. Substitution of Arg- 170 with Asp or Ala yielded nonfunctional receptors, whereas Lys caused an similar to 10-fold increase in EC50. Arg-249 was substituted with Ala, Glu, or Asp with relatively small (similar to 4-30-fold) changes in EC50. These and data from other residues that the model suggested could interact with GABA (His-105, Ser-168, and Ser-243) support a location for GABA in the binding site with its carboxylate pincered between Arg-158 and Arg-104, with Arg-104, Arg-170, and Arg-249 contributing to the structure of the binding pocket through salt bridges and/or hydrogen bonds.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England.	sl120@cam.ac.uk			Wellcome Trust [051097] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; HARRISON NJ, 2005, J MOL MODEL, P1; Hartvig L, 2000, J NEUROCHEM, V75, P1746, DOI 10.1046/j.1471-4159.2000.0751746.x; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; Johnston GAR, 1996, TRENDS PHARMACOL SCI, V17, P319, DOI 10.1016/S0165-6147(96)10038-9; Johnston GAR, 2003, CNS NEUROL DISORD-DR, V2, P260, DOI 10.2174/1568007033482805; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSAMA T, 1993, BRIT J PHARMACOL, V109, P200, DOI 10.1111/j.1476-5381.1993.tb13554.x; Le Novere N, 2002, P NATL ACAD SCI USA, V99, P3210, DOI 10.1073/pnas.042699699; Lummis SCR, 2005, CHEM BIOL, V12, P993, DOI 10.1016/j.chembiol.2005.06.012; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Maksay G, 2003, J RECEPT SIG TRANSD, V23, P255, DOI 10.1081/RRS-120025568; Price KL, 2004, J BIOL CHEM, V279, P23294, DOI 10.1074/jbc.M314075200; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; Schreiter C, 2003, J BIOL CHEM, V278, P22709, DOI 10.1074/jbc.M301801200; Sedelnikova A, 2005, J BIOL CHEM, V280, P1535, DOI 10.1074/jbc.M409908200; Thompson AJ, 2005, J BIOL CHEM, V280, P20476, DOI 10.1074/jbc.M413610200; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wagner DA, 2004, J NEUROSCI, V24, P2733, DOI 10.1523/JNEUROSCI.4316-03.2004; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009; WOODWARD RM, 1993, MOL PHARMACOL, V43, P609	28	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24455	24461		10.1074/jbc.M601775200	http://dx.doi.org/10.1074/jbc.M601775200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16754677	hybrid			2022-12-25	WOS:000239847800040
J	Kortholt, A; Rehmann, H; Kae, H; Bosgraaf, L; Keizer-Gunnink, I; Weeks, G; Wittinghofer, A; Van Haastert, PJM				Kortholt, Arjan; Rehmann, Holger; Kae, Helmut; Bosgraaf, Leonard; Keizer-Gunnink, Ineke; Weeks, Gerald; Wittinghofer, Alfred; Van Haastert, Peter J. M.			Characterization of the GbpD-activated Rap1 pathway regulating adhesion and cell polarity in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MEDIATES RAP1-INDUCED ADHESION; RAS-RELATED GENE; SOCIAL AMEBA; H-RAS; R-RAS; KINASE; CHEMOTAXIS; PROTEINS; FAMILY	The regulation of cell polarity plays an important role in chemotaxis. GbpD, a putative nucleotide exchange factor for small G-proteins of the Ras family, has been implicated in adhesion, cell polarity, and chemotaxis in Dictyostelium. Cells overexpressing GbpD are flat, exhibit strongly increased cell-substrate attachment, and extend many bifurcated and lateral pseudopodia. These cells overexpressing GbpD are severely impaired in chemotaxis, most likely due to the induction of many protrusions rather than an enhanced adhesion. The GbpD-overexpression phenotype is similar to that of cells overexpressing Rap1. Here we demonstrate that GbpD activates Rap1 both in vivo and in vitro but not any of the five other characterized Ras proteins. In a screen for Rap1 effectors, we overexpressed GbpD in several mutants defective in adhesion or cell polarity and identified Phg2 as Rap1 effector necessary for adhesion, but not cell polarity. Phg2, a serine/threonine-specific kinase, directly interacts with Rap1 via its Ras association domain.	Univ Groningen, Dept Mol Cell Biol, NL-9751 NN Haren, Netherlands; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	University of Groningen; Utrecht University; Utrecht University; University of British Columbia; Max Planck Society	Van Haastert, PJM (corresponding author), Univ Groningen, Dept Mol Cell Biol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	P.J.M.van.Haastert@rug.nl	kortholt, arjan/L-9795-2017	kortholt, arjan/0000-0001-8174-6397				Arigoni M, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-43; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Blaauw M, 2000, GENE, V252, P71, DOI 10.1016/S0378-1119(00)00227-4; Blanc C, 2005, EUR J CELL BIOL, V84, P951, DOI 10.1016/j.ejcb.2005.09.014; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Bosgraaf L, 2005, J CELL SCI, V118, P1899, DOI 10.1242/jcs.02317; Bosgraaf L, 2003, BBA-MOL CELL RES, V1643, P5, DOI 10.1016/j.bbamcr.2003.08.008; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chubb JR, 2002, CELL MOTIL CYTOSKEL, V53, P150, DOI 10.1002/cm.10064; Chubb JR, 2001, BBA-GEN SUBJECTS, V1525, P262, DOI 10.1016/S0304-4165(01)00111-8; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Fey P, 2002, J CELL BIOL, V159, P1109, DOI 10.1083/jcb.200206067; Gebbie L, 2004, MOL BIOL CELL, V15, P3915, DOI 10.1091/mbc.E03-12-0908; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Insall RH, 1996, CURR BIOL, V6, P719, DOI 10.1016/S0960-9822(09)00453-9; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kae H, 2004, EMBO REP, V5, P602, DOI 10.1038/sj.embor.7400151; Kang RJ, 2002, J CELL SCI, V115, P3675, DOI 10.1242/jcs.00039; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khosla M, 1996, MOL CELL BIOL, V16, P4156; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lim CJ, 2001, EMBO J, V20, P4490, DOI 10.1093/emboj/20.16.4490; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Niewohner J, 1997, J CELL BIOL, V138, P349, DOI 10.1083/jcb.138.2.349; REBSTEIN PJ, 1993, DEV GENET, V14, P347, DOI 10.1002/dvg.1020140504; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Seastone DJ, 1999, MOL BIOL CELL, V10, P393, DOI 10.1091/mbc.10.2.393; Soll DR, 1999, COMPUT MED IMAG GRAP, V23, P3, DOI 10.1016/S0895-6111(98)00058-5; Sutherland BW, 2001, EMBO REP, V2, P1024, DOI 10.1093/embo-reports/kve222; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Tuxworth RI, 1997, J CELL BIOL, V138, P605, DOI 10.1083/jcb.138.3.605; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Weeks G, 2005, DICTYOSTELIUM GENOMI, P173; Wilkins A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r68; Wilkins A, 2000, GENE DEV, V14, P1407; Wilkins A, 2000, CURR BIOL, V10, P1427, DOI 10.1016/S0960-9822(00)00797-1; Wilkins A, 2001, TRENDS GENET, V17, P41, DOI 10.1016/S0168-9525(00)02181-8; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	48	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23367	23376		10.1074/jbc.M600804200	http://dx.doi.org/10.1074/jbc.M600804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16769729	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000239702900011
J	Tong, EHY; Guo, JJ; Huang, AL; Liu, H; Hu, CD; Chung, SSM; Ko, BCB				Tong, Edith H. Y.; Guo, Jin-Jun; Huang, Ai-Long; Liu, Han; Hu, Chang-Deng; Chung, Stephen S. M.; Ko, Ben C. B.			Regulation of nucleocytoplasmic trafficking of transcription factor OREBP/TonEBP/NFAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; NUCLEAR EXPORT SIGNAL; BIMOLECULAR FLUORESCENCE COMPLEMENTATION; DAMAGE-INDUCIBLE KINASE; ALDOSE REDUCTASE GENE; FACTOR TONEBP/OREBP; OSMOTIC-STRESS; HIGH NACL; SUBCELLULAR-LOCALIZATION; STIMULATES TRANSCRIPTION	The osmotic response element-binding protein ( OREBP), also known as tonicity enhancer-binding protein ( TonEBP) or NFAT5, regulates the hypertonicity-induced expression of a battery of genes crucial for the adaptation of mammalian cells to extracellular hypertonic stress. The activity of OREBP/TonEBP is regulated at multiple levels, including nucleocytoplasmic trafficking. OREBP/TonEBP protein can be detected in both the cytoplasm and nucleus under isotonic conditions, although it accumulates exclusively in the nucleus or cytoplasm when subjected to hypertonic or hypotonic challenges, respectively. Using immunocytochemistry and green fluorescent protein fusions, the protein domains that determine its subcellular localization were identified and characterized. We found that OREBP/TonEBP nuclear import is regulated by a nuclear localization signal. However, under isotonic conditions, nuclear export of OREBP/TonEBP is mediated by a CRM1-dependent, leucine-rich canonical nuclear export sequence ( NES) located in the N terminus. Disruption of NES by site-directed mutagenesis yielded a mutant OREBP/TonEBP protein that accumulated in the nucleus under isotonic conditions but remained a target for hypotonicity-induced nuclear export. More importantly, a putative auxiliary export domain distal to the NES was identified. Disruption of the auxiliary export domain alone is sufficient to abolish the nuclear export of OREBP/TonEBP induced by hypotonicity. By using bimolecular fluorescence complementation assay, we showed that CRM1 interacts with OREBP/TonEBP, but not with a mutant protein deficient in NES. Our findings provide insight into how nucleocytoplasmic trafficking of OREBP/TonEBP is regulated by changes in extracellular tonicity.	Univ Hong Kong, Hong Kong Adm Reg, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Physiol, Hong Kong Special Adm Reg, Hong Kong, Hong Kong, Peoples R China; Chongqing Univ Med Sci, Key Lab Mol Biol Infect Dis, Minist Educ, Inst Viral Hepatitis, Chongqing, Peoples R China; Purdue Univ, Sch Pharm, Dept Med Chem & Pharmacol, W Lafayette, IN 47907 USA	University of Hong Kong; University of Hong Kong; University of Hong Kong; Chongqing Medical University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chung, SSM (corresponding author), Univ Hong Kong, Hong Kong Adm Reg, Dept Chem, Hong Kong, Hong Kong, Peoples R China.	smchung@hkucc.hku.hk; cbko@hkucc.hku.hk	Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899				Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Brown VM, 2004, J BIOL CHEM, V279, P5984, DOI 10.1074/jbc.M307071200; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200; Handler JS, 2001, KIDNEY INT, V60, P408, DOI 10.1046/j.1523-1755.2001.060002408.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang ZR, 2000, INVEST OPHTH VIS SCI, V41, P1467; Kitamura H, 1998, KIDNEY INT, V53, P146, DOI 10.1046/j.1523-1755.1998.00747.x; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Lopez-Rodriguez C, 1999, COLD SPRING HARB SYM, V64, P517, DOI 10.1101/sqb.1999.64.517; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Maallem S, 2006, NEUROSCIENCE, V137, P51, DOI 10.1016/j.neuroscience.2005.07.037; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mingot JM, 2004, EMBO J, V23, P3227, DOI 10.1038/sj.emboj.7600338; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Neuhofer W, 2005, ANNU REV PHYSIOL, V67, P531, DOI 10.1146/annurev.physiol.67.031103.154456; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Sheikh-Hamad D, 2001, J AM SOC NEPHROL, V12, P2732, DOI 10.1681/ASN.V12122732; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; Shyu YJ, 2006, BIOTECHNIQUES, V40, P61, DOI 10.2144/000112036; Song ZT, 2003, MOL CELL NEUROSCI, V23, P638, DOI 10.1016/S1044-7431(03)00096-4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Warskulat U, 2004, J INVEST DERMATOL, V123, P516, DOI 10.1111/j.0022-202X.2004.23313.x; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Woo SK, 2000, AM J PHYSIOL-CELL PH, V278, pC323, DOI 10.1152/ajpcell.2000.278.2.C323; Woo SK, 2002, PFLUG ARCH EUR J PHY, V444, P579, DOI 10.1007/s00424-002-0849-2; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhang Z, 2005, AM J PHYSIOL-RENAL, V289, pF506, DOI 10.1152/ajprenal.00417.2004; Zhou XM, 2006, AM J PHYSIOL-RENAL, V290, pF1169, DOI 10.1152/ajprenal.00378.2005	65	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23870	23879		10.1074/jbc.M602556200	http://dx.doi.org/10.1074/jbc.M602556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782704	hybrid			2022-12-25	WOS:000239702900062
J	Arita, M; Oh, SF; Chonan, T; Hong, S; Elangovan, S; Sun, YP; Uddin, J; Petasis, NA; Serhan, CN				Arita, Makoto; Oh, Sungwhan F.; Chonan, Tomomichi; Hong, Song; Elangovan, Siva; Sun, Yee-Ping; Uddin, Jasim; Petasis, Nicos A.; Serhan, Charles N.			Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; INFLAMMATION; RESOLUTION; ASPIRIN; A(4); NEUTROPHILS; PATHWAYS; CYTOKINE; DISEASE	The resolvins (Rv) are lipid mediators derived from omega-3 polyunsaturated fatty acids that act within a local inflammatory milieu to stop leukocyte recruitment and promote resolution. Resolvin E1 (RvE1; (5S, 12R, 18R)-trihydroxy-6Z, 8E, 10E, 14Z, 16E-eicosapentaenoic acid) is an oxygenase product derived from omega-3 eicosapentaenoic acid that displays potent anti-inflammation/pro-resolution actions in vivo. Here, we determined whether oxidoreductase enzymes catalyze the conversion of RvE1 and assessed the biological activity of the RvE1 metabolite. With NAD(+) as a cofactor, recombinant 15-hydroxyprostag-landin dehydrogenase acted as an 18-hydroxyl dehydrogenase to form 18-oxo-RvE1. In the murine lung, dehydrogenation of the hydroxyl group at carbon 18 position to form 18-oxo-RvE1 represented the major initial metabolic route for RvE1. At a concentration where RvE1 potently reduced polymorphonuclear leukocyte (PMN) recruitment in zymosan-induced peritonitis, 18-oxo-RvE1 was devoid of activity. In human neutrophils, carbon 20 hydroxylation of RvE1 was the main route of conversion. An RvE1 analog, i.e. 19-(p-fluorophenoxy)-RvE1, was synthesized that resisted rapid metabolic inactivation and proved to retain biological activity reducing PMN infiltration and pro-inflammatory cytokine/chemokine production in vivo. These results established the structure of a novel RvE1 initial metabolite, indicating that conversion of RvE1 to the oxo product represents a mode of RvE1 inactivation. Moreover, the designed RvE1 analog, which resisted further metabolism/inactivation, could be a useful tool to evaluate the actions of RvE1 in complex disease models.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA; Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; Univ So Calif, Loker Hydrocarbon Res Inst, Los Angeles, CA 90089 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard School of Dental Medicine; University of Southern California; University of Southern California	Serhan, CN (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446; Arita, Makoto/0000-0001-9902-0463	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074448] Funding Source: NIH RePORTER; NIDCR NIH HHS [P50-DE-016191] Funding Source: Medline; NIDDK NIH HHS [DK-074448] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aliberti J, 2005, NAT REV IMMUNOL, V5, P162, DOI 10.1038/nri1547; Arita M, 2005, BIOCHEM BIOPH RES CO, V338, P149, DOI 10.1016/j.bbrc.2005.07.181; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Blam ME, 2001, AM J GASTROENTEROL, V96, P1977, DOI 10.1016/S0002-9270(01)02494-7; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; Fiorucci S, 2004, P NATL ACAD SCI USA, V101, P15736, DOI 10.1073/pnas.0404722101; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Hamza A, 2005, BIOORGAN MED CHEM, V13, P4544, DOI 10.1016/j.bmc.2005.04.053; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kieran NE, 2003, KIDNEY INT, V64, P480, DOI 10.1046/j.1523-1755.2003.00106.x; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Majno G., 2004, CELLS TISSUES DIS PR; NACCACHE PH, 1982, J BIOL CHEM, V257, P8608; Perretti Mauro, 2003, Methods Mol Biol, V225, P139; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; POWELL WS, 1983, ANAL BIOCHEM, V128, P93, DOI 10.1016/0003-2697(83)90349-4; Schottelius AJ, 2002, J IMMUNOL, V169, P7063, DOI 10.4049/jimmunol.169.12.7063; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128	29	108	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22847	22854		10.1074/jbc.M603766200	http://dx.doi.org/10.1074/jbc.M603766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757471	hybrid, Green Published			2022-12-25	WOS:000239542600047
J	LeFebvre, AK; Korneeva, NL; Trutschl, M; Cvek, U; Duzan, RD; Bradley, CA; Hershey, JWB; Rhoads, RE				LeFebvre, Aaron K.; Korneeva, Nadejda L.; Trutschl, Marjan; Cvek, Urska; Duzan, Roy D.; Bradley, Christopher A.; Hershey, John W. B.; Rhoads, Robert E.			Translation initiation factor eIF4G-1 binds to eIF3 through the eIF3e subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; CAP-DEPENDENT TRANSLATION; AMINO-ACID-SEQUENCE; MAMMARY-TUMOR VIRUS; HEPATITIS-C VIRUS; PROTEIN-SYNTHESIS; POLY(A)-BINDING PROTEIN; PREINITIATION COMPLEX; MULTIFACTOR COMPLEX; CORE COMPLEX	eIF3 in mammals is the largest translation initiation factor (similar to 800 kDa) and is composed of 13 nonidentical subunits designated eIF3a-m. The role of mammalian eIF3 in assembly of the 48 S complex occurs through high affinity binding to eIF4G. Interactions of eIF4G with eIF4E, eIF4A, eIF3, poly(A)-binding protein, and Mnk1/2 have been mapped to discrete domains on eIF4G, and conversely, the eIF4G-binding sites on all but one of these ligands have been determined. The only eIF4G ligand for which this has not been determined is eIF3. In this study, we have sought to identify the mammalian eIF3 subunit(s) that directly interact(s) with eIF4G. Established procedures for detecting protein-protein interactions gave ambiguous results. However, binding of partially proteolyzed HeLa eIF3 to the eIF3-binding domain of human eIF4G-1, followed by high throughput analysis of mass spectrometric data with a novel peptide matching algorithm, identified a single subunit, eIF3e (p48/Int-6). In addition, recombinant FLAG-eIF3e specifically competed with HeLa eIF3 for binding to eIF4G in vitro. Adding FLAG-eIF3e to a cell-free translation system (i) inhibited protein synthesis, (ii) caused a shift of mRNA from heavy to light polysomes, (iii) inhibited cap-dependent translation more severely than translation dependent on the HCV or CSFV internal ribosome entry sites, which do not require eIF4G, and (iv) caused a dramatic loss of eIF4G and eIF2 alpha from complexes sedimenting at similar to 40 S. These data suggest a specific, direct, and functional interaction of eIF3e with eIF4G during the process of cap-dependent translation initiation, although they do not rule out participation of other eIF3 subunits.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Res Core Facil, Shreveport, LA 71130 USA; Louisiana State Univ, Dept Comp Sci, Shreveport, LA 71115 USA; Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Shreveport; University of California System; University of California Davis	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu	Cvek, Urska/ABA-4578-2020	Cvek, Urska/0000-0003-2042-6415; Bradley, Christopher/0000-0001-9531-996X	NIGMS NIH HHS [F32 GM020818, GM22135, R01 GM022135, R01 GM020818, GM20818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020818, R01GM020818, R01GM022135] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; Bandyopadhyay A, 2002, J BIOL CHEM, V277, P2360, DOI 10.1074/jbc.M107790200; Bradley CA, 2002, J BIOL CHEM, V277, P12559, DOI 10.1074/jbc.M111134200; Browning KS, 2001, TRENDS BIOCHEM SCI, V26, P284, DOI 10.1016/S0968-0004(01)01825-4; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Byrd MP, 2002, MOL CELL BIOL, V22, P4499, DOI 10.1128/MCB.22.13.4499-4511.2002; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; Clark BFC, 1996, BIOCHIMIE, V78, P1119, DOI 10.1016/S0300-9084(97)86738-7; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dunand-Sauthier I, 2002, MOL BIOL CELL, V13, P1626, DOI 10.1091/mbc.01-06-0301; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Grudzien E, 2006, J BIOL CHEM, V281, P1857, DOI 10.1074/jbc.M509121200; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hui DJ, 2005, J BIOL CHEM, V280, P3433, DOI 10.1074/jbc.M406700200; Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200; HUNTER T, 1975, J BIOL CHEM, V250, P409; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Jivotovskaya AV, 2006, MOL CELL BIOL, V26, P1355, DOI 10.1128/MCB.26.4.1355-1372.2006; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Kim TH, 2004, PLANT CELL, V16, P3341, DOI 10.1105/tpc.104.026880; Korneeva NL, 2005, J BIOL CHEM, V280, P1872, DOI 10.1074/jbc.M406168200; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; Morris-Desbois C, 2001, J BIOL CHEM, V276, P45988, DOI 10.1074/jbc.M104966200; Nielsen KH, 2006, MOL CELL BIOL, V26, P2984, DOI 10.1128/MCB.26.8.2984-2998.2006; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Park HS, 2004, EMBO J, V23, P1381, DOI 10.1038/sj.emboj.7600140; Park HS, 2001, CELL, V106, P723, DOI 10.1016/S0092-8674(01)00487-1; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RHOADS RE, 2005, WORMBOOK C ELEGANS R, DOI DOI 10.1895/WORMBOOK.1.7.1; Scheel H, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-71; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Shalev A, 2001, J BIOL CHEM, V276, P34948, DOI 10.1074/jbc.M102161200; SHEPHARD EG, 1988, ANAL BIOCHEM, V168, P306, DOI 10.1016/0003-2697(88)90323-5; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Valasek L, 2004, MOL CELL BIOL, V24, P9437, DOI 10.1128/MCB.24.21.9437-9455.2004; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Vende P, 2000, J VIROL, V74, P7064, DOI 10.1128/JVI.74.15.7064-7071.2000; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; von Arnim AG, 2003, CURR BIOL, V13, pR323, DOI 10.1016/S0960-9822(03)00238-0; Vornlocher HP, 1999, J BIOL CHEM, V274, P16802, DOI 10.1074/jbc.274.24.16802; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	89	127	141	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22917	22932		10.1074/jbc.M605418200	http://dx.doi.org/10.1074/jbc.M605418200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766523	hybrid, Green Accepted			2022-12-25	WOS:000239542600054
J	Neuenschwander, PF; Williamson, SR; Nalian, A; Baker-Deadmond, KJ				Neuenschwander, Pierre F.; Williamson, Stephen R.; Nalian, Armen; Baker-Deadmond, Kimberly J.			Heparin modulates the 99-loop of factor IXa - Effects on reactivity with isolated Kunitz-type inhibitor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; FACTOR-PATHWAY INHIBITOR; COAGULATION-FACTOR IXA; ACTIVATED FACTOR-IX; TISSUE-FACTOR; FACTOR-X; FACTOR VIIA; CONFORMATIONAL-CHANGE; INTRINSIC TENASE; ANTITHROMBIN-III	Reactivity of factor IXa with basic pancreatic trypsin inhibitor is enhanced by low molecular weight heparin (enoxaparin). Previous studies by us have suggested that this effect involves allosteric modulation of factor IXa. We examined the reactivity of factor IXa with several isolated Kunitz-type inhibitor domains: basic pancreatic trypsin inhibitor, the Kunitz inhibitor domain of protease Nexin-2, and the first two inhibitor domains of tissue factor pathway inhibitor. We find that enhancement of factor IXa reactivity by enoxaparin is greatest for basic pancreatic trypsin inhibitor (> 10-fold), followed by the second tissue factor pathway inhibitor domain (1.7-fold) and the Kunitz inhibitor domain of protease Nexin-2 (1.4-fold). Modeling studies of factor IXa with basic pancreatic trypsin inhibitor suggest that binding of this inhibitor is sterically hindered by the 99-loop of factor IXa, specifically residue Lys(98). Slow-binding kinetic studies support the formation of a weak initial enzyme-inhibitor complex between factor IXa and basic pancreatic trypsin inhibitor that is facilitated by enoxaparin binding. Mutation of Lys(98) to Ala in factor IXa results in enhanced reactivity with all inhibitors examined, whereas almost completely abrogating the enhancing effects of enoxaparin. The results implicate Lys(98) and the 99-loop of factor IXa in defining enzyme inhibitor specificity. More importantly, these results demonstrate the ability of factor IXa to be allosterically modulated by occupation of the heparin-binding exosite.	Univ Texas, Hlth Sci Ctr, Biomed Res Lab C8, Dept Biochem,Biomed Res Program, Tyler, TX 75708 USA; Stephen F Austin State Univ, Dept Biotechnol, Nacogdoches, TX 75962 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Neuenschwander, PF (corresponding author), Univ Texas, Hlth Sci Ctr, Biomed Res Lab C8, Dept Biochem,Biomed Res Program, 11937 US Hwy 271, Tyler, TX 75708 USA.	Pierre.Neuenschwander@uthct.edu			NHLBI NIH HHS [R01 HL075696-04, R01 HL075696-03, HL075696, R01 HL075696, R01 HL075696-05, R01 HL075696-02, R01 HL075696-05S2, R01 HL075696-02S1, R01 HL075696-05S1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075696] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERER FA, 1965, Z NATURFORSCH PT B, VB 20, P457; ANDERSON JA, 1965, THORAX, V20, P462, DOI 10.1136/thx.20.5.462; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Clark ED, 1998, BIOTECHNOL PROGR, V14, P47, DOI 10.1021/bp970123w; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P225; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hsu YC, 2001, BIOCHEMISTRY-US, V40, P11261, DOI 10.1021/bi010262t; JESTY J, 1995, WILLIAMS HEMATOLOGY, P1227; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P373, DOI 10.1021/bi00647a021; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MANN KG, 1990, BLOOD, V76, P755; MERTENS K, 1984, BIOCHEM J, V223, P607, DOI 10.1042/bj2230607; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Neuenschwander P.F., 2006, ENCY RESP MED, P509; Neuenschwander PF, 2004, BIOCHEMISTRY-US, V43, P2978, DOI 10.1021/bi035452d; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P8701, DOI 10.1021/bi00027a020; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; Neuenschwander PF, 1997, THROMB HAEMOST S, V78, P428; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1992, ADV EXP MED BIOL, V313, P155; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; Piro O, 2004, CIRCULATION, V110, P3567, DOI 10.1161/01.CIR.0000148778.76917.89; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P693, DOI 10.1021/bi971271y; ROSENBERG JS, 1975, J BIOL CHEM, V250, P8883; SCHMAIER AH, 1995, BIOCHEMISTRY-US, V34, P1171, DOI 10.1021/bi00004a010; Sheehan JP, 2003, BIOCHEMISTRY-US, V42, P11316, DOI 10.1021/bi0342923; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VILLANUEVA GB, 1984, J BIOL CHEM, V259, P2531; VILLANUEVA GB, 1977, BIOCHEM BIOPH RES CO, V74, P803, DOI 10.1016/0006-291X(77)90374-6; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V186, P1138, DOI 10.1016/0006-291X(92)90865-I; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; WUN TC, 1988, J BIOL CHEM, V263, P6001; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200; Yuan QP, 2005, BIOCHEMISTRY-US, V44, P3615, DOI 10.1021/bi047934a; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	45	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23066	23074		10.1074/jbc.M603743200	http://dx.doi.org/10.1074/jbc.M603743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766524	Green Accepted, hybrid			2022-12-25	WOS:000239542600070
J	Jensen, MV; Joseph, JW; Ilkayeva, O; Burgess, S; Lu, DH; Ronnebaum, SM; Odegaard, M; Becker, TC; Sherry, AD; Newgard, CB				Jensen, Mette V.; Joseph, Jamie W.; Ilkayeva, Olga; Burgess, Shawn; Lu, Danhong; Ronnebaum, Sarah M.; Odegaard, Matthew; Becker, Thomas C.; Sherry, A. Dean; Newgard, Christopher B.			Compensatory responses to pyruvate carboxylase suppression in islet beta-cells - Preservation of glucose-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNEL; PANCREATIC-ISLETS; REGULATED ANAPLEROSIS; FATTY-ACID; GLUTAMATE; METABOLISM; EXPRESSION; SHUTTLE; EXOCYTOSIS; RESISTANCE	We have previously reported that glucose-stimulated insulin secretion (GSIS) is tightly correlated with pyruvate carboxylase (PC)-catalyzed anaplerotic flux into the tricarboxylic acid cycle and stimulation of pyruvate cycling activity. To further evaluate the role of PC in beta-cell function, we constructed a recombinant adenovirus containing a small interfering RNA (siRNA) specific to PC (Ad-siPC). Ad-siPC reduced PC mRNA levels by 83 and 64% and PC protein by 56 and 35% in INS-1-derived 832/13 cells and primary rat islets, respectively. Surprisingly, this manipulation did not impair GSIS in rat islets. In Ad-siPC-treated 832/13 cells, GSIS was slightly increased, whereas glycolytic rate and glucose oxidation were unaffected. Flux through PC at high glucose was decreased by only 20%, suggesting an increase in PC-specific activity. Acetyl carnitine, a surrogate for acetyl-CoA, an allosteric activator of PC, was increased by 36% in Ad-siPC-treated cells, suggesting a mechanism by which PC enzymatic activity is maintained with suppressed PC protein levels. In addition, the NADPH: NADP ratio, a proposed coupling factor for GSIS, was unaffected in Ad-siPC-treated cells. We conclude that eta-cells activate compensatory mechanisms in response to suppression of PC expression that prevent impairment of anaplerosis, pyruvate cycling, NAPDH production, and GSIS.	Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Med Ctr, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75235 USA	Duke University; Duke University; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Med Ctr, Independence Pk Facil,4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	Newga002@mc.duke.edu	; Sherry, Dean/P-2348-2018	Ronnebaum, Sarah/0000-0003-4787-754X; Sherry, Dean/0000-0001-7150-8301	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42583, DK58398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bahl JJ, 1997, BIOCHEM PHARMACOL, V53, P67, DOI 10.1016/S0006-2952(96)00660-0; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Bertrand G, 2002, J BIOL CHEM, V277, P32883, DOI 10.1074/jbc.M205326200; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Carbone MA, 1998, AM J HUM GENET, V62, P1312, DOI 10.1086/301884; Efanov AM, 2004, DIABETES, V53, pS75, DOI 10.2337/diabetes.53.suppl_3.S75; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; FRANSSON U, 2006, DIABETOLOGIA; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; Hanson RW, 2005, J BIOL CHEM, V280, P1705, DOI 10.1074/jbc.X400009200; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Jitrapakdee S, 2006, CELL MOL LIFE SCI, V63, P843, DOI 10.1007/s00018-005-5410-y; Jitrapakdee S, 2001, BIOCHEM BIOPH RES CO, V287, P411, DOI 10.1006/bbrc.2001.5599; Jitrapakdee S, 1999, BIOCHEM J, V340, P1, DOI 10.1042/bj3400001; Jitrapakdee S, 1997, J BIOL CHEM, V272, P20522, DOI 10.1074/jbc.272.33.20522; Joseph JW, 2005, DIABETES, V54, pA43; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; Kim JY, 2002, AM J PHYSIOL-ENDOC M, V282, pE1014, DOI 10.1152/ajpendo.00233.2001; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Matschinsky F.M., 2001, HDB PHYSL 7, P125; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P85; Rabaglia ME, 2005, AM J PHYSIOL-ENDOC M, V289, pE218, DOI 10.1152/ajpendo.00573.2004; Ronnebaum SM, 2005, DIABETES, V54, pA423; Rubi B, 2001, J BIOL CHEM, V276, P36391, DOI 10.1074/jbc.M104999200; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Tarasov A, 2004, DIABETES, V53, pS113, DOI 10.2337/diabetes.53.suppl_3.S113; Yamada S, 2001, ENDOCR J, V48, P391, DOI 10.1507/endocrj.48.391	45	107	108	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22342	22351		10.1074/jbc.M604350200	http://dx.doi.org/10.1074/jbc.M604350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16740637	hybrid			2022-12-25	WOS:000239387100079
J	Nakagawa, SH; Hua, QX; Hu, SQ; Jia, WH; Wang, SH; Katsoyannis, PG; Weiss, MA				Nakagawa, Satoe H.; Hua, Qing-xin; Hu, Shi-Quan; Jia, Wenhua; Wang, Shuhua; Katsoyannis, Panayotis G.; Weiss, Michael A.			Chiral mutagenesis of insulin - Contribution of the B20-B23 beta-turn to activity and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; DESPENTAPEPTIDE B26-30 INSULIN; DIABETES-ASSOCIATED MUTATIONS; RECEPTOR-BINDING SURFACE; B-CHAIN; A-CHAIN; BIOLOGICAL-ACTIVITY; MUTANT INSULIN; FOLDING INTERMEDIATE; CIRCULAR-DICHROISM	Insulin contains a beta-turn (residues B20-B23) interposed between two receptor-binding elements, the central alpha-helix of the B chain (B9-B19) and its C-terminal beta-strand (B24-B28). The turn contains conserved glycines at B20 and B23. Although insulin exhibits marked conformational variability among crystal forms, these glycines consistently maintain positive phi dihedral angles within a classic type-I beta-turn. Because the Ramachandran conformations of Gly(B20) and Gly(B23) are ordinarily forbidden to L-amino acids, turn architecture may contribute to structure or function. Here, we employ "chiral mutagenesis," comparison of corresponding D- and L-Ala substitutions, to investigate this turn. Control substitutions are introduced at Glu(B21), a neighboring residue exhibiting a conventional (negative) phi angle. The D- and L-Ala substitutions at B23 are associated with a marked stereospecific difference in activity. Whereas the D-Ala(B23) analog retains native activity, the L analog exhibits a 20-fold decrease in receptor binding. By contrast, D- and L-Ala(B20) analogs each exhibit high activity. Stereospecific differences between the thermodynamic stabilities of the analogs are nonetheless more pronounced at B20 (Delta Delta G(u) 2.0 kcal/mole) than at B23 (Delta Delta G(u) 0.7 kcal/mole). Control substitutions at B21 are well tolerated without significant stereospecificity. Chiral mutagenesis thus defines the complementary contributions of these conserved glycines to protein stability (Gly(B20)) or receptor recognition (Gly(B23)).	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Case Western Reserve University; University of Chicago; Icahn School of Medicine at Mount Sinai	Weiss, MA (corresponding author), Case Western Reserve Univ, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	maw21@case.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056673] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56673, DK04949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anil B, 2004, J AM CHEM SOC, V126, P13194, DOI 10.1021/ja047119i; BADGER J, 1991, ACTA CRYSTALLOGR B, V47, P127, DOI 10.1107/S0108768190009570; BAILEY JL, 1959, J BIOL CHEM, V234, P1733; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; Bao SJ, 1997, P NATL ACAD SCI USA, V94, P2975, DOI 10.1073/pnas.94.7.2975; BARANY G, 1980, PEPTIDES ANAL SYNTHE, P3; BI RC, 1983, ACTA CRYSTALLOGR B, V39, P90; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; CISZAK E, 1994, BIOCHEMISTRY-US, V33, P1512, DOI 10.1021/bi00172a030; DAI JB, 1987, SCI CHINA SER B, V30, P55; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Guo ZY, 2004, BBA-PROTEINS PROTEOM, V1699, P103, DOI 10.1016/j.bbapap.2004.02.003; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HU SQ, 1993, BIOCHEMISTRY-US, V32, P2631, DOI 10.1021/bi00061a022; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUA QX, 2006, J BIOL CHEM; Huang K, 2004, J MOL BIOL, V341, P529, DOI 10.1016/j.jmb.2004.05.023; INOUYE K, 1979, J AM CHEM SOC, V101, P751, DOI 10.1021/ja00497a051; KAARSHOLM NC, 1993, BIOCHEMISTRY-US, V32, P10773, DOI 10.1021/bi00091a031; KATSOYAN.PG, 1966, P NATL ACAD SCI USA, V55, P1554, DOI 10.1073/pnas.55.6.1554; KITAGAWA K, 1984, BIOCHEMISTRY-US, V23, P1405, DOI 10.1021/bi00302a011; KOBAYASHI M, 1984, BIOCHEM BIOPH RES CO, V119, P49, DOI 10.1016/0006-291X(84)91616-4; KOBAYASHI M, 1982, BIOCHEM BIOPH RES CO, V107, P329, DOI 10.1016/0006-291X(82)91708-9; KOBAYASHI M, 1986, BIOCHEM BIOPH RES CO, V137, P250, DOI 10.1016/0006-291X(86)91203-9; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; KUBIAK T, 1986, INT J PEPT PROT RES, V27, P514; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Ludvigsen S, 1998, J MOL BIOL, V279, P1, DOI 10.1006/jmbi.1998.1801; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MIRMIRA RG, 1991, J BIOL CHEM, V266, P1428; MIRMIRA RG, 1989, J BIOL CHEM, V264, P6349; NAKAGAWA SH, 1987, J BIOL CHEM, V262, P12054; Nakagawa SH, 2005, BIOCHEMISTRY-US, V44, P4984, DOI 10.1021/bi048025o; NAKAGAWA SH, 1992, BIOCHEMISTRY-US, V31, P3204, DOI 10.1021/bi00127a023; Nakagawa SH, 2000, BIOCHEMISTRY-US, V39, P15826, DOI 10.1021/bi001802+; NARHI LO, 1993, BIOCHEMISTRY-US, V32, P5214, DOI 10.1021/bi00070a033; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; Sosnick TR, 2000, METHOD ENZYMOL, V317, P393; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STEINER DF, 1967, T NEW YORK ACAD SCI, V30, P60, DOI 10.1111/j.2164-0947.1967.tb02452.x; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; Wan ZL, 2005, BIOCHEMISTRY-US, V44, P5000, DOI 10.1021/bi047585k; Wan ZL, 2003, BIOCHEMISTRY-US, V42, P12770, DOI 10.1021/bi034430o; WANG CC, 1991, TRENDS BIOCHEM SCI, V16, P279, DOI 10.1016/0968-0004(91)90114-B; Weiss MA, 2002, BIOCHEMISTRY-US, V41, P809, DOI 10.1021/bi011839+; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; Weiss MA, 2001, J BIOL CHEM, V276, P40018, DOI 10.1074/jbc.M104634200; Xu B, 2004, BIOCHEMISTRY-US, V43, P8356, DOI 10.1021/bi0497796; Xu B, 2002, J MOL BIOL, V316, P435, DOI 10.1006/jmbi.2001.5377; Yan H, 2003, PROTEIN SCI, V12, P768, DOI 10.1110/ps.0237203; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187; ZHAO M, 1998, P AM PEPT S, P369	64	32	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22386	22396		10.1074/jbc.M603547200	http://dx.doi.org/10.1074/jbc.M603547200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751187	hybrid			2022-12-25	WOS:000239387100084
J	Reiss, K; Maretzky, T; Haas, IG; Schulte, M; Ludwig, A; Frank, M; Saftig, P				Reiss, Karina; Maretzky, Thorsten; Haas, Ingrid G.; Schulte, Marc; Ludwig, Andreas; Frank, Marcus; Saftig, Paul			Regulated ADAM10-dependent ectodomain shedding of gamma-protocadherin C3 modulates cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETASE ACTIVITY; CADHERIN; PROTEIN; CLEAVAGE; ADAM10; FAMILY; EXPRESSION; DIVERSITY; RELEASE; CATENIN	gamma-Protocadherins (Pcdh gamma) are type I transmembrane proteins, which are most notably expressed in the nervous system. They are enriched at synapses and involved in synapse formation, specification, and maintenance. In this study, we show that Pcdh gamma C3 and Pcdh gamma B4 are specifically cleaved within their ectodomains by the disintegrin and metalloprotease ADAM10. Analysis of ADAM10-deficient fibroblasts and embryos, inhibitor studies, as well as RNA interference-mediated down-regulation demonstrated that ADAM10 is not only responsible for the constitutive but also for the regulated shedding of these proteins in fibroblasts and in neuronal cells. In contrast to N-cadherin shedding, which was activated by N-methyl-D-aspartic acid receptor activation in neuronal cells, Pcdh gamma shedding was induced by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate stimulation, suggesting differential regulation mechanisms of cadherin-mediated functions at synapses. Cell aggregation assays in the presence or absence of metalloprotease inhibitors strongly suggest that the ectodomain shedding events modulate the cell adhesion role of Pcdh gamma. The identification of ADAM10 as the protease responsible for constitutive and regulated Pcdh gamma shedding may therefore provide new insight into the regulation of Pcdh gamma functions.	Univ Kiel, Biochem Inst, D-24098 Kiel, Germany; Max Planck Inst Immunobiol, Dept Mol Embryol, D-79108 Freiburg, Germany	University of Kiel; Max Planck Society	Saftig, P (corresponding author), Univ Kiel, Biochem Inst, Olshausenstr 40, D-24098 Kiel, Germany.	psaftig@biochem.uni-kiel.de	Saftig, Paul/A-7966-2010; Maretzky, Thorsten/AEN-1915-2022; Ludwig, Andreas/I-5685-2012; Reiss, Karina/B-3175-2010; Maretzky, Thorsten/GSN-2981-2022	Maretzky, Thorsten/0000-0003-1282-6080; Ludwig, Andreas/0000-0001-8536-4986; 				Aguilar J, 2004, BIOCHEM BIOPH RES CO, V317, P551, DOI 10.1016/j.bbrc.2004.03.080; Angst BD, 2001, J CELL SCI, V114, P625; BASARSKY TA, 1994, J NEUROSCI, V14, P6402; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Castonguay A, 2001, J NEUROSCI, V21, P1911, DOI 10.1523/JNEUROSCI.21-06-01911.2001; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Chen YC, 2005, J NEUROBIOL, V64, P4, DOI 10.1002/neu.20150; Chitaev NA, 1997, J CELL BIOL, V138, P193, DOI 10.1083/jcb.138.1.193; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Frank M, 2002, CURR OPIN CELL BIOL, V14, P557, DOI 10.1016/S0955-0674(02)00365-4; Frank M, 2005, MOL CELL NEUROSCI, V29, P603, DOI 10.1016/j.mcn.2005.05.001; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Heyers D, 2003, J COMP NEUROL, V460, P155, DOI 10.1002/cne.10631; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Huntley GW, 2002, NEUROSCIENTIST, V8, P221, DOI 10.1177/1073858402008003008; Junghans D, 2005, CURR OPIN CELL BIOL, V17, P446, DOI 10.1016/j.ceb.2005.08.008; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Phillips GR, 2003, J NEUROSCI, V23, P5096; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Serafini T, 1999, CELL, V98, P133, DOI 10.1016/S0092-8674(00)81008-9; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	44	84	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21735	21744		10.1074/jbc.M602663200	http://dx.doi.org/10.1074/jbc.M602663200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751190	hybrid			2022-12-25	WOS:000239387100019
J	Yamada, C; Sano, H; Shimizu, T; Mitsuzawa, H; Nishitani, C; Himi, T; Kuroki, Y				Yamada, Chieko; Sano, Hitomi; Shimizu, Takeyuki; Mitsuzawa, Hiroaki; Nishitani, Chiaki; Himi, Tetsuo; Kuroki, Yoshio			Surfactant protein a directly interacts with TLR4 and MD-2 and regulates inflammatory cellular response - Importance of supratrimeric oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; COLLAGEN-LIKE REGION; N-TERMINAL DOMAINS; PULMONARY SURFACTANT; II CELLS; BINDING PROTEIN; INNATE IMMUNITY; PHOSPHOLIPID AGGREGATION; SIGNAL-TRANSDUCTION	The purpose of the current study was to examine the binding of pulmonary surfactant protein A ( SP-A) to TLR4 and MD-2, which are critical signaling receptors for lipopolysaccharides ( LPSs). The direct binding of SP-A to the recombinant soluble form of extracellular TLR4 domain ( sTLR4) and MD-2 was detected using solid-phase binding, immunoprecipitation, and BIAcore. SP-A bound to sTLR4 and MD-2 in a Ca2+-dependent manner, and an anti-SP-A monoclonal antibody whose epitope lies in the region Thr(184)-Gly(194) blocked the SP-A binding to sTLR4 and MD-2, indicating the involvement of the carbohydrate recognition domain (CRD) in the binding. SP-A avidly bound to the deglycosylated forms of sTLR4 and MD-2, suggesting a protein/protein interaction. In addition, SP-A attenuated cell surface binding of smooth LPS and smooth LPS-induced NF-kappa B activation in TLR4/MD-2-expressing cells. To know the role of oligomerization in the interaction of SP-A with TLR4 and MD-2, the collagenase-resistant fragment (CRF), which consisted of CRD plus neck domain of SP-A, was isolated. CRF assembled as a trimer, whereas SP-A assembled as a higher order oligomer. Although CRD was suggested to be involved in the binding, CRF exhibited approximately 600- and 155-fold higher K-D for the binding to TLR4 and MD- 2, respectively, when compared with SP-A. Consistently significantly higher molar concentrations of CRF were required to inhibit smooth LPS-induced NF-kappa B activation and tumor necrosis factor-alpha secretion. These results demonstrate for the first time the direct interaction between SP-A and TLR4/MD-2 and suggest the importance of supratrimeric oligomerization in the immunomodulatory function of SP- A.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Otolaryngol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Japan Sci & Technol Agcy, Core Res Engn Sci & Technol, Kawaguchi 3320012, Japan	Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST)	Sano, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South-1,West-17, Sapporo, Hokkaido 0608556, Japan.	sanohito@sapmed.ac.jp						Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ALCORN JF, 2004, AM J PHYSIOL, V286, P6129; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; Chiba H, 1999, BIOCHEMISTRY-US, V38, P7321, DOI 10.1021/bi990353e; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; Garcia-Verdugo I, 2005, BIOCHEM J, V391, P115, DOI 10.1042/BJ20050529; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Hyakushima N, 2004, J IMMUNOL, V173, P6949, DOI 10.4049/jimmunol.173.11.6949; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; Ikegami M, 2001, J BIOL CHEM, V276, P38542, DOI 10.1074/jbc.M102054200; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1985, BIOCHIM BIOPHYS ACTA, V836, P201; KUROKI Y, 1993, AM REV RESPIR DIS, V147, P723, DOI 10.1164/ajrccm/147.3.723; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; Larsen F, 2004, J BIOL CHEM, V279, P21302, DOI 10.1074/jbc.M400520200; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; MCINTOSH JC, 1996, AM J PHYSIOL, V271, P6310; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; NISHITANI C, 2004, BIOCHEM BIOPH RES CO, V328, P586; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; Sanchez-Barbero F, 2005, J BIOL CHEM, V280, P7659, DOI 10.1074/jbc.M410266200; Sano H, 2005, MOL IMMUNOL, V42, P279, DOI 10.1016/j.molimm.2004.07.014; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Stamme C, 2002, AM J RESP CELL MOL, V27, P353, DOI 10.1165/rcmb.4812; Teillet F, 2005, J IMMUNOL, V174, P2870, DOI 10.4049/jimmunol.174.5.2870; Tsunezawa W, 1998, BBA-PROTEIN STRUCT M, V1387, P433, DOI 10.1016/S0167-4838(98)00159-9; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	53	108	115	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21771	21780		10.1074/jbc.M513041200	http://dx.doi.org/10.1074/jbc.M513041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754682	hybrid			2022-12-25	WOS:000239387100023
J	Aquilano, K; Vigilanza, P; Rotilio, G; Ciriolo, MR				Aquilano, Katia; Vigilanza, Paola; Rotilio, Giuseppe; Ciriolo, Maria Rosa			Mitochondrial damage due to SOD1 deficiency in SH-SY5Y neuroblastoma cells: a rationale for the redundancy of SOD1	FASEB JOURNAL			English	Article						oxidative stress; aging; Bcl-2; neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; OXIDATIVE STRESS; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; INTERMEMBRANE SPACE; SPORADIC ALS; FAMILIAL ALS; LIFE-SPAN	Superoxide dismutases (SODs) represent the first line of defense against oxidative stress, which is considered an essential factor in several neurodegenerative diseases and aging. We investigated the role of the copper, zinc superoxide dismutase (SOD1) in the maintenance of intracellular redox homeostasis by analyzing the early effects of SOD1 down-regulation in SH-SY5Y neuroblastoma cells. Through the use of small interference RNA, SOD1 was efficiently downregulated at 48 h after transfection without any significant effect on cell viability. The steady-state concentration of superoxide was significantly increased after 12 h, when SOD1 was only slightly decreased, and progressively returned to values close to those observed in control cells. The superoxide increase was buffered by the enhanced levels of antioxidant glutathione (GSH); however, GSH increase was not sufficient to avoid damage to proteins in terms of carbonyls. GSH-depleting agents, such as BSO or diamide, further increased protein damage and committed SOD1 deficient cells to death, confirming the pivotal role played by this antioxidant. Although SOD1 declined mostly in the cytosolic compartment, mitochondria were significantly affected with impairment of the mitochondrial transmembrane potential and a decrease in ATP production. Together with these effects carbonylation of mitochondrial proteins was detected and in particular a consistent carbonylation and decrease of the antiapoptotic protein Bcl-2. These conditions induced a high susceptibility of SOD1-depleted cells to treatment with the mitochondrial reactive oxygen species producing agent rotenone. Overall, the results demonstrate that loss of SOD1 leads to severe damage of mitochondria, suggesting an important biological role for this enzyme in the preservation of mitochondrial homeostasis.	Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy	University of Rome Tor Vergata	Ciriolo, MR (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.	ciriolo@bio.uniroma2.it	Ciriolo, Maria Rosa/K-6572-2016; AQUILANO, KATIA/K-8888-2016	AQUILANO, KATIA/0000-0002-5905-9870; Ciriolo, Maria Rosa/0000-0002-7863-9029				Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Blander G, 2003, J BIOL CHEM, V278, P38966, DOI 10.1074/jbc.M307146200; Busuttil RA, 2005, CANCER RES, V65, P11271, DOI 10.1158/0008-5472.CAN-05-2980; Cahuana GM, 2004, EXP CELL RES, V293, P22, DOI 10.1016/j.yexcr.2003.10.004; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Ciriolo MR, 2001, J NEUROCHEM, V77, P1433, DOI 10.1046/j.1471-4159.2001.00383.x; Cova E, 2006, NEUROSCI LETT, V399, P186, DOI 10.1016/j.neulet.2006.01.057; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gupta S, 2005, J CELL MOL MED, V9, P51, DOI 10.1111/j.1582-4934.2005.tb00336.x; Huang TT, 2000, J GERONTOL A-BIOL, V55, pB5; Inarrea P, 2005, BIOCHEM J, V387, P203, DOI 10.1042/BJ20041683; Kato S, 2005, ACTA NEUROPATHOL, V110, P101, DOI 10.1007/s00401-005-1019-3; Kira Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P96, DOI 10.1006/abbi.2001.2738; Kong JM, 1998, J NEUROSCI, V18, P3241; Landis GN, 2005, MECH AGEING DEV, V126, P365, DOI 10.1016/j.mad.2004.08.012; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manfredi G, 2005, MITOCHONDRION, V5, P77, DOI 10.1016/j.mito.2005.01.002; Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Noor Rana, 2002, Med Sci Monit, V8, pRA210; O'Brien KM, 2004, J BIOL CHEM, V279, P51817, DOI 10.1074/jbc.M405958200; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Parker JD, 2004, P NATL ACAD SCI USA, V101, P3486, DOI 10.1073/pnas.0400222101; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rizzardini M, 2005, J NEUROL SCI, V232, P95, DOI 10.1016/j.jns.2005.02.004; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; Rotilio G, 2003, IUBMB LIFE, V55, P629, DOI 10.1080/15216540310001628717; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Sentman ML, 2006, J BIOL CHEM, V281, P6904, DOI 10.1074/jbc.M510764200; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Troy CM, 1996, J NEUROSCI, V16, P253; Vijayvergiya C, 2005, J NEUROSCI, V25, P2463, DOI 10.1523/JNEUROSCI.4385-04.2005; Wallace MA, 2004, J BIOL CHEM, V279, P32055, DOI 10.1074/jbc.M403590200; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	46	48	49	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1683	+		10.1096/fj.05-5225fje	http://dx.doi.org/10.1096/fj.05-5225fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790527				2022-12-25	WOS:000240266600014
J	Mallawaarachchi, CM; Weissberg, PL; Siow, RCM				Mallawaarachchi, Chandike M.; Weissberg, Peter L.; Siow, Richard C. M.			Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs?	FASEB JOURNAL			English	Article						restenosis; vascular remodeling; balloon angioplasty; PDGF	SMOOTH-MUSCLE-CELLS; FACTOR-B-CHAIN; MATRIX METALLOPROTEINASES; PROGENITOR CELLS; BALLOON INJURY; PDGF; KINASE; INHIBITION; PROLIFERATION; ANGIOPLASTY	Migration of adventitial fibroblasts contributes to vascular remodeling after angioplasty. This study has used perivascular gene transfer of a truncated platelet-derived growth factor PDGF receptor (PDGFXR) to investigate whether antagonism of PDGF signaling alters adventitial cell migration after balloon injury in rat carotid arteries. Adenoviruses coordinating expression of beta-galactosidase (LacZ) and PDGFXR or LacZ and green fluorescent protein (GFP) were applied to the perivascular surface of arteries and balloon injury performed 4 days later. Vessels were excised at 3, 7, and 14 days to determine morphology and gene expression. Uninjured arteries only expressed LacZ positive cells in the adventitial compartment; however, after injury in LacZ and GFP transfected arteries, LacZ positive cells contributed to the population of cells within the media and neointima at 7-14 days. Overexpression of PDGFXR and LacZ resulted in a significant reduction in the number of LacZ labeled cells in the neointima after vascular injury, concomitant with reduced remodeling, collagen content, expression of matrix metalloproteinase-2, and increased levels of tissue inhibitors of metalloproteinase-1 and -2. We provide evidence that perivascular antagonism of PDGF attenuates remodeling and contribution of adventitial fibroblasts to neointima formation after balloon angioplasty. Perivascular gene transfer may represent a therapeutic strategy to reduce the incidence of restenosis.	Kings Coll London, Sch Biomed & Hlth Sci, Div Cardiovasc, London SE1 1UL, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Div Cardiovasc Med, Cambridge, England	University of London; King's College London; Addenbrooke's Hospital; University of Cambridge	Siow, RCM (corresponding author), Kings Coll London, Sch Biomed & Hlth Sci, Div Cardiovasc, Guys Hosp Campus, London SE1 1UL, England.	richard.siow@kcl.ac.uk						Buetow BS, 2003, AM J PATHOL, V163, P979, DOI 10.1016/S0002-9440(10)63457-8; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Deguchi J, 1999, GENE THER, V6, P956, DOI 10.1038/sj.gt.3300918; Dourron HM, 2005, AM J PHYSIOL-HEART C, V288, pH946, DOI 10.1152/ajpheart.00413.2004; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Lambiase PD, 2004, CIRCULATION, V109, P2986, DOI 10.1161/01.CIR.0000130639.97284.EC; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Levitzki A, 2005, CARDIOVASC RES, V65, P581, DOI 10.1016/j.cardiores.2004.08.008; LINDNER V, 1995, CIRC RES, V76, P951, DOI 10.1161/01.RES.76.6.951; Mallawaarachchi CM, 2005, ARTERIOSCL THROM VAS, V25, P1383, DOI 10.1161/01.ATV.0000168415.33812.51; Miyata T, 2005, J CELL PHYSIOL, V204, P948, DOI 10.1002/jcp.20362; Myllarniemi M, 1997, FASEB J, V11, P1119, DOI 10.1096/fasebj.11.13.9367346; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Ohashi N, 2000, ARTERIOSCL THROM VAS, V20, P2521, DOI 10.1161/01.ATV.20.12.2521; Peppel K, 2005, CARDIOVASC RES, V65, P674, DOI 10.1016/j.cardiores.2004.10.031; Pires NMM, 2005, BIOMATERIALS, V26, P5386, DOI 10.1016/j.biomaterials.2005.01.063; Rey FE, 2002, ARTERIOSCL THROM VAS, V22, P1962, DOI 10.1161/01.ATV.0000043452.30772.18; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rutherford C, 1997, ATHEROSCLEROSIS, V130, P45, DOI 10.1016/S0021-9150(96)06042-X; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; Schwartz SM, 1997, J CLIN INVEST, V100, pS87; Shi Y, 1999, ARTERIOSCL THROM VAS, V19, P1150, DOI 10.1161/01.ATV.19.5.1150; Siow RCM, 2003, CARDIOVASC RES, V59, P212, DOI 10.1016/S0008-6363(03)00292-X; Torsney E, 2005, TRENDS CARDIOVAS MED, V15, P64, DOI 10.1016/j.tcm.2005.02.003; Yamasaki Y, 2001, CIRC RES, V88, P630, DOI 10.1161/01.RES.88.6.630	30	18	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1686	+		10.1096/fj.05-5435fje	http://dx.doi.org/10.1096/fj.05-5435fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790526				2022-12-25	WOS:000240266600015
J	Amiri, KI; Ha, HC; Smulson, ME; Richmond, A				Amiri, K. I.; Ha, H. C.; Smulson, M. E.; Richmond, A.			Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1	ONCOGENE			English	Article						PARP-1; CXCL1; NF-kappa B; transcription; melanoma	NF-KAPPA-B; DNA-BINDING; GENE-EXPRESSION; CHROMATIN-STRUCTURE; GRO-ALPHA; ACTIVATION; PARP-1; IL-8; INTERLEUKIN-8; INHIBITION	The continuous production of the CXC ligand 1 ( CXCL1) chemokine by melanoma cells is a major effector of tumor growth. We have previously shown that the constitutive expression of this chemokine is dependent upon transcription factors nuclear factor- kappa B ( NF- kappa B), stimulating protein-1 (SP1), high- mobility group-I/Y ( HMGI/Y), CAAT displacement protein ( CDP) and poly( ADPribose) polymerase- 1 ( PARP-1). In this study, we demonstrate for the first time the mechanism of transcriptional regulation of CXCL1 through PARP-1 in melanoma cells. In its inactive state, PARP- 1 binds to the CXCL1 promoter in a sequence-specific manner and prevents binding of NF- kappa B ( p65/ p50) to its element. However, activation of the PARP- 1 enzymatic activity enhances CXCL1 expression, owing to the loss of PARP1 binding to the CXCL1 promoter, accompanied by enhanced binding of p65 to the promoter. The delineation of the role of NF-kappa B- interacting factors in the putative CXCL1 enhanceosome will provide key information in developing strategies to block constitutive expression of this and other chemokines in cancer and to develop targeted therapy.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Vet Affairs, Nashville, TN 37232 USA; Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA; Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA	Vanderbilt University; Vanderbilt University; Meharry Medical College; Georgetown University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 771 PRB,23rd Ave S Pierce, Nashville, TN 37232 USA.	ann.richmond@vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [P01CA-74175, CA-56704, R01 CA116021, R01 CA116021-03, R01 CA116021-02] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116021, R01CA056704, P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Gonzalez R, 1999, J BIOL CHEM, V274, P32122, DOI 10.1074/jbc.274.45.32122; BALENTIEN E, 1991, ONCOGENE, V6, P1115; Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cayuela ML, 2001, BIOCHEM BIOPH RES CO, V285, P289, DOI 10.1006/bbrc.2001.5178; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Ha HC, 2004, P NATL ACAD SCI USA, V101, P5087, DOI 10.1073/pnas.0306895101; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Huang K, 2004, BIOCHEMISTRY-US, V43, P217, DOI 10.1021/bi0301800; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Keane MP, 1997, J IMMUNOL, V159, P1437; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Li AH, 2001, CLIN CANCER RES, V7, P3298; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Olbina G, 1996, ANTICANCER RES, V16, P3525; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Richards BL, 1997, AM J SURG, V174, P507; Schadendorf D, 1996, BRIT J CANCER, V74, P194, DOI 10.1038/bjc.1996.337; Schadendorf M, 1994, J IMMUNOL, V153, P3360; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2003, CURR TOP DEV BIOL, V56, P55, DOI 10.1016/S0070-2153(03)01007-X; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Yang JM, 2001, CANCER RES, V61, P4901; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	36	43	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7714	7722		10.1038/sj.onc.1209751	http://dx.doi.org/10.1038/sj.onc.1209751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799643	Green Accepted			2022-12-25	WOS:000242830800006
J	David, G; Dannenberg, JH; Simpson, N; Finnerty, PM; Miao, L; Turner, GM; Ding, Z; Carrasco, R; DePinho, RA				David, G.; Dannenberg, J. -H.; Simpson, N.; Finnerty, P. M.; Miao, L.; Turner, G. M.; Ding, Z.; Carrasco, R.; DePinho, R. A.			Haploinsufficiency of the mSds3 chromatin regulator promotes chromosomal instability and cancer only upon complete neutralization of p53	ONCOGENE			English	Article						mSin3; chromatin; histone deacetylase; mouse model; aneuploidy; p53	PERICENTRIC HETEROCHROMATIN; DEACETYLASE COMPLEX; COREPRESSOR COMPLEX; INTEGRAL COMPONENT; MAMMALIAN-CELLS; ACETYLATION; SUPPRESSOR; GROWTH; MICE; CARCINOGENESIS	The mSin3 corepressor complex has been linked to diverse cancer signaling pathways through its capacity to regulate target gene expression via chromatin modification. mSds3, a cell essential gene, is a key component of the mSin3 complex serving to maintain its inherent histone deacetylase activity. mSds3 also serves an essential role in the establishment of pericentric heterochromatin, and genetic ablation of mSds3 results in chromosome mis-segregation. In contrast, mSin3A nullizygous cells show normal chromosome dynamics and cytogenetic profiles. The integral role of mSds3 in controlling chromosome segregation and mSin3-regulated transcriptional networks prompted efforts to determine the neoplastic impact of loss of one copy of mSds3 or mSin3A. In particular, we assessed whether loss of one copy of mSds3, alone or in combination with p53 mutation, results in aneuploidy and promotes a cancer-prone condition in the mouse. We observe that, in a p53 null background, loss of one mSds3 allele results in accelerated tumor onset and increased tumor burden. Notably, these mSds3(+/-) p53(-/-) tumors exhibit a more complex cytogenetic profile characterized by marked aneuploidy and centromeric associations. The presence of even one copy of p53 is sufficient to suppress the accelerated tumorigenesis in mSds3(+/-) mice, consistent with a key role for p53 in monitoring mitotic fidelity. These observations with Sds3 mutant mice contrast with mSin3A(+/-) p53(-/-) mice, which do not show an accelerated or increased tumor incidence relative to mSin3A(+/+) p53(-/-) controls, correlating with the absence of aneuploidy detected upon mSin3A genetic inactivation. This genetic study establishes that the capacity of mSds3 to cooperate with p53 deficiency in cancer predisposition relates to its specific role in chromosome segregation, rather than its central role in maintaining a functional mSin3A complex.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; New York University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bunz F, 2002, CANCER RES, V62, P1129; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cowley SM, 2005, MOL CELL BIOL, V25, P6990, DOI 10.1128/MCB.25.16.6990-7004.2005; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Dorland S, 2000, GENETICS, V154, P573; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kalitsis P, 2005, GENE CHROMOSOME CANC, V44, P29, DOI 10.1002/gcc.20215; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Maser RS, 2003, CANCER CELL, V3, P4, DOI 10.1016/S1535-6108(02)00243-X; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200	26	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7354	7360		10.1038/sj.onc.1209734	http://dx.doi.org/10.1038/sj.onc.1209734			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767157				2022-12-25	WOS:000242419100004
J	Yang, Y; Pan, X; Lei, W; Wang, J; Song, J				Yang, Y.; Pan, X.; Lei, W.; Wang, J.; Song, J.			Transforming growth factor-beta 1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism	ONCOGENE			English	Article						PKD; EMT; cell cycle; TGF-beta; apoptosis; signaling	PROTEIN-KINASE-D; GROWTH-FACTOR-BETA; CONFERS RESISTANCE; TRANSDIFFERENTIATION; ACTIVATION; PLASTICITY; MIGRATION; P38; HEPATOCYTES; PROGRESSION	Apoptosis and epithelial-to-mesenchymal transition (EMT) have been implicated in a variety of biological processes, such as embryonic development, fibrosis and tumor progression. Transforming growth factor-beta (TGF-beta) can induce simultaneously both EMT and apoptotic response of epithelial cells. However, the underlying mechanism of these biological events remains not well understood. In the present study, we show that TGF-beta 1 induces apoptosis and EMT in AML-12 cells in a cell cycle-related manner, in which apoptosis and EMT took place at G2/M and G1/S phases, respectively. TGF-beta 1-induced apoptosis was correlated with different extent of caspase activation at different cell cycle phases. Interestingly, increased phosphorylation of protein kinase D (PKD) can be observed in G1/S phase in response to TGF-beta 1, and inhibition of PKD by inhibitor or by small interference RNA blocked EMT but not apoptosis. Our data suggest a previously unrecognized role of cell cycle state in the regulation of TGF-beta-induced EMT and apoptosis, and demonstrate that PKD is involved in the TGF-beta 1-induced EMT.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Song, J (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jgsong@sibs.ac.cn	Yang, Yanan/F-1592-2010; Lei, Weiwei/H-4997-2012					Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bollag WB, 2004, DRUG NEWS PERSPECT, V17, P117, DOI 10.1358/dnp.2004.17.2.829045; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Piek E, 1999, J CELL SCI, V112, P4557; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; Valdes F, 2002, MOL CANCER RES, V1, P68; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Yang Y, 2004, INT J BIOCHEM CELL B, V36, P223, DOI 10.1016/S1357-2725(03)00215-2; Zhao S, 2004, J CELL PHYSIOL, V199, P47, DOI 10.1002/jcp.10453	32	84	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7235	7244		10.1038/sj.onc.1209712	http://dx.doi.org/10.1038/sj.onc.1209712			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16799646				2022-12-25	WOS:000242244700002
J	Joyce, MG; Levy, C; Gabor, K; Pop, SM; Biehl, BD; Doukov, TI; Ryter, JM; Mazon, H; Smidt, H; van den Heuvel, RHH; Ragsdale, SW; van der Oost, J; Leys, D				Joyce, M. Gordon; Levy, Colin; Gabor, Krisztina; Pop, Stelian M.; Biehl, Benjamin D.; Doukov, Tzanko I.; Ryter, Jodi M.; Mazon, Hortense; Smidt, Hauke; van den Heuvel, Robert H. H.; Ragsdale, Stephen W.; van der Oost, John; Leys, David			CprK crystal structures reveal mechanism for transcriptional control of halorespiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; PROTEIN; CAMP; PURIFICATION; REGULATOR; CHLORINE; LIGAND; ENZYME	Halorespiration is a bacterial respiratory process in which haloorganic compounds act as terminal electron acceptors. This process is controlled at transcriptional level by CprK, a member of the ubiquitous CRP-FNR family. Here we present the crystal structures of oxidized CprK in presence of the ligand orthochlorophenolacetic acid and of reduced CprK in absence of this ligand. These structures reveal that highly specific binding of chlorinated, rather than the corresponding non-chlorinated, phenolic compounds in the NH2-terminal beta-barrels causes reorientation of these domains with respect to the central alpha-helix at the dimer interface. Unexpectedly, the COOH-terminal DNA-binding domains dimerize in the non-DNA binding state. We postulate the ligand-induced conformational change allows formation of interdomain contacts that disrupt the DNA domain dimer interface and leads to repositioning of the helix-turn-helix motifs. These structures provide a structural framework for further studies on transcriptional control by CRP-FNR homologs in general and of halorespiration regulation by CprK in particular.	Manchester Interdisciplinary Bioctr, Manchester M60 1QD, Lancs, England; Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; Nebraska Wesleyan Univ, Dept Chem, Lincoln, NE 68504 USA; Univ Utrecht, Bijvoet Ctr, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands	University of Manchester; Wageningen University & Research; University of Nebraska System; University of Nebraska Lincoln; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Utrecht University; Utrecht University	Leys, D (corresponding author), Manchester Interdisciplinary Bioctr, POB 88, Manchester M60 1QD, Lancs, England.	david.leys@manchester.ac.uk	van+der+Oost, John/Y-2548-2019; Smidt, Hauke/D-7054-2014	Smidt, Hauke/0000-0002-6138-5026; Doukov, Tzanko/0000-0001-8625-2572; Levy, Colin/0000-0002-9724-310X	Biotechnology and Biological Sciences Research Council [BB/C00521X/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; Boyer A, 2003, BIOCHEM J, V373, P297, DOI 10.1042/BJ20021837; Chen R, 2003, J BIOL CHEM, V278, P13235, DOI 10.1074/jbc.M211551200; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Eiting M, 2005, MOL MICROBIOL, V56, P433, DOI 10.1111/j.1365-2958.2005.04561.x; El Fantroussi S, 1998, BIOTECHNOL PROGR, V14, P167, DOI 10.1021/bp980011k; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Furukawa K, 2003, TRENDS BIOTECHNOL, V21, P187, DOI 10.1016/S0167-7799(03)00054-4; Gabor K, 2006, J BACTERIOL, V188, P2604, DOI 10.1128/JB.188.7.2604-2613.2006; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; HENSCHLER D, 1994, ANGEW CHEM INT EDIT, V33, P1920, DOI 10.1002/anie.199419201; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Korner H, 2003, FEMS MICROBIOL REV, V27, P559, DOI 10.1016/S0168-6445(03)00066-4; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lawson CL, 2004, CURR OPIN STRUC BIOL, V14, P10, DOI 10.1016/j.sbi.2004.01.012; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Oberg G, 2002, APPL MICROBIOL BIOT, V58, P565, DOI 10.1007/s00253-001-0895-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palfey BA, 1999, BIOCHEMISTRY-US, V38, P1153, DOI 10.1021/bi9826613; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Pop SM, 2004, J BIOL CHEM, V279, P49910, DOI 10.1074/jbc.M409435200; RIGAKU MSC, 1999, CRYSAL CLEAR PROGRAM; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SHABB JB, 1992, J BIOL CHEM, V267, P5723; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; Tibbs GR, 1998, J BIOL CHEM, V273, P4497, DOI 10.1074/jbc.273.8.4497; van de Pas BA, 2001, APPL ENVIRON MICROB, V67, P3958, DOI 10.1128/AEM.67.9.3958-3963.2001; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; Villemur R, 2002, CAN J MICROBIOL, V48, P697, DOI 10.1139/w02-057; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yu SN, 2004, BIOCHEMISTRY-US, V43, P4662, DOI 10.1021/bi0362166	40	30	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2006	281	38					28318	28325		10.1074/jbc.M602654200	http://dx.doi.org/10.1074/jbc.M602654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	084LM	16803881	Green Published, hybrid			2022-12-25	WOS:000240534400069
J	Andriotis, VME; Rathjen, JP				Andriotis, Vasilios M. E.; Rathjen, John P.			The Pto kinase of tomato, which regulates plant immunity, is repressed by its myristoylated N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE RESISTANCE; III EFFECTOR; HYPERSENSITIVE RESPONSE; ARABIDOPSIS-THALIANA; SIGNAL-TRANSDUCTION; PEPTIDE SUBSTRATE; STRUCTURAL BASIS; FATTY ACYLATION; PROTEIN-KINASES; PLASMA-MEMBRANE	Specific recognition of the Pseudomonas syringae effector proteins AvrPto and AvrPtoB in tomato is mediated by Pto kinase resulting in induction of defense responses, including hypersensitive cell death via a signaling pathway requiring the nucleotide-binding leucine-rich repeats protein Prf. Pto is a myristoylated protein, and N-myristoylation is required for signaling. Here we demonstrated a role for Nmyristoylation in controlling Pto kinase activity. A myristoylated peptide corresponding to Pto residues 2 10 significantly impaired the kinase activity of Ntruncated Pto. We show that kinase inhibition was specific to the myristoylated form of the peptide and that free myristate supplied in trans was a potent suppressor of Pto kinase activity. Thus, myristate, but not Pto residues 2 10, contributes to suppression of kinase activity in vitro. Accordingly, elimination of the in vivo myristoylation potential of Pto derepressed kinase activity. The increased potency of free myristate relative to the myristoylated Npeptide inhibitor suggested that the peptide moiety is antagonistic to repression by myristate. Suppression of related protein kinases by myristate declined with similarity to Pto, and the inhibitory activity could be attributed to hydrophobicity. We present evidence that inhibition of Pto by the myristoylated Npeptide is mediated through a previously identified surface regulatory patch. The data show a role for negative regulation of Pto by Nmyristoylation, in addition to the previously demonstrated positive role, and are consistent with a model in which the acylated N terminus is sequestered in the catalytic cleft prior to release by Pto activation.	John Innes Inst, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Rathjen, JP (corresponding author), John Innes Inst, Sainsbury Lab, Coloney Lane,Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	john.rathjen@sainsbury-laboratory.ac.uk	rathjen, john p/C-9327-2009	rathjen, john p/0000-0003-4073-8088; Andriotis, Vasilios/0000-0003-2304-843X				Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Boisson B, 2003, J BIOL CHEM, V278, P43418, DOI 10.1074/jbc.M307321200; Chang JH, 2002, MOL PLANT MICROBE IN, V15, P281, DOI 10.1094/MPMI.2002.15.3.281; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; de Vries JS, 2006, PLANT J, V45, P31, DOI 10.1111/j.1365-313X.2005.02590.x; del Pozo O, 2004, EMBO J, V23, P3072, DOI 10.1038/sj.emboj.7600283; Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Matsubara M, 2003, J BIOL CHEM, V278, P48898, DOI 10.1074/jbc.M305488200; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Qi QG, 2000, J BIOL CHEM, V275, P9673, DOI 10.1074/jbc.275.13.9673; Ramdas L, 1999, J PEPT RES, V53, P569, DOI 10.1034/j.1399-3011.1999.00063.x; Rathjen JP, 2003, CURR OPIN PLANT BIOL, V6, P300, DOI 10.1016/S1369-5266(03)00057-8; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Sessa G, 1998, J BIOL CHEM, V273, P15860, DOI 10.1074/jbc.273.25.15860; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Shao F, 2003, SCIENCE, V301, P1230, DOI 10.1126/science.1085671; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Wu AJ, 2004, PLANT CELL, V16, P2809, DOI 10.1105/tpc.104.024141; Yoshida S, 2005, J BIOL CHEM, V280, P9203, DOI 10.1074/jbc.M411665200; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	35	15	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26578	26586		10.1074/jbc.M603197200	http://dx.doi.org/10.1074/jbc.M603197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16785235	Green Published, hybrid			2022-12-25	WOS:000240249500076
J	Thomas, AV; Herl, L; Spoelgen, R; Hiltunen, M; Jones, PB; Tanzi, RE; Hyman, BT; Berezovska, O				Thomas, Anne V.; Herl, Lauren; Spoelgen, Robert; Hiltunen, Mikko; Jones, Phill B.; Tanzi, Rudolph E.; Hyman, Bradley T.; Berezovska, Oksana			Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; MEMBRANE TOPOLOGY; SEL-12 PRESENILIN; ENDOPROTEOLYSIS; CONFORMATION; ASSOCIATION; NICASTRIN	Presenilin 1 (PS1) in its active heterodimeric form is the catalytic center of the gamma-secretase complex, an enzymatic activity that cleaves amyloid precursor protein (APP) to produce amyloid beta (A beta). Ubiquilin 1 is a recently described PS1 interacting protein, the overexpression of which increases PS1 holoprotein levels and leads to reduced levels of functionally active PS1 heterodimer. In addition, it has been suggested that splice variants of the UBQLN1 gene are associated with an increased risk of developing Alzheimer disease ( AD). However, it is still unclear whether PS1 and ubiquilin 1 interact when expressed at endogenous levels under normal physiological conditions. Here, we employ three novel fluorescence resonance energy transfer-based techniques to investigate the interaction between PS1 and ubiquilin 1 in intact cells. We consistently find that the ubiquilin 1N terminus is in close proximity to several epitopes on PS1. We show that ubiquilin 1 interacts both with PS1 holoprotein and heterodimer and that the interaction between PS1 and ubiquilin 1 takes place near the cell surface. Furthermore, we show that the PS1-ubiquilin 1 interaction can be detected between endogenous proteins in primary neurons in vitro as well as in brain tissue of healthy controls and Alzheimer disease patients, providing evidence of its physiological relevance.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Berezovska, O (corresponding author), Dept Neurol, Alzheimers Unit, 114 16th St, Charlestown, MA 02129 USA.	oberezovska@partners.org	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454; Jones, Phill/0000-0003-0525-6323	NATIONAL INSTITUTE ON AGING [P01AG015379] Funding Source: NIH RePORTER; NIA NIH HHS [5 P01 AG015379-08] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Berezovska O, 2005, J NEUROSCI, V25, P3009, DOI 10.1523/JNEUROSCI.0364-05.2005; Berezovska O, 2003, J NEUROSCI, V23, P4560; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Brouwers N, 2006, NEUROSCI LETT, V392, P72, DOI 10.1016/j.neulet.2005.08.064; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; Cervantes S, 2004, J BIOL CHEM, V279, P36519, DOI 10.1074/jbc.M404832200; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Herl L, 2006, BIOCHEM BIOPH RES CO, V340, P668, DOI 10.1016/j.bbrc.2005.12.063; JONES PJ, 2006, IN PRESS J BIOMED OP; Kamboh MI, 2006, MOL PSYCHIATR, V11, P273, DOI 10.1038/sj.mp.4001775; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Laudon H, 2004, J BIOL CHEM, V279, P23925, DOI 10.1074/jbc.M401277200; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Mah AL, 2000, J CELL BIOL, V151, P847, DOI 10.1083/jcb.151.4.847; Massey LK, 2005, BIOCHEM J, V391, P513, DOI 10.1042/BJ20050491; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Periz G, 2004, J NEUROSCI RES, V77, P309, DOI 10.1002/jnr.20203; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Slifer MA, 2005, NEW ENGL J MED, V352, P2752; Smemo S, 2006, ANN NEUROL, V59, P21, DOI 10.1002/ana.20673; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	32	19	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26400	26407		10.1074/jbc.M601085200	http://dx.doi.org/10.1074/jbc.M601085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16815845	hybrid			2022-12-25	WOS:000240249500057
J	Wang, Q; Lu, RJ; Zhao, JL; Limbird, LE				Wang, Qin; Lu, Roujian; Zhao, Jiali; Limbird, Lee E.			Arrestin serves as a molecular switch, linking endogenous alpha 2-adrenergic receptor to SRC-dependent, but not SRC-independent, ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR; PHOSPHODIESTERASE ACTIVATION; ALPHA(2A)-ADRENERGIC RECEPTOR; CLATHRIN ADAPTER; C-SRC; ENDOCYTOSIS; PHOSPHORYLATION	Our previous studies have demonstrated that neither receptor endocytosis nor arrestin is required for ERK activation by the alpha(2)-adrenergic receptor (Wang, Q., Zhao, J., Brady, A. E., Feng, J., Allen, P. B., Lefkowitz, R. J., Greengard, P., and Limbird, L. E. (2004) Science 304, 1940 -1944). The present studies address whether arrestin plays a role in determining the route of alpha(2)AR-evoked ERK signaling activation, taking advantage of endogenous expression of the alpha(2A)AR subtype in mouse embryonic fibroblasts (MEFs) and the availability of MEFs without arrestin expression (derived from Arr2,3(-/)-mice). Our data demonstrate that the endogenous alpha(2A)AR evokes ERK phosphorylation through both a Src-dependent and a Src-independent pathway, both of which are G protein dependent and converge on the Ras-Raf-MEK pathway. Arrestin is essential to recruit Src to this process, as alpha(2A)AR-mediated ERK signaling in Arr2,3(-/)-MEFs does not involve Src. Stimulation of alpha(2A)AR enhances arrestin-Src interaction and promotes activation of Src. alpha(2) agonists have similar potencies in stimulating Src-dependent and Src-independent ERK phosphorylation in wild-type and Arr2,3(-/)-cells, respectively. However, Src-independent alpha(2A)AR-mediated ERK stimulation has both a longer duration of activation and a more rapid translocation of pERK into the nucleus when compared with Src-dependent activation. These data not only affirm the role of arrestin as an escort for signaling molecules such as Src family kinases but also demonstrate the impact of arrestin-dependent modulation on both the temporal and spatial properties of ERK activation.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Meharry Med Coll, Dept Biomed Sci, Nashville, TN 37208 USA	University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Meharry Medical College	Wang, Q (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 958 MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.	qwang@uab.edu		Wang, Qin/0000-0002-1079-5914	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL25182] Funding Source: Medline; NICHD NIH HHS [HD15052] Funding Source: Medline; NIDDK NIH HHS [DK58404, DK43879, DK20593] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD015052] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK043879, P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Beom SR, 2004, J BIOL CHEM, V279, P28304, DOI 10.1074/jbc.M403899200; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Edwards SW, 1999, J BIOL CHEM, V274, P16331, DOI 10.1074/jbc.274.23.16331; FAURE M, 1994, J BIOL CHEM, V269, P7851; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Irby RB, 2002, CANCER RES, V62, P2669; KENAKIN TP, 1984, BRIT J PHARMACOL, V81, P131, DOI 10.1111/j.1476-5381.1984.tb10753.x; Lai YJ, 2005, MOL CELL BIOL, V25, P5859, DOI 10.1128/MCB.25.14.5859-5868.2005; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oomen SPMA, 2001, FEBS LETT, V503, P163, DOI 10.1016/S0014-5793(01)02729-6; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; Tan CM, 2002, P NATL ACAD SCI USA, V99, P12471, DOI 10.1073/pnas.122368499; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Werry TD, 2005, J NEUROCHEM, V93, P1603, DOI 10.1111/j.1471-4159.2005.03161.x; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; ZUCKERMAN R, 1986, FEBS LETT, V207, P35, DOI 10.1016/0014-5793(86)80008-4	46	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25948	25955		10.1074/jbc.M605415200	http://dx.doi.org/10.1074/jbc.M605415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16809338	hybrid			2022-12-25	WOS:000240249500009
J	Hontz, JS; Villar-Lecumberri, MT; Potter, BM; Yoder, MD; Dreyfus, LA; Laity, JH				Hontz, Jill S.; Villar-Lecumberri, Maria T.; Potter, Belinda M.; Yoder, Marilyn D.; Dreyfus, Lawrence A.; Laity, John H.			Differences in crystal and solution structures of the cytolethal distending toxin B subunit - Relevance to nuclear translocation and functional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI CDTB; MODEL-FREE APPROACH; CELL-CYCLE ARREST; BACKBONE DYNAMICS; CRYSTALLOGRAPHIC ANALYSIS; LOCALIZATION SEQUENCES; BACTERIAL GENOTOXIN; DEOXYRIBONUCLEASE-I	Cytolethal distending toxin (CDT) induces cell cycle arrest and apoptosis in eukaryotic cells, which are mediated by the DNA-damaging CdtB subunit. Here we report the first x-ray structure of an isolated CdtB subunit (Escherichia coli-II CdtB, EcCdtB). In conjunction with previous structural and biochemical observations, active site structural comparisons between free and holotoxin-assembled CdtBs suggested that CDT intoxication is contingent upon holotoxin disassembly. Solution NMR structural and N-15 relaxation studies of free EcCdtB revealed disorder in the interface with the CdtA and CdtC subunits (residues Gly(233)-Asp(242)). Residues Leu(186)-Thr(209) of EcCdtB, which encompasses tandem arginine residues essential for nuclear translocation and intoxication, were also disordered in solution. In stark contrast, nearly identical well defined alpha-helix and beta-strand secondary structures were observed in this region of the free and holotoxin CdtB crystallographic models, suggesting that distinct changes in structural ordering characterize subunit disassembly and nuclear localization factor binding functions.	Univ Missouri, Dept Cell Biol & Biophys, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Laity, JH (corresponding author), Univ Missouri, Dept Cell Biol & Biophys, Sch Biol Sci, 5007 Rockhill Rd,103 BSB, Kansas City, MO 64110 USA.	laityj@umkc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047999] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 047999] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aragon V, 1997, INFECT IMMUN, V65, P3774, DOI 10.1128/IAI.65.9.3774-3780.1997; Arnold, 2001, CRYSTALLOGRAPHY BIOL, P720; BRAUN D, 1994, J AM CHEM SOC, V116, P8466, DOI 10.1021/ja00098a005; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cortes-Bratti X, 2000, INFECT IMMUN, V68, P6903, DOI 10.1128/IAI.68.12.6903-6911.2000; De Rycke J, 2001, FEMS MICROBIOL LETT, V203, P141, DOI 10.1016/S0378-1097(01)00344-5; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; DREYFUS LA, 2003, BACTERIAL PROTEIN TO, P257; Elwell C, 2001, INFECT IMMUN, V69, P3418, DOI 10.1128/IAI.69.5.3418-3422.2001; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; Fontes MRM, 2003, BIOCHEM J, V375, P339, DOI 10.1042/BJ20030510; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Guerra L, 2005, CELL MICROBIOL, V7, P921, DOI 10.1111/j.1462-5822.2005.00520.x; GUEX N, 2006, PROTEIN DATA BANK Q, V77, P7; Hontz JS, 2006, ACTA CRYSTALLOGR F, V62, P192, DOI 10.1107/S1744309106002454; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lara-Tejero M, 2001, INFECT IMMUN, V69, P4358, DOI 10.1128/IAI.69.7.4358-4365.2001; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; McSweeney LA, 2004, CELL MICROBIOL, V6, P447, DOI 10.1111/j.1462-5822.2004.00373.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nesic D, 2004, NATURE, V429, P429, DOI 10.1038/nature02532; Nishikubo S, 2003, J BIOL CHEM, V278, P50671, DOI 10.1074/jbc.M305062200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pickett CL, 1999, TRENDS MICROBIOL, V7, P292, DOI 10.1016/S0966-842X(99)01537-1; PICKETT CL, 1994, INFECT IMMUN, V62, P1046, DOI 10.1128/IAI.62.3.1046-1051.1994; Potter BM, 2005, J BIOL CHEM, V280, P28529, DOI 10.1074/jbc.M505217200; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; VILLARLECUMBERR.M, 2006, J BIOMOL NMR, V34; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Yamada T, 2006, PROTEIN SCI, V15, P362, DOI 10.1110/ps.051790506; [No title captured]	46	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25365	25372		10.1074/jbc.M603727200	http://dx.doi.org/10.1074/jbc.M603727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809347	hybrid			2022-12-25	WOS:000240031300038
J	Madureira, PA; Varshochi, R; Constantinidou, D; Francis, RE; Coombes, RC; Yao, KM; Lam, EWF				Madureira, Patricia A.; Varshochi, Rana; Constantinidou, Demetra; Francis, Richard E.; Coombes, R. Charles; Yao, Kwok-Ming; Lam, Eric W. -F.			The forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ACTIVATION; BETA; PROLIFERATION; MECHANISM; FOXO3A; FOXM1; IDENTIFICATION; INHIBITION; THERAPY	In this study, we have identified the Forkhead transcription factor FoxM1 as a physiological regulator of estrogen receptor alpha (ER alpha) expression in breast carcinoma cells. Our survey of a panel of 16 different breast cell lines showed a good correlation (13/16) between FoxM1 expression and expression of ER alpha at both protein and mRNA levels. We have also demonstrated that ectopic expression of FoxM1 in two different estrogen receptor positive breast cancer cell lines, MCF-7 and ZR-75-30, led to up-regulation of ER alpha expression at protein and transcript levels. Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ER alpha expression. Consistent with this, silencing of FoxM1 expression in MCF-7 cells using small interfering RNA resulted in the almost complete abrogation of ER alpha expression. We also went on to show that FoxM1 can activate the transcriptional activity of human ER alpha promoter primarily through two closely located Forkhead response elements located at the proximal region of the ER alpha promoter. Chromatin immunoprecipitation and biotinylated oligonucleotide pulldown assays have allowed us to confirm these Forkhead response elements as important for FoxM1 binding. Further co-immunoprecipitation experiments showed that FoxO3a and FoxM1 interact in vivo. Together with the chromatin immunoprecipitation and biotinylated oligonucleotide pulldown data, the co-immunoprecipitation results also suggest the possibility that FoxM1 and FoxO3a cooperate to regulate ER alpha gene transcription.	Hammersmith Hosp, Canc Res United Kingdom Labs, Dept Oncol, MRC,Imperial Coll London, London W12 0NN, England; Univ Hong Kong, Dept Biochem, Pokfulam, Hong Kong, Peoples R China	Cancer Research UK; Imperial College London; University of Hong Kong	Lam, EWF (corresponding author), Hammersmith Hosp, Canc Res United Kingdom Labs, Dept Oncol, MRC,Imperial Coll London, Du Cane Rd,Cyclotron Bldg, London W12 0NN, England.	eric.lam@imperial.ac.uk	Yao, Kwok Ming/C-4457-2009; Madureira, Patricia/F-4656-2012; Lam, Eric W-F/AAW-8566-2020; Madureira, Patricia A/C-9666-2013	Madureira, Patricia/0000-0002-4856-3908; Lam, Eric W-F/0000-0003-1274-3576; Madureira, Patricia A/0000-0002-4856-3908; Coombes, Raoul Charles/0000-0002-4811-1100	Engineering and Physical Sciences Research Council [GR/S45713/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Altucci L, 1996, ONCOGENE, V12, P2315; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Clarke RB, 1997, CANCER RES, V57, P4987; COOMBES RC, 1987, LANCET, V2, P701; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dimitrakakis C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1374; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DUBIK D, 1992, ONCOGENE, V7, P1587; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Geum DH, 1997, MOL REPROD DEV, V46, P450, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;450::AID-MRD2&gt;3.0.CO;2-N; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004; Gustafsson JA, 2000, J STEROID BIOCHEM, V74, P245, DOI 10.1016/S0960-0760(00)00130-8; Hayashi S, 1997, CARCINOGENESIS, V18, P459, DOI 10.1093/carcin/18.3.459; Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kushner P J, 2000, Novartis Found Symp, V230, P20, DOI 10.1002/0470870818.ch3; Laganiere J, 2005, MOL ENDOCRINOL, V19, P1584, DOI 10.1210/me.2005-0040; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; RICKETTS D, 1991, CANCER RES, V51, P1817; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seo HS, 2002, J STEROID BIOCHEM, V80, P109, DOI 10.1016/S0960-0760(01)00175-3; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; TAYLOR RE, 1982, BRIT J CANCER, V45, P80, DOI 10.1038/bjc.1982.10; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097	37	138	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25167	25176		10.1074/jbc.M603906200	http://dx.doi.org/10.1074/jbc.M603906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809346	hybrid			2022-12-25	WOS:000240031300017
J	Mullin, MJ; Lightfoot, K; Marklund, U; Cantrell, DA				Mullin, Michael J.; Lightfoot, Kurt; Marklund, Ulrica; Cantrell, Doreen A.			Differential requirement for RhoA GTPase depending on the cellular localization of protein kinase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOCYTE DEVELOPMENT; IN-VIVO; RECEPTOR ACTIVATION; PHORBOL ESTERS; NUCLEAR EXPORT; T-CELLS; D PKD; C-MU; EXPRESSION; SIGNALS	This study explores the links between the GTPase RhoA and the serine kinase protein kinase D (PKD) during thymocyte development. The rationale is that RhoA and PKD regulate common biological responses during T cell development, but there is nothing known about their interdependence. In fibroblasts, Rho function is required for activation of PKD catalytic activity. However, the data show that activation of Rho is neither sufficient nor essential for PKD activation in T cells. One alternative explanation for the apparent convergence of PKD and Rho signaling in T cells is that PKD responses might be Rho-dependent. To address this latter possibility, we probed the Rho requirements for the actions of constitutively active PKD mutants in pre-T cells of transgenic mice. Active PKD can localize to either the plasma membrane or the cytosol, and we therefore compared the Rho requirements for the actions of membrane- or cytosol-localized PKD. Here we show that membrane-localized PKD regulation of pre-T cell differentiation is Rho-dependent, but the actions of cytosol-localized PKD are not. These studies demonstrate that a Rho requirement for PKD activation is not ubiquitous. Moreover, links between PKD and Rho are determined by the cellular location of PKD.	Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Gothenburg, Dept Clin Immunol, S-41346 Gothenburg, Sweden	University of Dundee; University of Gothenburg	Cantrell, DA (corresponding author), Univ Dundee, Div Cell Biol & Immunol, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	d.a.cantrell@dundee.ac.uk		Cantrell, Doreen/0000-0001-7525-3350	Wellcome Trust [GR065975] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254-004-0034-4; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Cleverley S, 1999, CURR BIOL, V9, P657, DOI 10.1016/S0960-9822(99)80289-9; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Genth H, 2003, J BIOL CHEM, V278, P28523, DOI 10.1074/jbc.M301915200; GODFREY DI, 1994, J IMMUNOL, V152, P4783; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Henning SW, 1998, J EXP MED, V188, P931, DOI 10.1084/jem.188.5.931; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Medeiros RB, 2005, IMMUNITY, V23, P213, DOI 10.1016/j.immuni.2005.07.006; Michie AM, 2002, SEMIN IMMUNOL, V14, P311, DOI 10.1016/S1044-5323(02)00064-7; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Song J, 2006, AM J PHYSIOL-CELL PH, V290, pC1469, DOI 10.1152/ajpcell.00486.2005; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Vielkind S, 2005, J IMMUNOL, V175, P350, DOI 10.4049/jimmunol.175.1.350; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; von Boehmer H, 1999, COLD SPRING HARB SYM, V64, P283, DOI 10.1101/sqb.1999.64.283; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wood CD, 2005, J BIOL CHEM, V280, P6245, DOI 10.1074/jbc.M411564200; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200	43	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25089	25096		10.1074/jbc.M603591200	http://dx.doi.org/10.1074/jbc.M603591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16772297	hybrid			2022-12-25	WOS:000240031300010
J	Tsai, TT; Danielson, KG; Guttapalli, A; Oguz, E; Albert, TJ; Shapiro, IM; Risbud, MV				Tsai, Tsung-Ting; Danielson, Keith G.; Guttapalli, Asha; Oguz, Erbil; Albert, Todd J.; Shapiro, Irving M.; Risbud, Makarand V.			TonEBP/OREBP is a regulator of nucleus pulposus cell function and survival in the intervertebral disc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN OREBP; STIMULATES TRANSCRIPTION; OSMOTIC-STRESS; EXPRESSION; GENE; NFAT5; IDENTIFICATION; DIFFUSION; SOLUTES; CULTURE	The nucleus pulposus is an aggrecan-rich hydrated tissue that permits the intervertebral disc to resist compressive loads. Adaptation to loading is achieved through an elevation in disc osmolarity mediated by the numerous charged glycosoaminoglycan side chains of the aggrecan molecule. The goal of this investigation was to determine the functional role of the osmoregulatory protein, TonEBP, in cells of the nucleus pulposus. We found that TonEBP and its downstream target genes were robustly expressed in the tissues of the disc. Above 330 mosmol/kg, cultured nucleus pulposus cells up-regulated target genes TauT, BGT-1, and SMIT; above 450 mosmol/kg, there was raised expression of HSP-70. In hypertonic media there was activation of TauT and heat shock protein-70 (HSP-70) reporter activity and increased binding of TonEBP to the TonE motif. When cells were transfected with the dominant-negative form of TonEBP (DN-TonEBP) there was suppression of TauT and HSP-70 reporter gene expression; pTonEBP enhanced reporter gene expression. Moreover, in hypertonic media, forced expression of DN-TonEBP induced apoptosis. We suppressed TonEBP using small interfering RNA technique and noted a decrease in TauT reporter activity in isotonic as well as hyperosmolar media. Finally, we report that the aggrecan promoter contains two conserved TonE motifs. To evaluate the importance of these motifs, we overexpressed DN-TonEBP and partially silenced TonEBP using small interfering RNA. Both approaches resulted in suppression of aggrecan promoter activity. It is concluded that TonEBP permits the disc cells to adapt to the hyperosmotic milieu while autoregulating the expression of molecules that generate the unique extracellular environment.	Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Chang Gung Univ, Chang Gung Mem Hosp, Dept Orthopaed Surg, Taoyuan 33305, Taiwan; Gulhane Mil Med Acad, Dept Orthopaed & Traumatol, TR-06018 Ankara, Turkey	Jefferson University; Chang Gung Memorial Hospital; Chang Gung University; Gulhane Military Medical Academy	Risbud, MV (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 1015 Walnut St,Suite 501 Curtis Bldg, Philadelphia, PA 19107 USA.	makarand.risbud@jefferson.edu		Tsai, Tsung-Ting/0000-0002-7776-7627	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050087] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR050087] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducat DC, 2003, BIOTECHNIQUES, V34, P1140, DOI 10.2144/03346bm04; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V272, pC1499; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KRAEMER J, 1985, SPINE, V10, P69, DOI 10.1097/00007632-198501000-00011; Lam AKM, 2004, J BIOL CHEM, V279, P48048, DOI 10.1074/jbc.M407224200; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; MAROUDAS A, 1970, BIOPHYS J, V10, P365, DOI 10.1016/S0006-3495(70)86307-X; MAROUDAS A, 1969, BIOCHIM BIOPHYS ACTA, V177, P492, DOI 10.1016/0304-4165(69)90311-0; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Na KY, 2003, J AM SOC NEPHROL, V14, P283, DOI 10.1097/01.ASN.0000045050.19544.B2; Rajpurohit R, 2002, CELL TISSUE RES, V308, P401, DOI 10.1007/s00441-002-0563-6; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Risbud MV, 2006, SPINE, V31, P884, DOI 10.1097/01.brs.0000209335.57767.b5; Risbud MV, 2006, J CELL BIOCHEM, V98, P152, DOI 10.1002/jcb.20765; Risbud MV, 2005, SPINE, V30, P2503, DOI 10.1097/01.brs.0000186326.82747.13; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shim EH, 2002, EMBO REP, V3, P857, DOI 10.1093/embo-reports/kvf175; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; Urban JPG, 2002, BIOCHEM SOC T, V30, P858, DOI 10.1042/bst0300858; URBAN JPG, 1978, BIORHEOLOGY, V15, P203; Wang Y, 2005, J BIOL CHEM, V280, P19986, DOI 10.1074/jbc.M501689200; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Zhang Z, 2003, AM J PHYSIOL-RENAL, V285, pF688, DOI 10.1152/ajprenal.00028.2003	31	89	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25416	25424		10.1074/jbc.M601969200	http://dx.doi.org/10.1074/jbc.M601969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16772300	hybrid			2022-12-25	WOS:000240031300044
J	Hong, IK; Jin, YJ; Byun, HJ; Jeoung, DI; Kim, YM; Lee, H				Hong, In-Kee; Jin, Young-June; Byun, Hee-Jung; Jeoung, Doo-Il; Kim, Young-Myeong; Lee, Hansoo			Homophilic interactions of tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GENE-EXPRESSION; TRANSMEMBRANE-4 SUPERFAMILY; CANCER-CELLS; INTEGRIN ALPHA-3-BETA-1; CLINICAL-SIGNIFICANCE; PROSTATE-CANCER; CARCINOMA CELLS; TUMOR-CELLS; IN-VIVO	The tetraspanin membrane protein CD151 has been suggested to regulate cancer invasion and metastasis by initiating signaling events. The CD151-mediated signaling pathways involved in this regulation remain to be revealed. In this study, we found that stable transfection of CD151 into MelJuSo human melanoma cells lacking CD151 expression significantly increased cell motility, matrix metalloproteinase-9 ( MMP-9) expression, and invasiveness. The enhancement of cell motility and MMP-9 expression by CD151 overexpression was abrogated by inhibitors and small interfering RNAs targeted to focal adhesion kinase ( FAK), Src, p38 MAPK, and JNK, suggesting an essential role of these signaling components in CD151 signaling pathways. Also, CD151-induced MMP-9 expression was shown to be mediated by c-Jun binding to AP-1 sites in the MMP-9 gene promoter, indicating AP-1 activation by CD151 signaling pathways. Meanwhile, CD151 was found to be associated with alpha(3)beta(1) and alpha(6)beta(1) integrins in MelJuSo cells, and activation of associated integrins was a prerequisite for CD151-stimulated MMP-9 expression and activation of FAK, Src, p38 MAPK, JNK, and c-Jun. Furthermore, CD151 on one cell was shown to bind to neighboring cells expressing CD151, suggesting that CD151 is a homophilic interacting protein. The homophilic interactions of CD151 increased motility and MMP-9 expression of CD151-transfected MelJuSo cells, along with FAK-, Src-, p38 MAPK-, and JNK-mediated activation of c-Jun in an adhesion-dependent manner. Furthermore, C8161 melanoma cells with endogenous CD151 were also shown to respond to homophilic CD151 interactions for the induction of adhesion-dependent activation of FAK, Src, and c-Jun. These results suggest that homophilic interactions of CD151 stimulate integrin-dependent signaling to c-Jun through FAK- Src- MAPKs pathways in human melanoma cells, leading to enhanced cell motility and MMP-9 expression.	Kangwon Natl Univ, Div Life Sci, Coll Nat Sci, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Vasc Syst Res Ctr, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea	Kangwon National University; Kangwon National University; Kangwon National University	Lee, H (corresponding author), Kangwon Natl Univ, Div Life Sci, Coll Nat Sci, Chunchon 200701, Kangwon Do, South Korea.	hslee@kangwon.ac.kr						Ang J, 2004, CANCER EPIDEM BIOMAR, V13, P1717; ATKINSON B, 1984, CANCER RES, V44, P2577; Bahassi EM, 2004, CLIN EXP METASTAS, V21, P293, DOI 10.1023/B:CLIN.0000046132.46946.dd; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Gabarra-Niecko V, 2002, BIOCHEM J, V365, P591, DOI 10.1042/BJ20020065; GIL ML, 1992, J IMMUNOL, V148, P2826; Hah N, 2003, BIOCHEM BIOPH RES CO, V305, P428, DOI 10.1016/S0006-291X(03)00788-5; Hasegawa H, 1996, J VIROL, V70, P3258, DOI 10.1128/JVI.70.5.3258-3263.1996; Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Hong S, 2005, J BIOL CHEM, V280, P25202, DOI 10.1074/jbc.M413985200; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jang HI, 2003, EXP MOL MED, V35, P317, DOI 10.1038/emm.2003.43; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kohno M, 2002, INT J CANCER, V97, P336, DOI 10.1002/ijc.1605; KONDOH M, 1993, MELANOMA RES, V3, P241; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; Lau LM, 2004, BLOOD, V104, P2368, DOI 10.1182/blood-2003-12-4430; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; Na HJ, 2004, J IMMUNOL, V173, P1276, DOI 10.4049/jimmunol.173.2.1276; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nishiuchi R, 2005, P NATL ACAD SCI USA, V102, P1939, DOI 10.1073/pnas.0409493102; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Radford KJ, 1997, J IMMUNOL, V158, P3353; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; SATO H, 1993, ONCOGENE, V8, P395; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; SCHICK MR, 1993, J IMMUNOL, V151, P1918; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; Sterk LMT, 2002, J CELL SCI, V115, P1161; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Stipp CS, 2000, J CELL SCI, V113, P1871; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Stokes KD, 2003, GENE, V320, P97, DOI 10.1016/S0378-1119(03)00814-X; Testa JE, 1999, CANCER RES, V59, P3812; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Vitha S, 2003, PLANT CELL, V15, P1918, DOI 10.1105/tpc.013292; Waetzig V, 2005, MOL CELL NEUROSCI, V30, P67, DOI 10.1016/j.mcn.2005.06.001; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yanez-Mo M, 2001, MICROCIRCULATION, V8, P153; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Zhang XA, 2002, MOL BIOL CELL, V13, P1, DOI 10.1091/mbc.01-10-0481; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	70	88	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24279	24292		10.1074/jbc.M601209200	http://dx.doi.org/10.1074/jbc.M601209200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798740	hybrid			2022-12-25	WOS:000239847800021
J	Lopes, FL; Desmarais, J; Ledoux, S; Gevry, NY; Lefevre, P; Murphy, BD				Lopes, Flavia L.; Desmarais, Joelle; Ledoux, Sandra; Gevry, Nicolas Y.; Lefevre, Pavine; Murphy, Bruce D.			Transcriptional regulation of uterine vascular endothelial growth factor during early gestation in a carnivore model, Mustela vison	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECIDUAL CELL REACTION; PROSTAGLANDIN E-2 RECEPTOR; FACTOR EXPRESSION; GENE-EXPRESSION; CANCER CELLS; PERMEABILITY FACTOR; OBLIGATE DIAPAUSE; LUTEAL FUNCTION; E SYNTHASE; IN-VITRO	Vascular endothelial growth factor ( VEGF) is an essential angiogenic signaling element that acts through its two tyrosine kinase receptors, inducing both proliferation of endothelial cells and vascular permeability. Given the importance of vasculogenesis and angiogenesis to early pregnancy, it is of interest to understand the mechanisms regulating vascular development at this stage. We previously demonstrated that VEGF and receptors are up-regulated during embryo implantation in an unique animal model, the mink, a species displaying obligate embryonic diapause. Herein we examined the role of prostaglandin E2 (PGE(2)) as a regulator of VEGF during early pregnancy and established the mechanisms of this regulation. We demonstrate that activated embryos secrete PGE(2) and that expression of PGE synthase protein in the uterus is dependent upon direct contact with invading trophoblast cells during implantation. Using mink uterine stromal cells transfected with mink VEGF promoter driving the luciferase reporter gene, we show that PGE(2) induces promoter transactivation and that this response can be eliminated by blockade of protein kinase A. Treatment with antagonists to PGE(2) receptors EP2 and EP4 eliminated the PGE(2)-induced response in transfected cells. Deletional studies of the promoter revealed that a region of 99 bp upstream of the transcription start site is required for PGE(2)-induced transactivation. Mutation of an AP2/Sp1 cluster, found within the 99 bp, completely eliminated the PGE(2) response. Furthermore, chromatin immunoprecipitation assays confirmed binding of the AP2 and Sp1 transcription factors to the endogenous mink VEGF promoter in uterine cells. PGE(2) stimulated acetylation of histone H3 associated with the promoter region containing the AP2/Sp1 cluster. Taken together, these results demonstrate that PGE(2) plays an important role in regulating uterine and thus placental vascular development, acting through its receptors EP2 and EP4, provoking protein kinase A activation of AP2 and Sp1 as well as acetylation of histone H3 to transactivate the VEGF promoter.	Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada	Universite de Montreal	Lopes, FL (corresponding author), McGill Univ, Montreal Childrens Hosp Res Inst, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.	flavia.lopes@mail.mcgill.ca	Lopes, Flavia Lombardi/A-6608-2009	Lopes, Flavia Lombardi/0000-0002-3173-3712; Murphy, Bruce/0000-0001-7158-3360				Abdel-Majid RM, 2004, J IMMUNOL, V172, P1227, DOI 10.4049/jimmunol.172.2.1227; Arosh JA, 2004, ENDOCRINOLOGY, V145, P2551, DOI 10.1210/en.2003-1607; Bradbury D, 2005, J BIOL CHEM, V280, P29993, DOI 10.1074/jbc.M414530200; BREIER G, 1992, DEVELOPMENT, V114, P521; Brenneisen P, 2003, BIOCHEM J, V369, P341, DOI 10.1042/BJ20021032; Chang SH, 2005, PROSTAG OTH LIPID M, V76, P48, DOI 10.1016/j.prostaglandins.2004.12.001; Desmarais JA, 2004, BIOL REPROD, V70, P662, DOI 10.1095/biolreprod.103.023572; Ding YB, 2005, EXP ONCOL, V27, P108; Eibl G, 2003, BIOCHEM BIOPH RES CO, V306, P887, DOI 10.1016/S0006-291X(03)01079-9; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Fukuda R, 2003, CANCER RES, V63, P2330; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; JOHNSTON MEA, 1984, BIOL REPROD, V31, P959, DOI 10.1095/biolreprod31.5.959; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENNEDY TG, 1977, BIOL REPROD, V16, P286, DOI 10.1095/biolreprod16.3.286; KENNEDY TG, 1979, BIOL REPROD, V20, P560, DOI 10.1095/biolreprod20.3.560; KENNEDY TG, 1988, PROSTAG OTH LIPID M, V35, P207, DOI 10.1016/0090-6980(88)90088-3; Kimura M, 2001, ENDOCRINOLOGY, V142, P4428, DOI 10.1210/en.142.10.4428; Klauber N, 1997, NAT MED, V3, P443, DOI 10.1038/nm0497-443; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LALA PK, 1989, AM J REPROD IMMUNOL, V20, P147, DOI 10.1111/j.1600-0897.1989.tb00987.x; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lopes FL, 2003, BIOL REPROD, V68, P1926, DOI 10.1095/biolreprod.102.013441; Martinet L, 1981, J Reprod Fertil Suppl, V29, P119; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MOREAU GM, 1995, BIOL REPROD, V53, P511, DOI 10.1095/biolreprod53.3.511; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murphy B.D., 1993, Journal of Reproduction and Fertility Supplement, V47, P181; MURPHY BD, 1981, BIOL REPROD, V25, P487, DOI 10.1095/biolreprod25.3.487; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Ni H, 2002, BIOL REPROD, V67, P351, DOI 10.1095/biolreprod67.1.351; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; PAPKE RL, 1980, J ANIM SCI, V50, P1102, DOI 10.2527/jas1980.5061102x; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Smith SK, 1998, HUM REPROD UPDATE, V4, P509, DOI 10.1093/humupd/4.5.509; Song JH, 1998, ENDOCRINOLOGY, V139, P3629, DOI 10.1210/en.139.8.3629; Tilley SL, 1999, J CLIN INVEST, V103, P1539, DOI 10.1172/JCI6579; Wang XH, 2004, J BIOL CHEM, V279, P30579, DOI 10.1074/jbc.M400573200; Xiao CW, 1999, BIOL REPROD, V60, P656, DOI 10.1095/biolreprod60.3.656; Zhang GQ, 2004, ENDOCRINOLOGY, V145, P2760, DOI 10.1210/en.2003-1545	52	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24602	24611		10.1074/jbc.M602146200	http://dx.doi.org/10.1074/jbc.M602146200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790435	hybrid			2022-12-25	WOS:000239847800055
J	McMahon, M; Thomas, N; Itoh, K; Yamamoto, M; Hayes, JD				McMahon, Michael; Thomas, Nerys; Itoh, Ken; Yamamoto, Masayuki; Hayes, John D.			Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "Tethering" mechanism - A two-site interaction model for the Nrf2-Keap1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT RESPONSE ELEMENT; UBIQUITIN LIGASE COMPLEX; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; HUMAN KEAP1; PROTEASOMAL DEGRADATION; DESTRUCTION MOTIF; CRYSTAL-STRUCTURE; PHASE-2 RESPONSE	The prevalence and mechanistic significance of self-association among substrate adaptors for the Cul-Rbx family of ubiquitin ligases remain unclear. We now report that it is as a homodimer that the substrate adaptor Keap1 interacts with Cul3. The resulting complex facilitates ubiquitylation of the Nrf2 transcription factor but only when this substrate possesses within its Neh2 domain a second cryptic Keap1-binding site, the DLG motif, in addition to its previously described ETGE site. Both motifs recognize overlapping surfaces on Keap1, and the seven lysine residues of Nrf2 that act as ubiquitin acceptors lie between them. Based on these data, we propose a "fixed-ends" model for Nrf2 ubiquitylation in which each binding site becomes tethered to a separate subunit of the Keap1 homodimer. This two-site interaction between Keap1 and Nrf2 constrains the mobility of the target lysine residues in the Neh2 domain, increasing their average concentration in the vicinity of the Rbx-bound ubiquitin-conjugating enzyme, and thus the rate at which the transcription factor is ubiquitylated. We show that self-association is a general feature of Cul3 substrate adaptors and propose that the fixed-ends mechanism is commonly utilized to recruit, orientate, and ubiquitylate substrates upon this family of ubiquitin ligases.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	University of Dundee; University of Tsukuba; University of Tsukuba	McMahon, M (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	mjmmcmahon@dundee.ac.uk	McMahon, Michael J/A-1702-2008; Yamamoto, Masayuki/A-4873-2010; McMahon, Michael J/F-7070-2010; Itoh, Ken/B-9506-2013	Yamamoto, Masayuki/0000-0002-9073-9436; McMahon, Michael J/0000-0001-8615-9351; Itoh, Ken/0000-0002-5518-0729; Hayes, John/0000-0002-2927-5548				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; An JH, 2005, P NATL ACAD SCI USA, V102, P16275, DOI 10.1073/pnas.0508105102; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2005, BIOCHEMISTRY-US, V44, P6889, DOI 10.1021/bi047434h; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li XC, 2004, J BIOL CHEM, V279, P54750, DOI 10.1074/jbc.M410073200; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Seibert V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-22; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	51	362	375	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24756	24768		10.1074/jbc.M601119200	http://dx.doi.org/10.1074/jbc.M601119200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790436	hybrid			2022-12-25	WOS:000239847800072
J	Rutz, C; Renner, A; Alken, M; Schulz, K; Beyermann, M; Wiesner, B; Rosenthal, W; Schulein, R				Rutz, Claudia; Renner, Armin; Alken, Martina; Schulz, Katharina; Beyermann, Michael; Wiesner, Burkhard; Rosenthal, Walter; Schuelein, Ralf			The corticotropin-releasing factor receptor type 2a contains an N-terminal pseudo signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOPRESSIN V-2 RECEPTOR; PRION PROTEIN; TRANSMEMBRANE FORM; MEMBRANE-PROTEINS; TRANSLOCATION; CRF; EXPRESSION; PREDICTION; SEQUENCES; TRANSPORT	The corticotropin-releasing factor receptor type 2a (CRF2(a) receptor) belongs to the family of G protein-coupled receptors. The receptor possesses a putative N-terminal signal peptide that is believed to be cleaved-off after mediating the endoplasmic reticulum targeting/insertion process, like the corresponding sequence of the homologous CRF1 receptor. Here, we have assessed the functional significance of the putative signal peptide of the CRF2(a) receptor and show that it is surprisingly completely incapable of mediating endoplasmic reticulum targeting, despite meeting all sequence criteria for a functional signal by prediction algorithms. Moreover, it is uncleaved and forms part of the mature receptor protein. Replacement of residue Asn(13) by hydrophobic or positively charged residues converts the sequence into a fully functional and cleaved signal peptide demonstrating that conventional signal peptide functions are inhibited by a single amino acid residue. Deletion of the domain leads to an increase in the amount of immature, intracellularly retained receptors demonstrating that the sequence has adopted a new function in receptor trafficking through the early secretory pathway. Taken together, our results identify a novel hydrophobic receptor domain in the family of the heptahelical G protein-coupled receptors and the first pseudo signal peptide of a eukaryotic membrane protein. Our data also show that the extreme N termini of the individual CRF receptor subtypes differ substantially.	Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schulein, R (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	schuelein@fmp-berlin.de						Alken M, 2005, BIOCHEM J, V390, P455, DOI 10.1042/BJ20050113; Andersson H, 2003, MOL PHARMACOL, V64, P570, DOI 10.1124/mol.64.3.570; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165-6147(02)01946-6; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Halic M, 2005, CURR OPIN STRUC BIOL, V15, P116, DOI 10.1016/j.sbi.2005.01.013; Hauger RL, 2003, PHARMACOL REV, V55, P21, DOI 10.1124/pr.55.1.3; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Higy M, 2004, BIOCHEMISTRY-US, V43, P12716, DOI 10.1021/bi048368m; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; Kochl R, 2002, J BIOL CHEM, V277, P16131, DOI 10.1074/jbc.M111674200; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Sambrook J, 2001, MOL CLONING LAB MANU; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 2004, REV PHYSIOL BIOCH P, V151, P45, DOI 10.1007/s10254-004-0022-8; Schulein R, 2001, J BIOL CHEM, V276, P8384, DOI 10.1074/jbc.M007045200; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Wietfeld D, 2004, J BIOL CHEM, V279, P38386, DOI 10.1074/jbc.M405335200	34	46	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24910	24921		10.1074/jbc.M601554200	http://dx.doi.org/10.1074/jbc.M601554200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16766521	hybrid			2022-12-25	WOS:000239847800084
J	Donahue, CP; Muratore, C; Wu, JY; Kosik, KS; Wolfe, MS				Donahue, Christine P.; Muratore, Christina; Wu, Jane Y.; Kosik, Kenneth S.; Wolfe, Michael S.			Stabilization of the tau exon 10 stem loop alters pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL FRONTOTEMPORAL DEMENTIA; TAU-GENE; EXON 10; SECONDARY STRUCTURE; REGULATORY ELEMENT; MUTATIONS; PARKINSONISM; EXPRESSION; CHROMOSOME-17; FTDP-17	Neurofibrillary tangles containing filaments of the microtubuleassociated protein tau are found in a variety of neurodegenerative diseases. Mutations in the tau gene itself cause frontotemporal dementia with parkinsonism, demonstrating the critical role of tau in pathogenesis. Many of these mutations in tau are silent, are found at the 5'-splice site of exon 10, and lead to increased inclusion of exon 10. These silent mutations are predicted to destabilize a stem loop structure at the exon 10 5'-splice site; however, the existence of this stem loop under physiological conditions and its role in splice regulation are controversial. Here we show that base changes that stabilize this stem loop in vitro substantially decrease exon 10 inclusion in a wild type tau minigene and rescue the increase in exon 10 splicing caused by a dementia-causing point mutation. Moreover, we probed the intracellular structure of the tau stem loop with antisense RNA and demonstrate that the stability of the stem loop dictates antisense effectiveness. Together these results validate the stem loop as a bonafide structure regulating tau exon 10 splicing.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Northwestern University; Feinberg School of Medicine; University of California System; University of California Santa Barbara	Wolfe, MS (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03, R01 EY014576] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, R01 GM070967] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; D'Souza I, 2005, BBA-MOL BASIS DIS, V1739, P104, DOI 10.1016/j.bbadis.2004.08.009; D'Souza I, 2002, J BIOL CHEM, V277, P26587, DOI 10.1074/jbc.M203794200; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Donahue CP, 2002, HIPPOCAMPUS, V12, P821, DOI 10.1002/hipo.10058; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 2003, J BIOL CHEM, V278, P18997, DOI 10.1074/jbc.M301800200; Kalbfuss B, 2001, J BIOL CHEM, V276, P42986, DOI 10.1074/jbc.M105113200; Kosik KS, 2005, BBA-MOL BASIS DIS, V1739, P298, DOI 10.1016/j.bbadis.2004.10.011; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Sczakiel G, 1997, ANTISENSE NUCLEIC A, V7, P439, DOI 10.1089/oli.1.1997.7.439; Toulme JJ, 1996, BIOCHIMIE, V78, P663, DOI 10.1016/S0300-9084(96)80012-5; Toulme JJ, 2001, PROG NUCLEIC ACID RE, V69, P1, DOI 10.1016/S0079-6603(01)69043-3; Varani L, 1999, P NATL ACAD SCI USA, V96, P8229, DOI 10.1073/pnas.96.14.8229; Varani L, 2000, NUCLEIC ACIDS RES, V28, P710, DOI 10.1093/nar/28.3.710; Vickers TA, 2000, NUCLEIC ACIDS RES, V28, P1340, DOI 10.1093/nar/28.6.1340; Yasuda M, 2000, ANN NEUROL, V47, P422, DOI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	28	73	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23302	23306		10.1074/jbc.C600143200	http://dx.doi.org/10.1074/jbc.C600143200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782711	hybrid, Green Accepted			2022-12-25	WOS:000239702900003
J	Roepke, TK; Anantharam, A; Kirchhoff, P; Busque, SM; Young, JB; Geibel, JP; Lerner, DJ; Abbott, GW				Roepke, Torsten K.; Anantharam, Arun; Kirchhoff, Philipp; Busque, Stephanie M.; Young, Jeffrey B.; Geibel, John P.; Lerner, Daniel J.; Abbott, Geoffrey W.			The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARIETAL-CELLS; CARDIAC-ARRHYTHMIA; K+ CHANNEL; BETA-SUBUNIT; MINK; MEMBRANE; EXPRESSION; MIRP1; KCNQ1; HERG	Genes in the KCNE family encode single transmembrane domain ancillary subunits that co-assemble with voltage-gated potassium (Kv) channel alpha subunits to alter their function. KCNE2 (also known as MiRP1) is expressed in the heart, is associated with human cardiac arrhythmia, and modulates cardiac Kv alpha subunits hERG and KCNQ1 in vitro. KCNE2 and KCNQ1 are also expressed in parietal cells, leading to speculation they form a native channel complex there. Here, we disrupted the murine kcne2 gene and found that kcne2 (-/-) mice have a severe gastric phenotype with profoundly reduced parietal cell proton secretion, abnormal parietal cell morphology, achlorhydria, hypergastrinemia, and striking gastric glandular hyperplasia arising from an increase in the number of non-acid secretory cells. KCNQ1 exhibited abnormal distribution in gastric glands from kcne2 (-/-) mice, with increased expression in non-acid secretory cells. Parietal cells from kcne2 (-/-) mice exhibited normal architecture but reduced proton secretion, and kcne2 (-/-) mice were hypochlorhydric, indicating a gene-dose effect and a primary defect in gastric acid secretion. These data demonstrate that KCNE2 is essential for gastric acid secretion, the first genetic evidence that a member of the KCNE gene family is required for normal gastrointestinal function.	Cornell Univ, Weill Med Coll, Greenberg Div Cardiol, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, Grad Program, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; FoxHollow Technol, Redwood City, CA 94063 USA	Cornell University; Cornell University; Cornell University; Yale University; Yale University	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Greenberg Div Cardiol, Dept Med, Starr 463,520 E 70th St, New York, NY 10021 USA.	gwa2001@med.cornell.edu		Abbott, Geoffrey/0000-0003-4552-496X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC007060] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079275] Funding Source: Medline; NIDCD NIH HHS [R03 DC07060] Funding Source: Medline; NIDDK NIH HHS [R01 DK50230] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Champagne E T, 1989, Adv Exp Med Biol, V249, P173; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; Derendorf H, 2005, J CLIN PHARMACOL, V45, P845, DOI 10.1177/0091270005276738; Francis SA, 2006, BLOOD, V107, P1627, DOI 10.1182/blood-2005-03-1164; Franic TV, 2001, AM J PHYSIOL-GASTR L, V281, pG1502, DOI 10.1152/ajpgi.2001.281.6.G1502; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; GEIBEL J, 1989, AM J PHYSIOL, V257, pR790; Geibel JP, 2005, WORLD J GASTROENTERO, V11, P5259, DOI 10.3748/wjg.v11.i34.5259; GOODMAN KI, 1990, POSTGRAD MED, V88, P147; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Gutman GA, 2005, PHARMACOL REV, V57, P473, DOI 10.1124/pr.57.4.10; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Jain RN, 2006, PHYSIOL GENOMICS, V24, P124, DOI 10.1152/physiolgenomics.00133.2005; Jiang M, 2004, CIRCULATION, V109, P1783, DOI 10.1161/01.CIR.0000124225.43852.50; Karvar S, 2002, J BIOL CHEM, V277, P50030, DOI 10.1074/jbc.M207694200; Lambrecht NWG, 2005, PHYSIOL GENOMICS, V21, P81, DOI 10.1152/physiolgenomics.00212.2004; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Lewis A, 2004, J BIOL CHEM, V279, P7884, DOI 10.1074/jbc.M310501200; Malinowska DH, 2004, AM J PHYSIOL-CELL PH, V286, pC495, DOI 10.1152/ajpcell.00386.2003; McCrossan ZA, 2003, J NEUROSCI, V23, P8077; McCrossan ZA, 2004, NEUROPHARMACOLOGY, V47, P787, DOI 10.1016/j.neuropharm.2004.06.018; Nagy A., 2003, MANIPULATING MOUSE E; Ray JE, 2005, BRIT J CLIN PHARMACO, V60, P291, DOI 10.1111/j.1365-2125.2005.02413.x; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; SPENNEY JG, 1983, J CLIN GASTROENTEROL, V5, P7, DOI 10.1097/00004836-198312001-00002; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Vallon V, 2005, P NATL ACAD SCI USA, V102, P17864, DOI 10.1073/pnas.0505860102; Waldegger S, 2003, PFLUG ARCH EUR J PHY, V446, P143, DOI 10.1007/s00424-003-1048-5; WANG WH, 1989, J MEMBRANE BIOL, V111, P277, DOI 10.1007/BF01871012; Watson SA, 2001, CANCER RES, V61, P625; Zaritsky JJ, 2001, J PHYSIOL-LONDON, V533, P697, DOI 10.1111/j.1469-7793.2001.t01-1-00697.x; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	41	112	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23740	23747		10.1074/jbc.M604155200	http://dx.doi.org/10.1074/jbc.M604155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16754665	hybrid			2022-12-25	WOS:000239702900049
J	Ray, D; Osmundson, EC; Kiyokawa, H				Ray, Dipankar; Osmundson, Evan C.; Kiyokawa, Hiroaki			Constitutive and UV-induced fibronectin degradation is a ubiquitination-dependent process controlled by beta-TrCP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ENDOPLASMIC-RETICULUM; IONIZING-RADIATION; DNA-DAMAGE; CELL-CYCLE; HUMAN SKIN; IN-VITRO; PROTEIN; EXPRESSION; GENE	Loss of fibronectin (FN) assembly in the extracellular matrix has long been recognized as a feature of cellular transformation. However, such assembly is regulated not only by FN synthesis but also by its post-translational modifications. The mechanism controlling FN protein stability has remained unclear so far. Recently it was demonstrated that FN matrix turnover occurs intracellularly at the lysosome following caveolin-1-dependent endocytosis. Although FN was reported to undergo ubiquitin-dependent degradation, the ubiquitin ligase responsible for FN ubiquitination is unknown. In this study, we have identified beta-TrCP as the ubiquitin ligase for lysosomal degradation of FN. We found two conserved beta-TrCP recognition motif (DSGVVYS and DSGSIVVS) in the primary amino acid sequence of human, mouse, and rat FN. Down-regulation of either beta-TrCP1 or beta-TrCP2 by small interference (siRNA) caused significant accumulation of FN. Immunolocalization studies showed intracellular accumulation of FN in beta-TrCP siRNA-treated cells without showing much alteration in its matrix association. We also observed that exposure of cells to UV irradiation effectively down-regulated FN following increased ubiquitination, which was significantly inhibited either by lysosomal inhibitor or by siRNA-mediated down-regulation of beta-TrCP. Taken together, constitutive FN degradation, as well as UV-induced degradation, is ubiquitination dependent and controlled by beta-TrCP.	Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ray, D (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem, 303 E Super,Rm 3-220, Chicago, IL 60611 USA.	dipankar-ray@northwestern.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [CA112282, R01 CA100204] Funding Source: Medline; NICHD NIH HHS [HD38085] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112282, R01CA100204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1984, FEBS LETT, V176, P169, DOI 10.1016/0014-5793(84)80934-5; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2002, INT J RADIAT BIOL, V78, P347, DOI 10.1080/09553000110117340; Cordes N, 2004, J MOL HISTOL, V35, P327; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giannopoulou E, 2001, INT J CANCER, V94, P690, DOI 10.1002/ijc.1535.abs; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hao XS, 2004, CANCER-AM CANCER SOC, V100, P1110, DOI 10.1002/cncr.20095; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Hynes R O, 1978, Ann N Y Acad Sci, V312, P317, DOI 10.1111/j.1749-6632.1978.tb16811.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Kumar KGS, 2003, EMBO J, V22, P5480; Labat-Robert J, 2002, SEMIN CANCER BIOL, V12, P187, DOI 10.1016/S1044-579X(02)00022-6; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MCDONALD GA, 2005, AM J PHYSIOL, V285, pF59; MORO L, 1992, INT J CANCER, V51, P1; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Ryu S, 1998, CANCER LETT, V133, P215, DOI 10.1016/S0304-3835(98)00260-2; Sander CS, 2006, BRIT J DERMATOL, V154, P218, DOI 10.1111/j.1365-2133.2005.07001.x; Seite S, 2004, PHOTOCHEM PHOTOBIOL, V79, P265, DOI 10.1562/YG-03-09.1; Sottile J, 2005, MOL BIOL CELL, V16, P757, DOI 10.1091/mbc.e04-08-0672; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Urbe S, 2005, ESSAYS BIOCHEM, V41, P81, DOI 10.1042/EB0410081; Vaheri A, 1978, Ann N Y Acad Sci, V312, P343, DOI 10.1111/j.1749-6632.1978.tb16812.x; Zhao W, 2000, INT J RADIAT BIOL, V76, P391, DOI 10.1080/095530000138736; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	41	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23060	23065		10.1074/jbc.M604311200	http://dx.doi.org/10.1074/jbc.M604311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757476	hybrid			2022-12-25	WOS:000239542600069
J	Korotkova, N; Le Trong, I; Samudrala, R; Korotkov, K; Van Loy, CP; Bui, AL; Moseley, SL; Stenkamp, RE				Korotkova, Natalia; Le Trong, Isolde; Samudrala, Ram; Korotkov, Konstantin; Van Loy, Cristina P.; Bui, Anh-Linh; Moseley, Steve L.; Stenkamp, Ronald E.			Crystal structure and mutational analysis of the DaaE adhesin of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; ALPHA-CHAIN; AMINO-ACIDS; BINDING; IDENTIFICATION; RECEPTOR; ANTIGEN; FAMILY; DOMAIN; COEFFICIENTS	DaaE is a member of the Dr adhesin family of Escherichia coli, members of which are associated with diarrhea and urinary tract infections. A receptor for Dr adhesins is the cell surface protein, decay-accelerating factor (DAF). We have carried out a functional analysis of Dr adhesins, as well as mutagenesis and crystallographic studies of DaaE, to obtain detailed molecular information about interactions of Dr adhesins with their receptors. The crystal structure of DaaE has been solved at 1.48 angstrom resolution. Trimers of the protein are found in the crystal, as has been the case for other Dr adhesins. Naturally occurring variants and directed mutations in DaaE have been generated and analyzed for their ability to bind DAF. Mapping of the mutation sites onto the DaaE molecular structure shows that several of them contribute to a contiguous surface that is likely the primary DAF-binding site. The DAF-binding properties of purified fimbriae and adhesin proteins from mutants and variants correlated with the ability of bacteria expressing these proteins to bind to human epithelial cells in culture. DaaE, DraE, AfaE-III, and AfaE-V interact with complement control protein (CCP) domains 2-4 of DAF, and analysis of the ionic strength dependence of their binding indicates that the intermolecular interactions are highly electrostatic in nature. The adhesins AfaE-I and NfaE-2 bind to CCP-3 and CCP-4 of DAF, and electrostatic interactions contribute significantly less to these interactions. These observations are consistent with structural predictions for these Dr variants and also suggest a role for the positively charged region linking CCP-2 and CCP-3 of DAF in electrostatic Dr adhesin-DAF interactions.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stenkamp, RE (corresponding author), Univ Washington, Dept Biol Struct, Box 357420, Seattle, WA 98195 USA.	stenkamp@u.washington.edu		Korotkov, Konstantin/0000-0002-2182-6843; Korotkova, Natalia/0000-0002-8696-4892	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064229] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-064229] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamczyk M, 2000, METHODS, V20, P319, DOI 10.1006/meth.1999.0925; Anderson KL, 2004, MOL CELL, V15, P647, DOI 10.1016/j.molcel.2004.08.003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Berger CN, 2004, MOL MICROBIOL, V52, P963, DOI 10.1111/j.1365-2958.2004.04033.x; BILGE SS, 1989, J BACTERIOL, V171, P4281, DOI 10.1128/JB.171.8.4281-4289.1989; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brodbeck WG, 2000, IMMUNOLOGY, V101, P104, DOI 10.1046/j.1365-2567.2000.00086.x; Carnoy C, 1997, MOL MICROBIOL, V23, P365, DOI 10.1046/j.1365-2958.1997.2231590.x; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; DECRISTOFARO R, 1992, J MOL BIOL, V226, P263, DOI 10.1016/0022-2836(92)90138-A; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Grucza RA, 2000, BIOCHEMISTRY-US, V39, P10072, DOI 10.1021/bi000891n; Guignot J, 2000, INFECT IMMUN, V68, P3554, DOI 10.1128/IAI.68.6.3554-3563.2000; Hasan RJ, 2002, INFECT IMMUN, V70, P4485, DOI 10.1128/IAI.70.8.4485-4493.2002; Herr AB, 2003, J MOL BIOL, V327, P645, DOI 10.1016/S0022-2836(03)00149-9; Hung LH, 2005, NUCLEIC ACIDS RES, V33, pW77, DOI 10.1093/nar/gki403; Hung LH, 2003, NUCLEIC ACIDS RES, V31, P3296, DOI 10.1093/nar/gkg541; Kansau I, 2004, INFECT IMMUN, V72, P3733, DOI 10.1128/IAI.72.7.3733-3742.2004; KLEMM P, 1985, MOL GEN GENET, V199, P410, DOI 10.1007/BF00330751; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; LABIGNEROUSSEL AF, 1984, INFECT IMMUN, V46, P251, DOI 10.1128/IAI.46.1.251-259.1984; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEBOUGUENEC C, 1993, INFECT IMMUN, V61, P5106, DOI 10.1128/IAI.61.12.5106-5114.1993; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MANIATIS T, 1982, MOL CLONING LABORATO, P98; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEDOF ME, 1987, J EXP MED, V165, P848, DOI 10.1084/jem.165.3.848; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morikis D, 2004, J IMMUNOL, V172, P7537, DOI 10.4049/jimmunol.172.12.7537; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; NICHOLSONWELLER A, 1994, J LAB CLIN MED, V123, P485; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettigrew D, 2004, J BIOL CHEM, V279, P46851, DOI 10.1074/jbc.M409284200; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RECORD MT, 1995, BIOPHYS J, V68, P786, DOI 10.1016/S0006-3495(95)80254-7; Sauer FG, 2004, BBA-MOL CELL RES, V1694, P259, DOI 10.1016/j.bbamcr.2004.02.010; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Selvarangan R, 2004, INFECT IMMUN, V72, P4827, DOI 10.1128/IAI.72.8.4827-4835.2004; Servin AL, 2005, CLIN MICROBIOL REV, V18, P264, DOI 10.1128/CMR.18.2.264-292.2005; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; SWANSON TN, 1991, INFECT IMMUN, V59, P261, DOI 10.1128/IAI.59.1.261-268.1991; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Van Loy CP, 2002, MOL MICROBIOL, V45, P439; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9; Zhang LX, 1997, INFECT IMMUN, V65, P2011, DOI 10.1128/IAI.65.6.2011-2018.1997	54	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22367	22377		10.1074/jbc.M604646200	http://dx.doi.org/10.1074/jbc.M604646200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751628	hybrid			2022-12-25	WOS:000239387100082
J	Zhou, YG; Zomot, E; Kanner, BI				Zhou, Yonggang; Zomot, Elia; Kanner, Baruch I.			Identification of a lithium interaction site in the gamma-aminobutyric acid (GABA) transporter GAT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL GLUTAMATE TRANSPORTER; TRANSMEMBRANE DOMAIN-I; RAT-BRAIN; NEUROTRANSMITTER TRANSPORTERS; XENOPUS OOCYTES; SODIUM; EXPRESSION; PLAYS; REACTIVITY; HOMOLOG	The sodium- and chloride-dependent electrogenic gamma-aminobutyric acid ( GABA) transporter GAT-1, which transports two sodium ions together with GABA, is essential for synaptic transmission by this neurotransmitter. Although lithium by itself does not support GABA transport, it has been proposed that lithium can replace sodium at one of the binding sites but not at the other. To identify putative lithium selectivity determinants, we have mutated the five GAT-1 residues corresponding to those whose side chains participate in the sodium binding sites Na1 and Na2 of the bacterial leucine-transporting homologue LeuT(Aa). In GAT-1 and in most other neurotransmitter transporter family members, four of these residues are conserved, but aspartate 395 replaces the Na2 residue threonine 354. At varying extracellular sodium, lithium stimulated sodium dependent transport currents as well as [H-3] GABA uptake in wild type GAT-1. The extent of this stimulation was dependent on the GABA concentration. In mutants in which aspartate 395 was replaced by threonine or serine, the stimulation of transport by lithium was abolished. Moreover, these mutants were unable to mediate the lithium leak currents. This phenotype was not observed in mutants at the four other positions, although their transport properties were severely impacted. Thus at saturating GABA, the site corresponding to Na2 behaves as a low affinity sodium binding site where lithium can replace sodium. We propose that GABA participates in the other sodium binding site, just like leucine does in the Na1 site, and that at limiting GABA, this site determines the apparent sodium affinity of GABA transport.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il						Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; MacAulay N, 2002, J PHYSIOL-LONDON, V544, P447, DOI 10.1113/jphysiol.2002.022897; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Mirza O, 2006, EMBO J, V25, P1177, DOI 10.1038/sj.emboj.7601028; Nelson N, 1998, J NEUROCHEM, V71, P1785; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Zhou YG, 2005, J BIOL CHEM, V280, P20316, DOI 10.1074/jbc.M412937200; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200	28	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22092	22099		10.1074/jbc.M602319200	http://dx.doi.org/10.1074/jbc.M602319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16757479	hybrid			2022-12-25	WOS:000239387100056
J	Richardson, JR; Caudle, WM; Wang, MZ; Dean, ED; Pennell, KD; Miller, GW				Richardson, Jason R.; Caudle, W. Michael; Wang, Minzheng; Dean, E. Danielle; Pennell, Kurt D.; Miller, Gary W.			Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease	FASEB JOURNAL			English	Article						PD; pesticides; MPTP; alpha-synuclein; dopamine transporter; vesicular monoamine transporter 2	SUBSTANTIA-NIGRA; MPTP NEUROTOXICITY; MONOAMINE NEURONS; GENE-EXPRESSION; MOUSE STRIATUM; RISK-FACTORS; EARLY-LIFE; IN-VITRO; TRANSPORTER; MIDBRAIN	Exposure to pesticides has been suggested to increase the risk of Parkinson's disease (PD), but the mechanisms responsible for this association are not clear. Here, we report that perinatal exposure of mice during gestation and lactation to low levels of dieldrin (0.3, 1, or 3 mg/ kg every 3 days) alters dopaminergic neurochemistry in their offspring and exacerbates MPTP toxicity. At 12 wk of age, protein and mRNA levels of the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) were increased by perinatal dieldrin exposure in a dose-related manner. We then administered MPTP (2 x 10 mg/ kg s. c) at 12 wk of age and observed a greater reduction of striatal dopamine in dieldrin-exposed offspring, which was associated with a greater DAT: VMAT2 ratio. Additionally, dieldrin exposure during development potentiated the increase in GFAP and alpha-synuclein levels induced by MPTP, indicating increased neurotoxicity. In all cases there were greater effects observed in the male offspring than the female, similar to that observed in human cases of PD. These data suggest that developmental exposure to dieldrin leads to persistent alterations of the developing dopaminergic system and that these alterations induce a "silent" state of dopamine dysfunction, thereby rendering dopamine neurons more vulnerable later in life.	Emory Univ, Ctr Neurodegenerat Dis, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Emory Univ, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA	Emory University; Rollins School Public Health; Emory University; University System of Georgia; Georgia Institute of Technology	Miller, GW (corresponding author), Emory Univ, Ctr Neurodegenerat Dis, Rollins Sch Publ Hlth, Whitehead Biomd Res,Bldg,Rm 505,615 Michael St, Atlanta, GA 30322 USA.	jricha3@eohsi.rutgers.edu; gary.miller@emory.edu	Richardson, Jason/AAG-5281-2019; Pennell, Kurt/ABD-8337-2020; Pennell, Kurt D/F-6862-2010	Richardson, Jason/0000-0001-6521-610X; Pennell, Kurt D/0000-0002-5788-6397	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012870, U54ES012068, F32ES013457, R21ES012315, R21ES013828] Funding Source: NIH RePORTER; NIEHS NIH HHS [F32ES013457, T32 ES012870, R21 ES012315, R21ES013828, U54 ES012068] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baldereschi M, 2003, ACTA NEUROL SCAND, V108, P239, DOI 10.1034/j.1600-0404.2003.00128.x; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Barlow BK, 2004, DEV NEUROSCI-BASEL, V26, P11, DOI 10.1159/000080707; Brosenitsch TA, 2001, J NEUROSCI, V21, P2571, DOI 10.1523/JNEUROSCI.21-08-02571.2001; Caudle WM, 2005, NEUROTOXICOLOGY, V26, P721, DOI 10.1016/j.neuro.2004.09.003; Corrigan FM, 1998, EXP NEUROL, V150, P339, DOI 10.1006/exnr.1998.6776; Corrigan FM, 2000, J TOXICOL ENV HEAL A, V59, P229, DOI 10.1080/009841000156907; Crispino M, 1998, MOL BRAIN RES, V59, P178, DOI 10.1016/S0169-328X(98)00143-0; Crofton KM, 2000, TOXICOL SCI, V57, P131, DOI 10.1093/toxsci/57.1.131; Donovan DM, 1999, MOL BRAIN RES, V73, P37, DOI 10.1016/S0169-328X(99)00235-1; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; FEKETE MIK, 1980, EUR J PHARMACOL, V64, P231, DOI 10.1016/0014-2999(80)90230-7; FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119; FORNSTEDT B, 1989, J NEURAL TRANSM, V76, P155, DOI 10.1007/BF01578755; Fumagalli F, 1999, J NEUROSCI, V19, P2424; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; Hermanson E, 2003, EXP CELL RES, V288, P324, DOI 10.1016/S0014-4827(03)00216-7; Jorgenson JL, 2001, ENVIRON HEALTH PERSP, V109, P113, DOI 10.2307/3434852; Kanthasamy AG, 2005, NEUROTOXICOLOGY, V26, P701, DOI 10.1016/j.neuro.2004.07.010; Lauder JM, 1998, PERSPECT DEV NEUROBI, V5, P247; Le Couteur DG, 1999, BIOMED PHARMACOTHER, V53, P122, DOI 10.1016/S0753-3322(99)80077-8; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu JP, 1997, J NEUROSCI, V17, P2420; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logroscino G, 2005, ENVIRON HEALTH PERSP, V113, P1234, DOI 10.1289/ehp.7573; Marek K, 2001, NEUROLOGY, V57, P2089, DOI 10.1212/WNL.57.11.2089; MARTYN CN, 1995, J NEUROL SCI, V132, P201, DOI 10.1016/0022-510X(95)00148-U; Miller DB, 1998, ANN NY ACAD SCI, V844, P153, DOI 10.1111/j.1749-6632.1998.tb08230.x; Miller GW, 1999, NEUROTOXICOLOGY, V20, P631; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Narahashi T, 1995, TOXICOL LETT, V82-3, P239, DOI 10.1016/0378-4274(95)03482-X; Narahashi T, 1996, PHARMACOL TOXICOL, V79, P1, DOI 10.1111/j.1600-0773.1996.tb00234.x; Okada H, 2004, J NEUROCHEM, V89, P7, DOI 10.1111/j.1471-4159.2004.02271.x; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Paladini CA, 1999, SYNAPSE, V32, P165, DOI 10.1002/(SICI)1098-2396(19990601)32:3<165::AID-SYN3>3.0.CO;2-N; Park M, 2005, NEUROLOGY, V64, P1047, DOI 10.1212/01.WNL.0000154532.98495.BF; Pohl HR, 2000, TOXICOL IND HEALTH, V16, P65, DOI 10.1191/074823300678827672; POLISHUK ZW, 1977, PESTIC MONIT J, V10, P121; Priyadarshi A, 2000, NEUROTOXICOLOGY, V21, P435; Purkerson-Parker S, 2001, TOXICOL SCI, V64, P216, DOI 10.1093/toxsci/64.2.216; Rabinovic AD, 2000, NEUROSCIENCE, V101, P67, DOI 10.1016/S0306-4522(00)00293-1; REINHARD JF, 1988, NEUROSCI LETT, V95, P246, DOI 10.1016/0304-3940(88)90665-9; Richardson JR, 2004, TOXICOL LETT, V148, P29, DOI 10.1016/j.toxlet.2003.12.006; ROGAN WJ, 1994, ENVIRON HEALTH PERSP, V102, P89, DOI 10.1289/ehp.94102s1189; SAVAGE EP, 1981, AM J EPIDEMIOL, V113, P413, DOI 10.1093/oxfordjournals.aje.a113109; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; Sim M, 1998, ARCH ENVIRON HEALTH, V53, P114, DOI 10.1080/00039896.1998.10545972; Smits SM, 2003, EUR J NEUROSCI, V18, P1731, DOI 10.1046/j.1460-9568.2003.02885.x; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Spencer JPE, 2002, J NEUROCHEM, V81, P122, DOI 10.1046/j.1471-4159.2002.00808.x; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; TANNER CM, 1990, NEUROLOGY, V40, P17; Tillerson JL, 2002, EXP NEUROL, V178, P80, DOI 10.1006/exnr.2002.8021; Uhl GR, 1998, ANN NEUROL, V43, P555, DOI 10.1002/ana.410430503; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; Vila M, 2000, J NEUROCHEM, V74, P721, DOI 10.1046/j.1471-4159.2000.740721.x	59	152	153	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1695	+		10.1096/fj.06-5864fje	http://dx.doi.org/10.1096/fj.06-5864fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809432				2022-12-25	WOS:000240266600018
J	Fessenden, JD; Feng, W; Pessah, IN; Allen, PD				Fessenden, James D.; Feng, Wei; Pessah, Isaac N.; Allen, Paul D.			Amino acid residues Gln(4020) and Lys(4021) of the ryanodine receptor type 1 are required for activation by 4-chloro-m-cresol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; IDENTIFICATION; SENSITIVITY; EXPRESSION; CAFFEINE; BINDING; REGION	The ryanodine receptor type 1 (RyR1) and type 2 (RyR2), but not type 3 (RyR3), are efficiently activated by 4-chloro-m-cresol (4-CmC). We previously showed that a 173-amino acid segment of RyR1 (residues 4007-4180) is required for channel activation by 4-CmC (Fessenden, J. D., Perez, C. F., Goth, S., Pessah, I. N., and Allen, P. D. (2003) J. Biol. Chem. 278, 28727-28735). In the present study, we used site-directed mutagenesis to identify individual amino acid(s) within this region that mediate 4-CmC activation. In RyR1, substitution of 11 amino acids conserved between RyR1 and RyR2, but divergent in RyR3, with their RyR3 counterparts reduced 4-CmC sensitivity to the same degree as substitution of the entire 173-amino acid segment. Further analysis of various RyR1 mutants containing successively smaller numbers of these mutations identified 2 amino acid residues (Gln(4020) and Lys(4021)) that, when mutated to their RyR3 counterparts (Leu(3873) and Gln(3874)), abolished 4-CmC activation of RyR1. Mutation of either of these residues alone did not abolish 4-CmC sensitivity, although Q4020L partially reduced 4-CmC-induced Ca2+ transients. In addition, mutation of the corresponding residues in RyR3 to their RyR1 counterparts (L3873Q/Q3874K) imparted 4-CmC sensitivity to RyR3. Recordings of single RyR1 channels indicated that 4-CmC applied to either the luminal or cytoplasmic side activated the channel with equal potency. Secondary structure modeling in the vicinity of the Gln4020-Lys4021 dipeptide suggests that the region contains a surface-exposed region adjacent to a hydrophobic segment, indicating that both hydrophilic and hydrophobic regions of RyR1 are necessary for 4-CmC binding to the channel activation.	Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02115 USA; Ctr Childrens Environm Hlth, Dept Vet Med Mol Biosci, Davis, CA 95616 USA	Harvard University; Brigham & Women's Hospital	Fessenden, JD (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	fessenden@bbri.org	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NHLBI NIH HHS [1F32 HL67572-01] Funding Source: Medline; NIAMS NIH HHS [R01-AR43640] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL067572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEELER TJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P216, DOI 10.1006/abbi.1993.1136; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Choisy S, 1999, J PHARMACOL EXP THER, V290, P578; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Fessenden JD, 2003, J BIOL CHEM, V278, P28727, DOI 10.1074/jbc.M303821200; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; George CH, 2004, MOL BIOL CELL, V15, P2627, DOI 10.1091/mbc.E03-09-0688; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; IVANENKO A, 1995, J BIOL CHEM, V270, P4220, DOI 10.1074/jbc.270.9.4220; JACOBSON AR, 2006, IN PRESS MOL PHARM; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Matyash M, 2001, FASEB J, V15, P84, DOI 10.1096/fj.01-0380fje; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Xiong H, 1998, BIOCHEMISTRY-US, V37, P4804, DOI 10.1021/bi971198b; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	26	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					21022	21031		10.1074/jbc.M600670200	http://dx.doi.org/10.1074/jbc.M600670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16737973	hybrid			2022-12-25	WOS:000239187300039
J	Soboloff, J; Spassova, MA; Tang, XD; Hewavitharana, T; Xu, W; Gill, DL				Soboloff, Jonathan; Spassova, Maria A.; Tang, Xiang D.; Hewavitharana, Thamara; Xu, Wen; Gill, Donald L.			Orai1 and STIM reconstitute store-operated calcium channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE RECEPTOR; CRAC CHANNELS; CA2+ SENSOR; IDENTIFICATION; ACTIVATION; BORATE	The two membrane proteins, STIM1 and Orail, have each been shown to be essential for the activation of store-operated channels ( SOC). Yet, how these proteins functionally interact is not known. Here, we reveal that STIM1 and Orail expressed together reconstitute functional SOCs. Expressed alone, Orail strongly reduces store-operated Ca2+ entry ( SOCE) in human embryonic kidney 293 cells and the Ca2+ release-activated Ca2+ current ( ICRAC) in rat basophilic leukemia cells. However, expressed along with the store-sensing STIM1 protein, Orail causes a massive increase in SOCE, enhancing the rate of Ca2+ entry by up to 103-fold. This entry is entirely store-dependent since the same coexpression causes no measurable store-independent Ca2+ entry. The entry is completely blocked by the SOC blocker, 2-aminoethoxydiphenylborate. Orail and STIM1 coexpression also caused a large gain in CRAC channel function in rat basophilic leukemia cells. The close STIM1 homologue, STIM2, inhibited SOCE when expressed alone but coexpressed with Orail caused substantial constitutive ( store-independent) Ca2+ entry. STIM proteins are known to mediate Ca2+ store-sensing and endoplasmic reticulum-plasma membrane coupling with no intrinsic channel properties. Our results revealing a powerful gain in SOC function dependent on the presence of both Orail and STIM1 strongly suggest that Orail contributes the PM channel component responsible for Ca2+ entry. The suppression of SOC function by Orail overexpression likely reflects a required stoichiometry between STIM1 and Orail.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	dgill@umaryland.edu	Soboloff, Jonathan/I-6995-2012	Soboloff, Jonathan/0000-0001-5192-1297	NHLBI NIH HHS [HL55426] Funding Source: Medline; NIAID NIH HHS [AI058173] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BIAN JH, 1991, J BIOL CHEM, V266, P8801; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; PEINELT C, 2006, IN PRESS NAT CELL BI; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2001, J CELL SCI, V114, P2223; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; SOBOLOFF J, 2006, IN PRESS CURR BIOL; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; SPASSSOVA MA, 2006, BIOPHYS J; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	24	442	473	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2006	281	30					20661	20665		10.1074/jbc.C600126200	http://dx.doi.org/10.1074/jbc.C600126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065VF	16766533	hybrid			2022-12-25	WOS:000239187300002
J	Yang, BH; Oo, TN; Rizzo, V				Yang, Baohua; Oo, Tin N.; Rizzo, Victor			Lipid rafts mediate H2O2 prosurvival effects in cultured endothelial cells	FASEB JOURNAL			English	Article						caveolae; apoptosis; reactive oxygen species; endothelium	NITRIC-OXIDE SYNTHASE; N-TERMINAL KINASE; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; SIGNALING PATHWAYS; CELLULAR-RESPONSE; ACTIVATION; PHOSPHORYLATION; APOPTOSIS; RECEPTOR	Reactive oxygen species (ROS) generated during pathological events, such as inflammation and ischemia-reperfusion, activates both proapoptotic and antiapoptotic signaling programs in endothelial cells. Because cholesterol-rich, plasma membrane rafts serve as platforms for organizing and integrating signaling transduction processes, we asked whether these membrane regions play a mechanistic role in H2O2-induced responses. Bovine aortic endothelial cell cultures exposed to a 500-mu M bolus of H2O2 showed progressive activation of caspase 3 and an increase in the number of TUNEL-positive cells. Pretreatment with either wortmannin or PD 098059 heightened these apoptotic responses, demonstrating that both PI3 kinase/Akt and ERK1/2 serve as signaling mediators to alleviate H2O2 cytotoxic effects. To investigate the role of lipid rafts in these signaling processes, endothelial cells were pretreated with methyl-beta-cyclodextrin (CD) or filipin to ablate raft structures. H2O2-induced phosphorylation of Akt and ERK 1/2 was attenuated, while caspase 3 and the number of TUNEL positive cells was enhanced in CD-pretreated cells exposed to H2O2. Reconstitution of raft domains restored H2O2-induced Akt and ERK1/ 2 phosphorylation, which was concomitant with reduction of caspase 3 activation and DNA fragmentation. Taken together, our findings suggest that plasma membrane compartments rich in cholesterol participate in signal transduction pathways activated by oxidative stress.	Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA; Albany Med Coll, Cardiovasc Res Ctr, Albany, NY 12208 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Albany Medical College	Rizzo, V (corresponding author), Temple Univ, Sch Med, Cardiovasc Res Ctr, Dept Anat & Cell Biol, 3420 N Broad St,MRB826, Philadelphia, PA 19140 USA.	rizzov@temple.edu			NHLBI NIH HHS [HL66301-VR] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066301] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325; Chambaut-Guerin AM, 2005, BIOL CELL, V97, P339, DOI 10.1042/BC200400062; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; D'Alessio A, 2005, AM J PATHOL, V166, P1273, DOI 10.1016/S0002-9440(10)62346-2; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Ferraro JT, 2004, AM J PHYSIOL-CELL PH, V286, pC831, DOI 10.1152/ajpcell.00224.2003; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Ko YG, 1999, J IMMUNOL, V162, P7217; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Nguyen A, 2004, FEBS LETT, V572, P307, DOI 10.1016/j.febslet.2004.06.061; Niwa K, 2003, ANTIOXID REDOX SIGN, V5, P713, DOI 10.1089/152308603770380016; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Oxhorn BC, 2003, CELL SIGNAL, V15, P489, DOI 10.1016/S0898-6568(02)00149-3; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Sudoh N, 2001, CIRCULATION, V103, P724; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zmijewski JW, 2005, BIOCHEM SOC T, V33, P1385, DOI 10.1042/BST0331385	34	100	102	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1501	+		10.1096/fj.05-5359fje	http://dx.doi.org/10.1096/fj.05-5359fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754746				2022-12-25	WOS:000240266000031
J	Trauzold, A; Siegmund, D; Schniewind, B; Sipos, B; Egberts, J; Zorenkov, D; Emme, D; Roder, C; Kalthoff, H; Wajant, H				Trauzold, A.; Siegmund, D.; Schniewind, B.; Sipos, B.; Egberts, J.; Zorenkov, D.; Emme, D.; Roeder, C.; Kalthoff, H.; Wajant, H.			TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; metastasis; invasion; TRAIL	INDUCED APOPTOSIS; BCL-X; CANCER; CELLS; ACTIVATION; EXPRESSION; BAX; PROLIFERATION; APO2L/TRAIL; RESISTANCE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention for its potential use in tumor therapy, as some recombinant variants of this ligand induce apoptosis in tumor cells without harming most normal cells. Here, we show that TRAIL strongly induces the expression of the proinflammatory cytokines interleukin-8 and monocyte chemoattractant protein 1 and enhances the invasion of apoptosis-resistant pancreatic ductal adenocarcinoma cells in vitro by upregulation of the urokinase-type plasminogen activator expression. Most importantly, we also demonstrate for the first time that TRAIL treatment results in strongly increased distant metastasis of pancreatic tumors in vivo. We orthotopically transplanted human pancreatic ductal adenocarcinoma cells to the pancreata of severe combined immunodeficiency mice and observed a dramatic increase in metastatic spread including a sixfold increase in the volume and fourfold increase in the number of liver metastases upon TRAIL treatment. Our results point to the necessity to carefully evaluate in vivo side effects of TRAIL and to select therapy conditions that not only enhance apoptosis induction but in addition prevent proinvasive and proinflammatory non-apoptotic TRAIL signaling.	Univ Kiel, Hosp Schleswig Holstein, Clin Gen Surg & Thorac Surg, Sect Mol Oncol, D-24105 Kiel, Germany; Univ Wurzburg, Med Clin & Polyclin 2, Dept Mol Internal Med, D-97070 Wurzburg, Germany; Univ Kiel, Hosp Schleswig Holstein, Inst Gen Pathol, D-24098 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg; University of Kiel; Schleswig Holstein University Hospital	Kalthoff, H (corresponding author), Clin Gen Surg & Thorac Surg, Sect Mol Oncol, Campus Kiel,Arnold Heller Str 7, D-24105 Kiel, Germany.	hkalthoff@email.uni-kiel.de	Wajant, Harald/A-3020-2017; Trauzold, Anna/P-4398-2014; Egberts, Jan-Hendrik/E-3211-2015; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010	Wajant, Harald/0000-0002-2005-3949; Roeder, Christian/0000-0001-7881-9110				Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Armeanu S, 2003, CANCER RES, V63, P2369; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baader E, 2005, CANCER RES, V65, P7888, DOI 10.1158/0008-5472.CAN-04-4278; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Evans JD, 2001, PANCREATOLOGY, V1, P254, DOI 10.1159/000055820; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Siegmund D, 2005, MOL CELL BIOL, V25, P6363, DOI 10.1128/MCB.25.15.6363-6379.2005; TEPEL J, 2005, INT J COLORECTAL DIS, V16, P1; Trauzold A, 2005, FASEB J, V19, P620, DOI 10.1096/fj.04-2984fje; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	27	186	193	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7434	7439		10.1038/sj.onc.1209719	http://dx.doi.org/10.1038/sj.onc.1209719			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16751802				2022-12-25	WOS:000242419100012
J	Finoux, AL; Seraphin, B				Finoux, Anne-Laure; Seraphin, Bertrand			In vivo targeting of the yeast Pop2 deadenylase subunit to reporter transcripts induces their rapid degradation and generates new decay intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLASE; SACCHAROMYCES-CEREVISIAE; POLY(A)-BINDING PROTEIN; CCR4-NOT COMPLEX; CAF1 PROTEINS; POLY(A); NUCLEASE; TURNOVER; PURIFICATION; TRANSLATION	Deadenylation is the rate-limiting step of mRNA decay, yet little is known about the mechanism regulating this process. In yeast, deadenylation is mainly mediated by the Pop2-Ccr4 complex. We tested whether the selective recruitment of this deadenylase to target mRNAs was sufficient to stimulate their decay in vivo. For this purpose, the Pop2 factor was fused to a U1A RNA binding domain while U1A binding sites were inserted in untranslated regions of a reporter transcript. Analysis of the reporter fate in strains expressing the Pop2-U1A-RBD fusion demonstrated a specific activation of target mRNA decay. Increased mRNA degradation involved accumulation of deadenylated mRNAs that was not detected when the control factors Dcp2 or Pub1 were tethered to the same transcript. The rapid target mRNA degradation was also accompanied by the appearance of new decay intermediates generated by the 3'-5' trimming of the corresponding 3'-untranslated region. Interestingly, this process was not mediated by the exosome but may result from the activity of the Pop2-Ccr4 deadenylase itself. These results indicate that selective recruitment of the Pop2-Ccr4 deadenylase is sufficient to activate mRNA decay, even though this process can also be stimulated by additional mechanisms. Furthermore, deadenylase recruitment affects the downstream path of mRNA decay.	Univ Paris 06, CNRS, Unite Propre Rech 2167, Ctr Mol Genet,Equipe Labelisee La Ligue, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Seraphin, B (corresponding author), Univ Paris 06, CNRS, Unite Propre Rech 2167, Ctr Mol Genet,Equipe Labelisee La Ligue, Ave Terrasse, F-91198 Gif Sur Yvette, France.	seraphin@cgm.cnrs-gif.fr		Seraphin, Bertrand/0000-0002-5168-1921				Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; Bianchin C, 2005, RNA, V11, P487, DOI 10.1261/rna.7135305; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Collart MA, 2004, PROG NUCLEIC ACID RE, V77, P289, DOI 10.1016/S0079-6603(04)77008-7; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; Cougot N, 2004, TRENDS BIOCHEM SCI, V29, P436, DOI 10.1016/j.tibs.2004.06.008; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; HARLOW E, 1998, ANTIBODIES LAB MANUA, P471; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Khanna R, 2004, EMBO J, V23, P1968, DOI 10.1038/sj.emboj.7600213; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Nagai K, 1995, Nucleic Acids Symp Ser, P1; Puig O, 1998, YEAST, V14, P1139; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SIKORSKI RS, 1989, GENETICS, V122, P19; Temme C, 2004, EMBO J, V23, P2862, DOI 10.1038/sj.emboj.7600273; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Dijk EL, 2001, NUCLEIC ACIDS RES, V29, P3477, DOI 10.1093/nar/29.17.3477; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					25940	25947		10.1074/jbc.M600132200	http://dx.doi.org/10.1074/jbc.M600132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16793769	hybrid			2022-12-25	WOS:000240249500008
J	Hidalgo, C; Sanchez, G; Barrientos, G; Aracena-Parks, P				Hidalgo, Cecilia; Sanchez, Gina; Barrientos, Genaro; Aracena-Parks, Paula			A transverse tubule NADPH oxidase activity stimulates calcium release from isolated triads via ryanodine receptor type 1 S-glutathionylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RAT SKELETAL-MUSCLE; RYANODINE RECEPTOR COMPLEX; HUMAN ENDOTHELIAL-CELLS; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; CA2+ RELEASE; OXIDATIVE STRESS; CONTRACTING DIAPHRAGM; NAD(P)H OXIDASES	We report here the presence of an NADPH oxidase (NOX) activity both in intact and in isolated transverse tubules and in triads isolated from mammalian skeletal muscle, as established by immunochemical, enzymatic, and pharmacological criteria. Immunohistochemical determinations with NOX antibodies showed that the gp91(phox) membrane subunit and the cytoplasmic regulatory p47(phox) subunit co-localized in transverse tubules of adult mice fibers with the alpha(1s) subunit of dihydropyridine receptors. Western blot analysis revealed that isolated triads contained the integral membrane subunits gp91(phox) and p22(phox), which were markedly enriched in isolated transverse tubules but absent from junctional sarcoplasmic reticulum vesicles. Isolated triads and transverse tubules, but not junctional sarcoplasmic reticulum, also contained varying amounts of the cytoplasmic NOX regulatory subunits p47phox and p67phox. NADPH or NADH elicited superoxide anion and hydrogen peroxide generation by isolated triads; both activities were inhibited by NOX inhibitors but not by rotenone. NADH diminished the total thiol content of triads by one-third; catalase or apocynin, a NOX inhibitor, prevented this effect. NADPH enhanced the activity of ryanodine receptor type 1 (RyR1) in triads, measured through [H-3] ryanodine binding and calcium release kinetics, and increased significantly RyR1 S-glutathionylation over basal levels. Preincubation with reducing agents or NOX inhibitors abolished the enhancement of RyR1 activity produced by NADPH and prevented NADPH- induced RyR1 S-glutathionylation. We propose that reactive oxygen species generated by the transverse tubule NOX activate via redox modification the neighboring RyR1 Ca2+ release channels. Possible implications of this	Univ Chile, Fac Med, ICBM, Ctr FONDAP Estudios Mol Celula, Santiago 7, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Patol, Santiago 7, Chile	Universidad de Chile; Universidad de Chile; Universidad de Chile	Hidalgo, C (corresponding author), Univ Chile, Fac Med, ICBM, Ctr FONDAP Estudios Mol Celula, Casilla 70005, Santiago 7, Chile.	chidalgo@med.uchile.cl	Barrientos, Genaro/I-2778-2013; Aracena, Paula/A-5607-2012	Aracena, Paula/0000-0002-2144-6875				Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Aracena P, 2005, ANTIOXID REDOX SIGN, V7, P870, DOI 10.1089/ars.2005.7.870; Aracena P, 2003, J BIOL CHEM, V278, P42927, DOI 10.1074/jbc.M306969200; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bal-Price A, 2002, J NEUROCHEM, V80, P73, DOI 10.1046/j.0022-3042.2001.00675.x; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brotto MAP, 1996, J APPL PHYSIOL, V81, P731, DOI 10.1152/jappl.1996.81.2.731; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P489, DOI 10.1016/S0968-0004(02)02191-6; DeCoursey TE, 2003, NATURE, V422, P531, DOI 10.1038/nature01523; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Griendling KK, 2004, HEART, V90, P491, DOI 10.1136/hrt.2003.029397; Grozdanovic Z, 2001, MICROSC RES TECHNIQ, V55, P148, DOI 10.1002/jemt.1165; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Haugaard N, 2000, ANN NY ACAD SCI, V899, P148; HIDALGO C, 1983, J BIOL CHEM, V258, P3937; HIDALGO C, 1993, J BIOL CHEM, V268, P15111; Hidalgo C, 2005, IUBMB LIFE, V57, P315, DOI 10.1080/15216540500092328; Jackson MJ, 2005, PHILOS T R SOC B, V360, P2285, DOI 10.1098/rstb.2005.1773; Javesghani D, 2002, AM J RESP CRIT CARE, V165, P412, DOI 10.1164/ajrccm.165.3.2103028; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Kishida KT, 2005, J NEUROCHEM, V94, P299, DOI 10.1111/j.1471-4159.2005.03189.x; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Matsuzaki I, 2005, AM J PHYSIOL-HEART C, V288, pH336, DOI 10.1152/ajpheart.00025.2004; Nethery D, 1999, J APPL PHYSIOL, V87, P792, DOI 10.1152/jappl.1999.87.2.792; Noh KM, 2000, J NEUROSCI, V20; Oba T, 2000, AM J PHYSIOL-CELL PH, V279, pC1366, DOI 10.1152/ajpcell.2000.279.5.C1366; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; Pessah IN, 2001, PEST MANAG SCI, V57, P941, DOI 10.1002/ps.391; Pessah IN, 2002, FRONT BIOSCI-LANDMRK, V7, pA72, DOI 10.2741/pessah; Posterino GS, 2003, J PHYSIOL-LONDON, V547, P807, DOI 10.1113/jphysiol.2002.035204; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Reid MB, 2002, ANN NY ACAD SCI, V959, P108, DOI 10.1111/j.1749-6632.2002.tb02087.x; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; RHEE SG, 2000, SCI STKE, pE1; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sanchez G, 2005, J MOL CELL CARDIOL, V39, P982, DOI 10.1016/j.yjmcc.2005.08.010; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Stofan DA, 2000, AM J RESP CRIT CARE, V161, P891; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Suzuki YJ, 1998, FREE RADICAL BIO MED, V24, P318, DOI 10.1016/S0891-5849(97)00227-X; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Tammariello SP, 2000, J NEUROSCI, V20; Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Xia RH, 2003, AM J PHYSIOL-CELL PH, V285, pC215, DOI 10.1152/ajpcell.00034.2002; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zuo L, 2000, AM J PHYSIOL-CELL PH, V279, pC1058, DOI 10.1152/ajpcell.2000.279.4.C1058	79	142	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26473	26482		10.1074/jbc.M600451200	http://dx.doi.org/10.1074/jbc.M600451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16762927	hybrid			2022-12-25	WOS:000240249500065
J	Helle, F; Wychowski, C; Vu-Dac, N; Gustafson, KR; Voisset, C; Dubuisson, J				Helle, Francois; Wychowski, Czeslaw; Vu-Dac, Ngoc; Gustafson, Kirk R.; Voisset, Cecile; Dubuisson, Jean			Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INACTIVATING PROTEIN; GLYCOPROTEIN E2; PSEUDOTYPE PARTICLES; CELL-CULTURE; GP120; HIV; GLYCOSYLATION; LOCALIZATION; COMPLEXES	Inhibition of viruses at the stage of viral entry provides a route for therapeutic intervention. Because of difficulties in propagating hepatitis C virus (HCV) in cell culture, entry inhibitors have not yet been reported for this virus. However, with the development of retroviral particles pseudotyped with HCV envelope glycoproteins (HCVpp) and the recent progress in amplification of HCV in cell culture (HCVcc), studying HCV entry is now possible. In addition, these systems are essential for the identification and the characterization of molecules that block HCV entry. The lectin cyanovirin-N (CV-N) has initially been discovered based on its potent activity against human immunodeficiency virus. Because HCV envelope glycoproteins are highly glycosylated, we sought to determine whether CV-N has an antiviral activity against this virus. CV-N inhibited the infectivity of HCVcc and HCVpp at low nanomolar concentrations. This inhibition is attributed to the interaction of CV-N with HCV envelope glycoproteins. In addition, we showed that the carbohydrate binding property of CV-N is involved in the anti-HCV activity. Finally, CV-N bound to HCV envelope glycoproteins and blocked the interaction between the envelope protein E2 and CD81, a cell surface molecule involved in HCV entry. These data demonstrate that targeting the glycans of HCV envelope proteins is a promising approach in the development of antiviral therapies to combat a virus that is a major cause of chronic liver diseases. Furthermore, CV-N is a new invaluable tool to further dissect the early steps of HCV entry into host cells.	Inst Pasteur, Ctr Natl Rech Sci, Inst Biol, Unite Mixt Rech 8161,Hepatitis C Lab,UMR8161, F-59021 Lille, France; NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dubuisson, J (corresponding author), Inst Pasteur, Ctr Natl Rech Sci, Inst Biol, Unite Mixt Rech 8161,Hepatitis C Lab,UMR8161, 1 Rue Calmette,BP447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Voisset, Cecile/AAK-1636-2020; HELLE, Francois/G-7427-2011; Dubuisson, Jean/E-6813-2016	HELLE, Francois/0000-0001-6884-2456; Dubuisson, Jean/0000-0003-1626-7693; Voisset, Cecile/0000-0001-7505-1927				Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200; Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3; Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e; Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949, DOI 10.1124/mol.59.5.949; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Ciczora Y, 2005, J GEN VIROL, V86, P2793, DOI 10.1099/vir.0.81140-0; Cocquerel L, 2006, J GEN VIROL, V87, P1075, DOI 10.1099/vir.0.81646-0; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; De Beeck AO, 2004, J VIROL, V78, P2994, DOI 10.1128/JVI.78.6.2994-3002.2004; De Francesco R, 2005, NATURE, V436, P953, DOI 10.1038/nature04080; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082; Flint M, 2004, J VIROL, V78, P6875, DOI 10.1128/JVI.78.13.6875-6882.2004; Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Goffard A, 2005, J VIROL, V79, P8400, DOI 10.1128/JVI.79.13.8400-8409.2005; Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X; Heile JM, 2000, J VIROL, V74, P6885, DOI 10.1128/JVI.74.15.6885-6892.2000; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542; Lindenbach B.D., 2020, FIELDS VIROLOGY, V7, P246; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; MAJOR ME, 2001, FIELDS VIROLOGY; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; O'Keefe BR, 2000, MOL PHARMACOL, V58, P982, DOI 10.1124/mol.58.5.982; O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003; Pawlotsky Jean-Michel, 2003, Clin Liver Dis, V7, P45, DOI 10.1016/S1089-3261(02)00065-X; Pawlotsky JM, 2006, HEPATOLOGY, V43, pS207, DOI 10.1002/hep.21064; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Rouille Y, 2006, J VIROL, V80, P2832, DOI 10.1128/JVI.80.6.2832-2841.2006; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5; Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005; Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	48	139	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25177	25183		10.1074/jbc.M602431200	http://dx.doi.org/10.1074/jbc.M602431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16809348	hybrid			2022-12-25	WOS:000240031300018
J	Hobe, S; Trostmann, I; Raunser, S; Paulsen, H				Hobe, Stephan; Trostmann, Inga; Raunser, Stefan; Paulsen, Harald			Assembly of the major light-harvesting chlorophyll-a/b complex - Thermodynamics and kinetics of neoxanthin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; ABSCISIC-ACID; IN-VITRO; PROTEIN COMPLEX; FLUORESCENCE; XANTHOPHYLLS; CAROTENOIDS; ARABIDOPSIS; SITES; PHOTOPROTECTION	The major light-harvesting chlorophyll-a/b complex in most higher plants contains three carotenoids, lutein, neoxanthin, and violaxanthin. How these pigments are assembled into the complex during its biogenesis is largely unknown. Here we show that neoxanthin but not lutein can dissociate from the fully assembled complex. Its equilibrium binding constant in a detergent system (0.1% n-dodecyl-beta-D-maltoside) was determined to be >= 106 M-1. Neoxanthin insertion into light-harvesting chlorophyll-a/b complex prefolded from overexpressed apoprotein (Lhcb1*2 from Pisum sativum) in the presence of chlorophylls a, b, and lutein as the sole carotenoid is kinetically controlled by an activation energy barrier of similar to 120 kJ mol(-1). This is the first thermodynamic and kinetic description of a binding equilibrium between a non-covalently bound pigment of the photosynthetic apparatus and its protein complex. Dissociation of neoxanthin from the major light-harvesting chlorophyll-a/b complex upon temperature increase is discussed in terms of providing a readily available substrate pool for synthesizing abscisic acid as part of a heat and drought stress response.	Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Johannes Gutenberg University of Mainz; Harvard University; Harvard Medical School	Paulsen, H (corresponding author), Johannes Gutenberg Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	paulsen@uni-mainz.de	Raunser, Stefan/AHE-1573-2022; Paulsen, Harald/D-3742-2011	Raunser, Stefan/0000-0001-9373-3016				Adamska I, 2001, J BIOL CHEM, V276, P8582, DOI 10.1074/jbc.M010447200; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Booth PJ, 1996, BIOCHEMISTRY-US, V35, P5103, DOI 10.1021/bi953053f; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Cseh Z, 2000, BIOCHEMISTRY-US, V39, P15250, DOI 10.1021/bi001600d; Cutler AJ, 1999, TRENDS PLANT SCI, V4, P472, DOI 10.1016/S1360-1385(99)01497-1; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; DREYFUSS BW, 1994, PLANT PHYSIOL, V106, P829, DOI 10.1104/pp.106.3.829; EUGSTER CH, 1995, CAROTENOIDS; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; Holt NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/bi0494020; Horn R, 2004, J BIOL CHEM, V279, P44400, DOI 10.1074/jbc.M407188200; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; Jahns P, 2001, J BIOL CHEM, V276, P22154, DOI 10.1074/jbc.M102147200; KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071; KRUPA Z, 1987, PLANT PHYSIOL, V84, P19, DOI 10.1104/pp.84.1.19; LINDAHL M, 1995, EUR J BIOCHEM, V231, P503, DOI 10.1111/j.1432-1033.1995.tb20725.x; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Lokstein H, 2002, BBA-BIOENERGETICS, V1553, P309, DOI 10.1016/S0005-2728(02)00184-6; MARTINSON TA, 1995, ANAL BIOCHEM, V228, P123, DOI 10.1006/abio.1995.1323; Mercadante AZ, 1998, J AGR FOOD CHEM, V46, P128, DOI 10.1021/jf9702860; Mick V, 2004, BIOCHEMISTRY-US, V43, P5467, DOI 10.1021/bi036198s; Milborrow BV, 2001, J EXP BOT, V52, P1145, DOI 10.1093/jexbot/52.359.1145; MOLNAR P, 1980, PHYTOCHEMISTRY, V19, P623, DOI 10.1016/0031-9422(80)87027-0; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; Niyogi KK, 2001, PHOTOSYNTH RES, V67, P139, DOI 10.1023/A:1010661102365; Palacios MA, 2004, BBA-BIOENERGETICS, V1656, P177, DOI 10.1016/j.bbabio.2004.04.002; PARRY AD, 1991, PHYTOCHEMISTRY, V30, P815, DOI 10.1016/0031-9422(91)85258-2; PARRY AD, 1990, PLANTA, V182, P118, DOI 10.1007/BF00239993; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Phillip D, 2002, J BIOL CHEM, V277, P25160, DOI 10.1074/jbc.M202002200; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Reinsberg D, 2001, J MOL BIOL, V308, P59, DOI 10.1006/jmbi.2001.4573; Rodrigo MJ, 2006, J EXP BOT, V57, P633, DOI 10.1093/jxb/erj048; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Schwartz SH, 2003, BBA-GEN SUBJECTS, V1619, P9, DOI 10.1016/S0304-4165(02)00422-1; Snyder AM, 2004, J BIOL CHEM, V279, P5162, DOI 10.1074/jbc.M309676200; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; Strand A, 2000, BIOCHEM SYST ECOL, V28, P443, DOI 10.1016/S0305-1978(99)00078-2; Takaichi S, 1998, PLANT CELL PHYSIOL, V39, P968, DOI 10.1093/oxfordjournals.pcp.a029461; Tardy F, 1996, J PHOTOCH PHOTOBIO B, V34, P87, DOI 10.1016/1011-1344(95)07272-1; Yang CH, 2003, BIOCHEMISTRY-US, V42, P4527, DOI 10.1021/bi0273157; Yang DH, 2000, FEBS LETT, V466, P385, DOI 10.1016/S0014-5793(00)01107-8	54	26	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25156	25166		10.1074/jbc.M604828200	http://dx.doi.org/10.1074/jbc.M604828200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803876	hybrid			2022-12-25	WOS:000240031300016
J	Patel, M; Siegel, AJ; Berry, JO				Patel, Minesh; Siegel, Alan J.; Berry, James O.			Untranslated regions of FbRbcS1 mRNA mediate bundle sheath cell-specific gene expression in leaves of a C-4 plant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLASE SMALL-SUBUNIT; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; PHOSPHOENOLPYRUVATE CARBOXYLASE; POSTTRANSCRIPTIONAL CONTROL; AMARANTH COTYLEDONS; PHOTOSYNTHESIS; PROMOTER; TOMATO; MAIZE; MESOPHYLL	C-4 photosynthesis typically requires two specialized leaf cell types, bundle sheath (bs) and mesophyll (mp), which provide the foundation for this highly efficient carbon assimilation pathway. In leaves of Flaveria bidentis, a dicotyledonous C-4 plant, ribulose 1,5-bisphosphate carboxylase (rubisco) accumulates only in bs cells surrounding the vascular centers and not in mp cells. This is in contrast to the more common C-3 plants, which accumulate rubisco in all photosynthetic cells. Many previous studies have focused on transcriptional control of C-4 cell type-specificity; however, post-transcriptional regulation has also been implicated in the bs-specific expression of genes encoding the rubisco subunits. In this current study, a biolistic leaf transformation assay has provided direct evidence that the 5 '- and 3 '-untranslated regions (UTRs) of F. bidentis FbRbcS1 mRNA ( from a nuclear gene encoding the rubisco small subunit), in themselves, confer strong bs cell-specific expression to gfpA reporter gene transcripts when transcribed from a constitutive CaMV promoter. In transformed leaf regions, strong bs cell-specific GFP expression was accompanied by corresponding bs cell-specific accumulation of the constitutively transcribed FbRbcS1 5 '-UTR-gfpA-3 '-UTR mRNAs. Control constructs lacking any RbcS mRNA sequences were expressed in all leaf cell types. These findings demonstrate that characteristic cell type-specific FbRbcS1 expression patterns in C-4 leaves can be established entirely by sequences contained within the transcribed UTRs of FbRbcS1 mRNAs. We conclude that selective transcript stabilization (in bs cells) or degradation (in mp cells) plays a key role in determining bs cell-specific localization of the rubisco enzyme.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Berry, JO (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.	camjob@buffalo.edu						BANSAL KC, 1992, P NATL ACAD SCI USA, V89, P3654, DOI 10.1073/pnas.89.8.3654; Berger S, 2004, PHYSIOL PLANTARUM, V122, P419, DOI 10.1111/j.1399-3054.2004.00433.x; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; BOINSKI JJ, 1993, PLANT MOL BIOL, V22, P397, DOI 10.1007/BF00015971; Brown NJ, 2005, TRENDS PLANT SCI, V10, P215, DOI 10.1016/j.tplants.2005.03.003; Cheng SH, 1998, PLANT PHYSIOL, V116, P715, DOI 10.1104/pp.116.2.715; Cheng YL, 2004, CURR OPIN PLANT BIOL, V7, P20, DOI 10.1016/j.pbi.2003.11.005; Curie C, 1997, PLANT CELL, V9, P2025; Edwards GE, 2001, J EXP BOT, V52, P577, DOI 10.1093/jexbot/52.356.577; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; Fedoroff NV, 2002, CURR OPIN PLANT BIOL, V5, P452, DOI 10.1016/S1369-5266(02)00280-7; FURBANK RT, 1995, PLANT CELL, V7, P797, DOI 10.2307/3870037; FURBANK RT, 2000, ADV PHOTOSYNTHESIS P, P459; Gowik U, 2004, PLANT CELL, V16, P1077, DOI 10.1105/tpc.019729; GREEN PJ, 1993, PLANT PHYSIOL, V102, P1065, DOI 10.1104/pp.102.4.1065; Gutierrez RA, 2002, P NATL ACAD SCI USA, V99, P11513, DOI 10.1073/pnas.152204099; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; He XY, 2002, NUCLEIC ACIDS RES, V30, P497, DOI 10.1093/nar/30.2.497; HENSEL LL, 1993, PLANT CELL, V5, P553, DOI 10.1105/tpc.5.5.553; Hu WW, 2005, PLANT PHYSIOL, V138, P276, DOI 10.1104/pp.104.056770; JIANG CZ, 1993, PLANT PHYSIOL, V101, P105, DOI 10.1104/pp.101.1.105; Kanai R., 1999, C4 PLANT BIOL, P49, DOI [10.5860/choice.36-6275, DOI 10.5860/CHOICE.36-6275, DOI 10.1016/B978-012614440-6/50004-5]; LANGDALE JA, 1991, MOL GEN GENET, V225, P49, DOI 10.1007/BF00282641; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Long JJ, 1996, PLANT PHYSIOL, V112, P473, DOI 10.1104/pp.112.2.473; McCormac D, 1997, PLANT PHYSIOL, V114, P801, DOI 10.1104/pp.114.3.801; Nomura M, 2000, PLANT J, V22, P211, DOI 10.1046/j.1365-313x.2000.00726.x; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patel M, 2004, PLANT PHYSIOL, V136, P3550, DOI 10.1104/pp.104.051508; Ramsperger VC, 1996, PLANT PHYSIOL, V111, P999, DOI 10.1104/pp.111.4.999; Rodermel S, 1996, P NATL ACAD SCI USA, V93, P3881, DOI 10.1073/pnas.93.9.3881; Sage RF, 2004, NEW PHYTOL, V161, P341, DOI 10.1111/j.1469-8137.2004.00974.x; SEELEY KA, 1992, PLANT CELL, V4, P29, DOI 10.1105/tpc.4.1.29; Sheen J, 1999, ANNU REV PLANT PHYS, V50, P187, DOI 10.1146/annurev.arplant.50.1.187; SHIRLEY BW, 1990, NUCLEIC ACIDS RES, V18, P3377, DOI 10.1093/nar/18.11.3377; Sinha AK, 2002, PLANT PHYSIOL, V128, P1480, DOI 10.1104/pp.010771; Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017; THOMPSON DM, 1990, NUCLEIC ACIDS RES, V18, P3621, DOI 10.1093/nar/18.12.3621; VIRET JF, 1994, P NATL ACAD SCI USA, V91, P8577, DOI 10.1073/pnas.91.18.8577; von Caemmerer S, 2003, PHOTOSYNTH RES, V77, P191, DOI 10.1023/A:1025830019591; WANG JL, 1992, PLANT CELL, V4, P173, DOI 10.1105/tpc.4.2.173; WANG JL, 1993, PLANT PHYSIOL, V102, P1085, DOI 10.1104/pp.102.4.1085; WANG JL, 1993, PLANT CELL, V5, P289, DOI 10.1105/tpc.5.3.289; WANNER LA, 1991, PLANT CELL, V3, P1289, DOI 10.1105/tpc.3.12.1289; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Zhou JL, 2001, PLANT CELL PHYSIOL, V42, P1049, DOI 10.1093/pcp/pce131; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	48	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25485	25491		10.1074/jbc.M604162200	http://dx.doi.org/10.1074/jbc.M604162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803877	hybrid			2022-12-25	WOS:000240031300051
J	Ricard-Blum, S; Beraud, M; Raynal, N; Farndale, RW; Ruggiero, F				Ricard-Blum, Sylvie; Beraud, Mickael; Raynal, Nicolas; Farndale, Richard W.; Ruggiero, Florence			Structural requirements for heparin/heparan sulfate binding to type V collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; HEPARIN-COFACTOR-II; GLYCOSAMINOGLYCAN INTERACTIONS; PROTEIN INTERACTIONS; DIVALENT-CATIONS; PEPTIDE MODELS; CELL-ADHESION; PROTEOGLYCANS; SITES; MECHANISM	Collagen-proteoglycan interactions participate in the regulation of matrix assembly and in cell-matrix interactions. We reported previously that a fragment (Ile824-Pro950) of the collagen alpha 1(V) chain, HepV, binds to heparin via a cluster of three major basic residues, Arg(912), Arg(918), and Arg(921), and two additional residues, Lys(905) and Arg(909) (Delacoux, F., Fichard, A., Cogne, S., Garrone, R., and Ruggiero, F. ( 2000) J. Biol. Chem. 275, 29377-29382). Here, we further characterized the binding of HepV and collagen V to heparin and heparan sulfate by surface plasmon resonance assays. HepV bound heparin and heparan sulfate with a similar affinity (K-D similar to 18 and 36 nM, respectively) in a cation-dependent manner, and 2-O-sulfation of heparin was shown to be crucial for the binding. An octasaccharide of heparin and a decasaccharide of heparan sulfate were required for HepV binding. Studies with HepV mutants showed that the same basic residues were involved in the binding to heparin, to heparan sulfate, and to the cell surface. The contribution of Lys905 and Arg909 was found to be significant. The triple-helical peptide GPC(GPP)(5)G(904)-R-918(GPP)(5)GPC-NH2 and native collagen V molecules formed much more stable complexes with heparin than HepV, and collagen V bound to heparin/heparan sulfate with a higher affinity (in the nanomolar range) than HepV. Heat and chemical denaturation strongly decreased the binding, indicating that the triple helix plays a major role in stabilizing the interaction with heparin. Collagen V and HepV may play different roles in cell-matrix interactions and in matrix assembly or remodeling mediated by their specific interactions with heparan sulfate.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot,Inst Fed Rech, F-69367 Lyon 07, France; Univ Grenoble 1, CNRS, CEA, UMR 5075,Inst Biol Struct, F-38027 Grenoble, France; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; University of Cambridge	Ruggiero, F (corresponding author), Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot,Inst Fed Rech, 128 BioSci Gerland,7 Passage Vercors, F-69367 Lyon 07, France.	f.ruggiero@ibcp.fr		RUGGIERO, Florence/0000-0003-2915-5359; RICARD-BLUM, Sylvie/0000-0001-9263-1851	MRC [G0400701] Funding Source: UKRI; Medical Research Council [G0400701] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; Coombe DR, 2005, CELL MOL LIFE SCI, V62, P410, DOI 10.1007/s00018-004-4293-7; Delacoux F, 2000, J BIOL CHEM, V275, P29377, DOI 10.1074/jbc.M004724200; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; Doss-Pepe E, 2004, BBA-PROTEINS PROTEOM, V1698, P187, DOI 10.1016/j.bbapap.2003.11.034; Doss-Pepe E, 2000, BIOCHEMISTRY-US, V39, P14884, DOI 10.1021/bi001108u; Eckert R, 2003, FEBS LETT, V541, P121, DOI 10.1016/S0014-5793(03)00322-3; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Guimond S, 2001, BIOCHEM SOC T, V29, P177, DOI 10.1042/BST0290177; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KODA JE, 1985, J BIOL CHEM, V260, P8157; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Raman R, 2005, CHEM BIOL, V12, P267, DOI 10.1016/j.chembiol.2004.11.020; Raynal N, 2006, J BIOL CHEM, V281, P3821, DOI 10.1074/jbc.M509818200; Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Ricard-Blum S, 2006, ANAL BIOCHEM, V352, P252, DOI 10.1016/j.ab.2006.02.011; Ruggiero F, 1996, J CELL SCI, V109, P1865; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Takagaki K, 2002, J BIOL CHEM, V277, P8882, DOI 10.1074/jbc.M106479200; Tillet E, 1997, J BIOL CHEM, V272, P10769; Vaughan-Thomas A, 2001, J BIOL CHEM, V276, P5303, DOI 10.1074/jbc.M008764200; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	41	37	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25195	25204		10.1074/jbc.M603096200	http://dx.doi.org/10.1074/jbc.M603096200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815843	hybrid			2022-12-25	WOS:000240031300020
J	Bushell, SR; Bottomley, SP; Rossjohn, J; Beddoe, T				Bushell, Simon R.; Bottomley, Stephen P.; Rossjohn, Jamie; Beddoe, Travis			Tracking the unfolding pathway of a multirepeat protein via tryptophan scanning - Evidence of localized instability in the mitochondrial import receptor Tom70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT; MOTIF; PREPROTEINS; DOMAIN; IDENTIFICATION; RECOGNITION; CONSENSUS; DESIGN; FAMILY; PROBES	The tetratricopeptide repeat ( TPR) is a degenerate 34-amino acid repeating motif that forms a repeating helix-turn-helix structure and is a well characterized mediator of protein-protein interactions. Recently, a biophysical investigation on one naturally occurring TPR protein, Tom70, found that the mitochondrial receptor displayed an unusual three-state unfolding pathway, distinct from the two-state model usually displayed by TPR proteins. To investigate this unusual behavior, we undertook a tryptophan-scanning analysis of Tom70, where both native and engineered tryptophan residues are used as fluorescent reporters to monitor the range of local and global unfolding events that comprise the unfolding pathway of Tom70. Specifically, seven Tom70 variants were constructed, each with a single tryptophan residue in each of the seven TPR repeats of Tom70. By combining equilibrium and kinetic fluorescent unfolding assays, with circular dichroism experiments, our study reveals that the unusual folding pathway of Tom70 is a consequence of the unfolding of two separate, autonomous TPR arrays, with the less stable region appearing to account for the low structural stability of Tom70.	Monash Univ, Prot Crystallog Unit, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia; Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia	Monash University; Monash University	Rossjohn, J (corresponding author), Monash Univ, Prot Crystallog Unit, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic 3800, Australia.	Jamie.Rossjohn@med.monash.edu.au	Rossjohn, Jamie/F-9032-2013; Beddoe, Travis/F-3415-2014	Rossjohn, Jamie/0000-0002-2020-7522; Beddoe, Travis/0000-0003-4550-2277; Bushell, Simon/0000-0001-5477-6777				BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beddoe T, 2004, J BIOL CHEM, V279, P46448, DOI 10.1074/jbc.M405639200; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BOTTOMLEY SP, 1994, PROTEIN ENG, V7, P1463, DOI 10.1093/protein/7.12.1463; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Cirillo SLG, 2000, MICROBIOL-SGM, V146, P1345, DOI 10.1099/00221287-146-6-1345; Clark PL, 1996, PROTEIN SCI, V5, P1108; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; Main ERG, 2003, CURR OPIN STRUC BIOL, V13, P482, DOI 10.1016/S0959-440X(03)00105-2; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; Makarova KS, 2005, NUCLEIC ACIDS RES, V33, P4626, DOI 10.1093/nar/gki775; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; Perry AJ, 2006, CURR BIOL, V16, P221, DOI 10.1016/j.cub.2005.12.034; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH CJ, 1991, BIOCHEMISTRY-US, V30, P1028, DOI 10.1021/bi00218a021; Stumpp MT, 2003, J MOL BIOL, V332, P471, DOI 10.1016/S0022-2836(03)00897-0; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	28	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24345	24350		10.1074/jbc.M602966200	http://dx.doi.org/10.1074/jbc.M602966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803880	hybrid			2022-12-25	WOS:000239847800027
J	Chen, L; Necela, BM; Su, WD; Yanagisawa, M; Anastasiadis, PZ; Fields, AP; Thompson, EA				Chen, Lu; Necela, Brian M.; Su, Weidong; Yanagisawa, Masahiro; Anastasiadis, Panos Z.; Fields, Alan P.; Thompson, E. Aubrey			Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by rho GTPase-dependent activation of ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-CASCADE ACTIVATION; TGF-BETA RECEPTOR; COLON TUMORS; SIGNALING PATHWAYS; ESTROGEN ACTION; GROWTH; EXPRESSION; PHOSPHORYLATION; CARCINOGENESIS; KINASE	Peroxisome proliferator-activated receptor gamma (PPAR gamma) causes epithelial to mesenchymal transformation (EMT) in intestinal epithelial cells, as evidenced by reorganization of the actin cytoskeleton, acquisition of a polarized, mesenchymal cellular morphology, increased cellular motility, and colony scattering. This response is due to activation of Cdc42, resulting in p21-activated kinase-dependent phosphorylation and activation of MEK1 Ser(298) and activation of ERK1/2. Dominant negative MEK1, MEK2, and ERK2 block PPAR gamma-induced EMT, whereas constitutively active MEK1 and MEK2 induce a mesenchymal phenotype similar to that evoked by PPAR gamma. PPAR gamma also stimulates ERK1/2 phosphorylation in the intestinal epithelium in vivo. PPAR gamma induces the p110 alpha subunit of phosphoinositide 3-kinase (PI3K), and inhibition of PI3K blocks PPAR gamma-dependent phosphorylation of MEK1 Ser298, activation of ERK1/2, and EMT. We conclude that PPAR gamma regulates the motility of intestinal epithelial cells through a mitogen-activated protein kinase cascade that involves PI3K, Cdc42, p21-activated kinase, MEK1, and ERK1/2. Regulation of cellular motility through Rho family GTPases has not been previously reported for nuclear receptors, and elucidation of the mechanism that accounts for the role of PPAR gamma in regulating motility of intestinal epithelial cells provides fundamental new insight into the function of this receptor during renewal of the intestinal epithelium.	Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Thompson, EA (corresponding author), 4500 San Pablo Rd,Griffin Canc Res Bldg,Rm 304, Jacksonville, FL 32224 USA.	thompson.aubrey@mayo.edu			NCI NIH HHS [CA24347, CA121349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA121349, R01CA024347, R37CA024347] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2006, GUT, V55, P1104, DOI 10.1136/gut.2005.081745; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alahari SK, 2002, INT REV CYTOL, V220, P145; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen L, 2006, MOL CELL ENDOCRINOL, V251, P17, DOI 10.1016/j.mce.2006.02.006; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267; Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUJITA TFT, 2001, Patent No. 6706746; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Pino MV, 2004, TOXICOL PATHOL, V32, P58, DOI 10.1080/01926230490261320; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Tanaka T, 2001, CANCER RES, V61, P2424; Temple KA, 2005, J BIOL CHEM, V280, P3529, DOI 10.1074/jbc.M411422200; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Turner CE, 2000, J CELL SCI, V113, P4139; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; Yang K, 2005, INT J CANCER, V116, P495, DOI 10.1002/ijc.21018; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	42	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24575	24587		10.1074/jbc.M604147200	http://dx.doi.org/10.1074/jbc.M604147200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16815847	hybrid			2022-12-25	WOS:000239847800053
J	Borysov, SI; Cheng, AWM; Guadagno, TM				Borysov, Sergiy I.; Cheng, Anthony W. M.; Guadagno, Thomas M.			B-raf is critical for MAPK activation during mitosis and is regulated in an m phase-dependent manner in xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; SOMATIC-CELL MITOSIS; PROTEIN-KINASE; FEEDBACK PHOSPHORYLATION; G(2)/M TRANSITION; DEFICIENT MICE; CENP-E; MOS; PATHWAY; KINETOCHORES	Activation of the MAPK cascade during mitosis is critical for spindle assembly and normal mitotic progression. The underlying regulatory mechanisms that control activation of the MEK/MAPK cascade during mitosis are poorly understood. Here we purified and characterized the MEK kinase activity present in Xenopus M phase-arrested egg extracts. Our results show that B-Raf was the critical MEK kinase required for M phase activation of the MAPK pathway. Consistent with this, B-Raf was activated and underwent hyperphosphorylation in an M phase-dependent manner. Interestingly B-Raf hyperphosphorylation at mitosis occurred, at least in part, as a consequence of a feedback loop involving MAPK-mediated phosphorylation within a conserved C-terminal SPKTP motif. The kinase activity of a B-Raf mutant defective at both phosphorylation sites was substantially greater than its wild type counterpart when incubated in Xenopus M phase egg extracts. Furthermore suppression of MAPK feedback at mitosis enhanced B-Raf activity, whereas constitutive activation of MAPK at mitosis strongly suppressed B-Raf activity. These results suggest that feedback phosphorylation by MAPK negatively regulates B-Raf activity at mitosis. Collectively our data demonstrate for the first time a role for B-Raf at mitosis and provide new insight into understanding the regulation and function of B-Raf during cell proliferation.	Univ S Florida, Coll Med, H Lee Moffitt Comprehens Canc Ctr, Mol Oncol Program,Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Guadagno, TM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Comprehens Canc Ctr, Mol Oncol Program,Dept Interdisciplinary Oncol, Bldg MRC 3 Annex,12902 Magnolia Dr, Tampa, FL 33612 USA.	guadagnt@moffitt.usf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brummer T, 2003, ONCOGENE, V22, P8823, DOI 10.1038/sj.onc.1207185; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hartkamp J, 1999, CANCER RES, V59, P2195; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Horne MM, 2003, J CELL BIOL, V161, P1021, DOI 10.1083/jcb.200304144; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lovric J, 1996, ONCOGENE, V12, P1109; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Yue J, 2006, ONCOGENE, V25, P3307, DOI 10.1038/sj.onc.1209354; Yue JB, 2004, CURR BIOL, V14, P1581, DOI 10.1016/j.cub.2004.08.056; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	40	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22586	22596		10.1074/jbc.M601432200	http://dx.doi.org/10.1074/jbc.M601432200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762920	hybrid			2022-12-25	WOS:000239542600019
J	Rahman, MM; Barrett, JW; Brouckaert, P; McFadden, G				Rahman, Masmudur M.; Barrett, John W.; Brouckaert, Peter; McFadden, Grant			Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-RECEPTOR HOMOLOG; IMMUNE EVASION; ALPHA MUTANTS; CD30 HOMOLOG; VIRUS; GENOME; DISTINCT; SUPERFAMILY; ECTROMELIA; INHIBITION	The Yatapoxviruses encode a distinct class of secreted TNF-binding protein (TNF-BP) that resembles an MHC class I heavy chain but distinct from any other known TNF inhibitor. Characterization of these viral TNF inhibitors from Tanapox virus, Yaba monkey tumor virus (YMTV) and a closely related version from Swinepox virus revealed dramatically differential TNF binding specificities for different mammalian species. The Tanapox virus 2L protein (TPV-2L) formed inhibitory complexes with human TNF, and interacted with monkey and canine TNF with high affinity but rabbit TNF with low affinity. On the other hand, YMTV-2L bound human and monkey TNF with high affinity but rabbit TNF with only low affinity. The TNF-BP from swinepox virus (SPV003/148) only interacted with porcine TNF with high affinity. The observed TNF binding analysis mirrored the biological activity of these TNF-binding protein to block TNF-induced cellular cytolysis. TPV-2L and YMTV-2L also inhibited the human TNF-mediated signaling in cells but TPV-2L exhibited higher affinity for human TNF (K-D, 43 pM) compared with monkey (K-D, 120 pM) whereas for YMTV-2L, the affinities were reversed (human TNF K-D, 440 pM; monkey TNF K-D, 230 pM). The interaction domain of human TNF with TNF-binding proteins is significantly different from that of TNFRs, as determined using human TNF mutants. We conclude that these poxvirus TNF-binding proteins represent a new class of TNF inhibitors and are distinct from the viral TNF receptor homologues characterized to date.	Robarts Res Inst, Biotherapeut Res Grp, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada; Univ Ghent VIB, Mol Pathophysiol & Expt Therapy Unit, Dept Mol Biomed Res, B-9052 Ghent, Belgium	Western University (University of Western Ontario); Western University (University of Western Ontario); Flanders Institute for Biotechnology (VIB); Ghent University	McFadden, G (corresponding author), Robarts Res Inst, Biotherapeut Res Grp, SDRI Rm 133,1400 Western Rd, London, ON N6G 2V4, Canada.	mcfadden@robarts.ca	barrett, john/ABD-8414-2020	McFadden, Grant/0000-0002-2556-3526				Afonso CL, 2005, J VIROL, V79, P966, DOI 10.1128/JVI.79.2.966-977.2005; Afonso CL, 2002, J VIROL, V76, P783, DOI 10.1128/JVI.76.2.783-790.2002; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alcami A, 1999, J GEN VIROL, V80, P949, DOI 10.1099/0022-1317-80-4-949; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Alejo A, 2006, P NATL ACAD SCI USA, V103, P5995, DOI 10.1073/pnas.0510462103; Ameloot P, 2001, J BIOL CHEM, V276, P27098, DOI 10.1074/jbc.M104486200; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Benedict CA, 2003, CYTOKINE GROWTH F R, V14, P349, DOI 10.1016/S1359-6101(03)00030-3; Brunetti CR, 2003, P NATL ACAD SCI USA, V100, P4831, DOI 10.1073/pnas.0737244100; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cunnion KM, 1999, MOL GENET METAB, V67, P278, DOI 10.1006/mgme.1999.2878; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; Lee HJ, 2001, VIROLOGY, V281, P170, DOI 10.1006/viro.2000.0761; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Loparev VN, 1998, P NATL ACAD SCI USA, V95, P3786, DOI 10.1073/pnas.95.7.3786; Mocellin S, 2005, CYTOKINE GROWTH F R, V16, P35, DOI 10.1016/j.cytogfr.2004.11.001; Nazarian SH, 2006, FUTURE VIROL, V1, P123; Panus JF, 2002, P NATL ACAD SCI USA, V99, P8348, DOI 10.1073/pnas.122238599; Rahman Masmudur M, 2006, PLoS Pathog, V2, pe4; Saraiva M, 2002, J EXP MED, V196, P829, DOI 10.1084/jem.20020319; Saraiva M, 2001, J VIROL, V75, P226, DOI 10.1128/JVI.75.1.226-233.2001; SCHREIBER M, 1994, VIROLOGY, V204, P692, DOI 10.1006/viro.1994.1585; Schreiber M, 1997, J VIROL, V71, P2171, DOI 10.1128/JVI.71.3.2171-2181.1997; Schreiber M, 1996, J BIOL CHEM, V271, P13333, DOI 10.1074/jbc.271.23.13333; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Senkevich TG, 1998, VIROLOGY, V250, P397, DOI 10.1006/viro.1998.9390; Smith CA, 1996, VIROLOGY, V223, P132, DOI 10.1006/viro.1996.0462; Smith VP, 2000, J GEN VIROL, V81, P1223, DOI 10.1099/0022-1317-81-5-1223; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; Ware CF, 2005, ANNU REV IMMUNOL, V23, P787, DOI 10.1146/annurev.immunol.23.021704.115719	36	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22517	22526		10.1074/jbc.M604645200	http://dx.doi.org/10.1074/jbc.M604645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16782702	hybrid			2022-12-25	WOS:000239542600012
J	Ralf, C; Hickson, ID; Wu, L				Ralf, Christine; Hickson, Ian D.; Wu, Leonard			The Bloom's syndrome helicase can promote the regression of a model replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; SISTER-CHROMATID EXCHANGES; TOPOISOMERASE-III-ALPHA; HOLLIDAY JUNCTIONS; SYNDROME PROTEINS; ESCHERICHIA-COLI; LAGGING-STRAND; HRDC DOMAIN; HOMOLOGOUS RECOMBINATION; SUBSTRATE-SPECIFICITY	Homozygous inactivation of BLM gives rise to Bloom's syndrome, a disorder associated with genomic instability and cancer predisposition. BLM encodes a member of the RecQ DNA helicase family that is required for the maintenance of genome stability and the suppression of sister-chromatid exchanges. BLM has been proposed to function in the rescue of replication forks that have collapsed or stalled as a result of encountering lesions that block fork progression. One proposed mechanism of fork rescue involves regression in which the nascent leading and lagging strands anneal to create a so-called "chicken foot" structure. Here we have developed an in vitro system for analysis of fork regression and show that BLM, but not Escherichia coli RecQ, can promote the regression of a model replication fork. BLM-mediated fork regression is ATP-dependent and occurs processively, generating regressed arms of > 250 bp in length. These data establish the existence of a eukaryotic protein that could promote replication fork regression in vivo and suggest a novel pathway through which BLM might suppress genetic exchanges.	Univ Oxford, John Radcliffe Hosp, Canc Res UK Labs, Weatherall Inst Mol Med, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Wu, L (corresponding author), Univ Oxford, John Radcliffe Hosp, Canc Res UK Labs, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	leonard.wu@cancer.org.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bolt EL, 2002, MOL CELL, V10, P187, DOI 10.1016/S1097-2765(02)00560-9; Brosh RM, 2001, EMBO J, V20, P5791; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Cheok CF, 2005, NUCLEIC ACIDS RES, V33, P3932, DOI 10.1093/nar/gki712; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Friedberg EC, 2005, NAT REV MOL CELL BIO, V6, P943, DOI 10.1038/nrm1781; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Hu YD, 2005, MOL CELL BIOL, V25, P3431, DOI 10.1128/MCB.25.9.3431-3442.2005; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Lopes M, 2006, MOL CELL, V21, P15, DOI 10.1016/j.molcel.2005.11.015; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Machwe A, 2005, J BIOL CHEM, V280, P23397, DOI 10.1074/jbc.M414130200; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McInerney P, 2004, J BIOL CHEM, V279, P21543, DOI 10.1074/jbc.M401649200; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Pages V, 2003, SCIENCE, V300, P1300, DOI 10.1126/science.1083964; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Rothstein R, 2000, GENE DEV, V14, P1; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang WS, 2003, MOL CELL BIOL, V23, P3527, DOI 10.1128/MCB.23.10.3527-3535.2003; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	41	178	179	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22839	22846		10.1074/jbc.M604268200	http://dx.doi.org/10.1074/jbc.M604268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16766518	hybrid			2022-12-25	WOS:000239542600046
J	Jaulmes, A; Thierry, S; Janvier, B; Raymondjean, M; Marechal, V				Jaulmes, Amandine; Thierry, Sylvain; Janvier, Brigitte; Raymondjean, Michel; Marechal, Vincent			Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1 beta	FASEB JOURNAL			English	Article						inflammation; atherosclerosis; VSMCs; sPLA2-IIA	GLYCATION END-PRODUCTS; FACTOR-KAPPA-B; TOLL-LIKE RECEPTOR-2; HUMAN ATHEROSCLEROTIC LESIONS; PROSTAGLANDIN-E SYNTHASE; PHOSPHOLIPASE A(2) GENE; GROUP BOX-1 PROTEIN; TRANSCRIPTIONAL REGULATION; NEURITE OUTGROWTH; HMGB1	Lipid mediators such as prostaglandin E2 (PGE2) play a central role during atherogenesis as a consequence of inflammation. PGE2 is produced from phospholipids by a cascade of enzymatic reactions involving phospholipase A2 (PLA2), cyclooxygenase ( COX), and prostaglandin E synthase (PGES). It is released by several cell types, including vascular smooth muscle cells (VSMCs). Recent work has shown that the secretory PLA2-IIA (sPLA2-IIA), the most abundant isoform of secreted PLA2 in VSMCs, acts as a potent cytokine and activates VSMCs through a positive feedback loop. High mobility group protein 1 (HMGB1), also known as amphoterin, is a ubiquitous protein that plays various roles in the nucleus. HMGB1 is released by necrotic cells and by immune cells in response to various inflammatory mediators and acts as a potent proinflammatory cytokine. The present study investigates the role of HMGB1 in the activation of sPLA2-IIA expression and PGE2 production in VSMCs. Recombinant HMGB1 slightly activated the sPLA2-IIA, COX-2, and mPGES-1 genes but dramatically stimulated these genes in VSMCs that had been incubated with the proinflammatory cytokine IL-1 beta for 24 h. This effect was accompanied by significantly increased PGE2 release. Induction of the three known receptors of HMGB1, namely RAGE, TLR-2, and TLR-4, by IL-1 beta suggests that proinflammatory cytokines sensitize VSMCs to HMGB1. This provides new insights into the role of HMGB1 in VSMCs, suggesting it may be essential for the progression of atherosclerosis.	Ctr Rech Biomed Cordeliers, F-75270 Paris 06, France; Univ Paris 06, CNRS, UMR Physiol & Physiopathol, F-75005 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Marechal, V (corresponding author), Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris 06, France.	vincent.marechal@snv.jussieu.fr	marechal, vincent/P-7719-2017					Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andreani M, 2000, BBA-MOL CELL BIOL L, V1488, P149, DOI 10.1016/S1388-1981(00)00117-7; Antonio V, 2002, BIOCHEM J, V368, P415, DOI 10.1042/BJ20020658; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Burke AP, 2004, ARTERIOSCL THROM VAS, V24, P1266, DOI 10.1161/01.ATV.0000131783.74034.97; Cipollone F, 2003, CIRCULATION, V108, P1070, DOI 10.1161/01.CIR.0000086014.80477.0D; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Fuentes L, 2002, FEBS LETT, V531, P7, DOI 10.1016/S0014-5793(02)03401-4; Gaillard Claire, 2000, BMC Biochemistry, V1, P1; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jaulmes A, 2005, ARTERIOSCL THROM VAS, V25, P1161, DOI 10.1161/01.ATV.0000164310.67356.a9; Jiang BB, 2002, ARTERIOSCL THROM VAS, V22, P1811, DOI 10.1161/01.ATV.0000037679.60584.3F; Jimenez R, 2005, P NATL ACAD SCI USA, V102, P4637, DOI 10.1073/pnas.0407655101; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P2320, DOI 10.1161/01.ATV.0000145573.36113.8a; Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; Morris GE, 2005, AM J RESP CRIT CARE, V171, P814, DOI 10.1164/rccm.200403-406OC; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; RITTHALER U, 1995, AM J PATHOL, V146, P688; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Seki N, 2003, METABOLISM, V52, P1558, DOI 10.1016/j.metabol.2003.07.010; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Stros M, 2004, BIOCHEMISTRY-US, V43, P7215, DOI 10.1021/bi049928k; Sunden-Cullberg J, 2005, CRIT CARE MED, V33, P564, DOI [10.1097/01.CCM.0000155991.88802.4D, 10.1097/01.ccm.0000155991.88802.4D]; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Wautier J L, 1998, Vasc Med, V3, P131, DOI 10.1191/135886398672565440; Zimmermann K, 2004, INFLAMMATION, V28, P221, DOI 10.1023/B:IFLA.0000049047.61014.e3	46	55	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1727	+		10.1096/fj.05-5514fje	http://dx.doi.org/10.1096/fj.05-5514fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807371				2022-12-25	WOS:000240266600029
J	Oloumi, A; Syam, S; Dedhar, S				Oloumi, A.; Syam, S.; Dedhar, S.			Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells	ONCOGENE			English	Article						integrin-linked kinase; nuclear beta-catenin; Wnt; signal transduction	GLYCOGEN-SYNTHASE KINASE; AP-1 TRANSCRIPTION FACTOR; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; WNT PATHWAY; PROTEIN; ADHESION; CANCER	The Wnt gene family encodes secreted signaling molecules that play important roles in tumorgenesis and embryogenesis. The canonical Wnt signaling pathway regulates target gene expression via the stabilization and nuclear translocation of the cytoplasmic pool of beta-catenin. The activation of integrin-linked kinase (ILK) is also known to regulate the stabilization and subsequent nuclear translocation of beta-catenin in several epithelial cell models. We now report that molecular and pharmacological inhibition of ILK activity in mammalian cells directly modulates Wnt signaling by suppressing the stabilization and nuclear translocation of beta-catenin, as well as beta-catenin/Lef-mediated transcription. Inhibition of ILK activity, but not phosphatidylinositol-3 kinase (PI3K) or MEK activities suppresses nuclear beta-catenin stabilization in cells stably expressing Wnt3a as well as in cells exposed to either Wnt3a conditioned media or purified Wnt3a. Furthermore, ILK inhibition reverses the Wnt3a-induced suppression of beta- catenin phosphorylation that accompanies beta-catenin stabilization. In addition, we show that ILK can be identified in a complex with Wnt pathway components such as adenomatous polyposis coli and GSK-3. Upon treatment of L cells with Wnt3a-CM, glycogen synthase kinase-3 (GSK-3b) becomes highly phosphorylated on Ser 9, which is completely abolished upon inhibition of ILK activity. However, acute exposure of L cells to purified Wnt3a does not result in the stimulation of GSK-3b Ser 9 phosphorylation, despite beta-catenin stabilization. Together our data demonstrate that ILK activity can modulate acute Wnt3a mediated b- catenin phosphorylation, stabilization and nuclear activation in a PI3K-independent manner, as well as the more prolonged PI3K-dependent secondary effects of Wnt signaling on GSK-3 phosphorylation. Finally, we suggest that a novel small molecule inhibitor of ILK, QLT-0267, may be a useful tool in the regulation of pathological Wnt signaling.	British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of British Columbia	Dedhar, S (corresponding author), Univ British Columbia, British Columbia Canc Res Ctr, Dept Biochem, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca		Dedhar, Shoukat/0000-0003-4355-1657				Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Kang UG, 2004, FEBS LETT, V560, P115, DOI 10.1016/S0014-5793(04)00082-1; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mills J, 2003, J NEUROSCI, V23, P1638; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pevarello P, 2004, J MED CHEM, V47, P3367, DOI 10.1021/jm031145u; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yasunaga T, 2005, GENES CELLS, V10, P369, DOI 10.1111/j.1365-2443.2005.00841.x; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	61	80	81	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7747	7757		10.1038/sj.onc.1209752	http://dx.doi.org/10.1038/sj.onc.1209752			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799642				2022-12-25	WOS:000242830800009
J	Tamborini, E; Pricl, S; Negri, T; Lagonigro, MS; Miselli, F; Greco, A; Gronchi, A; Casali, PG; Ferrone, M; Fermeglia, M; Carbone, A; Pierotti, MA; Pilotti, S				Tamborini, E.; Pricl, S.; Negri, T.; Lagonigro, M. S.; Miselli, F.; Greco, A.; Gronchi, A.; Casali, P. G.; Ferrone, M.; Fermeglia, M.; Carbone, A.; Pierotti, M. A.; Pilotti, S.			Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients	ONCOGENE			English	Article						imatinib secondary resistance; gastrointestinal stromal tumors (GIST); molecular modeling	GASTROINTESTINAL STROMAL TUMORS; CAVITY-CREATING MUTATIONS; ACQUIRED-RESISTANCE; BCR-ABL; PROTEIN; STABILITY; INSIGHTS; DYNAMICS; INTERIOR; POLAR	Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors. Here, transient transfection experiments with plasmids carrying two different KIT-acquired point mutations were performed along with immunoprecipitation of total protein extracts, derived from imatinib-treated and untreated cells. The molecular mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the molecular level. Biochemical analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes. Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concentrations, whereas V654A was inhibited by 6 mu M of imatinib. The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes. We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter. The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance.	Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, I-20133 Milan, Italy; Univ Trieste, DICAMP, Mol Simulat Engn Lab, Trieste, Italy; Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Surg, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Clin Oncol, I-20133 Milan, Italy; FIRC Inst Mol Oncol, IFOM, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Trieste; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pilotti, S (corresponding author), Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, Via Venezian 1, I-20133 Milan, Italy.	silvana.pilotti@istitutotumori.mi.it	Tamborini, Elena/C-3307-2017; Carbone, Antonino/AAA-2217-2019; casali, Paolo Giovanni/D-1524-2017; Gronchi, Alessandro/O-6589-2016; Pricl, Sabrina/M-7493-2015; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Fermeglia, Maurizio/O-3973-2018	Tamborini, Elena/0000-0002-3819-8687; Carbone, Antonino/0000-0003-2211-639X; casali, Paolo Giovanni/0000-0003-4056-8023; Gronchi, Alessandro/0000-0002-4703-3534; Pricl, Sabrina/0000-0001-8380-4474; Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Negri, Tiziana/0000-0002-3528-7115; Fermeglia, Maurizio/0000-0001-8810-5082	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; CASE DA, 2000, AMBER 7; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dwyer JJ, 2000, BIOPHYS J, V79, P1610, DOI 10.1016/S0006-3495(00)76411-3; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Lazaridis T, 1995, ADV PROTEIN CHEM, V47, P231, DOI 10.1016/S0065-3233(08)60547-1; LEE B, 1993, PROTEIN SCI, V2, P733, DOI 10.1002/pro.5560020505; Loladze VV, 2002, J MOL BIOL, V320, P343, DOI 10.1016/S0022-2836(02)00465-5; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; Pricl S, 2005, MOL CANCER THER, V4, P1167, DOI 10.1158/1535-7163.MCT-05-0101; Reyes CM, 2000, J MOL BIOL, V295, P1, DOI 10.1006/jmbi.1999.3319; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+; Takano K, 2001, BIOCHEMISTRY-US, V40, P4853, DOI 10.1021/bi002792f; Tamborini E, 2005, CANCER RES, V65, P1115; Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021; Wardelmann E, 2005, LANCET ONCOL, V6, P249, DOI 10.1016/S1470-2045(05)70097-8; Wilson E.B., 1995, MOL VIBRATIONS	35	90	97	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6140	6146		10.1038/sj.onc.1209639	http://dx.doi.org/10.1038/sj.onc.1209639			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16751810				2022-12-25	WOS:000241101200012
J	Jana, SS; Kawamoto, S; Adelstein, RS				Jana, Siddhartha S.; Kawamoto, Sachiyo; Adelstein, Robert S.			A specific isoform of nonmuscle myosin II-C is required for cytokinesis in a tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-DEPENDENT KINASE; HEAVY-CHAIN ISOFORMS; CLEAVAGE FURROW; EXPRESSION; GENE; CLONING; PHOSPHORYLATION; IDENTIFICATION; SEQUENCES; ADHESION	Nonmuscle myosin IIs play an essential role during cytokinesis. Here, we explore the function of an alternatively spliced isoform of nonmuscle myosin heavy chain(NMHC) II-C, called NMHCII-C1, in the A549 human lung tumor cell line during cytokinesis. NMHC II-C1 contains an insert of 8 amino acids in the head region of NMHCII-C. First, we show that there is a marked increase in both the mRNA encoding NMHC II-C1 and protein in tumor cell lines compared with nontumor cell lines derived from the same tissue. Quantification of the amount of myosin II isoforms in the A549 cells shows that the amounts of NMHCII-A and II-C1 protein are about equal and substantially greater than NMHCII-B. Using specific siRNAs to decrease NMHC II-C1 in cultured A549 cells resulted in a 5.5-fold decrease in the number of cells at 120 h, whereas decreasing NMHC II-A with siRNA does not affect cell proliferation. This decreased proliferation can be rescued by reintroducing NMHCII-C1 but not NMHCII-A or II-B into A549 cells, although noninserted NMHCII-C does rescue to a limited extent. Time lapse video microscopy revealed that loss of NMHC II-C1 leads to a delay in cytokinesis and prolongs it from 2 to 8-10 h. These findings are consistent with the localization of NMHCII-C1 to the intercellular bridge that attaches the two dividing cells during the late phases of cytokinesis. The results suggest a specific function for NMHC II-C1 in cytokinesis in the A549 tumor cell line.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adelstein, RS (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr,MSC 1762, Bethesda, MD 20892 USA.	adelster@nhlbi.nih.gov		Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004230, ZIAHL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao JJ, 2005, J BIOL CHEM, V280, P19594, DOI 10.1074/jbc.M501573200; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; Dean SO, 2005, P NATL ACAD SCI USA, V102, P13473, DOI 10.1073/pnas.0506810102; DeBiasio RL, 1996, MOL BIOL CELL, V7, P1259, DOI 10.1091/mbc.7.8.1259; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; Kamijo K, 2006, MOL BIOL CELL, V17, P43, DOI 10.1091/mbc.e05-06-0569; Kanada M, 2005, MOL BIOL CELL, V16, P3865, DOI 10.1091/mbc.E05-03-0233; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kim KY, 2005, J BIOL CHEM, V280, P22769, DOI 10.1074/jbc.M503488200; Kolega J, 1998, J CELL SCI, V111, P2085; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Mar XF, 2006, MOL BIOL CELL, V17, P2138, DOI 10.1091/mbc.E05-10-0097; Matsumura F, 2005, TRENDS CELL BIOL, V15, P371, DOI 10.1016/j.tcb.2005.05.004; MAUPIN P, 1994, J CELL SCI, V107, P3077; McCollum D, 2005, CURR BIOL, V15, pR998, DOI 10.1016/j.cub.2005.11.049; MURAKAMI N, 1993, DEV BIOL, V157, P19, DOI 10.1006/dbio.1993.1108; Neujahr R, 1997, J CELL SCI, V110, P123; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Piekny A, 2005, TRENDS CELL BIOL, V15, P651, DOI 10.1016/j.tcb.2005.10.006; Schweitzer JK, 2004, EXP CELL RES, V295, P1, DOI 10.1016/j.yexcr.2003.12.023; Sellers J. R., 1999, MYOSINS; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Uren D, 2000, J CLIN INVEST, V105, P663, DOI 10.1172/JCI8199; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Zang JH, 1997, MOL BIOL CELL, V8, P2617, DOI 10.1091/mbc.8.12.2617	37	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24662	24670		10.1074/jbc.M604606200	http://dx.doi.org/10.1074/jbc.M604606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16790446	hybrid			2022-12-25	WOS:000239847800061
J	Carrasco, JL; Castello, MJ; Vera, P				Carrasco, Jose L.; Castello, Maria Jose; Vera, Pablo			14-3-3 mediates transcriptional regulation by modulating nucleocytoplasmic shuttling of tobacco DNA-binding protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; INTRACELLULAR-LOCALIZATION; 14-3-3-PROTEINS; HOMEODOMAIN; INVOLVEMENT; PLANTS; PART	Tobacco DBP1 is the founding member of a novel class of plant transcription factors featuring sequence-specific DNA binding and protein phosphatase activity. To understand the mechanisms underlying the function of this family of transcriptional regulators, we have identified the tobacco 14-3-3 isoform G as the first protein interacting with a DBP factor. 14-3-3 recognition involves the N-terminal region of DBP1, which also supports the DNA binding activity attributed to DBP1. The relevance of this interaction is reinforced by its conservation in Arabidopsis plants, where the closest relative of DBP1 in this species also interacts with a homologous 14-3-3 protein through its N-terminal region. Furthermore, we show that in planta 14-3-3 G is directly involved in regulating DBP1 function by promoting nuclear export and subsequent cytoplasmic retention of DBP1 under conditions that in turn alleviate DBP1-mediated repression of target gene expression.	Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Vera, P (corresponding author), Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Ave Naranjos S-N, Valencia 46022, Spain.	vera@ibmcp.upv.es	; Carrasco, Jose Luis/M-5367-2015	Vera, Pablo/0000-0002-7787-7519; Carrasco, Jose Luis/0000-0002-5905-8042				Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Bornke F, 2005, J PLANT PHYSIOL, V162, P161, DOI 10.1016/j.jplph.2004.09.006; Carrasco JL, 2005, PLANT PHYSIOL, V137, P602, DOI 10.1104/pp.104.056002; Carrasco JL, 2003, EMBO J, V22, P3376, DOI 10.1093/emboj/cdg323; Coego A, 2005, PLANT CELL, V17, P2123, DOI 10.1105/tpc.105.032375; DEVETTEN NC, 1992, PLANT CELL, V4, P1295, DOI 10.1105/tpc.4.10.1295; Eckardt NA, 2001, PLANT CELL, V13, P2385; Ferl RJ, 2004, PHYSIOL PLANTARUM, V120, P173, DOI 10.1111/j.0031-9317.2004.0239.x; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Igarashi D, 2001, PLANT CELL, V13, P2483, DOI 10.1105/tpc.13.11.2483; Ishida S, 2004, PLANT CELL, V16, P2641, DOI 10.1105/tpc.104.024604; James P, 1996, GENETICS, V144, P1425; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; Mahalingam R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r20; Maleck K, 2000, NAT GENET, V26, P403, DOI 10.1038/82521; Mayda E, 2000, MOL PLANT MICROBE IN, V13, P23, DOI 10.1094/MPMI.2000.13.1.23; Pan SQ, 1999, PLANT CELL, V11, P1591, DOI 10.1105/tpc.11.8.1591; Paul AL, 2005, MOL BIOL CELL, V16, P1735, DOI 10.1091/mbc.E04-09-0839; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Roberts MR, 2003, TRENDS PLANT SCI, V8, P218, DOI 10.1016/S1360-1385(03)00056-6; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Soellick TR, 2001, GENOME BIOL, V2; Tang SJ, 1998, J BIOL CHEM, V273, P25356, DOI 10.1074/jbc.273.39.25356; Tornero P, 1996, PLANT J, V10, P315, DOI 10.1046/j.1365-313X.1996.10020315.x; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	31	19	23	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22875	22881		10.1074/jbc.M512611200	http://dx.doi.org/10.1074/jbc.M512611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762921	Green Published, hybrid			2022-12-25	WOS:000239542600050
J	Fiaschi, T; Cozzi, G; Raugei, G; Formigli, L; Ramponi, G; Chiarugi, P				Fiaschi, Tania; Cozzi, Giacomo; Raugei, Giovanni; Formigli, Lucia; Ramponi, Giampietro; Chiarugi, Paola			Redox regulation of beta-actin during integrin-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-II; F-ACTIN; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; PROTEINS; GLUTATHIONYLATION; CYTOKINESIS; IDENTIFICATION; RHO	Redox sensitivity of actin toward an exogenous oxidative stress has recently been reported. We report here the first evidence of in vivo actin redox regulation by a physiological source of reactive oxygen species, specifically those species generated by integrin receptors during cell adhesion. Actin oxidation takes place via the formation of a mixed disulfide between cysteine 374 and glutathione; this modification is essential for spreading and for cytoskeleton organization. Impairment of actin glutathionylation, either through GSH depletion or expression of the C374A redox-insensitive mutant, greatly affects cell spreading and the formation of stress fibers, leading to inhibition of the disassembly of the actinomyosin complex. These data suggest that actin glutathionylation is essential for cell spreading and cytoskeleton organization and that it plays a key role in disassembly of actinomyosin complex during cell adhesion.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Ctr Excellence Sci Res DENOTHE, I-50134 Florence, Italy; Univ Florence, Dept Anat, I-50134 Florence, Italy; Ist Interuniv Miol, I-50134 Florence, Italy	University of Florence; University of Florence; University of Florence	Chiarugi, P (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Chiarugi, Paola/CDD-7988-2022	raugei, giovanni/0000-0003-1294-786X; Chiarugi, Paola/0000-0001-7655-2969				Burgess DR, 2005, CURR BIOL, V15, pR310, DOI 10.1016/j.cub.2005.04.008; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Ghezzi P, 2005, ANTIOXID REDOX SIGN, V7, P964, DOI 10.1089/ars.2005.7.964; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Giustarini D, 2004, J CELL MOL MED, V8, P201, DOI 10.1111/j.1582-4934.2004.tb00275.x; Guha M, 2005, CURR BIOL, V15, P732, DOI 10.1016/j.cub.2005.03.042; Huang KP, 2002, BIOCHEM PHARMACOL, V64, P1049, DOI 10.1016/S0006-2952(02)01175-9; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Laragione T, 2003, P NATL ACAD SCI USA, V100, P14737, DOI 10.1073/pnas.2434516100; LIU SM, 1995, EXP CELL RES, V217, P1, DOI 10.1006/excr.1995.1056; Massoumi R, 2003, EXP CELL RES, V289, P342, DOI 10.1016/S0014-4827(03)00285-4; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Murthy K, 2005, CURR BIOL, V15, P724, DOI 10.1016/j.cub.2005.02.055; Nagata M, 2002, J ALLERGY CLIN IMMUN, V109, P676, DOI 10.1067/mai.2002.122841; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Orlova A, 2001, J MOL BIOL, V312, P95, DOI 10.1006/jmbi.2001.4945; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Piekny A, 2005, TRENDS CELL BIOL, V15, P651, DOI 10.1016/j.tcb.2005.10.006; Rosado JA, 2002, CELL SIGNAL, V14, P547, DOI 10.1016/S0898-6568(01)00273-X; Small JV, 2005, CURR OPIN CELL BIOL, V17, P517, DOI 10.1016/j.ceb.2005.08.004; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Winder SJ, 2003, CURR OPIN CELL BIOL, V15, P14, DOI 10.1016/S0955-0674(02)00002-9	29	139	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22983	22991		10.1074/jbc.M603040200	http://dx.doi.org/10.1074/jbc.M603040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757472	hybrid			2022-12-25	WOS:000239542600060
J	Rocnik, EF; Liu, PJ; Sato, K; Walsh, K; Vaziri, C				Rocnik, Edward F.; Liu, Peijun; Sato, Kaori; Walsh, Kenneth; Vaziri, Cyrus			The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRICELLULAR PROTEIN SPARC; ENDOTHELIAL-CELLS; MICE DEFICIENT; BINDING; GLYCOPROTEIN; OSTEONECTIN; EXPRESSION; CLONING; BM-40; IDENTIFICATION	SMOC-2 is a novel member of the SPARC family of matricellular proteins. The purpose of this study was to determine whether SMOC-2 can modulate angiogenic growth factor activity and angiogenesis. SMOC-2 was localized in the extracellular periphery of cultured human umbilical vein endothelial cells (HUVECs). Ectopically expressed SMOC-2 was also secreted into the tissue culture medium. In microarray profiling experiments, a recombinant SMOC-2 adenovirus induced the expression of transcripts required for cell cycle progression in HUVECs. Consistent with a growth-stimulatory role for SMOC-2, its overexpression stimulated DNA synthesis in a dose-dependent manner. Overexpressed SMOC-2 also synergized with vascular endothelial growth factor or with basic fibroblast growth factor to stimulate DNA synthesis. Ectopically expressed SMOC-2 stimulated formation of network-like structures as determined by in vitro matrigel angiogenesis assays. Fetal calf serum enhanced the stimulatory effect of overexpressed SMOC-2 in this assay. Conversely, small interference RNA directed toward SMOC-2 inhibited network formation and proliferation. The angiogenic activity of SMOC-2 was also examined in experimental mice by subdermal implantation of Matrigel((R)) plugs containing SMOC-2 adenovirus. SMOC-2 adenovirus induced a 3-fold increase in the number of cells invading Matrigel((R)) plugs when compared with a control adenoviral vector. Basic fibroblast growth factor and SMOC-2 elicited a synergistic effect on cell invasion. Taken together, our results demonstrate that SMOC-2 is a novel angiogenic factor that potentiates angiogenic effects of growth factors.	Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA	Boston University; Boston University	Rocnik, EF (corresponding author), Boston Univ, Sch Med, Dept Genet & Genom, 715 Albany St,E633, Boston, MA 02118 USA.	efrocnik@yahoo.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77774] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG17241] Funding Source: Medline; NIEHS NIH HHS [R01 ES09558] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; Basu A, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-15; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bradshaw AD, 2001, WOUND REPAIR REGEN, V9, P522, DOI 10.1046/j.1524-475x.2001.00522.x; Chlenski A, 2004, CANCER RES, V64, P7420, DOI 10.1158/0008-5472.CAN-04-2141; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Kozian DH, 1997, LAB INVEST, V76, P267; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; Leopold JA, 2003, J BIOL CHEM, V278, P32100, DOI 10.1074/jbc.M301293200; MAURER P, 1995, J MOL BIOL, V253, P347, DOI 10.1006/jmbi.1995.0557; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nishimoto S, 2002, BBA-GENE STRUCT EXPR, V1576, P225, DOI 10.1016/S0167-4781(02)00345-7; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; Rocnik EF, 2002, J BIOL CHEM, V277, P38571, DOI 10.1074/jbc.M206689200; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Schneyer A, 2001, MOL CELL ENDOCRINOL, V180, P33, DOI 10.1016/S0303-7207(01)00501-9; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Strandjord TP, 1999, AM J PHYSIOL-LUNG C, V277, pL628, DOI 10.1152/ajplung.1999.277.3.L628; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201	39	88	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22855	22864		10.1074/jbc.M513463200	http://dx.doi.org/10.1074/jbc.M513463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774925	hybrid			2022-12-25	WOS:000239542600048
J	Patwari, P; Higgins, LJ; Chutkow, WA; Yoshioka, J; Lee, RT				Patwari, Parth; Higgins, Luke J.; Chutkow, William A.; Yoshioka, Jun; Lee, Richard T.			The interaction of thioredoxin with Txnip - Evidence for formation of a mixed disulfide by disulfide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; UP-REGULATED PROTEIN-1; OXIDATIVE STRESS; ASK1-MEDIATED APOPTOSIS; INDEPENDENT MANNER; CRYSTAL-STRUCTURE; CELLS; DEGRADATION; RESOLUTION; PEPTIDE	The thioredoxin system plays an important role in maintaining a reducing environment in the cell. Recently, several thioredoxin binding partners have been identified and proposed to mediate aspects of redox signaling, but the significance of these interactions is unclear in part due to incomplete understanding of the mechanism for thioredoxin binding. Thioredoxin-interacting protein (Txnip) is critical for regulation of glucose metabolism, the only currently known function of which is to bind and inhibit thioredoxin. We explored the mechanism of the Txnip-thioredoxin interaction and present evidence that Txnip and thioredoxin form a stable disulfide-linked complex. We identified two Txnip cysteines that are important for thioredoxin binding and showed that this interaction is consistent with a disulfide exchange reaction between oxidized Txnip and reduced thioredoxin. These cysteines are not conserved in the broader family of arrestin domain-containing proteins, and we demonstrate that the thioredoxin-binding property of Txnip is unique. These data suggest that Txnip is a target of reduced thioredoxin and provide insight into the potential role of Txnip as a redox-sensitive signaling protein.	Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University	Patwari, P (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Dept Med, Partners Res Bldg,Rm 280,65 Landsdowne St, Cambridge, MA 02139 USA.	ppatwari@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073809, T32HL007604] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007604, R01 HL073809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen JF, 1997, BIOCHEMISTRY-US, V36, P13979, DOI 10.1021/bi971004s; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Dias-Gunasekara S, 2005, J BIOL CHEM, V280, P33066, DOI 10.1074/jbc.M505023200; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Goldberg SF, 2003, CANCER RES, V63, P432; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Guo Y, 2004, STEM CELLS, V22, P259, DOI 10.1634/stemcells.22-3-259; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Henrotin Y, 2005, OSTEOARTHR CARTILAGE, V13, P643, DOI 10.1016/j.joca.2005.04.002; Hitchon CA, 2004, ARTHRITIS RES THER, V6, P265, DOI 10.1186/ar1447; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hui TY, 2004, J BIOL CHEM, V279, P24387, DOI 10.1074/jbc.M401280200; Hwang CY, 2004, ONCOGENE, V23, P8868, DOI 10.1038/sj.onc.1208116; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LeMaster DM, 1997, J BIOL CHEM, V272, P29998, DOI 10.1074/jbc.272.48.29998; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Meuillet EJ, 2004, ARCH BIOCHEM BIOPHYS, V429, P123, DOI 10.1016/j.abb.2004.04.020; Nichols CD, 2004, J NEUROCHEM, V90, P576, DOI 10.1111/j.1471-4159.2004.02515.x; Nishinaka Y, 2004, CANCER RES, V64, P1287, DOI 10.1158/0008-5472.CAN-03-0908; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Oka S, 2005, FASEB J, V19, P121, DOI 10.1096/fj.05-443fje; OKA SI, 2005, ENDOCRINOPLOGY; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schulze PC, 2002, CIRC RES, V91, P689, DOI 10.1161/01.RES.0000037982.55074.F6; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Sheth SS, 2005, J LIPID RES, V46, P123, DOI 10.1194/jlr.M400341-JLR200; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; Yamamoto Y, 2001, CLIN CANCER RES, V7, P297; Yamanaka H, 2000, BIOCHEM BIOPH RES CO, V271, P796, DOI 10.1006/bbrc.2000.2699; Yoshioka J, 2004, CIRCULATION, V109, P2581, DOI 10.1161/01.CIR.0000129771.32215.44; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7	44	230	246	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21884	21891		10.1074/jbc.M600427200	http://dx.doi.org/10.1074/jbc.M600427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16766796	Green Accepted, hybrid			2022-12-25	WOS:000239387100035
J	Splawski, I; Yoo, DS; Stotz, SC; Cherry, A; Clapham, DE; Keating, MT				Splawski, Igor; Yoo, Dana S.; Stotz, Stephanie C.; Cherry, Allison; Clapham, David E.; Keating, Mark T.			CACNA1H mutations in autism spectrum disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; CHANNELS	Autism spectrum disorders (ASD) are neurodevelopmental conditions characterized by impaired social interaction, communication skills, and restricted and repetitive behavior. The genetic causes for autism are largely unknown. Previous studies implicate CACNA1C (L-type Ca(V)1.2) calcium channel mutations in a disorder associated with autism (Timothy syndrome). Here, we identify missense mutations in the calcium channel gene CACNA1H (T-type Ca(V)3.2) in 6 of 461 individuals with ASD. These mutations are located in conserved and functionally relevant domains and are absent in 480 ethnically matched controls (p = 0.014, Fisher's exact test). Non-segregation within the pedigrees between the mutations and the ASD phenotype clearly suggest that the mutations alone are not responsible for the condition. However, functional analysis shows that all these mutations significantly reduce CaV3.2 channel activity and thus could affect neuronal function and potentially brain development. We conclude that the identified mutations could contribute to the development of the ASD phenotype.	Childrens Hosp, Dept Cardiol, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Stotz, SC (corresponding author), Childrens Hosp, Dept Cardiol, Howard Hughes Med Inst, Enders 1314,320 Longwood Ave, Boston, MA 02115 USA.	scstotz@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 	NHLBI NIH HHS [HL52338, T32 HL007572, HL46401, T32 HL07572] Funding Source: Medline; NICHD NIH HHS [P30 HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046401, T32HL007572, P50HL052338, R01HL046401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brambilla P, 2003, BRAIN RES BULL, V61, P557, DOI 10.1016/j.brainresbull.2003.06.001; Bryson SE, 2003, CAN J PSYCHIAT, V48, P506, DOI 10.1177/070674370304800802; Chemin J, 2000, FEBS LETT, V478, P166, DOI 10.1016/S0014-5793(00)01832-9; Chen YC, 2003, ANN NEUROL, V54, P239, DOI 10.1002/ana.10607; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Geschwind DH, 2001, AM J HUM GENET, V69, P463, DOI 10.1086/321292; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; JOKSOVIC P, 2006, IN PRESS J PHYSL; Khosravani H, 2005, ANN NEUROL, V57, P745, DOI 10.1002/ana.20458; Khosravani H, 2004, J BIOL CHEM, V279, P9681, DOI 10.1074/jbc.C400006200; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; Muhle R, 2004, PEDIATRICS, V113, pE472, DOI 10.1542/peds.113.5.e472; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Sadamatsu Miyuki, 2006, Congenital Anomalies, V46, P1, DOI 10.1111/j.1741-4520.2006.00094.x; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Splawski I, 2005, P NATL ACAD SCI USA, V102, P8089, DOI 10.1073/pnas.0502506102; Talley EM, 1999, J NEUROSCI, V19, P1895; Vitko I, 2005, J NEUROSCI, V25, P4844, DOI 10.1523/JNEUROSCI.0847-05.2005; Volkmar FR, 2003, LANCET, V362, P1133, DOI 10.1016/S0140-6736(03)14471-6; Weiss LA, 2003, MOL PSYCHIATR, V8, P186, DOI 10.1038/sj.mp.4001241; Zhong XL, 2006, HUM MOL GENET, V15, P1497, DOI 10.1093/hmg/ddl068; Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071	26	158	169	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22085	22091		10.1074/jbc.M603316200	http://dx.doi.org/10.1074/jbc.M603316200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754686	hybrid			2022-12-25	WOS:000239387100055
J	Filomenko, R; Prevotat, L; Rebe, C; Cortier, M; Jeannin, JF; Solary, E; Bettaieb, A				Filomenko, R.; Prevotat, L.; Rebe, C.; Cortier, M.; Jeannin, J-F; Solary, E.; Bettaieb, A.			Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells	ONCOGENE			English	Article						caspase-10; apoptosis; cytotoxic drug; etoposide; acute leukemia	CHEMOTHERAPY-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; COLON-CANCER CELLS; CYTOCHROME-C; MITOCHONDRIAL PATHWAYS; INACTIVATING MUTATIONS; SIGNALING PATHWAYS; ARSENIC TRIOXIDE; DEATH RECEPTOR; ACTIVATION	Anticancer drugs can induce tumor cell death by caspase-dependent apoptosis. The observation that procaspase-10 expression decreased in leukemic cells from acute myeloblastic leukemia patients at first relapse led us to explore the role of caspase-10 in cytotoxic drug-induced apoptosis. We show that caspase-10 is activated in etoposide-treated cells in a dose- and time-dependent manner. A caspase-10 peptide inhibitor, a caspase-10 dominant-negative mutant or a small interfering RNA (siRNA)-mediated downregulation of the enzyme negatively interfere with drug-induced cell death and caspase-2, -3, -8 and -9 activation. The extrinsic pathway to apoptosis is not involved in drug-induced caspase-10 activation that occurs downstream of Bax redistribution to mitochondria and cytochrome c release from this organelle. siRNA-mediated downregulation of Apaf-1 prevents etoposide-mediated activation of caspase-10. In a cell-free assay, cytochrome c and dATP treatment of cell extracts after immunodepletion of either caspase-3 or caspase-9 indicates that caspase-10 is activated downstream of caspase-9. Then, caspase-10 is involved in a feedback amplification loop that amplifies caspase-9 and -3 activities. Altogether, these data indicate an active role for caspase-10 in cytotoxic drug-induced tumor cell death, downstream of the mitochondria.	Ecole Prat Hautes Etud, IFR 100, Fac Med, INSERM,U517, F-21079 Dijon, France; CHU Bocage, Clin Hematol Unit, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne	Bettaieb, A (corresponding author), Ecole Prat Hautes Etud, IFR 100, Fac Med, INSERM,U517, 7 Blvd Jeanne Arc, F-21079 Dijon, France.	ali.bettaieb@u-bourgogne.fr	REBE, Cédric/AAD-4316-2019	REBE, Cédric/0000-0001-8831-145X; Bettaieb, Ali/0000-0002-6018-9592; Solary, Eric/0000-0002-8629-1341				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Decaudin D, 1998, INT J ONCOL, V12, P141; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harada K, 2002, CANCER RES, V62, P5897; HIDDEMANN W, 1991, ANN HEMATOL, V62, P119, DOI 10.1007/BF01702925; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lacour S, 2001, CANCER RES, V61, P1645; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Millet A, 2002, GASTROENTEROLOGY, V123, P235, DOI 10.1053/gast.2002.34310; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Perkins C, 1998, CANCER RES, V58, P4561; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Rikhof B, 2003, CANCER BIOL THER, V2, P707; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7635	7645		10.1038/sj.onc.1209733	http://dx.doi.org/10.1038/sj.onc.1209733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767158				2022-12-25	WOS:000242655500008
J	Schmitz, I; Meyer, C; Schulze-Osthoff, K				Schmitz, I.; Meyer, C.; Schulze-Osthoff, K.			CD95 ligand mediates T-cell receptor-induced apoptosis of a CD4(+) CD8(+) double positive thymic lymphoma	ONCOGENE			English	Article						apoptosis; caspase; CD95; thymic lymphoma; thymus	NEGATIVE SELECTION; THYMOCYTE DEVELOPMENT; CASPASE INHIBITOR; C-FLIPSHORT; IN-VITRO; KAPPA-B; ACTIVATION; DEATH; MICE; GENES	Tumors in the thymus can be of different cellular origin. Among the most common tumors are thymoma and lymphoma, which are derived from transformed thymic epithelial cells and transformed lymphocytes, respectively. Thymic lymphoma and their response to apoptotic stimuli are poorly characterized. Here, we analyse apoptosis events in the thymic lymphoma cell line Thy278, which expresses cell surface antigens characteristic of immature double positive thymocytes. Upon T-cell receptor (TCR)/CD3 stimulation, Thy278 cells die by apoptosis, similar as primary thymocytes during negative selection. Caspases are crucial for deletion of both Thy278cells and normal thymocytes. Moreover, we show that deletion of primary thymocytes and Thy278 cells upon CD3 stimulation is considerably impaired by neutralizing CD95L antibody. Thus, our results not only demonstrate that TCR-induced apoptosis is still functional in transformed thymocytes, but also suggest that Thy278 cells are a helpful model for the molecular analysis of negative selection.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schmitz, I (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	ingo-schmitz@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Schmitz, Ingo/G-2093-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Schmitz, Ingo/0000-0002-5360-0419				AISENBERG AC, 1993, J CLIN ONCOL, V11, P2291, DOI 10.1200/JCO.1993.11.12.2291; Alam A, 1997, J EXP MED, V186, P1503, DOI 10.1084/jem.186.9.1503; BERG LJ, 1988, MOL CELL BIOL, V8, P5459, DOI 10.1128/MCB.8.12.5459; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; CHAHINIAN AP, 2003, CANC MED, V2, P1467; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Doerfler P, 2000, J IMMUNOL, V164, P4071, DOI 10.4049/jimmunol.164.8.4071; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Geisler C, 2004, CRIT REV IMMUNOL, V24, P67; GROVES T, 1995, J IMMUNOL, V154, P5011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kovalik JP, 1996, J IMMUNOL, V157, P5290; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Moulian N, 1998, SEMIN IMMUNOL, V10, P449, DOI 10.1006/smim.1998.0155; Muschen M, 2002, TRENDS IMMUNOL, V23, P75, DOI 10.1016/S1471-4906(01)02115-9; NAMBA T, 1978, MEDICINE, V57, P411, DOI 10.1097/00005792-197809000-00002; Nishida T, 2004, J IMMUNOL, V172, P6634, DOI 10.4049/jimmunol.172.11.6634; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; RATHMELL JC, 2002, CELL S, V109, P97; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; ROSAI J, 1976, ATLAS TUMOR PATHOLOG; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sasada T, 2001, J IMMUNOL, V166, P2394, DOI 10.4049/jimmunol.166.4.2394; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Venanzi ES, 2004, CURR OPIN IMMUNOL, V16, P197, DOI 10.1016/j.coi.2004.01.008; WADSWORTH S, 1990, EUR J IMMUNOL, V20, P723, DOI 10.1002/eji.1830200403; Yefenof E, 1999, ADV IMMUNOL, V73, P511, DOI 10.1016/S0065-2776(08)60792-0	49	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7587	7596		10.1038/sj.onc.1209741	http://dx.doi.org/10.1038/sj.onc.1209741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767155				2022-12-25	WOS:000242655500004
J	Liu, Z; Li, H; Wu, X; Yoo, BH; Yan, SR; Stadnyk, AW; Sasazuki, T; Shirasawa, S; LaCasse, EC; Korneluk, RG; Rosen, KV				Liu, Z.; Li, H.; Wu, X.; Yoo, B. H.; Yan, S. R.; Stadnyk, A. W.; Sasazuki, T.; Shirasawa, S.; LaCasse, E. C.; Korneluk, R. G.; Rosen, K. V.			Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells	ONCOGENE			English	Article						apoptosis; anoikis; XIAP; cIAP2; intestinal epithelial cells	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; RAS-INDUCED TRANSFORMATION; HUMAN PROSTATE-CANCER; ACID PHENETHYL ESTER; BCL-2 PROTEIN FAMILY; DOWN-REGULATION; INDUCED APOPTOSIS; SERINE-PROTEASE; CYTOCHROME-C	Detachment of normal epithelial cells from the extracellular matrix triggers apoptosis, a phenomenon called anoikis. Conversely, carcinoma cells tend to be relatively more anoikis- resistant than their normal counterparts, and this increased resistance represents a critical feature of the malignant phenotype. Mechanisms that control susceptibilityand resistance to anoikis are not fully understood. It is now known that detachment of non-malignant epithelial cells triggers both pro- and antiapoptotic signals, and it is the balance between these signals and the duration of detachment that determine further fate of the cells. Detachment- induced antiapoptotic events delay anoikis and if cells reattach relativelysoo n after detachment they survive. Direct regulators of apoptosis responsible for this delay of anoikis are unknown. We found that detachment of non-malignant intestinal epithelial cells triggers upregulation of inhibitors of apoptosis protein (IAP) family, such as X- chromosome- linked inhibitor of apoptosis protein and cellular inhibitor of apoptosis- 2 (cIAP2). We demonstrated that this upregulation requires detachment-dependent activation of the transcription factor nuclear factor-kappa B. We further observed that various IAP antagonists accelerate anoikis, indicating that upregulation of the IAPs delays detachment- triggered apoptosis. We conclude that the IAPs are important regulators of the balance between detachment- triggered life and death signals. Perhaps, not by coincidence, these proteins are often upregulated in carcinomas, tumors composed of cells that tend to be anoikis- resistant.	Dalhousie Univ, Dept Pediat, CRC, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, CRC, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada; Int Med Ctr Japan, Dept Pathol, Inst Res, Shinjyuku Ku, Tokyo, Japan; Childrens Hosp Eastern Ontario, Inst Res, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	Dalhousie University; Dalhousie University; Dalhousie University; National Center for Global Health & Medicine - Japan; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Rosen, KV (corresponding author), Dalhousie Univ, Dept Pediat, CRC, Atlantic Res Ctr, Room C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	kirill.rosen@dal.ca		Rosen, Kirill/0000-0002-4317-9907; Stadnyk, Andrew/0000-0002-1940-8036				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Biswas DK, 2003, CANCER RES, V63, P290; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810	69	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7680	7690		10.1038/sj.onc.1209753	http://dx.doi.org/10.1038/sj.onc.1209753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799641				2022-12-25	WOS:000242830800003
J	Janda, E; Nevolo, M; Lehmann, K; Downward, J; Beug, H; Grieco, M				Janda, E.; Nevolo, M.; Lehmann, K.; Downward, J.; Beug, H.; Grieco, M.			Raf plus TGF beta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin	ONCOGENE			English	Article						E-cadherin; Raf; TGFbeta; EMT; endocytosis; monoubiquitination	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; CELL-ADHESION MOLECULE; TUMOR-CELLS; EXPRESSION; PLASTICITY; MECHANISM; PROTEIN; TRANSFORMATION; PROGRESSION	Oncogenic Ras interferes with adhesive functions of epithelial cells, but requires tumor growth factor beta (TGF beta) signaling to cause epithelial-mesenchymal transition (EMT) and tumor progression in model systems. To investigate the mechanisms by which Ras and TGFb pathways cooperate in EMT induction, we introduced a tamoxifen-inducible version of Raf-1 (RafER) into fully polarized, mammary epithelial cells (EpH4). EMT characterized by loss of E-cadherin expression and upregulation of invasiveness-promoting genes was induced by TGF beta plus 4-hydroxytamoxifen (4HT) activation of RafER. Downregulation of E-cadherin by RafER plus TGF beta was detectable in total cell lysates after 48 h and much earlier in detergent-insoluble fractions of E-cadherin. Both pathways cooperated to strongly enhance endocytosis of E-cadherin, mainly via the clathrin-dependent route. Pulse-chase experiments showed decreased E-cadherin protein stability in cells stimulated with TGF beta and 4HT and increased E-cadherin half-life in the presence of monensin. Monensin and chloroquine prevented E-cadherin degradation to different extent, but only monensin effectively blocked the loss of E-cadherin from the junctional complexes. Both lysosome inhibitors caused accumulation of E-cadherin vesicles, some of which were positive for Cathepsin D and lysosome-associated membrane protein 1 (LAMP-1). In addition, TGF beta and mitogen-activated protein kinase hyperactivation synergistically induced E-cadherin ubiquitination, suggesting that the cooperation of Raf and TGF beta favors lysosomal degradation of E-cadherin instead of its recycling. Our data indicate that early stages of EMT involve cooperative, post-translational downregulation of E-cadherin, whereas loss of E-cadherin via transcriptional repression is a late event in EMT.	Univ Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Imperial Canc Res Fund, Signal Transduct Labs, London WC2A 3PX, England; Res Inst Mol Pathol, A-1030 Vienna, Austria	Magna Graecia University of Catanzaro; Cancer Research UK; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Grieco, M (corresponding author), Univ Magna Graecia, Dipartimento Med Sperimentale & Clin, Campus Germaneto Livello 7, I-88100 Catanzaro, Italy.	mgrieco@unicz.it	Downward, Julian/A-3251-2012; Janda, Elzbieta/AFQ-7061-2022; Janda, Elzbieta/AAD-5126-2022	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Downward, Julian/0000-0002-2331-4729; Grieco, Michele/0000-0002-4212-7814				Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kemler R, 1992, Semin Cell Biol, V3, P149; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; Negroiu G, 2005, BIOCHEM BIOPH RES CO, V328, P914, DOI 10.1016/j.bbrc.2005.01.040; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sun DZ, 2000, DEV BIOL, V228, P337, DOI 10.1006/dbio.2000.9946; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Viebahn C, 1995, ACTA ANAT, V154, P79; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	38	118	122	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7117	7130		10.1038/sj.onc.1209701	http://dx.doi.org/10.1038/sj.onc.1209701			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16751808				2022-12-25	WOS:000242046900001
J	Tzircotis, G; Thorne, RF; Isacke, CM				Tzircotis, G.; Thorne, R. F.; Isacke, C. M.			Directional sensing of a phorbol ester gradient requires CD44 and is regulated by CD44 phosphorylation	ONCOGENE			English	Article						CD44; chemotaxis; phorbol ester; protein kinase C; protein kinase A; metastasis	DEPENDENT PROTEIN-KINASE; BREAST-CANCER CELLS; CYTOPLASMIC DOMAIN; ENDOTHELIAL-CELLS; UP-REGULATION; CYTOSKELETAL INTERACTION; FACILITATES INVASION; SELECTIVE INHIBITOR; TUMOR PROGRESSION; BONE-MARROW	Cancer progression is associated with enhanced directional cell migration, both of the tumour cells invading into the stroma and stromal cells infiltrating the tumour site. In cell-based assays to study directional cell migration, phorbol esters are frequently used as a chemotactic agent. However, the molecular mechanism by which these activators of protein kinase C (PKC) result in the establishment of a polarized migratory phenotype is not known. Here we show that CD44 expression is essential for chemotaxis towards a phorbol ester gradient. In an investigation of CD44 phosphorylation kinetics in resting and stimulated cells, Ser316 was identified as a novel site of phosphorylation following activation of PKC. PKC does not phosphorylate Ser316 directly, but rather mediates the activation of downstream Ser316 kinase(s). In transfection studies, a phosphorylation-deficient Ser316 mutant was shown to act in a dominant-negative fashion to impair chemotaxis mediated by endogenous CD44 in response to a phorbol ester gradient. Importantly, this mutation had no effect on random cell motility or the ability of cells to migrate directionally towards a cocktail of chemoattractants. These studies demonstrate that CD44 functions to provide directional cues to migrating cells without affecting the motility apparatus.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk		Isacke, Clare/0000-0002-9222-3345	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Alstergren P, 2004, CELL IMMUNOL, V231, P146, DOI 10.1016/j.cellimm.2005.01.007; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cichy J, 2005, BBA-MOL CELL RES, V1745, P59, DOI 10.1016/j.bbamcr.2005.02.006; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dingemans KP, 2002, LAB INVEST, V82, P313, DOI 10.1038/labinvest.3780425; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Eccles SA, 2005, CURR OPIN GENET DEV, V15, P77, DOI 10.1016/j.gde.2004.12.001; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ESTENSEN RD, 1973, NATURE, V245, P458, DOI 10.1038/245458a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fujisaki T, 1999, CANCER RES, V59, P4427; GLASS DB, 1989, J BIOL CHEM, V264, P14579; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Herrera-Gayol A, 1999, EXP MOL PATHOL, V66, P99, DOI 10.1006/exmp.1999.2236; Herrera-Gayol A, 2001, INT J EXP PATHOL, V82, P193, DOI 10.1111/j.1365-2613.2001.iep196.x; ISACKE CM, 1986, IMMUNOGENETICS, V23, P326, DOI 10.1007/BF00398797; Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Kim HR, 2004, CANCER RES, V64, P4569, DOI 10.1158/0008-5472.CAN-04-0202; Kobayashi H, 2002, INT J CANCER, V102, P379, DOI 10.1002/ijc.10710; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lewis CA, 2001, BIOCHEM J, V357, P843, DOI 10.1042/0264-6021:3570843; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Miletti-Gonzalez KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008-5472.CAN-04-3478; Mine S, 2003, EXP CELL RES, V288, P189, DOI 10.1016/S0014-4827(03)00184-8; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; NEAME SJ, 1995, J CELL SCI, V108, P3127; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peck D, 1998, J CELL SCI, V111, P1595; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; PERSCHL A, 1995, J CELL SCI, V108, P1033; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Ratliff Timothy L, 2005, J Urol, V173, P1045, DOI 10.1016/S0022-5347(05)60440-5; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tzircotis G, 2005, J CELL SCI, V118, P5119, DOI 10.1242/jcs.02629; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Weber GF, 2002, CANCER RES, V62, P2281; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; Zhu BQ, 2004, J CELL PHYSIOL, V198, P155, DOI 10.1002/jcp.10394; Zhu H, 2006, STEM CELLS, V24, P928, DOI 10.1634/stemcells.2005-0186; ZICHA D, 1991, J CELL SCI, V99, P769	64	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7401	7410		10.1038/sj.onc.1209724	http://dx.doi.org/10.1038/sj.onc.1209724			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785995				2022-12-25	WOS:000242419100009
J	Shao, SJ; Wang, Y; Jin, SQ; Song, YM; Wang, XX; Fan, WH; Zhao, ZY; Fu, M; Tong, T; Dong, LJ; Fan, FY; Xu, NZ; Zhan, QM				Shao, Shujuan; Wang, Yang; Jin, Shunqian; Song, Yongmei; Wang, Xiaoxia; Fan, Wenhong; Zhao, Zhiying; Fu, Ming; Tong, Tong; Dong, Lijia; Fan, Feiyue; Xu, Ningzhi; Zhan, Qimin			Gadd45a interacts with Aurora-A and inhibits its kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTROSOME AMPLIFICATION; PROTEIN-KINASE; DUPLICATION; BRCA1; CELLS; INSTABILITY; ANEUPLOIDY; INDUCTION; RADIATION; ABSENCE	Centrosome stability is required for successful mitosis in mammalian cells. Amplification of the centrosome leads to chromosomal missegregation and generation of aneuploidy, which are closely associated with cell transformation and tumorigenesis (Doxsey, S. J. (2001) Nat. Cell Biol. 3, E105-E108; Hinchcliffe, E. H., and Sluder, G. (2001) Genes Dev. 15, 1167 1181; Pihan, G. A., Purohit, A., Wallace, J., Malhotra, R., Liotta, L., and Doxsey, S. J. (2001) Cancer Res. 61, 2212-2219). However, there are currently limited insights into mechanism(s) for this critical biological event. Here we show that Gadd45a, a DNA damage-inducible protein that is regulated by tumor suppressors p53 and BRCA1, participates in the maintenance of centrosome stability. Mouse embryonic fibroblasts derived from gadd45a knock-out mice exhibit centrosome amplification (designated as increased centrosome numbers). Introduction of exogenous Gadd45a into mouse embryonic fibroblasts isolated from gadd45a-null mice substantially restored the normal centrosome profile. In contrast to p21(waf1/cip1), which ensures coordinated initiation of centrosome, Gadd45a had no significant effect on centrosome duplication in S phase. Interestingly Gadd45a was found to physically associate with Aurora-A protein kinase, whose deregulated expression results in centrosome abnormality. Furthermore Gadd45a was demonstrated to strongly inhibit Aurora-A kinase activity and to antagonize Aurora-A-induced centrosome amplification. These findings identify a novel mechanism for Gadd45a in the maintenance of centrosome stability and broaden understandings of p53-and BRCA1-regulated signaling pathways in maintaining genomic fidelity.	Chinese Acad Med Sci, State Key Lab Mol Oncol, Inst Canc, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China; Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Inst Radiat Med, Tianjin 300192, Peoples R China; Dalian Med Univ, Dalian 116027, Peoples R China; Inst Basic Med Sci, Dept Neurobiol, Beijing 100850, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Dalian Medical University	Zhan, QM (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Inst Canc, Beijing 100021, Peoples R China.	Zhanqimin@pumc.edu.cn	Wang, Yang/A-1849-2010	Wang, Yang/0000-0001-9385-7393; song, yongmei/0000-0002-7789-0158	NCI NIH HHS [R01 CA93640] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Donaldson MM, 2001, J CELL SCI, V114, P2357; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2000, J CELL SCI, V113, P1973; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Giet R, 1999, J CELL SCI, V112, P3591; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Pihan GA, 2001, CANCER RES, V61, P2212; Raff JW, 2001, CURR BIOL, V11, pR159, DOI 10.1016/S0960-9822(01)00082-3; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang XY, 2004, J BIOL CHEM, V279, P29606, DOI 10.1074/jbc.M312279200; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	31	49	53	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2006	281	39					28943	28950		10.1074/jbc.M600235200	http://dx.doi.org/10.1074/jbc.M600235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	086NO	16772293	hybrid			2022-12-25	WOS:000240680500048
J	Plattner, F; Angelo, M; Giese, KP				Plattner, Florian; Angelo, Marco; Giese, K. Peter			The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; AMYLOID PRECURSOR PROTEIN; PHOSPHORYLATES TAU; ACTIVATOR P25; CDK5; LITHIUM; PHOSPHATASE-1; MODULATION; SUBSTRATE; TRANSPORT	Hyperphosphorylation of the microtubule-associated protein tau is a characteristic feature of neurodegenerative tauopathies including Alzheimer disease. Over-activation of proline-directed kinases, such as cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 (GSK3), has been implicated in the aberrant phosphorylation of tau at proline-directed sites. In this study we tested the roles of Cdk5 and GSK3 in tau hyperphosphorylation in vivo using transgenic mice with p25-induced Cdk5 over-activation. We found that over-activation of Cdk5 in young transgenic animals does not induce tau hyperphosphorylation at sites recognized by the antibodies AT8, AT100, PHF-1, and TG3. In fact, we observed that Cdk5 over-activation leads to inhibition of GSK3. However, in old transgenic animals the inhibition of GSK3 is lost and results in increased GSK3 activity, which coincides with tau hyperphosphorylation at the AT8 and PHF-1 sites. Pharmacological inhibition of GSK3 in old transgenic mice by chronic treatment with lithium leads to a reduction of the age-dependent increase in tau hyperphosphorylation. Furthermore, we found that Cdk5, GSK3, and PP2A co-immunoprecipitate, suggesting a functional association of these molecules. Together, these results reveal the role of GSK3 as a key mediator of tau hyperphosphorylation, whereas Cdk5 acts as a modulator of tau hyperphosphorylation via the inhibitory regulation of GSK3. Furthermore, these findings suggest that disruption of regulation of GSK3 activity underlies tau hyperphosphorylation in neurodegenerative tauopathies. Hence, GSK3 may be a prime target for therapeutic intervention in tauopathies including Alzheimer disease.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Giese, KP (corresponding author), UCL, Wolfson Inst Biomed Res, Gower St, London WC1E 6BT, England.	f.plattner@ucl.ac.uk; p.giese@ucl.ac.uk	Giese, Karl P/A-3112-2011	Giese, Karl P/0000-0003-4503-7344; Plattner, Florian/0000-0002-3150-1866	MRC [G0400983] Funding Source: UKRI; Medical Research Council [G0400983] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; Angelo M, 2003, EUR J NEUROSCI, V18, P423, DOI 10.1046/j.1460-9568.2003.02746.x; Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Cohen PTW, 2002, J CELL SCI, V115, P241; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Giese KP, 2005, NEUROREPORT, V16, P1725, DOI 10.1097/01.wnr.0000185019.67434.d2; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hallows JL, 2003, J NEUROSCI, V23, P10633; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Ishizawa T, 2003, AM J PATHOL, V163, P1057, DOI 10.1016/S0002-9440(10)63465-7; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lau LF, 2002, J MOL NEUROSCI, V19, P267, DOI 10.1385/JMN:19:3:267; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Li T, 2006, BIOCHEMISTRY-US, V45, P3134, DOI 10.1021/bi051635j; Li T, 2006, BIOCHEMISTRY-US, V45, P3125, DOI 10.1021/bi051634r; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; Liu F, 2003, FEBS LETT, V547, P193, DOI 10.1016/S0014-5793(03)00714-2; Liu SJ, 2004, J BIOL CHEM, V279, P50078, DOI 10.1074/jbc.M406109200; Mandelkow EM, 2004, J CELL BIOL, V167, P99, DOI 10.1083/jcb.200401085; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; Nakamura S, 1997, NEUROLOGY, V48, P267, DOI 10.1212/WNL.48.1.267; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Ris L, 2005, EUR J NEUROSCI, V21, P3023, DOI 10.1111/j.1460-9568.2005.04137.x; Sengupta A, 1997, MOL CELL BIOCHEM, V167, P99, DOI 10.1023/A:1006883924775; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; Shelton SB, 2004, J NEUROCHEM, V88, P1313, DOI 10.1111/j.1471-4159.2003.02328.x; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Takashima A, 2001, NEUROSCI LETT, V306, P37, DOI 10.1016/S0304-3940(01)01864-X; Vandebroek T, 2005, BIOCHEMISTRY-US, V44, P11466, DOI 10.1021/bi0506775	52	272	282	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25457	25465		10.1074/jbc.M603469200	http://dx.doi.org/10.1074/jbc.M603469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803897	hybrid			2022-12-25	WOS:000240031300048
J	Spofford, LS; Abel, EV; Boisvert-Adamo, K; Aplin, AE				Spofford, Laurie S.; Abel, Ethan V.; Boisvert-Adamo, Karen; Aplin, Andrew E.			Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G(1)-S progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT/PROTEIN KINASE-B; MALIGNANT-MELANOMA; D1; PROLIFERATION; GROWTH; GENE; ACTIVATION; MUTATIONS; PATHWAY; BRAF	D-type cyclins regulate G(1) cell cycle progression by enhancing the activities of cyclin-dependent kinases (CDKs), and their expression is frequently altered in malignant cells. We and others have previously shown that cyclin D1 is up-regulated in melanoma cells through adhesion-independent MEK-ERK1/2 signaling initiated by mutant B-RAF. Here, we describe the regulation and role of cyclin D3 in human melanoma cells. Cyclin D3 expression was enhanced in a cell panel of human melanoma cell lines compared with melanocytes and was regulated by fibronectin-mediated phosphatidylinositol 3-kinase/Akt signaling but not MEK activity. RNA interference experiments demonstrated that cyclin D3 contributed to G(1)-S cell cycle progression and proliferation in melanoma cells. Overexpression of cyclin D1 did not recover the effects of cyclin D3 knockdown. Finally, immunoprecipitation studies showed that CDK6 is a major binding partner for cyclin D3, whereas CDK4 preferentially associated with cyclin D1. Together, these findings demonstrate that cyclin D3 is an important regulator of melanoma G(1)-S cell cycle progression and that D-type cyclins are differentially regulated in melanoma cells.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA.	aplina@mail.amc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM067893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bales E, 2005, CANCER RES, V65, P692; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; BOISVETADAMO K, 2006, ONCOGENE; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Vita G, 2000, CANCER RES, V60, P3916; Dhawan P, 2002, CANCER RES, V62, P7335; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Florenes VA, 2000, CLIN CANCER RES, V6, P3614; Guldberg P, 1997, CANCER RES, V57, P3660; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Jetzt A, 2003, CANCER RES, V63, P6697; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Rieber M, 1999, CELL DEATH DIFFER, V6, P1209, DOI 10.1038/sj.cdd.4400606; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Sauter ER, 2002, CANCER RES, V62, P3200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Teng DHF, 1997, CANCER RES, V57, P5221; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zhu XY, 2001, CANCER RES, V61, P4569	43	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25644	25651		10.1074/jbc.M600197200	http://dx.doi.org/10.1074/jbc.M600197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16815849	Green Accepted, hybrid			2022-12-25	WOS:000240031300067
J	Hidalgo, P; Gonzalez-Gutierrez, G; Garcia-Olivares, J; Neely, A				Hidalgo, Patricia; Gonzalez-Gutierrez, Giovanni; Garcia-Olivares, Jennie; Neely, Alan			The alpha(1)-beta-subunit interaction that modulates calcium channel activity is reversible and requires a competent alpha-interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CA2+ CHANNELS; CHARGE MOVEMENT; AMINO-TERMINUS; TRAFFICKING; EXPRESSION; DELETIONS	High voltage-gated calcium channels consist of a pore-forming subunit (alpha(1)) and three nonhomologous subunits (alpha(2)/delta,beta, and gamma). Although it is well established that the beta-subunit promotes traffic of channels to the plasma membrane and modifies their activity, the reversible nature of the interaction with the alpha(1)-subunit remains controversial. Here, we address this issue by examining the effect of purified beta(2)a protein on Ca(V)1.2 and Ca(V)2.3 channels expressed in Xenopus oocytes. The beta(2a)-subunit binds to the alpha(1)-interaction domain ( AID) in vitro, and when injected into oocytes, it shifts the voltage dependence of activation and increases charge movement to ionic current coupling of CaV1.2 channels. This increase depended on the integrity of AID but was not abolished by bafilomycin, demonstrating that the alpha(1)-beta interaction through the AID site can take place at the plasma membrane. Furthermore, injection of beta(2a) protein inhibited inactivation of CaV2.3 channels and converted fast inactivating Ca(V)2.3/beta(1b) channels to slow inactivating channels. Inhibition of inactivation required larger concentration of beta(2a) in oocytes expressing Ca(V)2.3/beta(1b) channels than expressing CaV2.3 alone but reached the same maximal level as expected for a competitive interaction through a single binding site. Together, our data show that the alpha(1)-beta interaction is reversible in intact cells and defines calcium channels beta-subunits as regulatory proteins rather than stoichiometric subunits.	Univ Valparaiso, Fac Ciencias, Ctr Neurociencia Valparaiso, Valparaiso 2349400, Chile; Hannover Med Sch, Abt Neurophysiol, D-30625 Hannover, Germany; Ctr Estudios Cient, Valdivia 509000, Chile	Universidad de Valparaiso; Hannover Medical School	Neely, A (corresponding author), Univ Valparaiso, Fac Ciencias, Ctr Neurociencia Valparaiso, Gran Bretana 1111, Valparaiso 2349400, Chile.	alan@cnv.cl	Neely, Alan/A-8715-2009; Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590; Gonzalez-Gutierrez, Giovanni/0000-0002-1044-943X; Neely, Alan/0000-0002-6007-2159				Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Dalton S, 2005, J PHYSIOL-LONDON, V567, P757, DOI 10.1113/jphysiol.2005.093195; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Drose S, 1997, J EXP BIOL, V200, P1; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; Neely A, 2004, J BIOL CHEM, V279, P21689, DOI 10.1074/jbc.M312675200; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Olcese R, 1996, J PHYSIOL-LONDON, V497, P675, DOI 10.1113/jphysiol.1996.sp021799; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; REYES EP, 1992, J BIOL CHEM, V267, P1792; Sandoz G, 2004, P NATL ACAD SCI USA, V101, P6267, DOI 10.1073/pnas.0306804101; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Wei X, 1996, RECEPTOR CHANNEL, V4, P205; WEI XY, 1994, J BIOL CHEM, V269, P1635; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348	24	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24104	24110		10.1074/jbc.M605930200	http://dx.doi.org/10.1074/jbc.M605930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793763	hybrid			2022-12-25	WOS:000239847800005
J	Kuhnel, K; Blankenfeldt, W; Terner, J; Schlichting, I				Kuehnel, Karin; Blankenfeldt, Wulf; Terner, James; Schlichting, Ilme			Crystal structures of chloroperoxidase with its bound substrates and complexed with formate, acetate, and nitrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; ENANTIOSELECTIVE EPOXIDATION; BIOLOGICAL CHLORINATION; HYDROGEN-PEROXIDE; CATALYTIC CYCLE; LOW-TEMPERATURE; ACTIVE-SITE; CALDARIOMYCIN	Chloroperoxidase (CPO) is a heme-thiolate enzyme that catalyzes hydrogen peroxide-dependent halogenation reactions. Structural data on substrate binding have not been available so far. CPO was therefore crystallized in the presence of iodide or bromide. One halide binding site was identified at the surface near a narrow channel that connects the surface with the heme. Two other halide binding sites were identified within and at the other end of this channel. Together, these sites suggest a pathway for access of halide anions to the active site. The structure of CPO complexed with its natural substrate cyclopentanedione was determined at a resolution of 1.8 angstrom. This is the first example of a CPO structure with a bound organic substrate. In addition, structures of CPO bound with nitrate, acetate, and formate and of a ternary complex with dimethylsulfoxide (Me2SO) and cyanide were determined. These structures have implications for the mechanism of compound I formation. Before binding to the heme, the incoming hydrogen peroxide first interacts with Glu-183. The deprotonated Glu-183 abstracts a proton from hydrogen peroxide. The hydroperoxo-anion then binds at the heme, yielding compound 0. Glu-183 protonates the distal oxygen of compound 0, water is released, and compound I is formed.	Max Planck Inst Med Res, Abt Biomol Mechanismen, D-69120 Heidelberg, Germany; Max Planck Inst Mol Physiol, Abt Phys Biochem, D-44227 Dortmund, Germany; Virginia Commonwealth Univ, Dept Chem, Richmond, VA 23284 USA	Max Planck Society; Max Planck Society; Virginia Commonwealth University	Schlichting, I (corresponding author), Max Planck Inst Med Res, Abt Biomol Mechanismen, Jahnstr 29, D-69120 Heidelberg, Germany.	ilme.schlichting@mpimf-heidelberg.mpg.de	Schlichting, Ilme/I-1339-2013; Blankenfeldt, Wulf/F-8877-2010	Blankenfeldt, Wulf/0000-0001-9886-9668; Kuehnel, Karin/0000-0002-2663-703X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057042] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57042] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN EJ, 1993, J AM CHEM SOC, V115, P4415, DOI 10.1021/ja00063a091; BAEK HK, 1992, J AM CHEM SOC, V114, P718, DOI 10.1021/ja00028a046; BECKWITH JR, 1963, J BIOL CHEM, V238, P3091; BECKWITH JR, 1963, J BIOL CHEM, V238, P3086; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; BLANKE SR, 1989, BIOTECHNOL LETT, V11, P769, DOI 10.1007/BF01026094; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlsson GH, 2005, BIOCHEMISTRY-US, V44, P635, DOI 10.1021/bi0483211; CASELLA L, 1994, BIOCHEMISTRY-US, V33, P6377, DOI 10.1021/bi00187a001; COLONNA S, 1993, TETRAHEDRON-ASYMMETR, V4, P1325, DOI 10.1016/S0957-4166(00)80243-8; COLONNA S, 1990, BIOCHEMISTRY-US, V29, P10465, DOI 10.1021/bi00498a006; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fedorov R, 2003, ARCH BIOCHEM BIOPHYS, V409, P25, DOI 10.1016/S0003-9861(02)00555-6; Filizola M, 2000, J AM CHEM SOC, V122, P3599, DOI 10.1021/ja993000b; GEIGERT J, 1983, BIOCHEM BIOPH RES CO, V116, P82, DOI 10.1016/0006-291X(83)90383-2; GRIFFIN BW, 1983, BIOCHEM BIOPH RES CO, V116, P873, DOI 10.1016/S0006-291X(83)80223-X; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAGER LP, 1966, J BIOL CHEM, V241, P1769; Howes BD, 2000, J BIOL INORG CHEM, V5, P227, DOI 10.1007/s007750050367; Ibrahim M, 2003, J AM CHEM SOC, V125, P13714, DOI 10.1021/ja036949d; Indiani C, 2000, J INORG BIOCHEM, V79, P269, DOI 10.1016/S0162-0134(99)00156-7; ITOH N, 1987, BIOCHEMISTRY-US, V26, P282, DOI 10.1021/bi00375a039; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVINE SD, 1968, TETRAHEDRON, V24, P2979, DOI 10.1016/S0040-4020(01)98705-8; Libby RD, 1996, J BIOL CHEM, V271, P21820, DOI 10.1074/jbc.271.36.21820; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; LIU KKC, 1992, J ORG CHEM, V57, P3748, DOI 10.1021/jo00039a050; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NEIDLEMA.SL, 1966, TETRAHEDRON LETT, P5337; PATTERSON EL, 1967, APPL MICROBIOL, V15, P528, DOI 10.1128/AEM.15.3.528-530.1967; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RAMAKRISHNAN K, 1983, BIOCHEMISTRY-US, V22, P3271, DOI 10.1021/bi00282a036; Redaelli C, 2002, CHEMBIOCHEM, V3, P226, DOI 10.1002/1439-7633(20020301)3:2/3<226::AID-CBIC226>3.0.CO;2-7; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; Shintaku M, 2005, J BIOL CHEM, V280, P40934, DOI 10.1074/jbc.M503472200; SONO M, 1986, BIOCHEMISTRY-US, V25, P347, DOI 10.1021/bi00350a011; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; Wagenknecht HA, 1997, CHEM BIOL, V4, P367, DOI 10.1016/S1074-5521(97)90127-7; Wang XT, 1997, BBA-PROTEIN STRUCT M, V1339, P88, DOI 10.1016/S0167-4838(96)00216-6; Yi XW, 2003, J BIOL CHEM, V278, P13855, DOI 10.1074/jbc.M210906200	47	68	68	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23990	23998		10.1074/jbc.M603166200	http://dx.doi.org/10.1074/jbc.M603166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16790441	Green Published, hybrid			2022-12-25	WOS:000239702900073
J	Tao, JC; Shumay, E; McLaughlin, S; Wang, HY; Malbon, CC				Tao, Jiangchuan; Shumay, Elena; McLaughlin, Stuart; Wang, Hsien-yu; Malbon, Craig C.			Regulation of AKAP-membrane interactions by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ANCHORING PROTEINS; RECEPTOR; BINDING; CALMODULIN; SCAFFOLD; SEQUESTRATION; ACTIVATION; COMPLEXES; MOLECULES; PEPTIDES	The AKAP gravin is a scaffold for protein kinases, phosphatases, and adaptor molecules obligate for resensitization and recycling of beta(2)-adrenergic receptors. Gravin binds to the receptor through well characterized protein-protein interactions. These interactions are facilitated similar to 1000-fold when gravin is anchored to the cytoplasmic leaflet of the plasma membrane. Although the N-terminal region (similar to 550 residues) is highly negatively charged and probably natively unfolded, it could anchor gravin to the inner leaflet through hydrophobic insertion of its N-terminal myristate and electrostatic binding of three short positively charged domains (PCDs). Loss of the site of N-myristoylation was found to affect neither AKAP macroscopic localization nor AKAP function. Synthetic peptides corresponding to PCD1-3 bound in vitro to unilamellar phospholipid vesicles with high affinity, a binding reversed by calmodulin in the presence of Ca2+. In vivo gravin localization is regulated by intracellular Ca2+, a function mapping to theNterminus of the protein harboring PCD1, PCD2, and PCD3. Mutation of any two PCDs eliminates membrane association of the non-myristoylated gravin, the sensitivity to Ca2+/calmodulin, and the ability of this scaffold to catalyze receptor resensitization and recycling.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.	craig@pharm.sunysb.edu	malbon, craig/ABF-3604-2020		NIDDK NIH HHS [T32 DK007521, DK25410] Funding Source: Medline; NIGMS NIH HHS [GM69375, GM024971] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521, R01DK025410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024971, R01GM069375, R01GM024971] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Black DJ, 2004, CELL CALCIUM, V35, P415, DOI 10.1016/j.ceca.2003.10.005; CHO W, 2006, SCI STKE, pE7; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Gambhir A, 2004, BIOPHYS J, V86, P2188, DOI 10.1016/S0006-3495(04)74278-2; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; Gomez LL, 2002, J NEUROSCI, V22, P7027; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Gorski JA, 2005, MOL BIOL CELL, V16, P3574, DOI 10.1091/mbc.E05-02-0134; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; Malbon CC, 2004, BIOCHEM J, V379, P1, DOI 10.1042/BJ20031648; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; McLaughlin S, 2005, BIOCHEM SOC SYMP, V72, P189, DOI 10.1042/bss0720189; McLaughlin S, 2005, J GEN PHYSIOL, V126, P41, DOI 10.1085/jgp.200509274; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Okeley NM, 2004, J BIOL CHEM, V279, P21833, DOI 10.1074/jbc.M313469200; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Persechini A, 2002, TRENDS CARDIOVAS MED, V12, P32, DOI 10.1016/S1050-1738(01)00144-X; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Romero Pedro, 2004, Appl Bioinformatics, V3, P105, DOI 10.2165/00822942-200403020-00005; Rusu L, 2004, BIOPHYS J, V87, P1044, DOI 10.1529/biophysj.104.039958; Shih ML, 1996, J BIOL CHEM, V271, P21478, DOI 10.1074/jbc.271.35.21478; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Streb JW, 2005, J BIOL CHEM, V280, P28007, DOI 10.1074/jbc.M414017200; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628; Wang HY, 2006, EUR J CELL BIOL, V85, P643, DOI 10.1016/j.ejcb.2005.12.003; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527	36	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23932	23944		10.1074/jbc.M601813200	http://dx.doi.org/10.1074/jbc.M601813200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16762919	hybrid			2022-12-25	WOS:000239702900068
J	Arolas, JL; Bronsoms, S; Ventura, S; Aviles, FX; Calvete, JJ				Arolas, Joan L.; Bronsoms, Silvia; Ventura, Salvador; Aviles, Francesc X.; Calvete, Juan J.			Characterizing the tick carboxypeptidase inhibitor - Molecular basis for its two-domain nature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATABLE FIBRINOLYSIS INHIBITOR; DISULFIDE FOLDING PATHWAY; PROCARBOXYPEPTIDASE-B; UNFOLDING PATHWAY; PROTEINS; COMPLEX; BPTI; DIVERSITY; STABILITY; MECHANISM	Tick carboxypeptidase inhibitor (TCI) is a small, disulfide-rich protein that selectively inhibits metallocarboxypeptidases and strongly accelerates the fibrinolysis of blood clots. TCI consists of two domains that are structurally very similar, each containing three disulfide bonds arranged in an almost identical fashion. The oxidative folding and reductive unfolding pathways of TCI and its separated domains have been characterized by kinetic and structural analysis of the acid-trapped folding intermediates. TCI folding proceeds through a sequential formation of 1-, 2-, 3-, 4-, 5-, and 6-disulfide species to reach the native form. Folding intermediates of TCI comprise two predominant 3-disulfide species (named IIIa and IIIb) and a major 6-disulfide scrambled isomer (Xa) that consecutively accumulate along the reaction and are strongly prevented by the presence of protein disulfide isomerase. This study demonstrates that IIIa and IIIb are 3- disulfide species containing the native disulfide pairings of the N- and C-terminal domains of TCI, respectively, and explains why the two domains of TCI fold sequentially and independently. Also, we show that the reductive unfolding of TCI undergoes two main independent unfolding events through the formation of IIIa and IIIb intermediates. Together, the comparison of the folding, stability, and inhibitory activity of TCI with those of the isolated domains reveals the reasons behind the two-domain nature of this protein: both domains contribute to the specificity and high affinity of its double-headed binding to carboxypeptidases. The results obtained herein provide valuable information for the design of more potent and selective TCI molecules.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; CSIC, Inst Biomed Valencia, Valencia 46010, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.	FrancescXavier.Aviles@uab.es	Aviles, Francesc Xavier/F-3482-2019; Ventura, Salvador/AAY-3170-2021; Calvete, Juan/P-2555-2019; Ventura, Salvador/C-7021-2008; Calvete, Juan J/K-9619-2014; Avilés, Francesc Xavier/A-2664-2015	Aviles, Francesc Xavier/0000-0002-1399-6789; Ventura, Salvador/0000-0002-9652-6351; Calvete, Juan/0000-0001-5026-3122; Ventura, Salvador/0000-0002-9652-6351; Calvete, Juan J/0000-0001-5026-3122; Avilés, Francesc Xavier/0000-0002-1399-6789; Lopez Arolas, Joan/0000-0002-4198-5016; Bronsoms, Silvia/0000-0001-9763-762X				Arolas JL, 2005, J MOL BIOL, V350, P489, DOI 10.1016/j.jmb.2005.05.015; Arolas JL, 2005, J BIOL CHEM, V280, P3441, DOI 10.1074/jbc.M411086200; Arolas JL, 2004, J BIOL CHEM, V279, P37261, DOI 10.1074/jbc.M405565200; Arolas JL, 2006, TRENDS BIOCHEM SCI, V31, P292, DOI 10.1016/j.tibs.2006.03.005; Bastolla U, 2005, PROTEIN ENG DES SEL, V18, P405, DOI 10.1093/protein/gzi045; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; Bouma BN, 2003, J THROMB HAEMOST, V1, P1566, DOI 10.1046/j.1538-7836.2003.00329.x; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; Chang JY, 2004, BIOCHEMISTRY-US, V43, P4522, DOI 10.1021/bi0360354; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; Chang JY, 2002, FEBS LETT, V511, P73, DOI 10.1016/S0014-5793(01)03284-7; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; Chang JY, 2002, J BIOL CHEM, V277, P120, DOI 10.1074/jbc.M108057200; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Creighton TE, 1997, BIOL CHEM, V378, P731; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; Eichinger S, 2004, BLOOD, V103, P3773, DOI 10.1182/blood-2003-10-3422; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Hiniker A, 2004, TRENDS BIOCHEM SCI, V29, P516, DOI 10.1016/j.tibs.2004.08.002; Marx PF, 2004, CURR MED CHEM, V11, P2335, DOI 10.2174/0929867043364586; Nagashima M, 2000, THROMB RES, V98, P333, DOI 10.1016/S0049-3848(00)00184-5; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; Pereira PJB, 2002, J MOL BIOL, V321, P537, DOI 10.1016/S0022-2836(02)00648-4; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Reverter D, 1998, J BIOL CHEM, V273, P3535, DOI 10.1074/jbc.273.6.3535; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Salamanca S, 2003, BIOCHEMISTRY-US, V42, P6754, DOI 10.1021/bi034308p; Salamanca S, 2002, J BIOL CHEM, V277, P17538, DOI 10.1074/jbc.M200040200; Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387; Shin HC, 2000, J MOL BIOL, V300, P995, DOI 10.1006/jmbi.2000.3928; Torres AM, 2004, TOXICON, V44, P581, DOI 10.1016/j.toxicon.2004.07.011; van den Berg B, 1999, J MOL BIOL, V290, P781, DOI 10.1006/jmbi.1999.2915; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; VENDRELL J, 2004, METALLOCARBOXYPEPTID, V3, P176; Venhudova G, 2001, J BIOL CHEM, V276, P11683, DOI 10.1074/jbc.M007927200; Ventura S, 2002, NAT STRUCT BIOL, V9, P485, DOI 10.1038/nsb799; Walker JB, 2003, J BIOL CHEM, V278, P8913, DOI 10.1074/jbc.M205006200; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Welker E, 2001, P NATL ACAD SCI USA, V98, P2312, DOI 10.1073/pnas.041615798	43	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22906	22916		10.1074/jbc.M602301200	http://dx.doi.org/10.1074/jbc.M602301200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760476	hybrid			2022-12-25	WOS:000239542600053
J	Bracken, CP; Fedele, AO; Linke, S; Balrak, W; Lisy, K; Whitelaw, ML; Peet, DJ				Bracken, Cameron P.; Fedele, Anthony O.; Linke, Sarah; Balrak, Wiltiana; Lisy, Karolina; Whitelaw, Murray L.; Peet, Daniel J.			Cell-specific regulation of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha stabilization and transactivation in a graded oxygen environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR PROTEIN; DIOXIN RECEPTOR; PAS DOMAIN; HIF-1-ALPHA; FACTOR-1-ALPHA; BINDING; HYDROXYLATION; ASSOCIATION; DEGRADATION	The hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha are closely related, key transcriptional regulators of the hypoxic response, countering a low oxygen situation with the up-regulation of target genes associated with numerous processes, including vascularization and glycolysis. This involves a dual mechanism of control through both stabilization and transactivation, regulated via prolyl and asparaginyl hydroxylation. Despite high similarity with respect to protein sequence and activation pathway, a growing number of physiological and mechanistic differences between HIF-1 alpha and HIF-2 alpha are being reported. To further characterize this nonredundancy, the stabilization of endogenous proteins and regulation of the transactivation domains were compared in a graded oxygen environment across a series of cell lines. Although generally similar results were found, interesting and specific differences between the HIF-alpha proteins were observed within certain cell lines, such as rat adrenal PC12s, emphasizing the cell-specific nature of HIF-alpha regulation. We characterize a conserved amino acid substitution between HIF-1 alpha and HIF-2 alpha that contributes to the intrinsically higher FIH-1-mediated asparaginyl hydroxylation of HIF-1 alpha and, hence, lower HIF-1 alpha activity. In addition, our data demonstrate that the different cell lines can be classified into two distinct groups: those in which stabilization and transactivation proceed in conjunction (HeLa, 293T, and COS-1) and those cells in which HIF-alpha is stabilized prior to transactivation (PC12, HepG2, and CACO2). Interestingly, the initial stabilization of HIF-alpha prior to transactivation up-regulation predicted from in vitro derived hydroxylation data is only true for a subset of cells.	Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; Univ Adelaide, Australian Res Council Special Res Ctr Mol Genet, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Peet, DJ (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	daniel.peet@adelaide.edu.au	Peet, Daniel/AAE-6698-2020	Peet, Daniel/0000-0002-6085-8936; Bracken, Cameron/0000-0001-7722-625X				Bae MK, 2005, CANCER RES, V65, P2520, DOI 10.1158/0008-5472.CAN-03-2735; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Bracken CP, 2005, J BIOL CHEM, V280, P14240, DOI 10.1074/jbc.M409987200; Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li ZB, 2005, EMBO REP, V6, P373, DOI 10.1038/sj.embor.7400377; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	24	169	174	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22575	22585		10.1074/jbc.M600288200	http://dx.doi.org/10.1074/jbc.M600288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760477	hybrid			2022-12-25	WOS:000239542600018
J	Tzokov, SB; Wyborn, NR; Stillman, TJ; Jamieson, S; Czudnochowski, N; Artymiuk, PJ; Green, J; Bullough, PA				Tzokov, Svetomir B.; Wyborn, Neil R.; Stillman, Timothy J.; Jamieson, Stuart; Czudnochowski, Nadine; Artymiuk, Peter J.; Green, Jeffrey; Bullough, Per A.			Structure of the hemolysin E (HlyE, ClyA, and SheA) channel in its membrane-bound form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; BACTERIAL TOXIN; PROTEIN; SLYA; MICROSCOPY; RESOLUTION; MOLECULE; SYSTEM; FNR	Hemolysin E (HlyE, ClyA, SheA) is a pore-forming protein toxin isolated from Escherichia coli. The three-dimensional structure of its water-soluble form is known, but that of the membrane-bound HlyE complex is not. We have used electron microscopy and image processing to show that the pores are predominantly octameric. Three-dimensional reconstructions of HlyE pores assembled in lipid/detergent micelles suggest a degree of conformational variability in the octameric complexes. The reconstructed pores were significantly longer than the maximum dimension of the water-soluble molecule, indicating that conformational changes occur on pore formation.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Bullough, PA (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, 5th Ct,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	p.bullough@sheffield.ac.uk		Tzokov, Svetomir/0000-0001-7256-5279; Bullough, Per/0000-0001-8147-1127	Biotechnology and Biological Sciences Research Council [BB/D524975/1] Funding Source: Medline; BBSRC [BB/D524975/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Atkins A, 2000, J BIOL CHEM, V275, P41150, DOI 10.1074/jbc.M005420200; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; MILLER KI, 1990, P NATL ACAD SCI USA, V87, P1496, DOI 10.1073/pnas.87.4.1496; Orlova EV, 1997, J MOL BIOL, V271, P417, DOI 10.1006/jmbi.1997.1182; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Slade A, 2002, J STRUCT BIOL, V137, P283, DOI 10.1016/S1047-8477(02)00011-4; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033; VANDAM L, BIOCH BIOPHYS ACTA, V1664, P241; VANHEEL M, 1981, ULTRAMICROSCOPY, V7, P113, DOI 10.1016/0304-3991(81)90001-2; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200	24	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23042	23049		10.1074/jbc.M602421200	http://dx.doi.org/10.1074/jbc.M602421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754675	hybrid			2022-12-25	WOS:000239542600067
J	Warger, T; Hilf, N; Rechtsteiner, G; Haselmayer, P; Carrick, DM; Jonuleit, H; von Landenberg, P; Rammensee, HG; Nicchitta, CV; Radsak, MP; Schild, H				Warger, Tobias; Hilf, Nobert; Rechtsteiner, Gerd; Haselmayer, Philipp; Carrick, Deanna M.; Jonuleit, Helmut; von Landenberg, Philipp; Rammensee, Hans-Georg; Nicchitta, Christopher V.; Radsak, Markus P.; Schild, Hansjoerg			Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-4; ACTIVATES DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; PRODUCTION IN-VIVO; MURINE MACROPHAGES; HUMAN HEAT-SHOCK-PROTEIN-60; ENDOTOXIN CONTAMINATION; MEDIATED ENDOCYTOSIS	Activation of dendritic cells by ligands for Toll-like receptors (TLR) is a crucial event in the initiation of innate and adaptive immune responses. Several classes of TLR ligands have been identified that interact with distinct members of the TLR-family. TLR4 ligands include lipopolysaccharide derived from different Gram-negative bacteria and viral proteins. Recent reports have demonstrated the TLR-mediated activation of dendritic cells by heat shock proteins (HSPs). However, doubts were raised as to what extent this effect was due to lipopolysaccharide contaminations of the HSP preparations. We re-examined this phenomenon using Gp96 or its N-terminal domain, nominally endotoxin-free (< 0.5 enzyme units/mg). As described previously, innate immune cells are activated by Gp96 at high concentrations (> 50 mu g/ml) but not at lower concentrations. However, preincubation of low amounts of Gp96 with TLR2 and TLR4 ligands at concentrations unable to activate dendritic cells by themselves results in the production of high levels of proinflammatory cytokines, up-regulation of activation markers, and amplification of T cell activation. Our results provide significant new insights into the mechanism of HSP-mediated dendritic cell activation and present a new function of HSPs in the amplification of dendritic cell activation by bacterial products and induction of adaptive immune responses.	Univ Mainz, Inst Immunol, D-55131 Mainz, Germany; Immat Biotechnol, D-72076 Tubingen, Germany; Univ Hosp Mainz, Dept Dermatol, D-55101 Mainz, Germany; Inst Clin Chem & Lab Med, D-55101 Mainz, Germany; Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Mainz Univ Hosp, Dept Med 3, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz; Immatics Biotechnologies GmbH; University Hospital Mainz; Eberhard Karls University of Tubingen; Duke University; University Hospital Mainz	Radsak, MP (corresponding author), Univ Mainz, Inst Immunol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.	radsak@uni-mainz.de; schild@uni-mainz.de	Jonuleit, Helmut/D-8059-2011; Radsak, Markus P/L-3651-2013	Jonuleit, Helmut/0000-0002-5672-9365; Radsak, Markus P/0000-0002-3991-5721				Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baker-LePain JC, 2004, J IMMUNOL, V172, P4195, DOI 10.4049/jimmunol.172.7.4195; Baker-LePain JC, 2002, J EXP MED, V196, P1447, DOI 10.1084/jem.20020436; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gorczynski RM, 2004, INT IMMUNOPHARMACOL, V4, P1859, DOI 10.1016/j.intimp.2004.08.006; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; KACA W, 1994, J BIOL CHEM, V269, P25078; Liu B, 2003, P NATL ACAD SCI USA, V100, P15824, DOI 10.1073/pnas.2635458100; MACHNICKI M, 1993, INT J EXP PATHOL, V74, P433; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Radsak MP, 2003, BLOOD, V101, P2810, DOI 10.1182/blood-2002-07-2261; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Reed RC, 2003, J BIOL CHEM, V278, P31853, DOI 10.1074/jbc.M305480200; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Schild H, 2000, NAT IMMUNOL, V1, P100, DOI 10.1038/77770; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Soldano KL, 2003, J BIOL CHEM, V278, P48330, DOI 10.1074/jbc.M308661200; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Takakuwa T, 1996, EUR J IMMUNOL, V26, P2686, DOI 10.1002/eji.1830261121; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Tsan MF, 2004, AM J PHYSIOL-CELL PH, V286, pC739, DOI 10.1152/ajpcell.00364.2003; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wan T, 2004, BLOOD, V103, P1747, DOI 10.1182/blood-2003-08-2828; Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4; Zheng H, 2001, J IMMUNOL, V167, P6731, DOI 10.4049/jimmunol.167.12.6731	53	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22545	22553		10.1074/jbc.M502900200	http://dx.doi.org/10.1074/jbc.M502900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16754684	hybrid			2022-12-25	WOS:000239542600015
J	Yang, Y; Mahaffey, CL; Berube, N; Frankel, WN				Yang, Yan; Mahaffey, Connie L.; Berube, Nathalie; Frankel, Wayne N.			Interaction between fidgetin and protein kinase A-anchoring protein AKAP95 is critical for palatogenesis in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATOR; NUCLEAR-PROTEIN; CLEFT-LIP; SUBUNIT; GENES; IDENTIFICATION; CONDENSATION; CHROMATIN; GENETICS; CLONING	The gene defective in fidget mice encodes fidgetin, a member of the AAA (ATPases associated with diverse cellular activities) family of ATPases. Using a yeast two-hybrid screen, we identified cAMP-dependent protein kinase A anchoring protein 95 kDa (AKAP95) as a potential fidgetin-binding protein. Epitope-tagged fidgetin co-localized with endogenous AKAP95 in the nuclear matrix, and the physical interaction between fidgetin and AKAP95 was further confirmed by reciprocal immunoprecipitation. To evaluate the biological significance of the fidgetin-AKAP95 binding, we created AKAP95 mutant mice through a gene trap strategy. Akap95 mutant mice are surprisingly viable with no overt phenotype. However, a significant number of mice carrying both Akap95 and fidget mutations die soon after birth due to cleft palate, consistent with the overlapping expression of AKAP95 and fidgetin in the branchial arches during mouse embryogenesis. These results expand the spectrum of the pleiotropic phenotypes of fidget mice and provide new leads on the in vivo function of AKAP95.	Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Frankel, WN (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	wayne.frankel@jax.org			NIDCD NIH HHS [DC03611] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003611] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Arsenijevic T, 2004, BIOCHEM J, V378, P673, DOI 10.1042/BJ20031765; Asirvatham AL, 2004, J IMMUNOL, V173, P4806, DOI 10.4049/jimmunol.173.8.4806; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Collas P, 1999, J CELL BIOL, V147, P1167, DOI 10.1083/jcb.147.6.1167; Cox GA, 2000, NAT GENET, V26, P198, DOI 10.1038/79923; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Eide T, 2003, J BIOL CHEM, V278, P26750, DOI 10.1074/jbc.M300765200; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Frickey T, 2004, J STRUCT BIOL, V146, P2, DOI 10.1016/j.jsb.2003.11.020; Furusawa M, 2002, J BIOL CHEM, V277, P50885, DOI 10.1074/jbc.M206387200; Gruneberg H, 1943, J GENET, V45, P22, DOI 10.1007/BF02982771; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Jungmann RA, 2005, J BIOL CHEM, V280, P25170, DOI 10.1074/jbc.M502514200; Kamada S, 2005, MOL CELL BIOL, V25, P9469, DOI 10.1128/MCB.25.21.9469-9477.2005; KONYUKHOV BV, 1976, DEV BIOL, V54, P13, DOI 10.1016/0012-1606(76)90282-7; Langeberg LK, 2005, J CELL SCI, V118, P3217, DOI 10.1242/jcs.02416; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Martins SB, 2000, J CELL SCI, V113, P3703; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Mo R, 1997, DEVELOPMENT, V124, P113; Orstavik S, 2000, BIOL CELL, V92, P27, DOI 10.1016/S0248-4900(00)88761-4; Prescott NJ, 2001, ANN HUM GENET, V65, P505, DOI [10.1046/j.1469-1809.2001.6560505.x, 10.1017/S0003480001008867]; Riccomagno MM, 2002, GENE DEV, V16, P2365, DOI 10.1101/gad.1013302; Stanier P, 2004, HUM MOL GENET, V13, pR73, DOI 10.1093/hmg/ddh052; Steen RL, 2000, J CELL BIOL, V149, P531, DOI 10.1083/jcb.149.3.531; Truslove G. M., 1956, Journal of Genetics, V54, P64, DOI 10.1007/BF02981704; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Yakushiji Y, 2004, FEBS LETT, V578, P191, DOI 10.1016/j.febslet.2004.11.009; Yang Y, 2005, EXP CELL RES, V304, P50, DOI 10.1016/j.yexcr.2004.11.014; Zwickl P, 1999, NAT CELL BIOL, V1, pE97, DOI 10.1038/12097	35	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22352	22359		10.1074/jbc.M603626200	http://dx.doi.org/10.1074/jbc.M603626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16751186	hybrid			2022-12-25	WOS:000239387100080
J	Li, HW; Gao, YX; Freire, CD; Raizada, MK; Toney, GM; Sumners, C				Li, Hongwei; Gao, Yongxin; Freire, Carlos Diez; Raizada, Mohan K.; Toney, Glenn M.; Sumners, Colin			Macrophage migration inhibitory factor in the PVN attenuates the central pressor and dipsogenic actions of angiotensin II	FASEB JOURNAL			English	Article						ANG II; blood pressure; paraventricular nucleus; thiol-protein oxidoreductase	ROSTRAL VENTROLATERAL MEDULLA; PARAVENTRICULAR NUCLEUS; SUBFORNICAL ORGAN; BLOOD-PRESSURE; RAT; DRINKING; NEURONS; BRAIN; MIF; ACTIVATION	Macrophage migration inhibitory factor (MIF) acts intracellularly to counteract the angiotensin (ANG) II type 1 receptor (AT1-R)-mediated chronotropic effect of ANG II in hypothalamic neurons, an effect mediated by the thiol-protein oxidoreductase (TPOR) activity of the MIF molecule. Here we determined the in vivo actions of MIF in regulating the physiological actions of ANG II that are mediated via the paraventricular nucleus (PVN), an area that serves as a relay point in the central nervous system (CNS)-mediated effects of ANG II on cardiovascular functions and water intake. Intracerebroventricular (icv) injection of ANG II into normotensive rats selectively increased MIF protein levels in the PVN and produced significant pressor and drinking responses that were inhibited by PVN administration of the AT1-R antagonist losartan. Overexpression of MIF in PVN neurons via Ad-Syn-MIF gene transfer attenuated the pressor and drinking responses produced by icv-injected ANG II. Consistently, intracellular application of MIF or MIF-(50-65) (which harbors the TPOR activity of MIF) into PVN sympathetic regulatory neurons, blunted the electrophysiological actions of ANG II at these cells. These observations establish for the first time that MIF within the PVN, acting via TPOR, is an intracellular regulator of the central cardiovascular and dipsogenic effects of ANG II.	Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Health San Antonio	Sumners, C (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, Box 100274,1600 SW Archer Rd, Gainesville, FL 32610 USA.	csumners@phys.med.ufl.edu		Sumners, Colin/0000-0002-9689-2255	NHLBI NIH HHS [HL-071645, R01 HL071645, R01 HL076803, HL-076803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071645, R01HL076803] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Bacher M, 1997, AM J PATHOL, V150, P235; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; BAINS JS, 1992, BRAIN RES, V599, P223, DOI 10.1016/0006-8993(92)90395-P; Barnes KL, 2003, AM J PHYSIOL-REG I, V284, pR1340, DOI 10.1152/ajpregu.00505.2002; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Busche S, 2001, ENDOCRINOLOGY, V142, P4623, DOI 10.1210/en.142.11.4623; Cato MJ, 2005, J NEUROPHYSIOL, V93, P403, DOI 10.1152/jn.01055.2003; Chen QH, 2001, AM J PHYSIOL-REG I, V281, pR1844, DOI 10.1152/ajpregu.2001.281.6.R1844; Coote JH, 1995, BIOL SIGNAL, V4, P142; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Dampney RAL, 2002, CLIN EXP PHARMACOL P, V29, P467, DOI 10.1046/j.1440-1681.2002.03658.x; Falcon BL, 2004, PHYSIOL GENOMICS, V19, P255, DOI 10.1152/physiolgenomics.00170.2004; Ferguson AV, 2001, EXP BIOL MED, V226, P85, DOI 10.1177/153537020122600205; Fingerle-Rowson GR, 2001, IMMUNOL CELL BIOL, V79, P368, DOI 10.1046/j.1440-1711.2001.01024.x; Fleegal MA, 2003, AM J PHYSIOL-REG I, V285, pR632, DOI 10.1152/ajpregu.00151.2003; Hardy SGP, 2001, BRAIN RES, V894, P233, DOI 10.1016/S0006-8993(01)02053-4; Iyer SN, 1996, P NATL ACAD SCI USA, V93, P9960, DOI 10.1073/pnas.93.18.9960; JENSEN LL, 1992, AM J PHYSIOL, V262, pF1068, DOI 10.1152/ajprenal.1992.262.6.F1068; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Li DP, 2005, J PHARMACOL EXP THER, V313, P1035, DOI 10.1124/jpet.104.082495; Li HW, 2005, REGUL PEPTIDES, V126, P213, DOI 10.1016/j.regpep.2004.10.005; Li Y, 2003, NEUROSCIENCE, V118, P585, DOI 10.1016/S0306-4522(03)00042-3; LI ZH, 1993, AM J PHYSIOL, V265, pR302, DOI 10.1152/ajpregu.1993.265.2.R302; LIND RW, 1985, BRAIN RES BULL, V15, P79, DOI 10.1016/0361-9230(85)90064-4; McKinley MJ, 2003, INT J BIOCHEM CELL B, V35, P901, DOI 10.1016/S1357-2725(02)00306-0; Nguyen MT, 2003, J BIOL CHEM, V278, P33654, DOI 10.1074/jbc.M301735200; PAKHOMOV AG, IN PRESS J NEUROSCI; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Sumners C, 2002, CLIN EXP PHARMACOL P, V29, P483, DOI 10.1046/j.1440-1681.2002.03660.x; Sun CW, 2005, CIRC RES, V96, P659, DOI 10.1161/01.RES.0000161257.02571.4b; Sun CW, 2004, J NEUROSCI, V24, P9944, DOI 10.1523/JNEUROSCI.2856-04.2004; Tanaka J, 2001, BEHAV BRAIN RES, V118, P117, DOI 10.1016/S0166-4328(00)00320-X; Veerasingham SJ, 2004, PROG BIOPHYS MOL BIO, V84, P107, DOI 10.1016/j.pbiomolbio.2003.11.007; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; WRIGHT JW, 1987, BRAIN RES, V420, P289, DOI 10.1016/0006-8993(87)91249-2; WRIGHT JW, 1993, BRAIN RES BULL, V31, P649, DOI 10.1016/0361-9230(93)90136-Y; Zerrouk A, 1998, J CARDIOVASC PHARM, V31, P525, DOI 10.1097/00005344-199804000-00009; Zhu GQ, 2002, AM J PHYSIOL-HEART C, V282, pH2039, DOI 10.1152/ajpheart.00854.2001; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	42	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1748	+		10.1096/fj.06-5836fje	http://dx.doi.org/10.1096/fj.06-5836fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809436				2022-12-25	WOS:000240266600036
J	Shen, Y; Cranmer, SL; Aprico, A; Whisstock, JC; Jackson, SP; Berndt, MC; Andrews, RK				Shen, Yang; Cranmer, Susan L.; Aprico, Andrea; Whisstock, James C.; Jackson, Shaun P.; Berndt, Michael C.; Andrews, Robert K.			Leucine-rich repeats 2-4 (Leu(60)-Glu(128)) of platelet glycoprotein Ib alpha regulate shear-dependent cell adhesion to von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR A1 DOMAIN; IX-V COMPLEX; CRYSTAL-STRUCTURE; BINDING REGION; REVEALS; ACTIVATION; MECHANISM	Glycoprotein (GP) Ib-IX-V binds von Willebrand factor (VWF), initiating thrombosis at high shear stress. The VWF-A1 domain binds the N-terminal domain of GPIb alpha (His(1)-Glu(282)); this region contains seven leucine-rich repeats (LRR) plus N- and C-terminal flanking sequences and an anionic sequence containing three sulfated tyrosines. Our previous analysis of canine/human and human/canine chimeras of GPIb alpha expressed on Chinese hamster ovary (CHO) cells demonstrated that LRR2-4(Leu(60)-Glu(128)) were crucial for GPIb alpha-dependent adhesion to VWF. Paradoxically, co-crystal structures of the GPIb alpha N-terminal domain and GPIb alpha-binding VWF-A1 under static conditions revealed that the LRR2-4 sequence made minimal contact with VWF-A1. To resolve the specific functional role of LRR2-4, we compared wildtype human GPIb alpha with human GPIb alpha containing a homology domain swap of canine for human sequence within Leu(60)-Glu(128) and a reverse swap (canine GPIb alpha with human Leu(60)-Glu(128)) for the ability to support adhesion to VWF under flow. Binding of conformation-specific anti-GPIb alpha antibodies and VWF binding in the presence of botrocetin (which does not discriminate between species) confirmed equivalent expression of wild-type and mutant receptors in a functional form competent to bind ligand. Compared with CHO cells expressing wild-type GPIb alpha, cells expressing GPIb alpha, where human Leu(60)-Glu(128) sequence was replaced by canine sequence, supported adhesion to VWF at low shear rates but became increasingly ineffective as shear increased from 50 to 2000 s-(1). Together, these data demonstrate that LRR2-4, encompassing a pronounced negative charge patch on human GPIb alpha, is essential for GPIb alpha(VWF)-V-.-dependent adhesion as hydrodynamic shear increases.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Dept Immunol, Clayton, Vic 3800, Australia; Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia	Monash University; Monash University; Monash University	Andrews, RK (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	rob.andrews@med.monash.edu.au	Berndt, Michael C/D-5580-2012	Andrews, Robert Keith/0000-0001-9577-8082; Whisstock, James/0000-0003-4200-5611; Jackson, Shaun/0000-0002-4750-1991				Andrews RK, 2003, INT J BIOCHEM CELL B, V35, P1170, DOI 10.1016/S1357-2725(02)00280-7; Bhatt DL, 2003, NAT REV DRUG DISCOV, V2, P15, DOI 10.1038/nrd985; Cranmer SL, 2005, BIOCHEM J, V387, P849, DOI 10.1042/BJ20041836; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; De Luca M, 2000, BLOOD, V95, P164; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Kroll MH, 1996, BLOOD, V88, P1525; Ozaki Y, 2005, J THROMB HAEMOST, V3, P1745, DOI 10.1111/j.1538-7836.2005.01379.x; Phillips DR, 2005, J THROMB HAEMOST, V3, P1577, DOI 10.1111/j.1538-7836.2005.01418.x; Sadler JE, 2002, SCIENCE, V297, P1128, DOI 10.1126/science.1075452; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Shen Y, 2002, BLOOD, V99, P145, DOI 10.1182/blood.V99.1.145; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Whisstock JC, 2002, THROMB HAEMOSTASIS, V87, P329; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200	18	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2006	281	36					26419	26423		10.1074/jbc.M604296200	http://dx.doi.org/10.1074/jbc.M604296200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	080LO	16774914	hybrid			2022-12-25	WOS:000240249500059
J	Murooka, TT; Wong, MM; Rahbar, R; Majchrzak-Kita, B; Proudfoot, AEI; Fish, EN				Murooka, Thomas T.; Wong, Mark M.; Rahbar, Ramtin; Majchrzak-Kita, Beata; Proudfoot, Amanda E. I.; Fish, Eleanor N.			CCL5-CCR5-mediated apoptosis in T cells - Requirement for glycosaminoglycan binding and CCL5 aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CHEMOKINE RANTES; HEPARIN-BINDING; IN-VIVO; ACTIVATION; RECEPTOR; DEATH; CCR5; OLIGOMERIZATION; IDENTIFICATION	CCL5 (RANTES (regulated on activation normal T cell expressed and secreted)) and its cognate receptor, CCR5, have been implicated in T cell activation. CCL5 binding to glycosaminoglycans (GAGs) on the cell surface or in extracellular matrix sequesters CCL5, thereby immobilizing CCL5 to provide the directional signal. In two CCR5-expressing human T cell lines, PM1. CCR5 and MOLT4.CCR5, and in human peripheral blood-derived T cells, micromolar concentrations of CCL5 induce apoptosis. CCL5-induced cell death involves the cytosolic release of cytochrome c, the activation of caspase-9 and caspase-3, and poly(ADP-ribose) polymerase cleavage. CCL5-induced apoptosis is CCR5-dependent, since native PM1 and MOLT4 cells lacking CCR5 expression are resistant to CCL5-induced cell death. Furthermore, we implicate tyrosine 339 as a critical residue involved in CCL5-induced apoptosis, since PM1 cells expressing a tyrosine mutant receptor, CCR5Y339F, do not undergo apoptosis. We show that CCL5-CCR5-mediated apoptosis is dependent on cell surface GAG binding. The addition of exogenous heparin and chondroitin sulfate and GAG digestion from the cell surface protect cells from apoptosis. Moreover, the non-GAG binding variant, (44AANA47)-CCL5, fails to induce apoptosis. To address the role of aggregation in CCL5-mediated apoptosis, nonaggregating CCL5 mutant E66S, which forms dimers, and E26A, which form tetramers at micromolar concentrations, were utilized. Unlike native CCL5, the E66S mutant fails to induce apoptosis, suggesting that tetramers are the minimal higher ordered CCL5 aggregates required for CCL5-induced apoptosis. Viewed altogether, these data suggest that CCL5-GAG binding and CCL5 aggregation are important for CCL5 activity in T cells, specifically in the context of CCR5-mediated apoptosis.	Univ Toronto, Div Cellular & Mol Biol, Toronto Gen Res Inst, Canadian Blood Serv,Univ Hlth Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; Serono Pharmaceut Res Inst, Geneva, Switzerland	Canadian Blood Services; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Fish, EN (corresponding author), Univ Toronto, Div Cellular & Mol Biol, Toronto Gen Res Inst, Canadian Blood Serv,Univ Hlth Network, Bldg 67 Coll St,Rm 4-424, Toronto, ON M5G 2M1, Canada.	en.fish@utoronto.ca		Murooka, Thomas/0000-0002-3030-2726				Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; Appay V, 2000, INT IMMUNOL, V12, P1173, DOI 10.1093/intimm/12.8.1173; Appay V, 1999, J BIOL CHEM, V274, P27505, DOI 10.1074/jbc.274.39.27505; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baltus T, 2003, BLOOD, V102, P1985, DOI 10.1182/blood-2003-04-1175; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Burns JM, 1998, J EXP MED, V188, P1917, DOI 10.1084/jem.188.10.1917; Cartier L, 2003, J NEUROIMMUNOL, V145, P27, DOI 10.1016/j.jneuroim.2003.09.008; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; Cinamon G, 2001, J LEUKOCYTE BIOL, V69, P860; Colamussi ML, 2001, J LEUKOCYTE BIOL, V69, P263; Collette Y, 1998, BLOOD, V92, P1350, DOI 10.1182/blood.V92.4.1350.416k24_1350_1363; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dairaghi DJ, 1998, J IMMUNOL, V160, P426; Dong HF, 2005, GENES IMMUN, V6, P609, DOI 10.1038/sj.gene.6364247; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kawai T, 1999, J IMMUNOL, V163, P3269; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Laurence JS, 2001, BIOCHEMISTRY-US, V40, P4990, DOI 10.1021/bi002593w; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 2001, CURR BIOL, V11, P691, DOI 10.1016/S0960-9822(01)00199-3; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Noel PJ, 1996, J IMMUNOL, V157, P636; Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Rabin RL, 1999, J IMMUNOL, V162, P3840; Rahbar R, 2006, J VIROL, V80, P7245, DOI 10.1128/JVI.00463-06; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Siveke JT, 1998, J IMMUNOL, V160, P550; Szabo MC, 1997, EUR J IMMUNOL, V27, P1061, DOI 10.1002/eji.1830270504; Szekanecz Z, 2000, ARTHRITIS RES, V2, P368, DOI 10.1186/ar114; Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722; Taub DD, 1996, J IMMUNOL, V156, P2095; Turner L, 1996, BIOCHEM SOC T, V24, pS93, DOI 10.1042/bst024093s; Tyner JW, 2005, NAT MED, V11, P1180, DOI 10.1038/nm1303; Uddin S, 1997, BLOOD, V90, P2574; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Vita C, 2002, J IMMUNOL METHODS, V266, P53, DOI 10.1016/S0022-1759(02)00096-0; Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9; Zhang HFM, 2005, MOL CELL BIOL, V25, P6247, DOI 10.1128/MCB.25.14.6247-6258.2005	62	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25184	25194		10.1074/jbc.M603912200	http://dx.doi.org/10.1074/jbc.M603912200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16807236	hybrid			2022-12-25	WOS:000240031300019
J	Fitzgerald, JB; Jin, M; Grodzinsky, AJ				Fitzgerald, Jonathan B.; Jin, Moonsoo; Grodzinsky, Alan J.			Shear and compression differentially regulate clusters of functionally related temporal transcription patterns in cartilage tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR CHONDROCYTES; INTERMITTENT HYDROSTATIC-PRESSURE; GENE-EXPRESSION; FLUID-FLOW; DYNAMIC COMPRESSION; MECHANICAL COMPRESSION; INTRACELLULAR CALCIUM; INTERSTITIAL FLUID; CYTOSOLIC CALCIUM; II COLLAGEN	Chondrocytes are subjected to a variety of biophysical forces and flows during physiological joint loading, including mechanical deformation, fluid flow, hydrostatic pressure, and streaming potentials; however, the role of these physical stimuli in regulating chondrocyte behavior is still being elucidated. To isolate the effects of these forces, we subjected intact cartilage explants to 1 - 24 h of continuous dynamic compression or dynamic shear loading at 0.1 Hz. We then measured the transcription levels of 25 genes known to be involved in cartilage homeostasis using real-time PCR and compared the gene expression profiles obtained from dynamic compression, dynamic shear, and our recent results on static compression amplitude and duration. Using clustering analysis, we determined that transcripts for proteins with similar function had correlated responses to loading. However, the temporal expression patterns were strongly dependent on the type of loading applied. Most matrix proteins were up-regulated by 24 h of dynamic compression or dynamic shear, but down-regulated by 24 h of 50% static compression, suggesting that cyclic matrix deformation is a key stimulator of matrix protein expression. Most matrix proteases were up-regulated by 24 h under all loading types. Transcription factors c-Fos and c-Jun maximally responded within 1 h to all loading types. Pre-incubating cartilage explants with either a chelator of intracellular calcium or an inhibitor of the cyclic AMP pathway demonstrated the involvement of both pathways in transcription induced by dynamic loading.	MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Grodzinsky, AJ (corresponding author), MIT, Ctr Biomed Engn, 77 Massachusetts Ave,NE47-377, Cambridge, MA 02139 USA.	alg@mit.edu	Jin, Moonsoo/D-6128-2011		NIAMS NIH HHS [AR33236] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR033236, R01AR033236] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alford AI, 2003, J CELL BIOCHEM, V90, P938, DOI 10.1002/jcb.10715; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; BEHRENS F, 1989, J ORTHOPAED RES, V7, P335, DOI 10.1002/jor.1100070305; Blain EJ, 2001, ARCH BIOCHEM BIOPHYS, V396, P49, DOI 10.1006/abbi.2001.2575; Bonassar LJ, 2001, J ORTHOP RES, V19, P11, DOI 10.1016/S0736-0266(00)00004-8; Buschmann MD, 1999, ARCH BIOCHEM BIOPHYS, V366, P1, DOI 10.1006/abbi.1999.1197; D'Andrea P, 2000, BIORHEOLOGY, V37, P75; Davisson T, 2002, J ORTHOPAED RES, V20, P842, DOI 10.1016/S0736-0266(01)00160-7; Dougherty ER, 2002, J COMPUT BIOL, V9, P105, DOI 10.1089/10665270252833217; Edlich M, 2001, J BIOMECH, V34, P59, DOI 10.1016/S0021-9290(00)00158-5; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; Fitzgerald JB, 2004, J BIOL CHEM, V279, P19502, DOI 10.1074/jbc.M400437200; Frank EH, 2000, J BIOMECH, V33, P1523, DOI 10.1016/S0021-9290(00)00100-7; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; GRUSHKO G, 1989, CONNECT TISSUE RES, V19, P149, DOI 10.3109/03008208909043895; Guilak F, 1994, Osteoarthritis Cartilage, V2, P91, DOI 10.1016/S1063-4584(05)80059-7; Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356; Holter NS, 2000, P NATL ACAD SCI USA, V97, P8409, DOI 10.1073/pnas.150242097; Hunter CJ, 2004, OSTEOARTHR CARTILAGE, V12, P117, DOI 10.1016/j.joca.2003.08.009; Ikenoue T, 2003, J ORTHOPAED RES, V21, P110, DOI 10.1016/S0736-0266(02)00091-8; Jin M, 2001, ARCH BIOCHEM BIOPHYS, V395, P41, DOI 10.1006/abbi.2001.2543; Jortikka MO, 2000, ARCH BIOCHEM BIOPHYS, V374, P172, DOI 10.1006/abbi.1999.1543; Jortikka MO, 1997, ANN RHEUM DIS, V56, P255, DOI 10.1136/ard.56.4.255; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIM YJ, 1995, J BIOMECH, V28, P1055, DOI 10.1016/0021-9290(94)00159-2; KIM YJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P1, DOI 10.1006/abbi.1994.1201; Kisiday JD, 2004, J BIOMECH, V37, P595, DOI 10.1016/j.jbiomech.2003.10.005; KISIDAY JD, 2005, T ORTHOP RES SOC, V51, P1632; Lee JH, 2005, ARTHRITIS RHEUM-US, V52, P2386, DOI 10.1002/art.21215; Li KW, 2003, ARTHRITIS RHEUM-US, V48, P689, DOI 10.1002/art.10849; Liacini A, 2003, EXP CELL RES, V288, P208, DOI 10.1016/S0014-4827(03)00180-0; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; LOHMANDER LS, 1993, J RHEUMATOL, V20, P1362; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Millward-Sadler SJ, 2000, ARTHRITIS RHEUM, V43, P2091, DOI 10.1002/1529-0131(200009)43:9<2091::AID-ANR21>3.0.CO;2-C; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; Mow VC, 1999, OSTEOARTHR CARTILAGE, V7, P41, DOI 10.1053/joca.1998.0161; Roberts SR, 2001, J APPL PHYSIOL, V90, P1385, DOI 10.1152/jappl.2001.90.4.1385; SAAMAMEN AM, 1994, CONNECT TISSUE RES, V30, P191, DOI 10.3109/03008209409061971; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; Salter DM, 2001, CLIN ORTHOP RELAT R, pS49; Sauerland K, 2003, OSTEOARTHR CARTILAGE, V11, P343, DOI 10.1016/S1063-4584(03)00007-4; SLOWMAN SD, 1986, ARTHRITIS RHEUM, V29, P88, DOI 10.1002/art.1780290112; Smith RL, 2000, J REHABIL RES DEV, V37, P153; Smith RL, 2000, BIORHEOLOGY, V37, P95; Valhmu WB, 1998, ARCH BIOCHEM BIOPHYS, V353, P29, DOI 10.1006/abbi.1998.0633; Valhmu WB, 2002, BIOCHEM J, V361, P689, DOI 10.1042/0264-6021:3610689; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yellowley CE, 1997, AM J PHYSIOL-CELL PH, V273, pC30, DOI 10.1152/ajpcell.1997.273.1.C30; Yellowley CE, 1999, J CELL PHYSIOL, V180, P402, DOI 10.1002/(SICI)1097-4652(199909)180:3<402::AID-JCP11>3.0.CO;2-4	52	80	82	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24095	24103		10.1074/jbc.M510858200	http://dx.doi.org/10.1074/jbc.M510858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16782710	hybrid			2022-12-25	WOS:000239847800004
J	Zeidan, YH; Pettus, BJ; Elojeimy, S; Taha, T; Obeid, LM; Kawamori, T; Norris, JS; Hannun, YA				Zeidan, Youssef H.; Pettus, Benjamin J.; Elojeimy, Saeed; Taha, Tarek; Obeid, Lina M.; Kawamori, Toshihiko; Norris, James S.; Hannun, Yusuf A.			Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-alpha-induced PGE(2) production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICYCLIC ANTI-DEPRESSANTS; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE; INTERNALIZATION; ROLES; PURIFICATION; INFLAMMATION; MACROPHAGES; ACTIVATION; EXPRESSION	Sphingolipids are well established effectors of signal transduction downstream of the tumor necrosis factor (TNF) receptor. In a previous study, we showed that the sphingosine kinase/sphingosine 1-phosphate (S1P) pathway couples TNF receptor to induction of the cyclooxygenase 2 gene and prostaglandin synthesis (Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., Chalfant, C. E., Obeid, L. M., and Hannun, Y. A. ( 2003) FASEB J. 17, 1411-1421). In this study, the requirement for acid sphingomyelinase and sphingomyelin metabolites in the TNF alpha/prostaglandin E-2 (PGE(2)) pathway was investigated. The amphiphilic compound desipramine, a frequently employed inhibitor of acid sphingomyelinase (ASMase), blocked PGE2 production. However, the action of desipramine was independent of its action on ASMase, since neither genetic loss of ASMase ( Niemann- Pick fibroblasts) nor knockdown of ASMase using RNA interference affected TNF alpha-induced PGE2 synthesis. Further investigations revealed that desipramine down-regulated acid ceramidase (AC), but not sphingosine kinase, at the protein level. This resulted in a time-dependent drop in sphingosine and S1P levels. Moreover, exogenous administration of either sphingosine or S1P rescued PGE(2) biosynthesis after desipramine treatment. Interestingly, knockdown of endogenous AC by RNA interference attenuated cyclooxygenase 2 induction by TNF alpha and subsequent PGE(2) biosynthesis. Taken together, these results define a novel role for AC in the TNF alpha/ PGE(2) pathway. In addition, the results of this study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 175 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Kawamori, Toshihiko/G-7636-2012; Zeidan, Youssef H./H-7578-2019	Zeidan, Youssef H./0000-0002-1951-8585; obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA87584] Funding Source: Medline; NCRR NIH HHS [P20-RR017677] Funding Source: Medline; NIGMS NIH HHS [GM62887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBOUZ S, 1981, BIOMED EXPRESS, V35, P218; ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Gulbins Erich, 2002, Subcell Biochem, V36, P229; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Karakashian AA, 2004, FASEB J, V18, P968, DOI 10.1096/fj.03-0875fje; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolzer M, 2004, FEBS LETT, V559, P96, DOI 10.1016/S0014-5793(04)00033-X; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; MacKinnon AC, 2002, J IMMUNOL, V169, P6394, DOI 10.4049/jimmunol.169.11.6394; Manthey CL, 1998, CYTOKINE, V10, P654, DOI 10.1006/cyto.1998.0344; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pettus BJ, 2005, MOL PHARMACOL, V68, P330, DOI 10.1124/mol.104.008722; Pettus BJ, 2004, CURR MOL MED, V4, P405, DOI 10.2174/1566524043360573; Samsel L, 2004, PROSTATE, V58, P382, DOI 10.1002/pros.10350; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; WATANABE N, 1988, J BIOL CHEM, V263, P10262; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004	38	56	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24695	24703		10.1074/jbc.M604713200	http://dx.doi.org/10.1074/jbc.M604713200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803890	hybrid			2022-12-25	WOS:000239847800065
J	Kumanovics, A; Poruk, KE; Osborn, KA; Ward, DM; Kaplan, J				Kumanovics, Attila; Poruk, Katherine E.; Osborn, Katharine A.; Ward, Diane M.; Kaplan, Jerry			YKE4 (YIL023C) encodes a bidirectional zinc transporter in the endoplasmic reticulum of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; CELL INTEGRITY; KINASE PHO85; YEAST; PROTEIN; GENE; IDENTIFICATION; IRON; HOMEOSTASIS; COMPLEXES	YIL023C encodes a member of the SLC39A, or ZIP, family, which we refer to as yeast KE4 (YKE4) after its mouse ortholog. Yke4p was localized to the endoplasmic reticulum (ER) membrane using Yke4p-specific antiserum. YKE4 is not an essential gene; however, deletion of YKE4 resulted in a sensitivity to calcofluor white and poor growth at 36 degrees C on respiratory substrates containing high zinc. Overexpression of transition metal transporters Zrc1p and Cot1p or the mouse orthologue mKe4 in Delta yke4 suppressed the poor growth at 36 degrees C on respiratory substrates. We found that the role of Yke4p depends on the zinc status of the cells. In a zinc-adequate environment, Yke4p transports zinc into the secretory pathway, and the deletion of YKE4 leads to a zinc-suppressible cell wall defect. In high zinc medium, transport of zinc into the secretory pathway through Yke4p is a way to eliminate zinc from the cytosol, and deletion of YKE4 leads to toxic zinc accumulation in the cytosol. Under low cytosolic zinc conditions, however, Yke4p removes zinc from the secretory pathway, and deletion of YKE4 partially compensates for the loss of Msc2p, an ER zinc importer, and therefore helps to alleviate ER stress. In our model, Yke4p balances zinc levels between the cytosol and the secretory pathway, whereas the previously described Msc2p-Zrg17p ER zinc importer complex functions mainly in zinc-depleted conditions to ensure a ready supply of zinc essential for ER functions, such as phospholipid biosynthesis and unfolded protein response.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115, R37DK030534, R01DK030534] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30534, T32 DK07115-29] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal AK, 2003, J BIOL CHEM, V278, P34998, DOI 10.1074/jbc.M306291200; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; EDIE D, 1997, CURR OPIN CELL BIOL, V9, P573; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Felice MR, 2005, J BIOL CHEM, V280, P22181, DOI 10.1074/jbc.M414663200; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; Huang LP, 2005, J BIOL CHEM, V280, P15456, DOI 10.1074/jbc.M412188200; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; Kambe T, 2004, CELL MOL LIFE SCI, V61, P49, DOI 10.1007/s00018-003-3148-y; Lasswell J, 2000, PLANT CELL, V12, P2395, DOI 10.1105/tpc.12.12.2395; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; Stathakis DG, 1999, GENETICS, V153, P361; SUZUKI K, 1993, J BIOL CHEM, V268, P2755; Suzuki T, 2005, J BIOL CHEM, V280, P30956, DOI 10.1074/jbc.M506902200; Taylor KM, 2003, BBA-BIOMEMBRANES, V1611, P16, DOI 10.1016/S0005-2736(03)00048-8; Ward DM, 2003, TRAFFIC, V4, P403, DOI 10.1034/j.1600-0854.2003.00093.x	27	48	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22566	22574		10.1074/jbc.M604730200	http://dx.doi.org/10.1074/jbc.M604730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760462	hybrid			2022-12-25	WOS:000239542600017
J	Lu, DM; Huang, J; Basu, A				Lu, Dongmei; Huang, Jie; Basu, Alakananda			Protein kinase C epsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; SIGNALING PATHWAY; INDUCED APOPTOSIS; B-ALPHA; PHOSPHORYLATION; AKT; EXPRESSION; RECEPTOR	We have previously shown that protein kinase C epsilon(PKC epsilon) protects breast cancer cells from tumor necrosis factor-alpha (TNF)-induced cell death. In the present study, we have investigated if the antiapoptotic function of PKC epsilon is mediated via Akt and the mechanism by which PKC epsilon regulates Akt activity. TNF caused a transient increase in Akt phosphorylation at Ser(473) in MCF-7 cells. Overexpression of PKC epsilon in MCF-7 cells increased TNF-induced Akt phosphorylation at Ser(473) resulting in its activation. Knockdown of PKC epsilon by small interfering RNA (siRNA) decreased TNF-induced Akt phosphorylation/activation and increased cell death. Introduction of constitutively active Akt protected breast cancer MCF-7 cells from TNF-mediated cell death and partially restored cell survival in PKC epsilon-depleted cells. Depletion of Akt in MCF-7 cells abolished the antiapoptotic effect of PKC epsilon on TNF-mediated cell death. Akt was constitutively associated with PKC epsilon and DNA-dependent protein kinase (DNA-PK), and this association was increased by TNF treatment. Overexpression of PKC epsilon enhanced the interaction between Akt and DNA-PK. Knockdown of DNA-PK by siRNA inhibited TNF-induced Akt phosphorylation and the antiapoptotic effect of Akt and PKC epsilon. These results suggest that PKC epsilon activates Akt via DNA-PK to mediate its antiapoptotic function. Furthermore, we report for the first time that DNA-PK can regulate receptor-initiated apoptosis via Akt.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Basu, A (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	abasu@hsc.unt.edu		Basu, Alakananda/0000-0002-1656-0788	NATIONAL CANCER INSTITUTE [R01CA071727] Funding Source: NIH RePORTER; NCI NIH HHS [CA71727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bauer B, 2003, FEBS LETT, V541, P155, DOI 10.1016/S0014-5793(03)00287-4; Bauer B, 2002, MOL IMMUNOL, V38, P1087, DOI 10.1016/S0161-5890(02)00011-1; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; CACACE AM, 1993, ONCOGENE, V8, P2095; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065-6995(02)90926-1; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Hennequin C, 1999, Cancer Radiother, V3, P289, DOI 10.1016/S1278-3218(99)80070-5; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P561, DOI 10.1021/bi010719z; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li LW, 2006, J BIOL CHEM, V281, P3237, DOI 10.1074/jbc.M512167200; Lu DM, 2004, INT J ONCOL, V25, P671; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Toole A, 2001, BIOCHEM J, V359, P119, DOI 10.1042/0264-6021:3590119; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Venkatesan BA, 2006, CELL SIGNAL, V18, P508, DOI 10.1016/j.cellsig.2005.05.022; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; Zhou HZ, 2002, AM J PHYSIOL-HEART C, V283, pH165, DOI 10.1152/ajpheart.00408.2001	49	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22799	22807		10.1074/jbc.M603390200	http://dx.doi.org/10.1074/jbc.M603390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785234	hybrid			2022-12-25	WOS:000239542600041
J	Mo, X; Lu, N; Padilla, A; Lopez, JA; Li, RH				Mo, Xi; Lu, Nan; Padilla, Arnoldo; Lopez, Jose A.; Li, Renhao			The transmembrane domain of glycoprotein Ib beta is critical to efficient expression of glycoprotein Ib-IX complex in the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER-SYNDROME; VON-WILLEBRAND-FACTOR; PLATELET MEMBRANE; V COMPLEX; MONOCLONAL-ANTIBODY; CELL-ADHESION; VWF BINDING; GPIB-ALPHA; PROTEINS; ASSOCIATION	Lack of expression of glycoprotein (GP) Ib-IX-V complex in platelets often results from mutations in its three subunits: GP Ib alpha, GP Ib beta, or GP IX. The requirement of all three subunits in the efficient surface expression of the receptor complex has been reproduced in Chinese hamster ovary cells. Here, we probed the role of the transmembrane domains in expression of the GP Ib-IX complex and potential interactions between these domains. Replacing the transmembrane domains of either GP Ib beta or GP Ib beta, but not that of GP IX, with unrelated sequences markedly diminished surface expression of the GP Ib-IX complex in transiently transfected Chinese hamster ovary cells. Replacement of the Ib beta transmembrane domain produced the largest effect. Furthermore, several single-site mutations in the Ib beta transmembrane domain were found to significantly decrease overall expression as well as surface expression of GPIb , probably by perturbing the interaction between the Ib alpha and Ib beta transmembrane domains and in turn reducing the stability of GP Ib alpha in the cell. Mutations S503V and S503L in the Ib alpha transmembrane domain partly reversed the expression-decreasing effect of mutation H139L, but not the others, in the Ib beta transmembrane domain, suggesting a specific interaction between these two polar residues. Together, our results have demonstrated the importance of the Ib beta transmembrane domain, through its interaction with the Ib alpha counterpart, to the proper assembly and efficient surface expression of the GP Ib-IX complex.	Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA	University of Texas System; Baylor College of Medicine	Li, RH (corresponding author), Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, MSB 6-130,6431 Fannin St, Houston, TX 77030 USA.	Renhao.Li@uth.tmc.edu	Li, Renhao/B-1257-2012	Li, Renhao/0000-0002-5806-5080	NATIONAL CANCER INSTITUTE [K01CA096706] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082808] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA096706, CA096706] Funding Source: Medline; NHLBI NIH HHS [HL082808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamian L, 2001, J MOL BIOL, V311, P891, DOI 10.1006/jmbi.2001.4908; Andrews RK, 2003, INT J BIOCHEM CELL B, V35, P1170, DOI 10.1016/S1357-2725(02)00280-7; Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; Arkin IT, 1998, BBA-PROTEIN STRUCT M, V1429, P113, DOI 10.1016/S0167-4838(98)00225-8; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bodnar RJ, 2002, J BIOL CHEM, V277, P47080, DOI 10.1074/jbc.M208329200; CALVERLEY DC, 1995, BLOOD, V86, P1361, DOI 10.1182/blood.V86.4.1361.bloodjournal8641361; Choma C, 2000, NAT STRUCT BIOL, V7, P161; CLEMETSON KJ, 1981, P NATL ACAD SCI-BIOL, V78, P2712, DOI 10.1073/pnas.78.5.2712; Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7; Dai KS, 2005, BLOOD, V106, P1975, DOI 10.1182/blood-2005-01-0440; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; Dong JF, 1998, J BIOL CHEM, V273, P31449, DOI 10.1074/jbc.273.47.31449; DU XP, 1987, BLOOD, V69, P1524; Englund GD, 2001, J BIOL CHEM, V276, P16952, DOI 10.1074/jbc.M008048200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Kanaji T, 2004, BLOOD, V104, p434A, DOI 10.1182/blood.V104.11.1555.1555; Kanaji T, 2002, BLOOD, V100, P2102, DOI 10.1182/blood-2002-03-0997; Kenny D, 1999, BLOOD, V93, P2968; Kenny D, 2002, BLOOD, V99, P4428, DOI 10.1182/blood.V99.12.4428; Kunishima S, 2002, AM J HEMATOL, V71, P279, DOI 10.1002/ajh.10230; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Li CQ, 2002, THROMB HAEMOSTASIS, V88, P673, DOI 10.1055/s-0037-1613274; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; LOPEZ JA, 1995, BLOOD, V85, P1254, DOI 10.1182/blood.V85.5.1254.bloodjournal8551254; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Martin K, 2003, J THROMB HAEMOST, V1, P2643, DOI 10.1046/j.1538-7836.2003.00478.x; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; Noda M, 1995, THROMB HAEMOSTASIS, V74, P1411; Peng YD, 2004, BLOOD, V104, P3971, DOI 10.1182/blood-2004-07-2544; Perrault C, 2003, BLOOD, V101, P3477, DOI 10.1182/blood-2002-06-1847; Perrault C, 2001, THROMB HAEMOSTASIS, V86, P1238, DOI 10.1055/s-0037-1616057; Schade AJ, 2003, BIOCHEMISTRY-US, V42, P2245, DOI 10.1021/bi026549n; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Wang ZY, 2004, THROMB HAEMOSTASIS, V92, P606, DOI 10.1160/TH04-04-0240; Wu GX, 1996, BLOOD, V87, P2782, DOI 10.1182/blood.V87.7.2782.bloodjournal8772782; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	42	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23050	23059		10.1074/jbc.M600924200	http://dx.doi.org/10.1074/jbc.M600924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16757483	hybrid			2022-12-25	WOS:000239542600068
J	Ohira, M; Smardon, AM; Charsky, CMH; Liu, JZ; Tarsio, M; Kane, PM				Ohira, Masashi; Smardon, Anne M.; Charsky, Colleen M. H.; Liu, Jianzhong; Tarsio, Maureen; Kane, Patricia M.			The E and G subunits of the yeast V-ATPase interact tightly and are both present at more than one copy per V1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; MEDIATED CROSS-LINKING; COLI F1F0-ATP SYNTHASE; ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; ALPHA-SUBUNIT; B-SUBUNIT; IN-VIVO; STATOR	The E and G subunits of the yeast V-ATPase are believed to be part of the peripheral or stator stalk(s) responsible for physically and functionally linking the peripheral V-1 sector, responsible for ATP hydrolysis, to the membrane V-0 sector, containing the proton pore. The E and G subunits interact tightly and specifically, both on a far Western blot of yeast vacuolar proteins and in the yeast two-hybrid assay. Amino acids 13-79 of the E subunit are critical for the E-G two-hybrid interaction. Different tagged versions of the G subunit were expressed in a diploid cell, and affinity purification of cytosolic V-1 sectors via a FLAG-tagged G subunit resulted in copurification of a Myc-tagged G subunit, implying more than one G subunit was present in each V-1 complex. Similarly, hemagglutinin-tagged E subunit was able to affinity-purify V-1 sectors containing an untagged version of the E subunit from heterozygous diploid cells, suggesting that more than one E subunit is present. Overexpression of the subunit G results in a destabilization of subunit E similar to that seen in the complete absence of subunit G (Tomashek, J. J., Graham, L. A., Hutchins, M. U., Stevens, T. H., and Klionsky, D. J. (1997) J. Biol. Chem. 272, 26787 - 26793). These results are consistent with recent models showing at least two peripheral stalks connecting the V-1 and V-0 sectors of the V-ATPase and would allow both stalks to be based on an EG dimer.	SUNY, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; SUNY Maritime College	Kane, PM (corresponding author), SUNY, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	kanepm@upstate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050322, R01 GM50322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Armbruster A, 2003, FEBS LETT, V546, P395, DOI 10.1016/S0014-5793(03)00643-4; Carbajo RJ, 2005, J MOL BIOL, V351, P824, DOI 10.1016/j.jmb.2005.06.012; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fethiere J, 2005, BIOCHEMISTRY-US, V44, P15906, DOI 10.1021/bi051762f; Fethiere J, 2004, J BIOL CHEM, V279, P40670, DOI 10.1074/jbc.M407086200; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P11924, DOI 10.1021/bi058022r; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Liu ML, 2005, J BIOL CHEM, V280, P36978, DOI 10.1074/jbc.M505296200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Motz C, 2004, J BIOL CHEM, V279, P49074, DOI 10.1074/jbc.M404543200; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHYA Y, 1994, GENETICS, V138, P1041; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Shao E, 2004, J BIOL CHEM, V279, P48663, DOI 10.1074/jbc.M408278200; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Supekova L, 1996, J EXP BIOL, V199, P1147; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Venzke D, 2005, J MOL BIOL, V349, P659, DOI 10.1016/j.jmb.2005.04.033; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Wilkens S, 2005, BIOCHEMISTRY-US, V44, P11786, DOI 10.1021/bi0510678; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470; Zhang ZY, 2003, J BIOL CHEM, V278, P47299, DOI 10.1074/jbc.M309445200	50	54	57	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22752	22760		10.1074/jbc.M601441200	http://dx.doi.org/10.1074/jbc.M601441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16774922	hybrid			2022-12-25	WOS:000239542600036
J	Anong, WA; Weis, TL; Low, PS				Anong, William A.; Weis, Tahlia L.; Low, Philip S.			Rate of rupture and reattachment of the band 3-ankyrin bridge on the human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-CELL MEMBRANE; CYTOPLASMIC DOMAIN; ANKYRIN; PROTEIN; SKELETON; DEFORMABILITY; STABILITY; DEFORMATION; EQUILIBRIUM; ASSOCIATION	The principal bridge connecting the erythrocyte membrane to the spectrin-based skeleton is established by band 3 and ankyrin; mutations leading to reduced bridge formation or increased bridge rupture result in morphological and mechanical abnormalities. Because membrane mechanical properties are determined in part by the protein interactions that stabilize the membrane, we have evaluated the rates of rupture and reattachment of band 3-ankyrin bridges under both resting and mechanically stressed conditions. To accomplish this, we have examined the rate of ankyrin displacement from inside-out vesicles by the hexahistidine-tagged cytoplasmic domain of band 3, cdb3-(His)(6) and the rate of substitution of cdb3-(His) 6 into endogenous band 3-ankyrin bridges in resealed erythrocytes in the presence and absence of shear stress. We demonstrate that 1) exogenous cdb3-(His) 6 displaces endogenous ankyrin from IOVs with a half-time and first order rate constant of 42 +/- 14 min and 0.017 +/- 0.0058 min(-1), respectively; 2) exogenous cdb3-(His) 6 substitutes endogenous band 3 in its linkage to ankyrin in resealed cells with a half-time and first order rate constant of 12 +/- 3.6 min and 0.060 +/- 0.019 min(-1), respectively; 3) cdb3-(His)(6)-mediated rupture of the band 3-ankyrin bridge in resealed cells results in decreased membrane mechanical stability, decreased deformability, abnormal morphology, and spontaneous vesiculation of the cells; and 4) the above on/off rates are not significantly accelerated by mechanical shear stress. We conclude that the off rates of the band 3-ankyrin interaction are sufficiently slow to allow sustained erythrocyte deformation without loss of elasticity.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, 560 Oval Dr, W Lafayette, IN 47907 USA.	plow@purdue.edu		Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417-26, T32-GM008296-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417, T32GM008296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An XL, 2002, J BIOL CHEM, V277, P31796, DOI 10.1074/jbc.M204567200; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; BENNETT V, 1980, J BIOL CHEM, V255, P6424; CARTER DP, 1984, J CELL BIOCHEM, V24, P385, DOI 10.1002/jcb.240240408; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; Ding Y, 2004, PROTEIN EXPRES PURIF, V34, P167, DOI 10.1016/j.pep.2003.10.019; Evans E. A., 1978, CURR TOP MEMBR TRANS, P1; HEBBEL RP, 1991, BIOPHYS J, V60, P712, DOI 10.1016/S0006-3495(91)82100-2; JINBU Y, 1984, BIOCHIM BIOPHYS ACTA, V773, P237, DOI 10.1016/0005-2736(84)90087-7; Khan I, 2001, ARCH BIOCHEM BIOPHYS, V391, P25, DOI 10.1006/abbi.2001.2387; Lee JCM, 2001, BIOPHYS J, V81, P3178, DOI 10.1016/S0006-3495(01)75954-1; LI ZP, 1993, J BIOL CHEM, V268, P11489; LIU SC, 1995, BLOOD, V86, P349, DOI 10.1182/blood.V86.1.349.bloodjournal861349; MOHANDAS N, 1980, J CLIN INVEST, V66, P563, DOI 10.1172/JCI109888; MOHANDAS N, 1982, BLOOD, V59, P768; Mohler PJ, 2005, CURR OPIN CARDIOL, V20, P189, DOI 10.1097/01.hco.0000160372.95116.3e; Nicolas V, 2003, J BIOL CHEM, V278, P25526, DOI 10.1074/jbc.M302816200; PALEK J, 1992, BLOOD, V80, P308; PINDER JC, 1995, BLOOD, V85, P2951, DOI 10.1182/blood.V85.10.2951.bloodjournal85102951; Rybicki AC, 1996, BLOOD, V88, P2745, DOI 10.1182/blood.V88.7.2745.bloodjournal8872745; Shi ZT, 1999, J CLIN INVEST, V103, P331, DOI 10.1172/JCI3858; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; Van Dort HM, 2001, J BIOL CHEM, V276, P46968, DOI 10.1074/jbc.M107855200; Van Dort HM, 1998, J BIOL CHEM, V273, P14819, DOI 10.1074/jbc.273.24.14819	26	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22360	22366		10.1074/jbc.M513839200	http://dx.doi.org/10.1074/jbc.M513839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16762928	hybrid			2022-12-25	WOS:000239387100081
J	Maeda, M; Johnson, E; Mandal, SH; Lawson, KR; Keim, SA; Svoboda, RA; Caplan, S; Wahl, JK; Wheelock, MJ; Johnson, KR				Maeda, M.; Johnson, E.; Mandal, S. H.; Lawson, K. R.; Keim, S. A.; Svoboda, R. A.; Caplan, S.; Wahl, J. K., III; Wheelock, M. J.; Johnson, K. R.			Expression of inappropriate cadherins by epithelial tumor cells promotes endocytosis and degradation of E-cadherin via competition for p120(ctn)	ONCOGENE			English	Article						cadherin; endocytosis; p120(ctn)	MICROVASCULAR ENDOTHELIAL-CELLS; SQUAMOUS CARCINOMA-CELLS; N-CADHERIN; MESENCHYMAL TRANSITIONS; DOWN-REGULATION; CANCER CELLS; ADHERENS JUNCTIONS; PLASMA-MEMBRANE; P120 CATENIN; VE-CADHERIN	Cadherin cell-cell adhesion proteins play an important role in modulating the behavior of tumor cells. E-cadherin serves as a suppressor of tumor cell invasion, and when tumor cells turn on the expression of a non-epithelial cadherin, they often express less E-cadherin, enhancing the tumorigenic phenotype of the cells. Here, we show that when A431 cells are forced to express R-cadherin, they dramatically downregulate the expression of endogenous E- and P-cadherin. In addition, we show that this downregulation is owing to increased turnover of the endogenous cadherins via clathrin-dependent endocytosis. p120(ctn) binds to the juxtamembrane domain of classical cadherins and has been proposed to regulate cadherin adhesive activity. One way p120(ctn) may accomplish this is to serve as a rheostat to regulate the levels of cadherin. Here, we show that the degradation of E-cadherin in response to expression of R-cadherin is owing to competition for p120(ctn).	Univ Nebraska, Med Ctr, Dept Oral Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	mwheelock@unmc.edu		Keim, Sarah/0000-0002-7965-9267	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051188] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09746, P30-CA36727] Funding Source: Medline; NCRR NIH HHS [P20-RR018759] Funding Source: Medline; NIDCR NIH HHS [R01-DE12308] Funding Source: Medline; NIGMS NIH HHS [R01-GM51188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Dahl U, 2002, MOL CELL BIOL, V22, P1474, DOI 10.1128/MCB.22.5.1474-1487.2002; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Giroldi Laurence A., 2000, Morphologie, V84, P31; Grignani F, 1998, CANCER RES, V58, P14; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MATSUNAMI H, 1993, J CELL SCI, V106, P401; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieman MT, 1999, J CELL SCI, V112, P1621; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Pishvaian MJ, 1999, CANCER RES, V59, P947; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SUBTIL A, 1994, J CELL SCI, V107, P3461; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomita K, 2000, CANCER RES, V60, P3650; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200	48	48	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4595	4604		10.1038/sj.onc.1209396	http://dx.doi.org/10.1038/sj.onc.1209396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16786001				2022-12-25	WOS:000239457500009
J	Crean, JK; Furlong, F; Mitchell, D; McArdle, E; Godson, C; Martin, F				Crean, J. K.; Furlong, F.; Mitchell, D.; McArdle, E.; Godson, C.; Martin, F.			Connective tissue growth factor/CCN2 stimulates actin disassembly through Akt/protein kinase B-mediated phosphorylation and cytoplasmic translocation of p27(Kip-1)	FASEB JOURNAL			English	Article						CTGF; migration; actin cytoskeleton; p27(Kip-1); RhoA; PI-3 kinase; Akt/PKB; LIM kinase; cofilin; diabetic nephropathy	HUMAN MESANGIAL CELLS; DIABETIC-NEPHROPATHY; TGF-BETA; INTEGRIN ALPHA(V)BETA(3); SIGNALING PATHWAYS; FACTOR CTGF; P27; MIGRATION; EXPRESSION; PROTEINS	Connective tissue growth factor (CTGF/CCN2) is a 38-kDa secreted protein, a prototypic member of the CCN family, which is up-regulated in many diseases, including atherosclerosis, pulmonary fibrosis, and diabetic nephropathy. We previously showed that CTGF can cause actin disassembly with concurrent down-regulation of the small GTPase Rho A and proposed an integrated signaling network connecting focal adhesion dissolution and actin disassembly with cell polarization and migration. Here, we further delineate the role of CTGF in cell migration and actin disassembly in human mesangial cells, a primary target in the development of renal glomerulosclerosis. The functional response of mesangial cells to treatment with CTGF was associated with the phosphorylation of Akt/ protein kinase B (PKB) and resultant phosphorylation of a number of Akt/ PKB substrates. Two of these substrates were identified as FKHR and p27(Kip-1). CTGF stimulated the phosphorylation and cytoplasmic translocation of p27(Kip-1) on serine 10. Addition of the PI-3 kinase inhibitor LY294002 abrogated this response; moreover, addition of the Akt/ PKB inhibitor interleukin (IL)-6-hydroxymethyl-chiro-inositol-2(R)-2-methyl-3-O- octadecylcarbonate prevented p27(Kip-1) phosphorylation in response to CTGF. Immunocytochemistry revealed that serine 10 phosphorylated p27(Kip-1) colocalized with the ends of actin filaments in cells treated with CTGF. Further investigation of other Akt/ PKB sites on p27(Kip-1), revealed that phosphorylation on threonine 157 was necessary for CTGF mediated p27(Kip-1) cytoplasmic localization; mutation of the threonine 157 site prevented cytoplasmic localization, protected against actin disassembly and inhibited cell migration. CTGF also stimulated an increased association between Rho A and p27(Kip-1). Interestingly, this resulted in an increase in phosphorylation of LIM kinase and subsequent phosphorylation of cofilin, suggesting that CTGF mediated p27(Kip-1) activation results in uncoupling of the Rho A/LIM kinase/cofilin pathway. Confirming the central role of Akt/ PKB, CTGF-stimulated actin depolymerization only in wild-type mouse embryonic fibroblasts (MEFs) compared to Akt-1/3 (PKB alpha/gamma) knockout MEFs. These data reveal important mechanistic insights into how CTGF may contribute to mesangial cell dysfunction in the diabetic milieu and sheds new light on the proposed role of p27(Kip-1) as a mediator of actin rearrangement.	Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Sch Biomol & Biomed Sci, Dublin 4, Ireland; Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland; Dublin Mol Med Ctr, Dublin, Ireland	University College Dublin; University College Dublin; Trinity College Dublin; University College Dublin	Crean, JK (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Sch Biomol & Biomed Sci, Dublin 4, Ireland.	john.crean@ucd.ie		Godson, Catherine/0000-0003-0655-1041; Furlong, Fiona/0000-0002-9206-2297; /0000-0002-4337-6177				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Awazu M, 2003, J AM SOC NEPHROL, V14, P699, DOI 10.1097/01.ASN.0000051726.41601.C0; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Crean JK, 2004, FASEB J, V18, P1541, DOI 10.1096/fj.04-1546fje; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Gubbay O, 2004, REPRODUCTION, V128, P607, DOI 10.1530/rep.1.00272; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; MINATO M, J BIOCH TOKYO, V135, P347; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Oemar BS, 1997, CIRCULATION, V95, P831; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Twigg SM, 2004, DIABETOLOGIA, V47, P965, DOI 10.1007/s00125-004-1423-6; van Nieuwenhoven FA, 2005, NEPHROL DIAL TRANSPL, V20, P6, DOI 10.1093/ndt/gfh570; Wahab NA, 2005, J AM SOC NEPHROL, V16, P340, DOI 10.1681/ASN.2003100905; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02; Wolf G, 2003, DIABETOLOGIA, V46, P1090, DOI 10.1007/s00125-003-1163-z; Wolf G, 2005, KIDNEY INT, V68, P1583, DOI 10.1111/j.1523-1755.2005.00570.x; Wolf G, 2003, J AM SOC NEPHROL, V14, P819, DOI 10.1097/01.ASN.0000057518.58420.E4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x	54	32	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1712	+		10.1096/fj.05-5010fje	http://dx.doi.org/10.1096/fj.05-5010fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790529				2022-12-25	WOS:000240266600024
J	Yang, J; Zhang, W; Evans, PM; Chen, X; He, X; Liu, CM				Yang, Jun; Zhang, Wen; Evans, Paul M.; Chen, Xi; He, Xi; Liu, Chunming			Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEIN; KAPPA-B-ALPHA; COLORECTAL-CANCER; CRYSTAL-STRUCTURE; COMPLEX; AXIN; DEGRADATION; TRCP; MECHANISM; PATHWAY	Most colorectal cancers have mutations of the adenomatous polyposis coli (APC) gene or the beta-catenin gene that stabilize beta-catenin and activate beta-catenin target genes, leading ultimately to cancer. The molecular mechanisms of APC function in beta-catenin degradation are not completely known. APC binds beta-catenin and is involved in the Axin complex, suggesting that APC regulates beta-catenin phosphorylation. Some evidence also suggests that APC regulates beta-catenin nuclear export. Here, we examine the effects of APC mutations on beta-catenin phosphorylation, ubiquitination, and degradation in the colon cancer cell lines SW480, DLD-1, and HT29, each of which contains a different APC truncation. Although the current models suggest that beta-catenin phosphorylation should be inhibited by APC mutations, we detected significant beta-catenin phosphorylation in these cells. However, beta-catenin ubiquitination and degradation were inhibited in SW480 but not in DLD-1 and HT29cells. The ubiquitination of beta-catenin in SW480 cells can be rescued by exogenous expression of APC. The APC domains required for beta-catenin ubiquitination were analyzed. Our results suggest that APC regulates beta-catenin phosphorylation and ubiquitination by distinct domains and by separate molecular mechanisms.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Harvard University; Boston Children's Hospital; Harvard Medical School	Liu, CM (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA.	chliu@utmb.edu	高, 雨莉/HGU-8187-2022		NCI NIH HHS [CA 112007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA112007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; *AM CANC SOC, 2005, CANC FACTS FIG, P10; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Davies ML, 2004, ONCOGENE, V23, P1412, DOI 10.1038/sj.onc.1207266; Evans PM, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-22; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Matsumoto T, 2002, GUT, V50, P402, DOI 10.1136/gut.50.3.402; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sadot E, 2002, J CELL SCI, V115, P2771; Shih IM, 2000, CANCER RES, V60, P1671; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Wang ZH, 2003, CANCER RES, V63, P5234; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733	37	154	156	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17751	17757		10.1074/jbc.M600831200	http://dx.doi.org/10.1074/jbc.M600831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16798748	hybrid			2022-12-25	WOS:000238490300025
J	Simic, P; Culej, JB; Orlic, I; Grgurevic, L; Draca, N; Spaventi, R; Vukicevic, S				Simic, Petra; Culej, Jasminka Buljan; Orlic, Iva; Grgurevic, Lovorka; Draca, Natasa; Spaventi, Radan; Vukicevic, Slobodan			Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	27th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 23-27, 2005	Nashville, TN	Amer Soc Bone & Mineral Res			GROWTH-FACTOR; PARATHYROID-HORMONE; CANCELLOUS BONE; OSTEOGENIC PROTEIN; MINERAL DENSITY; EXPRESSION; ESTROGEN; STRENGTH; CELLS; FEMUR	Although recombinant human bone morphogenetic proteins (BMPs) are used locally for treating bone defects in humans, their systemic effect on bone augmentation has not been explored. We have previously demonstrated that demineralized bone (DB) from ovariectomized (OVX) rats cannot induce bone formation when implanted ectopically at the subcutaneous site. Here we showed in vitro that 17 beta-estradiol (E-2) specifically induced expression of Bmp6 mRNA in MC3T3-E1 preosteoblastic cells and that bone extracts from OVX rats lack BMPs. Next we demonstrated that I-125-BMP-6 administered systemically accumulated in the skeleton and also restored the osteoinductive capacity of ectopically implanted DB from OVX rats. BMP-6 applied systemically to aged OVX rats significantly increased bone volume and mechanical characteristics of both the trabecular and cortical bone, the osteoblast surface, serum osteocalcin and osteoprotegerin levels, and decreased the osteoclast surface, serum C-telopeptide, and interleukin-6. E-2 was significantly less effective, and was not synergistic with BMP-6. Animals that discontinued BMP-6 therapy maintained bone mineral density gains for another 12 weeks. BMP-6 increased in vivo the bone expression of Acvr-1, Bmpr1b, Smad5, alkaline phosphatase, and collagen type I and decreased expression of Bmp3 and BMP antagonists, chordin and cerberus. These results show, for the first time, that systemically administered BMP-6 restores the bone inductive capacity, microarchitecture, and quality of the skeleton in osteoporotic rats.	Univ Zagreb, Sch Med, Lab Mineralized Tissues, Zagreb 10000, Croatia; Pliva Res Inst, Zagreb 10000, Croatia	University of Zagreb; Teva Pharmaceutical Industries; Pliva	Vukicevic, S (corresponding author), Univ Zagreb, Sch Med, Lab Mineralized Tissues, Salata 11, Zagreb 10000, Croatia.	vukicev@mef.hr	Vukicevic, Slobodan/AEG-2646-2022	Vukicevic, Slobodan/0000-0003-4076-0285				Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Ahmed N, 2001, CELL BIOL INT, V25, P429, DOI 10.1006/cbir.2000.0662; Aspenberg P, 2000, ACTA ORTHOP SCAND, V71, P558, DOI 10.1080/000164700317362172; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bosukonda D, 2000, KIDNEY INT, V58, P1902, DOI 10.1046/j.1523-1755.2000.00362.x; Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546; CESNJAJ M, 1991, ACTA ORTHOP SCAND, V62, P471; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151; Friedlaender GE, 2004, PROG INFLAM RES, P157; Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101; HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756-3282(92)90078-B; Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167; Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692; Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756-3282(00)00316-1; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Ito M, 1998, BONE, V23, P163, DOI 10.1016/S8756-3282(98)00083-0; Iwaniec UT, 2002, ENDOCRINOLOGY, V143, P2515, DOI 10.1210/en.143.7.2515; Jamsa T, 1998, BONE, V23, P155, DOI 10.1016/S8756-3282(98)00076-3; JONES WK, 1994, GROWTH FACTORS, V11, P215, DOI 10.3109/08977199409046919; Karahan S, 2002, COMPARATIVE MED, V52, P143; KE HZ, 1995, ENDOCRINOLOGY, V136, P2435, DOI 10.1210/en.136.6.2435; KREMPIEN B, 1988, J BONE MINER RES, V3, P573; Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Liang K, 1999, ENDOCRINOLOGY, V140, P5780; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotinun S, 2004, J BONE MINER RES, V19, P1165, DOI 10.1359/JBMR.040404; Marcus R., 2001, OSTEOPOROSIS; Maric I, 2003, J CELL PHYSIOL, V196, P258, DOI 10.1002/jcp.10275; MARINOVIC S, 2004, BONE MORPHOGENETIC P, P45; Meng XW, 1996, J BONE MINER RES, V11, P421; Mundy GR, 2002, ANNU REV MED, V53, P337, DOI 10.1146/annurev.med.53.082901.104047; Ong DB, 2004, J BONE MINER RES, V19, P447, DOI 10.1359/JBMR.0301249; Oxlund H, 2002, EUR J ENDOCRINOL, V146, P431, DOI 10.1530/eje.0.1460431; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Papadopoulos NG, 1997, CLIN RHEUMATOL, V16, P162, DOI 10.1007/BF02247845; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Plant A, 2002, J BONE MINER RES, V17, P782, DOI 10.1359/jbmr.2002.17.5.782; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889-8529(02)00055-5; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; Rhee Y, 2004, J BONE MINER RES, V19, P931, DOI 10.1359/JBMR.040123; Rickard DJ, 1998, J CLIN INVEST, V101, P413, DOI 10.1172/JCI119880; ROSEN HN, 1995, J BONE MINER RES, V10, P1352; Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SAMPATH TK, 1984, P NATL ACAD SCI-BIOL, V81, P3419, DOI 10.1073/pnas.81.11.3419; Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112; SHEN V, 1995, J CLIN INVEST, V96, P2331, DOI 10.1172/JCI118289; Simic P, 2005, CYTOKINE GROWTH F R, V16, P299, DOI 10.1016/j.cytogfr.2005.02.010; Simic P, 2004, PROG INFLAM RES, P73; Srivastava AK, 2005, CURR MED RES OPIN, V21, P1015, DOI 10.1185/030079905X49635; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; VUKICEVIC S, 1987, J BONE MINER RES, V2, P533; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Wozney JM, 2004, CURR OPIN BIOTECH, V15, P392, DOI 10.1016/j.copbio.2004.08.001; Wronski TJ, 1998, PHARM TOXIC, P59	66	89	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25509	25521		10.1074/jbc.M513276200	http://dx.doi.org/10.1074/jbc.M513276200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	077LQ	16798745	hybrid, Green Accepted			2022-12-25	WOS:000240031300054
J	Henle, F; Fischer, C; Meyer, DK; Leemhuis, J				Henle, Frank; Fischer, Catharina; Meyer, Dieter K.; Leemhuis, Jost			Vasoactive intestinal peptide and PACAP38 control N-methyl-D-aspartic acid-induced dendrite motility by modifying the activities of rho GTPases and phosphatidylinositol 3-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; CENTRAL-NERVOUS-SYSTEM; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; PROTEIN-KINASE; PC12 CELLS; GROWTH; EXPRESSION; BRAIN; PHOSPHORYLATION	Dendrite morphogenesis is highly dynamic and characterized by the addition and elongation of processes and also by their selective maintenance, retraction, and elimination. Glutamate can influence these events via N-methyl-D-aspartic acid ( NMDA) receptors. The neuropeptides vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide-38 (PACAP38) affect neurogenesis and differentiation in the developing nervous system. We report here that the peptides and NMDA acted synergistically on dendrite and branch formation. In stage III hippocampal neurons, NMDA increased not only the addition but also the elimination of new dendrites and branches by activating Rac and Cdc42 and phosphatidylinositol 3-kinases, respectively. When applied alone, the neuropeptides did not influence dendrite or branch formation. However, they reduced the elimination of newly formed dendrites and branches caused by NMDA by preventing the NMDA-induced activation of phosphatidylinositol 3-kinases. This led to the formation of persistent dendrites and branches. Additional timelapse studies on the dynamics of dendrite elongation showed alternating periods of elongation and retraction. Phosphatidylinositol 3-kinases increased the velocities of dendrite elongation and retraction, whereas the neuropeptides prolonged the periods of elongation. By modifying NMDA-induced activation of Rho GTPases and phosphatidylinositol 3-kinases, vasoactive intestinal peptide and PACAP38 could play an important role in the control of dendrite growth and branching during development and in response to neuronal activity.	Univ Freiburg, Zentrum Neurowissensch, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Leemhuis, J (corresponding author), Univ Freiburg, Zentrum Neurowissensch, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany.	jost.leemhuis@pharmakol.uni-freiburg.de						Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Basille M, 2000, J COMP NEUROL, V425, P495; Blondel O, 2000, J NEUROSCI, V20, P8012; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Brenneman DE, 1998, ANN NY ACAD SCI, V865, P207, DOI 10.1111/j.1749-6632.1998.tb11180.x; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cazillis M, 2004, EUR J NEUROSCI, V19, P798, DOI 10.1111/j.0953-816X.2004.03138.x; de Anda FC, 2005, NATURE, V436, P704, DOI 10.1038/nature03811; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; GRESSENS P, 1993, NATURE, V362, P155, DOI 10.1038/362155a0; Guirland C, 2003, J NEUROSCI, V23, P2274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hua JYY, 2004, NAT NEUROSCI, V7, P327, DOI 10.1038/nn1218; Ikenoya M, 2002, J NEUROCHEM, V81, P9, DOI 10.1046/j.1471-4159.2002.00801.x; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KIRBY MA, 1986, J COMP NEUROL, V251, P532, DOI 10.1002/cne.902510408; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Konur S, 2005, NEURON, V46, P401, DOI 10.1016/j.neuron.2005.04.022; Leemhuis J, 2004, J BIOL CHEM, V279, P585, DOI 10.1074/jbc.M307066200; Li Z, 2003, NAT REV MOL CELL BIO, V4, P833, DOI 10.1038/nrm1242; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Lohmann C, 2005, CELL CALCIUM, V37, P403, DOI 10.1016/j.ceca.2005.01.008; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Meyer DK, 2005, J BIOL CHEM, V280, P25258, DOI 10.1074/jbc.M501630200; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Oh JS, 2004, J BIOL CHEM, V279, P17980, DOI 10.1074/jbc.M314109200; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pei L, 1997, REGUL PEPTIDES, V71, P153, DOI 10.1016/S0167-0115(97)01012-4; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Perez V, 2005, EUR J NEUROSCI, V21, P26, DOI 10.1111/j.1460-9568.2004.03845.x; Perkinton MS, 2002, J NEUROCHEM, V80, P239, DOI 10.1046/j.0022-3042.2001.00699.x; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; Portera-Cailliau C, 2003, J NEUROSCI, V23, P7129, DOI 10.1523/JNEUROSCI.23-18-07129.2003; Rao A, 1998, J NEUROSCI, V18, P1217; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sin WC, 2002, NATURE, V419, P475, DOI 10.1038/nature00987; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Aelst L, 2004, CURR OPIN NEUROBIOL, V14, P297, DOI 10.1016/j.conb.2004.05.012; Vaudry D, 2000, PHARMACOL REV, V52, P269; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Washbourne P, 2002, CURR OPIN NEUROBIOL, V12, P566, DOI 10.1016/S0959-4388(02)00365-3; Wong ROL, 2002, NAT REV NEUROSCI, V3, P803, DOI 10.1038/nrn941; Wong WT, 2000, J NEUROSCI, V20, P5024; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	63	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24955	24969		10.1074/jbc.M604114200	http://dx.doi.org/10.1074/jbc.M604114200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16803895	hybrid			2022-12-25	WOS:000239847800088
J	Mercer, JC; DeHaven, WI; Smyth, JT; Wedel, B; Boyles, RR; Bird, GS; Putney, JW				Mercer, Jason C.; DeHaven, Wayne I.; Smyth, Jeremy T.; Wedel, Barbara; Boyles, Rebecca R.; Bird, Gary S.; Putney, James W., Jr.			Large store-operated calcium selective currents due to co-expression of Orai1 or Orai2 with the intracellular calcium sensor, Stim1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; CA2+ SENSOR; RELEASE; CHANNELS; ENTRY; CRAC; POTENTIATION; DEPLETION; FAMILY; CELLS	The molecular nature of store-operated Ca2+-selective channels has remained an enigma, due largely to the continued inability to convincingly demonstrate Ca2+-selective store-operated currents resulting from exogenous expression of known genes. Recent findings have implicated two proteins, Stim1 and Orai1, as having essential roles in store-operated Ca2+ entry across the plasma membrane. However, transient overexpression of these proteins on their own results in little or no increase in store-operated entry. Here we demonstrate dramatic synergism between these two mediators; co-transfection of HEK293 cells with Stim1 and Orai1 results in an approximate 20-fold increase in store-operated Ca2+ entry and Ca2+-selective current. This demonstrates that these two proteins are limiting for both the signaling and permeation mechanisms for Ca2+-selective store-operated Ca2+ entry. There are three mammalian homologs of Orai1, and in expression experiments they all produced or augmented store-operated Ca2+ entry with efficacies in the order Orai1 > Orai2 > Orai3. Stim1 apparently initiates the signaling process by acting as a Ca2+ sensor in the endoplasmic reticulum. This results in rearrangement of Stim1 within the cell and migration toward the plasma membrane to regulate in some manner Orai1 located in the plasma membrane. However, we demonstrate that Stim1 does not incorporate in the surface membrane, and thus likely regulates or interacts with Orai1 at sites of close apposition between the plasma membrane and an intracellular Stim1-containing organelle.	NIEHS, NIH, Lab Signal Transduct, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, NIH, Lab Signal Transduct, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; Boyles, Rebecca/0000-0003-0073-6854	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 ES999999] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bolotina VM, 2005, TRENDS BIOCHEM SCI, V30, P378, DOI 10.1016/j.tibs.2005.05.009; Borszcz PD, 2003, EUR J IMMUNOL, V33, P1084, DOI 10.1002/eji.200323582; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Manji SSM, 2000, BBA-PROTEIN STRUCT M, V1481, P147, DOI 10.1016/S0167-4838(00)00105-9; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney J W Jr, 2001, Mol Interv, V1, P84; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Smyth JT, 2006, J BIOL CHEM, V281, P11712, DOI 10.1074/jbc.M510541200; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597	37	430	466	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24979	24990		10.1074/jbc.M604589200	http://dx.doi.org/10.1074/jbc.M604589200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16807233	hybrid, Green Accepted			2022-12-25	WOS:000239847800090
J	Mason, AB; Allen, KE; Slayman, CW				Mason, A. Brett; Allen, Kenneth E.; Slayman, Carolyn W.			Effects of C-terminal truncations on trafficking of the yeast plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL SORTING DETERMINANT; PDZ-INTERACTING DOMAIN; LARGE CYTOPLASMIC LOOP; ER QUALITY-CONTROL; P-TYPE ATPASE; TRANSMEMBRANE SEGMENTS; SECRETORY VESICLES; ESCHERICHIA-COLI; TRANSPORT; GENE	Within the large family of P-type cation-transporting ATPases, members differ in the number of C-terminal transmembrane helices, ranging from two in Cu2+-ATPases to six in H+-, Na+, K+-, Mg2+-, and Ca2+- ATPases. In this study, yeast Pma1 H+-ATPase has served as a model to examine the role of the C-terminal membrane domain in ATPase stability and targeting to the plasma membrane. Successive truncations were constructed from the middle of the major cytoplasmic loop to the middle of the extended cytoplasmic tail, adding back the C-terminal membrane-spanning helices one at a time. When the resulting constructs were expressed transiently in yeast, there was a steady increase in half-life from 70 min in Pma1 Delta 452 to 348 min in Pma1 Delta 901, but even the longest construct was considerably less stable than wild-type ATPase ( t(1/2) = 11 h). Confocal immunofluorescence microscopy showed that 11 of 12 constructs were arrested in the endoplasmic reticulum and degraded in the proteasome. The only truncated ATPase that escaped the ER, Pma1 Delta 901, traveled slowly to the plasma membrane, where it hydrolyzed ATP and supported growth. Limited trypsinolysis showed Pma1 Delta 901 to be misfolded, however, resulting in premature delivery to the vacuole for degradation. As model substrates, this series of truncations affirms the importance of the entire C-terminal domain to yeast H+-ATPase biogenesis and defines a sequence element of 20 amino acids in the carboxyl tail that is critical to ER escape and trafficking to the plasma membrane.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Slayman, CW (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	carolyn.slayman@yale.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Beggah AT, 1999, J BIOL CHEM, V274, P8217, DOI 10.1074/jbc.274.12.8217; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; Caplan MJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1101, DOI 10.1152/ajpcell.00004.2003; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Ferreira T, 2002, J BIOL CHEM, V277, P21027, DOI 10.1074/jbc.M112281200; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jahn TP, 2002, J BIOL CHEM, V277, P6353, DOI 10.1074/jbc.M109637200; Kuhlbrandt W, 2002, SCIENCE, V297, P1692, DOI 10.1126/science.1072574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mason AB, 1998, BBA-BIOMEMBRANES, V1372, P261, DOI 10.1016/S0005-2736(98)00065-0; Milewski MI, 2001, J CELL SCI, V114, P719; Miranda M, 2001, J BIOL CHEM, V276, P22485, DOI 10.1074/jbc.M102332200; MOLLER M, 1986, ADV PINEAL RES, V1, P51; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; Moutin MJ, 1998, EUR J BIOCHEM, V251, P682, DOI 10.1046/j.1432-1327.1998.2510682.x; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Muth TR, 2003, ANNU REV CELL DEV BI, V19, P333, DOI 10.1146/annurev.cellbio.19.110701.161425; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Petrov VV, 2000, J BIOL CHEM, V275, P15709, DOI 10.1074/jbc.M000546200; Portillo F, 2000, BBA-REV BIOMEMBRANES, V1469, P31, DOI 10.1016/S0304-4157(99)00011-8; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Shearer AG, 2004, J BIOL CHEM, V279, P188, DOI 10.1074/jbc.M307734200; Sherman F., 1986, METHODS YEAST GENETI; Takeda T, 2003, AM J PHYSIOL-CELL PH, V284, pC1105, DOI 10.1152/ajpcell.00514.2002; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972	58	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23887	23898		10.1074/jbc.M601818200	http://dx.doi.org/10.1074/jbc.M601818200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16751629	hybrid			2022-12-25	WOS:000239702900064
J	Mueller-Planitz, F; Herschlag, D				Mueller-Planitz, Felix; Herschlag, Daniel			Interdomain communication in DNA topoisomerase II - DNA binding and enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; ATP-OPERATED CLAMP; QUINOLONE ACTION; STRAND-PASSAGE; DOUBLE HELIX; CLEAVAGE; MECHANISM; ALPHA; TRANSPORT; DOMAIN	Topoisomerase II catalyzes the ATP-dependent transport of a DNA segment (T-DNA) through a transient double strand break in another DNA segment (G-DNA). A fundamental mechanistic question is how the individual steps in this process are coordinated. We probed communication between the DNA binding sites and the individual enzymatic activities, ATP hydrolysis, and DNA cleavage. We employed short DNA duplexes to control occupancy at the two binding sites of wild-type enzyme and a variant with a G-DNA site mutation. The DNA concentration dependence of ATP hydrolysis and a fluorescence anisotropy assay provided thermodynamic information about DNA binding. The results suggest that G-DNA binds with higher affinity than T-DNA. Enzyme with only G-DNA bound is competent to cleave DNA, indicating that T-DNA is dispensable for DNA cleavage. The ATPase activity of enzyme bound solely to G-DNA is partially stimulated. Full stimulation requires binding of T-DNA. Both DNA binding sites therefore signal to the ATPase domains. The results support and extend current mechanistic models for topoisomerase II-catalyzed DNA transport and provide a framework for future mechanistic dissection.	Stanford Univ, Sch Med, Beckman Ctr B400, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Herschlag, D (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B400, Dept Biochem, 279 Campus Dr, Stanford, CA 94305 USA.	herschla@cmgm.stanford.edu	Mueller-Planitz, Felix/P-8461-2014	Mueller-Planitz, Felix/0000-0001-8273-6473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Bromberg KD, 2003, BIOCHEMISTRY-US, V42, P3393, DOI 10.1021/bi027383t; Burden DA, 2000, METH MOL B, V95, P283; Campbell S, 2002, J MOL BIOL, V320, P171, DOI 10.1016/S0022-2836(02)00461-8; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Corbett KD, 2005, STRUCTURE, V13, P873, DOI 10.1016/j.str.2005.03.013; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Horst M, 1996, PROTEIN SCI, V5, P759; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; Kallansrud G, 1996, ANAL BIOCHEM, V236, P134, DOI 10.1006/abio.1996.0141; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; Kraut DA, 2006, PLOS BIOL, V4, P501, DOI 10.1371/journal.pbio.0040099; Lindsley JE, 2000, METH MOL B, V95, P57; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; Marians KJ, 1997, J BIOL CHEM, V272, P9401; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1983, J BIOL CHEM, V258, P8421; Schoeffler AJ, 2005, BIOCHEM SOC T, V33, P1465, DOI 10.1042/BST0331465; Strumberg D, 2002, ANTIMICROB AGENTS CH, V46, P2735, DOI 10.1128/AAC.46.9.2735-2746.2002; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	38	16	16	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23395	23404		10.1074/jbc.M604119200	http://dx.doi.org/10.1074/jbc.M604119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16782968	hybrid			2022-12-25	WOS:000239702900014
J	Turella, P; Filomeni, G; Dupuis, ML; Ciriolo, MR; Molinari, A; De Maria, F; Tombesi, M; Cianfriglia, M; Federici, G; Ricci, G; Caccuri, AM				Turella, Paola; Filomeni, Giuseppe; Dupuis, Maria Luisa; Ciriolo, Maria Rosa; Molinari, Agnese; De Maria, Francesca; Tombesi, Marina; Cianfriglia, Maurizio; Federici, Giorgio; Ricci, Giorgio; Caccuri, Anna Maria			A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells - 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE MONOCLONAL-ANTIBODY; MULTIDRUG-RESISTANCE; SUBSTRATE RECOGNITION; DEATH; ACTIVATION; VARIANTS; PROTEINS	The new glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol- 4-ylthio)hexanol (NBDHEX) is cytotoxic toward P-glycoprotein-overexpressing tumor cell lines, i.e. CEM-VBL10, CEM-VBL100, and U-2 OS/DX580. The mechanism of cell death triggered by NBDHEX has been deeply investigated in leukemia cell lines. Kinetic data indicate a similar NBDHEX membrane permeability between multidrug resistance cells and their sensitive counterpart revealing that NBDHEX is not a substrate of the P-glycoprotein export pump. Unexpectedly, this molecule promotes a caspase-dependent apoptosis that is unusual in the P-glycoprotein-overexpressing cells. The primary event of the apoptotic pathway is the dissociation of glutathione S-transferase P1-1 from the complex with c-Jun N-terminal kinase. Interestingly, leukemia MDR1-expressing cells show lower LC50 values and a higher degree of apoptosis and caspase-3 activity than their drug-sensitive counterparts. The increased susceptibility of the multidrug resistance cells toward the NBDHEX action may be related to a lower content of glutathione S-transferase P1-1. Given the low toxicity of NBDHEX in vivo, this compound may represent an attractive basis for the selective treatment of MDR1 P-glycoproteinpositive tumors.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy; Ist Super Sanita, Dept Technol & Hlth, I-00161 Rome, Italy; Childrens Hosp, IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); IRCCS Bambino Gesu	Caccuri, AM (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	caccuri@uniroma2.it	CACCURI, ANNA MARIA/AFU-2643-2022; DUPUIS, MARIA LUISA/D-7949-2016; Molinari, Agnese/E-7588-2015; Ciriolo, Maria Rosa/K-6572-2016; Molinari, Agnese/AAC-2918-2021	Molinari, Agnese/0000-0002-9592-5465; Molinari, Agnese/0000-0002-9592-5465; Ricci, Giorgio/0000-0002-7108-2846; Filomeni, Giuseppe/0000-0002-2719-1412; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ciriolo, Maria Rosa/0000-0002-7863-9029				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Bielak-Zmijewska A, 2000, NUTR CANCER, V38, P131, DOI 10.1207/S15327914NC381_18; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; CENCIARELLI C, 1991, INT J CANCER, V47, P533, DOI 10.1002/ijc.2910470411; CIANFRIGLIA M, 1990, INT J CANCER, V45, P95, DOI 10.1002/ijc.2910450118; CIANFRIGLIA M, 1994, INT J CANCER, V56, P153; Dai DJ, 2005, WORLD J GASTROENTERO, V11, P193, DOI 10.3748/wjg.v11.i2.193; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Ishisaki A, 2001, J NEUROCHEM, V77, P1362, DOI 10.1046/j.1471-4159.2001.00351.x; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; LING V, 1997, CANC CHEMOTHER PHA S, V40, P3; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200; Ruefli AA, 2002, INT J CANCER, V99, P292, DOI 10.1002/ijc.10327; Ruefli AA, 2000, BLOOD, V95, P2378, DOI 10.1182/blood.V95.7.2378.007k10_2378_2385; Schultz M, 1997, ADV DRUG DELIVER REV, V26, P91, DOI 10.1016/S0169-409X(97)00029-X; Scotlandi K, 1996, CANCER RES, V56, P2434; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x; Tainton KM, 2000, BIOCHEM BIOPH RES CO, V276, P231, DOI 10.1006/bbrc.2000.3459; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; TSURUO T, 1983, CANCER RES, V43, P2267; Turella P, 2005, CANCER RES, V65, P3751, DOI 10.1158/0008-5472.CAN-04-3903; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200	26	38	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					23725	23732		10.1074/jbc.M604372200	http://dx.doi.org/10.1074/jbc.M604372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16769721	hybrid, Green Published			2022-12-25	WOS:000239702900047
J	Ren, XY; Nicoll, DA; Philipson, KD				Ren, Xiaoyan; Nicoll, Debora A.; Philipson, Kenneth D.			Helix packing of the cardiac Na+-Ca2+ exchanger - Proximity of transmembrane segments 1, 2, and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA/CA-K EXCHANGER; NA+/CA2+ EXCHANGER; PURIFICATION; EXPRESSION; MECHANISM; TOPOLOGY; CHANNELS; REPEATS	The cardiac Na+-Ca2+ exchanger (NCX1) is a membrane protein that extrudes Ca2+ from cells using the energy of the Na+ gradient and is a key protein in regulating intracellular Ca2+ and contractility. Based on the current topological model, NCX1 consists of nine transmembrane segments (TMSs). The N-terminal five TMSs are separated from the C-terminal four TMSs by a large intracellular loop. Cysteine 768 is modeled to be in TMS 6 close to the intracellular surface. In this study, the proximity of TMS 6 to TMSs 1 and 2 was examined. Insect High Five cells were transfected with cDNAs encoding mutant NCX1 proteins. Each mutant contained cysteine 768 and an introduced cysteine in TMS 1 or 2. Cross-linking between cysteines was determined after reaction with thiol-specific cross-linkers containing spacer arms of 6.5-12 angstrom. The data indicate that residues in TMSs 1 and 2 are close to cysteine 768 in TMS 6. Cysteine 768 cross-linked with residues at both ends of TMSs 1 and 2 and is likely located toward the middle of TMS 6. Based on these results, we present an expanded helix-packing model for NCX1.	Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Cardiovasc Res Lab, MRL 3-645, Los Angeles, CA 90095 USA.	KPhilipson@mednet.ucla.edu			NHLBI NIH HHS [HL-49101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bers D. M., 2001, EXCITATION CONTRACTI, V2nd, P133, DOI [10.1007/978-94-010-0658-3_6, DOI 10.1007/978-94-010-0658-3_6]; Bowie JU, 1997, J MOL BIOL, V272, P780, DOI 10.1006/jmbi.1997.1279; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; GIMPL G, 1995, BIOCHEMISTRY-US, V34, P13794, DOI 10.1021/bi00042a010; Grottesi A, 2005, BIOCHEMISTRY-US, V44, P14586, DOI 10.1021/bi0510429; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Ottolia M, 2005, J BIOL CHEM, V280, P1061, DOI 10.1074/jbc.M411899200; Philipson KD, 2002, ANN NY ACAD SCI, V976, P1; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; VEMURI R, 1989, J BIOL CHEM, V264, P8680; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9; Winkfein RJ, 2003, BIOCHEMISTRY-US, V42, P543, DOI 10.1021/bi026982x; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	23	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22808	22814		10.1074/jbc.M604753200	http://dx.doi.org/10.1074/jbc.M604753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16785232	hybrid			2022-12-25	WOS:000239542600042
J	Sheckler, LR; Henry, L; Sugita, S; Sudhof, TC; Rudenko, G				Sheckler, Lauren R.; Henry, Lisa; Sugita, Shuzo; Sudhof, Thomas C.; Rudenko, Gabby			Crystal structure of the second LNS/LG domain from neurexin 1 alpha - Ca2+ binding and the effects of alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-NEUREXINS; CELL-ADHESION; SYNAPSE FORMATION; DIFFRACTION DATA; DYSTROGLYCAN; BETA; LATROTOXIN; RECEPTOR; HEPARIN; LIGAND	Neurexins mediate protein interactions at the synapse, playing an essential role in synaptic function. Extracellular domains of neurexins, and their fragments, bind a distinct profile of different proteins regulated by alternative splicing and Ca2+. The crystal structure of n1 alpha_LNS#2 (the second LNS/LG domain of bovine neurexin 1 alpha) reveals large structural differences compared with n1 alpha_LNS#6 (or n1 beta_LNS), the only other LNS/LG domain for which a structure has been determined. The differences overlap the so-called hyper-variable surface, the putative protein interaction surface that is reshaped as a result of alternative splicing. A Ca2+-binding site is revealed at the center of the hyper-variable surface next to splice insertion sites. Isothermal titration calorimetry indicates that the Ca2+-binding site in n1 alpha_LNS#2 has low affinity (K-d similar to 400 mu M). Ca2+-binding ceases to be measurable when an 8- or 15-residue splice insert is present at the splice site SS#2 indicating that alternative splicing can affect Ca2+-binding sites of neurexin LNS/LG domains. Our studies initiate a framework for the putative protein interaction sites of neurexin LNS/LG domains. This framework is essential to understand how incorporation of alternative splice inserts expands the information from a limited set of neurexin genes to produce a large array of synaptic adhesion molecules with potentially very different synaptic function.	Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75390 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rudenko, G (corresponding author), Univ Michigan, Life Sci Inst, 210 Washtenaw Ave,Rm 3163A, Ann Arbor, MI 48109 USA.	rudenko@umich.edu	Rudenko, Gabrielle (Gabby)/O-7938-2018	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530; Sugita, Shuzo/0000-0002-9182-873X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH077303] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR001646] Funding Source: Medline; NIGMS NIH HHS [DMR0225180] Funding Source: Medline; NIMH NIH HHS [R01 MH077303-02, R01MH077303, R01 MH077303-01, R01 MH077303, R01 MH077303-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boucard AA, 2005, NEURON, V48, P229, DOI 10.1016/j.neuron.2005.08.026; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cantallops I, 2000, CURR BIOL, V10, pR620, DOI 10.1016/S0960-9822(00)00663-1; Cline H, 2005, CURR BIOL, V15, pR203, DOI 10.1016/j.cub.2005.03.010; Cooper A, 2001, BIOPHYS CHEM, V93, P215, DOI 10.1016/S0301-4622(01)00222-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Craig AM, 2006, TRENDS NEUROSCI, V29, P8, DOI 10.1016/j.tins.2005.11.002; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Dean C, 2006, TRENDS NEUROSCI, V29, P21, DOI 10.1016/j.tins.2005.11.003; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Grant SGN, 2006, BIOCHEM SOC T, V34, P59, DOI 10.1042/BST0340059; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Grishkovskaya I, 2000, EMBO J, V19, P504, DOI 10.1093/emboj/19.4.504; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hopf C, 1996, J BIOL CHEM, V271, P5231; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kattenstroth G, 2004, P NATL ACAD SCI USA, V101, P2607, DOI 10.1073/pnas.0308626100; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kummer TT, 2006, CURR OPIN NEUROBIOL, V16, P74, DOI 10.1016/j.conb.2005.12.003; Levi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22-11-04274.2002; Li G, 2005, J NEUROSCI, V25, P10188, DOI 10.1523/JNEUROSCI.3560-05.2005; Littleton JT, 2003, NATURE, V423, P931, DOI 10.1038/423931a; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Missler M, 2003, TRENDS NEUROSCI, V26, P176, DOI 10.1016/S0166-2236(03)00066-3; Missler M, 1998, J BIOL CHEM, V273, P34716, DOI 10.1074/jbc.273.52.34716; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nam CI, 2005, P NATL ACAD SCI USA, V102, P6137, DOI 10.1073/pnas.0502038102; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patzke H, 2000, MOL CELL NEUROSCI, V15, P561, DOI 10.1006/mcne.2000.0853; Petrenko AG, 1996, J NEUROSCI, V16, P4360; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Rowen L, 2002, GENOMICS, V79, P587, DOI 10.1006/geno.2002.6734; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Smith SM, 2004, NEURON, V41, P243, DOI 10.1016/S0896-6273(03)00837-7; Sons MS, 2006, NEUROSCIENCE, V138, P433, DOI 10.1016/j.neuroscience.2005.11.040; Stetefeld J, 2004, STRUCTURE, V12, P503, DOI 10.1016/j.str.2004.02.001; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; Waites CL, 2005, ANNU REV NEUROSCI, V28, P251, DOI 10.1146/annurev.neuro.27.070203.144336; Wizemann H, 2003, J MOL BIOL, V332, P635, DOI 10.1016/S0022-2836(03)00848-9; Zeng ZH, 2006, INT J DEV BIOL, V50, P39, DOI 10.1387/ijdb.052068zz; Zhang WQ, 2005, J NEUROSCI, V25, P4330, DOI 10.1523/JNEUROSCI.0497-05.2005	67	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22896	22905		10.1074/jbc.M603464200	http://dx.doi.org/10.1074/jbc.M603464200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772286	hybrid, Green Accepted			2022-12-25	WOS:000239542600052
J	Sayama, K; Hanakawa, Y; Nagai, H; Shirakata, Y; Dai, XJ; Hirakawa, S; Tokumaru, S; Tohyama, M; Yang, LJ; Sato, S; Shizuo, A; Hashimoto, K				Sayama, Koji; Hanakawa, Yasushi; Nagai, Hiroshi; Shirakata, Yuji; Dai, Xiuju; Hirakawa, Satoshi; Tokumaru, Sho; Tohyama, Mikiko; Yang, Lujun; Sato, Shintaro; Shizuo, Akira; Hashimoto, Koji			Transforming growth factor-beta-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BETA SIGNAL-TRANSDUCTION; INCONTINENTIA PIGMENTI; IMMUNE-RESPONSES; MICE LACKING; TAK1 MAPKKK; KINASE TAK1; IKK-ALPHA; SKIN; TAB1	Transforming growth factor-beta-activated kinase 1 (TAK1) is a member of the mitogen-activated protein ( MAP) kinase family and is an upstream signaling molecule of nuclear factor-kappa B (NF-kappa B). Given that NF-kappa B regulates keratinocyte differentiation and apoptosis, TAK1 may be essential for epidermal functions. To test this, we generated keratinocyte-specific TAK1-deficient mice from Map3k7(flox/flox) mice and K5-Cre mice. The keratinocyte-specific TAK1-deficient mice were macroscopically indistinguishable from their littermates until postnatal day 2 or 3, when the skin started to roughen and wrinkle. This phenotype progressed, and the mice died by postnatal day 7. Histological analysis showed thickening of the epidermis with foci of keratinocyte apoptosis and intra-epidermal micro-abscesses. Immunohistochemical analysis showed that the suprabasal keratinocytes of the TAK1-deficient epidermis expressed keratin 5 and keratin 14, which are normally confined to the basal layer. The expression of keratin 1, keratin 10, and loricrin, which are markers for the suprabasal and late phase differentiation of the epidermis, was absent from the TAK1-deficient epidermis. Furthermore, the TAK1-deficient epidermis expressed keratin 16 and had an increased number of Ki67-positive cells. These data indicate that TAK1 deficiency in keratinocytes results in abnormal differentiation, increased proliferation, and apoptosis in the epidermis. However, the keratinocytes from the TAK1-deficient epidermis induced keratin 1 in suspension culture, indicating that the TAK1-deficient keratinocytes retain the ability to differentiate. Moreover, the removal of TAK1 from cultured keratinocytes of Map3k7(flox/flox) mice resulted in apoptosis, indicating that TAK1 is essential for preventing apoptosis. In conclusion, TAK1 is essential in the regulation of keratinocyte growth, differentiation, and apoptosis.	Ehime Univ, Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan; Osaka Univ, Res Inst Micobial Dis, Suita, Osaka 5650871, Japan	Ehime University; Osaka University	Sayama, K (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan.	sayama@m.ehime-u.ac.jp		Sato, Shintaro/0000-0001-5156-3354				Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Hanakawa Y, 2000, J CELL SCI, V113, P1803; Hinata K, 2003, ONCOGENE, V22, P1955, DOI 10.1038/sj.onc.1206198; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Komatsu Y, 2002, MECH DEVELOP, V119, P239, DOI 10.1016/S0925-4773(02)00391-X; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Smahi A, 2000, NATURE, V405, P466; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takeda J, 2000, J DERMATOL SCI, V23, P147, DOI 10.1016/S0923-1811(00)00082-7; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang JY, 2005, J CELL BIOL, V168, P561, DOI 10.1083/jcb.200411060; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904	29	44	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					22013	22020		10.1074/jbc.M601065200	http://dx.doi.org/10.1074/jbc.M601065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16754690	hybrid			2022-12-25	WOS:000239387100048
J	Wang, L; Mukhopadhyay, D; Xu, XL				Wang, Ling; Mukhopadhyay, Debabrata; Xu, Xiaolei			C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis	FASEB JOURNAL			English	Article						NRP-1; VPF/ VEGF; endothelial cells; zebrafish; PDZ-domain	DOMAIN-CONTAINING PROTEIN; GROWTH-FACTOR RECEPTOR-2; VASCULAR DEVELOPMENT; PDZ DOMAINS; WILD-TYPE; ZEBRAFISH; EXPRESSION; GENE; NEUROPILIN; RECOGNITION	Initially, it was thought that there was no intracellular signaling mediated by NRP-1 alone in response to its ligands. However, the emerging data from our group as well as others suggest that the signaling through NRP-1 actually promotes angiogenesis and is mediated through its C-terminal domain and downstream molecules such as phosphoinositide 3-kinase. Hence, understanding the signal transduction pathways mediated by NRP-1 and identification of its downstream molecules are of importance. By using both in vivo zebrafish model and in vitro tissue culture system, we have shown that the C-terminal three amino acids of NRP-1 (SEA-COOH) are required for NRP-1-mediated angiogenesis. Furthermore, knocking down of RGS-GAIP-interacting protein C terminus (GIPC) in zebrafish, which is associated with C-terminal domain of NRP-1, exhibits similar vasculature phenotypes to those from NRP-1 null. Specific and effective silencing of GIPC in vascular endothelium results in inhibition of NRP-1-mediated migration. In both cases as described, PDZ domain of GIPC is responsible for its function. Taken together, our data suggest a novel role of GIPC in angiogenesis and vessel formation and also support our hypothesis that NRP-1 can facilitate downstream signaling to promote angiogenesis through GIPC.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Ctr Canc, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Mukhopadhyay, D (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Gugg 1401A, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu; xu.xiaolei@mayo.edu			NCI NIH HHS [CA-78383] Funding Source: Medline; NHLBI NIH HHS [HL-072178, HL-70567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072178, R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bovenkamp DE, 2004, GENE EXPR PATTERNS, V4, P361, DOI 10.1016/j.modgep.2004.01.014; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Cai HB, 1999, J NEUROSCI, V19, P6519; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Childs S, 2002, DEVELOPMENT, V129, P973; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fouquet B, 1997, DEV BIOL, V183, P37, DOI 10.1006/dbio.1996.8495; Haffter P, 1996, DEVELOPMENT, V123, P1; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liao W, 1997, DEVELOPMENT, V124, P381; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; THISSE C, 1993, DEVELOPMENT, V119, P1203; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yu HH, 2004, GENE EXPR PATTERNS, V4, P371, DOI 10.1016/j.modgep.2004.01.011; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	53	92	99	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2006	20	9					1513	+		10.1096/fj.05-5504fje	http://dx.doi.org/10.1096/fj.05-5504fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RP	16754745				2022-12-25	WOS:000240266000035
J	Borgne, A; Versteege, I; Mahe, M; Studeny, A; Leonce, S; Naime, I; Rodriguez, M; Hickman, JA; Meijer, L; Golsteyn, RM				Borgne, A.; Versteege, I.; Mahe, M.; Studeny, A.; Leonce, S.; Naime, I.; Rodriguez, M.; Hickman, J. A.; Meijer, L.; Golsteyn, R. M.			Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment	ONCOGENE			English	Article						mitotic catastrophe; cyclins; cyclin-dependent kinases; roscovitine; CYC202; seliciclib; camptothecin	DEPENDENT KINASE-ACTIVITIES; DAMAGE-INDUCED APOPTOSIS; CANCER-CELL-LINES; DNA-DAMAGE; HEMATOPOIETIC-CELLS; MITOTIC CATASTROPHE; PROTEIN-KINASES; TUMOR-CELLS; DEATH; PHOSPHORYLATION	We have studied the role of cyclins and cyclin-dependent kinase (CDK) activity in apoptosis induced by camptothecin (CPT). In this model, 22% of the cells stain for annexin-V at 24 h and then proceed to be 93% positive by 72 h. This time window permits the analysis of cyclins in cells that are committed to apoptosis but not yet dead. We provide evidence that cyclin protein levels and then associated kinase levels increase after CPT treatment. Strikingly, cyclin B1 and cyclin E1 proteins are present at the same time in CPT treated HT29 cells. Although cyclin B1 and E1 CDK complexes are activated in CPT treated cells, only the cyclin B1 complex is required for apoptosis since reduction of cyclin B1 by RNAi or roscovitine treatment reduces the number of annexin-V-stained cells. We have detected poorly organized chromosomes and phosphorylated histone H3 epitopes at the time of maximum cyclin B1/CDK kinase activity in CPT-treated cells, which suggests that these cells enter a mitotic catastrophe. Understanding which CDKs are required for apoptosis may allow us to better adapt CDK inhibitors for use as anti-cancer compounds.	Inst Rech Servier, F-78290 Croissy Sur Seine, France; CNRS, Biol Stn, Roscoff, France	Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS)	Golsteyn, RM (corresponding author), Inst Rech Servier, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France.	roy.golsteyn@fr.netgrs.com	MEIJER, Laurent/ABE-7465-2021	, laurent/0000-0003-3511-4916				Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299; Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Borgne Annie, 2003, Prog Cell Cycle Res, V5, P453; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DE LA, 1997, J CELL BIOCHEM, V64, P579; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Golsteyn RM, 2005, CANCER LETT, V217, P129, DOI 10.1016/j.canlet.2004.08.005; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hsu SL, 1999, EXP CELL RES, V252, P332, DOI 10.1006/excr.1999.4625; Hyzy M, 2005, BIOCHEM PHARMACOL, V69, P801, DOI 10.1016/j.bcp.2004.11.028; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Leonce S, 2001, MOL PHARMACOL, V60, P1383, DOI 10.1124/mol.60.6.1383; Li KY, 2003, CANCER RES, V63, P3593; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Maity A, 1996, ONCOGENE, V13, P1647; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; Porter LA, 2000, BLOOD, V95, P2645; Price PM, 2004, AM J PHYSIOL-RENAL, V286, pF378, DOI 10.1152/ajprenal.00192.2003; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Shao RG, 1997, CANCER RES, V57, P4029; Shen Manli, 2002, Zhonghua Zhongliu Zazhi, V24, P215; Shen ML, 2004, CANCER RES, V64, P1607, DOI 10.1158/0008-5472.CAN-03-3321; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shi LF, 1996, J IMMUNOL, V157, P2381; SHIMIZU T, 1995, CANCER RES, V55, P228; Shirvan A, 1998, NEUROCHEM RES, V23, P767, DOI 10.1023/A:1022415611545; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	56	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7361	7372		10.1038/sj.onc.1209718	http://dx.doi.org/10.1038/sj.onc.1209718			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785996				2022-12-25	WOS:000242419100005
J	Smyczynski, C; Roudier, F; Gissot, L; Vaillant, E; Grandjean, O; Morin, H; Masson, T; Bellec, Y; Geelen, D; Faure, JD				Smyczynski, Cybelle; Roudier, Francois; Gissot, Lionel; Vaillant, Emilie; Grandjean, Olivier; Morin, Halima; Masson, Thimote; Bellec, Yannick; Geelen, Danny; Faure, Jean-Denis			The C terminus of the immunophilin PASTICCINO1 is required for plant development and for interaction with a NAC-like transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; RED FLUORESCENT PROTEIN; ARABIDOPSIS-THALIANA; CYTOPLASMIC DYNEIN; GLUCOCORTICOID-RECEPTOR; FK506-BINDING PROTEINS; CELL-PROLIFERATION; MERISTEM FORMATION; GENE FAMILY; FKBP52	PASTICCINO1 (PAS1) is a high molecular weight FK506-binding protein (FKBP) involved in the control of cell proliferation and differentiation during plant development. Mutations in the C-terminal region of PAS1 result in severe developmental defects. We show here that the C-terminal domain of PAS1 controls the subcellular distribution of this protein. We also demonstrated in vitro and in vivo, by Forster resonance energy transfer, that this C-terminal region is required for interaction with FAN (FKBP-associated NAC), a new member of the plant-specific family of NAC transcription factors. PAS1 and FAN are translocated into the nucleus upon auxin treatment in plant seedlings. The nuclear translocation of PAS1 is dependent on the presence of the C terminus of the protein. Finally, we showed that FAN is involved in PAS1-regulated processes because FAN overproduction partly complemented the pas1 phenotype. We suggest that PAS1 regulates the function of this NAC-like transcription factor by controlling its targeting to the nucleus upon plant cell division.	INRA, Inst Jean Pierre Bourgin, Biol Cellulaire Lab, F-78026 Versailles, France; INRA, Inst Jean Pierre Bourgin, Lab Commun Cytol, F-78026 Versailles, France; Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Flanders Institute for Biotechnology (VIB); Ghent University	Faure, JD (corresponding author), INRA, Inst Jean Pierre Bourgin, Biol Cellulaire Lab, Route St Cyr, F-78026 Versailles, France.	faure@versailles.inra.fr						Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Bellec Y, 2002, PLANT J, V32, P713, DOI 10.1046/j.1365-313X.2002.01456.x; Berardini TZ, 2001, SCIENCE, V291, P2405, DOI 10.1126/science.1057144; Breiman A, 2002, TRANSGENIC RES, V11, P321, DOI 10.1023/A:1016331814412; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carol RJ, 2001, PLANT SCI, V161, P527, DOI 10.1016/S0168-9452(01)00437-X; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899; Duval M, 2002, PLANT MOL BIOL, V50, P237, DOI 10.1023/A:1016028530943; Dwivedi RS, 2003, J EXP BOT, V54, P2679, DOI 10.1093/jxb/erg307; Faure JD, 1998, DEVELOPMENT, V125, P909; Fong S, 2003, P NATL ACAD SCI USA, V100, P14253, DOI 10.1073/pnas.2332307100; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Geisler M, 2004, MOL BIOL CELL, V15, P3393, DOI 10.1091/mbc.E03-11-0831; Geisler M, 2003, MOL BIOL CELL, V14, P4238, DOI 10.1091/mbc.E02-10-0698; Goodin MM, 2002, PLANT J, V31, P375, DOI 10.1046/j.1365-313X.2002.01360.x; Harrar Y, 2003, PLANT PHYSIOL, V132, P1217, DOI 10.1104/pp.102.019026; Harrar Y, 2001, TRENDS PLANT SCI, V6, P426, DOI 10.1016/S1360-1385(01)02044-1; Harrell JM, 2002, BIOCHEMISTRY-US, V41, P5581, DOI 10.1021/bi020073q; He ZY, 2004, PLANT PHYSIOL, V134, P1248, DOI 10.1104/pp.103.031005; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Kamphausen T, 2002, PLANT J, V32, P263, DOI 10.1046/j.1365-313X.2002.01420.x; KATO K, 1972, FERMENTATION TECHNOL; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Laufs P, 1998, DEVELOPMENT, V125, P1253; Lehnart SE, 2003, CURR TOP MED CHEM, V3, P1383, DOI 10.2174/1568026033451907; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Ooka H, 2003, DNA RES, V10, P239, DOI 10.1093/dnares/10.6.239; Peeters NM, 2000, J MOL EVOL, V50, P413, DOI 10.1007/s002390010044; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; Reddy RK, 1998, PLANT PHYSIOL, V118, P1395, DOI 10.1104/pp.118.4.1395; Romano PGN, 2004, PLANT PHYSIOL, V134, P1268, DOI 10.1104/pp.103.022160; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Takada S, 2001, DEVELOPMENT, V128, P1127; Vittorioso P, 1998, MOL CELL BIOL, V18, P3034, DOI 10.1128/MCB.18.5.3034; Vroemen CW, 2003, PLANT CELL, V15, P1563, DOI 10.1105/tpc.012203; Weir I, 2004, DEVELOPMENT, V131, P915, DOI 10.1242/dev.00993; Xie Q, 2000, GENE DEV, V14, P3024, DOI 10.1101/gad.852200; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yao DY, 2000, J BIOL CHEM, V275, P13149, DOI 10.1074/jbc.275.17.13149	51	49	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25475	25484		10.1074/jbc.M601815200	http://dx.doi.org/10.1074/jbc.M601815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16803883	hybrid, Green Published			2022-12-25	WOS:000240031300050
J	Doshida, M; Ohmichi, M; Tsutsumi, S; Kawagoe, J; Takahashi, T; Du, BT; Mori-Abe, A; Ohta, T; Saitoh-Sekiguchi, M; Takahashi, K; Kurachi, H				Doshida, Masakazu; Ohmichi, Masahide; Tsutsumi, Seiji; Kawagoe, Jun; Takahashi, Toshifumi; Du, Botao; Mori-Abe, Akiko; Ohta, Tsuyoshi; Saitoh-Sekiguchi, Maki; Takahashi, Kazuhiro; Kurachi, Hirohisa			Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR INJURY RESPONSE; PROTEIN-KINASE CASCADE; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; BREAST-CANCER; AKT CASCADE; PHOSPHORYLATION; ACTIVATION	Vascular endothelial senescence is involved in human atherosclerosis. Telomerase activity is known to be critical in cellular senescence and its level is modulated by regulation of telomerase catalytic subunit ( telomerase reverse transcriptase ( TERT)) at both the transcriptional and post-transcriptional levels. Since the cardioprotective effect of estrogen itself has not been ruled out, we examined that of raloxifene, which has been classified as a selective estrogen receptor modulator, on the proliferation and telomerase activity of human umbilical vein endothelial cells ( HUVECs). Raloxifene, like estrogen, clearly induced the telomerase activity and human TERT ( hTERT) expression via estrogen receptor ( ER) alpha and ER beta. Treatment with raloxifene for 5 days significantly induced cell growth, and either cotreatment with a telomerase inhibitor, 3'-azido-3'-deoxythymidine, or transfection with hTERT-specific small interfering RNA significantly attenuated the raloxifene-induced cell growth. Raloxifene also induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase inhibitor, LY294002, significantly attenuated the raloxifene-induced telomerase activity. In addition, raloxifene induced both the phosphorylation of hTERT and I kappa B. Moreover, cotreatment with an I kappa B alpha phosphorylation inhibitor, BAY-11-7082, or a specific NF kappa B nuclear translocation inhibitor, SN50, significantly attenuated the raloxifene-induced telomerase activity and the association of NF kappa B with hTERT. These results show that raloxifene induced the up-regulation of telomerase activity not only by the transcriptional regulation of hTERT but also by post-translational regulation of the phosphorylation of Akt and hTERT and the association of hTERT with NF kappa B in HUVECs. Thus, the up-regulation of telomerase activity in vascular endothelial cells might be one mechanism contributing to the potential atheroprotective effect of raloxifene.	Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan	Yamagata University; Osaka University	Ohmichi, M (corresponding author), Yamagata Univ, Sch Med, Dept Obstet & Gynecol, 2-2-2 Lidanishi, Yamagata 9909585, Japan.	masa@gyne.med.osaka-u.ac.jp	Takahashi, Toshifumi/AAU-1848-2020; Takahashi, Toshifumi/AAN-2416-2020	Takahashi, Toshifumi/0000-0003-0955-4248				Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Buys CHCM, 2000, NEW ENGL J MED, V342, P1282, DOI 10.1056/NEJM200004273421710; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Du BT, 2004, J ENDOCRINOL, V183, P605, DOI 10.1677/joe.1.05775; Evans MJ, 2002, ENDOCRINOLOGY, V143, P3785, DOI 10.1210/en.2002-220356; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Karas RH, 1999, P NATL ACAD SCI USA, V96, P15133, DOI 10.1073/pnas.96.26.15133; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kimura A, 2004, ONCOGENE, V23, P4505, DOI 10.1038/sj.onc.1207582; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kurz DJ, 2003, ARTERIOSCL THROM VAS, V23, P748, DOI 10.1161/01.ATV.0000069624.55424.61; Kyo S, 1999, CANCER RES, V59, P5917; Liu JG, 2002, HORM RES, V58, P16, DOI 10.1159/000063211; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Miller VM, 1999, CIRC RES, V85, P979; Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; Mori-Abe A, 2003, J ENDOCRINOL, V178, P417, DOI 10.1677/joe.0.1780417; Oishi A, 2004, BIOCHEM BIOPH RES CO, V324, P193, DOI 10.1016/j.bbrc.2004.09.032; ORSHAL IM, 2004, AM J PHYSIOL, V286, pR233; Ozes ON, 1999, NATURE, V401, P82; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STRAHL C, 1994, NUCLEIC ACIDS RES, V22, P893, DOI 10.1093/nar/22.6.893; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; Takahashi K, 2003, J ENDOCRINOL, V178, P319, DOI 10.1677/joe.0.1780319; Vasa M, 2000, CIRC RES, V87, P540, DOI 10.1161/01.RES.87.7.540; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Williams MRI, 2004, J CLIN ENDOCR METAB, V89, P4708, DOI 10.1210/jc.2003-031560; Xiao XM, 1999, J PEDIATR SURG, V34, P1603, DOI 10.1016/S0022-3468(99)90625-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yegorov YE, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1296	48	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24270	24278		10.1074/jbc.M513251200	http://dx.doi.org/10.1074/jbc.M513251200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16798746	hybrid			2022-12-25	WOS:000239847800020
J	Wojciechowska, M; Napierala, M; Larson, JE; Wells, RD				Wojciechowska, Marzena; Napierala, Marek; Larson, Jacquelynn E.; Wells, Robert D.			Non-B DNA conformations formed by long repeating tracts of myotonic dystrophy type 1, myotonic dystrophy type 2, and Friedreich's ataxia genes, not the sequences per se, promote mutagenesis in flanking regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; REPLICATION IN-VIVO; ESCHERICHIA-COLI; TRIPLET REPEATS; TRINUCLEOTIDE REPEATS; FORMING SEQUENCES; NEUROLOGICAL DISEASES; DYNAMIC MUTATIONS; MAMMALIAN-CELLS; GROSS DELETIONS	The expansions of long repeating tracts of CTG(.)CAG, CCTG(.)CAGG, and GAA(.)TTC are integral to the etiology of myotonic dystrophy type 1 (DM1), myotonic dystrophy type 2 (DM2), and Friedreich's ataxia ( FRDA). Essentially all studies on the molecular mechanisms of this expansion process invoke an important role for non-B DNA conformations which may be adopted by these repeat sequences. We have directly evaluated the role(s) of the repeating sequences per se, or of the non-B DNA conformations formed by these sequences, in the mutagenic process. Studies in Escherichia coli and three types of mammalian (COS-7, CV-1, and HEK-293) fibroblast-like cells revealed that conditions which promoted the formation of the non-B DNA structures enhanced the genetic instabilities, both within the repeat sequences and in the flanking sequences of up to similar to 4 kbp. The three strategies utilized included: the in vivo modulation of global negative supercoil density using topA and gyrB mutant E. coli strains; the in vivo cleavage of hairpin loops, which are an obligate consequence of slipped-strand structures, cruciforms, and intramolecular triplexes, by inactivation of the SbcC protein; and by genetic instability studies with plasmids containing long repeating sequence inserts that do, and do not, adopt non-B DNA structures in vitro. Hence, non-B DNA conformations are critical for these mutagenesis mechanisms.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Syst Hlth Sci Ctr, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Syst Hlth Sci Ctr, Houston, TX 77030 USA.	rwells@ibt.tamhsc.edu	wojciechowska, marzena/H-4900-2014		NIEHS NIH HHS [ES11347] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 2004, J BIOL CHEM, V279, P47411, DOI 10.1074/jbc.R400028200; Bacolla A, 2004, P NATL ACAD SCI USA, V101, P14162, DOI 10.1073/pnas.0405974101; Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Bacolla A, 2006, NUCLEIC ACIDS RES, V34, P2663, DOI 10.1093/nar/gkl354; Blaszak RT, 1999, NUCLEIC ACIDS RES, V27, P2610, DOI 10.1093/nar/27.13.2610; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; Bzymek M, 2001, P NATL ACAD SCI USA, V98, P8319, DOI 10.1073/pnas.111008398; Connelly JC, 1999, NUCLEIC ACIDS RES, V27, P1039, DOI 10.1093/nar/27.4.1039; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Dere R, 2004, J BIOL CHEM, V279, P41715, DOI 10.1074/jbc.M406415200; Edamura KN, 2005, HUM GENET, V118, P301, DOI 10.1007/s00439-005-0037-5; Fan HX, 2005, AM J MED GENET A, V136A, P214, DOI 10.1002/ajmg.a.30807; FEIGON J, 1985, SCIENCE, V230, P82, DOI 10.1126/science.4035359; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Marcadier JL, 2003, J BIOL CHEM, V278, P33848, DOI 10.1074/jbc.M304284200; Meservy JL, 2003, MOL CELL BIOL, V23, P3152, DOI 10.1128/MCB.23.9.3152-3162.2003; Mirkin EV, 2005, MOL CELL BIOL, V25, P888, DOI 10.1128/MCB.25.3.888-895.2005; Mochmann LH, 2004, NUCLEIC ACIDS RES, V32, P4469, DOI 10.1093/nar/gkh787; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Napierala M, 2005, J BIOL CHEM, V280, P37366, DOI 10.1074/jbc.M508065200; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Oussatcheva EA, 2001, J BIOL CHEM, V276, P30878, DOI 10.1074/jbc.M104697200; Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SCHROTH GP, 1995, NUCLEIC ACIDS RES, V23, P1977, DOI 10.1093/nar/23.11.1977; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; Sinden RR, 1998, ADV GENOM B, V5, P1; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; Sinden RR, 1999, AM J HUM GENET, V64, P346, DOI 10.1086/302271; Sobczak K, 2003, NUCLEIC ACIDS RES, V31, P5469, DOI 10.1093/nar/gkg766; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Van Raay T J, 1996, Microb Comp Genomics, V1, P317; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; WANG G, 2006, IN PRESS MUTAT RES; Wang GL, 2006, P NATL ACAD SCI USA, V103, P2677, DOI 10.1073/pnas.0511084103; Wang GL, 2004, P NATL ACAD SCI USA, V101, P13448, DOI 10.1073/pnas.0405116101; Wells R.D., 1998, GENETIC INSTABILITIE; Wells R.D., 2006, GENETIC INSTABILITIE; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Wells RD, 2005, NUCLEIC ACIDS RES, V33, P3785, DOI 10.1093/nar/gki697; Wojciechowska M, 2005, J BIOL CHEM, V280, P941, DOI 10.1074/jbc.M410427200; Yang Z, 2003, AM J HUM GENET, V73, P1092, DOI 10.1086/379523	54	24	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2006	281	34					24531	24543		10.1074/jbc.M603888200	http://dx.doi.org/10.1074/jbc.M603888200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	074YF	16793772	hybrid			2022-12-25	WOS:000239847800049
J	Christen, S; Srinivas, A; Bahler, P; Zeller, A; Pridmore, D; Bieniossek, C; Baumann, U; Erni, B				Christen, Sandra; Srinivas, Annapurna; Baehler, Priska; Zeller, Anja; Pridmore, David; Bieniossek, Christoph; Baumann, Ulrich; Erni, Bernhard			Regulation of the Dha operon of Lactococcus lactis - A deviation from the rule followed by the TetR family of transcription regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DIHYDROXYACETONE KINASE; COVALENT SUBSTRATE-BINDING; ESCHERICHIA-COLI; STRUCTURAL BASIS; PROTEIN; ATP; REFINEMENT; EXPRESSION; QACR; PHOSPHOENOLPYRUVATE	Dihydroxyacetone (Dha) kinases are a novel family of kinases with signaling and metabolic functions. Here we report the x-ray structures of the transcriptional activator DhaS and the coactivator DhaQ and characterize their function. DhaQ is a paralog of the Dha binding Dha kinase subunit; DhaS belongs to the family of TetR repressors although, unlike all known members of this family, it is a transcriptional activator. DhaQ and DhaS form a stable complex that in the presence of Dha activates transcription of the Lactococcus lactis dha operon. Dha covalently binds to DhaQ through a hemiaminal bond with a histidine and thereby induces a conformational change, which is propagated to the surface via a cantilever-like structure. DhaS binding protects an inverted repeat whose sequence is GGACACATN(6)ATTTGTCC and renders two GC base pairs of the operator DNA hypersensitive to DNase I cleavage. The proximal half-site of the inverted repeat partially overlaps with the predicted -35 consensus sequence of the dha promoter.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland	University of Bern; Nestle SA	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch; erni@ibc.unibe.ch	Baumann, Ulrich/B-1220-2013					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Bachler C, 2005, J BIOL CHEM, V280, P18321, DOI 10.1074/jbc.M500279200; Bachler C, 2005, EMBO J, V24, P283, DOI 10.1038/sj.emboj.7600517; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIMARCO AA, 1994, J BACTERIOL, V176, P4277, DOI 10.1128/jb.176.14.4277-4284.1994; Erni B, 2006, CELL MOL LIFE SCI, V63, P890, DOI 10.1007/s00018-005-5518-0; Garcia-Alles LF, 2004, BIOCHEMISTRY-US, V43, P13037, DOI 10.1021/bi048575m; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gralla JD, 1996, ESCHERICHIA COLI SAL, P1232; Griffith KL, 2002, BIOCHEM BIOPH RES CO, V290, P397, DOI 10.1006/bbrc.2001.6152; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Gutknecht R, 2001, EMBO J, V20, P2480, DOI 10.1093/emboj/20.10.2480; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miller JH., 1992, SHORT COURSE BACTERI, P72; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nunn RS, 1996, J MOL BIOL, V259, P502, DOI 10.1006/jmbi.1996.0335; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Siebold C, 2003, J BIOL CHEM, V278, P48236, DOI 10.1074/jbc.M305942200; Siebold C, 2003, P NATL ACAD SCI USA, V100, P8188, DOI 10.1073/pnas.0932787100; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3	33	34	39	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23129	23137		10.1074/jbc.M603486200	http://dx.doi.org/10.1074/jbc.M603486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16760471	hybrid, Green Published			2022-12-25	WOS:000239542600077
J	Liu, F; Arce, FT; Ramachandran, S; Lal, R				Liu, Fei; Arce, Fernando Teran; Ramachandran, Srinivasan; Lal, Ratnesh			Nanomechanics of hemichannel conformations - Connexin flexibility underlying channel opening and closing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; SINGLE-MOLECULE; FORCE SPECTROSCOPY; MIMETIC PEPTIDES; CALCIUM; BINDING; RECOGNITION; ELASTICITY; INHIBITORS; MEMBRANES	Gap junctional hemichannels mediate cell-extracellular communication. A hemichannel is made of six connexin (Cx) sub-units; each connexin has four transmembrane domains, two extracellular loops, and cytoplasmic amino- and carboxyl-terminals (CTs). The extracellular domains are arranged differently at non-junctional and junctional (gap junction) regions, although very little is known about their flexibility and conformational energetics. The cytoplasmic tail differs considerably in the size and amino acid sequence for different connexins and is predicted to be involved in the channel open and closed conformations. For large connexins, such as Cx43, the CT makes large cytoplasmic fuzz visible under electron microscopy. If this CT domain controls channel permeability by physical occlusion of the pore mouth, movement of this portion could open or close the channel. We used atomic force microscopy-based single molecule spectroscopy with antibody-modified atomic force microscopy tips and connexin mimetic peptide modified tips to examine the flexibility of extracellular loop and CT domains and to estimate the energetics of their movements. Antibody to the CT portion closer to the membrane stretches the tail to a shorter length, and the antibody to CT tail stretches the tail to a longer length. The stretch length and the energy required for stretching the various portions of the carboxyl tail support the ball and chain model for hemichannel conformational changes.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, 5126 BioSci 2 Bldg, Santa Barbara, CA 93106 USA.	lal@lifesci.ucsb.edu	Ramachandran, Srinivasan/G-5300-2010; Teran Arce, Fernando/I-7835-2018; Lal, Ratnesh/AAG-5424-2019	Ramachandran, Srinivasan/0000-0002-6155-4002; Teran Arce, Fernando/0000-0002-6518-8695; 				Almqvist N, 2004, BIOPHYS J, V86, P1753, DOI 10.1016/S0006-3495(04)74243-5; Arce FT, 2004, BIOPHYS J, V87, P4284, DOI 10.1529/biophysj.104.043307; Avci R, 2004, LANGMUIR, V20, P11053, DOI 10.1021/la036376i; Bao XY, 2005, J BIOL CHEM, V280, P8647, DOI 10.1074/jbc.M413536200; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; Berthoud VM, 2000, AM J PHYSIOL-LUNG C, V279, pL619, DOI 10.1152/ajplung.2000.279.4.L619; BEYER EC, 1991, J BIOL CHEM, V266, P7971; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Boitano S, 2000, AM J PHYSIOL-LUNG C, V279, pL623, DOI 10.1152/ajplung.2000.279.4.L623; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1; Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P99, DOI 10.1111/j.1469-7793.1997.099bi.x; Chaytor AT, 1999, J PHYSIOL-LONDON, V520, P539, DOI 10.1111/j.1469-7793.1999.00539.x; CLEVELAND JP, 1993, REV SCI INSTRUM, V64, P403, DOI 10.1063/1.1144209; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DAHL G, 1994, BIOPHYS J, V67, P1816, DOI 10.1016/S0006-3495(94)80663-0; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Delmar M, 2004, CARDIOVASC RES, V62, P268, DOI 10.1016/j.cardiores.2003.12.030; DELMAR M, 2000, MOL BASIS CELL COMMU, P22; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; Evans WH, 2001, BIOCHEM SOC T, V29, P606, DOI 10.1042/BST0290606; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; Gomez-Hernandez JM, 2003, P NATL ACAD SCI USA, V100, P16030, DOI 10.1073/pnas.2530348100; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Hinterdorfer P, 2002, METHOD CELL BIOL, V68, P115; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Horton M, 2002, J RECEPT SIGNAL TR R, V22, P169, DOI 10.1081/RRS-120014594; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970; Jiang JX, 2005, BBA-BIOMEMBRANES, V1711, P208, DOI 10.1016/j.bbamem.2004.10.001; Kessler M, 2006, STRUCTURE, V14, P521, DOI 10.1016/j.str.2005.11.023; Kienberger F, 2005, J MOL BIOL, V347, P597, DOI 10.1016/j.jmb.2005.01.042; Kienberger F, 2004, EMBO REP, V5, P579, DOI 10.1038/sj.embor.7400149; Kreuzer HJ, 1999, NEW J PHYS, V1, DOI 10.1088/1367-2630/1/1/321; Kufer SK, 2005, EUR BIOPHYS J BIOPHY, V35, P72, DOI 10.1007/s00249-005-0010-1; KUMAR NM, 1995, J CELL SCI, V108, P3725; LAIRD DW, 1990, J CELL SCI, V97, P109; LAL R, 1995, AM J PHYSIOL-CELL PH, V268, pC968, DOI 10.1152/ajpcell.1995.268.4.C968; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Marszalek PE, 1998, NATURE, V396, P661, DOI 10.1038/25322; Martin PEM, 2000, BIOCHEM J, V349, P281, DOI 10.1042/0264-6021:3490281; Mou JX, 1996, BIOCHEMISTRY-US, V35, P3222, DOI 10.1021/bi9520242; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Oesterhelt F, 1999, NEW J PHYS, V1, DOI 10.1088/1367-2630/1/1/006; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; Riener CK, 2003, ANAL CHIM ACTA, V479, P59, DOI 10.1016/S0003-2670(02)01373-9; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Sorgen PL, 2004, J BIOL CHEM, V279, P54695, DOI 10.1074/jbc.M409552200; Sorgen PL, 2002, J BIOMOL NMR, V23, P245, DOI 10.1023/A:1019892719979; Sosinsky GE, 2005, BBA-BIOMEMBRANES, V1711, P99, DOI 10.1016/j.bbamem.2005.04.001; Srinivas M, 2006, J GEN PHYSIOL, V127, P67, DOI 10.1085/jgp.200509397; Srinivas M, 2005, BIOPHYS J, V88, P1725, DOI 10.1529/biophysj.104.054023; Sulchek TA, 2005, P NATL ACAD SCI USA, V102, P16638, DOI 10.1073/pnas.0505208102; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Tortonese M, 1997, P SOC PHOTO-OPT INS, V3009, P53, DOI 10.1117/12.271229; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241	69	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23207	23217		10.1074/jbc.M605048200	http://dx.doi.org/10.1074/jbc.M605048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16769719	hybrid			2022-12-25	WOS:000239542600083
J	Radichev, I; Kwon, SW; Zhao, YM; DePamphilis, ML; Vassilev, A				Radichev, Ilian; Kwon, Sung Won; Zhao, Yingming; DePamphilis, Melvin L.; Vassilev, Alex			Genetic analysis of human ORC2 reveals specific domains that are required in vivo for assembly and nuclear localization of the origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; DNA-REPLICATION; CELL-CYCLE; MAMMALIAN-CELLS; CHROMATIN ASSOCIATION; PROTEINS; INITIATION; BINDING; SUBUNITS; CDC6	Eukaryotic DNA replication begins with the binding of a six subunit origin recognition complex (ORC) to DNA. To study the assembly and function of mammalian ORC proteins in their native environment, HeLa cells were constructed that constitutively expressed an epitope-tagged, recombinant human Orc2 subunit that had been genetically altered. Analysis of these cell lines revealed that Orc2 contains a single ORC assembly domain that is required in vivo for interaction with all other ORC subunits, as well as two nuclear localization signals (NLSs) that are required for ORC accumulation in the nucleus. The recombinant Orc2 existed in the nucleus either as an ORC-(2-5) or ORC-(1-5) complex; no other combinations of ORC subunits were detected. Moreover, only ORC-(1-5) was bound to the chromatin fraction, suggesting that Orc1 is required in vivo to load ORC-(2-5) onto chromatin. Surprisingly, recombinant Orc2 suppressed expression of endogenous Orc2, revealing that mammalian cells limit the intracellular level of Orc2, and thereby limit the amount of ORC-(2-5) in the nucleus. Because this suppression required only the ORC assembly and NLS domains, these domains appear to constitute the functional domain of Orc2.	NICHD, Natl Inst Hlth, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Vassilev, A (corresponding author), NICHD, Natl Inst Hlth, Bldg 6-3A-02,9000 Rockville Pike, Bethesda, MD 20892 USA.	vassilev@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000506] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000506] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdurashidova G, 2003, EMBO J, V22, P4294, DOI 10.1093/emboj/cdg404; Chesnokov I, 2001, P NATL ACAD SCI USA, V98, P11997, DOI 10.1073/pnas.211342798; DePamphilis ML, 2005, CELL CYCLE, V4, P70, DOI 10.4161/cc.4.1.1333; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Iyer Lakshminarayan M., 2006, V47, P751; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Kong DC, 2001, MOL CELL BIOL, V21, P8095, DOI 10.1128/MCB.21.23.8095-8103.2001; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; McNairn AJ, 2005, J CELL BIOCHEM, V96, P879, DOI 10.1002/jcb.20609; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Ohta S, 2003, J BIOL CHEM, V278, P41535, DOI 10.1074/jbc.M307535200; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Ranjan A, 2006, P NATL ACAD SCI USA, V103, P4864, DOI 10.1073/pnas.0510305103; Ritzi M, 2003, J CELL SCI, V116, P3971, DOI 10.1242/jcs.00708; Saha T, 2006, J CELL SCI, V119, P1371, DOI 10.1242/jcs.02851; Saitoh Y, 2002, NUCLEIC ACIDS RES, V30, P5205, DOI 10.1093/nar/gkf642; Takeda DY, 2005, GENE DEV, V19, P2827, DOI 10.1101/gad.1369805; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Zhou G, 2005, PROTEOMICS, V5, P3814, DOI 10.1002/pmic.200401230	31	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					23264	23273		10.1074/jbc.M603873200	http://dx.doi.org/10.1074/jbc.M603873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16762929	hybrid			2022-12-25	WOS:000239542600089
J	Motzkus, D; Schulz-Maronde, S; Heitland, A; Schulz, A; Forssmann, WG; Jubner, M; Maronde, E				Motzkus, Dirk; Schulz-Maronde, Sandra; Heitland, Aleksandra; Schulz, Axel; Forssmann, Wolf-Georg; Juebner, Martin; Maronde, Erik			The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo	FASEB JOURNAL			English	Article						antimicrobial peptide; LAL-assay; RAW264.7; TNF-alpha; murine sepsis model	HUMAN AIRWAY EPITHELIA; TUMOR-NECROSIS-FACTOR; ANTIMICROBIAL PEPTIDES; BINDING-PROTEIN; ANTIBACTERIAL PEPTIDES; HUMAN BETA-DEFENSIN-3; CATHELICIDIN FAMILY; CATIONIC PEPTIDE; EXPRESSION; CELLS	Defensins are a family of secreted antimicrobial peptides proposed to directly interfere with bacterial membranes. Here we show a functional analysis of the novel beta-defensin DEFB123. A peptide comprising the beta-defensin core region was synthesized and used for our analysis. Like other beta-defensins, DEFB123 exerted antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, which was assessed by microbroth dilution assay and radial diffusion zone assay. In addition, the peptide showed lipopolysaccharide (LPS)-binding activity in a Limulus amoebocyte lysate (LAL) assay. Moreover, DEFB123 prevented LPS-induced tumor necrosis factor (TNF)alpha secretion in a murine monocyte cell line (RAW264.7). Accordingly, DEFB123 abolished LPS-mediated MAPK induction in these cells. Protection against LPS-mediated effects was then investigated in a murine model of acute sepsis. Our experiments show that synthetic beta-defensin DEFB123 prevents LPS-induced mortality in C57BL/ 6 mice in a therapeutic approach. We propose that the physiological role of beta-defensins may include interference with LPS-action on macrophages, a function formerly thought to be restricted to the family of cathelicidins, a structurally unrelated group of antimicrobial peptides. -Motzkus, D., Schulz-Maronde, S., Heitland, A., Schulz, A., Forssmann, W.-G., Jubner, M., and Maronde, E. The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo.	IPF PharmaCeut, Hannover, Germany		Maronde, E (corresponding author), Goethe Univ Frankfurt, Inst Anat 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	e.maronde@em.uni-frankfurt.de	Maronde, Erik/J-1915-2019	Maronde, Erik/0000-0002-5574-6323				Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Ciornei CD, 2005, ANTIMICROB AGENTS CH, V49, P2845, DOI 10.1128/AAC.49.7.2845-2850.2005; Davidson DJ, 2004, J IMMUNOL, V172, P1146, DOI 10.4049/jimmunol.172.2.1146; Frolich O, 2001, BIOL REPROD, V64, P1072, DOI 10.1095/biolreprod64.4.1072; Garcia JRC, 2001, CELL TISSUE RES, V306, P257, DOI 10.1007/s004410100433; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Jerala R, 2004, CURR TOP MED CHEM, V4, P1173, DOI 10.2174/1568026043388079; Jia HP, 2001, GENE, V263, P211; Krause A, 2003, PROTEIN SCI, V12, P143, DOI 10.1110/ps.0213603; Krisanaprakornkit S, 2000, INFECT IMMUN, V68, P2907, DOI 10.1128/IAI.68.5.2907-2915.2000; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Maronde E, 1999, J NEUROSCI, V19, P3326; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Mignon A, 1999, AM J RESP CRIT CARE, V159, P1308, DOI 10.1164/ajrccm.159.4.9712012; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; Nagaoka I, 2002, CLIN DIAGN LAB IMMUN, V9, P972, DOI 10.1128/CDLI.9.5.972-982.2002; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; *NAT COMM CLIN LAB, 2000, M2A7 NAT COMM CLIN L; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x; OSTERHOFF C, 1994, BIOL REPROD, V50, P516, DOI 10.1095/biolreprod50.3.516; PIERS KL, 1994, ANTIMICROB AGENTS CH, V38, P2311, DOI 10.1128/AAC.38.10.2311; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Rodriguez-Jimenez FJ, 2003, GENOMICS, V81, P175, DOI 10.1016/S0888-7543(02)00034-4; Ryan LK, 2003, PEPTIDES, V24, P1785, DOI 10.1016/j.peptides.2003.09.021; Schultz J, 2005, STRENGTH COND J, V27, P28; Schulz A, 2005, BIOPOLYMERS, V80, P34, DOI 10.1002/bip.20193; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Scott MG, 1999, INFECT IMMUN, V67, P6445; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; Tan NS, 2000, FASEB J, V14, P1801, DOI 10.1096/fj.99-0866com; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Wain HM, 2004, NUCLEIC ACIDS RES, V32, pD255, DOI 10.1093/nar/gkh072; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yenugu S, 2004, ENDOCRINOLOGY, V145, P3165, DOI 10.1210/en.2003-1698; Yenugu S, 2003, BIOCHEM J, V372, P473, DOI 10.1042/BJ20020225; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4; Zhou CX, 2004, NAT CELL BIOL, V6, P458, DOI 10.1038/ncb1127	55	66	75	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1701	+		10.1096/fj.05-4970fje	http://dx.doi.org/10.1096/fj.05-4970fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16790530				2022-12-25	WOS:000240266600020
J	Tentori, L; Leonetti, C; Scarsella, M; Muzi, A; Mazzon, E; Vergati, M; Forini, O; Lapidus, R; Xu, WZ; Dorio, AS; Zhang, J; Cuzzocrea, S; Graziani, G				Tentori, Lucio; Leonetti, Carlo; Scarsella, Marco; Muzi, Alessia; Mazzon, Emanuela; Vergati, Matteo; Forini, Olindo; Lapidus, Rena; Xu, Weizheng; Dorio, Annalisa Susanna; Zhang, Jie; Cuzzocrea, Salvatore; Graziani, Grazia			Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma	FASEB JOURNAL			English	Article						chemotherapy; cancer; diarrhea; mucositis	PHASE-I TRIAL; CANCER RESISTANCE PROTEIN; NITRO-N-NITROSOGUANIDINE; MISMATCH REPAIR SYSTEM; BASE EXCISION-REPAIR; COLORECTAL-CANCER; TOPOISOMERASE-I; MICROSATELLITE INSTABILITY; ANTITUMOR-ACTIVITY; MALIGNANT GLIOMA	Poly(ADP-ribose) polymerase ( PARP) inhibitors enhance the antitumor activity of the topoisomerase I inhibitor irinotecan (CPT-11), which is used to treat advanced colorectal carcinoma. Since PARP inhibitors sensitize tumor cells also to the methylating agent temozolomide (TMZ) and clinical trials are evaluating CPT-11 in combination with TMZ, we tested whether the PARP inhibitor GPI 15427 (10-(4-methyl-piperazin-1-ylmethyl)-2H- 7-oxa-1,2-diaza-benzo[de]anthracen-3-one) increases the efficacy of CPT-11 + TMZ against colon cancer. Moreover, due to the ability of PARP inhibitors to avoid cell death consequent to PARP-1 overactivation, we evaluated whether oral administration of GPI 15427 provides protection from the dose-limiting intestinal toxicity of CPT-11. The results of colony formation assay indicated that GPI 15427 increased the antiproliferative effects (combination index < 1) of TMZ + SN-38 (the active metabolite of CPT-11) against colon cancer cells. Accordingly, GPI 15427 (40 mg/kg/day x 5 days per os) in combination with TMZ (10 mg/kg/day x 5 days) + CPT-11 (4 mg/kg/day x 5 days) significantly reduced the growth of tumor xenografts. Oral administration of GPI 15427 (40 mg/kg/ q2 x 3 days) prevented intestinal injury and diarrhea induced by CPT-11 (30 mg/kg/day + 3 days) reducing inflammation and PARP-1 overactivation, as evidenced by immunohistochemical staining of intestinal tissue with antipoly(ADP-ribose) antibody ( Ab). In conclusion, the PARP inhibitor represents a novel strategy to enhance the antitumor efficacy and reduce toxicity of chemotherapy in colon cancer.	Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Inst Canc Res Regina Elena, Expt Clin Lab, Rome, Italy; Univ Messina, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; IRCCS, Ctr Neurol Bonino Pulejo, Messina, Italy; MGI Pharma, Baltimore, MD USA	University of Rome Tor Vergata; University of Messina; IRCCS Bonino Pulejo	Graziani, G (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Montpellier 1, I-00133 Rome, Italy.	graziani@uniroma2.it	Leonetti, Carlo/B-2860-2018; Mazzon, Emanuela/AAL-4334-2020; Graziani, Grazia/G-5747-2012; Scarsella, Marco/AAA-1486-2020	Leonetti, Carlo/0000-0002-3526-7827; Graziani, Grazia/0000-0002-0221-768X; TENTORI, LUCIO/0000-0002-7691-527X; mazzon, emanuela/0000-0002-5073-717X; Muzi, Alessia/0000-0001-6946-3888; Scarsella, Marco/0000-0002-3386-9664				Bakondi E, 2002, J HISTOCHEM CYTOCHEM, V50, P91, DOI 10.1177/002215540205000110; Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Cuzzocrea S, 2005, PHARMACOL RES, V52, P72, DOI 10.1016/j.phrs.2005.02.016; Cuzzocrea S, 2000, FASEB J, V14, P1061, DOI 10.1096/fasebj.14.9.1061; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Fedier A, 2004, INT J ONCOL, V24, P1039; Fittkau M, 2004, J CANCER RES CLIN, V130, P388, DOI 10.1007/s00432-004-0557-8; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GIBSON NW, 1986, CANCER RES, V46, P4995; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Houghton PJ, 2000, CLIN CANCER RES, V6, P4110; Idogawa M, 2005, GASTROENTEROLOGY, V128, P1919, DOI 10.1053/j.gastro.2005.03.007; Jacob S, 2001, CANCER RES, V61, P6555; Jones Suzanne F, 2003, Oncology (Williston Park), V17, P41; KOI M, 1994, CANCER RES, V54, P4308; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; Mazzon E, 2002, BIOCHEM PHARMACOL, V64, P327, DOI 10.1016/S0006-2952(02)01075-4; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Patel VJ, 2000, CLIN CANCER RES, V6, P4154; Pourquier P, 2001, CANCER RES, V61, P53; Quinn JA, 2005, J CLIN ONCOL, V23, P7178, DOI 10.1200/JCO.2005.06.502; Rajendra R, 2003, CANCER RES, V63, P3228; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reardon DA, 2005, CANCER-AM CANCER SOC, V104, P1478, DOI 10.1002/cncr.21316; Roth RB, 2002, CANCER RES, V62, P656; Rowley PT, 2005, ANNU REV MED, V56, P539, DOI 10.1146/annurev.med.56.061704.135235; Saliba F, 1998, J CLIN ONCOL, V16, P2745, DOI 10.1200/JCO.1998.16.8.2745; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Tentori L, 2005, PHARMACOL RES, V52, P25, DOI 10.1016/j.phrs.2005.02.010; Tentori L, 2005, INT J ONCOL, V27, P525; Tentori L, 2005, INT J ONCOL, V26, P415; Tentori L, 2003, CLIN CANCER RES, V9, P5370; Tentori L, 2002, BLOOD, V99, P2241, DOI 10.1182/blood.V99.6.2241; TENTORI L, 2004, MED CHEM REV ONLINE, V1, P144; Trivedi RN, 2005, CANCER RES, V65, P6394, DOI 10.1158/0008-5472.CAN-05-0715; UMAR A, 1994, J BIOL CHEM, V269, P14367; Wagner LM, 2004, CLIN CANCER RES, V10, P840, DOI 10.1158/1078-0432.CCR-03-0175; Wedge SR, 1996, BRIT J CANCER, V73, P482, DOI 10.1038/bjc.1996.85; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200	48	85	90	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2006	20	10					1709	+		10.1096/fj.06-5916fje	http://dx.doi.org/10.1096/fj.06-5916fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16809434				2022-12-25	WOS:000240266600023
J	Malhi, H; Gores, GJ				Malhi, H.; Gores, G. J.			TRAIL resistance results in cancer progression: a TRAIL to perdition?	ONCOGENE			English	Editorial Material						TRAIL; NF-kappa B; meta stasis; invasion; cFLIP; Mcl-1	NF-KAPPA-B; CHOLANGIOCARCINOMA CELLS; INDUCED APOPTOSIS; RECEPTORS; DEATH; LIGAND; INHIBITION; PROTEIN; FLIP	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, APO-2L) is a mediator of cell death that preferentially targets cancer cells. The potential of TRAIL as a chemotherapeutic agent is limited, however, because of the emergence of TRAIL resistance. Furthermore, recent studies have demonstrated that alternative TRAIL signaling is unmasked in TRAIL resistant cells. In these cells, the predominant effect of TRAIL receptor activation is the activation of nuclear factor-kappa B (NF-kappa B), which promotes tumor metastases and invasion. TRAIL resistance can occur at the level of the death inducing signaling complex via upregulation of cFLIP or via an increase in antiapoptotic proteins of the Bcl-2 family. A paradigm emerges from this information, that chemotherapy, targeting NF-kappa B, cFLIP, or antiapoptotic proteins of the Bcl-2 family, in combination with TRAIL maybe more rational than TRAIL therapy alone.	Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; BUDD RC, NAT REV IMMUNOL, V6, P196; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Okano H, 2003, LAB INVEST, V83, P1033, DOI 10.1097/01.LAB.0000079328.76631.28; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; TRAUZOLDK A, 2006, IN PRESS ONCOGENE; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	17	66	71	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7333	7335		10.1038/sj.onc.1209765	http://dx.doi.org/10.1038/sj.onc.1209765			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785986				2022-12-25	WOS:000242419100001
J	Zernichow, L; Abrink, M; Hallgren, J; Grujic, M; Pejler, G; Kolset, SO				Zernichow, Lillian; Abrink, Magnus; Hallgren, Jenny; Grujic, Mirjana; Pejler, Gunnar; Kolset, Svein O.			Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; MOUSE MAST-CELLS; HEPARAN-SULFATE; CORE PROTEIN; TNF-ALPHA; MATRIX METALLOPROTEINASE-2; PERITONEAL-MACROPHAGES; OSTEOSARCOMA CELLS; INDUCED ACTIVATION; HUMAN-MONOCYTES	It has recently been shown that serglycin is essential for maturation of mast cell secretory granules. However, serglycin is expressed also by other cell types, and in this study we addressed the role of serglycin in macrophages. Adherent cells were prepared from murine peritoneal cell populations and from spleens, and analyzed for proteoglycan synthesis by biosynthetic labeling with [S-35] sulfate. Conditioned media from serglycin(-/-) peritoneal macrophages and adherent spleen cells displayed a 65-80% reduction of S-35-labeled proteoglycans, compared with corresponding material from serglycin(+/+) cells, indicating that serglycin is the dominant secretory proteoglycan in macrophages of these origins. In contrast, the levels of intracellular proteoglycans were similar in serglycin(+/+) and serglycin(-/-) cells, suggesting that serglycin is not stored intracellularly to a major extent in macrophages. This is in contrast to mast cells, in which serglycin is predominantly stored intracellularly. Transmission electron microscopy revealed that the absence of serglycin did not cause any major morphological effects on peritoneal macrophages, in contrast to dramatic defects in intracellular storage vesicles in peritoneal mast cells. Several secretory products were not found to be affected by the lack of serglycin. However, the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide stimulation was markedly higher in serglycin(-/-) cultures than in those of serglycin(+/+). The present report thus demonstrates that serglycin is the major proteoglycan secreted by peritoneal macrophages and suggests that the macrophage serglycin may have a role in regulating secretion of tumor necrosis factor-alpha.	Univ Oslo, Inst Basic Med Sci, Dept Nutr, N-0316 Oslo, Norway; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, S-75123 Uppsala, Sweden	University of Oslo; Swedish University of Agricultural Sciences	Kolset, SO (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Nutr, Box 1046 Blindern, N-0316 Oslo, Norway.	s.o.kolset@medisin.uio.no	Hallgren Martinsson, Jenny/AAZ-6356-2021; Åbrink, Magnus/AAK-8346-2020; Hallgren Martinsson, Jenny/AAZ-5937-2021	Hallgren Martinsson, Jenny/0000-0002-3685-5364; Abrink, Magnus/0000-0002-1335-3927				Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Armstrong L, 2006, AM J RESP CELL MOL, V34, P219, DOI 10.1165/rcmb.2005-0087OC; Biederbick A, 2003, EUR J CELL BIOL, V82, P19, DOI 10.1078/0171-9335-00287; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Grujic M, 2005, J BIOL CHEM, V280, P33411, DOI 10.1074/jbc.M501708200; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Henningsson F, 2002, BIOL CHEM, V383, P793, DOI 10.1515/BC.2002.083; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kaartinen M, 1996, CIRCULATION, V94, P2787, DOI 10.1161/01.CIR.94.11.2787; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kolset SO, 1999, CELL MOL LIFE SCI, V56, P857, DOI 10.1007/s000180050031; KOLSET SO, 1988, ACTA HISTOCHEM, V84, P67, DOI 10.1016/S0065-1281(88)80011-4; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; KOLSET SO, 1986, BIOCHEM BIOPH RES CO, V139, P377, DOI 10.1016/S0006-291X(86)80001-8; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; Lemansky P, 2003, J LEUKOCYTE BIOL, V74, P542, DOI 10.1189/jlb.1202616; Loennechen T, 2003, BIOCHEM PHARMACOL, V66, P2341, DOI 10.1016/j.bcp.2003.08.014; Makatsori E, 2003, ANTICANCER RES, V23, P3303; Mathisen B, 2003, CLIN EXP METASTAS, V20, P701, DOI 10.1023/B:CLIN.0000006819.21361.03; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Ohno N, 1998, PROG CLIN BIOL RES, V397, P179; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1994, J BIOL CHEM, V269, P14451; Princivalle M, 2001, GLYCOBIOLOGY, V11, P183, DOI 10.1093/glycob/11.3.183; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; SKUTELSKY E, 1995, HISTOCHEM CELL BIOL, V104, P453, DOI 10.1007/BF01464335; STERK AR, 1982, J IMMUNOL, V128, P838; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; Tufvesson E, 2002, FEBS LETT, V530, P124, DOI 10.1016/S0014-5793(02)03439-7; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; UHLINHANSEN L, 1988, J BIOL CHEM, V263, P2526; UHLINHANSEN L, 1993, BLOOD, V82, P2880; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WARFEL AH, 1986, J IMMUNOL, V137, P651; Winberg JO, 2003, EUR J BIOCHEM, V270, P3996, DOI 10.1046/j.1432-1033.2003.03788.x; Winberg JO, 2000, J MOL BIOL, V304, P669, DOI 10.1006/jmbi.2000.4235; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941; YURT RW, 1977, J BIOL CHEM, V252, P518	54	62	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2006	281	37					26792	26801		10.1074/jbc.M512889200	http://dx.doi.org/10.1074/jbc.M512889200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	082PB	16807245	hybrid			2022-12-25	WOS:000240397700006
J	Kloosterman, TG; Hendriksen, WT; Bijlsma, JJE; Bootsma, HJ; van Hijum, SAFT; Kok, J; Hermans, PWM; Kuipers, OP				Kloosterman, Tomas G.; Hendriksen, Wouter T.; Bijlsma, Jetta J. E.; Bootsma, Hester J.; van Hijum, Sacha A. F. T.; Kok, Jan; Hermans, Peter W. M.; Kuipers, Oscar P.			Regulation of glutamine and glutamate metabolism by GlnR and GlnA in Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED GENE-EXPRESSION; BACILLUS-SUBTILIS; LACTOCOCCUS-LACTIS; NITROGEN-METABOLISM; SYNTHETASE MUTANTS; TNRA; PROMOTER; CODY; IDENTIFICATION; VIRULENCE	Several genes involved in nitrogen metabolism are known to contribute to the virulence of pathogenic bacteria. Here, we studied the function of the nitrogen regulatory protein GlnR in the Gram-positive human pathogen Streptococcus pneumoniae. We demonstrate that GlnR mediates transcriptional repression of genes involved in glutamine synthesis and uptake (glnA and glnPQ), glutamate synthesis (gdhA), and the gene encoding the pentose phosphate pathway enzyme Zwf, which forms an operon with glnPQ. Moreover, the expression of gdhA is also repressed by the pleiotropic regulator CodY. The GlnR-dependent regulation occurs through a conserved operator sequence and is responsive to the concentration of glutamate, glutamine, and ammonium in the growth medium. By means of in vitro binding studies and transcriptional analyses, we show that the regulatory function of GlnR is dependent on GlnA. Mutants of glnA and glnP displayed significantly reduced adhesion to Detroit 562 human pharyngeal epithelial cells, suggesting a role for these genes in the colonization of the host by S. pneumoniae. Thus, our results provide a thorough insight into the regulation of glutamine and glutamate metabolism of S. pneumoniae mediated by both GlnR and GlnA.	Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands; Sophia Childrens Univ Hosp, Dept Pediat, Erasmus Med Ctr, NL-3000 DR Rotterdam, Netherlands; Radboud Univ, Dept Pediat, Med Ctr, NL-6500 HB Nijmegen, Netherlands	University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Radboud University Nijmegen	Kuipers, OP (corresponding author), Univ Groningen, Dept Mol Genet, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.	o.p.kuipers@rug.nl	Hermans, Peter W.M./H-8042-2014; Kok, Jan/C-9972-2012; Kuipers, Oscar/B-6752-2009; Hermans, Peter P.W.M./F-4655-2010; van Hijum, Sacha/F-6445-2014	Kuipers, Oscar/0000-0001-5596-7735; van Hijum, Sacha/0000-0003-0741-2991				ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; AVERY OT, 1995, MOL MED, V1, P344, DOI 10.1007/BF03401572; Baerends RJS, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r37; Belitsky BR, 2000, J BACTERIOL, V182, P5939, DOI 10.1128/JB.182.21.5939-5947.2000; Belitsky BR, 2004, J BACTERIOL, V186, P3392, DOI 10.1128/JB.186.11.3392-3398.2004; Bergara F, 2003, J BACTERIOL, V185, P3118, DOI 10.1128/JB.185.10.3118-3126.2003; Brandenburg JL, 2002, J BACTERIOL, V184, P6060, DOI 10.1128/JB.184.21.6060-6064.2002; Brown SW, 1996, J BACTERIOL, V178, P2450, DOI 10.1128/jb.178.8.2450-2454.1996; den Hengst CD, 2005, J BIOL CHEM, V280, P34332, DOI 10.1074/jbc.M502349200; den Hengst CD, 2005, J BACTERIOL, V187, P512, DOI 10.1128/JB.187.2.512-521.2005; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; EBNER E, 1970, METHOD ENZYMOL, V17, P922; FISHER SH, 1984, J BACTERIOL, V157, P612, DOI 10.1128/JB.157.2.612-621.1984; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; Guedon E, 2005, MICROBIOL-SGM, V151, P3895, DOI 10.1099/mic.0.28186-0; Guedon E, 2001, MOL MICROBIOL, V40, P1227, DOI 10.1046/j.1365-2958.2001.02470.x; GUTOWSKI JC, 1992, J BACTERIOL, V174, P671, DOI 10.1128/jb.174.3.671-681.1992; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.t01-1-03106.x; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; ISRAELSEN H, 1995, APPL ENVIRON MICROB, V61, P2540, DOI 10.1128/AEM.61.7.2540-2547.1995; Kharat AS, 2003, INFECT IMMUN, V71, P2758, DOI 10.1128/IAI.71.5.2758-2765.2003; Kim HJ, 2003, J BACTERIOL, V185, P1672, DOI 10.1128/JB.185.5.1672-1680.2003; Kloosterman TG, 2006, MICROBIOL-SGM, V152, P351, DOI 10.1099/mic.0.28521-0; Klose KE, 1997, INFECT IMMUN, V65, P587, DOI 10.1128/IAI.65.2.587-596.1997; Kuipers OP, 2002, ANTON LEEUW INT J G, V82, P113, DOI 10.1023/A:1020691801251; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Molle V, 2003, J BACTERIOL, V185, P1911, DOI 10.1128/JB.185.6.1911-1922.2003; Nakano MM, 1998, J BACTERIOL, V180, P5344, DOI 10.1128/JB.180.20.5344-5350.1998; NAKANO Y, 1991, J BIOCHEM-TOKYO, V109, P223; Paterson GK, 2006, MICROBES INFECT, V8, P145, DOI 10.1016/j.micinf.2005.06.009; Pearce BJ, 2002, RES MICROBIOL, V153, P243, DOI 10.1016/S0923-2508(02)01312-8; Polissi A, 1998, INFECT IMMUN, V66, P5620, DOI 10.1128/IAI.66.12.5620-5629.1998; Sanders JW, 1998, MOL GEN GENET, V257, P681, DOI 10.1007/s004380050697; SCHREIER HJ, 1986, J BACTERIOL, V167, P35, DOI 10.1128/jb.167.1.35-43.1986; SCHREIER HJ, 1985, P NATL ACAD SCI USA, V82, P3375, DOI 10.1073/pnas.82.10.3375; SCHREIER HJ, 1989, J MOL BIOL, V210, P51, DOI 10.1016/0022-2836(89)90290-8; Schultz AC, 2001, J BACTERIOL, V183, P3293, DOI 10.1128/JB.183.11.3293-3302.2001; Shivers RP, 2005, MOL MICROBIOL, V56, P1549, DOI 10.1111/j.1365-2958.2005.04634.x; Song JH, 2005, MOL CELLS, V19, P365; Tamura GS, 2002, INFECT IMMUN, V70, P2877, DOI 10.1128/IAI.70.6.2877-2885.2002; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Tullius MV, 2003, INFECT IMMUN, V71, P3927, DOI 10.1128/IAI.71.7.3927-3936.2003; van Hijum Sacha A F T, 2003, Appl Bioinformatics, V2, P241; van Hijum SAFT, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-77; Varmanen P, 2000, J BACTERIOL, V182, P146, DOI 10.1128/JB.182.1.146-154.2000; Wray LV, 1998, J BACTERIOL, V180, P2943, DOI 10.1128/JB.180.11.2943-2949.1998; Wray LV, 1996, P NATL ACAD SCI USA, V93, P8841, DOI 10.1073/pnas.93.17.8841; Wray LV, 1997, J BACTERIOL, V179, P5494, DOI 10.1128/jb.179.17.5494-5501.1997; Wray LV, 2001, CELL, V107, P427, DOI 10.1016/S0092-8674(01)00572-4; Yoshida K, 2003, MOL MICROBIOL, V49, P157, DOI 10.1046/j.1365-2958.2003.03567.x	53	96	99	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2006	281	35					25097	25109		10.1074/jbc.M601661200	http://dx.doi.org/10.1074/jbc.M601661200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	077LQ	16787930	Green Published, hybrid			2022-12-25	WOS:000240031300011
J	Glaaser, IW; Bankston, JR; Liu, HJ; Tateyama, M; Kass, RS				Glaaser, Ian W.; Bankston, John R.; Liu, Huajun; Tateyama, Michihiro; Kass, Robert S.			A carboxyl-terminal hydrophobic interface is critical to sodium channel function - Relevance to inherited disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; TRYPTOPHANYL RESIDUES; LQT-3 MUTATION; ALPHA-SUBUNIT; CARDIAC NA+; EF-HAND; LONG-QT; DOMAIN; INACTIVATION; CALMODULIN	Perturbation of sodium channel inactivation, a finely tuned process that critically regulates the flow of sodium ions into excitable cells, is a common functional consequence of inherited mutations associated with epilepsy, skeletal muscle disease, autism, and cardiac arrhythmias. Understanding the structural basis of inactivation is key to understanding these disorders. Here we identify a novel role for a structural motif in the COOH terminus of the heart Na(V)1.5 sodium channel in determining channel inactivation. Structural modeling predicts an interhelical hydrophobic interface between paired EF hands in the proximal region of the Na(V)1.5COOH terminus. The predicted interface is conserved among almost all EF hand-containing proteins and is the locus of a number of disease-associated mutations. Using the structural model as a guide, we provide biochemical and biophysical evidence that the structural integrity of this interface is necessary for proper Na+ channel inactivation gating. We thus demonstrate a novel role of the sodium channel COOH terminus structure in the control of channel inactivation and in pathologies caused by inherited mutations that disrupt it.	Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Kass, RS (corresponding author), Columbia Univ, Dept Pharmacol, New York, NY 10032 USA.	rsk20@columbia.edu	Bankston, John/I-7429-2019	Bankston, John/0000-0002-9478-2335	PHS HHS [R01-056810-07] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abriel H, 2005, TRENDS CARDIOVAS MED, V15, P35, DOI 10.1016/j.tcm.2005.01.001; An RH, 1998, CIRC RES, V83, P141, DOI 10.1161/01.RES.83.2.141; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; Berggard T, 2001, BIOCHEMISTRY-US, V40, P1257, DOI 10.1021/bi0014812; Bezzina C, 1999, CIRC RES, V85, P1206; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Clancy CE, 2005, PHYSIOL REV, V85, P33, DOI 10.1152/physrev.00005.2004; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Davis JP, 2004, J BIOL CHEM, V279, P17348, DOI 10.1074/jbc.M314095200; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P1193, DOI 10.1021/bi00219a005; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fujiwara T, 2003, BRAIN, V126, P531, DOI 10.1093/brain/awg053; Hubner CA, 2002, HUM MOL GENET, V11, P2435, DOI 10.1093/hmg/11.20.2435; Julenius K, 1998, BIOCHEMISTRY-US, V37, P8915, DOI 10.1021/bi972642d; Jurkat-Rott K, 2002, J NEUROL, V249, P1493, DOI 10.1007/s00415-002-0871-5; Kass RS, 2003, J CLIN INVEST, V112, P810, DOI 10.1172/JCI200319844; Kim J, 2004, J BIOL CHEM, V279, P45004, DOI 10.1074/jbc.M407286200; Kretsinger RH, 1996, NAT STRUCT BIOL, V3, P12, DOI 10.1038/nsb0196-12; Linse S, 2000, J MOL BIOL, V296, P473, DOI 10.1006/jmbi.1999.3452; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Meyer DF, 1996, J BIOL CHEM, V271, P11284, DOI 10.1074/jbc.271.19.11284; Motoike HK, 2004, J GEN PHYSIOL, V123, P155, DOI 10.1085/jgp.200308929; Nabbout R, 2003, NEUROLOGY, V60, P1961, DOI 10.1212/01.WNL.0000069463.41870.2F; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; Rivolta I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/jbc.M104471200; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Shah VN, 2006, P NATL ACAD SCI USA, V103, P3592, DOI 10.1073/pnas.0507397103; Spampanato J, 2004, J NEUROSCI, V24, P10022, DOI 10.1523/JNEUROSCI.2034-04.2004; Subramaniam V, 2001, J BIOL CHEM, V276, P21506, DOI 10.1074/jbc.M102292200; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tateyama M, 2004, BIOPHYS J, V86, P1843, DOI 10.1016/S0006-3495(04)74251-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Veldkamp MW, 2000, CIRC RES, V86, pE91, DOI 10.1161/01.RES.86.9.e91; Wingo TL, 2004, NAT STRUCT MOL BIOL, V11, P219, DOI 10.1038/nsmb737; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	39	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2006	281	33					24015	24023		10.1074/jbc.M605473200	http://dx.doi.org/10.1074/jbc.M605473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	072WE	16798729	hybrid			2022-12-25	WOS:000239702900075
J	Villagra, A; Cruzat, F; Carvallo, L; Paredes, R; Olate, J; van Wijnen, AJ; Stein, GS; Lian, JB; Stein, JL; Imbalzano, AN; Montecino, M				Villagra, Alejandro; Cruzat, Fernando; Carvallo, Loreto; Paredes, Roberto; Olate, Juan; van Wijnen, Andre J.; Stein, Gary S.; Lian, Jane B.; Stein, Janet L.; Imbalzano, Anthony N.; Montecino, Martin			Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST DIFFERENTIATION; GLUCOCORTICOID-RECEPTOR; MUSCLE DIFFERENTIATION; PROMOTER SEQUENCES; C/EBP-BETA; IN-VITRO; COMPLEX; EXPRESSION; CELLS; ACTIVATION	Tissue-specific activation of the osteocalcin (OC) gene is associated with changes in chromatin structure at the promoter region. Two nuclease-hypersensitive sites span the key regulatory elements that control basal tissue-specific and vitamin D-3-enhanced OC gene transcription. To gain understanding of the molecular mechanisms involved in chromatin remodeling of the OC gene, we have examined the requirement for SWI/SNF activity. We inducibly expressed an ATPase-defective BRG1 catalytic subunit that forms inactive SWI/SNF complexes that bind to the OC promoter. This interaction results in inhibition of both basal and vitamin D-3-enhanced OC gene transcription and a marked decrease in nuclease hypersensitivity. We find that SWI/SNF is recruited to the OC promoter via the transcription factor CCAAT/enhancer-binding protein beta, which together with Runx2 forms a stable complex to facilitate RNA polymerase II binding and activation of OC gene transcription. Together, our results indicate that the SWI/SNF complex is a key regulator of the chromatin-remodeling events that promote tissue-specific transcription in osteoblasts.	Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion, Chile; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Universidad de Concepcion; University of Massachusetts System; University of Massachusetts Worcester	Montecino, M (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Casilla 160-C 4079100, Concepcion, Chile.	mmonteci@udec.cl	Carvallo, Loreto/C-2237-2019; van Wijnen, Andre J./AAG-3578-2019	Carvallo, Loreto/0000-0001-9943-1342; van Wijnen, Andre J./0000-0002-4458-0946; Paredes, Roberto/0000-0002-6793-5404; Villagra, Alejandro/0000-0001-9346-8355	FIC NIH HHS [5R03TW00990] Funding Source: Medline; NIAMS NIH HHS [R01 AR049069, P01AR48818] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069, P01AR048818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gutierrez J, 2000, BIOCHEMISTRY-US, V39, P13565, DOI 10.1021/bi0013896; Gutierrez S, 2004, J BIOL CHEM, V279, P43581, DOI 10.1074/jbc.M408335200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Javed A, 1999, MOL CELL BIOL, V19, P7491; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lian JB, 2001, STEROIDS, V66, P159, DOI 10.1016/S0039-128X(00)00160-4; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; Montecino M, 1996, J CELL BIOCHEM, V63, P221, DOI 10.1002/(SICI)1097-4644(19961101)63:2<221::AID-JCB9>3.0.CO;2-#; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847-8861.2004; Paredes R, 2002, BIOCHEM J, V363, P667, DOI 10.1042/0264-6021:3630667; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332	40	64	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2006	281	32					22695	22706		10.1074/jbc.M511640200	http://dx.doi.org/10.1074/jbc.M511640200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	070RY	16772287	hybrid			2022-12-25	WOS:000239542600030
J	Miyano, K; Ueno, N; Takeya, R; Sumimoto, H				Miyano, Kei; Ueno, Noriko; Takeya, Ryu; Sumimoto, Hideki			Direct involvement of the small GTPase Rac in activation of the superoxide-producing NADPH oxidase Nox1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE-C; P67(PHOX) PARTICIPATE; NAD(P)H OXIDASE-1; SH3 DOMAINS; P47(PHOX); GENERATION; MEMBRANE; BINDING	Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1. However, the role of the small GTPase Rac remained to be clarified. Here we show that Rac directly participates in Nox1 activation via interacting with Noxa1. Electropermeabilized HeLa cells, ectopically expressing Nox1, Noxo1, and Noxa1, produce superoxide in a GTP-dependent manner, which is abrogated by expression of a mutant Noxa1(R103E), defective in Rac binding. Superoxide production in Nox1-expressing HeLa and Caco-2 cells is decreased by depletion or sequestration of Rac; on the other hand, it is enhanced by expression of the constitutively active Rac1(Q61L), but not by that of a mutant Rac1 with the A27K substitution, deficient in binding to Noxa1. We also demonstrate that Nox1 activation requires membrane recruitment of Noxa1, which is normally mediated via Noxa1 binding to Noxo1, a protein tethered to the Nox1 partner p22phox: the Noxa1-Noxo1 and Noxo1-p22phox interactions are both essential for Nox1 activity. Rac likely facilitates the membrane localization of Noxa1: although Noxa1(W436R), defective in Noxo1 binding, neither associates with the membrane nor activates Nox1, the effects of the W436R substitution are restored by expression of Rac1( Q61L). The Rac-Noxa1 interaction also serves at a step different from the Noxa1 localization, because the binding-defective Noxa1( R103E), albeit targeted to the membrane, does not support superoxide production by Nox1. Furthermore, a mutant Noxa1 carrying the substitution of Ala for Val-205 in the activation domain, which is expected to undergo a conformational change upon Rac binding, fully localizes to the membrane but fails to activate Nox1.	Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Sumimoto, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hsumi@bioreg.kyushu-u.ac.jp						Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Biberstine-Kinkade KJ, 2002, J BIOL CHEM, V277, P30368, DOI 10.1074/jbc.M203993200; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Dikalova A, 2005, CIRCULATION, V112, P2668, DOI 10.1161/CIRCULATIONAHA.105.538934; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; FINAN P, 1994, J BIOL CHEM, V269, P13752; Fortemaison N, 2005, EUR J ENDOCRINOL, V152, P127, DOI 10.1530/eje.1.01815; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gregg D, 2003, AM J PHYSIOL-CELL PH, V285, pC723, DOI 10.1152/ajpcell.00230.2003; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hanna IR, 2004, FREE RADICAL BIO MED, V37, P1542, DOI 10.1016/j.freeradbiomed.2004.08.011; Hashida S, 2004, J BIOL CHEM, V279, P26378, DOI 10.1074/jbc.M309724200; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kawahara T, 2005, J BIOL CHEM, V280, P31859, DOI 10.1074/jbc.M501882200; Kawahara T, 2005, AM J PHYSIOL-CELL PH, V288, pC450, DOI 10.1152/ajpcell.00319.2004; Kawahara T, 2004, J IMMUNOL, V172, P3051, DOI 10.4049/jimmunol.172.5.3051; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LEFFERS H, 1993, EXP CELL RES, V209, P165, DOI 10.1006/excr.1993.1298; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Matsuno K, 2005, CIRCULATION, V112, P2677, DOI 10.1161/CIRCULATIONAHA.105.573709; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; Mizuki K, 2005, ARCH BIOCHEM BIOPHYS, V444, P185, DOI 10.1016/j.abb.2005.10.012; Morozov I, 1998, J BIOL CHEM, V273, P15435, DOI 10.1074/jbc.273.25.15435; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Nobuhisa I, 2006, BIOCHEM J, V396, P183, DOI 10.1042/BJ20051899; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 2005, BIOCHEM BIOPH RES CO, V338, P677, DOI 10.1016/j.bbrc.2005.08.210; Takeya R, 2006, METHOD ENZYMOL, V406, P456, DOI 10.1016/S0076-6879(06)06034-4; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Tamura M, 1999, ARCH BIOCHEM BIOPHYS, V361, P257, DOI 10.1006/abbi.1998.0954; Ueno N, 2005, J BIOL CHEM, V280, P23328, DOI 10.1074/jbc.M414548200; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006	69	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2006	281	31					21857	21868		10.1074/jbc.M513665200	http://dx.doi.org/10.1074/jbc.M513665200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	068PO	16762923	hybrid			2022-12-25	WOS:000239387100032
J	Nakayama, M; Iida, M; Koseki, H; Ohara, O				Nakayama, Manabu; Iida, Midori; Koseki, Haruhiko; Ohara, Osamu			A gene-targeting approach for functional characterization of KIAA genes encoding extremely large proteins	FASEB JOURNAL			English	Article						comprehensive analysis; functional genomics; human genome project; KO mice	UNIDENTIFIED HUMAN GENES; EGF-LIKE MOTIFS; COMPLETE SEQUENCES; CDNA-CLONES; IN-VITRO; CODING SEQUENCES; MOUSE GENOME; BRAIN; PREDICTION; CODE	Given that thousands of genes exist in the mammalian genome, criteria are needed to prioritize their functional analysis and to decrease the likelihood of producing gene-targeted mice that lack overt phenotypes. Initial analysis efforts are likely to be fruitful if focused on genes encoding large proteins, since at least some large proteins serve as frameworks for intricate assembly of protein complexes, and their inactivation would render definitive, observable phenotypes. Here, we describe the functional characterization of the murine homologues of five human KIAA genes (KIAA1409, KIAA1440, KIAA1447, KIAA1768, and KIAA1276) that encode large proteins. Gene-targeted mice had phenotypic and developmental defects resulting from the functional deletion of three of these five genes. Mice with targeted disruption of KIAA1409 lacked the ability to drink, and those with targeted disruption of KIAA1447 displayed hind leg motor dysfunction. Disruption of KIAA1440 led to embryonic lethality at the blastocyst stage. The high success rate of our approach demonstrates the rationale for the genome-wide functional examination of large proteins in mice using reverse genetics.	Chiba Univ, Grad Sch Pharmaceut Sci, Kausa DNA Re Inst, Dept Human Genome Technol, Chiba, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Lab Phamacogenom, Dept Human Genome Technol, Chiba, Japan; RIKEN, Inst Phys & Chem Res, Res Ctr Allergy & Immunol, Lab Dev Genet, Yokohama, Kanagawa, Japan; RIKEN, Inst Phys & Chem Res, Res Ctr Allergy & Immunol, Lab Immunogenom, Yokohama, Kanagawa, Japan	Chiba University; Chiba University; RIKEN; RIKEN	Nakayama, M (corresponding author), 2-6-7 Kazusa Kamatari, Chiba 2920818, Japan.	nmanabu@kazusa.or.jp	Koseki, Haruhiko/I-3825-2014; Ohara, Osamu/A-9119-2012; Ohara, Osamu/G-5448-2015	Koseki, Haruhiko/0000-0001-8424-5854; Ohara, Osamu/0000-0002-3328-9571				Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Festing MFW, 1999, MAMM GENOME, V10, P836, DOI 10.1007/s003359901099; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Joyner AL, 2000, GENE TARGETING PRACT; Kikuno R, 2004, NUCLEIC ACIDS RES, V32, pD502, DOI 10.1093/nar/gkh035; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Mitsui K, 2002, BIOCHEM BIOPH RES CO, V290, P1260, DOI 10.1006/bbrc.2002.6338; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nagase T, 2000, DNA RES, V7, P273; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nakajima D, 2001, MOL BRAIN RES, V94, P85; Nakayama M, 2002, GENOME RES, V12, P1773, DOI 10.1101/gr.406902; Nakayama M, 2002, MOL CELL NEUROSCI, V20, P563, DOI 10.1006/mcne.2002.1146; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Suzuki Y, 2003, DNA RES, V10, P263, DOI 10.1093/dnares/10.6.263; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	31	24	28	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2006	20	10					1718	+		10.1096/fj.06-5952fje	http://dx.doi.org/10.1096/fj.06-5952fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	080RV	16807365				2022-12-25	WOS:000240266600026
